<SEC-DOCUMENT>0001047469-17-001128.txt : 20170301
<SEC-HEADER>0001047469-17-001128.hdr.sgml : 20170301
<ACCEPTANCE-DATETIME>20170301161204
ACCESSION NUMBER:		0001047469-17-001128
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		91
CONFORMED PERIOD OF REPORT:	20161231
FILED AS OF DATE:		20170301
DATE AS OF CHANGE:		20170301

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMICUS THERAPEUTICS INC
		CENTRAL INDEX KEY:			0001178879
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				200422823
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33497
		FILM NUMBER:		17654246

	BUSINESS ADDRESS:	
		STREET 1:		1 CEDAR BROOK DRIVE
		CITY:			CRANBURY
		STATE:			NJ
		ZIP:			08512
		BUSINESS PHONE:		(609) 662-2000

	MAIL ADDRESS:	
		STREET 1:		1 CEDAR BROOK DRIVE
		CITY:			CRANBURY
		STATE:			NJ
		ZIP:			08512
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>a2231065z10-k.htm
<DESCRIPTION>10-K
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<P><FONT SIZE=3 >
Use these links to rapidly review the document<BR>
<A HREF="#bg47301_table_of_contents">  TABLE OF CONTENTS</A><BR></font>
</P>

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><div
style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>UNITED STATES SECURITIES AND EXCHANGE COMMISSION<BR>  </B></FONT><FONT SIZE=2><B>Washington, D.C. 20549  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=2><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=5><B>FORM 10-K  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=5><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=5><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="72pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=3><FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=3><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=3><B> ANNUAL REPORT PURSUANT TO SECTION&nbsp;13 OR 15(d) OF THE<BR>
SECURITIES EXCHANGE ACT OF&nbsp;1934</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2><B> For the fiscal year ended December&nbsp;31, 2016</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> OR</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=3><FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=3><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=3><B> TRANSITION REPORT PURSUANT TO SECTION&nbsp;13 OR 15(d) OF THE<BR>
SECURITIES EXCHANGE ACT OF&nbsp;1934</B></FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=3 ALIGN="CENTER" VALIGN="TOP" style="font-family:times;"><BR><FONT SIZE=2><B> For the transition period
from&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<BR> </B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Commission File Number&nbsp;001-33497  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=2>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=6><B>Amicus Therapeutics,&nbsp;Inc.<BR>  </B></FONT><FONT SIZE=2><I>(Exact name of registrant as specified in its charter)  </I></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


</FONT> <FONT SIZE=2><I>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </I></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>
 <!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>Delaware</B></FONT><BR>
<FONT SIZE=2><I>(State or other jurisdiction of<BR>
incorporation or organization)</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> 71-0869350</B></FONT><BR>
<FONT SIZE=2><I>(IRS Employer<BR>
Identification No.)</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>1 Cedar Brook Drive, Cranbury, NJ 08512<BR>  </B></FONT><FONT SIZE=1><B>(Address of principal executive offices)<BR>  </B></FONT><FONT SIZE=2><B>Telephone: (609)&nbsp;662-2000  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Securities registered pursuant to Section&nbsp;12(b) of the Act:  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>
 <!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="41%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="41%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Title of each class

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name of each exchange on which registered

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Common Stock, par value $0.01 per share</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>The NASDAQ Stock Market&nbsp;LLC</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Securities registered pursuant to Section&nbsp;12(g) of the Act: None  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=2><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&nbsp;405 of the Securities
Act.&nbsp;Yes&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate by check mark if the registrant is not required to file reports pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the
Act.&nbsp;Yes&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT> </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate by check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12&nbsp;months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past
90&nbsp;days.&nbsp;Yes&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be
submitted and posted pursuant to Rule&nbsp;405 of Regulation&nbsp;S-T (&sect;232.405 of this chapter) during the preceding 12&nbsp;months (or for such shorter period that the registrant
was required to submit and post such files).&nbsp;Yes&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate by check mark if disclosure of delinquent filers pursuant to Item&nbsp;405 of Regulation&nbsp;S-K (&sect;22.405) is not contained herein, and
will not be contained, to the best of the registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part&nbsp;III of this Form&nbsp;10-K or any amendment
to this Form&nbsp;10-K.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, non-accelerated filer or a smaller reporting company. See
definition of "large accelerated filer", "accelerated filer" and "smaller reporting company" in Rule&nbsp;12b-2 of the Exchange Act. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="131pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="101pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="159pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Large accelerated filer <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Accelerated filer <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Non-accelerated filer <FONT FACE="WINGDINGS">&#111;</FONT><BR></FONT> <FONT SIZE=1>(Do not check if a<BR>
smaller reporting company)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Smaller Reporting Company <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate
by check mark if the registrant is a shell company (as defined in Rule&nbsp;12b-2 of the
Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The aggregate market value of the 99,320,855 shares of voting common equity held by non-affiliates of the registrant, computed by reference to the closing price as
reported on The NASDAQ Global Market, as of the last business day of the registrant's most recently completed second fiscal quarter (June&nbsp;30, 2016) was approximately $542,291,868. Shares of
voting and non-voting stock held by executive officers, directors and holders of more than 10% of the outstanding stock have been excluded from this calculation because such persons or institutions
may be deemed affiliates. This determination of affiliate status is not a conclusive determination for other purposes. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of February&nbsp;15, 2017, there were 194,824,362 shares of common stock outstanding. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DOCUMENTS
INCORPORATED BY REFERENCE: Portions of the Proxy Statement for the registrant's 2016 Annual Meeting of Stockholders which is to be filed subsequent to the date hereof are
incorporated by reference into Part&nbsp;III of this Annual Report on Form&nbsp;10-K. </FONT></P>
 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>

<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p>

<P style="font-family:times;"><FONT SIZE=2><div
style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div> </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=387350,FOLIO='blank',FILE='DISK124:[17ZAA1.17ZAA47301]BA47301A.;5',USER='VSTEFAN',CD='27-FEB-2017;04:19' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A> </FONT></P>

<A NAME="bg47301_table_of_contents"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="BG47301A_main_toc"></A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
<A NAME="BG47301_TOC"></A> </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="23pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><A HREF="#da1"><FONT SIZE=2></FONT><FONT SIZE=2><B>PART I</B></FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><A HREF="#da47301_item_1._business."><BR><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


  Item&nbsp;1.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#da47301_item_1._business."><BR><FONT SIZE=2>BUSINESS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#da47301_item_1._business."><BR><FONT SIZE=2>3</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><A HREF="#di47301_item_1a._risk_factors"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 Item&nbsp;1A.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#di47301_item_1a._risk_factors"><FONT SIZE=2>RISK FACTORS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#di47301_item_1a._risk_factors"><FONT SIZE=2>34</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><A HREF="#dq47301_item_1b._unresolved_staff_comments."><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 Item&nbsp;1B.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#dq47301_item_1b._unresolved_staff_comments."><FONT SIZE=2>UNRESOLVED STAFF COMMENTS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dq47301_item_1b._unresolved_staff_comments."><FONT SIZE=2>79</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><A HREF="#dq47301_item_2._properties."><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 Item&nbsp;2.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#dq47301_item_2._properties."><FONT SIZE=2>PROPERTIES</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dq47301_item_2._properties."><FONT SIZE=2>79</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><A HREF="#dq47301_item_3._legal_proceedings."><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 Item&nbsp;3.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#dq47301_item_3._legal_proceedings."><FONT SIZE=2>LEGAL PROCEEDINGS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dq47301_item_3._legal_proceedings."><FONT SIZE=2>79</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><A HREF="#dq47301_item_4._mine_safety_disclosures."><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 Item&nbsp;4.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#dq47301_item_4._mine_safety_disclosures."><FONT SIZE=2>MINE SAFETY DISCLOSURES</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dq47301_item_4._mine_safety_disclosures."><FONT SIZE=2>80</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><A HREF="#dq47301_part_ii"><BR><FONT SIZE=2><B>PART II</B></FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><A HREF="#dq47301_item_5._market_for_the_registr__ite04803"><BR><FONT SIZE=2>



<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


  Item&nbsp;5.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#dq47301_item_5._market_for_the_registr__ite04803"><BR><FONT SIZE=2>MARKET FOR THE REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dq47301_item_5._market_for_the_registr__ite04803"><BR><FONT SIZE=2>81</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><A HREF="#ds47301_item_6._selected_financial_data."><FONT SIZE=2>



<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 Item&nbsp;6.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#ds47301_item_6._selected_financial_data."><FONT SIZE=2>SELECTED FINANCIAL DATA</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#ds47301_item_6._selected_financial_data."><FONT SIZE=2>84</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><A HREF="#ds47301_item_7._management_s_discussio__ite03649"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 Item&nbsp;7.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#ds47301_item_7._management_s_discussio__ite03649"><FONT SIZE=2>MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#ds47301_item_7._management_s_discussio__ite03649"><FONT SIZE=2>85</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><A HREF="#dw47301_item_7a._quantitative_and_qual__ite02650"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 Item&nbsp;7A.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#dw47301_item_7a._quantitative_and_qual__ite02650"><FONT SIZE=2>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dw47301_item_7a._quantitative_and_qual__ite02650"><FONT SIZE=2>100</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><A HREF="#dy47301_item_8._financial_statements_and_supplementary_data."><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 Item&nbsp;8.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#dy47301_item_8._financial_statements_and_supplementary_data."><FONT SIZE=2>FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dy47301_item_8._financial_statements_and_supplementary_data."><FONT SIZE=2>101</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><A HREF="#gc47301_item_9._changes_in_and_disagre__ite03557"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 Item&nbsp;9.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#gc47301_item_9._changes_in_and_disagre__ite03557"><FONT SIZE=2>CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#gc47301_item_9._changes_in_and_disagre__ite03557"><FONT SIZE=2>147</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><A HREF="#gc47301_item_9a._controls_and_procedures."><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 Item&nbsp;9A.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#gc47301_item_9a._controls_and_procedures."><FONT SIZE=2>CONTROLS AND PROCEDURES</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#gc47301_item_9a._controls_and_procedures."><FONT SIZE=2>147</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><A HREF="#gc47301_item_9b._other_information."><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 Item&nbsp;9B.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#gc47301_item_9b._other_information."><FONT SIZE=2>OTHER INFORMATION</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#gc47301_item_9b._other_information."><FONT SIZE=2>147</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><A HREF="#gc47301_part_iii"><BR><FONT SIZE=2><B>PART III</B></FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><A HREF="#gc47301_item_10._directors,_executive___ite03057"><BR><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


  Item&nbsp;10.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#gc47301_item_10._directors,_executive___ite03057"><BR><FONT SIZE=2>DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#gc47301_item_10._directors,_executive___ite03057"><BR><FONT SIZE=2>148</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><A HREF="#gc47301_item_11._executive_compensation."><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 Item&nbsp;11.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#gc47301_item_11._executive_compensation."><FONT SIZE=2>EXECUTIVE COMPENSATION</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#gc47301_item_11._executive_compensation."><FONT SIZE=2>148</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><A HREF="#gc47301_item_12._security_ownership_of__ite03985"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 Item&nbsp;12.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#gc47301_item_12._security_ownership_of__ite03985"><FONT SIZE=2>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#gc47301_item_12._security_ownership_of__ite03985"><FONT SIZE=2>148</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><A HREF="#gc47301_item_13._certain_relationships__ite03069"><FONT SIZE=2>



<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 Item&nbsp;13.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#gc47301_item_13._certain_relationships__ite03069"><FONT SIZE=2>CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#gc47301_item_13._certain_relationships__ite03069"><FONT SIZE=2>148</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><A HREF="#gc47301_item_14._principal_accounting_fees_and_services."><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 Item&nbsp;14.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#gc47301_item_14._principal_accounting_fees_and_services."><FONT SIZE=2>PRINCIPAL ACCOUNTING FEES AND SERVICES</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#gc47301_item_14._principal_accounting_fees_and_services."><FONT SIZE=2>148</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><A HREF="#ge47301_part_iv"><BR><FONT SIZE=2><B> PART IV</B></FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><A HREF="#ge47301_item_15._exhibits,_financial_statement_schedule"><BR><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


  Item&nbsp;15.</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#ge47301_item_15._exhibits,_financial_statement_schedule"><BR><FONT SIZE=2>EXHIBITS, FINANCIAL STATEMENT SCHEDULES</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#ge47301_item_15._exhibits,_financial_statement_schedule"><BR><FONT SIZE=2>149</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;text-align:justify;"><A HREF="#jc47301_signatures"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 SIGNATURES</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#jc47301_signatures"><FONT SIZE=2>156</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=1012026,FOLIO='blank',FILE='DISK124:[17ZAA1.17ZAA47301]BG47301A.;7',USER='VSTEFAN',CD='27-FEB-2017;04:19' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_da47301_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="da47301_special_note_regarding_forward-looking_statements"> </A>
<A NAME="toc_da47301_1"> </A>
<BR></FONT><FONT SIZE=2><B>  SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This annual report on Form&nbsp;10-K contains forward-looking statements that involve substantial risks and uncertainties. All statements,
other than statements of historical facts, included in this annual report on Form&nbsp;10-K regarding our strategy, future operations, future financial position, future revenues, projected costs,
prospects, plans and objectives of management are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "potential," "intend," "may," "plan," "predict," "project,"
"will," "should," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
forward-looking statements in this annual report on Form&nbsp;10-K include, among other things, statements about:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the progress and results of our clinical trials of our drug candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the cost of manufacturing drug supply for our clinical and preclinical studies, including the significant cost of new Fabry enzyme replacement
therapy ("ERT") cell line development and manufacturing as well as the cost of manufacturing Pompe ERT; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the scope, progress, results and costs of preclinical development, laboratory testing and clinical trials for our product candidates including
those testing the use of pharmacological chaperones co-formulated and co-administered with ERT and for the treatment of lysosomal storage disorders ("LSDs"); </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the future results of on-going or later clinical trials for SD-101, including our ability to obtain regulatory approvals and commercialize
SD-101 and obtain market acceptance of SD-101; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the future results of on-going preclinical research and later clinical trials for cyclin-dependent kinase-like 5 ("CDKL5"), including our
ability to obtain regulatory approvals and commercialize CDKL5 and obtain market acceptance for CDKL5; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the costs, timing and outcome of regulatory review of our product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the number and development requirements of other product candidates that we pursue; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the costs of commercialization activities, including product marketing, sales and distribution; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the emergence of competing technologies and other adverse market developments; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to obtain reimbursement for migalastat HCI; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to obtain market acceptance of migalastat HCl in the European Union (the "EU"); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the costs of preparing, filing and prosecuting patent applications and maintaining, enforcing and defending intellectual property-related
claims; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the extent to which we acquire or invest in businesses, products and technologies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to successfully integrate our recent acquisitions of Scioderm,&nbsp;Inc. ("Scioderm") and MiaMed,&nbsp;Inc. ("MiaMed") and
their products and technologies into our business, including the possibility that the expected benefits of the transactions will not be fully realized by us or may take longer to realize than
expected; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to establish collaborations and obtain milestone, royalty or other payments from any such collaborators. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements.
Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward- </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-1-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=3,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=254412,FOLIO='1',FILE='DISK124:[17ZAA1.17ZAA47301]DA47301A.;6',USER='VSTEFAN',CD='27-FEB-2017;04:19' -->
<A NAME="page_da47301_1_2"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>looking
statements we make. We have included important factors in the cautionary statements included in this annual report on Form&nbsp;10-K, particularly in Part&nbsp;I, Item&nbsp;1A "Risk
Factors" that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact
of any future acquisitions, mergers, dispositions, joint ventures, collaborations or investments we may make. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
should read this annual report on Form&nbsp;10-K and the documents that we incorporate by reference in this annual report on Form&nbsp;10-K completely and with the understanding
that our actual future results may be materially different from what we expect. We do not assume any obligation to update any forward-looking statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-2-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=4,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=853013,FOLIO='2',FILE='DISK124:[17ZAA1.17ZAA47301]DA47301A.;6',USER='VSTEFAN',CD='27-FEB-2017;04:19' -->
<A NAME="page_da47301_1_3"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="da1"></A>PART I  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="da47301_item_1._business."> </A>
<A NAME="toc_da47301_2"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>BUSINESS.    <BR>    </I></B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Overview  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a global patient-focused biotechnology company engaged in the discovery, development and commercialization of a diverse set of novel
treatments for patients living with devastating rare and orphan diseases. Our lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme
replacement therapy ("ERT") for Fabry disease. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Also
in the pipeline, SD-101 is a product candidate in late-stage development, as a potential first-to-market therapy for the chronic, rare connective tissue disorder Epidermolysis
Bullosa ("EB"). We are also leveraging our Chaperone-Advanced Replacement Therapy ("CHART&#153;") platform technologies to develop novel ERT products for Pompe disease, Fabry disease, and
potentially other lysosomal storage disorders ("LSDs"). We are also investigating preclinical and discovery programs in other rare and devastating diseases including cyclin-dependent kinase-like 5
("CDKL5") deficiency. We believe that our platform technologies and our product pipeline uniquely position us at the forefront of advanced therapies to treat a range of devastating rare and orphan
diseases. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our Strategy  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our strategy is to internally develop or acquire first-in-class or potentially best-in-class therapies that have the potential to provide
significant benefits for individuals living with rare and devastating diseases. We intend to leverage our global capabilities to develop and commercialize our robust pipeline. During 2016, we made
significant progress toward fulfilling our vision to build a leading global biotechnology company focused on rare and devastating diseases: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> Global capabilities.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;We have established European headquarters in the
United Kingdom ("UK") and are building a world-class global commercial infrastructure, with key leadership in place to support the international launch of migalastat HCl.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> Commercial success.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;We received full approval in the EU of Galafold
("migalastat HCl") and commenced the commercial launch in Germany on May&nbsp;30, 2016. We have achieved success with reimbursement in several EU member states and through our expanded access
programs ("EAPs") and we continue to advance additional regulatory submissions worldwide.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> Pompe clinical study.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;We have reported positive preliminary data from a
clinical study to evaluate Pompe disease patients treated with our novel treatment paradigm ATB200/AT2221.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> Late-stage product development.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;We continue to investigate SD-101, a
proprietary topical cream for all major types of EB, in a single Phase&nbsp;3 registration study that we hope will support global applications for approval in a number of countries. SD-101 has been
granted Breakthrough Therapy designation by the U.S. Food and Drug Administration ("FDA").  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> Patient-centricity.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;We continue to focus on our patient advocacy, which has
always been a critical component of the values of our corporate culture, throughout all levels of the organization. The needs of patients in the rare disease community are at the center of our
inventive science, our commercial organization, and our clinical programs. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our Product Candidates  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Fabry franchise strategy is to develop migalastat HCl (which we may refer to as "migalastat") for all patients with Fabry disease as a
monotherapy for patients with amenable mutations and in combination with ERT for all other patients. We have completed two global Phase&nbsp;3 registration studies of our lead product candidate,
migalastat HCl, an orally administered small molecule pharmacological </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-3-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=5,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=395684,FOLIO='3',FILE='DISK124:[17ZAA1.17ZAA47301]DA47301A.;6',USER='VSTEFAN',CD='27-FEB-2017;04:19' -->
<A NAME="page_da47301_1_4"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>chaperone
for the treatment of Fabry disease, an LSD. In May 2016, we announced that we had received full European Commission approval for migalastat HC1, under the product name Galafold&#153;,
as a first-line therapy for long-term treatment of adults and adolescents aged 16&nbsp;years and older with a confirmed diagnosis of Fabry disease and who have an amenable mutation. The label
includes 313 Fabry-causing mutations, which represent between 35% and 50% of patients currently diagnosed with Fabry disease. We commenced commercial shipments in the EU in the second quarter of 2016
and recognized net product sales of $5.0&nbsp;million in 2016. For patients with non-amenable mutations, we are leveraging our CHART&#153; technology and advanced biologics capabilities to
move forward with a proprietary Fabry ERT for co-formulation with migalastat HCl. Master cell banking has been completed and process development work has commenced. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are also in Phase&nbsp;3 clinical development of a novel topical medicine, SD-101, for the treatment of the genetic connective tissue disorder EB, for which no other pharmacological
therapies are currently approved. We have also initiated a clinical study in patients with Pompe disease, another LSD, to investigate our novel treatment paradigm that consists of ATB200, a uniquely
engineered recombinant human acid alpha-glucosidase ("rhGAA") enzyme with an optimized carbohydrate structure to enhance uptake, co-administered with a pharmacological chaperone, AT2221, to improve
activity and stability. Leveraging our biologics capabilities and platform technologies, we are also investigating preclinical and discovery programs in other rare and devastating diseases including
cyclin-dependent kinase-like 5 ("CDKL5") deficiency. We believe that our platform technologies and our advanced product pipeline uniquely position us at the forefront of developing therapies to
potentially address significant unmet needs for devastating rare and orphan diseases. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
a regular basis we consider potential collaborations, alliances, and other business development opportunities to enhance our strategic plan to develop and provide therapies to
patients living with rare and orphan diseases and support our continued expansion as a commercial biotechnology company. We are currently exploring opportunities for licensing migalastat to further
enhance the development of the product in markets around the world. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our Technology Platforms  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Pharmacological Chaperone Technology  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are leveraging our pharmacological chaperone technology to develop next-generation treatments for human genetic diseases by targeting mutated
proteins that are unstable, unfolded, or misfolded. In the human body, proteins are involved in almost every aspect of cellular function. Proteins are linear strings of amino acids that fold and twist
into specific three-dimensional shapes in order to function properly. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain
human diseases result from mutations that cause changes in the amino acid sequence of a protein, and these changes often reduce protein stability and may prevent them from
folding properly. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pharmacological
chaperones are small molecules designed to selectively bind to a target protein, increase its stability, and help keep it folded in the correct three-dimensional shape.
For LSDs, pharmacological chaperones are designed to bind to, stabilize, and facilitate trafficking of both endogenous and exogenous enzymes to the lysosome. This important feature has allowed us to
develop our personalized medicine migalastat (a monotherapy) in addition to our Chaperone-Advanced Replacement Therapy ("CHART") platform of pharmacological chaperones in combination with ERT. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Pharmacological Chaperone Monotherapy  </B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Many natural proteins are made in the endoplasmic reticulum ("ER") and sent to other parts of the cell. Unstable, unfolded, or misfolded
proteins are generally eliminated or retained in the ER rather than being transported to the intended destination in the cell. The accumulation of unfolded or </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-4-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=6,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=44697,FOLIO='4',FILE='DISK124:[17ZAA1.17ZAA47301]DA47301A.;6',USER='VSTEFAN',CD='27-FEB-2017;04:19' -->
<A NAME="page_da47301_1_5"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>misfolded
proteins in the ER and the interruption of trafficking of important proteins to their proper cellular locations can cause several types of problems
including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Complete or partial loss of appropriate protein function; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Accumulation of lipids and other substances that should be degraded; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Disruption of cellular function and eventual cell death. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These
defects may lead to various types of human genetic diseases, including LSDs. As monotherapy agents for LSDs, pharmacological chaperones are designed to bind to and stabilize
endogenous lysosomal enzymes for proper trafficking to the lysosome, which may also alleviate the buildup of mutant proteins in the ER. Once in the lysosome, the pharmacological chaperone
disassociates and the enzyme is free to break down substrate. Based on this mechanism, individuals with certain genetic mutations (amenable mutations) that result in some residual biological activity
are potentially eligible for pharmacological chaperone monotherapy. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


CHART Technology Platform  </B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ERT is the standard of care for several LSDs, based on the intravenous infusion of recombinant or gene-activated human enzyme. The enzyme is
delivered into the blood in order to be taken up by cells and then transported to the lysosome. Upon entering the lysosome, this enzyme is intended to perform the function of the absent or deficient
endogenous enzyme. However, the pH in the infusion bag and in blood is higher than the enzyme's natural acidic environment in the lysosome. As a result, the infused enzyme may unfold and lose activity
and may be misdirected to non-target tissues or rapidly cleared from the body. Exposure to high concentrations of infused enzymes can impact efficacy or cause adverse effects. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Possible
problems related to the instability of infused enzyme include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Denaturation and reduced activity; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Poor targeting and uptake into key tissues of disease; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Poor tolerability and increased immunogenicity. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
our CHART programs, each chaperone is designed to bind to and stabilize a specific therapeutic enzyme. Clinical studies of pharmacological chaperones in combination with currently
marketed ERTs have established initial human proof of concept that a chaperone can stabilize enzyme activity and potentially improve ERT tolerability. We believe this technology may be able to improve
the stability, uptake, and activity of the enzyme, and may improve tolerability and lower immunogenicity compared to administration of currently marketed ERTs alone. This combination approach may
benefit patients with LSDs, including patients with inactive endogenous proteins who are not amenable to chaperone monotherapy. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Enzyme Targeting Technology  </B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The uptake of ERTs into a patient's cells is mediated by a particular carbohydrate called mannose 6-phosphate ("M6P"). M6P enables binding and
delivery of therapeutic drug to lysosomes via M6P receptors on cell surfaces. Many currently approved ERTs have limited amounts of M6P, thereby limiting the uptake of therapeutic drug into a patient's
cells. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are developing novel ERTs, including ERTs with significantly higher amounts of M6P for improved lysosomal targeting compared to existing ERTs. We believe that this technology to
enhance drug targeting, together with our CHART platform to improve enzyme stability, may be utilized to develop a pipeline of more effective next-generation ERTs for LSDs. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-5-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=7,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=393349,FOLIO='5',FILE='DISK124:[17ZAA1.17ZAA47301]DA47301A.;6',USER='VSTEFAN',CD='27-FEB-2017;04:19' -->
<A NAME="page_da47301_1_6"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Migalastat for Fabry Disease  </B></FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Overview  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our most advanced product, migalastat, is a small molecule pharmacological chaperone for the treatment of Fabry disease that has been approved
for use in the European Union ("EU") under the brand name Galafold&#153; as a first-line therapy for long-term treatment of adults and adolescents aged 16&nbsp;years and older with a
confirmed diagnosis of Fabry disease and who have an amenable mutation. Outside of the EU and Switzerland, migalastat is an investigational product. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have launched Galafold in Germany on a commercial basis as well as in select other European markets through reimbursed EAPs. We are currently pursuing the country-by-country pricing
and reimbursement process in the EU member states. We expect to launch Galafold in additional EU member states during 2017 as we secure final pricing and reimbursement. Outside of the EU, Galafold has
been approved in Switzerland and we have regulatory submissions under review in additional territories including Canada and Australia. We are targeting a first half 2017 regulatory submission
(Japanese New Drug Application, or J-NDA) in Japan. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
an orally administered monotherapy, migalastat is designed to bind to and stabilize an endogenous alpha-galactosidase A ("alpha-Gal A") enzyme in those patients with genetic mutations
identified as amenable in a GLP cell-based amenability assay. We are also developing the use of migalastat in combination with a novel Fabry ERT for patients who have non-amenable genetic mutations. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Patients
with the fatal, X-linked Fabry disease have an inherited deficiency of the alpha-Gal A enzyme that would normally degrade the lipid substrate globotriaosylceramide in the
lysosome. Genetic mutations that cause changes in the amino acid sequence of alpha-Gal A result in an unstable enzyme that does not efficiently fold into its correct three-dimensional shape and cannot
be trafficked properly
in the cell, even if it has the potential for biological activity. Migalastat is an oral small molecule pharmacological chaperone that is designed to bind to and stabilize a patient's own endogenous
target protein. This is considered a precision medicine because migalastat targets only patients with amenable mutations. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have completed two Phase&nbsp;3 global registration studies of migalastat monotherapy. We have reported Phase&nbsp;3 data in both treatment-na&iuml;ve patients ("Study
011") and ERT-switch patients ("Study&nbsp;012"). Results from these studies have shown that treatment with migalastat results in reductions in disease substrate, stability of kidney function,
reductions in cardiac mass, and improvement in gastrointestinal symptoms in patients with amenable mutations in a validated GLP amenability assay. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><I> Migalastat in Combination with ERT for Fabry Disease  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For patients with non-amenable mutations, we are leveraging our CHART&#153; technology and advanced biologics capabilities to move
forward with a proprietary Fabry ERT for co-formulation with migalastat. Master cell banking has been completed and process development work has commenced. Migalastat is an oral precision medicine
intended to treat Fabry disease in patients who have amenable genetic mutations, and at this time, it is not intended for concomitant use with ERT. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Clinical Manifestations of Fabry Disease  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fabry disease is an X-linked disease caused by mutations in the </FONT><FONT SIZE=2><I>GLA</I></FONT><FONT SIZE=2> gene, which encodes the
alpha-Gal A enzyme. These mutations can cause alpha-Gal A to be either absent or deficient. When alpha-Gal A is absent or deficient the substrates, GL-3 and lyso-Gb<SUB>3</SUB> accumulate, leading to
damage of cells within affected parts of the individual's body and causing the various pathologies seen in Fabry disease. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-6-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=8,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=797665,FOLIO='6',FILE='DISK124:[17ZAA1.17ZAA47301]DA47301A.;6',USER='VSTEFAN',CD='27-FEB-2017;04:19' -->
<A NAME="page_da47301_1_7"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fabry
disease leads to progressive, irreversible organ damage, typically involving the nervous, cardiac, and renal systems, as well as multiple other tissues. The symptoms can be severe,
differ from patient to
patient, and begin at an early age, resulting in significant clinical, humanistic, and healthcare costs. Fabry disease requires lifelong medical intervention to manage the complications of this
devastating disease across multiple organ systems. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;People
with Fabry disease are generally categorized in a spectrum of disease severity from a classic onset form to a more attenuated, late-onset onset form of the disease. Heterozygous
females can experience a variable presentation, ranging from asymptomatic or mild symptoms, to symptoms that are just as severe as those experienced by male patients. All Fabry disease is progressive
and leads to organ damage regardless of the time of symptom onset. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g878266.jpg" ALT="GRAPHIC" WIDTH="684" HEIGHT="394">
  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;People
with Fabry disease may experience severe symptoms, or seemingly none at all, with a variety of clinical presentations in between. But even when disease presentation is
asymptomatic or mild, disease substrate can accumulate, contributing to long-term damage of organs and tissues. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Organ
damage in Fabry disease is caused by the accumulation of GL-3 and lyso-Gb<SUB>3</SUB> in the cells, leading to dysfunction in affected cells. These deposits can potentially affect
multiple cell types, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Endothelial cells: vascular and neurovascular </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Cardiomyocytes </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Smooth muscle cells </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Neurons within the central and peripheral nervous systems </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Eccrine sweat glands </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Epithelial cells: cornea, lens, airway </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Perithelial cells: small intestine, colon, and rectum </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-7-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=9,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=86304,FOLIO='7',FILE='DISK124:[17ZAA1.17ZAA47301]DA47301A.;6',USER='VSTEFAN',CD='27-FEB-2017;04:19' -->
<A NAME="page_da47301_1_8"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Ganglion cells </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Individuals
with Fabry disease may experience a shorter lifespan compared with the general population. Lifespans for people with Fabry disease may be shortened to approximately
50&nbsp;years for men and 70 for women&nbsp;&#151; 20-, and 10-year reductions, respectively. Cardiovascular disease is the most common cause of death for both men and women. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With
more than 800 known mutations of the </FONT><FONT SIZE=2><I>GLA</I></FONT><FONT SIZE=2> gene, there is no single genotypic cause of Fabry disease. A variety of mutation types can
give rise to Fabry disease, such as missense mutations, splicing mutations, small deletions and insertions, and large deletions. Many genetic mutations are specific to individual families affected by
Fabry disease, whereas some are more widespread. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Fabry Disease Prevalence and Market Opportunity  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fabry disease is a relatively rare disorder. The annual incidence of Fabry disease in newborn males has been estimated to be 1:40,000-1:60,000
(Journal of the American Medical Association January 1999 and The Metabolic and Molecular Bases of Inherited Disease 8th&nbsp;edition 2001). The current estimates of approximately 5,000 patients
worldwide are generally based on a small number of studies in single ethnic populations in which people were screened for classic Fabry disease (University of Iowa, National Kidney Foundation). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Recent
newborn screening studies in Italy, Taiwan, and Austria, which screened more than 263,000 newborns, found the incidence of Fabry disease mutations to be between 1:2,400 to 1:
3,859, more than ten times higher than previous estimates for classic patients. (American Journal of Human Genetics 2006, Human Mutation 2009, and the Lancet 2011). This high incidence was attributed
to a large number of newborn males with alpha-Gal A mutations often associated with late-onset symptoms of Fabry disease, which may not have been identified in previous screening studies that relied
on diagnosis based on development of symptoms of classic Fabry disease. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
also believe that many types of genetic mutations may result in misfolded alpha-Gal A and therefore may also respond to treatment with monotherapy migalastat. Based on this, we
believe that approximately 35-50% of the Fabry disease patient population may benefit from treatment with migalastat as a monotherapy. However, the entire Fabry disease patient population has the
potential to benefit from migalastat in combination with ERT. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
expect that as awareness of late-onset symptoms of Fabry disease grows, the number of patients diagnosed with the disease will increase. Increased awareness of Fabry disease,
particularly for specialists not accustomed to treating Fabry disease patients, may lead to increased testing and diagnosis of patients with the disease. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Existing Products for the Treatment of Fabry Disease  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Currently, two ERT products are approved for the treatment of Fabry disease: agalsidase beta and agalsidase alfa. Agalsidase beta is approved
globally (conditionally in the U.S.) and commercialized by Sanofi Aventis through Genzyme Corporation, while agalsidase alfa is commercialized by Shire and approved in the EU and other countries but
not in the U.S. Orphan drug exclusivity for both agalsidase beta and agalsidase alfa has expired in the EU and for agalsidase beta in the U.S. as well. The net product sales of agalsidase beta and
agalsidase alfa for 2016 were
approximately $747&nbsp;million as publicly reported by Sanofi Aventis, and $453&nbsp;million as publicly reported by Shire, respectively. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> SD-101 for EB  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the fourth quarter of 2015, we expanded our pipeline through the acquisition of SD-101, a proprietary, topical cream for the treatment of the
rare, genetic connective tissue disorder EB. SD-101 has established proof of concept in Phase&nbsp;2 studies for the treatment of lesions in patients suffering </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-8-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=10,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=660779,FOLIO='8',FILE='DISK124:[17ZAA1.17ZAA47301]DA47301A.;6',USER='VSTEFAN',CD='27-FEB-2017;04:19' -->
<A NAME="page_da47301_1_9"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>with
EB and is currently being investigated in a Phase&nbsp;3 study to support global regulatory approvals. Based on promising Phase&nbsp;2 clinical data in EB patients, SD-101 became one of the
first drugs to receive Breakthrough Therapy designation from the FDA in 2013, and was the first treatment in EB clinical studies to show benefit in closure of chronic wounds and acceleration in wound
healing. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SD-101
is a soluble, high concentration, proprietary formulation of allantoin (6%). Allantoin is found in low concentrations (typically &#60;1%) in several over-the-counter
products and cosmetics; however, it is not soluble enough to penetrate the layers of skin affected by EB. SD-101's stable, high-concentration formulation has been shown to penetrate the skin and
enhance wound healing. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With
topical products, the formulation is just as important as the active ingredient in delivering the active medication across the various skin layers, without systemic absorption.
Comprehensive studies to assess dermal penetration of the SD-101 active ingredient at concentrations ranging from 0.5 to 9% were conducted in various skin models. Results from these studies showed
that SD-101 was delivered in a dose-related manner across skin barriers. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
proposed mechanism of action ("MoA") of SD-101 is multifaceted to impact inflammatory response, promote the formation of epithelial and granulation tissue, loosen protein bridges
(desmosomes) that hold together hyperkeratinized cells (e.g.in calluses), and has demonstrated direct bactericidal action </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> (Margraf and Covey
1977; Meixell and Mecca 1966; Settle 1969; Flesch 1958; Fisher 1981; Cajkovac et al., 1992; Medda 1976). </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><I> SD-101 for EB: Phase&nbsp;2 Human Proof of Concept  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Initial human proof of concept for SD-101 was demonstrated in a single-center, open-label, 8-patient Phase&nbsp;2a study in EB patients of all
major EB types, aged six months to nine years. All patients in this study had a target wound at baseline that was at least 10 cm<SUP>2</SUP> in size. In this single-arm study, SD-101 cream
containing SD-101 3% was applied to the entire body once daily for three months. Seven out of eight patients (87.5%) experienced complete closure of their target wound at month one, and a 57%
reduction in affected body surface area by month three. Daily administration of SD-101 3% was generally well-tolerated. Based on these results, SD-101 became one of the first treatments to receive
Breakthrough Therapy designation from the FDA in 2013. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Following
the completion of the Phase&nbsp;2a study and subsequent interactions with the FDA, a Phase&nbsp;2b study (SD-003) was conducted to further investigate SD-101 in 48
patients with all major EB types. The Phase&nbsp;2b study was a multicenter, three-arm study that included an arm with a higher concentration of SD-101 (6%), an arm with the 3% concentration that
was previously evalulated in the Phase&nbsp;2a study, and a placebo arm. Patients with smaller wounds than the ones on patients in the Phase&nbsp;2a study, at least 5 cm<SUP>2</SUP> in size,
were eligible for enrollment. Complete wound healing at month one (primary endpoint) was found for 41% (n=17), 38% (n=16), and 53% (n=15) for placebo, SD-101 3%, and SD-101 6% patients, respectively.
In the month two Intent to Treat ("ITT") population, complete wound healing was found for 41% (n=17), 44% (n=16), and 60% (n=15) for placebo, SD-101 3%, and SD-101 6% patients, respectively. In post
hoc analyses (month two; evaluable population), complete wound healing was found for 41% (n=17) , 44% (n=16), 82% (n=11) of placebo, SD-101 3%, and SD-101 6% patients, respectively (unadjusted p=0.04
for SD 101 6% versus placebo). The treatment effect for SD-101 6% was sustained at month three. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-9-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=11,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=207634,FOLIO='9',FILE='DISK124:[17ZAA1.17ZAA47301]DA47301A.;6',USER='VSTEFAN',CD='27-FEB-2017;04:19' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dc47301_1_10"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g97732.jpg" ALT="GRAPHIC" WIDTH="681" HEIGHT="357">
  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Median time to wound closure, an important secondary endpoint, was 91, 86, and 30&nbsp;days for placebo, SD-101 3%, and SD-101 6% patients, respectively, in the
evaluable population. Treatment-emergent adverse events were similar across treatment groups. No serious adverse events were reported with SD-101 6%. All patients that completed the SD-003 study were
eligible to continue to receive SD-101 6% in the Phase&nbsp;2 open-label extension study (SD-004) which is currently underway. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><I> SD-101 for EB: Phase&nbsp;3 Registration-directed Study (SD-005)  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A Phase&nbsp;3 registration-directed study, SD-005, was initiated in March of 2015. SD-005 is a randomized, double-blind, placebo-controlled
study being conducted at multiple sites worldwide that is designed to evaluate the safety and efficacy of SD-101 6% in up to 150 patients with the four major types of EB, who are at least one-month
old. Participants will be randomized 1:1 to two treatment groups receiving either SD-101 6% or placebo applied over their entire body once daily for three months. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
primary efficacy endpoints will be evaluation of closure of a selected target wound and time to wound closure. In addition, changes in full-body wound, lesion coverage, and
patient/caregiver reported itching and pain will be assessed. Investigators will also assess safety. An open-label extension trial, SD-006, which will evaluate long-term safety, will be offered to
patients completing SD-005. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on the results and experience in the Phase&nbsp;2 studies, we have incorporated key learnings from the Phase&nbsp;2 studies in the design of the Phase&nbsp;3 study to
maximize potential for success: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>1.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B>Dose selection</B></FONT><FONT SIZE=2>: SD-101 6% was identified as the optimal concentration to compare to placebo in Phase&nbsp;3.
Patients will be randomized 1:1 to receive SD-101 6% or placebo;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>2.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B>Sample size of ~150 patients</B></FONT><FONT SIZE=2>: the Phase&nbsp;2b results were used to calculate the sample size for the
Phase&nbsp;3 study. A treatment difference of ~17% or greater between the SD-101 6% arm versus placebo will result in a p-value of &#60;= 0.05; and
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>3.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B>Enrollment of patients with larger wounds (<FONT FACE="SYMBOL">&#179;</FONT> 10 cm<SUP>2</SUP> instead of &gt;= 5
cm<SUP>2</SUP>) and evaluation of primary endpoint at month two (instead of month one) to minimize placebo response</B></FONT><FONT SIZE=2>. In post-hoc analyses in Phase&nbsp;2b (month two;
evaluable population), complete wound healing was </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-10-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=12,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=692971,FOLIO='10',FILE='DISK124:[17ZAA1.17ZAA47301]DC47301A.;11',USER='BEGGER',CD='28-FEB-2017;16:08' -->
<A NAME="page_dc47301_1_11"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>found
for 41% (n=17), 44% (n=16), and 82% (n=11) of placebo patients, SD-101 3%, and SD-101 6%, respectively (nominal p=0.04 for SD 101 6% versus placebo). The placebo response was even lower in the
subset of patients with target wounds <FONT FACE="SYMBOL">&#179;</FONT> 10 cm<SUP>2</SUP> at month two in Phase&nbsp;2b: SD-101 6%&nbsp;- 50% (n= 4)&nbsp;vs.
Placebo&nbsp;&#151; 12.5% (n=8). </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2><I> SD-101 for EB: Regulatory Pathway  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SD-101 was one of the first therapies to receive Breakthrough Therapy designation by the FDA in 2013, following the completion of the
Phase&nbsp;2a initial human proof of concept study. The FDA and EMA each have also reviewed the Phase&nbsp;2b study results. Based on the currently available data and communications with FDA and
EMA, we believe that the global regulatory pathway forward for SD-101 will require a single Phase&nbsp;3 registration-directed study. The FDA agreed to a rolling NDA in the U.S., which was initiated
in the fourth quarter of 2015. Following the Phase&nbsp;2b study, our Paediatric Committee of the EMA has issued a positive opinion on our Paediatric Investigation Plan ("PIP") for SD-101. A PIP is
part of the EMA approval process and must be accepted prior to a submission of an MAA in the EU. Results from the Phase&nbsp;3 study are anticipated in mid-2016 to support marketing applications for
SD-101 in the U.S., EU, and other regions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
held a series of discussions with the Dermatology Division of the U.S. FDA regarding proposed revisions to the statistical analysis plan while remaining blinded to the Phase&nbsp;3
SD-005 study. Based on conversations with FDA and written communication received from the agency, the FDA has agreed to our proposed revisions. Importantly, the FDA agreed that "Time to Target Wound
Closure" may be elevated to a co-primary endpoint. We are currently in the process of finalizing the revised Statistical Analysis Plan ("SAP") with the FDA. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><I> Epidermolysis Bullosa Background  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inherited EB encompasses more than 30 phenotypically or genotypically distinct entities, which share as a common feature mechanical fragility of
epithelial lined or surfaced tissues,
most notably the skin. A characteristic feature of all types of EB is the presence of recurrent blistering or erosions, which is the result of even minor friction. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
are four types of genetically inherited EB:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Simplex (EBS) </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Dystrophic (DEB) </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Junctional (JEB) </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Kindler (an extremely rare form of EB) </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These
four types of EB are similar phenotypically (that is, in what their physical manifestations look like), but differ genotypically (in their genetic makeup) as well as in the area of
the skin where there is blistering, otherwise known as "the site of ultra-structural disruption or cleavage." There is also a rare autoimmune form of the disorder called EB acquisita. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the more severe forms of the disease, blistering can lead to deformities such as fusion of the fingers and toes, secondary skin infections, sepsis, and even death. EB may also affect
the mouth and esophagus, leading to eating and swallowing problems. Serious complications, including squamous cell carcinoma, may occur in EB patients who survive childhood, which results in a high
rate of mortality. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;EBS
accounts for the majority of these cases, with DEB the next most common form. JEB is less prevalent and Kindler is the rarest of the four. These types of EB are defined by the
precise ultra-structural level of the skin, which splits and blisters. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-11-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=13,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=776813,FOLIO='11',FILE='DISK124:[17ZAA1.17ZAA47301]DC47301A.;11',USER='BEGGER',CD='28-FEB-2017;16:08' -->
<A NAME="page_dc47301_1_12"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g657965.jpg" ALT="GRAPHIC" WIDTH="643" HEIGHT="558">
  </B></FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><I> Epidermolysis Bullosa Prevalence and Market Opportunity  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Even as a rare disease, EB presents a significant worldwide commercial opportunity supported by its profound unmet medical need, strong
stakeholder support, and high orphan prevalence. With 30,000-40,000 diagnosed patients in major markets, we estimate that EB may represent a potential $1&nbsp;billion+ global market opportunity
based on third party market research. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Current Standard of Care for the Treatment of EB and Potential Advantages of SD-101  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With no currently approved pharmacological therapies, SD-101 is a potential first-to-market therapy for EB. The current methods of care are
palliative. Current standard of care is high-cost treatment with significant patient/caregiver burden, which includes: bandaging, treating the open wounds to prevent infection, and trying to manage
patients' pain. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-12-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=14,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=981297,FOLIO='12',FILE='DISK124:[17ZAA1.17ZAA47301]DC47301A.;11',USER='BEGGER',CD='28-FEB-2017;16:08' -->
<A NAME="page_dc47301_1_13"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><I> EB Development Landscape  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SD-101 is the first investigational pharmaceutical therapy for EB to enter Phase&nbsp;3 clinical studies and is the one of the few therapies
in development to address all major types of EB. Several therapies across treatment modalities are in earlier stages of development and focused on addressing specific types of the disease. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Novel ERT for Pompe Disease  </B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are leveraging our biologics capabilities and CHART&#153; platform to develop a novel treatment paradigm for Pompe disease. This ERT
consists of a uniquely engineered rhGAA enzyme, ATB200, with an optimized carbohydrate structure to enhance uptake, administered in combination with a pharmacological chaperone to improve activity and
stability. We acquired ATB200 as well as our enzyme targeting technology through our purchase of Callidus Biopharma. The novel combination has been patented for method of use and ATB200, following
significant manufacturing scale-up, is our first biologic to enter clinical development. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
preclinical studies, ATB200 demonstrated greater tissue enzyme levels and further substrate reduction compared to the currently approved ERT for Pompe disease (alglucosidase alfa),
which were further improved with the addition of a chaperone. In 2013, we completed a Phase&nbsp;2 safety and pharmacokinetics study (Study 010) that investigated single, ascending oral doses of a
pharmacological chaperone co-administered with alglucosidase alfa or rhGAA enzyme marketed by Genzyme, in patients with Pompe disease. Each patient received one infusion of ERT alone, and then a
single oral dose of the pharmacological chaperone just prior to the next ERT infusion. Results from this study showed an increase in acid alpha glucosidase ("GAA") enzyme activity in plasma and muscle
when co-administered compared to ERT alone. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
pharmacological chaperone, AT2221 is not an active ingredient that contributes directly to GAA substrate reduction but instead acts to stabilize ATB200. The small molecule
pharmacological chaperone AT2221 binds and stabilizes ATB200 to improve the uptake of active enzyme in key disease-relevant tissues, resulting in increased clearance of accumulated substrate,
glycogen. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are currently conducting a Phase&nbsp;1/2 clinical study ATB200-02 to investigate our novel Pompe treatment paradigm in Pompe patients. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


<U>ATB200-02 Clinical Study&nbsp;&#151; Design and Objectives</U> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Primary
objectives: to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ATB200/AT2221 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Study
duration: 18-week primary treatment period followed by a long-term extension </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Patient
cohorts: ambulatory ERT-switch patients (Cohort 1), non-ambulatory ERT-switch patients (Cohort 2)&nbsp;and ERT-na&iuml;ve patients (Cohort 3). Enrolling up to ~20
total patients across all cohorts. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Preliminary
data now available:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Safety data for 13 patients through interim data analysis (maximum 36&nbsp;weeks) </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> PK and PD (muscle biomarker and disease substrate biomarker) data for 10 patients (eight ERT-switch patients and two na&iuml;ve
patients) </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-13-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=15,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=118370,FOLIO='13',FILE='DISK124:[17ZAA1.17ZAA47301]DC47301A.;11',USER='BEGGER',CD='28-FEB-2017;16:08' -->
<A NAME="page_dc47301_1_14"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


ATB200-02 Study&nbsp;&#151; Preliminary Data Highlights in Initial ERT-Switch and Naive
Patients  </B></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> ATB200/AT2221 safety measures (n=13) showed: </FONT> <FONT SIZE=2>
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> No serious adverse events (SAEs)  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> TEAEs were generally mild and transient </FONT><FONT SIZE=2>
<BR><BR></FONT></DD></DL>
</DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> To date, ATB200/AT2221 has shown no infusion-associated reactions following 150+ infusions </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Clinical PK profile was consistent with previously reported preclinical data (n=10). </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Reductions observed in biomarkers of muscle damage (creatine kinase (CK) enzyme, alanine aminotransferase (ALT), and aspartate aminotransferase
(AST)) in ambulatory switch patients (N=8, week 18)&nbsp;and na&iuml;ve patients (N=2, week 4) </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Reduction observed in a biomarker of glycogen substrate&nbsp;&#151; Urine Hexose Tetrasaccharide (Hex4)&nbsp;&#151; in all
eight ERT-switch patients and both na&iuml;ve patients </FONT></DD></DL>


<P style="font-family:times;"><FONT SIZE=2><B><I> Pompe Disease Background  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Like Fabry disease, Pompe disease is an LSD that results from a deficiency in an enzyme, GAA. Signs and symptoms of Pompe disease can be severe
and debilitating and include progressive muscle weakness throughout the body, particularly the heart and skeletal muscles. This leads to accumulation of glycogen in cells, which is believed to result
in the clinical manifestations of Pompe disease. Pompe disease ranges from a rapidly fatal infantile form with severe cardiac involvement to a more slowly progressive, late-onset form primarily
affecting skeletal muscle. All forms are characterized by severe muscle weakness that worsens over time. In the early-onset form, patients are usually diagnosed shortly after birth and often
experience enlargement of the heart and severe muscle weakness. In late-onset Pompe disease, symptoms may not appear until late childhood or adulthood and patients often experience progressive muscle
weakness. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;According
to reported estimates of the Acid Maltase Deficiency Association, the United Pompe Foundation, and the Lysosomal Disease Program at Massachusetts General Hospital, there are
5,000-10,000 patients with Pompe disease worldwide. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> CDKL5  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are researching a potential first-in-class protein replacement therapy approach for CDKL5 deficiency in preclinical studies. CDKL5
(cyclin-dependent kinase-like 5)&nbsp;is a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of several essential proteins for normal brain development. Genetic
mutations in the CDKL5 gene result in CDKL5 protein deficiency and the disorder manifests clinically as persistent seizures starting in infancy, followed by severe impairment in neurological
development. Most children affected by CDKL5 deficiency cannot walk or care for themselves and may also suffer from scoliosis, visual impairment, sensory issues, and gastrointestinal complications. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-14-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=16,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=696436,FOLIO='14',FILE='DISK124:[17ZAA1.17ZAA47301]DC47301A.;11',USER='BEGGER',CD='28-FEB-2017;16:08' -->
<A NAME="page_dc47301_1_15"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Acquisitions  </B></FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><I> MiaMed, Inc  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In July 2016, we acquired MiaMed,&nbsp;Inc., ("MiaMed"), which is a pre-clinical biotechnology company focused on developing protein
replacement therapy for CDKL5 and related diseases. Upon closing of the transaction we paid the former holders of MiaMed's capital stock an aggregate of $6.5&nbsp;million, comprised of
(i)&nbsp;approximately $1.8&nbsp;million in cash (plus MiaMed's cash and cash equivalents at closing and less any of MiaMed's unpaid third-party fees and expenses related to the transaction), and
(ii)&nbsp;825,603 shares of our Company's common stock. In addition, we also agreed to pay up to an additional $83.0&nbsp;million in connection with the achievement of certain clinical, regulatory
and commercial milestones, for a potential aggregate deal value of $89.5&nbsp;million. We accounted for this transaction as an acquisition of an asset as we did not acquire any employees from MiaMed
nor did we acquire any significant processes that we did not previously perform or manage. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><I> Scioderm,&nbsp;Inc.  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In September 2015, we entered into a merger agreement with Scioderm&nbsp;Inc., a privately held biotechnology company that was engaged in
developing innovative therapies for treating diseases with high unmet medical needs including a novel topical cream for the treatment of EB. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
acquired Scioderm in a cash and stock transaction. At closing, the Company paid Scioderm shareholders, option holders, and warrant holders approximately $223.9&nbsp;million, of
which approximately $141.1&nbsp;million was paid in cash and approximately $82.8&nbsp;million was paid through the issuance of approximately 5.9&nbsp;million newly issued Amicus shares. We
agreed to pay up to an additional $361&nbsp;million to Scioderm shareholders, option holders, and warrant holders upon achievement of certain clinical and regulatory milestones and
$257&nbsp;million to Scioderm shareholders, option holders, and warrant holders upon achievement of certain sales milestones. If SD-101 is approved, EB may qualify as a rare pediatric disease under
the Food and Drug Administration Safety and Innovation Act ("FDASIA") and we plan to request a Priority Review Voucher ("PRV") under FDASIA. If the PRV is obtained and subsequently sold, we will pay
Scioderm stockholders, option holders, and warrant holders the lesser of $100&nbsp;million in the aggregate or 50% of the proceeds of such sale. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the second quarter of 2016, we reached the first event-based milestone, which was the 50% enrollment of patients. The milestone payment for this event was $5.0&nbsp;million
which was paid in cash during the second quarter of 2016. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><I> Callidus Biopharma,&nbsp;Inc.  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In November 2013, we entered into a merger agreement with Callidus, a privately held biotechnology company that was engaged in developing a
next-generation Pompe ERT. Callidus did not have complementary technologies but their technology was complementary to our own pharmacological chaperone technology. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
connection with our acquisition of Callidus, we agreed to issue an aggregate of 7.2&nbsp;million shares of our common stock to the former stockholders of Callidus. In addition, we
will be obligated to make additional payments to the former stockholders of Callidus upon the achievement of certain clinical milestones of up to $35&nbsp;million and regulatory milestones of up to
$105&nbsp;million set forth in the merger agreement, provided that the aggregate merger consideration shall not exceed $130&nbsp;million. We may, at our election, satisfy certain milestone
payments identified in the merger agreement aggregating $40&nbsp;million in shares of our common stock. The milestone payments not permitted to be satisfied in common stock (as well as any payments
that we are permitted to, but chooses not to, satisfy in common stock), as a result of the terms of the merger agreement, will be paid in cash. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-15-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=17,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=611127,FOLIO='15',FILE='DISK124:[17ZAA1.17ZAA47301]DC47301A.;11',USER='BEGGER',CD='28-FEB-2017;16:08' -->
<A NAME="page_dc47301_1_16"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the second quarter of 2016, we reached the first clinical milestone, which was the dosing of the first patient in a Phase&nbsp;1 or 2 study. The milestone payment for this event
was $6.0&nbsp;million, which was paid in common stock of the Company, during the second quarter of 2016. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Strategic Alliances and Arrangements  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In November 2013, we entered into a Revised Agreement ("the Revised Agreement") with GlaxoSmithKline ("GSK"), pursuant to which, we obtained
global rights to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease. The
Revised Agreement amends and replaces in its entirety the earlier agreement entered into between us and GSK in July 2012. Under the terms of the Revised Agreement, for migalastat monotherapy, GSK is
eligible to receive post-approval and sales-based milestones, as well as tiered royalties in the mid-teens in eight major markets outside the U.S. There was no other consideration paid to GSK as part
of the Revised Agreement. In the second half of 2016, we recognized approximately $0.5&nbsp;million of royalty expense under the Revised Agreement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will continue to evaluate other business development opportunities as appropriate that build stockholder value and provide us with access to the financial, technical, clinical, and
commercial resources necessary to develop and market pharmacological chaperone therapeutics, ERTs, skin treatments, and other technologies or products. We are exploring potential collaborations,
alliances, and other business development opportunities on a regular basis. These opportunities may include the acquisition of preclinical-stage, clinical-stage, or marketed products so long as such
transactions are consistent with our strategic plan to develop and provide therapies to patients living with rare and orphan diseases, and support our continued transformation from a development-stage
company into a commercial biotechnology company. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Intellectual Property  </B></FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Patents and Trade Secrets  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our success depends in part on our ability to maintain proprietary protection surrounding our product candidates, technology, and know-how, to
operate without infringing the proprietary rights of others, and to prevent others from infringing our proprietary rights. Our policy is to seek to protect our proprietary position by filing U.S. and
foreign patent applications related to our proprietary technology, including both new inventions and improvements of existing technology, that are important to the development of our business, unless
this proprietary position would be better protected using trade secrets. Our patent strategy includes obtaining patent protection, where possible, on compositions of matter, methods of manufacture,
methods of use, combination therapies, dosing and administration regimens, formulations, therapeutic monitoring, screening methods, and assays. We also rely on trade secrets, know-how, continuing
technological innovation, in-licensing, and partnership opportunities to develop and maintain our proprietary position. Lastly, we monitor third parties for activities that may infringe our
proprietary rights, as well as the progression of third party patent applications that may have the potential to create blocks to our products or otherwise interfere with the development of our
business. We are aware, for example, of U.S. patents, and corresponding international counterparts, owned by third parties that contain claims related to ERTs, small molecules for stabilizing enzymes,
and therapies for EB. If any of these patents were to be asserted against us we do not believe that our proposed products would be found to infringe any valid claim of these patents.
There is no assurance that a court would find in our favor or that, if we choose or are required to seek a license, a license to any of these patents would be available to us on acceptable terms or at
all. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-16-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=18,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=510866,FOLIO='16',FILE='DISK124:[17ZAA1.17ZAA47301]DC47301A.;11',USER='BEGGER',CD='28-FEB-2017;16:08' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_de47301_1_17"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We own or license rights to several issued patents in the U.S., current member states of the European Patent Convention and numerous pending and issued foreign
applications, which are foreign counterparts of many of our U.S. patents. We also own or license rights to several pending U.S. applications. Our patent portfolio includes patents and patent
applications with claims relating to methods of increasing and/or stabilizing deficient enzyme activity to treat genetic diseases. The patent positions for migalastat, SD-101, and ATB200/AT2221
pharmacological chaperone/ERT combination therapy are described below and include both patents and patent applications we own or exclusively license:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We have an exclusive license to six issued U.S. patents that cover the use of migalastat to treat Fabry disease, as well as corresponding
European, Japanese, and Canadian patents. These exclusively licensed U.S. patents relating to migalastat expire in 2018 (not including the Hatch-Waxman statutory extension, which is described below),
while the European, Japanese, and Canadian patents will expire in 2019 (not including the Supplemental Protection Certificates or SPC extensions, which are described below). The patents include claims
covering methods of increasing the activity of and preventing the degradation of alpha-Gal A, and methods for the treatment of Fabry disease using migalastat. In addition, we own two issued U.S.
patents directed to dosing regimens with migalastat that expire in 2027 (not including any extensions), as well as a pending application which, if granted, may result in a patent that also expires in
2027 (not including any extensions). Foreign counterpart patents are issued in Australia, Europe, Hong Kong, and Japan, and foreign applications are pending in Australia, Canada, Europe, Hong Kong,
Japan, and Mexico. Further, we own an issued U.S. patent directed to synthetic steps related to the commercial process for preparing migalastat, which expires in 2026, as well as issued patents in
China, Europe, Hong Kong, Israel, and Japan. Foreign counterpart applications are pending in Brazil and India. We jointly own issued U.S., European, Hong Kong, and Mexican patents covering a method of
determining whether male Fabry disease patients are likely to respond to treatment with migalastat which expires in 2027. We have two issued U.S. patents covering a method of treating a patient
diagnosed with Fabry disease with migalastat wherein the Fabry patient has one of several alpha-Gal A mutations. These patents will expire in 2029. We also have a pending U.S. application covering a
method of determining which alpha-Gal A mutations are likely to be amenable to therapy with migalastat which, if granted, will expire in 2029. Foreign counterpart patents have also been issued in
Europe, Japan, Canada, Mexico, and Australia; all of which will also expire in 2029. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We have an exclusive license to pending patent applications covering the co-administration of migalastat with ERT (recombinant alpha-Gal A).
Patents covering specific combinations have issued in Europe, China, India, Hong Kong, Japan, and Mexico. These issued patents will expire in 2024. Other applications from this family are pending in
the U.S., Europe, Canada, Brazil, China, Hong Kong, India, Israel, Japan, and Mexico. If patents issue from these applications, expiration will be in 2024. We also own a U.S. patent application
covering specific doses and dosing regimens of migalastat to treat Fabry disease in combination with ERT (recombinant alpha-Gal A)&nbsp;in the U.S. and foreign counterpart applications in Australia,
Brazil, Canada, China, Eurasia, Europe, Hong Kong, Israel, India, Japan, South Korea, Mexico, Singapore, Taiwan, and South Africa, and issued patents in Australia and New Zealand. Any patents issuing
from these applications will expire in 2032. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We own two issued U.S. patents covering a high concentration co-formulation of recombinant acid alpha-glucosidase and pharmacological
chaperone, as well as pending patent applications in the U.S., Canada, Europe, Japan, Mexico, and South Korea. If patents issue from these applications, expiration will be in 2033. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-17-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=19,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=497702,FOLIO='17',FILE='DISK124:[17ZAA1.17ZAA47301]DE47301A.;8',USER='VSTEFAN',CD='27-FEB-2017;04:19' -->
<A NAME="page_de47301_1_18"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We own a U.S. patent application covering a co-formulation of recombinant alpha-Gal A and migalastat. If a patent issues from this application,
expiration will be in 2033. Foreign counterpart applications are pending in Canada, Europe, Hong Kong, and Taiwan. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> As part of the Callidus acquisition, we acquired a portfolio of patent applications including an application series covering reagents and
methods for coupling targeting peptides to recombinant lysosomal enzymes, including recombinant acid alpha-glucosidase. These applications are pending in the U.S., Europe, Japan, Brazil, Canada,
China, South Korea, and other countries. If patents issue from these applications, expiration will be in 2032 to 2034 depending on the specific application. Another patent application series covers a
variant recombinant beta-glucocerebrosidase. This series has issued patents in the U.S., Europe, and China, as well as pending applications in the U.S., Europe, Japan, Brazil, Canada, China, Hong
Kong, and South Korea. Any patents that issue from these applications will expire in 2031. Yet another patent application series covers novel signal sequences to improve protein expression and
secretion of proteins. We have issued patents in the U.S. and China, as well as pending applications in Europe, Brazil, Canada, Hong Kong, and South Korea. If patents issue from these applications,
expiration will be in 2031. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Another patent application portfolio focuses on a modified lysosomal enzyme (acid alpha-glucosidase) that binds more effectively to the
receptor and more potent than conventional recombinant enzymes. This is pending in the U.S., Argentina, and Taiwan currently with options to file in a number of other countries in the future. If
patents issue from this series, they will expire in 2035. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> As part of the Scioderm,&nbsp;Inc. acquisition, we acquired several U.S. patents and patent applications which cover the novel formulation of
SD-101, its method of use to treat EB, and a flexible applicator for applying SD-101. Expiration of these patents and patent applications, if and when the applications issue, will be in 2019 (not
including patent term extensions). Patent applications covering the novel formulation of SD-101 are pending in Europe and issued in Mexico. There are other patents and applications covering more
specific formulations of SD-101 and indications other than EB. Expiration of these patents and patent applications, if and when the applications issue, will be in 2031. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> As part of the acquisition of MiaMed, we acquired an exclusive worldwide license to certain patent rights held by the Universit&agrave;
di Bologna. These patent rights include an issued U.S. patent and a pending U.S. patent application directed to novel CDKL5 fusion proteins, as well as pending counterpart patent applications in
several foreign countries. Expiration of the issued U.S. patent and the patent applications, if and when the applications issue, will be in 2035. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Individual
patents extend for varying periods depending on the effective date of filing of the patent application or the date of patent issuance, and the legal term of the patents in the
countries in which they are obtained. Generally, patents issued in the U.S. are effective for:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The longer of 17&nbsp;years from the issue date or 20&nbsp;years from the earliest effective filing date, if the patent application was
filed prior to June&nbsp;8, 1995; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 20&nbsp;years from the earliest effective filing date, if the patent application was filed on or after June&nbsp;8, 1995. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
term of foreign patents varies in accordance with provisions of applicable local law, but typically is 20&nbsp;years from the earliest effective filing date. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
U.S. Drug Price Competition and Patent Term Restoration Act of 1984, and amendments thereto, more commonly known as the Hatch-Waxman Act, provides for an extension of one patent,
known as a Hatch-Waxman statutory extension, for each New Chemical Entity ("NCE") to compensate </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-18-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=20,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=153460,FOLIO='18',FILE='DISK124:[17ZAA1.17ZAA47301]DE47301A.;8',USER='VSTEFAN',CD='27-FEB-2017;04:19' -->
<A NAME="page_de47301_1_19"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>for
a portion of the time spent in clinical development and regulatory review. However, the maximum extension is five years and the extension cannot extend the patent beyond 14&nbsp;years from NDA
approval. Similar extensions are available in European countries, known as SPC extensions, Japan and other countries. However, in the United States we will not know what, if any, extensions are
available until a drug is approved. In addition, in the U.S., under provisions of the Best Pharmaceuticals for Children Act, we may be entitled to an additional six month period of patent protection
Market Exclusivity and Orphan Drug Exclusivity, for completing pediatric clinical studies in response to an FDA issued Pediatric Written Request before said exclusivities expire. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
patent positions of companies like ours are generally uncertain and involve complex legal, technical, scientific, and factual questions. Our ability to maintain and solidify our
proprietary position for our technology will depend on our success in promptly filing patent applications on new discoveries, and in obtaining effective claims and enforcing those claims once granted.
We focus special attention on filing patent applications for formulations and delivery regimens for our products in development to further enhance our patent exclusivity for those products. We seek to
protect our proprietary technology and processes, in part, by contracting with our employees, collaborators, scientific advisors, and our commercial consultants to ensure that any inventions resulting
from the relationship are disclosed promptly, maintained in confidence until a patent application is filed, and preferably until publication of the patent application, and assigned to us or subject to
a right to obtain a license. We do not know whether any of our owned patent applications or those patent applications that are licensed to us will result in the issuance of any patents. Our issued
patents and those that may issue in the future, or those licensed to us, may be challenged, narrowed, invalidated, circumvented, or be found to be invalid or unenforceable, which could limit our
ability to stop competitors from marketing related products and reduce the term of patent protection that we may have for our products. Neither we nor our licensors can be certain that we were the
first to invent the inventions claimed in our owned or licensed patents or patent applications. In addition, our competitors may independently develop similar technologies or duplicate any technology
developed by us and the rights granted under any issued patents may not provide us with any meaningful competitive advantages against these competitors. Furthermore, because of the extensive time
required for development, testing, and regulatory review of a potential product, it is possible that any related patent may expire prior to or shortly after commencing commercialization, thereby
reducing the advantage of the patent to our business and products. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may rely, in some circumstances, on trade secrets to protect our technology. However, trade secrets are difficult to protect. We seek to protect our trade secret technology and
processes, in part, by entering into confidentiality agreements with commercial partners, collaborators, employees, consultants, scientific advisors, and other contractors, and by contracting with our
employees and some of our commercial consultants to ensure that any trade secrets resulting from such employment or consulting are owned by us. We also seek to preserve the integrity and
confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in
these individuals, organizations, and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise
become known or be discovered
independently by others. To the extent that our consultants, contractors, or collaborators use intellectual property owned by others in their work for us, disputes may arise as to the rights in
related or resulting know-how and inventions. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-19-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=21,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=877764,FOLIO='19',FILE='DISK124:[17ZAA1.17ZAA47301]DE47301A.;8',USER='VSTEFAN',CD='27-FEB-2017;04:19' -->
<A NAME="page_de47301_1_20"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> License Agreements  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have acquired rights to develop and commercialize our product candidates through licenses granted by various parties. For information
regarding our migalastat collaboration with GSK, please see "Strategic Alliances and Arrangements". For our other license agreements, the following summarizes our material rights and obligations under
those licenses: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><I> Mt. Sinai School of Medicine  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have acquired exclusive worldwide patent rights to develop and commercialize migalastat and other pharmacological chaperones for the
prevention or treatment of human diseases or clinical conditions by increasing the activity of wild-type and mutant enzymes pursuant to a license agreement with Mt. Sinai School of Medicine ("MSSM")
of New York University. Under this agreement, to date, we have paid no upfront or annual license fees and we have no milestone or future payments other than royalties on net sales. This agreement
expires upon expiration of the last of the licensed patent rights, which will be in 2019, subject to any patent term extension that may be granted, or 2024 if we develop a product for combination
therapy (pharmacological chaperone plus/ERT) and a patent issues from the pending application covering the combination therapy, subject to any patent term extension that may be granted. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
our license agreements, if we owe royalties on net sales for one of our products to more than one of the above licensors, then we have the right to reduce the royalties owed to one
licensor for royalties paid to another. The amount of royalties to be offset is generally limited in each license and can vary under each agreement. For migalastat in 2016, we incurred
$0.1&nbsp;million of royalty expense under the agreement with MSSM. Our rights with respect to these agreements to develop and commercialize migalastat may terminate, in whole or in part, if we fail
to meet certain development or commercialization requirements or if we do not meet our obligations to make royalty payments. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Trademarks  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition to our patents and trade secrets, we own certain trademarks in the U.S. and/or abroad, including Amicus Therapeutics&reg;
and design, Amicus Assist&#153; and design, CHART&#153; and design, At the Forefront of Therapies for Rare and Orphan Diseases&reg;, Zorblisa&reg; and design, and
Galafold&#153; and design. These trademarks are registered or filed with the U.S. Patent and Trademark Office and corresponding government agencies in a number of other countries. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Manufacturing  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We continue to rely on contract manufacturers to supply the active biopharmaceutical ingredients and final drug product for migalastat, SD-101,
other pharmacological chaperones, and our next-generation ERT product candidates. The active biopharmaceutical ingredients and final formulations for these products are manufactured under current Good
Manufacturing Practice ("cGMP"). The components in the final formulation for each product are commonly used in other biopharmaceutical products and are well characterized ingredients. We have
implemented appropriate controls for assuring the quality of both active biopharmaceutical ingredients and final drug products. Product specifications will be established in concurrence with
regulatory bodies at the time of product registration. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-20-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=22,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=780574,FOLIO='20',FILE='DISK124:[17ZAA1.17ZAA47301]DE47301A.;8',USER='VSTEFAN',CD='27-FEB-2017;04:19' -->
<A NAME="page_de47301_1_21"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Competition </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Overview  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis
on proprietary products. In addition, several large pharmaceutical companies are increasingly focused on developing therapies for the treatment of rare diseases, both through organic growth and
acquisitions and partnerships. While we believe that our technologies, knowledge, experience, and scientific resources, provide us with competitive advantages, we face potential competition from many
different sources, including commercial enterprises, academic institutions, government agencies, and private and public research institutions. Any product candidates that we successfully develop and
commercialize will compete with both existing and new therapies that may become available in the future. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Many
of our competitors may have significantly greater financial resources and expertise associated with research and development, regulatory approvals, and marketing approved products.
These competitors also compete with us in recruiting and retaining qualified scientific and management personnel, as well as in acquiring technologies complementary to, or necessary for, our programs.
Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
commercial opportunities could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer side effects, are more
convenient, and/or are less expensive than products that we may develop. In addition, our ability to compete may be affected because in some cases insurers or other third party payors seek to
encourage the use of generic products. This may have the effect of making branded products less attractive to buyers. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Major Competitors  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our major competitors include pharmaceutical and biotechnology companies in the U.S. and abroad that have approved therapies or therapies in
development for LSDs or EB. Other competitors are pharmaceutical and biotechnology companies that have approved therapies or therapies in development for rare diseases for which pharmacological
chaperone technology, topical EB skin treatment, or next-generation ERT may be applicable. Additionally, we are aware of several early-stage, niche pharmaceutical and biotechnology companies whose
core business revolves around protein misfolding; however, we are not aware that any of these companies is currently working to develop products that would directly compete with ours. We are also
aware of several pharmaceutical and biotechnology companies who are developing various treatments for EB, and ones that are developing novel ERTs. The key competitive factors affecting the success of
our product candidates are likely to be their efficacy, safety, convenience, and price. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. The following table
lists our </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-21-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=23,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=596589,FOLIO='21',FILE='DISK124:[17ZAA1.17ZAA47301]DE47301A.;8',USER='VSTEFAN',CD='27-FEB-2017;04:19' -->
<A NAME="page_de47301_1_22"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>principal
competitors and publicly available information on the status of their clinical-stage product offerings (U.S. dollars in millions): </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="101pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="115pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="93pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Competitor

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Indication </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Product </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Class of Product </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Status </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 Sales </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>in millions</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=1><B>Sanofi Aventis:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>Fabry disease</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Fabrazyme&reg;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>ERT</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Marketed</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>747</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>Pompe disease</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Myozyme&reg;/ Lumizyme&reg;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>ERT</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Marketed</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>803</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>Fabry disease</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>GZ402671</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Oral GCS Inhibitor</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Phase&nbsp;2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>N/A</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>Pompe disease</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>GZ402666 ("neo GAA")</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>ERT</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Phase&nbsp;3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>N/A</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>Shire:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Fabry disease</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Replagal&reg;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>ERT</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Marketed</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
453</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>Epidermolysis Bullosa (DEB Only)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>SHP608</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Gene Therapy / Type&nbsp;VII Collagen</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Preclinical</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>N/A</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=1><B>Protalix Biotherapeutics</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Fabry disease</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>PRX-102</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>ERT</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Phase&nbsp;2/3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
N/A</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>RegeneRx Biopharmaceuticals, Inc</B></FONT><FONT SIZE=1>.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Epidermolysis Bullosa (JEB&nbsp;&amp; DEB)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>RGN-137</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>T&szlig;4 Topical Gel</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Phase&nbsp;2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
N/A</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=1><B>Intercytex&nbsp;Ltd</B></FONT><FONT SIZE=1>.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Epidermolysis Bullosa (RDEB Only)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>ICX-RHY</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Cell Therapy</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Phase&nbsp;2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
N/A</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>Amryt</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Epidermolysis Bullosa (All types)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Oleogel S10</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Herbal Medicine / Triterpene</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Phase&nbsp;3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
N/A</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=1><B>Castle Creek Pharma</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Epidermolysis Bullosa (Simplex only)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Diacerin</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Topical</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Phase&nbsp;2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
N/A</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>Fibrocell</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Epidermolysis Bullosa (RDEB Only)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>FCX-007</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Gene Therapy / Type&nbsp;VII Collagen</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Preclinical</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
N/A</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=1><B>InMed Pharmaceuticals&nbsp;Ltd</B></FONT><FONT SIZE=1>.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Epidermolysis Bullosa (EBS Only)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>INM-750</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Phytocannabinoids Topical Formulation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Phase&nbsp;1/2a</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
N/A</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>Abeona Pharmaceuticals</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Epidermolysis Bullosa (RDEB Only)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>EB-101 (LZRSE-COL7A1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Gene Therapy</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Phase&nbsp;1/2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
N/A</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>Epidermolysis Bullosa (All types)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>EB-201 (AAV-DJCOL7A1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Gene Editing</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Preclinical</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>N/A</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=1><B>Audentes</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Pompe Disease</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>AT982</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Gene Therapy</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Preclinical</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
N/A</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-22-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=24,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=977671,FOLIO='22',FILE='DISK124:[17ZAA1.17ZAA47301]DE47301A.;8',USER='VSTEFAN',CD='27-FEB-2017;04:19' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dg47301_1_23"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Government Regulation  </B></FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> FDA Approval Process  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the U.S., biopharmaceutical products are subject to extensive regulation by the FDA. The Federal Food, Drug, and Cosmetic Act, Public Health
Services Act, and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion
and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of biopharmaceutical
products. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as FDA refusal to file&nbsp;a marketing application, to
issue Complete Response letters or to not approve pending new drug applications (NDAs) or biologic product license applications ("BLAs"), or to issue warning letters, product recalls, product
seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties, litigation, government investigation, and criminal prosecution. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Biopharmaceutical
product development in the U.S. typically involves nonclinical laboratory and animal tests, the submission to the FDA of an Investigational New Drug application
("IND"), which must become effective before clinical testing may commence, and adequate and well-controlled clinical trials to establish the safety and effectiveness of the drug for each indication
for which FDA approval is sought. Satisfaction of FDA pre-market approval requirements typically takes many years and the actual time required varies substantially based upon the type, complexity, and
novelty of the product or disease. Preclinical tests include laboratory evaluation of product chemistry, formulation, and toxicity, as well as animal studies to assess the characteristics, potential
safety, and efficacy of the product. The conduct of the preclinical tests must comply with federal regulations and requirements including Good Laboratory Practice ("GLP"). The results of preclinical
testing are submitted to the FDA as part of an IND along with other information including information about product chemistry, manufacturing and controls, and at least one proposed clinical trial
protocol. Long-term preclinical safety evaluations, such as animal tests of reproductive toxicity and carcinogenicity, continue during the IND phase of development. Reproductive toxicity studies are
required to allow inclusion of women of child bearing potential in clinical trials, whereas carcinogenicity studies are required for registration. The results of these long-term studies would
eventually be described in product labeling. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
30-day review period after the submission and receipt of an IND is required prior to the commencement of clinical testing in humans. The IND becomes effective 30&nbsp;days after its
receipt by the FDA, and trials may begin at that point unless the FDA notifies the sponsor that the investigations are subject to a clinical hold. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clinical
trials usually involve the administration of the investigational new drug to healthy volunteers or patients under the supervision of a qualified investigator. Clinical trials
must be conducted in compliance with applicable government regulations, Good Clinical Practice ("GCP"), as well as under protocols detailing the objectives of the trial, the parameters to be used in
monitoring safety, and the effectiveness criteria to be evaluated. Each protocol involving testing on U.S. patients and subsequent protocol amendments must be submitted to the FDA as part of the IND. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA may order the temporary or permanent discontinuation of a clinical trial at any time or impose other sanctions if it believes that the clinical trial is not being conducted in
accordance with FDA requirements or presents an unacceptable risk to the clinical trial patients. The study protocol and informed consent information for patients in clinical trials must also be
submitted to an Institutional Review Board ("IRB"), for approval. An IRB may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the
IRB's requirements, or may impose other conditions. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-23-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=25,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=211769,FOLIO='23',FILE='DISK124:[17ZAA1.17ZAA47301]DG47301A.;7',USER='VSTEFAN',CD='27-FEB-2017;04:19' -->
<A NAME="page_dg47301_1_24"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clinical
trials to support an NDA or BLA for marketing approval are typically conducted in three sequential phases, but the phases may overlap. In Phase&nbsp;1, the initial
introduction of the drug into healthy human subjects or patients, the drug is tested to assess metabolism, pharmacokinetics, pharmacological actions, side effects associated with increasing doses,
and, if possible, early evidence on pharmacodynamics effects and effectiveness. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Phase&nbsp;2
usually involves trials in a limited patient population to determine the effectiveness of the drug for a particular indication or indications, dosage tolerance, and
optimum dosage, and identify common adverse effects and safety risks. If a compound demonstrates evidence of efficacy and an acceptable safety profile in Phase&nbsp;2 evaluations, Phase&nbsp;3
trials are undertaken to obtain the additional information about clinical efficacy and safety in a larger number of patients over longer treatment periods, typically at geographically dispersed
clinical trial sites, to permit the FDA to evaluate the overall benefit-risk relationship of the drug and to provide adequate information for the labeling of the drug. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;After
completion of the required clinical testing, an NDA or BLA is prepared and submitted to the FDA for the determination of effectiveness. FDA approval of the NDA or BLA is required
before marketing of the product may begin in the U.S. The NDA or BLA must include the results of all preclinical, clinical, and other testing and a compilation of data relating to the product's
pharmacology, chemistry, manufacture, and controls. The cost of preparing and submitting an NDA or BLA is substantial. Under federal law, the submission of most NDAs and BLAs is additionally subject
to a substantial application user fee; although for orphan drugs these fees are waived, and the holder of an approved NDA or BLA may also be subject to annual product and establishment user fees.
These fees are typically increased annually. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA has 60&nbsp;days from its receipt of an NDA or BLA to determine whether the application will be accepted for filing based on the agency's threshold determination that it is
sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins an in-depth review. The FDA has agreed to certain performance goals in the review of
NDAs. Marketing applications are assigned review status during the filing period. Review status could be either standard or priority. Most such applications for standard review are reviewed within
12&nbsp;months under PDUFA V (two months for filing plus ten months for review). The FDA attempts to review a drug candidate that is eligible for priority review within six months, as discussed
below. The review process may be extended by the FDA for three additional months to evaluate major amendments submitted during the pre-specified PDUFA V review clock. The FDA may also refer
applications for novel drug products or drug products which present difficult questions of safety or efficacy to an Advisory Committee for public review, typically a panel that includes clinicians and
other experts, for review, evaluation, and a recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an Advisory Committee, but it generally
follows such recommendations. Before approving an NDA or BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Additionally, the FDA will inspect the facility
or the facilities at which the drug
is manufactured. The FDA will not approve the product unless compliance with cGMP is satisfactory and the NDA or BLA contains data that provide substantial evidence that the drug is safe and effective
in the indication studied and to be marketed. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;After
the FDA evaluates the NDA or BLA and the manufacturing facilities, it issues an approval letter or a complete response letter. Complete response letters outline the deficiencies in
the submission that prevent approval and may require substantial additional testing or information for the FDA to reconsider the application. If and when those deficiencies have been addressed to the
FDA's satisfaction in an amendment submitted to the NDA or BLA, the FDA will then issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the
type and extent of information included. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-24-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=26,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=243406,FOLIO='24',FILE='DISK124:[17ZAA1.17ZAA47301]DG47301A.;7',USER='VSTEFAN',CD='27-FEB-2017;04:19' -->
<A NAME="page_dg47301_1_25"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;An
approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. As a condition of NDA approval, the FDA may require
substantial post-approval commitments or requirements to conduct additional testing and/or surveillance to monitor the drug's safety or efficacy and may impose other conditions, including distribution
and labeling restrictions which can materially affect the potential market and profitability of the drug. Once granted, product approvals may be withdrawn if compliance with regulatory standards is
not maintained, problems are identified following initial marketing, or post-marketing commitments are not met. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>The Hatch-Waxman Act </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
seeking approval for a drug through an NDA, applicants are required to list with the FDA certain patent(s) with claims that cover the applicant's product or approved
method of use. Upon approval of a drug, each of the patents listed in the application for the drug is then published in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations,
commonly known as the Orange Book. Drugs listed in the Orange Book can, in turn, be cited by potential competitors in support of approval of an Abbreviated New Drug Application ("ANDA"). An ANDA
provides for marketing of a drug product that has the same route of administration, active ingredients strength, and dosage form as the listed drug and has been shown through bioequivalence testing to
be, in most cases, therapeutically equivalent to the listed drug. ANDA applicants are not required to conduct or submit results of preclinical or clinical tests to prove the safety or effectiveness of
their drug product, other than the requirement for bioequivalence testing. Drugs approved in this way are commonly referred to as "generic equivalents" to the listed drug and can often be substituted
by pharmacists under prescriptions written for the original listed "innovator" drug. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
ANDA applicant is required to certify to the FDA concerning any patents listed for the approved product in the FDA's Orange Book. Specifically, the applicant must certify that:
(i)&nbsp;the required patent information has not been filed; (ii)&nbsp;the listed patent has expired; (iii)&nbsp;the listed patent has not expired, but will expire on a particular date and
approval is sought after patent expiration; or (iv)&nbsp;the listed patent is invalid or will not be infringed by the new product. A certification that the new product will not infringe the already
approved product's listed patents or that such patents are invalid is called a Paragraph&nbsp;4 certification. If the applicant does not challenge the listed patents, the ANDA application will not
be approved until all the listed patents claiming the referenced product have expired. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the ANDA applicant submits a Paragraph&nbsp;4 certification to the FDA, the applicant must also send notice of the Paragraph&nbsp;4 certification to the NDA and patent holders
once the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph&nbsp;4 certification. The
filing of a patent infringement lawsuit within 45&nbsp;days of the receipt of a Paragraph&nbsp;4 certification automatically prevents the FDA from approving the ANDA until the earlier of
30&nbsp;months, expiration of the patent, settlement of the lawsuit or a decision in the infringement case that is favorable to the ANDA applicant. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Patent
term and data exclusivity run in parallel. An ANDA application also will not be approved until any non-patent exclusivity, such as exclusivity for obtaining approval of a NCE,
listed in the Orange Book for the referenced product has expired (New Chemical Entity Market Exclusivity). Federal law provides a period of five years following approval of a drug containing no
previously approved active ingredients, during which ANDAs for generic versions of those drugs cannot be submitted unless the submission contains a Paragraph&nbsp;4 certification that challenges a
listed patent, in which case the submission may be made four years following the original product approval. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Federal
law provides for a period of three years of exclusivity following approval of a listed drug that contains previously approved active ingredients but is approved in a new dosage
form, route of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-25-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=27,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=497999,FOLIO='25',FILE='DISK124:[17ZAA1.17ZAA47301]DG47301A.;7',USER='VSTEFAN',CD='27-FEB-2017;04:19' -->
<A NAME="page_dg47301_1_26"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>administration
or combination, or for a new use, the approval of which was required to be supported by new clinical trials conducted by or for the sponsor, during which the FDA cannot grant effective
approval of an ANDA based on that listed drug for the same new dosage form, route of administration or combination, or new use. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Other Regulatory Requirements  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Once an NDA or BLA is approved, a product will be subject to certain post-approval requirements. For instance, the FDA closely regulates the
post-approval marketing and promotion of drugs, including standards and regulations for direct-to-consumer advertising, communications regarding unindicated uses, industry-sponsored scientific and
educational activities, and promotional activities involving the internet. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Drugs
may be promoted only for approved indications and in accordance with the provisions of the approved labeling. Changes to some of the conditions established in an approved
application, including changes in indications, new safety information, labeling, or manufacturing processes or facilities, require submission and FDA approval of a new NDA, NDA supplement, BLA, or BLA
supplement before the change can be implemented. New efficacy claims require submission and approval of an NDA supplement and BLA supplement for each new indication. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
efficacy claims typically require new clinical data similar to those included in the original application. The FDA uses the same procedures and actions in reviewing NDA and BLA
supplements as it does in reviewing NDAs and BLAs. Additional exclusivity may be granted for new efficacy claims. Generic ANDAs cannot be labeled for these types of claims until the new exclusivity
period expires. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adverse
event reporting and submission of periodic reports is required following FDA approval of an NDA or BLA. The FDA also may require post-marketing testing, known as Phase&nbsp;4
testing, risk evaluation and mitigation strategies, and surveillance to monitor the effects of an approved product, or place conditions on an approval that could restrict the distribution or use of
the product. In addition, quality control as well as drug manufacture, packaging, and labeling procedures must continue to conform to cGMP, after approval. Drug manufacturers and certain
subcontractors are required to register their establishments with FDA and certain state agencies, and are subject to routine inspections by the FDA during which the agency inspects manufacturing
facilities to access compliance with cGMP. Accordingly, manufacturers must continue to expend time, money, and effort in the areas of production and quality control to maintain compliance with cGMP.
Regulatory authorities may withdraw product approvals or request product recalls if a company fails to comply with regulatory standards, if it encounters problems following initial marketing, or if
previously unrecognized problems are subsequently discovered. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Orphan Drugs  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the Orphan Drug Act, the FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition, which is generally
a disease or condition that affects
fewer than 200,000 individuals in the U.S. Orphan drug designation must be requested before submitting an NDA or BLA. After the FDA grants orphan drug designation, the generic identity of the drug and
its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. The first
NDA or BLA applicant with FDA orphan drug designation for a particular active ingredient to receive FDA approval of the designated drug for the disease indication for which it has such designation, is
entitled to a seven-year exclusive marketing period (Orphan Drug Exclusivity) in the U.S. for that product, for that indication. During the seven-year period, the FDA may not finally approve any other
applications to market the same drug for the same disease, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or if the license
holder cannot supply </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-26-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=28,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=404440,FOLIO='26',FILE='DISK124:[17ZAA1.17ZAA47301]DG47301A.;7',USER='VSTEFAN',CD='27-FEB-2017;04:19' -->
<A NAME="page_dg47301_1_27"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>sufficient
quantities of the product. Orphan drug exclusivity does not prevent the FDA from approving a different drug for the same disease or condition, or the same drug for a different disease or
condition, provided that the sponsor has conducted appropriate clinical trials required for approval. Among the other benefits of orphan drug designation are tax credits for certain research and a
waiver of the NDA or BLA application user fee for the orphan indication. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Pediatric Information  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the Pediatric Research Equity Act of 2007 ("PREA"), NDAs or supplements to NDAs must contain data to assess the safety and effectiveness
of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the drug is safe and effective. The
FDA may grant deferrals for submission of data or full or partial waivers. Unless otherwise required by regulation, PREA does not apply to any drug for an indication for which orphan designation has
been granted. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Fast Track Designation  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the Fast Track program, the sponsor of an IND may request the FDA to designate the drug candidate as a Fast Track drug if it is intended
to treat a serious condition and fulfill an unmet medical need. The FDA must determine if the drug candidate qualifies for Fast Track designation within 60&nbsp;days of receipt of the sponsor's
request. Once the FDA designates a drug as a
Fast Track candidate, it is required to facilitate the development and expedite the review of that drug by providing more frequent communication with and guidance to the sponsor. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to other benefits such as the ability to use surrogate endpoints and have greater interactions with the FDA, the FDA may initiate review of sections of a Fast Track drug's
NDA or BLA before the application is complete. This rolling review is available if the applicant provides, and the FDA approves, a schedule for the submission of the remaining information and the
applicant pays applicable user fees. However, the FDA's review period as specified under PDUFA V for filing and reviewing an application does not begin until the last section of the NDA or BLA has
been submitted. Additionally, the Fast Track designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Breakthrough Therapy Designation  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Breakthrough Therapy designation is intended to expedite the development and review of a candidate that is planned for use to treat a serious or
life-threatening disease or condition when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant
endpoints. A Breakthrough Therapy designation conveys all of the Fast Track program features, as well as more intensive FDA guidance on an efficient drug development program. The FDA also has an
organizational commitment to involve senior management in such guidance. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Priority Review  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under FDA policies, a drug candidate is eligible for priority review, or review within six months from filing for a new molecular entity ("NME")
or six months from submission for a non-NME if the drug candidate provides a significant improvement compared to marketed drugs in the treatment, diagnosis, or prevention of a disease. A Fast Track
designated drug candidate would ordinarily meet the FDA's criteria for priority review. The FDA makes its determination of priority or standard review during the 60-day filing period after an initial
NDA or BLA submission. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-27-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=29,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=323599,FOLIO='27',FILE='DISK124:[17ZAA1.17ZAA47301]DG47301A.;7',USER='VSTEFAN',CD='27-FEB-2017;04:19' -->
<A NAME="page_dg47301_1_28"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Accelerated Approval  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the FDA's accelerated approval regulations, the FDA may approve a drug for a serious or life-threatening illness that provides meaningful
therapeutic benefit to patients over existing treatments based upon a surrogate endpoint that is reasonably likely to predict clinical benefit. This approval mechanism is provided for under 21CRF314
Subpart&nbsp;H and Subpart&nbsp;E. In this case, clinical trials are conducted in which a surrogate endpoint is used as the primary outcome for approval. A surrogate endpoint is reasonably likely
to predict clinical benefit, or an effect on a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality, that is reasonably likely to predict an effect on
irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. This
surrogate endpoint substitutes for a direct measurement of how a patient feels, functions, or survives and is considered reasonably likely to predict clinical benefit. Such surrogate endpoints may be
measured more easily or more rapidly than clinical endpoints. A drug candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of
Phase&nbsp;4 or post-approval clinical trials to confirm the effect on the clinical endpoint. When the Phase&nbsp;4 commitment is successfully completed, the biomarker is deemed to be a surrogate
endpoint. Failure to conduct required post-approval studies or confirm a clinical benefit during post-marketing studies, could lead the FDA to withdraw the drug from the market on an expedited basis.
All promotional materials for drug candidates approved under accelerated regulations are subject to prior review by the FDA. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Section&nbsp;505(b) (2)&nbsp;New Drug Applications  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Most drug products obtain FDA marketing approval pursuant to an NDA, an ANDA, or a BLA. A fourth alternative is a special type of NDA, commonly
referred to as a Section&nbsp;505(b) (2)&nbsp;NDA, which enables the applicant to rely, in part, on the safety and efficacy data of an existing product, or published literature, in support of its
application. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;505(b)
(2)&nbsp;NDAs often provide an alternate path to FDA approval for new or improved formulations or new uses of previously approved products. Section&nbsp;505(b)(2) permits the
submission of a NDA for which at least some of the information required for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of
reference. The applicant may rely upon certain preclinical or clinical studies conducted for an approved product. The FDA may also require companies to perform additional studies or measurements to
support the change from the approved product. The FDA may then approve the new product candidate for all or some of the label indications for which the referenced product has been approved, as well as
for any new indication sought by the Section&nbsp;505(b) (2)&nbsp;applicant. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the extent that the Section&nbsp;505(b) (2)&nbsp;applicant is relying on studies conducted for an already-approved product, the applicant is required to certify to the FDA
concerning any patents listed for the approved product in the Orange Book to the same extent as an ANDA applicant. Thus approval of a 505(b)(2) NDA can be stalled until all the listed patents claiming
the referenced product have expired, until any non-patent exclusivity, such as exclusivity for obtaining approval of an NCE, listed in the Orange Book for the referenced product has expired, and, in
the case of a Paragraph&nbsp;4 certification and subsequent patent infringement suit, until the earlier of 30&nbsp;months, settlement of the lawsuit or a decision in the infringement case that is
favorable to the Section&nbsp;505(b)(2) applicant. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Patient Protection and Affordable Care Act of 2010  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Biologics Price Competition and Innovation Act of 2009 ("BPCIA"), which was enacted as part of the Patient Protection and Affordable Care
Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010 ("PPACA") created an abbreviated approval pathway for </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-28-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=30,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=340963,FOLIO='28',FILE='DISK124:[17ZAA1.17ZAA47301]DG47301A.;7',USER='VSTEFAN',CD='27-FEB-2017;04:19' -->
<A NAME="page_dg47301_1_29"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>biological
products that are demonstrated to be "biosimilar" or "interchangeable" with an FDA-licensed reference biological product via an approved BLA. Biosimilarity to an approved reference product
requires that there be no differences in conditions of use, route of administration, dosage form, and strength, and no clinically meaningful differences between the biological product and the
reference product in terms of safety, purity, and potency. Biosimilarity is demonstrated in steps beginning with rigorous analytical studies or "fingerprinting", in vitro studies, in vivo animal
studies, and generally at least one clinical study, absent a waiver from the Secretary of Health and Human Services. The biosimilarity exercise tests the hypothesis that the investigational product
and the reference product are the same. If at any point in the stepwise biosimilarity process a significant difference is observed, then the products are not biosimilar, and the development of a
stand-alone NDA or BLA is necessary. In order to meet the higher hurdle of interchangeability, a sponsor must demonstrate that the biosimilar product can be expected to produce the same clinical
result as the reference product, and for a product that is administered more than once, that the risk of switching between the reference product and biosimilar product is not greater than the risk of
maintaining the patient on the reference product. Complexities associated with the larger, and often more complex, structures of biological products, as well as the process by which such products are
manufactured, pose significant hurdles to implementation that are still being evaluated by the FDA. Under the BPCIA, a reference biologic is granted 12&nbsp;years of exclusivity from the time of
first licensure of the reference product. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Anti-Kickback, False Claims Laws,&nbsp;&amp; the Prescription Drug Marketing Act  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition to FDA restrictions on marketing of pharmaceutical products, several other types of state and federal laws have been applied to
restrict certain marketing practices in the pharmaceutical industry in recent years. These laws include anti-kickback statutes and false claims statutes. The federal healthcare program anti-kickback
statute prohibits, among other things, knowingly and willfully offering, paying, soliciting, or receiving remuneration to induce or in return for purchasing, leasing, ordering, or arranging for the
purchase, lease or order of any healthcare item or service reimbursable under Medicare, Medicaid, or other federally financed healthcare programs. This statute has been interpreted to apply to
arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers, and formulary managers on the other. Violations of the anti-kickback statute are punishable by
imprisonment, criminal fines, civil monetary penalties, and exclusion from participation in federal healthcare programs. Although there are a number of statutory exemptions and regulatory safe harbors
protecting certain common activities from prosecution or other regulatory sanctions, the exemptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce
prescribing, purchases, or recommendations may be subject to scrutiny if they do not qualify for an exemption or safe harbor. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Federal
false claims laws prohibit any person from knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing
to be made, a false statement to have a false claim paid. Recently, several pharmaceutical and other healthcare companies have been prosecuted under these laws for allegedly inflating drug prices they
report to pricing services, which in turn were used by the government to set Medicare and Medicaid reimbursement rates, and for allegedly providing free product to customers with the expectation that
the customers would bill federal programs for the product. In addition, certain marketing practices, including off-label promotion, may also violate false claims laws. The majority of states also have
statutes or regulations similar to the federal anti-kickback law and false claims laws, which apply to items and services, reimbursed under Medicaid and other state programs, or, in several states,
apply regardless of the payor. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-29-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=31,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=867632,FOLIO='29',FILE='DISK124:[17ZAA1.17ZAA47301]DG47301A.;7',USER='VSTEFAN',CD='27-FEB-2017;04:19' -->
<A NAME="page_dg47301_1_30"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Physician Drug Samples  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As part of the sales and marketing process, pharmaceutical companies frequently provide samples of approved drugs to physicians. The
Prescription Drug Marketing Act (the "PDMA") imposes requirements and limitations upon the provision of drug samples to physicians, as well as prohibits states from licensing distributors of
prescription drugs unless the state licensing program
meets certain federal guidelines that include minimum standards for storage, handling, and record keeping. In addition, the PDMA sets forth civil and criminal penalties for violations. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Regulation Outside the U.S.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition to regulations in the U.S., we will be subject to a variety of regulations in other jurisdictions governing clinical studies,
commercial sales, and distribution of our products. Most countries outside the U.S. require that clinical trial applications be submitted to and approved by the local regulatory authority for each
clinical study. In addition, whether or not we obtain FDA approval for a product, we must obtain approval of a product by the comparable regulatory authorities of countries outside the U.S. before we
can commence clinical studies or marketing of the product in those countries. The approval process varies from country to country, and the time may be longer or shorter than that required for FDA
approval. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
obtain regulatory approval of an orphan drug under EU regulatory systems, we are mandated to submit MAAs in Centralized Procedure. The centralized procedure, which came into operation
in 1995, allows applicants to obtain a marketing authorization that is valid throughout the EU. It is compulsory for medicinal products manufactured using biotechnological processes, for orphan
medicinal products and for human products containing a new active substance which was not authorized in the Community before 20&nbsp;May 2004 (date of entry into force of Regulation (EC) No
726/2004) and which are intended for the treatment of AIDS, cancer, neurodegenerative disorder or diabetes. The centralized procedure is optional for any other products containing new active
substances not authorized in the Community before 20&nbsp;May 2004 or for products which constitute a significant therapeutic, scientific or technical innovation or for which a Community
authorization is in the interests of patients at Community level. When a company wishes to place on the market a medicinal product that is eligible for the centralized procedure, it sends an
application directly to the European Medicines Agency, to be assessed by the Committee for Medicinal Products for Human Use ("CHMP"). The procedure results in a Commission decision, which is valid in
all EU Member States. Centrally-authorized products may be marketed in all Member States. Centralized procedure: Full copies of the MA application are sent to a rapporteur and a co-rapporteur
designated by the competent EMA scientific committee. They coordinate the EMA's assessment of the medicinal product and prepare draft reports. Once the draft reports are prepared (other experts might
be called upon for this purpose), they are sent to the CHMP, whose comments or objections are communicated to the applicant. The rapporteur is therefore the privileged interlocutor of the applicant
and continues to play this role, even after the MA has been granted. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
rapporteur and co-rapporteur then assess the applicant's replies, submit them for discussion to the CHMP and, taking into account the conclusions of this debate, prepare a final
assessment report. Once the evaluation is completed, the CHMP gives a favorable or unfavorable opinion as to whether to grant the authorization. When the opinion is favorable, it shall include the
draft summary of the product's characteristics, the package leaflet and the texts proposed for the various packaging materials. The time limit for the evaluation procedure is 210&nbsp;days. The EMA
then has fifteen days to forward its opinion to the Commission. This is the start of the second phase of the procedure: the decision-making process. The Agency sends to the Commission its opinion and
assessment report, together with annexes containing: the SmPC (Annex&nbsp;1); the particulars of the MAH responsible for batch release, the
particulars of the manufacturer of the active substance and the conditions of the marketing authorization (Annex&nbsp;2); and the labelling and the package leaflet (Annex&nbsp;3). The annexes are </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-30-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=32,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=201048,FOLIO='30',FILE='DISK124:[17ZAA1.17ZAA47301]DG47301A.;7',USER='VSTEFAN',CD='27-FEB-2017;04:19' -->
<A NAME="page_dg47301_1_31"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>translated
into the 22 other official languages of the EU. During the decision-making process, the Commission services verify that the marketing authorization complies with Union law. The Commission
has fifteen days to prepare a draft decision. The medicinal product is assigned a Community registration number, which will be placed on its packaging if the marketing authorization is granted. During
this period, various Commission directorates-general are consulted on the draft marketing authorization decision. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
draft decision is then sent to the Standing Committee on Medicinal Products for Human Use, (Member States have one representative each in both of these committees) for their
opinions. The Centralized Procedure, which is compulsory for medicines produced by certain biotechnological processes and optional for those which are highly innovative, provides for the grant of a
single marketing authorization that is valid for all EU member states. The Decentralized Procedure provides for approval by one or more other, or concerned, member states of an assessment of an
application performed by one member state, known as the reference member state. Under this procedure, an applicant submits an application, or dossier, and related materials including a draft summary
of product characteristics, and draft labeling and package leaflet, to the reference member state and concerned member states. The reference member state prepares a draft assessment and drafts of the
related materials within 120&nbsp;days after receipt of a valid application. Within 90&nbsp;days of receiving the reference member state's assessment report, each concerned member state must
decide whether to approve the assessment report and related materials. If a member state cannot approve the assessment report and related materials on the grounds of potential serious risk to the
public health, the disputed points may eventually be referred to the European Commission, whose decision is binding on all member states. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have obtained an orphan medicinal product designation in the EU from the EMA for migalastat for the treatment of Fabry disease ("FD") and Gaucher disease ("GD") and for SD-101 for the
treatment of Epidermolysis Bullosa ("EB"). Applications from persons or companies seeking "orphan medicinal product designation" for products they intend to develop for the diagnosis, prevention, or
treatment of life-threatening or very serious conditions that affect not more than 5 in 10,000 persons in the EU are reviewed by the Committee for Orphan Medicinal Products ("COMP").In addition,
orphan drug designation can be granted if the drug is intended for a life threatening, seriously debilitating, or serious and chronic condition in the EU and that without incentives it is unlikely
that sales of the drug in the EU would be sufficient to justify developing the drug. Orphan drug designation is only available if there is no other satisfactory method approved in the EU of
diagnosing, preventing, or treating the condition, or if such a method exists, the proposed orphan drug will be of significant benefit to patients. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Orphan
drug designation provides opportunities for fee reductions for protocol assistance and access to the centralized regulatory procedures before and during the first year after
marketing approval, which reductions are not limited to the first year after marketing approval for small and medium enterprises. In addition, if a product which has an orphan drug designation
subsequently receives EMA marketing approval for the indication for which it has such designation, the product is entitled to orphan drug exclusivity, which means the EMA may not approve any other
application to market the same drug for the same indication for a period of 10&nbsp;years. The exclusivity period may be reduced to six years if the designation criteria are no longer met, including
where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity. Competitors may receive marketing approval of different drugs or biologics for the
indications for which the orphan product has exclusivity. In order to do so, however, they must demonstrate that the new drugs or biologics provide a significant benefit over the existing orphan
product. This demonstration of significant benefit may be done at the time of initial approval or in post-approval studies, depending on the type of marketing authorization granted. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have obtained a positive opinion for our PIP in the EU for SD-101 for the treatment of EB and for migalastat for the treatment of Fabry disease as well. In May 2016, we announced that
we had </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-31-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=33,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=866695,FOLIO='31',FILE='DISK124:[17ZAA1.17ZAA47301]DG47301A.;7',USER='VSTEFAN',CD='27-FEB-2017;04:19' -->
<A NAME="page_dg47301_1_32"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>received
full European Commission approval for migalastat HC1, under the product name Galafold&#153;, as a first-line therapy for long-term treatment of adults and adolescents aged
16&nbsp;years and older with a confirmed diagnosis of Fabry disease and who have an amenable mutation. A pediatric investigation plan is a development plan aimed at ensuring that the necessary data
are obtained to support the authorization of a medicine for children, through studies in children. All applications for marketing authorization for new medicines have to include the results of studies
as described in an agreed pediatric investigation plan, unless the medicine is exempt because of a deferral or waiver. This requirement also applies when a marketing-authorization holder wants to add
a new indication, pharmaceutical form, or route of administration for a medicine that is already authorized and covered by intellectual property rights. Several rewards and incentives for the
development of pediatric medicines for children are available in the EU. Medicines authorized across the EU with the results of studies from a pediatric investigation plan included in the product
information are eligible for an extension of their supplementary protection certificate by six months. This is the case even when the studies' results are negative. For orphan medicines, the incentive
is an additional two years of market exclusivity. Scientific advice and protocol assistance at the Agency are free of charge for questions relating to the development of pediatric medicines. Medicines
developed specifically for children that are already authorized but are not protected by a patent or supplementary protection certificate are eligible for a pediatric-use marketing authorization
("PUMA"). If a PUMA is granted, the product will benefit from 10&nbsp;years of market protection as an incentive. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;GSK
obtained orphan drug designation in Japan for migalastat for the treatment of Fabry Disease. Amicus has approval of migalastat in Switzerland and has followed all their applicable
regulations. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Ministry of Health, Labor, and Welfare, based on the opinion of the Pharmaceutical Affairs and Food Sanitation Council, grants orphan status to drugs intended to address serious
illnesses with high unmet medical need that affect fewer than 50,000 patients in Japan. Orphan designation provides certain benefits and incentives, including priority review for marketing
authorization and a period of 10&nbsp;years of market exclusivity if the drug candidate is approved for the designated indication. Now that we have acquired the rights to migalastat in Japan, we
have started the administrative process to obtain the orphan drug designation that was held by GSK. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Pharmaceutical Pricing and Reimbursement  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the U.S. and markets in other countries, sales of any products for which we receive regulatory approval for commercial sale will depend in
part on the availability of reimbursement from third party payors. Third party payors include government health administrative authorities, managed care providers, private health insurers, and other
organizations. These third party payors are increasingly challenging the price and examining the cost-effectiveness of medical products and services. In addition, significant uncertainty exists as to
the reimbursement status of newly approved healthcare product candidates. We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the cost-effectiveness of our products. Our
product candidates may not be considered cost-effective. Adequate third party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on
our investment in product development. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
2003, the U.S. government enacted legislation providing a partial prescription drug benefit for Medicare recipients that began in 2006. Government payment for some of the costs of
prescription drugs may increase demand for any products for which we receive marketing approval. However, to obtain payments under this program, we would be required to sell products to Medicare
recipients through managed care organizations and other health care delivery systems operating pursuant to this legislation. These organizations would negotiate prices for our products, which are
likely to be lower than we might otherwise obtain. Federal, state, and local governments in the U.S. continue to consider legislation to limit the growth of healthcare costs, including the cost of
prescription drugs. Future </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-32-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=34,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=359616,FOLIO='32',FILE='DISK124:[17ZAA1.17ZAA47301]DG47301A.;7',USER='VSTEFAN',CD='27-FEB-2017;04:19' -->
<A NAME="page_dg47301_1_33"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>legislation
could limit payments for biopharmaceuticals such as the drug candidates that we are developing. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
marketability of any products for which we receive regulatory approval for commercial sale may suffer if the government and third party payors fail to provide adequate coverage and
reimbursement.
In addition, an increasing emphasis on managed care in the U.S. has increased and will continue to increase the pressure on pharmaceutical pricing. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Employees  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of December&nbsp;31, 2016, we had 263 full-time employees, 146 of whom were primarily engaged in research and development activities and
117 of whom provided selling and administrative services. None of our employees were represented by a labor union. We have not experienced any work stoppages and consider our employee relations to be
good. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our Corporate Information  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We were incorporated under the laws of the State of Delaware on February&nbsp;4, 2002. Our global headquarters are located at 1 Cedar Brook
Drive, Cranbury, NJ 08512 and our telephone number is (609)&nbsp;662-2000. Our website address is </FONT><FONT SIZE=2><I>www.amicusrx.com</I></FONT><FONT SIZE=2> . We make available free of charge
on our website our annual, quarterly, and current reports, including amendments to such reports, as soon as reasonably practicable after we electronically file such material with, or furnish such
material to, the U.S. Securities and Exchange Commission. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Information
relating to our corporate governance, including our Code of Business Conduct for Employees, Executive Officers and Directors, Corporate Governance Guidelines, and information
concerning our senior management team, Board of Directors, including Board Committees and Committee charters, and transactions in our securities by directors and executive officers, is available on
our website at </FONT><FONT SIZE=2><I>www.amicusrx.com</I></FONT><FONT SIZE=2> under the "Investors&nbsp;&#151;&nbsp;Corporate Governance" caption and in print to any stockholder upon
request. Any waivers or material amendments to the Code will be posted promptly on our website. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have filed applications to register certain trademarks in the U.S. and abroad, including Amicus Therapeutics&reg;&nbsp;&amp; design, At the forefront of therapies for rare and
orphan diseases&#153;, Zorblisa&#153;, Galafold&#153;, and Amigal&#153;. Fabrazyme&reg;, Myozyme&reg;, Lumizyme&reg;, and Replagal&reg; are
the property of their respective owners. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-33-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=35,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=324186,FOLIO='33',FILE='DISK124:[17ZAA1.17ZAA47301]DG47301A.;7',USER='VSTEFAN',CD='27-FEB-2017;04:19' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_di47301_1_34"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="di47301_item_1a._risk_factors"> </A>
<A NAME="toc_di47301_1"> </A></FONT> <FONT SIZE=2><B>  ITEM 1A.&nbsp;&nbsp;&nbsp;&nbsp;RISK FACTORS    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following risk factors and other information included in this Annual Report on Form&nbsp;10-K should be carefully considered. The risks
and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we presently deem less significant may also impair our business
operations. Please see page&nbsp;1 of this Annual Report on Form&nbsp;10-K for a discussion of some of the forward-looking statements that are qualified by these risk factors. If any of the
following risks occur, our business, financial condition, results of operations, and future growth prospects could be materially and adversely affected. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to our Products and the Regulatory Approval and Clinical Development of our Product
Candidates  </B></FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> We depend heavily on the commercial success of our first product, migalastat HCl, in the EU. Moreover, if we are unable to obtain approval from the FDA or other foreign regulatory
authorities, or if we are unable to commercialize migalastat HCl successfully, or experience significant delays in doing so, our business could be materially harmed.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have invested a significant portion of our efforts and financial resources in the development of migalastat HCl for the treatment of Fabry
disease. Our ability to generate material product revenues, which may not occur for the foreseeable future, if ever, will depend heavily on the successful development, regulatory approval, and
commercialization of migalastat HCl. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
delay or impediment in our ability to obtain regulatory approval in any region to commercialize, or, if approved, obtain coverage and adequate reimbursement from third-parties,
including government payors, for migalastat HCl may cause us to be unable to generate the revenues necessary to continue our research and development pipeline activities, thereby adversely affecting
our business and our prospects for future growth. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Further,
the success of migalastat HCl will depend on a number of factors, including the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> obtaining a sufficiently broad label in each territory that would not unduly restrict patient access; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> FDA and PMDA approvals for migalastat HCl; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> building and maintaining an infrastructure capable of supporting product sales, marketing, and distribution of migalastat HCl in the EU and
territories where we pursue commercialization directly; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> establishing commercial manufacturing arrangements with third party manufacturers; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> establishing commercial distribution agreements with third party distributors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> launching commercial sales of migalastat HCl, where approved, whether alone or in collaboration with others; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> acceptance of migalastat HCl, where approved, by patients, the medical community and third party payors; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the regulatory approval pathway that we pursue for migalastat HCl in the U.S., including whether we collect additional data on gastrointestinal
(GI) symptoms in Fabry patients who have an amenable mutation and if we do collect data, whether it will be accepted by FDA; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> effectively competing with other therapies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a continued acceptable safety profile of migalastat HCl; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> obtaining and maintaining patent and trade secret protection and regulatory exclusivity; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-34-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=36,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=314210,FOLIO='34',FILE='DISK124:[17ZAA1.17ZAA47301]DI47301A.;11',USER='VSTEFAN',CD='27-FEB-2017;04:19' -->
<A NAME="page_di47301_1_35"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> protecting our rights in our intellectual property portfolio; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> obtaining a commercially viable price for our products </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize migalastat HCl, which
would materially harm our business. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize our product or product candidates, and our
ability to generate revenue will be materially impaired.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our product and product candidates, including migalastat HCl, and the activities associated with their development and commercialization,
including their testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution, commercialization and reimbursement are subject to
comprehensive regulation by the EMA, the FDA, and other regulatory agencies in the United States and by comparable authorities in other countries. We have only obtained regulatory approval to market
one product in the EU and Switzerland. Failure
to obtain regulatory approval for our product and product candidates will prevent us from commercializing our product in jurisdictions beyond those in which we have obtained regulatory approval for
our product or in any jurisdictions for our product candidates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have only limited experience in filing and supporting the applications necessary to obtain marketing approvals for product candidates and are and will need to rely on third party
contract research organizations, or CROs, to assist us in this process. Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information to
regulatory authorities for each therapeutic indication to establish the product candidate's safety and efficacy. Securing marketing approval also requires the submission of information about the
product manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities. Regulatory authorities may determine that migalastat HCl or any of our other product
candidates are not effective or only moderately effective, or have undesirable or unintended side effects, toxicities, safety profiles or other characteristics that preclude us from obtaining
marketing approval or that prevent or limit commercial use. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Obtaining
approval for our product candidates is highly uncertain and we may fail to obtain regulatory approval in any or all jurisdictions. The review processes and the processes of
regulatory authorities, including the FDA, are extensive, lengthy, expensive, and uncertain, and such regulatory authorities may delay, limit, or deny approval of migalastat HCl or any of our other
product candidates for many reasons, including, but not limited to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our failure to demonstrate to the satisfaction of the applicable regulatory authorities that migalastat HCl or any of our other product
candidates are safe and effective for a particular indication; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the results of clinical trials may not meet the level of statistical significance or other efficacy or safety parameters required by the
applicable regulatory authorities for approval; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the applicable regulatory authority may disagree with the number, design, size, conduct, or implementation of our clinical trials or conclude
that the data fail to meet statistical or clinical significance; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the applicable regulatory authority may not find the data from preclinical studies and clinical trials sufficient to demonstrate that the
product candidate's clinical and other benefits outweigh its safety risks; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-35-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=37,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=970542,FOLIO='35',FILE='DISK124:[17ZAA1.17ZAA47301]DI47301A.;11',USER='VSTEFAN',CD='27-FEB-2017;04:19' -->
<A NAME="page_di47301_1_36"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the applicable regulatory authority may disagree with our interpretation of data from preclinical studies or clinical trials, and may reject
conclusions from preclinical studies or clinical trials, or determine that primary or secondary endpoints from clinical trials were not met, or reject safety conclusions from such studies or trials; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the applicable regulatory authority may not accept data generated at one or more of our clinical trial sites; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the applicable regulatory authority may determine that we did not properly oversee our clinical trials or follow the regulatory authority's
advice or recommendations in designing and conducting our clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an advisory committee, if convened by the applicable regulatory authority, may recommend against approval of our application or may recommend
that the applicable regulatory authority require, as a condition of approval, additional preclinical studies or clinical trials, limitations on approved labeling or distribution and use restrictions,
or even if an advisory committee, if convened, makes a favorable recommendation, the respective regulatory authority may still not approve the product candidate; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the applicable regulatory authority may identify deficiencies in the chemistry, manufacturing, and control sections of our application, our
manufacturing processes, facilities, or analytical methods or those of our third party contract manufacturers, and this may lead to significant delays in the approval of our product candidates or to
the rejection of our applications altogether. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
process of obtaining marketing approvals is expensive, may take many years, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the
type, complexity, and novelty of the product candidates involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or
regulations, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. Regulatory authorities have substantial discretion
in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical, or other studies. In addition,
varying interpretations of the data obtained from preclinical and clinical testing could delay, limit, or prevent marketing approval of a product candidate. Any marketing approval we ultimately obtain
may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> If clinical trials of our product candidates fail to demonstrate safety and efficacy to the satisfaction of the FDA, EMA, or other foreign regulatory authorities, or do not otherwise
produce favorable results, we may experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with seeking marketing approval from regulatory authorities for the sale of any product candidate, we must complete preclinical
development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical testing is expensive, difficult to design and implement, can
take many years to complete, and is uncertain as to outcome. A failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical testing and early clinical trials
may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. Moreover, preclinical and clinical data are often
susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless
failed to obtain marketing approval of their products. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
example, if the FDA refuses to accept an NDA for accelerated approval or full approval, or accepts the filing, but ultimately decides not to approve the NDA, we may need to complete
additional </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-36-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=38,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=822041,FOLIO='36',FILE='DISK124:[17ZAA1.17ZAA47301]DI47301A.;11',USER='VSTEFAN',CD='27-FEB-2017;04:19' -->
<A NAME="page_di47301_1_37"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Phase&nbsp;3
clinical trial(s) and may need to expend significantly more capital to pursue FDA approval of migalastat HCl, SD 101 or other product candidates. If we are required to conduct
additional clinical trials or other testing of migalastat HCl, SD 101 or any other product candidate that we develop beyond those tests and trials that we contemplate; if we are unable to successfully
complete our clinical trials or other testing; if the results of these trials or tests are not positive or are only modestly positive; or if there are safety concerns, we
may:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> choose not to seek regulatory approval in the U.S.; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> be delayed in obtaining marketing approval for our product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> not obtain marketing approval at all; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> obtain approval for indications or patient populations that are not as broad as intended or desired; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> obtain approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> be subject to additional post-marketing testing requirements, safety strategies or restrictions, such as a requirement of a risk evaluation and
mitigation strategy, or REMS; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> have the product removed from the market after obtaining regulatory approval. </FONT></DD></DL>
</UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> If we experience any of a number of possible unforeseen events in connection with our clinical trials, potential regulatory approval or commercialization of our product candidates
could be delayed or prevented.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive
regulatory approval or commercialize our product candidates, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to
conduct additional clinical trials or abandon product development programs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical
trials may be slower than we anticipate, or patients may drop out of these clinical trials at a higher rate than we anticipate; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we may be unable to enroll a sufficient number of patients in our trials to ensure adequate statistical power to detect any statistically
significant treatment effects; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our third party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or
at all; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> regulators, institutional review boards, or independent ethics committees may not authorize us or our investigators to commence a clinical
trial or conduct a clinical trial at a prospective trial site; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we may have delays in reaching or fail to reach agreement on acceptable clinical trial contracts or clinical trial protocols with prospective
trial sites; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we may have to suspend or terminate clinical trials of our product candidates for various reasons, including a finding that the participants
are being exposed to unacceptable health risks; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> regulators, institutional review boards, or independent ethics committees may require that we or our investigators suspend or terminate
clinical research for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-37-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=39,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=370844,FOLIO='37',FILE='DISK124:[17ZAA1.17ZAA47301]DI47301A.;11',USER='VSTEFAN',CD='27-FEB-2017;04:19' -->
<A NAME="page_di47301_1_38"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the cost of clinical trials of our product candidates may be greater than we anticipate; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be
insufficient or inadequate; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators,
institutional review boards or independent ethics committees to suspend or terminate the trials. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
product development costs will increase if we experience delays in testing or regulatory approvals. We do not know whether any preclinical tests or clinical trials will begin as
planned, will need to be restructured or will be completed on schedule, or at all. Significant preclinical study or clinical trial delays also could shorten any periods during which we may have the
exclusive right to commercialize our product candidates, allow our competitors to bring products to market before we do, or impair our ability to successfully commercialize our product candidates, and
so may harm our business and results of operations. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> If we experience delays or difficulties in the enrollment of patients in our clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number
of eligible patients to participate in these trials. Each of our diseases that our lead product candidates are intended to treat are characterized by small patient populations, which could result in
slow enrollment of clinical trial participants. For example, the entry criteria for one of our Phase&nbsp;3 clinical trials in migalastat HCl for Fabry disease to support approval in the United
States (Study 011) required that patients must have a genetic mutation that we believe is responsive to migalastat HCl, and may not have received ERT in the past or must have stopped treatment for at
least six months prior to enrolling in the study. As a result, enrollment of the clinical trial lasted for over two years. In addition, our competitors have ongoing clinical trials for product
candidates that could be competitive with our product candidates. As a result, potential clinical trial sites may elect to dedicate their limited resources to participation in our competitors'
clinical trials and not ours, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors' product candidates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Patient
enrollment is affected by other factors including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> severity of the disease under investigation; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> eligibility criteria for the clinical trial in question; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> perceived risks and benefits of the product candidate under study; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> efforts to facilitate timely enrollment in clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> patient referral practices of physicians; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the ability to monitor patients adequately during and after treatment; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> proximity and availability of clinical trial sites for prospective patients. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Enrollment
delays in our clinical trials may result in increased development costs for our product candidates, which would cause the value of the company to decline and limit our ability
to obtain additional financing. Our inability to enroll a sufficient number of patients in any of our clinical trials would result in significant delays or may require us to abandon one or more
clinical trials altogether. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-38-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=40,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=586345,FOLIO='38',FILE='DISK124:[17ZAA1.17ZAA47301]DI47301A.;11',USER='VSTEFAN',CD='27-FEB-2017;04:19' -->
<A NAME="page_di47301_1_39"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> The FDA has indicated that we will need to complete additional clinical trials to support the NDA, of migalastat HCl in the United States.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We had planned, until on or about October&nbsp;1, 2015 to submit an NDA for accelerated approval (Subpart&nbsp;H) of migalastat HCl with the
FDA. Under the FDA's accelerated approval regulations, the FDA may approve a drug for a serious or life-threatening disease or condition that provides meaningful therapeutic benefit to patients over
available treatments based upon a surrogate or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA has broad discretion over whether to grant approval based
on a surrogate endpoint. Following several collaborative discussions, the FDA has indicated that (i)&nbsp;it has concluded that the surrogate endpoint we proposed is not currently a basis for
accelerated approval under Subpart&nbsp;H, and (ii)&nbsp;we will need to complete an additional clinical trial to collect additional data on GI symptoms in Fabry patients who have an amenable
mutation (the "GI Study") to support the NDA of migalastat HCl in the United States. Despite these discussions, we may continue to evaluate other regulatory pathways. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we decide to pursue the GI Study to complete an NDA and submit a NDA for migalastat HCl, there can be no assurance that the NDA will ultimately be accepted and/or approved. If the FDA
refuses to accept an NDA or accepts the filing, but ultimately does not approve the NDA, the FDA may require additional clinical trials beyond those already completed for us to continue to seek FDA
approval. If required to complete additional trials, we may choose not to complete those trials or pursue U.S. approval, or if we do, we may need to expend significantly more capital with no assurance
of the success of any such clinical trial nor of the FDA's ultimate decision regarding approval of migalastat HCl. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> If we do not or are not able to initiate the GI study, or if there are delays in conducting the GI study, there may be delays in obtaining required regulatory approval or required
regulatory approvals of migalastat HCl may never be obtained.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The protocol for any potential GI study has not yet been agreed with FDA. We and the FDA may not be able to agree to a protocol for the study or
we may determine that a protocol acceptable to the FDA is not a study we would conduct. In addition, should we decide to conduct the GI Study, we may not be able to initiate it if we are unable to
locate and enroll a sufficient number of eligible patients to participate in the study. Fabry patients who are not currently on treatment and have an amenable mutation and GI symptoms are a small
patient population. We may experience slow enrollment of study participants or not be able to enroll the study with sufficient patients or experience significant delays in enrollment. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, we may choose not to pursue or complete the GI study or pursue U.S. approval, or if we do, we may need to expend significantly more capital with no assurance of the success
of the GI study nor of the FDA's ultimate decision regarding approval of migalastat HCl. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> We may expend our limited resources to pursue a particular product, product candidate or indication and fail to capitalize on a product, product candidates or indications that may be
more profitable or for which there is a greater likelihood of success.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Because we have limited financial and managerial resources, we focus on research programs and product candidates for specific indications. As a
result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions
may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for
specific indications may not yield any commercially viable products. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-39-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=41,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=388165,FOLIO='39',FILE='DISK124:[17ZAA1.17ZAA47301]DI47301A.;11',USER='VSTEFAN',CD='27-FEB-2017;04:19' -->
<A NAME="page_di47301_1_40"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have based our research and development efforts on our Chaperone-Advanced Replacement Therapy ("CHART") platform technologies to develop next-generation ERT products for Fabry, Pompe,
and other LSDs, and on SD-101 for the treatment of EB. Notwithstanding our large investment to date and anticipated future expenditures in proprietary technologies, we have not yet developed, and may
never successfully develop, any marketed drugs using this approach. As a result of pursuing the development of our product and product candidates using our proprietary technologies, we may fail to
develop products or product candidates or address indications based on other scientific approaches that may offer greater commercial potential or for which there is a greater likelihood of success.
Research programs to identify new product candidates require substantial technical, financial and human resources. These research programs may initially show promise in identifying potential product
candidates, yet fail to yield product candidates for clinical development. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Initial results from a clinical trial do not ensure that the trial will be successful and success in early stage clinical trials does not ensure success in later-stage clinical
trials.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will only obtain regulatory approval to commercialize a product candidate if we can demonstrate to the satisfaction of the FDA or the
applicable non-U.S. regulatory authority, in
well-designed and conducted clinical trials, that the product candidate is safe and effective and otherwise meets the appropriate standards required for approval for a particular indication. Clinical
trials are lengthy, complex and extremely expensive processes with uncertain results. A failure of one or more of our clinical trials may occur at any stage of testing. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Success
in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful, and initial results from a clinical trial do not necessarily
predict final results. We cannot be assured that these trials will ultimately be successful. In addition, patients may not be compliant with their dosing regimen or trial protocols or they may
withdraw from the clinical trial at any time for any reason. For example, we recently reported preliminary data from a Phase&nbsp;1/2 clinical trial of ATB200/AT2221 in Pompe disease. The
preliminary data is based on a small patient sample and reported before completion of the study and therefore may not be predictive of future results, that the results of additional preliminary data
or data from the completed study or any future study may not yield results that are consistent with the preliminary data presented, that we may not be able to demonstrate the safety and efficacy of
ATB200/AT2221, that later study results may not support further development, or even if such later results are favorable, that we will not be able to successfully complete the development of, obtain
regulatory approval for, or successfully commercialize ATB200/AT2221. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Similarly,
we previously reported favorable results from a Phase&nbsp;2 trial of SD-101 in EB. However, there can be no assurance that the results from the ongoing Phase&nbsp;3 trial
will be favorable. Further, we remain in discussion with FDA regarding the statistical analysis plan for the Phase&nbsp;3 trial results and the outcome of those discussions may not yield positive
results and even if we and FDA agree on the statistical analysis plan, we may not demonstrate safety and efficacy of SD-101 and may not obtain regulatory approval of SD-101. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, while the clinical trials of our product candidates are designed based on the available relevant information, in view of the uncertainties inherent in drug development, such
clinical trials may not be designed with focus on indications, patient populations, dosing regimens, safety or efficacy parameters or other variables that will provide the necessary safety or efficacy
data to support regulatory approval to commercialize the resulting product candidates. In addition, individual patient responses to the dose administered of a product candidate may vary in a manner
that is difficult to predict. Also, the methods we select to assess particular safety or efficacy parameters may not yield statistical precision in estimating our product candidates' effects on study
participants. Even if we believe the data collected from clinical trials of our product candidates are promising, these data may not be sufficient to support approval by the FDA or foreign regulatory
authorities. Preclinical and </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-40-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=42,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=765466,FOLIO='40',FILE='DISK124:[17ZAA1.17ZAA47301]DI47301A.;11',USER='VSTEFAN',CD='27-FEB-2017;04:19' -->
<A NAME="page_di47301_1_41"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>clinical
data can be interpreted in different ways. Accordingly, the FDA or foreign regulatory authorities could interpret these data in different ways from us or our partners, which could delay,
limit or prevent regulatory approval. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, our product and certain of our product candidates are based on our active-site pharmacological chaperone technology. To date, we are not aware that any product based on
active-site pharmacological chaperone technology has been approved by the FDA. As a result, if the FDA requires different endpoints than the endpoints we anticipate using or have used in our clinical
trials, or a different analysis of those endpoints, it may be more difficult for us to obtain, or we may be delayed in obtaining, FDA approval of our product candidates. If we are not successful in
commercializing any of our products or product candidates, or are significantly delayed in doing so, our business will be materially harmed. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> We have limited experience in conducting and managing the preclinical development activities and clinical trials necessary to obtain regulatory approvals, including approval by the
FDA and EMA.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have limited experience in conducting and managing the preclinical development activities and clinical trials necessary to obtain regulatory
approvals, including approval by the FDA and EMA. We have only obtained regulatory approval for one product in the EU and Switzerland and are early in the process of commercializing that product. Our
limited experience might prevent us from successfully designing or implementing a clinical trial for our product candidates. We have limited experience in conducting and managing the application
process necessary to obtain regulatory approvals and we might not be able to demonstrate that our product candidates meet the appropriate standards for regulatory approval. If we are not successful in
conducting and managing our preclinical development activities or clinical trials or obtaining regulatory approvals, we might not be able to commercialize our product candidates, or might be
significantly delayed in doing so, which will materially harm our business. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> We may not be able to obtain or maintain orphan drug exclusivity for our product or product candidates. If our competitors are able to obtain orphan drug exclusivity for their
products, we may not be able to have competing products approved by the applicable regulatory authority for a significant period of time.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regulatory authorities in some jurisdictions, including the EU and the United States, may designate drugs for relatively small patient
populations as orphan drugs. We obtained orphan drug designations from the FDA for migalastat HCl for the treatment of Fabry disease in February 2004. We also obtained orphan medicinal product
designation in the EU for migalastat HCl in May 2006. SD-101 has also received these designations from the FDA and EMA. Generally, if a product with an orphan drug designation subsequently receives
the first marketing approval for the indication for which it has such designation, the product is entitled to a period of market exclusivity, which, subject to certain exceptions, precludes the EMA
from approving another marketing application for a similar medicinal product or the FDA from approving another marketing application for the same drug for the same indication for that time period. The
applicable market exclusivity period for orphan
drugs is ten years in the EU and seven years in the United States. The EU exclusivity period can be reduced to six years if a drug no longer meets the criteria for orphan drug designation, including
if the drug is sufficiently profitable so that market exclusivity is no longer justified. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the EU, a "similar medicinal product" is a medicinal product containing a similar active substance or substances as contained in a currently authorized orphan medicinal product, and
which is intended for the same therapeutic indication. For a drug such as migalastat HCl, which is composed of small molecules, the FDA defines "same drug" as a drug that contains the same active
moiety and is intended for the same use. Obtaining orphan drug exclusivity for migalastat HCl for these indications, both in the EU and in the United States, may be important to the product
candidate's and our CHART program's success. If a competitor obtains orphan drug exclusivity for and approval of a </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-41-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=43,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=48718,FOLIO='41',FILE='DISK124:[17ZAA1.17ZAA47301]DI47301A.;11',USER='VSTEFAN',CD='27-FEB-2017;04:19' -->
<A NAME="page_di47301_1_42"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>product
with the same indication as migalastat HCl before we do and if the competitor's product is the same drug or a similar medicinal product as ours, we could be excluded from the market for a
certain period of time. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Even
if we obtain orphan drug exclusivity for migalastat HCl for these indications, we may not be able to maintain it. For example, if a competitive product that is the same drug or a
similar medicinal product as our product or product candidate is shown to be clinically superior to our product or product candidate, as applicable, any orphan drug exclusivity we have obtained will
not block the approval of such competitive product. In addition, orphan drug exclusivity will not prevent the approval of a product that is the same drug as our product or product candidate if the FDA
finds that we cannot assure the availability of sufficient quantities of the drug to meet the needs of the persons with the disease or condition for which the drug was designated. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Failure to obtain or maintain regulatory approval in international jurisdictions would prevent us from marketing migalastat or our other products abroad.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In order to market and sell migalastat HCl and our other products in the EU and many other jurisdictions, we must obtain separate marketing
approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may
differ from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition,
some countries outside the United States require approval of the sales price of a drug before it can be marketed. In many countries, separate procedures must be followed to obtain reimbursement. We
may not obtain marketing, pricing or reimbursement
approvals outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one
regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. We may not be able to file for marketing approvals
and may not receive necessary approvals to commercialize our products in any market. Regulatory approvals in countries outside the United States do not ensure pricing approvals in those countries or
in any other countries, and regulatory approvals and pricing approvals do not ensure that reimbursement will be obtained. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Our product or product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval or commercialization.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Undesirable side effects caused by our product or product candidates could interrupt, delay or halt clinical trials and could result in the
denial of regulatory approval by the FDA, EMA or other regulatory authorities for any or all targeted indications, and in turn prevent us from commercializing our product or product candidates and
generating revenues from their sale. In addition, if we or others identify undesirable side effects caused by our products or product candidates after receipt of marketing
approval:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> regulatory authorities may require the addition of restrictive labeling statements; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> regulatory authorities may withdraw their approval of the product; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we may be required to change the way the product is administered or additional clinical trials are conducted. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
of these events could prevent us from achieving or maintaining market acceptance of the affected product or product candidate or could substantially increase the costs and expenses
of commercializing the product or product candidate, which in turn could delay or prevent us from generating significant revenues from its sale or adversely affect our reputation. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-42-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=44,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=960249,FOLIO='42',FILE='DISK124:[17ZAA1.17ZAA47301]DI47301A.;11',USER='VSTEFAN',CD='27-FEB-2017;04:19' -->
<A NAME="page_di47301_1_43"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our product or product candidates, we may not be
successful in commercializing migalastat HCl or any product candidate if and when they are approved.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have only recently built our sales and marketing infrastructure and have little experience in the sale and marketing of pharmaceutical
products. To achieve commercial success for any approved product, we must continue to develop and maintain a sales and marketing organization or outsource these functions to third parties. We are
continuing to establish our own sales and marketing capabilities and to promote migalastat HCl in the EU with a targeted sales force, and to do the same in the United States if or when migalastat HCl
or any other product candidate is approved in the United States. There are risks involved with establishing our own sales and marketing capabilities and entering into arrangements with third parties
to perform these services. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for
which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses.
This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. Similarly, if we enter into agreements with third parties, including the out
licensing of our product or product candidates, we may choose to reduce or eliminate our sales and marketing operations and thereby lose our commercialization investment. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Factors
that may inhibit our efforts to commercialize migalastat HCl and our product candidates, if and when they are approved by regulatory authorities, including the FDA and EMA, on
our own include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the inability of sales personnel to obtain access to adequate numbers of physicians to prescribe any future products; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with
more extensive product lines; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> unforeseen costs and expenses associated with creating an independent sales and marketing organization; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> efforts by our competitors to commercialize products at or about the time when our product candidates would be coming to market. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may also co-promote or out license our product or product candidates in various markets with pharmaceutical and biotechnology companies in instances where we believe that a larger
sales and marketing presence will expand the market or accelerate penetration. If we do enter into arrangements with third parties to perform sales and marketing services, our product revenues will be
lower than if we directly sold and marketed our products and any revenues received under such arrangements will depend on the skills and efforts of others. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may not be successful in entering into distribution arrangements and marketing alliances with third parties. Our failure to enter into these arrangements on favorable terms could
delay or impair our ability to commercialize our product and product candidates and could increase our costs of commercialization. Dependence on distribution arrangements and marketing alliances to
commercialize our products and product candidates will subject us to a number of risks, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we may not be able to control the amount and timing of resources that our distributors may devote to the commercialization of our product
candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our distributors may experience financial difficulties; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-43-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=45,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=242014,FOLIO='43',FILE='DISK124:[17ZAA1.17ZAA47301]DI47301A.;11',USER='VSTEFAN',CD='27-FEB-2017;04:19' -->
<A NAME="page_di47301_1_44"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> business combinations or significant changes in a distributor's business strategy may also adversely affect a distributor's willingness or
ability to complete its obligations under any arrangement; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> these arrangements are often terminated or allowed to expire, which could interrupt the marketing and sales of a product and decrease our
revenue. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we are unable to establish adequate sales, marketing and distribution capabilities, whether independently or with third parties, we may not be able to generate product revenue and may
not become profitable. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> If the market opportunities for our product or product candidates are smaller than we believe they are, then our revenues may be adversely affected and our business may suffer.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each of the diseases that our product and most advanced product candidates are being developed to address is rare. Our projections of both the
number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, are based on estimates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Currently,
most reported estimates of the prevalence of these diseases are based on studies of small subsets of the population of specific geographic areas, which are then extrapolated
to estimate the prevalence of the diseases in the broader world population. In addition, as new studies are performed the estimated prevalence of these diseases may change. There can be no assurance
that the prevalence of Fabry disease, EB or Pompe disease in the study populations, particularly in these newer studies, accurately reflects the prevalence of these diseases in the broader world
population. If our estimates of the prevalence of Fabry disease, EB or Pompe disease, or of the number of patients who may benefit from treatment with our product candidates prove to be incorrect, the
market opportunities for our
product and product candidates may be smaller than we believe they are, our prospects for generating revenue may be adversely affected and our business may suffer. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Migalastat HCl or any of our product candidates that receive regulatory approval may fail to achieve the degree of market acceptance by physicians, patients, third party payors and
others in the medical community necessary for commercial success.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Migalastat HCl and any of our other products or product candidates that receive regulatory approval may nonetheless fail to gain sufficient
market acceptance by physicians, patients, third party payors and others in the medical community. If these products do not achieve an adequate level of acceptance, we may not generate significant
product revenues or any profits from operations. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors,
including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the efficacy and potential advantages compared to alternative treatments; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the prevalence and severity of any side effects; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the ability to offer our product and product candidates for sale at competitive prices; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> convenience and ease of administration compared to alternative treatments; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the strength of marketing and distribution support and timing of market introduction of competitive products; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> publicity concerning our products or competing products and treatments; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> sufficient third party coverage or reimbursement. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-44-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=46,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=391519,FOLIO='44',FILE='DISK124:[17ZAA1.17ZAA47301]DI47301A.;11',USER='VSTEFAN',CD='27-FEB-2017;04:19' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dk47301_1_45"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our ability to negotiate, secure and maintain third party coverage and reimbursement may be affected by political, economic and regulatory developments in the
United States, the EU and other jurisdictions. Governments continue to impose cost containment measures, and third party payors are increasingly challenging prices charged for medicines and examining
their cost effectiveness, in addition to their safety and efficacy. These and other similar developments could significantly limit the degree of market acceptance of migalastat HCl or any of our
product candidates that receive marketing approval. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The development and commercialization of new drug products is highly competitive. We face competition with respect to our current product or
product candidates and any products we may seek to develop or commercialize in the future from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide.
For example, several large pharmaceutical and biotechnology companies currently market and sell products for the treatment of
lysosomal storage disorders, including Fabry disease. These products include Sanofi Aventis' Fabrazyme&reg; and Shire&nbsp;plc's Replagal&reg;, as well as other Fabry treatment
products in development. In addition, Sanofi markets and sells Myozyme&reg; and Lumizyme&reg; for the treatment of Pompe disease. We are also aware of other enzyme replacement and
substrate reduction therapies in development by third parties for Pompe and Birken AG has completed a Phase&nbsp;2 trial with Oleogel-S10 for the treatment of EB. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Potential
competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and
establish collaborative arrangements for research, development, manufacturing and commercialization. Our competitors may develop products that are more effective, safer, more convenient or less costly
than any that we are developing or that would render our product candidates obsolete or noncompetitive. Our competitors may also obtain FDA, EMA, or other regulatory approval for their products more
rapidly than we may obtain approval for ours. We may also face competition from off-label use of other approved therapies. There can be no assurance that developments by others will not render our
product candidates or any acquired products obsolete or noncompetitive either during the research phase or once the products reaches commercialization. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe that many competitors, including academic institutions, government agencies, public and private research organizations, large pharmaceutical companies and smaller more focused
companies, are attempting to develop therapies for many of our target indications. Many of our competitors have significantly greater financial resources and expertise in research and development,
manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, prosecuting intellectual property rights and marketing approved products than we do. Smaller and other
early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in
recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies
complementary to or necessary for our programs or advantageous to our business. In addition, if we obtain regulatory approvals for our products, manufacturing efficiency and marketing capabilities are
likely to be significant competitive factors. We currently relay on third party manufacturers for all our products and product candidates, and a limited sales force and marketing infrastructure for
migalastatHCI. Further, many of our competitors have substantial resources and expertise in conducting collaborative arrangements, sourcing in-licensing arrangements, manufacturing and acquiring new
business lines or businesses that are greater than our own. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-45-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=47,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=648541,FOLIO='45',FILE='DISK124:[17ZAA1.17ZAA47301]DK47301A.;8',USER='VSTEFAN',CD='27-FEB-2017;04:19' -->
<A NAME="page_dk47301_1_46"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> A variety of risks associated with international operations could materially adversely affect our business.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Migalastat HCl, and any of our other product candidates that may be approved in the future for commercialization in the EU, or in other foreign
countries, are or will be subject to additional risks related to international operations or entering into international business relationships, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> different regulatory requirements for maintaining approval of drugs in foreign countries; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reduced protection for contractual and intellectual property rights in some countries; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> unexpected changes in tariffs, trade barriers and regulatory requirements; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> economic weakness, including inflation, or political instability in particular foreign economies and markets; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing
business in another country; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> workforce uncertainty in countries where labor unrest is more common than in the United States; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> noncompliance with the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act 2010 and similar anti-bribery and anti-corruption laws in other
jurisdictions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> tighter restrictions on privacy and the collection and use of patient data; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters including earthquakes, typhoons,
floods and fires. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have no prior experience in these areas. In addition, there are complex regulatory, tax, labor and other legal requirements imposed by both the EU and many of the individual countries
in Europe with which we will need to comply. Many U.S.-based biopharmaceutical companies have found the process of marketing their own products in Europe to be very challenging. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Following the receipt of marketing approval of our product or any product candidates, the products may become subject to unfavorable pricing regulations, third party coverage and
reimbursement practices or healthcare reform initiatives, which would harm our business.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The regulations and practices that govern marketing approvals, pricing, commercialization, coverage and reimbursement for new drug products vary
widely from country to country. Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals.
Some countries, including almost all of the member states of the European Economic Area, require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review
period begins after marketing or product licensing approval is granted. In some foreign markets, including the European market,
prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product in a
particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact any revenues we are able to
generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates
obtain marketing approval. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
ability to commercialize migalastat HCl or any product candidate successfully also will depend in part on the extent to which coverage and reimbursement for these products and
related treatments will be available from government health administration authorities, private health insurers and other </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-46-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=48,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=785867,FOLIO='46',FILE='DISK124:[17ZAA1.17ZAA47301]DK47301A.;8',USER='VSTEFAN',CD='27-FEB-2017;04:19' -->
<A NAME="page_dk47301_1_47"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>organizations.
Government authorities and other third party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish
reimbursement levels. A primary trend in the EU and U.S. healthcare industries and elsewhere is cost containment. It is currently unknown what impact, if any, the change in administration in the US
will have on pricing and reimbursement. For the last several years government authorities and other third party payors have attempted to control costs by limiting coverage and the amount of
reimbursement for particular medications. Prices at which we or our customers seek reimbursement for our products can be subject to challenge, reduction or denial by the government and other payers.
Increasingly, third party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be
sure that coverage and reimbursement will be available for migalastat HCl or any product that we commercialize and, if coverage and reimbursement are available, the level of reimbursement.
Reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. Obtaining reimbursement for migalastat HCl may be particularly difficult because
of the higher prices typically associated with drugs directed at smaller populations of patients. In addition, third party payors are likely to impose strict requirements for reimbursement of a higher
priced drug. If reimbursement is not available or is available only to limited levels, we may not be able to successfully commercialize any product for which we obtain marketing approval. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the
applicable regulatory authority. Moreover, eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development,
manufacture, sale and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary
according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs, and may be incorporated into existing payments for
other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently
restrict imports of drugs from countries where they may be sold at lower prices than in the United States. In the United States,
third party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. In the EU, reference pricing systems and other measures may lead to
cost containment and reduced prices. Our inability to promptly obtain coverage and profitable payment rates from both government-funded and private payors for any approved products that we develop
could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition. In addition, in the EU, for medicines
authorized by the Centralised Authorisation Procedure, an authorized trader, such as a wholesaler, can purchase a medicine in one EU member state and import the product into another EU member state.
This process is called "parallel distribution." As a result, a purchaser in one EU member state may seek to import a product from another EU member state where such product is sold at a lower price.
This could have a negative impact on our business, financial condition, results of operations and growth if any of our product candidates are approved in the EU. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Any product or product candidate for which we obtain marketing approval could be subject to restrictions or withdrawal from the market and we may be subject to penalties or other
enforcement actions if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product or our product candidates, when and if any of them are approved.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any product or product candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data,
labeling, advertising and promotional activities for such product, will be subject to continual requirements of and review by the FDA and other regulatory authorities. The FDA's requirements include
submissions of safety and other post-marketing </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-47-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=49,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=926982,FOLIO='47',FILE='DISK124:[17ZAA1.17ZAA47301]DK47301A.;8',USER='VSTEFAN',CD='27-FEB-2017;04:19' -->
<A NAME="page_dk47301_1_48"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>information
and reports, registration requirements, Current Good Manufacturing Practices, or cGMP, requirements relating to manufacturing, quality control, quality assurance and complaints and
corresponding maintenance of records and documents, requirements regarding the distribution of samples to healthcare professionals and recordkeeping. Even if marketing approval of a product candidate
is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or may be subject to significant conditions of approval, including the requirement of
a REMS. The FDA also may impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of the product. The labeling, advertising,
promotion, marketing and distribution of a drug or biologic product also must be in compliance with FDA requirements which include, among others, promotional activities, standards and regulations for
direct-to-consumer advertising, promotional activities involving the internet, and industry sponsored scientific and educational activities. In general, all product promotion must be consistent with
the labeling approved by the FDA for such product, contain a balanced presentation of information on the product's uses, benefits, risks, and important safety information and limitations on use, and
otherwise not be false or misleading. The FDA, has very broad enforcement authority, and failure to abide by these regulations can result in penalties, including the issuance of a warning letter
directing a company
to correct deviations from regulatory standards and enforcement actions that can include seizures, injunctions and criminal prosecution. Failure to comply with applicable FDA requirements and
restrictions also may subject a company to adverse publicity and enforcement action by the FDA, the U.S. Department of Justice ("DOJ") or the Office of the Inspector General of the U.S. Department of
Health and Human Services ("HHS") as well as state authorities. This could subject the company to a range of penalties that could have a significant commercial impact, including civil and criminal
fines and agreements that materially restrict the manner in which a company promotes or distributes its products. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, later discovery of previously unknown adverse events or other problems with our products, manufacturers or manufacturing processes, or failure to comply with regulatory
requirements, may yield various results, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> restrictions on such products, manufacturers or manufacturing processes; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> changes to or restrictions on the labeling or marketing of a product; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> restrictions on product distribution or use; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> requirements to implement a REMS; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> requirements to conduct post-marketing studies or clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> warning or untitled letters; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> withdrawal of the products from the market; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> refusal to approve pending applications or supplements to approved applications that we submit; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> recall of products; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> fines, restitution or disgorgement of profits or revenues; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> suspension or withdrawal of marketing approvals; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> refusal to permit the import or export of our products; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> product seizure; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> injunctions; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the imposition of civil or criminal penalties. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-48-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=50,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=829006,FOLIO='48',FILE='DISK124:[17ZAA1.17ZAA47301]DK47301A.;8',USER='VSTEFAN',CD='27-FEB-2017;04:19' -->
<A NAME="page_dk47301_1_49"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-compliance
with EU requirements regarding safety monitoring or pharmacovigilance, and with requirements related to the development of products for the pediatric population, can also
result in significant financial penalties. Similarly, failure to comply with the EU's requirements regarding the protection of personal information can also lead to significant penalties and
sanctions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we, or our suppliers, third party contractors, clinical investigators or collaborators are slow to adapt, or are unable to adapt, to changes in existing regulatory requirements or
adoption of new regulatory requirements or policies, we or our collaborators may lose marketing approval for our products when and if any of them are approved, resulting in decreased revenue from
milestones, product sales or royalties. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Our relationships with customers, healthcare providers, patients, patient organizations and professionals and third party payors will be subject to applicable anti-kickback, fraud
and abuse, anti-bribery and corruption and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished
profits and future earnings.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Healthcare providers, physicians and payors play a primary role in the recommendation and prescription of any product candidates for which we
may obtain marketing approval. Our future arrangements with payors and customers may expose us to broadly applicable fraud and abuse, anti-bribery and corruption, and other healthcare laws and
regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute any product candidates for which we may obtain marketing approval.
Even though we do not and will not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third party payors, federal, state and foreign healthcare laws and
regulations pertaining to fraud and abuse, anti-bribery and corruption and patients' rights are and will be applicable to our business. Restrictions under applicable federal, state and foreign
healthcare laws and regulations may affect our ability to operate and expose us to areas of risk, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the U.S. federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, offering, receiving or
providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for
which payment may be made under federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to
violate it in order to have committed a violation. Several other countries, including the United Kingdom, have enacted similar anti-kickback, fraud and abuse, and healthcare laws and regulations; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the U.S. federal False Claims Act, which imposes criminal and civil penalties, including through civil whistleblower or qui tam actions,
against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid,
decrease or conceal an obligation to pay money to the federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the federal
Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act. There is also a separate false claims provision imposing criminal penalties. Applicable regulations
of both the EMA and EU member states also impose liability for failing to comply with fraud and abuse laws or improperly using information obtained in in the course of clinical trials with the EMA or
other regulatory authorities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The U.S. federal Health Insurance Portability and Accountability Act of 1996 ("HIPAA") which imposes criminal and civil liability for executing
a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have
actual knowledge of the statute </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-49-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=51,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=700341,FOLIO='49',FILE='DISK124:[17ZAA1.17ZAA47301]DK47301A.;8',USER='VSTEFAN',CD='27-FEB-2017;04:19' -->
<A NAME="page_dk47301_1_50"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>to
defraud any healthcare benefit program or specific intent to violate it in order to have committed a violation. This statute also may impose monetary penalties on any offers or transfers of
remuneration to Medicare or Medicaid beneficiaries (patients) which is likely to influence the beneficiary's selection of particular supplier of government payable items. Similarly, the collection and
use of personal health data in the EU is governed by the EU General Data Protection Regulation (the "GDPR"), with many requirements mandated by the GDPR for the consent of the individuals to whom the
personal data relates, the information provided to the individuals, transfer of personal data within and outside of the EU and the security and confidentiality of the personal data. Failure to comply
with the requirements
of the GDPR may result in substantial fines and other administrative penalties. The GDPR increases our responsibility and liability in relation to personal data that we process and we may be required
to put in place additional mechanisms ensuring compliance with theGDPR. This may be onerous and adversely affect our business, financial condition, results of operations and prospects; </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and its implementing regulations, which
also imposes obligations on certain covered entity healthcare providers, health plans, and healthcare clearinghouses as well as their business associates that perform certain services involving the
use or disclosure of individually identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually
identifiable health information; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> U.S. federal laws requiring drug manufacturers to report annually information related to certain payments and other transfers of value made to
physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership or investment interests held by physicians and their
immediate family members, including under the federal Open Payments program, commonly known as the Sunshine Act, as well as other state and foreign laws regulating marketing activities and requiring
manufacturers to report marketing expenditures, payments and other transfers of value to physicians and other healthcare providers. Similarly, payments made to physicians in certain EU member states
must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician's employer, his or her competent professional
organization and/or the regulatory authorities of the individual EU member states. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in
the EU member states. In addition, the provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of
medicinal products is prohibited in the EU. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> U.S. federal government price reporting laws, which require us to calculate and report complex pricing metrics to government programs, where
such reported prices may be used in the calculation of reimbursement and/or discounts on our marketed drugs. Participation in these programs and compliance with the applicable requirements may subject
us to potentially significant discounts on our products, increased infrastructure costs, potential liability for the failure to report such prices in an accurate and timely manner, and potentially
limit our ability to offer certain marketplace discounts; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> US Foreign Corrupt Practices Act, which prohibit us and third parties working on our behalf from making payments to foreign government
officials to assist in obtaining or retaining business. Specifically, the anti-bribery provisions of the FCPA prohibit the willful use of the mails or any means of instrumentality of interstate
commerce corruptly in furtherance of any offer, payment, promise to pay, or authorization of the payment of money or anything of value to any person, while knowing that all or a portion of such money
or thing of value will be offered, given or promised, directly or indirectly, to a foreign official to influence the foreign </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-50-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=52,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=295761,FOLIO='50',FILE='DISK124:[17ZAA1.17ZAA47301]DK47301A.;8',USER='VSTEFAN',CD='27-FEB-2017;04:19' -->
<A NAME="page_dk47301_1_51"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>official
in his or her official capacity, induce the foreign official to do or omit to do an act in violation of his or her lawful duty, or to secure any improper advantage in order to assist in
obtaining or retaining business for or with, or directing business to, any person; and </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> state and foreign equivalents of each of the above laws, including foreign anti-bribery and corruption laws and state anti-kickback and false
claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental payors, including private insurers; state laws which
require pharmaceutical companies to comply with the pharmaceutical industry's voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise
restricting payments that may be made to healthcare providers; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from
each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While
we do not submit claims and our customers will make the ultimate decision on how to submit claims, we may provide reimbursement guidance and support regarding migalastat HCl, and
our product candidates for which we receive regulatory approval, to our customers and patients. If a government authority were to conclude that we provided improper advice to our customers and/or
encouraged the submission of false claims for reimbursement, we could face action by government authorities. Efforts to ensure that our business arrangements with third parties will comply with
applicable healthcare laws and regulations will involve substantial costs. Nonetheless, it is possible that governmental authorities will conclude that our business practices may not comply with
current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws
or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion from participation in
government
funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we
may obtain.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes
regarding the healthcare system that could prevent or delay marketing approval of migalastat HCl or any of our product candidates, restrict or regulate post-approval activities and affect our ability
to profitably sell any product candidates, including migalastat HCl, for which we obtain marketing approval. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the United States, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or Medicare Modernization Act, changed the way Medicare covers and pays for
pharmaceutical products. The legislation expanded Medicare coverage for drug purchases by the elderly and introduced a new reimbursement methodology based on average sales prices for physician
administered drugs. In addition, this legislation provided authority for limiting the number of drugs that will be covered in any therapeutic class. Cost reduction initiatives and other provisions of
this legislation could decrease the coverage and price that we receive for any approved products. While the Medicare Modernization Act applies only to drug benefits for Medicare beneficiaries, private
payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from the Medicare Modernization
Act may result in a similar reduction in payments from private payors. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
pricing of pharmaceutical products, in general, and specialty drugs, in particular, has also been a topic of concern in the U.S. government, including by the new administration.
There can be no </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-51-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=53,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=32324,FOLIO='51',FILE='DISK124:[17ZAA1.17ZAA47301]DK47301A.;8',USER='VSTEFAN',CD='27-FEB-2017;04:19' -->
<A NAME="page_dk47301_1_52"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>assurance
as to how this scrutiny on pricing of pharmaceutical products will impact future pricing of our products or orphan drugs or pharmaceutical products generally. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
March 2010, President Obama signed into law the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the
Affordable Care Act, a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new
transparency requirements for
health care and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. Effective October&nbsp;1, 2010, the Affordable Care Act
revised the definition of "average manufacturer price" for reporting purposes, which could increase the amount of Medicaid drug rebates to states. Further, the new law imposes a significant annual fee
on companies that manufacture or import branded prescription drug products. A significant number of provisions are not yet, or have only recently become, effective, but the Affordable Care Act is
likely to continue the downward pressure on pharmaceutical pricing, especially under the Medicare program, and may also increase our regulatory burdens and operating costs. We expect that the
Affordable Care Act, as well as other healthcare reform measures that have been and may be adopted in the future, may result in more rigorous coverage criteria, new payment methodologies and in
additional downward pressure on the price that we receive for any approved product, and could seriously harm our future revenues. Any reduction in reimbursement from Medicare or other government
programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may compromise our ability to generate revenue,
attain profitability or commercialize our products. Finally, there are significant ongoing efforts to modify or eliminate the ACA. It is unknown what form any such modifications or any law proposed to
replace the ACA would take, and how or whether it may affect our business in the future. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Legislative
and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure
whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of
our product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA's approval process may significantly delay or prevent marketing approval, as well as subject us
to more stringent product labeling and post-marketing testing and other requirements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the EU, similar political, economic and regulatory developments may affect our ability to profitably commercialize our products. In addition to continuing pressure on prices and cost
containment measures, legislative developments at the EU or member state level may result in significant additional requirements or obstacles that may increase our operating costs. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. If we are found to have promoted off-label uses, we may
become subject to significant liability.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription drug products. In particular,
a product may not be promoted in the United States for uses that are not approved by the FDA as reflected in the product's approved labeling. In particular, any labeling approved by the FDA for
migalastat HCl, SD-101 or any of our other product candidates may include restrictions on use. The FDA may impose further requirements or restrictions on the distribution or use of migalastat HCl,
SD-101 or any of our other product candidates as part of a REMS plan. If we receive marketing approval for migalastat HCl, SD-101 or any other product candidates, physicians may nevertheless prescribe
such products to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label
uses, we may become subject to significant liability. The federal government has levied large civil and criminal fines and / or other penalties against companies for alleged improper promotion and has
investigated and / </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-52-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=54,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=964633,FOLIO='52',FILE='DISK124:[17ZAA1.17ZAA47301]DK47301A.;8',USER='VSTEFAN',CD='27-FEB-2017;04:19' -->
<A NAME="page_dk47301_1_53"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>or
prosecuted several companies in relation to off-label promotion. The FDA has also requested that certain companies enter into consent decrees or permanent injunctions under which specified
promotional conduct is changed, curtailed or prohibited. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and will face
an even greater risk when we commercially sell any products that we develop, including those which may arise from misuse or malfunction of, or design flaws in, such products, whether or not such
problems directly relate to the products and services we have provided. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we will incur
substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reduced resources of our management to pursue our business strategy; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> decreased demand for any product candidates or products that we may develop; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> injury to our reputation and significant negative media attention; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> regulatory investigations, prosecutions or enforcement actions that could require costly recalls or product modifications </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> withdrawal of clinical trial participants; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> significant costs to defend the related litigation; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> increased insurance costs, or an inability to maintain appropriate insurance coverage; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> substantial monetary awards to trial participants or patients, including awards that substantially exceed our product liability insurance,
which we would then be required to pay from other sources, if available, and would damage our ability to obtain liability insurance at reasonable costs, or at all, in the future; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> loss of revenue; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the inability to commercialize any products that we may develop. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
amount of insurance that we currently hold may not be adequate to cover all liabilities that we may incur. We have increased our insurance coverage for the commercialization of
migalastat HCl and may increase insurance coverage when, and if, we begin commercializing any other product candidate that receives marketing approval. Insurance coverage is increasingly expensive. We
may not be able to
maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. On occasion, large judgments have been awarded in lawsuits based on drugs that had
unanticipated side effects. A successful product liability claim or a series of claims brought against us could cause our stock price to fall and, if judgments exceed our insurance coverage, could
decrease our available cash and adversely affect our business. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> If the FDA or other applicable regulatory authorities approve generic or biosimiliar products with claims that compete with our product or any of our product candidates, it could
reduce our sales of our product or those product candidates.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the United States, after an NDA is approved, the product covered thereby becomes a "listed drug" which can, in turn, be cited by potential
competitors in support of approval of an abbreviated NDA, or ANDA. The Federal Food, Drug, and Cosmetic Act, or the FD&amp;C Act, FDA regulations and other applicable regulations and policies provide
incentives to manufacturers to create modified, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-53-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=55,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=211480,FOLIO='53',FILE='DISK124:[17ZAA1.17ZAA47301]DK47301A.;8',USER='VSTEFAN',CD='27-FEB-2017;04:19' -->
<A NAME="page_dk47301_1_54"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>non-infringing
versions of a drug to facilitate the approval of an ANDA or other application for generic substitutes. These manufacturers might only be required to conduct a relatively inexpensive
study to show that their product has the same active ingredients, dosage form, strength, route of administration, and conditions of use, or product labeling, as our product or product candidate and
that the generic product is absorbed in the body at the same rate and to the same extent as, or is bioequivalent to, our product or product candidate. These generic equivalents would be significantly
less costly than ours to bring to market and companies that produce generic equivalents are generally able to offer their products at lower prices. Thus, after the introduction of a generic
competitor, a significant percentage of the sales of any branded product are typically lost to the generic product. Accordingly, competition from generic equivalents to our product or product
candidates would substantially limit our ability to generate revenues and therefore to obtain a return on the investments we have made in our product or product candidates. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Biologics Price Competition and Innovation Act, or BPCIA, was enacted as part of the Patient Protection and Affordable Care Act of 2010, or the ACA, Pub. L. No.&nbsp;111-148
(2010). The BPCIA authorizes the FDA to approve "abbreviated" BLAs for products whose sponsors demonstrate they are "biosimilar" to reference products previously approved under BLAs. The FDA may also
separately determine whether "biosimilar" products are "interchangeable" with their reference products. However, the FDA may not approve an "abbreviated" BLA for a biosimilar product until at least
twelve years after the date on which the BLA for the reference product was approved. FDA approval could be further delayed if the reference products are subject to unexpired and otherwise valid
patents. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior
to the enactment of the BPCIA, information in approved BLAs could not be relied upon by other manufacturers to establish the safety and efficacy of their products for which they
were seeking FDA approval. Accordingly, if our products are approved under a BLA, other manufacturers potentially could develop and seek FDA approval of "biosimilar" products at some point in the
future. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to Our Financial Position and Need for Additional Capital  </B></FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> We have incurred significant losses since our inception and anticipate that we will continue to incur losses in the future.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are an early commercial-stage pharmaceutical company. To date, we have focused on developing our first product, migalastat HCl. Investment in
pharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that a product candidate will fail to gain regulatory approval
or become commercially viable. Since our inception we have not generated any material revenue from product sales. Although the European Commission has granted full approval for the oral small molecule
pharmacological chaperone migalastat HCl as a first-line therapy for long-term treatment of adults and adolescents aged 16&nbsp;years and older with a confirmed diagnosis of Fabry disease
(alpha-galactosidase A deficiency) and who have an amenable mutation, neither the FDA nor any other non-EU foreign regulatory authority (other than Switzerland) has granted regulatory approval to any
of our product candidates, and we continue to incur significant research, development, commercialization and other expenses related to our ongoing operations. As a result, we are not profitable and
have incurred losses in each period since our inception. For the year ended December&nbsp;31, 2016, we have a net loss of $200.0&nbsp;million, and we have an accumulated deficit of
$779.6&nbsp;million at December&nbsp;31, 2016. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-54-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=56,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=212325,FOLIO='54',FILE='DISK124:[17ZAA1.17ZAA47301]DK47301A.;8',USER='VSTEFAN',CD='27-FEB-2017;04:19' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dm47301_1_55"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We expect to continue to incur losses for the foreseeable future, and we expect these losses to increase as we:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> continue our development and commercialization of, and seek regulatory approvals for, our product and product candidates in the United States,
the European Union, and other foreign countries, as applicable; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> conduct additional clinical trials and/or further analysis of pre-existing clinical data to support the New Drug Application, or NDA, of
migalastat HCl in the United States; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> continue communicating with the EMA, as necessary, regarding post-marketing requirements and clinical trials for migalastat HCl; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> continue to or initiate the regulatory submission process for marketing approval of migalastat HCl outside of the United States and EU, as
applicable; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> build our commercial infrastructure so that it is capable of supporting product sales, marketing and distribution of migalastat HCl in the EU
and the US or other territories in which we may receive regulatory approval; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> continue our ongoing Phase&nbsp;3 clinical trial of SD-101 for the treatment of epidermolysis bullosa, or EB; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> continue our preclinical studies and clinical trials on the use of pharmacological chaperones co-formulated or co-administered with enzyme
replacement therapy, or ERT, for Fabry, Pompe, and other lysosomal storage disorders, or LSDs; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> continue our preclinical studies of and potentially conduct clinical studies of CDKL5. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may encounter unforeseen expenses, difficulties, complications, delays, and other unknown factors that may adversely affect our business. The size of our future losses will depend, in
part, on the rate of future growth of our expenses and our ability to generate revenues. If any of our product candidates fails in clinical trials or does not gain regulatory approval, or if approved,
fails to achieve market acceptance, we may never become profitable. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our prior losses
and expected future losses have had and will continue to have an adverse effect on our stockholders' equity and working capital. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> We currently generate no material revenue from the sale of products and may never become profitable.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We began the commercial launch of our first product, migalastat HCl, in May 2016. Accordingly, we have not generated any material revenue from
product sales. Our ability to generate material revenue and become profitable depends upon our ability to successfully commercialize our existing product and product candidates, or product candidates
that we may in-license or acquire in the future. Even if we are able to successfully achieve regulatory approval for our product candidates, we do not know when any of these product candidates will
generate revenue for us, if at all. Our ability to generate revenue from our current or future product and product candidates depends on a number of factors, including our ability
to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> successfully complete development activities and obtain additional regulatory and pricing and reimbursement approvals for, and successfully
commercialize, migalastat HCl; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> develop a commercial organization capable of sales, marketing, and distribution for migalastat HCl and any product candidates we intend to
market, if we receive regulatory approval, in the countries where we have chosen to commercialize the product candidates ourselves; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> manufacture commercial quantities of our products at acceptable cost levels; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-55-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=57,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=661469,FOLIO='55',FILE='DISK124:[17ZAA1.17ZAA47301]DM47301A.;7',USER='LBURNET',CD='28-FEB-2017;11:42' -->
<A NAME="page_dm47301_1_56"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> obtaining a commercially viable price for our products; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> obtain coverage and adequate reimbursement from third-parties, including government payors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> successfully satisfy post-marketing requirements that the FDA, EMA, or other foreign regulatory authorities may impose if migalastat HCl or any
of our other product candidates receive regulatory approval, including pediatric trials and patient registries; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> successfully complete development activities, including the necessary preclinical studies and clinical trials, with respect to product
candidates, including SD-101 and ATB200/ATB2221; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> complete and submit NDAs to the FDA and obtain regulatory approval for our product candidates including migalastat HCl; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> complete and submit applications to, and obtain regulatory approval from, foreign regulatory authorities. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, because of the numerous risks and uncertainties associated with product development, including that our product candidates may not advance through development or achieve the
safety and efficacy endpoints of applicable clinical trials, we are unable to predict the timing or amount of increased expenses, or when or if we will be able to achieve or maintain profitability.
Furthermore, we anticipate incurring significant costs associated with commercializing these products. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Even
if we are able to generate revenues from the sale of our products, we may not become profitable and may need to obtain additional funding to continue operations. If we fail to
become profitable or
are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce our operations. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> If we require substantial additional capital to fund our operations and we fail to obtain necessary financing, we may be unable to complete the development and commercialization of
our product and development and commercialization of our product candidates.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our operations have consumed substantial amounts of cash. We expect to continue to spend substantial amounts to advance the clinical development
of our product candidates, and launch and commercialize our product and product candidates for which we may receive regulatory approval, including continuing to build our own commercial organization.
We believe that our existing cash and cash equivalents will be sufficient to fund our operations into the second half of 2018, including the commercialization of migalastat HCl in the EU, and the
continuation of our development of our other product candidates. However, we may require substantial additional capital for the development and commercialization of our product and further development
and commercialization of our product candidates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
cannot be certain that additional funding will be available on acceptable terms, or at all. If we are unable to raise additional capital in sufficient amounts, when required or on
acceptable terms, we could also be required to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> significantly delay, scale back, or discontinue the development or the commercialization of our product or product candidates or one or more of
our other research and development initiatives; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> seek collaborators for migalastat HCl or one or more of our current or future product candidates at an earlier stage than otherwise would be
desirable, or on terms that are less favorable than might otherwise be available; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> relinquish or license on unfavorable terms our rights to our technologies, product or product candidates that we otherwise would seek to
develop or commercialize ourselves; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> significantly curtail operations. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-56-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=58,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=7870,FOLIO='56',FILE='DISK124:[17ZAA1.17ZAA47301]DM47301A.;7',USER='LBURNET',CD='28-FEB-2017;11:42' -->
<A NAME="page_dm47301_1_57"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties,
and actual results could vary as a result of a number of factors, including the factors discussed elsewhere in this "Risk Factors" section. We have based this estimate on assumptions that may prove to
be wrong, and we could utilize our available capital resources sooner than we currently expect. Our future funding requirements, both near and long-term, will depend on many factors, including, but
not limited to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the costs of commercialization activities, including establishing sales, marketing, and distribution capabilities for migalastat HCl and any
product candidates for which we may receive regulatory approval in regions where we choose to commercialize our products on our own; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the scope, progress, results, and costs of preclinical development, laboratory testing, and clinical trials for our product candidates and any
other product candidates that we may in-license or acquire; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the cost of manufacturing drug supply for our preclinical studies and clinical trials, including the significant cost of new Fabry ERT cell
line development and manufacturing as well as the cost of manufacturing Pompe ERT; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the outcome, timing, and cost of the regulatory approval process by the FDA, EMA, and other foreign regulatory authorities, including the
potential for regulatory authorities to require that we perform more studies than those that we currently anticipate for our product and product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the cost of filing, prosecuting, defending, and enforcing any patent claims and other intellectual property rights; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the cost and timing of completion of existing or expanded commercial-scale outsourced manufacturing activities; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the cost of defending any claims asserted against us; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the emergence of competing technologies and other adverse market developments; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the extent to which we acquire or invest in additional businesses, products, and technologies; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the cost to integrate our recent acquisitions of Scioderm,&nbsp;Inc., or Scioderm, and MiaMed,&nbsp;Inc., or MiaMed, their products and
technologies into our business. </FONT></DD></DL>
</UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Raising additional capital may cause dilution to our existing stockholders, restrict our operations, or require us to relinquish rights to our technologies, migalastat HCl or product
candidates.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may seek additional capital through a combination of private and public equity offerings, debt financings, receivables or royalty financings,
strategic collaborations and alliances, and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest
will be diluted, and the terms may include liquidation or other preferences that adversely affect the rights of existing stockholders. Debt, receivables, and royalty financings may be coupled with an
equity component, such as warrants to purchase stock, which could also result in dilution of our existing stockholders' ownership. For example, stockholders may experience dilution if the holders of
the convertible notes issued in connection with our private placement in December 2016 have their convertible notes converted. The incurrence of additional indebtedness beyond our existing
indebtedness with the convertible note holders could also result in increased fixed payment obligations and could also result in certain restrictive covenants, such as limitations on our ability to
incur further debt, limitations on our ability to acquire or license intellectual property rights, and other operating restrictions that could have a material adverse effect on our ability to conduct
our business and may result in liens being placed on our assets and intellectual </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-57-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=59,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=158656,FOLIO='57',FILE='DISK124:[17ZAA1.17ZAA47301]DM47301A.;7',USER='LBURNET',CD='28-FEB-2017;11:42' -->
<A NAME="page_dm47301_1_58"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>property.
If we were to default on any of our indebtedness, we could lose such assets and intellectual property. If we raise additional funds through strategic collaborations and alliances and
licensing arrangements with third parties, we may have to relinquish valuable rights to migalastat HCl or our product candidates, or grant licenses on terms that are not favorable to us. If we are
unable to raise additional funds through equity or debt financing when needed, we may be required to delay, limit, reduce or terminate our product development or commercialization efforts or grant
rights to develop and market our technologies that we would otherwise prefer to develop and market ourselves. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Servicing our debt requires a significant amount of cash, and we may not have sufficient cash flow from our business to pay our substantial debt.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On December&nbsp;21, 2016, we issued $250&nbsp;million aggregate principal amount of 3.00% unsecured Convertible Senior Notes due 2023 (the
"Convertible Notes"), in a private offering to qualified institutional buyers pursuant to Rule&nbsp;144A under the Securities Act. The Notes bear interest at a fixed rate of 3.00% per year, payable
semiannually on June&nbsp;15 and December&nbsp;15 of each year, beginning on June&nbsp;15, 2017. The Notes will mature on December&nbsp;15, 2023, unless earlier repurchased, redeemed, or
converted in accordance with their terms. The Notes are convertible at the option of the
holders, under certain circumstances and during certain periods, into cash, shares of the Company's common stock, par value $0.01 per share ("Common Stock"), or a combination thereof and may be
settled as described below. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
can be no assurance that our cash and cash equivalents, together with funds generated by our operations and any future financings, will be sufficient to satisfy our debt payment
obligations. Our inability to generate funds or obtain financing sufficient to satisfy our debt payment obligations may result in such obligations being accelerated by our lenders, which would likely
have a material adverse effect on our business, financial condition and results of operations. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> The conditional conversion feature of the Convertible Notes, if triggered, may adversely affect our financial condition and operating results.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event the conditional conversion feature of the Convertible Notes is triggered, holders of such notes will be entitled to convert the
notes at any time during specified periods at their option, which are set forth in the applicable indenture. If one or more holders elect to convert their Convertible Notes, we have the option to
settle conversions entirely in cash, in common stock or a combination thereof. In addition, even if holders do not elect to convert their Convertible Notes, we could be required under applicable
accounting rules to reclassify all or a portion of the outstanding principal of the notes as a current rather than long-term liability, which would result in a material reduction of our net working
capital. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> We have a limited operating history, which may make it difficult for you to evaluate the success of our business to date and to assess our future viability.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We commenced operations in February 2002. Our operations to date have been limited to organizing and staffing our company, acquiring and
developing our technology and undertaking preclinical studies and clinical trials of our most advanced product candidates, including our first product, migalastat HCl. We have not yet generated any
material commercial sales for any of our product candidates. We have not yet demonstrated our ability to obtain global regulatory approvals (including the US), manufacture a commercial scale product,
or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Consequently, any predictions about our future
success or viability may not be as accurate as they could be if we had a longer operating history. In addition, because we were successful in obtaining from the European Union full approval for
migalastat HCl, we will need to transition from </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-58-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=60,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=357202,FOLIO='58',FILE='DISK124:[17ZAA1.17ZAA47301]DM47301A.;7',USER='LBURNET',CD='28-FEB-2017;11:42' -->
<A NAME="page_dm47301_1_59"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>a
company with a research focus to a company capable of supporting commercial activities. We have not demonstrated an ability to commercialize a product and may not be successful in such a transition. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> We may not realize all of the anticipated benefits of the acquisitions of Scioderm or MiaMed.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The success of our acquisitions of Scioderm and MiaMed will depend, in part, on our ability to realize the anticipated growth opportunities and
synergies from combining the businesses of our company, Scioderm and MiaMed. Our ability to realize these benefits, and the timing of this realization, depend upon a number of factors and future
events, many of which we, Scioderm and MiaMed, individually or collectively, cannot control. These factors and events include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> integrating Scioderm's and MiaMed's technology platforms into our company; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reliance on the representations and warranties given by the former Scioderm management and board and former MiaMed management and board which
may prove to be incomplete, inaccurate or misleading. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reliance on the opinions of neutral or other third parties referred to us by the former Scioderm management and board and the former MiaMed
management and board prior to the acquisitions that may prove to be incomplete, inaccurate or misleading. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> obtaining and maintaining intellectual property rights relating to the Scioderm and MiaMed technologies; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> enforcing our intellectual property rights covering SD-101 against third party manufacturers or compounding pharmacies; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> third party manufacturers or compounding pharmacies designing around our intellectual property covering SD-101; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> effectively consolidating research and development operations; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> retaining and attracting key employees; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> consolidating corporate and administrative functions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any delays in enrollment in on-going clinical trials for SD-101; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the success of on-going or later clinical trials for SD-101; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> maintaining new chemical entity exclusivity and/or orphan drug market exclusivity; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> minimizing the diversion of management's attention from ongoing business concerns. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Acquisitions
involve risks, including inaccurate assessment of undisclosed, contingent, or other liabilities or problems. Following the completion of the mergers, the surviving
corporations, which are now wholly owned subsidiaries of our company, possess not only all of the assets, but also all of the liabilities of Scioderm and MiaMed. It is possible that undisclosed,
contingent, or other liabilities or problems may arise in the future of which we were previously unaware. These undisclosed liabilities could have an adverse effect on our business, financial
condition, and prospects. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> We may acquire other assets or businesses, or form collaborations or make investments in other companies or technologies that could harm our operating results, dilute our
stockholders' ownership, increase our debt, or cause us to incur significant expense.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As part of our business strategy, we may continue to pursue acquisitions of assets or businesses, or strategic alliances and collaborations, to
expand our existing technologies and operations. We may not identify or complete these transactions in a timely manner, on a cost-effective basis, or at all, and we may not realize the anticipated
benefits of any such transaction, any of which could have a detrimental </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-59-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=61,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=481016,FOLIO='59',FILE='DISK124:[17ZAA1.17ZAA47301]DM47301A.;7',USER='LBURNET',CD='28-FEB-2017;11:42' -->
<A NAME="page_dm47301_1_60"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>effect
on our financial condition, results of operations, and cash flows. We may not be able to find suitable acquisition candidates, and if we make any acquisitions, we may not be able to integrate
these acquisitions successfully into our existing business and we may incur additional debt or assume unknown or contingent liabilities in connection therewith. Integration of an acquired company or
assets may also disrupt ongoing operations, require the hiring of additional personnel and the implementation of additional internal systems and infrastructure, especially the acquisition of
commercial assets, and require management resources that would otherwise focus on developing our existing business. We may not be able to find suitable collaboration partners or identify other
investment opportunities, and we may experience losses related to any such investments. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
finance any acquisitions or collaborations, we may choose to issue debt or shares of our common stock as consideration. Any such issuance of shares would dilute the ownership of our
stockholders. If the price of our common stock is low or volatile, we may not be able to acquire other assets or companies or fund a transaction using our stock as consideration. Alternatively, it may
be necessary for us to raise additional funds for acquisitions through public or private financings. Additional funds may not be available on terms that are favorable to us, or at all. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of December&nbsp;31, 2016, we had federal, state, and foreign net operating loss carry forwards, or NOLs, of approximately
$637&nbsp;million, $623&nbsp;million, and $40&nbsp;million respectively. The federal carry forward will expire in 2029 through 2036. Most of the state carry forwards generated prior to 2009
expired in 2015. The remaining state carry forwards including those generated from 2009 through 2016 will expire in 2029 through 2036 due to a change in the New Jersey state law regarding the net
operating loss carry forward period. Under Section&nbsp;382 of the Internal Revenue Code of 1986, as amended, or Section&nbsp;382, if a corporation undergoes an "ownership change," generally
defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation's ability to use its pre-change NOLs and other pre-change tax attributes (such as
research and development tax credits) to offset its post-change income may be limited. We may experience ownership changes in the future as a result of shifts in our stock ownership some of which are
outside our control. We completed a detailed study of our NOLs and determined that there was not an ownership change in excess of 50%. Ownership changes in future periods may place additional limits
on our ability to utilize net operating loss and tax credit carry forwards. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which
could accelerate or permanently increase state taxes owed. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to our Intellectual Property  </B></FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> If we are unable to obtain and maintain patent protection for our technology and products, or if the scope of the patent protection is not sufficiently broad, our competitors could
develop and commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our technology and products may be adversely affected.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect
to our proprietary technology and products. We seek to protect our proprietary position by filing patent applications in the United States and in certain foreign jurisdictions related to our novel
technologies, product and product candidates that are important to our business. This process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable
patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to
obtain patent protection. Moreover, if we license technology or product candidates from third parties in the future, these license agreements may not permit us to control the preparation, filing and
prosecution of patent applications, or to maintain or enforce the patents, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-60-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=62,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=206235,FOLIO='60',FILE='DISK124:[17ZAA1.17ZAA47301]DM47301A.;7',USER='LBURNET',CD='28-FEB-2017;11:42' -->
<A NAME="page_dm47301_1_61"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>covering
this intellectual property. These agreements could also give our licensors the right to enforce the licensed patents without our involvement, or to decide not to enforce the patents at all.
Therefore, in these circumstances, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of
much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in
patents being issued which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes in either
the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
degree of future protection for our proprietary rights is uncertain, and we cannot ensure that:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we or our licensors were the first to make the inventions covered by each of our pending patent applications; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we or our licensors were the first to file patent applications for these inventions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> others will not independently develop similar or alternative technologies or duplicate any of our technologies; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any patents issued to us or our licensors will provide a basis for commercially viable products, will provide us with any competitive
advantages or will not be challenged by third parties; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we will develop additional proprietary technologies that are patentable; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we will file patent applications for new proprietary technologies promptly or at all; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our patents will not expire prior to or shortly after commencing commercialization of a product; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the patents of others will not have a negative effect on our ability to do business. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, we cannot be assured that any of our pending patent applications will result in issued patents. In particular, we have filed patent applications in the United States, the
European Patent Office and other countries outside the United States that have not been issued as patents. These pending applications include, among others, some of the patent applications we license
pursuant to a license agreement with Mount Sinai School of Medicine of New York University. If patents are not issued in respect of our pending patent applications, we may not be able to stop
competitors from marketing similar products in Europe and other countries in which we do not have issued patents. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
patents that we have licensed from Mt. Sinai School of Medicine relating to use of migalastat HCl to treat Fabry disease expire in 2018 in the United States and 2019 in Europe,
Japan, and Canada. In addition to patent protection outside of the United States, we intend to seek orphan medicinal product designation and to rely on statutory data exclusivity provisions in
jurisdictions outside the United States where such protections are available, including Europe. The patent rights that we own or have licensed relating to our product candidates are limited in ways
that may affect our ability to exclude third parties from competing against us if we obtain regulatory approval to market these product candidates. In
particular:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We do not hold composition of matter patents covering migalastat HCl. Composition of matter patents can provide protection for pharmaceutical
products to the extent that the specifically covered compositions are important. For our product candidates for which we do not hold composition of matter patents, competitors who obtain the requisite
regulatory approval can </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-61-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=63,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=442770,FOLIO='61',FILE='DISK124:[17ZAA1.17ZAA47301]DM47301A.;7',USER='LBURNET',CD='28-FEB-2017;11:42' -->
<A NAME="page_dm47301_1_62"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>offer
products with the same composition as our products so long as the competitors do not infringe any method of use patents that we may hold. </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> For some of our product candidates, the principal patent protection that covers or those we expect will cover, our product candidate is a
method of use patent. This type of patent only protects the product when used or sold for the specified method. However, this type of patent does not limit a competitor from making and marketing a
product that is identical to our product that is labeled for an indication that is outside of the patented method, or for which there is a substantial use in commerce outside the patented method. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Moreover,
physicians may prescribe such a competitive identical product for indications other than the one for which the product has been approved, or off-label indications, that are
covered by the applicable patents. Although such off-label prescriptions may infringe or induce infringement of method of use patents, the practice is common and such infringement is difficult to
prevent or prosecute. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
laws of foreign countries may not protect our rights to the same extent as the laws of the United States. For example, European patent law restricts the patentability of methods of
treatment of the human body more than U.S. law does. In addition, we may not pursue or obtain patent protection in all major markets. Assuming the other requirements for patentability are met,
currently, the first to file&nbsp;a patent application is generally entitled to the patent. However, prior to March&nbsp;16, 2013, in the United States, the first to invent was entitled to the
patent. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not
published until 18&nbsp;months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our patents or pending
patent applications, or that we were the first to file for patent protection of such inventions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Moreover,
we may be subject to a third party preissuance submission of prior art to the U.S. Patent and Trademark Office or become involved in opposition, derivation, reexamination,
inter partes review, post grant review, interference proceedings or other patent office proceedings or litigation, in the United States or elsewhere, challenging our patent rights or the patent rights
of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or
products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third party patent rights. In addition, if the
breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or
future product candidates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Even
if our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or
otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our owned or licensed patents by developing similar or alternative technologies or products in a
non-infringing manner. In addition, other companies may attempt to circumvent any regulatory data protection or market exclusivity that we obtain under applicable legislation, which may require us to
allocate significant resources to preventing such circumvention. Legal and regulatory developments in the EU and elsewhere may also result in clinical trial data submitted as part of an MAA becoming
publicly available. Such developments could enable other companies to circumvent our intellectual property rights and use our clinical trial data to obtain marketing authorizations in the EU and in
other jurisdictions. Such
developments may also require us to allocate significant resources to prevent other companies from circumventing or violating our intellectual property rights. Our attempts to prevent third parties
from circumventing our intellectual property and other rights may ultimately be unsuccessful. We may also fail to take the required actions or pay the necessary fees to maintain our patents. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-62-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=64,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=9896,FOLIO='62',FILE='DISK124:[17ZAA1.17ZAA47301]DM47301A.;7',USER='LBURNET',CD='28-FEB-2017;11:42' -->
<A NAME="page_dm47301_1_63"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices
in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part,
which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products.
Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates
are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Competitors may infringe our patents, trademarks, copyrights or other intellectual property. To counter infringement or unauthorized use, we may
be required to file claims, which can be expensive and time consuming. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we
infringe their intellectual property. In addition, in a patent infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable, in whole or in part, construe the patent's
claims narrowly or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material
adverse effect on the success of our business.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our research, development and commercialization activities, as well as any product candidates or products resulting from these activities, may
infringe or be accused of infringing one or more claims of an issued patent or may fall within the scope of one or more claims in a published patent application that may subsequently issue and to
which we do not hold a license or other rights. Third parties may own or control these patents or patent applications in the United States and abroad. These third parties could bring claims against us
that would cause us to incur substantial expenses and, if successful against us, could cause us to pay substantial damages. Further, if a patent infringement suit were brought against us, we or they
could be forced to stop or delay research, development, manufacturing or sales of the product or product candidate that is the subject of the suit. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
assurance can be given that patents do not exist, have not been filed, or could not be filed or issued, which contain claims covering our product candidates, technology or methods.
Because of the number of patents issued and patent applications filed in our field, we believe there is a risk that third parties may allege they have patent rights encompassing our product
candidates, technology or methods. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are aware, for example, of U.S. patents, and corresponding international counterparts, owned by third parties that contain claims related to treating protein misfolding. If any of
these patents were to be asserted against us, while we do not believe that our product candidates would be found to infringe any valid claim of such patents, there is no assurance that a court would
find in our favor or that, if we choose or are required to seek a license with respect to such patents, such license would be available to us on acceptable terms or at all. If we were to challenge the
validity of any issued U.S. patent in court, we would need to overcome a presumption of validity that attaches to every patent. This burden is high and would require us to present clear and convincing
evidence as to the invalidity of the patent's claims. There is no assurance that a court would find in our favor on infringement or validity. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-63-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=65,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=693431,FOLIO='63',FILE='DISK124:[17ZAA1.17ZAA47301]DM47301A.;7',USER='LBURNET',CD='28-FEB-2017;11:42' -->
<A NAME="page_dm47301_1_64"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
order to avoid or settle potential claims with respect to any of the patent rights described above or any other patent rights of third parties, we may choose or be required to seek a
license from a third party and be required to pay license fees or royalties or both. These licenses may not be available on acceptable terms, or at all. Even if we or our collaborators were able to
obtain a license, the rights may be nonexclusive, which could result in our competitors gaining access to the same intellectual property. Ultimately, we could be prevented from commercializing a
product, or be forced to cease some aspect of our business operations, if, as a result of actual or threatened patent infringement claims, we are
unable to enter into licenses on acceptable terms. This could harm our business significantly. Others may sue us for infringing their patent or other intellectual property rights or file nullity,
opposition or interference proceedings against our patents, even if such claims are without merit, which would similarly harm our business. Furthermore, during the course of litigation, confidential
information may be disclosed in the form of documents or testimony in connection with discovery requests, depositions or trial testimony. Disclosure of our confidential information and our involvement
in intellectual property litigation could materially adversely affect our business. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
has been substantial litigation and other proceedings regarding patent and other intellectual property rights in the pharmaceutical and biotechnology industries. In addition to
infringement claims against us, we may become a party to other patent litigation and other proceedings, including interference proceedings declared by the U.S. Patent and Trademark Office and
opposition proceedings in the European Patent Office, regarding intellectual property rights with respect to our products and technology. Even if we prevail, the cost to us of any patent litigation or
other proceeding could be substantial. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Some
of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any
uncertainties resulting from any litigation could significantly limit our ability to continue our operations. Patent litigation and other proceedings may also absorb significant management time. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> We may be subject to claims by third parties asserting that we or our employees have misappropriated their intellectual property, or claiming ownership of what we regard as our own
intellectual property.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Many of our employees were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or
potential competitors. Although we try to ensure that our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these
employees have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee's former employer. Litigation may be necessary to defend against
these claims. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, while we typically require our employees and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual
property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Our and their assignment agreements may not
be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our
intellectual property. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful
in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to management. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-64-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=66,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=772173,FOLIO='64',FILE='DISK124:[17ZAA1.17ZAA47301]DM47301A.;7',USER='LBURNET',CD='28-FEB-2017;11:42' -->
<A NAME="page_dm47301_1_65"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Intellectual property litigation could cause us to spend substantial resources and could distract our personnel from their normal responsibilities.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant
expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other
interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such
litigation or proceedings could substantially increase our operating losses and reduce the resources available for development, sales, marketing or distribution activities. We may not have sufficient
financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we
can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our
ability to compete in the marketplace. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition to seeking patents for some of our technology and products, we also rely on trade secrets, including unpatented know-how, technology
and other proprietary information, to maintain our competitive position. We seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties
who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. We also enter into
confidentiality and invention or patent assignment agreements with our employees and consultants. However, we cannot guarantee that we have executed these agreements with each party that may have or
have had access to our trade secrets or that the agreements we have executed will provide adequate protection. Any party with whom we have executed such an agreement may breach that agreement and
disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a
claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the
United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to
prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be obtained or independently developed by a
competitor, our competitive position would be harmed. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> If we fail to comply with our obligations in our intellectual property licenses with third parties, we could lose license rights that are important to our business.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a party to a license agreement with the Mount Sinai School of Medicine of New York University, pursuant to which we license key
intellectual property relating to our lead product candidates. We expect to enter into additional licenses in the future. Under our existing license, we have the right to enforce the licensed patent
rights. Our existing license imposes, and we expect that future licenses will impose, various diligences, milestone payment, royalty, insurance and other obligations on us. If we fail to comply with
these obligations, the licensor may have the right to terminate the license, in which event we might not be able to market any product that is covered by the licensed patents. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-65-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=67,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=741096,FOLIO='65',FILE='DISK124:[17ZAA1.17ZAA47301]DM47301A.;7',USER='LBURNET',CD='28-FEB-2017;11:42' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_do47301_1_66"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A> </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> We have not yet registered our trademarks in all of our potential markets, and failure to secure those registrations could adversely affect our business.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our trademark applications may not be allowed for registration, and our registered trademarks may not be maintained or enforced. During
trademark registration proceedings, we may receive rejections. Although we are given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the
U.S. Patent and Trademark Office and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel
registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. If we do not secure registrations for our
trademarks, we may encounter more difficulty in enforcing them against third parties than we otherwise would. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Obtaining and maintaining our patent protection depends on compliance with various procedural, document submissions, fee payment and other requirements imposed by governmental patent
agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The U.S. Patent and Trademark Office and various foreign governmental patent agencies require compliance with a number of procedural,
documentary, fee payment and other similar provisions during the patent application process. In addition, periodic maintenance fees on issued patents are required to be paid to the U.S. Patent and
Trademark Office and foreign patent agencies in several stages over the lifetime of the patents. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in
accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of
patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to
official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we fail to maintain the patents and patent applications covering
our product candidates, our competitive position would be adversely affected. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to our Dependence on Third Parties  </B></FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Use of third parties to manufacture our product or product candidates may increase the risk that we will not have sufficient quantities of our product or product candidates or such
quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We do not own or operate manufacturing facilities for clinical or commercial production of our product or product candidates. We lack the
resources and the capabilities to manufacture any of our product or product candidates on a clinical or commercial scale. We currently outsource all manufacturing and packaging of our product and
preclinical and clinical product candidates to third parties. The manufacture of pharmaceutical products requires significant expertise and capital investment, including the development of advanced
manufacturing techniques and process controls. In particular, the manufacture of our biologic product candidates, including ATB200 for Pompe are highly complex and we may encounter difficulties in
production, particularly in scaling up initial production. These problems include difficulties with production costs and yields and quality control, including stability of the product or product
candidate. The occurrence of any of these problems could significantly delay our clinical trials or the commercial availability of our products. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may be unable to enter into agreements for commercial supply with third party manufacturers, or may be unable to do so on acceptable terms. Even if we enter into these agreements, the
manufacturers of each product candidate will be single source suppliers to us for a significant period of time. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-66-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=68,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=131218,FOLIO='66',FILE='DISK124:[17ZAA1.17ZAA47301]DO47301A.;12',USER='VRIVERA',CD='28-FEB-2017;02:25' -->
<A NAME="page_do47301_1_67"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Even
if we are able to establish and maintain arrangements with third party manufacturers, reliance on third party manufacturers entails additional risks,
including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reliance on the third party for regulatory compliance and quality assurance; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> limitations on supply availability resulting from capacity and scheduling constraints of the third parties;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> impact on our reputation in the marketplace if manufacturers of our products, once commercialized, fail to meet the demands of our customers; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the possible breach of the manufacturing agreement by the third party; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the possible misappropriation of our proprietary information, including our trade secrets and know-how; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
failure of any of our contract manufacturers to maintain high manufacturing standards could result in injury or death of clinical trial participants or patients using products. Such
failure could also result in product liability claims, product recalls, product seizures or withdrawals, delays or failures in testing or delivery, cost overruns or other problems that could seriously
harm our business or profitability. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA and regulatory authorities in other jurisdictions require our contract manufacturers to comply with regulations setting forth cGMP. These regulations cover all aspects of the
manufacturing, testing, quality control and recordkeeping relating to our product candidates and any products that we may commercialize. Our manufacturers may not be able to comply with cGMP
regulations or similar regulatory requirements outside the United States. Our failure or the failure of our third party manufacturers, to comply with applicable regulations could significantly and
adversely affect regulatory approval and supplies of our product candidates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
product candidates and any products that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of
manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the third parties that we engage to manufacture product for our preclinical tests and clinical trials should cease to continue to do so for any reason, we likely would experience
delays in advancing these trials while we identify and qualify replacement suppliers and we may be unable to obtain replacement supplies on terms that are favorable to us. In addition, if we are not
able to obtain adequate supplies of our product candidates or the drug substances used to manufacture them, it will be more difficult for us to develop our product candidates and compete effectively. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
current and anticipated future dependence upon others for the manufacture of our product candidates may adversely affect our future profit margins and our ability to develop product
candidates and commercialize any products that receive regulatory approval on a timely and competitive basis. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> We rely on third parties to conduct certain preclinical development activities and our clinical trials, and those third parties may not perform satisfactorily, including failing to
meet deadlines for the completion of such trials.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We do not independently conduct clinical trials for our product candidates or certain preclinical development activities of our product
candidates, such as long-term safety studies in animals. We rely on third parties, such as CROs, clinical data management organizations, medical institutions and clinical investigators, to perform
these functions. Any of these third parties may terminate their engagements with us at any time. If we need to enter into alternative arrangements, it would delay our product development activities. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-67-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=69,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=75302,FOLIO='67',FILE='DISK124:[17ZAA1.17ZAA47301]DO47301A.;12',USER='VRIVERA',CD='28-FEB-2017;02:25' -->
<A NAME="page_do47301_1_68"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
reliance on these third parties for preclinical and clinical development activities reduces our control over these activities but does not relieve us of our responsibilities. For
example, we remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us
to comply with standards, commonly referred to as Good Clinical Practices, or GCP, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are
credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. We also are required to register certain ongoing clinical trials and post the results of
completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within particular timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal
sanctions. Similar GCP and transparency requirements apply in the EU. Failure to comply with such requirements, including with respect to clinical trials conducted outside the EU and United States,
can also lead regulatory authorities to refuse to take into account clinical trial data submitted as part of an MAA. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Furthermore,
third parties that we rely on for our clinical development activities may also have relationships with other entities, some of which may be our competitors. If these third
parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not
be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our product
candidates. Our product development costs will increase if we experience delays in testing or obtaining marketing approvals. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
also rely on other third parties to store and distribute drug supplies for our preclinical development activities and clinical trials. Any performance failure on the part of our
distributors could delay clinical development or marketing approval of our product candidates or commercialization of our products, producing additional losses and depriving us of potential product
revenue. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Extensions,
delays, suspensions or terminations of our preclinical development activities or our clinical trials as a result of the performance of our independent clinical investigators
and CROs will delay, and make more costly, regulatory approval for any product candidates that we may develop. Any change in a CRO during an ongoing preclinical development activity or clinical trial
could seriously delay that trial and potentially compromise the results of the activity or trial. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> We may not be successful in maintaining or establishing collaborations, which could adversely affect our ability to develop and, particularly in international markets, commercialize
products.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are collaborating with physicians, patient advocacy groups, foundations and government agencies in order to assist with the development of
our products and each of our product candidates. We plan to pursue similar activities in future programs and plan to evaluate the merits of retaining commercialization rights for ourselves or entering
into selective collaboration arrangements with leading pharmaceutical or biotechnology companies. We also may seek to establish collaborations for the sales, marketing and distribution of our
products. If we elect to seek collaborators in the future but are unable to reach agreements with suitable collaborators, we may fail to meet our business objectives for the affected product or
program. We face, and will continue to face, significant competition in seeking appropriate collaborators. Moreover, collaboration arrangements are complex and time consuming to negotiate, document
and implement. We may not be successful in our efforts, if any, to establish and implement collaborations or other alternative arrangements. The terms of any collaboration or other arrangements that
we establish, if any, may not be favorable to us. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
collaboration that we enter into may not be successful. The success of our collaboration arrangements, if any, will depend heavily on the efforts and activities of our collaborators.
It is likely that any collaborators of ours will have significant discretion in determining the efforts and resources </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-68-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=70,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=159727,FOLIO='68',FILE='DISK124:[17ZAA1.17ZAA47301]DO47301A.;12',USER='VRIVERA',CD='28-FEB-2017;02:25' -->
<A NAME="page_do47301_1_69"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>that
they will apply to these collaborations. The risks that we may be subject to in possible future collaborations include the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> collaborators may not pursue development and commercialization of our product or product candidates or may elect not to continue or renew
development or commercialization programs, based on clinical trial results, changes in the collaborators' strategic focus or available funding, or external factors such as an acquisition that diverts
resources or creates competing priorities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product
candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or
product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than
ours; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a collaborator with marketing and distribution rights to one or more products may not commit sufficient resources to the marketing and
distribution of such product or products; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to
invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> disputes may arise between the collaborator and us as to the ownership of intellectual property arising during the collaboration;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we may grant exclusive rights to our collaborators, which would prevent us from collaborating with others;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization
of our products or product candidates or that result in costly litigation or arbitration that diverts management attention and resources; and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or
commercialization of the applicable product candidates. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Collaboration
agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all. If a collaborator of ours were to be involved in a
business combination, the continued pursuit and emphasis on our product development or commercialization program could be delayed, diminished or terminated. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Collaborations
with pharmaceutical companies and other third parties often are terminated or allowed to expire by the other party. Such terminations or expirations may adversely affect
us financially and could harm our business reputation in the event we elect to pursue collaborations that ultimately expire or are terminated. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
initial co-formulated product candidate for Fabry Disease that we developed as part of our collaboration with GSK utilized migalastat HCl co-formulated with a proprietary human
recombinant alpha-Gal A enzyme. We plan to continue development of a co-formulated ERT with migalastat HCl with an internally developed Fabry cell line as a next-generation ERT for Fabry disease. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-69-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=71,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=593968,FOLIO='69',FILE='DISK124:[17ZAA1.17ZAA47301]DO47301A.;12',USER='VRIVERA',CD='28-FEB-2017;02:25' -->
<A NAME="page_do47301_1_70"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
risks involved with developing our own internal cell line are in addition to the risks described above with respect to securing and using third party manufacturers and it could
significantly and adversely affect the overall cost of developing the co-formulated product candidate and significantly increase the timelines for development. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Materials necessary to manufacture our product or product candidates may not be available on commercially reasonable terms, or at all, which may delay the development and
commercialization of our product or product candidates.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We rely on the manufacturers of our product and product candidates to purchase from third party suppliers the materials necessary to produce the
compounds for our preclinical studies and clinical trials, and we rely, or will rely, on these other manufacturers for commercial distribution of our product and, if we obtain marketing approval, for
any of our product candidates. Suppliers may not sell these materials to our manufacturers at the time we need them or on commercially reasonable terms and all such prices are susceptible to
fluctuations in price and availability due to transportation costs, government regulations, price controls and changes in economic climate or other foreseen circumstances. We do not have any control
over the process or timing of the acquisition of these materials by our manufacturers. Moreover, we currently do not have any agreements for the commercial production of these materials. If our
manufacturers are unable to obtain these materials for our preclinical studies and clinical trials, product testing and potential regulatory approval of our product candidates would be delayed,
significantly impacting our ability to develop and commercialize our product candidates. If our manufacturers or we are unable to purchase these materials for commercial distribution of our product
or, after regulatory approval has been obtained, our product candidates, the commercial launch of our product and product candidates would be delayed or there would be a shortage in supply, which
would materially affect our ability to generate revenues from the sale of our product or product candidates. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Manufacturing issues may arise that could increase product and regulatory approval costs or delay commercialization.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As we scale up manufacturing of our product and product candidates and conduct required stability testing, we may encounter product, packaging,
equipment and process-related issues that may require refinement or resolution in order to proceed with our planned clinical trials and obtain regulatory approval for commercial marketing. In the
future, we may identify impurities, which
could result in increased scrutiny by regulatory authorities, delays in our clinical programs and regulatory approval, increases in our operating expenses or failure to obtain or maintain approval for
our product or product candidates. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Our business activities involve the use of hazardous materials, which require compliance with environmental and occupational safety laws regulating the use of such materials. If we
violate these laws, we could be subject to significant fines, liabilities or other adverse consequences.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our research and development programs involve the controlled use of hazardous materials, including microbial agents, corrosive, explosive and
flammable chemicals and other hazardous compounds in addition to certain biological hazardous waste. Ultimately, the activities of our third party product manufacturers when a product candidate
reaches commercialization will also require the use of hazardous materials. Accordingly, we are subject to federal, state and local laws governing the use, handling and disposal of these materials.
Although we believe that our safety procedures for handling and disposing of these materials comply in all material respects with the standards prescribed by local, state and federal regulations, we
cannot completely eliminate the risk of accidental contamination or injury from these materials. In addition, our collaborators may not comply with these laws. In the event of an accident or failure
to comply with environmental laws, we could be held liable for damages that result, and any such liability could exceed our assets and resources or we could be </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-70-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=72,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=84374,FOLIO='70',FILE='DISK124:[17ZAA1.17ZAA47301]DO47301A.;12',USER='VRIVERA',CD='28-FEB-2017;02:25' -->
<A NAME="page_do47301_1_71"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>subject
to limitations or stoppages related to our use of these materials which may lead to an interruption of our business operations or those of our third party contractors. While we believe that
our existing insurance coverage is generally adequate for our normal handling of these hazardous materials, it may not be sufficient to cover pollution conditions or other extraordinary or
unanticipated events. Furthermore, an accident could damage or force us to shut down our operations. Changes in environmental laws may impose costly compliance requirements on us or otherwise subject
us to future liabilities and additional laws relating to the management, handling, generation, manufacture, transportation, storage, use and disposal of materials used in or generated by the
manufacture of our products or related to our clinical trials. In addition, we cannot predict the effect that these potential requirements may have on us, our suppliers and contractors or our
customers. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to our Business, Employee Matters and Managing Growth  </B></FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Our future success depends on our ability to retain our Chief Executive Officer and other key executives and to attract, retain and motivate qualified personnel.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are highly dependent on John F. Crowley, our Chairman and Chief Executive Officer, Bradley&nbsp;L. Campbell, our President and Chief
Operating Officer, and William D. Baird, III, our Chief Financial Officer. These executives each have significant pharmaceutical industry experience. The loss of the services of any of these
executives might impede the achievement of our research, development and commercialization objectives and materially adversely affect our business and we may not be able to replace these executives
with candidates with similar background and experience in the event of the loss of their services. We do not maintain "key person" insurance on Mr.&nbsp;Crowley or on any of our other executive
officers. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Recruiting
and retaining qualified scientific, clinical and sales and marketing personnel will also be critical to our success. In addition, maintaining a qualified finance and legal
department is key to our ability to meet our regulatory obligations as a public company and important in any potential capital raising activities. Our industry has experienced a high rate of turnover
in recent years. We may not be able to attract and retain these personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel,
particularly in New Jersey and surrounding areas. Although we believe we offer competitive salaries and benefits, we may have to increase spending in order to retain personnel. If we fail to retain
our remaining qualified personnel or replace them when they leave, we may be unable to recruit replacements nor continue our development and commercialization activities. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our
consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> We expect to expand our development, regulatory and sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our
operations.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of December&nbsp;31, 2016, we had 263 full-time employees. As our development and commercialization strategies develop, we will need
additional managerial, operational, sales, marketing, financial and other resources. Our management, personnel and systems currently in place may not be adequate to support this future growth. We may
not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of
employees and reduced productivity among remaining employees. Future growth could require significant capital expenditures and may divert financial resources from other projects, such as the
development of our existing or future product candidates and we may not be </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-71-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=73,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=553474,FOLIO='71',FILE='DISK124:[17ZAA1.17ZAA47301]DO47301A.;12',USER='VRIVERA',CD='28-FEB-2017;02:25' -->
<A NAME="page_do47301_1_72"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>able
to replace key personnel in the event of turnover. Future growth would impose significant added responsibilities on members of management, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> managing the commercialization of migalastat HCl and any product candidates approved for marketing; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> overseeing our ongoing preclinical studies and clinical trials effectively; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> identifying, recruiting, maintaining, motivating and integrating additional employees, including any sales and marketing personnel engaged in
connection with the commercialization of any approved product; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> managing our internal development efforts effectively while complying with our contractual obligations to licensors, licensees, contractors and
other third parties; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> improving our managerial, development, operational and financial systems and procedures;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> developing our compliance infrastructure and processes to ensure compliance with regulations applicable to public companies; and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> expanding our facilities. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
our operations expand, we will need to manage additional relationships with various strategic collaborators, suppliers and other third parties. Our future financial performance and
our ability to commercialize our product candidates and to compete effectively will depend, in part, on our ability to manage any future growth effectively. To that end, we must be able to manage our
development efforts and clinical trials effectively and hire, train and integrate additional management, administrative and sales and marketing personnel. We may not be able to accomplish these tasks,
and our failure to accomplish any of them could prevent us from successfully growing our company. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> We could be negatively impacted by securities class action complaints.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since October&nbsp;1, 2015, three purported securities class action lawsuits have been commenced in the United States District Court for New
Jersey, naming as defendants the Company, its Chairman and Chief Executive Officer, and in one of the actions, its Chief Medical Officer. The lawsuits allege violations of the Securities Exchange Act
of 1934 in connection with allegedly false and misleading statements made by the Company related to the regulatory approval path for migalastat. The plaintiffs seek, among other things, damages for
purchasers of the Company's Common Stock during different periods, all of which fall between March&nbsp;19, 2015 and October&nbsp;1, 2015. It is possible that additional suits will be filed, or
allegations received from stockholders, with respect to similar matters and also naming the Company and/or its officers and directors as defendants. On May&nbsp;26, 2016, the Court consolidated
these lawsuits into a single action and appointed a lead plaintiff. The lead plaintiff filed a Consolidated Amended Class Action Complaint on July&nbsp;11, 2016. On August&nbsp;25, 2016, the
defendants filed a motion to dismiss in response to the Consolidated Amended Class Action Complaint. This motion to dismiss was fully briefed on October&nbsp;28, 2016. Lead plaintiff and defendants
have reached an agreement in principal to fully and finally settle all claims asserted in the Consolidated Amended Class Action Complaint. The settlement is subject to, among other things,
documentation and court approval, and is expected to be fully covered by insurance. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
or about November&nbsp;2, 2015, a derivative lawsuit was filed by an Amicus shareholder purportedly on Amicus' behalf in the Superior Court of New Jersey, Middlesex County, Chancery
Division, against the individuals who serve on the Amicus Board of Directors. Amicus itself was named as a nominal defendant. The derivative lawsuit alleged claims for breach of state law fiduciary
duties, waste of corporate assets, and unjust enrichment based on allegedly false and misleading statements made by Amicus related to the regulatory approval path for migalastat HCl. On
February&nbsp;19, 2016, the complaint was dismissed by the Court and plaintiffs have not refiled. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-72-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=74,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=934293,FOLIO='72',FILE='DISK124:[17ZAA1.17ZAA47301]DO47301A.;12',USER='VRIVERA',CD='28-FEB-2017;02:25' -->
<A NAME="page_do47301_1_73"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
or about March&nbsp;3, 2016, a derivative lawsuit was filed by an Amicus shareholder purportedly on Amicus' behalf in the Superior Court of New Jersey, Middlesex County, Chancery
Division, against various officers and directors of the Company. Amicus itself is named as a nominal defendant. The derivative lawsuit alleges similar facts and circumstances as the three purported
securities class action lawsuits described above and further alleges claims for breach of state law fiduciary duties, waste of corporate assets, unjust enrichment, abuse of control, and gross
mismanagement based on allegedly false and misleading statements made by Amicus related to the regulatory approval path for migalastat HCl. The plaintiff seeks, among other things, to require the
Amicus Board to take certain actions to reform its corporate governance procedures, including greater shareholder input and a provision to permit shareholders to nominate candidates for election to
the Board, along with restitution, costs of suit and attorney's fees. On February&nbsp;7, 2017, the complaint was dismissed by the Court without prejudice. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These
lawsuits and any other related lawsuits are subject to inherent uncertainties and the actual cost will depend upon many unknown factors. The outcome of the litigation is
necessarily uncertain and we could be forced to expend significant resources in the defense of these suits, and we may not prevail. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Our employees, independent contractors, principal investigators, CROs, consultants and vendors may engage in misconduct or other improper activities, including noncompliance with
regulatory standards and requirements, which could cause significant liability for us and harm our reputation.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are exposed to the risk that our employees, independent contractors, principal investigators, CROs, consultants and vendors may engage in
fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that
violates:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> FDA, DEA or similar regulations of foreign regulatory authorities, including those laws requiring the reporting of true, complete and accurate
information to such authorities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> manufacturing standards; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> federal and state healthcare fraud and abuse laws and regulations, anti-bribery and corruption laws, and similar laws and regulations
established and enforced by foreign regulatory authorities; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> laws that require the reporting of financial information or data accurately. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing,
bribery and corruption and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer
incentive programs and other business arrangements. Activities subject to these laws also involve the improper use of information obtained in the course of clinical trials, which could result in
regulatory sanctions and serious harm to our reputation. We have adopted a Code of Business Conduct and Ethics, but it is not always possible to identify and deter misconduct by employees and other
third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or
losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted
against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a material adverse effect on our business and results of operations, including the
imposition of civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in healthcare programs, contractual damages, reputational harm, diminished
profits and future earnings, and curtailment of our operations, any of which could have a material adverse effect on our ability to operate our business and our results of operations. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-73-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=75,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=708749,FOLIO='73',FILE='DISK124:[17ZAA1.17ZAA47301]DO47301A.;12',USER='VRIVERA',CD='28-FEB-2017;02:25' -->
<A NAME="page_do47301_1_74"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Our business and operations would suffer in the event of computer system failures.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Despite the implementation of security measures, our internal computer systems, and those of our CROs, contract manufacturing organizations and
other third parties on which we rely, we are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. System
failures, accidents or security breaches could cause interruptions in our operations, and could result in a material disruption of our clinical activities and business operations, in addition to
possibly requiring substantial expenditures of resources to remedy. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our
commercialization of our product and our product candidate development programs. For example, the loss of clinical trial data from completed or ongoing clinical trials could result in delays in our
regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruptions or security breach was to result in a loss or damage to our data
or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development of our product candidates could be delayed. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to our Common Stock  </B></FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Our executive officers, directors and principal stockholders maintain the ability to exert significant influence and control over matters submitted to our stockholders for approval.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our executive officers, directors and affiliated stockholders beneficially own shares representing approximately 38% of our common stock as of
December&nbsp;31, 2016. As a result, if these stockholders were to choose to act together, they would be able to exert significant influence and control over matters submitted to our stockholders
for approval, as well as our management and affairs. For example, these persons, if they choose to act together, could influence the election of directors and approval of any merger, consolidation,
sale of all or substantially all of our assets or other business combination or reorganization. This concentration of voting power could delay or prevent an acquisition of us on terms that other
stockholders may desire. The interests of this group of stockholders may not always coincide with the interests of other stockholders, and they may act, whether by meeting or written consent of
stockholders, in a manner that advances their best interests and not necessarily those of other stockholders, including obtaining a premium value for their common stock, and might affect the
prevailing market price for our common stock. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent
attempts by our stockholders to replace or remove our current management.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Provisions in our corporate charter and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that
stockholders may consider favorable, including transactions in which our stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors
might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, these provisions may frustrate or prevent any attempts by
our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Because our board of directors is responsible
for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team. Among others, these
provisions:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> establish a classified board of directors, and, as a result, not all directors are elected at one time;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> allow the authorized number of our directors to be changed only by resolution of our board of directors;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> limit the manner in which stockholders can remove directors from our board of directors;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-74-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=76,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=445156,FOLIO='74',FILE='DISK124:[17ZAA1.17ZAA47301]DO47301A.;12',USER='VRIVERA',CD='28-FEB-2017;02:25' -->
<A NAME="page_do47301_1_75"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of
directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written
consent; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> limit who may call stockholder meetings; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> authorize our board of directors to issue preferred stock, without stockholder approval, which could be used to institute a "poison pill" that
would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> require the approval of the holders of at least 67% of the outstanding voting stock to amend or repeal certain provisions of our charter or
bylaws. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Moreover,
because we are incorporated in Delaware, we are governed by the provisions of Section&nbsp;203 of the Delaware General Corporation Law, which prohibits a person who owns in
excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our
outstanding voting stock, unless the merger or combination is approved in a prescribed manner. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> The price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common stock.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The market price of our common stock is highly volatile and may be subject to wide fluctuations in response to various factors, some of which
are beyond our control. In addition to the factors discussed in this prospectus, these factors include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the success of competitive products or technologies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> regulatory actions with respect to our product or product candidates or our competitors' products or product candidates;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> actual or anticipated changes in our growth rate relative to our competitors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the outcome of any patent infringement or other litigation that may be brought against us;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> announcements by us or our competitors of significant acquisitions, strategic collaborations, joint ventures, collaborations or capital
commitments; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> results of clinical trials of our product candidates or those of our competitors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> regulatory or legal developments in the EU, United States and other countries; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> developments or disputes concerning patent applications, issued patents or other proprietary rights;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the recruitment or departure of key personnel; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the level of expenses related to our product or any of our product candidates or clinical development programs;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> actual or anticipated variations in our quarterly operating results; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the number and characteristics of our efforts to in-license or acquire additional product candidates or products;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> introduction of new products or services by us or our competitors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> failure to meet the estimates and projections of the investment community or that we may otherwise provide to the
public;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-75-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=77,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=962598,FOLIO='75',FILE='DISK124:[17ZAA1.17ZAA47301]DO47301A.;12',USER='VRIVERA',CD='28-FEB-2017;02:25' -->
<A NAME="page_do47301_1_76"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> variations in our financial results or those of companies that are perceived to be similar to us;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> fluctuations in the valuation of companies perceived by investors to be comparable to us;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> announcement or expectation of additional financing efforts; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> sales of our common stock by us, our insiders or our other stockholders; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> changes in accounting practices; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> lawsuits and other claims asserted against us; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> changes in the structure of healthcare payment systems; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> market conditions in the pharmaceutical and biotechnology sectors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> general economic, industry and market conditions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> publication of research reports about us, our competitors or our industry, or positive or negative recommendations or withdrawal of research
coverage by securities or industry analysts; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> other events or factors, many of which are beyond our control; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the other factors described in this "Risk Factors" section. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, the stock market in general, and pharmaceutical and biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been
unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual
operating performance. The realization of any of the above risks or any of a broad range of other risks stated above could have a material adverse effect on the market price of our common stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
we operate in the pharmaceutical and biotechnology industry, we are especially vulnerable to these factors to the extent that they affect our industry or our products. In the past,
securities class action litigation has often been initiated against companies following periods of volatility in their stock price. This type of litigation could result in substantial costs and divert
our management's attention and resources, and could also require us to make substantial payments to satisfy judgments or to settle litigation. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> The capped call transactions may affect the value of the Convertible Notes and our common stock.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with the issuance of the Convertible Notes, we entered into capped call transactions with respect to the Convertible Notes with
certain hedge counterparties. The capped call transactions will cover, subject to customary anti-dilution adjustments, the aggregate number of shares of common stock underlying the Convertible Notes
and are expected generally to reduce potential dilution to the common stock upon conversion of the Convertible Notes in excess of the principal amount of such converted Convertible Notes. In
connection with establishing their initial hedges of the capped call transactions, the hedge counterparties (or their affiliates) entered into various derivative transactions with respect to the
common stock concurrently with, and/or purchased the common stock shortly after, the pricing of the Convertible Notes. The hedge counterparties (or their affiliates) are likely to modify their hedge
positions by entering into or unwinding various derivative transactions with respect to the common stock and/or by purchasing or selling the common stock or other securities of ours in secondary
market transactions prior to the maturity of the Convertible Notes (and are likely to do so during the settlement averaging period under the capped call transactions, which precedes the maturity date
of the Convertible Notes, and on or around any earlier conversion date related to a conversion of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-76-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=78,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=945011,FOLIO='76',FILE='DISK124:[17ZAA1.17ZAA47301]DO47301A.;12',USER='VRIVERA',CD='28-FEB-2017;02:25' -->
<A NAME="page_do47301_1_77"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>the
Convertible Notes). The effect, if any, of any of these transactions and activities on the market price of our common stock or the Convertible Notes will depend in part on market conditions and
cannot be ascertained at this time, but any of these activities could adversely affect the value of our common stock, which could affect the value of the Convertible Notes and the value of our common
stock, if any, that the convertible noteholders receive upon any conversion of the Convertible Notes. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> A significant portion of our total outstanding shares may be sold into the market. This could cause the market price of our common stock to drop significantly, even if our business
is doing well.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the
market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. Certain holders of our common stock have rights, subject to some
conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. We also have
registered on a Form&nbsp;S-8 registration statement all shares of common stock that we may issue under our equity compensation plans. As a result, these shares can be freely sold in the public
market upon issuance, subject to volume limitations applicable to affiliates. In addition, certain of our employees, executive officers and directors have entered into, or may enter into,
Rule&nbsp;10b5-1 plans providing for sales of shares of our common stock from time to time. Under a Rule&nbsp;10b5-1 plan, a broker executes trades pursuant to parameters established by the
employee, director or officer when entering into the plan, without further direction from the employee, officer or director. A Rule&nbsp;10b5-1 plan may be amended or terminated in some
circumstances. Our employees, executive officers and directors may also buy or sell additional shares outside of a Rule&nbsp;10b5-1 plan when they are not in possession of material, nonpublic
information. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> We may fail to qualify for continued listing on The NASDAQ Global Market which could make it more difficult for investors to sell their shares.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our common stock is listed on The NASDAQ Global Market, or NASDAQ. As a NASDAQ listed company, we are required to satisfy the continued listing
requirements of NASDAQ for inclusion in the Global Market to maintain such listing, including, among other things, the maintenance of a minimum closing bid price of $1.00 per share and stockholders'
equity of at least $10.0&nbsp;million. There can be no assurance that we will be able to maintain compliance with the continued listing requirements or that our common stock will not be delisted
from NASDAQ in the future. If our
common stock is delisted by NASDAQ, we could face significant material adverse consequences, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a limited availability of market quotations for our securities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reduced liquidity with respect to our securities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a determination that our shares are a "penny stock," which will require brokers trading in our shares to adhere to more stringent rules,
possibly resulting in a reduced level of trading activity in the secondary trading market for our shares; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a limited amount of news and analyst coverage for our company; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a decreased ability to issue additional securities or obtain additional financing in the future. </FONT></DD></DL>

<P style="font-family:times;"><FONT SIZE=2><B><I> If securities or industry analysts do not publish research or reports or publish unfavorable research about our business, the price of our common stock and trading volume could
decline.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The trading market for our common stock depends in part on the research and reports that securities or industry analysts publish about us or our
business. If securities or industry analysts do not initiate or continue coverage of us, the trading price for our common stock would be negatively affected. In the event we obtain securities or
industry analyst coverage, if one or more of the
analysts who covers us downgrades our common stock, the price of our common stock would likely decline. If </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-77-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=79,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=802767,FOLIO='77',FILE='DISK124:[17ZAA1.17ZAA47301]DO47301A.;12',USER='VRIVERA',CD='28-FEB-2017;02:25' -->
<A NAME="page_do47301_1_78"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>one
or more of these analysts ceases to cover us or fails to publish regular reports on us, interest in the purchase of our common stock could decrease, which could cause the price of our common stock
or trading volume to decline. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> We have broad discretion in the use of our cash and cash equivalents and may not use them effectively.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have broad discretion in the use of our cash and cash equivalents, and investors must rely on the judgment of our management regarding the
use of our cash and cash equivalents. Our management may not use cash and cash equivalents in ways that ultimately increase the value of your investment. Our failure to use our cash and cash
equivalents effectively could result in financial losses that could have a material adverse effect on our business, cause the price of our common stock to decline and delay the development of our
product and product candidates. Pending their use, we may invest our cash and cash equivalents in short-term or long-term, investment-grade, interest-bearing securities. These investments may not
yield favorable returns. If we do not invest or apply our cash and cash equivalents in ways that enhance stockholder value, we may fail to achieve expected financial results, which could cause the
price of our common stock to decline. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are subject to the periodic reporting requirements of the Exchange Act. Our disclosure controls and procedures are designed to reasonably
assure that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to management, recorded, processed, summarized and reported
within the time periods specified in the rules and forms of the Securities and Exchange Commission. We believe that any disclosure controls and procedures, no matter how well conceived and operated,
can provide only reasonable, not absolute, assurance that the objectives of the control system are met. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These
inherent limitations reflect the reality that judgments can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented
by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system,
misstatements due to error or fraud may occur and not be detected. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> If the common stock issued as consideration in our recent acquisitions is sold, such sales could cause our common stock price to decline.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The issuance of our common stock in connection with the Scioderm and MiaMed acquisitions could have the effect of depressing the market price
for our common stock, through dilution of earnings per share or otherwise. All of the shares of common stock issued to the former security holders of Scioderm and MiaMed in connection with the
closings of the acquisitions have been registered under the Securities Act of 1933, as amended (the "Securities Act"), pursuant to automatic shelf registration statements on Form&nbsp;S-3 (File
Nos.&nbsp;333-207210 and 333-212414, respectively for the Scioderm and MiaMed acquisitions) and may now be resold by the former security holders of Scioderm and MiaMed to investors in the general
market. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Because we do not anticipate paying any cash dividends on our capital in the foreseeable future, capital appreciation, if any, will be our stockholders sole source of gain.  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance
the development and growth of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock
will be our stockholders sole source of gain for the foreseeable future. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-78-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=13,SEQ=80,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=949494,FOLIO='78',FILE='DISK124:[17ZAA1.17ZAA47301]DO47301A.;12',USER='VRIVERA',CD='28-FEB-2017;02:25' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dq47301_1_79"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="dq47301_item_1b._unresolved_staff_comments."> </A>
<A NAME="toc_dq47301_1"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;1B.&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>UNRESOLVED STAFF COMMENTS.    <BR>    </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None.  </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><A
NAME="dq47301_item_2._properties."> </A>
<A NAME="toc_dq47301_2"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>PROPERTIES.    <BR>    </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table contains information about our current significant leased properties as of December&nbsp;31, 2016. </FONT></P>
 <div style="display:none;*display:block;margin-top:-4pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR style="line-height:0pt;"><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="100.00%" style="font-family:times;"><div style="width:100.00%;"></div></TD>
<TD WIDTH="12.0pt" style="font-family:times;"><div style="width:12.0pt;"></div></TD>
<TD WIDTH="8.56pt" style="font-family:times;"><div style="width:8.56pt;"></div></TD>
<TD WIDTH="5.0pt" ALIGN="RIGHT" style="font-family:times;"><div style="width:5.0pt;"></div></TD>
<TD WIDTH="22.52pt" style="font-family:times;"><div style="width:22.52pt;"></div></TD>
<TD WIDTH="8.56pt" style="font-family:times;"><div style="width:8.56pt;"></div></TD>
<TD WIDTH="12.0pt" style="font-family:times;"><div style="width:12.0pt;"></div></TD>
<TD WIDTH="93.78pt" style="font-family:times;"><div style="width:93.78pt;"></div></TD>
<TD WIDTH="12.0pt" style="font-family:times;"><div style="width:12.0pt;"></div></TD>
<TD WIDTH="69.86pt" style="font-family:times;"><div style="width:69.86pt;"></div></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="white-space:nowrap;font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Location

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="white-space:nowrap;font-family:times;"><FONT SIZE=1>&#8203;</FONT></TH>
<TH COLSPAN=4 ALIGN="CENTER" style="white-space:nowrap;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Approximate Square Feet </B></FONT></TH>
<TH style="white-space:nowrap;font-family:times;"><FONT SIZE=1>&#8203;</FONT></TH>
<TH ALIGN="CENTER" style="white-space:nowrap;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Use </B></FONT></TH>
<TH style="white-space:nowrap;font-family:times;"><FONT SIZE=1>&#8203;</FONT></TH>
<TH ALIGN="CENTER" style="white-space:nowrap;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Lease expiry date </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cranbury, New Jersey</FONT></TD>
<TD style="white-space:nowrap;font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;" COLSPAN=2><FONT SIZE=2>90,000</FONT></TD>
<TD VALIGN="BOTTOM" style="white-space:nowrap;font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Office and laboratory</FONT></TD>
<TD VALIGN="BOTTOM" style="white-space:nowrap;font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>September 2025</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Durham, North Carolina</FONT></TD>
<TD style="white-space:nowrap;font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;" COLSPAN=2><FONT SIZE=2>5,603</FONT></TD>
<TD VALIGN="BOTTOM" style="white-space:nowrap;font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Office</FONT></TD>
<TD VALIGN="BOTTOM" style="white-space:nowrap;font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>June 2018</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Buckinghamshire, United Kingdom</FONT></TD>
<TD style="white-space:nowrap;font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;" COLSPAN=2><FONT SIZE=2>9,821</FONT></TD>
<TD VALIGN="BOTTOM" style="white-space:nowrap;font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Office</FONT></TD>
<TD VALIGN="BOTTOM" style="white-space:nowrap;font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>September 2020</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Munich, Germany</FONT></TD>
<TD style="white-space:nowrap;font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;" COLSPAN=2><FONT SIZE=2>4,316</FONT></TD>
<TD VALIGN="BOTTOM" style="white-space:nowrap;font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Office</FONT></TD>
<TD VALIGN="BOTTOM" style="white-space:nowrap;font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>April 2017</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to the above, we also maintain small offices in Netherland, Italy, Spain and France. We believe that our current office and laboratory facilities are adequate and suitable
for our current and anticipated needs. We believe that, to the extent required, we will be able to lease or buy additional facilities at commercially reasonable rates.  </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="dq47301_item_3._legal_proceedings."> </A>
<A NAME="toc_dq47301_3"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;3.&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>LEGAL PROCEEDINGS.    <BR>    </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since October&nbsp;1, 2015, three purported securities class action lawsuits have been commenced in the United States District Court for New
Jersey, naming as defendants the Company, its Chairman and Chief Executive Officer, and in one of the actions, its Chief Medical Officer. The lawsuits allege violations of the Securities Exchange Act
of 1934 in connection with allegedly false and misleading statements made by the Company related to the regulatory approval path for migalastat. The plaintiffs seek, among other things, damages for
purchasers of the Company's Common Stock during different periods, all of which fall between March&nbsp;19, 2015 and October&nbsp;1, 2015. It is possible that additional suits will be filed, or
allegations received from stockholders, with respect to similar matters and also naming the Company and/or its officers and directors as defendants. On May&nbsp;26, 2016, the Court consolidated
these lawsuits into a single action and appointed a lead plaintiff. The lead plaintiff filed a Consolidated Amended Class Action Complaint on July&nbsp;11, 2016. On August&nbsp;25, 2016, the
defendants filed a motion to dismiss in response to the Consolidated Amended Class Action Complaint. This motion to dismiss was fully briefed on October&nbsp;28, 2016. Lead plaintiff and defendants
have reached an agreement in principal to fully and finally settle all claims asserted in the Consolidated Amended Class Action Complaint. The settlement is immaterial to the Company's consolidated
financial statements and is subject to, among other things, documentation and court approval. The settlement amount is expected to be fully covered under insurance. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
or about November&nbsp;2, 2015, a derivative lawsuit was filed by an Amicus shareholder purportedly on Amicus' behalf in the Superior Court of New Jersey, Middlesex County, Chancery
Division, against the individuals who serve on the Amicus Board of Directors. Amicus itself was named as a nominal defendant. The derivative lawsuit alleged claims for breach of state law fiduciary
duties, waste of corporate assets, and unjust enrichment based on allegedly false and misleading statements made by Amicus related to the regulatory approval path for migalastat HCl. On
February&nbsp;19, 2016, the complaint was dismissed by the Court and plaintiffs have not refiled. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
or about March&nbsp;3, 2016, a derivative lawsuit was filed by an Amicus shareholder purportedly on Amicus' behalf in the Superior Court of New Jersey, Middlesex County, Chancery
Division, against various officers and directors of the Company. Amicus itself is named as a nominal defendant. The derivative lawsuit alleges similar facts and circumstances as the three purported
securities class action lawsuits described above and further alleges claims for breach of state law fiduciary duties, waste of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-79-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=81,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=325163,FOLIO='79',FILE='DISK124:[17ZAA1.17ZAA47301]DQ47301A.;15',USER='JTAYLORA',CD=';1-MAR-2017;09:39' -->
<A NAME="page_dq47301_1_80"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>corporate
assets, unjust enrichment, abuse of control, and gross mismanagement based on allegedly false and misleading statements made by Amicus related to the regulatory approval path for migalastat
HCl. The plaintiff seeks, among other things, to require the Amicus Board to take certain actions to
reform its corporate governance procedures, including greater shareholder input and a provision to permit shareholders to nominate candidates for election to the Board, along with restitution, costs
of suit and attorney's fees. On February&nbsp;7, 2017, the complaint was dismissed by the Court without prejudice. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These
lawsuits and any other related lawsuits are subject to inherent uncertainties and the actual cost will depend upon many unknown factors. The outcome of the litigation is
necessarily uncertain and we could be forced to expend significant resources in the defense of these suits, and we may not prevail.  </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="dq47301_item_4._mine_safety_disclosures."> </A>
<A NAME="toc_dq47301_4"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;4.&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>MINE SAFETY DISCLOSURES.    <BR>    </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-80-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=82,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=523524,FOLIO='80',FILE='DISK124:[17ZAA1.17ZAA47301]DQ47301A.;15',USER='JTAYLORA',CD=';1-MAR-2017;09:39' -->
<A NAME="page_dq47301_1_81"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dq47301_part_ii"> </A>
<A NAME="toc_dq47301_5"> </A>
<BR></FONT><FONT SIZE=2><B>  PART II    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="dq47301_item_5._market_for_the_registr__ite04803"> </A>
<A NAME="toc_dq47301_6"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;5.&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>MARKET FOR THE REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.    <BR>
</I></B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Market For Our Common Stock  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our common stock has been traded on the NASDAQ Global Market under the symbol "FOLD" since May&nbsp;31, 2007. Prior to that time, there was no
public market for our common stock. The following table sets forth the range of high and low closing sales prices of our common stock as quoted on the NASDAQ Global Market for the periods indicated. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:75%;margin-left:12%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="32pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="32pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>High </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Low </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>2016</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>First Quarter</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9.21</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5.16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Second Quarter</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8.69</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5.00</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Third Quarter</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7.94</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5.58</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Fourth Quarter</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9.35</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.53</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:75%;margin-left:12%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>High </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Low </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>2015</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>First Quarter</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12.46</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7.13</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Second Quarter</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14.34</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10.06</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Third Quarter</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>18.23</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12.96</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Fourth Quarter</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13.75</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5.95</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
closing price for our common stock as reported by the NASDAQ Global Market on February&nbsp;13, 2017 was $6.05 per share. As of February&nbsp;10, 2017, there were 43 holders of
record of our common stock. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Dividends  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have never declared or paid any dividends on our capital stock. We currently intend to retain any future earnings to finance our research and
development efforts, the further development of our pharmacological chaperone technology and the expansion of our business. We do not intend to declare or pay cash dividends to our stockholders in the
foreseeable future. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Recent Sales of Unregistered Securities  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We did not sell any equity securities during the fiscal year ended December&nbsp;31, 2016 in transactions that were not registered under the
Securities Act, other than as previously disclosed in our Current Report on Form&nbsp;8-K filed with the SEC on February&nbsp;22, 2016, July&nbsp;1, 2016, July&nbsp;6, 2016 and
December&nbsp;21, 2016. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Performance Graph  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following performance graph compares the cumulative total return on our common stock during the last five fiscal years with the NASDAQ
Composite Index (U.S.) and the NASDAQ Biotechnology Index during the same period. The graph shows the value at the end of each of the last five fiscal years, of $100 invested in our common stock.
Pursuant to applicable SEC rules, all values assume reinvestment of the full amount of all dividends, however no dividends have been declared on our common stock to date. The stockholder return shown
on the graph below is not necessarily indicative of future performance, and we do not make or endorse any predictions as to future stockholder returns. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-81-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=83,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=796015,FOLIO='81',FILE='DISK124:[17ZAA1.17ZAA47301]DQ47301A.;15',USER='JTAYLORA',CD=';1-MAR-2017;09:39' -->
<A NAME="page_dq47301_1_82"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g725814.jpg" ALT="GRAPHIC" WIDTH="681" HEIGHT="403">
  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>The stock price performance included in this graph is not necessarily indicative of future stock price performance.</I></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Issuer Purchases of Equity Securities  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On December&nbsp;21, 2016, the Company issued $250&nbsp;million aggregate principal amount of unsecured Convertible Senior Notes due 2023
(the "Convertible Notes"), which included the exercise in full of the $25&nbsp;million over-allotment option granted to the initial purchasers of the Notes, in a private offering to qualified
institutional buyers pursuant to Rule&nbsp;144A under the Securities Act. Interest is payable semiannually on June&nbsp;15 and December&nbsp;15 of each year, beginning on June&nbsp;15, 2017.
The Notes will mature on December&nbsp;15, 2023, unless earlier repurchased, redeemed, or converted in accordance with their terms. The Notes are convertible at the option of the holders, under
certain circumstances and during certain periods, into cash, shares of the Company's common stock or a combination thereof and may be settled as described below. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Convertible Notes are governed by an indenture dated December&nbsp;21, 2016 (the "Indenture") by and between Amicus and Wilmington Trust, National Association, as trustee. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior
to the close of business on the business day immediately preceding September&nbsp;15, 2023, the Notes are convertible at the option of the holders of the Notes only under certain
conditions, as below:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> On or after September&nbsp;15, 2023, until the close of business on the second business day immediately preceding the maturity date, holders
of the Notes may convert their Notes at their option at the conversion rate then in effect, irrespective of these conditions. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The Company will settle conversions of the Notes by paying or delivering, as the case may be, cash, shares of Common Stock, or a combination of
cash and shares of Common Stock, at the Company's election. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-82-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=84,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=671976,FOLIO='82',FILE='DISK124:[17ZAA1.17ZAA47301]DQ47301A.;15',USER='JTAYLORA',CD=';1-MAR-2017;09:39' -->
<A NAME="page_dq47301_1_83"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
conversion rate will initially be 163.3987 shares of Common Stock per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $6.12 per share of
Common Stock). The conversion rate is subject to customary adjustments upon the occurrence of certain events. The Company may redeem for cash all or part of the Notes, at its option, on or after
December&nbsp;19, 2020, under certain circumstances at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the
redemption date (as defined in the Indenture). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
net proceeds from the Note Offering were $243.1&nbsp;million, after deducting fees and estimated expenses payable by the Company. The Company also used approximately
$13.5&nbsp;million of the net proceeds from the Note Offering to pay the cost of the capped call transactions the Company entered into in connection with the Note Offering. For additional
information, see "&#151;&nbsp;Note&nbsp;16. Debt Instruments and Related Party Transactions" in our Notes to Consolidated Financial Statements. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
did not repurchase any shares of our Common Stock during the year ended December&nbsp;31, 2016. We have not announced any plans or programs for the repurchase of our Common Stock.
However employees surrendered 136,563 shares to the Company, during the year ended December&nbsp;31, 2016 at a weighted average price of $8.13 per share for the payment of the minimum tax liability
withholding obligations upon the vesting of RSUs. We do not consider this a share buyback program. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-83-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=85,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=536613,FOLIO='83',FILE='DISK124:[17ZAA1.17ZAA47301]DQ47301A.;15',USER='JTAYLORA',CD=';1-MAR-2017;09:39' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_ds47301_1_84"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><A
NAME="ds47301_item_6._selected_financial_data."> </A>
<A NAME="toc_ds47301_1"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;6.&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>SELECTED FINANCIAL DATA.    <BR>    </I></B></FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Statement of Operations Data (in thousands except share and per share data)  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="60pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="60pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2013 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2012 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>Revenue:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Net product sales</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4,958</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Research revenue</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,224</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>363</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>11,591</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Collaboration and milestone revenue</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6,820 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Total revenue</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4,958</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,224</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>363</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>18,411 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>Cost of goods sold</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>833</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151; </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>Gross Profit</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4,125</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,224</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>363</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>18,411</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>Operating expenses:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Research and development</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>104,793</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>76,943</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>47,624</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>41,944</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>50,273</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Selling, general and administrative</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>71,151</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>47,269</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>20,717</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>18,893</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>19,364</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Changes in fair value of contingent consideration payable</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6,760</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4,377</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>100</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Restructuring charges</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>69</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>15</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(63</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,988</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Depreciation and amortization</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3,242</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,833</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,547</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,719</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,705 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>Total operating expenses</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>186,015</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>130,437</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>69,925</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>64,544</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>71,342</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>Loss from operations</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(181,890</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(130,437</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(68,701</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(64,181</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(52,931</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Other income (expenses):</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Interest income</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,602</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>929</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>223</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>174</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>316</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Interest expense</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(5,398</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(1,578</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(1,484</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(46</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(89</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Change in fair value of warrant liability</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>908</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>653</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Loss on extinguishment of debt</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(13,302</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(952</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Other (expense) income</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(4,793</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(80</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(77</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>21 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>Loss before tax benefit</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(203,781</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(132,118</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(70,039</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(63,145</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(52,030</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>Income tax benefit</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3,739</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,113</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3,512</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3,245 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>Net loss</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(200,042</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(132,118</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(68,926</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(59,633</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(48,785</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>Net loss per common share &#151; basic and diluted</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(1.49</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(1.20</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(0.93</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1.16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1.07</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>Weighted-average common shares outstanding &#151; basic and diluted</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>134,401,588</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>109,923,815</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>74,444,157</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>51,286,059</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>45,565,217</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Balance Sheet Data (in thousands)  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="46pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="46pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="46pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="46pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=14 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2013 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2012 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Cash and cash equivalents and marketable securities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>330,351</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>214,033</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>169,139</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>82,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>99,122</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Working capital</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>229,105</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>142,985</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>134,392</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>77,817</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>95,374</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Total assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,036,845</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>908,384</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>209,967</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>127,563</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>110,088</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Total liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>676,694</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>560,550</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>87,789</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>81,812</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>40,868</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Accumulated deficit</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(779,608</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(579,566</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(447,448</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(378,522</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(318,889</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Total stockholders' equity</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>360,151</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>347,834</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>122,178</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>45,751</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>69,220</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-84-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=86,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=87241,FOLIO='84',FILE='DISK124:[17ZAA1.17ZAA47301]DS47301A.;12',USER='JTAYLORA',CD=';1-MAR-2017;09:56' -->
<A NAME="page_ds47301_1_85"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><A
NAME="ds47301_item_7._management_s_discussio__ite03649"> </A>
<A NAME="toc_ds47301_2"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;7.&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.    <BR>    </I></B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Overview  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a global patient-focused biotechnology company engaged in the discovery, development and commercialization of a diverse set of novel
treatments for patients living with devastating rare and orphan diseases. Our lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme
replacement therapy ("ERT") for Fabry disease. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Also
in the pipeline, SD-101 is a product candidate in late-stage development, as a potential first-to-market therapy for the chronic, rare connective tissue disorder Epidermolysis
Bullosa ("EB"). We are also leveraging our Chaperone-Advanced Replacement Therapy ("CHART&#153;") platform technologies to develop novel ERT products for Pompe disease, Fabry disease, and
potentially other lysosomal storage disorders ("LSDs"). We are also investigating preclinical and discovery programs in other rare and devastating diseases including cyclin-dependent kinase-like 5
("CDKL5") deficiency. We believe that our platform technologies and our product pipeline uniquely position us at the forefront of advanced therapies to treat a range of devastating rare and orphan
diseases. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Critical Accounting Policies and Significant Judgments and Estimates  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The discussion and analysis of our financial condition and results of operations are based on our financial statements, which we have prepared
in accordance with U.S. generally accepted accounting principles ("U.S.&nbsp;GAAP"). The preparation of these financial statements requires us to make estimates and assumptions that affect the
reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the
reporting periods. On an ongoing basis, we evaluate our estimates and judgments, including those described in greater detail below. We base our estimates on historical experience and on various other
factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily
apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe that the following discussion represents our critical accounting
policies. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Revenue Recognition  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We recognize revenue when amounts are realized or realizable and earned, which is typically upon shipment to the end customer. Revenue is
considered realizable and earned when persuasive evidence an arrangement exists, title to product and associated risk of loss has passed to the customer, the price is fixed or determinable, collection
of the amounts due are reasonably assured and the we have no further performance obligations. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><I> Net Product Sales  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our net product sales consist solely of sales of Galafold for the treatment of Fabry disease in the EU. We have recorded revenue on sales where
Galafold is available either on a commercial basis or through a reimbursed early access program. Orders for Galafold are generally received from pharmacies and the ultimate payor is typically a
government authority. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
record revenue net of estimated third party discounts and rebates. Allowances are recorded as a reduction of revenue at the time revenues from product sales are recognized. These
allowances are adjusted to reflect known changes in factors and may impact such allowances in the quarter those changes are known. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-85-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=87,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=1000872,FOLIO='85',FILE='DISK124:[17ZAA1.17ZAA47301]DS47301A.;12',USER='JTAYLORA',CD=';1-MAR-2017;09:56' -->
<A NAME="page_ds47301_1_86"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><I> Collaboration Revenue  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In multiple element arrangements, revenue is allocated to each separate unit of accounting and each deliverable in an arrangement is evaluated
to determine whether it represents separate units of accounting. A deliverable constitutes a separate unit of accounting when it has standalone value and there is no general right of return for the
delivered elements. In instances when the aforementioned criteria are not met, the deliverable is combined with the undelivered elements and the allocation of the arrangement consideration and revenue
recognition is determined for the combined unit as a single unit of accounting. Allocation of the consideration is determined at arrangement inception on the basis of each unit's relative selling
price. In instances where there is determined to be a single unit of accounting, the total consideration is applied as revenue for the single unit of accounting and is recognized over the period of
inception through the date where the last deliverable within the single unit of accounting is expected to be delivered. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
current revenue recognition policies provide that, when a collaboration arrangement contains multiple deliverables, such as license and research and development services, we allocate
revenue to each separate unit of accounting based on a selling price hierarchy. The selling price hierarchy for a deliverable is based on (i)&nbsp;its vendor specific objective evidence ("VSOE") if
available, (ii)&nbsp;third party evidence ("TPE") if VSOE is not available, or (iii)&nbsp;best estimated selling price ("BESP") if neither VSOE nor TPE is available. We would establish the VSOE of
selling price using the price charged for a deliverable when sold separately. The TPE of selling price would be established by evaluating largely similar and interchangeable competitor products or
services in standalone sales to similarly situated customers. The BESP would be established considering internal factors such as an internal pricing analysis or an income approach using a discounted
cash flow model. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
also considers the impact of potential future payments it makes in its role as a vendor to its customers and evaluates if these potential future payments could be a reduction of
revenue from that customer. If the potential future payments to the customer are:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a payment for an identifiable benefit; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the identifiable benefit is separable from the existing relationship between the Company and its customer; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the identifiable benefit can be obtained from a party other than the customer; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the Company can reasonably estimate the fair value of the identifiable benefit </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;then
the payments are accounted for separate from the revenue received from that customer. If, however, all these criteria are not satisfied, then the payments are treated as a reduction
of revenue from that customer. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we determines that any potential future payments to its customers are to be considered as a reduction of revenue, it must evaluate if the total amount of revenue to be received under
the arrangement is fixed and determinable. If the total amount of revenue is not fixed and determinable due to the uncertain nature of the potential future payments to the customer, then any customer
payments cannot be recognized as revenue until the total arrangement consideration becomes fixed and determinable. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
reimbursements for research and development costs under collaboration agreements that meet the criteria for revenue recognition are included in Research Revenue and the costs
associated with these reimbursable amounts are included in research and development expenses. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
order to determine the revenue recognition for contingent milestones, we evaluate the contingent milestones using the criteria as provided by the Financial Accounting Standards Boards
("FASB") guidance on the milestone method of revenue recognition at the inception of a collaboration </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-86-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=88,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=127738,FOLIO='86',FILE='DISK124:[17ZAA1.17ZAA47301]DS47301A.;12',USER='JTAYLORA',CD=';1-MAR-2017;09:56' -->
<A NAME="page_ds47301_1_87"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>agreement.
The criteria requires that (i)&nbsp;we determines if the milestone is commensurate with either its performance to achieve the milestone or the enhancement of value resulting from our
activities to achieve the milestone, (ii)&nbsp;the milestone be related to past performance, and (iii)&nbsp;the milestone be reasonable relative to all deliverable and payment terms of the
collaboration arrangement. If these criteria are met then the contingent milestones can be considered as substantive milestones and will be recognized as revenue in the period that the milestone is
achieved. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Inventories and Cost of Goods Sold  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Until regulatory approval of Galafold, we expensed all manufacturing costs of Galafold as research and development expense. Upon regulatory
approval, we began capitalizing costs related to the purchase and manufacture of Galafold. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories
are stated at the lower of cost or market determined by the first-in, first-out method. Inventories are reviewed periodically to identify slow-moving or obsolete inventory
based on projected sales activity as well as product shelf-life. In evaluating the recoverability of inventories produced, the probability that revenue will be obtained from the future sale of the
related inventory is considered and inventory value is written down for inventory quantities in excess of expected requirements. Expired inventory is disposed of and the related costs are recognized
as cost of product sales in the consolidated statements of operations. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cost
of goods sold includes the cost of inventory sold, manufacturing and supply chain costs, product shipping and handling costs, provisions for excess and obsolete inventory, as well
as royalties payable. A portion of the inventory available for sale was expensed as research and development costs prior to regulatory approval and as such the cost of goods sold and related gross
margins are not necessarily indicative of future cost of goods sold and gross margin. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Research and Development Expenses  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We expect to continue to incur substantial research and development expenses as we continue to develop our product candidates and explore new
uses for our pharmacological chaperone technology. Research and development expense consists of:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> internal costs associated with our research and clinical development activities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> payments we make to third party contract research organizations, contract manufacturers, investigative sites, and consultants; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> technology license costs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> manufacturing development costs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> personnel-related expenses, including salaries, benefits, travel, and related costs for the personnel involved in drug discovery and
development; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> activities relating to regulatory filings and the advancement of our product candidates through preclinical studies and clinical trials; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> facilities and other allocated expenses, which include direct and allocated expenses for rent, facility maintenance, as well as laboratory and
other supplies. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have multiple research and development projects ongoing at any one time. We utilize our internal resources, employees, and infrastructure across multiple projects. We record and
maintain information regarding external, out-of-pocket research and development expenses on a project-specific basis. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
expense research and development costs as incurred, including payments made to date under our license agreements. We believe that significant investment in product development is a
competitive necessity and plan to continue these investments in order to realize the potential of our product candidates. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-87-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=89,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=198200,FOLIO='87',FILE='DISK124:[17ZAA1.17ZAA47301]DS47301A.;12',USER='JTAYLORA',CD=';1-MAR-2017;09:56' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_du47301_1_88"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes our principal product development programs, including the related stages of development for each product candidate in development,
and the out-of-pocket, third party expenses incurred with respect to each product candidate (in thousands): </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Years Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Projects</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Third party direct project expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Monotherapy Studies</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Migalastat (Fabry Disease&nbsp;&#151; Phase&nbsp;3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14,055</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16,805</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13,567</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SD-101 (EB-Epidermolysis Bullosa&nbsp;&#151; Phase&nbsp;3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9,530</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,240</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Combination Studies</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>ATB200&nbsp;+&nbsp;AT2221 (Pompe Disease&nbsp;&#151; Phase&nbsp;2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>20,548</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>21,003</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,478</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Fabry CHART (Fabry Disease&nbsp;&#151; Preclinical)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>435</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,001</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,050</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Neurodegenerative Diseases (Preclinical)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,504</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>280 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total third party direct project expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>51,072</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>41,060</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>22,375 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other project costs <SUP>(1)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Personnel costs</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>36,624</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25,659</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>18,366</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other costs <SUP>(2)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>17,097</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,224</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,883 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total other project costs</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>53,721</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>35,883</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25,249 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total research and development costs</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>104,793</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>76,943</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>47,624 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Other
project costs are leveraged across multiple projects.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Other
costs include facility, supply, overhead, and licensing costs that support multiple projects.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
successful development of our product candidates is highly uncertain. At this time, we cannot reasonably estimate or know the nature, timing, and costs of the efforts that will be
necessary to complete the remainder of the development of our product candidates. As a result, we are not able to reasonably estimate the period, if any, in which material net cash inflows may
commence from our product candidates, including migalastat or any of our other preclinical product candidates. This uncertainty is due to the numerous risks and uncertainties associated with the
conduct, duration, and cost of clinical trials, which vary significantly over the life of a project as a result of evolving events during clinical development,
including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the number of clinical sites included in the trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the length of time required to enroll suitable patients; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the number of patients that ultimately participate in the trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the results of our clinical trials; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any mandate by the FDA or other regulatory authority to conduct clinical trials beyond those currently anticipated. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
expenditures are subject to additional uncertainties, including the terms and timing of regulatory approvals, and the expense of filing, prosecuting, defending, and enforcing any
patent claims or other intellectual property rights. We may obtain unexpected results from our clinical trials. We may elect to discontinue, delay, or modify clinical trials of some product candidates
or focus on others. A change in the outcome of any of the foregoing variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated
with the development, regulatory approval, and commercialization of that product candidate. For example, if the FDA or </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-88-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=90,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=503948,FOLIO='88',FILE='DISK124:[17ZAA1.17ZAA47301]DU47301A.;10',USER='LBURNET',CD='27-FEB-2017;11:10' -->
<A NAME="page_du47301_1_89"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>other
regulatory authorities were to require us to conduct clinical trials beyond those which we currently anticipate, or if we experience significant delays in enrollment in any of our clinical
trials, we could be required to expend significant additional financial resources and time on the completion of clinical development. Drug development may take several years and millions of dollars in
development costs. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


General and Administrative Expense  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General and administrative expense consists primarily of salaries and other related costs, including equity-based compensation expense, for
persons serving in our executive, finance, accounting, legal, information technology, and human resource functions. Other general and administrative expense includes facility-related costs not
otherwise included in research, and development expense, promotional expenses, costs associated with industry and trade shows, and professional fees for legal services, including patent-related
expense and accounting services. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Interest Income and Interest Expense  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest income consists of interest earned on our cash and cash equivalents and marketable securities. Interest expense consists of interest
incurred on our debt agreements. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stock Option Grants  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In accordance with the applicable guidance, we estimate the fair value of each equity award granted. We chose the "straight-line" attribution
method for allocating compensation costs and recognized the fair value of each stock option on a straight-line basis over the vesting period of the related awards. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
use the Black-Scholes option pricing model when estimating the grant date fair value for stock-based awards. Use of a valuation model requires management to make certain assumptions
with respect to selected model inputs. Expected volatility was based on our historical volatility since our initial public offering in May 2007. We will continue to use a blended weighted average
approach using our own historical volatility and other similar public entity volatility information until our historical volatility is relevant to measure expected volatility for future option grants.
The average expected life was determined using a "simplified" method of estimating the expected exercise term which is the mid-point between the vesting date and the end of the contractual term. As
our stock price volatility has been over 75% and we have experienced significant business transactions, we believe that we do not have sufficient reliable exercise data in order to justify a change
from the use of the "simplified" method of estimating the expected exercise term of employee stock option grants. The risk-free interest rate is based on U.S. Treasury, zero-coupon issues with a
remaining term equal to the expected life assumed at the date of grant. Forfeitures are estimated based on expected turnover as well as a historical analysis of actual option forfeitures. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
weighted average assumptions used in the Black-Scholes option pricing model are as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="32pt" style="font-family:times;"></TD>
<TD WIDTH="21pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="32pt" style="font-family:times;"></TD>
<TD WIDTH="21pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="32pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Years Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected stock price volatility</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>81.3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>75.9</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>81.3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk free interest rate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.7</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.9</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected life of options (years)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.25</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.25</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.25</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected annual dividend per share</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.00</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.00</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.00</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-89-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=91,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=489321,FOLIO='89',FILE='DISK124:[17ZAA1.17ZAA47301]DU47301A.;10',USER='LBURNET',CD='27-FEB-2017;11:10' -->
<A NAME="page_du47301_1_90"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Restricted Stock Units ("RSUs")  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The RSUs awarded are generally subject to graded vesting and are contingent on an employee's continued service on such date. RSUs are generally
subject to forfeiture if employment terminates prior to the release of vesting restrictions. We expense the cost of the RSUs, which is determined to be the fair market value of the shares of common
stock underlying the RSUs at the date of grant, ratably over the period during which the vesting restrictions lapse. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
December&nbsp;30, 2016, the Compensation Committee approved a form of Performance-Based Restricted Stock Unit Award Agreement (the "Performance-Based RSU Agreement"), to be used for
performance-based RSUs granted to participants under the Amended and Restated Amicus Therapeutics,&nbsp;Inc. 2007 Equity Incentive Plan, including named executive officers. Awards under the form of
Performance-Based RSU Agreement will vest based on the Company meeting specified performance criteria. Vesting of the RSUs is generally subject to the participant's continuous service with the Company
through a specified date. As of December&nbsp;31, 2016, there were no RSUs issued under the Performance-Based RSU Agreement. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Warrants  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In October 2015, we entered into the October 2015 Purchase Agreement with Redmile, who beneficially owned approximately 6.7% of the Common Stock
as of December&nbsp;31, 2015, as set forth in the October 2015 Purchase Agreement, whereby we sold, on a private placement basis, (a) $50.0 million aggregate principal amount of its unsecured
promissory notes and (b)&nbsp;1.3&nbsp;million warrants that have a term of five-years. The warrants are classified as equity and included in stockholder's equity. The fair value of the warrants
were initially measured at $8.8&nbsp;million using the Black-Scholes valuation model. In accordance with applicable guidance, we allocated the proceeds received based on the relative fair value of
the notes and warrants, which resulted in $10.6&nbsp;million being recorded as a debt discount. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
February&nbsp;19, 2016, we entered into a Note and Warrant Purchase Agreement (the "February 2016 Purchase Agreement") with Redmile Capital fund,&nbsp;LP and certain funds and
accounts managed or advised by it (collectively referred to as "Redmile") whereby we sold, on a private placement basis, (a)&nbsp;$50&nbsp;million aggregate principal amount of unsecured
promissory notes and (b)&nbsp;five-year warrants to purchase up to 37 shares of our Common Stock for every $1,000 of the principal amount of notes purchased by each purchaser, for an aggregate of up
to 1,850,000 shares of Common Stock issuable under the warrants. We agreed with Redmile that in full consideration of the purchase price for the notes issued under the October 2015 Purchase Agreement,
Redmile surrendered for cancellation all notes and warrants acquired from the October 2015 Purchase Agreement and we paid Redmile any unpaid interest accrued thereunder. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
June&nbsp;30, 2016, following the marketing approval for migalastat in Europe, we entered into a Joinder to and Amendment of Note and Warrant Purchase Agreement (the "Amended
Purchase Agreement") with Redmile. Such amendment joined GCM Grosvenor Special Opportunities Master Fund,&nbsp;Ltd ("GCM") to the February 2016 Purchase Agreement. There were no changes to the
previously issued debt. Pursuant to the Amended Purchase Agreement, we sold an additional $30&nbsp;million unsecured promissory notes and five year warrants to purchase up to 42 shares of the our
Common Stock for every $1,000 of the principal amount of additional Notes purchased, for an aggregate of up to 1,260,000 shares of Common Stock issuable under the additional warrants. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
December&nbsp;15, 2016, we entered into a Note Purchase Agreement ("Note Purchase Agreement") with GCM and RedMile, pursuant to which we agreed to prepay all outstanding principal
and accrued and unpaid interest on the notes issued by the Company and held by GCM and Redmile. Such prepayment was made on December&nbsp;21, 2016, which resulted in a non-cash loss of
$13.3&nbsp;million and is included as loss on extinguishment in the Consolidated Statement of Operations for the year </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-90-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=92,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=716966,FOLIO='90',FILE='DISK124:[17ZAA1.17ZAA47301]DU47301A.;10',USER='LBURNET',CD='27-FEB-2017;11:10' -->
<A NAME="page_du47301_1_91"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>ended
December&nbsp;31, 2016. The Note Purchase Agreement did not cancel the warrants under the Amended Purchase Agreement described above. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Business Combinations  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We allocate the purchase price of acquired businesses to the tangible and intangible assets acquired and liabilities assumed based upon their
estimated fair values on the acquisition date. The purchase price allocation process requires management to make significant estimates and assumptions, especially at the acquisition date with respect
to intangible assets and in-process research and development ("IPR&amp;D"). In connection with the purchase price allocations for acquisitions, we estimate the fair value of contingent acquisition
consideration payments utilizing a probability-based income approach inclusive of an estimated discount rate. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although
we believe the assumptions and estimates made are reasonable, they are based in part on historical experience and information obtained from the management of the acquired
businesses and are inherently uncertain. Examples of critical estimates in valuing any contingent acquisition
consideration issued or which may be issued and the intangible assets we have acquired or may acquire in the future include but are not limited to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the feasibility and timing of achievement of development, regulatory and commercial milestones; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> expected costs to develop the in-process research and development into commercially viable products; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> future expected cash flows from product sales. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unanticipated
events and circumstances may occur which may affect the accuracy or validity of such assumptions, estimates or actual results. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Intangible Assets and Goodwill  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We record goodwill in a business combination when the total consideration exceeds the fair value of the net tangible and identifiable intangible
assets acquired. Purchased in-process research and development is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset
will be accounted for as a definite lived intangible asset, or abandoned, at which point the intangible asset will be written off or partially impaired. Goodwill and indefinite lived intangible assets
are assessed annually for impairment on October&nbsp;1 and whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. If it is determined that the full
carrying amount of an asset is not recoverable, an impairment loss is recorded in the amount by which the carrying amount of the asset exceeds its fair value. No indicators of impairment were noted
during the year ended December&nbsp;31, 2016. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Valuation of Contingent Consideration Payable  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each period we reassess the fair value of the contingent acquisition consideration payable associated with certain acquisitions and record
changes in the fair value as contingent consideration expense. Increases or decreases in the fair value of the contingent acquisition consideration payable can result from changes in estimated
probability adjustments with respect to regulatory approval, changes in the assumed timing of when milestones are likely to be achieved and changes in assumed discount periods and rates. Significant
judgment is employed in determining the appropriateness of these assumptions each period. Accordingly, future business and economic conditions, as well as changes in any of the assumptions described
in the accounting for business combinations above can materially impact the amount of contingent consideration expense that we record in any given period. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-91-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=93,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=1005933,FOLIO='91',FILE='DISK124:[17ZAA1.17ZAA47301]DU47301A.;10',USER='LBURNET',CD='27-FEB-2017;11:10' -->
<A NAME="page_du47301_1_92"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Accrued Expenses  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;When we are required to estimate accrued expenses because we have not yet been invoiced or otherwise notified of actual cost, we identify
services that have been performed on our behalf and estimate the level of service performed and the associated cost incurred. The majority of our service providers invoice us monthly in arrears for
services performed. We make estimates of our accrued expenses as of each balance sheet date in our financial statements based on facts and circumstances known to us. Examples of estimated accrued
expenses include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> fees owed to contract research organizations in connection with preclinical and toxicology studies and clinical trials; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> fees owed to investigative sites in connection with clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> fees owed to contract manufacturers in connection with the production of clinical trial materials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> fees owed for professional services, and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> unpaid salaries, wages and benefits. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Nonqualified Cash Deferral Plan  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Cash Deferral Plan (the "Deferral Plan") provides certain key employees and other service providers as selected by the Compensation
Committee, with an opportunity to defer the receipt of such Participant's base salary, bonus and director's fees, as applicable. The Deferral Plan is intended to be a nonqualified deferred
compensation plan that complies with the provisions of Section&nbsp;409A of the Internal Revenue Code (the "Code"). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
of the investments held in the Deferral Plan are classified as investments trading securities and recorded at fair value with changes in the investments' fair value recognized as
earnings in the period they occur. The corresponding liability for the Deferral Plan is included in other non-current liability in our consolidated balance sheets. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Foreign Currency Transactions and Derivative Financial Instruments  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We transact business in various foreign countries and therefore we are subject to risk of foreign currency exchange rate fluctuations. As such,
in June 2016, we entered into a forward contract to economically hedge transactional exposure associated with commitments arising from trade
accounts payable denominated in a currency other than the functional currency of the respective operating entity. We did not designate this forward contract as a hedging instrument under applicable
accounting guidance and, therefore, the change in fair value is recorded in the other income/(expense) line in the Consolidated Statements of Operations, with the corresponding liability in other
current liability on the Consolidated Balance Sheet. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
forward contract will settle in June 2017. There were no outstanding forward contracts at December&nbsp;31, 2015. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
the year ended December&nbsp;31, 2016, we recognized a loss of $0.3&nbsp;million, related to the foreign currency forward contract not designated as hedging instruments in other
expense in the Consolidated Statements of Operations and the corresponding liability of $0.3&nbsp;million is recorded as other current liability in the Consolidated Balance Sheets. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Results of Operations  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Year Ended December&nbsp;31, 2016 Compared to Year Ended December&nbsp;31, 2015  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Revenue.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Net product sales were $5.0&nbsp;million for the year ended December&nbsp;31, 2016 due to marketing approval of Galafold
granted in May
2016. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-92-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=94,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=963322,FOLIO='92',FILE='DISK124:[17ZAA1.17ZAA47301]DU47301A.;10',USER='LBURNET',CD='27-FEB-2017;11:10' -->
<A NAME="page_du47301_1_93"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cost of Goods Sold.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Cost of goods sold includes manufacturing costs as well as royalties associated with sales of our product. Cost of
goods sold as
a percentage of net sales was 16.8% for the year ended December&nbsp;31, 2016. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and Development Expense.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Research and development expense was $104.8&nbsp;million in 2016, representing an increase of
$27.9&nbsp;million or 36.3% from $76.9&nbsp;million in 2015. The increase in research and development costs was primarily due to increases in clinical research costs of $11.3&nbsp;million, due
to the advancement and enrollment of clinical studies, primarily for EB program of $8.3&nbsp;million. Also included in the research and development expenses was $6.5&nbsp;million which represents
a one-time expense associated with the acquisition of the CDKL5 asset. Other increases were in personnel costs of $11.0&nbsp;million. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Selling, General and Administrative Expense.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Selling, general and administrative expense was $71.2&nbsp;million in 2016, an increase of
$23.9&nbsp;million or 50.5% from $47.3&nbsp;million in 2015. The increase in 2016 was primarily from efforts to support the international activities and commercial launch of Galafold in May 2016.
The increases were seen in personnel costs of $16.2&nbsp;million, legal and audit fees of $3.2&nbsp;million and travel related expenses of $1.7&nbsp;million. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes in Fair Value of Contingent Consideration Payable.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;For the year ended December&nbsp;31, 2016, we recorded expense of
$6.8&nbsp;million
representing an increase of $2.4&nbsp;million from the $4.4&nbsp;million of expense for the year ended December&nbsp;31, 2015. The change in the fair value resulted from an increase in the
Scioderm contingent consideration of $8.5&nbsp;million and a decrease to the Callidus contingent consideration of $6.1&nbsp;million. The fair value is impacted by updates to the estimated
probability of achievement, assumed timing of milestones and adjustments to the discount periods and rates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Depreciation expense was $3.2&nbsp;million in 2016, representing an increase of $1.4&nbsp;million as compared to
$1.8&nbsp;million in 2015. Depreciation was higher due to increased asset acquisitions, resulting in a higher depreciation base in 2016. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest Income.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Interest income was $1.6&nbsp;million for the year ended December&nbsp;31, 2016, representing an increase of
$0.7&nbsp;million
from $0.9&nbsp;million for the year ended December&nbsp;31, 2015. The increase in interest
income was due to the overall higher average cash and investment balances as a result of our financing transactions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest Expense.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Interest expense was $5.4&nbsp;million in 2016 as compared to $1.6&nbsp;million in 2015. Interest expense was higher
due to the
$50&nbsp;million notes payable borrowed in October 2015 and the related revised agreement in February 2016, as well as the $250&nbsp;million convertible debt secured in December 2016. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loss from Extinguishment of Debt.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We recognized a non-cash loss of $13.3&nbsp;million for the year ended December&nbsp;31, 2016 arising
from the
early extinguishment of the $80&nbsp;million secured loan in the fourth quarter of 2016. For the year ended December&nbsp;31, 2015, we recognized a loss of $1.0&nbsp;million arising from the
early extinguishment of the $15&nbsp;million secured loan in the first quarter of 2015. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other Expense.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Other expense was $4.8&nbsp;million for the year ended December&nbsp;31, 2016 as compared to $0.1&nbsp;million for the
year
ended December&nbsp;31, 2015. The change was primarily from losses on foreign exchange transactions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tax Benefit.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;For the year ended December&nbsp;31, 2016, the Company recorded an income tax benefit of $3.7&nbsp;million, primarily
consisting of
$1.2&nbsp;million from reduction in its valuation allowances to reflect the income tax associated with the gain on foreign currency translation, and $2.7&nbsp;million in connection with the
reduction in state tax rates in North Carolina. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-93-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=95,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=753435,FOLIO='93',FILE='DISK124:[17ZAA1.17ZAA47301]DU47301A.;10',USER='LBURNET',CD='27-FEB-2017;11:10' -->
<A NAME="page_du47301_1_94"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Year Ended December&nbsp;31, 2015 Compared to Year Ended December&nbsp;31, 2014  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Revenue.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We recognized reimbursements for research and development costs of $1.2&nbsp;million under a collaborative agreement as
Research Revenue
in 2014. This collaboration agreement ended in September 2014, and no revenue was recognized for the year ended December&nbsp;31, 2015. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and Development Expense.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Research and development expense was $76.9&nbsp;million in 2015, representing an increase of
$29.3&nbsp;million
or 61.6% from $47.6&nbsp;million in 2014. The increase in research and development costs was primarily due to an increase in contract manufacturing and clinical research costs. Contract
manufacturing increased by $11.9&nbsp;million and clinical research by $7.0&nbsp;million due to scale up of Pompe ERT manufacturing and the continual progress of our programs through the clinical
development process. Other increases were in personnel costs of $7.4&nbsp;million and external program support of $2.2&nbsp;million. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General and Administrative Expense.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;General and administrative expense was $47.3&nbsp;million in 2015, an increase of
$26.6&nbsp;million or
128.5% from $20.7&nbsp;million in 2014. The increase was primarily due to consulting and legal fees of $10.4&nbsp;million, personnel costs of $7.5&nbsp;million, and recruiting fees of
$2.4&nbsp;million. The consulting and legal fees included $3.1&nbsp;million for Scioderm acquisition-related transaction costs. Also included within the $26.6&nbsp;million increase was
$12.7&nbsp;million related to pre-commercial organization costs. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes in Fair Value of Contingent Consideration Payable.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;For the year ended December&nbsp;31, 2015, we recorded expense of
$4.4&nbsp;million
representing an increase of $4.3&nbsp;million from the $0.1&nbsp;million of expense for the year ended December&nbsp;31, 2014. The change in the fair value resulted from an increase in the
Callidus contingent consideration of $5.6&nbsp;million and a decrease to the Scioderm contingent consideration of $1.2&nbsp;million. The fair value is impacted by updates to the estimated
probability of achievement, assumed timing of milestones and adjustments to the discount periods and rates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Depreciation was $1.8&nbsp;million in 2015, representing an increase of $0.3&nbsp;million or 20% as compared to
$1.5&nbsp;million
in 2014. Depreciation was higher due to increased asset acquisitions, resulting in a higher depreciation base, in 2015. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest Income.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Interest income was $0.9&nbsp;million for the year ended December&nbsp;31, 2015, representing an increase of
$0.7&nbsp;million
from $0.2&nbsp;million for the year ended December&nbsp;31, 2014. The increase in interest income was due to the overall higher average cash and investment balances as a result of our financing
transactions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest Expense.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Interest expense was $1.6&nbsp;million in 2015 as compared to $1.5&nbsp;million in 2014. Interest expense was higher
due to the
$50&nbsp;million notes payable secured in October 2015, partially offset by the early retirement of the $15&nbsp;million secured loan in June 2015. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loss from Extinguishment of Debt:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We recognized a non-cash loss of $1.0&nbsp;million for the year ended December&nbsp;31, 2015 arising
from the
early extinguishment of the $15&nbsp;million secured loan in the first quarter of 2015. No such loss was recorded in the year ended December&nbsp;31, 2014. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other Income/Expense.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Other expense was $0.1&nbsp;million for both 2015 and 2014. The charge primarily includes fair value changes to
deferred
compensation assets and fair value changes of the success fee payable related to the $15&nbsp;million loan. The $15&nbsp;million term loan was paid in full during the second quarter of 2015. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tax Benefit.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;During 2014, we sold a portion of our New Jersey state net operating loss carry forwards and research and development
credits, which
resulted in the recognition of $1.1&nbsp;million in income tax benefit for the year ended December&nbsp;31, 2014. We did not consummate any such sales in 2015. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-94-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=96,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=801872,FOLIO='94',FILE='DISK124:[17ZAA1.17ZAA47301]DU47301A.;10',USER='LBURNET',CD='27-FEB-2017;11:10' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dw47301_1_95"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Liquidity and Capital Resources  </B></FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Sources of Liquidity  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As a result of our significant research and development expenditures as well as expenditures to build a commercial organization to support the
launch of Galafold, we have not been profitable and have generated operating losses since we were incorporated in 2002. We have historically funded our operations principally through the issuance and
sale of stock, collaborations, debt financings, grants and non-refundable license fees. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
December&nbsp;21, 2016, we issued $250&nbsp;million aggregate principal amount of 3.00% unsecured Convertible Senior Notes due 2023 (the "Convertible Notes"), in a private
offering to qualified institutional buyers pursuant to Rule&nbsp;144A under the Securities Act. The Notes bear interest at a fixed rate of 3.00% per year, payable semiannually on June&nbsp;15 and
December&nbsp;15 of each year, beginning on June&nbsp;15, 2017. The Notes will mature on December&nbsp;15, 2023, unless earlier repurchased, redeemed, or converted in accordance with their
terms. The net proceeds from the Note Offering were $243.1&nbsp;million, after deducting fees and estimated expenses payable by the Company. The Company also used approximately $13.5&nbsp;million
of the net proceeds from the Note Offering to pay the cost of the capped call transactions ("Capped Call Confirmations") that the Company entered into in connection with the Note Offering. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beginning
in April 2016 and through July 2016, we sold 15.0&nbsp;million shares of Common Stock under an at-the-market ("ATM") equity program with Cowen and Company,&nbsp;LLC
("Cowen") acting as sales agent. Cowen was compensated at a fixed commission rate up to 3.0%. The ATM sales agreement resulted in net proceeds of $97.1&nbsp;million, after Cowen's commission of
$2.7&nbsp;million and other expenses of $0.2&nbsp;million. We have completed all sales under the ATM equity program. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
June 2015, the Company issued a total of 19.5&nbsp;million shares through a public offering at a price of $13.25 per share, with net proceeds of $243.0&nbsp;million. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
November 2014, the Company sold a total of 15.9&nbsp;million shares of our common stock, par value $0.01 per share, at a public offering price of $6.50 per share. The net offering
proceeds were approximately $97.2&nbsp;million. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
July 2014, the Company completed a $40&nbsp;million ATM equity offering under which the Company sold shares of its common stock, par value $0.01 per shares with Cowen and
Company&nbsp;LLC as sales agent. Under the ATM equity program the Company sold 14.3&nbsp;million shares of common stock resulting in net proceeds of $38.6&nbsp;million. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Cash flows  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of December&nbsp;31, 2016, we had cash and cash equivalents and marketable securities of $330.4&nbsp;million. We invest cash in excess of
our immediate requirements with regard to liquidity and capital preservation in a variety of interest-bearing instruments, including obligations of U.S. government agencies and money market accounts.
Wherever possible, we seek to minimize the potential effects of concentration and degrees of risk. Although we maintain cash balances with financial institutions in excess of insured limits, we do not
anticipate any losses with respect to such cash balances. For more details on the cash, cash equivalents and marketable securities, refer to
"&#151;&nbsp;Note&nbsp;5. Cash, Money Market Funds and Marketable Securities," in our Notes to Consolidated Financial Statements. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Net Cash Used in Operating Activities  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in operations for the year ended December&nbsp;31, 2016 was $150.5&nbsp;million due primarily to the net loss for the year
ended December&nbsp;31, 2016 of $200.0&nbsp;million and was offset by </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-95-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=97,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=466704,FOLIO='95',FILE='DISK124:[17ZAA1.17ZAA47301]DW47301A.;9',USER='LBURNET',CD='27-FEB-2017;11:08' -->
<A NAME="page_dw47301_1_96"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>increase
in accounts payable and accrued expenses of $7.1&nbsp;million, mainly related to program expenses and support for the commercial launch of Galafold. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net
cash used in operations for the year ended December&nbsp;31, 2015 was $100.1&nbsp;million due primarily to the net loss for the year ended December&nbsp;31, 2015 of
$132.1&nbsp;million and the change in operating assets and liabilities of $14.3&nbsp;million. The change in operating assets and liabilities was primarily due to an increase in accounts payable
and accrued expenses of $15.5&nbsp;million, mainly related to program expenses and partially offset by decrease of $0.3&nbsp;million in prepaid assets. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Net Cash Used in Investing Activities  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in investing activities for the year ended December&nbsp;31, 2016 was $4.5&nbsp;million. Our investing activities have
consisted primarily of purchases and sales and maturities of investments and capital expenditures. Net cash used in investing activities reflects $219.9&nbsp;million for the purchase of marketable
securities, $6.0&nbsp;million for the acquisition of property and equipment, partially offset by $221.4&nbsp;million for the sale and redemption of marketable securities. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net
cash used in investing activities for the year ended December&nbsp;31, 2015 was $145.3&nbsp;million. Our investing activities have consisted primarily of purchases and sales and
maturities of investments and
capital expenditures. Net cash used in investing activities reflects $289.6&nbsp;million for the purchase of marketable securities, $141.1&nbsp;million paid to the former Scioderm shareholders as
part of the Scioderm acquisition, $4.8&nbsp;million for the acquisition of property and equipment, partially offset by $290.1&nbsp;million for the sale and redemption of marketable securities. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Net Cash Provided by Financing Activities  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by financing activities for the year ended December&nbsp;31, 2016 was $272.7&nbsp;million. Net cash provided by financing
activities reflects $97.1&nbsp;million from issuance of common stock, $272.5&nbsp;million from proceeds of financing arrangements, $3.0&nbsp;million from exercise of stock options, partially
offset by $80.2&nbsp;million from payments on the secured loans and payments on capital lease arrangements, $13.5&nbsp;million for capped call fees related to securing debt and $1.3&nbsp;million
from vesting of RSUs. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net
cash provided by financing activities for the year ended December&nbsp;31, 2015 was $290.9&nbsp;million. Net cash provided by financing activities reflects $243.0&nbsp;million
from issuance of common stock, $50.0&nbsp;million from proceeds of financing arrangement with Redmile Group, $11.2&nbsp;million from exercise of stock options and $4.0&nbsp;million from exercise
of warrants, partially offset by $15.3&nbsp;million from paying the secured loan and $2.0&nbsp;million from vesting of RSUs. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Funding Requirements  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We expect to incur losses from operations for the foreseeable future primarily due to research and development expenses, including expenses
related to conducting clinical trials. Our future capital requirements will depend on a number of factors, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the progress and results of our clinical trials of our drug candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the cost of manufacturing drug supply for our clinical and preclinical studies, including the significant cost of new ERT cell line development
and manufacturing as well as the cost of manufacturing Pompe ERT; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the scope, progress, results and costs of preclinical development, laboratory testing and clinical trials for our product candidates including
those testing the use of pharmacological chaperones co-formulated and co-administered with ERT and for the treatment of LSDs; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-96-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=98,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=820426,FOLIO='96',FILE='DISK124:[17ZAA1.17ZAA47301]DW47301A.;9',USER='LBURNET',CD='27-FEB-2017;11:08' -->
<A NAME="page_dw47301_1_97"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the future results of on-going or later clinical trials for SD-101, including our ability to obtain regulatory approvals and commercialize
SD-101 and obtain market acceptance of SD-101; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the future results of on-going preclinical and later clinical trials for CDKL5, including our ability to obtain regulatory approvals and
commercialize CDKL5 and obtain market acceptance for CDKL5; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the costs, timing and outcome of regulatory review of our product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the number and development requirements of other product candidates that we pursue; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the costs of commercialization activities, including product marketing, sales and distribution; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the emergence of competing technologies and other adverse market developments; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to obtain reimbursement for migalastat HCI; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to obtain market acceptance of migalastat HCl in the EU; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the costs of preparing, filing and prosecuting patent applications and maintaining, enforcing and defending intellectual property-related
claims; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the extent to which we acquire or invest in businesses, products and technologies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to successfully integrate our recent acquisitions of Scioderm and MiaMed and their products and technologies into our business,
including the possibility that the expected benefits of the transactions will not be fully realized by us or may take longer to realize than expected; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to establish collaborations and obtain milestone, royalty or other payments from any such collaborators. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While
we generated revenue from product sales in the second half of 2016, in the absence of additional funding, we expect our continuing operating losses to result in increases in our
cash used in operations over the next several quarters and years. We may seek additional funding through public or private financings of debt or equity. We believe that our existing cash and cash
equivalents and short-term investments will be sufficient to fund the current operating plan into the second half of 2018. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Financial Uncertainties Related to Potential Future Payments  </I></B></FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><I> Milestone Payments / Royalties  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We acquired exclusive worldwide patent rights to develop and commercialize migalastat and other pharmacological chaperones for the prevention or
treatment of human diseases or clinical conditions by increasing the activity of wild-type and mutant enzymes pursuant to a license agreement with MSSM. This agreement expires upon expiration of the
last of the licensed patent rights, which will be in 2018 in the U.S. and 2019 in Europe and Japan for monotherapy. If we develop a product for combination therapy of specific pharmacological
chaperone such as migalastat plus an ERT for certain Lysosomal Storage Disorders such as Fabry disease and a patent issues from the pending MSSM applications covering such a combination therapy(ies),
expiration for the combination product(s) will be 2024. Under this agreement, to date we have paid no upfront or annual license fees and have no milestone or future payments other than royalties on
net sales. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
our license agreements, if we owe royalties on net sales for one of our products to more than one of the above licensors, then we have the right to reduce the royalties owed to one
licensor for royalties paid to another. The amount of royalties to be offset is generally limited in each license and </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-97-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=99,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=116156,FOLIO='97',FILE='DISK124:[17ZAA1.17ZAA47301]DW47301A.;9',USER='LBURNET',CD='27-FEB-2017;11:08' -->
<A NAME="page_dw47301_1_98"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>can
vary under each agreement. For migalastat in 2016, we incurred $0.1&nbsp;million of royalty expense under the agreement with MSSM. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
November 2013, we entered into the Revised Agreement with GlaxoSmithKline ("GSK"), pursuant to which we have obtained global rights to develop and commercialize migalastat as a
monotherapy and in combination with ERT for Fabry disease. The Revised Agreement amends and replaces in its entirety the earlier agreement entered into between us and GSK in July 2012. Under the terms
of the Revised Agreement, there was no upfront payment from us to GSK. For migalastat monotherapy, GSK is eligible to receive post-approval and sales-based milestones up to $40&nbsp;million, as well
as tiered royalties in the mid-teens in eight major markets outside the U.S. In addition, because we reacquired worldwide rights to migalastat, we are no longer eligible to receive any milestones or
royalties we would have been eligible to receive under the Original Collaboration Agreement. We will pay royalties to MSSM in addition to those owed to GSK. In the second half of 2016, we recognized
approximately $0.5&nbsp;million of royalty expense under the agreement with GSK. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
part of the merger agreement with Scioderm, we have agreed to pay up to an additional $361&nbsp;million to Scioderm stockholders, option holders, and warrant holders upon
achievement of certain clinical and regulatory milestones, and $257&nbsp;million to Scioderm stockholders, option holders, and warrant holders upon achievement of certain sales milestones. If SD-101
is approved, EB qualifies as a rare pediatric disease and we will request a Priority Review Voucher. If the Priority Review Voucher is obtained and subsequently sold, we will pay Scioderm
stockholders, option holders and warrant holders the lesser of $100&nbsp;million in the aggregate or 50% of the proceeds of such sale. In April 2016, while the total clinical and regulatory approval
milestone payments remain unchanged at $361&nbsp;million, the allocation between the clinical and regulatory approval milestone payments were revised as follows: clinical milestones of up to
$81&nbsp;million and regulatory approval milestones of up to $280&nbsp;million. The commercial milestone payments of up to $257&nbsp;million remained unchanged. During the second quarter of
2016, we reached the first event based milestone for Scioderm, which was the 50% enrollment of patients in the Phase&nbsp;3 study. The milestone payment for this event was $5.0&nbsp;million which
was paid in cash during the second quarter of 2016. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
part of the acquisition of Callidus, we will be obligated to make additional payments to the former stockholders of Callidus upon the achievement by the Company of certain clinical
milestones of up to $35&nbsp;million and regulatory approval milestones of up to $105&nbsp;million as set forth in the merger agreement, provided that the aggregate consideration shall not exceed
$130&nbsp;million. We may, at our election, satisfy certain milestone payments identified in the merger agreement aggregating $40&nbsp;million in shares of our Common Stock (calculated based on a
price per share equal to the average of the last closing bid price per share for the Common Stock on The NASDAQ Global Select Market for the ten trading days immediately preceding the date of
payment). The milestone payments not permitted to be satisfied in Common Stock (as well as any payments that the we are permitted to, but choose not to, satisfy in Common Stock), as a result of the
terms of the merger agreement, the rules of The NASDAQ Global Select Market, or otherwise, will be paid in cash. During the second quarter of 2016, we reached the first clinical milestone for
Callidus, which was the dosing of the first patient in a Phase&nbsp;1 or 2 study. The milestone payment for this event was $6.0&nbsp;million which was paid in the Company's stock during the second
quarter of 2016. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
part of the acquisition of MiaMed, we will be obligated to make additional payments to the former stockholders of MiaMed upon the achievement by the Company of certain clinical
milestones of up to $8&nbsp;million, regulatory approval milestones of up to $10&nbsp;million, and commercial milestones up to $65&nbsp;million. Any milestone payment may be satisfied in cash,
shares of Common Stock, or a combination of both. The milestone payments not permitted to be satisfied in Common Stock (as well
as any payments that the we are permitted to, but choose not to, satisfy in Common Stock), as a result of the terms of the merger agreement, the rules of The NASDAQ Global Select Market, or otherwise, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-98-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=100,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=403087,FOLIO='98',FILE='DISK124:[17ZAA1.17ZAA47301]DW47301A.;9',USER='LBURNET',CD='27-FEB-2017;11:08' -->
<A NAME="page_dw47301_1_99"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>will
be paid in cash. No milestone payments in connection with the acquisition of MiaMed have been paid. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Contractual Obligations  </B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes our significant contractual obligations and commercial commitments at December&nbsp;31, 2016 and the effects
such obligations are expected to have on our liquidity and cash flows in future periods (in thousands). </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="78pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="60pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Less than 1&nbsp;year </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>1-3&nbsp;years </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>3-5&nbsp;years </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Over 5&nbsp;years </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating lease obligations <SUP>(2)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>20,456</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,666</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,904</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,462</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8,424</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Capital lease obligations, including interest&nbsp;<SUP>(3)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>844</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>355</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>489</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Debt obligations, including interest <SUP>(4)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>302,396</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,083</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>265,313 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total fixed contractual obligations <SUP>(1)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>323,696</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,104</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>20,393</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>19,462</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>273,737 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>This
table does not include (a)&nbsp;any milestone payments which may become payable to third parties under license agreements as the timing and likelihood of such
payments are not known, (b)&nbsp;any royalty payments to third parties as the amounts of such payments, timing and/or the likelihood of such payments are not known, (c)&nbsp;amounts, if any, that
may be committed in the future to construct additional facilities, (d)&nbsp;agreements with clinical research organizations and other outside contractors who are partially responsible for conducting
and monitoring our clinical trials for our drug candidates including migalastat. These contractual obligations are not reflected in the table above because we may terminate them without penalty, and
(e)&nbsp;contracts that are entered into in the ordinary course of business which are not material in the aggregate in any period presented above.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Represents
the future payments on operating leases for the United States and international locations. For more details, refer to
"&#151;&nbsp;Note&nbsp;12. Leases," in our Notes to Consolidated Financial Statements.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Represents
the future payments of principal and interest to be made on our capital leases. These financing arrangements of $0.9&nbsp;million have interest of
approximately 0.2-5.7%, and lease terms of 36-48&nbsp;months. For more details, refer to "&#151;&nbsp;Note&nbsp;12. Leases," in our Notes to Consolidated Financial Statements.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Represents
the future payments of principal and interest to be made on our $250&nbsp;million 3% unsecured Convertible Senior Notes due 2023 (the "Convertible
Notes"). The Convertible Notes bear interest at a fixed rate of 3.00% per year, payable semiannually on June&nbsp;15 and December&nbsp;15 of each year, beginning on June&nbsp;15, 2017 and will
mature on December&nbsp;15, 2023. For more details, refer to "&#151;&nbsp;Note&nbsp;16. Debt Instruments and Related Party Transactions," in our Notes to Consolidated Financial
Statements.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have no other lines of credit or other committed sources of capital. To the extent our capital resources are insufficient to meet future capital requirements, we will need to raise
additional capital or
incur indebtedness to fund our operations. We cannot assure you that additional debt or equity financing will be available on acceptable terms, if at all. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Off-Balance Sheet Arrangements  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We had no off-balance sheet arrangements as of December&nbsp;31, 2016 and 2015. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-99-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=101,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=860020,FOLIO='99',FILE='DISK124:[17ZAA1.17ZAA47301]DW47301A.;9',USER='LBURNET',CD='27-FEB-2017;11:08' -->
<A NAME="page_dw47301_1_100"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Recent Accounting Pronouncements  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Please refer to "&#151; Note&nbsp;2. Summary of Significant Accounting Policies," in our Notes to Consolidated Financial Statements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="dw47301_item_7a._quantitative_and_qual__ite02650"> </A>
<A NAME="toc_dw47301_1"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;7A.&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.    <BR>    </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Market risk is the risk of change in fair value of a financial instrument due to changes in interest rates, equity prices, creditworthiness,
financing, exchange rates or other factors. Our primary market risk exposure relates to changes in interest rates in our cash, cash equivalents and marketable securities. We place our investments in
high-quality financial instruments, primarily money market funds, corporate debt securities, asset backed securities and U.S. government agency notes with maturities of less than one year, which we
believe are subject to limited interest rate and credit risk. The securities in our investment portfolio are not leveraged, are classified as available-for-sale and, due to the short-term nature, are
subject to minimal interest rate risk. We currently do not hedge interest rate exposure and consistent with our investment policy, we do not use derivative financial instruments in our investment
portfolio. At December&nbsp;31, 2016, we held $330.4&nbsp;million in cash, cash equivalents and available for sale securities and due to the short-term maturities of our investments, we do not
believe
that a 10% change in average interest rates would have a significant impact on our interest income. At December&nbsp;31, 2016, our cash, cash equivalents and available for sale securities were all
due on demand or within one year. Our outstanding debt has a fixed interest rate and therefore, we have no exposure to interest rate fluctuations. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have operated primarily in the U.S. with international operations increasing since the last quarter of 2015. We do conduct some clinical activities with vendors outside the U.S. While
most expenses are paid in U.S. dollars, we now have increased transactions of expenses and cash flows in foreign currencies that are exposed to changes in foreign currency rates. Foreign currency
forward contracts used to offset these exposures are not designated as hedges. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-100-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=102,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=1000981,FOLIO='100',FILE='DISK124:[17ZAA1.17ZAA47301]DW47301A.;9',USER='LBURNET',CD='27-FEB-2017;11:08' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dy47301_1_101"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><A
NAME="dy47301_item_8._financial_statements_and_supplementary_data."> </A>
<A NAME="toc_dy47301_1"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;8.&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.    <BR>    </I></B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dy47301_management_s_report_on_consoli__man04169"> </A>
<A NAME="toc_dy47301_2"> </A></FONT> <FONT SIZE=2><B>  Management's Report on Consolidated Financial Statements and<BR>  Internal Control over Financial Reporting    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The management of Amicus Therapeutics,&nbsp;Inc. has prepared, and is responsible for the Company's consolidated financial statements and
related footnotes. These consolidated financial
statements have been prepared in conformity with U.S. generally accepted accounting principles ("U.S.&nbsp;GAAP"). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rule&nbsp;13a-15(f) or
15d-15(f) promulgated under the Securities Exchange Act of 1934 as a process designed by, or under the supervision of the Company's principal executive and principal financial officers and effected by
the Company's board of directors, management, and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with U.S.&nbsp;GAAP and includes those policies and procedures that:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets
of Amicus Therapeutics,&nbsp;Inc.; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with
generally accepted accounting principles, and that receipts and expenditures of Amicus therapeutics,&nbsp;Inc. are being made only in accordance with authorizations of management and directors of
Amicus therapeutics,&nbsp;Inc.; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the assets of Amicus
Therapeutics,&nbsp;Inc. that could have a material effect on the financial statements. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Because
of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future
periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
assessed the effectiveness of our internal control over financial reporting as of December&nbsp;31, 2016. In making this assessment, we used the criteria set forth by the Committee
of Sponsoring Organizations of the Treadway Commission (2013 framework) ("COSO") in Internal Control&#151;Integrated Framework. Based on our assessment we believe that, as of
December&nbsp;31, 2016, our internal control over financial reporting is effective based on those criteria. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
effectiveness of the Company's internal control over financial reporting as of December&nbsp;31, 2016 has been audited by Ernst&nbsp;&amp; Young&nbsp;LLP, an independent registered
public accounting firm, as stated in their report. This report appears on the following page. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Dated
March&nbsp;1, 2017 </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>/s/&nbsp;JOHN F. CROWLEY<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Chairman and Chief Executive Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>/s/&nbsp;WILLIAM D. BAIRD III<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Chief Financial Officer</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-101-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=103,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=549684,FOLIO='101',FILE='DISK124:[17ZAA1.17ZAA47301]DY47301A.;6',USER='VSTEFAN',CD='27-FEB-2017;04:20' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_fc47301_1_102"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="fc47301_report_of_independent___fc402279"> </A>
<A NAME="toc_fc47301_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Report of Independent Registered Public Accounting Firm    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>The
Board of Directors and Stockholders of<BR>
Amicus Therapeutics,&nbsp;Inc. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have audited Amicus Therapeutics,&nbsp;Inc.'s internal control over financial reporting as of December&nbsp;31, 2016, based on criteria established in Internal
Control&#151;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework)(the "COSO criteria"). Amicus Therapeutics,&nbsp;Inc.'s
management is responsible for maintaining effective
internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying report on consolidated financial
statements and internal control over financial reporting. Our responsibility is to express an opinion on the company's internal control over financial reporting based on our audit. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to
obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control
over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and
performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures
that (1)&nbsp;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2)&nbsp;provide
reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and
expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3)&nbsp;provide reasonable assurance regarding prevention or timely
detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Because
of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future
periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
our opinion, Amicus Therapeutics,&nbsp;Inc. maintained, in all material respects, effective internal control over financial reporting as of December&nbsp;31, 2016, based on the
COSO criteria. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheets of Amicus
Therapeutics,&nbsp;Inc. as of December&nbsp;31, 2016 and 2015, and the related consolidated statements of operations, comprehensive loss, changes in stockholders' equity and cash flows for each of
the three years in the period ended December&nbsp;31, 2016 of Amicus Therapeutics,&nbsp;Inc., and our report dated March&nbsp;1, 2017 expressed an unqualified opinion thereon. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="50%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="50%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>/s/ Ernst&nbsp;&amp; Young&nbsp;LLP</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>Iselin,
New Jersey<BR>
March&nbsp;1, 2017 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-102-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=104,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=917240,FOLIO='102',FILE='DISK124:[17ZAA1.17ZAA47301]FC47301A.;5',USER='VSTEFAN',CD='27-FEB-2017;04:20' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_fe47301_1_103"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="fe47301_report_of_independent___fe402281"> </A>
<A NAME="toc_fe47301_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Report of Independent Registered Public Accounting Firm    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>The
Board of Directors and Stockholders of<BR>
Amicus Therapeutics,&nbsp;Inc. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have audited the accompanying consolidated balance sheets of Amicus Therapeutics,&nbsp;Inc. as of December&nbsp;31, 2016 and 2015, and the related consolidated statements of
operations, comprehensive loss, changes in stockholders' equity and cash flows for each of the three years in the period ended
December&nbsp;31, 2016. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to
obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in
the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement
presentation. We believe that our audits provide a reasonable basis for our opinion. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of Amicus Therapeutics,&nbsp;Inc. at
December&nbsp;31, 2016 and 2015, and the consolidated results of its operations and its cash flows for each of the three years in the period ended December&nbsp;31, 2016 in conformity with U.S.
generally accepted accounting principles. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), Amicus Therapeutics,&nbsp;Inc.'s internal control over
financial reporting as of December&nbsp;31, 2016, based on criteria established in Internal Control&#151;Integrated Framework issued by the Committee of Sponsoring Organizations of the
Treadway Commission (2013 framework) and our report dated March&nbsp;1, 2017 expressed an unqualified opinion thereon. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="50%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="50%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>/s/ Ernst&nbsp;&amp; Young&nbsp;LLP</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>Iselin,
New Jersey<BR>
March&nbsp;1, 2017 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-103-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=105,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=604985,FOLIO='103',FILE='DISK124:[17ZAA1.17ZAA47301]FE47301A.;4',USER='VSTEFAN',CD='27-FEB-2017;04:20' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_fg47301_1_104"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="fg47301_amicus_therapeutics,_inc._cons__ami03898"> </A>
<A NAME="toc_fg47301_1"> </A></FONT> <FONT SIZE=2><B><BR>  Amicus Therapeutics,&nbsp;Inc.    <BR>    <BR>    Consolidated Balance Sheets<BR>  (in thousands, except share and per share amounts)    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="58pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="54pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Assets</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Current assets:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:28pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>187,026</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>69,485</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:28pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Investments in marketable securities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>143,325</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>144,548</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:28pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accounts receivable</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,304</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:28pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Inventories</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,416</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:28pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Prepaid expenses and other current assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,993</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,568 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total current assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>340,064</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>216,601</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Property and equipment, less accumulated depreciation of $12,495 and $13,353 at December&nbsp;31, 2016 and 2015, respectively</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9,816</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,178</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>In-process research&nbsp;&amp; development</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>486,700</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>486,700</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Goodwill</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>197,797</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>197,797</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other non-current assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,468</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,108 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total Assets</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,036,845</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>908,384 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Liabilities and Stockholders' Equity</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Current liabilities:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:28pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accounts payable, accrued expenses, and other current liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>41,008</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>32,216</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:28pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred reimbursements, current portion</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>13,850</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:28pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Contingent consideration payable, current portion</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>56,101</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>41,400 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total current liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>110,959</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>73,616</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred reimbursements</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>21,906</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>35,756</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Convertible notes</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>154,464</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Due to related party</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>41,601</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Contingent consideration payable</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>213,621</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>232,677</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred income taxes</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>173,771</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>176,219</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other non-current liability</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,973</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>681</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Commitments and contingencies</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stockholders' equity:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:28pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Common stock, $.01 par value, 250,000,000 shares authorized, 142,691,986 shares issued and outstanding at December&nbsp;31, 2016 Common stock, $.01 par
value, 250,000,000 shares authorized, 125,027,034 shares issued and outstanding at December&nbsp;31, 2015,</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,480</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,306</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:28pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Additional paid-in capital</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,120,156</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>917,454</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:28pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accumulated other comprehensive loss:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:37pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Foreign currency translation adjustment, less tax benefit of $1,293 at December&nbsp;31, 2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,945</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:37pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Unrealized gain/ (loss) on available-for securities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>102</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(115</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:37pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Warrants</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>16,076</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8,755</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:37pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accumulated deficit</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(779,608</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(579,566</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total stockholders' equity</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>360,151</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>347,834 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total Liabilities and Stockholders' Equity</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,036,845</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>908,384 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:times;"> <FONT SIZE=2>
See accompanying notes to consolidated financial statements </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-104-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=106,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=776092,FOLIO='104',FILE='DISK124:[17ZAA1.17ZAA47301]FG47301A.;6',USER='VSTEFAN',CD='27-FEB-2017;04:20' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_fi47301_1_105"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="fi47301_amicus_therapeutics,_inc._cons__ami04382"> </A>
<A NAME="toc_fi47301_1"> </A></FONT> <FONT SIZE=2><B><BR>  Amicus Therapeutics,&nbsp;Inc.    <BR>    <BR>    Consolidated Statements of Operations<BR>  (in thousands, except share and per share amounts)    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="74pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="74pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Years Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Revenue:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net Product Sales</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,958</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research revenue</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,224 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total revenue</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,958</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,224</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cost of goods sold</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>833</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Gross Profit</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,125</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,224</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating Expenses:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>104,793</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>76,943</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>47,624</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Selling, general and administrative</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>71,151</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>47,269</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>20,717</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Changes in fair value of contingent consideration payable</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,760</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,377</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>100</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Restructuring charges</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>69</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(63</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Depreciation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,242</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,833</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,547 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total operating expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>186,015</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>130,437</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>69,925</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss from operations</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(181,890</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(130,437</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(68,701</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other income (expenses):</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest income</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,602</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>929</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>223</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest expense</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(5,398</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1,578</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1,484</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss on extinguishment of debt</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(13,302</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(952</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other expense</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(4,793</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(80</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(77</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss before income tax benefit</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(203,781</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(132,118</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(70,039</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Income tax benefit</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,739</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,113</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Net loss attributable to common stockholders</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(200,042</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(132,118</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(68,926</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss attributable to common stockholders per common share&nbsp;&#151; basic and diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1.49</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1.20</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.93</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted-average common shares outstanding&nbsp;&#151; basic and diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>134,401,588</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>109,923,815</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>74,444,157</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:times;"><font> </FONT> <FONT SIZE=2>
See accompanying notes to consolidated financial statements </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-105-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=107,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=710543,FOLIO='105',FILE='DISK124:[17ZAA1.17ZAA47301]FI47301A.;5',USER='VSTEFAN',CD='27-FEB-2017;04:20' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_fk47301_1_106"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="fk47301_amicus_therapeutics,_inc._cons__ami04714"> </A>
<A NAME="toc_fk47301_1"> </A></FONT> <FONT SIZE=2><B><BR>  Amicus Therapeutics,&nbsp;Inc.    <BR>    <BR>    Consolidated Statements of Comprehensive Loss<BR>  (in thousands, except share and per share amounts)    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Years Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(200,042</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(132,118</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(68,926</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other comprehensive gain/ (loss):</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Foreign currency translation adjustment, net of tax of $1,293</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,945</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Unrealized gain/ (loss) on available-for-sale securities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>217</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(133</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other comprehensive income/ (loss)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,162</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(133</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Comprehensive loss</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(197,880</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(132,101</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(69,059</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-106-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=108,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=426354,FOLIO='106',FILE='DISK124:[17ZAA1.17ZAA47301]FK47301A.;5',USER='VSTEFAN',CD='27-FEB-2017;04:20' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_fm47301_1_107"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="fm47301_amicus_therapeutics,_inc._cons__ami04683"> </A>
<A NAME="toc_fm47301_1"> </A></FONT> <FONT SIZE=2><B><BR>  Amicus Therapeutics,&nbsp;Inc.    <BR>    <BR>    Consolidated Statements of Changes in Stockholders' Equity<BR>  (in thousands, except share amounts)    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="36pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="42pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="94pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="58pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="59pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Common Stock </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Additional<BR>
Paid-In<BR>
Capital </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Other Comprehensive<BR>
Gain/(Loss) </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Accumulated<BR>
Deficit </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
Stockholders'<BR>
Equity </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Amount </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Warrants </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Balance at December&nbsp;31, 2013</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>61,975,416</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>679</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>423,593</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(378,522</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>45,751 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Stock issued from exercise of stock options, net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>965,544</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>10</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3,663</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3,673</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Stock issued for Callidus acquisition</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2,359,593</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>24</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(24</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Stock issued from public offering</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>15,927,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>159</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>97,010</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>97,169</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Stock issued from ATM transactions</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>14,328,224</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>143</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>38,493</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>38,636</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Stock-based compensation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6,008</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6,008</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Unrealized holding loss on available-for-sale securities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(133</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(133</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Net loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(68,926</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(68,926</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Balance at December&nbsp;31, 2014</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>95,556,277</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,015</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>568,743</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(132</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(447,448</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>122,178 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Stock issued from exercise of stock options, net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2,070,300</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>21</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>11,165</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>11,186</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Stock issued for Scioderm acquisition</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>5,921,771</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>59</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>82,787</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>82,846</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Stock issued for Callidus acquisition</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>25,762</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Stock issued from financing</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>19,528,302</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>195</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>242,847</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>243,042</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Stock issued from exercise of warrants</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,600,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3,984</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Restricted stock vesting</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>324,622</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(2,044</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(2,044</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Warrants issued in debt financing</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>8,755</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>8,755</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Stock-based compensation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>9,972</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>9,972</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Unrealized holding loss on available-for-sale securities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>17</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>17</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Net loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(132,118</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(132,118</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Balance at December&nbsp;31, 2015</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>125,027,034</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,306</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>917,454</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>8,755</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(115</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(579,566</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>347,834 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Stock issued from exercise of stock options, net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>723,102</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>7</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3,029</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3,036</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Stock issued from ATM transactions</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>14,989,027</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>150</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>96,918</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>97,068</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Stock issued for MiaMed acquisition</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>825,603</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4,599</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4,607</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Restricted stock tax vesting</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>268,425</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(1,282</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(1,282</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Stock issued for contingent consideration</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>858,795</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>9</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6,106</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6,115</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Receivable from investor</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>932</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>932</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Warrants issued in debt financing</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>7,321</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>7,321</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Equity component of the Convertible Notes issuance, net of issuance costs of $2,709</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>88,346</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>88,346</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Premium paid for Capped Call Confirmations</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(13,450</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(13,450</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Stock-based compensation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>17,504</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>17,504</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Unrealized holding gain on available-for-sale securities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>217</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>217</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Foreign currency translation adjustment</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,945</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,945</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Net loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(200,042</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(200,042</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Balance at December&nbsp;31, 2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>142,691,986</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,480</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,120,156</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>16,076</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2,047</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(779,608</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>360,151 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-107-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=109,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=948459,FOLIO='107',FILE='DISK124:[17ZAA1.17ZAA47301]FM47301A.;6',USER='VSTEFAN',CD='27-FEB-2017;04:20' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_fo47301_1_108"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="fo47301_amicus_therapeutics,_inc._cons__ami02961"> </A>
<A NAME="toc_fo47301_1"> </A></FONT> <FONT SIZE=2><B><BR>  Amicus Therapeutics,&nbsp;Inc.    <BR>    <BR>    Consolidated Statements of Cash Flows<BR>  (in thousands)    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="46pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="46pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="46pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Years Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>Operating activities</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Net loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(200,042</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(132,118</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(68,926</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Adjustments to reconcile net loss to net cash used in operating activities:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Non-cash interest expense</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2,689</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>492</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>277</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Depreciation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3,242</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,833</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,547</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Stock-based compensation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>17,504</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>9,972</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6,008</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Restructuring charges</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>69</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>15</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(63</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Change in fair value of derivative liability</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>265</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Non-cash changes in the fair value of contingent consideration payable</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6,760</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4,377</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>100</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Charges to research expense for stock issued in asset acquisition</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4,607</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Loss on extinguishment of debt</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>13,302</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>952</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Foreign currency remeasurement loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3,660</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Non-cash income tax benefit</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(1,293</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Non-cash deferred taxes</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(2,449</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Loss on disposal of assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>17</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Changes in operating assets and liabilities:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Accounts receivable</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(1,419</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Inventories</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(3,651</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Receivable due from collaboration agreements</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,083</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Prepaid expenses and other current assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(394</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>308</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2,293</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Other non-current assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(1,357</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(666</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>26</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Account payable and accrued expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>7,131</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>15,467</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6,169</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Non-current liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>825</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>93</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(126</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Deferred reimbursements</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(864</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(57</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Net cash used in operating activities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(150,534</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(100,139</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(51,669</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:9pt;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>Investing activities</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Sale and redemption of marketable securities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>221,374</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>290,129</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>55,914</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Purchases of marketable securities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(219,932</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(289,595</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(162,752</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Acquisitions, net of cash acquired</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(141,060</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Purchases of property and equipment</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(5,951</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(4,817</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(238</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Net cash used in investing activities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(4,509</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(145,343</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(107,076</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:9pt;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>Financing activities</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Proceeds from issuance of common stock and warrants, net of issuance costs</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>97,068</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>243,042</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>135,805</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Payments of secured loan agreement</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(80,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(15,291</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(299</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Payment of capital leases</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(193</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Purchase of vested restricted stock units</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(1,282</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(2,044</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Proceeds from exercise of stock options</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3,036</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>11,186</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3,673</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Proceeds from exercise of warrants</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Payment of contingent consideration</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(5,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Proceeds from issuance of convertible senior notes, net of issuance costs</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>242,536</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Premiums paid for Capped Call Confirmations</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(13,450</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Proceeds from secured loan agreement</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>30,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>50,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151; </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Net cash provided by financing activities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>272,715</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>290,893</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>139,179 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Effect of exchange rate changes on cash and cash equivalents</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(131</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151; </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>Net increase/(decrease) in cash and cash equivalents</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><B> 117,541</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><B>45,411</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><B>(19,566</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><B>)</B></FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Cash and cash equivalents at beginning of year/period</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>69,485</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>24,074</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>43,640 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>Cash and cash equivalents at end of year/period</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><B>
<!-- -->
$</B></FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><B>187,026</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><B>
<!-- -->
$</B></FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><B>69,485</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><B>
<!-- -->
$</B></FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><B>24,074</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>Supplemental disclosures of cash flow information</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Cash paid during the period for interest</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2,990</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>605</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,186</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Contingent consideration paid in shares</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6,115</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Capital expenditures funded by capital lease borrowings</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>944</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-108-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=110,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=722830,FOLIO='108',FILE='DISK124:[17ZAA1.17ZAA47301]FO47301A.;9',USER='VSTEFAN',CD='27-FEB-2017;04:20' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_fq47301_1_109"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="fq47301_amicus_therapeutics,_inc._note__ami02670"> </A>
<A NAME="toc_fq47301_1"> </A></FONT> <FONT SIZE=2><B><BR>  Amicus Therapeutics,&nbsp;Inc.    <BR>    <BR>    Notes To Consolidated Financial Statements    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


1. Description of Business  </B></FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Corporate Information, Status of Operations, and Management Plans  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amicus Therapeutics,&nbsp;Inc. (the "Company") is a global patient-focused biotechnology company engaged in the discovery, development, and
commercialization of a diverse set of novel treatments for patients living with devastating rare and orphan diseases. The lead product, migalastat HCl is a small molecule that can be used as a
monotherapy and in combination with enzyme replacement of therapy ("ERT") for Fabry disease. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company's Fabry franchise strategy is to develop migalastat HCl (which the Company may refer to as "migalastat") for all patients with Fabry disease as a monotherapy for patients
with amenable mutations and in combination with ERT for all other patients. In May 2016, the Company announced that the European Commission ("EC") had granted full approval for the oral small molecule
pharmacological chaperone Galafold&#153; (migalastat) as a first-line therapy for long-term treatment of adults and adolescents aged 16&nbsp;years and older with a confirmed diagnosis of
Fabry disease (alpha-galactosidase A deficiency) and who have an amenable mutation. The approved label includes 313 Fabry-causing mutations, which represent up to half of all patients with Fabry
disease. The Company commenced commercial shipments of Galafold in the EU in the second quarter of 2016 and recognized net product sales of $5.0&nbsp;million in 2016. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Also
in the pipeline, SD-101 is a product candidate in late-stage development, as a potential first-to-market therapy for the chronic, rare connective tissue disorder Epidermolysis
Bullosa ("EB"). The Company is also leveraging its biologics and Chaperone-Advanced Replacement Therapy ("CHART&#153;") platform technologies to develop novel ERT products for Pompe disease,
Fabry disease, and potentially other lysosomal storage disorders ("LSDs"). The Company is also investigating preclinical and discovery programs in other rare and devastating diseases including
cyclin-dependent kinase-like&nbsp;5 ("CDKL5") deficiency. The Company believes that the platform technologies and advanced product pipeline uniquely position the Company at the forefront of advanced
therapies to treat a range of devastating rare and orphan diseases. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
December&nbsp;21, 2016, the Company issued $250&nbsp;million aggregate principal amount of 3.00% unsecured Convertible Senior Notes due 2023 (the "Convertible Notes"), in a
private offering to qualified institutional buyers pursuant to Rule&nbsp;144A under the Securities Act of 1933, as amended (the "Securities Act"). Interest is payable semiannually on June&nbsp;15
and December&nbsp;15 of each year, beginning on June&nbsp;15, 2017. The Notes will mature on December&nbsp;15, 2023, unless earlier repurchased, redeemed, or converted in accordance with their
terms. The Notes are convertible at the option of the holders, under certain circumstances and during certain periods, into cash, shares of the Company's common stock, par value $0.01 per share
("Common Stock"), or a combination thereof. The net proceeds from the issuance of the Convertible Note offering were $243.1&nbsp;million, after deducting fees and estimated expenses payable by the
Company. In addition, the Company used approximately $13.5&nbsp;million of the net proceeds from the issuance of the Convertible Notes to pay the cost of the capped call transactions ("Capped Call
Confirmations") that the Company entered into in connection with the issuance of the Convertible Notes. For additional information, see "&#151;&nbsp;Note&nbsp;16. Debt Instruments and
Related Party Transactions." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
July 2016, the Company expanded its biologics pipeline with a new preclinical program for CDKL5 deficiency, a rare and devastating genetic neurological disease for which there is no
currently approved treatment. The Company has obtained the rights and related intellectual property to a preclinical CDKL5 program through its acquisition of MiaMed, Inc ("MiaMed"). The aggregate
value </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-109-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=111,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=340676,FOLIO='109',FILE='DISK124:[17ZAA1.17ZAA47301]FQ47301A.;9',USER='CHE106781',CD='27-FEB-2017;20:05' -->
<A NAME="page_fq47301_1_110"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Amicus Therapeutics,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes To Consolidated Financial Statements &#151; (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>of
the deal was approximately $89.5&nbsp;million, which included an upfront payment of $6.5&nbsp;million and Company stock, cash and potential milestones of up to $83.0&nbsp;million. For
additional information, see "&#151;&nbsp;Note&nbsp;3. Acquisitions". </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beginning
in April 2016 and through July 2016, the Company sold 15.0&nbsp;million shares of Common Stock under an at-the-market ("ATM") equity program with Cowen and
Company,&nbsp;LLC ("Cowen") acting as sales agent. Cowen was compensated at a fixed commission rate up to 3.0%. The ATM sales agreement resulted in net proceeds of $97.1&nbsp;million, after
Cowen's commission of $2.7&nbsp;million and other expenses of $0.2&nbsp;million. The Company has completed all sales under the ATM equity program. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company had an accumulated deficit of approximately $779.6&nbsp;million at December&nbsp;31, 2016 and anticipates incurring losses through the fiscal year ending
December&nbsp;31, 2017 and beyond. The
Company has been able to fund its operating losses to date through stock offering, debt issuances, and payments from partners during the terms of the collaboration agreements and other financing
arrangements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company believes that its existing cash and cash equivalents and short-term investments will be sufficient to fund the current operating plan into the second half of 2018. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


2. Summary of Significant Accounting Policies  </B></FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Basis of Presentation  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles
("U.S.&nbsp;GAAP") and include all adjustments necessary for the fair presentation of the Company's financial position for the periods presented. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Consolidation  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The consolidated financial statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions are
eliminated in consolidation. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Foreign Currency Transactions  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The functional currency for most of the Company's foreign subsidiaries is their local currency. For non-U.S. subsidiaries that transact in a
functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date.
Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of the Company's foreign operations
into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of equity. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company transacts business in various foreign countries and therefore, is subject to risk of foreign currency exchange rate fluctuations. As such, in June 2016, the Company entered
into a forward contract to economically hedge transactional exposure associated with commitments arising from trade accounts payable denominated in a currency other than the functional currency of the
respective operating entity. The Company does not designate this forward contract as a hedging instrument under applicable accounting guidance and, therefore, changes in fair value are recorded as
other expense the Consolidated Statements of Operations. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-110-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=112,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=228418,FOLIO='110',FILE='DISK124:[17ZAA1.17ZAA47301]FQ47301A.;9',USER='CHE106781',CD='27-FEB-2017;20:05' -->
<A NAME="page_fq47301_1_111"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Amicus Therapeutics,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes To Consolidated Financial Statements &#151; (Continued) </B></FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Use of Estimates  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The preparation of financial statements in conformity with U.S.&nbsp;GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during
the reporting periods. Actual results could differ from those estimates. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Cash, Money Market Funds, and Marketable Securities  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company considers all highly liquid investments purchased with a maturity of three months or less at the date of acquisition, to be cash
equivalents. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Marketable
securities consist of fixed income investments with a maturity of greater than three months and other highly liquid investments that can be readily purchased or sold using
established markets. These investments are classified as available-for-sale and are reported at fair value on the Company's balance sheet. Unrealized holding gains and losses are reported within
comprehensive income/ (loss) in the statements of comprehensive loss. Fair value is based on available market information including
quoted market prices, broker or dealer quotations or other observable inputs. See "&#151;&nbsp;Note&nbsp;5. Cash, Money Market Funds and Marketable Securities", for a summary of
available-for-sale securities as of December&nbsp;31, 2016 and 2015. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Concentration of Credit Risk  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company's financial instruments that are exposed to concentration of credit risk consist primarily of cash and cash equivalents and
marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in
high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed
to significant credit risk on cash and cash equivalents or its marketable securities. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company is subject to credit risk from its accounts receivable related to its product sales of Galafold. The majority of the Company's accounts receivable at December&nbsp;31, 2016
have arisen from product sales in Germany. The Company will periodically assess the financial strength of its customers to establish allowances for anticipated losses, if any. For accounts receivable
that have arisen from named patient sales, the payment terms are predetermined and the Company evaluates the creditworthiness of each customer on a regular basis. To date, the Company has not incurred
any credit losses. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Property and Equipment  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is calculated over the estimated useful
lives of the respective assets, which range from three to five years, or the lesser of the related initial term of the lease or useful life for leasehold improvements. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
initial cost of property and equipment consists of its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended
use. Expenditures incurred after the fixed assets have been put into operation, such as repairs and maintenance, are charged to income in the period in which the costs are incurred. Major
replacements, improvements and additions are capitalized in accordance with Company policy. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-111-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=113,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=263004,FOLIO='111',FILE='DISK124:[17ZAA1.17ZAA47301]FQ47301A.;9',USER='CHE106781',CD='27-FEB-2017;20:05' -->
<A NAME="page_fq47301_1_112"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Amicus Therapeutics,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes To Consolidated Financial Statements &#151; (Continued) </B></FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Revenue Recognition  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company recognizes revenue when amounts are realized or realizable and earned, which is typically upon shipment to the end-customer. Revenue
is considered realizable and earned when persuasive evidence an arrangement exists, title to product and associated risk of loss has passed to the customer, the price is fixed or determinable,
collection of the amounts due are reasonably assured and the Company has no further performance obligations. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><I> Net Product Sales  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company's net product sales consist solely of sales of Galafold for the treatment of Fabry disease in the EU. The Company has recorded
revenue on sales where Galafold is available either on a commercial basis or through a reimbursed early access program. Orders for Galafold are generally received from pharmacies and the ultimate
payor is typically a government authority. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company records revenue net of estimated third party discounts and rebates. Allowances are recorded as a reduction of revenue at the time revenues from product sales are recognized.
These allowances are adjusted to reflect known changes in factors and may impact such allowances in the quarter those changes are known. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><I> Collaboration Revenue  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In multiple element arrangements, revenue is allocated to each separate unit of accounting and each deliverable in an arrangement is evaluated
to determine whether it represents separate units of accounting. A deliverable constitutes a separate unit of accounting when it has standalone value and there is no general right of return for the
delivered elements. In instances when the aforementioned criteria are not met, the deliverable is combined with the undelivered elements and
the allocation of the arrangement consideration and revenue recognition is determined for the combined unit as a single unit of accounting. Allocation of the consideration is determined at arrangement
inception on the basis of each unit's relative selling price. In instances where there is determined to be a single unit of accounting, the total consideration is applied as revenue for the single
unit of accounting and is recognized over the period of inception through the date where the last deliverable within the single unit of accounting is expected to be delivered. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company's current revenue recognition policies provide that, when a collaboration arrangement contains multiple deliverables, such as license and research and development services,
the Company allocates revenue to each separate unit of accounting based on a selling price hierarchy. The selling price hierarchy for a deliverable is based on (i)&nbsp;its vendor specific objective
evidence ("VSOE") if available, (ii)&nbsp;third party evidence ("TPE") if VSOE is not available, or (iii)&nbsp;best estimated selling price ("BESP") if neither VSOE nor TPE is available. The
Company would establish the VSOE of selling price using the price charged for a deliverable when sold separately. The TPE of selling price would be established by evaluating largely similar and
interchangeable competitor products or services in standalone sales to similarly situated customers. The BESP would be established considering internal factors such as an internal pricing analysis or
an income approach using a discounted cash flow model. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company also considers the impact of potential future payments it makes in its role as a vendor to its customers and evaluates if these potential future payments could be a reduction
of revenue from that customer. If the potential future payments to the customer are:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a payment for an identifiable benefit; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the identifiable benefit is separable from the existing relationship between the Company and its customer; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-112-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=114,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=220636,FOLIO='112',FILE='DISK124:[17ZAA1.17ZAA47301]FQ47301A.;9',USER='CHE106781',CD='27-FEB-2017;20:05' -->
<A NAME="page_fq47301_1_113"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Amicus Therapeutics,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes To Consolidated Financial Statements &#151; (Continued) </B></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the identifiable benefit can be obtained from a party other than the customer; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the Company can reasonably estimate the fair value of the identifiable benefit </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;then
the payments are accounted for separate from the revenue received from that customer. If, however, all these criteria are not satisfied, then the payments are treated as a reduction
of revenue from that customer. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the Company determines that any potential future payments to its customers are to be considered as a reduction of revenue, it must evaluate if the total amount of revenue to be
received under the arrangement is fixed and determinable. If the total amount of revenue is not fixed and determinable due to the uncertain nature of the potential future payments to the customer,
then any customer payments cannot be recognized as revenue until the total arrangement consideration becomes fixed and determinable. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
reimbursements for research and development costs under collaboration agreements that meet the criteria for revenue recognition are included in Research Revenue and the costs
associated with these reimbursable amounts are included in research and development expenses. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
order to determine the revenue recognition for contingent milestones, the Company evaluates the contingent milestones using the criteria as provided by the Financial Accounting
Standards Boards ("FASB") guidance on the milestone method of revenue recognition at the inception of a collaboration agreement. The criteria requires that (i)&nbsp;the Company determines if the
milestone is commensurate with either its performance to achieve the milestone or the enhancement of value resulting from the Company's activities to achieve the milestone, (ii)&nbsp;the milestone
be related to past performance, and (iii)&nbsp;the milestone be reasonable relative to all deliverable and payment terms of the collaboration arrangement. If these criteria are met then the
contingent milestones can be considered as substantive milestones and will be recognized as revenue in the period that the milestone is achieved. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Inventories and Cost of Cost of Goods Sold  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Until regulatory approval of Galafold, the Company expensed all manufacturing costs of Galafold as research and development expense. Upon
regulatory approval, the Company began capitalizing costs related to the purchase and manufacture of Galafold. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories
are stated at the lower of cost or market determined by the first-in, first-out method. Inventories are reviewed periodically to identify slow-moving or obsolete inventory
based on projected sales activity as well as product shelf-life. In evaluating the recoverability of inventories produced, the probability that revenue will be obtained from the future sale of the
related inventory is considered and inventory value is written down for inventory quantities in excess of expected requirements. Expired inventory is disposed of and the related costs are recognized
as cost of product sales in the consolidated statements of operations. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cost
of goods sold includes the cost of inventory sold, manufacturing and supply chain costs, product shipping and handling costs, provisions for excess and obsolete inventory, as well
as royalties payable. A portion of the inventory available for sale was expensed as research and development costs prior to regulatory approval and as such the cost of goods sold and related gross
margins are not necessarily indicative of future cost of goods sold and gross margin. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Fair Value Measurements  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company records certain asset and liability balances under the fair value measurements as defined by the FASB guidance. Current FASB fair
value guidance emphasizes that fair value is a </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-113-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=115,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=180834,FOLIO='113',FILE='DISK124:[17ZAA1.17ZAA47301]FQ47301A.;9',USER='CHE106781',CD='27-FEB-2017;20:05' -->
<A NAME="page_fq47301_1_114"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Amicus Therapeutics,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes To Consolidated Financial Statements &#151; (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>market-based
measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset
or liability. As a basis for considering market participant assumptions in fair value measurements, current FASB guidance establishes a fair value hierarchy that distinguishes between market
participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels&nbsp;1 and 2 of the hierarchy) and the
reporting entity's own assumptions that market participants assumptions would use in pricing assets or liabilities (unobservable inputs classified within Level&nbsp;3 of the hierarchy). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Level&nbsp;1
inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at measurement date.
Level&nbsp;2 inputs are inputs other than quoted prices included in Level&nbsp;1 that are observable for the asset or liability, either directly or indirectly. Level&nbsp;2 inputs may include
quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability (other than quoted prices), such as interest rates, foreign
exchange rates, and yield curves that are observable at commonly quoted intervals. Level&nbsp;3 inputs are unobservable inputs for the asset or liability, which is typically based on an entity's own
assumptions, as there is little, if any, related market activity. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value
hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its
entirety. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Contingent Liabilities  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On an ongoing basis, the Company may be involved in various claims, and legal proceedings. On a quarterly basis, the Company reviews the status
of each significant matter and assesses its potential financial exposure. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be
reasonably estimated, the Company will accrue a liability for the estimated loss. Because of uncertainties related to claims and litigation, accruals will be based on our best estimates based on
available information. On a periodic basis, as additional information becomes available, or based on specific events such as the outcome of litigation or settlement of claims, the Company may reassess
the potential liability related to these matters and may revise these estimates, which could result in a material adverse adjustments to the Company's operating results. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Research and Development Costs  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development costs are expensed as incurred. Research and development expense consists primarily of costs related to personnel,
including salaries and other personnel related expenses, consulting fees and the cost of facilities and support services used in drug development. Assets acquired that are used for research and
development and have no future alternative use are expensed as in-process research and development. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Interest Income and Interest Expense  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest income consists of interest earned on the Company's cash and cash equivalents and marketable securities. Interest expense consists of
interest incurred on capital leases and debt. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-114-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=116,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=599193,FOLIO='114',FILE='DISK124:[17ZAA1.17ZAA47301]FQ47301A.;9',USER='CHE106781',CD='27-FEB-2017;20:05' -->
<A NAME="page_fq47301_1_115"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Amicus Therapeutics,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes To Consolidated Financial Statements &#151; (Continued) </B></FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Income Taxes  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company accounts for income taxes under the liability method. Under this method deferred income tax liabilities and assets are determined
based on the difference between the financial statement carrying amounts and tax basis of assets and liabilities and for operating losses and tax credit carry forwards, using enacted tax rates in
effect in the years in which the differences are expected to reverse. A valuation allowance is recorded if it is "more likely than not" that a portion or all of a deferred tax asset will not be
realized. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Other Comprehensive Income/ (Loss)  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Components of other comprehensive income/(loss) include unrealized gains and losses on available-for-sale securities and gain/(loss) on foreign
currency transactions, and are included in the statements of comprehensive loss. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Leases  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the ordinary course of business, the Company enters into lease agreements for office space as well as leases for certain property and
equipment. The leases have varying terms and expirations and have provisions to extend or renew the lease agreement, among other terms and conditions, as negotiated. Once the agreement is executed,
the lease is assessed to determine whether the lease qualifies as a capital or operating lease. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;When
a non-cancelable operating lease includes any fixed escalation clauses and lease incentives for rent holidays or build-out contributions, rent expense is recognized on a
straight-line basis over the initial term of the lease. The excess between the average rental amount charged to expense and amounts payable under the lease is recorded in accrued expenses. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Nonqualified Cash Deferral Plan  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company's Cash Deferral Plan (the "Deferral Plan"), provides certain key employees and members of the Board of Directors as selected by the
Compensation Committee of the Board of Directors of the Company (the "Compensation Committee"), with an opportunity to defer the receipt of such participant's base salary, bonus and director's fees,
as applicable. The Deferral Plan is intended to be a nonqualified deferred compensation plan that complies with the provisions of Section&nbsp;409A of the Internal Revenue Code (the "Code"). All of
the investments held in the Deferral Plan are classified as investments held-to-maturity and recorded at fair value with changes in the investments' fair value recognized as earnings in the period
they occur. The corresponding liability for the Deferral Plan is included in other non-current liability in the consolidated balance sheets. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Equity-based Compensation  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At December&nbsp;31, 2016, the Company had three equity-based employee compensation plans, which are described more fully in
"&#151;&nbsp;Note&nbsp;9. Stockholders' Equity." The Company applies the fair value method of measuring equity-based compensation, which requires a public entity to measure the cost of
employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Loss per Common Share  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company calculates net loss per share as a measurement of the Company's performance while giving effect to all dilutive potential common
shares that were outstanding during the reporting period. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-115-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=117,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=621273,FOLIO='115',FILE='DISK124:[17ZAA1.17ZAA47301]FQ47301A.;9',USER='CHE106781',CD='27-FEB-2017;20:05' -->
<A NAME="page_fq47301_1_116"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Amicus Therapeutics,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes To Consolidated Financial Statements &#151; (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>The
Company had a net loss for all periods presented; accordingly, the inclusion of common stock options, unvested RSUs and warrants would be anti-dilutive. Therefore, the weighted average shares
used to calculate both basic and diluted earnings per share are the same. See "&#151;&nbsp;Note&nbsp;18. Earnings per Share" for further discussion on net loss per share. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Dividends  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has not paid cash dividends on its capital stock to date. The Company currently intends to retain its future earnings, if any, to
fund the development and growth of the business and does not foresee payment of a dividend in any upcoming fiscal period. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Segment Information  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company currently operates in one business segment focused on the discovery, development and commercialization of advanced therapies to
treat a range of devastating rare and orphan diseases. The Company is not organized by market and is managed and operated as one business. A single management team reports to the chief operating
decision maker who comprehensively manages the entire business. The Company does not operate any separate lines of business or separate business entities with respect to its products. Accordingly, the
Company does not accumulate discrete financial information with respect to separate service lines and does not have separately reportable segments. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Business Combinations  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company allocates the purchase price of acquired businesses to the tangible and intangible assets acquired and liabilities assumed based
upon their estimated fair values on the acquisition date. The purchase price allocation process requires management to make significant estimates and assumptions, especially at the acquisition date
with respect to intangible assets and in-process research and development ("IPR&amp;D"). In connection with the purchase price allocations for acquisitions, the Company estimates the fair value of
contingent payments utilizing a probability-based income approach inclusive of an estimated discount rate. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Contingent Consideration Payable  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company determines the fair value of contingent acquisition consideration payable on the acquisition date using a probability-based income
approach utilizing an appropriate discount rate. Contingent acquisition consideration payable is shown as a non-current liability on the Company's consolidated balance sheets. The fair value of the
contingent consideration payable will be determined each period end and the resulting change will be recorded on the consolidated statements of operations. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Intangible Assets and Goodwill  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company records goodwill in a business combination when the total consideration exceeds the fair value of the net tangible and identifiable
intangible assets acquired. Purchased IPR&amp;D is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted
for as a definite lived intangible asset, or abandoned, at which point the intangible asset will be written off or partially impaired. Goodwill and indefinite lived intangible assets are assessed
annually for impairment and whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. If it is determined that the full carrying amount of an asset is not
recoverable, an impairment loss is recorded in the amount by which the carrying amount of the asset exceeds its fair value. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-116-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=118,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=675940,FOLIO='116',FILE='DISK124:[17ZAA1.17ZAA47301]FQ47301A.;9',USER='CHE106781',CD='27-FEB-2017;20:05' -->
<A NAME="page_fq47301_1_117"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Amicus Therapeutics,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes To Consolidated Financial Statements &#151; (Continued) </B></FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Recent Accounting Pronouncements  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In January 2017, the FASB issued ASU 2017-04, </FONT><FONT SIZE=2><I>Intangibles&nbsp;&#151; Goodwill and Other (Topic 350):
Simplifying the Test for Goodwill Impairment</I></FONT><FONT SIZE=2>. To simplify the subsequent measurement of goodwill, ASU 2017-04 eliminates Step 2 from the goodwill impairment test. The annual,
or interim, goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the
carrying amount exceeds the reporting unit's fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. In addition, income tax effects
from any tax deductible goodwill on the carrying amount of the reporting unit should be considered when
measuring the goodwill impairment loss, if applicable. ASU 2017-04 also eliminates the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment
and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the
quantitative impairment test is necessary. ASU 2017-04 should be applied on a prospective basis. The nature of and reason for the change in accounting principle should be disclosed upon transition. A
public business entity that is a U.S. SEC filer should adopt ASU 2017-04 for its annual or any interim goodwill impairment tests in fiscal years beginning after December&nbsp;15, 2019. Early
adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January&nbsp;1, 2017. The Company is currently assessing the impact that this standard will
have on its consolidated financial statements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
January 2017, the FASB issued ASU 2017-01, </FONT><FONT SIZE=2><I>Business Combinations (Topic 805): Clarifying the Definition of a Business.</I></FONT><FONT SIZE=2> This Accounting
Standards Update clarifies the definition of a business. The amendments affect all companies and other reporting organizations that must determine whether they have acquired or sold a business. The
amendments in this Update are effective for public companies for annual periods beginning after December&nbsp;15, 2017, including interim periods within those periods. Early adoption is permitted
under certain circumstances. The amendments should be applied prospectively as of the beginning of the period of adoption. The Company is currently assessing the impact that this standard will have on
its consolidated financial statements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
October 2016, the FASB issued ASU 2016-17, </FONT><FONT SIZE=2><I>Consolidation (Topic 810): Interests Held through Related Parties That Are under Common
Control.</I></FONT><FONT SIZE=2> This Accounting Standards Update changes the evaluation of whether a reporting entity is the primary beneficiary of a variable interest entity by changing how a
reporting entity that is a single decision maker of a variable interest entity treats indirect interests in the entity held through related parties that are under common control with the reporting
entity. If a reporting entity satisfies the first characteristic of a primary beneficiary (such that it is the single decision maker of a variable interest entity), the amendments require that
reporting entity, in determining whether it satisfies the second characteristic of a primary beneficiary, to include all of its direct variable interests in a variable interest entity and, on a
proportionate basis, its indirect variable interests in a variable interest entity held through related parties, including related parties that are under common control with the reporting entity. The
amendments in this Update are effective for public business entities for fiscal years beginning after December&nbsp;15, 2016, including interim periods within those fiscal years. Early adoption is
permitted, including adoption in an interim period. The Company adopted this ASU in 2016 and the adoption did not have a material impact on its consolidated financial statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-117-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=119,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=481781,FOLIO='117',FILE='DISK124:[17ZAA1.17ZAA47301]FQ47301A.;9',USER='CHE106781',CD='27-FEB-2017;20:05' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_fs47301_1_118"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Amicus Therapeutics,&nbsp;Inc.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes To Consolidated Financial Statements &#151; (Continued)  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In October 2016, the FASB issued ASU 2016-16, </FONT><FONT SIZE=2><I>Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than
Inventory</I></FONT><FONT SIZE=2>. This Accounting Standards Update requires an entity to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the
transfer occurs. The amendments eliminate the exception for an intra-entity transfer of an asset other than inventory. The amendments in this Update are effective for public business entities for
annual periods beginning after December&nbsp;15, 2017, including interim reporting periods within those annual reporting periods. Early adoption is permitted for all entities in the first interim
period if an entity issues interim financial statements. The Company is currently assessing the impact that this standard will have on its consolidated financial statements. We have not completed our
review of the impact of this guidance and do not expect this new guidance to have a material impact on our Consolidated Financial Statements. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
August 2016, the FASB issued ASU 2016-15, </FONT><FONT SIZE=2><I>Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash
Payments.</I></FONT><FONT SIZE=2> This Accounting Standards Update addresses the following eight specific cash flow issues including Debt prepayment or debt extinguishment costs, contingent
consideration payments made after a business combination and separately identifiable cash flows and application of the predominance principle. The amendments in this ASU apply to all entities. The
amendments in this Update are effective for public business entities for fiscal years beginning after December&nbsp;15, 2017, and interim periods within those fiscal years. Early adoption is
permitted, including adoption in an interim period. The Company adopted this ASU in 2016 and the adoption did not have a material impact on its consolidated financial statements. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
March 2016, the FASB issued ASU 2016-09, </FONT><FONT SIZE=2><I>Compensation&nbsp;&#151; Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment
Accounting</I></FONT><FONT SIZE=2>. The amendments are intended to improve the accounting for employee share-based payments and affect all organizations that issue share-based payment awards to their
employees. Several aspects of the accounting for share-based payment award transactions are simplified, including: (</FONT><FONT SIZE=2><I>a</I></FONT><FONT SIZE=2>) income tax consequences;
(</FONT><FONT SIZE=2><I>b</I></FONT><FONT SIZE=2>) classification of awards as either equity or liabilities; and (</FONT><FONT SIZE=2><I>c</I></FONT><FONT SIZE=2>) classification on the statement of
cash flows. For public companies, the amendments are effective for annual periods beginning after December&nbsp;15, 2016, and interim periods within those annual periods. Early adoption is permitted
for any organization in any interim or annual period. The Company is currently assessing the impact that this standard will have on its consolidated financial statements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
February 2016, the FASB issued ASU No.&nbsp;2016-02, </FONT><FONT SIZE=2><I>Leases (Topic 842)</I></FONT><FONT SIZE=2>. This update requires the recognition of lease assets and
lease liabilities on the balance sheet for all lease obligations and disclosing key information about leasing arrangements. This update requires the recognition of lease assets and lease liabilities
by lessees for those leases classified as operating leases under previous generally accepted accounting principles. This update will be effective for the Company for all annual and interim periods
beginning after December&nbsp;15, 2018, including interim periods within those fiscal years. Early application is permitted for all public business entities and all nonpublic business entities upon
issuance. The Company is currently assessing the impact that this standard will have on its consolidated financial statements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330): </FONT><FONT SIZE=2><I>Simplifying the Measurement of Inventory,</I></FONT><FONT SIZE=2> which requires an entity to
measure in scope inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of
completion, disposal, and transportation. The amendments apply to inventory that is measured using first-in, first-out (FIFO) or average cost. The ASU is effective for public business entities for
fiscal years beginning after December&nbsp;15, 2016, including interim periods </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-118-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=120,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=759307,FOLIO='118',FILE='DISK124:[17ZAA1.17ZAA47301]FS47301A.;15',USER='JTAYLORA',CD=';1-MAR-2017;09:41' -->
<A NAME="page_fs47301_1_119"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Amicus Therapeutics,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes To Consolidated Financial Statements &#151; (Continued) </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>within
those fiscal years. A reporting entity should apply the amendments prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The Company is
currently assessing the impact that this standard will have on its consolidated financial statements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
August 2014, the FASB issued ASU 2014-15, </FONT><FONT SIZE=2><I>Presentation of Financial Statements-Going Concern (Subtopic 205-40):</I></FONT><FONT SIZE=2> Disclosure of
Uncertainties about an Entity's Ability to Continue as a Going Concern, which defines management's responsibility to assess an entity's ability to continue as a going concern, and to provide related
footnote disclosures if there is substantial doubt about its ability to continue as a going concern. The pronouncement is effective for annual reporting periods ending after December&nbsp;15, 2016
with early adoption permitted. The Company adopted this ASU in 2016 and the adoption did not have a material impact on its consolidated financial statements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
May 2014, FASB issued ASU 2014-09, </FONT><FONT SIZE=2><I>Revenue from Contracts with Customers</I></FONT><FONT SIZE=2> which along with amendments issued in 2015 and 2016, will
replace substantially all current US&nbsp;GAAP guidance on this topic and eliminate industry-specific guidance. Early adoption of this standard is permitted but not before the original effective
date for all annual periods and interim reporting periods beginning after December&nbsp;15, 2017. The guidance permits two methods of adoption: full retrospective method (retrospective application
to each prior reporting period presented) or modified retrospective method (retrospective application with the cumulative effect of initially applying the guidance recognized at the date of initial
application and providing certain additional disclosures). To complete its assessment of the impact of the standard to its financial statements, the Company continues to assess all implications of
this standard, method of adoption and related financial disclosures. Additionally, the Company continues to monitor modifications, clarifications and interpretations issued by the FASB that may impact
its assessment. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


3. Acquisitions  </B></FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Acquisition of MiaMed,&nbsp;Inc.  </B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In July 2016, the Company entered into an Agreement and Plan of Merger (the "MiaMed Agreement") with MiaMed,&nbsp;Inc., ("MiaMed"). MiaMed is
a pre-clinical biotechnology company focused on developing protein replacement therapy for CDKL5 and related diseases. Under the terms of the MiaMed Agreement, the former holders of MiaMed's capital
stock received an aggregate of $6.5&nbsp;million, comprised of (i)&nbsp;approximately $1.8&nbsp;million in cash (plus MiaMed's cash and cash equivalents at closing and less any of MiaMed's
unpaid third-party fees and expenses related to the transaction), and (ii)&nbsp;825,603 shares of the Company's Common Stock. In addition, the Company also agreed to pay up to an additional
$83.0&nbsp;million in connection with the achievement of certain clinical, regulatory and commercial milestones, for a potential aggregate deal value of $89.5&nbsp;million. The Company evaluated
the transaction based on the guidance of Accounting Standard Codification ("ASC") 805</FONT><FONT SIZE=2><I>, Business Combinations</I></FONT><FONT SIZE=2> and concluded that it only acquired inputs
and did not acquire any processes. The Company will need to develop its own processes in order to produce an output. Therefore, the Company accounted for the transaction as an asset acquisition and
accordingly $6.5&nbsp;million was expensed to research and development. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Acquisition of Scioderm,&nbsp;Inc.  </B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In September 2015, Amicus acquired Scioderm, a privately-held biopharmaceutical company focused on developing innovative therapies for treating
the rare disease Epidermolysis Bullosa ("EB"). The acquisition leverages the Scioderm development team's EB expertise with Amicus' global clinical infrastructure to advance SD-101 toward regulatory
approvals and Amicus' commercial, patient </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-119-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=121,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=138941,FOLIO='119',FILE='DISK124:[17ZAA1.17ZAA47301]FS47301A.;15',USER='JTAYLORA',CD=';1-MAR-2017;09:41' -->
<A NAME="page_fs47301_1_120"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Amicus Therapeutics,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes To Consolidated Financial Statements &#151; (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>advocacy,
and medical affairs infrastructure to support a successful global launch. The acquisition of Scioderm was accounted for as a purchase of a business in accordance with FASB ASC 805 Business
Combinations. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company acquired Scioderm in a cash and stock transaction. At closing, the Company paid Scioderm shareholders, option holders, and warrant holders approximately
$223.9&nbsp;million, of which approximately $141.1&nbsp;million was paid in cash and approximately $82.8&nbsp;million was paid through the issuance of approximately 5.9&nbsp;million newly
issued Amicus shares. The Company has agreed to pay up to an additional $361&nbsp;million to Scioderm shareholders, option holders and warrant holders upon achievement of certain clinical and
regulatory milestones, and $257&nbsp;million to Scioderm shareholders, option holders, and warrant holders upon achievement of certain sales milestones. If SD-101 is approved, EB qualifies as a rare
pediatric disease under The Food and Drug Administration Safety and Innovation Act ("FDSIA") and Amicus will request a Priority Review Voucher ("PRV") under the FDSIA, if available. If the PRV is
obtained and subsequently sold, the Company will pay Scioderm shareholders, option holders, and warrant holders the lesser of $100&nbsp;million in the aggregate or 50% of the proceeds of such sale.
If Amicus obtains the PRV and has not entered into an agreement to sell or otherwise transfer to a third party the PRV within one year of its receipt, the shareholders 'agent may appoint a financial
advisor to conduct a process to sell the PRV. If Amicus determines in its sole discretion to use the PRV, Amicus shall give the shareholders' agent written notice thereof and shall pay to the Scioderm
shareholders, option holders, and warrant holders $100&nbsp;million. The inability to sell the PRV after complying with the provisions, shall not give rise to any payment. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
fair value of the contingent consideration payments on the acquisition date was $259.0&nbsp;million. This was an estimate based on significant inputs that are not observable in the
market, referred to as Level&nbsp;3 inputs. Key assumptions included a range of discount rates between 0.4% and 1.1% as interpolated from the U.S. Treasury constant maturity yield curve over the
time frame for clinical and regulatory milestones and a range of discount rates between 1.0% and 2.2% for revenue-based milestones. The range of outcomes and assumptions used to develop these
estimates have been updated to better reflect the probability of certain milestone outcomes and updated timelines related to clinical development and anticipated approval assumptions as of
December&nbsp;31, 2016 without limitation, the
$5&nbsp;million milestone paid in the second quarter, and milestone payments projected for 2017 (See "&#151;&nbsp;Note&nbsp;10. Assets and Liabilities Measured at Fair Value", for
additional discussion regarding fair value measurements of the contingent acquisition consideration payable). In April 2016, while the total clinical and regulatory approval milestone payments remain
unchanged at $361&nbsp;million, the allocation between the clinical and regulatory approval milestone payments were revised as follows: clinical milestones of up to $81&nbsp;million and regulatory
approval milestones of up to $280&nbsp;million. The commercial milestone payments of up to $257&nbsp;million remained unchanged. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company determined the fair value of the contingent consideration to be $260.0&nbsp;million at December&nbsp;31, 2016, of which $56.1&nbsp;million is payable in the next twelve
months, resulting in an increase in the contingent consideration payable and related expense of approximately $7.3&nbsp;million for the year ended December&nbsp;31, 2016. The expense is recorded
in the Consolidated Statement of Operations as the change within fair value of contingent consideration payable. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
additional information, see "&#151;&nbsp;Note&nbsp;4. Goodwill and Intangible Assets." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
purchase price allocation was subject to completion of the analysis of the fair value of the assets and liabilities as of the effective date of the acquisition. The final valuation
was completed as of December&nbsp;31, 2015. A substantial portion of the assets acquired consisted of intangible assets related to </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-120-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=122,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=463242,FOLIO='120',FILE='DISK124:[17ZAA1.17ZAA47301]FS47301A.;15',USER='JTAYLORA',CD=';1-MAR-2017;09:41' -->
<A NAME="page_fs47301_1_121"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Amicus Therapeutics,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes To Consolidated Financial Statements &#151; (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>SD-101.
The Company determined that the estimated acquisition-date fair value of the indefinite lived IPR&amp;D related to the SD-101 was $463.7&nbsp;million. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Acquisition of Callidus Biopharma,&nbsp;Inc.  </B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In November 2013, the Company acquired Callidus a privately-held biologics company focused on developing best-in-class ERTs for LSDs with its
lead ERT ATB200 for Pompe disease in late preclinical development. The acquisition of the Callidus assets and technology complements Amicus' CHART&#153; platform for the development of next
generation ERTs. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
fair value of the contingent acquisition consideration payments on the acquisition date was $10.6&nbsp;million and was estimated by applying a probability-based income approach
utilizing an appropriate discount rate. Key assumptions included a discount rate of 13.5% and various probability factors. This estimation was based on significant inputs that are not observable in
the market, referred to as Level&nbsp;3 inputs. Some of the more significant assumptions used in the valuation include (i)&nbsp;the probability and timing related to the achievement of certain
developmental milestones and (ii)&nbsp;and the discount rate. As of December&nbsp;31, 2016, the range of outcomes and assumptions used to develop these estimates has changed to better reflect the
probability of certain milestone outcomes. See "&#151;&nbsp;Note&nbsp;10. Assets and Liabilities Measured at Fair Value", for additional discussion regarding fair value measurements of the
contingent acquisition consideration payable. The Company determined the fair value of the contingent consideration to be $9.7&nbsp;million at December&nbsp;31, 2016, all of which is payable
beyond the next twelve months, resulting in an decrease in the contingent consideration payable and related gain of $0.5&nbsp;million year ended December&nbsp;31, 2016. The expense is recorded in
the Consolidated Statement of Operations within the changes in fair value of contingent consideration line item. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the second quarter of 2016, the Company reached the first clinical milestone, which was the dosing of the first patient in a Phase&nbsp;1 or 2 study. The milestone for this
event was $6.0&nbsp;million which was paid in Company stock during the second quarter of 2016, resulting in $6.1&nbsp;million impact on stockholder's equity. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
further information, see "&#151;&nbsp;Note&nbsp;4. Goodwill and Intangible Assets." </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


4. Goodwill and Intangible Assets  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with the acquisitions discussed in "&#151;&nbsp;Note&nbsp;3. Acquisitions, the Company has recognized goodwill of
$197.8&nbsp;million. The following table represents the changes in goodwill for the year ended December&nbsp;31, 2016: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:75%;margin-left:12%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="59pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>(in millions) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Balance at December&nbsp;31, 2015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>197.8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Change in goodwill</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Balance at December&nbsp;31, 2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>197.8 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
connection with the acquisitions discussed in "&#151;&nbsp;Note&nbsp;3. Acquisitions," the Company recognized IPR&amp;D of $486.7&nbsp;million. Intangible assets related to
IPR&amp;D assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. During the period the assets are considered indefinite-lived,
they will not be amortized but will be tested for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would
indicate a reduction in the fair value of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-121-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=123,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=133507,FOLIO='121',FILE='DISK124:[17ZAA1.17ZAA47301]FS47301A.;15',USER='JTAYLORA',CD=';1-MAR-2017;09:41' -->
<A NAME="page_fs47301_1_122"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Amicus Therapeutics,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes To Consolidated Financial Statements &#151; (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>the
IPR&amp;D assets below their respective carrying amounts. The following table represents the changes in IPR&amp;D for the year ended December&nbsp;31, 2016: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:75%;margin-left:12%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="59pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>(in millions) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Balance at December&nbsp;31, 2015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>486.7</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Change in IPR&amp;D</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Balance at December&nbsp;31, 2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>486.7 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Goodwill
and intangible assets are assessed annually for impairment on October&nbsp;1 and whenever events or circumstances indicate that the carrying amount of an asset may not be
recoverable. If it is determined that the full carrying amount of an asset is not recoverable, an impairment loss is recorded in the amount by which the carrying amount of the asset exceeds its fair
value. During the 2016 annual impairment assessment, it was determined that the goodwill and intangible assets had not been impaired therefore there were no changes to the balances of goodwill and
IPR&amp;D in 2016. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


5. Cash, Money Market Funds and Marketable Securities  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of December&nbsp;31, 2016, the Company held $187.0&nbsp;million in cash and cash equivalents and $143.3&nbsp;million of
available-for-sale securities which are reported at fair value on the Company's Consolidated Balance Sheets. Unrealized holding gains and losses are reported within accumulated other comprehensive
income/ (loss) in the statements of comprehensive loss. If a decline in the fair value of a marketable security below the Company's cost basis is determined to be other than temporary, such marketable
security is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge. To date, only temporary impairment
adjustments have been recorded. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company regularly invests excess operating cash in deposits with major financial institutions, money market funds, notes issued by the U.S. government, as well as fixed income
investments and U.S. bond funds both of which can be readily purchased and sold using established markets. The Company believes that the market risk arising from its holdings of these financial
instruments is mitigated as many of these securities are either government backed or of the highest credit rating. Investments that have original maturities or greater than 3&nbsp;months but less
than 1&nbsp;year are classified as short-term and investments with maturities that are greater than 1&nbsp;year are classified as long-term. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company transacts business in various foreign countries and therefore, is subject to risk of foreign currency exchange rate fluctuations. As such, in June 2016 the Company entered
into a forward contract to economically hedge transactional exposure associated with commitments arising from trade accounts payable denominated in a currency other than the functional currency of the
respective operating entity. The Company does not designate these forward contracts as hedging instruments under applicable accounting guidance and, therefore, changes in fair value are recorded
within other income (expense) in the Consolidated Statements of Operations, with the corresponding liability in current liabilities on the Consolidated Balance Sheet. For the year ended
December&nbsp;31, 2016, the Company recognized a loss of $0.3&nbsp;million, related to the derivative instruments not designated as hedging instruments in other expense in the Consolidated
Statements of Operations and the corresponding liability of $0.3&nbsp;million is recorded as other current liability in the Consolidated Balance Sheets. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-122-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=124,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=617866,FOLIO='122',FILE='DISK124:[17ZAA1.17ZAA47301]FS47301A.;15',USER='JTAYLORA',CD=';1-MAR-2017;09:41' -->
<A NAME="page_fs47301_1_123"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Amicus Therapeutics,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes To Consolidated Financial Statements &#151; (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash
and available for sale securities consisted of the following as of December&nbsp;31, 2016 and December&nbsp;31, 2015 (in thousands): </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:75%;margin-left:12%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of December&nbsp;31, 2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Cost </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Unrealized<BR>
Gain </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Unrealized<BR>
Loss </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fair<BR>
Value </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash balances</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>187,026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>187,026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Corporate debt securities, current portion</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>74,564</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>74,535</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Commercial paper</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>68,258</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>132</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>68,390</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Money market</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>350</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>350</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Certificate of deposit</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>330,248</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>134</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>330,351 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Included in cash and cash equivalents</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>187,026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>187,026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Included in marketable securities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>143,222</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>134</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>143,325 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total cash and marketable securities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>330,248</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>134</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>330,351 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:75%;margin-left:12%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of December&nbsp;31, 2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Cost </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Unrealized<BR>
Gain </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Unrealized<BR>
Loss </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fair<BR>
Value </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash balances</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>69,485</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>69,485</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Corporate debt securities, current portion</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>118,627</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(154</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>118,474</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Commercial paper</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25,686</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>38</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25,724</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Certificate of deposit</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>350</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>350 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>214,148</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>39</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(154</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>214,033 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Included in cash and cash equivalents</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>69,485</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>69,485</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Included in marketable securities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>144,663</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>39</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(154</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>144,548 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total cash and marketable securities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>214,148</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>39</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(154</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>214,033 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
the years ended December&nbsp;31, 2016 and 2015, there were no realized gains or losses. The cost of securities sold is based on the specific identification method. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unrealized
loss positions in the available for sale securities as of December&nbsp;31, 2016 and December&nbsp;31, 2015 reflect temporary impairments that have been in a loss position
for less than twelve months and as such are recognized in other comprehensive gain/ (loss). The fair value of these available for sale securities in unrealized loss positions was $58.7&nbsp;million
and $118.5&nbsp;million as of December&nbsp;31, 2016 and 2015, respectively. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company holds available-for-sale investment securities which are reported at fair value on the Company's balance sheet. Unrealized holding gains and losses are reported within
accumulated other comprehensive income ("AOCI") in the statements of comprehensive loss. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-123-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=125,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=73557,FOLIO='123',FILE='DISK124:[17ZAA1.17ZAA47301]FS47301A.;15',USER='JTAYLORA',CD=';1-MAR-2017;09:41' -->
<A NAME="page_fs47301_1_124"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Amicus Therapeutics,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes To Consolidated Financial Statements &#151; (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


6. Inventories  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories consist of work in process and finished goods related to the manufacture of Galafold. The following table summarizes the components
of inventories at December&nbsp;31, 2016 (in thousands): </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:75%;margin-left:12%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="88pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31,&nbsp;2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Work-in-process</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,308</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Finished goods</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>108 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total inventories</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,416 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
were no inventories on-hand as of December&nbsp;31, 2015. Inventory manufactured prior to commercialization was expensed to research and development. Inventories are reviewed
periodically to identify slow-moving or obsolete inventory based on projected sales activity, as well as product shelf-life. In evaluating the recoverability of inventories produced, the Company
considers the probability that revenue will be obtained from the future sale of the related inventory. Inventory becomes obsolete when it has aged past its shelf-life, cannot be recertified and is no
longer usable or able to be sold, or the inventory has been damaged. In such instances, a full reserve is taken against such inventory. Expired inventory is disposed of and the related costs are
recognized as cost of product sales in the consolidated statement of operations. There have been no write-downs of inventory from the time inventory was first capitalized. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


7. Property and Equipment  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property and equipment consist of the following (in thousands): </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:75%;margin-left:12%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Property and equipment consist of the following:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Computer equipment</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,511</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,075</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Computer software</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,347</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,354</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research equipment</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,465</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,483</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Furniture and fixtures</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,444</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Leasehold improvements</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,970</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,175 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>22,311</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>19,531</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Less accumulated depreciation</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(12,495</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(13,353</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9,816</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,178 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation
expense was $3.2&nbsp;million and $1.8&nbsp;million for the years ended December&nbsp;31, 2016 and 2015, respectively. As of December&nbsp;31, 2016,
$0.2&nbsp;million of the depreciation expense was related to capital lease obligation. There were no capital lease obligations outstanding as of December&nbsp;31, 2015. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-124-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=126,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=146052,FOLIO='124',FILE='DISK124:[17ZAA1.17ZAA47301]FS47301A.;15',USER='JTAYLORA',CD=';1-MAR-2017;09:41' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_fu47301_1_125"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Amicus Therapeutics,&nbsp;Inc.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes To Consolidated Financial Statements &#151; (Continued)  </B></FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


8. Accounts Payable and Accrued Expenses  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and accrued expenses consist of the following (in thousands): </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:75%;margin-left:12%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accounts payable</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,905</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16,477</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued professional fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,079</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,578</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued contract manufacturing&nbsp;&amp; contract research costs</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8,042</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,940</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued compensation and benefits</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9,981</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,201</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued facility costs</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,740</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,321</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Foreign currency forward contract</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>265</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Capital lease, short term portion</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>283</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued other</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,713</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,699 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>41,008</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>32,216 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


9. Stockholders' Equity  </B></FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Common Stock and Warrants  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of December&nbsp;31, 2016, the Company was authorized to issue 250&nbsp;million shares of common stock. Dividends on common stock will be
paid when, and if, declared by the board of directors. Each holder of common stock is entitled to vote on all matters that are appropriate for stockholder voting and is entitled to one vote for each
share held. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
discussed in "&#151;&nbsp;Note&nbsp;16. Debt Instruments and Related Party Transactions", on December&nbsp;21, 2016, the Company issued $250&nbsp;million aggregate
principal amount of 3.0% unsecured Convertible Senior Notes due 2023 (the "Convertible Notes), in a private offering. The Notes will mature on December&nbsp;15, 2023, unless earlier repurchased,
redeemed, or converted in accordance with
their terms. The Notes are convertible at the option of the holders, under certain circumstances and during certain periods, into cash, shares of the Company's common stock, par value $0.01 per share
("Common Stock"), or a combination thereof. Prior to the close of business on the business day immediately preceding September&nbsp;15, 2023, the Notes are convertible at the option of the holders
of the Notes only under certain conditions. On or after September&nbsp;15, 2023, until the close of business on the second business day immediately preceding the maturity date, holders of the Notes
may convert their Notes at their option at the conversion rate then in effect, irrespective of these conditions. The Company will settle conversions of the Notes by paying or delivering, as the case
may be, cash, shares of Common Stock, or a combination of cash and shares of Common Stock, at the Company's election. The conversion rate will initially be 163.3987 shares of Common Stock per $1,000
principal amount of Notes (equivalent to an initial conversion price of approximately $6.12 per share of Common Stock). The conversion rate is subject to customary adjustments upon the occurrence of
certain events. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beginning
in April 2016 and through July 2016, the Company sold 15.0&nbsp;million shares of Common Stock under an ATM equity program with Cowen and Company,&nbsp;LLC ("Cowen") acting
as sales agent. Cowen was compensated at a fixed commission rate up to 3.0%. The ATM sales agreement resulted in net proceeds of $97.1&nbsp;million, after Cowen's commission of $2.7&nbsp;million
and other expenses of $0.2&nbsp;million. The Company has completed all sales under the ATM equity program. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-125-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=127,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=582128,FOLIO='125',FILE='DISK124:[17ZAA1.17ZAA47301]FU47301A.;12',USER='MKEANE',CD='28-FEB-2017;20:43' -->
<A NAME="page_fu47301_1_126"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Amicus Therapeutics,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes To Consolidated Financial Statements &#151; (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
discussed in "&#151;&nbsp;Note&nbsp;16. Debt instruments and Related Party Transactions," the Company issued approximately 1.8&nbsp;million and 1.3&nbsp;million of
warrants in February 2016 and June 2016, respectively. The closing balance of the warrants was $16.1&nbsp;million as of December&nbsp;31, 2016 and is recorded within equity on the Consolidated
Balance Sheets. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
discussed in "&#151;&nbsp;Note&nbsp;3. Acquisitions, in July 2016, the Company entered into an Agreement and Plan of Merger (the "MiaMed Agreement") with MiaMed. Under the
terms of the MiaMed Agreement, the former holders of MiaMed's capital stock received an aggregate of $6.5&nbsp;million, comprised of (i)&nbsp;approximately $1.8&nbsp;million in cash (plus
MiaMed's cash and cash equivalents at closing and less any of MiaMed's unpaid third-party fees and expenses related to the transaction), and (ii)&nbsp;825,603 shares of the Company's Common Stock.
In addition, the Company also agreed to pay up to an additional $83.0&nbsp;million in connection with the achievement of certain clinical, regulatory and commercial milestones, for a potential
aggregate deal value of $89.5&nbsp;million. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
discussed in "&#151;&nbsp;Note&nbsp;3. Acquisitions, in September 2015, the Company acquired Scioderm with cash and stock. As part of the acquisition, the Company paid
holders of Scioderm an amount equal to $223.9&nbsp;million, of which approximately $141.1&nbsp;million was paid in cash and approximately $82.8&nbsp;million was paid through the issuance of
5.9&nbsp;million newly issued shares. The Company agreed to pay up to an additional $361&nbsp;million upon achievement of certain clinical and
regulatory milestones, and $257&nbsp;million to Scioderm shareholders, option holders, and warrant holders upon achievement of certain sales milestones. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
June 2015, the Company issued a total of 19.5&nbsp;million shares through a public offering at a price of $13.25 per share, with net proceeds of $243.0&nbsp;million. The Company
expects to use the net proceeds of the offering for investment in the global commercialization infrastructure for Galafold for Fabry disease, the continued clinical development of its product
candidates and for other general corporate purposes. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
November 2014, the Company sold a total of 15.9&nbsp;million shares of our common stock, par value $0.01 per share, at a public offering price of $6.50 per share. The aggregate
offering proceeds were approximately $97.2&nbsp;million. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
July 2014, the Company completed a $40&nbsp;million ATM equity offering under which the Company sold shares of its common stock, par value $0.01 per shares with Cowen and
Company&nbsp;LLC as sales agent. Under the ATM equity program the Company sold 14.3&nbsp;million shares of common stock resulting in net proceeds of $38.6&nbsp;million. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Nonqualified Cash Plan  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company's Deferral Plan, (the "Deferral Plan") provides certain key employees and members of the Board of Directors as selected by the
Compensation Committee, with an opportunity to defer the receipt of such participant's base salary, bonus and director's fees, as applicable. The Deferral Plan is intended to be a nonqualified
deferred compensation plan that complies with the provisions of Section&nbsp;409A of the Internal Revenue Code of 1986 as amended. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred
compensation amounts under the Deferral Plan as of December&nbsp;31, 2016 were approximately $1.5&nbsp;million, as compared to $0.7&nbsp;million on December&nbsp;31,
2015 and are included in other long-term liabilities. Deferral Plan assets as of December&nbsp;31, 2016 were $1.5&nbsp;million as compared to $0.7&nbsp;million as of December&nbsp;31, 2015 and
are classified as trading securities. The Deferred Plan assets are recorded at fair value with changes in the investments' fair value recognized in AOCI in the period they occur. The income from
investment for the year ended December&nbsp;31, 2016 and 2015 was </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-126-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=128,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=966489,FOLIO='126',FILE='DISK124:[17ZAA1.17ZAA47301]FU47301A.;12',USER='MKEANE',CD='28-FEB-2017;20:43' -->
<A NAME="page_fu47301_1_127"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Amicus Therapeutics,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes To Consolidated Financial Statements &#151; (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>$34&nbsp;thousand
and $17&nbsp;thousand respectively. Unrealized gain approximated $32&nbsp;thousand for the year ended December&nbsp;31, 2016, as compared to unrealized loss of
$50&nbsp;thousand for the year ended December&nbsp;31, 2015. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Equity Incentive Plans  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company's Equity Incentive Plans consist of the Amended and Restated 2007 Equity Incentive Plan (the "Plan") and the 2007 Director Option
Plan (the "2007 Director Plan"). The Plan provides for the granting of restricted stock and options to purchase common stock in the Company to employees, advisors and consultants at a price to be
determined by the Company's board of directors. The Plan is intended to encourage ownership of stock by employees and consultants of the Company and to provide additional incentives for them to
promote the success of the Company's business. The 2007 Director Plan is intended to promote the recruiting and retention of highly qualified eligible directors and strengthen the commonality of
interest between directors and stockholders by encouraging ownership of common stock of the Company. Under the provisions of each plan, no option will have a term in excess of 10&nbsp;years. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Board of Directors, or its committee, is responsible for determining the individuals to be granted options, the number of options each individual will receive, the option price per
share, and the exercise period of each option. Options granted pursuant to the Plan generally vest 25% on the first year anniversary date of grant plus an additional 1/48th&nbsp;for each month
thereafter and may be exercised in whole or in part for 100% of the shares vested at any time after the date of grant. Options under the 2007 Director Plan may be granted to new directors upon joining
the Board and vest in the same manner as options under the Plan. In addition, options are automatically granted to all directors at each annual meeting of stockholders and vest on the date of the
annual meeting of stockholders of the Company in the year following the year during which the options were granted. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of December&nbsp;31, 2016, the Company has reserved up to 12,630,511 shares for issuance under the Plan and the 2007 Director Plan. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><I> Stock Option Grants  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company adopted the fair value method of measuring stock-based compensation, using the fair value of each equity award granted. The Company
chose the "straight-line" attribution method for allocating compensation costs and recognized the fair value of each stock option on a straight-line basis over the vesting period of the related
awards. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company uses the Black-Scholes option pricing model when estimating the grant date fair value for stock-based awards. Use of a valuation model requires management to make certain
assumptions with respect to selected model inputs. Expected volatility was based on our historical volatility since our initial public offering in May 2007.The average expected life was determined
using the "simplified" method of estimating the expected exercise term which is the mid-point between the vesting date and the end of the contractual term. As the Company's stock price volatility has
been over 75% and it has experienced significant business transactions, the Company does not have sufficient reliable exercise data in order to justify a change in the use of the "simplified" method
of estimating the expected exercise term of employee stock option grants. The risk-free interest rate is based on U.S. Treasury, zero-coupon issues with a remaining term equal to the expected life
assumed at the date of grant. Forfeitures are estimated based on voluntary termination behavior, as well as a historical analysis of actual option forfeitures. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-127-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=129,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=814186,FOLIO='127',FILE='DISK124:[17ZAA1.17ZAA47301]FU47301A.;12',USER='MKEANE',CD='28-FEB-2017;20:43' -->
<A NAME="page_fu47301_1_128"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Amicus Therapeutics,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes To Consolidated Financial Statements &#151; (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
weighted average assumptions used in the Black-Scholes option pricing model are as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:75%;margin-left:12%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="32pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="32pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="32pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Years Ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected stock price volatility</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>81.3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>75.9</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>81.3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk free interest rate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.7</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.9</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected life of options (years)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.25</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.25</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.25</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected annual dividend per share</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.00</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.00</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.00</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
weighted average grant-date fair value per share of options granted during 2016, 2015 and 2014 were $5.28, $7.51 and $2.12, respectively. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table summarizes information about stock options outstanding: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:75%;margin-left:12%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="69pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="77pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="59pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Shares </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted<BR>
Average<BR>
Exercise<BR>
Price </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted<BR>
Average<BR>
Remaining<BR>
Contractual Life </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Aggregate<BR>
Intrinsic<BR>
Value </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(in thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(in millions)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Options outstanding, December&nbsp;31, 2013</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9,041.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5.65</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Granted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,993.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2.99</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Exercised</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(965.6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3.80</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Forfeited</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1,047.9</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5.76</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Options outstanding, December&nbsp;31, 2014</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,020.7</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5.02</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Granted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,917.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>11.61</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Exercised</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(2,070.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5.43</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Forfeited</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(138.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7.76</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Options outstanding, December&nbsp;31, 2015</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>11,729.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7.11</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Granted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,114.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7.67</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Exercised</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(723.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.20</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Forfeited</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(622.7</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8.62</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Options outstanding, December&nbsp;31, 2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,497.5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7.37</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7.3&nbsp;years</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7.8 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Vested and unvested expected to vest, December&nbsp;31, 2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(14,593.7</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7.31</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7.2&nbsp;years</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7.7</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Exercisable at December&nbsp;31, 2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,545.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6.57</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5.8&nbsp;years</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5.8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
aggregate intrinsic value of options exercised during the years ended December&nbsp;31, 2016, 2015 and 2014 was $2.6&nbsp;million, $14.7&nbsp;million and $2.8&nbsp;million
respectively. Cash proceeds from stock options exercised during the years ended December&nbsp;31, 2016, 2015, and 2014 were $3.0&nbsp;million, $11.2&nbsp;million, and $3.7&nbsp;million,
respectively. As of December&nbsp;31, 2016, the total unrecognized compensation cost related to non-vested stock options granted was $33.7&nbsp;million and is expected to be recognized over a
weighted average period of 2.8&nbsp;years. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-128-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=130,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=654029,FOLIO='128',FILE='DISK124:[17ZAA1.17ZAA47301]FU47301A.;12',USER='MKEANE',CD='28-FEB-2017;20:43' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_fw47301_1_129"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Amicus Therapeutics,&nbsp;Inc.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes To Consolidated Financial Statements &#151; (Continued)  </B></FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><I> Restricted Stock Units  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;RSUs awarded under the Plan are generally subject to graded vesting and are contingent on an employee's continued service. RSUs are generally
subject to forfeiture if employment terminates prior to the release of vesting restrictions. The Company expenses the cost of the RSUs, which is determined to be the fair market value of the shares of
common stock underlying the RSUs at the date of grant, ratably over the period during which the vesting restrictions lapse. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
summary of non-vested RSU activity under the Plan for the year ended December&nbsp;31, 2016 is as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="69pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="59pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Share </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted<BR>
Average Grant<BR>
Date Fair<BR>
Value </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted<BR>
Average<BR>
Remaining<BR>
Years </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Aggregate<BR>
Intrinsic<BR>
Value </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(in thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(in millions)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Non-vested units as of December&nbsp;31, 2014</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>955.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.28</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Granted</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>366.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12.63</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Vested</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(842.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Forfeited</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Non-vested units as of December&nbsp;31, 2015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>478.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10.38</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Granted</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>582.7</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.21</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Vested</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(281.9</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8.73</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Forfeited</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(34.9</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7.71</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Non-vested units as of December&nbsp;31, 2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>744.4</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7.86</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.62</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
the year ended December&nbsp;31, 2016, 0.3&nbsp;million of the RSUs vested and all non-vested units are expected to vest over their normal term. As of December&nbsp;31, 2016,
there was $4.2&nbsp;million of total unrecognized compensation cost related to unvested RSUs with service-based vesting conditions. These costs are expected to be recognized over a weighted average
period of 2.62&nbsp;years. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
December&nbsp;30, 2016, the Compensation Committee approved a form of Performance-Based Restricted Stock Unit Award Agreement (the "Performance-Based RSU Agreement"), to be used for
performance-based RSUs granted to participants under the Amended and Restated Amicus Therapeutics,&nbsp;Inc. 2007 Equity Incentive Plan, including named executive officers. Awards under the form of
Performance-Based RSU Agreement will vest based on the Company meeting specified performance criteria. Vesting of the RSUs is generally subject to the participant's continuous service with the Company
through a specified date. As of December&nbsp;31, 2016 there were no RSUs issued under the Performance-Based RSU Agreement. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-129-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=131,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=123061,FOLIO='129',FILE='DISK124:[17ZAA1.17ZAA47301]FW47301A.;20',USER='WWASSER',CD='28-FEB-2017;11:44' -->
<A NAME="page_fw47301_1_130"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Amicus Therapeutics,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes To Consolidated Financial Statements &#151; (Continued) </B></FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><I> Compensation Expense Related to Equity Awards  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes the equity-based compensation expense recognized in the statements of operations (in thousands): </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Years Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Equity compensation expense recognized in:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development expense</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8,071</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,600</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,703</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Selling, general and administrative expense</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9,433</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,372</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,305 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total equity compensation expense</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>17,504</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9,972</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,008 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


10. Assets and Liabilities Measured at Fair Value  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company's financial assets and liabilities are measured at fair value and classified within the fair value hierarchy which is defined as
follows: </FONT></P>

<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2><I>Level&nbsp;1</I></FONT><FONT SIZE=2> &#151; Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the
measurement date. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I>Level&nbsp;2</I></FONT><FONT SIZE=2> &#151; Inputs other than quoted prices in active markets that are observable for the asset or liability, either directly or
indirectly. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I>Level&nbsp;3</I></FONT><FONT SIZE=2> &#151; Inputs that are unobservable for the asset or liability. </FONT></P>

</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of
December&nbsp;31, 2016 are identified in the following table (in thousands): </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:75%;margin-left:12%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Level&nbsp;2 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Commercial paper</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>68,390</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>68,390</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Corporate debt securities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>74,535</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>74,535</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Money market funds</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,829</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,829 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>144,754</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>144,754 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:75%;margin-left:12%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Level&nbsp;2 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Level&nbsp;3 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B><I>Liabilities:</I></B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Contingent consideration payable</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>269,722</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>269,722</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Derivative liability</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>265</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>265</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred compensation plan liability</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,479</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,479 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,744</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>269,722</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>271,466 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-130-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=132,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=778731,FOLIO='130',FILE='DISK124:[17ZAA1.17ZAA47301]FW47301A.;20',USER='WWASSER',CD='28-FEB-2017;11:44' -->
<A NAME="page_fw47301_1_131"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Amicus Therapeutics,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes To Consolidated Financial Statements &#151; (Continued) </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
summary of the fair value of the Company's assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December&nbsp;31,
2015 are identified in the following table (in thousands): </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:75%;margin-left:12%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Level&nbsp;2 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Commercial paper</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25,724</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25,724</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Corporate debt securities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>118,474</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>118,474</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Certificate of deposit</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>350</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>350</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Market exchanged mutual funds</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>658</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>658 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>145,206</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>145,206 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:75%;margin-left:12%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="36pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Level&nbsp;2 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Level&nbsp;3 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B><I>Liabilities:</I></B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Contingent consideration payable</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>274,077</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>274,077</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred compensation plan liability</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>667</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>667 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>667</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>274,077</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>274,744 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;See
"&#151; Note&nbsp;16. Debt Instruments and Related Party Transactions" for the carrying amount and estimated fair value of the Company's Convertible Notes due in 2023. The
Company did not have any Level&nbsp;3 assets as of December&nbsp;31, 2016 or 2015. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Cash, Money Market Funds and Marketable Securities  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company classifies its cash and money market funds within the fair value hierarchy as Level&nbsp;1 as these assets are valued using quoted
prices in active market for identical assets at the measurement date. The Company considers its investments in marketable securities as available for sale and classifies these assets within the fair
value hierarchy as Level&nbsp;2 primarily utilizing broker quotes in a non-active market for valuation of these securities. No changes in valuation techniques or inputs occurred during the year
ended December&nbsp;31, 2016. No transfers of assets between Level&nbsp;1 and Level&nbsp;2 of the fair value measurement hierarchy occurred during the year ended December&nbsp;31, 2016. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Contingent Consideration Payable  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The contingent consideration payable resulted from the acquisitions of Scioderm and Callidus, as discussed in "&#151; Note&nbsp;3.
Acquisitions." The most recent valuation was determined using a probability weighted discounted cash flow valuation approach. Using this approach, expected future cash flows are calculated over the
expected life of the agreement, are discounted, and then exercise scenario probabilities are applied. The valuation is performed quarterly. Gains and losses are included in the statement of
operations. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
discussed in "&#151; Note&nbsp;3. Acquisitions," on July&nbsp;5, 2016, the Company entered into the MiaMed Agreement with MiaMed. MiaMed is a pre-clinical biotechnology
company focused on developing protein replacement for CDKL5 and related diseases. Under the terms of the MiaMed Agreement, the Company agreed to pay up to an additional $83.0&nbsp;million in
connection with the achievement of certain clinical, regulatory and commercial milestones, for a potential aggregate deal value of $89.5&nbsp;million. The MiaMed Agreement was accounted for as an
asset acquisition and as such the Company determined that a liability for future milestone payments is not required to be recorded until the actual </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-131-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=133,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=17636,FOLIO='131',FILE='DISK124:[17ZAA1.17ZAA47301]FW47301A.;20',USER='WWASSER',CD='28-FEB-2017;11:44' -->
<A NAME="page_fw47301_1_132"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Amicus Therapeutics,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes To Consolidated Financial Statements &#151; (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>contingencies
are met and will be recorded to research and development expenses when the contingency is resolved. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
contingent consideration payable for Scioderm and Callidus has been classified as a Level&nbsp;3 recurring liability as its valuation requires substantial judgment and estimation
of factors that are not currently observable in the market. If different assumptions were used for the various inputs to the valuation approach the estimated fair value could be significantly higher
or lower than the fair value the Company determined. The Company may be required to record losses in future periods, including expenses related to CDKL5. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following significant unobservable inputs were used in the valuation of the contingent consideration payable to former Scioderm stockholders: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:62%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"130%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="130%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="82pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="98pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="98pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="92pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Contingent Consideration Liability

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fair value as of<BR>
December&nbsp;31,<BR>
2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Valuation Technique </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Unobservable Input </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Range </B></FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Discount rate</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>0.62%&nbsp;-&nbsp;3.8%</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Clinical and regulatory milestones</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>$237.2&nbsp;million</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Probability weighted discounted cash flow</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Probability of achievement of milestones</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>66.5%&nbsp;-&nbsp;100.0%</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Projected year of payments</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2017-2019</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Revenue volatility</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>58%</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Probability of achievement of milestones</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>66.5%</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Revenue-based milestones</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>$22.8&nbsp;million</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Monte Carlo</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Discount rate</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>1.47%&nbsp;-&nbsp;2.55%</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Projected year of payments</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2019-2029</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following significant unobservable inputs were used in the valuation of the contingent consideration payable of Callidus for the ATB-200 Pompe program: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:62%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"130%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="130%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="73pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="98pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="98pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="86pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Contingent Consideration Liability

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fair value as of<BR>
December&nbsp;31,<BR>
2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Valuation Technique </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Unobservable Input </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Range </B></FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Discount rate</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>12.5%</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Clinical and regulatory milestones</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>$9.3&nbsp;million</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Probability weighted discounted cash flow</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Probability of achievement of milestones</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>30.4%-42.8%</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Projected year of payments</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2018-2022</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Contingent
consideration liabilities are remeasured to fair value each reporting period using projected revenues, discount rates, probabilities of payment and projected payment dates.
Projected </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-132-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=134,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=858064,FOLIO='132',FILE='DISK124:[17ZAA1.17ZAA47301]FW47301A.;20',USER='WWASSER',CD='28-FEB-2017;11:44' -->
<A NAME="page_fw47301_1_133"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Amicus Therapeutics,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes To Consolidated Financial Statements &#151; (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>contingent
payment amounts related to clinical and regulatory based milestones are discounted back to the current period using a discounted cash flow model. Revenue-based payments are valued using a
monte-carlo valuation model, which simulates future revenues during the earn out-period using
management's best estimates. Projected revenues are based on our most recent internal operational budgets and long-range strategic plans. Increases in projected revenues and probabilities of payment
may result in higher fair value measurements. Increases in discount rates and the time to payment may result in lower fair value measurements. Increases or decreases in any of those inputs together,
or in isolation, may result in a significantly lower or higher fair value measurement. There is no assurance that any of the conditions for the milestone payments will be met. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table shows the change in the balance of contingent consideration payable for the year ended December&nbsp;31, 2016 and 2015, respectively (in thousands): </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:75%;margin-left:12%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Balance, beginning of the period</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>274,077</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,700</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Additions, from business acquisitions</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>259,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Payment of contingent consideration in cash</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(5,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Payment of contingent consideration in stock</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(6,115</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Unrealized change in fair value change during the period, included in Statement of Operations</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,760</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,377 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Balance, end of the period</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>269,722</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>274,077 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Deferred Compensation Plan- Investment and Liability  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As disclosed in "&#151; Note&nbsp;9. Stockholders' Equity," the Deferral Plan provides certain key employees and members of the Board
of Directors with an opportunity to defer the receipt of such participant's base salary, bonus and director's fees, as applicable. Deferral Plan assets are classified as trading securities and
recorded at fair value with changes in the investments' fair value recognized in the period they occur. The asset investments consist of market exchanged mutual funds. The Company considers its
investments in marketable securities, as available-for-sale and classifies these assets and related liability within the fair value hierarchy as Level&nbsp;2 primarily utilizing broker quotes in a
non-active market for valuation of these securities. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Foreign Currency Exchange Rate Exposure  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company transacts business in various foreign countries and therefore, is subject to risk of foreign currency exchange rate fluctuations. As
such, in June 2016, the Company entered into a forward contract to economically hedge transactional exposure associated with commitments arising from trade accounts payable denominated in a currency
other than the functional currency of the respective operating entity. The Company did not designate this forward contract as a hedging instrument under applicable accounting guidance and, therefore,
the change in fair value is recorded in the Consolidated Statements of Operations. The forward contract settles in monthly installments with the final installment settlement in June 2017. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
were no outstanding forward contracts at December&nbsp;31, 2015. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-133-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=135,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=788895,FOLIO='133',FILE='DISK124:[17ZAA1.17ZAA47301]FW47301A.;20',USER='WWASSER',CD='28-FEB-2017;11:44' -->
<A NAME="page_fw47301_1_134"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Amicus Therapeutics,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes To Consolidated Financial Statements &#151; (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
the year ended December&nbsp;31, 2016, the Company recognized a loss of $265&nbsp;thousand, related to the derivative instruments not designated as hedging instruments in the
Consolidated Statements of Operations and the corresponding liability of $265&nbsp;thousand is recorded as other current liability in the Consolidated Balance Sheets. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
impact of gains and losses on foreign exchange contracts not designated as hedging instruments related to changes in the fair value of assets and liabilities denominated in foreign
currencies are generally offset by net foreign exchange gains and losses, which are also included on the Consolidated Statements of Operations in other income (expense), net for all periods presented.
When the Company enters into foreign exchange contracts not designated as hedging instruments to mitigate the impact of exchange rate volatility in the translation of foreign earnings, gains and
losses will generally be offset by fluctuations in the U.S. Dollar translated amounts of each account within the Consolidated Statements of Operations in current and/or future periods. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


11. 401(k) Plan  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has a 401(k) plan (the "401(k) Plan") covering all eligible employees and provides for a company match of up to 5% of salary and
bonus paid during the year. The Company's vesting policy is that the Company match vests immediately upon enrollment. There were no changes to the policy in 2016 or 2015. The Company's total
contribution to the 401(k) Plan was $1.2&nbsp;million, $0.9&nbsp;million and $0.6&nbsp;million for the years ended December&nbsp;31, 2016, 2015 and 2014, respectively. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


12. Leases  </B></FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Operating Leases  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company currently leases office space and research laboratory space in various facilities under operating agreements expiring at various
dates through 2025. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table contains information about our current significant leased properties as of December&nbsp;31, 2016: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="60pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="122pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="92pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Location

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Approximate<BR>
Square Feet </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Use </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Lease expiry date </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cranbury, New Jersey</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>90,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Office and laboratory</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>September 2025</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Durham, North Carolina</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,603</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Office</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>June 2018</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Buckinghamshire, United Kingdom</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9,821</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Office</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>September 2020</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Munich, Germany</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,316</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Office</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>April 2017</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to the above, we also maintain small offices in the Italy, France, Netherlands and Spain. We believe that our current office and laboratory facilities are adequate and
suitable for our current and anticipated needs. We believe that, to the extent required, we will be able to lease or buy additional facilities at commercially reasonable rates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rent
expenses for the Company's facilities are recognized over the term of the lease. The Company recognizes rent starting when possession of the facility is taken from the landlord.
When a lease contains a predetermined fixed escalation of the minimum rent, the Company recognizes the related rent expense on a straight-line basis and records the difference between the recognized
rental expense and the amounts payable under the lease as deferred rent liability. Tenant leasehold improvement allowances are reflected in accrued expenses on the consolidated balance sheets and are
amortized as a reduction to rent expense in the statement of operations over the term of the lease. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-134-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=136,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=793818,FOLIO='134',FILE='DISK124:[17ZAA1.17ZAA47301]FW47301A.;20',USER='WWASSER',CD='28-FEB-2017;11:44' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_fy47301_1_135"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Amicus Therapeutics,&nbsp;Inc.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes To Consolidated Financial Statements &#151; (Continued)  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At December&nbsp;31, 2016, aggregate annual future minimum lease payments under these leases are as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>(in thousands)


<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2020 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2021 and<BR>
beyond </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Minimum lease payments</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,666</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,483</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,421</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,349</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,537</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>20,456</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rent
expense, including fees for utilities and common area maintenances for the years ended December&nbsp;31, 2016, 2015 and 2014 were $3.5&nbsp;million, $2.6&nbsp;million and
$2.4&nbsp;million, respectively. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> Capital Leases  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In 2016, the Company purchased equipment of approximately $0.9&nbsp;million through financing arrangements. These financing arrangements
include interest of approximately 0.2-5.7%, and lease terms of 36-48&nbsp;months. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
December&nbsp;31, 2016, aggregate annual future minimum lease payments under these leases, including interest, are as follows (in thousands): </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:75%;margin-left:12%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Years ending December&nbsp;31:

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>355</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>355</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>134</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2020</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2021 and beyond</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total principal obligation</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>844 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


13. Income Taxes  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For financial reporting purposes, income (loss) before income taxes includes the following components (in thousands): </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:75%;margin-left:12%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Years Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>United States</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(174,913</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(123,697</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(70,030</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Foreign</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(28,868</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(8,421</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(9</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(203,781</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(132,118</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(70,039</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-135-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=137,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=1042911,FOLIO='135',FILE='DISK124:[17ZAA1.17ZAA47301]FY47301A.;19',USER='AGAETZ',CD=';1-MAR-2017;13:18' -->
<A NAME="page_fy47301_1_136"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Amicus Therapeutics,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes To Consolidated Financial Statements &#151; (Continued) </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
reconciliation of the statutory tax rates and the effective tax rates for the years ended December&nbsp;31, 2016, 2015 and 2014 are as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:75%;margin-left:12%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="25pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="25pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="25pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Years Ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Statutory rate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2> (34</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2> (34</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2> (34</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>State taxes, net of federal benefit</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Permanent adjustments</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>R&amp;D credit</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Foreign income tax rate differential</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Valuation allowance</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>36</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>37</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>38 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2> (2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2> (0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2> (2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)% </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company recognized a tax benefit of $1.1&nbsp;million in connection with the sale of net operating losses and research and development credits in the New Jersey Transfer Program
for the year ended December&nbsp;31, 2014. There were no sales of net operating losses and research and development credits for the years ended December&nbsp;31, 2016 and 2015. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company recorded an income tax benefit of $3.7&nbsp;million in the Consolidated Statement of Operations for the year ended December&nbsp;31, 2016. The benefit was primarily from
$2.7&nbsp;million in income tax benefit in connection with the reduction in state tax rates in North Carolina, and $1.2&nbsp;million from reduction in its valuation allowance to reflect the income
tax associated with the gain on foreign currency translation recorded in the Consolidated Statement of Comprehensive Loss for the year ended December&nbsp;31, 2016. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company did not recognize interest or penalties related to income tax during the period ended December&nbsp;31, 2016 and did not accrue for interest or penalties as of
December&nbsp;31, 2016. The Company does not have an accrual for uncertain tax positions as of December&nbsp;31, 2016. Tax returns for all years 2009 and thereafter are subject to future
examination by tax authorities. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-136-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=138,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=756992,FOLIO='136',FILE='DISK124:[17ZAA1.17ZAA47301]FY47301A.;19',USER='AGAETZ',CD=';1-MAR-2017;13:18' -->
<A NAME="page_fy47301_1_137"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Amicus Therapeutics,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes To Consolidated Financial Statements &#151; (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred
income taxes reflect the net effect of temporary difference between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for
income tax purposes. The significant components of the deferred tax assets and liabilities are as follows (in thousands): </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:75%;margin-left:12%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>For Years Ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Non-current deferred tax assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Intellectual property</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>95,956</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Amortization/depreciation</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,781</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,657</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research tax credit</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>32,851</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>27,170</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net operating loss carry forwards</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>253,661</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>159,889</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred revenue</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14,281</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14,281</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Non-cash stock issue</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,649</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,767</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Others</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,358</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,964 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Gross deferred tax assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>413,537</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>213,728</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred tax liability related to business acquisition</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(173,771</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(176,219</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred tax liability related to royalty payable</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(96,829</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred tax liability related to convertible notes</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(29,845</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total net deferred tax asset</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>113,092</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>37,509</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Less valuation allowance</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(286,863</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(213,728</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net deferred tax assets (liability)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(173,771</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(176,219</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company records a valuation allowance for temporary differences for which it is more likely than not that the Company will not receive future tax benefits. At December&nbsp;31,
2016 and 2015, the Company recorded valuation allowances of $286.9 million and $213.7&nbsp;million, respectively, representing an increase in the valuation allowance of $73.2&nbsp;million in 2016
and an increase of $65.3&nbsp;million in 2015, due to the uncertainty regarding the realization of such deferred tax assets, to offset the benefits of net operating losses generated during those
years. The deferred tax liability related to business acquisitions pertains to the basis difference in IPR&amp;D acquired by the Company. The Company's policy is to record a deferred tax liability related
to acquired IPR&amp;D that may eventually be realized either upon amortization of the asset when the research is completed and a product is successfully launched or the write-off of the asset if it is
abandoned or unsuccessful. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of December&nbsp;31, 2016, the Company had federal, state, and foreign net operating loss carry forwards ("NOLs") of approximately $637&nbsp;million, $623&nbsp;million, and
$40&nbsp;million respectively. The federal carry forward will expire in 2029 through 2036. Most of the state carry forwards generated prior to 2009 have expired through 2015. The remaining state
carry forwards including those generated in 2009 through 2016 will expire in 2029 through 2036. The foreign NOLs have indefinite expiration. Utilization of NOLs may be subject to a substantial
limitation pursuant to Section&nbsp;382 of the Code as well as similar state statutes in the event of an ownership change. Such ownership changes have occurred in the past, and could occur again in
the future As a result of these ownership changes, Section&nbsp;382 places an annual limitation on the amount of NOLs that can be utilized to offset future taxable income each year, which is based
on the value of the company at the change date. This limitation could result in expiration of those carry forwards before utilization. In general, an ownership change, as defined by
Section&nbsp;382, results from transactions that increase the ownership of certain stockholders or public groups in the stock of a corporation by more than 50&nbsp;percentage points over a three
year period. The Company completed a detailed study of its cumulative ownership changes for </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-137-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=139,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=1012863,FOLIO='137',FILE='DISK124:[17ZAA1.17ZAA47301]FY47301A.;19',USER='AGAETZ',CD=';1-MAR-2017;13:18' -->
<A NAME="page_fy47301_1_138"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Amicus Therapeutics,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes To Consolidated Financial Statements &#151; (Continued) </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>2016
and determined that in 2016, there was no ownership change in excess of 50%; therefore there was no write-down to net realizable value of the federal NOLs and research and development credits
subject to the 382 limitations. A tax benefit of $4.6&nbsp;million associated with the exercise of stock options will be recorded in additional paid-in capital when the associated net operating loss
is recognized. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


14. Licenses  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company acquired rights to develop and commercialize its product candidates through licenses granted by various parties. The following
summarizes the Company's material rights and obligations under those licenses: </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;GSK&nbsp;&#151;</I></FONT><FONT SIZE=2>&nbsp;For discussion of the royalties and milestone payments potentially due to GSK, see "&#151;&nbsp;Note&nbsp;15.
Collaborative Agreements." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mt. Sinai School of Medicine of New York University ("MSSM")&nbsp;&#151;</I></FONT><FONT SIZE=2>&nbsp;The company acquired exclusive worldwide patent rights to develop
and commercialize migalastat and other pharmacological chaperones for the prevention or treatment of human diseases or clinical conditions by increasing the activity of wild-type and mutant enzymes
pursuant to a license agreement with Mt. Sinai School of Medicine ("MSSM") of New York University. Under this agreement, to date, the Company has paid no upfront or annual license fees and there are
no milestone or future payments other than royalties on net sales. This agreement expires upon expiration of the last of the licensed patent rights, which will be in 2019, subject to any patent term
extension that may be granted, or 2024 if the Company develops a product for combination therapy (pharmacological chaperone plus/ERT) and a patent issues from the pending application covering the
combination therapy, subject to any patent term extension that may be granted. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
its license agreements, if the Company owes royalties on net sales for one of its products to more than one of the above licensors, then the Company has the right to reduce the
royalties owed to one licensor for royalties paid to another. The amount of royalties to be offset is generally limited in each license and can vary under each agreement. For migalastat, in 2016, the
Company incurred $0.1&nbsp;million of royalty expense under the agreement with MSSM. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company's rights with respect to these agreements to develop and commercialize migalastat may terminate, in whole or in part, if the Company fails to meet certain development or
commercialization requirements or if the Company does not meet its obligations to make royalty payments. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


15. Collaborative Agreements  </B></FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><I> GSK  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In November 2013, Amicus entered into the Revised Agreement with GSK, pursuant to which Amicus has obtained global rights to develop and
commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease. The Revised Agreement amends and replaces in its entirety the earlier agreement entered into between Amicus and
GSK in July 2012. Under the terms of the Revised Agreement, there was no upfront payment from Amicus to GSK. For migalastat monotherapy, GSK is eligible to receive post-approval and sales-based
milestones up to $40&nbsp;million, as well as tiered royalties in the mid-teens in eight major markets outside the U.S. In the second half of 2016, the Company recognized approximately
$0.5&nbsp;million under the revised agreement with GSK. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the terms of the Revised Agreement, GSK will no longer jointly fund development costs for all formulations of migalastat. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-138-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=140,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=786201,FOLIO='138',FILE='DISK124:[17ZAA1.17ZAA47301]FY47301A.;19',USER='AGAETZ',CD=';1-MAR-2017;13:18' -->
<A NAME="page_fy47301_1_139"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Amicus Therapeutics,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes To Consolidated Financial Statements &#151; (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
evaluating the impact of both the Expanded Collaboration Agreement and the Revised Agreement, the Company applied the accounting guidance regarding the impact of potential future
payments it may make in its role as a vendor (i.e.,&nbsp;Amicus) to its customer (i.e.,&nbsp;GSK) and evaluated if these potential future payments could be a reduction of revenue from GSK. If the
potential future payments to GSK are as follows:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a payment for an identifiable benefit, and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the identifiable benefit is separable from the existing relationship between the Company and GSK, and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the identifiable benefit can be obtained from a party other than GSK, and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the Company can reasonably estimate the fair value of the identifiable benefit, </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>then
the potential future payments would be treated separately from the collaboration and research revenue. However, if all these criteria are not satisfied, then the potential future payments are
treated as a reduction of revenue. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accordingly,
the Company did not believe that, for accounting purposes, the new U.S. licensing rights to migalastat obtained from GSK under the Expanded Collaboration Agreement, nor the
ex U.S. licensing rights to migalastat obtained from GSK under the Revised Agreement, represented a separate, identifiable benefit from the licenses in the Original Collaboration Agreement entered
into between Amicus and GSK in 2010. The contingent amounts payable to GSK were not sufficiently separable from GSK's original license and the research and development reimbursements such that Amicus
could not have entered into a similar exchange transaction with another party. Additionally, the Company cannot reasonably estimate the fair value of the worldwide licensing rights to migalastat. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company determined that the potential future payments to GSK would be treated as a reduction of revenue and that the total amount of revenue to be received under the arrangement is
no longer fixed or determinable as the contingent milestone payments are subject to significant uncertainty. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
a result, the Company no longer recognized any of the upfront license fees and premiums on the equity purchase from GSK until such time as the arrangement consideration becomes fixed
or determinable, because an indeterminable amount may ultimately be payable back to GSK. These amounts (the balance of the unrecognized upfront license fee and the premium on the equity purchases) are
classified as deferred reimbursements on the balance sheet. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
recognition of Research Revenue was also affected by the determination that the overall total arrangement consideration was no longer fixed and determinable, despite the fact that
the research activities continued and that the research expense reimbursements by GSK to Amicus were received as the research activities related to the reimbursement had been completed. Therefore the
research reimbursements from GSK were recorded as deferred reimbursements on the balance sheet and would not recognized until the total arrangement consideration becomes fixed and determinable. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
a result, all revenue recognition was suspended until the total arrangement consideration would become fixed and determinable. In addition, future milestone payments made by the
Company will be applied against the balance of this deferred reimbursements account. Revenue recognition for research expense reimbursements, the original upfront license fee, and the equity premiums
will resume once the total arrangement consideration becomes fixed and determinable which will occur when the balance of the deferred reimbursements account is sufficient to cover all the remaining
contingent milestone payments. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-139-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=141,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=729206,FOLIO='139',FILE='DISK124:[17ZAA1.17ZAA47301]FY47301A.;19',USER='AGAETZ',CD=';1-MAR-2017;13:18' -->
<A NAME="page_fy47301_1_140"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Amicus Therapeutics,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes To Consolidated Financial Statements &#151; (Continued) </B></FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><I> Biogen  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In September 2013, the Company entered into a license and collaboration agreement (the "Biogen Agreement") with Biogen to discover, develop and
commercialize novel small molecules for the treatment of Parkinson's disease. Under terms of the multi-year agreement, the Company and Biogen will collaborate in the discovery of a new class of small
molecules that target the GCase enzyme, for further development and commercialization by Biogen. Biogen was responsible for funding all discovery, development, and commercialization activities. In
addition the Company was reimbursed for all full-time employees working on the project as part of a cost sharing arrangement. The Company was also eligible to receive development and regulatory
milestones, as well as modest royalties in global net sales. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of December&nbsp;31, 2014, the Company recognized $1.2&nbsp;million in Research Revenue for work performed under the cost sharing arrangement of the Biogen Agreement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
September 2014, the Company and Biogen concluded their research collaboration. The Company's most advanced Parkinson's candidate is AT3375, which was developed outside the
collaboration and is wholly-owned by the Company. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


16. Debt Instruments and Related Party Transactions  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


October 2015 and February 2016 Notes and Warrants Purchase Agreement  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In October 2015, the Company entered into the October 2015 Purchase Agreement with Redmile, who beneficially owned approximately 6.7% of the
Common Stock as of December&nbsp;31, 2015, whereby it sold, on a private placement basis, (a)&nbsp;$50.0&nbsp;million aggregate principal amount of its unsecured promissory notes ("Notes") and
(b)&nbsp;five-year warrants ("Warrants") for 1.3&nbsp;million shares of Common Stock. The payment terms under the purchase agreement contained two installments, the first $15.0&nbsp;million in
October 2017 and the balance $35.0&nbsp;million in October 2020. Interest was payable at 4.1% on a monthly basis over the term of the loan. Due to the embedded redemption (put and/or call) features
in the note agreement, it was determined that the fair value of the warrants should be bifurcated from the value of the notes payable and recorded as a debt discount. The relative fair value of the
warrants and the debt discount as related to the October 2015 purchase agreement was determined to be $8.8&nbsp;million. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Purchase Agreement was modified in February 2016 when the Company entered into a Note and Warrant Purchase Agreement (the "February 2016 Purchase Agreement") with Redmile for an
aggregate amount of up to $75.0&nbsp;million. The Company agreed with Redmile that in full consideration of the purchase price for the notes issued under the October 2015 Purchase Agreement, Redmile
surrendered for cancellation all notes and warrants acquired from the October 2015 Purchase Agreement and the Company paid Redmile any unpaid interest accrued thereunder. Pursuant to the February 2016
agreement, at closing, it sold, on a private placement basis (a)&nbsp;$50.0&nbsp;million aggregate principal amount of unsecured promissory notes ("Initial Notes") and (b)&nbsp;five year
warrants to purchase up to 37 shares of the Company's Common Stock for every $1,000 of the principal amount of Initial Notes purchased ("Initial Warrants"), for an aggregate of up to 1,850,000 shares
of Common Stock issuable under the Initial Warrants. The payment terms contained two installments, the first $15.0&nbsp;million in October 2017 and the balance $35.0&nbsp;million in October 2021.
The interest rate was 3.875% and payable upon of maturity. This transaction was accounted for as a debt modification in accordance with ASC 470-50. The incremental fair value between the warrants that
were cancelled and the February issued warrants of $3.5&nbsp;million was recorded as additional unamortized debt discount on the balance sheet and added to the prior warrant balance within equity. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-140-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=142,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=893510,FOLIO='140',FILE='DISK124:[17ZAA1.17ZAA47301]FY47301A.;19',USER='AGAETZ',CD=';1-MAR-2017;13:18' -->
<A NAME="page_fy47301_1_141"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Amicus Therapeutics,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes To Consolidated Financial Statements &#151; (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Notes mentioned above were cancelled in December 2016. For more details, refer to section </FONT><FONT SIZE=2><I>December 2016 Note Purchase Agreement</I></FONT><FONT SIZE=2> below
in this footnote. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


June 2016 Amended Purchase Agreement  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In June 2016, following the marketing approval for migalastat in Europe, the Company entered into the Amended Purchase Agreement with Redmile.
Such amendment joined GCM to the February 2016 Purchase Agreement. Pursuant to the Amended Purchase Agreement, the Company sold an additional $30&nbsp;million unsecured promissory notes and five
year warrants to purchase up to purchase up to 42 shares of our Common Stock, par value $0.01 per share for every $1,000 of the principal amount of additional notes purchased, for an aggregate of up
to 1,260,000 shares of Common Stock issuable from the additional warrants. The payment was due in October 2021. The interest rate was 3.875% and payable upon of maturity. The Notes mentioned above
were cancelled in December 2016. For more details, refer to section </FONT><FONT SIZE=2><I>December 2016 Note Purchase Agreement</I></FONT><FONT SIZE=2> below in this footnote. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


December 2016 Note Purchase Agreement  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On December&nbsp;15, 2016, the Company entered into a Note Purchase Agreement ("Note Purchase Agreement") with GCM and RedMile, pursuant to
which the Company agreed to prepay all outstanding principal and accrued and unpaid interest on the notes issued by the Company and held by GCM and Redmile. Such prepayment was made on
December&nbsp;21, 2016. The Note Purchase Agreement did not cancel the warrants, under the Amended Purchase Agreement. The net loss on extinguishment of the debt was $13.3&nbsp;million and is
included as loss on extinguishment in the Consolidated Statement of Operations for the year ended December&nbsp;31, 2016. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


2016 Convertible Debt  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On December&nbsp;21, 2016, the Company issued at par value $250&nbsp;million aggregate principal amount of unsecured Convertible Senior
Notes due 2023 (the "Convertible Notes"), which included the exercise in full of the $25&nbsp;million over-allotment option granted to the initial purchasers of the Notes, in a private offering to
qualified institutional buyers pursuant to Rule&nbsp;144A under the Securities Act. Interest is payable semiannually on June&nbsp;15 and December&nbsp;15 of each year, beginning on
June&nbsp;15, 2017. The Notes will mature on December&nbsp;15, 2023, unless earlier repurchased, redeemed, or converted in accordance with their terms. The Notes are convertible at the option of
the holders, under certain circumstances and during certain periods, into cash, shares of the Company's common stock or a combination thereof and may be settled as described below. The net proceeds
from the Note Offering were $243.1&nbsp;million, after deducting fees and estimated expenses payable by the Company. In addition, the Company used approximately $13.5&nbsp;million of the net
proceeds from the issuance of the Convertible Notes to pay the cost of the capped call transactions ("Capped Call Confirmations") that the Company entered into in connection with the issuance of the
Convertible Notes. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Convertible Notes are governed by an indenture dated December&nbsp;21, 2016 (the "Indenture") by and between Amicus and Wilmington Trust, National Association, as trustee. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Convertible Notes are initially convertible into approximately 40,849,675 shares of the Company's common stock under certain circumstances prior to maturity at a conversion rate of
163.3987 shares per $1,000 principal amount of Convertible Notes, which represents a conversion price of approximately $6.12 per share of Common Stock, subject to adjustment under certain conditions. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-141-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=143,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=407774,FOLIO='141',FILE='DISK124:[17ZAA1.17ZAA47301]FY47301A.;19',USER='AGAETZ',CD=';1-MAR-2017;13:18' -->
<A NAME="page_fy47301_1_142"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Amicus Therapeutics,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes To Consolidated Financial Statements &#151; (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Holders
may convert their Convertible Notes at their option at specified times prior to the maturity date of December&nbsp;15, 2023, only if:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> during any fiscal quarter commencing after March&nbsp;31, 2017, if the last reported sale price of the Company's common stock for at least 20
trading days in the period of 30 consecutive trading days ending on the last trading day of the immediately preceding fiscal quarter is equal to or more than 130% of the conversion price of the
Convertible Notes on the last day of such preceding fiscal quarter; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a Holder submits its Convertible Notes for conversion during the five business day period following any five consecutive trading day period in
which the trading price for the Convertible Notes, per $1,000 principal amount of the Convertible Notes, for each such trading day was less than 98% of the product of the last reported sale price of
the Company's common stock and the conversion rate of the Convertible Notes on such date; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the Company issues to all or substantially all of the holders of common stock rights options or warrants entitling then them for a period of
not more than 60 calendar days after the date of such issuance to subscribe for or purchase shares of the Common Stock, at a price per share less than the average of the Last Reported Sale Prices of
the Common Stock for the 10 consecutive Trading Day period ending on, and including, the Trading Day immediately preceding the date of announcement of such issuance or distributes to all or
substantially all holders of the Common Stock the Company's assets, debt securities or rights to purchase the Company's securities which distribution has a per share value of exceeding 10% of the Last
Reported Sale Price of the Common Stock on the Trading Day immediately preceding the date of announcement of such distribution </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the Company enters into specified corporate transactions. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the Company has had a call for redemption, the holder can convert up until the second trading day immediately preceding the redemption date </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Convertible Notes will be convertible, at the option of the note holders, regardless of whether any of the foregoing conditions have been satisfied, on or after September&nbsp;15,
2023 at any time prior to the close of business on the second scheduled trading day immediately preceding the stated maturity date of December&nbsp;15, 2023. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
the occurrence of a make-whole fundamental change or if the Company call all or any portion of the Convertible Notes for redemption prior to July&nbsp;1, 2020, the Company will,
in certain circumstances, increase the conversion rate by a number of additional shares for a holder that elects to convert its Convertible Notes in connection with such make-whole fundamental change
or during the related redemption period. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
conversion, the Company may pay cash, shares of the Company's common stock or a combination of cash and stock, as determined by the Company in its discretion. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company accounts for the Convertible Notes as a liability and equity component where the carrying value of the liability component will be valued based on a similar instrument. In
accounting for the issuance of the Convertible Notes, the Company separated the Convertible Notes into liability and equity components. The carrying amount of the liability component was calculated by
measuring the fair value of a similar liability that does not have an associated convertible feature. The carrying amount of the equity component representing the conversion option was determined by
deducting the fair value of the liability component from the par value of the Convertible Notes as a whole. The excess of the principal amount of the liability component over its carrying amount,
referred to as the debt discount, is amortized to interest expense over the seven-year term of the Convertible Notes. The </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-142-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=144,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=120257,FOLIO='142',FILE='DISK124:[17ZAA1.17ZAA47301]FY47301A.;19',USER='AGAETZ',CD=';1-MAR-2017;13:18' -->
<A NAME="page_fy47301_1_143"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Amicus Therapeutics,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes To Consolidated Financial Statements &#151; (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>equity
component is not re-measured as long as it continues to meet the conditions for equity classification. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
accounting for the issuance of the Convertible Notes, the Company separated the Convertible Notes into liability and equity components based on their relative values. The carrying
amount of the liability component was calculated by measuring the fair value of a similar liability that does not have an associated convertible feature. The carrying amount of the equity component,
representing the conversion option, was determined by deducting the fair value of the liability component from the par value of the Convertible Notes. The difference between the principal amount of
the Convertible Notes and the liability component represents the debt discount, which is recorded as a direct deduction from the related debt liability in the Consolidated Balance Sheets and amortized
to interest expense using the effective interest method over the seven-year term of the Convertible Notes. The equity component of the Convertible Notes of approximately $88.3&nbsp;million is
included in additional paid-in capital in the Consolidated Balance Sheets and is not remeasured as long as it continues to meet the conditions for equity classification. Additionally, the Company
recorded a deferred tax liability of $29.8&nbsp;million in relation to the Convertible Notes. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company incurred transaction costs of approximately $7.5&nbsp;million, including approximately $6.9&nbsp;million that was paid from the gross proceeds of the Convertible Notes
offering. In accounting for the transaction costs, the Company allocated the total amount incurred to the liability and equity components using the same proportions as the proceeds from the
Convertible Notes. Transaction costs attributable to the liability component were recorded as a direct deduction from the related debt liability in the Consolidated Balance Sheets and amortized to
interest expense over the seven-year term of the Convertible Notes. Transaction costs attributable to the equity component were netted with the equity component in additional-paid-in-capital. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Convertible Notes consist of the following as of December&nbsp;31, 2016: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:75%;margin-left:12%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="70pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Liability component

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>(In thousands) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Principal</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>250,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Less: debt discount&nbsp;<SUP>(1)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(90,807</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Less: deferred financing&nbsp;<SUP>(1)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4,729</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net carrying value of the debt</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>154,464 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:12%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Included
in the Consolidated Balance Sheets within Convertible Senior Notes (due 2023) and amortized to interest expense over the remaining life of the Convertible
Senior Notes using the effective interest rate method.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
fair value of the debt at December&nbsp;31, 2016 was approximately $258.8&nbsp;million. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table sets forth total interest expense recognized related to the Convertible Notes for the year ended December&nbsp;31, 2016: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:75%;margin-left:12%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="70pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Components

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>(In thousands) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Contractual interest expense</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>208</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Amortization of deferred financing</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>26</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Amortization of debt discount</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>248</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>482 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Effective interest rate of the liability component</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10.85</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>% </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-143-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=145,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=451984,FOLIO='143',FILE='DISK124:[17ZAA1.17ZAA47301]FY47301A.;19',USER='AGAETZ',CD=';1-MAR-2017;13:18' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_ga47301_1_144"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Amicus Therapeutics,&nbsp;Inc.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes To Consolidated Financial Statements &#151; (Continued)  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Capped Call Confirmations of $13.5&nbsp;million are expected generally to reduce the potential dilution to the Common Stock upon any conversion of the
Convertible Notes and/or offset the cash payments the Company is required to make in excess of the principal amount upon conversion of the Notes in the event that the market price of the Common Stock
is greater than the strike price of the Capped Call Confirmations (which initially corresponds to the initial conversion price of the Convertible Notes and is subject to certain adjustments under the
terms of the Capped Call Confirmations), with such reduction and/or offset subject to a cap based on the cap price of the Capped Call Confirmations. The Capped Call Confirmations have an initial cap
price of $7.20 per share, which represents a premium of approximately 50% over the closing price of the Company's Common Stock on The NASDAQ Global Market on December&nbsp;15, 2016, and is subject
to certain adjustments under the terms of the Capped Call Confirmations. The Capped Call Confirmations will cover, subject to anti-dilution adjustments substantially similar to those applicable to the
Convertible Notes, the number of shares of Common Stock that will underlie the Convertible Notes. The Capped Call Confirmations do not meet the criteria for separate accounting as a derivative as they
are indexed to the Company's Common Stock. The premiums paid for the Capped Call Confirmations have been included as a net reduction to additional paid-in capital. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


17. Earnings per Share  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss attributable to
common stockholders per common share (in thousands except share amounts): </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="74pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="74pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Years Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Historical

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Numerator:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss attributable to common stockholders</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(200,042</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(132,118</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(68,926</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Denominator:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted average common shares outstanding&#151;basic and diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>134,401,588</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>109,923,815</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>74,444,157 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dilutive
common stock equivalents would include the dilutive effect of common stock options, convertible debt units, RSUs and warrants for common stock equivalents. Potentially dilutive
common stock equivalents were excluded from the diluted earnings per share denominator for all periods because of their anti-dilutive effect. For the year ended 2016 there was 40.9&nbsp;million
potential common shares outstanding as a result of the convertible debt that was excluded from the diluted net loss per share calculation because their effect would have been anti-dilutive. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-144-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=146,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=782132,FOLIO='144',FILE='DISK124:[17ZAA1.17ZAA47301]GA47301A.;7',USER='JTAYLORA',CD=';1-MAR-2017;09:46' -->
<A NAME="page_ga47301_1_145"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Amicus Therapeutics,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes To Consolidated Financial Statements &#151; (Continued) </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
table below presents potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method (in thousands): </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Options to purchase common stock</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15,528</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,729</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,021</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Convertible debt</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40,850</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Outstanding warrants, convertible to common stock</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,110</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,350</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,600</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Unvested restricted stock units</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>744</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>479</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>955 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total number of potentially issuable shares</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>60,232</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13,558</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,576 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Note&nbsp;18. Commitments and Contingencies  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since October&nbsp;1, 2015, three purported securities class action lawsuits have been commenced in the United States District Court for New
Jersey, naming as defendants the Company, its Chairman and Chief Executive Officer, and in one of the actions, its Chief Medical Officer. The lawsuits allege violations of the Securities Exchange Act
of 1934 in connection with allegedly false and misleading statements made by the Company related to the regulatory approval path for migalastat. The plaintiffs seek, among other things, damages for
purchasers of the Company's Common Stock during different periods, all of which fall between March&nbsp;19, 2015 and October&nbsp;1, 2015. It is possible that additional suits will be filed, or
allegations received from stockholders, with respect to similar matters and also naming the Company and/or its officers and directors as defendants. On May&nbsp;26, 2016, the Court consolidated
these lawsuits into a single action and appointed a lead plaintiff. The lead plaintiff filed a Consolidated Amended Class Action Complaint on July&nbsp;11, 2016. On August&nbsp;25, 2016, the
defendants filed a motion to dismiss in response to the Consolidated Amended Class Action Complaint. This motion to dismiss was fully briefed on October&nbsp;28, 2016. Lead plaintiff and defendants
have reached an agreement in principal to fully and finally settle all claims asserted in the Consolidated
Amended Class Action Complaint. The settlement is immaterial to the Company's consolidated financial statements and is subject to, among other things, documentation and court approval. The settlement
amount is expected to be fully covered under insurance. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
or about November&nbsp;2, 2015, a derivative lawsuit was filed by an Amicus shareholder purportedly on Amicus' behalf in the Superior Court of New Jersey, Middlesex County, Chancery
Division, against the individuals who serve on the Amicus Board of Directors. Amicus itself was named as a nominal defendant. The derivative lawsuit alleged claims for breach of state law fiduciary
duties, waste of corporate assets, and unjust enrichment based on allegedly false and misleading statements made by Amicus related to the regulatory approval path for migalastat HCl. On
February&nbsp;19, 2016, the complaint was dismissed by the Court and plaintiffs have not refiled. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
or about March&nbsp;3, 2016, a derivative lawsuit was filed by an Amicus shareholder purportedly on Amicus' behalf in the Superior Court of New Jersey, Middlesex County, Chancery
Division, against various officers and directors of the Company. Amicus itself is named as a nominal defendant. The derivative lawsuit alleges similar facts and circumstances as the three purported
securities class action lawsuits described above and further alleges claims for breach of state law fiduciary duties, waste of corporate assets, unjust enrichment, abuse of control, and gross
mismanagement based on allegedly false and misleading statements made by Amicus related to the regulatory approval path for migalastat HCl. The plaintiff seeks, among other things, to require the
Amicus Board to take certain actions to reform its corporate governance procedures, including greater shareholder input and a provision to </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-145-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=147,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=340351,FOLIO='145',FILE='DISK124:[17ZAA1.17ZAA47301]GA47301A.;7',USER='JTAYLORA',CD=';1-MAR-2017;09:46' -->
<A NAME="page_ga47301_1_146"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Amicus Therapeutics,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes To Consolidated Financial Statements &#151; (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>permit
shareholders to nominate candidates for election to the Board, along with restitution, costs of suit and attorney's fees. On February&nbsp;7, 2017, the complaint was dismissed by the Court
without prejudice. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These
lawsuits and any other related lawsuits are subject to inherent uncertainties and the actual cost will depend upon many unknown factors. The outcome of the litigation is
necessarily uncertain and we could be forced to expend significant resources in the defense of these suits, and we may not prevail. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


19. Subsequent Events  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company evaluated events that occurred subsequent to December&nbsp;31, 2016 and found there were no material recognized or non-recognized
subsequent events during this period. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


20. Selected Quarterly Financial Data (Unaudited&#151;in thousands except per share data)  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Quarters Ended </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>March&nbsp;31 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>June&nbsp;30 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>September&nbsp;30 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>2016</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(43,691</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(51,050</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(46,654</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(58,647</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Basic and diluted net loss per common share&nbsp;<SUP>(1)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(0.35</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(0.40</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(0.33</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(0.41</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>2015</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(24,288</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(27,133</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(37,800</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(42,897</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Basic and diluted net loss per common share&nbsp;<SUP>(1)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(0.25</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(0.27</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(0.32</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(0.34</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Per
common share amounts for the quarters and full years have been calculated separately. Accordingly, quarterly amounts do not add to the annual amounts because of
differences on the weighted-average common shares outstanding during each period principally due to the effect of the Company issuing shares of its common stock during the year.  </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-146-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=148,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=300664,FOLIO='146',FILE='DISK124:[17ZAA1.17ZAA47301]GA47301A.;7',USER='JTAYLORA',CD=';1-MAR-2017;09:46' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_gc47301_1_147"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><A
NAME="gc47301_item_9._changes_in_and_disagre__ite03557"> </A>
<A NAME="toc_gc47301_1"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;9.&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.    <BR>    </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None.  </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="gc47301_item_9a._controls_and_procedures."> </A>
<A NAME="toc_gc47301_2"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;9A.&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>CONTROLS AND PROCEDURES.    <BR>    </I></B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Evaluation of Disclosure Controls and Procedures  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our
disclosure controls and procedures as of December&nbsp;31, 2016. The term "disclosure controls and procedures," as defined in Rules&nbsp;13a-15(e) and 15d-15(e) under the Exchange Act, means
controls and other procedures of a company that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded,
processed, summarized and reported within the time periods specified in the SEC rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to
ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company's management, including its
principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well
designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible
controls and procedures. Based on the evaluation of our disclosure controls and procedures as of December&nbsp;31, 2016, our principal executive officer and principal financial officer concluded
that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
have been no changes in our internal controls over financial reporting during the fourth quarter of the year ended December&nbsp;31, 2016 that have materially affected, or are
reasonably likely to materially affect, our internal controls over financial reporting. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Management's Report on Internal Control Over Financial Reporting  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The information required by this section which includes the "Management's Report on Consolidated Financial Statements and Internal Control over
Financial Reporting" and the "Report of Independent Registered Public Accounting Firm" are incorporated by reference from "Item&nbsp;8. Financial Statements and Supplementary Data." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="gc47301_item_9b._other_information."> </A>
<A NAME="toc_gc47301_3"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;9B.&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>OTHER INFORMATION.    <BR>    </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-147-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=149,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=931436,FOLIO='147',FILE='DISK124:[17ZAA1.17ZAA47301]GC47301A.;4',USER='VSTEFAN',CD='27-FEB-2017;04:20' -->
<A NAME="page_gc47301_1_148"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="gc47301_part_iii"> </A>
<A NAME="toc_gc47301_4"> </A>
<BR></FONT><FONT SIZE=2><B>  PART III    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain information required by Part&nbsp;III is omitted from this Annual Report on Form&nbsp;10-K as we intend to file our definitive proxy
statement for our 2017 annual meeting of stockholders, pursuant to Regulation&nbsp;14A of the Securities Exchange Act, not later than 120&nbsp;days after the end of the fiscal year covered by this
Annual Report on Form&nbsp;10-K, and certain information to be included in the proxy statement is incorporated herein by reference.  </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="gc47301_item_10._directors,_executive___ite03057"> </A>
<A NAME="toc_gc47301_5"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;10.&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>DIRECTORS, EXECUTIVE OFFICERS OF THE REGISTRANT AND CORPORATE GOVERNANCE.    <BR>    </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The information required by this item is incorporated by reference from the Proxy Statement under the caption "Management,"
"Section&nbsp;16(a) Beneficial Ownership Reporting Compliance," and "Proposal No.&nbsp;1&nbsp;&#151; Election of Directors" </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have adopted a Code of Business Ethics and Conduct for Employees, Executive Officers and Directors that applies to our employees, officers and directors and incorporate guidelines
designed to deter wrongdoing and to promote the honest and ethical conduct and compliance with applicable laws and regulations. In addition, the code of ethics incorporates our guidelines pertaining
to topics such as conflicts of interest and workplace behavior. We have posted the text of our code on our website at </FONT><FONT SIZE=2><I>www.amicusrx.com</I></FONT><FONT SIZE=2> in connection
with "Investors/Corporate Governance" materials. In addition, we
intend to promptly disclose (1)&nbsp;the nature of any amendment to our code of ethics that applies to our principal executive officer, principal financial officer, principal accounting officer or
controller, or persons performing similar functions and (2)&nbsp;the nature of any waiver, including an implicit waiver, from provision of our code of ethics that is granted to one of these
specified officers, the name of such person who is granted the waiver and the date the waiver on our website in the future.  </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><A
NAME="gc47301_item_11._executive_compensation."> </A>
<A NAME="toc_gc47301_6"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;11.&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>EXECUTIVE COMPENSATION.    <BR>    </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The information required by this item is incorporated by reference from the Proxy Statement under the caption "Compensation Discussion and
Analysis."  </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="gc47301_item_12._security_ownership_of__ite03985"> </A>
<A NAME="toc_gc47301_7"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;12.&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.    <BR>    </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The information required by this item is incorporated by reference from the Proxy Statement under the captions "Security Ownership of Certain
Beneficial Owners and Management and Related Stockholder Matters" and "Equity Compensation Plan Information."  </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="gc47301_item_13._certain_relationships__ite03069"> </A>
<A NAME="toc_gc47301_8"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;13.&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE.    <BR>    </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The information required by this item is incorporated by reference from the Proxy Statement under the captions "Certain Relationships and
Related Transactions," "Director Independence," "Committee Compensation and Meetings of the Board of Directors," and "Compensation Committee Interlock and Insider Participation."  </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="gc47301_item_14._principal_accounting_fees_and_services."> </A>
<A NAME="toc_gc47301_9"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;14.&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>PRINCIPAL ACCOUNTING FEES AND SERVICES.    <BR>    </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The information required by this item is incorporated by reference from the Proxy Statement. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-148-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=150,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=972237,FOLIO='148',FILE='DISK124:[17ZAA1.17ZAA47301]GC47301A.;4',USER='VSTEFAN',CD='27-FEB-2017;04:20' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_ge47301_1_149"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ge47301_part_iv"> </A>
<A NAME="toc_ge47301_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PART IV    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="ge47301_item_15._exhibits,_financial_statement_schedule"> </A>
<A NAME="toc_ge47301_2"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;15.&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>EXHIBITS, FINANCIAL STATEMENT SCHEDULE    <BR>    </I></B></FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>1.
</FONT><FONT SIZE=2><I>Consolidated Financial Statements</I></FONT></DD></DL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Consolidated Financial Statements are filed as part of this report. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consolidated Financial Statement Schedules</I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
schedules are omitted because they are not required or because the required information is included in the Consolidated Financial Statements or notes thereto. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibits</I></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:62%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"130%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="130%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="42pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="112pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=6 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Incorporated by Reference<BR>
to SEC Filing </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit<BR>
No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Filed Exhibit Description </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Form </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Date </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Filed with this<BR>
Form&nbsp;10-K </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Agreement and Plan of Merger, dated November&nbsp;19, 2013, by and among Amicus Therapeutics,&nbsp;Inc., CB Acquisition Corp., Callidus BioPharma,&nbsp;Inc., and Cuong&nbsp;Do</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;8-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2/12/2014</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>+2.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Agreement and Plan of Merger, dated August&nbsp;30, 2015, by and among the Registrant, Titan Merger Sub Corp. and Scioderm,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;8-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>9/3/15</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Amendment to Agreement and Plan of Merger, dated September&nbsp;30, 2015, by and among the Registrant, Titan Merger Sub Corp. and Scioderm,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;8-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>9/30/15</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>+2.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Agreement and Plan of Merger, dated July&nbsp;5, 2016, by and among MiaMed,&nbsp;Inc., the Registrant and Minervas Merger Sub,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;8-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>7/6/16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>3.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Restated Certificate of Incorporation of the Registrant.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;10-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2/28/12</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>3.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Restated By-laws of the Registrant.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>S-1/A (333-141700)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4/27/07</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>3.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Certificate of Amendment to the Registrant's Restated Certificate of Incorporation, as amended.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;8-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>6/10/2015</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>4.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Specimen Stock Certificate evidencing shares of common stock</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>S-1 (333-141700)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3/30/07</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>4.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Third Amended and Restated Investor Rights Agreement, dated as of September&nbsp;13, 2006, as amended</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>S-1 (333-141700)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3/30/07</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>4.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form of Warrant issued on November&nbsp;20, 2013</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;8-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>11/21/13</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>4.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form of Warrant, issued on October&nbsp;1, 2015</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;8-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10/1/15</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-149-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=151,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=782967,FOLIO='149',FILE='DISK124:[17ZAA1.17ZAA47301]GE47301A.;5',USER='VSTEFAN',CD='27-FEB-2017;04:20' -->
<A NAME="page_ge47301_1_150"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:62%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"130%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="130%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="42pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="112pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=6 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Incorporated by Reference<BR>
to SEC Filing </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit<BR>
No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Filed Exhibit Description </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Form </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Date </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Filed with this<BR>
Form&nbsp;10-K </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>4.5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form of Warrant to Purchase Common Stock</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;8-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2/22/16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>4.6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form of Warrant to Purchase Common Stock</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;8-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>7/1/16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>4.7</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form of Indenture</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;S-3ASR</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4/29/16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.7</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>4.8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Indenture, dated December&nbsp;21, 2016, by and between the Registrant and Wilmington Trust, National Association</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;8-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12/21/16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>*10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>2002 Equity Incentive Plan, as amended, and forms of option agreements thereunder</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>S-1/A (333-141700)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4/27/07</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>+10.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Amended and Restated License Agreement, dated October, 31, 2008, by and between the Registrant and Mount Sinai School of Medicine of New York University</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;10-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2/6/09</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>+10.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>License Agreement, dated as of June&nbsp;26, 2003, by and between the Registrant and University of Maryland, Baltimore County, as amended</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>S-1 (333-141700)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3/30/07</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>+10.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Exclusive License Agreement, dated as of June&nbsp;8, 2005, by and between the Registrant and Novo Nordisk, A/S</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>S-1 (333-141700)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3/30/07</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>*10.5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Letter Agreement, dated as of December&nbsp;19, 2005, by and between the Registrant and David Lockhart, Ph.D.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>S-1 (333-141700)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3/30/07</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.10</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>10.6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form of Director and Officer Indemnification Agreement</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>S-1 (333-141700)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3/30/07</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.17</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>*10.7</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Amended and Restated 2007 Director Option Plan and form of option agreement</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;8-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>6/18/10</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>*10.8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>2007 Employee Stock Purchase Plan</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>S-1/A (333-141700)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>5/17/07</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.24</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>*10.11</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Management Bonus Program Summary</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;8-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>6/9/16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>*10.12</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Letter Agreement, dated as of May&nbsp;10, 2010 by and between the Registrant and Ken Valenzano</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;10-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3/4/11</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.32</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>*10.14</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Letter Agreement, dated as of January&nbsp;3, 2011 by and between the Registrant and Enrique Dilone</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;10-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3/4/11</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.34</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>10.15</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Lease Agreement dated August&nbsp;16, 2011 between the Registrant and Cedar Brook 3 Corporate Center,&nbsp;L.P.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;8-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8/16/11</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-150-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=152,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=166193,FOLIO='150',FILE='DISK124:[17ZAA1.17ZAA47301]GE47301A.;5',USER='VSTEFAN',CD='27-FEB-2017;04:20' -->
<A NAME="page_ge47301_1_151"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:62%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"130%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="130%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="42pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="112pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=6 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Incorporated by Reference<BR>
to SEC Filing </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit<BR>
No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Filed Exhibit Description </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Form </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Date </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Filed with this<BR>
Form&nbsp;10-K </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>10.17</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Second Amendment to Lease Agreement dated as of May&nbsp;16, 2013 by and between the Registrant and A/G Touchstone, TP,&nbsp;LLC.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;8-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>5/22/13</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>*10.18</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Letter Agreement, dated as of June&nbsp;5, 2013 by and between the Registrant and Jeffrey P. Castelli</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;10-Q</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8/7/13</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>*10.19</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Letter Agreement, dated as of June&nbsp;5, 2013 by and between the Registrant and Jayne Gershkowitz</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;10-Q</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8/7/13</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.7</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>10.20</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Securities Purchase Agreement, dated November&nbsp;20, 2013 by and among the Company and the purchasers identified therein</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;8-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>11/20/13</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>10.21</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Credit and Security Agreement, by and between MidCap Funding III,&nbsp;LLC, as administrative agent, the Lenders listed in the Credit Facility Schedule thereto, the Registrant, and Callidus Biopharma,&nbsp;Inc., dated as
of December&nbsp;27, 2013</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;8-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12/30/13</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>+10.23</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Second Restated Agreement, dated November&nbsp;19, 2013 by and between the Registrant and Glaxo Group Limited</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;10-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3/3/14</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.46</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>*10.24</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Amicus Therapeutics,&nbsp;Inc. Cash Deferral Plan</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;8-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>7/2/14</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>10.25</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Amendment No.1 to the Amicus Therapeutics,&nbsp;Inc. Cash Deferral Plan</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;8-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10/16/14</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>*10.26</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Employment Agreement dated April&nbsp;23, 2014, between the Registrant and John&nbsp;F. Crowley</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;8-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4/25/14</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>*10.27</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Employment Agreement dated April&nbsp;23, 2014, between the Registrant and William&nbsp;D. Baird,&nbsp;III</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;8-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4/25/14</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>*10.28</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Employment Agreement dated April&nbsp;23, 2014, between the Registrant and Bradley&nbsp;L. Campbell</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;8-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4/25/14</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>*10.29</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Employment Agreement dated April&nbsp;23, 2014, between the Registrant and Jay Barth,&nbsp;M.D.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;10-Q</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>5/5/14</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>*10.30</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Letter Agreement dated April&nbsp;24, 2014, between the Registrant and Julie&nbsp;Yu</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;10-Q</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>5/5/14</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.7</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-151-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=153,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=481148,FOLIO='151',FILE='DISK124:[17ZAA1.17ZAA47301]GE47301A.;5',USER='VSTEFAN',CD='27-FEB-2017;04:20' -->
<A NAME="page_ge47301_1_152"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:62%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"130%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="130%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="42pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="112pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=6 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Incorporated by Reference<BR>
to SEC Filing </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit<BR>
No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Filed Exhibit Description </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Form </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Date </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Filed with this<BR>
Form&nbsp;10-K </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>*10.31</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Letter Agreement dated April&nbsp;30, 2014, between the Registrant and Daphne&nbsp;Quimi</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;10-Q</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>5/5/14</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>*10.32</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Amended and Restated 2007 Equity Incentive Plan</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;8-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>6/13/16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>*10.33</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Amicus Therapeutics,&nbsp;Inc. Cash Deferral Plan</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;8-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10/28/16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>*10.34</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Employment Agreement dated December&nbsp;17, 2015 between the Registrant and Hung&nbsp;Do</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;10-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2/29/16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.37</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>*10.35</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Employment Agreement dated December&nbsp;17, 2015 between the Registrant and Dipal&nbsp;Doshi</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;10-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2/29/16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.38</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>*10.36</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Amendment No.&nbsp;1 to the Amicus Therapeutics,&nbsp;Inc. Cash Deferral Plan</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;8-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10/16/14</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>10.37</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>First Amendment to Credit and Security Agreement by and between MidCap Funding III,&nbsp;LLC, as administrative agent, the Lenders listed in the Credit Facility Schedule thereto, the Registrant, and Callidus Biopharma,
Inc., dated as of April&nbsp;27, 2015.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;8-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4/28/15</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>10.38</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Note and Warrant Purchase Agreement by and among the Registrant and the purchasers identified on the signature pages thereto, dated October&nbsp;1, 2015</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;8-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10/1/15</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>10.39</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>First Amendment to Lease, dated September&nbsp;9, 2015, by and between Cedar Brook&nbsp;3 Corporate Center,&nbsp;L.P. and the Registrant</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;8-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>9/14/15</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>10.40</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Sales Agreement, dated February&nbsp;26, 2016, by and between the Registrant and Cowen and Company,&nbsp;LLC</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;8-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2/26/16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>*10.41</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Retention Bonus Letter, dated March&nbsp;10, 2016, by and between the Registrant and Jay Barth, M.D.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;8-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3/15/16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>10.42</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Note and Warrant Purchase Agreement by and among the Registrant and the purchasers identified on the signature pages thereto, dated February&nbsp;19, 2016.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;8-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2/22/16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-152-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=154,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=657085,FOLIO='152',FILE='DISK124:[17ZAA1.17ZAA47301]GE47301A.;5',USER='VSTEFAN',CD='27-FEB-2017;04:20' -->
<A NAME="page_ge47301_1_153"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:62%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"130%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="130%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="42pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="112pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=6 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Incorporated by Reference<BR>
to SEC Filing </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit<BR>
No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Filed Exhibit Description </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Form </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Date </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Filed with this<BR>
Form&nbsp;10-K </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>10.43</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Joinder to and Amendment of Note and Warrant Purchase Agreement by and among Amicus Therapeutics,&nbsp;Inc., Amicus Therapeutics UK Limited, Amicus Therapeutics International Holding&nbsp;LTD and the purchasers identified
on the signature pages thereto, dated as of June&nbsp;30, 2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;8-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>7/1/16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>*10.44</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Amendment No.&nbsp;1 to the Amended and Restated Amicus Therapeutics,&nbsp;Inc. 2007 Equity Incentive Plan</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;8-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>7/29/16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>*10.45</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Secondment Letter, dated August&nbsp;22, 2016 by and between the Registrant and Bradley Campbell</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;8-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8/23/16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>10.46</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Base Capped Call Transaction, dated December&nbsp;15, 2016, by and between the Registrant and Goldman, Sachs&nbsp;&amp;&nbsp;Co.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;8-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12/21/16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>10.47</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Base Capped Call Transaction, dated December&nbsp;15, 2016, by and between the Registrant and JPMorgan Chase Bank, National Association</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;8-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12/21/16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>10.48</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Base Capped Call Transaction, dated December&nbsp;15, 2016, by and between the Registrant and Royal Bank of Canada</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;8-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12/21/16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>10.49</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Additional Capped Call Transaction, dated December&nbsp;19, 2016, by and between the Registrant and Goldman, Sachs&nbsp;&amp;&nbsp;Co.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;8-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12/21/16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>10.50</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Additional Capped Call Transaction, dated December&nbsp;19, 2016, by and between the Registrant and JPMorgan Chase Bank, National Association</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;8-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12/21/16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>10.51</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Additional Capped Call Transaction, dated December&nbsp;19, 2016, by and between the Registrant and Royal Bank of Canada</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;8-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12/21/16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>10.52</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Note Purchase Agreement, dated December&nbsp;15, 2016, by and among the Registrant, Amicus Therapeutics International Holding&nbsp;LTD and P&nbsp;Redmile&nbsp;Ltd.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;8-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12/21/16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.7</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-153-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=155,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=161523,FOLIO='153',FILE='DISK124:[17ZAA1.17ZAA47301]GE47301A.;5',USER='VSTEFAN',CD='27-FEB-2017;04:20' -->
<A NAME="page_ge47301_1_154"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:62%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"130%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="130%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="42pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="112pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=6 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Incorporated by Reference<BR>
to SEC Filing </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit<BR>
No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Filed Exhibit Description </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Form </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Date </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Filed with this<BR>
Form&nbsp;10-K </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>10.53</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Note Purchase Agreement, dated December&nbsp;15, 2016, by and among the Registrant, Amicus Therapeutics International Holding&nbsp;LTD and Redmile Capital Offshore Fund,&nbsp;Ltd.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;8-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12/21/16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>10.54</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Note Purchase Agreement, dated December&nbsp;15, 2016, by among the Registrant, Amicus Therapeutics International Holding&nbsp;LTD and Redmile Capital Offshore Fund II,&nbsp;Ltd.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;8-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12/21/16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.9</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>10.55</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Note Purchase Agreement, dated December&nbsp;15, 2016, by and among the Registrant, Amicus Therapeutics International Holding&nbsp;LTD and Redmile Special Opportunities Fund,&nbsp;Ltd.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;8-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12/21/16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.10</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>10.56</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Note Purchase Agreement, dated December&nbsp;15, 2016, by and among the Registrant, Amicus Therapeutics International Holding&nbsp;LTD and Redmile Capital Fund,&nbsp;LP</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;8-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12/21/16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.11</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>10.57</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Note Purchase Agreement, dated December&nbsp;15, 2016, by and between Amicus Therapeutics International Holding&nbsp;LTD and GCM Grosvenor Special Opportunities Master Fund,&nbsp;Ltd.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;8-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12/21/16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.12</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>*10.58</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form of Performance-Based Restricted Stock Unit Award Agreement under the Amended and Restated 2007 Equity Incentive Plan</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form&nbsp;8-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12/30/16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>21</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>List of Subsidiaries</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>X</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>23.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Consent of Independent Registered Public Accounting Firm.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>X</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>31.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Certification of Principal Executive Officer Pursuant to Rule&nbsp;13a-14(a) of the Securities Exchange Act of 1934.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>X</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>31.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Certification of Principal Financial Officer Pursuant to Rule&nbsp;13a-14(a) of the Securities Exchange Act of 1934.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>X</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>32.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Certificate of Principal Executive Officer pursuant to 18 U.S.C. Section&nbsp;1350 and Section&nbsp;906 of the Sarbanes-Oxley Act of 2002.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>X</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-154-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=156,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=463006,FOLIO='154',FILE='DISK124:[17ZAA1.17ZAA47301]GE47301A.;5',USER='VSTEFAN',CD='27-FEB-2017;04:20' -->
<A NAME="page_ge47301_1_155"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:62%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"130%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="130%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="42pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="112pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=6 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Incorporated by Reference<BR>
to SEC Filing </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit<BR>
No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Filed Exhibit Description </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Form </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Date </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Filed with this<BR>
Form&nbsp;10-K </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>32.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Certificate of Principal Financial Officer pursuant to 18 U.S.C. Section&nbsp;1350 and Section&nbsp;906 of the Sarbanes-Oxley Act of 2002.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>X</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>101</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>The following financial information from this Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2016, formatted in XBRL (Extensible Business Reporting Language) and filed electronically herewith:
(i)&nbsp;the Consolidated Balance Sheets; (ii)&nbsp;the Consolidated Statements of Operations; (iii)&nbsp;the Consolidated Statements of Comprehensive Loss; (iv)&nbsp;the Consolidated Statements of Cash Flows; (v)&nbsp;and the Notes to the
Consolidated Financial Statements.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>X</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>+</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Confidential
treatment has been granted as to certain portions of the document, which portions have been omitted and filed separately with the Securities and Exchange
Commission.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>*</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Indicates
management contract or compensatory plan.  </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-155-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=157,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=108482,FOLIO='155',FILE='DISK124:[17ZAA1.17ZAA47301]GE47301A.;5',USER='VSTEFAN',CD='27-FEB-2017;04:20' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_jc47301_1_156"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="jc47301_signatures"> </A>
<A NAME="toc_jc47301_1"> </A>
<BR></FONT><FONT SIZE=2><B>  SIGNATURES    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned, thereunto duly authorized on March&nbsp;1, 2017. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="49%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="22pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="46%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2>AMICUS THERAPEUTICS,&nbsp;INC.</FONT><FONT SIZE=2><BR>
(Registrant)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2> By:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;&nbsp;&nbsp;&nbsp;John F. Crowley<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> John F. Crowley<BR></FONT> <FONT SIZE=2><I>Chief Executive Officer</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on
the dates indicated. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="218pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="103pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Signature

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Title

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Date

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>/s/&nbsp;&nbsp;&nbsp;&nbsp;John F. Crowley<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> (John F. Crowley)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Chairman and Chief Executive Officer<BR>
(Principal Executive Officer)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>March&nbsp;1, 2017</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;&nbsp;&nbsp;&nbsp;William D. Baird III<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> (William D. Baird III)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Chief Financial Officer<BR>
(Principal Financial Officer)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>March&nbsp;1, 2017</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;&nbsp;&nbsp;&nbsp;Daphne Quimi<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> (Daphne Quimi)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Sr. Vice President, Finance<BR>
(Principal Accounting Officer)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>March&nbsp;1, 2017</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;&nbsp;&nbsp;&nbsp;Robert Essner<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> (Robert Essner)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;"><BR><FONT SIZE=2>March&nbsp;1, 2017</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;&nbsp;&nbsp;&nbsp;Donald J. Hayden<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> (Donald J. Hayden)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;"><BR><FONT SIZE=2>March&nbsp;1, 2017</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;&nbsp;&nbsp;&nbsp;Ted W. Love, M.D.<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> (Ted W. Love, M.D.)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;"><BR><FONT SIZE=2>March&nbsp;1, 2017</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;&nbsp;&nbsp;&nbsp;Margaret G. McGlynn, R.Ph.<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> (Margaret G. McGlynn, R.Ph.)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;"><BR><FONT SIZE=2>March&nbsp;1, 2017</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-156-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=158,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=183759,FOLIO='156',FILE='DISK124:[17ZAA1.17ZAA47301]JC47301A.;4',USER='VSTEFAN',CD='27-FEB-2017;04:20' -->
<A NAME="page_jc47301_1_157"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="218pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="103pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Signature

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Title

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Date

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>/s/&nbsp;&nbsp;&nbsp;&nbsp;Michael G. Raab<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> (Michael G. Raab)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>March&nbsp;1, 2017</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;&nbsp;&nbsp;&nbsp;Glenn Sblendorio<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> (Glenn Sblendorio)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;"><BR><FONT SIZE=2>March&nbsp;1, 2017</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;&nbsp;&nbsp;&nbsp;Craig Wheeler<BR>



<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> (Craig Wheeler)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;"><BR><FONT SIZE=2>March&nbsp;1, 2017</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-157-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=159,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=449803,FOLIO='157',FILE='DISK124:[17ZAA1.17ZAA47301]JC47301A.;4',USER='VSTEFAN',CD='27-FEB-2017;04:20' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_je47301_1_158"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg47301a_main_toc">Table of Contents</A> </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="42pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="27pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="25pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=6 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Incorporated by Reference to SEC Filing </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit<BR>
No. </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Filed with this<BR>
Form&nbsp;10-K </B></FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Filed Exhibit Description </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Form </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Date </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit No. </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>21</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>List of Subsidiaries</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>X</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>23.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Consent of Independent Registered Public Accounting Firm.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>X</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>31.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Certification of Principal Executive Officer Pursuant to Rule&nbsp;13a-14(a) of the Securities Exchange Act of 1934.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>X</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>31.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Certification of Principal Financial Officer Pursuant to Rule&nbsp;13a-14(a) of the Securities Exchange Act of 1934.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>X</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>32.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Certificate of Principal Executive Officer pursuant to 18 U.S.C. Section&nbsp;1350 and Section&nbsp;906 of the Sarbanes-Oxley Act of 2002.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>X</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>32.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Certificate of Principal Financial Officer pursuant to 18 U.S.C. Section&nbsp;1350 and Section&nbsp;906 of the Sarbanes-Oxley Act of 2002.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>X</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>101</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>The following financial information from this Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2016, formatted in XBRL (Extensible Business Reporting Language) and filed electronically herewith:
(i)&nbsp;the Consolidated Balance Sheets; (ii)&nbsp;the Consolidated Statements of Operations; (iii)&nbsp;the Consolidated Statements of Comprehensive Loss; (iv)&nbsp;the Consolidated Statements of Cash Flows; (v)&nbsp;and the Notes to the
Consolidated Financial Statements.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>X</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>-158-</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=160,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=799116,FOLIO='158',FILE='DISK124:[17ZAA1.17ZAA47301]JE47301A.;4',USER='VSTEFAN',CD='27-FEB-2017;04:20' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>2
<FILENAME>a2231065zex-21.htm
<DESCRIPTION>EX-21
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#17ZAA47301_2">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A
NAME="mf47301_exhibit_21"> </A>
<A NAME="toc_mf47301_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Exhibit&nbsp;21    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="mf47301_list_of_subsidiaries_of_the_registrant"> </A>
<A NAME="toc_mf47301_2"> </A>
<BR></FONT><FONT SIZE=2>List of Subsidiaries of the Registrant    <BR></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Callidus Biopharma,&nbsp;Inc. (Delaware)<BR>
Scioderm,&nbsp;Inc. (Delaware)<BR>
Scioderm Limited (Ireland)<BR>
MiaMed,&nbsp;Inc. (Delaware)<BR>
Amicus Therapeutics International Holding Limited (UK)<BR>
Amicus Therapeutics UK Limited (UK)<BR>
Amicus Therapeutics SAS (France)<BR>
Amicus Therapeutics&nbsp;B.V. (Netherlands)<BR>
Amicus Therapeutics&nbsp;GmbH (Germany)<BR>
Amicus Therapeutics S.L.U. (Spain)<BR>
Amicus Therapeutics&nbsp;S.r.l. (Italy)<BR>
Amicus Therapeutics K.K.. (Japan) </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="2",CHK=413569,FOLIO='blank',FILE='DISK124:[17ZAA1.17ZAA47301]MF47301A.;2',USER='DSLOAN',CD='28-FEB-2017;11:48' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="17ZAA47301_2">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_mf47301_1">Exhibit 21</A></FONT><BR>
</UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_mf47301_2">List of Subsidiaries of the Registrant</A></FONT><BR>
<!-- SEQ=,FILE='QUICKLINK',USER=JTAYLORA,SEQ=,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="2" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>a2231065zex-23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#17ZAA47301_3">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A
NAME="km47301_exhibit_23.1"> </A>
<A NAME="toc_km47301_1"> </A>
<BR></FONT><FONT SIZE=2><B>  EXHIBIT 23.1    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="km47301_consent_of_independent__km402323"> </A>
<A NAME="toc_km47301_2"> </A>
<BR></FONT><FONT SIZE=2><B>  Consent of Independent Registered Public Accounting Firm    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We consent to the incorporation by reference in the following Registration Statements: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>1.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Registration
Statement (Form&nbsp;S-3ASR No.&nbsp;333-212414) pertaining to the Amicus Therapeutics,&nbsp;Inc., Automatic shelf registration statement of
securities of well-known seasoned issuers
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>2.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Registration
Statement (Form&nbsp;S-3ASR No.&nbsp;333-211005) pertaining to the Amicus Therapeutics,&nbsp;Inc., Automatic shelf registration statement of
securities of well-known seasoned issuers
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>3.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Registration
Statement (Form&nbsp;S-3ASR No.&nbsp;333-207210) pertaining to the Amicus Therapeutics,&nbsp;Inc., Automatic shelf registration statement of
securities of well-known seasoned issuers
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>4.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Registration
Statement (Form&nbsp;S-8 No.&nbsp;333-197202) pertaining to the Amicus Therapeutics,&nbsp;Inc. Cash Deferral Plan,
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>5.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Registration
Statement (Form&nbsp;S-8 No.&nbsp;333-195194) pertaining to the Amicus Therapeutics,&nbsp;Inc. Restricted Stock Unit Deferral Plan,
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>6.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Registration
Statement (Form&nbsp;S-8 No.&nbsp;333-145305) pertaining to the: 1)&nbsp;Amicus Therapeutics,&nbsp;Inc. 2002 Equity Incentive Plan, as Amended,
2)&nbsp;Amicus Therapeutics,&nbsp;Inc. 2007 Equity Incentive Plan, 3)&nbsp;Amicus Therapeutics,&nbsp;Inc. 2007 Director Option Plan, 4)&nbsp;Amicus Therapeutics,&nbsp;Inc. 2007 Employee
Stock Purchase Plan,
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>7.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Registration
Statement (Form&nbsp;S-8 No.&nbsp;333-157219) pertaining to the: 1)&nbsp;Amicus Therapeutics,&nbsp;Inc. Amended and Restated 2007 Equity
Incentive Plan and 2)&nbsp;Amicus Therapeutics,&nbsp;Inc. 2007 Director Option Plan,
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>8.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Registration
Statement (Form&nbsp;S-8 No.&nbsp;333-174900) pertaining to the: 1)&nbsp;Amicus Therapeutics,&nbsp;Inc. Amended and Restated 2007 Equity
Incentive Plan and 2)&nbsp;Amicus Therapeutics,&nbsp;Inc. Amended and Restated 2007 Director Option Plan, </FONT></DD></DL>
</UL>
<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>of
our reports dated March&nbsp;1, 2017 with respect to the consolidated financial statements of Amicus Therapeutics,&nbsp;Inc., and the effectiveness of internal control over financial reporting
of Amicus Therapeutics, Inc. included in this Annual Report (Form&nbsp;10-K) for the year ended December&nbsp;31, 2016. </FONT></P>

</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>/s/
Ernst&nbsp;&amp; Young&nbsp;LLP<BR></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Iselin,
New Jersey<BR>
March&nbsp;1, 2017 </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="3",CHK=601583,FOLIO='blank',FILE='DISK124:[17ZAA1.17ZAA47301]KM47301A.;5',USER='JTAYLORA',CD=';1-MAR-2017;11:28' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="17ZAA47301_3">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_km47301_1">EXHIBIT 23.1</A></FONT><BR>
</UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_km47301_2">Consent of Independent Registered Public Accounting Firm</A></FONT><BR>
<!-- SEQ=,FILE='QUICKLINK',USER=JTAYLORA,SEQ=,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="3" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>a2231065zex-31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#17ZAA47301_4">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A
NAME="ko47301_exhibit_31.1"> </A>
<A NAME="toc_ko47301_1"> </A>
<BR></FONT><FONT SIZE=2><B>  EXHIBIT 31.1    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ko47301_certifications_pursuant_to_sec__cer04327"> </A>
<A NAME="toc_ko47301_2"> </A>
<BR></FONT><FONT SIZE=2><B>  CERTIFICATIONS PURSUANT TO SECTION&nbsp;302 OF<BR>  THE SARBANES-OXLEY ACT OF&nbsp;2002<BR>  CERTIFICATION BY PRINCIPAL EXECUTIVE OFFICER    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>I,
John F. Crowley, certify that: </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.
I have reviewed this annual report on Form&nbsp;10-K of Amicus Therapeutics,&nbsp;Inc.; </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading with respect to the period covered by this report; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of
operations and cash flows of the registrant as of, and for, the periods presented in this report; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.
The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules&nbsp;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f) and 15d-15(f)) for the registrant and have: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating
to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.
evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and
procedures, as of the end of the period covered by this report based on such evaluation; and </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.
disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's
fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.
The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and
the audit committee of the registrant's board of directors (or persons performing the equivalent functions): </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the
registrant's ability to record, process, summarize and report financial information; and </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>Date:
March&nbsp;1, 2017<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;text-align:left;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=2>/s/ John F. Crowley<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> John F. Crowley<BR>
Chairman and Chief Executive Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="4",CHK=275666,FOLIO='blank',FILE='DISK124:[17ZAA1.17ZAA47301]KO47301A.;5',USER='VSTEFAN',CD='27-FEB-2017;04:21' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="17ZAA47301_4">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ko47301_1">EXHIBIT 31.1</A></FONT><BR>
</UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ko47301_2">CERTIFICATIONS PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 CERTIFICATION BY PRINCIPAL EXECUTIVE OFFICER</A></FONT><BR>

<!-- SEQ=,FILE='QUICKLINK',USER=JTAYLORA,SEQ=,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="4" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>a2231065zex-31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#17ZAA47301_5">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A
NAME="kq47301_exhibit_31.2"> </A>
<A NAME="toc_kq47301_1"> </A>
<BR></FONT><FONT SIZE=2><B>  EXHIBIT 31.2    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="kq47301_certifications_pursuant_to_sec__cer04282"> </A>
<A NAME="toc_kq47301_2"> </A>
<BR></FONT><FONT SIZE=2><B>  CERTIFICATIONS PURSUANT TO SECTION&nbsp;302 OF<BR>  THE SARBANES-OXLEY ACT OF&nbsp;2002<BR>  CERTIFICATION BY PRINCIPAL FINANCIAL OFFICER    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>I,
William D. Baird III, certify that: </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.
I have reviewed this annual report on Form&nbsp;10-K of Amicus Therapeutics,&nbsp;Inc.; </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading with respect to the period covered by this report; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of
operations and cash flows of the registrant as of, and for, the periods presented in this report; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.
The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules&nbsp;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f) and 15d-15(f)) for the registrant and have: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating
to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.
evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and
procedures, as of the end of the period covered by this report based on such evaluation; and </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.
disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's
fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.
The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and
the audit committee of the registrant's board of directors (or persons performing the equivalent functions): </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the
registrant's ability to record, process, summarize and report financial information; and </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>Date:
March&nbsp;1, 2017 </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;text-align:left;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=2>/s/ William D. Baird III<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> William D. Baird III<BR>
Chief Financial Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="5",CHK=142466,FOLIO='blank',FILE='DISK124:[17ZAA1.17ZAA47301]KQ47301A.;3',USER='VSTEFAN',CD='27-FEB-2017;04:21' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="17ZAA47301_5">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_kq47301_1">EXHIBIT 31.2</A></FONT><BR>
</UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_kq47301_2">CERTIFICATIONS PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 CERTIFICATION BY PRINCIPAL FINANCIAL OFFICER</A></FONT><BR>

<!-- SEQ=,FILE='QUICKLINK',USER=JTAYLORA,SEQ=,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="5" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>a2231065zex-32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#17ZAA47301_6">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A
NAME="ks47301_exhibit_32.1"> </A>
<A NAME="toc_ks47301_1"> </A>
<BR></FONT><FONT SIZE=2><B>  EXHIBIT 32.1    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ks47301_certification_by_the_principal__cer05293"> </A>
<A NAME="toc_ks47301_2"> </A>
<BR></FONT><FONT SIZE=2><B>  Certification by the Principal Executive Officer Pursuant to 18 U. S. C. Section&nbsp;1350, as<BR>  Adopted Pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to 18 U. S. C. Section&nbsp;1350, I, John F. Crowley, hereby certify that, to the best of my knowledge, Amicus
Therapeutics&nbsp;Inc., (the "Company") Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2016 (the "Report"), as filed with the Securities and Exchange Commission on
March&nbsp;1, 2017, fully complies with the requirements of Section&nbsp;13(a) or Section&nbsp;15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in the
Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;text-align:left;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>/s/ John F. Crowley<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> John F. Crowley<BR>
Chairman and Chief Executive Officer<BR>
March&nbsp;1, 2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="6",CHK=851794,FOLIO='blank',FILE='DISK124:[17ZAA1.17ZAA47301]KS47301A.;3',USER='VSTEFAN',CD='27-FEB-2017;04:21' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="17ZAA47301_6">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ks47301_1">EXHIBIT 32.1</A></FONT><BR>
</UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ks47301_2">Certification by the Principal Executive Officer Pursuant to 18 U. S. C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</A></FONT><BR>

<!-- SEQ=,FILE='QUICKLINK',USER=JTAYLORA,SEQ=,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="6" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>a2231065zex-32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#17ZAA47301_7">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A
NAME="ku47301_exhibit_32.2"> </A>
<A NAME="toc_ku47301_1"> </A>
<BR></FONT><FONT SIZE=2><B>  EXHIBIT 32.2    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ku47301_certification_by_the_principal__cer05248"> </A>
<A NAME="toc_ku47301_2"> </A>
<BR></FONT><FONT SIZE=2><B>  Certification by the Principal Financial Officer Pursuant to 18 U. S. C. Section&nbsp;1350, as<BR>  Adopted Pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to 18 U. S. C. Section&nbsp;1350, I, William D. Baird III, hereby certify that, to the best of my knowledge, the Amicus
Therapeutics&nbsp;Inc. (the "Company") Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2016 (the "Report"), as filed with the Securities and Exchange Commission on
March&nbsp;1, 2017, fully complies with the requirements of Section&nbsp;13(a) or Section&nbsp;15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in the
Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;text-align:left;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>/s/ William D. Baird III<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> William D. Baird III<BR>
Chief Financial Officer<BR>
March&nbsp;1, 2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="7",CHK=787237,FOLIO='blank',FILE='DISK124:[17ZAA1.17ZAA47301]KU47301A.;3',USER='VSTEFAN',CD='27-FEB-2017;04:21' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="17ZAA47301_7">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ku47301_1">EXHIBIT 32.2</A></FONT><BR>
</UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ku47301_2">Certification by the Principal Financial Officer Pursuant to 18 U. S. C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</A></FONT><BR>

<!-- SEQ=,FILE='QUICKLINK',USER=JTAYLORA,SEQ=,EFW="2231065",CP="AMICUS THERAPEUTICS, INC.",DN="7" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>8
<FILENAME>fold-20161231.xml
<DESCRIPTION>EX-101.INS
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!--XBRL document created with Merrill Bridge  6.4.50.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/1/2017 2:05:48 PM-->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:fold="http://www.amicustherapeutics.com/20161231" xmlns:us-gaap="http://fasb.org/us-gaap/2015-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:type="simple" xlink:href="fold-20161231.xsd" />
  <!--Context Section-->
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_BusinessAcquisitionAxis_fold_MiaMedIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:MiaMedIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_BusinessAcquisitionAxis_fold_MiaMedIncMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:MiaMedIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:SciodermIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:SciodermIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_BusinessAcquisitionAxis_fold_CallidusBiopharmaIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_BusinessAcquisitionAxis_fold_MiaMedIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:MiaMedIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:SciodermIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_BusinessAcquisitionAxis_fold_CallidusBiopharmaIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_BusinessAcquisitionAxis_fold_CallidusBiopharmaIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2013_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2013_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2013_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="As_Of_6_30_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_PerformanceBasedRestrictedStockUnitAwardAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fold:PerformanceBasedRestrictedStockUnitAwardAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2013_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_fold_StockOptionPlan2007AndDirectorOptionPlan2007Member_us-gaap_RangeAxis_us-gaap_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fold:StockOptionPlan2007AndDirectorOptionPlan2007Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_4_1_2016_To_6_30_2016_us-gaap_ProductOrServiceAxis_us-gaap_ProductMember_us-gaap_StatementGeographicalAxis_us-gaap_EuropeanUnionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2016_To_12_31_2016_us-gaap_CounterpartyNameAxis_fold_GlaxoSmithKlinePLCMember_us-gaap_TypeOfArrangementAxis_fold_RevisedCollaborationAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">fold:GlaxoSmithKlinePLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:RevisedCollaborationAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-07-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_RangeAxis_us-gaap_MinimumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_RangeAxis_us-gaap_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fold_ResearchEquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fold:ResearchEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fold_ResearchEquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fold:ResearchEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="Duration_6_1_2015_To_6_30_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-06-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="Duration_11_1_2014_To_11_30_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-11-01</startDate>
      <endDate>2014-11-30</endDate>
    </period>
  </context>
  <context id="Duration_4_1_2016_To_4_30_2016_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityRegulatoryApprovalMilestoneMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:SciodermIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityRegulatoryApprovalMilestoneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-04-30</endDate>
    </period>
  </context>
  <context id="Duration_4_1_2016_To_4_30_2016_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityClinicalMilestoneMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:SciodermIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalMilestoneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-04-30</endDate>
    </period>
  </context>
  <context id="Duration_4_1_2016_To_4_30_2016_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:SciodermIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-04-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_BusinessAcquisitionAxis_fold_BusinessAcquisitionsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:BusinessAcquisitionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_ValuationTechniqueAxis_fold_MonteCarloMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:SciodermIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityRevenueBasedMilestonesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">fold:MonteCarloMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_ValuationTechniqueAxis_fold_MonteCarloMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:SciodermIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityRevenueBasedMilestonesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">fold:MonteCarloMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_BusinessAcquisitionAxis_fold_CallidusBiopharmaIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_ValuationTechniqueAxis_fold_ProbabilityWeightedDiscountedCashFlowMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">fold:ProbabilityWeightedDiscountedCashFlowMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_9_30_2015_To_9_30_2015_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:SciodermIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityRevenueBasedMilestonesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-09-30</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="Duration_9_30_2015_To_9_30_2015_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:SciodermIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityRevenueBasedMilestonesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-09-30</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="Duration_9_30_2015_To_9_30_2015_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:SciodermIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-09-30</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="Duration_9_30_2015_To_9_30_2015_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:SciodermIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-09-30</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="Duration_11_1_2013_To_11_30_2013_us-gaap_BusinessAcquisitionAxis_fold_CallidusBiopharmaIncMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-11-01</startDate>
      <endDate>2013-11-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:SciodermIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_BusinessAcquisitionAxis_fold_CallidusBiopharmaIncMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_CounterpartyNameAxis_fold_RedmileGroupMember_us-gaap_DebtInstrumentAxis_fold_NotePurchaseAgreementDecember2016Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">fold:RedmileGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:NotePurchaseAgreementDecember2016Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_10_1_2016_To_12_31_2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
    </entity>
    <period>
      <startDate>2016-10-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2016_To_9_30_2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
    </entity>
    <period>
      <startDate>2016-07-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="Duration_4_1_2016_To_6_30_2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_3_31_2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-03-31</endDate>
    </period>
  </context>
  <context id="Duration_10_1_2015_To_12_31_2015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
    </entity>
    <period>
      <startDate>2015-10-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2015_To_9_30_2015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
    </entity>
    <period>
      <startDate>2015-07-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="Duration_4_1_2015_To_6_30_2015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
    </entity>
    <period>
      <startDate>2015-04-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_3_31_2015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_9_30_2016_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-09-30</instant>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_9_30_2016_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="As_Of_12_15_2016_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-15</instant>
    </period>
  </context>
  <context id="Duration_2_1_2016_To_2_29_2016_us-gaap_CounterpartyNameAxis_fold_RedmileGroupMember_us-gaap_DebtInstrumentAxis_fold_NoteAndWarrantAgreement2016Member_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_BeneficialOwnerMember_us-gaap_TypeOfArrangementAxis_fold_PrivatePlacementPurchaseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">fold:RedmileGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:NoteAndWarrantAgreement2016Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:BeneficialOwnerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:PrivatePlacementPurchaseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-02-01</startDate>
      <endDate>2016-02-29</endDate>
    </period>
  </context>
  <context id="Duration_2_1_2016_To_2_29_2016_us-gaap_CounterpartyNameAxis_fold_RedmileGroupMember_us-gaap_DebtInstrumentAxis_fold_NoteAndWarrantAgreement2016Member_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodOneMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_BeneficialOwnerMember_us-gaap_TypeOfArrangementAxis_fold_PrivatePlacementPurchaseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">fold:RedmileGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:NoteAndWarrantAgreement2016Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:BeneficialOwnerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:PrivatePlacementPurchaseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-02-01</startDate>
      <endDate>2016-02-29</endDate>
    </period>
  </context>
  <context id="Duration_10_1_2015_To_10_31_2015_us-gaap_CounterpartyNameAxis_fold_RedmileGroupMember_us-gaap_DebtInstrumentAxis_fold_NoteAndWarrantAgreement2015Member_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">fold:RedmileGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:NoteAndWarrantAgreement2015Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-10-01</startDate>
      <endDate>2015-10-31</endDate>
    </period>
  </context>
  <context id="Duration_10_1_2015_To_10_31_2015_us-gaap_CounterpartyNameAxis_fold_RedmileGroupMember_us-gaap_DebtInstrumentAxis_fold_NoteAndWarrantAgreement2015Member_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodOneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">fold:RedmileGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:NoteAndWarrantAgreement2015Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-10-01</startDate>
      <endDate>2015-10-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_10_31_2015_us-gaap_CounterpartyNameAxis_fold_RedmileGroupMember_us-gaap_DebtInstrumentAxis_fold_NoteAndWarrantAgreement2015Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">fold:RedmileGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:NoteAndWarrantAgreement2015Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-10-31</instant>
    </period>
  </context>
  <context id="As_Of_12_21_2016_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_us-gaap_TypeOfArrangementAxis_fold_PrivatePlacementPurchaseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:PrivatePlacementPurchaseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-21</instant>
    </period>
  </context>
  <context id="As_Of_2_29_2016_us-gaap_CounterpartyNameAxis_fold_RedmileGroupMember_us-gaap_DebtInstrumentAxis_fold_NoteAndWarrantAgreement2016Member_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_BeneficialOwnerMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">fold:RedmileGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:NoteAndWarrantAgreement2016Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:BeneficialOwnerMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-02-29</instant>
    </period>
  </context>
  <context id="As_Of_2_29_2016_us-gaap_CounterpartyNameAxis_fold_RedmileGroupMember_us-gaap_DebtInstrumentAxis_fold_NoteAndWarrantAgreement2016Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_BeneficialOwnerMember_us-gaap_TypeOfArrangementAxis_fold_PrivatePlacementPurchaseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">fold:RedmileGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:NoteAndWarrantAgreement2016Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:BeneficialOwnerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:PrivatePlacementPurchaseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-02-29</instant>
    </period>
  </context>
  <context id="As_Of_10_31_2015_us-gaap_CounterpartyNameAxis_fold_RedmileGroupMember_us-gaap_DebtInstrumentAxis_fold_NoteAndWarrantAgreement2015Member_us-gaap_TypeOfArrangementAxis_fold_PrivatePlacementPurchaseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">fold:RedmileGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:NoteAndWarrantAgreement2015Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:PrivatePlacementPurchaseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-10-31</instant>
    </period>
  </context>
  <context id="Duration_12_21_2016_To_12_21_2016_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_StatementScenarioAxis_fold_ConvertibleNotesConditionOneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">fold:ConvertibleNotesConditionOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-12-21</startDate>
      <endDate>2016-12-21</endDate>
    </period>
  </context>
  <context id="As_Of_12_21_2016_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-21</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2013_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="As_Of_6_30_2016_us-gaap_CounterpartyNameAxis_fold_RedmileGroupMember_us-gaap_DebtInstrumentAxis_fold_AdditionalNoteAndWarrantAgreementJune2016Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_BeneficialOwnerMember_us-gaap_TypeOfArrangementAxis_fold_PrivatePlacementPurchaseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">fold:RedmileGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:AdditionalNoteAndWarrantAgreementJune2016Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:BeneficialOwnerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:PrivatePlacementPurchaseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="As_Of_11_30_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-11-30</instant>
    </period>
  </context>
  <context id="As_Of_7_31_2014_us-gaap_CounterpartyNameAxis_fold_CowenAndCompanyLLCMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_fold_AtMarketEquityOfferingMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">fold:CowenAndCompanyLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:AtMarketEquityOfferingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-07-31</instant>
    </period>
  </context>
  <context id="As_Of_6_30_2016_us-gaap_CounterpartyNameAxis_fold_RedmileGroupMember_us-gaap_DebtInstrumentAxis_fold_AdditionalNoteAndWarrantAgreementJune2016Member_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_BeneficialOwnerMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_us-gaap_TypeOfArrangementAxis_fold_PrivatePlacementPurchaseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">fold:RedmileGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:AdditionalNoteAndWarrantAgreementJune2016Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:BeneficialOwnerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:PrivatePlacementPurchaseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="As_Of_6_30_2016_us-gaap_CounterpartyNameAxis_fold_RedmileGroupMember_us-gaap_DebtInstrumentAxis_fold_AdditionalNoteAndWarrantAgreementJune2016Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_BeneficialOwnerMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_us-gaap_TypeOfArrangementAxis_fold_PrivatePlacementPurchaseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">fold:RedmileGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:AdditionalNoteAndWarrantAgreementJune2016Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:BeneficialOwnerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:PrivatePlacementPurchaseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="As_Of_2_29_2016_us-gaap_CounterpartyNameAxis_fold_RedmileGroupMember_us-gaap_DebtInstrumentAxis_fold_NoteAndWarrantAgreement2016Member_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_fold_PrivatePlacementPurchaseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">fold:RedmileGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:NoteAndWarrantAgreement2016Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:PrivatePlacementPurchaseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-02-29</instant>
    </period>
  </context>
  <context id="As_Of_10_31_2015_us-gaap_CounterpartyNameAxis_fold_RedmileGroupMember_us-gaap_DebtInstrumentAxis_fold_NoteAndWarrantAgreement2015Member_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_us-gaap_TypeOfArrangementAxis_fold_PrivatePlacementPurchaseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">fold:RedmileGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:NoteAndWarrantAgreement2015Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:PrivatePlacementPurchaseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-10-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2013">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_BusinessAcquisitionAxis_fold_BusinessAcquisitionsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:BusinessAcquisitionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:SciodermIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_BusinessAcquisitionAxis_fold_BusinessAcquisitionsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:BusinessAcquisitionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:SciodermIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityRevenueBasedMilestonesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:SciodermIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_BusinessAcquisitionAxis_fold_CallidusBiopharmaIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:SciodermIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_BusinessAcquisitionAxis_fold_CallidusBiopharmaIncMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_9_30_2015_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:SciodermIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="As_Of_11_30_2013_us-gaap_BusinessAcquisitionAxis_fold_CallidusBiopharmaIncMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-11-30</instant>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember_us-gaap_IncomeStatementLocationAxis_fold_ChangesInFairValueOfContingentConsiderationPayableMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:SciodermIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">fold:ChangesInFairValueOfContingentConsiderationPayableMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_BusinessAcquisitionAxis_fold_CallidusBiopharmaIncMember_us-gaap_IncomeStatementLocationAxis_fold_ChangesInFairValueOfContingentConsiderationPayableMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">fold:ChangesInFairValueOfContingentConsiderationPayableMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:SciodermIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityRevenueBasedMilestonesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_9_30_2015_To_9_30_2015_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:SciodermIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityRevenueBasedMilestonesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-09-30</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="Duration_7_5_2016_To_7_5_2016_dei_LegalEntityAxis_us-gaap_ParentCompanyMember_us-gaap_BusinessAcquisitionAxis_fold_MiamedIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">us-gaap:ParentCompanyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:MiamedIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-07-05</startDate>
      <endDate>2016-07-05</endDate>
    </period>
  </context>
  <context id="Duration_7_5_2016_To_7_5_2016_dei_LegalEntityAxis_us-gaap_ParentCompanyMember_us-gaap_BusinessAcquisitionAxis_fold_MiamedIncMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">us-gaap:ParentCompanyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:MiamedIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-07-05</startDate>
      <endDate>2016-07-05</endDate>
    </period>
  </context>
  <context id="Duration_9_30_2015_To_9_30_2015_dei_LegalEntityAxis_fold_SciodermIncMember_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">fold:SciodermIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:SciodermIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-09-30</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_MoneyMarketFundsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CertificatesOfDepositMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_fold_MarketExchangedMutualFundsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">fold:MarketExchangedMutualFundsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_fold_MarketExchangedMutualFundsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">fold:MarketExchangedMutualFundsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CertificatesOfDepositMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_fold_MarketExchangedMutualFundsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">fold:MarketExchangedMutualFundsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CertificatesOfDepositMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_fold_MarketExchangedMutualFundsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">fold:MarketExchangedMutualFundsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_GeographicDistributionAxis_fold_MunichGermanyMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fold_OfficeSpaceMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">fold:MunichGermanyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fold:OfficeSpaceMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_GeographicDistributionAxis_fold_DurhamNorthCarolinaMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fold_OfficeSpaceMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">fold:DurhamNorthCarolinaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fold:OfficeSpaceMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_GeographicDistributionAxis_fold_CranburyNewJerseyMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fold_OfficeAndLaboratorySpaceMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">fold:CranburyNewJerseyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fold:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_GeographicDistributionAxis_fold_BuckinghamshireUnitedKingdomMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fold_OfficeSpaceMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">fold:BuckinghamshireUnitedKingdomMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fold:OfficeSpaceMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fold_EmployeeAndDirectorsStockOptionsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fold_EmployeeAndDirectorsStockOptionsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fold_EmployeeAndDirectorsStockOptionsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_10_1_2015_To_10_31_2015_us-gaap_CounterpartyNameAxis_fold_RedmileGroupMember_us-gaap_DebtInstrumentAxis_fold_NoteAndWarrantAgreement2015Member_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_us-gaap_TypeOfArrangementAxis_fold_PrivatePlacementPurchaseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">fold:RedmileGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:NoteAndWarrantAgreement2015Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:PrivatePlacementPurchaseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-10-01</startDate>
      <endDate>2015-10-31</endDate>
    </period>
  </context>
  <context id="As_Of_2_29_2016_us-gaap_CounterpartyNameAxis_fold_RedmileGroupMember_us-gaap_DebtInstrumentAxis_fold_NoteAndWarrantAgreement2016Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_BeneficialOwnerMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_us-gaap_TypeOfArrangementAxis_fold_PrivatePlacementPurchaseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">fold:RedmileGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:NoteAndWarrantAgreement2016Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:BeneficialOwnerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:PrivatePlacementPurchaseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-02-29</instant>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_fold_StockOptionPlan2002AndStockOptionPlan2007Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fold:StockOptionPlan2002AndStockOptionPlan2007Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_CounterpartyNameAxis_fold_BiogenIdecMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">fold:BiogenIdecMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2014_To_7_31_2014_us-gaap_CounterpartyNameAxis_fold_CowenAndCompanyLLCMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_fold_AtMarketEquityOfferingMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">fold:CowenAndCompanyLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:AtMarketEquityOfferingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2014-07-31</endDate>
    </period>
  </context>
  <context id="As_Of_4_1_2016_us-gaap_RangeAxis_us-gaap_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-04-01</instant>
    </period>
  </context>
  <context id="Duration_6_1_2016_To_6_30_2016_us-gaap_CounterpartyNameAxis_fold_RedmileGroupMember_us-gaap_DebtInstrumentAxis_fold_AdditionalNoteAndWarrantAgreementJune2016Member_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_BeneficialOwnerMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_us-gaap_TypeOfArrangementAxis_fold_PrivatePlacementPurchaseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">fold:RedmileGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:AdditionalNoteAndWarrantAgreementJune2016Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:BeneficialOwnerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:PrivatePlacementPurchaseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-06-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="Duration_2_1_2016_To_2_29_2016_us-gaap_CounterpartyNameAxis_fold_RedmileGroupMember_us-gaap_DebtInstrumentAxis_fold_NoteAndWarrantAgreement2016Member_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_us-gaap_TypeOfArrangementAxis_fold_PrivatePlacementPurchaseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">fold:RedmileGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:NoteAndWarrantAgreement2016Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:PrivatePlacementPurchaseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-02-01</startDate>
      <endDate>2016-02-29</endDate>
    </period>
  </context>
  <context id="Duration_11_1_2013_To_11_30_2013_us-gaap_CounterpartyNameAxis_fold_GlaxoSmithKlinePLCMember_us-gaap_TypeOfArrangementAxis_fold_RevisedCollaborationAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">fold:GlaxoSmithKlinePLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:RevisedCollaborationAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-11-01</startDate>
      <endDate>2013-11-30</endDate>
    </period>
  </context>
  <context id="As_Of_4_1_2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
    </entity>
    <period>
      <instant>2016-04-01</instant>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_CounterpartyNameAxis_fold_MtSinaiSchoolOfMedicineOfNewYorkUniversityMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">fold:MtSinaiSchoolOfMedicineOfNewYorkUniversityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_CounterpartyNameAxis_fold_MtSinaiSchoolOfMedicineOfNewYorkUniversityMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">fold:MtSinaiSchoolOfMedicineOfNewYorkUniversityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_4_1_2016_To_7_31_2016_us-gaap_CounterpartyNameAxis_fold_CowenAndCompanyLLCMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_fold_SalesAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">fold:CowenAndCompanyLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:SalesAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-07-31</endDate>
    </period>
  </context>
  <context id="Duration_2_1_2016_To_2_29_2016_us-gaap_CounterpartyNameAxis_fold_CowenAndCompanyLLCMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_fold_SalesAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">fold:CowenAndCompanyLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:SalesAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-02-01</startDate>
      <endDate>2016-02-29</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_ValuationTechniqueAxis_fold_ProbabilityWeightedDiscountedCashFlowMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:SciodermIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">fold:ProbabilityWeightedDiscountedCashFlowMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_ValuationTechniqueAxis_fold_ProbabilityWeightedDiscountedCashFlowMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:SciodermIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">fold:ProbabilityWeightedDiscountedCashFlowMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_BusinessAcquisitionAxis_fold_CallidusBiopharmaIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_ValuationTechniqueAxis_fold_ProbabilityWeightedDiscountedCashFlowMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">fold:ProbabilityWeightedDiscountedCashFlowMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_BusinessAcquisitionAxis_fold_CallidusBiopharmaIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_ValuationTechniqueAxis_fold_ProbabilityWeightedDiscountedCashFlowMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">fold:ProbabilityWeightedDiscountedCashFlowMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_ValuationTechniqueAxis_fold_MonteCarloMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:SciodermIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityRevenueBasedMilestonesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">fold:MonteCarloMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_12_15_2016_To_12_15_2016_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-12-15</startDate>
      <endDate>2016-12-15</endDate>
    </period>
  </context>
  <context id="Duration_2_1_2016_To_2_29_2016_us-gaap_CounterpartyNameAxis_fold_RedmileGroupMember_us-gaap_DebtInstrumentAxis_fold_NoteAndWarrantAgreement2016Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_BeneficialOwnerMember_us-gaap_TypeOfArrangementAxis_fold_PrivatePlacementPurchaseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">fold:RedmileGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:NoteAndWarrantAgreement2016Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:BeneficialOwnerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:PrivatePlacementPurchaseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-02-01</startDate>
      <endDate>2016-02-29</endDate>
    </period>
  </context>
  <context id="Duration_10_1_2015_To_10_31_2015_us-gaap_CounterpartyNameAxis_fold_RedmileGroupMember_us-gaap_DebtInstrumentAxis_fold_NoteAndWarrantAgreement2015Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">fold:RedmileGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:NoteAndWarrantAgreement2015Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-10-01</startDate>
      <endDate>2015-10-31</endDate>
    </period>
  </context>
  <context id="Duration_12_21_2016_To_12_21_2016_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_StatementScenarioAxis_fold_ConvertibleNotesConditionOneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">fold:ConvertibleNotesConditionOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-12-21</startDate>
      <endDate>2016-12-21</endDate>
    </period>
  </context>
  <context id="Duration_12_21_2016_To_12_21_2016_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_StatementScenarioAxis_fold_ConvertibleNotesConditionTwoMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">fold:ConvertibleNotesConditionTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-12-21</startDate>
      <endDate>2016-12-21</endDate>
    </period>
  </context>
  <context id="Duration_12_21_2016_To_12_21_2016_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-12-21</startDate>
      <endDate>2016-12-21</endDate>
    </period>
  </context>
  <context id="Duration_6_1_2016_To_6_30_2016_us-gaap_CounterpartyNameAxis_fold_RedmileGroupMember_us-gaap_DebtInstrumentAxis_fold_AdditionalNoteAndWarrantAgreementJune2016Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_BeneficialOwnerMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_us-gaap_TypeOfArrangementAxis_fold_PrivatePlacementPurchaseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">fold:RedmileGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:AdditionalNoteAndWarrantAgreementJune2016Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:BeneficialOwnerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:PrivatePlacementPurchaseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-06-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="Duration_2_1_2016_To_2_29_2016_us-gaap_CounterpartyNameAxis_fold_RedmileGroupMember_us-gaap_DebtInstrumentAxis_fold_NoteAndWarrantAgreement2016Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_BeneficialOwnerMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_us-gaap_TypeOfArrangementAxis_fold_PrivatePlacementPurchaseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">fold:RedmileGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:NoteAndWarrantAgreement2016Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:BeneficialOwnerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:PrivatePlacementPurchaseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-02-01</startDate>
      <endDate>2016-02-29</endDate>
    </period>
  </context>
  <context id="Duration_4_1_2016_To_6_30_2016_us-gaap_BusinessAcquisitionAxis_fold_CallidusBiopharmaIncMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="Duration_4_1_2016_To_6_30_2016_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:SciodermIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="Duration_4_1_2016_To_7_31_2016_us-gaap_CounterpartyNameAxis_fold_CowenAndCompanyLLCMember_us-gaap_TypeOfArrangementAxis_fold_SalesAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">fold:CowenAndCompanyLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:SalesAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-07-31</endDate>
    </period>
  </context>
  <context id="As_Of_11_30_2013_us-gaap_CounterpartyNameAxis_fold_GlaxoSmithKlinePLCMember_us-gaap_TypeOfArrangementAxis_fold_RevisedCollaborationAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">fold:GlaxoSmithKlinePLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:RevisedCollaborationAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-11-30</instant>
    </period>
  </context>
  <context id="Duration_9_30_2015_To_9_30_2015_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:SciodermIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-09-30</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="Duration_7_5_2016_To_7_5_2016_us-gaap_BusinessAcquisitionAxis_fold_MiamedIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:MiamedIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-07-05</startDate>
      <endDate>2016-07-05</endDate>
    </period>
  </context>
  <context id="Duration_7_5_2016_To_7_5_2016_us-gaap_BusinessAcquisitionAxis_fold_MiamedIncMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:MiamedIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-07-05</startDate>
      <endDate>2016-07-05</endDate>
    </period>
  </context>
  <context id="Duration_9_30_2015_To_9_30_2015_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:SciodermIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-09-30</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_fold_ShortTermCorporateDebtSecuritiesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">fold:ShortTermCorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_fold_ShortTermCorporateDebtSecuritiesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">fold:ShortTermCorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_6_30_2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="As_Of_2_15_2017">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
    </entity>
    <period>
      <instant>2017-02-15</instant>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <!--Unit Section-->
  <unit id="Unit110">
    <measure>fold:segment</measure>
  </unit>
  <unit id="Unit19">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>fold:item</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="Unit18">
    <measure>utr:sqft</measure>
  </unit>
  <unit id="Unit17">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>xbrli:shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="Unit16">
    <measure>fold:lawsuit</measure>
  </unit>
  <unit id="Unit15">
    <measure>fold:installment</measure>
  </unit>
  <unit id="Unit14">
    <measure>fold:item</measure>
  </unit>
  <unit id="Unit13">
    <measure>xbrli:pure</measure>
  </unit>
  <unit id="Unit12">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="Unit1">
    <measure>xbrli:shares</measure>
  </unit>
  <!--Tuple Section-->
  <!--Element Section-->
  <dei:AmendmentFlag contextRef="Duration_1_1_2016_To_12_31_2016">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="Duration_1_1_2016_To_12_31_2016">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="Duration_1_1_2016_To_12_31_2016">FY</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="Duration_1_1_2016_To_12_31_2016">2016</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate contextRef="Duration_1_1_2016_To_12_31_2016">2016-12-31</dei:DocumentPeriodEndDate>
  <dei:DocumentType contextRef="Duration_1_1_2016_To_12_31_2016">10-K</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="Duration_1_1_2016_To_12_31_2016">0001178879</dei:EntityCentralIndexKey>
  <dei:EntityCommonStockSharesOutstanding contextRef="As_Of_2_15_2017" unitRef="Unit1" decimals="INF">194824362</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityCurrentReportingStatus contextRef="Duration_1_1_2016_To_12_31_2016">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityFilerCategory contextRef="Duration_1_1_2016_To_12_31_2016">Large Accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityPublicFloat contextRef="As_Of_6_30_2016" unitRef="Unit12" decimals="0">542291868</dei:EntityPublicFloat>
  <dei:EntityRegistrantName contextRef="Duration_1_1_2016_To_12_31_2016">AMICUS THERAPEUTICS INC</dei:EntityRegistrantName>
  <dei:EntityVoluntaryFilers contextRef="Duration_1_1_2016_To_12_31_2016">No</dei:EntityVoluntaryFilers>
  <dei:EntityWellKnownSeasonedIssuer contextRef="Duration_1_1_2016_To_12_31_2016">Yes</dei:EntityWellKnownSeasonedIssuer>
  <fold:AccruedContractManufacturingAndContractResearchCostsCurrent contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">2940000</fold:AccruedContractManufacturingAndContractResearchCostsCurrent>
  <fold:AccruedContractManufacturingAndContractResearchCostsCurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">8042000</fold:AccruedContractManufacturingAndContractResearchCostsCurrent>
  <fold:AccruedFacilityCostsCurrent contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">1321000</fold:AccruedFacilityCostsCurrent>
  <fold:AccruedFacilityCostsCurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">1740000</fold:AccruedFacilityCostsCurrent>
  <fold:AdjustmentsToAdditionalPaidinCapitalPremiumsPaidForCappedCallConfirmations contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">-13450000</fold:AdjustmentsToAdditionalPaidinCapitalPremiumsPaidForCappedCallConfirmations>
  <fold:AdjustmentsToAdditionalPaidinCapitalPremiumsPaidForCappedCallConfirmations contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">-13450000</fold:AdjustmentsToAdditionalPaidinCapitalPremiumsPaidForCappedCallConfirmations>
  <fold:AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">932000</fold:AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor>
  <fold:AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">932000</fold:AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor>
  <fold:AmortizationDeferredFinancingCosts contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">26000</fold:AmortizationDeferredFinancingCosts>
  <fold:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent contextRef="As_Of_12_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_fold_ShortTermCorporateDebtSecuritiesMember" unitRef="Unit12" decimals="-3">1000</fold:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
  <fold:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent contextRef="As_Of_12_31_2016_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_fold_ShortTermCorporateDebtSecuritiesMember" unitRef="Unit12" decimals="-3">2000</fold:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
  <fold:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent contextRef="As_Of_12_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_fold_ShortTermCorporateDebtSecuritiesMember" unitRef="Unit12" decimals="-3">154000</fold:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
  <fold:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent contextRef="As_Of_12_31_2016_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_fold_ShortTermCorporateDebtSecuritiesMember" unitRef="Unit12" decimals="-3">31000</fold:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
  <fold:AvailableForSaleSecuritiesAmortizedCostCurrent contextRef="As_Of_12_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_fold_ShortTermCorporateDebtSecuritiesMember" unitRef="Unit12" decimals="-3">118627000</fold:AvailableForSaleSecuritiesAmortizedCostCurrent>
  <fold:AvailableForSaleSecuritiesAmortizedCostCurrent contextRef="As_Of_12_31_2016_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_fold_ShortTermCorporateDebtSecuritiesMember" unitRef="Unit12" decimals="-3">74564000</fold:AvailableForSaleSecuritiesAmortizedCostCurrent>
  <fold:BusinessCombinationAdjustedCashConsiderationTransferred contextRef="Duration_9_30_2015_To_9_30_2015_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember" unitRef="Unit12" decimals="-5">141100000</fold:BusinessCombinationAdjustedCashConsiderationTransferred>
  <fold:BusinessCombinationAdjustedConsiderationTransferred contextRef="Duration_9_30_2015_To_9_30_2015_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember" unitRef="Unit12" decimals="-5">223900000</fold:BusinessCombinationAdjustedConsiderationTransferred>
  <fold:BusinessCombinationAdjustedEquityConsiderationTransferred contextRef="Duration_9_30_2015_To_9_30_2015_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember" unitRef="Unit12" decimals="-5">82800000</fold:BusinessCombinationAdjustedEquityConsiderationTransferred>
  <fold:BusinessCombinationConsiderationTransferredIncludingMilestonePayment contextRef="Duration_7_5_2016_To_7_5_2016_us-gaap_BusinessAcquisitionAxis_fold_MiamedIncMember" unitRef="Unit12" decimals="-5">89500000</fold:BusinessCombinationConsiderationTransferredIncludingMilestonePayment>
  <fold:BusinessCombinationContingentConsiderationMilestones contextRef="Duration_7_5_2016_To_7_5_2016_us-gaap_BusinessAcquisitionAxis_fold_MiamedIncMember" unitRef="Unit12" decimals="-5">83000000</fold:BusinessCombinationContingentConsiderationMilestones>
  <fold:BusinessCombinationContingentConsiderationMilestones contextRef="Duration_7_5_2016_To_7_5_2016_us-gaap_BusinessAcquisitionAxis_fold_MiamedIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember_us-gaap_RangeAxis_us-gaap_MaximumMember" unitRef="Unit12" decimals="-5">83000000</fold:BusinessCombinationContingentConsiderationMilestones>
  <fold:BusinessCombinationPriorityReviewVoucherSalePayment contextRef="Duration_9_30_2015_To_9_30_2015_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember_us-gaap_RangeAxis_us-gaap_MaximumMember" unitRef="Unit12" decimals="-6">100000000</fold:BusinessCombinationPriorityReviewVoucherSalePayment>
  <fold:BusinessCombinationPriorityReviewVoucherSalePaymentPercent contextRef="Duration_9_30_2015_To_9_30_2015_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember_us-gaap_RangeAxis_us-gaap_MaximumMember" unitRef="Unit13" decimals="2">0.50</fold:BusinessCombinationPriorityReviewVoucherSalePaymentPercent>
  <fold:BusinessCombinationPriorityReviewVoucherUsedPayment contextRef="Duration_9_30_2015_To_9_30_2015_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember" unitRef="Unit12" decimals="-6">100000000</fold:BusinessCombinationPriorityReviewVoucherUsedPayment>
  <fold:CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Cash, Money Market Funds, and Marketable Securities&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company considers all highly liquid investments purchased with a maturity of three months or less at the date of acquisition, to be cash equivalents.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;font-family:Times;"&gt;Marketable securities consist of fixed income investments with a maturity of greater than three months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Company's balance sheet. Unrealized holding gains and losses are reported within comprehensive income/ (loss) in the statements of comprehensive loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations or other observable inputs. See "&amp;#x2014;&amp;nbsp;Note&amp;nbsp;5. Cash, Money Market Funds and Marketable Securities", for a summary of available-for-sale securities as of December&amp;nbsp;31, 2016 and 2015.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</fold:CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock>
  <fold:CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">214033000</fold:CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure>
  <fold:CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">330351000</fold:CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure>
  <fold:CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments contextRef="As_Of_11_30_2013_us-gaap_CounterpartyNameAxis_fold_GlaxoSmithKlinePLCMember_us-gaap_TypeOfArrangementAxis_fold_RevisedCollaborationAgreementMember" unitRef="Unit12" decimals="-6">40000000</fold:CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments>
  <fold:CommonStockIssuanceCommissionExpenses contextRef="Duration_4_1_2016_To_7_31_2016_us-gaap_CounterpartyNameAxis_fold_CowenAndCompanyLLCMember_us-gaap_TypeOfArrangementAxis_fold_SalesAgreementMember" unitRef="Unit12" decimals="-5">2700000</fold:CommonStockIssuanceCommissionExpenses>
  <fold:CommonStockVotingRightsForEachShareHeld contextRef="As_Of_12_31_2016" unitRef="Unit14" decimals="INF">1</fold:CommonStockVotingRightsForEachShareHeld>
  <fold:ContingentAcquisitionConsiderationPayablePolicyTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Contingent Consideration Payable&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company determines the fair value of contingent acquisition consideration payable on the acquisition date using a probability-based income approach utilizing an appropriate discount rate. Contingent acquisition consideration payable is shown as a non-current liability on the Company's consolidated balance sheets. The fair value of the contingent consideration payable will be determined each period end and the resulting change will be recorded on the consolidated statements of operations.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</fold:ContingentAcquisitionConsiderationPayablePolicyTextBlock>
  <fold:ContingentConsiderationMilestonePayment contextRef="Duration_4_1_2016_To_6_30_2016_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" unitRef="Unit12" decimals="-6">5000000</fold:ContingentConsiderationMilestonePayment>
  <fold:ContingentConsiderationPaidInStock contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">6115000</fold:ContingentConsiderationPaidInStock>
  <fold:ContingentConsiderationPaidInStock contextRef="Duration_4_1_2016_To_6_30_2016_us-gaap_BusinessAcquisitionAxis_fold_CallidusBiopharmaIncMember" unitRef="Unit12" decimals="-5">6100000</fold:ContingentConsiderationPaidInStock>
  <fold:ConvertibleDebtPrincipalIncrementForConversion contextRef="Duration_2_1_2016_To_2_29_2016_us-gaap_CounterpartyNameAxis_fold_RedmileGroupMember_us-gaap_DebtInstrumentAxis_fold_NoteAndWarrantAgreement2016Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_BeneficialOwnerMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_us-gaap_TypeOfArrangementAxis_fold_PrivatePlacementPurchaseAgreementMember" unitRef="Unit12" decimals="-3">1000</fold:ConvertibleDebtPrincipalIncrementForConversion>
  <fold:ConvertibleDebtPrincipalIncrementForConversion contextRef="Duration_6_1_2016_To_6_30_2016_us-gaap_CounterpartyNameAxis_fold_RedmileGroupMember_us-gaap_DebtInstrumentAxis_fold_AdditionalNoteAndWarrantAgreementJune2016Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_BeneficialOwnerMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_us-gaap_TypeOfArrangementAxis_fold_PrivatePlacementPurchaseAgreementMember" unitRef="Unit12" decimals="0">1000</fold:ConvertibleDebtPrincipalIncrementForConversion>
  <fold:ConvertibleDebtPrincipalIncrementForConversion contextRef="Duration_12_21_2016_To_12_21_2016_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="Unit12" decimals="0">1000</fold:ConvertibleDebtPrincipalIncrementForConversion>
  <fold:DebtInstrumentConvertibleMaximumCalendarDaysAllowedToHoldersOfCommonStockRightsOptionsOrWarrantsToPurchaseOfCommonStock contextRef="Duration_12_21_2016_To_12_21_2016_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">P60D</fold:DebtInstrumentConvertibleMaximumCalendarDaysAllowedToHoldersOfCommonStockRightsOptionsOrWarrantsToPurchaseOfCommonStock>
  <fold:DebtInstrumentConvertibleMinimumPercentageOfPerShareValueOfLastReportedSalePriceOfCommonStock contextRef="Duration_12_21_2016_To_12_21_2016_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="Unit13" decimals="2">0.10</fold:DebtInstrumentConvertibleMinimumPercentageOfPerShareValueOfLastReportedSalePriceOfCommonStock>
  <fold:DebtInstrumentConvertibleTradingDaysForPricePerShareBasedOnLastReportedSalePrice contextRef="Duration_12_21_2016_To_12_21_2016_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">P10D</fold:DebtInstrumentConvertibleTradingDaysForPricePerShareBasedOnLastReportedSalePrice>
  <fold:DebtInstrumentsAndRelatedPartyTransactionsDisclosureTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;16. Debt Instruments and Related Party Transactions&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;October 2015 and February 2016 Notes and Warrants Purchase Agreement&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In October 2015, the Company entered into the October 2015 Purchase Agreement with Redmile, who beneficially owned approximately 6.7% of the Common Stock as of December&amp;nbsp;31, 2015, whereby it sold, on a private placement basis, (a)&amp;nbsp;$50.0&amp;nbsp;million aggregate principal amount of its unsecured promissory notes ("Notes") and (b)&amp;nbsp;five-year warrants ("Warrants") for 1.3&amp;nbsp;million shares of Common Stock. The payment terms under the purchase agreement contained two installments, the first $15.0&amp;nbsp;million in October 2017 and the balance $35.0&amp;nbsp;million in October 2020. Interest was payable at 4.1% on a monthly basis over the term of the loan. Due to the embedded redemption (put and/or call) features in the note agreement, it was determined that the fair value of the warrants should be bifurcated from the value of the notes payable and recorded as a debt discount. The relative fair value of the warrants and the debt discount as related to the October 2015 purchase agreement was determined to be $8.8&amp;nbsp;million.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;This Purchase Agreement was modified in February 2016 when the Company entered into a Note and Warrant Purchase Agreement (the "February 2016 Purchase Agreement") with Redmile for an aggregate amount of up to $75.0&amp;nbsp;million. The Company agreed with Redmile that in full consideration of the purchase price for the notes issued under the October 2015 Purchase Agreement, Redmile surrendered for cancellation all notes and warrants acquired from the October 2015 Purchase Agreement and the Company paid Redmile any unpaid interest accrued thereunder. Pursuant to the February 2016 agreement, at closing, it sold, on a private placement basis (a)&amp;nbsp;$50.0&amp;nbsp;million aggregate principal amount of unsecured promissory notes ("Initial Notes") and (b)&amp;nbsp;five year warrants to purchase up to 37 shares of the Company's Common Stock for every $1,000 of the principal amount of Initial Notes purchased ("Initial Warrants"), for an aggregate of up to 1,850,000 shares of Common Stock issuable under the Initial Warrants. The payment terms contained two installments, the first $15.0&amp;nbsp;million in October 2017 and the balance $35.0&amp;nbsp;million in October 2021. The interest rate was 3.875% and payable upon of maturity. This transaction was accounted for as a debt modification in accordance with ASC 470-50. The incremental fair value between the warrants that were cancelled and the February issued warrants of $3.5&amp;nbsp;million was recorded as additional unamortized debt discount on the balance sheet and added to the prior warrant balance within equity.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Notes mentioned above were cancelled in December 2016. For more details, refer to section&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;December 2016 Note Purchase Agreement&lt;/font&gt;&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;below in this footnote.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;June 2016 Amended Purchase Agreement&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In June 2016, following the marketing approval for migalastat in Europe, the Company entered into the Amended Purchase Agreement with Redmile. Such amendment joined GCM to the February 2016 Purchase Agreement. Pursuant to the Amended Purchase Agreement, the Company sold an additional $30&amp;nbsp;million unsecured promissory notes and five year warrants to purchase up to purchase up to 42 shares of our Common Stock, par value $0.01 per share for every $1,000 of the principal amount of additional notes purchased, for an aggregate of up to 1,260,000 shares of Common Stock issuable from the additional warrants. The payment was due in October 2021. The interest rate was 3.875% and payable upon of maturity. The Notes mentioned above were cancelled in December 2016. For more details, refer to section &lt;/font&gt;&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;December 2016 Note Purchase Agreement&lt;/font&gt;&lt;font style="display:inline;font-family:Times;"&gt; below in this footnote.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;December 2016 Note Purchase Agreement&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;On December&amp;nbsp;15, 2016, the Company entered into a Note Purchase Agreement ("Note Purchase Agreement") with GCM and RedMile, pursuant to which the Company agreed to prepay all outstanding principal and accrued and unpaid interest on the notes issued by the Company and held by GCM and Redmile. Such prepayment was made on December&amp;nbsp;21, 2016. The Note Purchase Agreement did not cancel the warrants, under the Amended Purchase Agreement. The net loss on extinguishment of the debt was $13.3&amp;nbsp;million and is included as loss on extinguishment in the Consolidated Statement of Operations for the year ended December&amp;nbsp;31, 2016.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;2016 Convertible Debt&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;On December&amp;nbsp;21, 2016, the Company issued at par value $250&amp;nbsp;million aggregate principal amount of unsecured Convertible Senior Notes due 2023 (the "Convertible Notes"), which included the exercise in full of the $25&amp;nbsp;million over-allotment option granted to the initial purchasers of the Notes, in a private offering to qualified institutional buyers pursuant to Rule&amp;nbsp;144A under the Securities Act. Interest is payable semiannually on June&amp;nbsp;15 and December&amp;nbsp;15 of each year, beginning on June&amp;nbsp;15, 2017. The Notes will mature on December&amp;nbsp;15, 2023, unless earlier repurchased, redeemed, or converted in accordance with their terms. The Notes are convertible at the option of the holders, under certain circumstances and during certain periods, into cash, shares of the Company's common stock or a combination thereof and may be settled as described below. The net proceeds from the Note Offering were $243.1&amp;nbsp;million, after deducting fees and estimated expenses payable by the Company. In addition, the Company used approximately $13.5&amp;nbsp;million of the net proceeds from the issuance of the Convertible Notes to pay the cost of the capped call transactions ("Capped Call Confirmations") that the Company entered into in connection with the issuance of the Convertible Notes.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Convertible Notes are governed by an indenture dated December&amp;nbsp;21, 2016 (the "Indenture") by and between Amicus and Wilmington Trust, National Association, as trustee.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Convertible Notes are initially convertible into approximately 40,849,675 shares of the Company's common stock under certain circumstances prior to maturity at a conversion rate of 163.3987 shares per $1,000 principal amount of Convertible Notes, which represents a conversion price of approximately $6.12 per share of Common Stock, subject to adjustment under certain conditions. Holders may convert their Convertible Notes at their option at specified times prior to the maturity date of December&amp;nbsp;15, 2023, only if:&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:15;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:15;"&gt;
				&lt;td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Aparajita;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Aparajita;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Aparajita;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:15;"&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2022;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;during any fiscal quarter commencing after March&amp;nbsp;31, 2017, if the last reported sale price of the Company's common stock for at least 20 trading days in the period of 30 consecutive trading days ending on the last trading day of the immediately preceding fiscal quarter is equal to or more than 130% of the conversion price of the Convertible Notes on the last day of such preceding fiscal quarter; &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:15;"&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2022;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;a Holder submits its Convertible Notes for conversion during the five business day period following any five consecutive trading day period in which the trading price for the Convertible Notes, per $1,000 principal amount of the Convertible Notes, for each such trading day was less than 98% of the product of the last reported sale price of the Company's common stock and the conversion rate of the Convertible Notes on such date; or &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:15;"&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2022;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;the Company issues to all or substantially all of the holders of common stock rights options or warrants entitling then them for a period of not more than 60 calendar days after the date of such issuance to subscribe for or purchase shares of the Common Stock, at a price per share less than the average of the Last Reported Sale Prices of the Common Stock for the 10 consecutive Trading Day period ending on, and including, the Trading Day immediately preceding the date of announcement of such issuance or distributes to all or substantially all holders of the Common Stock the Company's assets, debt securities or rights to purchase the Company's securities which distribution has a per share value of exceeding 10% of the Last Reported Sale Price of the Common Stock on the Trading Day immediately preceding the date of announcement of such distribution &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:15;"&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2022;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;the Company enters into specified corporate transactions. &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:15;"&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2022;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;the Company has had a call for redemption, the holder can convert up until the second trading day immediately preceding the redemption date&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Convertible Notes will be convertible, at the option of the note holders, regardless of whether any of the foregoing conditions have been satisfied, on or after September&amp;nbsp;15, 2023 at any time prior to the close of business on the second scheduled trading day immediately preceding the stated maturity date of December&amp;nbsp;15, 2023.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Upon the occurrence of a make-whole fundamental change or if the Company call all or any portion of the Convertible Notes for redemption prior to July&amp;nbsp;1, 2020, the Company will, in certain circumstances, increase the conversion rate by a number of additional shares for a holder that elects to convert its Convertible Notes in connection with such make-whole fundamental change or during the related redemption period.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Upon conversion, the Company may pay cash, shares of the Company's common stock or a combination of cash and stock, as determined by the Company in its discretion.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company accounts for the Convertible Notes as a liability and equity component where the carrying value of the liability component will be valued based on a similar instrument. In accounting for the issuance of the Convertible Notes, the Company separated the Convertible Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the fair value of a similar liability that does not have an associated convertible feature. The carrying amount of the equity component representing the conversion option was determined by deducting the fair value of the liability component from the par value of the Convertible Notes as a whole. The excess of the principal amount of the liability component over its carrying amount, referred to as the debt discount, is amortized to interest expense over the seven-year term of the Convertible Notes. The equity component is not re-measured as long as it continues to meet the conditions for equity classification.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In accounting for the issuance of the Convertible Notes, the Company separated the Convertible Notes into liability and equity components based on their relative values. The carrying amount of the liability component was calculated by measuring the fair value of a similar liability that does not have an associated convertible feature. The carrying amount of the equity component, representing the conversion option, was determined by deducting the fair value of the liability component from the par value of the Convertible Notes. The difference between the principal amount of the Convertible Notes and the liability component represents the debt discount, which is recorded as a direct deduction from the related debt liability in the Consolidated Balance Sheets and amortized to interest expense using the effective interest method over the seven-year term of the Convertible Notes. The equity component of the Convertible Notes of approximately $88.3&amp;nbsp;million is included in additional paid-in capital in the Consolidated Balance Sheets and is not remeasured as long as it continues to meet the conditions for equity classification. Additionally, the Company recorded a deferred tax liability of $29.8&amp;nbsp;million in relation to the Convertible Notes.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company incurred transaction costs of approximately $7.5&amp;nbsp;million, including approximately $6.9&amp;nbsp;million that was paid from the gross proceeds of the Convertible Notes offering. In accounting for the transaction costs, the Company allocated the total amount incurred to the liability and equity components using the same proportions as the proceeds from the Convertible Notes. Transaction costs attributable to the liability component were recorded as a direct deduction from the related debt liability in the Consolidated Balance Sheets and amortized to interest expense over the seven-year term of the Convertible Notes. Transaction costs attributable to the equity component were netted with the equity component in additional-paid-in-capital.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Convertible Notes consist of the following as of December&amp;nbsp;31, 2016:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Liability component &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(In thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Principal&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;250,000
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Less: debt discount&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;font-family:Times;font-size:6pt;top:-4pt;position:relative;line-height:100%"&gt;(1)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(90,807
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Less: deferred financing&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;font-family:Times;font-size:6pt;top:-4pt;position:relative;line-height:100%"&gt;(1)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(4,729
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Net carrying value of the debt&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;154,464
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;div&gt;&lt;hr style="border-width:0;width:26%;height:1.5pt;color:black;background-color:black;" align="left"&gt;&lt;/hr&gt;&lt;/div&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:15;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:15;"&gt;
				&lt;td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:15;"&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;(1)&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Included in the Consolidated Balance Sheets within Convertible Senior Notes (due 2023) and amortized to interest expense over the remaining life of the Convertible Senior Notes using the effective interest rate method.&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The fair value of the debt at December&amp;nbsp;31, 2016 was approximately $258.8&amp;nbsp;million.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The following table sets forth total interest expense recognized related to the Convertible Notes for the year ended December&amp;nbsp;31, 2016:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Components &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(In thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Contractual interest expense&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;208&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Amortization of deferred financing&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;26&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Amortization of debt discount&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;248&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;482&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Effective interest rate of the liability component&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;10.85&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Capped Call Confirmations of $13.5&amp;nbsp;million are expected generally to reduce the potential dilution to the Common Stock upon any conversion of the Convertible Notes and/or offset the cash payments the Company is required to make in excess of the principal amount upon conversion of the Notes in the event that the market price of the Common Stock is greater than the strike price of the Capped Call Confirmations (which initially corresponds to the initial conversion price of the Convertible Notes and is subject to certain adjustments under the terms of the Capped Call Confirmations), with such reduction and/or offset subject to a cap based on the cap price of the Capped Call Confirmations. The Capped Call Confirmations have an initial cap price of $7.20 per share, which represents a premium of approximately 50% over the closing price of the Company's Common Stock on The NASDAQ Global Market on December&amp;nbsp;15, 2016, and is subject to certain adjustments under the terms of the Capped Call Confirmations. The Capped Call Confirmations will cover, subject to anti-dilution adjustments substantially similar to those applicable to the Convertible Notes, the number of shares of Common Stock that will underlie the Convertible Notes. The Capped Call Confirmations do not meet the criteria for separate accounting as a derivative as they are indexed to the Company's Common Stock. The premiums paid for the Capped Call Confirmations have been included as a net reduction to additional paid-in capital.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</fold:DebtInstrumentsAndRelatedPartyTransactionsDisclosureTextBlock>
  <fold:DebtInstrumentsConvertibleThresholdMaximumPercentageOfStockPriceTrigger contextRef="Duration_12_21_2016_To_12_21_2016_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_StatementScenarioAxis_fold_ConvertibleNotesConditionTwoMember" unitRef="Unit13" decimals="2">0.98</fold:DebtInstrumentsConvertibleThresholdMaximumPercentageOfStockPriceTrigger>
  <fold:DebtInstrumentsConvertibleThresholdTradingDays contextRef="Duration_12_21_2016_To_12_21_2016_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_StatementScenarioAxis_fold_ConvertibleNotesConditionTwoMember">P5D</fold:DebtInstrumentsConvertibleThresholdTradingDays>
  <fold:DebtInstrumentsConvertibleThresholdTradingDays contextRef="Duration_12_21_2016_To_12_21_2016_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_StatementScenarioAxis_fold_ConvertibleNotesConditionOneMember">P20D</fold:DebtInstrumentsConvertibleThresholdTradingDays>
  <fold:DebtInstrumentsNumberOfInstallments contextRef="Duration_10_1_2015_To_10_31_2015_us-gaap_CounterpartyNameAxis_fold_RedmileGroupMember_us-gaap_DebtInstrumentAxis_fold_NoteAndWarrantAgreement2015Member" unitRef="Unit15" decimals="0">2</fold:DebtInstrumentsNumberOfInstallments>
  <fold:DebtInstrumentsNumberOfInstallments contextRef="Duration_2_1_2016_To_2_29_2016_us-gaap_CounterpartyNameAxis_fold_RedmileGroupMember_us-gaap_DebtInstrumentAxis_fold_NoteAndWarrantAgreement2016Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_BeneficialOwnerMember_us-gaap_TypeOfArrangementAxis_fold_PrivatePlacementPurchaseAgreementMember" unitRef="Unit14" decimals="0">2</fold:DebtInstrumentsNumberOfInstallments>
  <fold:DeferredTaxAssetsIntellectualProperty contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">95956000</fold:DeferredTaxAssetsIntellectualProperty>
  <fold:DeferredTaxAssetsLiabilitiesGross contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">37509000</fold:DeferredTaxAssetsLiabilitiesGross>
  <fold:DeferredTaxAssetsLiabilitiesGross contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">113092000</fold:DeferredTaxAssetsLiabilitiesGross>
  <fold:DeferredTaxAssetsNonCashStockIssueNonCurrent contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">6767000</fold:DeferredTaxAssetsNonCashStockIssueNonCurrent>
  <fold:DeferredTaxAssetsNonCashStockIssueNonCurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">11649000</fold:DeferredTaxAssetsNonCashStockIssueNonCurrent>
  <fold:DeferredTaxLiabilitiesConvertibleNotes contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">29845000</fold:DeferredTaxLiabilitiesConvertibleNotes>
  <fold:DeferredTaxLiabilitiesRoyaltyPayable contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">96829000</fold:DeferredTaxLiabilitiesRoyaltyPayable>
  <fold:DerivativeCapPricePercentageOfPremiumOnCommonStockClosingPrice contextRef="Duration_12_15_2016_To_12_15_2016_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="Unit13" decimals="2">0.50</fold:DerivativeCapPricePercentageOfPremiumOnCommonStockClosingPrice>
  <fold:FairValueAssumptionsRevenueVolatilityRate contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_ValuationTechniqueAxis_fold_MonteCarloMember" unitRef="Unit13" decimals="2">0.58</fold:FairValueAssumptionsRevenueVolatilityRate>
  <fold:FairValueInputsProbabilityOfAchievementOfMilestones contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_ValuationTechniqueAxis_fold_MonteCarloMember" unitRef="Unit13" decimals="3">0.665</fold:FairValueInputsProbabilityOfAchievementOfMilestones>
  <fold:FairValueInputsProbabilityOfAchievementOfMilestones contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_BusinessAcquisitionAxis_fold_CallidusBiopharmaIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_ValuationTechniqueAxis_fold_ProbabilityWeightedDiscountedCashFlowMember" unitRef="Unit13" decimals="3">0.428</fold:FairValueInputsProbabilityOfAchievementOfMilestones>
  <fold:FairValueInputsProbabilityOfAchievementOfMilestones contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_BusinessAcquisitionAxis_fold_CallidusBiopharmaIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_ValuationTechniqueAxis_fold_ProbabilityWeightedDiscountedCashFlowMember" unitRef="Unit13" decimals="3">0.304</fold:FairValueInputsProbabilityOfAchievementOfMilestones>
  <fold:FairValueInputsProbabilityOfAchievementOfMilestones contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_ValuationTechniqueAxis_fold_ProbabilityWeightedDiscountedCashFlowMember" unitRef="Unit13" decimals="2">1.00</fold:FairValueInputsProbabilityOfAchievementOfMilestones>
  <fold:FairValueInputsProbabilityOfAchievementOfMilestones contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_ValuationTechniqueAxis_fold_ProbabilityWeightedDiscountedCashFlowMember" unitRef="Unit13" decimals="3">0.665</fold:FairValueInputsProbabilityOfAchievementOfMilestones>
  <fold:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityBusinessAcquisition contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">259000000</fold:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityBusinessAcquisition>
  <fold:FixedCommissionRateAsPercentageOfGrossProceedsPerShareSold contextRef="Duration_2_1_2016_To_2_29_2016_us-gaap_CounterpartyNameAxis_fold_CowenAndCompanyLLCMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_fold_SalesAgreementMember" unitRef="Unit13" decimals="3">0.030</fold:FixedCommissionRateAsPercentageOfGrossProceedsPerShareSold>
  <fold:FixedCommissionRateAsPercentageOfGrossProceedsPerShareSold contextRef="Duration_4_1_2016_To_7_31_2016_us-gaap_CounterpartyNameAxis_fold_CowenAndCompanyLLCMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_fold_SalesAgreementMember" unitRef="Unit13" decimals="3">0.030</fold:FixedCommissionRateAsPercentageOfGrossProceedsPerShareSold>
  <fold:IncomeTaxExpensesBenefitFromSaleOfNetOperatingLossesAndResearchAndDevelopmentCredits contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-5">1100000</fold:IncomeTaxExpensesBenefitFromSaleOfNetOperatingLossesAndResearchAndDevelopmentCredits>
  <fold:IncomeTaxExpensesBenefitFromSaleOfNetOperatingLossesAndResearchAndDevelopmentCredits contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-5">0</fold:IncomeTaxExpensesBenefitFromSaleOfNetOperatingLossesAndResearchAndDevelopmentCredits>
  <fold:IncomeTaxExpensesBenefitFromSaleOfNetOperatingLossesAndResearchAndDevelopmentCredits contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-5">0</fold:IncomeTaxExpensesBenefitFromSaleOfNetOperatingLossesAndResearchAndDevelopmentCredits>
  <fold:IncreaseDecreaseInDeferredReimbursements contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">-57000</fold:IncreaseDecreaseInDeferredReimbursements>
  <fold:IncreaseDecreaseInDeferredReimbursements contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">-864000</fold:IncreaseDecreaseInDeferredReimbursements>
  <fold:IncreaseDecreaseInDueFromCollaborationAgreements contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">-1083000</fold:IncreaseDecreaseInDueFromCollaborationAgreements>
  <fold:IncreaseDecreaseInNoncurrentOperatingLiabilities contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">-126000</fold:IncreaseDecreaseInNoncurrentOperatingLiabilities>
  <fold:IncreaseDecreaseInNoncurrentOperatingLiabilities contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">93000</fold:IncreaseDecreaseInNoncurrentOperatingLiabilities>
  <fold:IncreaseDecreaseInNoncurrentOperatingLiabilities contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">825000</fold:IncreaseDecreaseInNoncurrentOperatingLiabilities>
  <fold:InterestIncomeAndInterestExpensePolicyTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Interest Income and Interest Expense&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Interest income consists of interest earned on the Company's cash and cash equivalents and marketable securities. Interest expense consists of interest incurred on capital leases and debt.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</fold:InterestIncomeAndInterestExpensePolicyTextBlock>
  <fold:LesseeLeasingArrangementsCapitalLeasesTermOfContract contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_us-gaap_RangeAxis_us-gaap_MaximumMember">P48M</fold:LesseeLeasingArrangementsCapitalLeasesTermOfContract>
  <fold:LesseeLeasingArrangementsCapitalLeasesTermOfContract contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_us-gaap_RangeAxis_us-gaap_MinimumMember">P36M</fold:LesseeLeasingArrangementsCapitalLeasesTermOfContract>
  <fold:LicenseAgreementMilestonePaymentsPotential contextRef="As_Of_12_31_2016_us-gaap_CounterpartyNameAxis_fold_MtSinaiSchoolOfMedicineOfNewYorkUniversityMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember" unitRef="Unit12" decimals="-3">0</fold:LicenseAgreementMilestonePaymentsPotential>
  <fold:LicenseAgreementUpfrontPaymentAndAnnualLicenseFees contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_CounterpartyNameAxis_fold_MtSinaiSchoolOfMedicineOfNewYorkUniversityMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember" unitRef="Unit12" decimals="0">0</fold:LicenseAgreementUpfrontPaymentAndAnnualLicenseFees>
  <fold:NonCashDeferredTaxes contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">-2449000</fold:NonCashDeferredTaxes>
  <fold:NoncashIncomeTaxExpenseBenefit contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">-1293000</fold:NoncashIncomeTaxExpenseBenefit>
  <fold:NonqualifiedCashDeferralPlansPolicy contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Nonqualified Cash Deferral Plan&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;font-family:Times;"&gt;The Company's Cash Deferral Plan (the "Deferral Plan"), provides certain key employees and members of the Board of Directors as selected by the Compensation Committee of the Board of Directors of the Company (the "Compensation Committee"), with an opportunity to defer the receipt of such participant's base salary, bonus and director's fees, as applicable. The Deferral Plan is intended to be a nonqualified deferred compensation plan that complies with the provisions of Section&amp;nbsp;409A of the Internal Revenue Code (the "Code"). All of the investments held in the Deferral Plan are classified as investments held-to-maturity and recorded at fair value with changes in the investments' fair value recognized as earnings in the period they occur. The corresponding liability for the Deferral Plan is included in other non-current liability in the consolidated balance sheets.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</fold:NonqualifiedCashDeferralPlansPolicy>
  <fold:NumberOfFabryCausingMutationsIncludedInCHMPLabelApproval contextRef="As_Of_4_1_2016" unitRef="Unit14" decimals="INF">313</fold:NumberOfFabryCausingMutationsIncludedInCHMPLabelApproval>
  <fold:NumberOfForwardContracts contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit14" decimals="0">0</fold:NumberOfForwardContracts>
  <fold:NumberOfLawsuits contextRef="As_Of_12_31_2016" unitRef="Unit16" decimals="INF">3</fold:NumberOfLawsuits>
  <fold:NumberOfLawsuitsNamingAdditionalOfficer contextRef="As_Of_12_31_2016" unitRef="Unit16" decimals="INF">1</fold:NumberOfLawsuitsNamingAdditionalOfficer>
  <fold:NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones contextRef="Duration_11_1_2013_To_11_30_2013_us-gaap_CounterpartyNameAxis_fold_GlaxoSmithKlinePLCMember_us-gaap_TypeOfArrangementAxis_fold_RevisedCollaborationAgreementMember" unitRef="Unit14" decimals="INF">8</fold:NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones>
  <fold:NumberOfSharesIssuedPerIncrementOfConvertibleDebt contextRef="Duration_2_1_2016_To_2_29_2016_us-gaap_CounterpartyNameAxis_fold_RedmileGroupMember_us-gaap_DebtInstrumentAxis_fold_NoteAndWarrantAgreement2016Member_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_us-gaap_TypeOfArrangementAxis_fold_PrivatePlacementPurchaseAgreementMember" unitRef="Unit1" decimals="INF">37</fold:NumberOfSharesIssuedPerIncrementOfConvertibleDebt>
  <fold:NumberOfSharesIssuedPerIncrementOfConvertibleDebt contextRef="Duration_6_1_2016_To_6_30_2016_us-gaap_CounterpartyNameAxis_fold_RedmileGroupMember_us-gaap_DebtInstrumentAxis_fold_AdditionalNoteAndWarrantAgreementJune2016Member_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_BeneficialOwnerMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_us-gaap_TypeOfArrangementAxis_fold_PrivatePlacementPurchaseAgreementMember" unitRef="Unit1" decimals="INF">42</fold:NumberOfSharesIssuedPerIncrementOfConvertibleDebt>
  <fold:NumberOfSharesIssuedPerIncrementOfConvertibleDebt contextRef="Duration_12_21_2016_To_12_21_2016_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="Unit1" decimals="INF">40849675</fold:NumberOfSharesIssuedPerIncrementOfConvertibleDebt>
  <fold:OperatingLeasesFutureMinimumPaymentsDueInFiveYearsAndThereafter contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">10537000</fold:OperatingLeasesFutureMinimumPaymentsDueInFiveYearsAndThereafter>
  <fold:OperatingLossCarryforwardsLimitationsOnUseMinimumOwnershipPercentageChangeRelatingToSection382 contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit13" decimals="2">0.50</fold:OperatingLossCarryforwardsLimitationsOnUseMinimumOwnershipPercentageChangeRelatingToSection382>
  <fold:OperatingLossCarryforwardsLimitationsOnUseMinimumPercentageOwnershipChangePeriod contextRef="Duration_1_1_2016_To_12_31_2016">P3Y</fold:OperatingLossCarryforwardsLimitationsOnUseMinimumPercentageOwnershipChangePeriod>
  <fold:OtherComprehensiveIncomePolicyPolicyTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Other Comprehensive Income/ (Loss)&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Components of other comprehensive income/(loss) include unrealized gains and losses on available-for-sale securities and gain/(loss) on foreign currency transactions, and are included in the statements of comprehensive loss.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</fold:OtherComprehensiveIncomePolicyPolicyTextBlock>
  <fold:PaymentOfContingentConsideration contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">5000000</fold:PaymentOfContingentConsideration>
  <fold:PaymentsForRepurchaseOfRestrictedStockUnits contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">2044000</fold:PaymentsForRepurchaseOfRestrictedStockUnits>
  <fold:PaymentsForRepurchaseOfRestrictedStockUnits contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">1282000</fold:PaymentsForRepurchaseOfRestrictedStockUnits>
  <fold:PortionOfPatientsWithFabryCausedByMutationsIncludedInLabelApprovedByChmp contextRef="As_Of_4_1_2016_us-gaap_RangeAxis_us-gaap_MaximumMember" unitRef="Unit13" decimals="1">0.5</fold:PortionOfPatientsWithFabryCausedByMutationsIncludedInLabelApprovedByChmp>
  <fold:PremiumsPaidForCappedCallConfirmations contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">13450000</fold:PremiumsPaidForCappedCallConfirmations>
  <fold:PremiumsPaidForCappedCallConfirmations contextRef="Duration_12_21_2016_To_12_21_2016_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="Unit12" decimals="-5">13500000</fold:PremiumsPaidForCappedCallConfirmations>
  <fold:PriorityReviewVoucherTransferYears contextRef="Duration_9_30_2015_To_9_30_2015_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember">P1Y</fold:PriorityReviewVoucherTransferYears>
  <fold:ProceedsFromIssuanceOfCommonStockGross contextRef="Duration_7_1_2014_To_7_31_2014_us-gaap_CounterpartyNameAxis_fold_CowenAndCompanyLLCMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_fold_AtMarketEquityOfferingMember" unitRef="Unit12" decimals="-6">40000000</fold:ProceedsFromIssuanceOfCommonStockGross>
  <fold:ResearchExpenseForStockIssuanceInAssetAcquisition contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">4607000</fold:ResearchExpenseForStockIssuanceInAssetAcquisition>
  <fold:ResearchRevenue contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">1224000</fold:ResearchRevenue>
  <fold:ResearchRevenue contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_CounterpartyNameAxis_fold_BiogenIdecMember" unitRef="Unit12" decimals="-5">1200000</fold:ResearchRevenue>
  <fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="Unit17" decimals="2">0.00</fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare>
  <fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="Unit17" decimals="2">0.00</fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare>
  <fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="Unit17" decimals="2">0.00</fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare>
  <fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionPercentageOfSharesVestedThatMayBeExercisedInWholeOrPart contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_fold_StockOptionPlan2002AndStockOptionPlan2007Member" unitRef="Unit13" decimals="2">1.00</fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionPercentageOfSharesVestedThatMayBeExercisedInWholeOrPart>
  <fold:ShareBasedCompensationNumberOfPlans contextRef="As_Of_12_31_2016" unitRef="Unit14" decimals="INF">3</fold:ShareBasedCompensationNumberOfPlans>
  <fold:StockAndWarrantsIssuedDuringPeriodValueNewIssues contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">8755000</fold:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
  <fold:StockAndWarrantsIssuedDuringPeriodValueNewIssues contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" unitRef="Unit12" decimals="-3">8755000</fold:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
  <fold:StockAndWarrantsIssuedDuringPeriodValueNewIssues contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">7321000</fold:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
  <fold:StockAndWarrantsIssuedDuringPeriodValueNewIssues contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" unitRef="Unit12" decimals="-3">7321000</fold:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
  <fold:StockIssuedDuringPeriodSharesAtMarketOffering contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">14328224</fold:StockIssuedDuringPeriodSharesAtMarketOffering>
  <fold:StockIssuedDuringPeriodSharesAtMarketOffering contextRef="Duration_7_1_2014_To_7_31_2014_us-gaap_CounterpartyNameAxis_fold_CowenAndCompanyLLCMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_fold_AtMarketEquityOfferingMember" unitRef="Unit1" decimals="-5">14300000</fold:StockIssuedDuringPeriodSharesAtMarketOffering>
  <fold:StockIssuedDuringPeriodSharesAtMarketOffering contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">14989027</fold:StockIssuedDuringPeriodSharesAtMarketOffering>
  <fold:StockIssuedDuringPeriodSharesAtMarketOffering contextRef="Duration_4_1_2016_To_7_31_2016_us-gaap_CounterpartyNameAxis_fold_CowenAndCompanyLLCMember_us-gaap_TypeOfArrangementAxis_fold_SalesAgreementMember" unitRef="Unit1" decimals="-5">15000000</fold:StockIssuedDuringPeriodSharesAtMarketOffering>
  <fold:StockIssuedDuringPeriodSharesContingentConsideration contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">858795</fold:StockIssuedDuringPeriodSharesContingentConsideration>
  <fold:StockIssuedDuringPeriodSharesWarrantsExercised contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">1600000</fold:StockIssuedDuringPeriodSharesWarrantsExercised>
  <fold:StockIssuedDuringPeriodValueAtMarketOffering contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">38636000</fold:StockIssuedDuringPeriodValueAtMarketOffering>
  <fold:StockIssuedDuringPeriodValueAtMarketOffering contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">38493000</fold:StockIssuedDuringPeriodValueAtMarketOffering>
  <fold:StockIssuedDuringPeriodValueAtMarketOffering contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3">143000</fold:StockIssuedDuringPeriodValueAtMarketOffering>
  <fold:StockIssuedDuringPeriodValueAtMarketOffering contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">97068000</fold:StockIssuedDuringPeriodValueAtMarketOffering>
  <fold:StockIssuedDuringPeriodValueAtMarketOffering contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">96918000</fold:StockIssuedDuringPeriodValueAtMarketOffering>
  <fold:StockIssuedDuringPeriodValueAtMarketOffering contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3">150000</fold:StockIssuedDuringPeriodValueAtMarketOffering>
  <fold:StockIssuedDuringPeriodValueAtMarketOffering contextRef="Duration_4_1_2016_To_7_31_2016_us-gaap_CounterpartyNameAxis_fold_CowenAndCompanyLLCMember_us-gaap_TypeOfArrangementAxis_fold_SalesAgreementMember" unitRef="Unit12" decimals="-5">97100000</fold:StockIssuedDuringPeriodValueAtMarketOffering>
  <fold:StockIssuedDuringPeriodValueContingentConsideration contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">6115000</fold:StockIssuedDuringPeriodValueContingentConsideration>
  <fold:StockIssuedDuringPeriodValueContingentConsideration contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">6106000</fold:StockIssuedDuringPeriodValueContingentConsideration>
  <fold:StockIssuedDuringPeriodValueContingentConsideration contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3">9000</fold:StockIssuedDuringPeriodValueContingentConsideration>
  <fold:StockIssuedDuringPeriodValueIssuedForContingentConsiderations contextRef="Duration_4_1_2016_To_6_30_2016_us-gaap_BusinessAcquisitionAxis_fold_CallidusBiopharmaIncMember" unitRef="Unit12" decimals="-5">6000000</fold:StockIssuedDuringPeriodValueIssuedForContingentConsiderations>
  <fold:StockIssuedDuringPeriodValueWarrantsExercised contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">4000000</fold:StockIssuedDuringPeriodValueWarrantsExercised>
  <fold:StockIssuedDuringPeriodValueWarrantsExercised contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">3984000</fold:StockIssuedDuringPeriodValueWarrantsExercised>
  <fold:StockIssuedDuringPeriodValueWarrantsExercised contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3">16000</fold:StockIssuedDuringPeriodValueWarrantsExercised>
  <fold:VestingRightsPercentageOnFirstYearAnniversary contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_fold_StockOptionPlan2002AndStockOptionPlan2007Member" unitRef="Unit13" decimals="2">0.25</fold:VestingRightsPercentageOnFirstYearAnniversary>
  <fold:WarrantsNotSettleableInCashIncrementalFairValueDisclosure contextRef="As_Of_2_29_2016_us-gaap_CounterpartyNameAxis_fold_RedmileGroupMember_us-gaap_DebtInstrumentAxis_fold_NoteAndWarrantAgreement2016Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_BeneficialOwnerMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_us-gaap_TypeOfArrangementAxis_fold_PrivatePlacementPurchaseAgreementMember" unitRef="Unit12" decimals="-5">3500000</fold:WarrantsNotSettleableInCashIncrementalFairValueDisclosure>
  <fold:WarrantTerm contextRef="Duration_10_1_2015_To_10_31_2015_us-gaap_CounterpartyNameAxis_fold_RedmileGroupMember_us-gaap_DebtInstrumentAxis_fold_NoteAndWarrantAgreement2015Member_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_us-gaap_TypeOfArrangementAxis_fold_PrivatePlacementPurchaseAgreementMember">P5Y</fold:WarrantTerm>
  <fold:WarrantTerm contextRef="Duration_2_1_2016_To_2_29_2016_us-gaap_CounterpartyNameAxis_fold_RedmileGroupMember_us-gaap_DebtInstrumentAxis_fold_NoteAndWarrantAgreement2016Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_BeneficialOwnerMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_us-gaap_TypeOfArrangementAxis_fold_PrivatePlacementPurchaseAgreementMember">P5Y</fold:WarrantTerm>
  <fold:WarrantTerm contextRef="Duration_6_1_2016_To_6_30_2016_us-gaap_CounterpartyNameAxis_fold_RedmileGroupMember_us-gaap_DebtInstrumentAxis_fold_AdditionalNoteAndWarrantAgreementJune2016Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_BeneficialOwnerMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_us-gaap_TypeOfArrangementAxis_fold_PrivatePlacementPurchaseAgreementMember">P5Y</fold:WarrantTerm>
  <fold:WritedownOfOperatingLossCarryforwardAndResearchAndDevelopmentCreditsSubjectToSection382Limitations contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember" unitRef="Unit12" decimals="-5">0</fold:WritedownOfOperatingLossCarryforwardAndResearchAndDevelopmentCreditsSubjectToSection382Limitations>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">32216000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">41008000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;8. Accounts Payable and Accrued Expenses&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Accounts payable and accrued expenses consist of the following (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Accounts payable&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;12,905&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;16,477&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Accrued professional fees&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5,079&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,578&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Accrued contract manufacturing&amp;nbsp;&amp;amp; contract research costs&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8,042&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,940&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Accrued compensation and benefits&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9,981&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6,201&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Accrued facility costs&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,740&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,321&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Foreign currency forward contract&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;265&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Capital lease, short term portion&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;283&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Accrued other&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,713&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,699&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;41,008&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;32,216&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
  <us-gaap:AccountsPayableCurrent contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">16477000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">12905000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">1304000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">3578000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">5079000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">13353000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">12495000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">-115000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">102000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">1945000</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">917454000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">1120156000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">88346000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">88346000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt contextRef="Duration_12_21_2016_To_12_21_2016_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="Unit12" decimals="-5">88300000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">-2044000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">-2044000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">-1282000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">-1282000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-5">4600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">6008000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit12" decimals="-3">2703000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="Unit12" decimals="-3">3305000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">9972000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit12" decimals="-3">4600000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="Unit12" decimals="-3">5372000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">17504000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit12" decimals="-3">8071000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="Unit12" decimals="-3">9433000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AmortizationOfDebtDiscountPremium contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">248000</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="-3">12576000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="Unit1" decimals="-3">10021000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit1" decimals="-3">955000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" unitRef="Unit1" decimals="-3">1600000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">13558000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="Unit1" decimals="-3">11729000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit1" decimals="-3">479000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" unitRef="Unit1" decimals="-3">1350000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit1" decimals="-3">60232000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="Unit1" decimals="-3">15528000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember" unitRef="Unit1" decimals="-3">40850000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit1" decimals="-3">744000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" unitRef="Unit1" decimals="-3">3110000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AreaOfRealEstateProperty contextRef="As_Of_12_31_2016_us-gaap_GeographicDistributionAxis_fold_BuckinghamshireUnitedKingdomMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fold_OfficeSpaceMember" unitRef="Unit18" decimals="0">9821</us-gaap:AreaOfRealEstateProperty>
  <us-gaap:AreaOfRealEstateProperty contextRef="As_Of_12_31_2016_us-gaap_GeographicDistributionAxis_fold_CranburyNewJerseyMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fold_OfficeAndLaboratorySpaceMember" unitRef="Unit18" decimals="0">90000</us-gaap:AreaOfRealEstateProperty>
  <us-gaap:AreaOfRealEstateProperty contextRef="As_Of_12_31_2016_us-gaap_GeographicDistributionAxis_fold_DurhamNorthCarolinaMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fold_OfficeSpaceMember" unitRef="Unit18" decimals="0">5603</us-gaap:AreaOfRealEstateProperty>
  <us-gaap:AreaOfRealEstateProperty contextRef="As_Of_12_31_2016_us-gaap_GeographicDistributionAxis_fold_MunichGermanyMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fold_OfficeSpaceMember" unitRef="Unit18" decimals="0">4316</us-gaap:AreaOfRealEstateProperty>
  <us-gaap:Assets contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">908384000</us-gaap:Assets>
  <us-gaap:Assets contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">1036845000</us-gaap:Assets>
  <us-gaap:AssetsCurrent contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">216601000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">340064000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsFairValueDisclosure contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">145206000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="As_Of_12_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_fold_MarketExchangedMutualFundsMember" unitRef="Unit12" decimals="-3">658000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="As_Of_12_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CertificatesOfDepositMember" unitRef="Unit12" decimals="-3">350000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="As_Of_12_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="Unit12" decimals="-3">25724000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="As_Of_12_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit12" decimals="-3">118474000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="As_Of_12_31_2015_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="Unit12" decimals="-3">145206000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="As_Of_12_31_2015_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_fold_MarketExchangedMutualFundsMember" unitRef="Unit12" decimals="-3">658000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="As_Of_12_31_2015_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CertificatesOfDepositMember" unitRef="Unit12" decimals="-3">350000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="As_Of_12_31_2015_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="Unit12" decimals="-3">25724000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="As_Of_12_31_2015_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit12" decimals="-3">118474000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">144754000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="As_Of_12_31_2016_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_fold_MarketExchangedMutualFundsMember" unitRef="Unit12" decimals="-3">1829000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="As_Of_12_31_2016_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="Unit12" decimals="-3">68390000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="As_Of_12_31_2016_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit12" decimals="-3">74535000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="As_Of_12_31_2016_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="Unit12" decimals="-3">144754000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="As_Of_12_31_2016_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_fold_MarketExchangedMutualFundsMember" unitRef="Unit12" decimals="-3">1829000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="As_Of_12_31_2016_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="Unit12" decimals="-3">68390000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="As_Of_12_31_2016_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit12" decimals="-3">74535000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AvailableForSaleSecurities contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">144548000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="As_Of_12_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CertificatesOfDepositMember" unitRef="Unit12" decimals="-3">350000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="As_Of_12_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="Unit12" decimals="-3">25724000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">143325000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="As_Of_12_31_2016_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CertificatesOfDepositMember" unitRef="Unit12" decimals="-3">50000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="As_Of_12_31_2016_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="Unit12" decimals="-3">68390000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="As_Of_12_31_2016_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_MoneyMarketFundsMember" unitRef="Unit12" decimals="-3">350000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">39000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="As_Of_12_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="Unit12" decimals="-3">38000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">134000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="As_Of_12_31_2016_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="Unit12" decimals="-3">132000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">154000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">31000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">144663000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="As_Of_12_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CertificatesOfDepositMember" unitRef="Unit12" decimals="-3">350000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="As_Of_12_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="Unit12" decimals="-3">25686000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">143222000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="As_Of_12_31_2016_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CertificatesOfDepositMember" unitRef="Unit12" decimals="-3">50000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="As_Of_12_31_2016_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="Unit12" decimals="-3">68258000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="As_Of_12_31_2016_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_MoneyMarketFundsMember" unitRef="Unit12" decimals="-3">350000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-5">118500000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue>
  <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-5">58700000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue>
  <us-gaap:AvailableForSaleSecuritiesCurrent contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">144548000</us-gaap:AvailableForSaleSecuritiesCurrent>
  <us-gaap:AvailableForSaleSecuritiesCurrent contextRef="As_Of_12_31_2015_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_fold_ShortTermCorporateDebtSecuritiesMember" unitRef="Unit12" decimals="-3">118474000</us-gaap:AvailableForSaleSecuritiesCurrent>
  <us-gaap:AvailableForSaleSecuritiesCurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">143325000</us-gaap:AvailableForSaleSecuritiesCurrent>
  <us-gaap:AvailableForSaleSecuritiesCurrent contextRef="As_Of_12_31_2016_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_fold_ShortTermCorporateDebtSecuritiesMember" unitRef="Unit12" decimals="-3">74535000</us-gaap:AvailableForSaleSecuritiesCurrent>
  <us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">0</us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet>
  <us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">0</us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Basis of Presentation&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("U.S.&amp;nbsp;GAAP") and include all adjustments necessary for the fair presentation of the Company's financial position for the periods presented.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued contextRef="Duration_9_30_2015_To_9_30_2015_dei_LegalEntityAxis_fold_SciodermIncMember_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" unitRef="Unit1" decimals="-5">5900000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
  <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued contextRef="Duration_7_5_2016_To_7_5_2016_dei_LegalEntityAxis_us-gaap_ParentCompanyMember_us-gaap_BusinessAcquisitionAxis_fold_MiamedIncMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">825603</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
  <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued contextRef="Duration_7_5_2016_To_7_5_2016_dei_LegalEntityAxis_us-gaap_ParentCompanyMember_us-gaap_BusinessAcquisitionAxis_fold_MiamedIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">825603</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
  <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="Duration_7_5_2016_To_7_5_2016_us-gaap_BusinessAcquisitionAxis_fold_MiamedIncMember" unitRef="Unit12" decimals="-5">6500000</us-gaap:BusinessCombinationConsiderationTransferred1>
  <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable contextRef="Duration_9_30_2015_To_9_30_2015_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember" unitRef="Unit12" decimals="-6">257000000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
  <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember_us-gaap_RangeAxis_us-gaap_MaximumMember" unitRef="Unit12" decimals="-6">257000000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
  <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">100000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
  <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">4377000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
  <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">6760000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
  <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_BusinessAcquisitionAxis_fold_CallidusBiopharmaIncMember_us-gaap_IncomeStatementLocationAxis_fold_ChangesInFairValueOfContingentConsiderationPayableMember" unitRef="Unit12" decimals="-5">-500000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
  <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember_us-gaap_IncomeStatementLocationAxis_fold_ChangesInFairValueOfContingentConsiderationPayableMember" unitRef="Unit12" decimals="-5">7300000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
  <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="As_Of_11_30_2013_us-gaap_BusinessAcquisitionAxis_fold_CallidusBiopharmaIncMember" unitRef="Unit12" decimals="-5">10600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
  <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="As_Of_9_30_2015_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember" unitRef="Unit12" decimals="-5">259000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
  <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">274077000</us-gaap:BusinessCombinationContingentConsiderationLiability>
  <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="As_Of_12_31_2015_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" unitRef="Unit12" decimals="-3">274077000</us-gaap:BusinessCombinationContingentConsiderationLiability>
  <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">269722000</us-gaap:BusinessCombinationContingentConsiderationLiability>
  <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="As_Of_12_31_2016_us-gaap_BusinessAcquisitionAxis_fold_CallidusBiopharmaIncMember" unitRef="Unit12" decimals="-5">9700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
  <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="As_Of_12_31_2016_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember" unitRef="Unit12" decimals="-5">260000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
  <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="As_Of_12_31_2016_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" unitRef="Unit12" decimals="-3">269722000</us-gaap:BusinessCombinationContingentConsiderationLiability>
  <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="As_Of_12_31_2016_us-gaap_BusinessAcquisitionAxis_fold_CallidusBiopharmaIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" unitRef="Unit12" decimals="-5">9300000</us-gaap:BusinessCombinationContingentConsiderationLiability>
  <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="As_Of_12_31_2016_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" unitRef="Unit12" decimals="-5">237200000</us-gaap:BusinessCombinationContingentConsiderationLiability>
  <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="As_Of_12_31_2016_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember" unitRef="Unit12" decimals="-5">22800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
  <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">41400000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
  <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">56101000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
  <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="As_Of_12_31_2016_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember" unitRef="Unit12" decimals="-5">56100000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
  <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">232677000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
  <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">213621000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
  <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;3. Acquisitions&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 46pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;Acquisition of MiaMed,&amp;nbsp;Inc.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In July 2016, the Company entered into an Agreement and Plan of Merger (the "MiaMed Agreement") with MiaMed,&amp;nbsp;Inc., ("MiaMed"). MiaMed is a pre-clinical biotechnology company focused on developing protein replacement therapy for CDKL5 and related diseases. Under the terms of the MiaMed Agreement, the former holders of MiaMed's capital stock received an aggregate of $6.5&amp;nbsp;million, comprised of (i)&amp;nbsp;approximately $1.8&amp;nbsp;million in cash (plus MiaMed's cash and cash equivalents at closing and less any of MiaMed's unpaid third-party fees and expenses related to the transaction), and (ii)&amp;nbsp;825,603 shares of the Company's Common Stock. In addition, the Company also agreed to pay up to an additional $83.0&amp;nbsp;million in connection with the achievement of certain clinical, regulatory and commercial milestones, for a potential aggregate deal value of $89.5&amp;nbsp;million. The Company evaluated the transaction based on the guidance of Accounting Standard Codification ("ASC") 805, &lt;/font&gt;&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Business Combinations&lt;/font&gt;&lt;font style="display:inline;font-family:Times;"&gt; and concluded that it only acquired inputs and did not acquire any processes. The Company will need to develop its own processes in order to produce an output. Therefore, the Company accounted for the transaction as an asset acquisition and accordingly $6.5&amp;nbsp;million was expensed to research and development.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 46pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;Acquisition of Scioderm,&amp;nbsp;Inc.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In September 2015, Amicus acquired Scioderm, a privately-held biopharmaceutical company focused on developing innovative therapies for treating the rare disease Epidermolysis Bullosa ("EB"). The acquisition leverages the Scioderm development team's EB expertise with Amicus' global clinical infrastructure to advance SD-101 toward regulatory approvals and Amicus' commercial, patient advocacy, and medical affairs infrastructure to support a successful global launch. The acquisition of Scioderm was accounted for as a purchase of a business in accordance with FASB ASC 805 Business Combinations.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company acquired Scioderm in a cash and stock transaction. At closing, the Company paid Scioderm shareholders, option holders, and warrant holders approximately $223.9&amp;nbsp;million, of which approximately $141.1&amp;nbsp;million was paid in cash and approximately $82.8&amp;nbsp;million was paid through the issuance of approximately 5.9&amp;nbsp;million newly issued Amicus shares. The Company has agreed to pay up to an additional $361&amp;nbsp;million to Scioderm shareholders, option holders and warrant holders upon achievement of certain clinical and regulatory milestones, and $257&amp;nbsp;million to Scioderm shareholders, option holders, and warrant holders upon achievement of certain sales milestones. If SD-101 is approved, EB qualifies as a rare pediatric disease under The Food and Drug Administration Safety and Innovation Act ("FDSIA") and Amicus will request a Priority Review Voucher ("PRV") under the FDSIA, if available. If the PRV is obtained and subsequently sold, the Company will pay Scioderm shareholders, option holders, and warrant holders the lesser of $100&amp;nbsp;million in the aggregate or 50% of the proceeds of such sale. If Amicus obtains the PRV and has not entered into an agreement to sell or otherwise transfer to a third party the PRV within one year of its receipt, the shareholders 'agent may appoint a financial advisor to conduct a process to sell the PRV. If Amicus determines in its sole discretion to use the PRV, Amicus shall give the shareholders' agent written notice thereof and shall pay to the Scioderm shareholders, option holders, and warrant holders $100&amp;nbsp;million. The inability to sell the PRV after complying with the provisions, shall not give rise to any payment.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The fair value of the contingent consideration payments on the acquisition date was $259.0&amp;nbsp;million. This was an estimate based on significant inputs that are not observable in the market, referred to as Level&amp;nbsp;3 inputs. Key assumptions included a range of discount rates between 0.4% and 1.1% as interpolated from the U.S. Treasury constant maturity yield curve over the time frame for clinical and regulatory milestones and a range of discount rates between 1.0% and 2.2% for revenue-based milestones. The range of outcomes and assumptions used to develop these estimates have been updated to better reflect the probability of certain milestone outcomes and updated timelines related to clinical development and anticipated approval assumptions as of December&amp;nbsp;31, 2016 without limitation, the $5&amp;nbsp;million milestone paid in the second quarter, and milestone payments projected for 2017 (See "&amp;#x2014;&amp;nbsp;Note&amp;nbsp;10. Assets and Liabilities Measured at Fair Value", for additional discussion regarding fair value measurements of the contingent acquisition consideration payable). In April 2016, while the total clinical and regulatory approval milestone payments remain unchanged at $361&amp;nbsp;million, the allocation between the clinical and regulatory approval milestone payments were revised as follows: clinical milestones of up to $81&amp;nbsp;million and regulatory approval milestones of up to $280&amp;nbsp;million. The commercial milestone payments of up to $257&amp;nbsp;million remained unchanged.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company determined the fair value of the contingent consideration to be $260.0&amp;nbsp;million at December&amp;nbsp;31, 2016, of which $56.1&amp;nbsp;million is payable in the next twelve months, resulting in an increase in the contingent consideration payable and related expense of approximately $7.3&amp;nbsp;million for the year ended December&amp;nbsp;31, 2016. The expense is recorded in the Consolidated Statement of Operations as the change within fair value of contingent consideration payable.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;For additional information, see "&amp;#x2014;&amp;nbsp;Note&amp;nbsp;4. Goodwill and Intangible Assets."&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The purchase price allocation was subject to completion of the analysis of the fair value of the assets and liabilities as of the effective date of the acquisition. The final valuation was completed as of December&amp;nbsp;31, 2015. A substantial portion of the assets acquired consisted of intangible assets related to SD-101. The Company determined that the estimated acquisition-date fair value of the indefinite lived IPR&amp;amp;D related to the SD-101 was $463.7&amp;nbsp;million.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 46pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;Acquisition of Callidus Biopharma,&amp;nbsp;Inc.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In November 2013, the Company acquired Callidus a privately-held biologics company focused on developing best-in-class ERTs for LSDs with its lead ERT ATB200 for Pompe disease in late preclinical development. The acquisition of the Callidus assets and technology complements Amicus' CHART&amp;#x2122; platform for the development of next generation ERTs.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The fair value of the contingent acquisition consideration payments on the acquisition date was $10.6&amp;nbsp;million and was estimated by applying a probability-based income approach utilizing an appropriate discount rate. Key assumptions included a discount rate of 13.5% and various probability factors. This estimation was based on significant inputs that are not observable in the market, referred to as Level&amp;nbsp;3 inputs. Some of the more significant assumptions used in the valuation include (i)&amp;nbsp;the probability and timing related to the achievement of certain developmental milestones and (ii)&amp;nbsp;and the discount rate. As of December&amp;nbsp;31, 2016, the range of outcomes and assumptions used to develop these estimates has changed to better reflect the probability of certain milestone outcomes. See "&amp;#x2014;&amp;nbsp;Note&amp;nbsp;10. Assets and Liabilities Measured at Fair Value", for additional discussion regarding fair value measurements of the contingent acquisition consideration payable. The Company determined the fair value of the contingent consideration to be $9.7&amp;nbsp;million at December&amp;nbsp;31, 2016, all of which is payable beyond the next twelve months, resulting in an decrease in the contingent consideration payable and related gain of $0.5&amp;nbsp;million year ended December&amp;nbsp;31, 2016. The expense is recorded in the Consolidated Statement of Operations within the changes in fair value of contingent consideration line item.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;During the second quarter of 2016, the Company reached the first clinical milestone, which was the dosing of the first patient in a Phase&amp;nbsp;1 or 2 study. The milestone for this event was $6.0&amp;nbsp;million which was paid in Company stock during the second quarter of 2016, resulting in $6.1&amp;nbsp;million impact on stockholder's equity.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;For further information, see "&amp;#x2014;&amp;nbsp;Note&amp;nbsp;4. Goodwill and Intangible Assets."&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="As_Of_12_31_2015_us-gaap_BusinessAcquisitionAxis_fold_BusinessAcquisitionsMember" unitRef="Unit12" decimals="-5">486700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="As_Of_12_31_2015_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="Unit12" decimals="-5">463700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="As_Of_12_31_2016_us-gaap_BusinessAcquisitionAxis_fold_BusinessAcquisitionsMember" unitRef="Unit12" decimals="-5">486700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
  <us-gaap:BusinessCombinationsPolicy contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Business Combinations&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company allocates the purchase price of acquired businesses to the tangible and intangible assets acquired and liabilities assumed based upon their estimated fair values on the acquisition date. The purchase price allocation process requires management to make significant estimates and assumptions, especially at the acquisition date with respect to intangible assets and in-process research and development ("IPR&amp;amp;D"). In connection with the purchase price allocations for acquisitions, the Company estimates the fair value of contingent payments utilizing a probability-based income approach inclusive of an estimated discount rate&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
  <us-gaap:CapitalLeaseObligations contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="0">0</us-gaap:CapitalLeaseObligations>
  <us-gaap:CapitalLeaseObligations contextRef="As_Of_12_31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember" unitRef="Unit12" decimals="-5">900000</us-gaap:CapitalLeaseObligations>
  <us-gaap:CapitalLeaseObligationsCurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">283000</us-gaap:CapitalLeaseObligationsCurrent>
  <us-gaap:CapitalLeaseObligationsIncurred contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">944000</us-gaap:CapitalLeaseObligationsIncurred>
  <us-gaap:CapitalLeasesFutureMinimumPaymentsDue contextRef="As_Of_12_31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember" unitRef="Unit12" decimals="-3">844000</us-gaap:CapitalLeasesFutureMinimumPaymentsDue>
  <us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent contextRef="As_Of_12_31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember" unitRef="Unit12" decimals="-3">355000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent>
  <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInThreeYears contextRef="As_Of_12_31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember" unitRef="Unit12" decimals="-3">134000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInThreeYears>
  <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInTwoYears contextRef="As_Of_12_31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember" unitRef="Unit12" decimals="-3">355000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-5">200000</us-gaap:CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_12_31_2013" unitRef="Unit12" decimals="-3">43640000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">24074000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">69485000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">187026000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">69485000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">187026000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">-19566000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">45411000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">117541000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">214148000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
  <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">330248000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
  <us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;5. Cash, Money Market Funds and Marketable Securities&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;As of December&amp;nbsp;31, 2016, the Company held $187.0&amp;nbsp;million in cash and cash equivalents and $143.3&amp;nbsp;million of available-for-sale securities which are reported at fair value on the Company's Consolidated Balance Sheets. Unrealized holding gains and losses are reported within accumulated other comprehensive income/ (loss) in the statements of comprehensive loss. If a decline in the fair value of a marketable security below the Company's cost basis is determined to be other than temporary, such marketable security is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge. To date, only temporary impairment adjustments have been recorded.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company regularly invests excess operating cash in deposits with major financial institutions, money market funds, notes issued by the U.S. government, as well as fixed income investments and U.S. bond funds both of which can be readily purchased and sold using established markets. The Company believes that the market risk arising from its holdings of these financial instruments is mitigated as many of these securities are either government backed or of the highest credit rating. Investments that have original maturities or greater than 3&amp;nbsp;months but less than 1&amp;nbsp;year are classified as short-term and investments with maturities that are greater than 1&amp;nbsp;year are classified as long-term.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company transacts business in various foreign countries and therefore, is subject to risk of foreign currency exchange rate fluctuations. As such, in June 2016 the Company entered into a forward contract to economically hedge transactional exposure associated with commitments arising from trade accounts payable denominated in a currency other than the functional currency of the respective operating entity. The Company does not designate these forward contracts as hedging instruments under applicable accounting guidance and, therefore, changes in fair value are recorded within other income (expense) in the Consolidated Statements of Operations, with the corresponding liability in current liabilities on the Consolidated Balance Sheet. For the year ended December&amp;nbsp;31, 2016, the Company recognized a loss of $0.3&amp;nbsp;million, related to the derivative instruments not designated as hedging instruments in other expense in the Consolidated Statements of Operations and the corresponding liability of $0.3&amp;nbsp;million is recorded as other current liability in the Consolidated Balance Sheets.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Cash and available for sale securities consisted of the following as of December&amp;nbsp;31, 2016 and December&amp;nbsp;31, 2015 (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;As of December&amp;nbsp;31, 2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Cost&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Unrealized&lt;br /&gt;Gain&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Unrealized&lt;br /&gt;Loss&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Fair&lt;br /&gt;Value&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Cash balances&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;187,026
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;187,026
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Corporate debt securities, current portion&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;74,564
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(31
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;74,535
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Commercial paper&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;68,258
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;132
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;68,390
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Money market&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;350
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;350
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Certificate of deposit&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;50
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;50
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;330,248
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;134
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(31
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;330,351
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Included in cash and cash equivalents&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;187,026
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;187,026
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Included in marketable securities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;143,222
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;134
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(31
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;143,325
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Total cash and marketable securities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;330,248
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;134
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(31
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;330,351
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;As of December&amp;nbsp;31, 2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Cost&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Unrealized&lt;br /&gt;Gain&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Unrealized&lt;br /&gt;Loss&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Fair&lt;br /&gt;Value&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Cash balances&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;69,485
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;69,485
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Corporate debt securities, current portion&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;118,627
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(154
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;118,474
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Commercial paper&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;25,686
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;38
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;25,724
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Certificate of deposit&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;350
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;350
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;214,148
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;39
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(154
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;214,033
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Included in cash and cash equivalents&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;69,485
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;69,485
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Included in marketable securities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;144,663
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;39
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(154
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;144,548
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Total cash and marketable securities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;214,148
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;39
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(154
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;214,033
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;For the years ended December&amp;nbsp;31, 2016 and 2015, there were no realized gains or losses. The cost of securities sold is based on the specific identification method.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Unrealized loss positions in the available for sale securities as of December&amp;nbsp;31, 2016 and December&amp;nbsp;31, 2015 reflect temporary impairments that have been in a loss position for less than twelve months and as such are recognized in other comprehensive gain/ (loss). The fair value of these available for sale securities in unrealized loss positions was $58.7&amp;nbsp;million and $118.5&amp;nbsp;million as of December&amp;nbsp;31, 2016 and 2015, respectively.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company holds available-for-sale investment securities which are reported at fair value on the Company's balance sheet. Unrealized holding gains and losses are reported within accumulated other comprehensive income ("AOCI") in the statements of comprehensive loss.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="As_Of_10_31_2015_us-gaap_CounterpartyNameAxis_fold_RedmileGroupMember_us-gaap_DebtInstrumentAxis_fold_NoteAndWarrantAgreement2015Member_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_us-gaap_TypeOfArrangementAxis_fold_PrivatePlacementPurchaseAgreementMember" unitRef="Unit1" decimals="-5">1300000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="As_Of_2_29_2016_us-gaap_CounterpartyNameAxis_fold_RedmileGroupMember_us-gaap_DebtInstrumentAxis_fold_NoteAndWarrantAgreement2016Member_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_fold_PrivatePlacementPurchaseAgreementMember" unitRef="Unit1" decimals="INF">1850000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="As_Of_2_29_2016_us-gaap_CounterpartyNameAxis_fold_RedmileGroupMember_us-gaap_DebtInstrumentAxis_fold_NoteAndWarrantAgreement2016Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_BeneficialOwnerMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_us-gaap_TypeOfArrangementAxis_fold_PrivatePlacementPurchaseAgreementMember" unitRef="Unit1" decimals="-5">1800000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="As_Of_6_30_2016_us-gaap_CounterpartyNameAxis_fold_RedmileGroupMember_us-gaap_DebtInstrumentAxis_fold_AdditionalNoteAndWarrantAgreementJune2016Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_BeneficialOwnerMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_us-gaap_TypeOfArrangementAxis_fold_PrivatePlacementPurchaseAgreementMember" unitRef="Unit1" decimals="-5">1300000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="As_Of_6_30_2016_us-gaap_CounterpartyNameAxis_fold_RedmileGroupMember_us-gaap_DebtInstrumentAxis_fold_AdditionalNoteAndWarrantAgreementJune2016Member_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_BeneficialOwnerMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_us-gaap_TypeOfArrangementAxis_fold_PrivatePlacementPurchaseAgreementMember" unitRef="Unit1" decimals="INF">1260000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;15. Collaborative Agreements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;GSK&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In November 2013, Amicus entered into the Revised Agreement with GSK, pursuant to which Amicus has obtained global rights to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease. The Revised Agreement amends and replaces in its entirety the earlier agreement entered into between Amicus and GSK in July 2012. Under the terms of the Revised Agreement, there was no upfront payment from Amicus to GSK. For migalastat monotherapy, GSK is eligible to receive post-approval and sales-based milestones up to $40&amp;nbsp;million, as well as tiered royalties in the mid-teens in eight major markets outside the U.S. In the second half of 2016, the Company recognized approximately $0.5&amp;nbsp;million under the revised agreement with GSK.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Under the terms of the Revised Agreement, GSK will no longer jointly fund development costs for all formulations of migalastat.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In evaluating the impact of both the Expanded Collaboration Agreement and the Revised Agreement, the Company applied the accounting guidance regarding the impact of potential future payments it may make in its role as a vendor (i.e.,&amp;nbsp;Amicus) to its customer (i.e.,&amp;nbsp;GSK) and evaluated if these potential future payments could be a reduction of revenue from GSK. If the potential future payments to GSK are as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:15;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:15;"&gt;
				&lt;td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:AngsanaUPC;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:AngsanaUPC;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:AngsanaUPC;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:15;"&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2022;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;a payment for an identifiable benefit, and &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:15;"&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2022;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;the identifiable benefit is separable from the existing relationship between the Company and GSK, and &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:15;"&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2022;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;the identifiable benefit can be obtained from a party other than GSK, and &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:15;"&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2022;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;the Company can reasonably estimate the fair value of the identifiable benefit,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;then the potential future payments would be treated separately from the collaboration and research revenue. However, if all these criteria are not satisfied, then the potential future payments are treated as a reduction of revenue.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Accordingly, the Company did not believe that, for accounting purposes, the new U.S. licensing rights to migalastat obtained from GSK under the Expanded Collaboration Agreement, nor the ex U.S. licensing rights to migalastat obtained from GSK under the Revised Agreement, represented a separate, identifiable benefit from the licenses in the Original Collaboration Agreement entered into between Amicus and GSK in 2010. The contingent amounts payable to GSK were not sufficiently separable from GSK's original license and the research and development reimbursements such that Amicus could not have entered into a similar exchange transaction with another party. Additionally, the Company cannot reasonably estimate the fair value of the worldwide licensing rights to migalastat.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company determined that the potential future payments to GSK would be treated as a reduction of revenue and that the total amount of revenue to be received under the arrangement is no longer fixed or determinable as the contingent milestone payments are subject to significant uncertainty.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;As a result, the Company no longer recognized any of the upfront license fees and premiums on the equity purchase from GSK until such time as the arrangement consideration becomes fixed or determinable, because an indeterminable amount may ultimately be payable back to GSK. These amounts (the balance of the unrecognized upfront license fee and the premium on the equity purchases) are classified as deferred reimbursements on the balance sheet.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The recognition of Research Revenue was also affected by the determination that the overall total arrangement consideration was no longer fixed and determinable, despite the fact that the research activities continued and that the research expense reimbursements by GSK to Amicus were received as the research activities related to the reimbursement had been completed. Therefore the research reimbursements from GSK were recorded as deferred reimbursements on the balance sheet and would not recognized until the total arrangement consideration becomes fixed and determinable.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;As a result, all revenue recognition was suspended until the total arrangement consideration would become fixed and determinable. In addition, future milestone payments made by the Company will be applied against the balance of this deferred reimbursements account. Revenue recognition for research expense reimbursements, the original upfront license fee, and the equity premiums will resume once the total arrangement consideration becomes fixed and determinable which will occur when the balance of the deferred reimbursements account is sufficient to cover all the remaining contingent milestone payments.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Biogen&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In September 2013, the Company entered into a license and collaboration agreement (the "Biogen Agreement") with Biogen to discover, develop and commercialize novel small molecules for the treatment of Parkinson's disease. Under terms of the multi-year agreement, the Company and Biogen will collaborate in the discovery of a new class of small molecules that target the GCase enzyme, for further development and commercialization by Biogen. Biogen was responsible for funding all discovery, development, and commercialization activities. In addition the Company was reimbursed for all full-time employees working on the project as part of a cost sharing arrangement. The Company was also eligible to receive development and regulatory milestones, as well as modest royalties in global net sales.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;As of December&amp;nbsp;31, 2014, the Company recognized $1.2&amp;nbsp;million in Research Revenue for work performed under the cost sharing arrangement of the Biogen Agreement.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In September 2014, the Company and Biogen concluded their research collaboration. The Company's most advanced Parkinson's candidate is AT3375, which was developed outside the collaboration and is wholly-owned by the Company.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <us-gaap:CommitmentsAndContingencies xsi:nil="true" contextRef="As_Of_12_31_2015" unitRef="Unit12" />
  <us-gaap:CommitmentsAndContingencies xsi:nil="true" contextRef="As_Of_12_31_2016" unitRef="Unit12" />
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;Note&amp;nbsp;18. Commitments and Contingencies&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Since October&amp;nbsp;1, 2015, three purported securities class action lawsuits have been commenced in the United States District Court for New Jersey, naming as defendants the Company, its Chairman and Chief Executive Officer, and in one of the actions, its Chief Medical Officer. The lawsuits allege violations of the Securities Exchange Act of 1934 in connection with allegedly false and misleading statements made by the Company related to the regulatory approval path for migalastat. The plaintiffs seek, among other things, damages for purchasers of the Company's Common Stock during different periods, all of which fall between March&amp;nbsp;19, 2015 and October&amp;nbsp;1, 2015. It is possible that additional suits will be filed, or allegations received from stockholders, with respect to similar matters and also naming the Company and/or its officers and directors as defendants. On May&amp;nbsp;26, 2016, the Court consolidated these lawsuits into a single action and appointed a lead plaintiff. The lead plaintiff filed a Consolidated Amended Class Action Complaint on July&amp;nbsp;11, 2016. On August&amp;nbsp;25, 2016, the defendants filed a motion to dismiss in response to the Consolidated Amended Class Action Complaint. This motion to dismiss was fully briefed on October&amp;nbsp;28, 2016. Lead plaintiff and defendants have reached an agreement in principal to fully and finally settle all claims asserted in the Consolidated Amended Class Action Complaint. The settlement is immaterial to the Company's consolidated financial statements and is subject to, among other things, documentation and court approval. The settlement amount is expected to be fully covered under insurance.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;On or about November&amp;nbsp;2, 2015, a derivative lawsuit was filed by an Amicus shareholder purportedly on Amicus' behalf in the Superior Court of New Jersey, Middlesex County, Chancery Division, against the individuals who serve on the Amicus Board of Directors. Amicus itself was named as a nominal defendant. The derivative lawsuit alleged claims for breach of state law fiduciary duties, waste of corporate assets, and unjust enrichment based on allegedly false and misleading statements made by Amicus related to the regulatory approval path for migalastat HCl. On February&amp;nbsp;19, 2016, the complaint was dismissed by the Court and plaintiffs have not refiled.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;On or about March&amp;nbsp;3, 2016, a derivative lawsuit was filed by an Amicus shareholder purportedly on Amicus' behalf in the Superior Court of New Jersey, Middlesex County, Chancery Division, against various officers and directors of the Company. Amicus itself is named as a nominal defendant. The derivative lawsuit alleges similar facts and circumstances as the three purported securities class action lawsuits described above and further alleges claims for breach of state law fiduciary duties, waste of corporate assets, unjust enrichment, abuse of control, and gross mismanagement based on allegedly false and misleading statements made by Amicus related to the regulatory approval path for migalastat HCl. The plaintiff seeks, among other things, to require the Amicus Board to take certain actions to reform its corporate governance procedures, including greater shareholder input and a provision to permit shareholders to nominate candidates for election to the Board, along with restitution, costs of suit and attorney's fees. On February&amp;nbsp;7, 2017, the complaint was dismissed by the Court without prejudice.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;These lawsuits and any other related lawsuits are subject to inherent uncertainties and the actual cost will depend upon many unknown factors. The outcome of the litigation is necessarily uncertain and we could be forced to expend significant resources in the defense of these suits, and we may not prevail.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="As_Of_7_31_2014_us-gaap_CounterpartyNameAxis_fold_CowenAndCompanyLLCMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_fold_AtMarketEquityOfferingMember" unitRef="Unit17" decimals="INF">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="As_Of_11_30_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit17" decimals="INF">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="As_Of_12_31_2015" unitRef="Unit17" decimals="INF">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="As_Of_6_30_2016_us-gaap_CounterpartyNameAxis_fold_RedmileGroupMember_us-gaap_DebtInstrumentAxis_fold_AdditionalNoteAndWarrantAgreementJune2016Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_BeneficialOwnerMember_us-gaap_TypeOfArrangementAxis_fold_PrivatePlacementPurchaseAgreementMember" unitRef="Unit17" decimals="INF">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="As_Of_12_31_2016" unitRef="Unit17" decimals="INF">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="INF">250000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="INF">250000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="INF">125027034</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="INF">142691986</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding contextRef="As_Of_12_31_2013_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">61975416</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="As_Of_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">95556277</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="INF">125027034</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="As_Of_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">125027034</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="INF">142691986</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="As_Of_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">142691986</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockValue contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">1306000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">1480000</us-gaap:CommonStockValue>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">-69059000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">-132101000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">-197880000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ConcentrationRiskCreditRisk contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Concentration of Credit Risk&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company's financial instruments that are exposed to concentration of credit risk consist primarily of cash and cash equivalents and marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on cash and cash equivalents or its marketable securities.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;font-family:Times;"&gt;The Company is subject to credit risk from its accounts receivable related to its product sales of Galafold. The majority of the Company's accounts receivable at December&amp;nbsp;31, 2016 have arisen from product sales in Germany. The Company will periodically assess the financial strength of its customers to establish allowances for anticipated losses, if any. For accounts receivable that have arisen from named patient sales, the payment terms are predetermined and the Company evaluates the creditworthiness of each customer on a regular basis. To date, the Company has not incurred any credit losses.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <us-gaap:ConsolidationPolicyTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Consolidation&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The consolidated financial statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions are eliminated in consolidation.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
  <us-gaap:ContingentLiabilityReserveEstimatePolicy contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Contingent Liabilities&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;On an ongoing basis, the Company may be involved in various claims, and legal proceedings. On a quarterly basis, the Company reviews the status of each significant matter and assesses its potential financial exposure. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated, the Company will accrue a liability for the estimated loss. Because of uncertainties related to claims and litigation, accruals will be based on our best estimates based on available information. On a periodic basis, as additional information becomes available, or based on specific events such as the outcome of litigation or settlement of claims, the Company may reassess the potential liability related to these matters and may revise these estimates, which could result in a material adverse adjustments to the Company's operating results.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ContingentLiabilityReserveEstimatePolicy>
  <us-gaap:ConvertibleDebtFairValueDisclosures contextRef="As_Of_12_31_2016_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="Unit12" decimals="-5">258800000</us-gaap:ConvertibleDebtFairValueDisclosures>
  <us-gaap:ConvertibleDebtTableTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Convertible Notes consist of the following as of December&amp;nbsp;31, 2016:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Liability component &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(In thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Principal&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;250,000
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Less: debt discount&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;font-family:Times;font-size:6pt;top:-4pt;position:relative;line-height:100%"&gt;(1)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(90,807
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Less: deferred financing&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;font-family:Times;font-size:6pt;top:-4pt;position:relative;line-height:100%"&gt;(1)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(4,729
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Net carrying value of the debt&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;154,464
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;div&gt;&lt;hr style="border-width:0;width:26%;height:1.5pt;color:black;background-color:black;" align="left"&gt;&lt;/hr&gt;&lt;/div&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:15;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:15;"&gt;
				&lt;td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:15;"&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;(1)&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Included in the Consolidated Balance Sheets within Convertible Senior Notes (due 2023) and amortized to interest expense over the remaining life of the Convertible Senior Notes using the effective interest rate method.&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ConvertibleDebtTableTextBlock>
  <us-gaap:ConvertibleLongTermNotesPayable contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">154464000</us-gaap:ConvertibleLongTermNotesPayable>
  <us-gaap:CostOfGoodsSold contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">833000</us-gaap:CostOfGoodsSold>
  <us-gaap:DebtInstrumentCarryingAmount contextRef="As_Of_12_31_2016_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="Unit12" decimals="-3">250000000</us-gaap:DebtInstrumentCarryingAmount>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="As_Of_12_21_2016_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="Unit17" decimals="2">6.12</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:DebtInstrumentConvertibleConversionRatio1 contextRef="Duration_12_21_2016_To_12_21_2016_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="Unit13" decimals="INF">0.1633987</us-gaap:DebtInstrumentConvertibleConversionRatio1>
  <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays contextRef="Duration_12_21_2016_To_12_21_2016_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_StatementScenarioAxis_fold_ConvertibleNotesConditionOneMember">P30D</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays>
  <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays contextRef="Duration_12_21_2016_To_12_21_2016_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_StatementScenarioAxis_fold_ConvertibleNotesConditionTwoMember">P5D</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays>
  <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger contextRef="Duration_12_21_2016_To_12_21_2016_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_StatementScenarioAxis_fold_ConvertibleNotesConditionOneMember" unitRef="Unit13" decimals="2">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
  <us-gaap:DebtInstrumentFaceAmount contextRef="As_Of_10_31_2015_us-gaap_CounterpartyNameAxis_fold_RedmileGroupMember_us-gaap_DebtInstrumentAxis_fold_NoteAndWarrantAgreement2015Member_us-gaap_TypeOfArrangementAxis_fold_PrivatePlacementPurchaseAgreementMember" unitRef="Unit12" decimals="-5">50000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFaceAmount contextRef="As_Of_2_29_2016_us-gaap_CounterpartyNameAxis_fold_RedmileGroupMember_us-gaap_DebtInstrumentAxis_fold_NoteAndWarrantAgreement2016Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_BeneficialOwnerMember_us-gaap_TypeOfArrangementAxis_fold_PrivatePlacementPurchaseAgreementMember" unitRef="Unit12" decimals="-5">50000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFaceAmount contextRef="As_Of_2_29_2016_us-gaap_CounterpartyNameAxis_fold_RedmileGroupMember_us-gaap_DebtInstrumentAxis_fold_NoteAndWarrantAgreement2016Member_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_BeneficialOwnerMember" unitRef="Unit12" decimals="-5">75000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFaceAmount contextRef="As_Of_6_30_2016_us-gaap_CounterpartyNameAxis_fold_RedmileGroupMember_us-gaap_DebtInstrumentAxis_fold_AdditionalNoteAndWarrantAgreementJune2016Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_BeneficialOwnerMember_us-gaap_TypeOfArrangementAxis_fold_PrivatePlacementPurchaseAgreementMember" unitRef="Unit12" decimals="-6">30000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFaceAmount contextRef="As_Of_12_21_2016_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="Unit12" decimals="-6">250000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFaceAmount contextRef="As_Of_12_21_2016_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_us-gaap_TypeOfArrangementAxis_fold_PrivatePlacementPurchaseAgreementMember" unitRef="Unit12" decimals="-6">25000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="As_Of_12_31_2016" unitRef="Unit13" decimals="4">0.1085</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="As_Of_10_31_2015_us-gaap_CounterpartyNameAxis_fold_RedmileGroupMember_us-gaap_DebtInstrumentAxis_fold_NoteAndWarrantAgreement2015Member" unitRef="Unit13" decimals="3">0.041</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="As_Of_2_29_2016_us-gaap_CounterpartyNameAxis_fold_RedmileGroupMember_us-gaap_DebtInstrumentAxis_fold_NoteAndWarrantAgreement2016Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_BeneficialOwnerMember_us-gaap_TypeOfArrangementAxis_fold_PrivatePlacementPurchaseAgreementMember" unitRef="Unit13" decimals="INF">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="As_Of_6_30_2016_us-gaap_CounterpartyNameAxis_fold_RedmileGroupMember_us-gaap_DebtInstrumentAxis_fold_AdditionalNoteAndWarrantAgreementJune2016Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_BeneficialOwnerMember_us-gaap_TypeOfArrangementAxis_fold_PrivatePlacementPurchaseAgreementMember" unitRef="Unit13" decimals="INF">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="As_Of_12_21_2016_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="Unit13" decimals="INF">0.03</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentInterestRateStatedPercentageRateRangeMaximum contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember" unitRef="Unit13" decimals="3">0.057</us-gaap:DebtInstrumentInterestRateStatedPercentageRateRangeMaximum>
  <us-gaap:DebtInstrumentInterestRateStatedPercentageRateRangeMinimum contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember" unitRef="Unit13" decimals="3">0.002</us-gaap:DebtInstrumentInterestRateStatedPercentageRateRangeMinimum>
  <us-gaap:DebtInstrumentPeriodicPaymentPrincipal contextRef="Duration_10_1_2015_To_10_31_2015_us-gaap_CounterpartyNameAxis_fold_RedmileGroupMember_us-gaap_DebtInstrumentAxis_fold_NoteAndWarrantAgreement2015Member_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodOneMember" unitRef="Unit12" decimals="-5">15000000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
  <us-gaap:DebtInstrumentPeriodicPaymentPrincipal contextRef="Duration_10_1_2015_To_10_31_2015_us-gaap_CounterpartyNameAxis_fold_RedmileGroupMember_us-gaap_DebtInstrumentAxis_fold_NoteAndWarrantAgreement2015Member_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" unitRef="Unit12" decimals="-5">35000000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
  <us-gaap:DebtInstrumentPeriodicPaymentPrincipal contextRef="Duration_2_1_2016_To_2_29_2016_us-gaap_CounterpartyNameAxis_fold_RedmileGroupMember_us-gaap_DebtInstrumentAxis_fold_NoteAndWarrantAgreement2016Member_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodOneMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_BeneficialOwnerMember_us-gaap_TypeOfArrangementAxis_fold_PrivatePlacementPurchaseAgreementMember" unitRef="Unit12" decimals="-5">15000000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
  <us-gaap:DebtInstrumentPeriodicPaymentPrincipal contextRef="Duration_2_1_2016_To_2_29_2016_us-gaap_CounterpartyNameAxis_fold_RedmileGroupMember_us-gaap_DebtInstrumentAxis_fold_NoteAndWarrantAgreement2016Member_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_BeneficialOwnerMember_us-gaap_TypeOfArrangementAxis_fold_PrivatePlacementPurchaseAgreementMember" unitRef="Unit12" decimals="-5">35000000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
  <us-gaap:DebtInstrumentTerm contextRef="Duration_12_21_2016_To_12_21_2016_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">P7Y</us-gaap:DebtInstrumentTerm>
  <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="As_Of_12_31_2016_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="Unit12" decimals="-3">90807000</us-gaap:DebtInstrumentUnamortizedDiscount>
  <us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-5">700000</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
  <us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-5">1500000</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
  <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">667000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
  <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent contextRef="As_Of_12_31_2015_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="Unit12" decimals="-3">667000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
  <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">1479000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
  <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent contextRef="As_Of_12_31_2016_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="Unit12" decimals="-3">1479000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
  <us-gaap:DeferredCreditsAndOtherLiabilitiesCurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">13850000</us-gaap:DeferredCreditsAndOtherLiabilitiesCurrent>
  <us-gaap:DeferredCreditsAndOtherLiabilitiesNoncurrent contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">35756000</us-gaap:DeferredCreditsAndOtherLiabilitiesNoncurrent>
  <us-gaap:DeferredCreditsAndOtherLiabilitiesNoncurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">21906000</us-gaap:DeferredCreditsAndOtherLiabilitiesNoncurrent>
  <us-gaap:DeferredFinanceCostsNet contextRef="As_Of_12_21_2016_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="Unit12" decimals="-5">7500000</us-gaap:DeferredFinanceCostsNet>
  <us-gaap:DeferredFinanceCostsNet contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">2709000</us-gaap:DeferredFinanceCostsNet>
  <us-gaap:DeferredIncomeTaxLiabilities contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">176219000</us-gaap:DeferredIncomeTaxLiabilities>
  <us-gaap:DeferredIncomeTaxLiabilities contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">173771000</us-gaap:DeferredIncomeTaxLiabilities>
  <us-gaap:DeferredOfferingCosts contextRef="As_Of_12_31_2016_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="Unit12" decimals="-3">4729000</us-gaap:DeferredOfferingCosts>
  <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">14281000</us-gaap:DeferredTaxAssetsDeferredIncome>
  <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">14281000</us-gaap:DeferredTaxAssetsDeferredIncome>
  <us-gaap:DeferredTaxAssetsGross contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">213728000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsGross contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">413537000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">159889000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">253661000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsOther contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">2964000</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:DeferredTaxAssetsOther contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">3358000</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">2657000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
  <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">1781000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">27170000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">32851000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">213728000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">286863000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxLiabilities contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">176219000</us-gaap:DeferredTaxLiabilities>
  <us-gaap:DeferredTaxLiabilities contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">173771000</us-gaap:DeferredTaxLiabilities>
  <us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">176219000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
  <us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">173771000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
  <us-gaap:DefinedContributionPlanCostRecognized contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-5">600000</us-gaap:DefinedContributionPlanCostRecognized>
  <us-gaap:DefinedContributionPlanCostRecognized contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-5">900000</us-gaap:DefinedContributionPlanCostRecognized>
  <us-gaap:DefinedContributionPlanCostRecognized contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-5">1200000</us-gaap:DefinedContributionPlanCostRecognized>
  <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit13" decimals="2">0.05</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
  <us-gaap:Depreciation contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">1547000</us-gaap:Depreciation>
  <us-gaap:Depreciation contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">1833000</us-gaap:Depreciation>
  <us-gaap:Depreciation contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">3242000</us-gaap:Depreciation>
  <us-gaap:DerivativeCapPrice contextRef="As_Of_12_15_2016_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="Unit19" decimals="2">7.20</us-gaap:DerivativeCapPrice>
  <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">265000</us-gaap:DerivativeFairValueOfDerivativeLiability>
  <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="As_Of_12_31_2016_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="Unit12" decimals="-3">265000</us-gaap:DerivativeFairValueOfDerivativeLiability>
  <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="Duration_1_1_2016_To_9_30_2016_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="Unit12" decimals="-5">-300000</us-gaap:DerivativeGainLossOnDerivativeNet>
  <us-gaap:DerivativeLiabilitiesCurrent contextRef="As_Of_9_30_2016_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" unitRef="Unit12" decimals="-5">300000</us-gaap:DerivativeLiabilitiesCurrent>
  <us-gaap:DerivativeLiabilitiesCurrent contextRef="As_Of_12_31_2016_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" unitRef="Unit12" decimals="-3">265000</us-gaap:DerivativeLiabilitiesCurrent>
  <us-gaap:DueToRelatedPartiesNoncurrent contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">41601000</us-gaap:DueToRelatedPartiesNoncurrent>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit17" decimals="2">-0.93</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit17" decimals="2">-0.25</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit17" decimals="2">-1.20</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_4_1_2015_To_6_30_2015" unitRef="Unit17" decimals="2">-0.27</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_7_1_2015_To_9_30_2015" unitRef="Unit17" decimals="2">-0.32</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_10_1_2015_To_12_31_2015" unitRef="Unit17" decimals="2">-0.34</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_1_1_2016_To_3_31_2016" unitRef="Unit17" decimals="2">-0.35</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit17" decimals="2">-1.49</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_4_1_2016_To_6_30_2016" unitRef="Unit17" decimals="2">-0.40</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_7_1_2016_To_9_30_2016" unitRef="Unit17" decimals="2">-0.33</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_10_1_2016_To_12_31_2016" unitRef="Unit17" decimals="2">-0.41</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Loss per Common Share&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company calculates net loss per share as a measurement of the Company's performance while giving effect to all dilutive potential common shares that were outstanding during the reporting period. The Company had a net loss for all periods presented; accordingly, the inclusion of common stock options, unvested RSUs and warrants would be anti-dilutive. Therefore, the weighted average shares used to calculate both basic and diluted earnings per share are the same. See "&amp;#x2014;&amp;nbsp;Note&amp;nbsp;18. Earnings per Share" for further discussion on net loss per share.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:EarningsPerShareTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;17. Earnings per Share&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss attributable to common stockholders per common share (in thousands except share amounts):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Years Ended December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;text-decoration:underline;"&gt;Historical &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Numerator:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Net loss attributable to common stockholders&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(200,042
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(132,118
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(68,926
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Denominator:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Weighted average common shares outstanding&amp;#x2014;basic and diluted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;134,401,588
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;109,923,815
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;74,444,157
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Dilutive common stock equivalents would include the dilutive effect of common stock options, convertible debt units, RSUs and warrants for common stock equivalents. Potentially dilutive common stock equivalents were excluded from the diluted earnings per share denominator for all periods because of their anti-dilutive effect. For the year ended 2016 there was 40.9&amp;nbsp;million potential common shares outstanding as a result of the convertible debt that was excluded from the diluted net loss per share calculation because their effect would have been anti-dilutive.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The table below presents potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Year ended December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Options to purchase common stock&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;15,528&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;11,729&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;10,021&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Convertible debt&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;40,850&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Outstanding warrants, convertible to common stock&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,110&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,350&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,600&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Unvested restricted stock units&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;744&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;479&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;955&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Total number of potentially issuable shares&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;60,232&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;13,558&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;12,576&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit13" decimals="2">0.02</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit13" decimals="2">0.00</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit13" decimals="2">0.02</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit13" decimals="INF">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit13" decimals="INF">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit13" decimals="INF">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit13" decimals="2">-0.38</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit13" decimals="2">-0.37</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit13" decimals="2">-0.36</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit13" decimals="2">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
  <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit13" decimals="2">-0.02</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
  <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit13" decimals="2">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
  <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit13" decimals="2">-0.02</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
  <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit13" decimals="2">-0.03</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
  <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit13" decimals="2">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
  <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit13" decimals="2">-0.02</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
  <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit13" decimals="2">0.01</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit13" decimals="2">0.04</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit13" decimals="2">0.05</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit13" decimals="2">0.05</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit13" decimals="2">0.04</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit13" decimals="2">0.03</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit13" decimals="2">0.03</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">-131000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">6201000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">9981000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="Unit12" decimals="-5">3700000</us-gaap:EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions>
  <us-gaap:EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="Unit12" decimals="-5">11200000</us-gaap:EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions>
  <us-gaap:EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="Unit12" decimals="-5">3000000</us-gaap:EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember">P2Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember">P2Y7M13D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="As_Of_12_31_2016_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="Unit12" decimals="-5">33700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="As_Of_12_31_2016_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="Unit12" decimals="-5">4200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:ExtinguishmentOfDebtGainLossNetOfTax contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">-952000</us-gaap:ExtinguishmentOfDebtGainLossNetOfTax>
  <us-gaap:ExtinguishmentOfDebtGainLossNetOfTax contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">-13302000</us-gaap:ExtinguishmentOfDebtGainLossNetOfTax>
  <us-gaap:ExtinguishmentOfDebtGainLossNetOfTax contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_CounterpartyNameAxis_fold_RedmileGroupMember_us-gaap_DebtInstrumentAxis_fold_NotePurchaseAgreementDecember2016Member" unitRef="Unit12" decimals="-5">-13300000</us-gaap:ExtinguishmentOfDebtGainLossNetOfTax>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">265000</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December&amp;nbsp;31, 2016 are identified in the following table (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Level&amp;nbsp;2&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Commercial paper&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;68,390&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;68,390&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Corporate debt securities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;74,535&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;74,535&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Money market funds&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,829&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,829&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;144,754&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;144,754&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Level&amp;nbsp;2&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Level&amp;nbsp;3&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Liabilities:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Contingent consideration payable&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;269,722&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;269,722&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Derivative liability&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;265&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;265&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Deferred compensation plan liability&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,479&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,479&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,744&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;269,722&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;271,466&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;A summary of the fair value of the Company's assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December&amp;nbsp;31, 2015 are identified in the following table (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Level&amp;nbsp;2&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Commercial paper&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;25,724&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;25,724&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Corporate debt securities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;118,474&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;118,474&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Certificate of deposit&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;350&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;350&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Market exchanged mutual funds&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;658&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;658&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;145,206&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;145,206&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Level&amp;nbsp;2&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Level&amp;nbsp;3&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Liabilities:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Contingent consideration payable&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;274,077&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;274,077&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Deferred compensation plan liability&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;667&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;667&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;667&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;274,077&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;274,744&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_BusinessAcquisitionAxis_fold_CallidusBiopharmaIncMember">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Contingent Consideration Liability &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Fair value as of&lt;br /&gt;December&amp;nbsp;31,&lt;br /&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Valuation Technique&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Unobservable Input&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Range&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Discount rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;12.5%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Clinical and regulatory milestones&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$9.3&amp;nbsp;million&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Probability weighted discounted cash flow&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Probability of achievement of milestones&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;30.4%-42.8%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Projected year of payments&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;2018-2022&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Contingent Consideration Liability &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Fair value as of&lt;br /&gt;December&amp;nbsp;31,&lt;br /&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Valuation Technique&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Unobservable Input&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Range&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Discount rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;0.62%&amp;nbsp;-&amp;nbsp;3.8%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Clinical and regulatory milestones&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$237.2&amp;nbsp;million&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Probability weighted discounted cash flow&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Probability of achievement of milestones&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;66.5%&amp;nbsp;-&amp;nbsp;100.0%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Projected year of payments&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;2017-2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Revenue volatility&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;58%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Probability of achievement of milestones&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;66.5%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Revenue-based milestones&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$22.8&amp;nbsp;million&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Monte Carlo&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Discount rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;1.47%&amp;nbsp;-&amp;nbsp;2.55%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Projected year of payments&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;2019-2029&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
  <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-5">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
  <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-5">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
  <us-gaap:FairValueDisclosuresTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;10. Assets and Liabilities Measured at Fair Value&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company's financial assets and liabilities are measured at fair value and classified within the fair value hierarchy which is defined as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 72pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Level&amp;nbsp;1 &amp;#x2014;&lt;/font&gt;&lt;font style="display:inline;font-family:Times;"&gt; Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 72pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Level&amp;nbsp;2 &amp;#x2014;&lt;/font&gt;&lt;font style="display:inline;font-family:Times;"&gt; Inputs other than quoted prices in active markets that are observable for the asset or liability, either directly or indirectly.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 72pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Level&amp;nbsp;3 &amp;#x2014;&lt;/font&gt;&lt;font style="display:inline;font-family:Times;"&gt; Inputs that are unobservable for the asset or liability.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December&amp;nbsp;31, 2016 are identified in the following table (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Level&amp;nbsp;2&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Commercial paper&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;68,390&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;68,390&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Corporate debt securities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;74,535&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;74,535&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Money market funds&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,829&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,829&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;144,754&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;144,754&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Level&amp;nbsp;2&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Level&amp;nbsp;3&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Liabilities:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Contingent consideration payable&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;269,722&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;269,722&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Derivative liability&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;265&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;265&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Deferred compensation plan liability&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,479&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,479&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,744&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;269,722&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;271,466&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;A summary of the fair value of the Company's assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December&amp;nbsp;31, 2015 are identified in the following table (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Level&amp;nbsp;2&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Commercial paper&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;25,724&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;25,724&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Corporate debt securities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;118,474&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;118,474&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Certificate of deposit&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;350&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;350&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Market exchanged mutual funds&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;658&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;658&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;145,206&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;145,206&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Level&amp;nbsp;2&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Level&amp;nbsp;3&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Liabilities:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Contingent consideration payable&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;274,077&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;274,077&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Deferred compensation plan liability&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;667&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;667&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;667&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;274,077&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;274,744&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;See "&amp;#x2014; Note&amp;nbsp;16. Debt Instruments and Related Party Transactions" for the carrying amount and estimated fair value of the Company's Convertible Notes due in 2023. The Company did not have any Level&amp;nbsp;3 assets as of December&amp;nbsp;31, 2016 or 2015.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Cash, Money Market Funds and Marketable Securities&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company classifies its cash and money market funds within the fair value hierarchy as Level&amp;nbsp;1 as these assets are valued using quoted prices in active market for identical assets at the measurement date. The Company considers its investments in marketable securities as available for sale and classifies these assets within the fair value hierarchy as Level&amp;nbsp;2 primarily utilizing broker quotes in a non-active market for valuation of these securities. No changes in valuation techniques or inputs occurred during the year ended December&amp;nbsp;31, 2016. No transfers of assets between Level&amp;nbsp;1 and Level&amp;nbsp;2 of the fair value measurement hierarchy occurred during the year ended December&amp;nbsp;31, 2016.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Contingent Consideration Payable&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The contingent consideration payable resulted from the acquisitions of Scioderm and Callidus, as discussed in "&amp;#x2014; Note&amp;nbsp;3. Acquisitions." The most recent valuation was determined using a probability weighted discounted cash flow valuation approach. Using this approach, expected future cash flows are calculated over the expected life of the agreement, are discounted, and then exercise scenario probabilities are applied. The valuation is performed quarterly. Gains and losses are included in the statement of operations.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;As discussed in "&amp;#x2014; Note&amp;nbsp;3. Acquisitions," on July&amp;nbsp;5, 2016, the Company entered into the MiaMed Agreement with MiaMed. MiaMed is a pre-clinical biotechnology company focused on developing protein replacement for CDKL5 and related diseases. Under the terms of the MiaMed Agreement, the Company agreed to pay up to an additional $83.0&amp;nbsp;million in connection with the achievement of certain clinical, regulatory and commercial milestones, for a potential aggregate deal value of $89.5&amp;nbsp;million. The MiaMed Agreement was accounted for as an asset acquisition and as such the Company determined that a liability for future milestone payments is not required to be recorded until the actual contingencies are met and will be recorded to research and development expenses when the contingency is resolved.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The contingent consideration payable for Scioderm and Callidus has been classified as a Level&amp;nbsp;3 recurring liability as its valuation requires substantial judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for the various inputs to the valuation approach the estimated fair value could be significantly higher or lower than the fair value the Company determined. The Company may be required to record losses in future periods, including expenses related to CDKL5.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The following significant unobservable inputs were used in the valuation of the contingent consideration payable to former Scioderm stockholders:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Contingent Consideration Liability &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Fair value as of&lt;br /&gt;December&amp;nbsp;31,&lt;br /&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Valuation Technique&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Unobservable Input&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Range&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Discount rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;0.62%&amp;nbsp;-&amp;nbsp;3.8%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Clinical and regulatory milestones&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$237.2&amp;nbsp;million&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Probability weighted discounted cash flow&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Probability of achievement of milestones&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;66.5%&amp;nbsp;-&amp;nbsp;100.0%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Projected year of payments&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;2017-2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Revenue volatility&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;58%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Probability of achievement of milestones&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;66.5%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Revenue-based milestones&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$22.8&amp;nbsp;million&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Monte Carlo&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Discount rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;1.47%&amp;nbsp;-&amp;nbsp;2.55%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Projected year of payments&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;2019-2029&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The following significant unobservable inputs were used in the valuation of the contingent consideration payable of Callidus for the ATB-200 Pompe program:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Contingent Consideration Liability &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Fair value as of&lt;br /&gt;December&amp;nbsp;31,&lt;br /&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Valuation Technique&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Unobservable Input&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Range&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Discount rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;12.5%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Clinical and regulatory milestones&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$9.3&amp;nbsp;million&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Probability weighted discounted cash flow&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Probability of achievement of milestones&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;30.4%-42.8%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Projected year of payments&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;2018-2022&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Contingent consideration liabilities are remeasured to fair value each reporting period using projected revenues, discount rates, probabilities of payment and projected payment dates. Projected contingent payment amounts related to clinical and regulatory based milestones are discounted back to the current period using a discounted cash flow model. Revenue-based payments are valued using a monte-carlo valuation model, which simulates future revenues during the earn out-period using management's best estimates. Projected revenues are based on our most recent internal operational budgets and long-range strategic plans. Increases in projected revenues and probabilities of payment may result in higher fair value measurements. Increases in discount rates and the time to payment may result in lower fair value measurements. Increases or decreases in any of those inputs together, or in isolation, may result in a significantly lower or higher fair value measurement. There is no assurance that any of the conditions for the milestone payments will be met.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The following table shows the change in the balance of contingent consideration payable for the year ended December&amp;nbsp;31, 2016 and 2015, respectively (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Year ended December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Balance, beginning of the period&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;274,077
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;10,700
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Additions, from business acquisitions&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;259,000
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Payment of contingent consideration in cash&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(5,000
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Payment of contingent consideration in stock&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(6,115
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Unrealized change in fair value change during the period, included in Statement of Operations&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6,760
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,377
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Balance, end of the period&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;269,722
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;274,077
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Deferred Compensation Plan- Investment and Liability&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;As disclosed in "&amp;#x2014; Note&amp;nbsp;9. Stockholders' Equity," the Deferral Plan provides certain key employees and members of the Board of Directors with an opportunity to defer the receipt of such participant's base salary, bonus and director's fees, as applicable. Deferral Plan assets are classified as trading securities and recorded at fair value with changes in the investments' fair value recognized in the period they occur. The asset investments consist of market exchanged mutual funds. The Company considers its investments in marketable securities, as available-for-sale and classifies these assets and related liability within the fair value hierarchy as Level&amp;nbsp;2 primarily utilizing broker quotes in a non-active market for valuation of these securities.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Foreign Currency Exchange Rate Exposure&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company transacts business in various foreign countries and therefore, is subject to risk of foreign currency exchange rate fluctuations. As such, in June 2016, the Company entered into a forward contract to economically hedge transactional exposure associated with commitments arising from trade accounts payable denominated in a currency other than the functional currency of the respective operating entity. The Company did not designate this forward contract as a hedging instrument under applicable accounting guidance and, therefore, the change in fair value is recorded in the Consolidated Statements of Operations. The forward contract settles in monthly installments with the final installment settlement in June 2017.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;There were no outstanding forward contracts at December&amp;nbsp;31, 2015.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;For the year ended December&amp;nbsp;31, 2016, the Company recognized a loss of $265&amp;nbsp;thousand, related to the derivative instruments not designated as hedging instruments in the Consolidated Statements of Operations and the corresponding liability of $265&amp;nbsp;thousand is recorded as other current liability in the Consolidated Balance Sheets.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The impact of gains and losses on foreign exchange contracts not designated as hedging instruments related to changes in the fair value of assets and liabilities denominated in foreign currencies are generally offset by net foreign exchange gains and losses, which are also included on the Consolidated Statements of Operations in other income (expense), net for all periods presented. When the Company enters into foreign exchange contracts not designated as hedging instruments to mitigate the impact of exchange rate volatility in the translation of foreign earnings, gains and losses will generally be offset by fluctuations in the U.S. Dollar translated amounts of each account within the Consolidated Statements of Operations in current and/or future periods.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:FairValueInputsDiscountRate contextRef="Duration_11_1_2013_To_11_30_2013_us-gaap_BusinessAcquisitionAxis_fold_CallidusBiopharmaIncMember" unitRef="Unit13" decimals="3">0.135</us-gaap:FairValueInputsDiscountRate>
  <us-gaap:FairValueInputsDiscountRate contextRef="Duration_9_30_2015_To_9_30_2015_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_us-gaap_RangeAxis_us-gaap_MaximumMember" unitRef="Unit13" decimals="3">0.011</us-gaap:FairValueInputsDiscountRate>
  <us-gaap:FairValueInputsDiscountRate contextRef="Duration_9_30_2015_To_9_30_2015_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_us-gaap_RangeAxis_us-gaap_MinimumMember" unitRef="Unit13" decimals="3">0.004</us-gaap:FairValueInputsDiscountRate>
  <us-gaap:FairValueInputsDiscountRate contextRef="Duration_9_30_2015_To_9_30_2015_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember_us-gaap_RangeAxis_us-gaap_MaximumMember" unitRef="Unit13" decimals="3">0.022</us-gaap:FairValueInputsDiscountRate>
  <us-gaap:FairValueInputsDiscountRate contextRef="Duration_9_30_2015_To_9_30_2015_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember_us-gaap_RangeAxis_us-gaap_MinimumMember" unitRef="Unit13" decimals="3">0.010</us-gaap:FairValueInputsDiscountRate>
  <us-gaap:FairValueInputsDiscountRate contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_BusinessAcquisitionAxis_fold_CallidusBiopharmaIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_ValuationTechniqueAxis_fold_ProbabilityWeightedDiscountedCashFlowMember" unitRef="Unit13" decimals="4">0.1250</us-gaap:FairValueInputsDiscountRate>
  <us-gaap:FairValueInputsDiscountRate contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_ValuationTechniqueAxis_fold_ProbabilityWeightedDiscountedCashFlowMember" unitRef="Unit13" decimals="3">0.038</us-gaap:FairValueInputsDiscountRate>
  <us-gaap:FairValueInputsDiscountRate contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_ValuationTechniqueAxis_fold_ProbabilityWeightedDiscountedCashFlowMember" unitRef="Unit13" decimals="4">0.0062</us-gaap:FairValueInputsDiscountRate>
  <us-gaap:FairValueInputsDiscountRate contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_ValuationTechniqueAxis_fold_MonteCarloMember" unitRef="Unit13" decimals="4">0.0255</us-gaap:FairValueInputsDiscountRate>
  <us-gaap:FairValueInputsDiscountRate contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_ValuationTechniqueAxis_fold_MonteCarloMember" unitRef="Unit13" decimals="4">0.0147</us-gaap:FairValueInputsDiscountRate>
  <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Fair Value Measurements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company records certain asset and liability balances under the fair value measurements as defined by the FASB guidance. Current FASB fair value guidance emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, current FASB guidance establishes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels&amp;nbsp;1 and 2 of the hierarchy) and the reporting entity's own assumptions that market participants assumptions would use in pricing assets or liabilities (unobservable inputs classified within Level&amp;nbsp;3 of the hierarchy).&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Level&amp;nbsp;1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at measurement date. Level&amp;nbsp;2 inputs are inputs other than quoted prices included in Level&amp;nbsp;1 that are observable for the asset or liability, either directly or indirectly. Level&amp;nbsp;2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals. Level&amp;nbsp;3 inputs are unobservable inputs for the asset or liability, which is typically based on an entity's own assumptions, as there is little, if any, related market activity. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">-100000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">-4377000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">-6760000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">6115000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">10700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">274077000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">269722000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">-265000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
  <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">265000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">-3660000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Foreign Currency Transactions&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The functional currency for most of the Company's foreign subsidiaries is their local currency. For non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of the Company's foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of equity.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company transacts business in various foreign countries and therefore, is subject to risk of foreign currency exchange rate fluctuations. As such, in June 2016, the Company entered into a forward contract to economically hedge transactional exposure associated with commitments arising from trade accounts payable denominated in a currency other than the functional currency of the respective operating entity. The Company does not designate this forward contract as a hedging instrument under applicable accounting guidance and, therefore, changes in fair value are recorded as other expense the Consolidated Statements of Operations.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
  <us-gaap:GainLossOnDispositionOfAssets1 contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">-17000</us-gaap:GainLossOnDispositionOfAssets1>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">-952000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">-13302000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:Goodwill contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">197797000</us-gaap:Goodwill>
  <us-gaap:Goodwill contextRef="As_Of_12_31_2015_us-gaap_BusinessAcquisitionAxis_fold_BusinessAcquisitionsMember" unitRef="Unit12" decimals="-5">197800000</us-gaap:Goodwill>
  <us-gaap:Goodwill contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">197797000</us-gaap:Goodwill>
  <us-gaap:Goodwill contextRef="As_Of_12_31_2016_us-gaap_BusinessAcquisitionAxis_fold_BusinessAcquisitionsMember" unitRef="Unit12" decimals="-5">197800000</us-gaap:Goodwill>
  <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;4. Goodwill and Intangible Assets&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In connection with the acquisitions discussed in "&amp;#x2014;&amp;nbsp;Note&amp;nbsp;3. Acquisitions, the Company has recognized goodwill of $197.8&amp;nbsp;million. The following table represents the changes in goodwill for the year ended December&amp;nbsp;31, 2016:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(in millions)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Balance at December&amp;nbsp;31, 2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;197.8&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Change in goodwill&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Balance at December&amp;nbsp;31, 2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;197.8&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In connection with the acquisitions discussed in "&amp;#x2014;&amp;nbsp;Note&amp;nbsp;3. Acquisitions," the Company recognized IPR&amp;amp;D of $486.7&amp;nbsp;million. Intangible assets related to IPR&amp;amp;D assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. During the period the assets are considered indefinite-lived, they will not be amortized but will be tested for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&amp;amp;D assets below their respective carrying amounts. The following table represents the changes in IPR&amp;amp;D for the year ended December&amp;nbsp;31, 2016:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(in millions)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Balance at December&amp;nbsp;31, 2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;486.7&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Change in IPR&amp;amp;D&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Balance at December&amp;nbsp;31, 2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;486.7&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Goodwill and intangible assets are assessed annually for impairment on October&amp;nbsp;1 and whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. If it is determined that the full carrying amount of an asset is not recoverable, an impairment loss is recorded in the amount by which the carrying amount of the asset exceeds its fair value. During the 2016 annual impairment assessment, it was determined that the goodwill and intangible assets had not been impaired therefore there were no changes to the balances of goodwill and IPR&amp;amp;D in 2016.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
  <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Intangible Assets and Goodwill&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company records goodwill in a business combination when the total consideration exceeds the fair value of the net tangible and identifiable intangible assets acquired. Purchased IPR&amp;amp;D is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset, or abandoned, at which point the intangible asset will be written off or partially impaired. Goodwill and indefinite lived intangible assets are assessed annually for impairment and whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. If it is determined that the full carrying amount of an asset is not recoverable, an impairment loss is recorded in the amount by which the carrying amount of the asset exceeds its fair value.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
  <us-gaap:GoodwillImpairmentLoss contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_BusinessAcquisitionAxis_fold_BusinessAcquisitionsMember" unitRef="Unit12" decimals="-5">0</us-gaap:GoodwillImpairmentLoss>
  <us-gaap:GrossProfit contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">1224000</us-gaap:GrossProfit>
  <us-gaap:GrossProfit contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">4125000</us-gaap:GrossProfit>
  <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_BusinessAcquisitionAxis_fold_BusinessAcquisitionsMember" unitRef="Unit12" decimals="-5">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">-70030000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">-123697000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">-174913000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">-70039000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">-132118000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">-203781000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">-9000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">-8421000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">-28868000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;13. Income Taxes&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;For financial reporting purposes, income (loss) before income taxes includes the following components (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Years Ended December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;United States&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(174,913
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(123,697
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(70,030
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Foreign&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(28,868
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(8,421
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(9
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(203,781
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(132,118
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(70,039
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;A reconciliation of the statutory tax rates and the effective tax rates for the years ended December&amp;nbsp;31, 2016, 2015 and 2014 are as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Years Ended&lt;br /&gt;December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Statutory rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(34
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(34
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(34
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;State taxes, net of federal benefit&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(5
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(5
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(4
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Permanent adjustments&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;R&amp;amp;D credit&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(3
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(3
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(4
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Foreign income tax rate differential&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Other&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Valuation allowance&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;36
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;37
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;38
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Net&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company recognized a tax benefit of $1.1&amp;nbsp;million in connection with the sale of net operating losses and research and development credits in the New Jersey Transfer Program for the year ended December&amp;nbsp;31, 2014. There were no sales of net operating losses and research and development credits for the years ended December&amp;nbsp;31, 2016 and 2015.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company recorded an income tax benefit of $3.7&amp;nbsp;million in the Consolidated Statement of Operations for the year ended December&amp;nbsp;31, 2016. The benefit was primarily from $2.7&amp;nbsp;million in income tax benefit in connection with the reduction in state tax rates in North Carolina, and $1.2&amp;nbsp;million from reduction in its valuation allowance to reflect the income tax associated with the gain on foreign currency translation recorded in the Consolidated Statement of Comprehensive Loss for the year ended December&amp;nbsp;31, 2016.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company did not recognize interest or penalties related to income tax during the period ended December&amp;nbsp;31, 2016 and did not accrue for interest or penalties as of December&amp;nbsp;31, 2016. The Company does not have an accrual for uncertain tax positions as of December&amp;nbsp;31, 2016. Tax returns for all years 2009 and thereafter are subject to future examination by tax authorities.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Deferred income taxes reflect the net effect of temporary difference between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The significant components of the deferred tax assets and liabilities are as follows (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;For Years Ended&lt;br /&gt;December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Non-current deferred tax assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Intellectual property&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;95,956
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Amortization/depreciation&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,781
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,657
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Research tax credit&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;32,851
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;27,170
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Net operating loss carry forwards&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;253,661
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;159,889
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Deferred revenue&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;14,281
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;14,281
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Non-cash stock issue&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;11,649
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6,767
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Others&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,358
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,964
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Gross deferred tax assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;413,537
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;213,728
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Deferred tax liability related to business acquisition&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(173,771
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(176,219
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Deferred tax liability related to royalty payable&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(96,829
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Deferred tax liability related to convertible notes&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(29,845
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Total net deferred tax asset&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;113,092
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;37,509
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Less valuation allowance&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(286,863
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(213,728
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Net deferred tax assets (liability)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(173,771
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(176,219
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company records a valuation allowance for temporary differences for which it is more likely than not that the Company will not receive future tax benefits. At December&amp;nbsp;31, 2016 and 2015, the Company recorded valuation allowances of $286.9 million and $213.7&amp;nbsp;million, respectively, representing an increase in the valuation allowance of $73.2&amp;nbsp;million in 2016 and an increase of $65.3&amp;nbsp;million in 2015, due to the uncertainty regarding the realization of such deferred tax assets, to offset the benefits of net operating losses generated during those years. The deferred tax liability related to business acquisitions pertains to the basis difference in IPR&amp;amp;D acquired by the Company. The Company's policy is to record a deferred tax liability related to acquired IPR&amp;amp;D that may eventually be realized either upon amortization of the asset when the research is completed and a product is successfully launched or the write-off of the asset if it is abandoned or unsuccessful.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;As of December&amp;nbsp;31, 2016, the Company had federal, state, and foreign net operating loss carry forwards ("NOLs") of approximately $637&amp;nbsp;million, $623&amp;nbsp;million, and $40&amp;nbsp;million respectively. The federal carry forward will expire in 2029 through 2036. Most of the state carry forwards generated prior to 2009 have expired through 2015. The remaining state carry forwards including those generated in 2009 through 2016 will expire in 2029 through 2036. The foreign NOLs have indefinite expiration. Utilization of NOLs may be subject to a substantial limitation pursuant to Section&amp;nbsp;382 of the Code as well as similar state statutes in the event of an ownership change. Such ownership changes have occurred in the past, and could occur again in the future As a result of these ownership changes, Section&amp;nbsp;382 places an annual limitation on the amount of NOLs that can be utilized to offset future taxable income each year, which is based on the value of the company at the change date. This limitation could result in expiration of those carry forwards before utilization. In general, an ownership change, as defined by Section&amp;nbsp;382, results from transactions that increase the ownership of certain stockholders or public groups in the stock of a corporation by more than 50&amp;nbsp;percentage points over a three year period. The Company completed a detailed study of its cumulative ownership changes for 2016 and determined that in 2016, there was no ownership change in excess of 50%; therefore there was no write-down to net realizable value of the federal NOLs and research and development credits subject to the 382 limitations. A tax benefit of $4.6&amp;nbsp;million associated with the exercise of stock options will be recorded in additional paid-in capital when the associated net operating loss is recognized.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">-1113000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">-3739000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Income Taxes&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company accounts for income taxes under the liability method. Under this method deferred income tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax basis of assets and liabilities and for operating losses and tax credit carry forwards, using enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance is recorded if it is "more likely than not" that a portion or all of a deferred tax asset will not be realized.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-5">-1200000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-5">-2700000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">6169000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">15467000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">7131000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">1419000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInInventories contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">3651000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">-26000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">666000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">1357000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">-2293000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">-308000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">394000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;14. Licenses&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company acquired rights to develop and commercialize its product candidates through licenses granted by various parties. The following summarizes the Company's material rights and obligations under those licenses:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;GSK&amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;For discussion of the royalties and milestone payments potentially due to GSK, see "&amp;#x2014;&amp;nbsp;Note&amp;nbsp;15. Collaborative Agreements."&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Mt. Sinai School of Medicine of New York University ("MSSM")&amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;The company acquired exclusive worldwide patent rights to develop and commercialize migalastat and other pharmacological chaperones for the prevention or treatment of human diseases or clinical conditions by increasing the activity of wild-type and mutant enzymes pursuant to a license agreement with Mt. Sinai School of Medicine ("MSSM") of New York University. Under this agreement, to date, the Company has paid no upfront or annual license fees and there are no milestone or future payments other than royalties on net sales. This agreement expires upon expiration of the last of the licensed patent rights, which will be in 2019, subject to any patent term extension that may be granted, or 2024 if the Company develops a product for combination therapy (pharmacological chaperone plus/ERT) and a patent issues from the pending application covering the combination therapy, subject to any patent term extension that may be granted.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Under its license agreements, if the Company owes royalties on net sales for one of its products to more than one of the above licensors, then the Company has the right to reduce the royalties owed to one licensor for royalties paid to another. The amount of royalties to be offset is generally limited in each license and can vary under each agreement. For migalastat, in 2016, the Company incurred $0.1&amp;nbsp;million of royalty expense under the agreement with MSSM.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company's rights with respect to these agreements to develop and commercialize migalastat may terminate, in whole or in part, if the Company fails to meet certain development or commercialization requirements or if the Company does not meet its obligations to make royalty payments.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">486700000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">486700000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:InterestExpense contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">1484000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">1578000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">5398000</us-gaap:InterestExpense>
  <us-gaap:InterestExpenseDebt contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">482000</us-gaap:InterestExpenseDebt>
  <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">208000</us-gaap:InterestExpenseDebtExcludingAmortization>
  <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The following table sets forth total interest expense recognized related to the Convertible Notes for the year ended December&amp;nbsp;31, 2016:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Components &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(In thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Contractual interest expense&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;208&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Amortization of deferred financing&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;26&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Amortization of debt discount&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;248&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;482&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Effective interest rate of the liability component&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;10.85&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
  <us-gaap:InterestPaid contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">1186000</us-gaap:InterestPaid>
  <us-gaap:InterestPaid contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">605000</us-gaap:InterestPaid>
  <us-gaap:InterestPaid contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">2990000</us-gaap:InterestPaid>
  <us-gaap:InventoryDisclosureTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;6. Inventories&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Inventories consist of work in process and finished goods related to the manufacture of Galafold. The following table summarizes the components of inventories at December&amp;nbsp;31, 2016 (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31,&amp;nbsp;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Work-in-process&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,308&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Finished goods&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;108&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;Total inventories&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,416&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;There were no inventories on-hand as of December&amp;nbsp;31, 2015. Inventory manufactured prior to commercialization was expensed to research and development. Inventories are reviewed periodically to identify slow-moving or obsolete inventory based on projected sales activity, as well as product shelf-life. In evaluating the recoverability of inventories produced, the Company considers the probability that revenue will be obtained from the future sale of the related inventory. Inventory becomes obsolete when it has aged past its shelf-life, cannot be recertified and is no longer usable or able to be sold, or the inventory has been damaged. In such instances, a full reserve is taken against such inventory. Expired inventory is disposed of and the related costs are recognized as cost of product sales in the consolidated statement of operations. There have been no write-downs of inventory from the time inventory was first capitalized.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
  <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">108000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <us-gaap:InventoryNet contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">0</us-gaap:InventoryNet>
  <us-gaap:InventoryNet contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">3416000</us-gaap:InventoryNet>
  <us-gaap:InventoryPolicyTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Inventories and Cost of Cost of Goods Sold&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Until regulatory approval of Galafold, the Company expensed all manufacturing costs of Galafold as research and development expense. Upon regulatory approval, the Company began capitalizing costs related to the purchase and manufacture of Galafold.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Inventories are stated at the lower of cost or market determined by the first-in, first-out method. Inventories are reviewed periodically to identify slow-moving or obsolete inventory based on projected sales activity as well as product shelf-life. In evaluating the recoverability of inventories produced, the probability that revenue will be obtained from the future sale of the related inventory is considered and inventory value is written down for inventory quantities in excess of expected requirements. Expired inventory is disposed of and the related costs are recognized as cost of product sales in the consolidated statements of operations.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Cost of goods sold includes the cost of inventory sold, manufacturing and supply chain costs, product shipping and handling costs, provisions for excess and obsolete inventory, as well as royalties payable. A portion of the inventory available for sale was expensed as research and development costs prior to regulatory approval and as such the cost of goods sold and related gross margins are not necessarily indicative of future cost of goods sold and gross margin.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
  <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">3308000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <us-gaap:InventoryWriteDown contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">0</us-gaap:InventoryWriteDown>
  <us-gaap:InvestmentIncomeInterest contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">223000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterest contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">929000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterest contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">1602000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterestAndDividend contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">17000</us-gaap:InvestmentIncomeInterestAndDividend>
  <us-gaap:InvestmentIncomeInterestAndDividend contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">34000</us-gaap:InvestmentIncomeInterestAndDividend>
  <us-gaap:LeasePolicyTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Leases&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In the ordinary course of business, the Company enters into lease agreements for office space as well as leases for certain property and equipment. The leases have varying terms and expirations and have provisions to extend or renew the lease agreement, among other terms and conditions, as negotiated. Once the agreement is executed, the lease is assessed to determine whether the lease qualifies as a capital or operating lease.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;When a non-cancelable operating lease includes any fixed escalation clauses and lease incentives for rent holidays or build-out contributions, rent expense is recognized on a straight-line basis over the initial term of the lease. The excess between the average rental amount charged to expense and amounts payable under the lease is recorded in accrued expenses.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:LeasePolicyTextBlock>
  <us-gaap:LeasesOfLesseeDisclosureTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;"&gt;12. Leases&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Operating Leases&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company currently leases office space and research laboratory space in various facilities under operating agreements expiring at various dates through 2025.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The following table contains information about our current significant leased properties as of December&amp;nbsp;31, 2016:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Location &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Approximate&lt;br /&gt;Square Feet&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Use&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Lease expiry date&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Cranbury, New Jersey&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;90,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Office and laboratory&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;September 2025&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Durham, North Carolina&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5,603&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Office&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;June 2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Buckinghamshire, United Kingdom&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9,821&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Office&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;September 2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Munich, Germany&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,316&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Office&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;April 2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In addition to the above, we also maintain small offices in the Italy, France, Netherlands and Spain. We believe that our current office and laboratory facilities are adequate and suitable for our current and anticipated needs. We believe that, to the extent required, we will be able to lease or buy additional facilities at commercially reasonable rates.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Rent expenses for the Company's facilities are recognized over the term of the lease. The Company recognizes rent starting when possession of the facility is taken from the landlord. When a lease contains a predetermined fixed escalation of the minimum rent, the Company recognizes the related rent expense on a straight-line basis and records the difference between the recognized rental expense and the amounts payable under the lease as deferred rent liability. Tenant leasehold improvement allowances are reflected in accrued expenses on the consolidated balance sheets and are amortized as a reduction to rent expense in the statement of operations over the term of the lease.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;At December&amp;nbsp;31, 2016, aggregate annual future minimum lease payments under these leases are as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(in thousands) &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2021 and&lt;br /&gt;beyond&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Minimum lease payments&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,666&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,483&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,421&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,349&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;10,537&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;20,456&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Rent expense, including fees for utilities and common area maintenances for the years ended December&amp;nbsp;31, 2016, 2015 and 2014 were $3.5&amp;nbsp;million, $2.6&amp;nbsp;million and $2.4&amp;nbsp;million, respectively.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Capital Leases&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In 2016, the Company purchased equipment of approximately $0.9&amp;nbsp;million through financing arrangements. These financing arrangements include interest of approximately 0.2-5.7%, and lease terms of 36-48&amp;nbsp;months.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;At December&amp;nbsp;31, 2016, aggregate annual future minimum lease payments under these leases, including interest, are as follows (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Years ending December&amp;nbsp;31: &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;355&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;355&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;134&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;2021 and beyond&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Total principal obligation&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;844&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:LeasesOfLesseeDisclosureTextBlock>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">908384000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">1036845000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">73616000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">110959000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">274744000</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="As_Of_12_31_2015_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="Unit12" decimals="-3">667000</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="As_Of_12_31_2015_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" unitRef="Unit12" decimals="-3">274077000</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">271466000</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="As_Of_12_31_2016_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="Unit12" decimals="-3">1744000</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="As_Of_12_31_2016_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" unitRef="Unit12" decimals="-3">269722000</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:LiabilityForUncertainTaxPositionsCurrent contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-5">0</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
  <us-gaap:LongTermDebt contextRef="As_Of_12_31_2016_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="Unit12" decimals="-3">154464000</us-gaap:LongTermDebt>
  <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef="As_Of_10_31_2015_us-gaap_CounterpartyNameAxis_fold_RedmileGroupMember_us-gaap_DebtInstrumentAxis_fold_NoteAndWarrantAgreement2015Member_us-gaap_TypeOfArrangementAxis_fold_PrivatePlacementPurchaseAgreementMember" unitRef="Unit13" decimals="3">0.067</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">139179000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">290893000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">272715000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">-107076000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">-145343000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">-4509000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">-51669000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">-100139000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">-150534000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">-68926000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3">-68926000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">-24288000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">-132118000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3">-132118000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_4_1_2015_To_6_30_2015" unitRef="Unit12" decimals="-3">-27133000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_7_1_2015_To_9_30_2015" unitRef="Unit12" decimals="-3">-37800000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_10_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">-42897000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2016_To_3_31_2016" unitRef="Unit12" decimals="-3">-43691000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">-200042000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3">-200042000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_4_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">-51050000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_7_1_2016_To_9_30_2016" unitRef="Unit12" decimals="-3">-46654000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_10_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">-58647000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">-68926000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">-132118000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">-200042000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Recent Accounting Pronouncements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In January 2017, the FASB issued ASU 2017-04, &lt;/font&gt;&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Intangibles&amp;nbsp;&amp;#x2014; Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&lt;/font&gt;&lt;font style="display:inline;font-family:Times;"&gt;. To simplify the subsequent measurement of goodwill, ASU 2017-04 eliminates Step 2 from the goodwill impairment test. The annual, or interim, goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit's fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. In addition, income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit should be considered when measuring the goodwill impairment loss, if applicable. ASU 2017-04 also eliminates the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. ASU 2017-04 should be applied on a prospective basis. The nature of and reason for the change in accounting principle should be disclosed upon transition. A public business entity that is a U.S. SEC filer should adopt ASU 2017-04 for its annual or any interim goodwill impairment tests in fiscal years beginning after December&amp;nbsp;15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January&amp;nbsp;1, 2017. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In January 2017, the FASB issued ASU 2017-01&lt;/font&gt;&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;, Business Combinations (Topic 805): Clarifying the Definition of a Business&lt;/font&gt;&lt;font style="display:inline;font-family:Times;"&gt;. This Accounting Standards Update clarifies the definition of a business. The amendments affect all companies and other reporting organizations that must determine whether they have acquired or sold a business. The amendments in this Update are effective for public companies for annual periods beginning after December&amp;nbsp;15, 2017, including interim periods within those periods. Early adoption is permitted under certain circumstances. The amendments should be applied prospectively as of the beginning of the period of adoption. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In October 2016, the FASB issued ASU 2016-17, &lt;/font&gt;&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Consolidation (Topic 810): Interests Held through Related Parties That Are under Common Control.&lt;/font&gt;&lt;font style="display:inline;font-family:Times;"&gt; This Accounting Standards Update changes the evaluation of whether a reporting entity is the primary beneficiary of a variable interest entity by changing how a reporting entity that is a single decision maker of a variable interest entity treats indirect interests in the entity held through related parties that are under common control with the reporting entity. If a reporting entity satisfies the first characteristic of a primary beneficiary (such that it is the single decision maker of a variable interest entity), the amendments require that reporting entity, in determining whether it satisfies the second characteristic of a primary beneficiary, to include all of its direct variable interests in a variable interest entity and, on a proportionate basis, its indirect variable interests in a variable interest entity held through related parties, including related parties that are under common control with the reporting entity. The amendments in this Update are effective for public business entities for fiscal years beginning after December&amp;nbsp;15, 2016, including interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The Company adopted this ASU in 2016 and the adoption did not have a material impact on its consolidated financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In October 2016, the FASB issued ASU 2016-16, &lt;/font&gt;&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory.&lt;/font&gt;&lt;font style="display:inline;font-family:Times;"&gt; This Accounting Standards Update requires an entity to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. The amendments eliminate the exception for an intra-entity transfer of an asset other than inventory. The amendments in this Update are effective for public business entities for annual periods beginning after December&amp;nbsp;15, 2017, including interim reporting periods within those annual reporting periods. Early adoption is permitted for all entities in the first interim period if an entity issues interim financial statements. The Company is currently assessing the impact that this standard will have on its consolidated financial statements. We have not completed our review of the impact of this guidance and do not expect this new guidance to have a material impact on our Consolidated Financial Statements. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In August 2016, the FASB issued ASU 2016-15, &lt;/font&gt;&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments.&lt;/font&gt;&lt;font style="display:inline;font-family:Times;"&gt; This Accounting Standards Update addresses the following eight specific cash flow issues including Debt prepayment or debt extinguishment costs, contingent consideration payments made after a business combination and separately identifiable cash flows and application of the predominance principle. The amendments in this ASU apply to all entities. The amendments in this Update are effective for public business entities for fiscal years beginning after December&amp;nbsp;15, 2017, and interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The Company adopted this ASU in 2016 and the adoption did not have a material impact on its consolidated financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In March 2016, the FASB issued ASU 2016-09, &lt;/font&gt;&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Compensation&amp;nbsp;&amp;#x2014; Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting&lt;/font&gt;&lt;font style="display:inline;font-family:Times;"&gt;. The amendments are intended to improve the accounting for employee share-based payments and affect all organizations that issue share-based payment awards to their employees. Several aspects of the accounting for share-based payment award transactions are simplified, including: (a) income tax consequences; (b) classification of awards as either equity or liabilities; and (c) classification on the statement of cash flows. For public companies, the amendments are effective for annual periods beginning after December&amp;nbsp;15, 2016, and interim periods within those annual periods. Early adoption is permitted for any organization in any interim or annual period. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In February 2016, the FASB issued ASU No.&amp;nbsp;2016-02&lt;/font&gt;&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;, Leases (Topic 842).&lt;/font&gt;&lt;font style="display:inline;font-family:Times;"&gt; This update requires the recognition of lease assets and lease liabilities on the balance sheet for all lease obligations and disclosing key information about leasing arrangements. This update requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous generally accepted accounting principles. This update will be effective for the Company for all annual and interim periods beginning after December&amp;nbsp;15, 2018, including interim periods within those fiscal years. Early application is permitted for all public business entities and all nonpublic business entities upon issuance. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In July 2015, the FASB issued ASU 2015-11&lt;/font&gt;&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;, Inventory (Topic 330): Simplifying the Measurement of Inventory&lt;/font&gt;&lt;font style="display:inline;font-family:Times;"&gt;, which requires an entity to measure in scope inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The amendments apply to inventory that is measured using first-in, first-out (FIFO) or average cost. The ASU is effective for public business entities for fiscal years beginning after December&amp;nbsp;15, 2016, including interim periods within those fiscal years. A reporting entity should apply the amendments prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In August 2014, the FASB issued ASU 2014-15, &lt;/font&gt;&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Presentation of Financial Statements-Going Concern (Subtopic 205-40):&lt;/font&gt;&lt;font style="display:inline;font-family:Times;"&gt; Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern, which defines management's responsibility to assess an entity's ability to continue as a going concern, and to provide related footnote disclosures if there is substantial doubt about its ability to continue as a going concern. The pronouncement is effective for annual reporting periods ending after December&amp;nbsp;15, 2016 with early adoption permitted. The Company adopted this ASU in 2016 and the adoption did not have a material impact on its consolidated financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In May 2014, FASB issued ASU 2014-09, &lt;/font&gt;&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/font&gt;&lt;font style="display:inline;font-family:Times;"&gt; which along with amendments issued in 2015 and 2016, will replace substantially all current US&amp;nbsp;GAAP guidance on this topic and eliminate industry-specific guidance. Early adoption of this standard is permitted but not before the original effective date for all annual periods and interim reporting periods beginning after December&amp;nbsp;15, 2017. The guidance permits two methods of adoption: full retrospective method (retrospective application to each prior reporting period presented) or modified retrospective method (retrospective application with the cumulative effect of initially applying the guidance recognized at the date of initial application and providing certain additional disclosures). To complete its assessment of the impact of the standard to its financial statements, the Company continues to assess all implications of this standard, method of adoption and related financial disclosures. Additionally, the Company continues to monitor modifications, clarifications and interpretations issued by the FASB that may impact its assessment.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:NumberOfOperatingSegments contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit110" decimals="INF">1</us-gaap:NumberOfOperatingSegments>
  <us-gaap:OperatingExpenses contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">69925000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">130437000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">186015000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">-68701000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">-130437000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">-181890000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">20456000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">2666000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">2349000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">2421000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">2483000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-5">2400000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-5">2600000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-5">3500000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:OperatingLossCarryforwards contextRef="As_Of_12_31_2016_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember" unitRef="Unit12" decimals="-6">637000000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards contextRef="As_Of_12_31_2016_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember" unitRef="Unit12" decimals="-6">40000000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards contextRef="As_Of_12_31_2016_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember" unitRef="Unit12" decimals="-6">623000000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;1. Description of Business&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Corporate Information, Status of Operations, and Management Plans&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Amicus Therapeutics,&amp;nbsp;Inc. (the "Company") is a global patient-focused biotechnology company engaged in the discovery, development, and commercialization of a diverse set of novel treatments for patients living with devastating rare and orphan diseases. The lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement of therapy ("ERT") for Fabry disease.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company's Fabry franchise strategy is to develop migalastat HCl (which the Company may refer to as "migalastat") for all patients with Fabry disease as a monotherapy for patients with amenable mutations and in combination with ERT for all other patients. In May 2016, the Company announced that the European Commission ("EC") had granted full approval for the oral small molecule pharmacological chaperone Galafold&amp;#x2122; (migalastat) as a first-line therapy for long-term treatment of adults and adolescents aged 16&amp;nbsp;years and older with a confirmed diagnosis of Fabry disease (alpha-galactosidase A deficiency) and who have an amenable mutation. The approved label includes 313 Fabry-causing mutations, which represent up to half of all patients with Fabry disease. The Company commenced commercial shipments of Galafold in the EU in the second quarter of 2016 and recognized net product sales of $5.0&amp;nbsp;million in 2016.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Also in the pipeline, SD-101 is a product candidate in late-stage development, as a potential first-to-market therapy for the chronic, rare connective tissue disorder Epidermolysis Bullosa ("EB"). The Company is also leveraging its biologics and Chaperone-Advanced Replacement Therapy ("CHART&amp;#x2122;") platform technologies to develop novel ERT products for Pompe disease, Fabry disease, and potentially other lysosomal storage disorders ("LSDs"). The Company is also investigating preclinical and discovery programs in other rare and devastating diseases including cyclin-dependent kinase-like&amp;nbsp;5 ("CDKL5") deficiency. The Company believes that the platform technologies and advanced product pipeline uniquely position the Company at the forefront of advanced therapies to treat a range of devastating rare and orphan diseases.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;On December&amp;nbsp;21, 2016, the Company issued $250&amp;nbsp;million aggregate principal amount of 3.00% unsecured Convertible Senior Notes due 2023 (the "Convertible Notes"), in a private offering to qualified institutional buyers pursuant to Rule&amp;nbsp;144A under the Securities Act of 1933, as amended (the "Securities Act"). Interest is payable semiannually on June&amp;nbsp;15 and December&amp;nbsp;15 of each year, beginning on June&amp;nbsp;15, 2017. The Notes will mature on December&amp;nbsp;15, 2023, unless earlier repurchased, redeemed, or converted in accordance with their terms. The Notes are convertible at the option of the holders, under certain circumstances and during certain periods, into cash, shares of the Company's common stock, par value $0.01 per share ("Common Stock"), or a combination thereof. The net proceeds from the issuance of the Convertible Note offering were $243.1&amp;nbsp;million, after deducting fees and estimated expenses payable by the Company. In addition, the Company used approximately $13.5&amp;nbsp;million of the net proceeds from the issuance of the Convertible Notes to pay the cost of the capped call transactions ("Capped Call Confirmations") that the Company entered into in connection with the issuance of the Convertible Notes. For additional information, see "&amp;#x2014;&amp;nbsp;Note&amp;nbsp;16. Debt Instruments and Related Party Transactions."&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In July 2016, the Company expanded its biologics pipeline with a new preclinical program for CDKL5 deficiency, a rare and devastating genetic neurological disease for which there is no currently approved treatment. The Company has obtained the rights and related intellectual property to a preclinical CDKL5 program through its acquisition of MiaMed, Inc ("MiaMed"). The aggregate value of the deal was approximately $89.5&amp;nbsp;million, which included an upfront payment of $6.5&amp;nbsp;million and Company stock, cash and potential milestones of up to $83.0&amp;nbsp;million. For additional information, see "&amp;#x2014;&amp;nbsp;Note&amp;nbsp;3. Acquisitions".&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Beginning in April 2016 and through July 2016, the Company sold 15.0&amp;nbsp;million shares of Common Stock under an at-the-market ("ATM") equity program with Cowen and Company,&amp;nbsp;LLC ("Cowen") acting as sales agent. Cowen was compensated at a fixed commission rate up to 3.0%. The ATM sales agreement resulted in net proceeds of $97.1&amp;nbsp;million, after Cowen's commission of $2.7&amp;nbsp;million and other expenses of $0.2&amp;nbsp;million. The Company has completed all sales under the ATM equity program.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company had an accumulated deficit of approximately $779.6&amp;nbsp;million at December&amp;nbsp;31, 2016 and anticipates incurring losses through the fiscal year ending December&amp;nbsp;31, 2017 and beyond. The Company has been able to fund its operating losses to date through stock offering, debt issuances, and payments from partners during the terms of the collaboration agreements and other financing arrangements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company believes that its existing cash and cash equivalents and short-term investments will be sufficient to fund the current operating plan into the second half of 2018.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">1699000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">2713000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">1108000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">2468000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">-133000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
  <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember" unitRef="Unit12" decimals="-3">-133000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
  <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">17000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
  <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember" unitRef="Unit12" decimals="-3">17000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
  <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">217000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
  <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember" unitRef="Unit12" decimals="-3">217000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">1945000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember" unitRef="Unit12" decimals="-3">1945000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">1293000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">-133000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">17000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">2162000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
  <us-gaap:OtherExpenses contextRef="Duration_4_1_2016_To_7_31_2016_us-gaap_CounterpartyNameAxis_fold_CowenAndCompanyLLCMember_us-gaap_TypeOfArrangementAxis_fold_SalesAgreementMember" unitRef="Unit12" decimals="-5">200000</us-gaap:OtherExpenses>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">681000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">1973000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">-77000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">-80000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">-4793000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:PaidInKindInterest contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">277000</us-gaap:PaidInKindInterest>
  <us-gaap:PaidInKindInterest contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">492000</us-gaap:PaidInKindInterest>
  <us-gaap:PaidInKindInterest contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">2689000</us-gaap:PaidInKindInterest>
  <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="Duration_12_21_2016_To_12_21_2016_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="Unit12" decimals="-5">6900000</us-gaap:PaymentsOfDebtIssuanceCosts>
  <us-gaap:PaymentsToAcquireAvailableForSaleSecurities contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">162752000</us-gaap:PaymentsToAcquireAvailableForSaleSecurities>
  <us-gaap:PaymentsToAcquireAvailableForSaleSecurities contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">289595000</us-gaap:PaymentsToAcquireAvailableForSaleSecurities>
  <us-gaap:PaymentsToAcquireAvailableForSaleSecurities contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">219932000</us-gaap:PaymentsToAcquireAvailableForSaleSecurities>
  <us-gaap:PaymentsToAcquireBusinessesAndInterestInAffiliates contextRef="Duration_7_5_2016_To_7_5_2016_us-gaap_BusinessAcquisitionAxis_fold_MiamedIncMember" unitRef="Unit12" decimals="-5">1800000</us-gaap:PaymentsToAcquireBusinessesAndInterestInAffiliates>
  <us-gaap:PaymentsToAcquireBusinessesGross contextRef="Duration_9_30_2015_To_9_30_2015_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_us-gaap_RangeAxis_us-gaap_MaximumMember" unitRef="Unit12" decimals="-6">361000000</us-gaap:PaymentsToAcquireBusinessesGross>
  <us-gaap:PaymentsToAcquireBusinessesGross contextRef="Duration_4_1_2016_To_4_30_2016_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_us-gaap_RangeAxis_us-gaap_MaximumMember" unitRef="Unit12" decimals="-6">361000000</us-gaap:PaymentsToAcquireBusinessesGross>
  <us-gaap:PaymentsToAcquireBusinessesGross contextRef="Duration_4_1_2016_To_4_30_2016_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityClinicalMilestoneMember_us-gaap_RangeAxis_us-gaap_MaximumMember" unitRef="Unit12" decimals="-6">81000000</us-gaap:PaymentsToAcquireBusinessesGross>
  <us-gaap:PaymentsToAcquireBusinessesGross contextRef="Duration_4_1_2016_To_4_30_2016_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember_us-gaap_ContingentConsiderationByTypeAxis_fold_ContingentConsiderationLiabilityRegulatoryApprovalMilestoneMember_us-gaap_RangeAxis_us-gaap_MaximumMember" unitRef="Unit12" decimals="-6">280000000</us-gaap:PaymentsToAcquireBusinessesGross>
  <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">141060000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">238000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">4817000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">5951000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;11. 401(k) Plan&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company has a 401(k) plan (the "401(k) Plan") covering all eligible employees and provides for a company match of up to 5% of salary and bonus paid during the year. The Company's vesting policy is that the Company match vests immediately upon enrollment. There were no changes to the policy in 2016 or 2015. The Company's total contribution to the 401(k) Plan was $1.2&amp;nbsp;million, $0.9&amp;nbsp;million and $0.6&amp;nbsp;million for the years ended December&amp;nbsp;31, 2016, 2015 and 2014, respectively.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">2568000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">4993000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">242536000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="Duration_12_21_2016_To_12_21_2016_us-gaap_DebtInstrumentAxis_fold_ConvertibleSeniorNotes2016Due2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="Unit12" decimals="-5">243100000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">135805000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Duration_7_1_2014_To_7_31_2014_us-gaap_CounterpartyNameAxis_fold_CowenAndCompanyLLCMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_fold_AtMarketEquityOfferingMember" unitRef="Unit12" decimals="-5">38600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Duration_11_1_2014_To_11_30_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-5">97200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">243042000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Duration_6_1_2015_To_6_30_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-5">243000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">97068000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfSecuredDebt contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">50000000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
  <us-gaap:ProceedsFromIssuanceOfSecuredDebt contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">30000000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
  <us-gaap:ProceedsFromLicenseFeesReceived contextRef="Duration_11_1_2013_To_11_30_2013_us-gaap_CounterpartyNameAxis_fold_GlaxoSmithKlinePLCMember_us-gaap_TypeOfArrangementAxis_fold_RevisedCollaborationAgreementMember" unitRef="Unit12" decimals="-6">0</us-gaap:ProceedsFromLicenseFeesReceived>
  <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">55914000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
  <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">290129000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
  <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">221374000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">3673000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">11186000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">3036000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromWarrantExercises contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">4000000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;"&gt;7. Property and Equipment&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Property and equipment consist of the following (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Property and equipment consist of the following:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Computer equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,511
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5,075
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Computer software&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,347
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,354
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Research equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7,465
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6,483
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,018
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,444
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Leasehold improvements&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6,970
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,175
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;22,311
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;19,531
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Less accumulated depreciation&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(12,495
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(13,353
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9,816
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6,178
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Depreciation expense was $3.2&amp;nbsp;million and $1.8&amp;nbsp;million for the years ended December&amp;nbsp;31, 2016 and 2015, respectively. As of December&amp;nbsp;31, 2016, $0.2&amp;nbsp;million of the depreciation expense was related to capital lease obligation. There were no capital lease obligations outstanding as of December&amp;nbsp;31, 2015.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">19531000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2015_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fold_ResearchEquipmentMember" unitRef="Unit12" decimals="-3">6483000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2015_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember" unitRef="Unit12" decimals="-3">5075000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2015_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" unitRef="Unit12" decimals="-3">2444000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2015_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" unitRef="Unit12" decimals="-3">4175000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2015_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" unitRef="Unit12" decimals="-3">1354000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">22311000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fold_ResearchEquipmentMember" unitRef="Unit12" decimals="-3">7465000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember" unitRef="Unit12" decimals="-3">3511000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" unitRef="Unit12" decimals="-3">3018000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" unitRef="Unit12" decimals="-3">6970000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" unitRef="Unit12" decimals="-3">1347000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">6178000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">9816000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Property and Equipment&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is calculated over the estimated useful lives of the respective assets, which range from three to five years, or the lesser of the related initial term of the lease or useful life for leasehold improvements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The initial cost of property and equipment consists of its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use. Expenditures incurred after the fixed assets have been put into operation, such as repairs and maintenance, are charged to income in the period in which the costs are incurred. Major replacements, improvements and additions are capitalized in accordance with Company policy.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Property and equipment consist of the following (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Property and equipment consist of the following:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Computer equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,511
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5,075
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Computer software&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,347
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,354
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Research equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7,465
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6,483
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,018
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,444
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Leasehold improvements&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6,970
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,175
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;22,311
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;19,531
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Less accumulated depreciation&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(12,495
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(13,353
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9,816
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6,178
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_RangeAxis_us-gaap_MaximumMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_RangeAxis_us-gaap_MinimumMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:QuarterlyFinancialInformationTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;20. Selected Quarterly Financial Data (Unaudited&amp;#x2014;in thousands except per share data)&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Quarters Ended&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;March&amp;nbsp;31&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;June&amp;nbsp;30&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;September&amp;nbsp;30&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Net loss&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(43,691
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(51,050
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(46,654
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(58,647
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Basic and diluted net loss per common share&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;font-family:Times;font-size:6pt;top:-4pt;position:relative;line-height:100%"&gt;(1)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.35
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.40
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.33
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.41
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Net loss&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(24,288
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(27,133
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(37,800
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(42,897
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Basic and diluted net loss per common share&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;font-family:Times;font-size:6pt;top:-4pt;position:relative;line-height:100%"&gt;(1)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.25
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.27
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.32
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.34
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;div&gt;&lt;hr style="border-width:0;width:26%;height:1.5pt;color:black;background-color:black;" align="left"&gt;&lt;/hr&gt;&lt;/div&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:15;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:15;"&gt;
				&lt;td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:15;"&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;(1)&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Per common share amounts for the quarters and full years have been calculated separately. Accordingly, quarterly amounts do not add to the annual amounts because of differences on the weighted-average common shares outstanding during each period principally due to the effect of the Company issuing shares of its common stock during the year.&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
  <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">193000</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
  <us-gaap:RepaymentsOfSecuredDebt contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">299000</us-gaap:RepaymentsOfSecuredDebt>
  <us-gaap:RepaymentsOfSecuredDebt contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">15291000</us-gaap:RepaymentsOfSecuredDebt>
  <us-gaap:RepaymentsOfSecuredDebt contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">80000000</us-gaap:RepaymentsOfSecuredDebt>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="Duration_7_5_2016_To_7_5_2016_us-gaap_BusinessAcquisitionAxis_fold_MiamedIncMember" unitRef="Unit12" decimals="-5">6500000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">47624000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
  <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">76943000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
  <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">104793000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Research and Development Costs&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Research and development costs are expensed as incurred. Research and development expense consists primarily of costs related to personnel, including salaries and other personnel related expenses, consulting fees and the cost of facilities and support services used in drug development. Assets acquired that are used for research and development and have no future alternative use are expensed as in-process research and development.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:RestructuringCharges contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">-63000</us-gaap:RestructuringCharges>
  <us-gaap:RestructuringCharges contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">15000</us-gaap:RestructuringCharges>
  <us-gaap:RestructuringCharges contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">69000</us-gaap:RestructuringCharges>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">-579566000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">-779608000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="Duration_7_1_2016_To_12_31_2016_us-gaap_CounterpartyNameAxis_fold_GlaxoSmithKlinePLCMember_us-gaap_TypeOfArrangementAxis_fold_RevisedCollaborationAgreementMember" unitRef="Unit12" decimals="-5">500000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Revenue Recognition&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company recognizes revenue when amounts are realized or realizable and earned, which is typically upon shipment to the end-customer. Revenue is considered realizable and earned when persuasive evidence an arrangement exists, title to product and associated risk of loss has passed to the customer, the price is fixed or determinable, collection of the amounts due are reasonably assured and the Company has no further performance obligations.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Net Product Sales&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company's net product sales consist solely of sales of Galafold for the treatment of Fabry disease in the EU. The Company has recorded revenue on sales where Galafold is available either on a commercial basis or through a reimbursed early access program. Orders for Galafold are generally received from pharmacies and the ultimate payor is typically a government authority.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company records revenue net of estimated third party discounts and rebates. Allowances are recorded as a reduction of revenue at the time revenues from product sales are recognized. These allowances are adjusted to reflect known changes in factors and may impact such allowances in the quarter those changes are known.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Collaboration Revenue&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In multiple element arrangements, revenue is allocated to each separate unit of accounting and each deliverable in an arrangement is evaluated to determine whether it represents separate units of accounting. A deliverable constitutes a separate unit of accounting when it has standalone value and there is no general right of return for the delivered elements. In instances when the aforementioned criteria are not met, the deliverable is combined with the undelivered elements and the allocation of the arrangement consideration and revenue recognition is determined for the combined unit as a single unit of accounting. Allocation of the consideration is determined at arrangement inception on the basis of each unit's relative selling price. In instances where there is determined to be a single unit of accounting, the total consideration is applied as revenue for the single unit of accounting and is recognized over the period of inception through the date where the last deliverable within the single unit of accounting is expected to be delivered.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company's current revenue recognition policies provide that, when a collaboration arrangement contains multiple deliverables, such as license and research and development services, the Company allocates revenue to each separate unit of accounting based on a selling price hierarchy. The selling price hierarchy for a deliverable is based on (i)&amp;nbsp;its vendor specific objective evidence ("VSOE") if available, (ii)&amp;nbsp;third party evidence ("TPE") if VSOE is not available, or (iii)&amp;nbsp;best estimated selling price ("BESP") if neither VSOE nor TPE is available. The Company would establish the VSOE of selling price using the price charged for a deliverable when sold separately. The TPE of selling price would be established by evaluating largely similar and interchangeable competitor products or services in standalone sales to similarly situated customers. The BESP would be established considering internal factors such as an internal pricing analysis or an income approach using a discounted cash flow model.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company also considers the impact of potential future payments it makes in its role as a vendor to its customers and evaluates if these potential future payments could be a reduction of revenue from that customer. If the potential future payments to the customer are:&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:15;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:15;"&gt;
				&lt;td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Arabic Typesetting;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Arabic Typesetting;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Arabic Typesetting;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:15;"&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2022;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;a payment for an identifiable benefit; &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:15;"&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;height:27.75pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;height:27.75pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2022;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;height:27.75pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;the identifiable benefit is separable from the existing relationship between the Company and its customer;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:15;"&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2022;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;the identifiable benefit can be obtained from a party other than the customer; and &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:15;"&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2022;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;the Company can reasonably estimate the fair value of the identifiable benefit&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;then the payments are accounted for separate from the revenue received from that customer. If, however, all these criteria are not satisfied, then the payments are treated as a reduction of revenue from that customer.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;If the Company determines that any potential future payments to its customers are to be considered as a reduction of revenue, it must evaluate if the total amount of revenue to be received under the arrangement is fixed and determinable. If the total amount of revenue is not fixed and determinable due to the uncertain nature of the potential future payments to the customer, then any customer payments cannot be recognized as revenue until the total arrangement consideration becomes fixed and determinable.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The reimbursements for research and development costs under collaboration agreements that meet the criteria for revenue recognition are included in Research Revenue and the costs associated with these reimbursable amounts are included in research and development expenses.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In order to determine the revenue recognition for contingent milestones, the Company evaluates the contingent milestones using the criteria as provided by the Financial Accounting Standards Boards ("FASB") guidance on the milestone method of revenue recognition at the inception of a collaboration agreement. The criteria requires that (i)&amp;nbsp;the Company determines if the milestone is commensurate with either its performance to achieve the milestone or the enhancement of value resulting from the Company's activities to achieve the milestone, (ii)&amp;nbsp;the milestone be related to past performance, and (iii)&amp;nbsp;the milestone be reasonable relative to all deliverable and payment terms of the collaboration arrangement. If these criteria are met then the contingent milestones can be considered as substantive milestones and will be recognized as revenue in the period that the milestone is achieved.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:RoyaltyExpense contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_CounterpartyNameAxis_fold_MtSinaiSchoolOfMedicineOfNewYorkUniversityMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember" unitRef="Unit12" decimals="-5">100000</us-gaap:RoyaltyExpense>
  <us-gaap:SalesRevenueGoodsNet contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">4958000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="Duration_4_1_2016_To_6_30_2016_us-gaap_ProductOrServiceAxis_us-gaap_ProductMember_us-gaap_StatementGeographicalAxis_us-gaap_EuropeanUnionMember" unitRef="Unit12" decimals="-5">5000000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueNet contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">1224000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">4958000</us-gaap:SalesRevenueNet>
  <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;font-family:Times;"&gt;Accounts payable and accrued expenses consist of the following (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Accounts payable&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;12,905&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;16,477&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Accrued professional fees&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5,079&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,578&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Accrued contract manufacturing&amp;nbsp;&amp;amp; contract research costs&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8,042&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,940&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Accrued compensation and benefits&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9,981&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6,201&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Accrued facility costs&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,740&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,321&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Foreign currency forward contract&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;265&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Capital lease, short term portion&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;283&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Accrued other&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,713&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,699&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;41,008&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;32,216&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The table below presents potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Year ended December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Options to purchase common stock&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;15,528&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;11,729&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;10,021&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Convertible debt&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;40,850&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Outstanding warrants, convertible to common stock&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,110&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,350&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,600&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Unvested restricted stock units&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;744&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;479&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;955&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Total number of potentially issuable shares&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;60,232&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;13,558&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;12,576&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The following table shows the change in the balance of contingent consideration payable for the year ended December&amp;nbsp;31, 2016 and 2015, respectively (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Year ended December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Balance, beginning of the period&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;274,077
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;10,700
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Additions, from business acquisitions&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;259,000
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Payment of contingent consideration in cash&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(5,000
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Payment of contingent consideration in stock&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(6,115
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Unrealized change in fair value change during the period, included in Statement of Operations&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6,760
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,377
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Balance, end of the period&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;269,722
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;274,077
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock>
  <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;font-family:Times;"&gt;Cash and available for sale securities consisted of the following as of December&amp;nbsp;31, 2016 and December&amp;nbsp;31, 2015 (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;As of December&amp;nbsp;31, 2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Cost&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Unrealized&lt;br /&gt;Gain&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Unrealized&lt;br /&gt;Loss&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Fair&lt;br /&gt;Value&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Cash balances&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;187,026
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;187,026
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Corporate debt securities, current portion&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;74,564
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(31
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;74,535
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Commercial paper&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;68,258
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;132
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;68,390
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Money market&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;350
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;350
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Certificate of deposit&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;50
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;50
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;330,248
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;134
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(31
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;330,351
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Included in cash and cash equivalents&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;187,026
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;187,026
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Included in marketable securities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;143,222
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;134
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(31
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;143,325
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Total cash and marketable securities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;330,248
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;134
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(31
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;330,351
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;As of December&amp;nbsp;31, 2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Cost&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Unrealized&lt;br /&gt;Gain&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Unrealized&lt;br /&gt;Loss&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Fair&lt;br /&gt;Value&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Cash balances&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;69,485
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;69,485
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Corporate debt securities, current portion&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;118,627
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(154
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;118,474
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Commercial paper&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;25,686
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;38
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;25,724
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Certificate of deposit&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;350
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;350
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;214,148
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;39
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(154
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;214,033
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Included in cash and cash equivalents&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;69,485
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;69,485
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Included in marketable securities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;144,663
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;39
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(154
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;144,548
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Total cash and marketable securities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;214,148
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;39
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(154
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;214,033
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;The significant components of the deferred tax assets and liabilities are as follows (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;For Years Ended&lt;br /&gt;December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Non-current deferred tax assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Intellectual property&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;95,956
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Amortization/depreciation&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,781
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,657
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Research tax credit&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;32,851
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;27,170
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Net operating loss carry forwards&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;253,661
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;159,889
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Deferred revenue&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;14,281
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;14,281
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Non-cash stock issue&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;11,649
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6,767
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Others&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,358
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,964
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Gross deferred tax assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;413,537
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;213,728
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Deferred tax liability related to business acquisition&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(173,771
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(176,219
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Deferred tax liability related to royalty payable&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(96,829
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Deferred tax liability related to convertible notes&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(29,845
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Total net deferred tax asset&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;113,092
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;37,509
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Less valuation allowance&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(286,863
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(213,728
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Net deferred tax assets (liability)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(173,771
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(176,219
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss attributable to common stockholders per common share (in thousands except share amounts):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Years Ended December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;text-decoration:underline;"&gt;Historical &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Numerator:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Net loss attributable to common stockholders&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(200,042
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(132,118
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(68,926
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Denominator:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Weighted average common shares outstanding&amp;#x2014;basic and diluted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;134,401,588
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;109,923,815
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;74,444,157
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Years Ended&lt;br /&gt;December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Statutory rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(34
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(34
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(34
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;State taxes, net of federal benefit&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(5
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(5
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(4
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Permanent adjustments&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;R&amp;amp;D credit&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(3
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(3
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(4
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Foreign income tax rate differential&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Other&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Valuation allowance&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;36
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;37
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;38
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Net&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The following table summarizes the equity-based compensation expense recognized in the statements of operations (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Years Ended December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Equity compensation expense recognized in:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Research and development expense&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8,071&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,600&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,703&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Selling, general and administrative expense&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9,433&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5,372&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,305&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Total equity compensation expense&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;17,504&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9,972&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6,008&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;At December&amp;nbsp;31, 2016, aggregate annual future minimum lease payments under these leases, including interest, are as follows (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Years ending December&amp;nbsp;31: &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;355&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;355&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;134&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;2021 and beyond&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Total principal obligation&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;844&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock>
  <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;At December&amp;nbsp;31, 2016, aggregate annual future minimum lease payments under these leases are as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(in thousands) &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2021 and&lt;br /&gt;beyond&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Minimum lease payments&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,666&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,483&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,421&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,349&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;10,537&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;20,456&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
  <us-gaap:ScheduleOfGoodwillTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(in millions)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Balance at December&amp;nbsp;31, 2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;197.8&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Change in goodwill&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Balance at December&amp;nbsp;31, 2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;197.8&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
  <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;For financial reporting purposes, income (loss) before income taxes includes the following components (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Years Ended December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;United States&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(174,913
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(123,697
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(70,030
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Foreign&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(28,868
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(8,421
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(9
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(203,781
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(132,118
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(70,039
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
  <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(in millions)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Balance at December&amp;nbsp;31, 2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;486.7&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Change in IPR&amp;amp;D&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Balance at December&amp;nbsp;31, 2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;486.7&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
  <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; The following table summarizes the components of inventories at December&amp;nbsp;31, 2016 (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31,&amp;nbsp;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Work-in-process&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,308&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Finished goods&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;108&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;Total inventories&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,416&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
  <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;Selected Quarterly Financial Data (Unaudited&amp;#x2014;in thousands except per share data)&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Quarters Ended&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;March&amp;nbsp;31&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;June&amp;nbsp;30&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;September&amp;nbsp;30&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Net loss&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(43,691
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(51,050
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(46,654
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(58,647
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Basic and diluted net loss per common share&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;font-family:Times;font-size:6pt;top:-4pt;position:relative;line-height:100%"&gt;(1)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.35
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.40
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.33
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.41
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Net loss&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(24,288
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(27,133
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(37,800
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(42,897
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Basic and diluted net loss per common share&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;font-family:Times;font-size:6pt;top:-4pt;position:relative;line-height:100%"&gt;(1)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.25
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.27
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.32
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.34
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;div&gt;&lt;hr style="border-width:0;width:26%;height:1.5pt;color:black;background-color:black;" align="left"&gt;&lt;/hr&gt;&lt;/div&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:15;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:15;"&gt;
				&lt;td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:15;"&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;(1)&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Per common share amounts for the quarters and full years have been calculated separately. Accordingly, quarterly amounts do not add to the annual amounts because of differences on the weighted-average common shares outstanding during each period principally due to the effect of the Company issuing shares of its common stock during the year.&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
  <us-gaap:ScheduleOfRealEstatePropertiesTableTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The following table contains information about our current significant leased properties as of December&amp;nbsp;31, 2016:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Location &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Approximate&lt;br /&gt;Square Feet&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Use&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Lease expiry date&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Cranbury, New Jersey&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;90,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Office and laboratory&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;September 2025&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Durham, North Carolina&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5,603&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Office&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;June 2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Buckinghamshire, United Kingdom&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9,821&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Office&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;September 2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Munich, Germany&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,316&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Office&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;April 2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfRealEstatePropertiesTableTextBlock>
  <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Number of&lt;br /&gt;Share&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Weighted&lt;br /&gt;Average Grant&lt;br /&gt;Date Fair&lt;br /&gt;Value&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Weighted&lt;br /&gt;Average&lt;br /&gt;Remaining&lt;br /&gt;Years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Aggregate&lt;br /&gt;Intrinsic&lt;br /&gt;Value&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(in thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(in millions)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Non-vested units as of December&amp;nbsp;31, 2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;955.0
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2.28
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Granted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;366.0
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;12.63
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Vested&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(842.5
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Forfeited&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Non-vested units as of December&amp;nbsp;31, 2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;478.5
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;10.38
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Granted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;582.7
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6.21
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Vested&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(281.9
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8.73
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Forfeited&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(34.9
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7.71
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Non-vested units as of December&amp;nbsp;31, 2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;744.4
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7.86
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2.62
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Number of&lt;br /&gt;Shares&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Weighted&lt;br /&gt;Average&lt;br /&gt;Exercise&lt;br /&gt;Price&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Weighted&lt;br /&gt;Average&lt;br /&gt;Remaining&lt;br /&gt;Contractual Life&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Aggregate&lt;br /&gt;Intrinsic&lt;br /&gt;Value&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(in thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(in millions)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Options outstanding, December&amp;nbsp;31, 2013&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9,041.1
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5.65
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Granted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,993.1
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2.99
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Exercised&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(965.6
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3.80
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Forfeited&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1,047.9
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5.76
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Options outstanding, December&amp;nbsp;31, 2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;10,020.7
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5.02
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Granted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,917.2
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;11.61
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Exercised&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,070.3
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5.43
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Forfeited&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(138.4
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7.76
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Options outstanding, December&amp;nbsp;31, 2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;11,729.2
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7.11
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Granted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5,114.1
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7.67
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Exercised&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(723.1
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4.20
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Forfeited&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(622.7
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8.62
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Options outstanding, December&amp;nbsp;31, 2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;15,497.5
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7.37
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;7.3&amp;nbsp;years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7.8
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Vested and unvested expected to vest, December&amp;nbsp;31, 2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(14,593.7
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7.31
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;7.2&amp;nbsp;years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7.7
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Exercisable at December&amp;nbsp;31, 2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7,545.3
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6.57
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;5.8&amp;nbsp;years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5.8
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Years Ended&lt;br /&gt;December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Expected stock price volatility&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;81.3&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;75.9&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;81.3&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Risk free interest rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1.5&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1.7&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1.9&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Expected life of options (years)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6.25&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6.25&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6.25&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Expected annual dividend per share&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0.00&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0.00&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0.00&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Segment Information&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company currently operates in one business segment focused on the discovery, development and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases. The Company is not organized by market and is managed and operated as one business. A single management team reports to the chief operating decision maker who comprehensively manages the entire business. The Company does not operate any separate lines of business or separate business entities with respect to its products. Accordingly, the Company does not accumulate discrete financial information with respect to separate service lines and does not have separately reportable segments.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">20717000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">47269000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">71151000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">6008000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">9972000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">17504000</us-gaap:ShareBasedCompensation>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_fold_StockOptionPlan2002AndStockOptionPlan2007Member" unitRef="Unit13" decimals="4">0.0208</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit1" decimals="-2">34900</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit17" decimals="2">7.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit1" decimals="-2">366000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit1" decimals="-2">582700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit17" decimals="2">12.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit17" decimals="2">6.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="As_Of_12_31_2015_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit1" decimals="-2">478500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="As_Of_12_31_2016_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit1" decimals="-2">744400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="As_Of_12_31_2015_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit17" decimals="2">10.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="As_Of_12_31_2016_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit17" decimals="2">7.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">P2Y7M13D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit1" decimals="-2">842500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit1" decimals="-2">281900</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit17" decimals="2">8.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="Unit13" decimals="3">0.813</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="Unit13" decimals="3">0.759</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="Unit13" decimals="3">0.813</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit13" decimals="2">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="Unit13" decimals="3">0.019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="Unit13" decimals="3">0.017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="Unit13" decimals="3">0.015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="As_Of_12_31_2016_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_fold_StockOptionPlan2007AndDirectorOptionPlan2007Member_us-gaap_RangeAxis_us-gaap_MaximumMember" unitRef="Unit1" decimals="INF">12630551</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="As_Of_12_31_2016_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="Unit1" decimals="-1">7545300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="As_Of_12_31_2016_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="Unit17" decimals="2">6.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="Unit12" decimals="-5">2800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="Unit12" decimals="-5">14700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="Unit12" decimals="-5">2600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="Unit1" decimals="-1">1047900</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="Unit1" decimals="-1">138400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="Unit1" decimals="-1">622700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="Unit1" decimals="-1">2993100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="Unit1" decimals="-1">3917200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="Unit1" decimals="-1">5114100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="Unit17" decimals="2">2.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="Unit17" decimals="2">7.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="Unit17" decimals="2">5.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="As_Of_12_31_2016_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="Unit12" decimals="-2">7800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="As_Of_12_31_2013_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="Unit1" decimals="-1">9041100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="As_Of_12_31_2014_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="Unit1" decimals="-1">10020700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="As_Of_12_31_2014_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit1" decimals="-2">955000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="As_Of_12_31_2015_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="Unit1" decimals="-1">11729200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="As_Of_12_31_2016_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="Unit1" decimals="-1">15497500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="As_Of_12_31_2013_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="Unit17" decimals="2">5.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="As_Of_12_31_2014_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="Unit17" decimals="2">5.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="As_Of_12_31_2014_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit17" decimals="2">2.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="As_Of_12_31_2015_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="Unit17" decimals="2">7.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="As_Of_12_31_2016_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="Unit17" decimals="2">7.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember">P7Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="As_Of_12_31_2016_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="Unit12" decimals="-2">5800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="As_Of_12_31_2016_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="Unit12" decimals="-2">7700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="As_Of_12_31_2016_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="Unit1" decimals="-1">14593700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="As_Of_12_31_2016_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="Unit17" decimals="2">7.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember">P7Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_fold_PerformanceBasedRestrictedStockUnitAwardAgreementMember" unitRef="Unit1" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="Unit17" decimals="2">3.80</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="Unit17" decimals="2">5.43</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="Unit17" decimals="2">4.20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="Unit17" decimals="2">5.76</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="Unit17" decimals="2">7.76</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="Unit17" decimals="2">8.62</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="Unit17" decimals="2">2.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="Unit17" decimals="2">11.61</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="Unit17" decimals="2">7.67</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Equity-based Compensation&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;At December&amp;nbsp;31, 2016, the Company had three equity-based employee compensation plans, which are described more fully in "&amp;#x2014;&amp;nbsp;Note&amp;nbsp;9. Stockholders' Equity." The Company applies the fair value method of measuring equity-based compensation, which requires a public entity to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:SharesIssuedPricePerShare contextRef="As_Of_11_30_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit17" decimals="2">6.50</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="As_Of_6_30_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit17" decimals="2">13.25</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;2. Summary of Significant Accounting Policies&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Basis of Presentation&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("U.S.&amp;nbsp;GAAP") and include all adjustments necessary for the fair presentation of the Company's financial position for the periods presented.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Consolidation&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The consolidated financial statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions are eliminated in consolidation.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Foreign Currency Transactions&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The functional currency for most of the Company's foreign subsidiaries is their local currency. For non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of the Company's foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of equity.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company transacts business in various foreign countries and therefore, is subject to risk of foreign currency exchange rate fluctuations. As such, in June 2016, the Company entered into a forward contract to economically hedge transactional exposure associated with commitments arising from trade accounts payable denominated in a currency other than the functional currency of the respective operating entity. The Company does not designate this forward contract as a hedging instrument under applicable accounting guidance and, therefore, changes in fair value are recorded as other expense the Consolidated Statements of Operations.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Use of Estimates&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The preparation of financial statements in conformity with U.S.&amp;nbsp;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Cash, Money Market Funds, and Marketable Securities&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company considers all highly liquid investments purchased with a maturity of three months or less at the date of acquisition, to be cash equivalents.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Marketable securities consist of fixed income investments with a maturity of greater than three months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Company's balance sheet. Unrealized holding gains and losses are reported within comprehensive income/ (loss) in the statements of comprehensive loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations or other observable inputs. See "&amp;#x2014;&amp;nbsp;Note&amp;nbsp;5. Cash, Money Market Funds and Marketable Securities", for a summary of available-for-sale securities as of December&amp;nbsp;31, 2016 and 2015.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Concentration of Credit Risk&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company's financial instruments that are exposed to concentration of credit risk consist primarily of cash and cash equivalents and marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on cash and cash equivalents or its marketable securities.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company is subject to credit risk from its accounts receivable related to its product sales of Galafold. The majority of the Company's accounts receivable at December&amp;nbsp;31, 2016 have arisen from product sales in Germany. The Company will periodically assess the financial strength of its customers to establish allowances for anticipated losses, if any. For accounts receivable that have arisen from named patient sales, the payment terms are predetermined and the Company evaluates the creditworthiness of each customer on a regular basis. To date, the Company has not incurred any credit losses.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Property and Equipment&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is calculated over the estimated useful lives of the respective assets, which range from three to five years, or the lesser of the related initial term of the lease or useful life for leasehold improvements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The initial cost of property and equipment consists of its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use. Expenditures incurred after the fixed assets have been put into operation, such as repairs and maintenance, are charged to income in the period in which the costs are incurred. Major replacements, improvements and additions are capitalized in accordance with Company policy.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Revenue Recognition&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company recognizes revenue when amounts are realized or realizable and earned, which is typically upon shipment to the end-customer. Revenue is considered realizable and earned when persuasive evidence an arrangement exists, title to product and associated risk of loss has passed to the customer, the price is fixed or determinable, collection of the amounts due are reasonably assured and the Company has no further performance obligations.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Net Product Sales&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company's net product sales consist solely of sales of Galafold for the treatment of Fabry disease in the EU. The Company has recorded revenue on sales where Galafold is available either on a commercial basis or through a reimbursed early access program. Orders for Galafold are generally received from pharmacies and the ultimate payor is typically a government authority.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company records revenue net of estimated third party discounts and rebates. Allowances are recorded as a reduction of revenue at the time revenues from product sales are recognized. These allowances are adjusted to reflect known changes in factors and may impact such allowances in the quarter those changes are known.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Collaboration Revenue&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In multiple element arrangements, revenue is allocated to each separate unit of accounting and each deliverable in an arrangement is evaluated to determine whether it represents separate units of accounting. A deliverable constitutes a separate unit of accounting when it has standalone value and there is no general right of return for the delivered elements. In instances when the aforementioned criteria are not met, the deliverable is combined with the undelivered elements and the allocation of the arrangement consideration and revenue recognition is determined for the combined unit as a single unit of accounting. Allocation of the consideration is determined at arrangement inception on the basis of each unit's relative selling price. In instances where there is determined to be a single unit of accounting, the total consideration is applied as revenue for the single unit of accounting and is recognized over the period of inception through the date where the last deliverable within the single unit of accounting is expected to be delivered.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company's current revenue recognition policies provide that, when a collaboration arrangement contains multiple deliverables, such as license and research and development services, the Company allocates revenue to each separate unit of accounting based on a selling price hierarchy. The selling price hierarchy for a deliverable is based on (i)&amp;nbsp;its vendor specific objective evidence ("VSOE") if available, (ii)&amp;nbsp;third party evidence ("TPE") if VSOE is not available, or (iii)&amp;nbsp;best estimated selling price ("BESP") if neither VSOE nor TPE is available. The Company would establish the VSOE of selling price using the price charged for a deliverable when sold separately. The TPE of selling price would be established by evaluating largely similar and interchangeable competitor products or services in standalone sales to similarly situated customers. The BESP would be established considering internal factors such as an internal pricing analysis or an income approach using a discounted cash flow model.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company also considers the impact of potential future payments it makes in its role as a vendor to its customers and evaluates if these potential future payments could be a reduction of revenue from that customer. If the potential future payments to the customer are:&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:15;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:15;"&gt;
				&lt;td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Arabic Typesetting;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Arabic Typesetting;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Arabic Typesetting;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:15;"&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2022;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;a payment for an identifiable benefit; &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:15;"&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;height:35.40pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;height:35.40pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2022;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;height:35.40pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;the identifiable benefit is separable from the existing relationship between the Company and its customer;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:15;"&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2022;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;the identifiable benefit can be obtained from a party other than the customer; and &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:15;"&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2022;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;the Company can reasonably estimate the fair value of the identifiable benefit&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;then the payments are accounted for separate from the revenue received from that customer. If, however, all these criteria are not satisfied, then the payments are treated as a reduction of revenue from that customer.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;If the Company determines that any potential future payments to its customers are to be considered as a reduction of revenue, it must evaluate if the total amount of revenue to be received under the arrangement is fixed and determinable. If the total amount of revenue is not fixed and determinable due to the uncertain nature of the potential future payments to the customer, then any customer payments cannot be recognized as revenue until the total arrangement consideration becomes fixed and determinable.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The reimbursements for research and development costs under collaboration agreements that meet the criteria for revenue recognition are included in Research Revenue and the costs associated with these reimbursable amounts are included in research and development expenses.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In order to determine the revenue recognition for contingent milestones, the Company evaluates the contingent milestones using the criteria as provided by the Financial Accounting Standards Boards ("FASB") guidance on the milestone method of revenue recognition at the inception of a collaboration agreement. The criteria requires that (i)&amp;nbsp;the Company determines if the milestone is commensurate with either its performance to achieve the milestone or the enhancement of value resulting from the Company's activities to achieve the milestone, (ii)&amp;nbsp;the milestone be related to past performance, and (iii)&amp;nbsp;the milestone be reasonable relative to all deliverable and payment terms of the collaboration arrangement. If these criteria are met then the contingent milestones can be considered as substantive milestones and will be recognized as revenue in the period that the milestone is achieved.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Inventories and Cost of Cost of Goods Sold&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Until regulatory approval of Galafold, the Company expensed all manufacturing costs of Galafold as research and development expense. Upon regulatory approval, the Company began capitalizing costs related to the purchase and manufacture of Galafold.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Inventories are stated at the lower of cost or market determined by the first-in, first-out method. Inventories are reviewed periodically to identify slow-moving or obsolete inventory based on projected sales activity as well as product shelf-life. In evaluating the recoverability of inventories produced, the probability that revenue will be obtained from the future sale of the related inventory is considered and inventory value is written down for inventory quantities in excess of expected requirements. Expired inventory is disposed of and the related costs are recognized as cost of product sales in the consolidated statements of operations.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Cost of goods sold includes the cost of inventory sold, manufacturing and supply chain costs, product shipping and handling costs, provisions for excess and obsolete inventory, as well as royalties payable. A portion of the inventory available for sale was expensed as research and development costs prior to regulatory approval and as such the cost of goods sold and related gross margins are not necessarily indicative of future cost of goods sold and gross margin.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Fair Value Measurements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company records certain asset and liability balances under the fair value measurements as defined by the FASB guidance. Current FASB fair value guidance emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, current FASB guidance establishes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels&amp;nbsp;1 and 2 of the hierarchy) and the reporting entity's own assumptions that market participants assumptions would use in pricing assets or liabilities (unobservable inputs classified within Level&amp;nbsp;3 of the hierarchy).&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Level&amp;nbsp;1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at measurement date. Level&amp;nbsp;2 inputs are inputs other than quoted prices included in Level&amp;nbsp;1 that are observable for the asset or liability, either directly or indirectly. Level&amp;nbsp;2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals. Level&amp;nbsp;3 inputs are unobservable inputs for the asset or liability, which is typically based on an entity's own assumptions, as there is little, if any, related market activity. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Contingent Liabilities&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;On an ongoing basis, the Company may be involved in various claims, and legal proceedings. On a quarterly basis, the Company reviews the status of each significant matter and assesses its potential financial exposure. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated, the Company will accrue a liability for the estimated loss. Because of uncertainties related to claims and litigation, accruals will be based on our best estimates based on available information. On a periodic basis, as additional information becomes available, or based on specific events such as the outcome of litigation or settlement of claims, the Company may reassess the potential liability related to these matters and may revise these estimates, which could result in a material adverse adjustments to the Company's operating results.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Research and Development Costs&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Research and development costs are expensed as incurred. Research and development expense consists primarily of costs related to personnel, including salaries and other personnel related expenses, consulting fees and the cost of facilities and support services used in drug development. Assets acquired that are used for research and development and have no future alternative use are expensed as in-process research and development.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Interest Income and Interest Expense&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Interest income consists of interest earned on the Company's cash and cash equivalents and marketable securities. Interest expense consists of interest incurred on capital leases and debt.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Income Taxes&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company accounts for income taxes under the liability method. Under this method deferred income tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax basis of assets and liabilities and for operating losses and tax credit carry forwards, using enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance is recorded if it is "more likely than not" that a portion or all of a deferred tax asset will not be realized.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Other Comprehensive Income/ (Loss)&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Components of other comprehensive income/(loss) include unrealized gains and losses on available-for-sale securities and gain/(loss) on foreign currency transactions, and are included in the statements of comprehensive loss.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Leases&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In the ordinary course of business, the Company enters into lease agreements for office space as well as leases for certain property and equipment. The leases have varying terms and expirations and have provisions to extend or renew the lease agreement, among other terms and conditions, as negotiated. Once the agreement is executed, the lease is assessed to determine whether the lease qualifies as a capital or operating lease.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;When a non-cancelable operating lease includes any fixed escalation clauses and lease incentives for rent holidays or build-out contributions, rent expense is recognized on a straight-line basis over the initial term of the lease. The excess between the average rental amount charged to expense and amounts payable under the lease is recorded in accrued expenses.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Nonqualified Cash Deferral Plan&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company's Cash Deferral Plan (the "Deferral Plan"), provides certain key employees and members of the Board of Directors as selected by the Compensation Committee of the Board of Directors of the Company (the "Compensation Committee"), with an opportunity to defer the receipt of such participant's base salary, bonus and director's fees, as applicable. The Deferral Plan is intended to be a nonqualified deferred compensation plan that complies with the provisions of Section&amp;nbsp;409A of the Internal Revenue Code (the "Code"). All of the investments held in the Deferral Plan are classified as investments held-to-maturity and recorded at fair value with changes in the investments' fair value recognized as earnings in the period they occur. The corresponding liability for the Deferral Plan is included in other non-current liability in the consolidated balance sheets.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Equity-based Compensation&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;At December&amp;nbsp;31, 2016, the Company had three equity-based employee compensation plans, which are described more fully in "&amp;#x2014;&amp;nbsp;Note&amp;nbsp;9. Stockholders' Equity." The Company applies the fair value method of measuring equity-based compensation, which requires a public entity to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Loss per Common Share&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company calculates net loss per share as a measurement of the Company's performance while giving effect to all dilutive potential common shares that were outstanding during the reporting period. The Company had a net loss for all periods presented; accordingly, the inclusion of common stock options, unvested RSUs and warrants would be anti-dilutive. Therefore, the weighted average shares used to calculate both basic and diluted earnings per share are the same. See "&amp;#x2014;&amp;nbsp;Note&amp;nbsp;18. Earnings per Share" for further discussion on net loss per share.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Dividends&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company has not paid cash dividends on its capital stock to date. The Company currently intends to retain its future earnings, if any, to fund the development and growth of the business and does not foresee payment of a dividend in any upcoming fiscal period.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Segment Information&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company currently operates in one business segment focused on the discovery, development and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases. The Company is not organized by market and is managed and operated as one business. A single management team reports to the chief operating decision maker who comprehensively manages the entire business. The Company does not operate any separate lines of business or separate business entities with respect to its products. Accordingly, the Company does not accumulate discrete financial information with respect to separate service lines and does not have separately reportable segments.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Business Combinations&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company allocates the purchase price of acquired businesses to the tangible and intangible assets acquired and liabilities assumed based upon their estimated fair values on the acquisition date. The purchase price allocation process requires management to make significant estimates and assumptions, especially at the acquisition date with respect to intangible assets and in-process research and development ("IPR&amp;amp;D"). In connection with the purchase price allocations for acquisitions, the Company estimates the fair value of contingent payments utilizing a probability-based income approach inclusive of an estimated discount rate.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Contingent Consideration Payable&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company determines the fair value of contingent acquisition consideration payable on the acquisition date using a probability-based income approach utilizing an appropriate discount rate. Contingent acquisition consideration payable is shown as a non-current liability on the Company's consolidated balance sheets. The fair value of the contingent consideration payable will be determined each period end and the resulting change will be recorded on the consolidated statements of operations.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Intangible Assets and Goodwill&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company records goodwill in a business combination when the total consideration exceeds the fair value of the net tangible and identifiable intangible assets acquired. Purchased IPR&amp;amp;D is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset, or abandoned, at which point the intangible asset will be written off or partially impaired. Goodwill and indefinite lived intangible assets are assessed annually for impairment and whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. If it is determined that the full carrying amount of an asset is not recoverable, an impairment loss is recorded in the amount by which the carrying amount of the asset exceeds its fair value.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Recent Accounting Pronouncements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In January 2017, the FASB issued ASU 2017-04, &lt;/font&gt;&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Intangibles&amp;nbsp;&amp;#x2014; Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&lt;/font&gt;&lt;font style="display:inline;font-family:Times;"&gt;. To simplify the subsequent measurement of goodwill, ASU 2017-04 eliminates Step 2 from the goodwill impairment test. The annual, or interim, goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit's fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. In addition, income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit should be considered when measuring the goodwill impairment loss, if applicable. ASU 2017-04 also eliminates the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. ASU 2017-04 should be applied on a prospective basis. The nature of and reason for the change in accounting principle should be disclosed upon transition. A public business entity that is a U.S. SEC filer should adopt ASU 2017-04 for its annual or any interim goodwill impairment tests in fiscal years beginning after December&amp;nbsp;15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January&amp;nbsp;1, 2017. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In January 2017, the FASB issued ASU 2017-01, &lt;/font&gt;&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Business Combinations (Topic 805): Clarifying the Definition of a Business&lt;/font&gt;&lt;font style="display:inline;font-family:Times;"&gt;. This Accounting Standards Update clarifies the definition of a business. The amendments affect all companies and other reporting organizations that must determine whether they have acquired or sold a business. The amendments in this Update are effective for public companies for annual periods beginning after December&amp;nbsp;15, 2017, including interim periods within those periods. Early adoption is permitted under certain circumstances. The amendments should be applied prospectively as of the beginning of the period of adoption. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In October 2016, the FASB issued ASU 2016-17, &lt;/font&gt;&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Consolidation (Topic 810): Interests Held through Related Parties That Are under Common Control.&lt;/font&gt;&lt;font style="display:inline;font-family:Times;"&gt; This Accounting Standards Update changes the evaluation of whether a reporting entity is the primary beneficiary of a variable interest entity by changing how a reporting entity that is a single decision maker of a variable interest entity treats indirect interests in the entity held through related parties that are under common control with the reporting entity. If a reporting entity satisfies the first characteristic of a primary beneficiary (such that it is the single decision maker of a variable interest entity), the amendments require that reporting entity, in determining whether it satisfies the second characteristic of a primary beneficiary, to include all of its direct variable interests in a variable interest entity and, on a proportionate basis, its indirect variable interests in a variable interest entity held through related parties, including related parties that are under common control with the reporting entity. The amendments in this Update are effective for public business entities for fiscal years beginning after December&amp;nbsp;15, 2016, including interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The Company adopted this ASU in 2016 and the adoption did not have a material impact on its consolidated financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In October 2016, the FASB issued ASU 2016-16, &lt;/font&gt;&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory&lt;/font&gt;&lt;font style="display:inline;font-family:Times;"&gt;. This Accounting Standards Update requires an entity to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. The amendments eliminate the exception for an intra-entity transfer of an asset other than inventory. The amendments in this Update are effective for public business entities for annual periods beginning after December&amp;nbsp;15, 2017, including interim reporting periods within those annual reporting periods. Early adoption is permitted for all entities in the first interim period if an entity issues interim financial statements. The Company is currently assessing the impact that this standard will have on its consolidated financial statements. We have not completed our review of the impact of this guidance and do not expect this new guidance to have a material impact on our Consolidated Financial Statements. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In August 2016, the FASB issued ASU 2016-15, &lt;/font&gt;&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments&lt;/font&gt;&lt;font style="display:inline;font-family:Times;"&gt;. This Accounting Standards Update addresses the following eight specific cash flow issues including Debt prepayment or debt extinguishment costs, contingent consideration payments made after a business combination and separately identifiable cash flows and application of the predominance principle. The amendments in this ASU apply to all entities. The amendments in this Update are effective for public business entities for fiscal years beginning after December&amp;nbsp;15, 2017, and interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The Company adopted this ASU in 2016 and the adoption did not have a material impact on its consolidated financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In March 2016, the FASB issued ASU 2016-09&lt;/font&gt;&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;, Compensation&amp;nbsp;&amp;#x2014; Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting&lt;/font&gt;&lt;font style="display:inline;font-family:Times;"&gt;. The amendments are intended to improve the accounting for employee share-based payments and affect all organizations that issue share-based payment awards to their employees. Several aspects of the accounting for share-based payment award transactions are simplified, including: (a) income tax consequences; (b) classification of awards as either equity or liabilities; and (c) classification on the statement of cash flows. For public companies, the amendments are effective for annual periods beginning after December&amp;nbsp;15, 2016, and interim periods within those annual periods. Early adoption is permitted for any organization in any interim or annual period. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In February 2016, the FASB issued ASU No.&amp;nbsp;2016-02&lt;/font&gt;&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;, Leases (Topic 842)&lt;/font&gt;&lt;font style="display:inline;font-family:Times;"&gt;. This update requires the recognition of lease assets and lease liabilities on the balance sheet for all lease obligations and disclosing key information about leasing arrangements. This update requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous generally accepted accounting principles. This update will be effective for the Company for all annual and interim periods beginning after December&amp;nbsp;15, 2018, including interim periods within those fiscal years. Early application is permitted for all public business entities and all nonpublic business entities upon issuance. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330): &lt;/font&gt;&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Simplifying the Measurement of Inventory,&lt;/font&gt;&lt;font style="display:inline;font-family:Times;"&gt; which requires an entity to measure in scope inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The amendments apply to inventory that is measured using first-in, first-out (FIFO) or average cost. The ASU is effective for public business entities for fiscal years beginning after December&amp;nbsp;15, 2016, including interim periods within those fiscal years. A reporting entity should apply the amendments prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In August 2014, the FASB issued ASU 2014-15&lt;/font&gt;&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;, Presentation of Financial Statements-Going Concern (Subtopic 205-40):&lt;/font&gt;&lt;font style="display:inline;font-family:Times;"&gt; Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern, which defines management's responsibility to assess an entity's ability to continue as a going concern, and to provide related footnote disclosures if there is substantial doubt about its ability to continue as a going concern. The pronouncement is effective for annual reporting periods ending after December&amp;nbsp;15, 2016 with early adoption permitted. The Company adopted this ASU in 2016 and the adoption did not have a material impact on its consolidated financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In May 2014, FASB issued ASU 2014-09, &lt;/font&gt;&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/font&gt;&lt;font style="display:inline;font-family:Times;"&gt; which along with amendments issued in 2015 and 2016, will replace substantially all current US&amp;nbsp;GAAP guidance on this topic and eliminate industry-specific guidance. Early adoption of this standard is permitted but not before the original effective date for all annual periods and interim reporting periods beginning after December&amp;nbsp;15, 2017. The guidance permits two methods of adoption: full retrospective method (retrospective application to each prior reporting period presented) or modified retrospective method (retrospective application with the cumulative effect of initially applying the guidance recognized at the date of initial application and providing certain additional disclosures). To complete its assessment of the impact of the standard to its financial statements, the Company continues to assess all implications of this standard, method of adoption and related financial disclosures. Additionally, the Company continues to monitor modifications, clarifications and interpretations issued by the FASB that may impact its assessment.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2013" unitRef="Unit12" decimals="-3">45751000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2013_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">423593000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2013_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3">679000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2013_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember" unitRef="Unit12" decimals="-3">1000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2013_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3">-378522000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">122178000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">568743000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3">1015000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember" unitRef="Unit12" decimals="-3">-132000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3">-447448000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">347834000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">917454000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3">1306000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember" unitRef="Unit12" decimals="-3">-115000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3">-579566000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" unitRef="Unit12" decimals="-3">8755000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">360151000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">1120156000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3">1480000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_ComprehensiveIncomeMember" unitRef="Unit12" decimals="-3">2047000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3">-779608000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" unitRef="Unit12" decimals="-3">16076000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;9. Stockholders' Equity&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Common Stock and Warrants&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;As of December&amp;nbsp;31, 2016, the Company was authorized to issue 250&amp;nbsp;million shares of common stock. Dividends on common stock will be paid when, and if, declared by the board of directors. Each holder of common stock is entitled to vote on all matters that are appropriate for stockholder voting and is entitled to one vote for each share held.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;As discussed in "&amp;#x2014;&amp;nbsp;Note&amp;nbsp;16. Debt Instruments and Related Party Transactions", on December&amp;nbsp;21, 2016, the Company issued $250&amp;nbsp;million aggregate principal amount of 3.0% unsecured Convertible Senior Notes due 2023 (the "Convertible Notes), in a private offering. The Notes will mature on December&amp;nbsp;15, 2023, unless earlier repurchased, redeemed, or converted in accordance with their terms. The Notes are convertible at the option of the holders, under certain circumstances and during certain periods, into cash, shares of the Company's common stock, par value $0.01 per share ("Common Stock"), or a combination thereof. Prior to the close of business on the business day immediately preceding September&amp;nbsp;15, 2023, the Notes are convertible at the option of the holders of the Notes only under certain conditions. On or after September&amp;nbsp;15, 2023, until the close of business on the second business day immediately preceding the maturity date, holders of the Notes may convert their Notes at their option at the conversion rate then in effect, irrespective of these conditions. The Company will settle conversions of the Notes by paying or delivering, as the case may be, cash, shares of Common Stock, or a combination of cash and shares of Common Stock, at the Company's election. The conversion rate will initially be 163.3987 shares of Common Stock per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $6.12 per share of Common Stock). The conversion rate is subject to customary adjustments upon the occurrence of certain events.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Beginning in April 2016 and through July 2016, the Company sold 15.0&amp;nbsp;million shares of Common Stock under an ATM equity program with Cowen and Company,&amp;nbsp;LLC ("Cowen") acting as sales agent. Cowen was compensated at a fixed commission rate up to 3.0%. The ATM sales agreement resulted in net proceeds of $97.1&amp;nbsp;million, after Cowen's commission of $2.7&amp;nbsp;million and other expenses of $0.2&amp;nbsp;million. The Company has completed all sales under the ATM equity program.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;As discussed in "&amp;#x2014;&amp;nbsp;Note&amp;nbsp;16. Debt instruments and Related Party Transactions," the Company issued approximately 1.8&amp;nbsp;million and 1.3&amp;nbsp;million of warrants in February 2016 and June 2016, respectively. The closing balance of the warrants was $16.1&amp;nbsp;million as of December&amp;nbsp;31, 2016 and is recorded within equity on the Consolidated Balance Sheets.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;As discussed in "&amp;#x2014;&amp;nbsp;Note&amp;nbsp;3. Acquisitions, in July 2016, the Company entered into an Agreement and Plan of Merger (the "MiaMed Agreement") with MiaMed. Under the terms of the MiaMed Agreement, the former holders of MiaMed's capital stock received an aggregate of $6.5&amp;nbsp;million, comprised of (i)&amp;nbsp;approximately $1.8&amp;nbsp;million in cash (plus MiaMed's cash and cash equivalents at closing and less any of MiaMed's unpaid third-party fees and expenses related to the transaction), and (ii)&amp;nbsp;825,603 shares of the Company's Common Stock. In addition, the Company also agreed to pay up to an additional $83.0&amp;nbsp;million in connection with the achievement of certain clinical, regulatory and commercial milestones, for a potential aggregate deal value of $89.5&amp;nbsp;million.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;As discussed in "&amp;#x2014;&amp;nbsp;Note&amp;nbsp;3. Acquisitions, in September 2015, the Company acquired Scioderm with cash and stock. As part of the acquisition, the Company paid holders of Scioderm an amount equal to $223.9&amp;nbsp;million, of which approximately $141.1&amp;nbsp;million was paid in cash and approximately $82.8&amp;nbsp;million was paid through the issuance of 5.9&amp;nbsp;million newly issued shares. The Company agreed to pay up to an additional $361&amp;nbsp;million upon achievement of certain clinical and regulatory milestones, and $257&amp;nbsp;million to Scioderm shareholders, option holders, and warrant holders upon achievement of certain sales milestones.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In June 2015, the Company issued a total of 19.5&amp;nbsp;million shares through a public offering at a price of $13.25 per share, with net proceeds of $243.0&amp;nbsp;million. The Company expects to use the net proceeds of the offering for investment in the global commercialization infrastructure for Galafold for Fabry disease, the continued clinical development of its product candidates and for other general corporate purposes.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In November 2014, the Company sold a total of 15.9&amp;nbsp;million shares of our common stock, par value $0.01 per share, at a public offering price of $6.50 per share. The aggregate offering proceeds were approximately $97.2&amp;nbsp;million.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In July 2014, the Company completed a $40&amp;nbsp;million ATM equity offering under which the Company sold shares of its common stock, par value $0.01 per shares with Cowen and Company&amp;nbsp;LLC as sales agent. Under the ATM equity program the Company sold 14.3&amp;nbsp;million shares of common stock resulting in net proceeds of $38.6&amp;nbsp;million.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Nonqualified Cash Plan&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company's Deferral Plan, (the "Deferral Plan") provides certain key employees and members of the Board of Directors as selected by the Compensation Committee, with an opportunity to defer the receipt of such participant's base salary, bonus and director's fees, as applicable. The Deferral Plan is intended to be a nonqualified deferred compensation plan that complies with the provisions of Section&amp;nbsp;409A of the Internal Revenue Code of 1986 as amended.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Deferred compensation amounts under the Deferral Plan as of December&amp;nbsp;31, 2016 were approximately $1.5&amp;nbsp;million, as compared to $0.7&amp;nbsp;million on December&amp;nbsp;31, 2015 and are included in other long-term liabilities. Deferral Plan assets as of December&amp;nbsp;31, 2016 were $1.5&amp;nbsp;million as compared to $0.7&amp;nbsp;million as of December&amp;nbsp;31, 2015 and are classified as trading securities. The Deferred Plan assets are recorded at fair value with changes in the investments' fair value recognized in AOCI in the period they occur. The income from investment for the year ended December&amp;nbsp;31, 2016 and 2015 was $34&amp;nbsp;thousand and $17&amp;nbsp;thousand respectively. Unrealized gain approximated $32&amp;nbsp;thousand for the year ended December&amp;nbsp;31, 2016, as compared to unrealized loss of $50&amp;nbsp;thousand for the year ended December&amp;nbsp;31, 2015.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Equity Incentive Plans&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company's Equity Incentive Plans consist of the Amended and Restated 2007 Equity Incentive Plan (the "Plan") and the 2007 Director Option Plan (the "2007 Director Plan"). The Plan provides for the granting of restricted stock and options to purchase common stock in the Company to employees, advisors and consultants at a price to be determined by the Company's board of directors. The Plan is intended to encourage ownership of stock by employees and consultants of the Company and to provide additional incentives for them to promote the success of the Company's business. The 2007 Director Plan is intended to promote the recruiting and retention of highly qualified eligible directors and strengthen the commonality of interest between directors and stockholders by encouraging ownership of common stock of the Company. Under the provisions of each plan, no option will have a term in excess of 10&amp;nbsp;years.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Board of Directors, or its committee, is responsible for determining the individuals to be granted options, the number of options each individual will receive, the option price per share, and the exercise period of each option. Options granted pursuant to the Plan generally vest 25% on the first year anniversary date of grant plus an additional 1/48th&amp;nbsp;for each month thereafter and may be exercised in whole or in part for 100% of the shares vested at any time after the date of grant. Options under the 2007 Director Plan may be granted to new directors upon joining the Board and vest in the same manner as options under the Plan. In addition, options are automatically granted to all directors at each annual meeting of stockholders and vest on the date of the annual meeting of stockholders of the Company in the year following the year during which the options were granted.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;As of December&amp;nbsp;31, 2016, the Company has reserved up to 12,630,511 shares for issuance under the Plan and the 2007 Director Plan.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Stock Option Grants&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company adopted the fair value method of measuring stock-based compensation, using the fair value of each equity award granted. The Company chose the "straight-line" attribution method for allocating compensation costs and recognized the fair value of each stock option on a straight-line basis over the vesting period of the related awards.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company uses the Black-Scholes option pricing model when estimating the grant date fair value for stock-based awards. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs. Expected volatility was based on our historical volatility since our initial public offering in May 2007.The average expected life was determined using the "simplified" method of estimating the expected exercise term which is the mid-point between the vesting date and the end of the contractual term. As the Company's stock price volatility has been over 75% and it has experienced significant business transactions, the Company does not have sufficient reliable exercise data in order to justify a change in the use of the "simplified" method of estimating the expected exercise term of employee stock option grants. The risk-free interest rate is based on U.S. Treasury, zero-coupon issues with a remaining term equal to the expected life assumed at the date of grant. Forfeitures are estimated based on voluntary termination behavior, as well as a historical analysis of actual option forfeitures.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The weighted average assumptions used in the Black-Scholes option pricing model are as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Years Ended&lt;br /&gt;December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Expected stock price volatility&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;81.3&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;75.9&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;81.3&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Risk free interest rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1.5&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1.7&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1.9&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Expected life of options (years)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6.25&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6.25&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6.25&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Expected annual dividend per share&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0.00&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0.00&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0.00&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The weighted average grant-date fair value per share of options granted during 2016, 2015 and 2014 were $5.28, $7.51 and $2.12, respectively.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The following table summarizes information about stock options outstanding:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Number of&lt;br /&gt;Shares&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Weighted&lt;br /&gt;Average&lt;br /&gt;Exercise&lt;br /&gt;Price&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Weighted&lt;br /&gt;Average&lt;br /&gt;Remaining&lt;br /&gt;Contractual Life&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Aggregate&lt;br /&gt;Intrinsic&lt;br /&gt;Value&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(in thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(in millions)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Options outstanding, December&amp;nbsp;31, 2013&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9,041.1
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5.65
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Granted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,993.1
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2.99
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Exercised&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(965.6
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3.80
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Forfeited&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1,047.9
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5.76
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Options outstanding, December&amp;nbsp;31, 2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;10,020.7
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5.02
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Granted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,917.2
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;11.61
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Exercised&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,070.3
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5.43
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Forfeited&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(138.4
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7.76
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Options outstanding, December&amp;nbsp;31, 2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;11,729.2
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7.11
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Granted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5,114.1
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7.67
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Exercised&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(723.1
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4.20
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Forfeited&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(622.7
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8.62
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Options outstanding, December&amp;nbsp;31, 2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;15,497.5
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7.37
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;7.3&amp;nbsp;years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7.8
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Vested and unvested expected to vest, December&amp;nbsp;31, 2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(14,593.7
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7.31
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;7.2&amp;nbsp;years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7.7
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Exercisable at December&amp;nbsp;31, 2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7,545.3
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6.57
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;5.8&amp;nbsp;years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5.8
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The aggregate intrinsic value of options exercised during the years ended December&amp;nbsp;31, 2016, 2015 and 2014 was $2.6&amp;nbsp;million, $14.7&amp;nbsp;million and $2.8&amp;nbsp;million respectively. Cash proceeds from stock options exercised during the years ended December&amp;nbsp;31, 2016, 2015, and 2014 were $3.0&amp;nbsp;million, $11.2&amp;nbsp;million, and $3.7&amp;nbsp;million, respectively. As of December&amp;nbsp;31, 2016, the total unrecognized compensation cost related to non-vested stock options granted was $33.7&amp;nbsp;million and is expected to be recognized over a weighted average period of 2.8&amp;nbsp;years.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Restricted Stock Units&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;RSUs awarded under the Plan are generally subject to graded vesting and are contingent on an employee's continued service. RSUs are generally subject to forfeiture if employment terminates prior to the release of vesting restrictions. The Company expenses the cost of the RSUs, which is determined to be the fair market value of the shares of common stock underlying the RSUs at the date of grant, ratably over the period during which the vesting restrictions lapse.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;A summary of non-vested RSU activity under the Plan for the year ended December&amp;nbsp;31, 2016 is as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Number of&lt;br /&gt;Share&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Weighted&lt;br /&gt;Average Grant&lt;br /&gt;Date Fair&lt;br /&gt;Value&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Weighted&lt;br /&gt;Average&lt;br /&gt;Remaining&lt;br /&gt;Years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Aggregate&lt;br /&gt;Intrinsic&lt;br /&gt;Value&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(in thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(in millions)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Non-vested units as of December&amp;nbsp;31, 2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;955.0
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2.28
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Granted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;366.0
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;12.63
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Vested&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(842.5
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Forfeited&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Non-vested units as of December&amp;nbsp;31, 2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;478.5
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;10.38
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Granted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;582.7
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6.21
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Vested&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(281.9
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8.73
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Forfeited&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(34.9
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7.71
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Non-vested units as of December&amp;nbsp;31, 2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;744.4
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7.86
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2.62
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;For the year ended December&amp;nbsp;31, 2016, 0.3&amp;nbsp;million of the RSUs vested and all non-vested units are expected to vest over their normal term. As of December&amp;nbsp;31, 2016, there was $4.2&amp;nbsp;million of total unrecognized compensation cost related to unvested RSUs with service-based vesting conditions. These costs are expected to be recognized over a weighted average period of 2.62&amp;nbsp;years.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;On December&amp;nbsp;30, 2016, the Compensation Committee approved a form of Performance-Based Restricted Stock Unit Award Agreement (the "Performance-Based RSU Agreement"), to be used for performance-based RSUs granted to participants under the Amended and Restated Amicus Therapeutics,&amp;nbsp;Inc. 2007 Equity Incentive Plan, including named executive officers. Awards under the form of Performance-Based RSU Agreement will vest based on the Company meeting specified performance criteria. Vesting of the RSUs is generally subject to the participant's continuous service with the Company through a specified date. As of December&amp;nbsp;31, 2016 there were no RSUs issued under the Performance-Based RSU Agreement.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-style:italic;"&gt;Compensation Expense Related to Equity Awards&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The following table summarizes the equity-based compensation expense recognized in the statements of operations (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Years Ended December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Equity compensation expense recognized in:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Research and development expense&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8,071&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,600&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,703&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Selling, general and administrative expense&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9,433&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5,372&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,305&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Total equity compensation expense&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;17,504&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9,972&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6,008&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:StockholdersEquityPolicyTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Dividends&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company has not paid cash dividends on its capital stock to date. The Company currently intends to retain its future earnings, if any, to fund the development and growth of the business and does not foresee payment of a dividend in any upcoming fiscal period.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:StockholdersEquityPolicyTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_BusinessAcquisitionAxis_fold_CallidusBiopharmaIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">2359593</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
  <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_BusinessAcquisitionAxis_fold_CallidusBiopharmaIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">25762</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
  <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">5921771</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
  <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_BusinessAcquisitionAxis_fold_MiaMedIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">825603</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">15927500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_11_1_2014_To_11_30_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="-5">15900000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">19528302</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_6_1_2015_To_6_30_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="-5">19500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">324622</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">268425</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="Unit1" decimals="-1">965600</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">965544</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="Unit1" decimals="-1">2070300</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">2070300</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_fold_EmployeeAndDirectorsStockOptionsMember" unitRef="Unit1" decimals="-1">723100</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">723102</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_BusinessAcquisitionAxis_fold_CallidusBiopharmaIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">-24000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_BusinessAcquisitionAxis_fold_CallidusBiopharmaIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3">24000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember" unitRef="Unit12" decimals="-3">82846000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">82787000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_BusinessAcquisitionAxis_fold_SciodermIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3">59000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_BusinessAcquisitionAxis_fold_MiaMedIncMember" unitRef="Unit12" decimals="-3">4607000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_BusinessAcquisitionAxis_fold_MiaMedIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">4599000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_BusinessAcquisitionAxis_fold_MiaMedIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3">8000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">97169000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">97010000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3">159000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">243042000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">242847000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3">195000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">6008000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">6008000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">9972000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">9972000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">17504000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">17504000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">3673000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">3663000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3">10000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">11186000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">11165000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3">21000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">3036000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">3029000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3">7000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:SubsequentEventsTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;19. Subsequent Events&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company evaluated events that occurred subsequent to December&amp;nbsp;31, 2016 and found there were no material recognized or non-recognized subsequent events during this period.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:TradingSecurities contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-5">700000</us-gaap:TradingSecurities>
  <us-gaap:TradingSecurities contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-5">1500000</us-gaap:TradingSecurities>
  <us-gaap:TradingSecuritiesUnrealizedHoldingGainLoss contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">50000</us-gaap:TradingSecuritiesUnrealizedHoldingGainLoss>
  <us-gaap:TradingSecuritiesUnrealizedHoldingGainLoss contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">32000</us-gaap:TradingSecuritiesUnrealizedHoldingGainLoss>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-5">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-5">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
  <us-gaap:UseOfEstimates contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;"&gt;Use of Estimates&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The preparation of financial statements in conformity with U.S.&amp;nbsp;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-5">65300000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-5">73200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:WarrantsAndRightsOutstanding contextRef="As_Of_10_31_2015_us-gaap_CounterpartyNameAxis_fold_RedmileGroupMember_us-gaap_DebtInstrumentAxis_fold_NoteAndWarrantAgreement2015Member" unitRef="Unit12" decimals="-5">8800000</us-gaap:WarrantsAndRightsOutstanding>
  <us-gaap:WarrantsAndRightsOutstanding contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">8755000</us-gaap:WarrantsAndRightsOutstanding>
  <us-gaap:WarrantsAndRightsOutstanding contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">16076000</us-gaap:WarrantsAndRightsOutstanding>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="0">74444157</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="0">109923815</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit1" decimals="0">134401588</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <!--Footnote Section-->
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>fold-20161231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!--XBRL document created with Merrill Bridge  6.4.50.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/1/2017 2:07:09 PM-->
<!--Modified on: 3/1/2017 2:07:09 PM-->
<xsd:schema targetNamespace="http://www.amicustherapeutics.com/20161231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2015-01-31" xmlns:us-roles="http://fasb.org/us-roles/2015-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-types="http://fasb.org/us-types/2015-01-31" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:attributeFormDefault="unqualified" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:fold="http://www.amicustherapeutics.com/20161231">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/StatementConsolidatedStatementsOfOperations" id="StatementConsolidatedStatementsOfOperations">
        <link:definition>00200 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" id="StatementConsolidatedStatementsOfComprehensiveLoss">
        <link:definition>00300 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>00500 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureAcquisitionsDetails" id="DisclosureAcquisitionsDetails">
        <link:definition>40301 - Disclosure - Acquisitions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureCashMoneyMarketFundsAndMarketableSecuritiesDetails" id="DisclosureCashMoneyMarketFundsAndMarketableSecuritiesDetails">
        <link:definition>40501 - Disclosure - Cash, Money Market Funds and Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureCashMoneyMarketFundsAndMarketableSecuritiesDetailsCalc2" id="DisclosureCashMoneyMarketFundsAndMarketableSecuritiesDetailsCalc2">
        <link:definition>40501 - Disclosure - Cash, Money Market Funds and Marketable Securities (Details) (Calc 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureInventoriesDetails" id="DisclosureInventoriesDetails">
        <link:definition>40601 - Disclosure - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosurePropertyAndEquipmentDetails" id="DisclosurePropertyAndEquipmentDetails">
        <link:definition>40701 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails" id="DisclosureAccountsPayableAndAccruedExpensesDetails">
        <link:definition>40801 - Disclosure - Accounts Payable and Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetails" id="DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetails">
        <link:definition>41001 - Disclosure - Assets and Liabilities Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureLeasesDetails" id="DisclosureLeasesDetails">
        <link:definition>41201 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureIncomeTaxesStatutoryRateDetails" id="DisclosureIncomeTaxesStatutoryRateDetails">
        <link:definition>41301 - Disclosure - Income Taxes - Statutory Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureIncomeTaxesDeferredAndValuationDetails" id="DisclosureIncomeTaxesDeferredAndValuationDetails">
        <link:definition>41302 - Disclosure - Income Taxes - Deferred and Valuation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureDebtInstrumentsAndRelatedPartyTransactionsConvertibleDebtDetails" id="DisclosureDebtInstrumentsAndRelatedPartyTransactionsConvertibleDebtDetails">
        <link:definition>41602 - Disclosure - Debt Instruments and Related Party Transactions - Convertible Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/StatementConsolidatedStatementsOfComprehensiveLossParenthetical" id="StatementConsolidatedStatementsOfComprehensiveLossParenthetical">
        <link:definition>00305 - Statement - Consolidated Statements of Comprehensive Loss (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" id="StatementConsolidatedStatementsOfChangesInStockholdersEquity">
        <link:definition>00400 - Statement - Consolidated Statements of Changes in Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" id="StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical">
        <link:definition>00405 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureDescriptionOfBusiness" id="DisclosureDescriptionOfBusiness">
        <link:definition>10101 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>10201 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureAcquisitions" id="DisclosureAcquisitions">
        <link:definition>10301 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureGoodwillAndIntangibleAssets" id="DisclosureGoodwillAndIntangibleAssets">
        <link:definition>10401 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureCashMoneyMarketFundsAndMarketableSecurities" id="DisclosureCashMoneyMarketFundsAndMarketableSecurities">
        <link:definition>10501 - Disclosure - Cash, Money Market Funds and Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureInventories" id="DisclosureInventories">
        <link:definition>10601 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosurePropertyAndEquipment" id="DisclosurePropertyAndEquipment">
        <link:definition>10701 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpenses" id="DisclosureAccountsPayableAndAccruedExpenses">
        <link:definition>10801 - Disclosure - Accounts Payable and Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>10901 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValue" id="DisclosureAssetsAndLiabilitiesMeasuredAtFairValue">
        <link:definition>11001 - Disclosure - Assets and Liabilities Measured at Fair Value</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/Disclosure401KPlan" id="Disclosure401KPlan">
        <link:definition>11101 - Disclosure - 401(k) Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureLeases" id="DisclosureLeases">
        <link:definition>11201 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>11301 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureLicenses" id="DisclosureLicenses">
        <link:definition>11401 - Disclosure - Licenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureCollaborativeAgreements" id="DisclosureCollaborativeAgreements">
        <link:definition>11501 - Disclosure - Collaborative Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureDebtInstrumentsAndRelatedPartyTransactions" id="DisclosureDebtInstrumentsAndRelatedPartyTransactions">
        <link:definition>11601 - Disclosure - Debt Instruments and Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureEarningsPerShare" id="DisclosureEarningsPerShare">
        <link:definition>11701 - Disclosure - Earnings per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>11801 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>11901 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureSelectedQuarterlyFinancialDataUnauditedInThousandsExceptPerShareData" id="DisclosureSelectedQuarterlyFinancialDataUnauditedInThousandsExceptPerShareData">
        <link:definition>12001 - Disclosure - Selected Quarterly Financial Data (Unaudited - in thousands except per share data)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureGoodwillAndIntangibleAssetsTables" id="DisclosureGoodwillAndIntangibleAssetsTables">
        <link:definition>30403 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureCashMoneyMarketFundsAndMarketableSecuritiesTables" id="DisclosureCashMoneyMarketFundsAndMarketableSecuritiesTables">
        <link:definition>30503 - Disclosure - Cash, Money Market Funds and Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureInventoriesTables" id="DisclosureInventoriesTables">
        <link:definition>30603 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosurePropertyAndEquipmentTables" id="DisclosurePropertyAndEquipmentTables">
        <link:definition>30703 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesTables" id="DisclosureAccountsPayableAndAccruedExpensesTables">
        <link:definition>30803 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureStockholdersEquityTables" id="DisclosureStockholdersEquityTables">
        <link:definition>30903 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueTables" id="DisclosureAssetsAndLiabilitiesMeasuredAtFairValueTables">
        <link:definition>31003 - Disclosure - Assets and Liabilities Measured at Fair Value (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureLeasesTables" id="DisclosureLeasesTables">
        <link:definition>31203 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>31303 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureDebtInstrumentsAndRelatedPartyTransactionsTables" id="DisclosureDebtInstrumentsAndRelatedPartyTransactionsTables">
        <link:definition>31603 - Disclosure - Debt Instruments and Related Party Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureEarningsPerShareTables" id="DisclosureEarningsPerShareTables">
        <link:definition>31703 - Disclosure - Earnings per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureSelectedQuarterlyFinancialDataUnauditedInThousandsExceptPerShareDataTables" id="DisclosureSelectedQuarterlyFinancialDataUnauditedInThousandsExceptPerShareDataTables">
        <link:definition>32003 - Disclosure - Selected Quarterly Financial Data (Unaudited - in thousands except per share data) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureDescriptionOfBusinessDetails" id="DisclosureDescriptionOfBusinessDetails">
        <link:definition>40101 - Disclosure - Description of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails">
        <link:definition>40201 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEquityIncentivePlanAndStockBasedCompensationDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesEquityIncentivePlanAndStockBasedCompensationDetails">
        <link:definition>40202 - Disclosure - Summary of Significant Accounting Policies - Equity Incentive Plan and Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentInformationDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesSegmentInformationDetails">
        <link:definition>40203 - Disclosure - Summary of Significant Accounting Policies - Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureGoodwillAndIntangibleAssetsGoodwillDetails" id="DisclosureGoodwillAndIntangibleAssetsGoodwillDetails">
        <link:definition>40401 - Disclosure - Goodwill and Intangible Assets - Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureGoodwillAndIntangibleAssetsIprDDetails" id="DisclosureGoodwillAndIntangibleAssetsIprDDetails">
        <link:definition>40402 - Disclosure - Goodwill and Intangible Assets - IPR&amp;D (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureStockholdersEquityCommonStockAndWarrantsDetails" id="DisclosureStockholdersEquityCommonStockAndWarrantsDetails">
        <link:definition>40901 - Disclosure - Stockholders' Equity - Common Stock and Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureStockholdersEquityEquityIncentivePlansDetails" id="DisclosureStockholdersEquityEquityIncentivePlansDetails">
        <link:definition>40902 - Disclosure - Stockholders' Equity - Equity Incentive Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureStockholdersEquityCompensationExpenseDetails" id="DisclosureStockholdersEquityCompensationExpenseDetails">
        <link:definition>40903 - Disclosure - Stockholders' Equity - Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/Disclosure401KPlanDetails" id="Disclosure401KPlanDetails">
        <link:definition>41101 - Disclosure - 401(k) Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureIncomeTaxesLossCarryforwardsDetails" id="DisclosureIncomeTaxesLossCarryforwardsDetails">
        <link:definition>41303 - Disclosure - Income Taxes - Loss Carryforwards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureLicensesDetails" id="DisclosureLicensesDetails">
        <link:definition>41401 - Disclosure - Licenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureCollaborativeAgreementsDetails" id="DisclosureCollaborativeAgreementsDetails">
        <link:definition>41501 - Disclosure - Collaborative Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureDebtInstrumentsAndRelatedPartyTransactionsNoteAndWarrantPurchaseAgreementsDetails" id="DisclosureDebtInstrumentsAndRelatedPartyTransactionsNoteAndWarrantPurchaseAgreementsDetails">
        <link:definition>41601 - Disclosure - Debt Instruments and Related Party Transactions - Note and Warrant Purchase Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureEarningsPerShareDetails" id="DisclosureEarningsPerShareDetails">
        <link:definition>41701 - Disclosure - Earnings per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails" id="DisclosureCommitmentsAndContingenciesDetails">
        <link:definition>41801 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amicustherapeutics.com/role/DisclosureSelectedQuarterlyFinancialDataUnauditedInThousandsExceptPerShareDataDetails" id="DisclosureSelectedQuarterlyFinancialDataUnauditedInThousandsExceptPerShareDataDetails">
        <link:definition>42001 - Disclosure - Selected Quarterly Financial Data (Unaudited - in thousands except per share data) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="fold-20161231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="fold-20161231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="fold-20161231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="fold-20161231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <import namespace="http://fasb.org/us-gaap/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd" xmlns="http://www.w3.org/2001/XMLSchema" />
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_BusinessCombinationContingentConsiderationLiabilityRollForward" name="BusinessCombinationContingentConsiderationLiabilityRollForward" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element name="NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones" id="fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BiogenIdecMember" id="fold_BiogenIdecMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AccruedContractManufacturingAndContractResearchCostsCurrent" id="fold_AccruedContractManufacturingAndContractResearchCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="AccruedFacilityCostsCurrent" id="fold_AccruedFacilityCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" id="fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure" id="fold_CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="CollaborativeArrangementDisclosureAbstract" id="fold_CollaborativeArrangementDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <element id="fold_VestingRightsPercentageOnFirstYearAnniversary" name="VestingRightsPercentageOnFirstYearAnniversary" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element name="CommonStockVotingRightsForEachShareHeld" id="fold_CommonStockVotingRightsForEachShareHeld" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="DeferredTaxAssetsLiabilitiesGross" id="fold_DeferredTaxAssetsLiabilitiesGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="DeferredTaxAssetsNoncurrentAbstract" id="fold_DeferredTaxAssetsNoncurrentAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DocumentAndEntityInformationAbstract" id="fold_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="GlaxoSmithKlinePLCMember" id="fold_GlaxoSmithKlinePLCMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IncomeTaxExpensesBenefitFromSaleOfNetOperatingLossesAndResearchAndDevelopmentCredits" id="fold_IncomeTaxExpensesBenefitFromSaleOfNetOperatingLossesAndResearchAndDevelopmentCredits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="InterestIncomeAndInterestExpensePolicyTextBlock" id="fold_InterestIncomeAndInterestExpensePolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LicenseAgreementMilestonePaymentsPotential" id="fold_LicenseAgreementMilestonePaymentsPotential" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="LicenseAgreementUpfrontPaymentAndAnnualLicenseFees" id="fold_LicenseAgreementUpfrontPaymentAndAnnualLicenseFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="MtSinaiSchoolOfMedicineOfNewYorkUniversityMember" id="fold_MtSinaiSchoolOfMedicineOfNewYorkUniversityMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OperatingLeasesFutureMinimumPaymentsDueInFiveYearsAndThereafter" id="fold_OperatingLeasesFutureMinimumPaymentsDueInFiveYearsAndThereafter" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="OperatingLossCarryforwardsLimitationsOnUseMinimumOwnershipPercentageChangeRelatingToSection382" id="fold_OperatingLossCarryforwardsLimitationsOnUseMinimumOwnershipPercentageChangeRelatingToSection382" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OperatingLossCarryforwardsLimitationsOnUseMinimumPercentageOwnershipChangePeriod" id="fold_OperatingLossCarryforwardsLimitationsOnUseMinimumPercentageOwnershipChangePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OtherComprehensiveIncomePolicyPolicyTextBlock" id="fold_OtherComprehensiveIncomePolicyPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ProceedsFromIssuanceOfCommonStockGross" id="fold_ProceedsFromIssuanceOfCommonStockGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ResearchEquipmentMember" id="fold_ResearchEquipmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <element id="fold_ResearchRevenue" name="ResearchRevenue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" id="fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" type="num:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionPercentageOfSharesVestedThatMayBeExercisedInWholeOrPart" id="fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionPercentageOfSharesVestedThatMayBeExercisedInWholeOrPart" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageContractualLifeAbstract" id="fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageContractualLifeAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationNumberOfPlans" id="fold_ShareBasedCompensationNumberOfPlans" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="StockIssuedDuringPeriodSharesWarrantsExercised" id="fold_StockIssuedDuringPeriodSharesWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodValueWarrantsExercised" id="fold_StockIssuedDuringPeriodValueWarrantsExercised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="StockOptionPlan2007AndDirectorOptionPlan2007Member" id="fold_StockOptionPlan2007AndDirectorOptionPlan2007Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="WarrantTerm" id="fold_WarrantTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EmployeeAndDirectorsStockOptionsMember" id="fold_EmployeeAndDirectorsStockOptionsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockOptionPlan2002AndStockOptionPlan2007Member" id="fold_StockOptionPlan2002AndStockOptionPlan2007Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ContingentAcquisitionConsiderationPayablePolicyTextBlock" id="fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CallidusBiopharmaIncMember" id="fold_CallidusBiopharmaIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RevisedCollaborationAgreementMember" id="fold_RevisedCollaborationAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RedmileGroupMember" id="fold_RedmileGroupMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <element id="fold_StockAndWarrantsIssuedDuringPeriodValueNewIssues" name="StockAndWarrantsIssuedDuringPeriodValueNewIssues" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element name="CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments" id="fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="SalesAgreementMember" id="fold_SalesAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CowenAndCompanyLLCMember" id="fold_CowenAndCompanyLLCMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="FixedCommissionRateAsPercentageOfGrossProceedsPerShareSold" id="fold_FixedCommissionRateAsPercentageOfGrossProceedsPerShareSold" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CommonStockIssuanceCommissionExpenses" id="fold_CommonStockIssuanceCommissionExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <element id="fold_StockIssuedDuringPeriodValueAtMarketOffering" name="StockIssuedDuringPeriodValueAtMarketOffering" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_StockIssuedDuringPeriodSharesAtMarketOffering" name="StockIssuedDuringPeriodSharesAtMarketOffering" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_AvailableForSaleSecuritiesAmortizedCostCurrent" name="AvailableForSaleSecuritiesAmortizedCostCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element name="AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" id="fold_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <element id="fold_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" name="AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element name="NonqualifiedCashDeferralPlansPolicy" id="fold_NonqualifiedCashDeferralPlansPolicy" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="fold_ShortTermCorporateDebtSecuritiesMember" name="ShortTermCorporateDebtSecuritiesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_ContingentConsiderationMilestonePayment" name="ContingentConsiderationMilestonePayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element name="PaymentsForRepurchaseOfRestrictedStockUnits" id="fold_PaymentsForRepurchaseOfRestrictedStockUnits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <element id="fold_SciodermIncMember" name="SciodermIncMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_BusinessCombinationPriorityReviewVoucherSalePayment" name="BusinessCombinationPriorityReviewVoucherSalePayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_BusinessCombinationPriorityReviewVoucherSalePaymentPercent" name="BusinessCombinationPriorityReviewVoucherSalePaymentPercent" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_NoteAndWarrantAgreement2015Member" name="NoteAndWarrantAgreement2015Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element name="DebtInstrumentsNumberOfInstallments" id="fold_DebtInstrumentsNumberOfInstallments" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="fold_BusinessAcquisitionsMember" name="BusinessAcquisitionsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element name="NumberOfLawsuits" id="fold_NumberOfLawsuits" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="NumberOfLawsuitsNamingAdditionalOfficer" id="fold_NumberOfLawsuitsNamingAdditionalOfficer" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <element id="fold_BusinessCombinationAdjustedConsiderationTransferred" name="BusinessCombinationAdjustedConsiderationTransferred" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_BusinessCombinationAdjustedCashConsiderationTransferred" name="BusinessCombinationAdjustedCashConsiderationTransferred" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_BusinessCombinationAdjustedEquityConsiderationTransferred" name="BusinessCombinationAdjustedEquityConsiderationTransferred" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_CranburyNewJerseyMember" name="CranburyNewJerseyMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_DurhamNorthCarolinaMember" name="DurhamNorthCarolinaMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_BuckinghamshireUnitedKingdomMember" name="BuckinghamshireUnitedKingdomMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_MunichGermanyMember" name="MunichGermanyMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_PrivatePlacementPurchaseAgreementMember" name="PrivatePlacementPurchaseAgreementMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_DeferredTaxAssetsNonCashStockIssueNonCurrent" name="DeferredTaxAssetsNonCashStockIssueNonCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_PriorityReviewVoucherTransferYears" name="PriorityReviewVoucherTransferYears" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_NoteAndWarrantAgreement2016Member" name="NoteAndWarrantAgreement2016Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" name="ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember" name="ContingentConsiderationLiabilityRevenueBasedMilestonesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_ProbabilityWeightedDiscountedCashFlowMember" name="ProbabilityWeightedDiscountedCashFlowMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_MonteCarloMember" name="MonteCarloMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_NumberOfFabryCausingMutationsIncludedInCHMPLabelApproval" name="NumberOfFabryCausingMutationsIncludedInCHMPLabelApproval" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_PortionOfPatientsWithFabryCausedByMutationsIncludedInLabelApprovedByChmp" name="PortionOfPatientsWithFabryCausedByMutationsIncludedInLabelApprovedByChmp" nillable="true" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_MarketExchangedMutualFundsMember" name="MarketExchangedMutualFundsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt" name="NumberOfSharesIssuedPerIncrementOfConvertibleDebt" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_ConvertibleDebtPrincipalIncrementForConversion" name="ConvertibleDebtPrincipalIncrementForConversion" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_DebtInstrumentsAndRelatedPartyTransactionsAbstract" name="DebtInstrumentsAndRelatedPartyTransactionsAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_DebtInstrumentsAndRelatedPartyTransactionsDisclosureTextBlock" name="DebtInstrumentsAndRelatedPartyTransactionsDisclosureTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_ScheduleOfDebtInstrumentsAndRelatedPartyTransactionsByRelatedPartyTable" name="ScheduleOfDebtInstrumentsAndRelatedPartyTransactionsByRelatedPartyTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems" name="DebtInstrumentsAndRelatedPartyTransactionsLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_WarrantsNotSettleableInCashIncrementalFairValueDisclosure" name="WarrantsNotSettleableInCashIncrementalFairValueDisclosure" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_AdditionalNoteAndWarrantAgreementJune2016Member" name="AdditionalNoteAndWarrantAgreementJune2016Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_PaymentOfContingentConsideration" name="PaymentOfContingentConsideration" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_ContingentConsiderationPaidInStock" name="ContingentConsiderationPaidInStock" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_MiamedIncMember" name="MiamedIncMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_StockIssuedDuringPeriodValueIssuedForContingentConsiderations" name="StockIssuedDuringPeriodValueIssuedForContingentConsiderations" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_NumberOfForwardContracts" name="NumberOfForwardContracts" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_BusinessCombinationContingentConsiderationMilestones" name="BusinessCombinationContingentConsiderationMilestones" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_ContingentConsiderationLiabilityClinicalMilestoneMember" name="ContingentConsiderationLiabilityClinicalMilestoneMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_ContingentConsiderationLiabilityRegulatoryApprovalMilestoneMember" name="ContingentConsiderationLiabilityRegulatoryApprovalMilestoneMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_NoncashIncomeTaxExpenseBenefit" name="NoncashIncomeTaxExpenseBenefit" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember" name="ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_BusinessCombinationPriorityReviewVoucherUsedPayment" name="BusinessCombinationPriorityReviewVoucherUsedPayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityBusinessAcquisition" name="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityBusinessAcquisition" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_FairValueInputsProbabilityOfAchievementOfMilestones" name="FairValueInputsProbabilityOfAchievementOfMilestones" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_FairValueAssumptionsRevenueVolatilityRate" name="FairValueAssumptionsRevenueVolatilityRate" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_IncreaseDecreaseInDueFromCollaborationAgreements" name="IncreaseDecreaseInDueFromCollaborationAgreements" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_IncreaseDecreaseInNoncurrentOperatingLiabilities" name="IncreaseDecreaseInNoncurrentOperatingLiabilities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_IncreaseDecreaseInDeferredReimbursements" name="IncreaseDecreaseInDeferredReimbursements" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_ChangesInFairValueOfContingentConsiderationPayableMember" name="ChangesInFairValueOfContingentConsiderationPayableMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_BusinessCombinationConsiderationTransferredIncludingMilestonePayment" name="BusinessCombinationConsiderationTransferredIncludingMilestonePayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_ResearchExpenseForStockIssuanceInAssetAcquisition" name="ResearchExpenseForStockIssuanceInAssetAcquisition" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_AtMarketEquityOfferingMember" name="AtMarketEquityOfferingMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_WritedownOfOperatingLossCarryforwardAndResearchAndDevelopmentCreditsSubjectToSection382Limitations" name="WritedownOfOperatingLossCarryforwardAndResearchAndDevelopmentCreditsSubjectToSection382Limitations" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_MiaMedIncMember" name="MiaMedIncMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_NotePurchaseAgreementDecember2016Member" name="NotePurchaseAgreementDecember2016Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_PerformanceBasedRestrictedStockUnitAwardAgreementMember" name="PerformanceBasedRestrictedStockUnitAwardAgreementMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_LesseeLeasingArrangementsCapitalLeasesTermOfContract" name="LesseeLeasingArrangementsCapitalLeasesTermOfContract" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_ConvertibleSeniorNotes2016Due2023Member" name="ConvertibleSeniorNotes2016Due2023Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_LiabilityComponentsAbstract" name="LiabilityComponentsAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_AmortizationDeferredFinancingCosts" name="AmortizationDeferredFinancingCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_StockIssuedDuringPeriodValueContingentConsideration" name="StockIssuedDuringPeriodValueContingentConsideration" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_StockIssuedDuringPeriodSharesContingentConsideration" name="StockIssuedDuringPeriodSharesContingentConsideration" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_PremiumsPaidForCappedCallConfirmations" name="PremiumsPaidForCappedCallConfirmations" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_AdjustmentsToAdditionalPaidinCapitalPremiumsPaidForCappedCallConfirmations" name="AdjustmentsToAdditionalPaidinCapitalPremiumsPaidForCappedCallConfirmations" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_DerivativeCapPricePercentageOfPremiumOnCommonStockClosingPrice" name="DerivativeCapPricePercentageOfPremiumOnCommonStockClosingPrice" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor" name="AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_NonCashDeferredTaxes" name="NonCashDeferredTaxes" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_DebtInstrumentsConvertibleThresholdTradingDays" name="DebtInstrumentsConvertibleThresholdTradingDays" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_ConvertibleNotesConditionOneMember" name="ConvertibleNotesConditionOneMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_ConvertibleNotesConditionTwoMember" name="ConvertibleNotesConditionTwoMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_DebtInstrumentsConvertibleThresholdMaximumPercentageOfStockPriceTrigger" name="DebtInstrumentsConvertibleThresholdMaximumPercentageOfStockPriceTrigger" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_DebtInstrumentConvertibleMaximumCalendarDaysAllowedToHoldersOfCommonStockRightsOptionsOrWarrantsToPurchaseOfCommonStock" name="DebtInstrumentConvertibleMaximumCalendarDaysAllowedToHoldersOfCommonStockRightsOptionsOrWarrantsToPurchaseOfCommonStock" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_DebtInstrumentConvertibleTradingDaysForPricePerShareBasedOnLastReportedSalePrice" name="DebtInstrumentConvertibleTradingDaysForPricePerShareBasedOnLastReportedSalePrice" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_DebtInstrumentConvertibleMinimumPercentageOfPerShareValueOfLastReportedSalePriceOfCommonStock" name="DebtInstrumentConvertibleMinimumPercentageOfPerShareValueOfLastReportedSalePriceOfCommonStock" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_DeferredTaxLiabilitiesRoyaltyPayable" name="DeferredTaxLiabilitiesRoyaltyPayable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_OfficeSpaceMember" name="OfficeSpaceMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_OfficeAndLaboratorySpaceMember" name="OfficeAndLaboratorySpaceMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_DeferredTaxLiabilitiesConvertibleNotes" name="DeferredTaxLiabilitiesConvertibleNotes" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fold_DeferredTaxAssetsIntellectualProperty" name="DeferredTaxAssetsIntellectualProperty" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>fold-20161231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!--XBRL document created with Merrill Bridge  6.4.50.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/1/2017 2:07:09 PM-->
<!--Modified on: 3/1/2017 2:07:10 PM-->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.amicustherapeutics.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.amicustherapeutics.com/role/StatementConsolidatedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#StatementConsolidatedStatementsOfComprehensiveLoss" roleURI="http://www.amicustherapeutics.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.amicustherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureAcquisitionsDetails" roleURI="http://www.amicustherapeutics.com/role/DisclosureAcquisitionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureCashMoneyMarketFundsAndMarketableSecuritiesDetails" roleURI="http://www.amicustherapeutics.com/role/DisclosureCashMoneyMarketFundsAndMarketableSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureCashMoneyMarketFundsAndMarketableSecuritiesDetailsCalc2" roleURI="http://www.amicustherapeutics.com/role/DisclosureCashMoneyMarketFundsAndMarketableSecuritiesDetailsCalc2" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureInventoriesDetails" roleURI="http://www.amicustherapeutics.com/role/DisclosureInventoriesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosurePropertyAndEquipmentDetails" roleURI="http://www.amicustherapeutics.com/role/DisclosurePropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureAccountsPayableAndAccruedExpensesDetails" roleURI="http://www.amicustherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetails" roleURI="http://www.amicustherapeutics.com/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureLeasesDetails" roleURI="http://www.amicustherapeutics.com/role/DisclosureLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureIncomeTaxesStatutoryRateDetails" roleURI="http://www.amicustherapeutics.com/role/DisclosureIncomeTaxesStatutoryRateDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureIncomeTaxesDeferredAndValuationDetails" roleURI="http://www.amicustherapeutics.com/role/DisclosureIncomeTaxesDeferredAndValuationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureDebtInstrumentsAndRelatedPartyTransactionsConvertibleDebtDetails" roleURI="http://www.amicustherapeutics.com/role/DisclosureDebtInstrumentsAndRelatedPartyTransactionsConvertibleDebtDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <calculationLink xlink:role="http://www.amicustherapeutics.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="Assets" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_AssetsCurrent_636239740244645282" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_636239740244645282" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_636239740244645282" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_636239740244645282" xlink:to="us-gaap_AccountsReceivableNetCurrent_636239740244645282" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesCurrent_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_636239740244645282" xlink:to="us-gaap_AvailableForSaleSecuritiesCurrent_636239740244645282" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_636239740244645282" xlink:to="us-gaap_InventoryNet_636239740244645282" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_636239740244645282" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_636239740244645282" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_636239740244645282" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_Goodwill_636239740244645282" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_636239740244645282" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_636239740244645282" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent_636239740244645282" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_636239740244645282" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_636239740244645282" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" xlink:label="us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_636239740244645282" xlink:to="us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_636239740244645282" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_636239740244645282" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_636239740244645282" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent" xlink:label="us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_636239740244645282" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_ConvertibleLongTermNotesPayable_636239740244645282" order="3" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DueToRelatedPartiesNoncurrent" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_DueToRelatedPartiesNoncurrent_636239740244645282" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_636239740244645282" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent_636239740244645282" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_636239740244645282" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_636239740244645282" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_636239740244645282" xlink:to="us-gaap_CommonStockValue_636239740244645282" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_636239740244645282" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_636239740244645282" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_636239740244645282" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_636239740244645282" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_636239740244645282" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_636239740244645282" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_636239740244645282" xlink:to="us-gaap_WarrantsAndRightsOutstanding_636239740244645282" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_636239740244645282" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_636239740244645282" order="6" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.amicustherapeutics.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Statements of Operations" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_636239740244645282" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_636239740244645282" xlink:to="us-gaap_OperatingIncomeLoss_636239740244645282" order="1" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_636239740244645282" xlink:to="us-gaap_GrossProfit_636239740244645282" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit_636239740244645282" xlink:to="us-gaap_SalesRevenueNet_636239740244645282" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SalesRevenueNet_636239740244645282" xlink:to="us-gaap_SalesRevenueGoodsNet_636239740244645282" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ResearchRevenue" xlink:label="fold_ResearchRevenue_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SalesRevenueNet_636239740244645282" xlink:to="fold_ResearchRevenue_636239740244645282" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit_636239740244645282" xlink:to="us-gaap_CostOfGoodsSold_636239740244645282" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_636239740244645282" xlink:to="us-gaap_OperatingExpenses_636239740244645282" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_636239740244645282" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_636239740244645282" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_636239740244645282" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_636239740244645282" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_636239740244645282" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_636239740244645282" order="3" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_636239740244645282" xlink:to="us-gaap_RestructuringCharges_636239740244645282" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_636239740244645282" xlink:to="us-gaap_Depreciation_636239740244645282" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_636239740244645282" xlink:to="us-gaap_InvestmentIncomeInterest_636239740244645282" order="2" use="optional" weight="1" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_636239740244645282" xlink:to="us-gaap_InterestExpense_636239740244645282" order="3" use="optional" weight="-1" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ExtinguishmentOfDebtGainLossNetOfTax" xlink:label="us-gaap_ExtinguishmentOfDebtGainLossNetOfTax_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_636239740244645282" xlink:to="us-gaap_ExtinguishmentOfDebtGainLossNetOfTax_636239740244645282" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_636239740244645282" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_636239740244645282" order="5" use="optional" weight="1" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit_636239740244645282" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.amicustherapeutics.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended" xlink:title="00300 - Statement - Consolidated Statements of Comprehensive Loss" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="ComprehensiveIncomeNetOfTax" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss_636239740244645282" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_636239740244645282" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_636239740244645282" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_636239740244645282" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_636239740244645282" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_636239740244645282" order="2" use="optional" weight="1" priority="5" />
  </calculationLink>
  <calculationLink xlink:role="http://www.amicustherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00500 - Statement - Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636239740244645282" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636239740244645282" xlink:to="us-gaap_NetIncomeLoss_636239740244645282" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636239740244645282" xlink:to="us-gaap_PaidInKindInterest_636239740244645282" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636239740244645282" xlink:to="us-gaap_Depreciation_636239740244645282" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636239740244645282" xlink:to="us-gaap_ShareBasedCompensation_636239740244645282" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ResearchExpenseForStockIssuanceInAssetAcquisition" xlink:label="fold_ResearchExpenseForStockIssuanceInAssetAcquisition_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636239740244645282" xlink:to="fold_ResearchExpenseForStockIssuanceInAssetAcquisition_636239740244645282" order="5" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636239740244645282" xlink:to="us-gaap_RestructuringCharges_636239740244645282" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636239740244645282" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_636239740244645282" order="7" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636239740244645282" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_636239740244645282" order="8" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636239740244645282" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_636239740244645282" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636239740244645282" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_636239740244645282" order="10" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636239740244645282" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_636239740244645282" order="11" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_NoncashIncomeTaxExpenseBenefit" xlink:label="fold_NoncashIncomeTaxExpenseBenefit_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636239740244645282" xlink:to="fold_NoncashIncomeTaxExpenseBenefit_636239740244645282" order="12" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_NonCashDeferredTaxes" xlink:label="fold_NonCashDeferredTaxes_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636239740244645282" xlink:to="fold_NonCashDeferredTaxes_636239740244645282" order="13" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_IncreaseDecreaseInDueFromCollaborationAgreements" xlink:label="fold_IncreaseDecreaseInDueFromCollaborationAgreements_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636239740244645282" xlink:to="fold_IncreaseDecreaseInDueFromCollaborationAgreements_636239740244645282" order="14" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636239740244645282" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_636239740244645282" order="15" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636239740244645282" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_636239740244645282" order="16" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636239740244645282" xlink:to="us-gaap_IncreaseDecreaseInInventories_636239740244645282" order="17" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636239740244645282" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_636239740244645282" order="18" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636239740244645282" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_636239740244645282" order="19" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_IncreaseDecreaseInNoncurrentOperatingLiabilities" xlink:label="fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636239740244645282" xlink:to="fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_636239740244645282" order="20" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_IncreaseDecreaseInDeferredReimbursements" xlink:label="fold_IncreaseDecreaseInDeferredReimbursements_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636239740244645282" xlink:to="fold_IncreaseDecreaseInDeferredReimbursements_636239740244645282" order="21" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_636239740244645282" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_636239740244645282" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_636239740244645282" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecurities_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_636239740244645282" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecurities_636239740244645282" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_636239740244645282" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_636239740244645282" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_636239740244645282" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_636239740244645282" order="4" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_636239740244645282" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_636239740244645282" xlink:to="us-gaap_ProceedsFromConvertibleDebt_636239740244645282" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_PaymentOfContingentConsideration" xlink:label="fold_PaymentOfContingentConsideration_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_636239740244645282" xlink:to="fold_PaymentOfContingentConsideration_636239740244645282" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt" xlink:label="us-gaap_RepaymentsOfSecuredDebt_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_636239740244645282" xlink:to="us-gaap_RepaymentsOfSecuredDebt_636239740244645282" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_636239740244645282" xlink:to="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_636239740244645282" order="4" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_636239740244645282" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_636239740244645282" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_PaymentsForRepurchaseOfRestrictedStockUnits" xlink:label="fold_PaymentsForRepurchaseOfRestrictedStockUnits_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_636239740244645282" xlink:to="fold_PaymentsForRepurchaseOfRestrictedStockUnits_636239740244645282" order="6" use="optional" weight="-1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_636239740244645282" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_636239740244645282" xlink:to="us-gaap_ProceedsFromWarrantExercises_636239740244645282" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_PremiumsPaidForCappedCallConfirmations" xlink:label="fold_PremiumsPaidForCappedCallConfirmations_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_636239740244645282" xlink:to="fold_PremiumsPaidForCappedCallConfirmations_636239740244745283" order="8" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_636239740244645282" xlink:to="us-gaap_ProceedsFromIssuanceOfSecuredDebt_636239740244745283" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_636239740244645282" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_636239740244745283" order="10" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_636239740244745283" order="4" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureAcquisitionsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Acquisitions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BusinessCombinationAdjustedConsiderationTransferred" xlink:label="fold_BusinessCombinationAdjustedConsiderationTransferred_635956138061307734" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fold_BusinessCombinationAdjustedConsiderationTransferred_635956138061307734" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_636239740244745283" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fold_BusinessCombinationAdjustedConsiderationTransferred_635956138061307734" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_636239740244745283" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureCashMoneyMarketFundsAndMarketableSecuritiesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Cash, Money Market Funds and Marketable Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_AvailableForSaleSecuritiesAmortizedCostCurrent" xlink:label="AvailableForSaleSecuritiesAmortizedCostCurrent" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:label="fold_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AvailableForSaleSecuritiesAmortizedCostCurrent" xlink:to="fold_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent_636239740244745283" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:label="fold_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AvailableForSaleSecuritiesAmortizedCostCurrent" xlink:to="fold_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent_636239740244745283" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesCurrent_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AvailableForSaleSecuritiesAmortizedCostCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesCurrent_636239740244745283" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="CashCashEquivalentsAndShortTermInvestments" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_636239740244745283" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost_636239740244745283" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesAmortizedCost_636239740244745283" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_636239740244745283" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesAmortizedCost_636239740244745283" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_636239740244745283" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesAmortizedCost_636239740244745283" xlink:to="us-gaap_AvailableForSaleSecurities_636239740244745283" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureCashMoneyMarketFundsAndMarketableSecuritiesDetailsCalc2" xlink:type="extended" xlink:title="40501 - Disclosure - Cash, Money Market Funds and Marketable Securities (Details) (Calc 2)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="CashCashEquivalentsAndShortTermInvestments" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_636239740244745283" order="1" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_636239740244745283" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure" xlink:label="fold_CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsAndShortTermInvestments" xlink:to="fold_CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure_636239740244745283" order="3" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fold_CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure_636239740244745283" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_636239740244745283" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fold_CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure_636239740244745283" xlink:to="us-gaap_AvailableForSaleSecurities_636239740244745283" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureInventoriesDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Inventories (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_636239740244745283" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_636239740244745283" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosurePropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Property and Equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_636239740244745283" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_636239740244745283" order="2" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Accounts Payable and Accrued Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="AccountsPayableAndAccruedLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent_636239740244745283" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_AccruedContractManufacturingAndContractResearchCostsCurrent" xlink:label="fold_AccruedContractManufacturingAndContractResearchCostsCurrent_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="fold_AccruedContractManufacturingAndContractResearchCostsCurrent_636239740244745283" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_AccruedFacilityCostsCurrent" xlink:label="fold_AccruedFacilityCostsCurrent_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="fold_AccruedFacilityCostsCurrent_636239740244745283" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_636239740244745283" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_636239740244745283" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_636239740244745283" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="us-gaap_CapitalLeaseObligationsCurrent_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_CapitalLeaseObligationsCurrent_636239740244745283" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_636239740244745283" order="8" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Assets and Liabilities Measured at Fair Value (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="LiabilitiesFairValueDisclosure" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesFairValueDisclosure" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_636239740244745283" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesFairValueDisclosure" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability_636239740244745283" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:label="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesFairValueDisclosure" xlink:to="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_636239740244745283" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureLeasesDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Leases (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_636239740244745283" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_636239740244745283" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_636239740244745283" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="OperatingLeasesFutureMinimumPaymentsDue" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_636239740244745283" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_636239740244745283" order="2" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_636239740244745283" order="3" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_636239740244745283" order="4" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_OperatingLeasesFutureMinimumPaymentsDueInFiveYearsAndThereafter" xlink:label="fold_OperatingLeasesFutureMinimumPaymentsDueInFiveYearsAndThereafter_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingLeasesFutureMinimumPaymentsDue" xlink:to="fold_OperatingLeasesFutureMinimumPaymentsDueInFiveYearsAndThereafter_636239740244745283" order="5" use="optional" weight="1" priority="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureIncomeTaxesStatutoryRateDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Income Taxes - Statutory Rate (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="EffectiveIncomeTaxRateContinuingOperations" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_636239740244745283" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_636239740244745283" order="2" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_636239740244745283" order="3" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_636239740244745283" order="4" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_636239740244745283" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_636239740244745283" order="6" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_636239740244745283" order="7" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_636239740244745283" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_636239740244745283" order="2" use="optional" weight="1" priority="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureIncomeTaxesDeferredAndValuationDetails" xlink:type="extended" xlink:title="41302 - Disclosure - Income Taxes - Deferred and Valuation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="DeferredTaxLiabilities" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DeferredTaxAssetsLiabilitiesGross" xlink:label="fold_DeferredTaxAssetsLiabilitiesGross_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxLiabilities" xlink:to="fold_DeferredTaxAssetsLiabilitiesGross_636239740244745283" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fold_DeferredTaxAssetsLiabilitiesGross_636239740244745283" xlink:to="us-gaap_DeferredTaxAssetsGross_636239740244745283" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DeferredTaxAssetsIntellectualProperty" xlink:label="fold_DeferredTaxAssetsIntellectualProperty_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_636239740244745283" xlink:to="fold_DeferredTaxAssetsIntellectualProperty_636239740244745283" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_636239740244745283" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_636239740244745283" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_636239740244745283" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_636239740244745283" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_636239740244745283" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_636239740244745283" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_636239740244745283" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_636239740244745283" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DeferredTaxAssetsNonCashStockIssueNonCurrent" xlink:label="fold_DeferredTaxAssetsNonCashStockIssueNonCurrent_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_636239740244745283" xlink:to="fold_DeferredTaxAssetsNonCashStockIssueNonCurrent_636239740244745283" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_636239740244745283" xlink:to="us-gaap_DeferredTaxAssetsOther_636239740244745283" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fold_DeferredTaxAssetsLiabilitiesGross_636239740244745283" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_636239740244745283" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DeferredTaxLiabilitiesRoyaltyPayable" xlink:label="fold_DeferredTaxLiabilitiesRoyaltyPayable_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fold_DeferredTaxAssetsLiabilitiesGross_636239740244745283" xlink:to="fold_DeferredTaxLiabilitiesRoyaltyPayable_636239740244745283" order="3" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DeferredTaxLiabilitiesConvertibleNotes" xlink:label="fold_DeferredTaxLiabilitiesConvertibleNotes_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fold_DeferredTaxAssetsLiabilitiesGross_636239740244745283" xlink:to="fold_DeferredTaxLiabilitiesConvertibleNotes_636239740244745283" order="4" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_636239740244745283" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureDebtInstrumentsAndRelatedPartyTransactionsConvertibleDebtDetails" xlink:type="extended" xlink:title="41602 - Disclosure - Debt Instruments and Related Party Transactions - Convertible Debt (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization_636239740244745283" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_AmortizationDeferredFinancingCosts" xlink:label="fold_AmortizationDeferredFinancingCosts_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="fold_AmortizationDeferredFinancingCosts_636239740244745283" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_636239740244745283" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_DebtInstrumentCarryingAmount_636239740244745283" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_636239740244745283" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts_636239740244745283" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_DeferredOfferingCosts_636239740244745283" order="3" use="optional" weight="-1" priority="2" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>fold-20161231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!--XBRL document created with Merrill Bridge  6.4.50.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/1/2017 2:07:09 PM-->
<!--Modified on: 3/1/2017 2:07:11 PM-->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#StatementConsolidatedStatementsOfChangesInStockholdersEquity" roleURI="http://www.amicustherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureAssetsAndLiabilitiesMeasuredAtFairValueTables" roleURI="http://www.amicustherapeutics.com/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureDescriptionOfBusinessDetails" roleURI="http://www.amicustherapeutics.com/role/DisclosureDescriptionOfBusinessDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" roleURI="http://www.amicustherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureAcquisitionsDetails" roleURI="http://www.amicustherapeutics.com/role/DisclosureAcquisitionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureGoodwillAndIntangibleAssetsGoodwillDetails" roleURI="http://www.amicustherapeutics.com/role/DisclosureGoodwillAndIntangibleAssetsGoodwillDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureGoodwillAndIntangibleAssetsIprDDetails" roleURI="http://www.amicustherapeutics.com/role/DisclosureGoodwillAndIntangibleAssetsIprDDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureCashMoneyMarketFundsAndMarketableSecuritiesDetails" roleURI="http://www.amicustherapeutics.com/role/DisclosureCashMoneyMarketFundsAndMarketableSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosurePropertyAndEquipmentDetails" roleURI="http://www.amicustherapeutics.com/role/DisclosurePropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureStockholdersEquityCommonStockAndWarrantsDetails" roleURI="http://www.amicustherapeutics.com/role/DisclosureStockholdersEquityCommonStockAndWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureStockholdersEquityEquityIncentivePlansDetails" roleURI="http://www.amicustherapeutics.com/role/DisclosureStockholdersEquityEquityIncentivePlansDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureStockholdersEquityCompensationExpenseDetails" roleURI="http://www.amicustherapeutics.com/role/DisclosureStockholdersEquityCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetails" roleURI="http://www.amicustherapeutics.com/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureLeasesDetails" roleURI="http://www.amicustherapeutics.com/role/DisclosureLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureIncomeTaxesLossCarryforwardsDetails" roleURI="http://www.amicustherapeutics.com/role/DisclosureIncomeTaxesLossCarryforwardsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureLicensesDetails" roleURI="http://www.amicustherapeutics.com/role/DisclosureLicensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureCollaborativeAgreementsDetails" roleURI="http://www.amicustherapeutics.com/role/DisclosureCollaborativeAgreementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureDebtInstrumentsAndRelatedPartyTransactionsNoteAndWarrantPurchaseAgreementsDetails" roleURI="http://www.amicustherapeutics.com/role/DisclosureDebtInstrumentsAndRelatedPartyTransactionsNoteAndWarrantPurchaseAgreementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureDebtInstrumentsAndRelatedPartyTransactionsConvertibleDebtDetails" roleURI="http://www.amicustherapeutics.com/role/DisclosureDebtInstrumentsAndRelatedPartyTransactionsConvertibleDebtDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureEarningsPerShareDetails" roleURI="http://www.amicustherapeutics.com/role/DisclosureEarningsPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <definitionLink xlink:role="http://www.amicustherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statements of Changes in Stockholders' Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_636239740244745283" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_636239740244745283" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeMember" xlink:label="us-gaap_ComprehensiveIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_ComprehensiveIncomeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_636239740244745283" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_636239740244745283" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_SciodermIncMember" xlink:label="fold_SciodermIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="fold_SciodermIncMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_CallidusBiopharmaIncMember" xlink:label="fold_CallidusBiopharmaIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="fold_CallidusBiopharmaIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_MiaMedIncMember" xlink:label="fold_MiaMedIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="fold_MiaMedIncMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="fold_StockIssuedDuringPeriodValueWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="fold_StockIssuedDuringPeriodValueWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="fold_StockIssuedDuringPeriodSharesWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="fold_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="fold_StockIssuedDuringPeriodSharesWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_StockIssuedDuringPeriodValueAtMarketOffering" xlink:label="fold_StockIssuedDuringPeriodValueAtMarketOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="fold_StockIssuedDuringPeriodValueAtMarketOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_StockIssuedDuringPeriodSharesAtMarketOffering" xlink:label="fold_StockIssuedDuringPeriodSharesAtMarketOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="fold_StockIssuedDuringPeriodValueAtMarketOffering" xlink:to="fold_StockIssuedDuringPeriodSharesAtMarketOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_StockIssuedDuringPeriodValueContingentConsideration" xlink:label="fold_StockIssuedDuringPeriodValueContingentConsideration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="fold_StockIssuedDuringPeriodValueContingentConsideration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_StockIssuedDuringPeriodSharesContingentConsideration" xlink:label="fold_StockIssuedDuringPeriodSharesContingentConsideration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="fold_StockIssuedDuringPeriodValueContingentConsideration" xlink:to="fold_StockIssuedDuringPeriodSharesContingentConsideration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor" xlink:label="fold_AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="fold_AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_StockAndWarrantsIssuedDuringPeriodValueNewIssues" xlink:label="fold_StockAndWarrantsIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="fold_StockAndWarrantsIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_AdjustmentsToAdditionalPaidinCapitalPremiumsPaidForCappedCallConfirmations" xlink:label="fold_AdjustmentsToAdditionalPaidinCapitalPremiumsPaidForCappedCallConfirmations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="fold_AdjustmentsToAdditionalPaidinCapitalPremiumsPaidForCappedCallConfirmations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueTables" xlink:type="extended" xlink:title="31003 - Disclosure - Assets and Liabilities Measured at Fair Value (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_SciodermIncMember" xlink:label="fold_SciodermIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="fold_SciodermIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_CallidusBiopharmaIncMember" xlink:label="fold_CallidusBiopharmaIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="fold_CallidusBiopharmaIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureDescriptionOfBusinessDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Description of Business (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_MiamedIncMember" xlink:label="fold_MiamedIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="fold_MiamedIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_LongtermDebtTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_636239740244845284" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_636239740244845284" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_636239740244845284" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_636239740244845284" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ConvertibleSeniorNotes2016Due2023Member" xlink:label="fold_ConvertibleSeniorNotes2016Due2023Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="fold_ConvertibleSeniorNotes2016Due2023Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_636239740244845284" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_636239740244845284" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_CowenAndCompanyLLCMember" xlink:label="fold_CowenAndCompanyLLCMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fold_CowenAndCompanyLLCMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_636239740244845284" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember_636239740244845284" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="7" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636239740244845284" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636239740244845284" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_SalesAgreementMember" xlink:label="fold_SalesAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fold_SalesAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_AtMarketEquityOfferingMember" xlink:label="fold_AtMarketEquityOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fold_AtMarketEquityOfferingMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="8" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain_636239740244845284" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain_636239740244845284" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="9" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain_636239740244845284" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain_636239740244845284" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EuropeanUnionMember" xlink:label="us-gaap_EuropeanUnionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="us-gaap_EuropeanUnionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_NumberOfFabryCausingMutationsIncludedInCHMPLabelApproval" xlink:label="fold_NumberOfFabryCausingMutationsIncludedInCHMPLabelApproval" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fold_NumberOfFabryCausingMutationsIncludedInCHMPLabelApproval" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_PortionOfPatientsWithFabryCausedByMutationsIncludedInLabelApprovedByChmp" xlink:label="fold_PortionOfPatientsWithFabryCausedByMutationsIncludedInLabelApprovedByChmp" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fold_PortionOfPatientsWithFabryCausedByMutationsIncludedInLabelApprovedByChmp" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SalesRevenueGoodsNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_PremiumsPaidForCappedCallConfirmations" xlink:label="fold_PremiumsPaidForCappedCallConfirmations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fold_PremiumsPaidForCappedCallConfirmations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BusinessCombinationContingentConsiderationMilestones" xlink:label="fold_BusinessCombinationContingentConsiderationMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fold_BusinessCombinationContingentConsiderationMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BusinessCombinationConsiderationTransferredIncludingMilestonePayment" xlink:label="fold_BusinessCombinationConsiderationTransferredIncludingMilestonePayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fold_BusinessCombinationConsiderationTransferredIncludingMilestonePayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_StockIssuedDuringPeriodSharesAtMarketOffering" xlink:label="fold_StockIssuedDuringPeriodSharesAtMarketOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fold_StockIssuedDuringPeriodSharesAtMarketOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_FixedCommissionRateAsPercentageOfGrossProceedsPerShareSold" xlink:label="fold_FixedCommissionRateAsPercentageOfGrossProceedsPerShareSold" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fold_FixedCommissionRateAsPercentageOfGrossProceedsPerShareSold" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_StockIssuedDuringPeriodValueAtMarketOffering" xlink:label="fold_StockIssuedDuringPeriodValueAtMarketOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fold_StockIssuedDuringPeriodValueAtMarketOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_CommonStockIssuanceCommissionExpenses" xlink:label="fold_CommonStockIssuanceCommissionExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fold_CommonStockIssuanceCommissionExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherExpenses" xlink:label="us-gaap_OtherExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_OtherExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureAcquisitionsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Acquisitions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain_636239740244945285" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain_636239740244945285" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember" xlink:label="fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" xlink:label="fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember" xlink:label="fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ContingentConsiderationLiabilityClinicalMilestoneMember" xlink:label="fold_ContingentConsiderationLiabilityClinicalMilestoneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="fold_ContingentConsiderationLiabilityClinicalMilestoneMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ContingentConsiderationLiabilityRegulatoryApprovalMilestoneMember" xlink:label="fold_ContingentConsiderationLiabilityRegulatoryApprovalMilestoneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="fold_ContingentConsiderationLiabilityRegulatoryApprovalMilestoneMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_636239740244945285" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_636239740244945285" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ParentCompanyMember" xlink:label="us-gaap_ParentCompanyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="us-gaap_ParentCompanyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_SciodermIncMember" xlink:label="fold_SciodermIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="dei_EntityDomain" xlink:to="fold_SciodermIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="fold_SciodermIncMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_CallidusBiopharmaIncMember" xlink:label="fold_CallidusBiopharmaIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="fold_CallidusBiopharmaIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_MiamedIncMember" xlink:label="fold_MiamedIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="fold_MiamedIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_636239740245045286" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_636239740245045286" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_636239740245045286" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_636239740245045286" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="7" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_636239740245045286" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_636239740245045286" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ChangesInFairValueOfContingentConsiderationPayableMember" xlink:label="fold_ChangesInFairValueOfContingentConsiderationPayableMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="fold_ChangesInFairValueOfContingentConsiderationPayableMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates" xlink:label="us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BusinessCombinationContingentConsiderationMilestones" xlink:label="fold_BusinessCombinationContingentConsiderationMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="fold_BusinessCombinationContingentConsiderationMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BusinessCombinationConsiderationTransferredIncludingMilestonePayment" xlink:label="fold_BusinessCombinationConsiderationTransferredIncludingMilestonePayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="fold_BusinessCombinationConsiderationTransferredIncludingMilestonePayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BusinessCombinationAdjustedConsiderationTransferred" xlink:label="fold_BusinessCombinationAdjustedConsiderationTransferred" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="fold_BusinessCombinationAdjustedConsiderationTransferred" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BusinessCombinationAdjustedCashConsiderationTransferred" xlink:label="fold_BusinessCombinationAdjustedCashConsiderationTransferred" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="fold_BusinessCombinationAdjustedCashConsiderationTransferred" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BusinessCombinationAdjustedEquityConsiderationTransferred" xlink:label="fold_BusinessCombinationAdjustedEquityConsiderationTransferred" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="fold_BusinessCombinationAdjustedEquityConsiderationTransferred" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BusinessCombinationPriorityReviewVoucherSalePayment" xlink:label="fold_BusinessCombinationPriorityReviewVoucherSalePayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="fold_BusinessCombinationPriorityReviewVoucherSalePayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BusinessCombinationPriorityReviewVoucherSalePaymentPercent" xlink:label="fold_BusinessCombinationPriorityReviewVoucherSalePaymentPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="fold_BusinessCombinationPriorityReviewVoucherSalePaymentPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_PriorityReviewVoucherTransferYears" xlink:label="fold_PriorityReviewVoucherTransferYears" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="fold_PriorityReviewVoucherTransferYears" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BusinessCombinationPriorityReviewVoucherUsedPayment" xlink:label="fold_BusinessCombinationPriorityReviewVoucherUsedPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="fold_BusinessCombinationPriorityReviewVoucherUsedPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="us-gaap_FairValueInputsDiscountRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_FairValueInputsDiscountRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ContingentConsiderationMilestonePayment" xlink:label="fold_ContingentConsiderationMilestonePayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="fold_ContingentConsiderationMilestonePayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_StockIssuedDuringPeriodValueIssuedForContingentConsiderations" xlink:label="fold_StockIssuedDuringPeriodValueIssuedForContingentConsiderations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="fold_StockIssuedDuringPeriodValueIssuedForContingentConsiderations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ContingentConsiderationPaidInStock" xlink:label="fold_ContingentConsiderationPaidInStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="fold_ContingentConsiderationPaidInStock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureGoodwillAndIntangibleAssetsGoodwillDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Goodwill and Intangible Assets - Goodwill (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BusinessAcquisitionsMember" xlink:label="fold_BusinessAcquisitionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="fold_BusinessAcquisitionsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillRollForward" xlink:label="us-gaap_GoodwillRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GoodwillRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GoodwillRollForward" xlink:to="us-gaap_Goodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureGoodwillAndIntangibleAssetsIprDDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Goodwill and Intangible Assets - IPR&amp;D (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BusinessAcquisitionsMember" xlink:label="fold_BusinessAcquisitionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="fold_BusinessAcquisitionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsRollForward" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsRollForward" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureCashMoneyMarketFundsAndMarketableSecuritiesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Cash, Money Market Funds and Marketable Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_636239740245345289" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_636239740245345289" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ShortTermCorporateDebtSecuritiesMember" xlink:label="fold_ShortTermCorporateDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="fold_ShortTermCorporateDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_MoneyMarketFundsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_CertificatesOfDepositMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_BalanceSheetLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_636239740245345289" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_636239740245345289" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="us-gaap_OtherCurrentLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherCurrentLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_AvailableForSaleSecuritiesAmortizedCostCurrent" xlink:label="fold_AvailableForSaleSecuritiesAmortizedCostCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="fold_AvailableForSaleSecuritiesAmortizedCostCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:label="fold_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="fold_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:label="fold_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="fold_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure" xlink:label="fold_CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="fold_CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.amicustherapeutics.com/role/DisclosurePropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Property and Equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_636239740245345289" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_636239740245345289" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ResearchEquipmentMember" xlink:label="fold_ResearchEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="fold_ResearchEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation" xlink:label="us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeaseObligations" xlink:label="us-gaap_CapitalLeaseObligations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_CapitalLeaseObligations" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureStockholdersEquityCommonStockAndWarrantsDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Stockholders' Equity - Common Stock and Warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ParentCompanyMember" xlink:label="us-gaap_ParentCompanyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="us-gaap_ParentCompanyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_CowenAndCompanyLLCMember" xlink:label="fold_CowenAndCompanyLLCMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fold_CowenAndCompanyLLCMember" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_RedmileGroupMember" xlink:label="fold_RedmileGroupMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fold_RedmileGroupMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_636239740245445290" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_636239740245445290" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BeneficialOwnerMember" xlink:label="us-gaap_BeneficialOwnerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_BeneficialOwnerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_PrivatePlacementPurchaseAgreementMember" xlink:label="fold_PrivatePlacementPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fold_PrivatePlacementPurchaseAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_SalesAgreementMember" xlink:label="fold_SalesAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fold_SalesAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_AtMarketEquityOfferingMember" xlink:label="fold_AtMarketEquityOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fold_AtMarketEquityOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_LongtermDebtTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_NoteAndWarrantAgreement2015Member" xlink:label="fold_NoteAndWarrantAgreement2015Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="fold_NoteAndWarrantAgreement2015Member" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_NoteAndWarrantAgreement2016Member" xlink:label="fold_NoteAndWarrantAgreement2016Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="fold_NoteAndWarrantAgreement2016Member" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ConvertibleSeniorNotes2016Due2023Member" xlink:label="fold_ConvertibleSeniorNotes2016Due2023Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="fold_ConvertibleSeniorNotes2016Due2023Member" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_AdditionalNoteAndWarrantAgreementJune2016Member" xlink:label="fold_AdditionalNoteAndWarrantAgreementJune2016Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="fold_AdditionalNoteAndWarrantAgreementJune2016Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="7" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="8" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="9" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_SciodermIncMember" xlink:label="fold_SciodermIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="fold_SciodermIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_MiamedIncMember" xlink:label="fold_MiamedIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="fold_MiamedIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="10" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" xlink:label="fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember" xlink:label="fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:label="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_CommonStockVotingRightsForEachShareHeld" xlink:label="fold_CommonStockVotingRightsForEachShareHeld" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fold_CommonStockVotingRightsForEachShareHeld" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_FixedCommissionRateAsPercentageOfGrossProceedsPerShareSold" xlink:label="fold_FixedCommissionRateAsPercentageOfGrossProceedsPerShareSold" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fold_FixedCommissionRateAsPercentageOfGrossProceedsPerShareSold" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_StockIssuedDuringPeriodSharesAtMarketOffering" xlink:label="fold_StockIssuedDuringPeriodSharesAtMarketOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fold_StockIssuedDuringPeriodSharesAtMarketOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_StockIssuedDuringPeriodValueAtMarketOffering" xlink:label="fold_StockIssuedDuringPeriodValueAtMarketOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fold_StockIssuedDuringPeriodValueAtMarketOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_CommonStockIssuanceCommissionExpenses" xlink:label="fold_CommonStockIssuanceCommissionExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fold_CommonStockIssuanceCommissionExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherExpenses" xlink:label="us-gaap_OtherExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_OtherExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates" xlink:label="us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BusinessCombinationContingentConsiderationMilestones" xlink:label="fold_BusinessCombinationContingentConsiderationMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fold_BusinessCombinationContingentConsiderationMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BusinessCombinationConsiderationTransferredIncludingMilestonePayment" xlink:label="fold_BusinessCombinationConsiderationTransferredIncludingMilestonePayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fold_BusinessCombinationConsiderationTransferredIncludingMilestonePayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BusinessCombinationAdjustedConsiderationTransferred" xlink:label="fold_BusinessCombinationAdjustedConsiderationTransferred" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fold_BusinessCombinationAdjustedConsiderationTransferred" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BusinessCombinationAdjustedCashConsiderationTransferred" xlink:label="fold_BusinessCombinationAdjustedCashConsiderationTransferred" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fold_BusinessCombinationAdjustedCashConsiderationTransferred" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BusinessCombinationAdjustedEquityConsiderationTransferred" xlink:label="fold_BusinessCombinationAdjustedEquityConsiderationTransferred" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fold_BusinessCombinationAdjustedEquityConsiderationTransferred" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ProceedsFromIssuanceOfCommonStockGross" xlink:label="fold_ProceedsFromIssuanceOfCommonStockGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fold_ProceedsFromIssuanceOfCommonStockGross" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureStockholdersEquityEquityIncentivePlansDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Stockholders' Equity - Equity Incentive Plans (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_636239740245945295" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_636239740245945295" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_EmployeeAndDirectorsStockOptionsMember" xlink:label="fold_EmployeeAndDirectorsStockOptionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="fold_EmployeeAndDirectorsStockOptionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_636239740246045296" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_636239740246045296" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_StockOptionPlan2007AndDirectorOptionPlan2007Member" xlink:label="fold_StockOptionPlan2007AndDirectorOptionPlan2007Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="fold_StockOptionPlan2007AndDirectorOptionPlan2007Member" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_StockOptionPlan2002AndStockOptionPlan2007Member" xlink:label="fold_StockOptionPlan2002AndStockOptionPlan2007Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="fold_StockOptionPlan2002AndStockOptionPlan2007Member" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_PerformanceBasedRestrictedStockUnitAwardAgreementMember" xlink:label="fold_PerformanceBasedRestrictedStockUnitAwardAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PlanNameDomain" xlink:to="fold_PerformanceBasedRestrictedStockUnitAwardAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:label="us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TradingSecurities" xlink:label="us-gaap_TradingSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_TradingSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TradingSecuritiesUnrealizedHoldingGainLoss" xlink:label="us-gaap_TradingSecuritiesUnrealizedHoldingGainLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_TradingSecuritiesUnrealizedHoldingGainLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_VestingRightsPercentageOnFirstYearAnniversary" xlink:label="fold_VestingRightsPercentageOnFirstYearAnniversary" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="fold_VestingRightsPercentageOnFirstYearAnniversary" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionPercentageOfSharesVestedThatMayBeExercisedInWholeOrPart" xlink:label="fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionPercentageOfSharesVestedThatMayBeExercisedInWholeOrPart" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionPercentageOfSharesVestedThatMayBeExercisedInWholeOrPart" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" xlink:label="fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageContractualLifeAbstract" xlink:label="fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageContractualLifeAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageContractualLifeAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageContractualLifeAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageContractualLifeAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageContractualLifeAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureStockholdersEquityCompensationExpenseDetails" xlink:type="extended" xlink:title="40903 - Disclosure - Stockholders' Equity - Compensation Expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Assets and Liabilities Measured at Fair Value (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_NoteAndWarrantAgreement2015Member" xlink:label="fold_NoteAndWarrantAgreement2015Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="fold_NoteAndWarrantAgreement2015Member" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_AdditionalNoteAndWarrantAgreementJune2016Member" xlink:label="fold_AdditionalNoteAndWarrantAgreementJune2016Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="fold_AdditionalNoteAndWarrantAgreementJune2016Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_636239740246245298" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_636239740246245298" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_RedmileGroupMember" xlink:label="fold_RedmileGroupMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fold_RedmileGroupMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BeneficialOwnerMember" xlink:label="us-gaap_BeneficialOwnerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_BeneficialOwnerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_CertificatesOfDepositMember" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_MarketExchangedMutualFundsMember" xlink:label="fold_MarketExchangedMutualFundsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="fold_MarketExchangedMutualFundsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_PrivatePlacementPurchaseAgreementMember" xlink:label="fold_PrivatePlacementPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fold_PrivatePlacementPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="7" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" xlink:label="fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember" xlink:label="fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember" xlink:label="fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="8" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_ValuationTechniqueAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain_636239740246345299" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain_636239740246345299" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ProbabilityWeightedDiscountedCashFlowMember" xlink:label="fold_ProbabilityWeightedDiscountedCashFlowMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="fold_ProbabilityWeightedDiscountedCashFlowMember" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_MonteCarloMember" xlink:label="fold_MonteCarloMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="fold_MonteCarloMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="9" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="10" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_CallidusBiopharmaIncMember" xlink:label="fold_CallidusBiopharmaIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="fold_CallidusBiopharmaIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_SciodermIncMember" xlink:label="fold_SciodermIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="fold_SciodermIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_MiamedIncMember" xlink:label="fold_MiamedIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="fold_MiamedIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="11" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_BalanceSheetLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="us-gaap_OtherCurrentLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherCurrentLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TradingSecurities" xlink:label="us-gaap_TradingSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_TradingSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:label="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BusinessCombinationContingentConsiderationMilestones" xlink:label="fold_BusinessCombinationContingentConsiderationMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="fold_BusinessCombinationContingentConsiderationMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BusinessCombinationConsiderationTransferredIncludingMilestonePayment" xlink:label="fold_BusinessCombinationConsiderationTransferredIncludingMilestonePayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="fold_BusinessCombinationConsiderationTransferredIncludingMilestonePayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="us-gaap_FairValueInputsDiscountRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueInputsDiscountRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_FairValueInputsProbabilityOfAchievementOfMilestones" xlink:label="fold_FairValueInputsProbabilityOfAchievementOfMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="fold_FairValueInputsProbabilityOfAchievementOfMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_FairValueAssumptionsRevenueVolatilityRate" xlink:label="fold_FairValueAssumptionsRevenueVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="fold_FairValueAssumptionsRevenueVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BusinessCombinationContingentConsiderationLiabilityRollForward" xlink:label="fold_BusinessCombinationContingentConsiderationLiabilityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="fold_BusinessCombinationContingentConsiderationLiabilityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="fold_BusinessCombinationContingentConsiderationLiabilityRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityBusinessAcquisition" xlink:label="fold_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityBusinessAcquisition" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="fold_BusinessCombinationContingentConsiderationLiabilityRollForward" xlink:to="fold_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityBusinessAcquisition" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_PaymentOfContingentConsideration" xlink:label="fold_PaymentOfContingentConsideration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="fold_BusinessCombinationContingentConsiderationLiabilityRollForward" xlink:to="fold_PaymentOfContingentConsideration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="fold_BusinessCombinationContingentConsiderationLiabilityRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="fold_BusinessCombinationContingentConsiderationLiabilityRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsAbstract" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_NumberOfForwardContracts" xlink:label="fold_NumberOfForwardContracts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsAbstract" xlink:to="fold_NumberOfForwardContracts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsAbstract" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsAbstract" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureLeasesDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Leases (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeographicDistributionAxis" xlink:label="us-gaap_GeographicDistributionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GeographicDistributionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeographicDistributionDomain" xlink:label="us-gaap_GeographicDistributionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_GeographicDistributionAxis" xlink:to="us-gaap_GeographicDistributionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeographicDistributionDomain" xlink:label="us-gaap_GeographicDistributionDomain_636239740246545301" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_GeographicDistributionAxis" xlink:to="us-gaap_GeographicDistributionDomain_636239740246545301" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeographicDistributionDomesticMember" xlink:label="us-gaap_GeographicDistributionDomesticMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GeographicDistributionDomain" xlink:to="us-gaap_GeographicDistributionDomesticMember" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_CranburyNewJerseyMember" xlink:label="fold_CranburyNewJerseyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GeographicDistributionDomesticMember" xlink:to="fold_CranburyNewJerseyMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DurhamNorthCarolinaMember" xlink:label="fold_DurhamNorthCarolinaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_GeographicDistributionDomesticMember" xlink:to="fold_DurhamNorthCarolinaMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeographicDistributionForeignMember" xlink:label="us-gaap_GeographicDistributionForeignMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_GeographicDistributionDomain" xlink:to="us-gaap_GeographicDistributionForeignMember" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BuckinghamshireUnitedKingdomMember" xlink:label="fold_BuckinghamshireUnitedKingdomMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GeographicDistributionForeignMember" xlink:to="fold_BuckinghamshireUnitedKingdomMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_MunichGermanyMember" xlink:label="fold_MunichGermanyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_GeographicDistributionForeignMember" xlink:to="fold_MunichGermanyMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_OfficeAndLaboratorySpaceMember" xlink:label="fold_OfficeAndLaboratorySpaceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="fold_OfficeAndLaboratorySpaceMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_OfficeSpaceMember" xlink:label="fold_OfficeSpaceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="fold_OfficeSpaceMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="us-gaap_LeasesOperatingAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LeasesOperatingAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_AreaOfRealEstateProperty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_OperatingLeasesFutureMinimumPaymentsDueInFiveYearsAndThereafter" xlink:label="fold_OperatingLeasesFutureMinimumPaymentsDueInFiveYearsAndThereafter" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="fold_OperatingLeasesFutureMinimumPaymentsDueInFiveYearsAndThereafter" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeasesCapitalAbstract" xlink:label="us-gaap_LeasesCapitalAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LeasesCapitalAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeaseObligations" xlink:label="us-gaap_CapitalLeaseObligations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LeasesCapitalAbstract" xlink:to="us-gaap_CapitalLeaseObligations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LeasesCapitalAbstract" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMaximum" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LeasesCapitalAbstract" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_LesseeLeasingArrangementsCapitalLeasesTermOfContract" xlink:label="fold_LesseeLeasingArrangementsCapitalLeasesTermOfContract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LeasesCapitalAbstract" xlink:to="fold_LesseeLeasingArrangementsCapitalLeasesTermOfContract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LeasesCapitalAbstract" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LeasesCapitalAbstract" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LeasesCapitalAbstract" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_LeasesCapitalAbstract" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureIncomeTaxesLossCarryforwardsDetails" xlink:type="extended" xlink:title="41303 - Disclosure - Income Taxes - Loss Carryforwards (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_636239740246645302" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_636239740246645302" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_OperatingLossCarryforwardsLimitationsOnUseMinimumPercentageOwnershipChangePeriod" xlink:label="fold_OperatingLossCarryforwardsLimitationsOnUseMinimumPercentageOwnershipChangePeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="fold_OperatingLossCarryforwardsLimitationsOnUseMinimumPercentageOwnershipChangePeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_OperatingLossCarryforwardsLimitationsOnUseMinimumOwnershipPercentageChangeRelatingToSection382" xlink:label="fold_OperatingLossCarryforwardsLimitationsOnUseMinimumOwnershipPercentageChangeRelatingToSection382" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="fold_OperatingLossCarryforwardsLimitationsOnUseMinimumOwnershipPercentageChangeRelatingToSection382" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_WritedownOfOperatingLossCarryforwardAndResearchAndDevelopmentCreditsSubjectToSection382Limitations" xlink:label="fold_WritedownOfOperatingLossCarryforwardAndResearchAndDevelopmentCreditsSubjectToSection382Limitations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="fold_WritedownOfOperatingLossCarryforwardAndResearchAndDevelopmentCreditsSubjectToSection382Limitations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureLicensesDetails" xlink:type="extended" xlink:title="41401 - Disclosure - Licenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_636239740246645302" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_636239740246645302" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_MtSinaiSchoolOfMedicineOfNewYorkUniversityMember" xlink:label="fold_MtSinaiSchoolOfMedicineOfNewYorkUniversityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fold_MtSinaiSchoolOfMedicineOfNewYorkUniversityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_LicenseAgreementUpfrontPaymentAndAnnualLicenseFees" xlink:label="fold_LicenseAgreementUpfrontPaymentAndAnnualLicenseFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="fold_LicenseAgreementUpfrontPaymentAndAnnualLicenseFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_LicenseAgreementMilestonePaymentsPotential" xlink:label="fold_LicenseAgreementMilestonePaymentsPotential" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="fold_LicenseAgreementMilestonePaymentsPotential" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_RoyaltyExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureCollaborativeAgreementsDetails" xlink:type="extended" xlink:title="41501 - Disclosure - Collaborative Agreements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_GlaxoSmithKlinePLCMember" xlink:label="fold_GlaxoSmithKlinePLCMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fold_GlaxoSmithKlinePLCMember" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BiogenIdecMember" xlink:label="fold_BiogenIdecMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fold_BiogenIdecMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_RevisedCollaborationAgreementMember" xlink:label="fold_RevisedCollaborationAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fold_RevisedCollaborationAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments" xlink:label="fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones" xlink:label="fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ResearchRevenue" xlink:label="fold_ResearchRevenue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fold_ResearchRevenue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureDebtInstrumentsAndRelatedPartyTransactionsNoteAndWarrantPurchaseAgreementsDetails" xlink:type="extended" xlink:title="41601 - Disclosure - Debt Instruments and Related Party Transactions - Note and Warrant Purchase Agreements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ScheduleOfDebtInstrumentsAndRelatedPartyTransactionsByRelatedPartyTable" xlink:label="fold_ScheduleOfDebtInstrumentsAndRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="fold_ScheduleOfDebtInstrumentsAndRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_NoteAndWarrantAgreement2015Member" xlink:label="fold_NoteAndWarrantAgreement2015Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="fold_NoteAndWarrantAgreement2015Member" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_NoteAndWarrantAgreement2016Member" xlink:label="fold_NoteAndWarrantAgreement2016Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="fold_NoteAndWarrantAgreement2016Member" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_AdditionalNoteAndWarrantAgreementJune2016Member" xlink:label="fold_AdditionalNoteAndWarrantAgreementJune2016Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="fold_AdditionalNoteAndWarrantAgreementJune2016Member" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_NotePurchaseAgreementDecember2016Member" xlink:label="fold_NotePurchaseAgreementDecember2016Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="fold_NotePurchaseAgreementDecember2016Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="fold_ScheduleOfDebtInstrumentsAndRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_636239740246745303" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_636239740246745303" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="fold_ScheduleOfDebtInstrumentsAndRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_RedmileGroupMember" xlink:label="fold_RedmileGroupMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fold_RedmileGroupMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="fold_ScheduleOfDebtInstrumentsAndRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_PrivatePlacementPurchaseAgreementMember" xlink:label="fold_PrivatePlacementPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fold_PrivatePlacementPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="fold_ScheduleOfDebtInstrumentsAndRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BeneficialOwnerMember" xlink:label="us-gaap_BeneficialOwnerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_BeneficialOwnerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="fold_ScheduleOfDebtInstrumentsAndRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="7" xlink:from="fold_ScheduleOfDebtInstrumentsAndRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems" xlink:label="fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems" xlink:to="fold_ScheduleOfDebtInstrumentsAndRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_WarrantTerm" xlink:label="fold_WarrantTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems" xlink:to="fold_WarrantTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt" xlink:label="fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems" xlink:to="fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ConvertibleDebtPrincipalIncrementForConversion" xlink:label="fold_ConvertibleDebtPrincipalIncrementForConversion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems" xlink:to="fold_ConvertibleDebtPrincipalIncrementForConversion" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DebtInstrumentsNumberOfInstallments" xlink:label="fold_DebtInstrumentsNumberOfInstallments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems" xlink:to="fold_DebtInstrumentsNumberOfInstallments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_WarrantsNotSettleableInCashIncrementalFairValueDisclosure" xlink:label="fold_WarrantsNotSettleableInCashIncrementalFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems" xlink:to="fold_WarrantsNotSettleableInCashIncrementalFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ExtinguishmentOfDebtGainLossNetOfTax" xlink:label="us-gaap_ExtinguishmentOfDebtGainLossNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems" xlink:to="us-gaap_ExtinguishmentOfDebtGainLossNetOfTax" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureDebtInstrumentsAndRelatedPartyTransactionsConvertibleDebtDetails" xlink:type="extended" xlink:title="41602 - Disclosure - Debt Instruments and Related Party Transactions - Convertible Debt (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ScheduleOfDebtInstrumentsAndRelatedPartyTransactionsByRelatedPartyTable" xlink:label="fold_ScheduleOfDebtInstrumentsAndRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="fold_ScheduleOfDebtInstrumentsAndRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_LongtermDebtTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="fold_ScheduleOfDebtInstrumentsAndRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ConvertibleSeniorNotes2016Due2023Member" xlink:label="fold_ConvertibleSeniorNotes2016Due2023Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="fold_ConvertibleSeniorNotes2016Due2023Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="fold_ScheduleOfDebtInstrumentsAndRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_636239740246845304" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_636239740246845304" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="fold_ScheduleOfDebtInstrumentsAndRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_PrivatePlacementPurchaseAgreementMember" xlink:label="fold_PrivatePlacementPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fold_PrivatePlacementPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="fold_ScheduleOfDebtInstrumentsAndRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain_636239740246845304" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain_636239740246845304" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ConvertibleNotesConditionOneMember" xlink:label="fold_ConvertibleNotesConditionOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="fold_ConvertibleNotesConditionOneMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ConvertibleNotesConditionTwoMember" xlink:label="fold_ConvertibleNotesConditionTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="fold_ConvertibleNotesConditionTwoMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="fold_ScheduleOfDebtInstrumentsAndRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems" xlink:label="fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems" xlink:to="fold_ScheduleOfDebtInstrumentsAndRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:label="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems" xlink:to="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_PremiumsPaidForCappedCallConfirmations" xlink:label="fold_PremiumsPaidForCappedCallConfirmations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:to="fold_PremiumsPaidForCappedCallConfirmations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt" xlink:label="fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:to="fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ConvertibleDebtPrincipalIncrementForConversion" xlink:label="fold_ConvertibleDebtPrincipalIncrementForConversion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:to="fold_ConvertibleDebtPrincipalIncrementForConversion" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DebtInstrumentsConvertibleThresholdTradingDays" xlink:label="fold_DebtInstrumentsConvertibleThresholdTradingDays" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:to="fold_DebtInstrumentsConvertibleThresholdTradingDays" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DebtInstrumentsConvertibleThresholdMaximumPercentageOfStockPriceTrigger" xlink:label="fold_DebtInstrumentsConvertibleThresholdMaximumPercentageOfStockPriceTrigger" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:to="fold_DebtInstrumentsConvertibleThresholdMaximumPercentageOfStockPriceTrigger" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DebtInstrumentConvertibleMaximumCalendarDaysAllowedToHoldersOfCommonStockRightsOptionsOrWarrantsToPurchaseOfCommonStock" xlink:label="fold_DebtInstrumentConvertibleMaximumCalendarDaysAllowedToHoldersOfCommonStockRightsOptionsOrWarrantsToPurchaseOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:to="fold_DebtInstrumentConvertibleMaximumCalendarDaysAllowedToHoldersOfCommonStockRightsOptionsOrWarrantsToPurchaseOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DebtInstrumentConvertibleTradingDaysForPricePerShareBasedOnLastReportedSalePrice" xlink:label="fold_DebtInstrumentConvertibleTradingDaysForPricePerShareBasedOnLastReportedSalePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:to="fold_DebtInstrumentConvertibleTradingDaysForPricePerShareBasedOnLastReportedSalePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DebtInstrumentConvertibleMinimumPercentageOfPerShareValueOfLastReportedSalePriceOfCommonStock" xlink:label="fold_DebtInstrumentConvertibleMinimumPercentageOfPerShareValueOfLastReportedSalePriceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:to="fold_DebtInstrumentConvertibleMinimumPercentageOfPerShareValueOfLastReportedSalePriceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:to="us-gaap_DebtInstrumentTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DeferredTaxLiabilitiesConvertibleNotes" xlink:label="fold_DeferredTaxLiabilitiesConvertibleNotes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:to="fold_DeferredTaxLiabilitiesConvertibleNotes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:to="us-gaap_DeferredFinanceCostsNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_LiabilityComponentsAbstract" xlink:label="fold_LiabilityComponentsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:to="fold_LiabilityComponentsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="fold_LiabilityComponentsAbstract" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="fold_LiabilityComponentsAbstract" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="fold_LiabilityComponentsAbstract" xlink:to="us-gaap_DeferredOfferingCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="fold_LiabilityComponentsAbstract" xlink:to="us-gaap_LongTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpenseDebtAbstract" xlink:label="us-gaap_InterestExpenseDebtAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:to="us-gaap_InterestExpenseDebtAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_InterestExpenseDebtAbstract" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_AmortizationDeferredFinancingCosts" xlink:label="fold_AmortizationDeferredFinancingCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_InterestExpenseDebtAbstract" xlink:to="fold_AmortizationDeferredFinancingCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_InterestExpenseDebtAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_InterestExpenseDebtAbstract" xlink:to="us-gaap_InterestExpenseDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_InterestExpenseDebtAbstract" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeCapPrice" xlink:label="us-gaap_DerivativeCapPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:to="us-gaap_DerivativeCapPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DerivativeCapPricePercentageOfPremiumOnCommonStockClosingPrice" xlink:label="fold_DerivativeCapPricePercentageOfPremiumOnCommonStockClosingPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:to="fold_DerivativeCapPricePercentageOfPremiumOnCommonStockClosingPrice" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureEarningsPerShareDetails" xlink:type="extended" xlink:title="41701 - Disclosure - Earnings per Share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_636239740246945305" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_636239740246945305" use="optional" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_EmployeeAndDirectorsStockOptionsMember" xlink:label="fold_EmployeeAndDirectorsStockOptionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="fold_EmployeeAndDirectorsStockOptionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_NetIncomeLossAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>fold-20161231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!--XBRL document created with Merrill Bridge  6.4.50.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/1/2017 2:07:09 PM-->
<!--Modified on: 3/1/2017 2:07:10 PM-->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DocumentAndEntityInformationAbstract" xlink:label="fold_DocumentAndEntityInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_DocumentAndEntityInformationAbstract" xlink:to="fold_DocumentAndEntityInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Balance Sheets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents at end of year/period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents at beginning of year/ period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents, Amortized Cost</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available-for-sale Securities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments in marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable securities, Fair Value current portion</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total inventories</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, less accumulated depreciation of $12,495 and $13,353 at December 31, 2016 and 2015, respectively</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets, Net (Excluding Goodwill)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">In-process research &amp; development</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at end of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at beginning of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable, accrued expenses , and other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable and accrued expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" xlink:label="us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" xlink:to="us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Credits and Other Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred reimbursements, current portion</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Contingent Consideration, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent consideration payable, current portion</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent" xlink:label="us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent" xlink:to="us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Credits and Other Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred reimbursements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongTermNotesPayable" xlink:to="us-gaap_ConvertibleLongTermNotesPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Notes Payable, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible notes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DueToRelatedPartiesNoncurrent" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesNoncurrent" xlink:to="us-gaap_DueToRelatedPartiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Due to Related Parties, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Due to related party</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Contingent Consideration, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent consideration payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Gross, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred income taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-current liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, $.01 par value, 250,000,000 shares authorized, 142,691,986 shares issued and outstanding at December 31, 2016 Common stock, $.01 par value, 250,000,000 shares authorized, 125,027,034 shares issued and outstanding at December 31, 2015</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital, Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive loss:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency translation adjustment, less tax benefit of $1,293 at December 31, 2016</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized gain/(loss) on available-for securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and Rights Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Liabilities and Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less accumulated depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated depreciation of property and equipment (in dollars)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Authorized number of shares of common stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency translation adjustment, tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency translation adjustment, tax</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Operations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueNetAbstract" xlink:label="us-gaap_SalesRevenueNetAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetAbstract" xlink:to="us-gaap_SalesRevenueNetAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue, Net [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalesRevenueNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueGoodsNet" xlink:to="us-gaap_SalesRevenueGoodsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueGoodsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales Revenue, Goods, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalesRevenueGoodsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Product Sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SalesRevenueGoodsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net product sales</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ResearchRevenue" xlink:label="fold_ResearchRevenue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_ResearchRevenue" xlink:to="fold_ResearchRevenue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_ResearchRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This element represents reimbursements for research and development costs under collaboration agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_ResearchRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_ResearchRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="fold_ResearchRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research revenue for work performed under cost sharing arrangement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNet" xlink:to="us-gaap_SalesRevenueNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_SalesRevenueNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total revenue</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsSold" xlink:to="us-gaap_CostOfGoodsSold_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of Goods Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CostOfGoodsSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of goods sold</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross Profit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross Profit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense (Excluding Acquired in Process Cost)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, general and administrative</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in fair value of contingent consideration payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized change in fair value change during the period, included in Statement of Operations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCharges" xlink:to="us-gaap_RestructuringCharges_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCharges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring Charges.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringCharges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring charges</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income (expenses):</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment Income, Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ExtinguishmentOfDebtGainLossNetOfTax" xlink:label="us-gaap_ExtinguishmentOfDebtGainLossNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExtinguishmentOfDebtGainLossNetOfTax" xlink:to="us-gaap_ExtinguishmentOfDebtGainLossNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExtinguishmentOfDebtGainLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Extinguishment of Debt, Gain (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ExtinguishmentOfDebtGainLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on extinguishment of debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ExtinguishmentOfDebtGainLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on extinguishment of debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss before income tax benefit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax benefit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss attributable to common stockholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss attributable to common stockholders per common share - basic and diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic and diluted net loss per common share (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average common shares outstanding - basic and diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average common shares outstanding - basic and diluted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive gain/ (loss):</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency translation adjustment, net of tax of $1,293</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency translation adjustment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized holding gain/(loss) on available-for-sale securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized gain/ (loss) on available-for-sale securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income/ (loss)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Changes in Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition Acquiree [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition, Acquiree [Domain]</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_SciodermIncMember" xlink:label="fold_SciodermIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_SciodermIncMember" xlink:to="fold_SciodermIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_SciodermIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Scioderm, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_SciodermIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scioderm Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_SciodermIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scioderm</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_CallidusBiopharmaIncMember" xlink:label="fold_CallidusBiopharmaIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_CallidusBiopharmaIncMember" xlink:to="fold_CallidusBiopharmaIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_CallidusBiopharmaIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Callidus Biopharma, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_CallidusBiopharmaIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Callidus Biopharma Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_CallidusBiopharmaIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Callidus</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_MiaMedIncMember" xlink:label="fold_MiaMedIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_MiaMedIncMember" xlink:to="fold_MiaMedIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_MiaMedIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to MiaMed, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_MiaMedIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Mia Med Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_MiaMedIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">MiaMed</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid In Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-In Capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeMember" xlink:label="us-gaap_ComprehensiveIncomeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeMember" xlink:to="us-gaap_ComprehensiveIncomeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Gain/ (Loss)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock issued from exercise of stock options, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options exercised (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock issued from exercise of stock options, net (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Acquisitions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock issued for acquisition</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Acquisitions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock issued for acquisition (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock issued from public offering / financing</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock issued from public offering / financing (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock issued from public offering / financing (in shares)</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="fold_StockIssuedDuringPeriodValueWarrantsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="fold_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This element represents Stock issued from exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock issued from exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="fold_StockIssuedDuringPeriodSharesWarrantsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="fold_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This element represents Stock issued from exercise of warrants (in shares).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock issued from exercise of warrants (in shares)</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_StockIssuedDuringPeriodValueAtMarketOffering" xlink:label="fold_StockIssuedDuringPeriodValueAtMarketOffering" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_StockIssuedDuringPeriodValueAtMarketOffering" xlink:to="fold_StockIssuedDuringPeriodValueAtMarketOffering_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_StockIssuedDuringPeriodValueAtMarketOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity impact of the value of new stock issued during the period related to at the market (ATM) equity offerings.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_StockIssuedDuringPeriodValueAtMarketOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Value At The Market Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_StockIssuedDuringPeriodValueAtMarketOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds from stock issued at ATM transactions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="fold_StockIssuedDuringPeriodValueAtMarketOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock issued from ATM transactions</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_StockIssuedDuringPeriodSharesAtMarketOffering" xlink:label="fold_StockIssuedDuringPeriodSharesAtMarketOffering" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_StockIssuedDuringPeriodSharesAtMarketOffering" xlink:to="fold_StockIssuedDuringPeriodSharesAtMarketOffering_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_StockIssuedDuringPeriodSharesAtMarketOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of new stock issued during the period related to at the market (ATM) equity offerings.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_StockIssuedDuringPeriodSharesAtMarketOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Shares At Market Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_StockIssuedDuringPeriodSharesAtMarketOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued from ATM transactions (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="fold_StockIssuedDuringPeriodSharesAtMarketOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock issued from ATM transactions (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Share-based Compensation, Restricted Stock Unit or Restricted Stock Award, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted stock vesting</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted stock vesting (in shares)</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_StockIssuedDuringPeriodValueContingentConsideration" xlink:label="fold_StockIssuedDuringPeriodValueContingentConsideration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_StockIssuedDuringPeriodValueContingentConsideration" xlink:to="fold_StockIssuedDuringPeriodValueContingentConsideration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_StockIssuedDuringPeriodValueContingentConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity impact of the value of new stock issued during the period for contingent consideration.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_StockIssuedDuringPeriodValueContingentConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Value Contingent Consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_StockIssuedDuringPeriodValueContingentConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock issued for contingent consideration</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_StockIssuedDuringPeriodSharesContingentConsideration" xlink:label="fold_StockIssuedDuringPeriodSharesContingentConsideration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_StockIssuedDuringPeriodSharesContingentConsideration" xlink:to="fold_StockIssuedDuringPeriodSharesContingentConsideration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_StockIssuedDuringPeriodSharesContingentConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued during the period for contingent consideration.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_StockIssuedDuringPeriodSharesContingentConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Shares Contingent Consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_StockIssuedDuringPeriodSharesContingentConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock issued for contingent consideration (in shares)</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor" xlink:label="fold_AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor" xlink:to="fold_AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase in additional paid in capital (APIC) resulting from the receivable from investor.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Receivable from Investor</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivable from investor</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_StockAndWarrantsIssuedDuringPeriodValueNewIssues" xlink:label="fold_StockAndWarrantsIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_StockAndWarrantsIssuedDuringPeriodValueNewIssues" xlink:to="fold_StockAndWarrantsIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_StockAndWarrantsIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the value of new stock and warrants issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_StockAndWarrantsIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock and Warrants Issued During Period Value New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_StockAndWarrantsIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants issued in debt financing</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity component of the Convertible Notes issuance, net of issuance costs of $2,709</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity component of the Convertible Notes</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_AdjustmentsToAdditionalPaidinCapitalPremiumsPaidForCappedCallConfirmations" xlink:label="fold_AdjustmentsToAdditionalPaidinCapitalPremiumsPaidForCappedCallConfirmations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_AdjustmentsToAdditionalPaidinCapitalPremiumsPaidForCappedCallConfirmations" xlink:to="fold_AdjustmentsToAdditionalPaidinCapitalPremiumsPaidForCappedCallConfirmations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_AdjustmentsToAdditionalPaidinCapitalPremiumsPaidForCappedCallConfirmations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of decrease in additional paid in capital (APIC) resulting from Premium paid for Capped Call Confirmations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_AdjustmentsToAdditionalPaidinCapitalPremiumsPaidForCappedCallConfirmations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments To Additional PaidIn Capital Premiums Paid for Capped Call Confirmations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_AdjustmentsToAdditionalPaidinCapitalPremiumsPaidForCappedCallConfirmations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Premium paid for Capped Call Confirmations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Finance Costs, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible notes issuance costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Cash Flows</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaidInKindInterest" xlink:to="us-gaap_PaidInKindInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaidInKindInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Paid-in-Kind Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaidInKindInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash interest expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Adjustment of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of warrant liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in fair value of contingent consideration payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash changes in the fair value of contingent consideration payable</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ResearchExpenseForStockIssuanceInAssetAcquisition" xlink:label="fold_ResearchExpenseForStockIssuanceInAssetAcquisition" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_ResearchExpenseForStockIssuanceInAssetAcquisition" xlink:to="fold_ResearchExpenseForStockIssuanceInAssetAcquisition_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_ResearchExpenseForStockIssuanceInAssetAcquisition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of research expense charged to statement of operations for stock issued in assets acquisition transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_ResearchExpenseForStockIssuanceInAssetAcquisition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research Expense For Stock Issuance In Asset Acquisition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_ResearchExpenseForStockIssuanceInAssetAcquisition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Charges to research expense for stock issued in asset acquisition</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gains (Losses) on Extinguishment of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on extinguishment of debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Transaction Gain (Loss), before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency remeasurement loss</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_NoncashIncomeTaxExpenseBenefit" xlink:label="fold_NoncashIncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_NoncashIncomeTaxExpenseBenefit" xlink:to="fold_NoncashIncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_NoncashIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The portion of the non-cash component of income tax expense for the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_NoncashIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncash Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_NoncashIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash income tax benefit</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_NonCashDeferredTaxes" xlink:label="fold_NonCashDeferredTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_NonCashDeferredTaxes" xlink:to="fold_NonCashDeferredTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_NonCashDeferredTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The portion of the non-cash component of deferred taxes for the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_NonCashDeferredTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non Cash Deferred Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_NonCashDeferredTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash deferred taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Disposition of Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on disposal of assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_IncreaseDecreaseInDueFromCollaborationAgreements" xlink:label="fold_IncreaseDecreaseInDueFromCollaborationAgreements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_IncreaseDecreaseInDueFromCollaborationAgreements" xlink:to="fold_IncreaseDecreaseInDueFromCollaborationAgreements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_IncreaseDecreaseInDueFromCollaborationAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The aggregate increase (decrease) during the reporting period in the amount due from collaboration agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_IncreaseDecreaseInDueFromCollaborationAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) In Due From Collaboration Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="fold_IncreaseDecreaseInDueFromCollaborationAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivable due from collaboration agreements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Other Operating Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable and accrued expenses</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_IncreaseDecreaseInNoncurrentOperatingLiabilities" xlink:label="fold_IncreaseDecreaseInNoncurrentOperatingLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_IncreaseDecreaseInNoncurrentOperatingLiabilities" xlink:to="fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase (decrease) during the reporting period in the aggregate amount of noncurrent liabilities that result from activities that generate operating income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) In Noncurrent Operating Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current liabilities</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_IncreaseDecreaseInDeferredReimbursements" xlink:label="fold_IncreaseDecreaseInDeferredReimbursements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_IncreaseDecreaseInDeferredReimbursements" xlink:to="fold_IncreaseDecreaseInDeferredReimbursements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_IncreaseDecreaseInDeferredReimbursements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase (decrease) during the reporting period in the amount of deferred reimbursements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_IncreaseDecreaseInDeferredReimbursements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) In Deferred Reimbursements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_IncreaseDecreaseInDeferredReimbursements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred reimbursements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Sale and Maturity of Available-for-sale Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale and redemption of marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Available-for-sale Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Businesses, Net of Cash Acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquisitions, net of cash acquired</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from the issuance of common stock (in dollars)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock and warrants, net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds from the issuance of common stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt" xlink:label="us-gaap_RepaymentsOfSecuredDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfSecuredDebt" xlink:to="us-gaap_RepaymentsOfSecuredDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfSecuredDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of Secured Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfSecuredDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of secured loan agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of Debt and Capital Lease Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of capital leases</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_PaymentsForRepurchaseOfRestrictedStockUnits" xlink:label="fold_PaymentsForRepurchaseOfRestrictedStockUnits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_PaymentsForRepurchaseOfRestrictedStockUnits" xlink:to="fold_PaymentsForRepurchaseOfRestrictedStockUnits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_PaymentsForRepurchaseOfRestrictedStockUnits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash outflow to reacquire restricted stock units during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_PaymentsForRepurchaseOfRestrictedStockUnits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments For Repurchase Of Restricted Stock Units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="fold_PaymentsForRepurchaseOfRestrictedStockUnits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of vested restricted stock units</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_PaymentOfContingentConsideration" xlink:label="fold_PaymentOfContingentConsideration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_PaymentOfContingentConsideration" xlink:to="fold_PaymentOfContingentConsideration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_PaymentOfContingentConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash outflow associated with the payment of contingent consideration liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_PaymentOfContingentConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment Of Contingent Consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="fold_PaymentOfContingentConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of contingent consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="fold_PaymentOfContingentConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of contingent consideration in cash</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Convertible Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of convertible senior notes, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_PremiumsPaidForCappedCallConfirmations" xlink:label="fold_PremiumsPaidForCappedCallConfirmations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_PremiumsPaidForCappedCallConfirmations" xlink:to="fold_PremiumsPaidForCappedCallConfirmations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_PremiumsPaidForCappedCallConfirmations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash outflow for premiums paid for capped call confirmations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_PremiumsPaidForCappedCallConfirmations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Premiums Paid for Capped Call Confirmations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="fold_PremiumsPaidForCappedCallConfirmations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Premiums paid for Capped Call Confirmations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="fold_PremiumsPaidForCappedCallConfirmations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds from convertible notes to pay capped call transactions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfSecuredDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Secured Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from secured loan agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of Exchange Rate on Cash and Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of exchange rate changes on cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net increase/(decrease) in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental disclosures of cash flow information</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid during the period for interest</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ContingentConsiderationPaidInStock" xlink:label="fold_ContingentConsiderationPaidInStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_ContingentConsiderationPaidInStock" xlink:to="fold_ContingentConsiderationPaidInStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_ContingentConsiderationPaidInStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of contingent consideration liability in stock during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_ContingentConsiderationPaidInStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Consideration Paid In Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_ContingentConsiderationPaidInStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent consideration paid in shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="fold_ContingentConsiderationPaidInStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of contingent consideration in stock, impact on stockholder's equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeaseObligationsIncurred" xlink:label="us-gaap_CapitalLeaseObligationsIncurred" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsIncurred" xlink:to="us-gaap_CapitalLeaseObligationsIncurred_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeaseObligationsIncurred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Lease Obligations Incurred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalLeaseObligationsIncurred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital expenditures funded by capital lease borrowings</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of Business</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of Business</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquisitions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquisitions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill and Intangible Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill and Intangible Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Money Market Funds and Marketable Securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, and Short-term Investments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Money Market Funds and Marketable Securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets and Liabilities Measured at Fair Value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets and Liabilities Measured at Fair Value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">401(k) Plan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pension and Other Postretirement Benefits Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">401(k) Plan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases of Lessee Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licenses</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_CollaborativeArrangementDisclosureAbstract" xlink:label="fold_CollaborativeArrangementDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_CollaborativeArrangementDisclosureAbstract" xlink:to="fold_CollaborativeArrangementDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_CollaborativeArrangementDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Agreements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Agreements</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DebtInstrumentsAndRelatedPartyTransactionsAbstract" xlink:label="fold_DebtInstrumentsAndRelatedPartyTransactionsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_DebtInstrumentsAndRelatedPartyTransactionsAbstract" xlink:to="fold_DebtInstrumentsAndRelatedPartyTransactionsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_DebtInstrumentsAndRelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_DebtInstrumentsAndRelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instruments and Related Party Transactions</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DebtInstrumentsAndRelatedPartyTransactionsDisclosureTextBlock" xlink:label="fold_DebtInstrumentsAndRelatedPartyTransactionsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_DebtInstrumentsAndRelatedPartyTransactionsDisclosureTextBlock" xlink:to="fold_DebtInstrumentsAndRelatedPartyTransactionsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_DebtInstrumentsAndRelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents entire disclosure of Debt Instruments and related Party Transactions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_DebtInstrumentsAndRelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instruments and Related Party Transactions Disclosure Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_DebtInstrumentsAndRelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instruments and Related Party Transactions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Contingencies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selected Quarterly Financial Data (Unaudited - in thousands except per share data)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Quarterly Financial Information [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selected Quarterly Financial Data (Unaudited - in thousands except per share data)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidation, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Transactions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" xlink:label="fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" xlink:to="fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents and Marketable Securities [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Money Market Funds, and Marketable Securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration of Credit Risk</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Recognition, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Recognition</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories and Cost of Cost of Goods Sold</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContingentLiabilityReserveEstimatePolicy" xlink:label="us-gaap_ContingentLiabilityReserveEstimatePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentLiabilityReserveEstimatePolicy" xlink:to="us-gaap_ContingentLiabilityReserveEstimatePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContingentLiabilityReserveEstimatePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Liability Reserve Estimate, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContingentLiabilityReserveEstimatePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Costs</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_InterestIncomeAndInterestExpensePolicyTextBlock" xlink:label="fold_InterestIncomeAndInterestExpensePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_InterestIncomeAndInterestExpensePolicyTextBlock" xlink:to="fold_InterestIncomeAndInterestExpensePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_InterestIncomeAndInterestExpensePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for interest income and interest expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_InterestIncomeAndInterestExpensePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Income and Interest Expense [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_InterestIncomeAndInterestExpensePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Income and Interest Expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_OtherComprehensiveIncomePolicyPolicyTextBlock" xlink:label="fold_OtherComprehensiveIncomePolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_OtherComprehensiveIncomePolicyPolicyTextBlock" xlink:to="fold_OtherComprehensiveIncomePolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_OtherComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for other comprehensive income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_OtherComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_OtherComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income/ (Loss)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeasePolicyTextBlock" xlink:label="us-gaap_LeasePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasePolicyTextBlock" xlink:to="us-gaap_LeasePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeasePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_NonqualifiedCashDeferralPlansPolicy" xlink:label="fold_NonqualifiedCashDeferralPlansPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_NonqualifiedCashDeferralPlansPolicy" xlink:to="fold_NonqualifiedCashDeferralPlansPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_NonqualifiedCashDeferralPlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for nonqualified cash deferral plans sponsored by the entity. This disclosure may include (1) the groups that participate in (or are covered by) each plan and (2) significant plan provisions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_NonqualifiedCashDeferralPlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonqualified Cash Deferral Plans Policy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_NonqualifiedCashDeferralPlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonqualified Cash Deferral Plan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity-based Compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss per Common Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividends</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Information</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsPolicy" xlink:to="us-gaap_BusinessCombinationsPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combinations Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combinations</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock" xlink:label="fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock" xlink:to="fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for determination of contingent consideration, which is payable to acquiree.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Acquisition Consideration Payable [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Consideration Payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill and Intangible Assets, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets and Goodwill</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recent Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="us-gaap_ScheduleOfGoodwillTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Goodwill [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of changes in goodwill</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of changes in IPR&amp;D</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents and Investments [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of cash and available-for-sale securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Inventory, Current [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of inventories for the period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of accounts payable and accrued expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of fair value weighted-average assumptions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of stock options outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of non-vested Restricted Stock Units activity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of the equity-based compensation expense recognized in the statements of operations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of assets and liabilities subject to fair value measurements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of significant unobservable inputs used in the valuation of the contingent consideration payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of changes in contingent consideration payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock" xlink:label="us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock" xlink:to="us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Real Estate Properties [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of current significant leased properties</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of aggregate annual future minimum lease payments under the operating leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of aggregate annual future minimum lease payments under the capital leases, including interest</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of income (loss) before income taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of reconciliation of the statutory tax rates and the effective tax rates</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of significant components of the deferred tax assets and liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="us-gaap_ConvertibleDebtTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtTableTextBlock" xlink:to="us-gaap_ConvertibleDebtTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Debt [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of liability components of the Convertible Notes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Income and Interest Expense Disclosure [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of total interest expense recognized related to the Convertible Notes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of reconciliation of the numerator and denominator used in computing basic and diluted net loss per common share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Quarterly Financial Information [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of selected quarterly financial data</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_CounterpartyNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repurchase Agreement Counterparty Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_CowenAndCompanyLLCMember" xlink:label="fold_CowenAndCompanyLLCMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_CowenAndCompanyLLCMember" xlink:to="fold_CowenAndCompanyLLCMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_CowenAndCompanyLLCMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Cowen and Company, LLC (Cowen).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_CowenAndCompanyLLCMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cowen And Company L L C [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_CowenAndCompanyLLCMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cowen and Company, LLC</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate Information, Status of Operations and Management Plans</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_NumberOfFabryCausingMutationsIncludedInCHMPLabelApproval" xlink:label="fold_NumberOfFabryCausingMutationsIncludedInCHMPLabelApproval" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_NumberOfFabryCausingMutationsIncludedInCHMPLabelApproval" xlink:to="fold_NumberOfFabryCausingMutationsIncludedInCHMPLabelApproval_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_NumberOfFabryCausingMutationsIncludedInCHMPLabelApproval_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of mutations causing Fabry disease included in approved CHMP label.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_NumberOfFabryCausingMutationsIncludedInCHMPLabelApproval_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Fabry-Causing Mutations Included In CHMP Label Approval</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_NumberOfFabryCausingMutationsIncludedInCHMPLabelApproval_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Fabry causing mutations included in the label approved by the CHMP</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_PortionOfPatientsWithFabryCausedByMutationsIncludedInLabelApprovedByChmp" xlink:label="fold_PortionOfPatientsWithFabryCausedByMutationsIncludedInLabelApprovedByChmp" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_PortionOfPatientsWithFabryCausedByMutationsIncludedInLabelApprovedByChmp" xlink:to="fold_PortionOfPatientsWithFabryCausedByMutationsIncludedInLabelApprovedByChmp_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_PortionOfPatientsWithFabryCausedByMutationsIncludedInLabelApprovedByChmp_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the portion of patients with Fabry disease caused by mutations included in the label approved by the CHMP.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_PortionOfPatientsWithFabryCausedByMutationsIncludedInLabelApprovedByChmp_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Portion Of Patients With Fabry Caused By Mutations Included In Label Approved By CHMP</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_PortionOfPatientsWithFabryCausedByMutationsIncludedInLabelApprovedByChmp_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of patients with Fabry disease caused by mutations included in the label approved by the CHMP</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Face Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate principle amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from note and warrant purchase agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Debt, Net of Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds after deducting fees and estimated expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Consideration Transferred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total consideration, stock and cash</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BusinessCombinationContingentConsiderationMilestones" xlink:label="fold_BusinessCombinationContingentConsiderationMilestones" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_BusinessCombinationContingentConsiderationMilestones" xlink:to="fold_BusinessCombinationContingentConsiderationMilestones_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_BusinessCombinationContingentConsiderationMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of contingent consideration payable in a business combination upon achievement of certain clinical, regulatory and commercial milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_BusinessCombinationContingentConsiderationMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination Contingent Consideration Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_BusinessCombinationContingentConsiderationMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent consideration payable upon achievement of milestones</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BusinessCombinationConsiderationTransferredIncludingMilestonePayment" xlink:label="fold_BusinessCombinationConsiderationTransferredIncludingMilestonePayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_BusinessCombinationConsiderationTransferredIncludingMilestonePayment" xlink:to="fold_BusinessCombinationConsiderationTransferredIncludingMilestonePayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_BusinessCombinationConsiderationTransferredIncludingMilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Includes payments for achievement of certain clinical, regulatory and commercial milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_BusinessCombinationConsiderationTransferredIncludingMilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination Consideration Transferred Including Milestone Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_BusinessCombinationConsiderationTransferredIncludingMilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Potential aggregate deal value</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_FixedCommissionRateAsPercentageOfGrossProceedsPerShareSold" xlink:label="fold_FixedCommissionRateAsPercentageOfGrossProceedsPerShareSold" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_FixedCommissionRateAsPercentageOfGrossProceedsPerShareSold" xlink:to="fold_FixedCommissionRateAsPercentageOfGrossProceedsPerShareSold_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_FixedCommissionRateAsPercentageOfGrossProceedsPerShareSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the fixed commission rate, expressed as a percentage of gross proceeds per Share sold.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_FixedCommissionRateAsPercentageOfGrossProceedsPerShareSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Commission Rate as Percentage of Gross Proceeds Per Share Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_FixedCommissionRateAsPercentageOfGrossProceedsPerShareSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed commission rate as a percentage of gross proceeds per Share sold</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_CommonStockIssuanceCommissionExpenses" xlink:label="fold_CommonStockIssuanceCommissionExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_CommonStockIssuanceCommissionExpenses" xlink:to="fold_CommonStockIssuanceCommissionExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_CommonStockIssuanceCommissionExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the commission expenses incurred for the issuance of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_CommonStockIssuanceCommissionExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Issuance Commission Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_CommonStockIssuanceCommissionExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commission expenses incurred on issue of common stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherExpenses" xlink:label="us-gaap_OtherExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other expenses paid</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated useful lives</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="us-gaap_ShareBasedCompensationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ShareBasedCompensationNumberOfPlans" xlink:label="fold_ShareBasedCompensationNumberOfPlans" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_ShareBasedCompensationNumberOfPlans" xlink:to="fold_ShareBasedCompensationNumberOfPlans_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_ShareBasedCompensationNumberOfPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of plans under the share-based arrangements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_ShareBasedCompensationNumberOfPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Number of Plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_ShareBasedCompensationNumberOfPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of stock-based employee compensation plans</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of business segments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Business Acquisitions, by Acquisition [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquisitions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates" xlink:label="us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates" xlink:to="us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Businesses and Interest in Affiliates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash consideration paid</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consideration paid in common stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expense</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BusinessCombinationAdjustedConsiderationTransferred" xlink:label="fold_BusinessCombinationAdjustedConsiderationTransferred" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_BusinessCombinationAdjustedConsiderationTransferred" xlink:to="fold_BusinessCombinationAdjustedConsiderationTransferred_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_BusinessCombinationAdjustedConsiderationTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer, adjusted to excluding the exercise price of outstanding acquiree options and warrants and acquiree cash and cash equivalents.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_BusinessCombinationAdjustedConsiderationTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Adjusted Consideration Transferred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_BusinessCombinationAdjustedConsiderationTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial amount to Effective Time Holders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="fold_BusinessCombinationAdjustedConsiderationTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial amount to Effective Time Holders</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BusinessCombinationAdjustedCashConsiderationTransferred" xlink:label="fold_BusinessCombinationAdjustedCashConsiderationTransferred" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_BusinessCombinationAdjustedCashConsiderationTransferred" xlink:to="fold_BusinessCombinationAdjustedCashConsiderationTransferred_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_BusinessCombinationAdjustedCashConsiderationTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash outflow associated with the acquisition of business during the period, excluding payments to holders of Series B Preferred Stock related to the Series B Additional Purchase Price Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_BusinessCombinationAdjustedCashConsiderationTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination Adjusted Cash Consideration Transferred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_BusinessCombinationAdjustedCashConsiderationTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial amount cash payment excluding Series B Preferred</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BusinessCombinationAdjustedEquityConsiderationTransferred" xlink:label="fold_BusinessCombinationAdjustedEquityConsiderationTransferred" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_BusinessCombinationAdjustedEquityConsiderationTransferred" xlink:to="fold_BusinessCombinationAdjustedEquityConsiderationTransferred_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_BusinessCombinationAdjustedEquityConsiderationTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the value of Common Stock outflow or payments associated with the acquisition of business during the period, excluding payments to holders of Series B Preferred Stock related to the Series B Additional Purchase Price Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_BusinessCombinationAdjustedEquityConsiderationTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination Adjusted Equity Consideration Transferred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_BusinessCombinationAdjustedEquityConsiderationTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial amount paid in shares of Common Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Businesses, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront cash payments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront equity payments</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BusinessCombinationPriorityReviewVoucherSalePayment" xlink:label="fold_BusinessCombinationPriorityReviewVoucherSalePayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_BusinessCombinationPriorityReviewVoucherSalePayment" xlink:to="fold_BusinessCombinationPriorityReviewVoucherSalePayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_BusinessCombinationPriorityReviewVoucherSalePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of Priority Review Voucher sale proceeds shared with qualifying equity holders of the acquired entity in the event a specified PRV is obtained and sold.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_BusinessCombinationPriorityReviewVoucherSalePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination Priority Review Voucher Sale Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_BusinessCombinationPriorityReviewVoucherSalePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Priority Review Voucher sale proceeds shared</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BusinessCombinationPriorityReviewVoucherSalePaymentPercent" xlink:label="fold_BusinessCombinationPriorityReviewVoucherSalePaymentPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_BusinessCombinationPriorityReviewVoucherSalePaymentPercent" xlink:to="fold_BusinessCombinationPriorityReviewVoucherSalePaymentPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_BusinessCombinationPriorityReviewVoucherSalePaymentPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the percentage of Priority Review Voucher sale proceeds shared with qualifying equity holders of the acquired entity in the event a specified PRV is obtained and sold.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_BusinessCombinationPriorityReviewVoucherSalePaymentPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination Priority Review Voucher Sale Payment Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_BusinessCombinationPriorityReviewVoucherSalePaymentPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Priority Review Voucher sale proceeds shared (as a percent)</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_PriorityReviewVoucherTransferYears" xlink:label="fold_PriorityReviewVoucherTransferYears" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_PriorityReviewVoucherTransferYears" xlink:to="fold_PriorityReviewVoucherTransferYears_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_PriorityReviewVoucherTransferYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of years of Priority Review Voucher sale transfer to third party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_PriorityReviewVoucherTransferYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Priority Review Voucher Transfer Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="fold_PriorityReviewVoucherTransferYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Priority review voucher transfer years</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BusinessCombinationPriorityReviewVoucherUsedPayment" xlink:label="fold_BusinessCombinationPriorityReviewVoucherUsedPayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_BusinessCombinationPriorityReviewVoucherUsedPayment" xlink:to="fold_BusinessCombinationPriorityReviewVoucherUsedPayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_BusinessCombinationPriorityReviewVoucherUsedPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the payment that will be made to qualifying equity holders of the acquired entity in the event that the Priority Review Voucher is obtained and used.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_BusinessCombinationPriorityReviewVoucherUsedPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination Priority Review Voucher Used Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_BusinessCombinationPriorityReviewVoucherUsedPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment to be made if Priority Review Voucher is obtained and used</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Contingent Consideration, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent consideration payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="us-gaap_FairValueInputsDiscountRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsDiscountRate" xlink:to="us-gaap_FairValueInputsDiscountRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsDiscountRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Inputs, Discount Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsDiscountRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discount rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ContingentConsiderationMilestonePayment" xlink:label="fold_ContingentConsiderationMilestonePayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_ContingentConsiderationMilestonePayment" xlink:to="fold_ContingentConsiderationMilestonePayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_ContingentConsiderationMilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of milestone payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_ContingentConsiderationMilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Consideration, Milestone Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_ContingentConsiderationMilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at end of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at beginning of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets-IPR&amp;D</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_StockIssuedDuringPeriodValueIssuedForContingentConsiderations" xlink:label="fold_StockIssuedDuringPeriodValueIssuedForContingentConsiderations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_StockIssuedDuringPeriodValueIssuedForContingentConsiderations" xlink:to="fold_StockIssuedDuringPeriodValueIssuedForContingentConsiderations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_StockIssuedDuringPeriodValueIssuedForContingentConsiderations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of shares issued for noncash contingent consideration upon achieving event based milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_StockIssuedDuringPeriodValueIssuedForContingentConsiderations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Value Issued For Contingent Considerations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_StockIssuedDuringPeriodValueIssuedForContingentConsiderations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payment, value of shares issued</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BusinessAcquisitionsMember" xlink:label="fold_BusinessAcquisitionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_BusinessAcquisitionsMember" xlink:to="fold_BusinessAcquisitionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_BusinessAcquisitionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the aggregation and reporting of combined amounts of business combinations that were completed during the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_BusinessAcquisitionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisitions [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_BusinessAcquisitionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisitions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillRollForward" xlink:label="us-gaap_GoodwillRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillRollForward" xlink:to="us-gaap_GoodwillRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in goodwill</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill, Impairment Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill impairment loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsRollForward" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsRollForward" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Indefinite-lived Intangible Assets [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in IPR&amp;D</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of IPR&amp;D</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Available-for-sale Securities [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Major Types of Debt and Equity Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Major Types Of Debt And Equity Securities [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Major Types of Debt and Equity Securities [Domain]</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ShortTermCorporateDebtSecuritiesMember" xlink:label="fold_ShortTermCorporateDebtSecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_ShortTermCorporateDebtSecuritiesMember" xlink:to="fold_ShortTermCorporateDebtSecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_ShortTermCorporateDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_ShortTermCorporateDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short Term Corporate Debt Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_ShortTermCorporateDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short term corporate debt securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Paper Not Included With Cash And Cash Equivalents [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial paper</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Available-for-sale Securities [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Money Market Funds, and Marketable Securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative, Gain (Loss) on Derivative, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (loss) on derivative instruments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents, Fair Value</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_AvailableForSaleSecuritiesAmortizedCostCurrent" xlink:label="fold_AvailableForSaleSecuritiesAmortizedCostCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_AvailableForSaleSecuritiesAmortizedCostCurrent" xlink:to="fold_AvailableForSaleSecuritiesAmortizedCostCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_AvailableForSaleSecuritiesAmortizedCostCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This item represents the current cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_AvailableForSaleSecuritiesAmortizedCostCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available For Sale Securities Amortized Cost Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="fold_AvailableForSaleSecuritiesAmortizedCostCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable securities, Amortized cost current portion</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:label="fold_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:to="fold_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before tax of current portion of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized Gain current portion</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:label="fold_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:to="fold_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before tax of current portion of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="fold_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized Loss current portion</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available-for-sale Securities, Amortized Cost Basis</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable securities, Amortized Cost</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized Gain</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized Loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecurities" xlink:to="us-gaap_AvailableForSaleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available-for-sale Securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable securities, Fair Value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, and Short-term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and marketable securities, Amortized Cost</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure" xlink:label="fold_CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure" xlink:to="fold_CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents cash and cash equivalents and short-term investments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents and Short Term Investments, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="fold_CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and marketable securities, Fair Value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available-for-sale Securities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available-for-sale investments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available-for-sale Securities, Gross Realized Gain (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Realized gain (loss) on securities available-for-sale</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of available for sale securities in unrealized loss positions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:label="us-gaap_InventoryCurrentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="us-gaap_InventoryCurrentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryCurrentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Current [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="us-gaap_InventoryLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories components</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Work in Process, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Work-in-process</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Finished Goods, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finished goods</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWriteDown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory Write-down</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWriteDown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory write-downs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property Plant And Equipment Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computer Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computer equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Software And Software Development Costs [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computer software</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ResearchEquipmentMember" xlink:label="fold_ResearchEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_ResearchEquipmentMember" xlink:to="fold_ResearchEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_ResearchEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents tangible property used for research.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_ResearchEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_ResearchEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Furniture And Fixtures [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Furniture and fixtures</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold Improvements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold improvements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, gross</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation" xlink:label="us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation" xlink:to="us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Leases, Lessee Balance Sheet, Assets by Major Class, Accumulated Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation expense for capital lease obligation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeaseObligations" xlink:label="us-gaap_CapitalLeaseObligations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligations" xlink:to="us-gaap_CapitalLeaseObligations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeaseObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Lease Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalLeaseObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital lease obligations outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CapitalLeaseObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital lease obligation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Professional Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued professional fees</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_AccruedContractManufacturingAndContractResearchCostsCurrent" xlink:label="fold_AccruedContractManufacturingAndContractResearchCostsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_AccruedContractManufacturingAndContractResearchCostsCurrent" xlink:to="fold_AccruedContractManufacturingAndContractResearchCostsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_AccruedContractManufacturingAndContractResearchCostsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the carrying value as of the balance sheet date of obligations incurred through that date and payable for contract manufacturing and contract research costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle, if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_AccruedContractManufacturingAndContractResearchCostsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Contract Manufacturing and Contract Research Costs Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_AccruedContractManufacturingAndContractResearchCostsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued contract manufacturing &amp; contract research costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued compensation and benefits</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_AccruedFacilityCostsCurrent" xlink:label="fold_AccruedFacilityCostsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_AccruedFacilityCostsCurrent" xlink:to="fold_AccruedFacilityCostsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_AccruedFacilityCostsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the carrying value as of the balance sheet date of obligations incurred through that date and payable for facility expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle, if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_AccruedFacilityCostsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Facility Costs Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_AccruedFacilityCostsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued facility costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:to="us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Contracts, Liability, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency forward contract</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="us-gaap_CapitalLeaseObligationsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsCurrent" xlink:to="us-gaap_CapitalLeaseObligationsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeaseObligationsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Lease Obligations, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalLeaseObligationsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital lease, short term portion</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued other</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_NoteAndWarrantAgreement2015Member" xlink:label="fold_NoteAndWarrantAgreement2015Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_NoteAndWarrantAgreement2015Member" xlink:to="fold_NoteAndWarrantAgreement2015Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_NoteAndWarrantAgreement2015Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to 2015 Loan Agreement that matures in October 2020. Purchasers of the Notes receive a five-year Warrant in addition to interest.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_NoteAndWarrantAgreement2015Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Note And Warrant Agreement2015 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_NoteAndWarrantAgreement2015Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">October 2015 Purchase Agreement</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_RedmileGroupMember" xlink:label="fold_RedmileGroupMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_RedmileGroupMember" xlink:to="fold_RedmileGroupMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_RedmileGroupMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Redmile Group.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_RedmileGroupMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redmile Group [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_RedmileGroupMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redmile Group</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Arrangements And Nonarrangement Transactions [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Arrangements and Non-arrangement Transactions [Domain]</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_PrivatePlacementPurchaseAgreementMember" xlink:label="fold_PrivatePlacementPurchaseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_PrivatePlacementPurchaseAgreementMember" xlink:to="fold_PrivatePlacementPurchaseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_PrivatePlacementPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information related to private placement purchase agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_PrivatePlacementPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private Placement Purchase Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_PrivatePlacementPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private Placement Purchase Agreement</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_SalesAgreementMember" xlink:label="fold_SalesAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_SalesAgreementMember" xlink:to="fold_SalesAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_SalesAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the Sales Agreement entered into by the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_SalesAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_SalesAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales Agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ParentCompanyMember" xlink:label="us-gaap_ParentCompanyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ParentCompanyMember" xlink:to="us-gaap_ParentCompanyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ParentCompanyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Parent Company [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ParentCompanyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amicus</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:label="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:to="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Debt [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Convertible, Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt conversion ratio (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Convertible, Conversion Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_CommonStockVotingRightsForEachShareHeld" xlink:label="fold_CommonStockVotingRightsForEachShareHeld" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_CommonStockVotingRightsForEachShareHeld" xlink:to="fold_CommonStockVotingRightsForEachShareHeld_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_CommonStockVotingRightsForEachShareHeld_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of votes entitled for each share held.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_CommonStockVotingRightsForEachShareHeld_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Voting Rights for Each Share Held</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_CommonStockVotingRightsForEachShareHeld_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Voting right for each share held, number</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issuable for warrants (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Public offering share price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ProceedsFromIssuanceOfCommonStockGross" xlink:label="fold_ProceedsFromIssuanceOfCommonStockGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_ProceedsFromIssuanceOfCommonStockGross" xlink:to="fold_ProceedsFromIssuanceOfCommonStockGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_ProceedsFromIssuanceOfCommonStockGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The gross cash inflow from the additional capital contribution to the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_ProceedsFromIssuanceOfCommonStockGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_ProceedsFromIssuanceOfCommonStockGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate offering proceeds from issuance of common stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Award [Domain]</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_EmployeeAndDirectorsStockOptionsMember" xlink:label="fold_EmployeeAndDirectorsStockOptionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_EmployeeAndDirectorsStockOptionsMember" xlink:to="fold_EmployeeAndDirectorsStockOptionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_EmployeeAndDirectorsStockOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">An arrangement whereby an employee or member of the Board of Directors is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_EmployeeAndDirectorsStockOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee And Directors Stock Options [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_EmployeeAndDirectorsStockOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock Units R S U [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted stock units (RSUs)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_PerformanceBasedRestrictedStockUnitAwardAgreementMember" xlink:label="fold_PerformanceBasedRestrictedStockUnitAwardAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_PerformanceBasedRestrictedStockUnitAwardAgreementMember" xlink:to="fold_PerformanceBasedRestrictedStockUnitAwardAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_PerformanceBasedRestrictedStockUnitAwardAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pertaining to the Performance-Based Restricted Stock Unit Award Agreement (the "Performance-Based RSU Agreement"), to be used for performance-based RSUs granted to participants under the Amended and Restated Amicus Therapeutics, Inc. 2007 Equity Incentive Plan, including named executive officers. Awards under the form of Performance-Based RSU Agreement will vest based on the Company meeting specified performance criteria. Vesting of the RSUs is generally subject to the participant's continuous service with the Company through a specified date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_PerformanceBasedRestrictedStockUnitAwardAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Performance Based Restricted Stock Unit Award Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_PerformanceBasedRestrictedStockUnitAwardAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Performance-Based RSU Agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:label="us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:to="us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Compensation Liability, Classified, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred compensation liability, noncurrent</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TradingSecurities" xlink:label="us-gaap_TradingSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradingSecurities" xlink:to="us-gaap_TradingSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradingSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TradingSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterestAndDividend" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment Income, Interest and Dividend</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income from deferred compensation investments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TradingSecuritiesUnrealizedHoldingGainLoss" xlink:label="us-gaap_TradingSecuritiesUnrealizedHoldingGainLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradingSecuritiesUnrealizedHoldingGainLoss" xlink:to="us-gaap_TradingSecuritiesUnrealizedHoldingGainLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradingSecuritiesUnrealizedHoldingGainLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Securities, Change in Unrealized Holding Gain (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TradingSecuritiesUnrealizedHoldingGainLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized gain/(loss)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value weighted-average assumptions:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum term of option</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_VestingRightsPercentageOnFirstYearAnniversary" xlink:label="fold_VestingRightsPercentageOnFirstYearAnniversary" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_VestingRightsPercentageOnFirstYearAnniversary" xlink:to="fold_VestingRightsPercentageOnFirstYearAnniversary_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_VestingRightsPercentageOnFirstYearAnniversary_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of award terms as to how many shares or portion of an award are no longer contingent on satisfaction of either a service condition, market condition or a performance condition, thereby giving the employee the legal right to convert the award to shares on the first anniversary (as defined), shown as a percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_VestingRightsPercentageOnFirstYearAnniversary_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting Rights Percentage on First Year Anniversary</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_VestingRightsPercentageOnFirstYearAnniversary_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of options vest on the first year anniversary</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional percentage of options that will vest each month after first anniversary</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionPercentageOfSharesVestedThatMayBeExercisedInWholeOrPart" xlink:label="fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionPercentageOfSharesVestedThatMayBeExercisedInWholeOrPart" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionPercentageOfSharesVestedThatMayBeExercisedInWholeOrPart" xlink:to="fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionPercentageOfSharesVestedThatMayBeExercisedInWholeOrPart_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionPercentageOfSharesVestedThatMayBeExercisedInWholeOrPart_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the percentage of shares vested that may be exercised in whole or part.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionPercentageOfSharesVestedThatMayBeExercisedInWholeOrPart_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement by Share Based Payment Award Option Percentage of Shares Vested that May be Exercised in Whole or Part</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionPercentageOfSharesVestedThatMayBeExercisedInWholeOrPart_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of shares vested that may be exercised in whole or part</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares reserved for issuance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum stock price volatility (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected stock price volatility (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk free interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected life of options</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" xlink:label="fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" xlink:to="fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the estimated dividend per share to be paid (expected dividends) to holders of the underlying shares over the option's term.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement by Share Based Payment Award, Fair Value Assumptions Expected Dividend Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected annual dividend per share (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the end of the period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the beginning of the period (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options forfeited (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and unvested expected to vest as of the end of the period (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable at the end of the period (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the end of the period (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the beginning of the period (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options exercised (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options forfeited (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and unvested expected to vest as of the end of the period (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable at the end of the period (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageContractualLifeAbstract" xlink:label="fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageContractualLifeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageContractualLifeAbstract" xlink:to="fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageContractualLifeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageContractualLifeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement by Share Based Payment Award Options Weighted Average Contractual Life [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageContractualLifeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Remaining Contractual Life</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the end of the period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and unvested expected to vest at the end of the period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable at the end of the period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate intrinsic value of options outstanding (in dollars)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate intrinsic value of options vested and unvested expected to vest (in dollars)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate intrinsic value of options exercisable (in dollars)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate intrinsic value of options exercised (in dollars)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Cash Received from Exercise of Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash proceeds from stock options exercised (in dollars)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total unrecognized compensation cost related to non-vested stock options granted (in dollars)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period of recognition unrecognized compensation costs (in years)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock Units, Number of Shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-vested units as of the end of the period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-vested units as of the beginning of the period (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Grant Date Fair Value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-vested units as of the end of the period (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-vested units as of the beginning of the period (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Remaining Years</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-vested units as of the end of the period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Units issued under the Plan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research And Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity compensation expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total equity compensation expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Hierarchy [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements Fair Value Hierarchy [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Inputs Level2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 2</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Inputs Level3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 3</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate Debt Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate debt securities</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_MarketExchangedMutualFundsMember" xlink:label="fold_MarketExchangedMutualFundsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_MarketExchangedMutualFundsMember" xlink:to="fold_MarketExchangedMutualFundsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_MarketExchangedMutualFundsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to mutual funds exchanged in a market.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_MarketExchangedMutualFundsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Market Exchanged Mutual Funds [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_MarketExchangedMutualFundsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Market exchanged mutual funds</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial assets and liabilities subject to fair value measurements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets, Level 1 to Level 2 Transfers, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfer of assets from Level 1 to Level 2</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets, Level 2 to Level 1 Transfers, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfer of assets from Level 2 to Level 1</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Fair Value Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Fair Value Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Liability, Fair Value, Gross Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:label="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:to="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Compensation Share-based Arrangements, Liability, Current and Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred compensation plan liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial and Nonfinancial Liabilities, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of liabilities</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_FairValueInputsProbabilityOfAchievementOfMilestones" xlink:label="fold_FairValueInputsProbabilityOfAchievementOfMilestones" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_FairValueInputsProbabilityOfAchievementOfMilestones" xlink:to="fold_FairValueInputsProbabilityOfAchievementOfMilestones_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_FairValueInputsProbabilityOfAchievementOfMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of likelihood that milestones will be achieved, used as an input to measure fair value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_FairValueInputsProbabilityOfAchievementOfMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Inputs Probability Of Achievement Of Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_FairValueInputsProbabilityOfAchievementOfMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Probability of achievement of milestones (as a percent)</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_FairValueAssumptionsRevenueVolatilityRate" xlink:label="fold_FairValueAssumptionsRevenueVolatilityRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_FairValueAssumptionsRevenueVolatilityRate" xlink:to="fold_FairValueAssumptionsRevenueVolatilityRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_FairValueAssumptionsRevenueVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of assumed revenue volatility, used as an input to measure fair value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_FairValueAssumptionsRevenueVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Assumptions Revenue Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_FairValueAssumptionsRevenueVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue volatility (as a percent)</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BusinessCombinationContingentConsiderationLiabilityRollForward" xlink:label="fold_BusinessCombinationContingentConsiderationLiabilityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_BusinessCombinationContingentConsiderationLiabilityRollForward" xlink:to="fold_BusinessCombinationContingentConsiderationLiabilityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_BusinessCombinationContingentConsiderationLiabilityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent consideration payable rollforward.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_BusinessCombinationContingentConsiderationLiabilityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination Contingent Consideration Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_BusinessCombinationContingentConsiderationLiabilityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent consideration payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance, end of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance, beginning of the period</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityBusinessAcquisition" xlink:label="fold_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityBusinessAcquisition" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityBusinessAcquisition" xlink:to="fold_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityBusinessAcquisition_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityBusinessAcquisition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase (decrease) from business acquisitions of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityBusinessAcquisition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Business Acquisition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityBusinessAcquisition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additions, from business acquisitions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of contingent consideration in stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsAbstract" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of Exchange Rate on Cash and Cash Equivalents [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Exchange Rate Exposure</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_NumberOfForwardContracts" xlink:label="fold_NumberOfForwardContracts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_NumberOfForwardContracts" xlink:to="fold_NumberOfForwardContracts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_NumberOfForwardContracts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This element represents the number of forward contracts negotiated to purchase and sell a specific quantity of a financial instrument, foreign currency, or commodity at a price specified at origination of the contract, with delivery and settlement at a specified future date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_NumberOfForwardContracts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Forward Contracts</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Servicing Liability at Fair Value, Period Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash changes in the fair value of derivative liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:label="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Pension and Other Postretirement Plans Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">401 (k) Plan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum contribution by the company as a percentage of employee's salary and bonus paid during the year</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Cost Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total contribution to the plan (in dollars)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeographicDistributionAxis" xlink:label="us-gaap_GeographicDistributionAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeographicDistributionAxis" xlink:to="us-gaap_GeographicDistributionAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeographicDistributionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographic Distribution [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeographicDistributionDomain" xlink:label="us-gaap_GeographicDistributionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeographicDistributionDomain" xlink:to="us-gaap_GeographicDistributionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeographicDistributionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographic Distribution [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeographicDistributionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographic Distribution [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeographicDistributionDomesticMember" xlink:label="us-gaap_GeographicDistributionDomesticMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeographicDistributionDomesticMember" xlink:to="us-gaap_GeographicDistributionDomesticMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeographicDistributionDomesticMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographic Distribution Domestic [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeographicDistributionDomesticMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Domestic</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_CranburyNewJerseyMember" xlink:label="fold_CranburyNewJerseyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_CranburyNewJerseyMember" xlink:to="fold_CranburyNewJerseyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_CranburyNewJerseyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents activity related to Cranbury, New Jersey location.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_CranburyNewJerseyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cranbury New Jersey [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_CranburyNewJerseyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cranbury, New Jersey</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DurhamNorthCarolinaMember" xlink:label="fold_DurhamNorthCarolinaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_DurhamNorthCarolinaMember" xlink:to="fold_DurhamNorthCarolinaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_DurhamNorthCarolinaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents activity related to Durham, North Carolina location.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_DurhamNorthCarolinaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Durham North Carolina [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_DurhamNorthCarolinaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Durham, North Carolina</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeographicDistributionForeignMember" xlink:label="us-gaap_GeographicDistributionForeignMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeographicDistributionForeignMember" xlink:to="us-gaap_GeographicDistributionForeignMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeographicDistributionForeignMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographic Distribution Foreign [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeographicDistributionForeignMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign.</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BuckinghamshireUnitedKingdomMember" xlink:label="fold_BuckinghamshireUnitedKingdomMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_BuckinghamshireUnitedKingdomMember" xlink:to="fold_BuckinghamshireUnitedKingdomMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_BuckinghamshireUnitedKingdomMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents activity related to San Diego, California location.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_BuckinghamshireUnitedKingdomMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Buckinghamshire United Kingdom [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_BuckinghamshireUnitedKingdomMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Buckinghamshire, United Kingdom</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_MunichGermanyMember" xlink:label="fold_MunichGermanyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_MunichGermanyMember" xlink:to="fold_MunichGermanyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_MunichGermanyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents activity related to Munich, Germany location.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_MunichGermanyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Munich Germany [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_MunichGermanyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Munich, Germany</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="us-gaap_LeasesOperatingAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LeasesOperatingAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesOperatingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases, Operating [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeasesOperatingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Area of Real Estate Property</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Area of space leased (in square feet)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum lease payments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments Due, Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2017</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments, Due in Two Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2018</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments, Due in Three Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2019</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments, Due in Four Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2020</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_OperatingLeasesFutureMinimumPaymentsDueInFiveYearsAndThereafter" xlink:label="fold_OperatingLeasesFutureMinimumPaymentsDueInFiveYearsAndThereafter" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_OperatingLeasesFutureMinimumPaymentsDueInFiveYearsAndThereafter" xlink:to="fold_OperatingLeasesFutureMinimumPaymentsDueInFiveYearsAndThereafter_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_OperatingLeasesFutureMinimumPaymentsDueInFiveYearsAndThereafter_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of required minimum rental payments maturing in the fifth fiscal year following the latest fiscal year and thereafter for operating leases having an initial or remaining non-cancelable letter-term in excess of one year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_OperatingLeasesFutureMinimumPaymentsDueInFiveYearsAndThereafter_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases Future Minimum Payments Due in Five Years and Thereafter</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_OperatingLeasesFutureMinimumPaymentsDueInFiveYearsAndThereafter_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2021 and beyond</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseNet" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Rent Expense, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rent expense, including fees for utilities and common area maintenances</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeasesCapitalAbstract" xlink:label="us-gaap_LeasesCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesCapitalAbstract" xlink:to="us-gaap_LeasesCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases, Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeasesCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Interest Rate, Stated Percentage Rate Range, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital leases, interest rate, minimum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMaximum" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMaximum" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Interest Rate, Stated Percentage Rate Range, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital leases, interest rate, maximum</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_LesseeLeasingArrangementsCapitalLeasesTermOfContract" xlink:label="fold_LesseeLeasingArrangementsCapitalLeasesTermOfContract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_LesseeLeasingArrangementsCapitalLeasesTermOfContract" xlink:to="fold_LesseeLeasingArrangementsCapitalLeasesTermOfContract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_LesseeLeasingArrangementsCapitalLeasesTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of the lessee's capital leasing arrangement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_LesseeLeasingArrangementsCapitalLeasesTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee Leasing Arrangements Capital Leases Term Of Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_LesseeLeasingArrangementsCapitalLeasesTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of capital lease (in months)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Leases, Future Minimum Payments Due, Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2017</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Leases, Future Minimum Payments Due in Two Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2018</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Leases, Future Minimum Payments Due in Three Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2019</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Leases, Future Minimum Payments Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total principle obligation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (loss) before income taxes:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Domestic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">United States</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Foreign</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of the statutory tax rates and the effective tax rates</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statutory rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State taxes, net of federal benefit (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Permanent adjustments (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">R&amp;D credit (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign income tax rate differential (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation allowance (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net (as a percent)</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_IncomeTaxExpensesBenefitFromSaleOfNetOperatingLossesAndResearchAndDevelopmentCredits" xlink:label="fold_IncomeTaxExpensesBenefitFromSaleOfNetOperatingLossesAndResearchAndDevelopmentCredits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_IncomeTaxExpensesBenefitFromSaleOfNetOperatingLossesAndResearchAndDevelopmentCredits" xlink:to="fold_IncomeTaxExpensesBenefitFromSaleOfNetOperatingLossesAndResearchAndDevelopmentCredits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_IncomeTaxExpensesBenefitFromSaleOfNetOperatingLossesAndResearchAndDevelopmentCredits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the income tax benefit from the sale of net operating losses and research and development credits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_IncomeTaxExpensesBenefitFromSaleOfNetOperatingLossesAndResearchAndDevelopmentCredits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expenses (Benefit) from Sale of Net Operating Losses and Research and Development Credits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_IncomeTaxExpensesBenefitFromSaleOfNetOperatingLossesAndResearchAndDevelopmentCredits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax benefit from the sale of net operating losses and research and development credits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reduction in valuation allowance related to income tax associated with gain on foreign currency translation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax benefit in connection with the reduction in North Carolina state tax rates</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recognized interest and penalties</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrual for interest and penalties</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liability for Uncertain Tax Positions, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrual for uncertain tax positions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of Deferred Tax Assets and Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant components of the deferred tax assets and liabilities</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DeferredTaxAssetsNoncurrentAbstract" xlink:label="fold_DeferredTaxAssetsNoncurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_DeferredTaxAssetsNoncurrentAbstract" xlink:to="fold_DeferredTaxAssetsNoncurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_DeferredTaxAssetsNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Noncurrent Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_DeferredTaxAssetsNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DeferredTaxAssetsIntellectualProperty" xlink:label="fold_DeferredTaxAssetsIntellectualProperty" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_DeferredTaxAssetsIntellectualProperty" xlink:to="fold_DeferredTaxAssetsIntellectualProperty_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_DeferredTaxAssetsIntellectualProperty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intellectual property.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_DeferredTaxAssetsIntellectualProperty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Intellectual Property</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_DeferredTaxAssetsIntellectualProperty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intellectual property</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Property, Plant and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization/depreciation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research tax credit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carry forwards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Deferred Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred revenue</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DeferredTaxAssetsNonCashStockIssueNonCurrent" xlink:label="fold_DeferredTaxAssetsNonCashStockIssueNonCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_DeferredTaxAssetsNonCashStockIssueNonCurrent" xlink:to="fold_DeferredTaxAssetsNonCashStockIssueNonCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_DeferredTaxAssetsNonCashStockIssueNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from non-cash stock issue and carryforwards expected to be realized or consumed within one year or operating cycle, if longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_DeferredTaxAssetsNonCashStockIssueNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Non Cash Stock Issue Non Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_DeferredTaxAssetsNonCashStockIssueNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash stock issue</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Other Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Others</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liability related to business acquisition</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DeferredTaxLiabilitiesRoyaltyPayable" xlink:label="fold_DeferredTaxLiabilitiesRoyaltyPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_DeferredTaxLiabilitiesRoyaltyPayable" xlink:to="fold_DeferredTaxLiabilitiesRoyaltyPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_DeferredTaxLiabilitiesRoyaltyPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of deferred tax liability attributable to taxable temporary differences from royalty payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_DeferredTaxLiabilitiesRoyaltyPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Royalty Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="fold_DeferredTaxLiabilitiesRoyaltyPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liability related to royalty payable</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DeferredTaxLiabilitiesConvertibleNotes" xlink:label="fold_DeferredTaxLiabilitiesConvertibleNotes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_DeferredTaxLiabilitiesConvertibleNotes" xlink:to="fold_DeferredTaxLiabilitiesConvertibleNotes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_DeferredTaxLiabilitiesConvertibleNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of deferred tax consequences attributable to taxable temporary differences derived from convertible notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_DeferredTaxLiabilitiesConvertibleNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Convertible Notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="fold_DeferredTaxLiabilitiesConvertibleNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liability related to convertible notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_DeferredTaxLiabilitiesConvertibleNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liability in relation to the Convertible Notes</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DeferredTaxAssetsLiabilitiesGross" xlink:label="fold_DeferredTaxAssetsLiabilitiesGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_DeferredTaxAssetsLiabilitiesGross" xlink:to="fold_DeferredTaxAssetsLiabilitiesGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_DeferredTaxAssetsLiabilitiesGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards, net of deferred tax liability attributable to taxable temporary differences.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_DeferredTaxAssetsLiabilitiesGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Liabilities Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="fold_DeferredTaxAssetsLiabilitiesGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total net deferred tax asset</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less valuation allowance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred tax assets (liability)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowance, Deferred Tax Asset, Change in Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in the valuation allowance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Domestic Country [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State And Local Jurisdiction [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carry forwards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of net operating loss carry forwards</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_OperatingLossCarryforwardsLimitationsOnUseMinimumPercentageOwnershipChangePeriod" xlink:label="fold_OperatingLossCarryforwardsLimitationsOnUseMinimumPercentageOwnershipChangePeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_OperatingLossCarryforwardsLimitationsOnUseMinimumPercentageOwnershipChangePeriod" xlink:to="fold_OperatingLossCarryforwardsLimitationsOnUseMinimumPercentageOwnershipChangePeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_OperatingLossCarryforwardsLimitationsOnUseMinimumPercentageOwnershipChangePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the period over which the basis percentage increase in the shareholders' equity is measured for the purpose of calculating the ownership change as defined in section 382 of the Internal Revenue Code of 1986, as amended, which will affect the ability of the entity to utilize its net operating loss carry forwards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_OperatingLossCarryforwardsLimitationsOnUseMinimumPercentageOwnershipChangePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards Limitations on Use Minimum Percentage Ownership Change Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_OperatingLossCarryforwardsLimitationsOnUseMinimumPercentageOwnershipChangePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period for measuring the change in ownership</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_OperatingLossCarryforwardsLimitationsOnUseMinimumOwnershipPercentageChangeRelatingToSection382" xlink:label="fold_OperatingLossCarryforwardsLimitationsOnUseMinimumOwnershipPercentageChangeRelatingToSection382" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_OperatingLossCarryforwardsLimitationsOnUseMinimumOwnershipPercentageChangeRelatingToSection382" xlink:to="fold_OperatingLossCarryforwardsLimitationsOnUseMinimumOwnershipPercentageChangeRelatingToSection382_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_OperatingLossCarryforwardsLimitationsOnUseMinimumOwnershipPercentageChangeRelatingToSection382_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The limitation imposed by Section 382 related to the use of all operating loss carryforwards available to reduce future taxable income in the event of a more than specified percentage change in ownership.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_OperatingLossCarryforwardsLimitationsOnUseMinimumOwnershipPercentageChangeRelatingToSection382_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards, Limitations on Use, Minimum Ownership Percentage Change Relating to Section 382</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_OperatingLossCarryforwardsLimitationsOnUseMinimumOwnershipPercentageChangeRelatingToSection382_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum change in ownership percentage allowed before statutory limitations imposed on the availability of net operating losses</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_WritedownOfOperatingLossCarryforwardAndResearchAndDevelopmentCreditsSubjectToSection382Limitations" xlink:label="fold_WritedownOfOperatingLossCarryforwardAndResearchAndDevelopmentCreditsSubjectToSection382Limitations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_WritedownOfOperatingLossCarryforwardAndResearchAndDevelopmentCreditsSubjectToSection382Limitations" xlink:to="fold_WritedownOfOperatingLossCarryforwardAndResearchAndDevelopmentCreditsSubjectToSection382Limitations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_WritedownOfOperatingLossCarryforwardAndResearchAndDevelopmentCreditsSubjectToSection382Limitations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Writedown to net realizable value of the federal NOL's and research and development credits subject to Section 382 limitations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_WritedownOfOperatingLossCarryforwardAndResearchAndDevelopmentCreditsSubjectToSection382Limitations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Writedown Of Operating Loss Carryforward And Research And Development Credits Subject To Section 382 Limitations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_WritedownOfOperatingLossCarryforwardAndResearchAndDevelopmentCreditsSubjectToSection382Limitations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Writedown of NOL's and R&amp;D credits subject to Section 382 limitation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax benefit associated with exercise of stock options to be recorded in additional paid-in capital on recognition of associated NOL</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research And Development Arrangement Contract To Perform For Others Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAgreementTermsMember" xlink:to="us-gaap_LicenseAgreementTermsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseAgreementTermsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement Terms [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LicenseAgreementTermsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Arrangement, Contract to Perform for Others [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licenses</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_LicenseAgreementUpfrontPaymentAndAnnualLicenseFees" xlink:label="fold_LicenseAgreementUpfrontPaymentAndAnnualLicenseFees" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_LicenseAgreementUpfrontPaymentAndAnnualLicenseFees" xlink:to="fold_LicenseAgreementUpfrontPaymentAndAnnualLicenseFees_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_LicenseAgreementUpfrontPaymentAndAnnualLicenseFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of upfront and annual license fees paid.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_LicenseAgreementUpfrontPaymentAndAnnualLicenseFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement upfront Payment and Annual License Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_LicenseAgreementUpfrontPaymentAndAnnualLicenseFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront and annual license fees paid</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_LicenseAgreementMilestonePaymentsPotential" xlink:label="fold_LicenseAgreementMilestonePaymentsPotential" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_LicenseAgreementMilestonePaymentsPotential" xlink:to="fold_LicenseAgreementMilestonePaymentsPotential_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_LicenseAgreementMilestonePaymentsPotential_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of potential payments that the entity could be required to make under the license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_LicenseAgreementMilestonePaymentsPotential_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement Milestone Payments Potential</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_LicenseAgreementMilestonePaymentsPotential_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Potential milestone payments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty expense</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_GlaxoSmithKlinePLCMember" xlink:label="fold_GlaxoSmithKlinePLCMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_GlaxoSmithKlinePLCMember" xlink:to="fold_GlaxoSmithKlinePLCMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_GlaxoSmithKlinePLCMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the Glaxo Group Limited, an affiliate of GlaxoSmithKline PLC (GSK).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_GlaxoSmithKlinePLCMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Glaxo Smith Kline P L C [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_GlaxoSmithKlinePLCMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">GSK</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BiogenIdecMember" xlink:label="fold_BiogenIdecMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_BiogenIdecMember" xlink:to="fold_BiogenIdecMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_BiogenIdecMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Biogen Idec.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_BiogenIdecMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Biogen Idec [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_BiogenIdecMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Biogen Idec</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_RevisedCollaborationAgreementMember" xlink:label="fold_RevisedCollaborationAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_RevisedCollaborationAgreementMember" xlink:to="fold_RevisedCollaborationAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_RevisedCollaborationAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the License and Collaboration Agreement entered into by the entity on November 19, 2013.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_RevisedCollaborationAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revised Collaboration Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_RevisedCollaborationAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revised Agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLicenseFeesReceived" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from License Fees Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront payment received</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments" xlink:label="fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments" xlink:to="fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of potential payments upon achievement of post-approval and sales-based milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement Achievement of Post Approval and Sales Based Milestones Potential Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Potential milestone payments upon achievement of post-approval and sales-based milestones</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones" xlink:label="fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones" xlink:to="fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the number of major markets outside the U.S. from whom parties to contractual arrangement is eligible to receive post-approval and sales-based milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Major Markets Outside United States from Whom Parties to Contractual Arrangement is Eligible to Receive Post Approval and Sales Based Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of major markets outside the U.S. from whom parties to contractual arrangement is eligible to receive post-approval and sales-based milestones</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Recognition, Milestone Method, Revenue Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone revenue recognized</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ScheduleOfDebtInstrumentsAndRelatedPartyTransactionsByRelatedPartyTable" xlink:label="fold_ScheduleOfDebtInstrumentsAndRelatedPartyTransactionsByRelatedPartyTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_ScheduleOfDebtInstrumentsAndRelatedPartyTransactionsByRelatedPartyTable" xlink:to="fold_ScheduleOfDebtInstrumentsAndRelatedPartyTransactionsByRelatedPartyTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_ScheduleOfDebtInstrumentsAndRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_ScheduleOfDebtInstrumentsAndRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Debt Instruments And Related Party Transactions By Related Party [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Redemption, Period [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Redemption Period [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Redemption, Period [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Redemption Period One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">October 2017 payment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Redemption Period Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">October 2020 payment</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems" xlink:label="fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems" xlink:to="fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instruments and Related Party Transactions [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instruments and Related Party Transactions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ownership position in the company (as a percent)</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_WarrantTerm" xlink:label="fold_WarrantTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_WarrantTerm" xlink:to="fold_WarrantTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_WarrantTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the term of warrants issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_WarrantTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant Term</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt" xlink:label="fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt" xlink:to="fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of shares per increment of convertible debt that will be issued upon conversion. For example, X number of shares may be issued for every $1,000 of convertible debt principal.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Shares Issued Per Increment Of Convertible Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares of common stock issued per increment of note principal</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ConvertibleDebtPrincipalIncrementForConversion" xlink:label="fold_ConvertibleDebtPrincipalIncrementForConversion" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_ConvertibleDebtPrincipalIncrementForConversion" xlink:to="fold_ConvertibleDebtPrincipalIncrementForConversion_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_ConvertibleDebtPrincipalIncrementForConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the increments of convertible debt principle used to determine the number of shares into which the debt may be converted. For example, X number of shares may be issued for each $1,000 principal of debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_ConvertibleDebtPrincipalIncrementForConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Debt Principal Increment For Conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_ConvertibleDebtPrincipalIncrementForConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increment used for debt conversion</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DebtInstrumentsNumberOfInstallments" xlink:label="fold_DebtInstrumentsNumberOfInstallments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_DebtInstrumentsNumberOfInstallments" xlink:to="fold_DebtInstrumentsNumberOfInstallments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_DebtInstrumentsNumberOfInstallments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of installments for repayment of debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_DebtInstrumentsNumberOfInstallments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instruments Number Of Installments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_DebtInstrumentsNumberOfInstallments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of installments for repayment of debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Periodic Payment, Principal</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Installment payment</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_WarrantsNotSettleableInCashIncrementalFairValueDisclosure" xlink:label="fold_WarrantsNotSettleableInCashIncrementalFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_WarrantsNotSettleableInCashIncrementalFairValueDisclosure" xlink:to="fold_WarrantsNotSettleableInCashIncrementalFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_WarrantsNotSettleableInCashIncrementalFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incremental fair value portion of warrants not settleable in cash classified as equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_WarrantsNotSettleableInCashIncrementalFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Not Settleable In Cash Incremental Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_WarrantsNotSettleableInCashIncrementalFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incremental fair value of warrant liability</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ConvertibleSeniorNotes2016Due2023Member" xlink:label="fold_ConvertibleSeniorNotes2016Due2023Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_ConvertibleSeniorNotes2016Due2023Member" xlink:to="fold_ConvertibleSeniorNotes2016Due2023Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_ConvertibleSeniorNotes2016Due2023Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pertaining to the 3.0% unsecured Convertible Senior Notes due 2023 (the "Convertible Notes).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_ConvertibleSeniorNotes2016Due2023Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Senior Notes2016 Due2023 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_ConvertibleSeniorNotes2016Due2023Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2016 Convertible Notes</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DebtInstrumentsConvertibleThresholdTradingDays" xlink:label="fold_DebtInstrumentsConvertibleThresholdTradingDays" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_DebtInstrumentsConvertibleThresholdTradingDays" xlink:to="fold_DebtInstrumentsConvertibleThresholdTradingDays_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_DebtInstrumentsConvertibleThresholdTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_DebtInstrumentsConvertibleThresholdTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instruments, Convertible, Threshold Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_DebtInstrumentsConvertibleThresholdTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold trading days</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Convertible, Threshold Consecutive Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold consecutive trading days</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold percentage</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DebtInstrumentsConvertibleThresholdMaximumPercentageOfStockPriceTrigger" xlink:label="fold_DebtInstrumentsConvertibleThresholdMaximumPercentageOfStockPriceTrigger" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_DebtInstrumentsConvertibleThresholdMaximumPercentageOfStockPriceTrigger" xlink:to="fold_DebtInstrumentsConvertibleThresholdMaximumPercentageOfStockPriceTrigger_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_DebtInstrumentsConvertibleThresholdMaximumPercentageOfStockPriceTrigger_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_DebtInstrumentsConvertibleThresholdMaximumPercentageOfStockPriceTrigger_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instruments, Convertible, Threshold Maximum Percentage of Stock Price Trigger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_DebtInstrumentsConvertibleThresholdMaximumPercentageOfStockPriceTrigger_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum threshold percentage</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DebtInstrumentConvertibleMaximumCalendarDaysAllowedToHoldersOfCommonStockRightsOptionsOrWarrantsToPurchaseOfCommonStock" xlink:label="fold_DebtInstrumentConvertibleMaximumCalendarDaysAllowedToHoldersOfCommonStockRightsOptionsOrWarrantsToPurchaseOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_DebtInstrumentConvertibleMaximumCalendarDaysAllowedToHoldersOfCommonStockRightsOptionsOrWarrantsToPurchaseOfCommonStock" xlink:to="fold_DebtInstrumentConvertibleMaximumCalendarDaysAllowedToHoldersOfCommonStockRightsOptionsOrWarrantsToPurchaseOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_DebtInstrumentConvertibleMaximumCalendarDaysAllowedToHoldersOfCommonStockRightsOptionsOrWarrantsToPurchaseOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum calendar days allowed to holders of common stock rights options or warrants to purchase of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_DebtInstrumentConvertibleMaximumCalendarDaysAllowedToHoldersOfCommonStockRightsOptionsOrWarrantsToPurchaseOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Convertible, Maximum Calendar Days Allowed to Holders of Common Stock Rights Options or Warrants to Purchase of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_DebtInstrumentConvertibleMaximumCalendarDaysAllowedToHoldersOfCommonStockRightsOptionsOrWarrantsToPurchaseOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum calendar days allowed to holders of common stock rights options or warrants to purchase of common stock</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DebtInstrumentConvertibleTradingDaysForPricePerShareBasedOnLastReportedSalePrice" xlink:label="fold_DebtInstrumentConvertibleTradingDaysForPricePerShareBasedOnLastReportedSalePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_DebtInstrumentConvertibleTradingDaysForPricePerShareBasedOnLastReportedSalePrice" xlink:to="fold_DebtInstrumentConvertibleTradingDaysForPricePerShareBasedOnLastReportedSalePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_DebtInstrumentConvertibleTradingDaysForPricePerShareBasedOnLastReportedSalePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading days for price per share based on last reported sale price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_DebtInstrumentConvertibleTradingDaysForPricePerShareBasedOnLastReportedSalePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Convertible, Trading Days for Price Per Share Based on Last Reported Sale Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_DebtInstrumentConvertibleTradingDaysForPricePerShareBasedOnLastReportedSalePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading days for price per share based on last reported sale price</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DebtInstrumentConvertibleMinimumPercentageOfPerShareValueOfLastReportedSalePriceOfCommonStock" xlink:label="fold_DebtInstrumentConvertibleMinimumPercentageOfPerShareValueOfLastReportedSalePriceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_DebtInstrumentConvertibleMinimumPercentageOfPerShareValueOfLastReportedSalePriceOfCommonStock" xlink:to="fold_DebtInstrumentConvertibleMinimumPercentageOfPerShareValueOfLastReportedSalePriceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_DebtInstrumentConvertibleMinimumPercentageOfPerShareValueOfLastReportedSalePriceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum percentage of per share value of last reported sale price of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_DebtInstrumentConvertibleMinimumPercentageOfPerShareValueOfLastReportedSalePriceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Convertible, Minimum Percentage of Per Share Value of Last Reported Sale Price of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_DebtInstrumentConvertibleMinimumPercentageOfPerShareValueOfLastReportedSalePriceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum percentage of per share value of last reported sale price of common stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt instrument term</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Debt Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible notes issuance cost paid</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_LiabilityComponentsAbstract" xlink:label="fold_LiabilityComponentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_LiabilityComponentsAbstract" xlink:to="fold_LiabilityComponentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_LiabilityComponentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pertains to components of the convertible notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_LiabilityComponentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liability Components [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_LiabilityComponentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liability components of convertible notes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principle</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Unamortized Discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: debt discount</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Offering Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: deferred financing</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net carrying value of debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Debt, Fair Value Disclosures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of the debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpenseDebtAbstract" xlink:label="us-gaap_InterestExpenseDebtAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebtAbstract" xlink:to="us-gaap_InterestExpenseDebtAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebtAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense, Debt [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense, Debt, Excluding Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual interest expense</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_AmortizationDeferredFinancingCosts" xlink:label="fold_AmortizationDeferredFinancingCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_AmortizationDeferredFinancingCosts" xlink:to="fold_AmortizationDeferredFinancingCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_AmortizationDeferredFinancingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_AmortizationDeferredFinancingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization Deferred Financing Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_AmortizationDeferredFinancingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of deferred financing costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of Debt Discount (Premium)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of debt discount</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense, Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total interest expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Interest Rate, Effective Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective interest rate of the liability component</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeCapPrice" xlink:label="us-gaap_DerivativeCapPrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeCapPrice" xlink:to="us-gaap_DerivativeCapPrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeCapPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative, Cap Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeCapPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial cap price</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DerivativeCapPricePercentageOfPremiumOnCommonStockClosingPrice" xlink:label="fold_DerivativeCapPricePercentageOfPremiumOnCommonStockClosingPrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_DerivativeCapPricePercentageOfPremiumOnCommonStockClosingPrice" xlink:to="fold_DerivativeCapPricePercentageOfPremiumOnCommonStockClosingPrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_DerivativeCapPricePercentageOfPremiumOnCommonStockClosingPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of premium on closing price of common stock under derivative arrangements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_DerivativeCapPricePercentageOfPremiumOnCommonStockClosingPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative, Cap Price, Percentage of Premium on Common Stock Closing Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="fold_DerivativeCapPricePercentageOfPremiumOnCommonStockClosingPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capped call premium on closing price</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Numerator:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss attributable to common stockholders</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Denominator:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive securities excluded from computation of diluted earnings per share (in shares)</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_NumberOfLawsuits" xlink:label="fold_NumberOfLawsuits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_NumberOfLawsuits" xlink:to="fold_NumberOfLawsuits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_NumberOfLawsuits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of lawsuits commenced</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_NumberOfLawsuits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Lawsuits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_NumberOfLawsuits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of purported securities class action lawsuits</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_NumberOfLawsuitsNamingAdditionalOfficer" xlink:label="fold_NumberOfLawsuitsNamingAdditionalOfficer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_NumberOfLawsuitsNamingAdditionalOfficer" xlink:to="fold_NumberOfLawsuitsNamingAdditionalOfficer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_NumberOfLawsuitsNamingAdditionalOfficer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of lawsuit that list one or more of the entity's officers as named defendant(s)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_NumberOfLawsuitsNamingAdditionalOfficer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Lawsuits Naming Additional Officer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_NumberOfLawsuitsNamingAdditionalOfficer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of purported securities class action lawsuits naming additional company officers as defendants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:label="us-gaap_SelectedQuarterlyFinancialInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:to="us-gaap_SelectedQuarterlyFinancialInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SelectedQuarterlyFinancialInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selected Quarterly Financial Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SelectedQuarterlyFinancialInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selected Quarterly Financial Data</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_MiamedIncMember" xlink:label="fold_MiamedIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_MiamedIncMember" xlink:to="fold_MiamedIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_MiamedIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to MiaMed Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_MiamedIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Miamed Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_MiamedIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">MiaMed Inc</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Longterm Debt Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtMember" xlink:to="us-gaap_ConvertibleDebtMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Debt [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Notes</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_AtMarketEquityOfferingMember" xlink:label="fold_AtMarketEquityOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_AtMarketEquityOfferingMember" xlink:to="fold_AtMarketEquityOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_AtMarketEquityOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pertains to the at the market ("ATM) equity offering under which the Company sold shares of its common stock through a sales agent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_AtMarketEquityOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At Market Equity Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_AtMarketEquityOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At the market ("ATM") equity offering</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductOrServiceAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductOrServiceAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Products and Services [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="us-gaap_ProductsAndServicesDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductsAndServicesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Products And Services [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProductsAndServicesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Products and Services [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Galafold</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_StatementGeographicalAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementGeographicalAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="us-gaap_SegmentGeographicalDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentGeographicalDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Geographical [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentGeographicalDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EuropeanUnionMember" xlink:label="us-gaap_EuropeanUnionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EuropeanUnionMember" xlink:to="us-gaap_EuropeanUnionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EuropeanUnionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">European Union [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EuropeanUnionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">EU</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Consideration by Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="us-gaap_ContingentConsiderationTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContingentConsiderationTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Consideration Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContingentConsiderationTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Consideration Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember" xlink:label="fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember" xlink:to="fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to clinical, regulatory and commercial contingent consideration milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Consideration Liability Clinical Regulatory And Commercial Milestones [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Clinical, Regulatory and Commercial milestones</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" xlink:label="fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" xlink:to="fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to clinical and regulatory contingent consideration milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Consideration Liability Clinical And Regulatory Milestones [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Clinical and Regulatory Approval milestones</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember" xlink:label="fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember" xlink:to="fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to revenue-based contingent consideration milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Consideration Liability Revenue Based Milestones [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue-based milestones</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ContingentConsiderationLiabilityClinicalMilestoneMember" xlink:label="fold_ContingentConsiderationLiabilityClinicalMilestoneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_ContingentConsiderationLiabilityClinicalMilestoneMember" xlink:to="fold_ContingentConsiderationLiabilityClinicalMilestoneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_ContingentConsiderationLiabilityClinicalMilestoneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to clinical based contingent consideration milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_ContingentConsiderationLiabilityClinicalMilestoneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Consideration Liability Clinical Milestone [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_ContingentConsiderationLiabilityClinicalMilestoneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Clinical milestone</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ContingentConsiderationLiabilityRegulatoryApprovalMilestoneMember" xlink:label="fold_ContingentConsiderationLiabilityRegulatoryApprovalMilestoneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_ContingentConsiderationLiabilityRegulatoryApprovalMilestoneMember" xlink:to="fold_ContingentConsiderationLiabilityRegulatoryApprovalMilestoneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_ContingentConsiderationLiabilityRegulatoryApprovalMilestoneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to regulatory approval based contingent consideration milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_ContingentConsiderationLiabilityRegulatoryApprovalMilestoneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Consideration Liability Regulatory Approval Milestone [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_ContingentConsiderationLiabilityRegulatoryApprovalMilestoneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Regulatory Approval milestone</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Indefinite-lived Intangible Assets [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Indefinite Lived Intangible Assets Major Class Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Indefinite-lived Intangible Assets, Major Class Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">In Process Research And Development [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IPR&amp;D</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ChangesInFairValueOfContingentConsiderationPayableMember" xlink:label="fold_ChangesInFairValueOfContingentConsiderationPayableMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_ChangesInFairValueOfContingentConsiderationPayableMember" xlink:to="fold_ChangesInFairValueOfContingentConsiderationPayableMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_ChangesInFairValueOfContingentConsiderationPayableMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pertains to the location on the Statement of Operations, Changes in fair value of contingent consideration payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_ChangesInFairValueOfContingentConsiderationPayableMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes In Fair Value Of Contingent Consideration Payable [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_ChangesInFairValueOfContingentConsiderationPayableMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in fair value of contingent consideration payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money Market Funds [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money market</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CertificatesOfDepositMember" xlink:to="us-gaap_CertificatesOfDepositMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Certificates Of Deposit [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Certificate of deposit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="us-gaap_OtherCurrentLiabilitiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentLiabilitiesMember" xlink:to="us-gaap_OtherCurrentLiabilitiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Current Liabilities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCurrentLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BeneficialOwnerMember" xlink:label="us-gaap_BeneficialOwnerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BeneficialOwnerMember" xlink:to="us-gaap_BeneficialOwnerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BeneficialOwnerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beneficial Owner [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BeneficialOwnerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beneficial Owner</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_NoteAndWarrantAgreement2016Member" xlink:label="fold_NoteAndWarrantAgreement2016Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_NoteAndWarrantAgreement2016Member" xlink:to="fold_NoteAndWarrantAgreement2016Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_NoteAndWarrantAgreement2016Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to 2016 Loan Agreement that matures in October 2021. Purchasers of the Notes receive a five-year Warrant in addition to interest.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_NoteAndWarrantAgreement2016Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Note And Warrant Agreement2016 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_NoteAndWarrantAgreement2016Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">February 2016 Purchase Agreement</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_AdditionalNoteAndWarrantAgreementJune2016Member" xlink:label="fold_AdditionalNoteAndWarrantAgreementJune2016Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_AdditionalNoteAndWarrantAgreementJune2016Member" xlink:to="fold_AdditionalNoteAndWarrantAgreementJune2016Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_AdditionalNoteAndWarrantAgreementJune2016Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the June 2016 Additional Note and Warrant Purchase Agreement (the "Purchase Agreement").</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_AdditionalNoteAndWarrantAgreementJune2016Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Note And Warrant Agreement June2016 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_AdditionalNoteAndWarrantAgreementJune2016Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Note and Warrant Agreement June 2016</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_StockOptionPlan2007AndDirectorOptionPlan2007Member" xlink:label="fold_StockOptionPlan2007AndDirectorOptionPlan2007Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_StockOptionPlan2007AndDirectorOptionPlan2007Member" xlink:to="fold_StockOptionPlan2007AndDirectorOptionPlan2007Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_StockOptionPlan2007AndDirectorOptionPlan2007Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the 2007 Plan and the 2007 Director Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_StockOptionPlan2007AndDirectorOptionPlan2007Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Option Plan2007 And Director Option Plan2007 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_StockOptionPlan2007AndDirectorOptionPlan2007Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2007 Plan and 2007 Director Plan</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_StockOptionPlan2002AndStockOptionPlan2007Member" xlink:label="fold_StockOptionPlan2002AndStockOptionPlan2007Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_StockOptionPlan2002AndStockOptionPlan2007Member" xlink:to="fold_StockOptionPlan2002AndStockOptionPlan2007Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_StockOptionPlan2002AndStockOptionPlan2007Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the 2002 Plan and the 2007 Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_StockOptionPlan2002AndStockOptionPlan2007Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Option Plan2002 And Stock Option Plan2007 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_StockOptionPlan2002AndStockOptionPlan2007Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2002 Plan and 2007 Plan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling General And Administrative Expenses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, general and administrative expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationTechniqueAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Technique [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_ValuationTechniqueDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationTechniqueDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Technique [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationTechniqueDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Technique [Domain]</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ProbabilityWeightedDiscountedCashFlowMember" xlink:label="fold_ProbabilityWeightedDiscountedCashFlowMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_ProbabilityWeightedDiscountedCashFlowMember" xlink:to="fold_ProbabilityWeightedDiscountedCashFlowMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_ProbabilityWeightedDiscountedCashFlowMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to valuation technique of probability weighted discounted cash flow.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_ProbabilityWeightedDiscountedCashFlowMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Probability Weighted Discounted Cash Flow [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_ProbabilityWeightedDiscountedCashFlowMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Probability weighted discounted cash flow</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_MonteCarloMember" xlink:label="fold_MonteCarloMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_MonteCarloMember" xlink:to="fold_MonteCarloMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_MonteCarloMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to valuation technique of Monte Carlo.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_MonteCarloMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Monte Carlo [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_MonteCarloMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Monte Carlo</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equipment</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_OfficeAndLaboratorySpaceMember" xlink:label="fold_OfficeAndLaboratorySpaceMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_OfficeAndLaboratorySpaceMember" xlink:to="fold_OfficeAndLaboratorySpaceMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_OfficeAndLaboratorySpaceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pertains to leased office and laboratory space.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_OfficeAndLaboratorySpaceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office And Laboratory Space [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_OfficeAndLaboratorySpaceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office and laboratory space</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_OfficeSpaceMember" xlink:label="fold_OfficeSpaceMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_OfficeSpaceMember" xlink:to="fold_OfficeSpaceMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_OfficeSpaceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pertains to leased office space.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_OfficeSpaceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office Space [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_OfficeSpaceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office space</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Country [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_MtSinaiSchoolOfMedicineOfNewYorkUniversityMember" xlink:label="fold_MtSinaiSchoolOfMedicineOfNewYorkUniversityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_MtSinaiSchoolOfMedicineOfNewYorkUniversityMember" xlink:to="fold_MtSinaiSchoolOfMedicineOfNewYorkUniversityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_MtSinaiSchoolOfMedicineOfNewYorkUniversityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to license agreement with Mt. Sinai School of Medicine of New York University.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_MtSinaiSchoolOfMedicineOfNewYorkUniversityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Mt Sinai School Of Medicine Of New York University [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_MtSinaiSchoolOfMedicineOfNewYorkUniversityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">MSSM</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_NotePurchaseAgreementDecember2016Member" xlink:label="fold_NotePurchaseAgreementDecember2016Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_NotePurchaseAgreementDecember2016Member" xlink:to="fold_NotePurchaseAgreementDecember2016Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_NotePurchaseAgreementDecember2016Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the Note Purchase Agreement ("Note Purchase Agreement") with GCM and RedMile, pursuant to which the Company agreed to prepay all outstanding principal and accrued and unpaid interest on the notes issued by the Company and held by GCM and Redmile.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_NotePurchaseAgreementDecember2016Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Note Purchase Agreement December2016 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_NotePurchaseAgreementDecember2016Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">December Note Purchase Agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodThreeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Redemption Period Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">October 2021 payment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale Of Stock Name Of Transaction [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Over Allotment Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Over-allotment Option</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_StatementScenarioAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementScenarioAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioUnspecifiedDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario Unspecified [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario, Unspecified [Domain]</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ConvertibleNotesConditionOneMember" xlink:label="fold_ConvertibleNotesConditionOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_ConvertibleNotesConditionOneMember" xlink:to="fold_ConvertibleNotesConditionOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_ConvertibleNotesConditionOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to condition 1 embedded in the convertible notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_ConvertibleNotesConditionOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Notes Condition One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_ConvertibleNotesConditionOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Notes, condition 1</label>
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ConvertibleNotesConditionTwoMember" xlink:label="fold_ConvertibleNotesConditionTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fold_ConvertibleNotesConditionTwoMember" xlink:to="fold_ConvertibleNotesConditionTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fold_ConvertibleNotesConditionTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to condition 2 embedded in the convertible notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fold_ConvertibleNotesConditionTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Notes Condition Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fold_ConvertibleNotesConditionTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Notes, condition 2</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Debt Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible debt</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>fold-20161231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!--XBRL document created with Merrill Bridge  6.4.50.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/1/2017 2:07:09 PM-->
<!--Modified on: 3/1/2017 2:07:09 PM-->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.amicustherapeutics.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.amicustherapeutics.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.amicustherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.amicustherapeutics.com/role/StatementConsolidatedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#StatementConsolidatedStatementsOfComprehensiveLoss" roleURI="http://www.amicustherapeutics.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#StatementConsolidatedStatementsOfComprehensiveLossParenthetical" roleURI="http://www.amicustherapeutics.com/role/StatementConsolidatedStatementsOfComprehensiveLossParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#StatementConsolidatedStatementsOfChangesInStockholdersEquity" roleURI="http://www.amicustherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" roleURI="http://www.amicustherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.amicustherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureDescriptionOfBusiness" roleURI="http://www.amicustherapeutics.com/role/DisclosureDescriptionOfBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://www.amicustherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureAcquisitions" roleURI="http://www.amicustherapeutics.com/role/DisclosureAcquisitions" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureGoodwillAndIntangibleAssets" roleURI="http://www.amicustherapeutics.com/role/DisclosureGoodwillAndIntangibleAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureCashMoneyMarketFundsAndMarketableSecurities" roleURI="http://www.amicustherapeutics.com/role/DisclosureCashMoneyMarketFundsAndMarketableSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureInventories" roleURI="http://www.amicustherapeutics.com/role/DisclosureInventories" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosurePropertyAndEquipment" roleURI="http://www.amicustherapeutics.com/role/DisclosurePropertyAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureAccountsPayableAndAccruedExpenses" roleURI="http://www.amicustherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureStockholdersEquity" roleURI="http://www.amicustherapeutics.com/role/DisclosureStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureAssetsAndLiabilitiesMeasuredAtFairValue" roleURI="http://www.amicustherapeutics.com/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#Disclosure401KPlan" roleURI="http://www.amicustherapeutics.com/role/Disclosure401KPlan" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureLeases" roleURI="http://www.amicustherapeutics.com/role/DisclosureLeases" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureIncomeTaxes" roleURI="http://www.amicustherapeutics.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureLicenses" roleURI="http://www.amicustherapeutics.com/role/DisclosureLicenses" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureCollaborativeAgreements" roleURI="http://www.amicustherapeutics.com/role/DisclosureCollaborativeAgreements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureDebtInstrumentsAndRelatedPartyTransactions" roleURI="http://www.amicustherapeutics.com/role/DisclosureDebtInstrumentsAndRelatedPartyTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureEarningsPerShare" roleURI="http://www.amicustherapeutics.com/role/DisclosureEarningsPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.amicustherapeutics.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureSubsequentEvents" roleURI="http://www.amicustherapeutics.com/role/DisclosureSubsequentEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureSelectedQuarterlyFinancialDataUnauditedInThousandsExceptPerShareData" roleURI="http://www.amicustherapeutics.com/role/DisclosureSelectedQuarterlyFinancialDataUnauditedInThousandsExceptPerShareData" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.amicustherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureGoodwillAndIntangibleAssetsTables" roleURI="http://www.amicustherapeutics.com/role/DisclosureGoodwillAndIntangibleAssetsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureCashMoneyMarketFundsAndMarketableSecuritiesTables" roleURI="http://www.amicustherapeutics.com/role/DisclosureCashMoneyMarketFundsAndMarketableSecuritiesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureInventoriesTables" roleURI="http://www.amicustherapeutics.com/role/DisclosureInventoriesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosurePropertyAndEquipmentTables" roleURI="http://www.amicustherapeutics.com/role/DisclosurePropertyAndEquipmentTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureAccountsPayableAndAccruedExpensesTables" roleURI="http://www.amicustherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureStockholdersEquityTables" roleURI="http://www.amicustherapeutics.com/role/DisclosureStockholdersEquityTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureAssetsAndLiabilitiesMeasuredAtFairValueTables" roleURI="http://www.amicustherapeutics.com/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureLeasesTables" roleURI="http://www.amicustherapeutics.com/role/DisclosureLeasesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureIncomeTaxesTables" roleURI="http://www.amicustherapeutics.com/role/DisclosureIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureDebtInstrumentsAndRelatedPartyTransactionsTables" roleURI="http://www.amicustherapeutics.com/role/DisclosureDebtInstrumentsAndRelatedPartyTransactionsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureEarningsPerShareTables" roleURI="http://www.amicustherapeutics.com/role/DisclosureEarningsPerShareTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureSelectedQuarterlyFinancialDataUnauditedInThousandsExceptPerShareDataTables" roleURI="http://www.amicustherapeutics.com/role/DisclosureSelectedQuarterlyFinancialDataUnauditedInThousandsExceptPerShareDataTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureDescriptionOfBusinessDetails" roleURI="http://www.amicustherapeutics.com/role/DisclosureDescriptionOfBusinessDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" roleURI="http://www.amicustherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesEquityIncentivePlanAndStockBasedCompensationDetails" roleURI="http://www.amicustherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEquityIncentivePlanAndStockBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSegmentInformationDetails" roleURI="http://www.amicustherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureAcquisitionsDetails" roleURI="http://www.amicustherapeutics.com/role/DisclosureAcquisitionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureGoodwillAndIntangibleAssetsGoodwillDetails" roleURI="http://www.amicustherapeutics.com/role/DisclosureGoodwillAndIntangibleAssetsGoodwillDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureGoodwillAndIntangibleAssetsIprDDetails" roleURI="http://www.amicustherapeutics.com/role/DisclosureGoodwillAndIntangibleAssetsIprDDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureCashMoneyMarketFundsAndMarketableSecuritiesDetails" roleURI="http://www.amicustherapeutics.com/role/DisclosureCashMoneyMarketFundsAndMarketableSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureInventoriesDetails" roleURI="http://www.amicustherapeutics.com/role/DisclosureInventoriesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosurePropertyAndEquipmentDetails" roleURI="http://www.amicustherapeutics.com/role/DisclosurePropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureAccountsPayableAndAccruedExpensesDetails" roleURI="http://www.amicustherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureStockholdersEquityCommonStockAndWarrantsDetails" roleURI="http://www.amicustherapeutics.com/role/DisclosureStockholdersEquityCommonStockAndWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureStockholdersEquityEquityIncentivePlansDetails" roleURI="http://www.amicustherapeutics.com/role/DisclosureStockholdersEquityEquityIncentivePlansDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureStockholdersEquityCompensationExpenseDetails" roleURI="http://www.amicustherapeutics.com/role/DisclosureStockholdersEquityCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetails" roleURI="http://www.amicustherapeutics.com/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#Disclosure401KPlanDetails" roleURI="http://www.amicustherapeutics.com/role/Disclosure401KPlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureLeasesDetails" roleURI="http://www.amicustherapeutics.com/role/DisclosureLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureIncomeTaxesStatutoryRateDetails" roleURI="http://www.amicustherapeutics.com/role/DisclosureIncomeTaxesStatutoryRateDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureIncomeTaxesDeferredAndValuationDetails" roleURI="http://www.amicustherapeutics.com/role/DisclosureIncomeTaxesDeferredAndValuationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureIncomeTaxesLossCarryforwardsDetails" roleURI="http://www.amicustherapeutics.com/role/DisclosureIncomeTaxesLossCarryforwardsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureLicensesDetails" roleURI="http://www.amicustherapeutics.com/role/DisclosureLicensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureCollaborativeAgreementsDetails" roleURI="http://www.amicustherapeutics.com/role/DisclosureCollaborativeAgreementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureDebtInstrumentsAndRelatedPartyTransactionsNoteAndWarrantPurchaseAgreementsDetails" roleURI="http://www.amicustherapeutics.com/role/DisclosureDebtInstrumentsAndRelatedPartyTransactionsNoteAndWarrantPurchaseAgreementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureDebtInstrumentsAndRelatedPartyTransactionsConvertibleDebtDetails" roleURI="http://www.amicustherapeutics.com/role/DisclosureDebtInstrumentsAndRelatedPartyTransactionsConvertibleDebtDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureEarningsPerShareDetails" roleURI="http://www.amicustherapeutics.com/role/DisclosureEarningsPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.amicustherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fold-20161231.xsd#DisclosureSelectedQuarterlyFinancialDataUnauditedInThousandsExceptPerShareDataDetails" roleURI="http://www.amicustherapeutics.com/role/DisclosureSelectedQuarterlyFinancialDataUnauditedInThousandsExceptPerShareDataDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DocumentAndEntityInformationAbstract" xlink:label="DocumentAndEntityInformationAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_636239740246945305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName_636239740246945305" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_636239740246945305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey_636239740246945305" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType_636239740246945305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType_636239740246945305" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_636239740246945305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate_636239740246945305" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_636239740246945305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag_636239740246945305" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_636239740246945305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate_636239740246945305" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_636239740246945305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_636239740246945305" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_636239740246945305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityVoluntaryFilers_636239740246945305" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_636239740246945305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCurrentReportingStatus_636239740246945305" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_636239740246945305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory_636239740246945305" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_636239740246945305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityPublicFloat_636239740246945305" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_636239740246945305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_636239740246945305" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_636239740246945305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus_636239740246945305" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_636239740246945305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_636239740246945305" order="14" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_636239740246945305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_636239740246945305" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_636239740246945305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_636239740246945305" xlink:to="us-gaap_AssetsCurrentAbstract_636239740246945305" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_636239740246945305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_636239740246945305" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_636239740246945305" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesCurrent_636239740246945305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_636239740246945305" xlink:to="us-gaap_AvailableForSaleSecuritiesCurrent_636239740246945305" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_636239740246945305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_636239740246945305" xlink:to="us-gaap_AccountsReceivableNetCurrent_636239740246945305" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_636239740246945305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_636239740246945305" xlink:to="us-gaap_InventoryNet_636239740246945305" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_636239740246945305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_636239740246945305" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_636239740246945305" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_636239740246945305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_636239740246945305" xlink:to="us-gaap_AssetsCurrent_636239740246945305" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_636239740246945305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_636239740246945305" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_636239740246945305" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_636239740246945305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_636239740246945305" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_636239740246945305" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill_636239740246945305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_636239740246945305" xlink:to="us-gaap_Goodwill_636239740246945305" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_636239740246945305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_636239740246945305" xlink:to="us-gaap_OtherAssetsNoncurrent_636239740246945305" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_636239740246945305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_636239740246945305" xlink:to="us-gaap_Assets_636239740246945305" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636239740246945305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636239740246945305" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_636239740246945305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636239740246945305" xlink:to="us-gaap_LiabilitiesCurrentAbstract_636239740246945305" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_636239740246945305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_636239740246945305" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_636239740246945305" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" xlink:label="us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_636239740246945305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_636239740246945305" xlink:to="us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_636239740246945305" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_636239740246945305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_636239740246945305" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_636239740246945305" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_636239740246945305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_636239740246945305" xlink:to="us-gaap_LiabilitiesCurrent_636239740246945305" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent" xlink:label="us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_636239740246945305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636239740246945305" xlink:to="us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_636239740246945305" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_636239740246945305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636239740246945305" xlink:to="us-gaap_ConvertibleLongTermNotesPayable_636239740246945305" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DueToRelatedPartiesNoncurrent" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent_636239740246945305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636239740246945305" xlink:to="us-gaap_DueToRelatedPartiesNoncurrent_636239740246945305" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_636239740246945305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636239740246945305" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_636239740246945305" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent_636239740246945305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636239740246945305" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent_636239740246945305" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_636239740246945305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636239740246945305" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_636239740246945305" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_636239740246945305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636239740246945305" xlink:to="us-gaap_CommitmentsAndContingencies_636239740246945305" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_636239740246945305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636239740246945305" xlink:to="us-gaap_StockholdersEquityAbstract_636239740246945305" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_636239740246945305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_636239740246945305" xlink:to="us-gaap_CommonStockValue_636239740246945305" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_636239740246945305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_636239740246945305" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_636239740246945305" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_636239740246945305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_636239740246945305" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_636239740246945305" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_636239740246945305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_636239740246945305" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_636239740246945305" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_636239740246945305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_636239740246945305" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_636239740246945305" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding_636239740246945305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_636239740246945305" xlink:to="us-gaap_WarrantsAndRightsOutstanding_636239740246945305" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_636239740246945305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_636239740246945305" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_636239740246945305" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_636239740246945305" xlink:to="us-gaap_StockholdersEquity_636239740247045306" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636239740246945305" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_636239740247045306" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - Consolidated Balance Sheets (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_636239740247045306" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_636239740247045306" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_636239740247045306" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_636239740247045306" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_636239740247045306" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_636239740247045306" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Statements of Operations" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueNetAbstract" xlink:label="us-gaap_SalesRevenueNetAbstract_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_SalesRevenueNetAbstract_636239740247045306" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SalesRevenueNetAbstract_636239740247045306" xlink:to="us-gaap_SalesRevenueGoodsNet_636239740247045306" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ResearchRevenue" xlink:label="fold_ResearchRevenue_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SalesRevenueNetAbstract_636239740247045306" xlink:to="fold_ResearchRevenue_636239740247045306" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SalesRevenueNetAbstract_636239740247045306" xlink:to="us-gaap_SalesRevenueNet_636239740247045306" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_CostOfGoodsSold_636239740247045306" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_GrossProfit_636239740247045306" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_636239740247045306" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_636239740247045306" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_636239740247045306" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_636239740247045306" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_636239740247045306" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_636239740247045306" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_636239740247045306" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_636239740247045306" xlink:to="us-gaap_RestructuringCharges_636239740247045306" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_636239740247045306" xlink:to="us-gaap_Depreciation_636239740247045306" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_636239740247045306" xlink:to="us-gaap_OperatingExpenses_636239740247045306" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss_636239740247045306" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_636239740247045306" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_636239740247045306" xlink:to="us-gaap_InvestmentIncomeInterest_636239740247045306" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_636239740247045306" xlink:to="us-gaap_InterestExpense_636239740247045306" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ExtinguishmentOfDebtGainLossNetOfTax" xlink:label="us-gaap_ExtinguishmentOfDebtGainLossNetOfTax_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_636239740247045306" xlink:to="us-gaap_ExtinguishmentOfDebtGainLossNetOfTax_636239740247045306" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_636239740247045306" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_636239740247045306" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_636239740247045306" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_636239740247045306" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_636239740247045306" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_636239740247045306" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_636239740247045306" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended" xlink:title="00300 - Statement - Consolidated Statements of Comprehensive Loss" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss_636239740247045306" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_636239740247045306" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_636239740247045306" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_636239740247045306" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_636239740247045306" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_636239740247045306" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_636239740247045306" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_636239740247045306" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_636239740247045306" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/StatementConsolidatedStatementsOfComprehensiveLossParenthetical" xlink:type="extended" xlink:title="00305 - Statement - Consolidated Statements of Comprehensive Loss (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_636239740247045306" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statements of Changes in Stockholders' Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_636239740247045306" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636239740247045306" xlink:to="us-gaap_BusinessAcquisitionAxis_636239740247045306" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_SciodermIncMember" xlink:label="fold_SciodermIncMember_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_636239740247045306" xlink:to="fold_SciodermIncMember_636239740247045306" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_CallidusBiopharmaIncMember" xlink:label="fold_CallidusBiopharmaIncMember_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_636239740247045306" xlink:to="fold_CallidusBiopharmaIncMember_636239740247045306" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_MiaMedIncMember" xlink:label="fold_MiaMedIncMember_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_636239740247045306" xlink:to="fold_MiaMedIncMember_636239740247045306" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_636239740247045306" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_636239740247045306" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636239740247045306" xlink:to="us-gaap_StatementEquityComponentsAxis_636239740247045306" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_636239740247045306" xlink:to="us-gaap_CommonStockMember_636239740247045306" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_636239740247045306" xlink:to="us-gaap_AdditionalPaidInCapitalMember_636239740247045306" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_636239740247045306" xlink:to="us-gaap_WarrantMember_636239740247045306" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeMember" xlink:label="us-gaap_ComprehensiveIncomeMember_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_636239740247045306" xlink:to="us-gaap_ComprehensiveIncomeMember_636239740247045306" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_636239740247045306" xlink:to="us-gaap_RetainedEarningsMember_636239740247045306" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_636239740247045306" xlink:to="us-gaap_EquityComponentDomain_636239740247045306" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636239740247045306" xlink:to="us-gaap_StatementLineItems_636239740247045306" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636239740247045306" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_636239740247045306" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_636239740247045306" xlink:to="us-gaap_StockholdersEquity_636239740247045306" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_636239740247045306" xlink:to="us-gaap_CommonStockSharesOutstanding_636239740247045306" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_636239740247045306" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_636239740247045306" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_636239740247045306" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_636239740247045306" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_636239740247045306" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_636239740247045306" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions_636239740247045306" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_636239740247045306" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_636239740247045306" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_636239740247045306" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues_636239740247045306" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_636239740247045306" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="fold_StockIssuedDuringPeriodValueWarrantsExercised_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_636239740247045306" xlink:to="fold_StockIssuedDuringPeriodValueWarrantsExercised_636239740247045306" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="fold_StockIssuedDuringPeriodSharesWarrantsExercised_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_StockIssuedDuringPeriodValueWarrantsExercised_636239740247045306" xlink:to="fold_StockIssuedDuringPeriodSharesWarrantsExercised_636239740247045306" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_StockIssuedDuringPeriodValueAtMarketOffering" xlink:label="fold_StockIssuedDuringPeriodValueAtMarketOffering_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_636239740247045306" xlink:to="fold_StockIssuedDuringPeriodValueAtMarketOffering_636239740247045306" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_StockIssuedDuringPeriodSharesAtMarketOffering" xlink:label="fold_StockIssuedDuringPeriodSharesAtMarketOffering_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_StockIssuedDuringPeriodValueAtMarketOffering_636239740247045306" xlink:to="fold_StockIssuedDuringPeriodSharesAtMarketOffering_636239740247045306" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_636239740247045306" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_636239740247045306" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_636239740247045306" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_636239740247045306" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_StockIssuedDuringPeriodValueContingentConsideration" xlink:label="fold_StockIssuedDuringPeriodValueContingentConsideration_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_636239740247045306" xlink:to="fold_StockIssuedDuringPeriodValueContingentConsideration_636239740247045306" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_StockIssuedDuringPeriodSharesContingentConsideration" xlink:label="fold_StockIssuedDuringPeriodSharesContingentConsideration_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_StockIssuedDuringPeriodValueContingentConsideration_636239740247045306" xlink:to="fold_StockIssuedDuringPeriodSharesContingentConsideration_636239740247045306" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor" xlink:label="fold_AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_636239740247045306" xlink:to="fold_AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor_636239740247045306" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_StockAndWarrantsIssuedDuringPeriodValueNewIssues" xlink:label="fold_StockAndWarrantsIssuedDuringPeriodValueNewIssues_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_636239740247045306" xlink:to="fold_StockAndWarrantsIssuedDuringPeriodValueNewIssues_636239740247045306" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_636239740247045306" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_636239740247045306" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_AdjustmentsToAdditionalPaidinCapitalPremiumsPaidForCappedCallConfirmations" xlink:label="fold_AdjustmentsToAdditionalPaidinCapitalPremiumsPaidForCappedCallConfirmations_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_636239740247045306" xlink:to="fold_AdjustmentsToAdditionalPaidinCapitalPremiumsPaidForCappedCallConfirmations_636239740247045306" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_636239740247045306" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_636239740247045306" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_636239740247045306" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_636239740247045306" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_636239740247045306" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_636239740247045306" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_636239740247045306" xlink:to="us-gaap_NetIncomeLoss_636239740247045306" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_6362397402470453061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_636239740247045306" xlink:to="us-gaap_StockholdersEquity_6362397402470453061" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_6362397402470453061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_636239740247045306" xlink:to="us-gaap_CommonStockSharesOutstanding_6362397402470453061" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" xlink:type="extended" xlink:title="00405 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_DeferredFinanceCostsNet_636239740247045306" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00500 - Statement - Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_636239740247045306" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_636239740247045306" xlink:to="us-gaap_NetIncomeLoss_636239740247045306" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_636239740247045306" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636239740247045306" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636239740247045306" xlink:to="us-gaap_PaidInKindInterest_636239740247045306" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636239740247045306" xlink:to="us-gaap_Depreciation_636239740247045306" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636239740247045306" xlink:to="us-gaap_ShareBasedCompensation_636239740247045306" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636239740247045306" xlink:to="us-gaap_RestructuringCharges_636239740247045306" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636239740247045306" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_636239740247045306" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636239740247045306" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_636239740247045306" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ResearchExpenseForStockIssuanceInAssetAcquisition" xlink:label="fold_ResearchExpenseForStockIssuanceInAssetAcquisition_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636239740247045306" xlink:to="fold_ResearchExpenseForStockIssuanceInAssetAcquisition_636239740247045306" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636239740247045306" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_636239740247045306" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636239740247045306" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_636239740247045306" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_NoncashIncomeTaxExpenseBenefit" xlink:label="fold_NoncashIncomeTaxExpenseBenefit_636239740247045306" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636239740247045306" xlink:to="fold_NoncashIncomeTaxExpenseBenefit_636239740247045306" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_NonCashDeferredTaxes" xlink:label="fold_NonCashDeferredTaxes_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636239740247045306" xlink:to="fold_NonCashDeferredTaxes_636239740247145307" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636239740247045306" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_636239740247145307" order="12" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_636239740247045306" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_636239740247145307" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_636239740247145307" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_636239740247145307" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_636239740247145307" xlink:to="us-gaap_IncreaseDecreaseInInventories_636239740247145307" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_IncreaseDecreaseInDueFromCollaborationAgreements" xlink:label="fold_IncreaseDecreaseInDueFromCollaborationAgreements_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_636239740247145307" xlink:to="fold_IncreaseDecreaseInDueFromCollaborationAgreements_636239740247145307" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_636239740247145307" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_636239740247145307" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_636239740247145307" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_636239740247145307" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_636239740247145307" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_636239740247145307" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_IncreaseDecreaseInNoncurrentOperatingLiabilities" xlink:label="fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_636239740247145307" xlink:to="fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_636239740247145307" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_IncreaseDecreaseInDeferredReimbursements" xlink:label="fold_IncreaseDecreaseInDeferredReimbursements_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_636239740247145307" xlink:to="fold_IncreaseDecreaseInDeferredReimbursements_636239740247145307" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_636239740247045306" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636239740247145307" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_636239740247145307" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_636239740247145307" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_636239740247145307" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecurities_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_636239740247145307" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecurities_636239740247145307" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_636239740247145307" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_636239740247145307" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_636239740247145307" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_636239740247145307" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_636239740247145307" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_636239740247145307" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_636239740247145307" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_636239740247145307" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_636239740247145307" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt" xlink:label="us-gaap_RepaymentsOfSecuredDebt_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_636239740247145307" xlink:to="us-gaap_RepaymentsOfSecuredDebt_636239740247145307" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_636239740247145307" xlink:to="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_636239740247145307" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_PaymentsForRepurchaseOfRestrictedStockUnits" xlink:label="fold_PaymentsForRepurchaseOfRestrictedStockUnits_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_636239740247145307" xlink:to="fold_PaymentsForRepurchaseOfRestrictedStockUnits_636239740247145307" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_636239740247145307" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_636239740247145307" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_636239740247145307" xlink:to="us-gaap_ProceedsFromWarrantExercises_636239740247145307" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_PaymentOfContingentConsideration" xlink:label="fold_PaymentOfContingentConsideration_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_636239740247145307" xlink:to="fold_PaymentOfContingentConsideration_636239740247145307" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_636239740247145307" xlink:to="us-gaap_ProceedsFromConvertibleDebt_636239740247145307" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_PremiumsPaidForCappedCallConfirmations" xlink:label="fold_PremiumsPaidForCappedCallConfirmations_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_636239740247145307" xlink:to="fold_PremiumsPaidForCappedCallConfirmations_636239740247145307" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_636239740247145307" xlink:to="us-gaap_ProceedsFromIssuanceOfSecuredDebt_636239740247145307" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_636239740247145307" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_636239740247145307" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_636239740247145307" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_636239740247145307" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_636239740247145307" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_6362397402471453071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_6362397402471453071" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_636239740247145307" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_636239740247145307" xlink:to="us-gaap_InterestPaid_636239740247145307" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ContingentConsiderationPaidInStock" xlink:label="fold_ContingentConsiderationPaidInStock_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_636239740247145307" xlink:to="fold_ContingentConsiderationPaidInStock_636239740247145307" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeaseObligationsIncurred" xlink:label="us-gaap_CapitalLeaseObligationsIncurred_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_636239740247145307" xlink:to="us-gaap_CapitalLeaseObligationsIncurred_636239740247145307" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureDescriptionOfBusiness" xlink:type="extended" xlink:title="10101 - Disclosure - Description of Business" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_636239740247145307" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - Summary of Significant Accounting Policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_636239740247145307" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureAcquisitions" xlink:type="extended" xlink:title="10301 - Disclosure - Acquisitions" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="BusinessCombinationsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_636239740247145307" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureGoodwillAndIntangibleAssets" xlink:type="extended" xlink:title="10401 - Disclosure - Goodwill and Intangible Assets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_636239740247145307" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureCashMoneyMarketFundsAndMarketableSecurities" xlink:type="extended" xlink:title="10501 - Disclosure - Cash, Money Market Funds and Marketable Securities" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:label="CashCashEquivalentsAndShortTermInvestmentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_636239740247145307" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureInventories" xlink:type="extended" xlink:title="10601 - Disclosure - Inventories" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock_636239740247145307" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosurePropertyAndEquipment" xlink:type="extended" xlink:title="10701 - Disclosure - Property and Equipment" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_636239740247145307" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpenses" xlink:type="extended" xlink:title="10801 - Disclosure - Accounts Payable and Accrued Expenses" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_636239740247145307" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureStockholdersEquity" xlink:type="extended" xlink:title="10901 - Disclosure - Stockholders' Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_636239740247145307" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValue" xlink:type="extended" xlink:title="11001 - Disclosure - Assets and Liabilities Measured at Fair Value" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_636239740247145307" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/Disclosure401KPlan" xlink:type="extended" xlink:title="11101 - Disclosure - 401(k) Plan" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_636239740247145307" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureLeases" xlink:type="extended" xlink:title="11201 - Disclosure - Leases" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock_636239740247145307" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="11301 - Disclosure - Income Taxes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_636239740247145307" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureLicenses" xlink:type="extended" xlink:title="11401 - Disclosure - Licenses" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_636239740247145307" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureCollaborativeAgreements" xlink:type="extended" xlink:title="11501 - Disclosure - Collaborative Agreements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_CollaborativeArrangementDisclosureAbstract" xlink:label="CollaborativeArrangementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementDisclosureAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_636239740247145307" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureDebtInstrumentsAndRelatedPartyTransactions" xlink:type="extended" xlink:title="11601 - Disclosure - Debt Instruments and Related Party Transactions" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DebtInstrumentsAndRelatedPartyTransactionsAbstract" xlink:label="fold_DebtInstrumentsAndRelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DebtInstrumentsAndRelatedPartyTransactionsDisclosureTextBlock" xlink:label="fold_DebtInstrumentsAndRelatedPartyTransactionsDisclosureTextBlock_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_DebtInstrumentsAndRelatedPartyTransactionsAbstract" xlink:to="fold_DebtInstrumentsAndRelatedPartyTransactionsDisclosureTextBlock_636239740247145307" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureEarningsPerShare" xlink:type="extended" xlink:title="11701 - Disclosure - Earnings per Share" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_636239740247145307" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="11801 - Disclosure - Commitments and Contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_636239740247145307" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="11901 - Disclosure - Subsequent Events" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_636239740247145307" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureSelectedQuarterlyFinancialDataUnauditedInThousandsExceptPerShareData" xlink:type="extended" xlink:title="12001 - Disclosure - Selected Quarterly Financial Data (Unaudited - in thousands except per share data)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="QuarterlyFinancialInformationDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock_636239740247145307" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - Summary of Significant Accounting Policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_636239740247145307" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock_636239740247145307" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_636239740247145307" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_636239740247145307" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" xlink:label="fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock_636239740247145307" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk_636239740247145307" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_636239740247145307" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_636239740247145307" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock_636239740247145307" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_636239740247145307" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContingentLiabilityReserveEstimatePolicy" xlink:label="us-gaap_ContingentLiabilityReserveEstimatePolicy_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ContingentLiabilityReserveEstimatePolicy_636239740247145307" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_636239740247145307" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_InterestIncomeAndInterestExpensePolicyTextBlock" xlink:label="fold_InterestIncomeAndInterestExpensePolicyTextBlock_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="fold_InterestIncomeAndInterestExpensePolicyTextBlock_636239740247145307" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_636239740247145307" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_OtherComprehensiveIncomePolicyPolicyTextBlock" xlink:label="fold_OtherComprehensiveIncomePolicyPolicyTextBlock_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="fold_OtherComprehensiveIncomePolicyPolicyTextBlock_636239740247145307" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeasePolicyTextBlock" xlink:label="us-gaap_LeasePolicyTextBlock_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_LeasePolicyTextBlock_636239740247145307" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_NonqualifiedCashDeferralPlansPolicy" xlink:label="fold_NonqualifiedCashDeferralPlansPolicy_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="fold_NonqualifiedCashDeferralPlansPolicy_636239740247145307" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_636239740247145307" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_636239740247145307" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock_636239740247145307" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_636239740247145307" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessCombinationsPolicy_636239740247145307" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock" xlink:label="fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock_636239740247145307" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_636239740247145307" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_636239740247145307" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureGoodwillAndIntangibleAssetsTables" xlink:type="extended" xlink:title="30403 - Disclosure - Goodwill and Intangible Assets (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfGoodwillTextBlock_636239740247145307" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_636239740247145307" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureCashMoneyMarketFundsAndMarketableSecuritiesTables" xlink:type="extended" xlink:title="30503 - Disclosure - Cash, Money Market Funds and Marketable Securities (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:label="CashCashEquivalentsAndShortTermInvestmentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_636239740247145307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_636239740247145307" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureInventoriesTables" xlink:type="extended" xlink:title="30603 - Disclosure - Inventories (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract_636021009228885651" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract_636021009228885651" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_636239740247245308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosurePropertyAndEquipmentTables" xlink:type="extended" xlink:title="30703 - Disclosure - Property and Equipment (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_636239740247245308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesTables" xlink:type="extended" xlink:title="30803 - Disclosure - Accounts Payable and Accrued Expenses (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_636239740247245308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureStockholdersEquityTables" xlink:type="extended" xlink:title="30903 - Disclosure - Stockholders' Equity (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_636239740247245308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_636239740247245308" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_636239740247245308" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_636239740247245308" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueTables" xlink:type="extended" xlink:title="31003 - Disclosure - Assets and Liabilities Measured at Fair Value (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_StatementTable_636239740247245308" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636239740247245308" xlink:to="us-gaap_BusinessAcquisitionAxis_636239740247245308" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_636239740247245308" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_636239740247245308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_SciodermIncMember" xlink:label="fold_SciodermIncMember_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_636239740247245308" xlink:to="fold_SciodermIncMember_636239740247245308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_CallidusBiopharmaIncMember" xlink:label="fold_CallidusBiopharmaIncMember_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_636239740247245308" xlink:to="fold_CallidusBiopharmaIncMember_636239740247245308" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636239740247245308" xlink:to="us-gaap_StatementLineItems_636239740247245308" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636239740247245308" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_636239740247245308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636239740247245308" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_636239740247245308" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636239740247245308" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_636239740247245308" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureLeasesTables" xlink:type="extended" xlink:title="31203 - Disclosure - Leases (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock" xlink:label="us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock_636239740247245308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_636239740247245308" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_636239740247245308" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="31303 - Disclosure - Income Taxes (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_636239740247245308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_636239740247245308" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_636239740247245308" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureDebtInstrumentsAndRelatedPartyTransactionsTables" xlink:type="extended" xlink:title="31603 - Disclosure - Debt Instruments and Related Party Transactions (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DebtInstrumentsAndRelatedPartyTransactionsAbstract" xlink:label="fold_DebtInstrumentsAndRelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="us-gaap_ConvertibleDebtTableTextBlock_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_DebtInstrumentsAndRelatedPartyTransactionsAbstract" xlink:to="us-gaap_ConvertibleDebtTableTextBlock_636239740247245308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_DebtInstrumentsAndRelatedPartyTransactionsAbstract" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_636239740247245308" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureEarningsPerShareTables" xlink:type="extended" xlink:title="31703 - Disclosure - Earnings per Share (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_636239740247245308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_636239740247245308" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureSelectedQuarterlyFinancialDataUnauditedInThousandsExceptPerShareDataTables" xlink:type="extended" xlink:title="32003 - Disclosure - Selected Quarterly Financial Data (Unaudited - in thousands except per share data) (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="QuarterlyFinancialInformationDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_636239740247245308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureDescriptionOfBusinessDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Description of Business (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_636239740247245308" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_636239740247245308" xlink:to="us-gaap_BusinessAcquisitionAxis_636239740247245308" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_636239740247245308" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_636239740247245308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_MiamedIncMember" xlink:label="fold_MiamedIncMember_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_636239740247245308" xlink:to="fold_MiamedIncMember_636239740247245308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_636239740247245308" xlink:to="us-gaap_RangeAxis_636239740247245308" order="2" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis_636239740247245308" xlink:to="us-gaap_RangeMember_636239740247245308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_636239740247245308" xlink:to="us-gaap_MaximumMember_636239740247245308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_636239740247245308" xlink:to="us-gaap_LongtermDebtTypeAxis_636239740247245308" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis_636239740247245308" xlink:to="us-gaap_LongtermDebtTypeDomain_636239740247245308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain_636239740247245308" xlink:to="us-gaap_ConvertibleDebtMember_636239740247245308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_636239740247245308" xlink:to="us-gaap_DebtInstrumentAxis_636239740247245308" order="4" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_636239740247245308" xlink:to="us-gaap_DebtInstrumentNameDomain_636239740247245308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ConvertibleSeniorNotes2016Due2023Member" xlink:label="fold_ConvertibleSeniorNotes2016Due2023Member_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_636239740247245308" xlink:to="fold_ConvertibleSeniorNotes2016Due2023Member_636239740247245308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_636239740247245308" xlink:to="us-gaap_StatementEquityComponentsAxis_636239740247245308" order="5" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_636239740247245308" xlink:to="us-gaap_EquityComponentDomain_636239740247245308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_636239740247245308" xlink:to="us-gaap_CommonStockMember_636239740247245308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_636239740247245308" xlink:to="us-gaap_CounterpartyNameAxis_636239740247245308" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis_636239740247245308" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_636239740247245308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_CowenAndCompanyLLCMember" xlink:label="fold_CowenAndCompanyLLCMember_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain_636239740247245308" xlink:to="fold_CowenAndCompanyLLCMember_636239740247245308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_636239740247245308" xlink:to="us-gaap_TypeOfArrangementAxis_636239740247245308" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_636239740247245308" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636239740247245308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_SalesAgreementMember" xlink:label="fold_SalesAgreementMember_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636239740247245308" xlink:to="fold_SalesAgreementMember_636239740247245308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_AtMarketEquityOfferingMember" xlink:label="fold_AtMarketEquityOfferingMember_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636239740247245308" xlink:to="fold_AtMarketEquityOfferingMember_636239740247245308" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_636239740247245308" xlink:to="us-gaap_ProductOrServiceAxis_636239740247245308" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis_636239740247245308" xlink:to="us-gaap_ProductsAndServicesDomain_636239740247245308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductsAndServicesDomain_636239740247245308" xlink:to="us-gaap_ProductMember_636239740247245308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_636239740247245308" xlink:to="us-gaap_StatementGeographicalAxis_636239740247245308" order="9" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementGeographicalAxis_636239740247245308" xlink:to="us-gaap_SegmentGeographicalDomain_636239740247245308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EuropeanUnionMember" xlink:label="us-gaap_EuropeanUnionMember_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentGeographicalDomain_636239740247245308" xlink:to="us-gaap_EuropeanUnionMember_636239740247245308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_636239740247245308" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636239740247245308" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_NumberOfFabryCausingMutationsIncludedInCHMPLabelApproval" xlink:label="fold_NumberOfFabryCausingMutationsIncludedInCHMPLabelApproval_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636239740247245308" xlink:to="fold_NumberOfFabryCausingMutationsIncludedInCHMPLabelApproval_636239740247245308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_PortionOfPatientsWithFabryCausedByMutationsIncludedInLabelApprovedByChmp" xlink:label="fold_PortionOfPatientsWithFabryCausedByMutationsIncludedInLabelApprovedByChmp_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636239740247245308" xlink:to="fold_PortionOfPatientsWithFabryCausedByMutationsIncludedInLabelApprovedByChmp_636239740247245308" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636239740247245308" xlink:to="us-gaap_SalesRevenueGoodsNet_636239740247245308" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636239740247245308" xlink:to="us-gaap_DebtInstrumentFaceAmount_636239740247245308" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636239740247245308" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_636239740247245308" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636239740247245308" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_636239740247245308" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636239740247245308" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_636239740247245308" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_PremiumsPaidForCappedCallConfirmations" xlink:label="fold_PremiumsPaidForCappedCallConfirmations_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636239740247245308" xlink:to="fold_PremiumsPaidForCappedCallConfirmations_636239740247245308" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636239740247245308" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_636239740247245308" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BusinessCombinationContingentConsiderationMilestones" xlink:label="fold_BusinessCombinationContingentConsiderationMilestones_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636239740247245308" xlink:to="fold_BusinessCombinationContingentConsiderationMilestones_636239740247245308" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BusinessCombinationConsiderationTransferredIncludingMilestonePayment" xlink:label="fold_BusinessCombinationConsiderationTransferredIncludingMilestonePayment_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636239740247245308" xlink:to="fold_BusinessCombinationConsiderationTransferredIncludingMilestonePayment_636239740247245308" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_6362397402472453081" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636239740247245308" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_6362397402472453081" order="12" use="optional" priority="6" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_StockIssuedDuringPeriodSharesAtMarketOffering" xlink:label="fold_StockIssuedDuringPeriodSharesAtMarketOffering_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636239740247245308" xlink:to="fold_StockIssuedDuringPeriodSharesAtMarketOffering_636239740247245308" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_FixedCommissionRateAsPercentageOfGrossProceedsPerShareSold" xlink:label="fold_FixedCommissionRateAsPercentageOfGrossProceedsPerShareSold_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636239740247245308" xlink:to="fold_FixedCommissionRateAsPercentageOfGrossProceedsPerShareSold_636239740247245308" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_StockIssuedDuringPeriodValueAtMarketOffering" xlink:label="fold_StockIssuedDuringPeriodValueAtMarketOffering_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636239740247245308" xlink:to="fold_StockIssuedDuringPeriodValueAtMarketOffering_636239740247245308" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_CommonStockIssuanceCommissionExpenses" xlink:label="fold_CommonStockIssuanceCommissionExpenses_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636239740247245308" xlink:to="fold_CommonStockIssuanceCommissionExpenses_636239740247245308" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherExpenses" xlink:label="us-gaap_OtherExpenses_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636239740247245308" xlink:to="us-gaap_OtherExpenses_636239740247245308" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636239740247245308" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_636239740247245308" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636239740247245308" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_636239740247245308" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_636239740247245308" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_636239740247245308" xlink:to="us-gaap_RangeAxis_636239740247245308" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis_636239740247245308" xlink:to="us-gaap_RangeMember_636239740247245308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_636239740247245308" xlink:to="us-gaap_MinimumMember_636239740247245308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_636239740247245308" xlink:to="us-gaap_MaximumMember_636239740247245308" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_636239740247245308" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_636239740247245308" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_636239740247245308" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_636239740247245308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEquityIncentivePlanAndStockBasedCompensationDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Summary of Significant Accounting Policies - Equity Incentive Plan and Stock-Based Compensation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="us-gaap_ShareBasedCompensationAbstract_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationAbstract_636239740247245308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ShareBasedCompensationNumberOfPlans" xlink:label="fold_ShareBasedCompensationNumberOfPlans_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract_636239740247245308" xlink:to="fold_ShareBasedCompensationNumberOfPlans_636239740247245308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentInformationDetails" xlink:type="extended" xlink:title="40203 - Disclosure - Summary of Significant Accounting Policies - Segment Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_636166991900121962" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_636166991900121962" xlink:to="us-gaap_NumberOfOperatingSegments_636239740247245308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureAcquisitionsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Acquisitions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="BusinessCombinationsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_636239740247245308" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_636239740247245308" xlink:to="us-gaap_ContingentConsiderationByTypeAxis_636239740247245308" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis_636239740247245308" xlink:to="us-gaap_ContingentConsiderationTypeDomain_636239740247245308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember" xlink:label="fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain_636239740247245308" xlink:to="fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember_636239740247245308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" xlink:label="fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain_636239740247245308" xlink:to="fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_636239740247245308" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember" xlink:label="fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain_636239740247245308" xlink:to="fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember_636239740247245308" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ContingentConsiderationLiabilityClinicalMilestoneMember" xlink:label="fold_ContingentConsiderationLiabilityClinicalMilestoneMember_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain_636239740247245308" xlink:to="fold_ContingentConsiderationLiabilityClinicalMilestoneMember_636239740247245308" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ContingentConsiderationLiabilityRegulatoryApprovalMilestoneMember" xlink:label="fold_ContingentConsiderationLiabilityRegulatoryApprovalMilestoneMember_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain_636239740247245308" xlink:to="fold_ContingentConsiderationLiabilityRegulatoryApprovalMilestoneMember_636239740247245308" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_636239740247245308" xlink:to="us-gaap_BusinessAcquisitionAxis_636239740247245308" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_636239740247245308" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_636239740247245308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_SciodermIncMember" xlink:label="fold_SciodermIncMember_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_636239740247245308" xlink:to="fold_SciodermIncMember_636239740247245308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_CallidusBiopharmaIncMember" xlink:label="fold_CallidusBiopharmaIncMember_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_636239740247245308" xlink:to="fold_CallidusBiopharmaIncMember_636239740247245308" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_MiamedIncMember" xlink:label="fold_MiamedIncMember_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_636239740247245308" xlink:to="fold_MiamedIncMember_636239740247245308" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_636239740247245308" xlink:to="dei_LegalEntityAxis_636239740247245308" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_636239740247245308" xlink:to="dei_EntityDomain_636239740247245308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ParentCompanyMember" xlink:label="us-gaap_ParentCompanyMember_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_636239740247245308" xlink:to="us-gaap_ParentCompanyMember_636239740247245308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_SciodermIncMember" xlink:label="fold_SciodermIncMember_6362397402472453081" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_636239740247245308" xlink:to="fold_SciodermIncMember_6362397402472453081" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_636239740247245308" xlink:to="us-gaap_RangeAxis_636239740247245308" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis_636239740247245308" xlink:to="us-gaap_RangeMember_636239740247245308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_636239740247245308" xlink:to="us-gaap_MinimumMember_636239740247245308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_636239740247245308" xlink:to="us-gaap_MaximumMember_636239740247245308" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_636239740247245308" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_636239740247245308" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_636239740247245308" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_636239740247245308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_636239740247245308" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember_636239740247245308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_636239740247245308" xlink:to="us-gaap_StatementClassOfStockAxis_636239740247245308" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_636239740247245308" xlink:to="us-gaap_ClassOfStockDomain_636239740247245308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_636239740247245308" xlink:to="us-gaap_SeriesBPreferredStockMember_636239740247245308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_636239740247245308" xlink:to="us-gaap_CommonStockMember_636239740247245308" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_636239740247245308" xlink:to="us-gaap_IncomeStatementLocationAxis_636239740247245308" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_636239740247245308" xlink:to="us-gaap_IncomeStatementLocationDomain_636239740247245308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ChangesInFairValueOfContingentConsiderationPayableMember" xlink:label="fold_ChangesInFairValueOfContingentConsiderationPayableMember_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_636239740247245308" xlink:to="fold_ChangesInFairValueOfContingentConsiderationPayableMember_636239740247245308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_636239740247245308" xlink:to="us-gaap_BusinessAcquisitionLineItems_636239740247245308" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_636239740247245308" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_636239740247245308" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates" xlink:label="us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_636239740247245308" xlink:to="us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates_636239740247245308" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_636239740247245308" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_636239740247245308" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BusinessCombinationContingentConsiderationMilestones" xlink:label="fold_BusinessCombinationContingentConsiderationMilestones_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_636239740247245308" xlink:to="fold_BusinessCombinationContingentConsiderationMilestones_636239740247245308" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BusinessCombinationConsiderationTransferredIncludingMilestonePayment" xlink:label="fold_BusinessCombinationConsiderationTransferredIncludingMilestonePayment_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_636239740247245308" xlink:to="fold_BusinessCombinationConsiderationTransferredIncludingMilestonePayment_636239740247245308" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_636239740247245308" xlink:to="us-gaap_ResearchAndDevelopmentExpense_636239740247245308" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BusinessCombinationAdjustedConsiderationTransferred" xlink:label="fold_BusinessCombinationAdjustedConsiderationTransferred_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_636239740247245308" xlink:to="fold_BusinessCombinationAdjustedConsiderationTransferred_636239740247245308" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BusinessCombinationAdjustedCashConsiderationTransferred" xlink:label="fold_BusinessCombinationAdjustedCashConsiderationTransferred_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_636239740247245308" xlink:to="fold_BusinessCombinationAdjustedCashConsiderationTransferred_636239740247245308" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BusinessCombinationAdjustedEquityConsiderationTransferred" xlink:label="fold_BusinessCombinationAdjustedEquityConsiderationTransferred_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_636239740247245308" xlink:to="fold_BusinessCombinationAdjustedEquityConsiderationTransferred_636239740247245308" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_636239740247245308" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_636239740247245308" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_636239740247245308" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_636239740247245308" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BusinessCombinationPriorityReviewVoucherSalePayment" xlink:label="fold_BusinessCombinationPriorityReviewVoucherSalePayment_636239740247245308" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_636239740247245308" xlink:to="fold_BusinessCombinationPriorityReviewVoucherSalePayment_636239740247245308" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BusinessCombinationPriorityReviewVoucherSalePaymentPercent" xlink:label="fold_BusinessCombinationPriorityReviewVoucherSalePaymentPercent_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_636239740247245308" xlink:to="fold_BusinessCombinationPriorityReviewVoucherSalePaymentPercent_636239740247345309" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_PriorityReviewVoucherTransferYears" xlink:label="fold_PriorityReviewVoucherTransferYears_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_636239740247245308" xlink:to="fold_PriorityReviewVoucherTransferYears_636239740247345309" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BusinessCombinationPriorityReviewVoucherUsedPayment" xlink:label="fold_BusinessCombinationPriorityReviewVoucherUsedPayment_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_636239740247245308" xlink:to="fold_BusinessCombinationPriorityReviewVoucherUsedPayment_636239740247345309" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_636239740247245308" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_636239740247345309" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="us-gaap_FairValueInputsDiscountRate_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_636239740247245308" xlink:to="us-gaap_FairValueInputsDiscountRate_636239740247345309" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ContingentConsiderationMilestonePayment" xlink:label="fold_ContingentConsiderationMilestonePayment_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_636239740247245308" xlink:to="fold_ContingentConsiderationMilestonePayment_636239740247345309" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_636239740247245308" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_636239740247345309" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_636239740247245308" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_636239740247345309" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_636239740247245308" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_636239740247345309" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_StockIssuedDuringPeriodValueIssuedForContingentConsiderations" xlink:label="fold_StockIssuedDuringPeriodValueIssuedForContingentConsiderations_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_636239740247245308" xlink:to="fold_StockIssuedDuringPeriodValueIssuedForContingentConsiderations_636239740247345309" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ContingentConsiderationPaidInStock" xlink:label="fold_ContingentConsiderationPaidInStock_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_636239740247245308" xlink:to="fold_ContingentConsiderationPaidInStock_636239740247345309" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureGoodwillAndIntangibleAssetsGoodwillDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Goodwill and Intangible Assets - Goodwill (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_StatementTable_636239740247345309" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636239740247345309" xlink:to="us-gaap_BusinessAcquisitionAxis_636239740247345309" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_636239740247345309" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_636239740247345309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BusinessAcquisitionsMember" xlink:label="fold_BusinessAcquisitionsMember_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_636239740247345309" xlink:to="fold_BusinessAcquisitionsMember_636239740247345309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636239740247345309" xlink:to="us-gaap_StatementLineItems_636239740247345309" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillRollForward" xlink:label="us-gaap_GoodwillRollForward_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636239740247345309" xlink:to="us-gaap_GoodwillRollForward_636239740247345309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillRollForward_636239740247345309" xlink:to="us-gaap_Goodwill_636239740247345309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill_6362397402473453091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillRollForward_636239740247345309" xlink:to="us-gaap_Goodwill_6362397402473453091" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636239740247345309" xlink:to="us-gaap_GoodwillImpairmentLoss_636239740247345309" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureGoodwillAndIntangibleAssetsIprDDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Goodwill and Intangible Assets - IPR&amp;D (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_StatementTable_636239740247345309" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636239740247345309" xlink:to="us-gaap_BusinessAcquisitionAxis_636239740247345309" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_636239740247345309" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_636239740247345309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BusinessAcquisitionsMember" xlink:label="fold_BusinessAcquisitionsMember_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_636239740247345309" xlink:to="fold_BusinessAcquisitionsMember_636239740247345309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636239740247345309" xlink:to="us-gaap_StatementLineItems_636239740247345309" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsRollForward" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsRollForward_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636239740247345309" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsRollForward_636239740247345309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsRollForward_636239740247345309" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_636239740247345309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_6362397402473453091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsRollForward_636239740247345309" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_6362397402473453091" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636239740247345309" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_636239740247345309" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureCashMoneyMarketFundsAndMarketableSecuritiesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Cash, Money Market Funds and Marketable Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:label="CashCashEquivalentsAndShortTermInvestmentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_636239740247345309" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_636239740247345309" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_636239740247345309" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_636239740247345309" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_636239740247345309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ShortTermCorporateDebtSecuritiesMember" xlink:label="fold_ShortTermCorporateDebtSecuritiesMember_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_636239740247345309" xlink:to="fold_ShortTermCorporateDebtSecuritiesMember_636239740247345309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_636239740247345309" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_636239740247345309" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_636239740247345309" xlink:to="us-gaap_MoneyMarketFundsMember_636239740247345309" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_636239740247345309" xlink:to="us-gaap_CertificatesOfDepositMember_636239740247345309" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_636239740247345309" xlink:to="us-gaap_IncomeStatementLocationAxis_636239740247345309" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_636239740247345309" xlink:to="us-gaap_IncomeStatementLocationDomain_636239740247345309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseMember_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_636239740247345309" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseMember_636239740247345309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_636239740247345309" xlink:to="us-gaap_BalanceSheetLocationAxis_636239740247345309" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis_636239740247345309" xlink:to="us-gaap_BalanceSheetLocationDomain_636239740247345309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="us-gaap_OtherCurrentLiabilitiesMember_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain_636239740247345309" xlink:to="us-gaap_OtherCurrentLiabilitiesMember_636239740247345309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_636239740247345309" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_636239740247345309" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_636239740247345309" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_636239740247345309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_636239740247345309" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_636239740247345309" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_636239740247345309" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_636239740247345309" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_636239740247345309" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_636239740247345309" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_AvailableForSaleSecuritiesAmortizedCostCurrent" xlink:label="fold_AvailableForSaleSecuritiesAmortizedCostCurrent_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_636239740247345309" xlink:to="fold_AvailableForSaleSecuritiesAmortizedCostCurrent_636239740247345309" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:label="fold_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_636239740247345309" xlink:to="fold_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent_636239740247345309" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:label="fold_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_636239740247345309" xlink:to="fold_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent_636239740247345309" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesCurrent_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_636239740247345309" xlink:to="us-gaap_AvailableForSaleSecuritiesCurrent_636239740247345309" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_636239740247345309" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost_636239740247345309" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_636239740247345309" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_636239740247345309" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_636239740247345309" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_636239740247345309" order="11" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_636239740247345309" xlink:to="us-gaap_AvailableForSaleSecurities_636239740247345309" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_636239740247345309" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_636239740247345309" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure" xlink:label="fold_CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_636239740247345309" xlink:to="fold_CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure_636239740247345309" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesAbstract_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_636239740247345309" xlink:to="us-gaap_AvailableForSaleSecuritiesAbstract_636239740247345309" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract_636239740247345309" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_636239740247345309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract_636239740247345309" xlink:to="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_636239740247345309" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureInventoriesDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Inventories (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract_636021014275124251" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract_636021014275124251" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_636239740247345309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract_636021014275124251" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_636239740247345309" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract_636021014275124251" xlink:to="us-gaap_InventoryNet_636239740247345309" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract_636021014275124251" xlink:to="us-gaap_InventoryWriteDown_636239740247345309" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosurePropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Property and Equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_636239740247345309" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_636239740247345309" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_636239740247345309" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_636239740247345309" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_636239740247345309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_636239740247345309" xlink:to="us-gaap_ComputerEquipmentMember_636239740247345309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_636239740247345309" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_636239740247345309" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ResearchEquipmentMember" xlink:label="fold_ResearchEquipmentMember_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_636239740247345309" xlink:to="fold_ResearchEquipmentMember_636239740247345309" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_636239740247345309" xlink:to="us-gaap_FurnitureAndFixturesMember_636239740247345309" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_636239740247345309" xlink:to="us-gaap_LeaseholdImprovementsMember_636239740247345309" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_636239740247345309" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_636239740247345309" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_636239740247345309" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_636239740247345309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_636239740247345309" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_636239740247345309" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_636239740247345309" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_636239740247345309" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation" xlink:label="us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_636239740247345309" xlink:to="us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation_636239740247345309" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeaseObligations" xlink:label="us-gaap_CapitalLeaseObligations_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_636239740247345309" xlink:to="us-gaap_CapitalLeaseObligations_636239740247345309" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Accounts Payable and Accrued Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_636239740247345309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_636239740247345309" xlink:to="us-gaap_AccountsPayableCurrent_636239740247345309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_636239740247345309" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_636239740247345309" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_AccruedContractManufacturingAndContractResearchCostsCurrent" xlink:label="fold_AccruedContractManufacturingAndContractResearchCostsCurrent_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_636239740247345309" xlink:to="fold_AccruedContractManufacturingAndContractResearchCostsCurrent_636239740247345309" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_636239740247345309" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_636239740247345309" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_AccruedFacilityCostsCurrent" xlink:label="fold_AccruedFacilityCostsCurrent_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_636239740247345309" xlink:to="fold_AccruedFacilityCostsCurrent_636239740247345309" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_636239740247345309" xlink:to="us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_636239740247345309" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="us-gaap_CapitalLeaseObligationsCurrent_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_636239740247345309" xlink:to="us-gaap_CapitalLeaseObligationsCurrent_636239740247345309" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_636239740247345309" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_636239740247345309" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_636239740247345309" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_636239740247345309" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureStockholdersEquityCommonStockAndWarrantsDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Stockholders' Equity - Common Stock and Warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_636239740247345309" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_636239740247345309" xlink:to="us-gaap_DebtInstrumentAxis_636239740247345309" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_636239740247345309" xlink:to="us-gaap_DebtInstrumentNameDomain_636239740247345309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_NoteAndWarrantAgreement2015Member" xlink:label="fold_NoteAndWarrantAgreement2015Member_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_636239740247345309" xlink:to="fold_NoteAndWarrantAgreement2015Member_636239740247345309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_NoteAndWarrantAgreement2016Member" xlink:label="fold_NoteAndWarrantAgreement2016Member_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_636239740247345309" xlink:to="fold_NoteAndWarrantAgreement2016Member_636239740247345309" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ConvertibleSeniorNotes2016Due2023Member" xlink:label="fold_ConvertibleSeniorNotes2016Due2023Member_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_636239740247345309" xlink:to="fold_ConvertibleSeniorNotes2016Due2023Member_636239740247345309" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_AdditionalNoteAndWarrantAgreementJune2016Member" xlink:label="fold_AdditionalNoteAndWarrantAgreementJune2016Member_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_636239740247345309" xlink:to="fold_AdditionalNoteAndWarrantAgreementJune2016Member_636239740247345309" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_636239740247345309" xlink:to="us-gaap_BusinessAcquisitionAxis_636239740247345309" order="2" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_636239740247345309" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_636239740247345309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_SciodermIncMember" xlink:label="fold_SciodermIncMember_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_636239740247345309" xlink:to="fold_SciodermIncMember_636239740247345309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_MiamedIncMember" xlink:label="fold_MiamedIncMember_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_636239740247345309" xlink:to="fold_MiamedIncMember_636239740247345309" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_636239740247345309" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_636239740247345309" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_636239740247345309" xlink:to="us-gaap_RelatedPartyDomain_636239740247345309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BeneficialOwnerMember" xlink:label="us-gaap_BeneficialOwnerMember_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_636239740247345309" xlink:to="us-gaap_BeneficialOwnerMember_636239740247345309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_636239740247345309" xlink:to="us-gaap_CounterpartyNameAxis_636239740247345309" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis_636239740247345309" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_636239740247345309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_CowenAndCompanyLLCMember" xlink:label="fold_CowenAndCompanyLLCMember_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain_636239740247345309" xlink:to="fold_CowenAndCompanyLLCMember_636239740247345309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_RedmileGroupMember" xlink:label="fold_RedmileGroupMember_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain_636239740247345309" xlink:to="fold_RedmileGroupMember_636239740247345309" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_636239740247345309" xlink:to="us-gaap_LongtermDebtTypeAxis_636239740247345309" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis_636239740247345309" xlink:to="us-gaap_LongtermDebtTypeDomain_636239740247345309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain_636239740247345309" xlink:to="us-gaap_ConvertibleDebtMember_636239740247345309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_636239740247345309" xlink:to="us-gaap_TypeOfArrangementAxis_636239740247345309" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_636239740247345309" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636239740247345309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_PrivatePlacementPurchaseAgreementMember" xlink:label="fold_PrivatePlacementPurchaseAgreementMember_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636239740247345309" xlink:to="fold_PrivatePlacementPurchaseAgreementMember_636239740247345309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_SalesAgreementMember" xlink:label="fold_SalesAgreementMember_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636239740247345309" xlink:to="fold_SalesAgreementMember_636239740247345309" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_AtMarketEquityOfferingMember" xlink:label="fold_AtMarketEquityOfferingMember_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636239740247345309" xlink:to="fold_AtMarketEquityOfferingMember_636239740247345309" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_636239740247345309" xlink:to="dei_LegalEntityAxis_636239740247345309" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_636239740247345309" xlink:to="dei_EntityDomain_636239740247345309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ParentCompanyMember" xlink:label="us-gaap_ParentCompanyMember_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_636239740247345309" xlink:to="us-gaap_ParentCompanyMember_636239740247345309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_636239740247345309" xlink:to="us-gaap_RangeAxis_636239740247345309" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis_636239740247345309" xlink:to="us-gaap_RangeMember_636239740247345309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_636239740247345309" xlink:to="us-gaap_MaximumMember_636239740247345309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_636239740247345309" xlink:to="us-gaap_StatementEquityComponentsAxis_636239740247345309" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_636239740247345309" xlink:to="us-gaap_EquityComponentDomain_636239740247345309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_636239740247345309" xlink:to="us-gaap_WarrantMember_636239740247345309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_636239740247345309" xlink:to="us-gaap_CommonStockMember_636239740247345309" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_636239740247345309" xlink:to="us-gaap_ContingentConsiderationByTypeAxis_636239740247345309" order="10" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis_636239740247345309" xlink:to="us-gaap_ContingentConsiderationTypeDomain_636239740247345309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" xlink:label="fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain_636239740247345309" xlink:to="fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_636239740247345309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember" xlink:label="fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain_636239740247345309" xlink:to="fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember_636239740247345309" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_636239740247345309" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636239740247345309" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:label="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636239740247345309" xlink:to="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_636239740247345309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_636239740247345309" xlink:to="us-gaap_DebtInstrumentFaceAmount_636239740247345309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_636239740247345309" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_636239740247345309" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_636239740247345309" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_636239740247345309" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_636239740247345309" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1_636239740247345309" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_636239740247345309" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_636239740247345309" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636239740247345309" xlink:to="us-gaap_CommonStockSharesAuthorized_636239740247345309" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_CommonStockVotingRightsForEachShareHeld" xlink:label="fold_CommonStockVotingRightsForEachShareHeld_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636239740247345309" xlink:to="fold_CommonStockVotingRightsForEachShareHeld_636239740247345309" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_6362397402473453091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636239740247345309" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_6362397402473453091" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_FixedCommissionRateAsPercentageOfGrossProceedsPerShareSold" xlink:label="fold_FixedCommissionRateAsPercentageOfGrossProceedsPerShareSold_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636239740247345309" xlink:to="fold_FixedCommissionRateAsPercentageOfGrossProceedsPerShareSold_636239740247345309" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_StockIssuedDuringPeriodSharesAtMarketOffering" xlink:label="fold_StockIssuedDuringPeriodSharesAtMarketOffering_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636239740247345309" xlink:to="fold_StockIssuedDuringPeriodSharesAtMarketOffering_636239740247345309" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_StockIssuedDuringPeriodValueAtMarketOffering" xlink:label="fold_StockIssuedDuringPeriodValueAtMarketOffering_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636239740247345309" xlink:to="fold_StockIssuedDuringPeriodValueAtMarketOffering_636239740247345309" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_CommonStockIssuanceCommissionExpenses" xlink:label="fold_CommonStockIssuanceCommissionExpenses_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636239740247345309" xlink:to="fold_CommonStockIssuanceCommissionExpenses_636239740247345309" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherExpenses" xlink:label="us-gaap_OtherExpenses_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636239740247345309" xlink:to="us-gaap_OtherExpenses_636239740247345309" order="9" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_636239740247345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636239740247345309" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_636239740247345309" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636239740247345309" xlink:to="us-gaap_WarrantsAndRightsOutstanding_636239740247445310" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636239740247345309" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_636239740247445310" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates" xlink:label="us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636239740247345309" xlink:to="us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates_636239740247445310" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636239740247345309" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_636239740247445310" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BusinessCombinationContingentConsiderationMilestones" xlink:label="fold_BusinessCombinationContingentConsiderationMilestones_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636239740247345309" xlink:to="fold_BusinessCombinationContingentConsiderationMilestones_636239740247445310" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BusinessCombinationConsiderationTransferredIncludingMilestonePayment" xlink:label="fold_BusinessCombinationConsiderationTransferredIncludingMilestonePayment_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636239740247345309" xlink:to="fold_BusinessCombinationConsiderationTransferredIncludingMilestonePayment_636239740247445310" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BusinessCombinationAdjustedConsiderationTransferred" xlink:label="fold_BusinessCombinationAdjustedConsiderationTransferred_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636239740247345309" xlink:to="fold_BusinessCombinationAdjustedConsiderationTransferred_636239740247445310" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BusinessCombinationAdjustedCashConsiderationTransferred" xlink:label="fold_BusinessCombinationAdjustedCashConsiderationTransferred_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636239740247345309" xlink:to="fold_BusinessCombinationAdjustedCashConsiderationTransferred_636239740247445310" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BusinessCombinationAdjustedEquityConsiderationTransferred" xlink:label="fold_BusinessCombinationAdjustedEquityConsiderationTransferred_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636239740247345309" xlink:to="fold_BusinessCombinationAdjustedEquityConsiderationTransferred_636239740247445310" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636239740247345309" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_636239740247445310" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636239740247345309" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_636239740247445310" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636239740247345309" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_636239740247445310" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636239740247345309" xlink:to="us-gaap_SharesIssuedPricePerShare_636239740247445310" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636239740247345309" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_636239740247445310" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ProceedsFromIssuanceOfCommonStockGross" xlink:label="fold_ProceedsFromIssuanceOfCommonStockGross_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636239740247345309" xlink:to="fold_ProceedsFromIssuanceOfCommonStockGross_636239740247445310" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureStockholdersEquityEquityIncentivePlansDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Stockholders' Equity - Equity Incentive Plans (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636239740247445310" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636239740247445310" xlink:to="us-gaap_RangeAxis_636239740247445310" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis_636239740247445310" xlink:to="us-gaap_RangeMember_636239740247445310" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_636239740247445310" xlink:to="us-gaap_MaximumMember_636239740247445310" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636239740247445310" xlink:to="us-gaap_AwardTypeAxis_636239740247445310" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_636239740247445310" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_636239740247445310" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_EmployeeAndDirectorsStockOptionsMember" xlink:label="fold_EmployeeAndDirectorsStockOptionsMember_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_636239740247445310" xlink:to="fold_EmployeeAndDirectorsStockOptionsMember_636239740247445310" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_636239740247445310" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_636239740247445310" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_636239740247445310" xlink:to="us-gaap_RestrictedStockMember_636239740247445310" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636239740247445310" xlink:to="us-gaap_PlanNameAxis_636239740247445310" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_636239740247445310" xlink:to="us-gaap_PlanNameDomain_636239740247445310" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_StockOptionPlan2007AndDirectorOptionPlan2007Member" xlink:label="fold_StockOptionPlan2007AndDirectorOptionPlan2007Member_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_636239740247445310" xlink:to="fold_StockOptionPlan2007AndDirectorOptionPlan2007Member_636239740247445310" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_StockOptionPlan2002AndStockOptionPlan2007Member" xlink:label="fold_StockOptionPlan2002AndStockOptionPlan2007Member_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_636239740247445310" xlink:to="fold_StockOptionPlan2002AndStockOptionPlan2007Member_636239740247445310" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_PerformanceBasedRestrictedStockUnitAwardAgreementMember" xlink:label="fold_PerformanceBasedRestrictedStockUnitAwardAgreementMember_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_636239740247445310" xlink:to="fold_PerformanceBasedRestrictedStockUnitAwardAgreementMember_636239740247445310" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636239740247445310" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636239740247445310" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:label="us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636239740247445310" xlink:to="us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_636239740247445310" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TradingSecurities" xlink:label="us-gaap_TradingSecurities_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636239740247445310" xlink:to="us-gaap_TradingSecurities_636239740247445310" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636239740247445310" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend_636239740247445310" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TradingSecuritiesUnrealizedHoldingGainLoss" xlink:label="us-gaap_TradingSecuritiesUnrealizedHoldingGainLoss_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636239740247445310" xlink:to="us-gaap_TradingSecuritiesUnrealizedHoldingGainLoss_636239740247445310" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636239740247445310" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_636239740247445310" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_636239740247445310" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_636239740247445310" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_VestingRightsPercentageOnFirstYearAnniversary" xlink:label="fold_VestingRightsPercentageOnFirstYearAnniversary_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_636239740247445310" xlink:to="fold_VestingRightsPercentageOnFirstYearAnniversary_636239740247445310" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_636239740247445310" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_636239740247445310" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionPercentageOfSharesVestedThatMayBeExercisedInWholeOrPart" xlink:label="fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionPercentageOfSharesVestedThatMayBeExercisedInWholeOrPart_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_636239740247445310" xlink:to="fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionPercentageOfSharesVestedThatMayBeExercisedInWholeOrPart_636239740247445310" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_636239740247445310" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_636239740247445310" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_636239740247445310" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_636239740247445310" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_636239740247445310" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_636239740247445310" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_636239740247445310" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_636239740247445310" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_636239740247445310" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_636239740247445310" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" xlink:label="fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_636239740247445310" xlink:to="fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare_636239740247445310" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636239740247445310" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_636239740247445310" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636239740247445310" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_636239740247445310" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_636239740247445310" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_636239740247445310" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_636239740247445310" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_636239740247445310" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_636239740247445310" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_636239740247445310" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_636239740247445310" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_636239740247445310" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6362397402474453101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_636239740247445310" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6362397402474453101" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_636239740247445310" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_636239740247445310" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_636239740247445310" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_636239740247445310" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636239740247445310" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_636239740247445310" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_636239740247445310" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_636239740247445310" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_636239740247445310" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_636239740247445310" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_636239740247445310" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_636239740247445310" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_636239740247445310" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_636239740247445310" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6362397402474453101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_636239740247445310" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6362397402474453101" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_636239740247445310" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_636239740247445310" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_636239740247445310" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_636239740247445310" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageContractualLifeAbstract" xlink:label="fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageContractualLifeAbstract_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636239740247445310" xlink:to="fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageContractualLifeAbstract_636239740247445310" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageContractualLifeAbstract_636239740247445310" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_636239740247445310" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageContractualLifeAbstract_636239740247445310" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_636239740247445310" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageContractualLifeAbstract_636239740247445310" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_636239740247445310" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636239740247445310" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_636239740247445310" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_636239740247445310" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_636239740247445310" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_636239740247445310" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_636239740247445310" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_636239740247445310" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_636239740247445310" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636239740247445310" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_636239740247445310" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636239740247445310" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions_636239740247445310" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636239740247445310" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_636239740247445310" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636239740247445310" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_636239740247445310" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636239740247445310" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_636239740247445310" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_636239740247445310" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_636239740247445310" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_636239740247445310" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_636239740247445310" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_636239740247445310" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_636239740247445310" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_636239740247445310" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_636239740247445310" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6362397402474453101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_636239740247445310" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6362397402474453101" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636239740247445310" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_636239740247445310" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_636239740247445310" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_636239740247445310" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_636239740247445310" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_636239740247445310" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_636239740247445310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_636239740247445310" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_636239740247445310" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_636239740247445310" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_636239740247545311" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_636239740247445310" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_636239740247545311" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636239740247445310" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_636239740247545311" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_636239740247545311" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_636239740247545311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636239740247445310" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_636239740247545311" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureStockholdersEquityCompensationExpenseDetails" xlink:type="extended" xlink:title="40903 - Disclosure - Stockholders' Equity - Compensation Expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_636239740247545311" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_636239740247545311" xlink:to="us-gaap_IncomeStatementLocationAxis_636239740247545311" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_636239740247545311" xlink:to="us-gaap_IncomeStatementLocationDomain_636239740247545311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_636239740247545311" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_636239740247545311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_636239740247545311" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_636239740247545311" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_636239740247545311" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_636239740247545311" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_636239740247545311" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_636239740247545311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Assets and Liabilities Measured at Fair Value (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_636239740247545311" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_636239740247545311" xlink:to="us-gaap_CounterpartyNameAxis_636239740247545311" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis_636239740247545311" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_636239740247545311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_RedmileGroupMember" xlink:label="fold_RedmileGroupMember_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain_636239740247545311" xlink:to="fold_RedmileGroupMember_636239740247545311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_636239740247545311" xlink:to="us-gaap_DebtInstrumentAxis_636239740247545311" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_636239740247545311" xlink:to="us-gaap_DebtInstrumentNameDomain_636239740247545311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_NoteAndWarrantAgreement2015Member" xlink:label="fold_NoteAndWarrantAgreement2015Member_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_636239740247545311" xlink:to="fold_NoteAndWarrantAgreement2015Member_636239740247545311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_AdditionalNoteAndWarrantAgreementJune2016Member" xlink:label="fold_AdditionalNoteAndWarrantAgreementJune2016Member_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_636239740247545311" xlink:to="fold_AdditionalNoteAndWarrantAgreementJune2016Member_636239740247545311" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_636239740247545311" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_636239740247545311" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_636239740247545311" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_636239740247545311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_636239740247545311" xlink:to="us-gaap_FairValueInputsLevel2Member_636239740247545311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_636239740247545311" xlink:to="us-gaap_FairValueInputsLevel3Member_636239740247545311" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_636239740247545311" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_636239740247545311" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_636239740247545311" xlink:to="us-gaap_RelatedPartyDomain_636239740247545311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BeneficialOwnerMember" xlink:label="us-gaap_BeneficialOwnerMember_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_636239740247545311" xlink:to="us-gaap_BeneficialOwnerMember_636239740247545311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_636239740247545311" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_636239740247545311" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_636239740247545311" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_636239740247545311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_636239740247545311" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_636239740247545311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_636239740247545311" xlink:to="us-gaap_CorporateDebtSecuritiesMember_636239740247545311" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_636239740247545311" xlink:to="us-gaap_CertificatesOfDepositMember_636239740247545311" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_MarketExchangedMutualFundsMember" xlink:label="fold_MarketExchangedMutualFundsMember_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_636239740247545311" xlink:to="fold_MarketExchangedMutualFundsMember_636239740247545311" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_636239740247545311" xlink:to="us-gaap_TypeOfArrangementAxis_636239740247545311" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_636239740247545311" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636239740247545311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_PrivatePlacementPurchaseAgreementMember" xlink:label="fold_PrivatePlacementPurchaseAgreementMember_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636239740247545311" xlink:to="fold_PrivatePlacementPurchaseAgreementMember_636239740247545311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_636239740247545311" xlink:to="us-gaap_RangeAxis_636239740247545311" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis_636239740247545311" xlink:to="us-gaap_RangeMember_636239740247545311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_636239740247545311" xlink:to="us-gaap_MinimumMember_636239740247545311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_636239740247545311" xlink:to="us-gaap_MaximumMember_636239740247545311" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_636239740247545311" xlink:to="us-gaap_ContingentConsiderationByTypeAxis_636239740247545311" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis_636239740247545311" xlink:to="us-gaap_ContingentConsiderationTypeDomain_636239740247545311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" xlink:label="fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain_636239740247545311" xlink:to="fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_636239740247545311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember" xlink:label="fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain_636239740247545311" xlink:to="fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember_636239740247545311" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember" xlink:label="fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain_636239740247545311" xlink:to="fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember_636239740247545311" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_636239740247545311" xlink:to="us-gaap_ValuationTechniqueAxis_636239740247545311" order="9" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueAxis_636239740247545311" xlink:to="us-gaap_ValuationTechniqueDomain_636239740247545311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ProbabilityWeightedDiscountedCashFlowMember" xlink:label="fold_ProbabilityWeightedDiscountedCashFlowMember_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueDomain_636239740247545311" xlink:to="fold_ProbabilityWeightedDiscountedCashFlowMember_636239740247545311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_MonteCarloMember" xlink:label="fold_MonteCarloMember_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueDomain_636239740247545311" xlink:to="fold_MonteCarloMember_636239740247545311" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_636239740247545311" xlink:to="us-gaap_BusinessAcquisitionAxis_636239740247545311" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_636239740247545311" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_636239740247545311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_CallidusBiopharmaIncMember" xlink:label="fold_CallidusBiopharmaIncMember_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_636239740247545311" xlink:to="fold_CallidusBiopharmaIncMember_636239740247545311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_SciodermIncMember" xlink:label="fold_SciodermIncMember_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_636239740247545311" xlink:to="fold_SciodermIncMember_636239740247545311" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_MiamedIncMember" xlink:label="fold_MiamedIncMember_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_636239740247545311" xlink:to="fold_MiamedIncMember_636239740247545311" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_636239740247545311" xlink:to="us-gaap_BalanceSheetLocationAxis_636239740247545311" order="11" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis_636239740247545311" xlink:to="us-gaap_BalanceSheetLocationDomain_636239740247545311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="us-gaap_OtherCurrentLiabilitiesMember_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain_636239740247545311" xlink:to="us-gaap_OtherCurrentLiabilitiesMember_636239740247545311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_636239740247545311" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_636239740247545311" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_636239740247545311" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_636239740247545311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_636239740247545311" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_636239740247545311" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_636239740247545311" xlink:to="us-gaap_DebtInstrumentFaceAmount_636239740247545311" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_636239740247545311" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_636239740247545311" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_636239740247545311" xlink:to="us-gaap_AssetsFairValueDisclosure_636239740247545311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TradingSecurities" xlink:label="us-gaap_TradingSecurities_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_636239740247545311" xlink:to="us-gaap_TradingSecurities_636239740247545311" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_636239740247545311" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_636239740247545311" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract_636239740247545311" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_636239740247545311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract_636239740247545311" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability_636239740247545311" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:label="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract_636239740247545311" xlink:to="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_636239740247545311" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract_636239740247545311" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_636239740247545311" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BusinessCombinationContingentConsiderationMilestones" xlink:label="fold_BusinessCombinationContingentConsiderationMilestones_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_636239740247545311" xlink:to="fold_BusinessCombinationContingentConsiderationMilestones_636239740247545311" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BusinessCombinationConsiderationTransferredIncludingMilestonePayment" xlink:label="fold_BusinessCombinationConsiderationTransferredIncludingMilestonePayment_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_636239740247545311" xlink:to="fold_BusinessCombinationConsiderationTransferredIncludingMilestonePayment_636239740247545311" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_6362397402475453111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_636239740247545311" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_6362397402475453111" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="us-gaap_FairValueInputsDiscountRate_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_636239740247545311" xlink:to="us-gaap_FairValueInputsDiscountRate_636239740247545311" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_FairValueInputsProbabilityOfAchievementOfMilestones" xlink:label="fold_FairValueInputsProbabilityOfAchievementOfMilestones_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_636239740247545311" xlink:to="fold_FairValueInputsProbabilityOfAchievementOfMilestones_636239740247545311" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_FairValueAssumptionsRevenueVolatilityRate" xlink:label="fold_FairValueAssumptionsRevenueVolatilityRate_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_636239740247545311" xlink:to="fold_FairValueAssumptionsRevenueVolatilityRate_636239740247545311" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BusinessCombinationContingentConsiderationLiabilityRollForward" xlink:label="fold_BusinessCombinationContingentConsiderationLiabilityRollForward_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_636239740247545311" xlink:to="fold_BusinessCombinationContingentConsiderationLiabilityRollForward_636239740247545311" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_BusinessCombinationContingentConsiderationLiabilityRollForward_636239740247545311" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_636239740247545311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityBusinessAcquisition" xlink:label="fold_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityBusinessAcquisition_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_BusinessCombinationContingentConsiderationLiabilityRollForward_636239740247545311" xlink:to="fold_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityBusinessAcquisition_636239740247545311" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_PaymentOfContingentConsideration" xlink:label="fold_PaymentOfContingentConsideration_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_BusinessCombinationContingentConsiderationLiabilityRollForward_636239740247545311" xlink:to="fold_PaymentOfContingentConsideration_636239740247545311" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_BusinessCombinationContingentConsiderationLiabilityRollForward_636239740247545311" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_636239740247545311" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_BusinessCombinationContingentConsiderationLiabilityRollForward_636239740247545311" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_636239740247545311" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6362397402475453111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_BusinessCombinationContingentConsiderationLiabilityRollForward_636239740247545311" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6362397402475453111" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsAbstract" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsAbstract_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_636239740247545311" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsAbstract_636239740247545311" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_NumberOfForwardContracts" xlink:label="fold_NumberOfForwardContracts_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsAbstract_636239740247545311" xlink:to="fold_NumberOfForwardContracts_636239740247545311" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsAbstract_636239740247545311" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_636239740247545311" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsAbstract_636239740247545311" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_636239740247545311" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/Disclosure401KPlanDetails" xlink:type="extended" xlink:title="41101 - Disclosure - 401(k) Plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:label="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract_636239740247545311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract_636239740247545311" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_636239740247545311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract_636239740247545311" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_636239740247545311" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureLeasesDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Leases (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_StatementTable_636239740247545311" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeographicDistributionAxis" xlink:label="us-gaap_GeographicDistributionAxis_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636239740247545311" xlink:to="us-gaap_GeographicDistributionAxis_636239740247545311" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeographicDistributionDomain" xlink:label="us-gaap_GeographicDistributionDomain_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeographicDistributionAxis_636239740247545311" xlink:to="us-gaap_GeographicDistributionDomain_636239740247545311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeographicDistributionDomesticMember" xlink:label="us-gaap_GeographicDistributionDomesticMember_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeographicDistributionDomain_636239740247545311" xlink:to="us-gaap_GeographicDistributionDomesticMember_636239740247545311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_CranburyNewJerseyMember" xlink:label="fold_CranburyNewJerseyMember_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeographicDistributionDomesticMember_636239740247545311" xlink:to="fold_CranburyNewJerseyMember_636239740247545311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DurhamNorthCarolinaMember" xlink:label="fold_DurhamNorthCarolinaMember_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeographicDistributionDomesticMember_636239740247545311" xlink:to="fold_DurhamNorthCarolinaMember_636239740247545311" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeographicDistributionForeignMember" xlink:label="us-gaap_GeographicDistributionForeignMember_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeographicDistributionDomain_636239740247545311" xlink:to="us-gaap_GeographicDistributionForeignMember_636239740247545311" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BuckinghamshireUnitedKingdomMember" xlink:label="fold_BuckinghamshireUnitedKingdomMember_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeographicDistributionForeignMember_636239740247545311" xlink:to="fold_BuckinghamshireUnitedKingdomMember_636239740247545311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_MunichGermanyMember" xlink:label="fold_MunichGermanyMember_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeographicDistributionForeignMember_636239740247545311" xlink:to="fold_MunichGermanyMember_636239740247545311" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636239740247545311" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_636239740247545311" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_636239740247545311" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_636239740247545311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_636239740247545311" xlink:to="us-gaap_EquipmentMember_636239740247545311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_OfficeAndLaboratorySpaceMember" xlink:label="fold_OfficeAndLaboratorySpaceMember_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_636239740247545311" xlink:to="fold_OfficeAndLaboratorySpaceMember_636239740247545311" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_OfficeSpaceMember" xlink:label="fold_OfficeSpaceMember_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_636239740247545311" xlink:to="fold_OfficeSpaceMember_636239740247545311" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636239740247545311" xlink:to="us-gaap_RangeAxis_636239740247545311" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis_636239740247545311" xlink:to="us-gaap_RangeMember_636239740247545311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_636239740247545311" xlink:to="us-gaap_MinimumMember_636239740247545311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_636239740247545311" xlink:to="us-gaap_MaximumMember_636239740247545311" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636239740247545311" xlink:to="us-gaap_StatementLineItems_636239740247545311" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="us-gaap_LeasesOperatingAbstract_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636239740247545311" xlink:to="us-gaap_LeasesOperatingAbstract_636239740247545311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract_636239740247545311" xlink:to="us-gaap_AreaOfRealEstateProperty_636239740247545311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract_636239740247545311" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_636239740247545311" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_636239740247545311" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_636239740247545311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_636239740247545311" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_636239740247545311" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_636239740247545311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_636239740247545311" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_636239740247545311" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_636239740247545311" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_636239740247645312" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_OperatingLeasesFutureMinimumPaymentsDueInFiveYearsAndThereafter" xlink:label="fold_OperatingLeasesFutureMinimumPaymentsDueInFiveYearsAndThereafter_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_636239740247545311" xlink:to="fold_OperatingLeasesFutureMinimumPaymentsDueInFiveYearsAndThereafter_636239740247645312" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_636239740247545311" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_636239740247645312" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract_636239740247545311" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_636239740247645312" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeasesCapitalAbstract" xlink:label="us-gaap_LeasesCapitalAbstract_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636239740247545311" xlink:to="us-gaap_LeasesCapitalAbstract_636239740247645312" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeaseObligations" xlink:label="us-gaap_CapitalLeaseObligations_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesCapitalAbstract_636239740247645312" xlink:to="us-gaap_CapitalLeaseObligations_636239740247645312" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesCapitalAbstract_636239740247645312" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum_636239740247645312" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMaximum" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMaximum_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesCapitalAbstract_636239740247645312" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMaximum_636239740247645312" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_LesseeLeasingArrangementsCapitalLeasesTermOfContract" xlink:label="fold_LesseeLeasingArrangementsCapitalLeasesTermOfContract_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesCapitalAbstract_636239740247645312" xlink:to="fold_LesseeLeasingArrangementsCapitalLeasesTermOfContract_636239740247645312" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesCapitalAbstract_636239740247645312" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_636239740247645312" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesCapitalAbstract_636239740247645312" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_636239740247645312" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesCapitalAbstract_636239740247645312" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_636239740247645312" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesCapitalAbstract_636239740247645312" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDue_636239740247645312" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureIncomeTaxesStatutoryRateDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Income Taxes - Statutory Rate (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract_636239740247645312" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract_636239740247645312" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_636239740247645312" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract_636239740247645312" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_636239740247645312" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract_636239740247645312" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_636239740247645312" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_636239740247645312" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_636239740247645312" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_636239740247645312" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_636239740247645312" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_636239740247645312" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_636239740247645312" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_636239740247645312" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_636239740247645312" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_636239740247645312" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_636239740247645312" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_636239740247645312" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_636239740247645312" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_636239740247645312" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_636239740247645312" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_636239740247645312" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_636239740247645312" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_636239740247645312" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_IncomeTaxExpensesBenefitFromSaleOfNetOperatingLossesAndResearchAndDevelopmentCredits" xlink:label="fold_IncomeTaxExpensesBenefitFromSaleOfNetOperatingLossesAndResearchAndDevelopmentCredits_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_636239740247645312" xlink:to="fold_IncomeTaxExpensesBenefitFromSaleOfNetOperatingLossesAndResearchAndDevelopmentCredits_636239740247645312" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_636239740247645312" xlink:to="us-gaap_IncomeTaxExpenseBenefit_636239740247645312" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_636239740247645312" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_636239740247645312" order="11" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_636239740247645312" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_636239740247645312" order="12" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureIncomeTaxesDeferredAndValuationDetails" xlink:type="extended" xlink:title="41302 - Disclosure - Income Taxes - Deferred and Valuation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_636239740247645312" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_636239740247645312" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent_636239740247645312" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_636239740247645312" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DeferredTaxAssetsNoncurrentAbstract" xlink:label="fold_DeferredTaxAssetsNoncurrentAbstract_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_636239740247645312" xlink:to="fold_DeferredTaxAssetsNoncurrentAbstract_636239740247645312" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DeferredTaxAssetsIntellectualProperty" xlink:label="fold_DeferredTaxAssetsIntellectualProperty_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_DeferredTaxAssetsNoncurrentAbstract_636239740247645312" xlink:to="fold_DeferredTaxAssetsIntellectualProperty_636239740247645312" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_DeferredTaxAssetsNoncurrentAbstract_636239740247645312" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_636239740247645312" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_DeferredTaxAssetsNoncurrentAbstract_636239740247645312" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_636239740247645312" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_DeferredTaxAssetsNoncurrentAbstract_636239740247645312" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_636239740247645312" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_DeferredTaxAssetsNoncurrentAbstract_636239740247645312" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_636239740247645312" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DeferredTaxAssetsNonCashStockIssueNonCurrent" xlink:label="fold_DeferredTaxAssetsNonCashStockIssueNonCurrent_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_DeferredTaxAssetsNoncurrentAbstract_636239740247645312" xlink:to="fold_DeferredTaxAssetsNonCashStockIssueNonCurrent_636239740247645312" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_DeferredTaxAssetsNoncurrentAbstract_636239740247645312" xlink:to="us-gaap_DeferredTaxAssetsOther_636239740247645312" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_636239740247645312" xlink:to="us-gaap_DeferredTaxAssetsGross_636239740247645312" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_636239740247645312" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_636239740247645312" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DeferredTaxLiabilitiesRoyaltyPayable" xlink:label="fold_DeferredTaxLiabilitiesRoyaltyPayable_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_636239740247645312" xlink:to="fold_DeferredTaxLiabilitiesRoyaltyPayable_636239740247645312" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DeferredTaxLiabilitiesConvertibleNotes" xlink:label="fold_DeferredTaxLiabilitiesConvertibleNotes_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_636239740247645312" xlink:to="fold_DeferredTaxLiabilitiesConvertibleNotes_636239740247645312" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DeferredTaxAssetsLiabilitiesGross" xlink:label="fold_DeferredTaxAssetsLiabilitiesGross_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_636239740247645312" xlink:to="fold_DeferredTaxAssetsLiabilitiesGross_636239740247645312" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_636239740247645312" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_636239740247645312" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_636239740247645312" xlink:to="us-gaap_DeferredTaxLiabilities_636239740247645312" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_636239740247645312" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_636239740247645312" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureIncomeTaxesLossCarryforwardsDetails" xlink:type="extended" xlink:title="41303 - Disclosure - Income Taxes - Loss Carryforwards (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable_636239740247645312" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_636239740247645312" xlink:to="us-gaap_IncomeTaxAuthorityAxis_636239740247645312" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_636239740247645312" xlink:to="us-gaap_IncomeTaxAuthorityDomain_636239740247645312" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_636239740247645312" xlink:to="us-gaap_DomesticCountryMember_636239740247645312" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_636239740247645312" xlink:to="us-gaap_ForeignCountryMember_636239740247645312" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_636239740247645312" xlink:to="us-gaap_StateAndLocalJurisdictionMember_636239740247645312" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_636239740247645312" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_636239740247645312" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_636239740247645312" xlink:to="us-gaap_OperatingLossCarryforwards_636239740247645312" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_OperatingLossCarryforwardsLimitationsOnUseMinimumPercentageOwnershipChangePeriod" xlink:label="fold_OperatingLossCarryforwardsLimitationsOnUseMinimumPercentageOwnershipChangePeriod_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_636239740247645312" xlink:to="fold_OperatingLossCarryforwardsLimitationsOnUseMinimumPercentageOwnershipChangePeriod_636239740247645312" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_OperatingLossCarryforwardsLimitationsOnUseMinimumOwnershipPercentageChangeRelatingToSection382" xlink:label="fold_OperatingLossCarryforwardsLimitationsOnUseMinimumOwnershipPercentageChangeRelatingToSection382_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_636239740247645312" xlink:to="fold_OperatingLossCarryforwardsLimitationsOnUseMinimumOwnershipPercentageChangeRelatingToSection382_636239740247645312" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_WritedownOfOperatingLossCarryforwardAndResearchAndDevelopmentCreditsSubjectToSection382Limitations" xlink:label="fold_WritedownOfOperatingLossCarryforwardAndResearchAndDevelopmentCreditsSubjectToSection382Limitations_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_636239740247645312" xlink:to="fold_WritedownOfOperatingLossCarryforwardAndResearchAndDevelopmentCreditsSubjectToSection382Limitations_636239740247645312" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_636239740247645312" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_636239740247645312" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureLicensesDetails" xlink:type="extended" xlink:title="41401 - Disclosure - Licenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_636239740247645312" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_636239740247645312" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_636239740247645312" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_636239740247645312" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_636239740247645312" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_636239740247645312" xlink:to="us-gaap_LicenseAgreementTermsMember_636239740247645312" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_636239740247645312" xlink:to="us-gaap_CounterpartyNameAxis_636239740247645312" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis_636239740247645312" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_636239740247645312" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_MtSinaiSchoolOfMedicineOfNewYorkUniversityMember" xlink:label="fold_MtSinaiSchoolOfMedicineOfNewYorkUniversityMember_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain_636239740247645312" xlink:to="fold_MtSinaiSchoolOfMedicineOfNewYorkUniversityMember_636239740247645312" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_636239740247645312" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_636239740247645312" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_LicenseAgreementUpfrontPaymentAndAnnualLicenseFees" xlink:label="fold_LicenseAgreementUpfrontPaymentAndAnnualLicenseFees_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_636239740247645312" xlink:to="fold_LicenseAgreementUpfrontPaymentAndAnnualLicenseFees_636239740247645312" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_LicenseAgreementMilestonePaymentsPotential" xlink:label="fold_LicenseAgreementMilestonePaymentsPotential_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_636239740247645312" xlink:to="fold_LicenseAgreementMilestonePaymentsPotential_636239740247645312" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_636239740247645312" xlink:to="us-gaap_RoyaltyExpense_636239740247645312" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureCollaborativeAgreementsDetails" xlink:type="extended" xlink:title="41501 - Disclosure - Collaborative Agreements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_CollaborativeArrangementDisclosureAbstract" xlink:label="CollaborativeArrangementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_636239740247645312" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_636239740247645312" xlink:to="us-gaap_CounterpartyNameAxis_636239740247645312" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis_636239740247645312" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_636239740247645312" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_GlaxoSmithKlinePLCMember" xlink:label="fold_GlaxoSmithKlinePLCMember_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain_636239740247645312" xlink:to="fold_GlaxoSmithKlinePLCMember_636239740247645312" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_BiogenIdecMember" xlink:label="fold_BiogenIdecMember_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain_636239740247645312" xlink:to="fold_BiogenIdecMember_636239740247645312" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_636239740247645312" xlink:to="us-gaap_TypeOfArrangementAxis_636239740247645312" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_636239740247645312" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636239740247645312" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_RevisedCollaborationAgreementMember" xlink:label="fold_RevisedCollaborationAgreementMember_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636239740247645312" xlink:to="fold_RevisedCollaborationAgreementMember_636239740247645312" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_636239740247645312" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636239740247645312" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636239740247645312" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived_636239740247645312" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments" xlink:label="fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636239740247645312" xlink:to="fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments_636239740247645312" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones" xlink:label="fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones_636239740247645312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636239740247645312" xlink:to="fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones_636239740247645312" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636239740247645312" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_636239740247745313" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ResearchRevenue" xlink:label="fold_ResearchRevenue_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636239740247645312" xlink:to="fold_ResearchRevenue_636239740247745313" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureDebtInstrumentsAndRelatedPartyTransactionsNoteAndWarrantPurchaseAgreementsDetails" xlink:type="extended" xlink:title="41601 - Disclosure - Debt Instruments and Related Party Transactions - Note and Warrant Purchase Agreements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DebtInstrumentsAndRelatedPartyTransactionsAbstract" xlink:label="fold_DebtInstrumentsAndRelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ScheduleOfDebtInstrumentsAndRelatedPartyTransactionsByRelatedPartyTable" xlink:label="fold_ScheduleOfDebtInstrumentsAndRelatedPartyTransactionsByRelatedPartyTable_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_DebtInstrumentsAndRelatedPartyTransactionsAbstract" xlink:to="fold_ScheduleOfDebtInstrumentsAndRelatedPartyTransactionsByRelatedPartyTable_636239740247745313" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_ScheduleOfDebtInstrumentsAndRelatedPartyTransactionsByRelatedPartyTable_636239740247745313" xlink:to="us-gaap_CounterpartyNameAxis_636239740247745313" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis_636239740247745313" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_636239740247745313" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_RedmileGroupMember" xlink:label="fold_RedmileGroupMember_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain_636239740247745313" xlink:to="fold_RedmileGroupMember_636239740247745313" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_ScheduleOfDebtInstrumentsAndRelatedPartyTransactionsByRelatedPartyTable_636239740247745313" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis_636239740247745313" order="2" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis_636239740247745313" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_636239740247745313" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain_636239740247745313" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember_636239740247745313" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain_636239740247745313" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_636239740247745313" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain_636239740247745313" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodThreeMember_636239740247745313" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_ScheduleOfDebtInstrumentsAndRelatedPartyTransactionsByRelatedPartyTable_636239740247745313" xlink:to="us-gaap_DebtInstrumentAxis_636239740247745313" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_636239740247745313" xlink:to="us-gaap_DebtInstrumentNameDomain_636239740247745313" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_NoteAndWarrantAgreement2015Member" xlink:label="fold_NoteAndWarrantAgreement2015Member_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_636239740247745313" xlink:to="fold_NoteAndWarrantAgreement2015Member_636239740247745313" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_NoteAndWarrantAgreement2016Member" xlink:label="fold_NoteAndWarrantAgreement2016Member_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_636239740247745313" xlink:to="fold_NoteAndWarrantAgreement2016Member_636239740247745313" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_AdditionalNoteAndWarrantAgreementJune2016Member" xlink:label="fold_AdditionalNoteAndWarrantAgreementJune2016Member_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_636239740247745313" xlink:to="fold_AdditionalNoteAndWarrantAgreementJune2016Member_636239740247745313" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_NotePurchaseAgreementDecember2016Member" xlink:label="fold_NotePurchaseAgreementDecember2016Member_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_636239740247745313" xlink:to="fold_NotePurchaseAgreementDecember2016Member_636239740247745313" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_ScheduleOfDebtInstrumentsAndRelatedPartyTransactionsByRelatedPartyTable_636239740247745313" xlink:to="us-gaap_TypeOfArrangementAxis_636239740247745313" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_636239740247745313" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636239740247745313" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_PrivatePlacementPurchaseAgreementMember" xlink:label="fold_PrivatePlacementPurchaseAgreementMember_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636239740247745313" xlink:to="fold_PrivatePlacementPurchaseAgreementMember_636239740247745313" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_ScheduleOfDebtInstrumentsAndRelatedPartyTransactionsByRelatedPartyTable_636239740247745313" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_636239740247745313" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_636239740247745313" xlink:to="us-gaap_RelatedPartyDomain_636239740247745313" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BeneficialOwnerMember" xlink:label="us-gaap_BeneficialOwnerMember_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_636239740247745313" xlink:to="us-gaap_BeneficialOwnerMember_636239740247745313" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_ScheduleOfDebtInstrumentsAndRelatedPartyTransactionsByRelatedPartyTable_636239740247745313" xlink:to="us-gaap_StatementEquityComponentsAxis_636239740247745313" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_636239740247745313" xlink:to="us-gaap_EquityComponentDomain_636239740247745313" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_636239740247745313" xlink:to="us-gaap_WarrantMember_636239740247745313" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_ScheduleOfDebtInstrumentsAndRelatedPartyTransactionsByRelatedPartyTable_636239740247745313" xlink:to="us-gaap_RangeAxis_636239740247745313" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis_636239740247745313" xlink:to="us-gaap_RangeMember_636239740247745313" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_636239740247745313" xlink:to="us-gaap_MaximumMember_636239740247745313" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems" xlink:label="fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_ScheduleOfDebtInstrumentsAndRelatedPartyTransactionsByRelatedPartyTable_636239740247745313" xlink:to="fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems_636239740247745313" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems_636239740247745313" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_636239740247745313" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems_636239740247745313" xlink:to="us-gaap_DebtInstrumentFaceAmount_636239740247745313" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_WarrantTerm" xlink:label="fold_WarrantTerm_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems_636239740247745313" xlink:to="fold_WarrantTerm_636239740247745313" order="3" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems_636239740247745313" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_636239740247745313" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt" xlink:label="fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems_636239740247745313" xlink:to="fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt_636239740247745313" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ConvertibleDebtPrincipalIncrementForConversion" xlink:label="fold_ConvertibleDebtPrincipalIncrementForConversion_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems_636239740247745313" xlink:to="fold_ConvertibleDebtPrincipalIncrementForConversion_636239740247745313" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DebtInstrumentsNumberOfInstallments" xlink:label="fold_DebtInstrumentsNumberOfInstallments_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems_636239740247745313" xlink:to="fold_DebtInstrumentsNumberOfInstallments_636239740247745313" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems_636239740247745313" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_636239740247745313" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems_636239740247745313" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_636239740247745313" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems_636239740247745313" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_636239740247745313" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems_636239740247745313" xlink:to="us-gaap_WarrantsAndRightsOutstanding_636239740247745313" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_WarrantsNotSettleableInCashIncrementalFairValueDisclosure" xlink:label="fold_WarrantsNotSettleableInCashIncrementalFairValueDisclosure_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems_636239740247745313" xlink:to="fold_WarrantsNotSettleableInCashIncrementalFairValueDisclosure_636239740247745313" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ExtinguishmentOfDebtGainLossNetOfTax" xlink:label="us-gaap_ExtinguishmentOfDebtGainLossNetOfTax_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems_636239740247745313" xlink:to="us-gaap_ExtinguishmentOfDebtGainLossNetOfTax_636239740247745313" order="13" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureDebtInstrumentsAndRelatedPartyTransactionsConvertibleDebtDetails" xlink:type="extended" xlink:title="41602 - Disclosure - Debt Instruments and Related Party Transactions - Convertible Debt (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DebtInstrumentsAndRelatedPartyTransactionsAbstract" xlink:label="fold_DebtInstrumentsAndRelatedPartyTransactionsAbstract_636225751017938871" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ScheduleOfDebtInstrumentsAndRelatedPartyTransactionsByRelatedPartyTable" xlink:label="fold_ScheduleOfDebtInstrumentsAndRelatedPartyTransactionsByRelatedPartyTable_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_DebtInstrumentsAndRelatedPartyTransactionsAbstract_636225751017938871" xlink:to="fold_ScheduleOfDebtInstrumentsAndRelatedPartyTransactionsByRelatedPartyTable_636239740247745313" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_ScheduleOfDebtInstrumentsAndRelatedPartyTransactionsByRelatedPartyTable_636239740247745313" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_636239740247745313" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_636239740247745313" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_636239740247745313" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_636239740247745313" xlink:to="us-gaap_OverAllotmentOptionMember_636239740247745313" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_ScheduleOfDebtInstrumentsAndRelatedPartyTransactionsByRelatedPartyTable_636239740247745313" xlink:to="us-gaap_TypeOfArrangementAxis_636239740247745313" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_636239740247745313" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636239740247745313" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_PrivatePlacementPurchaseAgreementMember" xlink:label="fold_PrivatePlacementPurchaseAgreementMember_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636239740247745313" xlink:to="fold_PrivatePlacementPurchaseAgreementMember_636239740247745313" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_ScheduleOfDebtInstrumentsAndRelatedPartyTransactionsByRelatedPartyTable_636239740247745313" xlink:to="us-gaap_LongtermDebtTypeAxis_636239740247745313" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis_636239740247745313" xlink:to="us-gaap_LongtermDebtTypeDomain_636239740247745313" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain_636239740247745313" xlink:to="us-gaap_ConvertibleDebtMember_636239740247745313" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_ScheduleOfDebtInstrumentsAndRelatedPartyTransactionsByRelatedPartyTable_636239740247745313" xlink:to="us-gaap_DebtInstrumentAxis_636239740247745313" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_636239740247745313" xlink:to="us-gaap_DebtInstrumentNameDomain_636239740247745313" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ConvertibleSeniorNotes2016Due2023Member" xlink:label="fold_ConvertibleSeniorNotes2016Due2023Member_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_636239740247745313" xlink:to="fold_ConvertibleSeniorNotes2016Due2023Member_636239740247745313" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_ScheduleOfDebtInstrumentsAndRelatedPartyTransactionsByRelatedPartyTable_636239740247745313" xlink:to="us-gaap_StatementScenarioAxis_636239740247745313" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis_636239740247745313" xlink:to="us-gaap_ScenarioUnspecifiedDomain_636239740247745313" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ConvertibleNotesConditionOneMember" xlink:label="fold_ConvertibleNotesConditionOneMember_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain_636239740247745313" xlink:to="fold_ConvertibleNotesConditionOneMember_636239740247745313" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ConvertibleNotesConditionTwoMember" xlink:label="fold_ConvertibleNotesConditionTwoMember_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain_636239740247745313" xlink:to="fold_ConvertibleNotesConditionTwoMember_636239740247745313" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_ScheduleOfDebtInstrumentsAndRelatedPartyTransactionsByRelatedPartyTable_636239740247745313" xlink:to="us-gaap_RangeAxis_636239740247745313" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis_636239740247745313" xlink:to="us-gaap_RangeMember_636239740247745313" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_636239740247745313" xlink:to="us-gaap_MinimumMember_636239740247745313" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems" xlink:label="fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_ScheduleOfDebtInstrumentsAndRelatedPartyTransactionsByRelatedPartyTable_636239740247745313" xlink:to="fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems_636239740247745313" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:label="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems_636239740247745313" xlink:to="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_636239740247745313" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_636239740247745313" xlink:to="us-gaap_DebtInstrumentFaceAmount_636239740247745313" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_636239740247745313" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_636239740247745313" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_PremiumsPaidForCappedCallConfirmations" xlink:label="fold_PremiumsPaidForCappedCallConfirmations_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_636239740247745313" xlink:to="fold_PremiumsPaidForCappedCallConfirmations_636239740247745313" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt" xlink:label="fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_636239740247745313" xlink:to="fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt_636239740247745313" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_636239740247745313" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1_636239740247745313" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_ConvertibleDebtPrincipalIncrementForConversion" xlink:label="fold_ConvertibleDebtPrincipalIncrementForConversion_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_636239740247745313" xlink:to="fold_ConvertibleDebtPrincipalIncrementForConversion_636239740247745313" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_636239740247745313" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_636239740247745313" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DebtInstrumentsConvertibleThresholdTradingDays" xlink:label="fold_DebtInstrumentsConvertibleThresholdTradingDays_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_636239740247745313" xlink:to="fold_DebtInstrumentsConvertibleThresholdTradingDays_636239740247745313" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_636239740247745313" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays_636239740247745313" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_636239740247745313" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_636239740247745313" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DebtInstrumentsConvertibleThresholdMaximumPercentageOfStockPriceTrigger" xlink:label="fold_DebtInstrumentsConvertibleThresholdMaximumPercentageOfStockPriceTrigger_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_636239740247745313" xlink:to="fold_DebtInstrumentsConvertibleThresholdMaximumPercentageOfStockPriceTrigger_636239740247745313" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DebtInstrumentConvertibleMaximumCalendarDaysAllowedToHoldersOfCommonStockRightsOptionsOrWarrantsToPurchaseOfCommonStock" xlink:label="fold_DebtInstrumentConvertibleMaximumCalendarDaysAllowedToHoldersOfCommonStockRightsOptionsOrWarrantsToPurchaseOfCommonStock_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_636239740247745313" xlink:to="fold_DebtInstrumentConvertibleMaximumCalendarDaysAllowedToHoldersOfCommonStockRightsOptionsOrWarrantsToPurchaseOfCommonStock_636239740247745313" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DebtInstrumentConvertibleTradingDaysForPricePerShareBasedOnLastReportedSalePrice" xlink:label="fold_DebtInstrumentConvertibleTradingDaysForPricePerShareBasedOnLastReportedSalePrice_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_636239740247745313" xlink:to="fold_DebtInstrumentConvertibleTradingDaysForPricePerShareBasedOnLastReportedSalePrice_636239740247745313" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DebtInstrumentConvertibleMinimumPercentageOfPerShareValueOfLastReportedSalePriceOfCommonStock" xlink:label="fold_DebtInstrumentConvertibleMinimumPercentageOfPerShareValueOfLastReportedSalePriceOfCommonStock_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_636239740247745313" xlink:to="fold_DebtInstrumentConvertibleMinimumPercentageOfPerShareValueOfLastReportedSalePriceOfCommonStock_636239740247745313" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_636239740247745313" xlink:to="us-gaap_DebtInstrumentTerm_636239740247745313" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_636239740247745313" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_636239740247745313" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DeferredTaxLiabilitiesConvertibleNotes" xlink:label="fold_DeferredTaxLiabilitiesConvertibleNotes_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_636239740247745313" xlink:to="fold_DeferredTaxLiabilitiesConvertibleNotes_636239740247745313" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_636239740247745313" xlink:to="us-gaap_DeferredFinanceCostsNet_636239740247745313" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_636239740247745313" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_636239740247745313" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_LiabilityComponentsAbstract" xlink:label="fold_LiabilityComponentsAbstract_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_636239740247745313" xlink:to="fold_LiabilityComponentsAbstract_636239740247745313" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_636239740247745313" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_LiabilityComponentsAbstract_636239740247745313" xlink:to="us-gaap_DebtInstrumentCarryingAmount_636239740247745313" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_636239740247845314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_LiabilityComponentsAbstract_636239740247745313" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_636239740247845314" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts_636239740247845314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_LiabilityComponentsAbstract_636239740247745313" xlink:to="us-gaap_DeferredOfferingCosts_636239740247845314" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_636239740247845314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fold_LiabilityComponentsAbstract_636239740247745313" xlink:to="us-gaap_LongTermDebt_636239740247845314" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_636239740247845314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_636239740247745313" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures_636239740247845314" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpenseDebtAbstract" xlink:label="us-gaap_InterestExpenseDebtAbstract_636239740247845314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_636239740247745313" xlink:to="us-gaap_InterestExpenseDebtAbstract_636239740247845314" order="22" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_636239740247845314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InterestExpenseDebtAbstract_636239740247845314" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization_636239740247845314" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_AmortizationDeferredFinancingCosts" xlink:label="fold_AmortizationDeferredFinancingCosts_636239740247845314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InterestExpenseDebtAbstract_636239740247845314" xlink:to="fold_AmortizationDeferredFinancingCosts_636239740247845314" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_636239740247845314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InterestExpenseDebtAbstract_636239740247845314" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_636239740247845314" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_636239740247845314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InterestExpenseDebtAbstract_636239740247845314" xlink:to="us-gaap_InterestExpenseDebt_636239740247845314" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_636239740247845314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InterestExpenseDebtAbstract_636239740247845314" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_636239740247845314" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeCapPrice" xlink:label="us-gaap_DerivativeCapPrice_636239740247845314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_636239740247745313" xlink:to="us-gaap_DerivativeCapPrice_636239740247845314" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_DerivativeCapPricePercentageOfPremiumOnCommonStockClosingPrice" xlink:label="fold_DerivativeCapPricePercentageOfPremiumOnCommonStockClosingPrice_636239740247845314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_636239740247745313" xlink:to="fold_DerivativeCapPricePercentageOfPremiumOnCommonStockClosingPrice_636239740247845314" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureEarningsPerShareDetails" xlink:type="extended" xlink:title="41701 - Disclosure - Earnings per Share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_636239740247845314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_636239740247845314" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_636239740247845314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_636239740247845314" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_636239740247845314" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_636239740247845314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_636239740247845314" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_636239740247845314" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_EmployeeAndDirectorsStockOptionsMember" xlink:label="fold_EmployeeAndDirectorsStockOptionsMember_636239740247845314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_636239740247845314" xlink:to="fold_EmployeeAndDirectorsStockOptionsMember_636239740247845314" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember_636239740247845314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_636239740247845314" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember_636239740247845314" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_636239740247845314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_636239740247845314" xlink:to="us-gaap_WarrantMember_636239740247845314" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_636239740247845314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_636239740247845314" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_636239740247845314" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_636239740247845314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_636239740247845314" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_636239740247845314" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract_636239740247845314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_636239740247845314" xlink:to="us-gaap_NetIncomeLossAbstract_636239740247845314" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_636239740247845314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_636239740247845314" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_636239740247845314" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_636239740247845314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_636239740247845314" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_636239740247845314" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_636239740247845314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_636239740247845314" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_636239740247845314" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_636239740247845314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_636239740247845314" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_636239740247845314" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="41801 - Disclosure - Commitments and Contingencies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_NumberOfLawsuits" xlink:label="fold_NumberOfLawsuits_636239740247845314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="fold_NumberOfLawsuits_636239740247845314" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fold-20161231.xsd#fold_NumberOfLawsuitsNamingAdditionalOfficer" xlink:label="fold_NumberOfLawsuitsNamingAdditionalOfficer_636239740247845314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="fold_NumberOfLawsuitsNamingAdditionalOfficer_636239740247845314" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.amicustherapeutics.com/role/DisclosureSelectedQuarterlyFinancialDataUnauditedInThousandsExceptPerShareDataDetails" xlink:type="extended" xlink:title="42001 - Disclosure - Selected Quarterly Financial Data (Unaudited - in thousands except per share data) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="QuarterlyFinancialInformationDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:label="us-gaap_SelectedQuarterlyFinancialInformationAbstract_636239740247845314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_SelectedQuarterlyFinancialInformationAbstract_636239740247845314" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_636239740247845314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SelectedQuarterlyFinancialInformationAbstract_636239740247845314" xlink:to="us-gaap_NetIncomeLoss_636239740247845314" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_636239740247845314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SelectedQuarterlyFinancialInformationAbstract_636239740247845314" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_636239740247845314" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g878266.jpg
<DESCRIPTION>G878266.JPG
<TEXT>
begin 644 g878266.jpg
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M' 63:248 >JV).?K@8J_<EQ_B)M^EN#ZX&*OW)<?XB;?I?B,83% =")0'YB
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M1!515!9F8@* 22 .)4?K@XI#NTN(??!-?TO_ #UQGZX&*OW)<>V_ZQ-?TO\
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M(!XDW#G!Q4/9I<?O^@FO3Y?UW_Q;XS]<#%7[DN(??!-?TOQ&,)B@/40#H'J
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ML(+<O6"'(2Q7&%<5+DGKNSR7.$5Q_6#DF,C1QUSL+Y)D-&"1[<69G3HS:R.
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MA*\K.!HK-=[P!C.%Y#</7RJR%%S7A_E\5OMVFHA-%Q(S=^S2JTK\_#0)V:3
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MH?/C.A[ 'PZ:'M_T .N#0B/0![?#KU_F ]M??Z<3P?8?Y?\ 4??X?W& _/\
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M^8WE%PGR*9[YK,KX$Q]0\JI_J3V6I-:W/X^M%60M,]:)V8FFI0IK.!2?Q49
ML4$+;.7V5?@T@8E)1(2GROI'4,<O)DMQC?9/(V^JHD2-:::G@J.=*U2(H6BD
MJJ8.DKHX2:.7;RFW\6+>;:Z[UJ=R[HT&(9R2TJ.\85>5N8.L;D,H*^J1G/3B
M=C@XJ$<SGX0%S$WQGX:.5>0OE^N4QBOF,S6TH^1H"ROL5(V/)&4H64<P=XY,
MHP+01R^HEQCQ3B[#&YE3".J\I$V2*]W60>,IF+9R+94\:'(<#E%?EXP1X=7,
M-S+\R6,\.X^RSS6XPHMWQY$PW+0YR!3XRVM\<3.0GGTE#7R_1)'R\>XB:RQ1
M+++LU/Q<4F%RO&C'))HZ_1+ 6IH \RU;O$U=1QR4BT50*6=JTS3QQTJB=DC5
MY) ADDCB+"9Q&;5O5O<N!*X"F%5<PS;9C.ADC$("%I"5#$@+GU6(!521/#P<
M5[;G^$.\OT1ACD>SI0<!9RRK6^=#(F6\1M:15VL.&8\>90Q2TCF2E#5H!3OF
M]RL-EN<S#5V)0CK'$()1<DWM"[@S<#QH)FC^$+Y 76S]C5'PK.;=US/<KY'=
MFSKA2.MF.).NXUQ4QA$K O?K+EQE[:)(\<QBQ',+48FL2[ZR(@JXK\A)-FSM
M5"Q-'ZCD4N+:R!7F1N=4T4#*:>K-#.66>IC94BJP())"!&CR0Y8":$O<UXMJ
MD U2DL$(VQS/D21<^/&R-NK1>N!WVALC*L!9>X.($,B^.]21KO)4GRR<K66N
M9G*_._AV2SMCO%#:[XQQ(X@Z'7WB\/9FLQ<+U,GK\A=8VPM'T0QJ,)[VYFSL
M5E&+P%5F+1W,_A3(DIEK$F.LESF.KMB.9O%0A+++8QR.P3B[W0I*49D7>U6U
ML$C'2;S4*X%1F]*F84S'3]H0 *< !,K;/<;=%%-6T_HZ322QQJ\T!F+0RRPR
M%J=96G1!+!-&LCQK&[1N$=MIXVH:NGJ'*0R;V"ASA) NUE1AAV0(QQ(A*ABR
MYPP!! 5#@X.#A-XV>#@X.#@X.#@X.#@X.*__ (N7)KSLYFYNO#EYL.3B@8ER
M7+\G%HR=;)VI95R>IC2-E7UE;UUK",P?(0DPZ79+(M),SM=F4'#19)J4454E
MSB1C'.GX8'B!<[>4>7/GDR_RE<CF1,VXYJUYP5EGDRR=E^X6+!MPQ8C+R4YB
M_(-:R*PAF#YC>H^0MUK/)L'Z)&T>Y:5^0;DE"&?Q86Y^/P*J0=U$P^\Y0_R\
M.BBU9<J".@C@AHMUNI*J@AG:.<3O15DM5-/3RO'4QC:TE7(ZO&L4R,L924%,
ME,EM-+,TS.TWT\\52RAQM6:!8UC= 4."%B4$$D'+=,GI41R]X/'-M?\ D.I&
M.*%RD\B> ;9!<[D!GC)7)QA;*^4J]@GF#PQ7J$SKD76,N9+<HFFI2Y(6!65,
MNSC?HNK)UA1HO'>QL;33Q&\=> =S?6O 7BM8MM6,>5/E37YOX'E3LO+WC[!-
M\L5AP]1K=@6XR]T=T^4^E(%>RQ<;(F%%K,SI4'S9Y8YQ_,Q;0L4U!@:ZC[9+
M^VI_\<O^?@]LE_;4_P#CE_S\;D>O+Y#"T,0I$!JHJM7*5,DB2PUU)<$ ,U5(
ML@%110#F3K-.8E,/.Y> ->2P4$KAY#,QVLI&] I#P2TQR%C7&(II, 87<Q<@
MMUXK&4/D^\7'.G/EX:/--SAT#E.H%%Y-FV5:C,5S"^3+'8[*HRMN*5ZRYOTL
MI/Q9&$DO:+ V@6D74ZXY-^+C%M)O9-^X%P@F#1,.>"9SUTK ')MC^<@\5)67
M#/C&S7.C>D&F4&KAJSP:^/12H2,8]+"%3E;-JMR!S5A $G $.U 70**J)H7+
MO;)?VU/_ (Y?\_![9+^VI_\ '+_GXQ+K6ZQ;5@I[;3Q)#'3QP0TTBPQQQ2W*
M8!%:H9@6DNM6SL6))*8QM.ZIL-$V=[5,C-*TS.\VYV=HZ>').T9"QTL**/(*
M>I))XIV^,'RP9GP5DWQG>?\ MS2KM>7K/_A_8LY;\?2;9NSR%9'.0G=BPU .
MD[!CQR6/;0,.FI7YEJUNS^7,:LO7,19HME(2#-%@=KO@AY6KF$_$/P+C+(56
MJO,KECF"Y>9.CXOSEB_GM7YVG_*[B2FP)+2?&MEKC6$CXC#-+>NX9-BZBG3Q
M:?K;QS&193J1KMP@M><L$)7+9"2E:M$3"62NSC)Q&S4#/,6,Q"R\<Z(*3IA*
M1<@DX8OV3E,137:ND%4%2")3D$.$7P_RK<K7+W(2LM@?EYP3A>4G4@0FI+%6
M+*+0)"70 Q3@A)/:M"Q;EZ@!R$/[%PJHD)R%.)1,4!!0I]:1?)VJLU?0O/*]
M+Z)3S4\S4T8BBH::BI#,482DTQIQ/*N9(JS<872*,N6UY;(_QE'74\R(O-$T
MHE4R.K&9Y9A$I'+(F#! 7PT&T/&2V,1>^)KR#\TF1^9_E1\17D2LV/OK0\J\
M=8*,\Q3F.5DJ]C/+N);<K*.)>N/+%!LG,E#RZ#B8DDR$7.@Q>-GQ'17\<_AV
MP/VC<[?*WXTWB.<J%SQKF/'O)_A4]:R=AJ\5;"&.,[9.EF?,!7:Q*V!7)= S
M'D@(E@SAJG),UZT^JT;#LFZSF69203DBV(G%*DL]^V2_MJ?_ !R_Y^#VR7]M
M3_XY?\_")1ZGKJ-;=BFM\\]IVK;ZNIIG>IIX5J35"G#I-&C1"5Y=K/&TT:S2
M"*6,["BA-:X)O2 9*A$JB&GBCFVQNVP(6V[206 7< 0K%1N!&0:<?+5X'7->
M,SXD;.[80Y2N32B<X_(BIR^XPH7+A?++=Z)0;\$\Q=MC6)M.QJ=@=+27T.E+
M6^RLE5VCQ>0_I6R,Z372!4<8<@7C!7[(?A(I\R]'Y1ZMB7PV\JUMNJ.,LH6"
M<R#<JI#U-"LN,AR99. :UY(C>'KT!$QM/A#$EG\D]DIJ148($1:(VR_;)?VU
M/_CE_P _![9+^VI_\<O^?C=DUQ=I6E:2"W.SILC9X)I'ILVYK4[P225+2<R2
MB;EN\SS$L!(,/ZQP_$E(!@/4C+%G"RA0^9UJ,.JH%($JA@ !T]7ZO3BI50?"
M;YZKUXB^->9&XX'Y-N2JJ05FRPOS)Y)Y/\J9$,[YMJ9?(J5AU*_8,+S#'\7(
MB0L2#Y4T[+R*B3TCF8E)U1VZEF$8@9L^ O AYI< .H#"LYX=OA2<S<!4\C":
M*YR,QW7+#+),WCA>Y!-%>W''-?*S<REPAJXLK$PC9JZ91C-PSBF+L\PP9K2#
MZ[;[9+^VI_\ '+_GX/;)?VU/_CE_S\7'7=[V\L+2K"(::%8D%7'L]$DJY()!
M,E8M2S(:V=!&\[TXB*1K $C0+1;%0H^\&;>2^274@B1(4=2IC*8;D(Q(4,7+
M$L<]*KW,IX8_/;GWQ*:)S"4C!')[RSM<?\T]6R.\YW,+Y:R16<\Y4Y?ZQ),_
M:4+*&)6;):MVZZ6&J-F\%-OI<PQKY=E[D=^W@':Y%))?%_Y',[<WV/N6N^<K
MTU0&7,+R><S='YEL;U_*;V3C*%>E*JB\1DJ9-RL2S?NXH\B)X]=H^% J.FCE
MDJ[C@=D?MI?/;)?VU/\ XY?\_![9+^VI_P#'+_GX3FU/<6GM%1LI0UF@:GI4
M,<DB/"ZE)8J@S322/%(C,AB22.*)7<4Z0EB3L"UTPCJXLRXK6#S'> V]<;70
MJH"L" =Q!+$ L6XK;4GD+\1+F9YG\]\[W.Q7N7G$=[-R$9:Y->7S"&%;_.WJ
M*-)Y(;3KUY<[Q=9J#9(L6JK^7<LD6[0KY4J;\JRK1JG$B:6DA\(+E?RKR:>'
M/RT\MF;6=?891QE 6MC;&E7G4[+!H.IG(MLLS,K&<2:LTWX?1<NR%<Y&Y").
M!5;E,H"0*&DH]LE_;4_^.7_/P>V2_MJ?_'+_ )^,=?J&NN%$;?)'20T8EHI8
MH*>%HU@] IZJG@CB+2.W+*UE1))S&DD>5]Q< !>*T]MIZ>?TE&E>8K.C/))N
M+"HE260MZH!(:- N,!5& .I)JB\O/*SXV_(_DSGS:<LV!>3.UUGFOYI+_FFJ
M9/RYGFP-W=.9SJCN.K[]S0J[7//(>[1YV\JM&NG@+I2/F;K)/6R14U$VRM^#
MK9<KW)ERIUZCR& ^9KF8P=S(95YELZ47.[>PP."N9"6SHA$(7NEOI"**G.-H
MV )7*^C /9(L:I+"VD)%TK#G6;1A;@?MDO[:G_QR_P"?@]LE_;4_^.7_ #\*
M2ZVN\=0*J"*@IIFEAEJG@IY%:N,%')0Q)5.T[R<M:::90E.].-\AE_GJQNF
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M=4W&J>9VBHXN?\;F1889%7??*>"GN$@#S.0TBTZR)U*QRLY"[2J+DCM=/$$
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MR11SQ*T-TH(\I4&$R[QS"&+<F(Y(ST]A/%='E1\('G0Q,EX"Y+E"8U:F\/\
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M[(X2S/7(]V+]A Y4Q>7($.Q?' A1>,HZTTZ4:-7)RIID.X0234.4A"G,8"%
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M&^5S@LQ!.<J"% '$B >-CXL&NO/KGX?7^NU6UH._7\4^_P OB.OAQD?&Q\6
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M4]-U,(XYO2+KRI%!CD#5&QU+QQ J>Q!D>.,'.-[HHR6 X<]^O8^+" ;^OIS
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MDV>*![-O[4X@4=<-394Z4E;+S,)3\Q')OI*"BTVAT*I7SQ+^2F:O)H0CAR^
M]MA47(1KZQHNT0E$41.1DS34*BFH%9J<'4H]*/A&9D2)H-VRCMTX<2,J]2:
MH5I])3#]1Q)RAVR:ITFZL@Z<*(HB"29BD  X[UPDFN@JBL4#HK)G25*;]J9)
M4HIJ ;TT)#& =^G&;TF.#"4BD+D<R>0**B8 @D  LM/'T.(XV9CD\V60! FJ
MM!-5,L]T=)'7)AH(68T--G'5RRH]=.,8](G1(E 'H]+ 3*TU%[DQYVLYO^<S
MDTR?,7:2=V;F!LT7C+F KGOLJ,%D.DY<8/Y%C;I.%,]<Q<=)XUL4C2F-7DP1
M;.'BSB;CD//%M!10D?\ &$L=IK=!DV5=$$7"J#_7M/,"0>1<!\J@%T/E,&@$
M [!KOQ78Q>QNG(YXHN4ZADJ'?J5C&N8@C,(MW+8J$%*#6<J0#:HHB^7\PG3@
M\?H2RD5%H+$2=3#5TW\YC>\&"QCXZ[=^VQF]DX$!437ASJH+$#?G2<%2.DJ
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M-G#*NE%7B0MP.&H.L-5'"6&&V09Z2CV</(V9Y9X6":/7J,.:+-%')%O5F#I
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MBQ055$1$=B85#F,([\P['>QZB@O,]G1CRX8.O&7W<1^,+JN-6#6!K@//H_\
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MM"E8F5NI*A@=C$;D9HRKM-4!C>@F  WK0[WK8CL>W;?8/SZ#C/G$1#[0[ZB
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MQ[=>H%UZ=0T'WB&NO$(!N=/FQB.5G!G,/;,D\NL$VSYDVGTYF[D,13S""Q9
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MIK?8-8#H(&]0]?3>^@] 'H(:Z:#8"&O7C0J*:GK*>6EJHDG@F0Q212J&C=6
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M^K#^RP9LQ-N96Y5]A@R3CN9%JS<6L6%(F6].N45*N4D[-&O<CI)1\HP8HK$
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M'NF"N:>41O(J$\-466X3.FR%(1//'#"LT\:L9)D@E2/UW5G98ZF%W(&5$@+
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M?EH&6,L)"O*PI(&U^\98D8("DY48HTDZH=P !41[N6A<*8D7"OM+H7A"*2K
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MLM7B\EYGO6(^;#&>$LAR-(C74^,W,U*'98?"#1O-=H%D1G%J%)QKVHS!:[#
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M<I+ (PL<A8%@N0!DM&2$.T X926?!  &0Q/4'APPX'PZ+D'?ZGE?!0&M<9E
M#2@-01J$!(56LC[@$F# ',+6I61@&DA[I](C$NC,7#MPBFW*BEV5^4ZF9'E:
M[.PLJOCN7@HLT$=Y Q)GRCV-;5V,JM=6072GX*0B9ZE0D6@RJ$LA(NF; AS#
M)0,RJFBJFZKX" = #MUT A\=_?L/GTXS_8Z'8!Z]0W\===:'U[=M=1XTUJ9T
M*E97R 4PS;_5; 92KEE.X8SE3UPW0@$&Y@V[)W=/6R<^K@*,^87 VCRP,8P.
M$H:X5Q\%,GJ)-Q*]P@K39Y&Z6<]M>JOY2=MTG*M9E6RNY)B$2JRF6TA'QJ\<
M_@PAUXM6.:+1QFK@AU5.,IR_885K[ZK#CN$2@9.1BIE^P:.)V/,[EH."4J\9
M(J2$?,-)<KQO75EX15=.13,_CG+IK)>^D=NA66#N'QZ"&P ?OZ_/>M#\1'8#
MQCIZ_+8;Z:T(@(>H?DZ]1#777%.?,2WTLHWON;#. 7./7(!"YR, X!&!C&.
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M\^GGGN.OECBWBP)R ?[F6H^O]/;OU^/]5DGUZ]?S[_-KAZ7#+N0'_<S5'0[
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ML/WO=P?+[0?3U!^!W]WLAZ?\OLX<A^L\^%L'_P P%RH?^I>H>G;_ +!]/0>
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MVKV8&*4LD8"@ Z#0)I .A+H-; VO7H(#KA'_ -4:6,R032DW12%*0@$*Y5
M   .@%/H-  !T$ UW[<>F=X\+M.ZI%MNS2RVVZ+24TWI]%*U/5*7C1@R2Q,C
MXST*$LAP-PZ\0LH=0WN@%3"($K:-ZRHA2-\!%$$SQJLR2))&^T+E)-@==Q"G
M!W"R!>^1#P:\M6!U,P_.HVQ<NX7.LI7LBQ+.,.@=4XF%,[^/%TT4*43"7VA
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MP<'!P<'!P<'!P<'!P<'!P<:AD#_8)=/_ #2LG_(K[C;^-0R!_L$NO_FE9/\
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M"1@9.TDWH846BV@22R!F;!V*3RU4)AEZ*'+%FP&[;$*GUL< V;3G)8A"#G:
M27+@C:W90@'7JS>0!POT/DF@6"5BX*#N$%+S4Y#+V&*B6+I9>1=PC:1D(9S*
MBS!$%V;-&8BI.(54D"-3$EH]W%B4)! [<.I',V)RI2:PY"JQDX=0B$B9!\HY
M,DHI(/XDONR;9NLK*I#*14I&&=0R<FU)(1L@Q47(Z:.$D_Q0,60N/)M:PQ#@
M/I%W78^!?(,XMG$13M5G;[)=%)HS!NL[6"4DI:S.S29EY!R1V9!%X80>+N%#
M(JTY0*E&01X&#ML_"HI2!%F$HTBHX;"$$-FG[6XI<_-$=H+66FN9:Q.'1X4R
M,.@9ZPB9%R#QVS5,[Q(*8D[I) OJA2,;NH8OV1\@80#&"22< ?5JP3<P5FP"
MNTE<[@64,2<J5(4D@;6S@G.0%;?TN93$3F94AV5E0>^SL%7KXRJ:K%O K!<*
M@I>8>9CI=^_9-)J&/ IBNJ>#-(28F\RK2)=L4EWR/;+<P^"F\ 2U+Y;HR5=5
M$H)2YY@WN:R:D"%H3<) 5N9=9@:MF"?)*(MSQ2D.8L@1Z9L8%!2M/E"JR=?J
M]5"]W,T!5#XZ=LFAFE>%RYF<<XODL3LY9V_]S Q1F:W(%<RD<V009HRS-)Q'
M V05<-3)KEGE E9)>O/:'(.YX\70H>CKQEALH5Z.=)TK&3?&E7;3J48>+&;I
M]EBA>CDF"!TJ9ZD#9M$19VRBA4-KDVUR-M3,OJ,<L@VLX=0@8OM"AD]<GL-H
M4#+*1:N"ZA@=A= S;P-J"'=(V-AW,90411C&X$E@IR_Q!=)T@BY;G!9NX11<
M-U"@;RJH+ID614#S 0_E424*<I3E P%,'F*40X^PZZ" !Z]^VN_78=-#U].G
M;>^F@8VC,@Q5><)Y,L,'8+0]G9F1*%8CE8ZMP$(X73)"5>$*Y;MY)ZQB&38I
MAD)<AY-RZ>.4U53H-VQAW_KZCT_\;Y_=H1[ZV/7TUKHGLH5F4,K;3M#(25(!
M'K G:>_8X!/OXI_+^7;C'KO6@UZ]._<-^H]][ZZWZAP=-;T&]['J [#KTZB/
M7[OEZ]OUZ_?OI\A  #8AO0? ?AOKO8<8ZA\/70"'KL.@"'YP\OKZ!TXL!_Y=
M<].G3'7'EW&3VZ'@XL!<@.OJRU'7;Z<N_P /WV2?P /R[Z\/2X9;R ?[F6H?
M^7+O\/WV2GP_R]?7AZ7$3]3_ *([[_G:X?ZU+Q+K2WZ&K!_F>W?ZI%P<'!P<
M(?"]P<'!P<'!P<'!P<'!Q![XD-UEI;,4'23.E/H*HU..DT(\#F]@,Q8EGYW<
M@8@CY3./<&K-HD<0$4T2JD(8 64*,=HE$1T.@T !OX^OP#0!UUT[]-CZ/<\0
MC_=*S'?I2Z6.PWT_H>2^[8=]B []/APRA$0]ND&A\OMT@[#TVH78:[]]!KX]
M>G0.)4Z0BCATS91&@13;X)2   9)U661C@C)>1V8D]<G.21Q$S6,TDVJ+X\C
M%V6X3Q DDXCA;DQJ,]0J1HJJ/( #CC>T2 !/[1+RE,(&.*J8%*8- 8AS>8"$
M, B "!Q*)1Z" ".A!50 ?(99N0_V?L&70*<-_P#>F.!P\P" EV&S;#6P'K6C
MR'/9<1Y'/$"BHNC55]B]7FZRVI-Y =Y.?1MRB'_ZJU0,+",QZ6GO$99F"R;!
M$K[\<XT?9O'2WN919%3=.FQQC)EDCGMYI3S. </9GB863Y6O?;'E"XF@IS&C
M-WBJ&6<2=$@U*I8"6>07!M](+,/I2NE5>QC% SL!=>\(O5J (DKF8XB*YP@)
M88AZX,R@'$O8D$A>^''".:0*C.TJX!GQCEG/*:E50Q,JB-F])RR,=Z[,!6+
M<3;B<GG*43I@H8!,"8G("FNPF*GOSB :$1, " :ZZUQCVR7G]E[5(5!$ ]C[
M9,%=C_8@B!A4V/<"@43#\]\5Q,W9\B"\T=VYT(^3O4D? W,#0\4TR/;TN^NZ
M'+8%KT5*T?-\@I>6%?<XY9N9*YV=[)QII2QINBGCE"&:'6>,$1UKFLADI3./
M/3:@I%<-!L>8?E2BU^9@9J7+>.7*)LE2AG*5PJ==BTF3F6@Y)-!)6;>'L+!G
M'K!'>^Q;XRZ+EE>MM)9%:50750_J &-R8U>-LNH.SF @@]<$8R.*I0NP!9F0
M&%) 6B(R[2TT9C4%@7*"JC8E<LS9BCC=\9LO"X0*82F<MRFZAY1<HE, _P#?
M *@&#0]! ^A#0[#H(<?HZB:8@*BJ2?F^R45%4TP,(AO[(G, #H/]Z(Z[]AUQ
M$'DWESP)+^(WR]U^3Q7CZ?@<@\N.>+Y>D7D"@XC\@7:.F8L8^^6)N*@HR4^K
M[PL]0DE-J$%ZH8@B!Q'A5.=:F5&[<Q/AUT6YUV&LU*F,N9:C9>JSC8CNOR;!
MCB,%V3-^P4.5%PV;.&315NBJ(E(HW1$O4H;U5@5G""1QZDTA^B4>K%&[@ ;^
MI81D$$J5R#U^J+32J/1?I2144[U#?1C,81IE* <S#DF!\$E!@J?,@25',4"D
M4$Q2IG /(<QB%3.4PZ**:@B":A1$! @D.;S&#RE^T \ B'G]F8Q04\OG*F)B
M H9,?VIP((@<4Q !$IP)Y>GF 1XKBY20BJG'<VF+\123F0Y>:/S?\D7XG,6D
MJ[FJ_4,CS=I:N,E42JR2SUXJA#1BR3,30K1=2.9*Z!+RJ *8.2?U=A@?G?AL
MDY#K./N8.L\Q/-H6+Q3G.M7U\7+V&[YY7L9^IQ,5Z/DG4?-TJMIIKL7T#'@1
MHFLFH>7:I.D$F([1MP7^K$DQ\R-!"%D;HK%"#*JHP4EF4L6(4E0V"%#2$(&W
MY9Q(8U(52VRGHZD DR8#%*O!0%F5HF50[,!Q-*"R)C>0JZ!C[$!3(X1.H(AT
M$/(503B( 'V@ /3]J&M\?LITS'.4JA!,30&*10ICD >P'(!A.01UT\X!YNN@
MWKB$'P[JQ6*Y4+7GB\8*PR2"H>3.9FQNN8U]="*Y@CPK-GG15AT*<XJY"HQ2
M,>+^&:RXW0?Z$7 X, ]N*14;Y/LJ-ZQS*XTRU.SEUC)CG>9YIB,M+V^F7ZMU
MVLV>0FW]XP"->LUJKD33YD[2I,FD,H-:E95 PBHZ4<-V"BJ_&/T'K,JR=8LJ
MOJKB60 NRIMD<Y"*#ZPSE@N#N7=5Z,JU0H<MZ.N20F02%E=]Y1F$2!()#F3#
M[MBM&H9G2Q$)B?LA1.3S)?ZJ!CE Z6N@"L78&2^&E2EZB(;XURRW*K4V%<V"
MS3C&)AVQVR*SM0R[TQG+Y8K=FU;LHI!_)OWKQ<?9-64>S=.W!]@B@?RF$*]D
M95FG+;&Y+POD"E4.\9$O_*_S.W#&?-UBZ_2TM+90J 0SV<FULL5M25? XD2I
MG;,J_..%G+&.%L@E#+J"NNZ![7)]AR\M.6&'F,58IY?>7K*5TQ)C%A!9HAY]
MY?;';8*2;H/K18+?",J?#K5RV@U20?5]!RYM$>A97X/Y%1PA%"WD+IJ"*!$D
M:=W1Y#'G8B Y4,""))/5Q@$<LR(P;$9 5CB:GV[SS%VYA,3G:%ECD=D:3&\R
M*$9'&U8W<;<2)&00).:?<:ID&L0MUI$_&6JI65B61@+##KBYC)9B=11$KIHN
M)$C&)[9%5%0JJ::Z2R2B2R:9R&*&RB(@._E\.GQT'4.VAUOKOI\^$RPYCF'Q
M#C&FXTKT1'0,)3(D8>,C(R7E; W2;@[=.1<*S<ZQCI>4?R"[I:1E7CQ@V,K(
MNG7LDB-@0*"F;'U =>H;UU$1'MTWW =!KMZ!PGN%#,4R4W$*6P&V ^J6QTW8
M S@GULXQQ@; 8A22N3@G&2,]"<$C..^"1[^,]Q^X!#0!Z" ]-==&[[V/RZ[X
MQT]-ZZ?GZ[UZ@/3N B&PZCKL=NFQ[;[CUT.MAWUH/O#0 .OADH=1UK6QWT$/
MB'J AZ]OE]_% .GW .^/9@]N_3IGV^6<"G&-_MM?G$.N]A]V@ =?X]? 'H(=
M! 0UUUW'7;YCL!Z^H].W4#?70=/41UU 0$=]?B/;KWWK0;UP:#1M".OY-[#N
M'?X=@Z?/@['KGK^7(4=<=/;[O9[S@[B/4.WH #W  T !U[? 1U\>XB?R=_0=
M#TZ"&_70;WT^7KL#8]N@]0] UO6]AK8!Z .]]/3MQGH._AUV #T ?0/AH>^_
M4?NZG48^WR^YW'ED9]@'WCP<2X>&/=9%9+)>/'*ZR\<P^AK;%HG5.=%BI(*.
M(J43;IB(E3*\5;-72H$ @&7(=42B94YN)9.(8?#$#_3#REK]Y5?Z_+\8'GI_
MFZ>OKQ,]Q&;Q#BCBU9<A&H42+1RL%& 9)*.!G;'D6;);VL23DDDR?\.)9)M(
MVWF,7,;UD2$]Q''5S"-<]>BKA5]B@#H!C@X.#@X97#YX.#@X.#@X.#@X.#@X
M.#@X.#@X.#CYJ+)(E\RJJ:1?]\H<I ^.MF$ WKTXU"9R%2X!)165L4<V*D B
M8H+>V/L $1#R(@H.^@AUT&^@B'&2.&69@L44DK$X"QHSDGV *"<\:]154M*A
MDJJF"F0#)>>:.)0/>TC*/R\;GQ^3G(F0RBARD(0HF.<Y@*0A2ALQC&,( 4H!
MU$1$  .HCQ'OFCQ&,.XI8O#LDW=B?-TU!(0I@9MO.0!UYSG(<XEV&A  *(^G
M%>#G \8_*&0"2-<K,B-7@5 52!C#G]W.<@@)=.'1"%76V7J.S@7?37IQT72W
MA5JW5,R+!1&BIF9=]35^KM4XR4A!YCL <A6Y8/ZH<,:]>).GK5&_H\WQE.H.
M$@)2 $8QOJ'7:5/7!A6;./('/%E//W/?R_8(:/49FV-)VPMR'*2!@U"/%@7+
MKRD<+E,#=+8B & %#&]-;[1;90YR)+,V!<K7&7(E$0TPFWBZ]%$,8/9,4EA6
M%54?./G65,F0!/T ""( 4H#KBK?&Y1M.2;(1>6DG;HBSCSJG55.<->?9O-YA
M$3;]3>FM^NA=5GSF&9T_  U&-=Z*@AI<"&'2CDX 4NPZ@(^8Q0#S#T$PCQ(*
MV>"=!8*BU4L1DN-WJ*ZD:>JE"[:=(Y4D(@B7U(MSJHR2TA'3>5[\4U#X@W*]
MP5,\\RTEM@C=N13DQQLH!R96)9YAL)&'8KU)5%)QQ US@N49B]SLDV$HBX<B
MH(E["83CZCU'1=>NOGTX8JG,F1<';J''7F$H .Q H (CK8" ;V AOX;V <.2
MR+/*6!Z[<+C[519110XB.NNM]-ZT!=!T#X=._1G$\JHB^<G*4?*BJ)Q$!T!@
M#T[#L>@B  (=Q^X95Z@DELE#;'B;K!%%3O@C!2%%)/WL]>GNQVX8&C(Q=(:I
M9X]O.GGJHPP 9/2)BRCW,,C/7OGKUX[:YOO;HE()S%#V8CL V( 8/L_V._-Z
MAH '8"/0-<=-2GGL%R_:Z@(D,)=B " AO8"/V3:$!WUV'H''22;\738@B;J.
M@,;8" !O8;$0#?0!Z_#N/'PB''L!4,'42^82B'0P?9T;0]^NNX@(]!UZ:YQ+
M>>;J&.X9Z+RW!Z=!M!QGWXQ@GR'MXZ5%;>79I*,J?-?+&20/?GN21G][JKSR
M>$BY44C_ &C'$3=]AZ!U#7Y1T ?: 1T/3A?<#E3"TQ;EQ_J97Z"@F'0_]<$P
M" B/7RB&NW41-WWPSY@L=Z\!4#"<! /B.P'[.P'?81#IY@'H&PUTX=-1'IH]
M!B[*(D,'E'8=! Q1\Q1[=P$.@C\O0 XZ-IFNFO,U;)(6$?+D6 8[*ZB,D>\!
MLGWC Z]>.>:PHUM]K$$*@RMLWCS9D/,VGIDY"D=1CB^QR(<QLG0^5UY.U5TF
MI,5:082ZK(YA%)X1!(S9PV5*4Q#>55 !T.]@<"F*/70R]<NGB58#S.T8Q<Y.
MHT>WG!-%>/F1!%@L[$"E,1L] QR$V<0 I5P2'?KKBEQX?W,L1&NVJCRSL0;3
M42*0)G4$0]NF53KU)H!.'D, !\1 !Z"'&J9%N$M3+.Z?PSY=) [DZY#)*&*(
M )^@[WK8=@UV$-#U#K&74O@W;[]?;W15PEHZ]JGTJAKX,!FCG128Y P*3(&&
M0&&0,[6'7AW:6U[<;/14U90SB:BF YU'.I>(," _JY5HI%8%7Y;QMGH^<!>/
M2&:/&K]ND[9.4';5<@*(N6RI%D%2&#93IJIF,0Y1 0$!*(@/'(XHT<H?BR9@
MPTX910V-Q+0(*)D5AI@_OS$R9=%,5,%P.*!M .C(F((=^H=!LDX \4K%&6&3
M)*R1KFN22Y4RJ+M5/?6)SF#[1BE\A%2AOT#S:ZAUXCUJWP?U;I>60BF^,Z,%
MBM12#$@0=N93L=X;'_9F0'OTSCCM]C\3;!=(T%6YMTYP#S-TM.S' ]69%W)D
MG)$L:*N?KMU/$IW!PGE=RMC^TH$<0UFCW!5"E,4BAS(* !@ 0V58I0WU[ 81
M#KQOJ+ANX*!T%DEBF#8"FH4X"'Q^R(]..72P3P,4GAEA<="LL;QL/M#@'A_4
MU;1UB"2DJJ>J0]=U/-',OWXV8#W@]1Y\?;@X.#C%QL\'!QTMCG&5:@I:?D7#
M)JSB6#AZLM(OVT8R+[%,PID<2#PZ;5F19;V:/O#@Y4DQ4 QQT&AT>*L>4WS2
M/=.\=UR-,[:5]PY:J9 %TY8JOZG(2<\U4%K556BZD+;DHNMM%6SM5"7BGKNR
M%59F8)PS[.E-+)&TJ\M8U8KF2>&(LP"DJBRR(TA4,I;8&VAEW8W#.G-7T\%0
ME*W/>=T$NR"DJJD)&S,BO,]/#(D"NR.J&9D#E'V9V-A4N#A.6TUDXZ+4SJBU
MA!=3Z(][12OCEP1O[S4WDA,^Q6&GHBY^C+DFRK3(!30^E(9RO9CBP6:E@7&6
MTUDXZ+8SJBUA!<XQ/O:25\<N"-P<U-Y(3/LE1IZ N/HRY)LJTSVFC]*0SE>S
M']P6:E@7%QI9!GUZ;H QQ64AR#CH,3>L1GJHR1UR.+!<8#MQ%7^LQ49MEQ&"
M.Y;-*-B^QGVJ?(GA1>-0R!_L$NO_ )I63_D5]QU#::R>=!L=U1:N@X.$3[TB
ME?7+A- 7%2>2,R"2PT]$7'T;<DV5:9;21^DX9RO9S^X+-2P+C6;A+9%6J4^C
M)4VN,F#BNOTYAVVNSEZXCV;C'<J_F'+)F-4:EDEXZVD0KK)JHY8DDXE4]C4<
MQRB7T*?+!2R"HBR]/ZLD;G%72MD;U.%"S$L__<7+$] ,\8:BX0M3R 15PWAX
MQNMMP0!B",N6I@(X_;*^V,#J7P0>*R#<1]W;B/?V"/?M_J)-=.O7X#L>W7X\
M?;T#H'7?00#73O\ EZCZ@&O3TX^;<?Z':[#_ +'0V(?-%/0AL-B #Z:[Z$>O
M3CZ#TZ (CUUK7Q^'Q$/R=>WKQ, Y)[#H>_7 &00/M[$^6/,>4.U[#[!^]P:
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M0YMCUZD\WF'8Z$!#\H &N(O<,<PRN-V#=VB[5<239$AQ%50?9E,3XD/LIC$
M/3>Q[COAS,1XN>9*VX*BR,B=JD8"$]JV9' Q"_9 /*=(PZUO8>;8Z'KVXUI=
M(:NMM1)%II(7@A)4FIDY < C&T[">H['S!^_8-16*:G@DJJB,/.@;E(LD[1M
MA<AC$K[2I(5L@888ZXX5D>7B?Q^U4<N&#A%1,! /,B8AMAL 'R[Z  FZ]A#7
MS';(.9Q.;;UANS4*L)GKP%E $#"!2I[,41'IHH_L0:$! >FNO#T">,4^GBI-
M+QC^MV,BPE(I[>,:)J>78 8?:(>0Q1 OVMAU 0[B(=4FR7XA?+);7 H3?+L6
M1%-+RF4:V=S') <VA,!4/8J@  'EZ"&@V&@V'"C9:?6E%<(*FZZ;EJF23>TE
M)643+ZH  #U$T !!;(SD].@/"9=:ZUU]%+245P6-Y$PJ^BU<F!N4DM&D)D9#
M@HQ"X&2"V3CB%&0CGAUEO,0^RD/OS!TZAK8_#IO0?\^VYVEB<'[@@ ;R^8^@
M$ ZF\P_;$1$- &A\N@UH.X!T&7VZ9TY1[&R>J1>#9ZM/'!#%1<L[PJN1,1V/
MG,W79 0^QZZ'N&M@&PXCZM<;5YR0<.(,RR+=0RATD77E,HFF8X^4AE":(<P%
M$I?-HNS (@'IQT&Z4LVH*$0O15%MG63>L=8](W-5@ PC:GJ*@8'3H2.H'3MQ
M33=WEM=8>?&)(>7L$U/!6"-&0KTE%32TQ1CD[0O, ]8;@>A9ZX;J-U%";,&_
M:'3WOJ(@8! H==&#6BF#IKN4=#QQVY5EC@@4@D,L("HF B(ET'4  = /E\VC
M!KJ8 [!H 7Z?QRJY9E=,B@J9(@@<I=B<HE PE,'EV(:[;[@77QZ9K^*9!N9P
MY?I>[)M (!A-LHJ"H4HD'0Z,<>N_-KOU, "'7F3:'NZW7D<L\EU1EER-JQ9&
M1O)(Z%PN" P)'0=..KQZOM)MSU1GCWQD1M&?YYSL$HH4'<2VPR#"] ,Y XT>
MLQ9C2""*2>@\H &M[[=2B40#Y[T/VAV;77?#DH.&=F8 1NFH*8:.0/*(F(8H
M@8R8CU'8" ZZ[$-!H WOI:A$5^)FFR\JJH=N"@^T20$H*G)Y1$Y2G-]@##H
MV;8 &QUZ</XQ)S$\LU+.DTF,+NK*LL/LEW3RS+$ QB&,8AR-TT@*4=@8! IB
M[*/7?E*''2K71RZ;H"(J*:X54DCXAII*6,@$1@*SU,\(R<9(3<22O0]#QS:_
MW22\5.V%Q3PQ11R-43P5DJLQYA)18()=Y& "SO&J!F]8]N/CRRMYYA8$'#<B
MY"$4;@8Q"GT(&,8JA0T %$2D-UWL1 "ZT(CN5E?!DY?40%!HNL+A,%DO*F)]
MB(?:  [[ PCH-]C!TZ<-;KW/[RWTUV0L7RULVXD$#MG![$Y72,0=F*8$3)E
M *(Z,43[#N.@$.''Q_B_-VD&<:1CVMUUTR#R(I"Q;N7)BD#8 598IMF,GH2F
M$0V8HAU'7#'U(FL;G7+5V[3,U,X"1AJBLHN@Z!2_H\L[  CKE>@)'?'&M9ZB
MU6VC:&IN<<JN\LS-Z-4PQ9=]YY8FC&1UVC:V7()4$].-WJG(C;O.60<LG31
M@@<3JHJ)@(!UWH1 0Z>OYQV/"QQ[1EA94AG\PHD5H "8A3'( &)H![B)0'0;
M#UT/3KPQ"=\8?-TXJ*7F;)-3[#R)-6">B^GE(1#8]-CY>FA_)I$,D\V[_*L2
M=><<*)NUTC 95'20@8?[85,I0#0B&M]>GW:1ETKKBOD07^.G6ED]4I2RBH9%
M; ((* DXR>XQ[^%*/4&GT60T]2BNBDXE2: .?8KRHF>O?:"/:!D<3/MO$:9U
M-,C*'EUA5;AY2G%43C]G[(=PT/;X;^.^%GQYXL]_9NT/9V$#H@< ]FJ(%#V?
MF -  I]-]!'6A$!#OL XIS3&0YB'D7#@L@Y,8RQS ?VAQ P&-YP'RF$2Z#H
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M$TR81T.V;3$1.B,8+2%),E,YDX5DN[:OYI_$*&]Y71BD'BQ7:3=*ES49"O\
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M(8 QPH,0Z7<J$ QA-YC=-;V)AZ>4/43#\0 .N^@@(<.;H-=26%)1\Z;QB)@
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M-#Z[Z_>/F$.O^;M<M1."3S7R=X;<[$_2QF)SU)&YXR5+=\=B#C;4LQ !8D
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MF I$TTR@)SJ',)2)D( F.<Q0* B)0&TD#![8QW&,9(S]F,$^0/7O@\'?MQ8
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M=* UB45/8H*-DY!BL9-0A7Y)$$B*1#%23,1%),4T">5 @D3*44VY1 IBH$,
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M:?"M G96S2JT1"Q$Z*D>TK#1$#.&ZC ' E;T^E!$= ?0F ?4/-VZ;Z[Z!UZ
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M Z$-E#?7;FKLJA2F3.7H(!Y=_'0;V(]._P /OWZ-\C99,Y]@*@AYNO0 $-]
M -F$ #0  B8 V [ O00X42,?G() 'H(AL $>H@(= T.A'8!T$>FPUT#B55IO
M25D:Y8,N -P.>V.N1V).??T)&<<0GN]BY!;"[6ZG:1C)Z' !P>@P"1[<C!QP
MM3$B2OE*L0#I^8HF'R[Z"/Q_WP?G^?7CO;!BJ37;,I%@T6D8N0(7RJH)&44:
MJG$WF2. ;-HHZUO6P'H.PXU2NO@7.F0X"(>8H[[@(AK[M;#0A\?NXESY0:0S
MO+=C O42ND72J9"D.0##]LY  Q/.!]& PAZ:Z@ %#0:RZ@O!LM%Z>5$L:$B5
M#T#(5.2IP<,,;AY-G!'#0L]'+->)*(SR4S^CM(DB'<H99(P"4)ZDAB&(P0=N
M#T(-?/(-75@Y!TQ50$@)J&(JV, E]F8!, G( @(E,8W<HEZ=PT&^.!E1J^J1
M*YBYR218*4V.))V",>IV^',2[VALWDYQ23JEI!(D-8HI@,35GSZ':(1LVS@V
M$DV.NDNFH-A/Q).0"LXQ<4O.=>6<KPSN8.;(E;^@_IYK'1E<KBU@<V0\:E(P
MJ[V'<JLOHNP,49!JX*BY*X9K"N;R\5NK8Z=2\I(3#T !U(/EGBQ2J.5R)BX4
M,I[%%5XX=O#-VI1*W0,Z<KK W23 ZJA@$P\7O-10WBE2]VAML%:N#%MVM T4
MJ^D0$$9&VH0,NW 9 64E'/'<=.U$TE1%0UC"22VIS)&&0)*BH0PTT_0D9-*:
MDO$Q8KSHV<!TB<_:OR)B'+^R"&A\I]"(;-T$.G8 $! =!]D -OX\/:PA<',)
M-1KM)8R8H+H'T ]!2,?RJ%[]0$!V'7T 0#8<,'BU!(KTT ^<@AL1#?00'>NF
MQ'0!H!^8" <.:Q^_%)TV,)C &P*.QUKKL Z]M]M['OZ=^'3H*KYR3T,IW))'
MRV5NH(9<=1[L].F<=/M1]?4.ZE:>%0)8BL\;#NLL1212" ,>L  .^.G7KQZ%
MG@99P"8E'%06=@9.:KYO(D)][=,2H*)"!=Z PD,)1-H=@4 *(!OBS?Q0]\!S
M)#@F?\>QWO)@([<J,%@ X@!@]B4HD$ , :,!$P !'XB(]>+X7$$_'RR)9=?5
M2(H5:JGCF( QEEDDC)^ZJKC[/=QW;P?N9N.F,DDA)DE7/4J*B",LI\@1)&Y(
MZ=68X]AP<'!QQ/CJ_#8.8;E5H/,$T0>2:B];N4>@#>-M\4W05=BT*)SDC99J
ML)$I6-(HH95))11%RU4,8[1TB!U"'C6F_#:S<R=G2A+#C^<9 8P).G$E+PJP
MICKRBHT4B9$"G\O0Q2KF !WY3>40XG(X.'5:-9Z@LD I:.K5Z9<\N"IB6=(L
MG)$3'$D:Y).Q7" DD+DG+1O.B-.WRH:KK*1XZI\<RHI96@>7  !E4!HG;  Y
MC1F0CH7(  @>#PYN88-?L^-_@/\ 55)]M!L?]C(=1^[\O!^MR\PV_P#7&.-#
MZ_C7);#[MUGI\ $/@'3B>'@X6/G-U/\ JJ#]R'[G]5]O7[>_"-\UFEO9<?W8
MO_!X@>'PYN8<-Z<8XZ]1_JKDNOR'=9_+WZ=0^'!^MR\PW7^B,<]1#J-KDQ'H
M(#W_ !9^_P" ]NOKQ/#P< \3=3CLU!^X_?G_ +7[WLX/FLTM[+C^[%_X/$#W
MZW+S#!O3C'/7XVN3UU_^AGT'XAU >_ /AS<P_P#;\<;$!#86N3  #_!GKO[N
M_$\/!P?.;J?]50?N3[/\+[AP?-9I;V7']V+_ ,'B![];EYAO5QCCKW ;7)C^
M3?XL].XCL.H#\>#];EYAO1QCC8ZWNUR8]>^^M9'^4.)X>#@^<[4_ZJ@Z=/Z$
M]G_S?R]^#YK-+>RX_NQ?^#Q \/AS<PP]/;XX_P *I/X"'0/Q9[!OIVT.QUQC
M];EYA^O[/CC0Z'06N3 .@#T_V,]M]_C\NNIXN#BH\3M3C]-0>7]:>S&/ZK[N
M#YK-+>RX_NP?\'B![];FYA_[?C?XC_57)ZV/_P!#/77^4=!P?K<W,,/07&.!
M#701M4ET'[_Q8W^77?KKTXGAX.*?.;J?]50=.WYT[9.3_5?Y=>#YK-+>RX_N
MP?\ !X@>'PY>88>GO&./3K^-4GOI\OQ:U_,1[\'ZW+S#=_;XY$>FA_&N3$0$
M.F]#6=#\0V/3^3B>'@X/G-U./TU!^Y/L_P +[OY9/!\UFEO9<?W8O_!X@=_6
MY>8?K_1&.=]PU:Y/7KL.M9[]1'?7\_&1\.7F&'LXQP'R&UR?SZ;"L] $!Z@'
M3X?'B>'@XK\YVI_U5 /LI,=L?X7W?E([=.#YK-+>RX_NQ?\ @\02M?#AS^JN
M0CJ0QTT1$?MK_C'*NQ('IM$E>1,?X#HX?Y>'N\O7(;3\33#&YW:63OMPCCD<
M1*(,?<ZU!/4S&$CYFR7.LZD7Z0"46SJ1.5-H<!5;M"K 18K_ '@X3KEKW4ES
MII*26KC@@F4I,M)"L#RH1@HTN6E",,AE1U#*2K J<<*-L\/M,VNI2KBI):B>
M)@\+5DS3I$ZD%76(!(BZD95I$<HWK+A@"#@X.#AF\/;@X.#@X.#@X.#@X.#@
MX.#@X.#B(WQ'L*S;F4A,UP;-P_B6\0WK5Q(V1.L:'*Q<.W,3..O(4?91BY':
MT:[<'TFU<$9"H8J;@Y@B=#H&^H@.A\WW]=AK>_B/70@ ;'J !;-=-6SYLNS>
MMT';1TBHW<M7*2:[=P@J42*HKH*E.DLBJ0PD424(8AR")3E$HB'#1K7R*\N%
MKDUY4].=U]PZ5.NX1JLY(P3%190QS'.2/0449MP,)_\ 4FB+= NB@1(@!H>M
M:3\1*:UVZ*V7>GJ72D4QTM32JDAY.<K%-%))%UCR55U9@4"JR J6?C^K_#>J
MNMRGNMGJ*9'K&$E52U;21J)L!6EAECCE]63 9XW0;7+,K$-M6O6/P^.P -=
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MQ@.G<1#T'KK7;0;^(>O;0?<(<3V?K=O+A_<^Z_X:RGR_[S7373@#P[N7 /\
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M/)ER]X\DT)F,I!)F5:'!1F\MD@[LON:A=B55NTD3&CRK$-Y3)+*-%%43E*=
MZ1P\W&&;Q3T\D;-!37.:4 %(V@@A1F&.A?TE]@SC+!'(&?5;MQEA\*-1O(BS
M5%KAB)&^19ZB5D7IDK'Z,F]L$X4NH)&"P&2$3\//"TY0*-/W^TQZL;*9#4CC
M0S!VFH@_;5>,(L=JY=MS@4[<TN\<JO4$52@J#)-JJ<I!7\O$B?&     #L
M ?<'&>.(7BZ3WJY5=SJ0JRU4@;EJ24BC15CBB4GJ1'$B)NP-Q!8@$D<=ULMI
M@L=KI+73%GCI8RID8 -+([-)+*P'0&21V;:,A00H) '!P<'!PF<*O!Q0K_"
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M9V^3G.4BNRMVDWM]Q&5NNJ6-L\O/,5U'*?T20KV1.W*ZT&N0_B*<UGAW9/Y
M<K>'I/<M#Z,Y#K!B-IE.Q9MP]*UB[9HJ->KU>HE5H56J,_8))O7+FE$O7,C9
M[.ZAVM?=&01.#AHM[YPUUWR\\S^3_"ZY,^67F(\(OF$MUFY5754QXVD<7<UN
M#<6\P5+FZ#C)@T@L_P"%+(SMCF)9P4Y.*2%1FH*<GD95%!!*3-$OVR;58N<6
M[2S0+324='#(E\99I(=2VVIJ#;/1&-/+'.]1!3O%--$PFA603(6+!HVEIU7
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MC3^^#1_\+ZW^E./$\]V;;$/=FW8!$!;HAT^/[0-AZAT^\WJ./=V^M^[MM=0
M0;H .@WL.I!'OK6Q'8=M:'@_,_QGMJI\=!ULH'?';^:A/GT^T>_@^<X_WG'[
MM_\ ZW'MB?JJ8T_O@T?_  OK?Z4X/U4\:_WP*1_A?7/TIQXG8(-]#_0K4 ["
M(-D?78=Q((B&^^OY0XS[N@.OZ%;:,/8&Z'78;WOR /Y!V'?Y<5/P?D']M38_
MS,ON]MTZ$]<>7M/!\YQ_O./+^O?O_P!;?>X]L/\ 54QI_?!H_P#A?6_TIP?J
MIXT'MD&D#_\ 1?6_TIQXG@MVX= :MM@4=_T,@ @(Z#H()@(B/8/7IOIUXS[L
MU -BV:^O9J@/37R3[ .P$0T/30\4_,_QC^VI^_E9E]W7I=#[>GGU'W0>)^?[
M#C]V_9^UAY'][V\>V#^JIC3^^#1^O;^J^M]?_:G!^JIC3^^#1_\ "^M_I3CQ
M/?8MQ ?Z&:FZ@ ?T*C\.X!Y-[UUZ]PWO>^F/8-NP-VPAW'^AF_P]/V,.NM]!
MZ#\A#@'P?TZ9U2_<?V%'L!_OGT\Q]OV$\ \3SYV<8_\ ._O?G;CVQ/U4\:_W
MP*1_A?7/TIP?JIXU_O@4C_"^N?I3CQ._8-O-H6[3S"78 +=#S&#8?:\H%WK7
M?7V0#UZ\?OV"&M^[- V&P &Z AH1'8;]G]D0'XCV#0=A#@'P?T./_BIO+^PP
M]V<8N9SCKGV=/9P'Q/(_L..O[=/\&^WCVP?U5,:?WP:/_A?6_P!*<'ZJ>-/[
MX-(_POK?Z4X\3SW=OW!LVWK>_8( 'P[B00[_ &A*/<>@]?LB>[M@$/Z%:Z#0
M#MLCU'[_ &?8![]=]!^[@'P?T/?53C_]F7/EGO=![>G?N//H3YSC_><?NW_^
MMQ[8?ZJ>-/[X%(_POK?Z4X/U4\:?WP:1\?\ 9?6^WQ_KIQXG@-4/M"+9M\/]
M;M_S[]F( &M^H!KU#H/&00;B/E!JU$!#M[NW+TZZ#?LQZ^O3OWZAO@_,_P ?
MZZF/3)_F,ON/]].V,X/;L#P?.>?[SCW_ )]^_P#UM_+W<>V%^JGC7^^!2/\
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MJ"GN-!5T=4\%1055+<5>5(YC!44[QU-&#%*)(*E#)'&\T4\<\$D:\F6-XY7
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M@]P^_BR[XS#DUKLT9:NJB9BOXL%-;T#%=T)2[T =E!-K]MW'KOI6JG %"4$
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MP=3V[?\ 3]_K^3C(>7IZ".AZ .@#M\>PB B/V1'L(!KJ'Z$H['8B41V.NVQ
M=Z#J/36M=1T( ("&]<?G7H "'^4= (!L- &A ?4>X@&N, (#W$1V(CTWOTZ
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M9V&3@[>I\L\;AS25JKY&BW$E!JMEW %463 AR[\QB@!B#L=Z.&M=!#S  B
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M)DDGMTE4\$4VUI94IQ20$ '!WR%8]WK=5;&2,'0XB$5?SSM($#@B206;)D,
MF\J G'R"81U]L%2^T$1 =&.8 '6]R_<G&*VQ7S";FR$3:( 0B1U?LBF)>AE@
M,)B[ 2_9 OV@$/-H2B #Q&'3YN';K'?NQ %3*@=31>JGG/YRF#[0CYBF^R(]
MQ*)1'KU%TC#F8EHU@2'@E@9(>Q*A[1$/(<IBE\I% -Y^A@#91\H:T8QNX\>X
M=!9V@T[!;;=-3QRSP)%+,SA2D04)M4 ;B3CV8!W   GCP-UO=*V]:CJ:R>BK
M9J6*JGK8TCC7$M0TC/&79W6-%B5MX7/1M@'U,&S+4,P5RN),:]7'"+AVJ"30
MHMC% !4^P3R%$VB@?>M 8VNO[;KYN'LTFV.#XNNDL=<YE$63P_M#Z*81%(>I
MM!O90T'VP.(%T3SCH-5F>47($A8IB7D)MZHZ)',VWNA%5(MT*DK*NB,V@.&$
M@Y3<K,@2%RHJ\C&[EQ'+D:K'(FF;VA;)M)@Q'EGO,JF&P3KRBHF#^R$4DB]1
M$/VW70]=!H>NN."Z[L$-BJ(:5WYTLU92B64]3(TDD1V]1ZN%<=._4>0'";8Z
M]KDSSE)(!3\R T[$927>N\L5)#X CY9&,!VR.OJP*>(! N+9@I"U F*QHZ[3
MC910 WY4UVZ*I/,/H405,(#H!WK>NW%9RW(>PD9  ]#^30 ( &M;[CZB ^H;
M$=#U 1&X?E['Y[CRB9+;>Q!5S&2OTT@(D$3 4S0Z)Q+H#&#1R$\Q@Z ;0#TU
MNHKDA@+:6DTC%\IB.UBCOH)3 )NH]NAA#7[7IZ=!#A\4\J5ND*JG4AGM-WGC
M&.N(YH1-'T'8!F?S]V,\/G3+&GOC ]%K:"GF!SWDBEY,F![HUA!ZY&X>WA/(
MA0!/Y!$1UK0"&@^WL.FPT80ZFT B(=1$->4!<70UR%61[!]HHAT$!WUZ[Z@/
M8=AH1WKITX;&R.*3DA@#0")RC\1 0V&A#6_M!UZ:'H!1Z=%SJ+X2&2-YNH"7
MH&A'>QZ#K90Z!OOWV @'?A1T%5(E8%8]2,8)]I&>GMR#VQCIYC/"_K.D,M'(
M%.0\9&1CH<8/M]F?;UZYXLT^%WE$U?E6K5NZ]DJ)4D1 # 00.BHBHGL/40T7
MRZ'0]-[XO_<OM]1R1B*EV@BP+.%XE!G("!@,)9!@0K9P4W0! PB0IQV #]O\
MO'E^\C&1C5[(40@=84TG#EL;J;N/M$B'V/FT'V?*/4-#H=>G'H1^%U>1G<96
M^KJK>T-"3C249$$P#Y64NQ2\XD#S#]CVZ'4?03!U'8<<!^$[IM8IS=DCP5EA
MG#@=XYR()%SC) D>,GR]3N3PI^"-W>.IIJ&1A])!46V5<X^EI/IH&(R3N,49
MVDX.)3[>)1>,".@Z=^@!OML1T&_EL0WQGCXN#^S144_M9?/_ ,40-_DXAOQ*
M+CR:?'AYT9;G4\2+.EC1EW+S&V&YQY@3$L>95Q[@PK6.))Y%3\JT;.! B+FV
M74D_./EDBF!RF>/\JAVK9F1*(F'KT_8COTZ] S<^K%1CV<E$X.(D9A2,A8XA
M32$Q(DC&KH[&)8)F*9]*.RH,&9# =VX1 0$=DRH]=2>3\F2;Q8SAZ_R+?GKQ
MP<1.HNY<W&;765.;H(F544$QC#L1$W77"L<M7-UG_E#F<DS_ "_W@M(D\MXG
MMF$[ZJK P-A3FL=W1-$LY$%:V"/D$&+L3MT7,=+LR(R,:Z("S=4!V7B<M%2&
MV6:BH[9% WH='3P4\4TKPQ/RXXE8R2QQ3.K, TC.L;%I#E@&8MQ'R>9:JX3S
M5DC@2SRO+)&H=U)8G"HSJ.^.@8 #MPVO8[WVZ (" =3=NH!^8.@]M#OJ @XC
M#W*CGK/=<E;;BNE,;% 0]PA\?*O9&^XTI:DE?K%!RMDK]%K,??+E5Y2Y7&;A
M(.5?1-9J+*<F9 &9F[9FJ[4;MU6ZID!,I2%Z$(0A" &Q^PF0"$+L>_E*4 V'
M4?7N'#[N7+F8PUC;$"^+LN8WR?<30W-'BGFFI[_'5UIE4:N+'BJCVJJ1]-MP
M6JI69ZG7YA[8&L@_EZR9M--&K)PU9D]Z<(.V^:Y25L%*SVZ)9Z@21*%*"0<M
MY$65@IJ*7+*I+9$PQ];:0"IMH8:66HV5<IBAV/M<G9ZP V@D+)MR,D8'UL+N
M .>$0Q;RM\P>9KSCK'M!Q#?I&QY6N[O'5&4D*G8H& F+C&^_#-PGXRR\4U@V
M[RLHQ<JXM2*SSV]8;Q<DK-(,@8NBI<:?Y:<W5^R*U=3'TY,/&\36K"XD*NU<
M6*OQU=M[]S%UF?L<['HF8TJ+F'K1R@DI?355VQ,@L299QIT5DTY:&WC33#E?
M"]KE\>3\5<J-D*EW?)D'15Z)"4G(BU2RAF+)OO4)9Y2&D\J4N1=2&8)=L#1.
M<D(Y<@2:$TZEXZ9<-")\/BH5^5Q#AW&TU1LZ5Z7PG"8"/&VC&6<8VL+90LN)
M,0K8DL43F(DA4I-W8<96EH=2:CX!JZ-,M#S=PAI-^Z;V(\BU05N&IS.2UFIU
M@P(PJU(D97Y[AI2S,@=.6(QL2/ #F4ODM%&I"DLI0 5TH?!8%MHW 1*P4!59
M4/,#*0PW9.P 8WO%=*X<RO#.I%N\QS=5215^DL5NI*+K,Q.P"N2(ETLTD*/&
MV:":25<F;2BNV5\D'#RC^0<HE!RU06;'(L;\AAS, SLG5RXERG^,T-#H6&:K
M08WO!K'#U]THB@VGI> "!&7BX-RLX;HMIA\S0C%EEVZ:3DYUDBFFE8>-'&-+
M51[HVPQ+5QW2\Z$R&YK56-BX(^WTUAS5V?FEB6LE=YNI/KW5,F$L%F&/F;;4
M%V\=-.X=H^40;Q<M,PBC8YGQ(UKKR\0.(;NSSRTR-5:K#+H9]H&:$XC*%ZO%
M)MG,=,4>'R18)^(EYJ?Q!"0F>D&;.K(R:<W&3E2%Y&OOHZ9(UB<T5QU&R_26
M.*/$D<1"U88B-G;?/MP%*1*F61'D9C-'M;Z.55L-':%95%?(<H6!PH7U5!";
ML,5+NP WA0HC<,"&0F,LU5M"81HGK5B($S,/*]#B: ER!+V".=MF4C 10F9@
M$G-Q[YZR9/H9A[S)LWCQJT<M$G#I!-1:F7*EGYSCK-&59#&EGJM+P ]I,1DY
M]=8&?J;Z!G\B%?+U&NEA9B&1E5IJ6CX]U+BW<-F3..AQ92$F]:)2\($E(WS'
M^()2V'.=RT99Q2PC;+C+ ]/A[M-0./)V8J\1(<PW,!3UK9S:WO'<W+0+9>M7
M-ODNWOR4FTJU0J=>G,?U4B3:7@H*.7<-\S7SWLL@\OMWY<*K#9="LS#?EMAX
M._Y.R@VM>2YJ"P4IG"0D2Y9>PL9%1=P?RCS,3.#IB3-!O'TRBT*KUYW].+-6
MSMKE6OO=0*)XK8D"U II9VEEW&&.2N19XS&3&1,E .;MP<23%5WB%EDM-);(
MC/OJV<QM)&BKC#L*<LK>J,LO/ 7<"O0;2,MGAA[K']]8UYA;GM&NC.J2: NH
MRU.JC8VU8DFH/BQAG4=8G$:G"OVQ9(Y8T7+1^LB$@<K$3^]G*@9277++FV/Q
M<PS))TYO%466@BVR$4E[G0(BXS].-.%K9;M7\6R=K:94L%'4FS'8IW2&I3ZL
M+BBZ<(2JC-FZ<HR*9'\4"GW+!$YCN-Q)=4K)81Y4))Q1[W:J1D?E*A9?E>QB
M[Q(A$UO!$O46L@QIE_B)-W>IV-/9??$<D1M:?*'D&$1YCZ-%\_&%7M8BYC(/
M+:XM>7(S!6+,"I$8RM!BL3,H[#=IA'-$R;1E'5'D<T8>R5$T./D:>FGC>_QM
M:;R,F:QQ:,<4GT62P7"_E58681XJUC9!+',S4Y$9;;F:%$V[I4,Y>53R@P@*
M29CN%':_6'QAEO1]XW*RJ) 2"-RHQ8O@%8<!E!PSDCAA[SE_S#%5'(-TL%"G
MZG#XO6QNC<V]RC7M.L$<7+3R994)RVK%E:Q<[)Q\\O 2HI2#%DJS1;H)N5%A
M1734-P;;A#+-'QMB_,-NHDY XQS1^-/ZEUQ?IM?HFY!2I!&*LHQWL72SMN$<
M]<))I#)M(_Z42*N[AQ?LFKIRC);SL>)I1>9_%4KBJCX6L]!9NZK0*RPG)^TU
M:3=-TZ1S"YNSF@H\CZ]7V*;PA6N8$:DT56D'+]=2ON+%*.UG$XLS;)=GWGWH
M.:>6ZS<LC'EOBZ55H1'EX3P1<D<@VVQWBD*X1ITGCF;4MZ<_)/J8_)D:FV.P
MGGDL;U3'BSVRC7Y6><SJ4+[%?)3UU]<4K36GE&6KVU,8EA9X*014Z&0,9UW.
MU1+)48"R%((9(2@E:.8XY*6V RJM:?5C)B.TL&<,6&<1 $!5Y>%QEG5P5 P6
M(H8BRR[<5ALUQ7DUTZNT4O.TIJVQY<W#FY0C84 <3-1;HP2B]HAVYG38%Y6
M)(QR)G#8%')3+H@?]#A_+98:5L0XIR>2O0+^;BYR>-CFZA!PLG6C*$LD;,3
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MBR7;X#@7 0#TZB 0]E$0W_*'S^>N*[?FZ>8 #X=^H  #KIZ#\.X#\^W%B/\
M"BM_KLMV  _^4)@,0'T ?H>R>H?</W[UVXKMZUKIO6OM".P_S '8 WO8!O7I
MQ/#00'R+TQGKFS4&/_L)T(Z>P8'7R..AXC=JG]$5W_\ .R_[.,[* @45"[,
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M.GC+(KT_KQU3F-T=X1.518)5B>)'<&/TB0%RABDJ($J9*=02@MCL6%R"QDN
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M.L[UY8=74B3J"VY.G3IU(.%,#@G3 RI#*)%.393@*I ,F8HZ.!MF 2>4V@,
MZ\H_(>N2@4>I1 Y3 ( 8@@<O0P!H#  E$-@(#Z[^R/<=SR<N_BBX!Q\SK<%F
M'&][R35Z%$<LK+%$$O7*BYC\4VBA8FS/CW,61JFF2R0<BRM#V>R'4[? .8F8
MB)^VK5%JG)66HR$/7G["+#FXS#$YYSM:<EP8MW+"6B:9'&F$ZK/T^2LCNN5"
M&K[NR66*M.3LP6)U:I9>-%2=L,SD6R2EG>)C./W"#M\JU2W*&Y7*IKYZ.IM$
MM'3QP++'7F<2P3N3%B%%$$9614DQ*KL )%=(N<BM*-.>EIHZ2*HBK!+*[['I
M]@62+;D%F.\@JY7U-H.58%PA;;PVG74 #8Z'7E'U'9OVH;[%V/7>]B/;J(9
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MUH!^8#H=% 0[Z#L.A'?01ZCO]L =.N>X#]GU .G4=_[[Y!V#?<-B <?D1$=
M @ =._IY>FNO< WT\P>;8>@=>#O]OVCIG!'7K]SR)'7RX/\ GGKYG!_EUZ<7
M OP/G7UG.<8 [!@7&H!OJ.OU3I;OKM]W%_GB@-^!\Z^L[SC:_:_J!XR_/^J;
M+[_+_P! ]0XO\\0P\8?T>W7_ ,O;/;_>^F]O7B0>A_T.47_BF_\ </!P<'&!
M'0;^&A'[M]?Y-\<PX=W%#CQV;P64YR[ZB#CS)P#*/CM IYO(9BR%'RE 3:
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MQWHV^H=!#N/&_P"%=?OU/<JV)A)#-7J'*D$JD])3.K=\$ 2;NG0X[Y[\:U)
MT5#'N]5XH%JE##JQI:J1BN.^6$)0=S]O7B);EAQD;)O,)CNMN6QEXXUA"7E$
MP(8Q!C:\V=3;H% \HZ34]Q(B(F'R@*H;ZCP[#F-QVG#2+N94.LDY?.G"KCS
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M6:1Y,+&,Q(LM>CR/1(0ZJH^T$H>4H!KN40^(B/Y>FP#7&_F@E8]5+R><R8B
M%'T#YCT#RZ >_P 0[!T =%QZX*=5 1'13>0P;#9A VM"(CT$-"&^OH #L1$>
M'\4'%)+W]$IBJU0;NG1/>W#WWPK)M'I#[1\Y?+1[-^^;LDVY%?>73=FY4;)B
M*P)B4@ZDK9/0!9XJV;$8;'T@))7:,X/?)Z=OR\18U/7UE#<C3I%)/'RY'>)%
M'1$"[V4=,E0<=^I/3KPY?E1@71/Q K[=PFX.^,K=I<K21A)9LV7DEBQ$,U/[
MG')S,!+-XUF[--P4G(NR&%>+D$4&H+"4]LR@QP-.4+(S4_VU4JXKHPAL=+$;
MD*38]= (;#L/40#J/%;[E^5:1MM?3KU5RN=R_228^]N_I-VA$QJ:$?!Q@2!F
MS([U&/C&K1D@Z4;(JKI(E67(54YPXLO858O[1RLWI91$4_I=2.C&R8@(B)7+
MAN5,H:[FZ".@]?3>^.">+M<TU302L D45QH,MN'K2254;N V 2%W,F[R55Z
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M[CI1JN^\HICOU#0@(#]X; 1UUUZ!K?<===!7*)'"Q>GVB@( (;WZG$H%#KT
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M]42<U=?(2BEZ6@UBGCEK@<]D40/+B9V.:FH=0HT//O,3QI+&\B\B%FFC5LO
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MT(:XH)D43.10 $IA I@#8"&@V&C;$0'8_9$0$-AUZAL>^@VYEG2>@$?:KAT
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M*\MP$E9Q+Q!QD?D4SU58N4F(NLQEYBHUBX?2KK&UCC+J1C'))B9VN]B6!T+
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MQIT"+4TL4J!1A15VMHRBCITWPI F.Y ;V\4:IE$6SX"CL/MF+Y0UK0"'81
M#>Q 0*   "'F\H!QP&2IB.4S&T!CE#SE)YP*&AZ]#@40'L)O.'<=AL!#>_9!
MBCL99XD)="14_E 0V("4=CZ!H! 1UH>XZZ!L>$X ^U$3$V!C&[CL #[0#KH&
MA* AU#OZ"/'>;O2O;KW-'C'+F= 2.GJL"IS@'!'GU/0=<<8K94)76V"9,,)8
M%]8>QEW#RZ@@@]>N1CKUX7:J/O9K-C>?7E,7K\]@.M  Z#8=0T/??4=<6KO!
M4R&=E?: B#C0L[7""(>;7E(5^T PZ$0$ %-0W80Z"'KTXJ4P#GR"F(].I3;
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M0>HAL0UO?01#?V0WZ#L!WQ@V][#J/[4>W?O^7?7J&^_0>P#D-=!$-@(F =[
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M;VBFH:^.,R">!RL%2&B).UOJF7E'V@@9P.O'G;\T#YXRMTR@?SE*FKY-;,
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M@T4U33V6&EJ5/,AB501C&T ;2#W(';'<CSXV)HJ+9,IC!O8!U[#T$=!T#>]
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MR85IG *EB7W;"$VMMY@8;>Q0/G"\3V(S= 6..QW$W=O*7FK9"PP\;Y)91+6
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M]Z*;[\O_ !.*<H_@>?+P(_[LW/7K_P#*\Q3U^ C^Q>G77W]=]=Y_T'GR\?\
M#.ST/;7^EYBKH(?#]C[; .G;IQ<9X.#YT->_KCJO;_0]#]O]R\'R1TW_ 'II
MOOR_\3BG-_H//EXZZYSL]AW[8\Q3W'U_U+KKM]PCQC_0>?+SK0\Y^>Q^ _J>
M8IV&NW_6M=/F&NW0-<7&N#@^=#7GZXZK/M]'H<_?]%_Z]?:>#Y):;_O33?\
MY?\ B?R^Z>*<P_@>G+R(COG.ST("/][O%7IU]4Q_*.MCU#MP?Z#SY>-:^N=G
MON([_4\Q3L-_#]B_G\N+C/!P?.?KS]<55[?Z'H?=^U?</M\^#Y):;_O33?\
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M+W:KBC^Y(P0_;T/;SXVO$&G2IT;?T<9"433CW- Z2J1[P5''G&^)G&$+D*;
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M3VJH^_,9-(?*55-=XJV<Q#DY1-YC-'*K8C05DP,DBL!4U#$.JF!F?S996M2
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M;L(AC<W+7FC>/JC(J0DA%T\*:SBOHZ8CYA;W&Z2OU)S"(K+"(TD?+/5T^:A
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M=;&M<D^-6@I@G[T+MZ  7R[!9-KU[!OJ!@#OQ)=PT[D<K9JKRKX;BCI@F?\
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MHPCGP-A#8&92+!Q'/T2F$547 O"'$Q/9#P[KE1G20MRKB@G$FGB)#==?MQ
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M4Q*!A%9!+WE/RE$!V?S(Z+TWYA#77AG::K_BO4%EN&[8*6Y4<KM[(Q.@D/\
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M;(1@LD$FL;%.VV2IJ7/+Q;!C*Q;Q!HK!RD8U,Y35533WX0U.*V!ZEQ2K3O\
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M:1D)"141._?.W"VACO6PZ_ ->G0- 'P$.H_X@'LYJ*.:*FBCJ9!+*-X+AS(
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M@9QUZ;;'%%=8HZT41#OTT.^X=P#S:'UZ[UL>O$O/AKT!:U9MI#8B J&4F6!
MZ;#S+N"(E\VP'_?F^X0WH>PQ+UIL*[E$/M#LQ0#X=]@ [WO0Z\NNO<0#BU;X
M!F!7&0^8VB.E&9E&$;,-)1V?V>RD:0Q5GZPG/O7E,9( Z]=@ ?V0</=JZ*QZ
M)U->Y6"+!;)T5B<9+QD8'EDJ",_<Z>?+M3I)<+K8[+3@O)5W&GPB]RL+B1,C
MN<R+$A][CIY\>@[C2 +5L>TJND3*D$-5X5@*9>A2'08(%4*&M= 4\WIQN_&
M "@!2@      '0   T  'H !T#C/'F#-*T\LLSG+S2/*Y]K2,78_=)/$S:6!
M:6EIJ5/J4T$,"?\ AAC6-?R*.#BI=XRMG<R5TN!R+G%)N!V92@;H0C-,R)0*
M'F'I]D>WKUV'%M'BI5XL5<<.+'<ES)F$#R$B & -AU5..N_3H8.V_NV/'8O
MP1#6B228RE-A,X_33P[L>_U1^]TR..&^/LTJ:=M,2$A);E,7[XWI1RB/./=)
M(1GS'%)O+9UW$@]*0IU%E5UB)E*&SJ*'4,5,I ]3*',4I2_V1QT'?KT^1'K5
MG?*#6UC).(JF5VF0DG&-% 41%Q'IM7EG8)"82IJN5W:\BW64T8%' J%$QB!Y
MN%8MM?%?(4<P75]T(C.@Y<+^S\XHMXE5217.1,PAYC^P:'*F4>@G,7?0.&JS
MSI2;R3[RU+IQ+6%?W9)0W0%9!XH"*9S".OVZY0.8.@#U .P\>AVN8UDL%PDW
M%5%JE3<I(VB5&RX/0@A8V P<C<<@=,\5\$JP+=M*PJ V+I;Y)EVG<0E5#$J$
MYZAI'9@I!R\8[9ZVD\<H9]L9W5NP#5AM4#D)PK8*7>Z?4$9><=0GM%VK%K$3
MAF#B7KJD0@D>%?1C$\8YCW#%5F<I4T$CF<-$4_)M#JZTIGZ0DXA\]2.>*K\Y
M/@]N<M+*")$W+N'!X\<LHMN8X*OGDRJP<*B1%%HDJ*IC)LCY0;KE6!JD-CS!
ML=93,VL8VK,S;H-E--W%M<13I^L9=S)%U'QL,V=O'GN4>FX:MTVY2OI(ZKY5
M94KJ&=)01ESN<KY'K4.Y*XV_CV[]:Z601,("J46D"=XP!?0B >^S*0^;R^<H
M@)N/E]\3J)K5JF\6MC0145/6SF@J$I6DU'5V^"1HZ4RQ*\GH\TL2(TLJ1Q[M
MYS14<@,2?5!815WG3-O%T6Q0\V@H):FGMMOEJKU,\=.BR(7IYY#%!'(!3H4@
MK5Y2GERP,Z\K2\Y.'*E0Q:X?>\*M8^4M972"BJAT173D(I0$3>8Q@(B9B=N8
MI"AY/(HH)2@!S".AEQ?*3\B6:Q@_:V%N8IY%2!CW23>TQ)/:'6.U/"+*(+O3
M-]#[!2&%^"I0 Y"$/M(KC;/<J%+HA4INWL5\9(.EE8RNACQVE9(KRHF2*_86
MX'PR'TNNH +OS/4',6X-Y&OT>#)JW2*U"Z5U6D.(JY5686<PXO&Q$URJ%;R$
M<]<$5D&!E#HJ;<H/6B2JT=,-B(H.E&;YJ=!E(1[QD@VZ(UE71TT*/Z-41I5[
M%FIY7HIDK)1(D$R2I!)'-$["'FQ&2"-I$C$LQD6,[6EXA:9'HHX9+=435K2T
MPJ:.H-)5+435E2L,G,CI"*J-68R113C:0626I0L.%HQU8IJQ2+&@71-2>K3Q
MXJJFD_47&8@7*29O?7%:>J@LLVD?*B*:L4J4[*0=)HD6317_ *)*I^0.7VM5
MIFPD&F1HUA'S3%M.P+:R,)J(F9"%<-P=$>"QCV,N@"!1$[451<)@LZ;.B()F
M22\XI]?[HE(R6)+>Q$J,S9*K#24TX0 J:BD^A(/(9P_5$@%T[>E8-7BZH:,J
MY.HL<QE3G,.SYGL[Z]Y4>UV*?)K2D*^9TIB@Y7*D+H(=BC&&6*HJ!4P3,=-R
M=T3H*)?:+:,01$&!*M0\]+44Q:TK-#737".,K)!#)0SI3EF1T:)2S[D>98DW
M(A=U)VE>D,][EKZ&>C>6T6N:BK*BY4L?(>(5%'+%#.VZ:F909)IE;TE%B,L2
M2O)$TDBR1(8VIM>,OM7(\"5 _M4$W!&TZHF=1,4SG(40C/;'$H&3'_4BZ 2A
MWZ Z#"5>QG$23,\I>I5^!%2F-]"UAVL @GYSG'VDJ[C \GE*83") +Y0$=!L
M X1NL!AN.<+,K4ZM=I-&(K(%+3E(^)CA>+.1,NY"1EFKY=T013332,DR0 $T
M0$#F\X #FL7M\!JE%5V3(D,BY35;-%57L(_)L \HBN#=@T=BB4I@24.V %3;
M,!1Z' ,=]KIUMD\;R7=DDQ&,4<46Y<$H0JT\$PWQL&.!DG<5(7J>6:MB6X5+
MQ2)?6B1IV62GI*%@_,Y:DQI) :EF 7)Q" ?TI[D2(T;F6Y<Z! @VIL5+3EZ0
M2$\(&37+:O4]Y*>42H-WTA MYA]&(JJ"5)%18"MA553!V]8HBHZ1JW^)9%V:
M]R]TS%89:9G+(_R#/M+ZUL;)@RLE"FI X.(BFR*<6 1;V 8,V[B.ITO%HH-%
MHA@BQ7;I.TB+O9@,JP-1AZ+:;%6Y-N\5C%8TZ#=O.I/UG\:^47;NG3V(?0L/
M+1J;!0C8GF(>29*>]!^SIB7S&C2YU(T@\N"F5$WJ2SJW0-*I]QAC!MZVDV5D
MDEZ/:%P$3"NWFJQ!R# KM0"*D?18("90'29@[W\$J[?)_7=JAM44$-/?[K2V
MBO#TU,U35RRFEF8U-5&AG=J>G)JH6>;Z*>!J>4-Z4R)SZ^:!T[9]&:IOD+7)
MZFOHJFCGJKM)+-50/#3^GQ4:1MLIZ6BJG"AXXX8W-;Z$G-]4TS5^<6WN4QME
MB-M4.<"/8]V4Q"*E]H@NF</8.&CA/S%*HV>-CJMG"8_94;J'(/01X<!<ZU"5
M?)IE:LS"*JUIC(*\5R) YCA#1=I:&>FAB'. &%&+?IOFC/8F'W!-H0RASE,(
MM"*H(6L3E[E61 H#T,/;[777;X_ 0Z]=\/QNB97[' KU9(J<JXQ>=J\* @"B
ML?&W&P-8!=4FN@'8"JDB8W[=%(AMF* ;^F?1 "VBPS[<2-2FD9LX+1^C-4QA
M\GUA&\<@4G)CYS8'KGCYK/&24PZBU93[CZ,]5<Y]O9$ECJ]C.OJG:9(W"MU"
MN(TR!M -@3PH[&[93].=)JJ$%L]8*?9,8O\ J"R6NH&#H/D !V/4==-=.+W<
M4Y]]BXUYU'WM@S<['N/MVZ:O7Y_;XHI>&)6'";ZM&*F;9!:&$  1ZF]D;6_4
M/,;H(ZW]PZXO.U5,Z58KJ2G[=.#B2&WW\Q6" #OY].OSX@]\(\0MJFGECQN+
M5B''ZD/$PR?/!)Z^>>YZ\/?X-LDXI+S3R%BBT5E<Y! YH6K1C@]B5QGH"<=1
MQW_'Y4(14ATU"@8BA#$.40V!B' 2F*(>H" B A\!X_7!Q'/MVXE 0",$ @]P
M>H/W./.R\>/EW6QQG6Y>Q9^R9+2*S]DH4@%3.RDR(+I')Y$R_8\QRAH  I=C
MO8AOBJ19&1FKQ8!#0D.;T[?:'?;H.MCL>G76QZ!QZ7GX0=RQ#D#%,/EB)8^U
M<,&KB"G%2)><2F*+<\6NH(" ]0**(!Z^3X;X\XS*E?/%2SU%5(4S)KJD,42^
M42F*8 ,42B(=A >FNFM]!#7'HYX=7I-8^%%JJ2XDK;./0JL Y=3&!&21DD!F
M5G&?TK*3Q#ZKH6TMKZ\6IE*4U:_I5)U&&0;%0#./ZV:E+8_3EL8ZCA"4S@;S
M 8-:,(!\= 80 P@/;?7IUUK?<>!P8$B%/Y1/HQ0T&MZ,<"[WTZ%WO7K_ "\<
M)WYRK@']@8HB(E$W[8NR &^GV3=1WT,.]_V/4:K&$WL3[^P0#%.(B(G   #>
M;IT\HCKS"(>8=@ =!XT3E=R-U"G.TGR#8(!SWZ9P.P.[J,\/KE842K@K@.4R
M0=I." P.<@_=QUQ@'C:853R.$AUK1P_LM?:$2B ] ZB4 $/N$/CUM4_@ZUT+
M#<X6-F1U/*67D31)^OETG),';8QA'S>AM=PZ=0$.O6J='&$BY1 -CYB] #>@
M-K>P[B&MAUXL(>!S95(/G&PPN4X%$UUKB(!O7V5) $CEV(:T)5C ([T(#H0$
M!'AQ5D'I_AYK:A?M)8*L@']4L).1VSC/?/EY=>&=<Y#2ZATS6K@<B[0D]2/K
M(XQT8'N5QD]\>P<0K<SN/IG%',?GS&M@8NXV8H^9\FUQZS?)F1=)F8729(W4
M4(<I1\KIF=N\0/H"K-W"*R?V5"CPA8]-=>@]-C_+L1W^3Y?D$+>7X4MX:-EQ
MEGE;GVQG77#S%V721C',PQ3(3(T_(3)!*-86Z5%(#>RBKJS*R8OI%0I4D+$R
M3*Y.095$QZAO7>M"'RT'00WL!Z"(=>G4-[ >.4Z6O=-J&Q6^YT[(SR01I5Q!
M@33UL2HE3 _0E"DH+)D#?"T<JY6127Y>+?+;;C4TTBG"R,\3GZLL+G=%(IZY
MRN,]258,K>LIXQW'L "&P'N(!KI]D!$>W3KTT/;B57DPSSRYUSEVE\+\Q+C'
M:E3+SHX"S1:*M9<6N+1:;SC&'H61Z;8V]7ML#6'<\S"J7*7I$[=($+M1I*<Q
M4I>:Y5)*5<3\I6I:*L  -CO8:WT'?;>];WZ]>_?^4[;$1^0Z'IW^ ] U]_??
M"G7T45QI_1I7EC7F0S(\+*DL<L,B2(R,ZOL(*X#8WH#E&5P&&G25+TDAD14;
M,;Q%7!*E)$VL" 0?/L3UP0<J2.)#<U<PT'B[)^)LA<K%PH=:S?"8+E*-G#+W
M+C0@QAB2QY"L<Q;F#JS8-JDO2J3*T20)BB3JU6L]J@Z305W-NCYJ1K,<R!P^
MFIU1:IS.S69^7GG=:YYYE\95FR95H>&:_CC#RU.L=0C9>;POD*E6B//5ZCB'
M#CC%E/BD*)%6"K5=%66K;0UBDI5)RPBV\_(S[J*T=AU'J  .NH"&M:#?Q#X=
M_O'IQG8Z -_#H';TWWZ==[#U^7QTS9*,PTZ#K-"U,R5C1T[56VFK(ZR.'F-
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M@X.&;PO<'!P<'!P<'!P<'!P<''P,Y;D15<'71(@@"HKK&53*DB"'F]L*J@F
MB8)>4WM?:&+[/RF\_ET.OL;0!U$ ^T7OUZB8  .X=1'0!\!$!T/;B%*IO,3R
MV!N:?"%>YJ^6.WM<NSF2)^'A,>T5X@O5I7F"G)A6H5YQ4K#FYW^J%(HDI-_=
MV.GQ,C 6>[.V4DHP95HYD6,E:S!02>P!/OZ#. .Y^YQDBC::1(DZO(Z1H,@
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MYT&3=L5H\,7"-8RM1,<0?/<>NY%R_3*$]HD:U@LJN#V^@061#W2!BD,CUK+
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M<&,JF4$5A(J)CD*!1$Y0'FG71(8I#JD*<Q?,4ACE QB^<B>P*(@80$ZA" (
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M*MI8CE(%VQXQ=-8R;\KA$Q5D#-#+ JD(*)B8@@8>S P".OM; -]2F /AW$
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MR\14SNL+Q1Q-0Z 2%Q300(9=55=%+RD QS&64.4J2) #J8P@9,A0* >8YM@
MCQ(C(P1Y?,\94&Y#'&FP%(H;@B9P5*G(04.W--(E$OV?Z%DWKUJOHPE]LW5$
M3& =\,VP0S21MJMYDM)Q-5<#87+HY3"E[RT/YX1BD8"&\[N6F",V3-OY1,H<
MZBHE!!NL8LI7(5BMQ<+LG:K.N"39-XM*S,L_.": +NE#/)%ZX<*"!.JBB@B(
M" &,<0*'7R\?2):7^(],P5500HH+6S;>NYJFH2)84&!]=$B.5]8E9E/8C/RG
M>*M<EXU!=UISGXTND\2 -E13>D25-5( <G BV ,,#<-O3HILY^&+@]1$E:=.
M6HD*X<,$TP,7R@)0%N<P 'IHI0#8>@ZZZZVJ6R(-FS=N77E0021+KMI),I U
M\M%Z<5X^4+-=);6*JQ-642/$P#QFD9T00 'I4#I(KK$'R]$SZ$Q-[$2@ B
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M#\6Z]_<.)_B]K_[K@^>K4G3^9=C]OU*_W?MS'D/(>>>_0^0=J_NFN\OT\/\
MPO\ K]WCQ[1\*[Q%=_[CO-HZZ_['H_7K\9CX=M??KT 'PK_$5#?_ %'>;1
M >M?CPZ]_67W_)Z=.O3CV$OQ;KW]PXG^+VO_ +KK^7@_%NO?W#B>O_@]KZ__
M '+@^>K4G3^9EC]_T=>/O8K1@^_O[^#Y!VH_US6_^J'W?X+RZ_D[<>/8/A7^
M(KTUR>9LT&NH5Z/^[0_TWUZ[T.@#X=>,_K6'B*^G)YFT1WZU^/UUWTZRWIZ
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MTU2JG>IEY<89PQ"G+9R<C.1G/$4M-EK=<[O9$8R4]MN,M- [>J>4=DBIM!(
MC$A11DX10/;GH8\WLUQ#IO0#L>P^7?41#8Z, B/;KY?GP_[E'G@C+]7%#'\O
ME?HDV/0 \WF 0#>AUO6NX]0WO8#Q'PUZ."ZZ=0#I\! =A]P^H>O#L^7E10EL
M@A(<Y!"0:Z$IC%$/V8.P@(:X4-$2,U15TS=4J*.IC?[#!)UP?_#[>YX-<1J+
M>L_Z>":EG3R]:&6.11D>],9ZX!['S]>_DKMB5UY5\'3R:_O(JT&$9K*; 1%>
M-;@P6 =".A(9#RB&_0/CPZ+B.+PGU55>1K#IE5%%1*VF"%%0YCB4A9$_E( F
M$1 H;'10Z!L=!UXD=X\W]44Z4NI+_31_4@O%RC3R]5:N8#I[ATXD]IZ5IK%9
MY&^LUMH\X]H@C'Y<9X.#@X.$+A8X.#@X.#@X.#@X.#@X.#@X.#@X.#@X.#@X
M.#@X.#@X.#@X.#@X..K5FX=&4;0:TK')3+QLL\:1*KYHG)NFC<=.'3:/.L5X
MNV0,&EG"2)T4AZ'.70\=F/;\H?XPX\U'F2ROE)+QY9^QIY)OR=AKO-[5JA7Y
MTEQL1)F"J2LA$Q*M7AY0LB#Z,KJL4Y<1JD(R70C#QZZS,S86RITS/G0NC!K.
MHOD!N)MWQ-8*^]AA2"K](-$$Q3%34TW*$A?K-F0J!@1MG(:^J-1G3D-LE%&*
MSXQNM+;2IG,'*%06S,"(9MY4+T3" DY+#&#Z5_!P<'#&X='!P<'!P<'!P<'!
+P<'!P<'!P<''_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g97732.jpg
<DESCRIPTION>G97732.JPG
<TEXT>
begin 644 g97732.jpg
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M;H]7A3@3%)6O;4[#(C4)J146L+:%ZS=,8F/T.UTV),#7:    1'S\_E$1#\
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MUI-/!-GA&WZ;(2U:D7]C]1!@.6)X\S,HM^LR<D+ G_KX>]0J \!>I5[H>>[
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MB?EJ.2R1H9=90A:/>1W;#SMR(=0$/#Y@'Q=A$!#YPV 0V 1\^X@/<>X]_:.
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MNWVQUF^?58P]\4K./'#=/.Z<Z>:_J6WPRO5W6RU1M73-@R661^D:NIE^6P-
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MT7'UE2L.=QW1FH%"H3,G'#>N7R17QN 7G*:(HO6@^6U4=2&P.)4<C\XG8WA
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MR]<C3Q ^P!$?W\LS]*LWP"3&,8P!G [:ZAWV$-0^41  _E'RSG*9>O5=UO\
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MRV,Z)L23)X+)=Y*4Z.9)2K2<., A0JZ</!%=9]4W.LXGT8IM"D62&1ZKIH?
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M594T15XP"[2MLG&VQD\;UNBA*>@3(I^?MLJGZ5K1("9RL'UR6:/"G_7<F+C
M((UGTPNGM3;<XM56\-^/4$0/"Z$.;N3&ZU86X75PK6?E6E7RQS.+)%0O4PJP
M$Z251@Y6:;NRNB)!N@$DE"C(([-8/3TX06LQOD;L3BQ2$O9)+>+AR6D#>\P)
MF4%/%\O"%M:GVUG'?4DL]5,I$S-#<QR5U,.$9(PIM&-^*<6G8Q'O,C& 83C?
M&V@(A2/ZFJ-4Q63/Q]]X'V*;4HDA;"%7&1>3K7)PD,<-@YJ(V/&L;RM>'10X
MM)J#="I,7*1,($#!#,*5/TXN"=&5VY5/4O%&CX)7KU8D1MEYC#%!6LI"[V-7
M\B1RN!2]T.4:J'!P>(-(6]$YPPY8M.)BQR4G1B(0$:>B&:^, AVR=/KA'';F
MLGD(T<6*-2W-;R&4MUD6!M7K"J>Y:EGB0U!/P<@6)E+?J=82(\U+82M$A2+)
MX1N)4O4/6G<!Z P]*GIS1FK+0I1EX:4 CJRYU<;66;"Q@3>J:989"EJIQ@Y*
MX5NRE:F0P1:O7*(&V-BQ VPDQ:L&+)&D%2@#+ \8!%FI>$/$.AET.<:7XVTQ
M5BVO5]DND&40. L,8WB3A<22)(+261T&I*GT:3Y\B@<,2RK='J5[\$1AE+5!
MMJ@(#7^"DN!_#?C?9<\N&A^--.5-9ME)U2*83."PAH8'MQ;7!ST?'1H1GI"=
M2F!D>'XO20/;'&R&=G>Y#IJ_.R%8[ZZK EKC (80#A'6$&D',8DTTZ2U)S.L
M5#;D_I-[;4(PUIL)V@[!!;:<VQ4EV)=5[+<B:'11^F49=3#VP9(3)5Q0G(Y<
MY-Y71N2W33XR<B4W(%[(@T9JVYN3M8!1EQ<@X)$8^5<$CI9]41]KLF#%21<G
M,U1&V'73']3AUDI9&[VE8O><STJ[:*QU,AL(Q@'IH['F2),#)%HTUHF2.QMI
M;6%@96TC1*W-#*S(B&UI:T"8L +3HFYO2ID:0C0 T*3D%EZAVUSW.,8 QC&
M,8Q@'CM[ ^EI^7KD:>('V (C^_EF?I5F^26V]@?2T_+UR-/$#[ $1_?RS/TJ
MS? ),8QC &8WM2H*OO"*!!K>@46L>'@_Q>4A&I@T)7QF^$4*?T$IB;SZBLTW
M)]\8](FMO>6I2.H[HW!&G4E]MRPS)&, Q]-ZHK:REL!<9]!XQ+UU63U#:5<J
MY"T)'-1";%;&=]C[?-8T8HTVV:I*C9)-(6M.[)AT5%(7EQ3Z[^C5& ."DW _
MATAY&.7+EOXWU AY,.A"S55=2>%M>LZ!>X,N\;7R AR$OT*65N,=V^#SI+DB
M4B4NL?TT8W%Y5-6FJ0);8P"J_A-T>N$G"VCBJC8Z7K*QY!(:7UHBX[5FE9Q#
M>77E7YJU<M=&&Q$NB58UKF>0&K"C)(RE:>H2-6A1.+[HY+TJ901(FI>GQPFH
MJ,1.'U+QAIN#,$'M=%>D72LT-0 I:KC;(\\Q!JLW1U6>MO"N;-$2D#Q%6B0N
M#@L7M,:7GL+<:E:O DTF/C (WZ\/N+FDZ<[,TH.J2Y\\V[&K]=)87#6DM[77
M9#XF_P %C5K*5FA.NQD_9X?*9%'$DH\(.H-+RXI#%!FBG?OB&-=,/I[P_P"K
M2$9X<\>V<OD.U+H_<J=)6K""6=QIS>TTF<XHZ)#"-TJ6).<F2)I,XQ1F):XX
MODA.C^K:SG8!6#.[& 8UBM.57!IW9UGP^OXG&K#NA5$%UL3-E94:"26(L@,<
M+B,*4R]U(+U5/9T6C!1;"QF+-S-FYKTU1IQU*  R-\6Z;G R$R.[I;%.)-#L
M4BY&Q>8PBZG-!7C(4;/X98OI=K"B#L4).R5+%IZH/.7S:.LQ#6T2QT,W=G]&
MX.6WK>3:Q@&+YA2=0V#4[A1$ZK.#3&F7:+HH4YU=)XRTOL$7Q1M3I$K:P*XR
MYIE+6<V-Q*! #>FW3B"$Q"C/2;$GI2#2XT,'3-X"1?CN_<3X_P 2:.:N/<G?
M2Y5(:P1PAOT8WF7)CR%*"9."O8=WY3,VDU(B]Y)=N\#)&,M @(9W1"G1)2BI
MSXP")C%P0X:QB$,5;1_C+2K/ HU4MI42R1-O@+&F8T%17>H1K+C@!:$M.!9L
M=M-<WI'&PDJGTYLO<BA<7T]<N-.4&80Y4=+KB_RAB[%%G"$12#(M;9XDS^PM
MH["(ZK"VH5P\D3@ZUI3$\(<"P)<Z]*97N0Q%.C, W=D8G]T*;"O$HWU&R+&
M1%A/ ?A=7,2A$$A?&"DF.'UU%;9A$.CQ-?,*IL:(I?*=L278QB0X)5@.2.VT
MK*TI[)]^!<3IJ4WI2Y":OU*U .GPGID]/ZN:VD=0POB%0S#7,NF\6L>21A-
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M"ZV8X9)#FQID$GG\'B<=*F<DD>S'3,@<:/8(X[,C!&;.E3CKM(8P#!W&KZO
MT-50\G?@C]7H8<V;6?\  ?772/#)]@-$X2="#3V[1R%&*,9#HQGGQO21B[ZQ
MD\Z/ V&[YQQC &,8P!C&, 8QC &,8P!C&, 8QC &,8P!C&, 8QC &,8P!C&,
M 8QC &,8P!C&, 8QC &,8P!C&, \=O8'TM/R]<C3Q ^P!$?W\LS]*LWR2VWL
M#Z6GY>N1IX@?8 B/[^69^E6;X!)C&,8 QC& ,8Q@#&,8 QC& ,8Q@#&,X$0
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M.FH<YD$[VKAS89'-7O.:QRHN_=N5,FG@5[K]YR[DD&;<9.)H;&$$&[ !ES
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MW?CC!N*3G:<JFSIQJ>GZV9?S(LBV9TXO3RKD\5<,VKM>_;S]O?;^3Q#X?_\
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MP,#70# +,\6@&!KKKN&OCU  V ,H4Y@=-6?.TBOZ:<#J@IWC-.](JW6O%YU
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MU<QY8QC*ZDHC&,8!X[>P/I:?EZY&GB!]@"(_OY9GZ59ODEMO8'TM/R]<C3Q
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ML]J>>-+BH9(ZY VRJ%OC2^$M[NC-1":62X-QS@BT7)BU&GI2#!V,*U/T$PL
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M-RL_7+L$+R=DD\=WI*,8Q@X&[Y[C<^OZA7Q_K^+WY%Z?B]N7@_4G(_O9%_\
ME8,7_P"YRCWW&Y]?U"OI\7OR;TR[+X$1_P#N+\2/\I9=_P#,W*3\+GXPK_\
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MK_YFG_ U_P#=CPZ_^9I_P-?_ '9SC/AS)=<!0U_5H<;.VNH?^$U'YAKJ _\
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M]3?\3B#?IANO-6+-GX-^8VFNCF^ME-\U9SBNWE3OF:,8QF[FNG<ZX^R'7_\
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M/W1_'G&81ZHQC& ;"G"#[59?/\,K0_YB$Y"3;VC]T?QY-OA!]JLOG^&5H?\
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M3XO?DWIEV7P(C_\ <7XD?Y2R[_YFY2=[C<^OZA7L^OXO>WZ%Z?Y_D^?+LO\
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M/?;?8-*TU#;?<?/??;OMN/GL(CYY^8^X^N$^P"&W)GE+L [^D$-D]([!L9V
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M,XQC .!]GX=?QAF@1+1VUD$MVU[^+5_E>VG;V^/5Y=!U[>WS\0!V]OG\6;_
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MXP*C(=NI?249ZV'HD;@PKDFZ_P!8(;'-<ZMS8X:;&;I3R+& Z8U5   %A6,
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M5_4U;8D/L(ACV>25"AHT>#8B\O&C9LZITBH]M!:)'KY*90:D]-H2;MI%CG+
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MC&, 8QC &,8P!C&, 8QC &,8P!C&, 8QC &,8P!C&, 8QC &,8P!C&, 8QC
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MR)6N4&.#@ZV!*K?E[5;5EH&R"Q%05/(J7:"""D'F2BW)+O&(R<+?8K>P*8W
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M( /M !\P'S#XP]@_=#XASGL =^P '?V_/]W&, X[  ]P ._;MW[>?8/8'?Y
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JC& ,8Q@#&,8 QC& 9#K?_P ;+_WN_P#U).9EQC &,8P!C&, 8QC /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g657965.jpg
<DESCRIPTION>G657965.JPG
<TEXT>
begin 644 g657965.jpg
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M0?#TI?I]'"]M&N(J>1[PW Z[<_7H//=_Z3T_;6,S\L"._P#5C@&H>S+J@8B
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M"?\ 1R.T=0CTR-Y@DB1 X(D9/2F")(@8V V ,@$[B).?8"8)KI+ N3RLYO\
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M9[#8D9-$'^4\_.E;_3^#';1J'M4_\PZ7_-]N@#'Y[W_2"/\ M*F?RD#^\=N
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MVBS,*;ETB1C3L!"96,LQ8<$).HH2D%,$U!C*&A#"X(Q($N" 4%06E![X&DJ
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M*HRH022! @QPMV<1514 ,2 /X1-2""64P88MQ 4D0X"%)/X2% ]@")"0H;Y
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MW^87-^FN_BYYF5O-]_7[]Y=7HCFV^\A6I=":=_2]-2NIT[8ZU:D4BJ93H>1
M:6ZCRU*BC9=&E4SD.9A3,&8E%PDJ09>*I(,697+#5%8)A@18:D)*J+(4 0$J
MQ+#*(J$+A+AQ$K22DHB)4%,$*!0Q[[I4"6) !2:A0>T"/W"!_8!MZ9_/;@?7
M P?<_N@_+^.U;WB0^UC\#_A<YBKY.<Q>:-QU!S<I:5NNO/+?E3HS5',_5.FJ
M%Q"W&ZS4U#I6WU;=D;J4-NN,,UE2W5 -K0XR' 4\/WX6_&AX:?&CHZXZW\-G
M-*R\Q[78:UNV:GMM,S<[-JK1MR<4M*:'6&E[]04%XT_4U!:>%*BLIR'U-.=#
MA""2U673Z)=,W$E)I$NK21'7!B)ALJB3K*6 4:))HHT222 6AE+,,*08@N@+
M05@,%.4@E0&E0-18O;$IO[<QOV@G(]NQQB(W*-\>FT;SF8[$1/MQ#'FM]H)X
M1>1W,#F9RQYN<Z=-<O\ 6/*+E[I[FAKZ@U%3W1FGM.C]7K=9TQ4454Q2O)OE
MXO=0A+%OT_9FJNZUSK@2Q3B)XC]R>^V=^SZYU\T=/\G-.\VK_I37FM:INCT+
M;^:/+37?+:AUK75*D)HZ#3MVU59J"BKJRN4XA%*$.AM]:@EL]8*.!.6YBJ$(
MXD)OLC+PYL+,O&2#+Q=)1%!* "A25)((V4"]L!8'25PP22 .TAN2"Q#:GU N
M""Q!!#.,6G[1 [@2!VG)VCM!^A].!WV]" 9[9)&""<]CGZ<>1/Q B%ME;;B>
MJ>AU!*5M$B I25@@J3A1$C?CUOTF8D'&^XG?MM]8XID,0"*MJJ/"[/3E:[X4
MI*;AO,<G^6 <8WP<&/S)_.?7)C'!#:09],QW_?)WD[F! /!F,3ZS[]SC<G/I
MO.,8X!/TG8;9.<D;>L8/L20. /UK3Q#MR;<"_,;X3 _,]MY,QN=H_/OZ\#US
MD#L23(GMW[8.^QG' $_F02>W:1G/8QVVSP-\S]<;1.)F(G,YS\AP 5#&KW#T
MM?8C;QN6;!@#(,R/W$#M.3[Y/O[R63D@8]#VGY$';UQ[&./1VW]L^^!@8.XP
M>V3P0'I^Z(R9[[[G;&^ 8'"?V?PY>="_P.#!'L!_#><'ZP2=H.?3@;X(R/<1
MZ2"!([; 9':#QZ,[3O/:>X@Y]/GOF."]_P!V(& ,]QC,X@=IP3;S._ALQ_OY
M8, >OKG;MCW[3OZ^P' @^\=HB?2/E&1WWG,< [Y&![3W&V-_4>F1,< [9]3(
M&=R8&?201CL.!C3RN/2O*HNUQ3!CT,?WG]_ X\X_I1[?"(_C]??@<+I/7T)Y
M;[W/BW7!C>OL?I&O]/-=(& -VOE!!QN?;TX3F_P#,>OK$#.<>GT]^%*^?\HU
M^TEUV "-X:G8#]QQCY\)K9A _(?D/I.,3WQWXB@?P$'D?BQOXW_7%B:(,S&M
M5:CO_K?HS],>CGM,^_IF-HR,[Y[8@\'@CVVG\A QL=L8^NQ_PW[^V\C&<]MO
MGP#V,;9SV'?O_"1Q)TYTON2/G3SWHV*^"[F/KO!/]6/:#(.2.! P-HG$]C.?
M:1)&WI/!C_;B!/R/J3V^IX+?MC?8QW]-\YB!(,G@OSV',[A@*;/0^#UJ8&V3
MWCL=Y,[3W/\ 9/ )'K!)(&/7V@'T/SC<;B#]1&9'U^7S$&.TB",@Y[^F8,]L
M>D>P]SNI%G.VY%M@.5#3SIS,&!MV@@B<9$0?0?V;^G#'^([P]<I/%3R8UQR#
MYX::I]6<M.85L=M=_M*ZAZAK&U%27*6YVBZTL55KN]MJ$HJ:"LIU(4TZD2OI
M*DJ>Y49W&<Q )CUG<',=SF.(@^,?F-XM^6.@]+ZD\(7(71?B)U8UK%FGUUR]
MU=K)_0]8O0CEMJG'[GI2[,MN(=OM/<FV$?=J@):+#GF;B.)Y3[3]I@JE%H@S
M,.(E<O'B1A 3#B)*5@]J5)[,A204J<!VJ'+2P_=)8J2'UI"2HE) !&D%R.;
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M<*R]?X-DE5UK7J]VF\!'.ZT_>5J#KQMU#9=34M);U%$)2VPREII"A*^EDH)
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MCKOS,:63G'$N9JS%"\GGY'-8>7I1$1V\P)J"M$A*F70HQ(:H2UP.T$1 AP!
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M[^",=YS.?0  9["3D1N8X.I<-:GA^5A^N#'L?V_EV_=P./)"),Q/?/\ KX'
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M<Q.YW.\B-H[9';;;@]+![\QY^+>7/!@$]]@(.8G)_<()'K@[]Q!,2/S@^LC
M'8GVD?4CY$Y^4XQ^T-OGW/;N??Y;^DG^)CU[1P/2@'-^5OES.]JUP8&9_*9)
M_,#/M'USQYG!&,8Q[^N!V,@@02#\N#]Q\\]YVC, DR-OG$QP,9R1,Y^4R!W
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M :.LG_BKGM\,^L2?28/[YC=X( !A*/GU%1[YDIC\.\;$@_(0F,I09B"%1\A
M']A/KWX3[R3SOT^%!]' .' 2!V]VW3T?H17GMAGON59_U9W8 _#OG/\ $YQD
MD^D#[E6;_=G=Q^S[ '&_;':?EP\'PB?A1@B05R3@^J<"=R)Q'<SP9"3^RD=@
M2LC/Y 2=ORVX7[S%#8G^FFQ:@:F^ <.C>./A7W:_$^9L ,,^**LD12N]]Q!W
M]SGZ]YC;@ON59_U9Z#ZIWB ?SV/S.^P>'X<_ C&#\8@2?^S[0"<#^(@0/@0,
M9/42-M\)B <_+;!X/O,<]MP_)A8@^&V#]G4_Y[>+;Z>KW)\_##0"BK"#%*['
M_9GZ&3@>^T>D<$:.L_ZJZ(C'3'S^4=H$CU'#P$)W+:?7\9 _*,#VX!Z?Z"/4
MCJS _P#:B/S^>#PGWD!5][MR:EO7QV;!^S@_[P*BEFV#OYOR'489_P"YUF8I
M78$1\.8'YS_5WG@?<ZW(^[.'![3WQ.<B/SC?>'@( STH [#JS& =QO.QC$X!
MW!0B/PI_[YG(^7M,_38\+]X@_P#_ #X-MU^JX!PX*_X@'K3F/ 5!_3?#0?<Z
MP;TSWKM^7IO^6Q SP/N5:3_Q9[O *,3@S],YQB/4\/!"/Z*#.,+(&YQ^$9/Y
MGMO'  '9"-QNN8,' )'[B")C&W ,R3S^'.GR/TQ8_9P4_P 0.M@]J/M5^NVU
M&?\ N=9VIG?7;\Y]1_<;3P/N59'_ !5W\HS$YB-P9^>V=G@^'^@C<D?%V^J<
MB)WD ]@(D0#/P)'8?'';W']0.#PGWDG_ %3_ &/QP#AP$C_$<N71W?H=J#?#
M/BBJQM2NSF#T_03G\S\XP>#^YUG_ %5WMVCUW_U_/&.'?A/9"2( _&3ZYP,3
MF8C.>"/2"/A;CN.J9QB#V_?[SPOWD#\_=YMR'/;;UPO[.!_XXZV:R=^M?+#0
M_<ZS_JKL8(E.8V[GYYG;\^"%%5G!IG<Q^QN9_+.-XX>"$C]A&)_YPGON1TB0
M/48&T^GI*4D'X0-C(/5]<C89.Y].%3F(*@&=Q_*U&!=V%6K3PWJAX= #]N]1
M0,]6#;V<GG:N&?-'5@D?=GO^Y_LX'#PE(GO_ -\#]PQP.)?MP_D'JKI_?X],
M-_9__P 7Y=.O7X=1CT^!Y[GLZ!/<CH[[;;[CO\N,,#.XD;3M'8;XSGMQL/\
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M:!GZQ!Q"NY^GSX$C^\&1'XI]O4D[>O"L*!@;GR< &AW OSZ/@8-];,WUTP0
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M^^/W_2!ZY[8$=X"U0!5K,'?N^=7.Y?GA6%O!O$,WRZX(@2)/R!VGWQ_'_5P
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MO .)X/;_ %#\L#)C^_L)C^\0.\R>V_OCY\#T@;Y),_WS&TXQ(C'!<TW-6.P
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M3>I+^DQ*5"]5AZ5 2"(7B%#JQ[_5%<U)KT?@U7J.(_$F]5@5'>"AY*H!W@R
M3,[<5HGM E4D!.3J#ARZ]7(73#(%K4N3UQJP_8A/1DA7[12" &'[^4C1":BH
M*"IA1F?J&#M:P4)_92^<_MH=3,>Y ]H ,X!.W!%L?T'0< _SD>A/X3@[=O0Y
MGBI*KU'S%5_,ZUU.%A64&]W2 "#.[Q$S'<Y^IX1GM1<U""!K+5*0-NB]7$SL
M(D/D'?V&)]>*B_:7+PU:1DYHQNST2U>S%Z[5?J0-&#[ 9V(E)5Q7DJ'V7(32
M2SIJ02#X4%WQ</$&.EWTV=.<;X]=HGYYX(]_@>/;\#D&>V1G:/S'%,KE]YMK
M)+.MM5XQT_INZ!4YVE\$SC/MD09&,7_G$,'6&K#'K>KFK;.2E\B<^O;\XO\
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MZ?'ITZGTZXSO_P ^Z #_ #H[3^Q[^LP,@3[8.#:#'KW$F?I'8'<0/8<;#_\
M/.GT='T^#YCY?7C7^$9P(W]<;Y&^X]<^_"D.6Z [O>U#^1:],.5[Q_OR'/\
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M=[8, ",'OCZ1M(  [XCY=^!$9_+)DR9 [1)R9G<C8<"/W8.V 1\A ^48]\<
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M@. QD@P"IHOM4@P M<1W,J.Y((0ILI'["@O.20 <78&9I"@2L#NLX2HO5/\
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MFL4Z2ZD"3U*=>#KA4)E)4L#()Q''1LZR=*@I#Z$'/4$""HPK,]2@"(R E*2
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MI5 =;;?J2$I(]L@2#B,;9D>L2JCQU<AK>#_PR<J%!.$T5ANKQ,3\(*J8)ZC
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M^KT_?'PD=(6E=D 7 RH)5=DN)!@$!2$* P4@XXSX\])PPDF8A%S^ NP87=@
M]-VZ7-:)FJ"D"'!"MG2$T#!JDAP:].?+&:DL[X(0EM:NN$GK$S)@@1!P/4';
MT,<+]+8'/A/E&,Q@]Q@8 V]NVYXYX<XK,W!3I6X8$C_.%G.V<]5:F8.XZDS&
M%=^-YGG9IP) ?T_?65#?R'[#4;&!\!O Z@8@D*$0=\CB!.92"B7FH**AM9(/
MB&2:7\*UK3+7,S*BZ8"2-ZCXUMR;'8,V-0 )9))&T3GW)$?G[Q '"Q3V,J@^
M6I$?LC$[YR#D# R?;L!Q:.>.C$I <M>H6SV*V[*F8$1 O1 @9.(Q/&<<]M%(
M_#2W@1*AYHLX/TZ;B\".V2"(,)()/%E$_(L3]KA$$W27Y!J@&[@[N[=,V,9B
M(LJ,%0-/=HDADUO3?]#NX+=C>ZL)P0""L[G,P!$[B#&WOLJ,V9;82HJ^(@$@
MF4I,XQT@P1ZY]9[-0OG_ *20 M%!<7MPE:JRTM&9_#T?>]AL%&2K. !PF5'B
M0L+?4&;#6OP=_P!+6=)(!DB!42-X DD"9WXE$Y(L#]HAD%JN6#E-6"38-SZ7
MQ3,O-J): MG=V%GZJM\/$7?9FQ/G\0<,&05%)@3G]D'IR/3N.\\*2+*I"%**
M082H8)ZOB24F 00(ZC!([#B+#WBE+(5Y&C*QPC8'4%D$@# )#ZB 9 D)5_V2
M<'FKEXOM3L-.HH.5_P!X5TD(<J-44'1.\K#20HC<  224D^TD'-)"&DI5&<D
M$ !R"[ !K&IM>O5\10\KS6*4D04@/5UI2  0[DJ + N6VJ]L6_>'5IQBU:I9
M6E2$IJZ5:08@D4;34P!DE#0D[E1)V@"2B)Z)&3"<GY#>9VW^1Q!P*_\ P"<U
M-4\V=)\PKQJC3%%IERWZCI+91TE#6*K/O%%^C*5\O/K\Q02\775C 1CT CBP
M('TV&)&=NT#TD9R2,GL>/I7A6/#CY#E<Q#U&'&04H<!QHUDN 6 &@@,[E@1C
MXW]H4%<#C+/H433VB%0@H)+@$IER6(H;_&],'GL1^4_U\#@HG]E)^>_\#_$\
M#CI'ZC;\(_IZ_3'D&X>OUY=/'ZML/F'W3O\ K1^Y!]OW^^^XXUS[>F3_ %F"
M)Q/R[;\;#\><Y,1YP)V,_ <Y^0^0$[<:X[9^0VD?+)P!(S.<QPY7@#04W+GU
MHWA5]L/5[QP)'N8]/4=L03N-\;9X*!]1@8(_<!!,#Y$0(&./0@=HG'R[C_7'
MRSP6#[Y!F/4R!)^>V\;#A* .3=O.U68%MO#J:M^OKZK@3V.!L9SZ8G8@YGOG
M,08'T)P3F<[X@R>^_MM!' !D;$",8/\ 5M[9G]T@_F1\^^/I/;,;G,<)4$.0
MU+M0T-@:;. 6WLV# S^?YC\A)C DG/J,'@#U]S']\'/<1N/7)$3/OOM('IWG
MN,G';TX';'YF9]LG)^O;$0>$+4<5W)&U [N*==^CX,#&>T0!OGY#Y[1Z<#)Q
MM_?$?/<[Q$$<'^>/61V[SO\ OSOP#_&!L9.\[?G^>TSP[HQ-7.YLFNYH]&)-
MJWP8(_, >OH>_>-^Y^69X'Y3WR1WQD3_  S)VR.!WWS$SD?3,Q&)]=^V2)!]
M, '>,$SW_P#:SCU[P"@#L.0'*H<.+;5#-R>Y<P??W(]C]?X2!@'YSP>V>_T$
MF.WS@8]N/,CM@ 9_/8_O_.1/!SF?I,=Y'_RPC)VQG,<%AX4WZ,_2O)PST);!
M@Y[R ),SZ[;_ )0,=L]N"S\C@2!V_?@^F8P3P)_=W/M,_7!!.PGY G$SF)@Q
ML1\XSV@Y[&".R'T-.>S$O>QJYH16M\&/(!VR.^/F<>NWI'KF>#'M.?E.^_[R
M=N_; X @P=MP,C^K![>H' ^D$[>\'()$1MB=Q!SD<+S%4AB_+8;BNUCS;9S
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M.Y/ZQ8P8$3_)V<;^G:3.4A%*GJ$-4R!F07$9,P(B^G:=S@3CWWVF$=0'12I
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M,SWP2@CO_6?23'[@=AD]AP!WV[Q .VWKC82 1'>.$ZG8IO<.P-P.5^C@"^#
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M&@*_ZQP(BT@DPQ 6ZR&(0"Y92J $V%6OB+C1JE)A"FDXF34UH!@$X)LP'5F
M)F?R.=**L&5.-","'ZY4R?464Y ]!,_+B9%!X'.9U2$]+-.TCI!ZEV!\ D]B
M'*\I!.=\@#!R>.JI/ ;KY^$55PM-,1 !=LB5D]0SC[PHB $SZSL8S;'LNXW6
MR3D\- :JHTXB%##:2ZEZ%:7(84(*B!N6SXOM7X(""?M\9V21V4NN/$J4T3"
M25;D]YPGO;-B#255>>E;(!F25UX'_P#1@9CU!'83VV$?>5 #SF>N#/QW",[9
M_0IQC!CZS'%@%+]G_J-E8-;J:QA!@E+5I73QMB$U/2I6X"B#B 9B.%T>!"V,
MYJ;Q1OO$RM;0<1U*]0WY#P0 "$])<5)S@DCBQ!]D?%\4E,27RN7 &H+5FT-0
M)[O=;L@02"2YLUJXH*]K/!:0Z(^;3)-"F%E$1)% Y*C&+AZ6=U"KC%=S2*A(
ME19,@G#MR,B!DS91WS$D D'\/&5E50M)!+&<$FHK@,G\((M.!($]@8RH1Q8,
M[X+++3X#M.OI$?&_4M2$DB#--$G]KI(@F00!QSK7AFTPF_+TZY1L-U(I@^I\
MW>I4QY2B82"74GKQ/1U3W!R!Q<A^QGBB*A1,QE4(IT@:9B-,A>H7/V> K0 H
M?C;5^%V+5(_MBX60I AR^;J2IRKM)>7E2EBAM(F)A&MW.K1J +:B"L/"IOS2
M.B6)B?@?K51'H4V@DQW@$8[".,S:'B3)@",@UQ[X!#EF(S["3WW/%A5-X1M
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M")8/5(+VI7%&)[;^']8")&>1##"(J*E'2G[LE H+A:AL]6Q66TY6I'XFNG,
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M.VC3;:R),TUJ200,@ T0*0#! (ZP-]YX? Z4Y3'J-=4+J4P0K[YJ:X*;63@
MDU'0%B("4JR0F0# X1ZBT>'ZV*ZZ]G3R"D9;N%Q6IU !A*UH<JEK*%&#YBD
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MW**VM(2PS0.@?"54UJJ*FH<$#+CGW-;A$C!5TCJ@ @X/74^NN6[0!8LE;5D
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M&:8\NV^(W[ZXW;]066XUKQ+[5D15MLAW[NV6*-VOHG7:QU*EI4E !+,RXTS
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MK]0>*>F<=13Z#Y(W-*#5I &N]86VI>6TXH4<A_3K[37WE$*<0V\ZA"B4I<6
M%&03M1:6"4OO)95!)34+8:,)DD]+KZ"0._2,<)+^NM$4+C5/5ZITS2O.!7DL
MU6H+0R\X&!\90R[7)6KRS^/H2>@SU1OPY4,I%8T0A]R(;&EBLK?>G+?G31-Q
MIHA*<HEHZ@':!EL26.Q):!%2Z3=@S4(H^&:J==^(FDH:5YCD9I&ZW):J05=O
MM_-NAHF:5I3B$O.HJKI:PX^IMN7/+"FROIZ.M/4#PVNH^=WC$M[-8JR>#RWW
MMQC4;%#2*1SITHQ]_L#B$AS4A;+"13_=W%%I=H!E2$%X2N)?ZIY[<F::O7:'
M>:G+NGO I36BU)U;9EUYIOPIJ/NGWUQU3"E2 X6U(4<$1@\Y7>)3DQ;0[Y_,
MG2P2VRNJ=6S6_>6FZ=H*6XZI5)3+8* $J,%<F(2"3'$07!![V:PI4T.F)&ER
M5BG> [,L :5N:$48:LG(9BHZU<"HGP"DI,S+9\-(843]FFD)4E3NZG5XWQ%'
M6/B:\;5FO&HZ*G\(]+0Z8MNGE72VZM8U"]K"NN5Q:2VNJM%-INS55"Y4KZ"\
MFF>:JV3YK:0@_$GB*_,3Q:>,C4#;-ELEJUIRMU%K'3*:G3"J/DS?JFATE7-]
M27DW^[52;\EFO<(*_+?K&WPU!0@I'7Q9A:O&7X;[K9'=24'.31[NGF%.MO7C
M[P]1VEE;2U(>\ZJ>IFJ=I#:TJ2MY2TI"P4%0)X\N>-7PV_?GK8.<.DW*UJWM
M7=ZEIZJOJ'U6QXI2S6MIIJ=P*HJ@J'EU,>4N4]"R#QF3TO!FE$)S^52HL-7:
M0$*L&=2=+L#S9Z[#'=Y-F4QE)0L^QG*9]:%5,Q*<0Q$DG3=$PJ.ETLEZ%ZV"
MSB@FTZLYSHU3:>9R]'4O.5- VI',VDUPSJ_2M5K/6=L6NA8M-(_>Z!)8M'EK
M2Y3TULIQ0/E*BZ7$RH6;Z7^T>*:QS0=Q\/6HK3>+/I"DO;NG;9=J2HHV%I!6
M;)0N"R4UO6*8A(:6Q4N(4!)5UA0XFW2^)[P[76J=HF^9>BJJYT[++]5;6KHR
M[<*)ET!3"JRB=0*JD+B2" ^R@0H%)@@\>'/$QX96T%RIYL<N:=*:Q-M6:C4E
MJ8+=P<PB@<"W$J:K%D@(I%!+JL0@SQ4D\N@2*DKE\ZR]49+:EQ(4G$5K2 '2
MN(HQ*ES[P-2:$MC8XBXF_:<2(S?V.YA!AR$(0Y>%ELSG<G*PZ@ZH,*#!3#2#
M;4(?:% 0DK[HQ%JA^T.N=?3Z.72>&OFG6.:G>?\ OB:6Z6RH%BMS2G$FLJVV
MK=YCI0I*E>4T0ZI Z6Y6H$XZ'Q_:UOM>6M(>%+FAJ&C:U*;)<ZZJK:C3@LM&
MA*_/O*J2]Z;M[]SIVD#K2Q;*JJ6M93TK,$B6J/$CX?\ ](.VEOFCIA-Q89^\
M.,>:PVRVP#^-3Q"6PD[)45!)5MDSPB*\8'A?;<O8J.=^B4)TQ5M4-]357FWI
M;M%94%"6*2L*G *5]Y3K?2A9"@VKS0.E,C14P2I2\YE8FD*5I$&725:4@E 4
M0R2IKN-+@B@<<LJ'(+2M,'V/9P%*00E0FN+R4ZC10HA)9P$ZB$!G4% G#F^&
M;F_<>=%KU1JBJT7JC05-1UC%GH['J:BJK?5/HI>M\71AJMIV'ETM6FH"&G4%
M31#0 B.)3)E0"CA1'X>PC<@P2)[D;GT/$<.1G.;ESS?K=;O<N-7,:KI=,+L]
MJO2J%JO-%;ZYVF56-4S5;74[3=>IVD>8J4/T;KK'D.MK2>EQ*C(Y(F3NE2$@
M9,2!!![3)@Y)P/4CCK,O4A<K"*%C3H%04J"V6>]W"4BH&],?/'%2$HS_ #)*
M<NB90$""V71C%5$@$H@DH)C@1=3'45+91<[''L"1.=SL2.Y[3CWX'!P#G/YG
M^T1\NVW XNEGN+\Q_3UZ''-XS/\ \\Z?1T=IW1'Y;>O\>,)])@YWD X[SN(W
MW^G&=_\ GW)('ZT9!C=! VF#^4]XGC7W(CYE6,[[3/K]!\^%)K\>IY"QI>E[
ML.;E>\?[_7Y>6!]0>Q]"(CY ""?G(!WX&W?ODQ/:/IMD[3[8X$84)WGZ SO]
M9SW_ '< =QWC&"/W;?41/TX:?G<FE"4[L'^0M9L-P.XP9G,QF ?H=L1@&#[<
M")F#'5MW/J)(_+T(P.#Q]=_4]S&/W"<B8$<%OC&\[F8[B)SF1O'MPM7#T#48
MN:D?!^C;<C@P#/?N ,?OQ/J<GL!ZD0??<2/W3OC<8VR=_8<>8)C;OF!'H(&\
M$8/K&#$<&1&=HR2!OOV]0"3/[CL$K9J@I\"' 8L[%Q>IHV# ,]C_ &X/MCY@
M $^O;@\X^0[P)_CDXSCZ\ ;_ +]B/2=]LP?J9$B>"P/48.(VS\HGL/W3.5!;
MQJ!0#<-RI448\WP8!'OG _AV,B,S\PGN>!,=NT;2=]L8CMOO\CP?IVW'O/K&
M9]<Y[D[R,;S&_J!G8[@'??OZ\ - SWWIR9A4$5%P;OXEZ<^7]M_C@N_<F(R?
MW3DXGY#'MP"#)W(^F^X(B#N(B1ZSO (&($1&8'; $F8.T&#P/RGOD [Q/H1,
MS/Y3CA!^;A[^%[O=JTJ"X&# C,YVG.P^DR#_ *\\ SG _N<=^X.-H/SX&\$8
M_AO[059._P"'<_,HV]=QCW,[@>I[B,=X)!5M@&L#NU :W=C4'F^#'KWQ&_KZ
M?U?O]>"@8R<^L GT]/7TQ VC)X/>) B#'KV^6W^K@I&-_P!^YGU@GZ^Q@#/!
M6O.VP)=F!41?>S\V+8,#!&!O.^#C$;&!V,;3C@?4;_EV2(C:1[;G<YX&,[;0
M1N<[C'\!WG<G@=N_TF?GG/O\]I,2C !PYL^QND\_1NE=R8/Y[P3@_+Y []X
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MV;Q?XTK(05AOXFHE+ML(9J'\!3;'%Q)+V:Y>2E/$$WF!0:B' 7"U:2D.\=2
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ME*27)?%C=5<;4ME4%(2!!ZW D"5%*0% %)422>E)) (D3(X;"_U]J1YOP(4
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M],X$$C\^/928W_<8B!GV_,1[\%(F")Q&"<[ '()R9W]/2>$"DC\:5*<. 7(
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M2>_;'H,QG!P.!@$?4>L[8DY$9P/0D['@'JG88]"#[;_7V^?;@CDQ CJ]#[F
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MWFU/K<(GR:QEU2NC\(4&D$* V 22B-L#BG&RW.)F&-&:9GI!U:H<F@)V:TP
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M)20.*.1YAG<"%!DDR<2+!AH#JTGNJ4 5@*:H"B0Q#N;8W>-.'^#<P0J-.YG
ME8ZPE*RA2%Q%D$0]2H14DZF#A:5MI 22#:Y1V_Z:U71*ME[I:*XTU0 C[N^V
MW6#K3'46R@+#04(A;A0%R>DJ@<8=.<ON45IK?OU)IVBH*KS&U!;'FT8;4)"$
M%M#J>@$D]2>F$R5?%/%=5+X-]=62NTJYI+G+J72EDLU"FAOEDH[>JN>U.PTR
M6Z8/7&NN*ZAFII93_E"$CJ(R))EQ*#DKS=TVS;4VKG1K2L_1I?:C4"*2XFH9
M?42K[\M2$*J'FPHAEU2P6PE $] ''>RN89VA 'V";[.A&E,%;)[M$E2T'2*
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M3QMZV&'?>\[_ #(V_ GITYN?1FKCZ01_A-_C(/\ [IKP^YVA&K1CY_I>!\^
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M.VTA1"I_65:4)2 ZC=!(3$"03PF7+F%2-@J4M$I R DD#TRKIV'Q&8$Q (S
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MS-Q%PH+VO3=31TB:=I-+;7$4+XK'Z:H90%5+EQZD.+4ZI92D)E1! $X+5;5
M(2$2H D2,9D&<$S&?W8[2\.2,/[MAJB2DBI2@>TB&7&H@EG<J) TEKLP?^;#
M_:#QI._>\R96=BPX:=)AI1'5#2@B&A7=TZ0DA>HA6D%W;NA)+)VSD;HRVTE)
M;[7INPVZW4C IZ2BH[71,4E/3C9EFG;:#33:8!#:$I2!L.%2DY*:0MZZARCT
M[8:-ZL/FU3U%9K;2N5+A,E=4ZQ3-N/. YZW%+4, &,<=OS.YA_XLK$F]U%E?
MN* 7$$M)"&J?RT()74*Z  A?5"<B% ]Y/$8=.^,96I;^W9V["PPAYYM#;E+0
M.5JU)<*0272I">L=1PA*D[&<P.EAY*B)WQ)RJ88%5! +, 0&  8V]YA\<<')
MSW&>:RT:?E8T:)*P M<2(9X*.E!!4H((,2C$FA?J*EUE<GM*T:GG*33UHI77
M7_O#CM-9[?3N.U,0:AY;-.VIU^,%YQ1<,253/#6:VY$Z%U&Q<&K]HRP7=-RH
MW[77/5%JI_T@_;ZA ;J*%5;3MLUIIG$#H4TFH 4D""#)XG$+2T;%2WM5T86N
MN92Y^CGF4T]:A*D J*F$J4I*3)Z3$@$=4'AN;A2-%3A21'6>B592DJ,'JP<8
MS@^H,<01LM@I0I/V&5B!@.]!0 20+!R/4V>V(\FXUS2)%,2'F$R4P5F&I2EQ
M01$00%I03H(9J$4(L^*5^?GALL&@J;E?=-%Z4O#^F-$ZG=:19[/?*MA-@-Z\
MMZEN];YZ@JMM:KBE+%<PX5FWTJG"".+!N5U/1772FGZYFVTMN75VVCJ7:-@-
ME#%4M#@J6TE"4X9=3TS(4H*(6"9X7^9EC1<]-ZBM[RX%5:KGY92 M2'&*1Y;
M:P#U?&5)!3B5K@"3Q%/P<:AMC'+^W:>H[M?:\4;]TNMN7J5:A=%6^]7*JK'F
M$I=5YY;H*I"F0'4_Y.T$-_""!QSDM+09'.82#*0(,&9@++(2E".T2L ;%SI(
M8 @6 Y8]FF,TG^(N%#%7,Q%S67QX:0OOK48,9"E%2R% $B*D@D@DI=1+AS83
M9=.->8H%I(0XV%*;DAM2NH25(2>@G)R4Y'#DT-AID)0%-)Z&Q\*$ I(20!*0
M-@) A(SQQNGKFUY+3B5H65M H(6E04B4@J"@H2@*^$J3(DP3B..VKO+NUKJZ
M!%8ND56TCE.'Z=?14,)6F//97( 4@D )!*B8,$">.P@:4J"4E"7)*5!#I 4Q
M OR?UO1\>"9Q,SIFDHC1HR$K6(:HC+(0!I2I6D%W"7+ @FB7=CCP_4Z:HG2T
M]=+2VZ(!2_<:)+J#_1(>?2XD@S\/3W($B>-AMFR5?5Y-;0/I<R2S54KO7.Q^
M%U8,1N !ON0>*_\ 57A?YG.WL/V;6RJRB^\I<4NKJ5^=]W*U+"ELJ;6A;P!A
M7ZV%P" .)Q\IK WH?2BK/J)IG4=>^E#"E5--3-TK+0F7"IOI?"B5?$EL@G<
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M%3\03(WXCK:>=?-2[7AFFK;?<W:9U:DF0U;V@0<]"6&0\A&P2E:BL#!5Z]+
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MFZ:AIF]0??JN\UBF+=57-UEE$(!J8&A%" Q<,2GP+,?!AB5 HZ>S71.E7?\
M>[1"#0CJ_P"%P"1J);%QW.SQ+<O>0-;R:8UTWJ.H=YZ<U['R5T0FQ6HW4_RQ
MU)2UM;35%^0[64;-LL;5/:GGJV[TZZEZF0VI7W9OX J1;56\PEQ"DK?Z7HZD
M!02$^84%U*W $J;*ATI<22DJA()6H)/S>^,SPW\X?#YS0^S6KKYXM.<OB&TW
M=O'IRCM6O[+SOI])7=2M>T6F+XNGUOR[NEHLEB?T$Q<;@_5L772M/55MDJJ!
MQFEI6?O#(85GYJ>)KFKS^\6?C7T55<ZO'-R:T1X9^8]#R4Y*:>\&7(>X:\MA
MUO2:$LFJ+[S1YM:OH=%:H;U/47#45X1:+7RXN:Z:U,Z<MCSSH<=K7*FD@ 8O
M2A#V%2P))^0Z@4JUG4%!.E*5!25$G3$<!*@!0!W<L]0U34-CZ3D7)@A7F$MJ
M2D*AP*PVKJAP?#\32@E1#J06B$*(7"51Z_2-(DD*?;00E*R%R@A#F&U0M CS
M8(:$RZ4.!'46W.GYQM0>)?[0K7O(W[*"S.ZBO/AG\0GB*\0FN.1/B"K=5:#M
M]IK+KIVT<O==^=S38Y:WNCJV+-J*JH;-;.8FD=(U%126JWZJJZ>AN;59:P]3
M%[_$=H;Q1\HN<GV=/A.Y4^,WG:6/$%KCQ.(YY<WM?-:$U9S+ONC=+\M+#J%M
MBPU/\DZ&S:<O5HKJI1T&_;[2W0Z7=K:]Y2*\*:;XF=ZAR  [$!K= YY7L#6@
MQ E$,L"H!1)[K++!![SG0IG:E"P-6KB\_P"_4Z4J4M]M"0%J4HJ$!+0'FDG&
M6R4A84)"B!OPU/.[GGR^\/7+ZY<T^9E?<[?H^T772EDJZZT62Z:DN#=SUIJJ
MUZ+L3%)9[)1UUQ>;>OEYM[574,TK[-(AQ=34K8IZ=]UND/0'*OQ1ZE^T&Y_>
M!2O\>WB53X=.6?(KDAXB;5>V'=!H\0;VIN:ESU=HF\:$5SE&CO/'+RAJ=+?R
MN8HT6,75%TK1;Q7&VLK2XV5T\5?BCT+]FGXF*VMYY:BU5SF\-/VB6G?"Y8^>
M]99]*T&KM9\N&/$WRTTPRK5EL_1*M(JOS_+W6E?HR^72AMC+EP2PF]-II;R\
MAYM2+ .":"K]Z@Y,&(OO0"E FB$2D!>IREPE)"F40 Q+BHJS*O<*=./IF#S2
M90>CK05)< "EP4D@E1\J J$E2U$ ?"LCX4*/&PEYAU,H!6"#\2?PSM'5$29P
M"9(R! GCYX?&CKCG+R\\5G.FX^+/Q >+GPK>"9FQ\NZ;PQ\ZO##8+5>^4&E[
MN_8&U:_N'B+OEOTOK/6VG-5-:\2T-/#4UD<Y?5VG&ZP5-QH:;SP[=GR\J*>I
MT#H.KMVM:CF?1/Z5L57;.9(JZ%:]>TCE *BCU:M=J0W:2+S2/*K.BB:33K!
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MG#WL]S$ (7G4ME,..&B:IOLT*24C4E24EJCNG4L&P<FF+5ZW6E(AI##*7"V
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M,H,!1BR*E1XBUF(LE 4I)(T!BVG2DA(;87OC=XF1PM/QT0Y;/X$*7A08,*%
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MM(>"@?+??8==;</4TZC!$G-:ZNT]RSI&;A>:9]YYY"_NZEF!#25+Z0\Y)0@
M$)2"00 D)S'':VZOI:5LR4#"9)*0"01$R3N< $9(@$[!4NZ=*ZCMXH+W;:&Y
M,J24AJNI4U"$G!/ERWYB%0D06E))[R@QQ:R^7RR0"(*(4*&M@8BDH2EUTJMA
MWE,X!+EJ5VSLRS_,\TS*',9I"G)N3&I)3#CQ$Z8;A10D$LE+ER$L#NQ).&)T
M-XEM/:MO;5DMK-#0J?4AKKJ%5;X05@GJ4BG0I0E8$F$ISTXF.)IN6M]BC9J*
MIVS/MU%.PXRNA75?>%$I/45LU,%")4F828@Y3 '$4V-*\IM#U)U#24-LM#],
M[U=;E73TK3:U]02I0?4DI!*H0GJG8)R(/.ZL\5O*S35U9TS5:VL*M35;#M11
M61%7]ZN]53,A)=^[4Y"5N--%Q 7TN>6GJ28(@B]F,[EL&$(JYL((":(BB'8
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MTK)60"R-:3ITF@(#F] 4M4XEXHG\^F5I050))*=*(,,E"1#2D)2J)V9 B+4
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M;JZJ6JIU!>%I4&+=:T- NO/NE0('PA"96LI )XK*7+RJ%15P8) #'5#00 &
MH>K;5+ ,<1?LYF4_&1+2\6/$B1"$I2%K4HJN &[U@HJ/NA(*C1.'JYG7_2VG
MK?8WJFKJK;6UM[IZ:U6^TJ=\ZY5CJ^EJF6TVX26W"(>7$-I 48F3V^B:6H:+
MMQN[[[M;<%IJ6:"J<#[=K3"0&VH$!SLH+ZE08*H@<1$Y>5.J]27.MU3KX4?Z
M3KGZ=RQ61JG6MK2M"U2I5]V#CRG4??GI\YZK8*%+ZN@J)3Q*"GO]'9Z$UMRJ
M6:2F9!6X\\I:1U$#J*0-UF/VI.W<SPZ2AJB$S:1H0I;IA!D ) '>6DD)"CR
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M',[7&M+706.NL'FWFT:3H+GJ)%,Y2W^EMRE"MN5%1+4M*_,:<'E$H\U7PF)
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MZ>?7Y,*8LK[*Q!D-NO=*4E[J"3T.=) Z5QOQT:=7,/)(+X$I!CJVGNJ0(!V
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MSUESDHN4EVYL:XI':R\,<PF**U48M]OI=)45!]X<TN;DA@T@54* :?82V&U
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M5O\ OA+PYX2KDISC3U$P!5Z;)F2)$*]?6(DQWXZ"V_;X^'NX%/D\F^;J I<
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M572<R[W5+JC>;HPVS96F:9M773)*&VR'E,((ZG4D)G"DG/&!+<13 4D19*/
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MUEVU=I&ML]-1L,@/5-PI=4,,4E,A0^%2TT]25.* Z6@2%$P3PF=Y7F.4041
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MW/XGE?\ OX[8:4*K3W0_-W:M&!N[#YC \U9_:7N1B.WIL0?>8^L28<5W4O\
M,9. ,[1Z@Y.\=N/'2#O@R#D;=I[3D>Q QD9 "9.0=_>1L#'?Y_/WX/#?XV_0
M>@PX0HEV # BH!%KUV_(]'R>88RI8)W@C$^G]]_SX(ND&"I<P?Z]Q^0]9D#@
MBDGN9W&)A,8QC.XW^0C'!  @]1(WR209SC(DG^&-SPCAK^5[^#WPS2HJTL0U
MUFB P=RNPM3F:,<>@X=NM<C?*<X&=I]?3]_ #AD_$YOM\,_3V)GO'IQC5T@X
M*LF(,1F!B,C\YP2.,@2@"25 [1\._P"T1.8QVZLYD'@)L^[ #?Z&&H*8FK2I
M+)+%6H ;5<MSO; \T[]2^DP>T_EGY0/7&9X'FD;J7MZ")^>8'T^O&,]/[,D@
MI&0#$9DX[$Y^<8,D'$QGO,?U".VQ]S@ \+A4 +4I*%!90SE)<5:KV-15B12N
MV/8=.?B7B<F ._K.T;CUV$<$IU28A2U20.PQGV(WW@#L,R. $20)G$0 /Q&3
MD'MB>Q'?O$@/"ER:HO$/X@^67)6X7>OL#',2\7&Q_IFULL557;GVM/7>Z4E6
M*>H0XV_2MU5O8^_M)27E4)J/NQ%3Y*D@!4=(]X_!W8_ ^F()V8@Y=+Q9N;5V
M4"%!F(\1;%6F'+0A%C%DNHZ4$$!()400'.& "BH ^8HP9,$DSU8$E*4GN# /
MM$@\.?I<*"FB'"07"2,"<( DD8SN!OW''2^)/PY\T_"KS6O7*7FM9:FAO5OJ
MW5V2\T]/4G3NM-/^8%4.H]*UM04)K:&X4SE.XIA*U5=MJ5.4%>RA]H%?-Z6Z
MOU*H E9.)@0$@A0)^!:8*5))D$9,'"D%*@"1L207%0D@N+TY>&,^!F,GFV6R
M\_ET9$Y*S,!$>'%@$1$F$L!25+ J@V<$!B"#;$B=*=?2VHJ7L0 # $J(!C$I
MB"?SG/#V4C(JD6YE16!]X\U700$GH;*5!1B3)DC,Q@YX9;2B<([XCU.%0<F9
M[_(;</?;W4TS-$N M:E/A*5[%2DJ@2"#@D1D 0.W%.;8I )V(/0=WZ]-FQQ^
M8G0J)R*E5 V4Y!!?D:!]W?;"PJW4;NGZRM6%&C715BNEQ+:T-I:<-.GH*OB"
MG'(4@S@&,F>.]TGH>W*LUEHZRBID./-4R ZE"V2[4K"GPM*D **VD8"5&%*.
M04\<)>:MIC12[8VGH<<-NH49'6MU^L;>?QZ)/6! [29XD90.T\:;2Q"E6_4U
M Z4D)^*F+"6"ATIW;"#U#I@E0C:>,&8E(<4I 6D(41J.H. 0 2 ]6VV(!KCD
M9J:FX$LB'"CK!227<ITA(%?&NPW:U<-+J'3+.D[OIMEBDNEX;K:]^M;MUM:(
MNK:THZ%.]2 FG<;/2$@.%)Z@,DP.-QJ]5J;+4N5^HE6^\INZ?N"=24CS;]I:
M54!*&0PZA25CH^%3K*U(Z^KXL'A^%TS=VYJ45*PL?=%Z1++:>LI27OTZZV5G
MIC*6U22% 0$DXGAWG^7%AU1IFI_2UK9<HF7;I0I^^-LFI;%&VZD55.]T>8CI
M6WYS0ZE-^8I2B"">,J/ :&M,"+VJ$%(4%* KJ%G:QM\+8K0.+HLF82)B%VS!
M)4M2=1H7J"#4;LY<;VQ%!^YV%==<JBT7=JVZA9>M:K]74]M=K3=6*=*%KIJ!
MM+;K#JGT*^/J\LM$J 4"!&9K2.H-=6JZW+EQ9JNDIG+\BXU5?=[DFU>?7TBI
M#-MMJP]4,L-=)EIS\)/21Q)#PV:"M3_+72-72TC?W_4MSU"S]Y?"'7JM%'65
MC:5UK[B%.J9-.T/*A02GX4I/3@.CR+M5):[?6,)HT&AKN<^IK(VLMHZD6U+I
M2Y7-N0>CRZKJ9:(_4E $I*SQDS$&:[I2I"$I4-9[5+E- UR]Z-LQY8I9Y[1)
MB)"B_9Y?2B$$I*M+$.0@,D5/>%!4#;?#7<G>0.GM::)LE^NR'';]J9Q3]QO2
M:I5GJTW^H\ZGJ&Z5FE!I_O"%L]##;C:Y>4GK24D@\5RAY!N:YO&NK)<=0ZG0
MQRRYEW2CLC-.];%4%$Y;NE+M96!RB:<Z^I8;?:==0Z4$O90(,M^6:+=IO4',
M/EG4U*&4:(YLTVMM.NJZ_*J=+W6II;U1)I0I22VTE8K:4N**:9"6DER%=:CU
M=(YI_17-+F976VHI+9ISG=:7+HL*_54MGYD?HVKHKFI"PEQ*F+W:RN[4XZW'
M5N4L]9/PFI&E9&)]G,>;B!<*.E:AVIA=W2!9QJ8@"X+'D,>??M-Q#*Q)Y<.:
M5#5,2I,&&J$8J5:U)6EC4(!AFS 4(N6Q"[F-RTYIZ"YQ:&&F6K!=JG7K%>:B
MO=%11>?:K(RU6U5/=*EMYVD^YJ;(JDO4C'FA]E*%'H4 46_.\R>7^N*.VWZP
M:WU56<PG/OVD+)I[6++NF+;6V% >JDM..N43[!;35,N%"^MEX#J(A"@9]5U]
MTNKF=X<[57UU$]^@K'KBR"M2ZXP:RL<TL%!#:W6DE3C@1(4LA"H@94..LU9:
M-.WGFCX6].U2:2KO%$WS(J]1WI1IUI<53:8;32T7FI\PE;IJ6$@J*%>8R(D]
M7%*)(ZHT5<CF*T!40E*51=0)5I_%8DDO<,Q#N,68'M1XGRV% ^T2<I,B'  4
M52X45:-1%4EZ!(&S@\L5/7KFYSZO?,+17+"^6_6&C]<UEXN=7;Z).J#;M-WZ
MP4[+I=_2ZF%U+E>VP.A52Q3K'6E4-A*E \<)SVY5\Y^4]GTGK^[WW3^F.6M'
MK.TV?5MIY6.7BR(IZ+6MW2W<[C<*ZM#C];57,FJ2]6$@L*2I;0$"+&O%#I>U
MV5/A5YW7*R+TQJ2P\\Z#1ERMI"4U"K!JB[?H4J!27'W*>L2VS4IZW%(#:G"I
M) @34YL\L-(<Z^3W/+E1JFAH+=0WRW)M^B+JA37547%-EJZRWW-SS$N!*K5?
MU(:IE-MH4&G'.L*>*5BA'RJ=S!$Q+3F:([6%#,2&DQTTA$.D%1)96D!)3=_A
M9S#VQ9_,'*QVLM*Y?-!,.8@2<H9:+"BZPF)#*TAXAAZBRPX54N0[P,N_@/Y*
M<T-/U&AK1HS3%-J356B;AJ/3-]H[<3<G&$4[=+;M3U&H_,<+M8U65U$_4K>Z
MO-Z75N(DJ''9>!_2MJU7X<D7#5;;E'?.23E]Y><Q:=^F4;C8[ORQKZBUW,?=
M00M:*VA-'=:<I:3]\;<0\CJ0VN5KP"^)Y+/(:FT5KMN@;YD\EZG4')34E55I
M"KD&;!6HIFU%Q7FO?<;G2MMU+BRH *;9*>B%0W/+[GKH[EOXS?$#1T6I]/4V
MG.?'+/2FL[OIBHN]%^BW.8-!<:O3-T4IM2VJ)JZZDT^\U4W"D2Y]Y=#'FJ/P
MA);+_<$*+EDT5PU)82T=1N#$*89I4D$J(/X2*4+OP^83/$L\C.,OG)B8BKA+
M$] G5*4N+%3![Y257 4@ @&CAF8T:SQI^$'26K?$5X7+I3_I&WHYB4NK[/<K
MUIM;%GU#>&;;IEG4FEFTUK;233U":954E]?0I]31Z6H3YDQP\2'A'Y@<LF:/
M66E-6W#5%-K>\:7Y*76WZNU!6,5U@KM55;%'1-6:]VRF#;*BE"7G3=6EU*5>
M6JE)EV;!.>'/[2U5XA/"$*ZYVR@3:.96J+G0BIJ:)IFFM-#R_N=D2D%52I!0
M^JJ99HP%(0XI+<J,=)3_ !MZ_L%KY1U=ZH*BGJD7'Q6<@-?,-,I<6W9F&=16
M*CK$NJ9<?: 8;0^\_+R4MH<ZDGIZN(9B5RZ,,P5"G1!5KA)ED(<ZDKCPPJU0
MZ2L5JS\L=+D?&O'&0G)(<K/1^R1!C$B(%+AI_=1@ I!NPTD"I<= ,55>('D+
MS[T?RY5>3I/EHBT::>TVY<-8V&[7^JUVAO3ZA:F*^[55P%.W=V&JOI>>*4](
M;0GJ5L$S2I_ I1:KT93)U7J/F%6WK45IMZ]27FW7YNR4UPNZK>P[FSTU(67Z
M&F<)=IV7G75K0V'7%%3AB:?CG.FM*^$GQ/7ZS79N_P!;J73](G2UE*4IJ-/T
M]?3V^UW"GZNM3*TU-5YUU3Y"DPXME82"ISKDCIROM5=;_#REMH)MMHT^BZZT
M>0I"45#K6B*2WT-$^%D@K<KGRZOK!*G$I4A0!X64X=E1&C(C9@"F%)KF4=YN
M^5PH22]:@1"6;W22P8LN=^UGCK-I66$S.S'9KS$01]G0N LE,%2^\0Q**$,2
MVL)+=W%"7@9\']KU]S$Y\46O;2-;7;E-KMW0EH7J-517TE.Y3J#J'^AQ22VZ
MY1A+E6A!0WU+4EM*6E \/9XTO#-;>4?+&AOW+ZEHM(ZDN6I=,Z;TW8[.L4NF
M=95FJ+ST&T5]C4Z]1*80UYU2:FC6A:66S*BJ9DOX(=4VNTWCQDZI#S5.GF=X
MD^:ATRZ^\TVEFALK;%CI7S5)6I"'5.I=2 2$B!T(20>$SQ%W2SZDNWV?'):[
M7FGJ=66SG127J^L"H-<7;5IC35WNE34W!IQ)JTT;/53(HJYP!OS%J"E$A)"2
MV4RB,I2I,[IFH<>(00L:4IB+0P%&JE&HV8@C?%-7&'$:>*(<XB;S)<*!+P=(
MB1XAA%4.%K7KAE7>3J3IMS;K6_S-TUK[DAI"BM/-[2=FM&B:^QIL#/-/DE;*
MY=XTY=_OBGG:6[&I4BJH*%TOPVXA19<"7E$J@#CB7^:6F4:0U>:V_P"HM'67
M[OIVS:.YH:;7?*C5FNJ"WI;=6EQ-0!::AIP^<NX5*7&E#I4RUYBQT\7&_:!Z
M>8MWAW\5%XI:J@K+9J*DY6V_2C%34,USS-$O5UKH[^Y1LM!(H7TLUB@AQ"0M
M2<.]:29YSQ/^'G353X:]8Z$M]KH%6^S>'*NYFZ99990BAMM^T4JGJF*-FF;:
M2RP'&$5#JVV>BH6ZZL]?2K*S&6S\%79P)Y49,*5AS$:((@ 2%JB("0[NID.0
M*U'3'J^0_P#2(S]$C!AYG(9?'BKS&/)P(L25"5A$&'*Q %)4DE@8A!41I4ZF
MJ*5)7'7',+5+UPOVC.6&I><NDZ;3U$.7E_O6C*NV4NG:QBV.)N>I*2Z5#K=>
M_7.,>:M II#CP(253Q*'P%> 1'-K2^G>=O.*IJ]3LW"HNMTT%H6XU:JK3MKH
M6JI;BK[?K>^%J6Y7U)?=8MSR^BF?84[5 NX%H/A$I>67,GD3R%N+##M-5:WY
M/6Z^6Y884W::"JTU;[4Q64+J>CH9\Y]VI6BG60IUM9*BJ3PSWV>W,BJLW)'F
M1H"YU"6M0:'YN\]N7E"ZZ"CR^C4-=66EMF5=2:.E%Y6AIO"&T,,(;  7U)#R
ME4./(QLQCJ7+SP"B 3$40*,I(+I-$T(L:.+<;QK[7.(^*I+.(,JJ'EAD8J4*
M@R9THF 4@$E*6 &H'4S%W)9ZLO\ :2\D$V;P\V[FU:D(KW.6FJ=":LL5R$O(
M9MAO]M%336Y8;0A-OJ&C3^8">@MM  @%!%DEIU+3-\K>76O-)T*;HC7E]Y:L
MMEM@U"D675E33*?64M3Y70TXNG6^?U2'2'%PTE0X8CQMWFS7?P4:\Y<MOLU%
M1:.4U)0*^Z%MU=16V*GH*D5+3:04@*J:.,)E+)/3"P"&H\!7/.JJ?"QR5%8_
M]Y?MFE&+#5A+2ZP&HTY5U;-)6+6%.)H'6$4Z%M(>3YW63Y29  MPXF69?G/9
M@PA+)2HE3@E- 7T@\A7<$4Y#R^.C,\ZX1D)F-VJYB4F(HB!3MI4 H,2VH$I<
MLU2/YACA?M)^7=#HWQ]^"C52BPWIB^LU6A3<G6T+I:?4=MU.\]0TK_F0VE3R
M+PE5.LJZD!A<$J4CBQ&R\D[**6UT-V<HJ15_N#5FHJ>M+"FKQ75:'WJBC6Q4
ME2*[I;IBX62E;9;6"A/4@DP5\>E-5\_>3-S5:UK&N^7EQI^9.@[HX'TNTM]T
MRH71^G:=4P5MJNK5(IHEI2%EU20E0'$@N2G/RP\].5_AXYHKNC=-7:6<L^JK
ME0J)?6QJ5BS+M5UM=P\Y*0Q4)K$/%)6L.>2ISK)44J#I(Y%'S:9B+[!4"9+0
MTA22HU[0TN&8D/\ RUWPZ:3FR.'\LB0UQ]<M#4%:24K!+Z"#0APK2^[&H<XI
MD^T7\'^C^6GB(Y/(TS:6M,V+GA<&[)>F+8U3LT]OO-+=+;1UUPMR&J<)8=K&
M;H7UI 4LEN1 XFUI#[.'D);:.C95RWMMV=2ZNEMU5JRMN-PJ[A5^1YKOF-HJ
MZ2F54N+0M0++).4!1)3/')_:D:X8U3>?"[?:?REU]CY[IZ4LK24K9KV+6\EI
M50DN-A,TBE!A"DNK4"I,A)XN&=MMAU2KEG<4W.CMU-HS6BM27VF47&:FX6Y-
MNJ$M,4Z"0%?KE-)>2ZE0Z52DA1'%3+,LRR<S;,HBXRTPC%U2\, U".ZYN.Z%
M@5:A8EJG:S;B#B"6X:R(";GX*HLO%@K4)I8!&M)TJ(4/>"1XL=S7Y\KOX>-(
M\H?M%?#QIFR6BDT]9]8T=5J%RS4Z5JIJ.Y69RLI&Q1,OK6EIE]U#*W6E..+6
M)2A?40!=?>Z!RR\XN15@9<+5NU<NLMU13( 12UKM54)HT"H"AAQ"WPI"MD@0
M 2(%5'VG>I4Z(\;OA(YGV-SRF:5=$VZ:94*"6M;T%/5TJ"DR&ZBCJ I]*CU=
M2L$(QQ:W<;Q:-4ZAY<:E5<V:*IY>WQ=VIDK<3YE13J?34,(9<0#TJ\]*$N01
MTY4 "D'B[P^G+<KG)R%-A.E,8K2I9U$(6M3%&Y) =0JW=<6QE<50HL]E>2SB
M)F,8\676A>N*5ZXD$0W!U$Z=)6&5^(&EB<5Z^-CE?6\@?M)_";SKHBXUI/F%
M>K+HN[7%(666]24KMYM9H'_P)0JNME=35%.%J!\MI94#\/#\\_:5]WG!65-N
M0IS]-&RU=F6)*99:12J(6A)2A=-64;Q6-RF B#)X6/'_ %])SAY$ZL?86V=5
M\OZH<U]%5BW%I71ZMT8TY7LJIZHM++'WVVL5%N5Y90MPK9"%(6KK,#]+?:%4
M&OA9K9R\Y/\ -;F=K5R@IEN6G3=BHJXV:M6EHU%.Y=JA3K-(P*]RH"7:E2>A
M+J/,^,JF>0SR!DN<SWV2"9F!/)5$2I""LCM!V>@LY2VD$.=P>6(9G+9WB3*<
MJ*#KF<MAIDXI*DH1IAJ[9)UJ[O\ O2[$BAL^)#^*&R6V\_:/>#/4S3;#;%RT
MQK&S7EY2D>6M6GZ=3K?4L'I+B&KJAA+?Q.+4VXH ('%FATOIR\ZLNFE:YFF7
MI1'*11N;:F&%T55=-179^TJ9:>(+=0^U:4N5)2X"EI+7PI*S/%-&N.3'CAYY
M:\Y9<TK1HG1')"Z\LZV]7C3]+S!U<JZWJJJ+ZRVU5T]XI;!15]+3M>4S"&V3
M2K_6(E3A2KIDLSK?QGZ2M2&-><CZ;6;3(0JHN/)35U#752DAIQHNITYJQZT7
M5X(4''IIZAYB7@AECK0I/%:7F(B(V9&-D\<PYI6N$42ZU@ZD@EV# %18T]7I
MIYADDU%@Y$F7GH8C2*2F91VZ0(9$=:T]FIV62@A]"BQ<&H?$9O )R_MNC=$^
M)JUUM/\ =E\GN=&I[==6Z< 5519;=;FTVUM50.AY'F----B7 E)*>D! CA2\
M=7*.T7^K\"MU-&"KFQSNL5GI:FJ0IVL%B-JIKLNB?7U0XRE]1IPDE?5Y:RHD
MJRH^%+F)HNBK_%5IWF(]<^4>L^>G,EVOI=)<RZ->DK\[:/Y.VFW(NE&U>&V*
M*YU3]TIZEY^FH*JK#J5CR2EPF'J\:-]M/^+CPL7NB>:JT>&OG)ROU-55+8#"
M7; _64NF[M5AQ]266@Z_4(J4!#Z2BG(ZTN$'B@9;*E9+-+BIAP<P$9:(<*(1
M#*&B-I42P"DIH4N"""EML2B=SF7XN@1/M,Q]D[(!2TA1=X(L 2X,1@% LU/%
M_P"IT.FV\Q]&\N$,%[^4%EKZQ7FJ<2EE%$BL=IJ6DIDK53HI$TU$ZP6UMK \
MY$  'B'_ (-^0U!HGQ>>-'1+=(VBWV^KY;7*TM);;2XFEU.+E>$TH*D@"D80
MHMLA*8ZDJ7)21%ACNH;96\Z=$\TTUE"NTZ>TC6T"VU/I"G:NX-5C5,XRTJ5O
M-*:K%K<J4DLPA'3 )!B3H?FK;*'QO>*6OH7&?,JM"<@G:E+'07&WK=8[U2.5
M"5MK"5,O)=0XHF7.H"2$XXV)Z4R673DL:%V9*3"A1[!@50Q_Y@XV)^;8V3SN
M=S$KGDK',4 PUQT)[Q<H(-&<$@&C5&V)\6S1-AU'?.9>FZ>B:9J>6UZL%NKZ
M@E*T5JKG0"ZI<80D%;: PPY2J#DJ+Z^L?JY'$(?LZV[;I;57BWT36!+8TOXK
M]7/LTZTI26*.]TE#<*=@)5'_ #3A;*H"5.)4I,H,\2+TSS+9L&HN:]\->T\C
M7UXL=:A3#OF+4FWV55.P5-(4ZXI2BXH#8!0.8 '%6?*7GOI;1/BT\85NNFJ+
M5IPZJYC:?U11-7FYLVY-;4,4;M'<6Z=;X:;%4E :,.=0" DK5 CAF<3N6R&8
MY?'E$P50PA2XI4I*0+-<<B!=R7H=J^02&93>69U**$RKM3"*$A"ZE"TDL&+5
M<N;"E\6X<MGK=;.?/B0HZHE-!6L4-XI$]0"EKJ:PJHP"OX5!NG4$2D; P8B(
M,<N;GI^G^TP\2>K7%4X3ISEER>T]3K4II"V7KDS5OU:NAQ226S2(2A:D[^:A
M?X >,>I/&ER&TK45]WN_-+0E%>J^BI::X55)J%BZ5]0BB)4U1+I[<777ZL)'
ME);;3$I"0.HD\5&/\T_$;KKQ+<Q^;WAPT3KG5='KJLMEM8?;T%=;G:[U;;51
MHMUO=J'*Q-$VS3T])3HJ:4^;A;R^L]/2GBCGO$B9U<F9*43&T1D+=""R0E2#
M=F%B U[#GC6X:X5G84'-($QKEC&ETH!CJ$)"F6F@4HA)+)#@;.32F+Z>5-!<
MM%\Y=4WFN;>8M+=!JE#MS>'^2UM#?5.U5IZ'2.EUPA096VF%-J,F4@\<_P"$
M6P6-SQ*^-#7KJ4ES5/.'1=OMSJ5M*;-'0:!HG'&'2)Z"+@ZVXXB?@"%*4,B(
M.:?'VGFI+;Y3O)GEQI0O*2&JW5]Q3;ZA#BCTAU- S?ZM3<$A0!87Y< H08 /
M4<DM"^/;D'<=7W/4G+O3?-JV:WU0[J_4"-&ZNMUOU93W6HH:6W+73,W)%';W
MV:>EI4-,,!2774%2 Z%E*DW,PSB=S&=D)A66*,M+JAK42@A0"4(%$L26T@C<
MGG?$O[)S,A(9EV4W*F/,P1#2E,U")5WTJ-0HBP.XJU<6V>'_ $S26[1O->_:
MD952775',;4%?;6G4="U6^B==IVG$I7\24NK2DM*!Z5),@D'$&?#C7VQG[1S
MQ?TK4?=?Y)<KNI"ND)^\);I6B!GI"?-<3U*(P>X,#CL*OQ-5M)0^7KJRZRY6
MUH: 50<PM/5]C;84E:0VX_=:)-PTY4-=76VIUB\-+<;ZGRTD!:A6KX:.?UCJ
M/'=XD]1L:EL]1;M96MJU6&N3=:845ZJ]-7*V*89IZSS5,.><&W2E+3BG"E/P
M$09ASS/8<2<RV83 $%4*8!6(B3#.@+3I<*J H=&+T>N,[)\CG$2V:(*HFI4H
ME.D.4ZP$.E*F8MIN'!JV+//#_8+@QXD+>S74[\:<OU_NU\>6RZ&V&GOO+;#Z
ME+ 2NF=#K1;()"@"<#=G/'%;[-J;QU> &W/MLU%)<KUS-9*%!"FRM@VVHHUM
M=&>MIU"G>I6/B@?$D\2F:YL"F;<?IV/\IJZ9I#M:U2H:K:ACIE3-57MK;6^D
MJP?U9;"4I#:CU$FNGG[S#IJWQO>"6OKG66UZ8<Y@WA0=?0C-P9Z*!0+BJ=IM
MMU=($Y7U$E4*!(B[Q'G\G/2R8;)7JAN2$T?2'8U<,&ZT8[XK<*9//2V934<=
MJDQ)-<%)%S$*"""!8.6!+!Q>V+FJCE+I*A-GL]964*+YJ>BN]9:[4ZM"UW:W
M6R37J<'E^4ML!:RII:2%)!0J>KCY6+7X7=>ZL\2_B/Y=<KKW:K!9^7FN+O:J
MREO N%3:[U;WK^^BGHJNSV]ORZI92IM!26R@4BTE #C85Q]'UQYDT%\U-HG6
MC]?6"Y:,LU]LU'2-A:FO+U""FH!JFR^@P2$ME"DP"2H+@'B!_@:NVG[IXI?&
MCJ*Z/,^?<>;].*9M[^=:IW;<%FJ864E;J&JQM$*7TH#BC.0$\9V?#*\R.5P)
M+LY?0E,",00D)$4PT%0_F;4KP'@3CH.$<\XCX<@YS/RAF(4T_P!H@H2E6E:H
M"RM*5$, ^D,YKR9QBP#[*W1/,GE[I_G#IGF6BQT=Q5<M(W2R6_2CE5_)BGTZ
M_9$45(NVTU6RVY2/K>I'T5; <46UH"5!,P;:@3MZ >GH)D$@X]OKQ$7PAVEZ
MRZ5U+27"K9K+J]?*VM>>:J5/EJUW"OJZFTTI+A4ZE++:G"A"U!#840A(XEX<
MD&9&0#W&P&\[[ #;8SCCV3)(,.7RF3EQ%$?LX02A3N=()) \ XVZ5?'DG%.;
MS.>9[F.:S04)B<,-4QJ!2>U2B"DT-?P=0;N:8+X>_3GUC^OTX'!%))F$Y]U?
MU<#C3_Y_GRW>NS'P\^<;P]1];_/D<;#^7W>WZT">WX,_W]<[".-5:@$*4N"@
M$$X4,!22#($_6)G(QMMOR7W(D_K0(G$%!]Q_'N>YXUU=/2OKCIZ%=6"1^$[[
MP-L?7/#C[W5ALX%:GX=-O)RO>-:O0G8_H/ECY _M]>;M9J[Q,\M^4])6*_0_
M*7ERB]7"F;>/0=4\P;H]7*=*$D#SJ6U6>EIX4E7EM/@(Z/-6#0\8ZRD00.KI
M 3'2%K4M24P!"0LJ6$[ DD#)'%C_ -K;5U;WVA?B,;JU*FGO>FZ:B2M14$T2
M=&V!:6VP20AM+KJU)0/@"G%J !42:X<1,1/NF#$"1']7MV)'%E0 00 +"@VJ
M.@?<5KZ#'Z6^R[+Y/+N!>%I>2A%!BR$.>F%@I(7'F80B1%4#N5Q2Q(9@>F"]
MA':#G,_([C?Z1GCU('I@F3&8^IS.9WCVX+Z^I R(.WU]H)]XSQE9 )7UF<04
MDXVS$ @0!,=\]SF!18.=B/KZW;'I"4&)%APTE*3$44ZUD(0@A)4%'5<,EB :
MW%CC(TU4O4C]0Q2UE53TAI55M534%744U.'WUHBHJF6U,4 Z4@)56*;2LB6R
M>VMCN( P([Q^[ CL)]>+3?!BVV/ /]JA4*;;<=8T'RS<IWEM-..L*<JKBV%,
M+<25-K6@)22A2"L)"%$#([>K\ '*-/CL\.'AF%UUV-!\W^2>G>9%_K?TS0-:
MC3>KEI.LOK[%EN;=K=8H:$UM"\P:"HI*QPR$HK$)2"7)2&N!1)K2^IWM[H22
M?08\O/M,R^2S/.LNS=X*,JC1D0(\)28J)B%*24"=G(E$IT*1#C(2A!42O02#
M<)I[G&Y'<9[#$#;?O&3&W 3VB1 @'U.\=A\ACWGBWE'A#\'F@.3'([FYSHNO
M/RK5S?YU\S^22M-\N[M8&OUFG^8=\T_9M5KNMPMM4*)BT6.UT[=RH[6Q4/W2
MN6\6ET3P5QDU1]GUR@Y&:F\6VNN>>O-;7OD/X;;YH73]@M.@J.CM_,3F3=>9
MNG[3K'36GEW*X!VWV$T=JO%-;ZN_IMK@56-.JAA)Z0_1R4"'(=C<%CL?UO3G
M+_M5X91$7#CP\RAJ$Q,2L)4.3B1D3,S*S@D(T&"I#!41$V4P2[)[Z%:M*BU/
MKKB&0"X\EI+G4VDJ*&R%)'4XZ%NJZ'$L(Z5*I^E*E!?470 $\+;.G]1.6)W4
MYL%W.G::Y-6BMOZ+=6?H.EN[R2JEM+EY-,NTTU74M#S13N5KSZE?JT%I0\L7
M5^!S3?@AN-;X[+O8[)SDU9HJQ^%6HNU&UKA&EJ75%BTM45[5+KVQ6SSK554J
M];V:^LT=)9-9FFHZ:IM+BOU#KBUO\-_RNY&(Y]^#:\Z5Y+:SYFZ=T7K[Q[Z
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M^Y/>??;B=_V7:4*\?_A;<6E*DCF+4&%I"TA0TIJ$)5TG=3:B'&SGH<2E8^(
M"!Q$[ 9G8;^N,D1GO&,>\\OLQ2I/C_\ "X@$@'F!4R)*<_R4U%^SL8.Y/M&\
M@31;O=)_]+^MWK2F+?&^D\+\0*B@JAP,CS3N)++[29ES "@2&"4Z0H@EU"VS
M?9=XUO!1RG\:G*BKT)K^A30ZBMJZNOT%KRA8;5?]%7YM)=I*ZF>"4U%5:':E
MJG=OEA2X&KJPV>H!]"%#XJ^=/AYYH>%?FC>N4/-6U"EU!:GQ4V6Z4R%)LNMK
M ^^\FFU5IVK>+K;M#7AEQ_[D^LUUN7YE'5)#C04?T)RV@E)6E!4E! !2#E21
M,8/H">^QSMQ4U]KD/"X?#O4IY]!"]9><ZKDVO3ZJ9KF#_+8T]5]U;LKJFUU#
M=A+I4K4"J]0L 9*DUTU"V.$ )5M4@/R% 2>@_0$T#?$_L?\ :+GO#.:P,A@"
M/F&59I&ARL242#$7+F(M*51H(4^E()4J*@,D)!B#20K5\J&E0!Y82H*$$A0^
M($%74,I $@2E6X!$SP]+%$Y<*.F-,\&BVX1UD203\)CJRK((QV,#;#)Z4+A2
MPIPCS"$]70.E&#'ZM&Z&\2E*_B"8ZNPXD#I](Z:<*&"9(W23(!/3)@[DGWWG
M>"9A%?="@+BH)W ) =W^+;8^K\XTI*M( !+)!:@9-P  2W7GT;81RUN][>I7
M5ZG33IH'4O4].;>I32W$D%/G$']8D'<+!,P1CA[;%8-:4[C$.VB['J2H*IT+
MI*I3C8AM24NJ%,$C'6.CK. D@YXVM,T:5($(25+C<"20($S/;M[^L\/GIZV=
M8;Z0D=T_A[1@1@1!SC/TXQU24(%/>4=/4=!TY$[UZ8XO,8XAG2HA08NPV-3M
MX]2?%L,XI',.UZFM-XI="7NOI$6VHM]6[05%'45*4/OEXFD;ZDE3A?!()GH
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MYJU>O=3VI5ST?;*.NH6VV=,6V@J+);M2JMCC%-3W5YIZF8>Z^IP=0 J=V)$
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M?\K"AW)^/7%C5DZ>E"I ,P2?Z0.!U$[' P=XX=2T"0G()   ,=0B01TS(/\
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M@0S%*$,D"J8@*@"0FNH  5N".8V:POAO,H20L0I902$NRU@J-$M6SZF[I2S
MT-<65>"OPL^)GPX\VO'CXAZ7PC\B^4]!SSY8<E*GDEX8.6?,/2ULLM/J?EQI
M_5-IN^A=<ZPLVE**Q4U]NC]735=PU<Q9*K3]2U=F*&G2ZW:W7%<ER&\'W.6]
M>,C3G.;3O@FLWV;O*N[Z2YF6_P 6.G=%\\]&:VL_BKJ==V$6RS6)SE=RN9I=
M%V.ZZ9U#5/ZK_P ;3U/;]9U3=,U:FF/NU=6=#N:%^VUY!U+##7-[E9SLY67:
M *UZBTB>9FDZ=V E2*2_:/J*JM=9!Z^D/66G>"!YA:2EQ$JFO?ML/#1;[6\G
MD_HKG!SCU0XDMT-OI.7][T%IFG?4DJ;7?M6:U8M;5MHNOI#SE'07*H1U$HIW
M()&,9#, LC1$+T+L4F@ <L4E_%GW"JXS3E^8)64&3.I5 1J*1:RM90;N"IV-
M7#-B W(_[/K7?AYT=8?#IKC[%[PK>+-7+ZZ.:0TSXKT<R.2&D:?F=R\I=35+
MFG=;<T-(:PTE4ZQMNO:.Q5#;^I;?2JU"U<[O2_>+?4MMNI+=L/+SPU\T]*_:
MA<[_ !*/:=M-LY&:R\$W('DEI*YT%\I7JMW77+SF5S!U!>[,K2J/\KMUNM5B
MU!;3;KHZD4U1YSS#2E*:4E-7=P^V$\9M;6FJM?*SPW:>M@<<Z+#<JWF'?ZXM
MEQ2FT/:@HZVWTZW&VRAMUYBVLM.K0MUIIM"DMI<OE]]NG>[?4KM_/[PT5-,W
M3NI;5J7D;JYG6##\!1):TGJMC3MZ;4@=(#-/<;BZX2>@8@V#EF8 !905:@Y
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MD*3E\+ZD$E*4=*E/$I-"\**HL >Z3RY7-KUPZ))3@HJ44D?T@J <@U[ZRS,
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M_>_?BQS_ .-3P^2>_P"E]9X]H_D^<28!Q&3Z<#0_YAZCI\&^?A@'MBX '_\
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M_P V9!M_\PZ.Q[$&MZMY4Q16DH"@2M"DB9'?OB".Y.?S,8/ E(/XVXD1^*0
M<Q ]9C^L#B]0?X/UXL"3_P"-3P^@'8_IC6@( ]?^#_?)'Y#)G@C_ (/UXL"
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M03UD?AXG@3@ERT,D.&-06)TN6KZ/_9R5*0#I/(> H.OU1Z/B"'A^Y7VYZO\
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MO19Y?]"TMPJ+3<*2F:8J[9K16M;@DB7;K<QIRKLR748!#E2AVG2H#J\I"%E
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M.9_F3MLVPW??F?-\)^RTRP_Q%=OW1<OI#^\WAR;I7[Y/NYD?J5#YLCJ,"?\
MH]R8&^X!VSP/N^#^J(Q)!8!WWV;$D0>W^KX&_P#''S;W_P :O,L]LZYU G':
M0;A*3W@^L3L."/.+FX9 YK\S#Z#^66H?W_YP]MH^NYX49%,4=26H+>&WR\KX
M/V5F3_OQM_NO"YU4?Q?XO]\WW>1!94!^R0R)C:1^KQZ^TXR!P18C 949._E9
MS\V^XV.?X<? U_CCYN?^ROS+]_\ AGJ(3'I_EX@;G$S\CP?^.+FW'_G6YEC
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M'974Z:=5$VPE(*_.0XVM3BUJ2V%2J<2K )DF<1!QQHZ;13>=5#I;4X&T=/\
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M33J6W$@-M+*0KK3(3U$%74<;%9@$1CJ@;#E[H^;M4LV^GZ5--^8*B$RA:$.
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M$W[C762X4[KB$L)2$]2##H^-.ZE3F9$" 1L#QWE);6J']8I8J:IT!3SYR.L
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M$=(_9_"H$9B)@$GC/T;?"8W_  B/E,']QQ^7&.V5'WRC;Z2//9_5/ 1+C:1
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MMQ&S[3>E8IOLZ?&KY(2E2/#CS"*5( 2I)3;T*"@I)D?$A)(G/3!!$@M$114
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MR'#0DT_\1BX_\E>O+Q?"_M1"O]F-K&*]>5$5'*OJU?@Q^_4'_7Z#M_Z;2_\
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MQ )&^?7/%N'#*$G<._(UTAMZ_FX8'%R$@(2 ^IZV#BHZ['IMSNFW53=<XOJ
M)R4F/AS&WKM V]!/9'II2M3+V(D)*NG(Q&\23,8GN/GT@9:[$0<C>"!.^8,&
M=_;TXTZRB0ZV%I3*V\A02! !![F1&^\&=CGB9CR(J-QN12FSDEF]+8E;F0Q;
MI5Z&[^-7I3&BX@-)"BG;(QWR,B)SVP#MZ<)K3)>JRKI5T@=1!2>GU@J(@_VB
M)( C>54.K2$/3U)!'4=CG?!F=MS@")'"O0L2PI?3\!/XHE,=Y^1R=Y$<%2'-
MJ,"?  N XW?Y8 #5R?'TJ.5=K>.$WH3B$)@?Z(A/RQ@G\OZSZ9_9WVE(^N(_
M,'.^V.%?RVY)ZO?8^A&\X!_J^G!^4WZX_P#;;]L3M]($#VX5S_*1S]0+CI7R
MPS0?YB/+^_081^C(^#(V/2)]X[_/;A-N#"50H!"%1TE1 "OQ;3(.9(/O&\1Q
MUB&&B"HD)B"!,03(&V_OW&#'HAUK J*CH2)&0.F/Z1@B3F/;W/?@=Z<P#6N_
M*C_7/"I214DFEK<GW(LU/!R,('E@1L2",F,&?Q=0V2!('[05)SPM4LNI3B2E
M*03T]R-R?7;!,$P=]E=%!3(9Z%@=1&T;J([B(P,=I^8XU:=OR'/NY!0VM1()
MF(.1C]K\Y[>D(2;,S6JU!=N5/"G4-A20UV--Z[.+M8^ ORQAZ!W2,;?#L#],
M<#IQ(3]0GT]R.WY<+)80 #/2#L0-_D9/KOWD0=^"\ILG]D]]C/?WR2?S[#&5
M<\NMQT?T\<-T%[^;=!_4>7RO?"2E,?L].%':.WL/7Z3WXP,IE!E)DK,DB>K/
MO[8'I_%6J6TH;Z0 "M02(P3B8&_:<>Q^7&5##26F0%#J()4,R"?4Y@Q!CYSW
MX1Z@@5J&>IL7\*&N "FER30N/*W>:C<R!M7"1Y04%("0.I)F !,G;WWQ\HXT
M*8!ITTRFTDS *DB0#D$8D R1 $>GKQU'E(C\0'N,&3 G?!.9Q^7"96T_2\TZ
MGXAF2!@>O>?XR=I,@JYJ304N19_A0GX;BJLP-Q;<"M+5-:;[V(&-*HZ6&CL5
M'<!()/S WQ .,C G@4U,0TJH()4M.#!)"8VR) ]L@;$ \&TTNH>!Z"0DP%8V
M, G<8[9(WSQT(;2AHM).R%=7?'2?J<^T@;Q/"$L;AZW(Z-O8LYH_(;X>BJDA
MV[P>KFZ7Y"_DUKEKD/LQ4]/*[F..D _XP:<&1"H_DO:QG96%3\CC!.;+E9B<
M0/<2( @GWP??BMS[-)'1RXYEG!4>8")R-_T#0SG?)W!W@8XLD4<;G;?TQ_5L
M/I@<8DQ[W*K.U0XKRY[>-V?@<T_[=-?\2>7]/Y["E;V?QT Y,_3]W[O]6.!P
M9)_NE1_?P.(&)JR:M_\ ;Y_ZGF'S?/Y?I]/X-L/F'G3M#HS_ .T]#O\ +C7B
M,"3_  D21D@[1&YB #QG?'ZYS_XZ),Q^Q\H'YQ^<#!)S$XVQW($R,>O>,G;$
MAQOO0>#]+5/(?(BKE>\?K88$1^1D_P!9_M!^@$0?^L[S(QF2,?($#WX'KF#G
M/RV/:8$3^1X(3VD3ZR8)^8['.\9,QCA >5>I\1M<D$CE048X;@]OK/J?<8$3
M@?/$2>#'08DF3GN0?2 .P^4[$P<\>>PB?IMC!!]!\Y(/K' ^@]!B8SOB?[,9
MB8 *7ZTO9F+4(V9R_(5&"W+S#_,8]_" (_?,;X&Y[=\[_EYW&P]Q)P8'I[$_
MQC,\$9]8V@^_RD;SMD0,\")VWQF9&/3UVR#$D GW5Q=D$==K#F/,M2E.;M71
M/H.E/KJQM@\;X&^!U3L<#$[ 1/MW X!@S(F,D2K.!C'RV],[D#@AN<SO]([
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M#OP*,=86T1('X!B)D8)[$C8XQMVA=\I)C!]^\SC;!V!S]-N$PHZ'5%"3\))
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M"5*DB#U9Q@D C;;)W&_?C&FDE9=4E1*\D0"!L D3M( ,]1W..W"H&RZL$[
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M[E(/U[[ ['<1M.2N%EP_L@CN8C:!!Z>T?UB9W'D."?A!S.(CWWSWQ@Y$^IX
MM0JY]>3/MZ'GSKAH _E#T_&I["A8_KY;(A:,0&R#N3G\.8[G$[$ 9';A,4P7
M:@A(3$^\ 002?WJ*1D^PXZE^6S@)!QU83OD0)!D;S&/8<:])3%*NH)!7!)D2
M,CT[8G??)$!/"!1&YZ5>M/T^75P)38@>1+V#WMM7K:PPAI953J4);4#F0#U
M1$#,0=X'OOVW4M@H2L)))(!@82#\A/MZ1,=CPLOT:GQAE*5&#U) "A!R1&8&
M?GF(R>-=I ;4IO!*1D$]0B1.YQV!,';(,<&H[D^3#?FW+#E::[@-N=F)Y'K1
MN@MC0#)*LH@29D1&9$&?0@9$['UXQ/-)4ORVQ, '8 R1!VD3CN)^>W"P\"I!
M2@'J)[# 2>^V"8';U!@@R3- 6X<Z"7,*"BHD1M'23&(]/RP>#6:5+CSY;_*E
M+>")TW9G#7)H*/7P%"W1MD9NDZ3)2>J#,@ 3V]_0Y](SP'*1+F.DI!P D "-
MI,C<;[&/7CH2PXHDE"3W(C .VWY#W[C@@PX 80 8F0!@ ']HP1V[G,".W"A:
MKN?AMY'=NGY*#_3YD]1RZ/Y[[XY8,&G6(E209^,2-LC$#?<9@^N_&\A 6@*"
M05%60))CZF?<9]!PJO4?6%=39[GJ!4!B.R<9,Q]9D9*<GS6% )@)(QU)!$B3
M$GJ]\$D&!N. K50$NW4&G)Z\OU?"$ [.=JF].5NE#RZC'Y4D)Z8!F3WG<]XF
M,=NY /;'5LM]*4MDE1.08)!)(&1&!CT] /5445J0CICJ4%=AG.X@'&8! VG
MX\TU&XHDK!)))&\!.(VQV!_K@9-9H7/5R[V]!RI2K80)2:D-L0ZMF%'-10$?
MEA+:HPD24E1@3\,CN<*C/;!Q!SQG\DXA"HS(C( ,1^0S)V'R'"ZMESJ,)$&
M",F(],;^I_,XX\^2[)'2(.YQ_P!J?8]L3!V!@< 4JC'U(K;S^NAPH<!M(LP[
MU=JD>!+7!;?'.N4)7/PE.(E($I.\C!.0<C;UP,X0E3,H">H3DG?;&T8@?(Q\
M1(CCJ/NJY!D")[8[#/[OX[#C6>H5$=2<J"@"1 @3^1Q[R)]>)2X#[@$NS,6!
M!^/.G5\*PMM8[4\OR!\,<XAHJ>0HE"!U'\4D$'T^0R?<C&W"CY/X@ %@J!!1
MU1)SG^EB,3M'I'&9MHE8$!1;.Y2"1U0, B,]S,@S$F>%0,KB0A$&-DP)Q&P
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M8X+H7W;5@X@'_L@Q@XC!_>-^#;ZZ=/'?TW0:1NK_ )^H/+PW+<ZX3&*8)1(
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M.<]]ML?(8'!8D".^(G&(SMZ$#U$8X$_,X[>O>, &"-XW,8GA!7:E+.X=MPU
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M\]L@=@??:.(=>-EM"N65B2M:$)_E=3J0I:T-B#0/-JZBYG9PP1N0)@'$PR3
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M^FUF<_\ 2>_;.1'%[QT+H@8&C],#)_\ <';AVR"33G$$F=HP-^#_ )":(/\
MZGZ7B3'^8[;@F,8IQ/?$GM'L?:2SDD6Y]'#:C6_AY8/O\4_<JH7NG=G^7GTQ
M1 &6MPI.Y'XVCZ>KA@#M.>!Y+0&X '^FUF>W\Z8 'OC'?B]_^0FB,G^1VEP?
M>Q6T#\@Q^?8[Y' .A=$&?^"&F!&3%CMLX]S3X@>^)^4GVHT[QY6-32OO4O\
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M%H'^CW_8_*?B[?O[^X$T8D[.-MC;R\:E\#==G^7Z_1H,1^L_(P3[P(CU_LX
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MTQBC>0 ,?(G_ %&1MD'@9CT.<^OU[23M\XXR^3B93N?V(C _TMC(Q[8WX :
MVZ-P3\$SZ[J._P"[@TU&XZUY?$E^C4M3 $[.+#GNWCN<88G!!/SVB(QGUVG.
M9WD\' ]# &)R?7W((]L_D.,I:!_HXV^$^^<*$G/RC$<#RA_H_P#<S_\ +?/8
M >H,<+I^ASHQJ[&C&[X4I:Y^J?K\.N,<@=L[;$#VSM[?7MG@C]?:,_OB!)&Q
M.V\;#*&@   C!G*)[R/VNWM'[HX'E#<=,F)/1Z>T@?Q]/3@"6W/B_KTKN[OY
M5331W#>?0<N9;&'V)DQ]9/T,=C@X@$".#/M!)'YC&,9C,S.#';C+Y?\ V/\
MN?UA0(^F/;@!H#;HV(_!M/I\6_ W,[UV!I8\_-Z4+X&LW@!;E3X_#&+>)[SC
M/;U!.<^TG& )X&V!_LD]H],^GL>,H;!&0G,?L[=P-SL>^_ +*9@A!B1^$CVQ
M\6,;[S\^!J,[[,S#\SYOY85J NXO\0#\3T\<8SOW[;8B?<1C'[OD."C/]_4P
M2!@YF#N.X[C+Y0_T??X<?..K'O&_MP/*&,(Q_H'\OQ_W_.33UI3GLUJE@XK3
M"-6A%6]:?7EX8QYP -_W"8Q'?&WN",<%M.)[#Y1,?0C![2,S/&4M [].W]#V
M@_M?PC?,\>DLA1_9W CI_I&/6<;[_P!<C$6OUWL[[[6'F[X&J*W'+?E?G3;T
MQKP1@ D",]4=O3@<;0IQ&>DY(_ >Q(_I<#@ -*<N7]/3H?3P8( +/NUO#^_I
$UQ__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g725814.jpg
<DESCRIPTION>G725814.JPG
<TEXT>
begin 644 g725814.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@!!1$E32S$R-#I;,3=:04$Q+C$W6D%!
M-#<S,#$N3U544%5473$Q-S-?,5]015)&3U)-04Y#15]+7TQ)3D4N15!3_]L
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M8S2T+8M65.$SL&>R8B(,,6B:!:]OCB86B9HQ&V./L#(B:6)H;B$3:5TJ4;K
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M9>%&J3I:.NZ#1-R<7BGJBWH[MJCV_'KW9TD"1!3L#M5>VL$3CLF>%KJM>X=
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M &6*[$1Y=+F ^%ZG!_? #T=W?9,C+RZS43<LP8$&0"(#E@"?$U?@& ^ 1 O
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MNCRYASR1B.7/KQ =?6CVFUB)H*9(KF$T5"/2--DDF6FXF9B//+(2T.*++K\
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M+P#F @/+'$.8#X0'D'@'UPUY=''D(=''D(\Q#D'(1ZNL0\?4'F#0   Y
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M#(P,N0?:W<-RHG-44Z6W.[ANIV',3%1DVG2\MN4&"(B.0(6SL*LO$?!T!=C
MY"("(\^6K,0?;!M[KC$KT&T_ FD\G+#,I?G'T;J[89X  8Y]UWG!Q<^R=0".
M8*PR'+GE_G"(ZF=P:&IU;%C*YMR)>SN",YO7-:M,2H;U:!05D2>C4(S<,TYJ
M8XG+(LPG,O(O/ 1QRQ$-5&MW9!35B1*.M$1:2:EED!2)R*XG$$3]RW>,"A,S
M4HDRCM0Y,<\MN"S+)5G@I5X.A"DU0M;G9"M4*#CX9@&ZJQJ#E+=2^])#@W&J
M310PB_FPC+.$S),4(8$YR124004VK\<>AVXX@F2FI1SQ,D;2VDAD^+=E*54F
M6IDZQ&H)5)%9!2E*J3&EGIU*8\O$TA00>5EF4<0<5EB84<5GF6:7ECGAEECD
M C[]------1],ZKK^P"LL)9%FMT.'$<<' 2.U74D.CR#L3JC$A?@&(\A# 3\
MBA$ Z1>0=6H/RHJQ:_')33%HN25$4(YX0R;_ /?AASQY<Q(3JL23.T\<N70Q
M'!O+.#F Y+L?\\,X;@)I!<\4MUU>\,1&.78QET3Q[MQPT1Y!B:9@!IO:N @
MF988.*A0 "  CQ'\'4[P^RH+/2 /B4G:GG+H=,Q(0H MR(Q  $14MB@"7 @
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MG+$5 999B<D;#Z7/3$CTA#+#-7FX*2A .QJ<>8\[ X\6VC<,0QQVU<2[''$
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M:::::::::::\,S,"L,LS,\<,,,1SSSSR#''##$!'++++(0QQQQ !'++(0Q
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M:G%]?7%$T,S0B4N+HZ.*@I(A;T",K(]4L5J3LL"B$Y!6&1AIIF08XXAX>8@
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M=P5@(EV?3=H'4()*EA.6/7S2X$)C5B4\C+GT1R]#*//H<\>0"(98V"JKA'[
MZG-(7(*!C\V?"LL<S'^U5[M9*]4;B..79SD4D5J(_@=F9CV3/).R$@.>67+$
M,1Z.M@L;B47AS82RQ&.,469DP<DS3&VAN8FQ/B <@Q)0-29&D+Q .0!CB4 <
M@#Q:[   '/D !S'F/(.7,?&/C'6=----------<!*93'H3'GB62QX0,$<8$)
MSD[N[D?BG1H49 <\S3C!YY".60XE$DE8F'J3S"DR8HY0:45GJZ_\8O$3E?\
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MFZ[<:TYJ"H+O4X:H)L05&&G3W=C9Z0W(A&=@6K*]#5*4X4>6>&(F% G!_5F
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M_P %CAQL>6)BF@?1(=CGAGV64V#8SQS' D2L\<R1E"9,9@=EED>:7F0. J!
MS#' ,<< F^,\-+83$1*%EVH4MTB,DF19CO$$\D.#)$.61&69TD.=C#<P'(>R
MYF999*>6(*1.##$,9U8ML^W2+X8X1JA:8C^..(X!W&JZ#MP]#([M@<.DF8L,
MQP%0 ']$<A#LH 9RZ0 (2Z@9VIJ+ EL;4#<4&1F8%(425&6&9H@)N08)22L0
MR,$ ',0#GF( .0CR#7(!B >OE_CGF/\ SR'0<,1Y<\<1Y>#F "/G'60  \
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MM6G9YY"(G*,Q#D'( XY\J>KI-T@D=<P1_P"ER >[,1CSEERQ#  #IJVXW/J
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MH/GTZ>'XV/N@^?3IX?C8^Z#Y].GA^-C[H/GTZ>'XV/N@^?60$!\ @/ZA ?\
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M<?\ ;]<5KY0"V_J-.]-Q_P!OUQ6OE +;^HT[TW'_ &_7%:^4 MOZC3O3<?\
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M<?\ ;]<5KY0"V_J-.]-Q_P!OUQ6OE +;^HT[TW'_ &_7%:^4 MOZC3O3<?\
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M,FY#F@Q011PE..!L?:E89BJ<$",.Q+%V."HT>GAB 6@TTTTTY '/]/\ [_\
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M1QU7?;3O\W(RAHEA;K1<KW!F)'SMTE]KI&2R81HAY[.K+C;D64UKD!Z1-CB
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MR1TF?#JLI@)?IQ6:ZQ9=M5A:]_@S\KC5A0M+8^ZBB8F^*XU(&_,A0V29G;I
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M76:L:'"P8#%)DN86B:L+,KD;,D=%#8S6/'\HI/&Q$:IPRR3H9=&\\F.0)RQ
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MW.LCQ:N%IB&(Y<1_8IB&8".&66["C,<<P >B(X",X ,P#(!Q$<1$ R <1$!
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MS8UY_ \5_I&GI-U+^;&O/X'BO](T])NI?S8UY_ \5_I&GI-U+^;&O/X'BO\
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MW4OYL:\_@>*_TC3TFZE_-C7G\#Q7^D:>DW4OYL:\_@>*_P!(T])NI?S8UY_
M\5_I&GI-U+^;&O/X'BO](T])NI?S8UY_ \5_I&GI-U+^;&O/X'BO](UU&?T/
M7#[!IFR,M9UWB[/,2D[0VY90^+)<07.K"X-Z3IJ,6D!)P%0I+#,WK## 1RR
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MTHD/7:FK#<W9/$!H^[IMMMN2EEM/U]?%87XMFUK02=;-G*.OK VQNOU&R&O
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MEACEGGGC@.(99#D CKVZ::::::U1VE6FXVO+5XDMZ53M^8;M>['VZ;2&+;[
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M#6>0>(/!R_P\7ZNL=8Y!X@Z^H>H/!XM   #D   >( Y!YM! !Y<P >0\PY@
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MR@<8?>PQPO<5ZCX=T(5XV9[6QW8BC*4X[??3"PE>4@+FV2D[%DP7'0PN-&2
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MJ&NKXC(-S:JUYA%$LV5+TC))W2"0WN<8Y$1]<LR>'G->UQS%YS1D&*NJ;_\
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M"$UA8U>&Y-3TICBJ$75B1G4<DE,T1Q=1#:W;K,P4ILH)E93]$#I2"@CN04I
MXL<H'X@7$7LO8K8=?1\KAPV'=]:VY:%/4-5MO0ZX=M439YC?%UJW)MB58$P^
M:R5'-F53FZ-IB!1+']J;840;GB<L?4282SC>@(^-CM0JR\GO;IOO@K5L+M=C
MKRBY@ICUM2^!3Y,#[>+],VA!%3)#42251A*DBJ6-L3I*IZI?"X,S%S5A1/+N
MS+1S+-O1+]_W#\@>Z**[+I=?-.,FYN9FQ](P52JQRS=#G:7(LW*'QQR>TS.?
M$8_+IDW@6MAL.D,A:I3+DBE$?'&=S+7H<E,62/BT<*Z)DV^:^[IJ13YT,YIF
M.V$21 \N[M$9$ML!XJY'%CF9HBRYV=I<KF\?>FE-$X^B=Y&>G;E3X4V91[#N
ML/LE7%CX6<*IZK+\DNZ*DVZJ;L03U?54EQ;GI<IG&=7*VE#8;,Q1AMBJR7'2
MV'+7UJ1O\*/84\O0*UF"<QC[+@=B7]EA\5;A:U5&Z)E\\W5T Q1C<JRIY-33
MYVQFZ-THBJEVQ8/1<X*&5D<L83#TD@[+'7663X(M'6:1(W%A=W)$[MCBC2S9
M,=Y&RFOR[P-F%NU2Q%[;7BG6"\3%F&(EUN\;@<&$RF$$B-(:CRBS+&+E$?,C
M)B+-:0K+=D9IAQ!9@Y8Z[&;C9[4[$GD^KJF( USB159Q#*)V$3G"32R%5JER
M.NYZ<(TDMV$'/C>O&:-C3)6.21Y!7A6#7-Y4[1IX*;24R7% K7W+8.)/PVY-
M?ME[8&C<C1QMWU BGBZPX:L-[DD1\JK&O-\LY,$N=V=!!WAUK=E)5N]@LC#)
MG5YA3:WNJV2H&U.TN9B3NNU3>]L?WMC*R]L%J0.TED)2L+E)&A-&'^+2!"Q2
MHI0=%963'9U%XL^N<)E)215G&)NTMR^(R+%.?W'>E@E9 '"[D=X-2[9MQFSW
M;]-(#@H'=L?N0%)/2084<=K=JVU4DX7C+7F4I%*7-Q<$2^.MJI(D!IY&I%!>
M2A3B80 8#TRDN*+PQ-Q:^S&VFMT%#S4^G:K.NZR#TQAC0U1FI41 'O%@F/DC
M8V5F<XO&1'%),G-E7.1<+<\RFF5@S.AI2/.5]HV]+9)OOCDKE6TRUZZN9I@S
MJW,\PP8F9R9WF-JWI#DYL)SQ&9;'X[)435(V\M0MC+Z:T QR1,D6G,;BOQ1*
MQ(MWZ'F#_8;/[V(OJ-/0\P?[#9_>Q%]1K7KQ#-Y<?V15XP.4<IAJMNU9\FLQ
M17T)7OT=K>**4]15F_6S.W24SUX;'0&Y,UQ&/*\VV/QM@E,WE+F>2DC\;/0I
M'UW9+9TA)<;7K*.S>4TH_P!,RA>8^-<FK2PV1D+DD6D,7D+M%GE,"YJR5L\A
MCZUP9E#K#9>S*,VB9P]>Q2ILQ(2.Y:8F5_0['_\ 83/[V(OJ-/0['_\ 8;/[
MV(OJ-/0['_\ 83/[V(OJ-5;WF;B:SV6[<[,W%3*KYQ8317D7D3]C$:CJB2V-
M*7E4QQI[DF*4]-#XT_%Q%AS3L:D'JP9B#/ 8<F$'.5OS8A#',RMVXO?[&:55
M$H8-MAE]]+8=MR;-X&X%+ W:K6 RE=N#B<]IT\KRSG+NQ%6%,WC*'V JBM=1
M//%Q?VZO9.?F[-2PZ,-TC^&4<1FLVFTS&R+T!(Y[MPBEGT+2%O;K&%SK%' Z
MUM?<VSUH]U$RC"WEX13Z6QS)'==,X6!+F-NP20939K"5V@_8LTW,BNT((_'Q
M#F#&S^N'_FQ%U" \A#J)\(" @/Z=:H=RW$/QIK<^R;<JKVE2#<&KCIT657:H
MB#Q#6><1]HFM77#;3 DIVKW-,;(KIE)4-I:7/KBA3J(E'5.1":&1J3O]BK,H
MR@VNX,$?SQQR!B:0#( $ S:DF&7(0YATL,TX98CR'KQR ,L1ZL@#(! /+T.Q
M_P#V$S^]B+ZC3T.Q_P#V&S^]B+ZC3T.Q_P#V&S^]B+ZC08['_#W"9Q$/!_WL
M1?4=6M:=E;M+HJ[<16%-ONQ-*NAURWL54-=6(R7S3K@]/D;3(W"1RFV3JH!C
M+EC?$('!&9XFDS3'KA<&E E0M16:M]?65 N^'9WQ"8/NTL6+0_#;J]UK&[EI
M.7;DMN$Y=Y+4<Q2VA2T)GL2KU\=Y5&H.^.DDIZ8XNT]B*U/")>E6&]IKW1J7
M/:"916415JV<Y1^/XAS%C9_#CC_YL1>'+(,0_P#F/&(<]:H=KW$0QW/[D9!6
MT7VE2(B@C"3TD*W MKM#Y,>4[MLIO^(GJ[CK5J2@\4U%I0^[<Y\SPEP>7=WD
M!#[C'&"Q8S!'F:1]!K:_Z'H__L-G][$7U&GH=C_^PF?WL1?4:>AV/_["9_>Q
M%]1IZ'F#_8;/[V(OJ-=9FCA7-=P^5S^:%1V/0^$1M]E\K?UK6G%$R1J,-*Q\
M?7=9V%*:=VJV-2!6M/[$689V(C("\,\QQQ'56CXG;,SU-<MV6QLBN:J:^@E=
M1"SJ[=G1;2,F*L%ML*5QR%PN!S)QBLT7Q[;]<:QVFL*>'ZOK<?6PB)P:2#,7
MJ2EI(M.4<9MSM)W$-NY JXXU+Z,SI6W-OMDH:OM: .+]7]CM"![?*^AUIQQQ
MB]@P$]4P21G=85.V!0H+4I&"0L;QBY,[TP)!3)%CA)NYBWJOVM4-:.X&>Q<7
M&*57%%LI=6V/LS*:\N8$')D2%L09NAS8S(37%S6H463L_NK3'64D\QXD+NU,
MB%>X)X&V,[DY;NFC<]56MM54T'(85,)0Q(%:9\CEH59.FAALRS*Q,40FSV1H
M94CM)8Y(*N?6^?QDYD1Y,6:R-OK.O?XG+X^[G7M]#L?_ -A,_O8B^HT]#L?_
M -A,_O8B^HT]#L?_ -A,_O8B^HU$E[V! J J"P;CDD&>)0TU_&UK^;%J^A6,
MLG$H5E9%)6N,Q./(R<,W.02!V5(6=K*4*$+<4K6EJ79R;&LA:X)JH5'O3BR_
M/<6Q;J*)#9_--L,$@%OV2V326UG947QIVT")T$.F[1-ZU4+T2M9D\UC/XP]P
M\]K2R%(_L*?!E)DC5(8\ZN,8Q7B&*+=I3;[8- ;(;4LJS-Q&5\.+'3;ZHK^K
ME=>1;;S8J^MIPYW!8$O$8=!)$JD(1]FCT -R<94YR)_.:C$R9NB<QD#+>#;%
M<-8;J:$J_<#!(F:SQFT(NGD*-CE#&S)9''UF"I6U/<<?"VT]S:3'6//[:Z,J
MY4S.CJR+CT&:UE=')K4)%I];>(9O+C^R*O&!RCE,-5MVK/DUF**^A*]^CM;Q
M12GJ*LWZV9VZ2F>O#8Z W)FN(QY7FVQ^-L$IF\I<SR4D?C9Z%(^N[);.D)+C
M:]91V;RFE'^F90O,?&N35I8;(R%R2+2&+R%VBSRF!<U9*V>0Q]:X,RAUALO9
ME&;1,X>O8I4V8D)'<M,3*_H=C_\ L)GZ_#_WL1?4:>AV/_[#9_>Q%]1IZ'8_
M_L-G][$7U&JQ[F[A&C&JOVNO]OK]?=KVY.,H#75=Q$F-QEM-7H8P_P WD4CG
MMBR<G"*5U"(W$XN\+5KZ[ N6N;OFRQ6-LCW(7U B'7I*>+3#FB',CC'=G\VD
M-C1R";H;+W$52XSBA8:[4A$]F-IJ:9W"$H9=(927!;>DK+.T2PJ)-5?O9C3(
M&#!*_2"1PDIU:4JV3++XD,8@SHIE[-M'LV5;9(2JV_H;EW&'EU_#&V!JMR+1
M7S_"S(O7$L6(IO;3?$V6UZ[76DMA6 Y1<^1'Q]A33*5QR3,+5M:QC\?R#F#&
MS^'+'_S8B\..0XC_ /,>,!UJIW:\0?T@-Q<2V[51M.>]Q<G3(X3*+:1Q=\AL
M7E+-#[!B6X*71A#44,?4IKM<5B+VG;=8JW!@(,BL4R.3,\4PG&<WDS8QD;3D
M;/'%R1,L+C[>64K3D*2RU;$4B58%J"L#L,%*-6D)5)#\<<PQ/2J22E"<T,R3
MB\#,,L0^GT.Q_P#V$S]7@_[V(OJ-/0\P?[#9_>Q%]1IZ'8__ +#9_>Q%]1JG
M&Y#=75NW&T-M%2O=43J52'<O<<7J5B?8W5T@.K>%F20B0FEOL[M;.,F5O'E(
M'L&2)FA*^3I)U+#UI9\;8US:A=EZ'XK!W@TC!MX% [,$T0.E5EW8W3=Z>7-B
M:FK*,5$TQFNYA8,9"PG,\D,$S[9Z2"2\J!1A%D8\.3;%)/)E)*9C:R3W! =W
M])6=O,M39O"H>8]OU/56V3^8V2F;&@:^]$ZB:>A%^JIE< )$Y]FL"!4QKK [
MGB:UQ19(FV+."D)2E?&MGO04440462046225B&!116&)91>&(<L<"R\ QQPQ
MQ#J#'$   Z@#7LTTTTTTTTTTTUKGXJ^V6^-YNR>T=JNW^70J OM\+897MAS:
M9NKXVXQRCG.6-2JY3(R0QQ^0Y/4O>X.A<8NR,;H0VLK@#ZKQ<GIL*P W+2W8
M_ <W91M'Q!J_IG=.RW%66_#8= Z+?7/<>H8X/.H_N H)VC\2H1S-1452C3!U
M%5LM"MZZ!.3L4QY3LAP+;#5261)"@,(DK='P6]Q-TI.*,3$)71#8=O0BO"18
M:>S>GF6(PBINPV1Q]SMP)EDWU^X9LR61-[/DF@ 1T'X73/%,4_E1LD.F7\#W
MPEMZM6W<OW;TTX;<K,M2"\7;>7ONK:F[$G<VBE?32EMVNW:OJ.P:Y?,D=;/Z
MR'W!7J^&FR-F*;HW)H[A@KR-3R/):66E-ZG9/"BXCC4LK.:5 FX?I\_G_#+W
M2\/[<%&8\U2_;51-3O>Y6ZWN[U%DTQ *WK^3XRIMCZR2*X^Z)5R*'O<U?T"R
MP'L2G.8.)+1#L[X)7$,93**;J&DM%5E.X[M@X>]"2O<;7NXR[88AS/VFPJ(Q
M&>I-RNU"65E9='[XXHFQ9W8ZB3E"&A7-F(-9R9JW+5K6#B?OJXC^T"R=W\?V
M:-5=/L+:%6WKB&;2MV,U-F:]W;BG6OJ'E;N^2YICO<5C?14R]S2KRL6!N<,&
MQG/4 :6M>VXK# W.AV^7A.WSN8GO%MF$*D-+(@WS[*MN6W*E#I:]2=(Y1J85
M/():]2\^>F-T#>NX,2=,W".G-:N-J)0O7*V_LC@R(<FY&:=72?\ !?W1.^\R
MS90C45'.-N&X'<YM3W03!^E>Y/<Y#'2KW:B6*OD<SC6&W"L"XM7]U2$'>ODB
M^C)Y))W',8,"\").T/#>CS;5':IEPF=Z$6VQ+X'5#W22B>O?%PNK??8C+&;0
MDM(R*RJ3L">S20Q")QS=$S4G*+)HJX61"\1<'&<U[%BW]G;VMSCD7FN3>8!+
MI0F,;%=_^Q7<]PEH;":_H2YKVB=R<:B]F_![LB\WNB"8_>\0IEX8VF6WI)ZW
M?+'CD_!!D_(&20SAFDCA)GAO-*=9"XJGMT>&_+-_W.YO9J>(Q_.)2*@;9DMW
M;1K2VY[E8&LW$[DMME2U_)[6W%VE>ZDR))Z2CJ9]NS;PW(+:=HC)*6DQ\'52
M-:PHW]I>&?)T MIL3NBX+&_>2.6]2E=OCQM26;>=Z3#PRU;K.+(L"WHK/:Q7
M\/>'U;"E4188DCAEG92%'/L:P;7=HD4@FJU:U-QRAI?3WAY.!^*L=->$INXD
M5_VO)T<CV^8U9)>-ALRXI,/=3YS8),[.@=+MK2S6S6\CBF-6J&%ME.**--"F
M!*VV7NS7(%2UQ(?5,8(2I#SNH0#A2[Z8FAL;; NC'#FFNV)KM'?[<U>7!=L%
MF=M7'9+EO!C\V016 RR+-S3!7RELVM3/G2.W%;%57#E-I;6[:CB$3[EE*#E&
M7 ;2=GO%,X=<*W#VK$6BO)'BBI_;53&WG:/*-PMV;UV7T6LEM1QFGCI [5D5
M0UU<E,TPAK1Q>&VHJ+6R>3P6$/:H999TY:(RPN+^7L\X@NQ6V=UVY/8[<5>R
M& ,\;VTQS?NSSA%+71^0/3HIW0[1Y10D ,BZ=ICCTC6$M,N>4CC*\W)>T9HH
M_@>K:L'A?C@V&:P7/@4;A9/1%#TLOL.E8CE!>"A</#JFT@C;I+%H8WU/)?6<
MV9I6QH<H(T9OU6K'>&O.$N=7 ]AE9Y#PH-2QE6K<%!A%WMN%(<5&OVN<6<[U
M7PPZ]NQZ1[1Z68HQ%44]7HE-&TFE5M-LRB<WK&ZYB-C2N1.C>ZK_ %/U1K6D
MV!U/@5D2O>7/-X=,S=XH#U=8X\^8^ >KES'H^'U^CRY^MSY\NK6>8>,/.&M3
M7&*V[W)N4VG2V#5A4-/[CV3**627*:"M%$A1/4A?72#KV^LK(I^<+HO,<(Q:
M]0S',M^8FON8S8S!N='9J+FL57)T1RVSFPJB)_MNVUQ:J['>DRQZ;Y19DB:8
MNW3:764PU+"YM8LEE\$H^,6//R$DWGD8IN)/+37K'*I*A:UCLA8BS4;*Q,V+
M8S(+D\P\8><-.8>,/.&G,/&'G#4 ;KZL?KTVN;DJ3B:UH;Y3<%!W'5L:7OZA
M6E8D3_85<R2(LRMZ4H$;BN3M*9Q>$QSB>C;UZHI'@<8F1JCL<"#-:VY+:%O%
M3NDX4;:4U+2O'<SL#A.Q:VSK+L60P$NEY! ,[4)B5^P\IJJRP#;3:T#7>EA%
M/-;*QA"]S<(]"^TWHA*[/JAHZ,]</C=!'W"9;7J_.JMVVA7+N)V<[AI?=,BG
MSNS737:#;)'-L#1.ZO9JD25F]1V:JK6<=J$15QN8FV/'$T01V+,<7)K5'1%@
M(DF]_'D <N8<Q'(1ZP'KRR'(0 >KF "/(!Y!U>MK\\W%5V%[F=U^X:HG&#U1
M2$W;S'-U;*FW/>BZ3TO>VRE:IV_W-&W%V7RNO8DX3RP8.W6J]0:]*_;F:P(Q
M@OLZ.)*ND+*VL$F&>H/T$,J14W-#6@<'0YY7(FY"D6.ZHI.G4NBM,E)(4N2@
MA+C@F)/7G%F*SB4^&)!1IV99( 7CB&N3YAXP\X:<P\8><-.8>,/.&G,/&'G#
M5+B=OUC/F\&W-PDLDS CCB;;A$*$VSE,JUQ='^OEDBD$LFFX&=/3&[-29C2/
M<RD"2E&UI%J=7#!<P56B*=<4.1XDYZZ.'%P\+NVSWA7$VEU.[:*,*K';;,Z5
MNRTJ,L.3S>=<0.TI',()(&J][A9'RM(0;&'%I<(O.; S63*56;8.,QN.31E%
M(L(PWK'*0[YQ'JZL@Y\P\0]7,.8>$.L0Y@ ^L/7K\ZE#\/\ W1M'%'<=QLOK
MFEZF]"F,/?K1W24A*9!#\]Z30H0[KF%1%YA0+##X["\9A*"[ IB27&[3Z0SI
M7!WZE8DX0%\DJN? YP[]%8"   #D B   CS#K'Q_XZSS#QAYPTYAXP\X:<P\
M8><-1)?M5)+WHNYZ06OBJ-HKCJ>QZK62) GP5KV%+8<->H@H>D*4PY.6I5M9
M3SDO3)S#R<#CD^!61I09B9C^>=IX3VXMPJB:1.,;?ME>T]4V;7*^VZRFOJ1L
M6;+JYWZ+X;=]+V/*W#<4\LM10&11&%SJMJNL&HFYR>VZVK::V[<O:.<FD;\R
MH5S;.MGO#?VLSO;=AN/>7^I:8VOP:Z+78)Q7.TO;]*CIK6%.IV>N(W#I;(D[
M^7 JNCY$IMV2LQLMDL>AL$:HPS@D:CA7/DD<Y&Z'7+W&Q.QYY1]E0^HW&OT%
MA2",JFZ/%VK&\);6CWF8<GS<HC/6/-*X=L1";LN#E#9 KP:GD]H;7Y0\IV1[
M/;RVE;JGX.>RRW-K@WU+Y?546VJ5_9<IE"*);3H!9LCLB%QUT9=PFX.4#:R)
M.XQJ&PV!8R"O9S7=91B/5M%FMND=?5=%9Y*NUWV0)HQ%=X?,/&'G#3F'C#SA
MIS#QAYPU!>YA%?KI0EK->UIW@S#N"<X<YMM4O]CJ%":',$L7]B2)'YW.31F:
M=$65,<K<VW%7$)0V&O"5O*=V!W:LUJ$_5]6W#;G$UKQXA-LHUFUZ3%W[3^X]
MVN^D-U&>[^[=RME5>B=R659N8DVZ[: T1Q^8(2ZD1*50&#)X@[P",R%A8 A,
M5@###VUB<(G;>'SO[K7;74FV1KM-CW"UF9:6[6P-QT=E&Y=_VI2*P6BU[:=Y
MC45=M5N[>]I[A-RZU.02>83>\HVVIX;*Y984B,B+?9&5+)A@9NZ^@8NO@U+5
MC"W2M*UII5$H6Q1G&JJ>?E,FJ^OT;$CP:VV*P1\60BMU+A&FAM2HTS::;!HP
M.!6(D@U$8E!F9KXXQ6W>Y-RFTZ6P:L*AI_<>R912R2Y305HHD*)ZD+ZZ0=>W
MUE9%/SA=%YCA&+7J&8YEOS$U]S&;&8-SH[-1<UBJY.B.6V<V%41/]MVVN+57
M8[TF6/3?*+,D33%VZ;2ZRF&I87-K%DLO@E'QBQY^0DF\\C%-Q)Y::]8Y5)4+
M6L=D+$6:C96)FQ;&9!<GF'C#SAIS#QAYPTYAXP\X:HIOSK[=C:4"@4,VOND<
M0-B^P,3[Y1*[VF6VN:RJI4L8D'*%UY=L#I^Z)97+G()L;%?1-)HK'F.:$0I"
M_-L+FT/D+JE?T.IZ]^&'<<[BU7-)&QG8=/X/&-KEK;<H1M?F6X*Q%E6;5+)F
M-C.\H1[HZPLAYVY'2&:S.PV=<T&V\[A!(5<K?)8FW.49LJ1K)!(W8RPBW:'O
MH<;EJU==+#26\ZJ:&0;<$E.YVINNM>H&ELFE:U]#$%F;B9]MYB^V:Q8E;=^/
M%KIIC/:^?;,M&3,T";TL-)@[9 YD9)YHX[QP$ #ESQ#K'P9<^KF/(1$>0\Q#
MK'](CUCX1_/SQ:-C&XW=;<U+JH12U$V_',7](V5S<#S+I+25U[/9*HIG<1'I
M#,<K*KF'NMD26LE,VD]0VPT((G.(FYHK,J]HAJMG5MLY*F$4WNP9C=HO"XE&
MY!*%LU?6",1]D>IBZ)R4;E*W9I:$3>Y25P2)S#4Z5<_K4Q[LL3$&9DD*%AI1
M6>>&&.>7:N8>,/.&G,/&'G#3F'C#SAJHN[2A9;>^>VC*).4=;PIS=K2U\2;N
M^K7I16Q*N<I0+TWL@(&UR!1(%7=I+W-2K.T$!W0/[9<DO1+[)1R1<+.Q$&[>
MH]Q-=;R;V31]+NIO#<Q;\7E..WYR5DN-I4/*ZE:F2NW@_;4Y2YS9V5J61BK&
MEGG<X<2H/2S:*&!KV65-;8[Y?=M.X7\[VE[L(1:#!NNMZSZ.@^UF2TLGB5I%
MT4?,I#,)5=+I:CNY2QS@NW2#.K^C<7=Y=+#?)PLFF5FRNU7%Q72Q\>XVO5-!
MFY#3333333333336LW?WOBK_ &&US/-P%WRV7QRHH4[P5D=U,0CV4K=$2V<K
MVR/L^:=B3FI52I-F[+L,UYA2C(Q,G$PXHA1F&)&?38OOS@$VO6 ;>(?93[)I
MY:.VPC=K W%E0$K()(J/62]HA+?)$4QQSQ3"N<7E];#$3/DB TQL/R7&J"<B
M34V,/4%Q;MM.Y2*;GIW65ZO&4+V?.S^@O:42EC.CC1'6F.-LH=ETW:#,L5ZF
M1P$]#"Y2:UR-$E*S<\V540F;A/S3%GQW37&@IRXI6EAYS3NWIIQE-,SO<-3J
MW<'M[?ZI9-P],5M'#YA,)U13NN6.:29HVZ(E$2<EN<,H\ZKF1P0K4J7,#<\"
M_';[QK]O.XR<U# (XY;H:X<]PC<J<: ?KYVY3JH8!=XI&G)^S;:LL-Y3+HE+
MG8]EP,<6U*B<\2'@O#%,TJUK@H1HU,UTMQ/J.W 7SN8VWUI<#XX6;M).,PN4
MMW:BV*+-Z="[KH]('2-RE8;DBDC-$) W*V.7NI9*%(PN188'9G)L\56H"K_C
M?[>;$G]=QA"LW01BN+GG6-7T=NCL"@)3"MI]U6,H6GMK3$:YN=U_R"Y;)W%&
MO01%P?&!@9)*L0J$S>Y"8&(#:G=1O\BFT*,Q%ZLM]M&32>RI:$!J2H:@A"^S
M[IMV; BS<U4;KNO6?!,K>%34U%9N;ZO7+FIF9$0D9.+B2H6H$ROJE#<3:H+Y
MKFS;'(LN4TJGHV780*^X?N=;&_;]/**F*@A.J;F2U66<KR&R- ^I51*B-NV#
M\N9)!_ETK8X'.*)<B36#=-T\,8HHTSQ\W"5PR05_9UDA8)L\VG7C3#GY@;DF
M*]P?&&4N#TF87MG;T.6*Q>Y-+@L1HDN6)ZHXDO(,A\D>Z*'N2E_2M^X&O5ZN
M)15EG4K3(;0@"H^+0>3(BG*.363D)WC/*/PZ0MIZ=Q8I4]8HF!U0*$ZUO<3T
MR@DTSZXON4CTX+EAL)O.$3,J JS4$[.B%B0>4$0A<0A,<ST<R/87-P)BJDAM
M).<3B7\QNS*0$*%A@8ITYYA?"MF[JNGJO'BW6;<I5CQ4T>,4E2"TVJVZW<JT
M8#41I!"PE\GR)[/B3,<E/4IB3R7-X2FEFJ4Q>6 9J"0,C2=<0"!P-UHHI38;
MO*(;N!1VLZQ&X(&X0V64JQ,5/0!78THD4WLM%(RV-D8%S*A5-T;=6_)[2NLD
M)R8U&;<<.)H^57\1"B[<IFI+^BVY:%-E77F;@BJU]GLUA]=*Y4^Y*S4.412L
M\O<VQ?A-R%)705PP<,Y(CQ4(C%+<46O1Y'6BRGDTQRRPSD+KCGCEEAGAGD3C
MECEB(XY89XY)PRQRQR <<L<@ <1 0$ $!#6/1],ORC<_VA'\OIZ/IE^4;G^T
M(_E]/1],ORC<_P!H1_+Z>CZ9?E&Y_M"/Y?3T?3+\HW/]H1_+ZK#NIWV(-I<#
M*F,S-M*=/+LEF"F(5K5<?22:>3 NOXFLG,Y7(R5RAGC[!&89$T1KY+YC*WQG
MCS C.0$G*E#FZM3<MEBIMR)UTP!CL>%228%L3X:]H<F^5,*V(RQ@?8O('2)R
MR*RR+/*,IRC\HB<J8WB.O[6?V8HAR;3\T*UQ;34;BJD;T?3+\HW/]H1_+Z>C
MZ9?E&Y_M"/Y?3T?3+\HW/]H1_+Z@[<7O/@NTVI)5>&X&Y$M<5S$4*Q2M=WI<
MB*4N[BG;'%U1Q6*MIF)*B2S20$-2U/&(LVCFY/B\OM9-CB &G%1M=O$:@5!@
MPA,GNZ'[-SK/"[Y(35]42:SSJHHT#TR19=5R%Q5$H&OZT;EJ@Y&J>5'=-U4&
ML\F/9V)U;HK(ES;F4<1NN(G;;;4*V6VHZ*5,HK.!OMGQFMY!(Z%K^P[I;VYU
MIVO;(N-M19QB(S&SFY\C2N*MQP+$.!<QA&,D=(Z=,XV2XVY]'TS 1 9&Z ("
M(" YD@("'4(" IP$! >H0$.8#U#JC=_\3^";=+-9ZQEQEXR=5@:U&V;+JYKM
M7,(/1+/((--K%C[U:;PER(78"Y0VOY/+U$?A35+Y0Q0%K73]\9T4=(39N%Y/
M1],O6DKCD'K98')C,,@\(9X&8$#@87F'++ S 1PSP''/$1Q$!%Z/IE^4;G^T
M(_E]/1],ORC<_P!H1_+Z>CZ9?E&Y_M"/Y?4 6/O@KRJ;=I*@YI<I*&Y]PTE,
MC=5UHD5(E\P?,$[%+9 ME2QD*Z"UJ@C<FA3VWKY>I)%M*?A;V,KLZ]<!96$6
M^&NW7<F;M%9;F(?=P+?6[W:\DK]E6('%=!X<R.L*:,5,\/)RZ,2<GXZ?QY;%
MVAU++5OC,+B]%=@;D6!RKIE,<1&#WS.2H+ WB[DV3Y&)--JSF\VIZ:02K;TA
M<*?FZ,S&7458,A:$[/8C!&W=Y9@5*R\&@YV9GEIEL62R&'N!$@RML7.IL:86
M45(74PTXPLDHO#,@<S#3<\2RR\0[!UY9YY8XXAZXB :HM5O%#@-O7N?1D447
M:3W03&#7EO/E?*6NE;?=&]3:B9Z9JZF YGKE(I I>RE$=?9(QQV,V,GA<L,@
M#L^ QX"YWF]'TR_*-S_:$?R^GH^F7Y1N?[0C^7T]'TR_*-S_ &A'\OIZ/ID'
MADCG^T(^HU7:([[JOGMR7/0\-O!ODEA[=X<RS2[D[4Y-JIAK%"]O<J8RV67R
M+#(4#-+FHV&O3G)8TL[$LC;$"!U=LT^"\LK"'XUQ5*<D,<G<O<)-?%?1>%5D
MSW4UO=JT/9%>IK:J"2R1%#(M8U%)'B.Y.UJLDLF3O'(K%VAI;4<W>GJ7PK!+
M$>T)>P."V=Z+W@%[@&N8JHNIMN%R.N9>,$LBM+D@+E5MJ5[*36)IE38W2R%O
M1:DQ(1((H^LTHC3PVN+LR/S&Y$JD#B8<2N2I.[VAN)PIJO)A:EC3MU8(/ V0
MY_DCJ6B5.ZE.B+/3(DZ=N9FAO6.[V\NKFM;V5A8VI(J<WM\<FYI;TYJM:3@,
M);8=^A&Z-).2F%LNVK9?7$@<&675S=4-3PR9-Z,B8SJ#M4E38H%C_'G9C>I!
M6\T9S>Y3\L<XQ)8T_1.5H&IX;,06VH]'TR_*-S_:$?R^GH^F7Y1N?[0C^7T]
M'TR_*-S_ &A'\OKC7FUWN.L[M(9!-\V-A86QP>WQ[=UZ%O:F9F:49S@ZNSHX
M*BRDJ!M;4"90M7K5)I:=(D(.4'F8%%YYA4EFXF5.RNA/5)0*S)I9M7N5OO%#
MP116436S>2V_:C7/%M<(HO3L99R\U<\RE<F;E^40=$Y[>T.\>1+)4K7-4?2J
M%Y7#9\4& 'QB).L?(W,3:=3*7VK!&_;W"J(E+YN5:I510MN-U-TJJ W%O5QI
M+5^;[&BY.^.#WZ'U)\NAR:*NDF52IE(5VAJC<@1=M:P>W:SGSG(H#8L=12B*
M/.2-4T*%;6LR.(R*7L[PW(G=E=FU>E6M#VR.R-(Z,KTWN#4X)B5:,XO&(=U.
M^Q!M+@94QF9MI3IY=DLP4Q"M:KCZ233R8%U_$UDYG*Y&2N4,\?8(S#(FB-?)
M?,96^,\>8$9R DY4H<W5J;ELL5-N1.NF ,=CPJ23 MB?#7M#DWRIA6Q&6,#[
M%Y Z1.616619Y1E.4?E$3E3&\1U_:S^S%$.3:?FA6N+::C<54C>CZ9?E&Y_M
M"/Y?3T?3+\HW/]H1_+Z>CZ9?E&Y_M"/Y?4/WSN[B&V*JI9==[W$AK6MH8W*E
MSQ(Y&Y(49)RDE N7(F!F(-P+->Y5(!;ST$8C:#LCG(';(AN0%9GFAT85M3B5
M0"I&Z$KW5=?DV-F5.I-Q"MFI^F95:\AKJ@E*5"I-N.V&B*)5!T&@R+-=D@./
M,S='YP<VN0I(XP/WH>=S4OQ3/B?U+"I?G&CY?;DICK2HJ5)/KGKZL'^;T!4"
MN^$3&Z4^FMVVF=.+/#3)VSRN(/R(PI$\)F&/3&)/LS41ALD"!09=DR=S4HPP
MHR0NI9I1AA1I>69 9%FE9Y%F%Y!V#JRPSQRQR#UA =4>W'\3F$[99XQ5]+_3
MSF3H;BQNEANE55VIG#%2D.DL9L^6L4QLQ8FS2*<"'2/T]8L@1Q2'(I7.CHA$
M9+,<8YW%:"\G*[2>QI6K3IU:65+E*56G(5I52<].8G5)%1."A*J3F@GY&IU*
M<TH\@P.HPDS#,.K+7M]'TR_*-S_:$?R^GH^F7Y1N?[0C^7T]'TR_*-S_ &A'
M\OJH5\\1N#;=I*\Q::.=XR=;"X&WVO;:^HZDDEJ,=#5,[.3JUM=G7>Z1M,.,
M%B#D9'I0O19D$/LA/C\2E,GPCHQYD5.6O;WQFO,[G04HEE%L.*USGB2H4=J-
M=:2%PV]F7<XP_&?ME&#=I"(8H%LND1,3NB".8XYMABQ6CC)L@(EZDN/Z^&!\
M1 Z;W'#*,<:KWGU9.+ CL]E<6/N>@\8#%UT>K5,TGRUV.?RI8_\ :"%$?((Z
MTI5BQ 4C7OTA8V1.H[H.)10;=8DJ4+8PPJU9V:A2I:D9QYY@@)AIIA..69F8
MXAB Y9"(B(AB <_6#78M-----------:(>-10EH[E-ODAJVGH<5.YF;N#VBS
M0R.'N$=;$YT3KRY()+INX*3Y2Y-+.>F:(PVN#BI;C%>2QS((,1-Z->L.*2&Z
M5'C81OZVG[M=WDOVGUR;:%&QGA[[AJ$X=:E!-X"Q/M<ONX_<)&K1:Z0<@FDR
MCZY*R[>7Y_LJ4P)Z7I6]E)KMKB\;3OBU^+)0$?;MFX8&^C9Q:,8CA*7;9N5I
M6X>').=F%JL;;!EU5U;%)37$<=I;13QN%8'2REDQM]-8,SE,KK6=SBL2&IS*
MCK\YNIC4P\DRW/K6U'9UOA@M@1B,U5MTW7;/J 2[6-RL&W*T1>>\>&;A=L<P
MLF54C(873\6V9157+)S,HFA*LQ>F>\I?(I&WIVR%E(6=W<\@(4*)!RE?4/Q)
MI;M_X9M+278<]5$3PMD<8W FRB5[B-OLK?=PMYT-44PCE/5#4D7ALF=R(NU3
MV>/K=G-I#8,B8F=HC:7LI[@:>A2$+HUH3A*<1*DU>U&23"6UG886E2FZ?:]N
M_05_%D<7MFK8?OI8YK84^LVTK%D5F*V+< OIN^92A<4X5XR)G<Y(R%I&!L>&
MTQ.X(OMGE0<5J7[:]BG#K>]BRV/4WMMF6VB+[B[[A\KJ:Q$,NC.W.X*XQKVW
M=N!A=FQ*0X Y0Q#(7NPH5)Z_0R5K)4N3F+H6!3NTZV_<0NFKZ4;D]CF^3;]5
MAFX5[V@3/<&U3O;XRR:+1&:SFM=RT&009[E562&<G((IE-Z[4M:9U(:'AQ:3
MGUB6+4;:IQ4BH*U2W<?5.^W=2U4KN"NS8A!)+7-,[YVVVPX>1<@J]RO*U=O#
M?5[K 6617I(7N1.=$6=:T1G+KG.HS63@M2,S;#P/9UAJQ:<>297ZC>%;=SC8
M>R]TN7:U!FS;:AWS<2W<K)]JDM=:TL*%;4*6W$49'(_0M5O$:4.SG%) M-LZ
M/'28^-5XA?X_"'MT3''$MH(S,D5-Y5PT+JVH</N 3N2[>8W6$EK3A&\3BN-Y
M4N872N<WU=8<\F O-(M,]=HU(%SI9:C*+$H?0\Y(LY.UQ1N;D3.H7,N+>@0D
M247PW-T>XFJ;Z=-O.SYJV'0Z9<+';-MS35Z%@UJRM6].UXG;E:79(Y3W0JEZ
MS;TC'-:KC3_7Z&R["3-4G?3I^B23!3AV1][B]^M'AXWY;^.Y*UZ_X=,WVC4_
M.)#L4QBFT&I;-VQL-M>CC;:YRUVEVYQOJ14E?ML5C91DA\;88TTU/7:&+KH9
MLE\I<GYG=VXX7J0-OW#XWD21;L7-OC;97K?!JYW$\4N26,RN<.HNOEZRJMR6
MV)+7-43._:-@DQE].,MA6G8I2PN20>F"WJ'1QK)97!X:T BK<%%*E/"BWEMU
M.;5VF3;(YA(VN([!;:V@S:F:\4[$Y2_16_'JWI#,U5]9+[ARG, B;->,9D+"
MB.W"5_AGN!KQ;!"SW+(LG!G0NG[%-O,&D-8T#1M:RUS<7F55Y3U9P:2NSO),
M9DZN+[$X6RL+HI<IA@S1S"6+LEB W!3)\(^QX/YI>3M@TM^*L$I4P:::::U/
M<82M7BQ]K;QBCH66W2VQF.6ZZF/M02MUBNX*F)0X5FY,T+GU:8M<S@IDIASN
ML4ND,O2'@Y/9[S WA'EA"9>D3+T:.XNSYHO)CH=@;]PKM.':>XRFR%+-E:C]
M%97<#34ZR>ORFEXW=$K@Q!,.D]P1VM#(\UV&^1S-<W*7T@PC-W>G!*O=UMG-
M--0!NP@TAL_:SN9K>'M);],; V[WG!X<S&&MR;NG+I?54NC<:;RUKL<F;F\U
M<].B)'@X+521*C$\3U*M,GP--PUZ[@JOW%P=\M1SK7;M*+X-W.\,^N=FZ48>
MYUBD(IV[Z_;K?8D*ZX%,\GL1%/2;RW7LK=W>5Q J6J6Q?7[FW9L2I2^1\U5&
M*W:[N,AC%8^SEDII]FD5NO<SLINQ'NL:U-?)JAA,"I>+[0TES)+#1O,Z;K12
MV.T.NU)T05@R,4&?R9:AL&(*R75M(:9-BW[W%!O9U"E1T>AVPI4*.AS >AV<
M[,WH"(=0CAT^B(AU#RYAU:T$<2&H+\?=U=4SF@J4O"-7<X*CF6BMT>VFT&6)
MLS@]M>VB^D;1'-W,?G,M] Y3!5MF/")Q3OSI5LJSD>W!_L:"QR092IT*A2[?
M.WXKL$"#!T.2*73! @P=5+>2:F;U+K@C(P=%+>F._P LF;U#@"D] F._RR=&
M802< &X9Z^O3356-R5:2V?S39J]11C+=DU4;QX/:4\6]LM20YAKYGIJ_HJY/
M'27J$RIP*(D,VC2(6IJ[<<#<W+MHI 8G2K3T_ V;3<PF.[&IYZW-A"6#-VT+
M>)3LJF F-P@RS&XY/MOSA*=4UX*T[\[EJ6N$2YR$]"G/3)26+)$I6H%*]MP4
MT0X=^W>\Z.E]!Q3.K=T%1,]6;?)!5V[N3WGN%"W:CW'6)%&&&0ZE)!MYBV5K
MSY*@;61S8Y3,FR6,%?T:DB-4N[-4SS&W=S-!$R[N"<L<#B<\LS2L<#B<\C20
MYGE8XF8Y9&D!SQYG%8@)A0=+'F9CB'2Q_P X/S][8:<W%PCB+R9?!J7N#;/%
M3?0.][J8VVV4TR38O840<5>\%<L=*.B\CE<REI,IL&P7VJ[$KYKA;16:6M'P
M^^CK CS*5($B.5[_ ,.?(.?+GR#GR\'/U^7Z.>LZ::U]7-MOL"TKHW;G-*5O
MCL5O7AI%;88O.EIK?FW)K7>; W'J513JTHCLW[-&R-%C15\<G(QMS2*T2HY(
MC4K7!*H0EZV67:KN>=JT-9ZRH7<[62.O:OVZSBT*GW:;CVFX4.Y[=KMOW(T!
M;3*=3#B]W+9<<CB)P@%6VU%S+2+RIF 2L^P:L85D!0)8HH51?:7M08+*>[:W
MA;B[ JB84:V;@YW226N:PLST&%VJ@AE&4TGKTZ6V&@@$PG<99'2:2=T?3F-D
M)D[BZI(LS-"MYQ1J'$E(5-NYF+.\WV_VW#V2JX=>2^20Y4TY4Y/G<Z/Q:S6U
M0N09/L.5OY"]JS8G9U8"W0(@\YN[.G;)L5&UBMY9DI)SLAUT<).#WI"V.X29
M"W[E8=MN-E<\(J"MMVLS8YM:3!86&Y7<&NGCO%E25^FDO:*Z6P);6#0^EV!.
MY,XRZY6J?S2,''1IPQ?Y'N*TTUX&8AF7GAECCGCGAEAEAGCCGAGCEB..6.>&
M8#AECD B&6.0#CD B&0" B&M,]O[7K@<]L4S@B^HI=.&1?Q4[/W+SFMJIF,1
MBEV2O;8Y;@IA9,9?Z%FA\DCR:&6D4L40*9-9;5-:^L/"+-DLBK)(HQ(7C HZ
M+(/7>\RHJG9X#4NW/<O Z_L;<+NNGZV61>3;69QO[J6D)J[UX]0J&2"T+RMP
MJ-M]M7//PG\RE-L.,DO2P8#7T;KF-N';M@I&>3Q+<'MOAL=KRA:E@T1JV44G
M&HI"FUD9ZHF[TRR2:0A,E/5Y&MDODD>E<Z9Y'*5RTU4_2&0HYE)A?'=X6.JQ
MW4N"M9B70GC"5J\6/M;>,4="RVZ6V,QRW74Q]J"5NL5W!4Q*'"LW)FA<^K3%
MKF<%,E,.=UBETAEZ0\')[/>8&\(\L(3+TB9>C1W%V?-%Y,=#L#?N%=IP[3W&
M4V0I9LK4?HK*[@::G63U^4TO&[HE<&()ATGN".UH9'FNPWR.9KFY2^D&$9N[
MTX)5[NMLYIIJ*;YB[K-Z*O"&,+<4[2&7TK;\4CC:;DB+Q7223UI*F"/H\3W'
M,I$D,5O#DB2X+%1R=.D$[M@]00068;AJHW$T%?K?!:%)K"M-U!%F*]@\:VLS
M26;5;@H>+";)F6)L:=KJ7<2W7,V+T47I]KE+I)G]OW)TL]+K,A&1\\C;0VFI
MI,PN2GBS:4OQO>:TVT67MKORQ]IU$1;:C#FQ+MX<]KT/KG<Y,ZDK2J4;[;&Y
MB33ZZ(=>4EKR%V!$D*6,4HQQ2.I'UAKML>)XZV0F6LL):=XIV669QV>9O9\\
MSCLS#_PO\OGF9EEF?^%CAE_ELA$W\+##+\/\+##+GB&AOB<5)<\CW%4O.*9H
MZ^$=L9/,98*.W.[4K1980_)Y4W4KNDR2P;<PU3F7I*_*B,#LA\A\MADNDE;S
M9L]*.1WG$D[NVOSN5$I3O#BQ,C3Q>,)YBM;'*8)XS'4\O<F1.:D9'*7$,B J
M5.+(D/P+.2,KA(<')8T)3BRC4S:>E(-*+S+R+QYW336J/>LPW]9EH/M3!MPW
M#3G:1(*QBQ=FK-KCUMCALZW)OCBKE261TQ:=EV[<E=V)#*6B\6%M9W..UTT)
M9%9 3:3-&5F1:)IW%A?XZ24?N 231OVXMVWB0M==AQ1VG?V1N+P4UB13[/1A
M4X1W\-=G(DD_SL0B]V::$!1Z>+((*KCHL21++TTISB8XY8WPH6N9T3<>Z*\+
M7C^#-)9I8Z>IJ;2FKFIS-9MJE/M3:5 \T)S4M6E-9=L68]67<4B:5 I'<5SS
M'$S^B)41YL)2[B(1_P"A\:_^ID'_ .'PUVG3333333333351-V5M;8-K-;23
M<9NDL(BJZP9G*+-$AFSH$C6-3:X2=W;HG&R3T49:'MR+P7NZU"C%26@S3)1-
MR5KSDJ0LY07\3=.=J[S=D=V[--AHW6XY;1^>Y&,P]M<'EP%]H["4-D,"Q6R0
M)&TZ+*V(V2O#8W)L2GS)Q5]NDK4J$YO$5>,>4KN2V'[B&V_'JG+WBLT9=KLJ
MD,-OU\(?G9G9*Q?(HB<G&0#('F1MK.V9,C:@9G=6;*FU4OBIJ=J<C4ST?B@5
M"5 = \2CA8[FI1*(;3NX@7B2Q:O9#;![;)8=<5;&2FLXH4N42*>UH=9-?1)/
M;43:4;<L7JWFM#96FQ;2\7' <T)I9^7NVT\2?A3;O;.8J9V][HX[.;/E;*OD
M$2AJU!9L$=YBU-:,UQ<3H:%C0B()9<>A;4ZIS5M\<4N;B0V(USB8D!$A5GDV
M.J:\=EEZ71?&WBIK>:)M<VV-P;&N]((UN#^4Y5\O=LUA*1.X*W!I1,[D)2E
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ML3UZF.]WAP0:O:PM1]O]J4P6WHD_6!!7F+HK#GAI\#B*XEJF<\D3+!HA(Y!
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/O%S]?EX?7UG333337__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6831126832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Feb. 15, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AMICUS THERAPEUTICS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001178879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 542,291,868<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194,824,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6831585360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 187,026<span></span>
</td>
<td class="nump">$ 69,485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Investments in marketable securities</a></td>
<td class="nump">143,325<span></span>
</td>
<td class="nump">144,548<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">1,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">3,416<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,993<span></span>
</td>
<td class="nump">2,568<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">340,064<span></span>
</td>
<td class="nump">216,601<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, less accumulated depreciation of $12,495 and $13,353 at December 31, 2016 and 2015, respectively</a></td>
<td class="nump">9,816<span></span>
</td>
<td class="nump">6,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">In-process research &amp; development</a></td>
<td class="nump">486,700<span></span>
</td>
<td class="nump">486,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">197,797<span></span>
</td>
<td class="nump">197,797<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">2,468<span></span>
</td>
<td class="nump">1,108<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">1,036,845<span></span>
</td>
<td class="nump">908,384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable, accrued expenses , and other current liabilities</a></td>
<td class="nump">41,008<span></span>
</td>
<td class="nump">32,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent', window );">Deferred reimbursements, current portion</a></td>
<td class="nump">13,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration payable, current portion</a></td>
<td class="nump">56,101<span></span>
</td>
<td class="nump">41,400<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">110,959<span></span>
</td>
<td class="nump">73,616<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent', window );">Deferred reimbursements</a></td>
<td class="nump">21,906<span></span>
</td>
<td class="nump">35,756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible notes</a></td>
<td class="nump">154,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesNoncurrent', window );">Due to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration payable</a></td>
<td class="nump">213,621<span></span>
</td>
<td class="nump">232,677<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNoncurrent', window );">Deferred income taxes</a></td>
<td class="nump">173,771<span></span>
</td>
<td class="nump">176,219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liability</a></td>
<td class="nump">1,973<span></span>
</td>
<td class="nump">681<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $.01 par value, 250,000,000 shares authorized, 142,691,986 shares issued and outstanding at December 31, 2016 Common stock, $.01 par value, 250,000,000 shares authorized, 125,027,034 shares issued and outstanding at December 31, 2015</a></td>
<td class="nump">1,480<span></span>
</td>
<td class="nump">1,306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,120,156<span></span>
</td>
<td class="nump">917,454<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract', window );"><strong>Accumulated other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment, less tax benefit of $1,293 at December 31, 2016</a></td>
<td class="nump">1,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gain/(loss) on available-for securities</a></td>
<td class="nump">102<span></span>
</td>
<td class="num">(115)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants</a></td>
<td class="nump">16,076<span></span>
</td>
<td class="nump">8,755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(779,608)<span></span>
</td>
<td class="num">(579,566)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">360,151<span></span>
</td>
<td class="nump">347,834<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity</a></td>
<td class="nump">$ 1,036,845<span></span>
</td>
<td class="nump">$ 908,384<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3-4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 3<br> -Subparagraph a(1)<br> -Article 5<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 4<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated appreciation or loss, net of tax, in value of the total of available-for-sale securities at the end of an accounting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669686-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e681-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e681-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669646-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e637-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6915805&amp;loc=d3e32022-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669686-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 31<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 12<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51813488&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income during the current period and current obligations not separately disclosed in the balance sheet (other liabilities, current).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income after one year or beyond the normal operating cycle, if longer and noncurrent obligations not separately disclosed in the balance sheet (other liabilities, noncurrent).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, netted by jurisdiction and classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31958-109318<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Portion of the carrying amount as of the balance sheet date of obligations due all related parties that is payable after one year or beyond the normal operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.23)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=51655945&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.32)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 25<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 8<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 13<br> -Subparagraph a<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 8<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section E<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6831128800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Consolidated Balance Sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation of property and equipment (in dollars)</a></td>
<td class="nump">$ 12,495<span></span>
</td>
<td class="nump">$ 13,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">142,691,986<span></span>
</td>
<td class="nump">125,027,034<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">142,691,986<span></span>
</td>
<td class="nump">125,027,034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustment, tax</a></td>
<td class="nump">$ 1,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6831505392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNetAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Net Product Sales</a></td>
<td class="nump">$ 4,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ResearchRevenue', window );">Research revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,224<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Total revenue</a></td>
<td class="nump">4,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of goods sold</a></td>
<td class="nump">833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross Profit</a></td>
<td class="nump">4,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">104,793<span></span>
</td>
<td class="nump">$ 76,943<span></span>
</td>
<td class="nump">47,624<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">71,151<span></span>
</td>
<td class="nump">47,269<span></span>
</td>
<td class="nump">20,717<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Changes in fair value of contingent consideration payable</a></td>
<td class="nump">6,760<span></span>
</td>
<td class="nump">4,377<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="num">(63)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">3,242<span></span>
</td>
<td class="nump">1,833<span></span>
</td>
<td class="nump">1,547<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">186,015<span></span>
</td>
<td class="nump">130,437<span></span>
</td>
<td class="nump">69,925<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(181,890)<span></span>
</td>
<td class="num">(130,437)<span></span>
</td>
<td class="num">(68,701)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expenses):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">1,602<span></span>
</td>
<td class="nump">929<span></span>
</td>
<td class="nump">223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(5,398)<span></span>
</td>
<td class="num">(1,578)<span></span>
</td>
<td class="num">(1,484)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtGainLossNetOfTax', window );">Loss on extinguishment of debt</a></td>
<td class="num">(13,302)<span></span>
</td>
<td class="num">(952)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense</a></td>
<td class="num">(4,793)<span></span>
</td>
<td class="num">(80)<span></span>
</td>
<td class="num">(77)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax benefit</a></td>
<td class="num">(203,781)<span></span>
</td>
<td class="num">(132,118)<span></span>
</td>
<td class="num">(70,039)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">3,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,113<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (200,042)<span></span>
</td>
<td class="num">$ (132,118)<span></span>
</td>
<td class="num">$ (68,926)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss attributable to common stockholders per common share - basic and diluted</a></td>
<td class="num">$ (1.49)<span></span>
</td>
<td class="num">$ (1.20)<span></span>
</td>
<td class="num">$ (0.93)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average common shares outstanding - basic and diluted</a></td>
<td class="nump">134,401,588<span></span>
</td>
<td class="nump">109,923,815<span></span>
</td>
<td class="nump">74,444,157<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ResearchRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents reimbursements for research and development costs under collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ResearchRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs related to goods produced and sold during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtGainLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the reacquisition price and the net carrying amount of the extinguished debt recognized currently as a component of income in the period of extinguishment, net of tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6401765&amp;loc=d3e13305-112630<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtGainLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51673353&amp;loc=d3e41242-110953<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 10<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Research and Development<br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 5<br> -Section P<br> -Subsection 3, 4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=51677171&amp;loc=d3e3636-108311<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6831130480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Consolidated Statements of Comprehensive Loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (200,042)<span></span>
</td>
<td class="num">$ (132,118)<span></span>
</td>
<td class="num">$ (68,926)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive gain/ (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment, net of tax of $1,293</a></td>
<td class="nump">1,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain/ (loss) on available-for-sale securities</a></td>
<td class="nump">217<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="num">(133)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income/ (loss)</a></td>
<td class="nump">2,162<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="num">(133)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (197,880)<span></span>
</td>
<td class="num">$ (132,101)<span></span>
</td>
<td class="num">$ (69,059)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831223<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=51664549&amp;loc=SL4569643-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=51664549&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=51664549&amp;loc=SL4569643-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=51664549&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=51664549&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=51664549&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6604884816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Consolidated Statements of Comprehensive Loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustment, tax</a></td>
<td class="num">$ (1,293)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6835591520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Scioderm </div>
<div>Common Stock</div>
</th>
<th class="th">
<div>Scioderm </div>
<div>Additional Paid-In Capital</div>
</th>
<th class="th"><div>Scioderm</div></th>
<th class="th">
<div>Callidus </div>
<div>Common Stock</div>
</th>
<th class="th">
<div>Callidus </div>
<div>Additional Paid-In Capital</div>
</th>
<th class="th">
<div>MiaMed </div>
<div>Common Stock</div>
</th>
<th class="th">
<div>MiaMed </div>
<div>Additional Paid-In Capital</div>
</th>
<th class="th"><div>MiaMed</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Warrants</div></th>
<th class="th"><div>Accumulated Other Comprehensive Gain/ (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 679<span></span>
</td>
<td class="nump">$ 423,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">$ (378,522)<span></span>
</td>
<td class="nump">$ 45,751<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,975,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock issued from exercise of stock options, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">3,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock issued from exercise of stock options, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">965,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Stock issued for acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
<td class="num">$ (24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock issued for acquisition (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,359,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued from public offering / financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 159<span></span>
</td>
<td class="nump">97,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued from public offering / financing (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,927,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_StockIssuedDuringPeriodValueAtMarketOffering', window );">Stock issued from ATM transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 143<span></span>
</td>
<td class="nump">38,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,636<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_StockIssuedDuringPeriodSharesAtMarketOffering', window );">Stock issued from ATM transactions (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,328,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized holding gain/(loss) on available-for-sale securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(133)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(133)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(68,926)<span></span>
</td>
<td class="num">(68,926)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,015<span></span>
</td>
<td class="nump">568,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(132)<span></span>
</td>
<td class="num">(447,448)<span></span>
</td>
<td class="nump">122,178<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,556,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock issued from exercise of stock options, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">11,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock issued from exercise of stock options, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,070,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Stock issued for acquisition</a></td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">$ 82,787<span></span>
</td>
<td class="nump">$ 82,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock issued for acquisition (in shares)</a></td>
<td class="nump">5,921,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued from public offering / financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 195<span></span>
</td>
<td class="nump">242,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">243,042<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued from public offering / financing (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,528,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_StockIssuedDuringPeriodValueWarrantsExercised', window );">Stock issued from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">3,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Stock issued from exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition', window );">Restricted stock vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,044)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,044)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">324,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_StockAndWarrantsIssuedDuringPeriodValueNewIssues', window );">Warrants issued in debt financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,755<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized holding gain/(loss) on available-for-sale securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(132,118)<span></span>
</td>
<td class="num">(132,118)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,306<span></span>
</td>
<td class="nump">917,454<span></span>
</td>
<td class="nump">8,755<span></span>
</td>
<td class="num">(115)<span></span>
</td>
<td class="num">(579,566)<span></span>
</td>
<td class="nump">$ 347,834<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,027,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,027,034<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock issued from exercise of stock options, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">3,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,036<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock issued from exercise of stock options, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">723,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Stock issued for acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 4,599<span></span>
</td>
<td class="nump">$ 4,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock issued for acquisition (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">825,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_StockIssuedDuringPeriodValueAtMarketOffering', window );">Stock issued from ATM transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
<td class="nump">96,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,068<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_StockIssuedDuringPeriodSharesAtMarketOffering', window );">Stock issued from ATM transactions (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,989,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition', window );">Restricted stock vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,282)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,282)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">268,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_StockIssuedDuringPeriodValueContingentConsideration', window );">Stock issued for contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">6,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_StockIssuedDuringPeriodSharesContingentConsideration', window );">Stock issued for contingent consideration (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">858,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor', window );">Receivable from investor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">932<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_StockAndWarrantsIssuedDuringPeriodValueNewIssues', window );">Warrants issued in debt financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Equity component of the Convertible Notes issuance, net of issuance costs of $2,709</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,346<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_AdjustmentsToAdditionalPaidinCapitalPremiumsPaidForCappedCallConfirmations', window );">Premium paid for Capped Call Confirmations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,450)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,450)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,504<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized holding gain/(loss) on available-for-sale securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,945<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(200,042)<span></span>
</td>
<td class="num">(200,042)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,480<span></span>
</td>
<td class="nump">$ 1,120,156<span></span>
</td>
<td class="nump">$ 16,076<span></span>
</td>
<td class="nump">$ 2,047<span></span>
</td>
<td class="num">$ (779,608)<span></span>
</td>
<td class="nump">$ 360,151<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,691,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,691,986<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the receivable from investor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_AdjustmentsToAdditionalPaidInCapitalReceivableFromInvestor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_AdjustmentsToAdditionalPaidinCapitalPremiumsPaidForCappedCallConfirmations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from Premium paid for Capped Call Confirmations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_AdjustmentsToAdditionalPaidinCapitalPremiumsPaidForCappedCallConfirmations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_StockAndWarrantsIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the value of new stock and warrants issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_StockAndWarrantsIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_StockIssuedDuringPeriodSharesAtMarketOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period related to at the market (ATM) equity offerings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_StockIssuedDuringPeriodSharesAtMarketOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_StockIssuedDuringPeriodSharesContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period for contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_StockIssuedDuringPeriodSharesContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents Stock issued from exercise of warrants (in shares).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_StockIssuedDuringPeriodValueAtMarketOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period related to at the market (ATM) equity offerings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_StockIssuedDuringPeriodValueAtMarketOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_StockIssuedDuringPeriodValueContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period for contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_StockIssuedDuringPeriodValueContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents Stock issued from exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=51819886&amp;loc=SL6014347-161799<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity-based compensation, related to restricted stock units or restricted stock awards, recognized as expense or an asset, if compensation is capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=51664549&amp;loc=SL4569643-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=51664549&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=51664549&amp;loc=SL4569643-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=51664549&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28,29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28,29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section E<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=fold_SciodermIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=fold_SciodermIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=fold_MiaMedIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=fold_MiaMedIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_ComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_ComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6821529168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Consolidated Statements of Changes in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Convertible notes issuance costs</a></td>
<td class="nump">$ 2,709<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, the carrying amount (net of accumulated amortization) as of the balance sheet date of capitalized costs associated with the issuance of debt instruments (for example, legal, accounting, underwriting, printing, and registration costs) that will be charged against earnings over the life of the debt instruments to which such costs pertain.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28555-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6833356624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (200,042)<span></span>
</td>
<td class="num">$ (132,118)<span></span>
</td>
<td class="num">$ (68,926)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest expense</a></td>
<td class="nump">2,689<span></span>
</td>
<td class="nump">492<span></span>
</td>
<td class="nump">277<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">3,242<span></span>
</td>
<td class="nump">1,833<span></span>
</td>
<td class="nump">1,547<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">17,504<span></span>
</td>
<td class="nump">9,972<span></span>
</td>
<td class="nump">6,008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="num">(63)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Non-cash changes in the fair value of contingent consideration payable</a></td>
<td class="nump">6,760<span></span>
</td>
<td class="nump">4,377<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ResearchExpenseForStockIssuanceInAssetAcquisition', window );">Charges to research expense for stock issued in asset acquisition</a></td>
<td class="nump">4,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">13,302<span></span>
</td>
<td class="nump">952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency remeasurement loss</a></td>
<td class="nump">3,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_NoncashIncomeTaxExpenseBenefit', window );">Non-cash income tax benefit</a></td>
<td class="num">(1,293)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_NonCashDeferredTaxes', window );">Non-cash deferred taxes</a></td>
<td class="num">(2,449)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposal of assets</a></td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(1,419)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(3,651)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_IncreaseDecreaseInDueFromCollaborationAgreements', window );">Receivable due from collaboration agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,083<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(394)<span></span>
</td>
<td class="nump">308<span></span>
</td>
<td class="nump">2,293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other non-current assets</a></td>
<td class="num">(1,357)<span></span>
</td>
<td class="num">(666)<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">7,131<span></span>
</td>
<td class="nump">15,467<span></span>
</td>
<td class="nump">6,169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities', window );">Non-current liabilities</a></td>
<td class="nump">825<span></span>
</td>
<td class="nump">93<span></span>
</td>
<td class="num">(126)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_IncreaseDecreaseInDeferredReimbursements', window );">Deferred reimbursements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(864)<span></span>
</td>
<td class="num">(57)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
<td class="num">(150,534)<span></span>
</td>
<td class="num">(100,139)<span></span>
</td>
<td class="num">(51,669)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Sale and redemption of marketable securities</a></td>
<td class="nump">221,374<span></span>
</td>
<td class="nump">290,129<span></span>
</td>
<td class="nump">55,914<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(219,932)<span></span>
</td>
<td class="num">(289,595)<span></span>
</td>
<td class="num">(162,752)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions, net of cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(141,060)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(5,951)<span></span>
</td>
<td class="num">(4,817)<span></span>
</td>
<td class="num">(238)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash used in investing activities</a></td>
<td class="num">(4,509)<span></span>
</td>
<td class="num">(145,343)<span></span>
</td>
<td class="num">(107,076)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock and warrants, net of issuance costs</a></td>
<td class="nump">97,068<span></span>
</td>
<td class="nump">243,042<span></span>
</td>
<td class="nump">135,805<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSecuredDebt', window );">Payments of secured loan agreement</a></td>
<td class="num">(80,000)<span></span>
</td>
<td class="num">(15,291)<span></span>
</td>
<td class="num">(299)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations', window );">Payment of capital leases</a></td>
<td class="num">(193)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_PaymentsForRepurchaseOfRestrictedStockUnits', window );">Purchase of vested restricted stock units</a></td>
<td class="num">(1,282)<span></span>
</td>
<td class="num">(2,044)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">3,036<span></span>
</td>
<td class="nump">11,186<span></span>
</td>
<td class="nump">3,673<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_PaymentOfContingentConsideration', window );">Payment of contingent consideration</a></td>
<td class="num">(5,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible senior notes, net of issuance costs</a></td>
<td class="nump">242,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_PremiumsPaidForCappedCallConfirmations', window );">Premiums paid for Capped Call Confirmations</a></td>
<td class="num">(13,450)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from secured loan agreement</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
<td class="nump">272,715<span></span>
</td>
<td class="nump">290,893<span></span>
</td>
<td class="nump">139,179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(131)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase/(decrease) in cash and cash equivalents</a></td>
<td class="nump">117,541<span></span>
</td>
<td class="nump">45,411<span></span>
</td>
<td class="num">(19,566)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of year/ period</a></td>
<td class="nump">69,485<span></span>
</td>
<td class="nump">24,074<span></span>
</td>
<td class="nump">43,640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of year/period</a></td>
<td class="nump">187,026<span></span>
</td>
<td class="nump">69,485<span></span>
</td>
<td class="nump">24,074<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid during the period for interest</a></td>
<td class="nump">2,990<span></span>
</td>
<td class="nump">$ 605<span></span>
</td>
<td class="nump">$ 1,186<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ContingentConsiderationPaidInStock', window );">Contingent consideration paid in shares</a></td>
<td class="nump">6,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsIncurred', window );">Capital expenditures funded by capital lease borrowings</a></td>
<td class="nump">$ 944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ContingentConsiderationPaidInStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of contingent consideration liability in stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ContingentConsiderationPaidInStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_IncreaseDecreaseInDeferredReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of deferred reimbursements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_IncreaseDecreaseInDeferredReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_IncreaseDecreaseInDueFromCollaborationAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate increase (decrease) during the reporting period in the amount due from collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_IncreaseDecreaseInDueFromCollaborationAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of noncurrent liabilities that result from activities that generate operating income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_IncreaseDecreaseInNoncurrentOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_NonCashDeferredTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the non-cash component of deferred taxes for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_NonCashDeferredTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_NoncashIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the non-cash component of income tax expense for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_NoncashIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_PaymentOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the payment of contingent consideration liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_PaymentOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_PaymentsForRepurchaseOfRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire restricted stock units during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_PaymentsForRepurchaseOfRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_PremiumsPaidForCappedCallConfirmations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for premiums paid for capped call confirmations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_PremiumsPaidForCappedCallConfirmations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ResearchExpenseForStockIssuanceInAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of research expense charged to statement of operations for stock issued in assets acquisition transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ResearchExpenseForStockIssuanceInAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase during the period in capital lease obligations due to entering into new capital leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30700-110894<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=51824106&amp;loc=d3e2443-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other assets used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current assets, other noncurrent assets, or a combination of other current and noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire debt and equity securities not classified as either held-to-maturity securities or trading securities which would be classified as available-for-sale securities and reported at fair value, with unrealized gains and losses excluded from earnings and reported in a separate component of shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale or maturity (principal being due) of securities not classified as either held-to-maturity securities or trading securities which are classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26853-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt and payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 5<br> -Section P<br> -Subsection 3, 4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6811917616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Description of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Description of Business</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;">1. Description of Business</font>
		</p>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Corporate Information, Status of Operations, and Management Plans</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amicus Therapeutics,&nbsp;Inc. (the "Company") is a global patient-focused biotechnology company engaged in the discovery, development, and commercialization of a diverse set of novel treatments for patients living with devastating rare and orphan diseases. The lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement of therapy ("ERT") for Fabry disease.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company's Fabry franchise strategy is to develop migalastat HCl (which the Company may refer to as "migalastat") for all patients with Fabry disease as a monotherapy for patients with amenable mutations and in combination with ERT for all other patients. In May 2016, the Company announced that the European Commission ("EC") had granted full approval for the oral small molecule pharmacological chaperone Galafold&#x2122; (migalastat) as a first-line therapy for long-term treatment of adults and adolescents aged 16&nbsp;years and older with a confirmed diagnosis of Fabry disease (alpha-galactosidase A deficiency) and who have an amenable mutation. The approved label includes 313 Fabry-causing mutations, which represent up to half of all patients with Fabry disease. The Company commenced commercial shipments of Galafold in the EU in the second quarter of 2016 and recognized net product sales of $5.0&nbsp;million in 2016.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Also in the pipeline, SD-101 is a product candidate in late-stage development, as a potential first-to-market therapy for the chronic, rare connective tissue disorder Epidermolysis Bullosa ("EB"). The Company is also leveraging its biologics and Chaperone-Advanced Replacement Therapy ("CHART&#x2122;") platform technologies to develop novel ERT products for Pompe disease, Fabry disease, and potentially other lysosomal storage disorders ("LSDs"). The Company is also investigating preclinical and discovery programs in other rare and devastating diseases including cyclin-dependent kinase-like&nbsp;5 ("CDKL5") deficiency. The Company believes that the platform technologies and advanced product pipeline uniquely position the Company at the forefront of advanced therapies to treat a range of devastating rare and orphan diseases.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On December&nbsp;21, 2016, the Company issued $250&nbsp;million aggregate principal amount of 3.00% unsecured Convertible Senior Notes due 2023 (the "Convertible Notes"), in a private offering to qualified institutional buyers pursuant to Rule&nbsp;144A under the Securities Act of 1933, as amended (the "Securities Act"). Interest is payable semiannually on June&nbsp;15 and December&nbsp;15 of each year, beginning on June&nbsp;15, 2017. The Notes will mature on December&nbsp;15, 2023, unless earlier repurchased, redeemed, or converted in accordance with their terms. The Notes are convertible at the option of the holders, under certain circumstances and during certain periods, into cash, shares of the Company's common stock, par value $0.01 per share ("Common Stock"), or a combination thereof. The net proceeds from the issuance of the Convertible Note offering were $243.1&nbsp;million, after deducting fees and estimated expenses payable by the Company. In addition, the Company used approximately $13.5&nbsp;million of the net proceeds from the issuance of the Convertible Notes to pay the cost of the capped call transactions ("Capped Call Confirmations") that the Company entered into in connection with the issuance of the Convertible Notes. For additional information, see "&#x2014;&nbsp;Note&nbsp;16. Debt Instruments and Related Party Transactions."</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In July 2016, the Company expanded its biologics pipeline with a new preclinical program for CDKL5 deficiency, a rare and devastating genetic neurological disease for which there is no currently approved treatment. The Company has obtained the rights and related intellectual property to a preclinical CDKL5 program through its acquisition of MiaMed, Inc ("MiaMed"). The aggregate value of the deal was approximately $89.5&nbsp;million, which included an upfront payment of $6.5&nbsp;million and Company stock, cash and potential milestones of up to $83.0&nbsp;million. For additional information, see "&#x2014;&nbsp;Note&nbsp;3. Acquisitions".</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beginning in April 2016 and through July 2016, the Company sold 15.0&nbsp;million shares of Common Stock under an at-the-market ("ATM") equity program with Cowen and Company,&nbsp;LLC ("Cowen") acting as sales agent. Cowen was compensated at a fixed commission rate up to 3.0%. The ATM sales agreement resulted in net proceeds of $97.1&nbsp;million, after Cowen's commission of $2.7&nbsp;million and other expenses of $0.2&nbsp;million. The Company has completed all sales under the ATM equity program.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company had an accumulated deficit of approximately $779.6&nbsp;million at December&nbsp;31, 2016 and anticipates incurring losses through the fiscal year ending December&nbsp;31, 2017 and beyond. The Company has been able to fund its operating losses to date through stock offering, debt issuances, and payments from partners during the terms of the collaboration agreements and other financing arrangements.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company believes that its existing cash and cash equivalents and short-term investments will be sufficient to fund the current operating plan into the second half of 2018.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=35735333&amp;loc=d3e288-107754<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6811865248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;">2. Summary of Significant Accounting Policies</font>
		</p>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Basis of Presentation</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("U.S.&nbsp;GAAP") and include all adjustments necessary for the fair presentation of the Company's financial position for the periods presented.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Consolidation</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The consolidated financial statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions are eliminated in consolidation.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Foreign Currency Transactions</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The functional currency for most of the Company's foreign subsidiaries is their local currency. For non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of the Company's foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of equity.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company transacts business in various foreign countries and therefore, is subject to risk of foreign currency exchange rate fluctuations. As such, in June 2016, the Company entered into a forward contract to economically hedge transactional exposure associated with commitments arising from trade accounts payable denominated in a currency other than the functional currency of the respective operating entity. The Company does not designate this forward contract as a hedging instrument under applicable accounting guidance and, therefore, changes in fair value are recorded as other expense the Consolidated Statements of Operations.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Use of Estimates</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The preparation of financial statements in conformity with U.S.&nbsp;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Cash, Money Market Funds, and Marketable Securities</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company considers all highly liquid investments purchased with a maturity of three months or less at the date of acquisition, to be cash equivalents.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Marketable securities consist of fixed income investments with a maturity of greater than three months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Company's balance sheet. Unrealized holding gains and losses are reported within comprehensive income/ (loss) in the statements of comprehensive loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations or other observable inputs. See "&#x2014;&nbsp;Note&nbsp;5. Cash, Money Market Funds and Marketable Securities", for a summary of available-for-sale securities as of December&nbsp;31, 2016 and 2015.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Concentration of Credit Risk</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company's financial instruments that are exposed to concentration of credit risk consist primarily of cash and cash equivalents and marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on cash and cash equivalents or its marketable securities.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company is subject to credit risk from its accounts receivable related to its product sales of Galafold. The majority of the Company's accounts receivable at December&nbsp;31, 2016 have arisen from product sales in Germany. The Company will periodically assess the financial strength of its customers to establish allowances for anticipated losses, if any. For accounts receivable that have arisen from named patient sales, the payment terms are predetermined and the Company evaluates the creditworthiness of each customer on a regular basis. To date, the Company has not incurred any credit losses.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Property and Equipment</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is calculated over the estimated useful lives of the respective assets, which range from three to five years, or the lesser of the related initial term of the lease or useful life for leasehold improvements.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The initial cost of property and equipment consists of its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use. Expenditures incurred after the fixed assets have been put into operation, such as repairs and maintenance, are charged to income in the period in which the costs are incurred. Major replacements, improvements and additions are capitalized in accordance with Company policy.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Revenue Recognition</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company recognizes revenue when amounts are realized or realizable and earned, which is typically upon shipment to the end-customer. Revenue is considered realizable and earned when persuasive evidence an arrangement exists, title to product and associated risk of loss has passed to the customer, the price is fixed or determinable, collection of the amounts due are reasonably assured and the Company has no further performance obligations.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Net Product Sales</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company's net product sales consist solely of sales of Galafold for the treatment of Fabry disease in the EU. The Company has recorded revenue on sales where Galafold is available either on a commercial basis or through a reimbursed early access program. Orders for Galafold are generally received from pharmacies and the ultimate payor is typically a government authority.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company records revenue net of estimated third party discounts and rebates. Allowances are recorded as a reduction of revenue at the time revenues from product sales are recognized. These allowances are adjusted to reflect known changes in factors and may impact such allowances in the quarter those changes are known.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Collaboration Revenue</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In multiple element arrangements, revenue is allocated to each separate unit of accounting and each deliverable in an arrangement is evaluated to determine whether it represents separate units of accounting. A deliverable constitutes a separate unit of accounting when it has standalone value and there is no general right of return for the delivered elements. In instances when the aforementioned criteria are not met, the deliverable is combined with the undelivered elements and the allocation of the arrangement consideration and revenue recognition is determined for the combined unit as a single unit of accounting. Allocation of the consideration is determined at arrangement inception on the basis of each unit's relative selling price. In instances where there is determined to be a single unit of accounting, the total consideration is applied as revenue for the single unit of accounting and is recognized over the period of inception through the date where the last deliverable within the single unit of accounting is expected to be delivered.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company's current revenue recognition policies provide that, when a collaboration arrangement contains multiple deliverables, such as license and research and development services, the Company allocates revenue to each separate unit of accounting based on a selling price hierarchy. The selling price hierarchy for a deliverable is based on (i)&nbsp;its vendor specific objective evidence ("VSOE") if available, (ii)&nbsp;third party evidence ("TPE") if VSOE is not available, or (iii)&nbsp;best estimated selling price ("BESP") if neither VSOE nor TPE is available. The Company would establish the VSOE of selling price using the price charged for a deliverable when sold separately. The TPE of selling price would be established by evaluating largely similar and interchangeable competitor products or services in standalone sales to similarly situated customers. The BESP would be established considering internal factors such as an internal pricing analysis or an income approach using a discounted cash flow model.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company also considers the impact of potential future payments it makes in its role as a vendor to its customers and evaluates if these potential future payments could be a reduction of revenue from that customer. If the potential future payments to the customer are:</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:15;margin-left:0pt;">
			<tr style="CellSpacing:15;">
				<td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Arabic Typesetting;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Arabic Typesetting;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Arabic Typesetting;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:15;">
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2022;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">a payment for an identifiable benefit; </font></p>
				</td>
			</tr>
			<tr style="CellSpacing:15;">
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;height:35.40pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;height:35.40pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2022;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;height:35.40pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">the identifiable benefit is separable from the existing relationship between the Company and its customer;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:15;">
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2022;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">the identifiable benefit can be obtained from a party other than the customer; and </font></p>
				</td>
			</tr>
			<tr style="CellSpacing:15;">
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2022;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">the Company can reasonably estimate the fair value of the identifiable benefit</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;then the payments are accounted for separate from the revenue received from that customer. If, however, all these criteria are not satisfied, then the payments are treated as a reduction of revenue from that customer.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the Company determines that any potential future payments to its customers are to be considered as a reduction of revenue, it must evaluate if the total amount of revenue to be received under the arrangement is fixed and determinable. If the total amount of revenue is not fixed and determinable due to the uncertain nature of the potential future payments to the customer, then any customer payments cannot be recognized as revenue until the total arrangement consideration becomes fixed and determinable.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The reimbursements for research and development costs under collaboration agreements that meet the criteria for revenue recognition are included in Research Revenue and the costs associated with these reimbursable amounts are included in research and development expenses.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In order to determine the revenue recognition for contingent milestones, the Company evaluates the contingent milestones using the criteria as provided by the Financial Accounting Standards Boards ("FASB") guidance on the milestone method of revenue recognition at the inception of a collaboration agreement. The criteria requires that (i)&nbsp;the Company determines if the milestone is commensurate with either its performance to achieve the milestone or the enhancement of value resulting from the Company's activities to achieve the milestone, (ii)&nbsp;the milestone be related to past performance, and (iii)&nbsp;the milestone be reasonable relative to all deliverable and payment terms of the collaboration arrangement. If these criteria are met then the contingent milestones can be considered as substantive milestones and will be recognized as revenue in the period that the milestone is achieved.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Inventories and Cost of Cost of Goods Sold</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Until regulatory approval of Galafold, the Company expensed all manufacturing costs of Galafold as research and development expense. Upon regulatory approval, the Company began capitalizing costs related to the purchase and manufacture of Galafold.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories are stated at the lower of cost or market determined by the first-in, first-out method. Inventories are reviewed periodically to identify slow-moving or obsolete inventory based on projected sales activity as well as product shelf-life. In evaluating the recoverability of inventories produced, the probability that revenue will be obtained from the future sale of the related inventory is considered and inventory value is written down for inventory quantities in excess of expected requirements. Expired inventory is disposed of and the related costs are recognized as cost of product sales in the consolidated statements of operations.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cost of goods sold includes the cost of inventory sold, manufacturing and supply chain costs, product shipping and handling costs, provisions for excess and obsolete inventory, as well as royalties payable. A portion of the inventory available for sale was expensed as research and development costs prior to regulatory approval and as such the cost of goods sold and related gross margins are not necessarily indicative of future cost of goods sold and gross margin.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Fair Value Measurements</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company records certain asset and liability balances under the fair value measurements as defined by the FASB guidance. Current FASB fair value guidance emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, current FASB guidance establishes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels&nbsp;1 and 2 of the hierarchy) and the reporting entity's own assumptions that market participants assumptions would use in pricing assets or liabilities (unobservable inputs classified within Level&nbsp;3 of the hierarchy).</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Level&nbsp;1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at measurement date. Level&nbsp;2 inputs are inputs other than quoted prices included in Level&nbsp;1 that are observable for the asset or liability, either directly or indirectly. Level&nbsp;2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals. Level&nbsp;3 inputs are unobservable inputs for the asset or liability, which is typically based on an entity's own assumptions, as there is little, if any, related market activity. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Contingent Liabilities</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On an ongoing basis, the Company may be involved in various claims, and legal proceedings. On a quarterly basis, the Company reviews the status of each significant matter and assesses its potential financial exposure. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated, the Company will accrue a liability for the estimated loss. Because of uncertainties related to claims and litigation, accruals will be based on our best estimates based on available information. On a periodic basis, as additional information becomes available, or based on specific events such as the outcome of litigation or settlement of claims, the Company may reassess the potential liability related to these matters and may revise these estimates, which could result in a material adverse adjustments to the Company's operating results.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Research and Development Costs</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development costs are expensed as incurred. Research and development expense consists primarily of costs related to personnel, including salaries and other personnel related expenses, consulting fees and the cost of facilities and support services used in drug development. Assets acquired that are used for research and development and have no future alternative use are expensed as in-process research and development.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Interest Income and Interest Expense</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest income consists of interest earned on the Company's cash and cash equivalents and marketable securities. Interest expense consists of interest incurred on capital leases and debt.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Income Taxes</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company accounts for income taxes under the liability method. Under this method deferred income tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax basis of assets and liabilities and for operating losses and tax credit carry forwards, using enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance is recorded if it is "more likely than not" that a portion or all of a deferred tax asset will not be realized.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Other Comprehensive Income/ (Loss)</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Components of other comprehensive income/(loss) include unrealized gains and losses on available-for-sale securities and gain/(loss) on foreign currency transactions, and are included in the statements of comprehensive loss.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Leases</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the ordinary course of business, the Company enters into lease agreements for office space as well as leases for certain property and equipment. The leases have varying terms and expirations and have provisions to extend or renew the lease agreement, among other terms and conditions, as negotiated. Once the agreement is executed, the lease is assessed to determine whether the lease qualifies as a capital or operating lease.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;When a non-cancelable operating lease includes any fixed escalation clauses and lease incentives for rent holidays or build-out contributions, rent expense is recognized on a straight-line basis over the initial term of the lease. The excess between the average rental amount charged to expense and amounts payable under the lease is recorded in accrued expenses.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Nonqualified Cash Deferral Plan</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company's Cash Deferral Plan (the "Deferral Plan"), provides certain key employees and members of the Board of Directors as selected by the Compensation Committee of the Board of Directors of the Company (the "Compensation Committee"), with an opportunity to defer the receipt of such participant's base salary, bonus and director's fees, as applicable. The Deferral Plan is intended to be a nonqualified deferred compensation plan that complies with the provisions of Section&nbsp;409A of the Internal Revenue Code (the "Code"). All of the investments held in the Deferral Plan are classified as investments held-to-maturity and recorded at fair value with changes in the investments' fair value recognized as earnings in the period they occur. The corresponding liability for the Deferral Plan is included in other non-current liability in the consolidated balance sheets.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Equity-based Compensation</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At December&nbsp;31, 2016, the Company had three equity-based employee compensation plans, which are described more fully in "&#x2014;&nbsp;Note&nbsp;9. Stockholders' Equity." The Company applies the fair value method of measuring equity-based compensation, which requires a public entity to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Loss per Common Share</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company calculates net loss per share as a measurement of the Company's performance while giving effect to all dilutive potential common shares that were outstanding during the reporting period. The Company had a net loss for all periods presented; accordingly, the inclusion of common stock options, unvested RSUs and warrants would be anti-dilutive. Therefore, the weighted average shares used to calculate both basic and diluted earnings per share are the same. See "&#x2014;&nbsp;Note&nbsp;18. Earnings per Share" for further discussion on net loss per share.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Dividends</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has not paid cash dividends on its capital stock to date. The Company currently intends to retain its future earnings, if any, to fund the development and growth of the business and does not foresee payment of a dividend in any upcoming fiscal period.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Segment Information</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company currently operates in one business segment focused on the discovery, development and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases. The Company is not organized by market and is managed and operated as one business. A single management team reports to the chief operating decision maker who comprehensively manages the entire business. The Company does not operate any separate lines of business or separate business entities with respect to its products. Accordingly, the Company does not accumulate discrete financial information with respect to separate service lines and does not have separately reportable segments.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Business Combinations</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company allocates the purchase price of acquired businesses to the tangible and intangible assets acquired and liabilities assumed based upon their estimated fair values on the acquisition date. The purchase price allocation process requires management to make significant estimates and assumptions, especially at the acquisition date with respect to intangible assets and in-process research and development ("IPR&amp;D"). In connection with the purchase price allocations for acquisitions, the Company estimates the fair value of contingent payments utilizing a probability-based income approach inclusive of an estimated discount rate.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Contingent Consideration Payable</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company determines the fair value of contingent acquisition consideration payable on the acquisition date using a probability-based income approach utilizing an appropriate discount rate. Contingent acquisition consideration payable is shown as a non-current liability on the Company's consolidated balance sheets. The fair value of the contingent consideration payable will be determined each period end and the resulting change will be recorded on the consolidated statements of operations.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Intangible Assets and Goodwill</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company records goodwill in a business combination when the total consideration exceeds the fair value of the net tangible and identifiable intangible assets acquired. Purchased IPR&amp;D is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset, or abandoned, at which point the intangible asset will be written off or partially impaired. Goodwill and indefinite lived intangible assets are assessed annually for impairment and whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. If it is determined that the full carrying amount of an asset is not recoverable, an impairment loss is recorded in the amount by which the carrying amount of the asset exceeds its fair value.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Recent Accounting Pronouncements</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In January 2017, the FASB issued ASU 2017-04, </font><font style="display:inline;font-family:Times;font-style:italic;">Intangibles&nbsp;&#x2014; Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment</font><font style="display:inline;font-family:Times;">. To simplify the subsequent measurement of goodwill, ASU 2017-04 eliminates Step 2 from the goodwill impairment test. The annual, or interim, goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit's fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. In addition, income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit should be considered when measuring the goodwill impairment loss, if applicable. ASU 2017-04 also eliminates the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. ASU 2017-04 should be applied on a prospective basis. The nature of and reason for the change in accounting principle should be disclosed upon transition. A public business entity that is a U.S. SEC filer should adopt ASU 2017-04 for its annual or any interim goodwill impairment tests in fiscal years beginning after December&nbsp;15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January&nbsp;1, 2017. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In January 2017, the FASB issued ASU 2017-01, </font><font style="display:inline;font-family:Times;font-style:italic;">Business Combinations (Topic 805): Clarifying the Definition of a Business</font><font style="display:inline;font-family:Times;">. This Accounting Standards Update clarifies the definition of a business. The amendments affect all companies and other reporting organizations that must determine whether they have acquired or sold a business. The amendments in this Update are effective for public companies for annual periods beginning after December&nbsp;15, 2017, including interim periods within those periods. Early adoption is permitted under certain circumstances. The amendments should be applied prospectively as of the beginning of the period of adoption. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In October 2016, the FASB issued ASU 2016-17, </font><font style="display:inline;font-family:Times;font-style:italic;">Consolidation (Topic 810): Interests Held through Related Parties That Are under Common Control.</font><font style="display:inline;font-family:Times;"> This Accounting Standards Update changes the evaluation of whether a reporting entity is the primary beneficiary of a variable interest entity by changing how a reporting entity that is a single decision maker of a variable interest entity treats indirect interests in the entity held through related parties that are under common control with the reporting entity. If a reporting entity satisfies the first characteristic of a primary beneficiary (such that it is the single decision maker of a variable interest entity), the amendments require that reporting entity, in determining whether it satisfies the second characteristic of a primary beneficiary, to include all of its direct variable interests in a variable interest entity and, on a proportionate basis, its indirect variable interests in a variable interest entity held through related parties, including related parties that are under common control with the reporting entity. The amendments in this Update are effective for public business entities for fiscal years beginning after December&nbsp;15, 2016, including interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The Company adopted this ASU in 2016 and the adoption did not have a material impact on its consolidated financial statements.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In October 2016, the FASB issued ASU 2016-16, </font><font style="display:inline;font-family:Times;font-style:italic;">Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory</font><font style="display:inline;font-family:Times;">. This Accounting Standards Update requires an entity to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. The amendments eliminate the exception for an intra-entity transfer of an asset other than inventory. The amendments in this Update are effective for public business entities for annual periods beginning after December&nbsp;15, 2017, including interim reporting periods within those annual reporting periods. Early adoption is permitted for all entities in the first interim period if an entity issues interim financial statements. The Company is currently assessing the impact that this standard will have on its consolidated financial statements. We have not completed our review of the impact of this guidance and do not expect this new guidance to have a material impact on our Consolidated Financial Statements. </font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In August 2016, the FASB issued ASU 2016-15, </font><font style="display:inline;font-family:Times;font-style:italic;">Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments</font><font style="display:inline;font-family:Times;">. This Accounting Standards Update addresses the following eight specific cash flow issues including Debt prepayment or debt extinguishment costs, contingent consideration payments made after a business combination and separately identifiable cash flows and application of the predominance principle. The amendments in this ASU apply to all entities. The amendments in this Update are effective for public business entities for fiscal years beginning after December&nbsp;15, 2017, and interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The Company adopted this ASU in 2016 and the adoption did not have a material impact on its consolidated financial statements.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In March 2016, the FASB issued ASU 2016-09</font><font style="display:inline;font-family:Times;font-style:italic;">, Compensation&nbsp;&#x2014; Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting</font><font style="display:inline;font-family:Times;">. The amendments are intended to improve the accounting for employee share-based payments and affect all organizations that issue share-based payment awards to their employees. Several aspects of the accounting for share-based payment award transactions are simplified, including: (a) income tax consequences; (b) classification of awards as either equity or liabilities; and (c) classification on the statement of cash flows. For public companies, the amendments are effective for annual periods beginning after December&nbsp;15, 2016, and interim periods within those annual periods. Early adoption is permitted for any organization in any interim or annual period. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In February 2016, the FASB issued ASU No.&nbsp;2016-02</font><font style="display:inline;font-family:Times;font-style:italic;">, Leases (Topic 842)</font><font style="display:inline;font-family:Times;">. This update requires the recognition of lease assets and lease liabilities on the balance sheet for all lease obligations and disclosing key information about leasing arrangements. This update requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous generally accepted accounting principles. This update will be effective for the Company for all annual and interim periods beginning after December&nbsp;15, 2018, including interim periods within those fiscal years. Early application is permitted for all public business entities and all nonpublic business entities upon issuance. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330): </font><font style="display:inline;font-family:Times;font-style:italic;">Simplifying the Measurement of Inventory,</font><font style="display:inline;font-family:Times;"> which requires an entity to measure in scope inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The amendments apply to inventory that is measured using first-in, first-out (FIFO) or average cost. The ASU is effective for public business entities for fiscal years beginning after December&nbsp;15, 2016, including interim periods within those fiscal years. A reporting entity should apply the amendments prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In August 2014, the FASB issued ASU 2014-15</font><font style="display:inline;font-family:Times;font-style:italic;">, Presentation of Financial Statements-Going Concern (Subtopic 205-40):</font><font style="display:inline;font-family:Times;"> Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern, which defines management's responsibility to assess an entity's ability to continue as a going concern, and to provide related footnote disclosures if there is substantial doubt about its ability to continue as a going concern. The pronouncement is effective for annual reporting periods ending after December&nbsp;15, 2016 with early adoption permitted. The Company adopted this ASU in 2016 and the adoption did not have a material impact on its consolidated financial statements.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In May 2014, FASB issued ASU 2014-09, </font><font style="display:inline;font-family:Times;font-style:italic;">Revenue from Contracts with Customers</font><font style="display:inline;font-family:Times;"> which along with amendments issued in 2015 and 2016, will replace substantially all current US&nbsp;GAAP guidance on this topic and eliminate industry-specific guidance. Early adoption of this standard is permitted but not before the original effective date for all annual periods and interim reporting periods beginning after December&nbsp;15, 2017. The guidance permits two methods of adoption: full retrospective method (retrospective application to each prior reporting period presented) or modified retrospective method (retrospective application with the cumulative effect of initially applying the guidance recognized at the date of initial application and providing certain additional disclosures). To complete its assessment of the impact of the standard to its financial statements, the Company continues to assess all implications of this standard, method of adoption and related financial disclosures. Additionally, the Company continues to monitor modifications, clarifications and interpretations issued by the FASB that may impact its assessment.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18861-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18726-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18743-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18854-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6811917616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;">3. Acquisitions</font>
		</p>
		<p style="margin:5pt 0pt 5pt 46pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;">Acquisition of MiaMed,&nbsp;Inc.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In July 2016, the Company entered into an Agreement and Plan of Merger (the "MiaMed Agreement") with MiaMed,&nbsp;Inc., ("MiaMed"). MiaMed is a pre-clinical biotechnology company focused on developing protein replacement therapy for CDKL5 and related diseases. Under the terms of the MiaMed Agreement, the former holders of MiaMed's capital stock received an aggregate of $6.5&nbsp;million, comprised of (i)&nbsp;approximately $1.8&nbsp;million in cash (plus MiaMed's cash and cash equivalents at closing and less any of MiaMed's unpaid third-party fees and expenses related to the transaction), and (ii)&nbsp;825,603 shares of the Company's Common Stock. In addition, the Company also agreed to pay up to an additional $83.0&nbsp;million in connection with the achievement of certain clinical, regulatory and commercial milestones, for a potential aggregate deal value of $89.5&nbsp;million. The Company evaluated the transaction based on the guidance of Accounting Standard Codification ("ASC") 805, </font><font style="display:inline;font-family:Times;font-style:italic;">Business Combinations</font><font style="display:inline;font-family:Times;"> and concluded that it only acquired inputs and did not acquire any processes. The Company will need to develop its own processes in order to produce an output. Therefore, the Company accounted for the transaction as an asset acquisition and accordingly $6.5&nbsp;million was expensed to research and development.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 46pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;">Acquisition of Scioderm,&nbsp;Inc.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In September 2015, Amicus acquired Scioderm, a privately-held biopharmaceutical company focused on developing innovative therapies for treating the rare disease Epidermolysis Bullosa ("EB"). The acquisition leverages the Scioderm development team's EB expertise with Amicus' global clinical infrastructure to advance SD-101 toward regulatory approvals and Amicus' commercial, patient advocacy, and medical affairs infrastructure to support a successful global launch. The acquisition of Scioderm was accounted for as a purchase of a business in accordance with FASB ASC 805 Business Combinations.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company acquired Scioderm in a cash and stock transaction. At closing, the Company paid Scioderm shareholders, option holders, and warrant holders approximately $223.9&nbsp;million, of which approximately $141.1&nbsp;million was paid in cash and approximately $82.8&nbsp;million was paid through the issuance of approximately 5.9&nbsp;million newly issued Amicus shares. The Company has agreed to pay up to an additional $361&nbsp;million to Scioderm shareholders, option holders and warrant holders upon achievement of certain clinical and regulatory milestones, and $257&nbsp;million to Scioderm shareholders, option holders, and warrant holders upon achievement of certain sales milestones. If SD-101 is approved, EB qualifies as a rare pediatric disease under The Food and Drug Administration Safety and Innovation Act ("FDSIA") and Amicus will request a Priority Review Voucher ("PRV") under the FDSIA, if available. If the PRV is obtained and subsequently sold, the Company will pay Scioderm shareholders, option holders, and warrant holders the lesser of $100&nbsp;million in the aggregate or 50% of the proceeds of such sale. If Amicus obtains the PRV and has not entered into an agreement to sell or otherwise transfer to a third party the PRV within one year of its receipt, the shareholders 'agent may appoint a financial advisor to conduct a process to sell the PRV. If Amicus determines in its sole discretion to use the PRV, Amicus shall give the shareholders' agent written notice thereof and shall pay to the Scioderm shareholders, option holders, and warrant holders $100&nbsp;million. The inability to sell the PRV after complying with the provisions, shall not give rise to any payment.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The fair value of the contingent consideration payments on the acquisition date was $259.0&nbsp;million. This was an estimate based on significant inputs that are not observable in the market, referred to as Level&nbsp;3 inputs. Key assumptions included a range of discount rates between 0.4% and 1.1% as interpolated from the U.S. Treasury constant maturity yield curve over the time frame for clinical and regulatory milestones and a range of discount rates between 1.0% and 2.2% for revenue-based milestones. The range of outcomes and assumptions used to develop these estimates have been updated to better reflect the probability of certain milestone outcomes and updated timelines related to clinical development and anticipated approval assumptions as of December&nbsp;31, 2016 without limitation, the $5&nbsp;million milestone paid in the second quarter, and milestone payments projected for 2017 (See "&#x2014;&nbsp;Note&nbsp;10. Assets and Liabilities Measured at Fair Value", for additional discussion regarding fair value measurements of the contingent acquisition consideration payable). In April 2016, while the total clinical and regulatory approval milestone payments remain unchanged at $361&nbsp;million, the allocation between the clinical and regulatory approval milestone payments were revised as follows: clinical milestones of up to $81&nbsp;million and regulatory approval milestones of up to $280&nbsp;million. The commercial milestone payments of up to $257&nbsp;million remained unchanged.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company determined the fair value of the contingent consideration to be $260.0&nbsp;million at December&nbsp;31, 2016, of which $56.1&nbsp;million is payable in the next twelve months, resulting in an increase in the contingent consideration payable and related expense of approximately $7.3&nbsp;million for the year ended December&nbsp;31, 2016. The expense is recorded in the Consolidated Statement of Operations as the change within fair value of contingent consideration payable.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For additional information, see "&#x2014;&nbsp;Note&nbsp;4. Goodwill and Intangible Assets."</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The purchase price allocation was subject to completion of the analysis of the fair value of the assets and liabilities as of the effective date of the acquisition. The final valuation was completed as of December&nbsp;31, 2015. A substantial portion of the assets acquired consisted of intangible assets related to SD-101. The Company determined that the estimated acquisition-date fair value of the indefinite lived IPR&amp;D related to the SD-101 was $463.7&nbsp;million.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 46pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;">Acquisition of Callidus Biopharma,&nbsp;Inc.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In November 2013, the Company acquired Callidus a privately-held biologics company focused on developing best-in-class ERTs for LSDs with its lead ERT ATB200 for Pompe disease in late preclinical development. The acquisition of the Callidus assets and technology complements Amicus' CHART&#x2122; platform for the development of next generation ERTs.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The fair value of the contingent acquisition consideration payments on the acquisition date was $10.6&nbsp;million and was estimated by applying a probability-based income approach utilizing an appropriate discount rate. Key assumptions included a discount rate of 13.5% and various probability factors. This estimation was based on significant inputs that are not observable in the market, referred to as Level&nbsp;3 inputs. Some of the more significant assumptions used in the valuation include (i)&nbsp;the probability and timing related to the achievement of certain developmental milestones and (ii)&nbsp;and the discount rate. As of December&nbsp;31, 2016, the range of outcomes and assumptions used to develop these estimates has changed to better reflect the probability of certain milestone outcomes. See "&#x2014;&nbsp;Note&nbsp;10. Assets and Liabilities Measured at Fair Value", for additional discussion regarding fair value measurements of the contingent acquisition consideration payable. The Company determined the fair value of the contingent consideration to be $9.7&nbsp;million at December&nbsp;31, 2016, all of which is payable beyond the next twelve months, resulting in an decrease in the contingent consideration payable and related gain of $0.5&nbsp;million year ended December&nbsp;31, 2016. The expense is recorded in the Consolidated Statement of Operations within the changes in fair value of contingent consideration line item.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During the second quarter of 2016, the Company reached the first clinical milestone, which was the dosing of the first patient in a Phase&nbsp;1 or 2 study. The milestone for this event was $6.0&nbsp;million which was paid in Company stock during the second quarter of 2016, resulting in $6.1&nbsp;million impact on stockholder's equity.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For further information, see "&#x2014;&nbsp;Note&nbsp;4. Goodwill and Intangible Assets."</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=56956515&amp;loc=d3e1497-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=56956515&amp;loc=d3e1490-128463<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=56956515&amp;loc=d3e1392-128463<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=56956515&amp;loc=d3e1486-128463<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4845-128472<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=56956515&amp;loc=d3e1500-128463<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=56956515&amp;loc=d3e1524-128463<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7000-128479<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4922-128472<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4934-128472<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4926-128472<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=56956515&amp;loc=d3e1383-128463<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6996-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6811952704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;">4. Goodwill and Intangible Assets</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with the acquisitions discussed in "&#x2014;&nbsp;Note&nbsp;3. Acquisitions, the Company has recognized goodwill of $197.8&nbsp;million. The following table represents the changes in goodwill for the year ended December&nbsp;31, 2016:</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(in millions)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Balance at December&nbsp;31, 2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>197.8&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Change in goodwill</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Balance at December&nbsp;31, 2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>197.8&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with the acquisitions discussed in "&#x2014;&nbsp;Note&nbsp;3. Acquisitions," the Company recognized IPR&amp;D of $486.7&nbsp;million. Intangible assets related to IPR&amp;D assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. During the period the assets are considered indefinite-lived, they will not be amortized but will be tested for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&amp;D assets below their respective carrying amounts. The following table represents the changes in IPR&amp;D for the year ended December&nbsp;31, 2016:</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(in millions)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Balance at December&nbsp;31, 2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>486.7&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Change in IPR&amp;D</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Balance at December&nbsp;31, 2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>486.7&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Goodwill and intangible assets are assessed annually for impairment on October&nbsp;1 and whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. If it is determined that the full carrying amount of an asset is not recoverable, an impairment loss is recorded in the amount by which the carrying amount of the asset exceeds its fair value. During the 2016 annual impairment assessment, it was determined that the goodwill and intangible assets had not been impaired therefore there were no changes to the balances of goodwill and IPR&amp;D in 2016.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final.  May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16265-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6821730288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Money Market Funds and Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Money Market Funds and Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock', window );">Cash, Money Market Funds and Marketable Securities</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;">5. Cash, Money Market Funds and Marketable Securities</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of December&nbsp;31, 2016, the Company held $187.0&nbsp;million in cash and cash equivalents and $143.3&nbsp;million of available-for-sale securities which are reported at fair value on the Company's Consolidated Balance Sheets. Unrealized holding gains and losses are reported within accumulated other comprehensive income/ (loss) in the statements of comprehensive loss. If a decline in the fair value of a marketable security below the Company's cost basis is determined to be other than temporary, such marketable security is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge. To date, only temporary impairment adjustments have been recorded.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company regularly invests excess operating cash in deposits with major financial institutions, money market funds, notes issued by the U.S. government, as well as fixed income investments and U.S. bond funds both of which can be readily purchased and sold using established markets. The Company believes that the market risk arising from its holdings of these financial instruments is mitigated as many of these securities are either government backed or of the highest credit rating. Investments that have original maturities or greater than 3&nbsp;months but less than 1&nbsp;year are classified as short-term and investments with maturities that are greater than 1&nbsp;year are classified as long-term.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company transacts business in various foreign countries and therefore, is subject to risk of foreign currency exchange rate fluctuations. As such, in June 2016 the Company entered into a forward contract to economically hedge transactional exposure associated with commitments arising from trade accounts payable denominated in a currency other than the functional currency of the respective operating entity. The Company does not designate these forward contracts as hedging instruments under applicable accounting guidance and, therefore, changes in fair value are recorded within other income (expense) in the Consolidated Statements of Operations, with the corresponding liability in current liabilities on the Consolidated Balance Sheet. For the year ended December&nbsp;31, 2016, the Company recognized a loss of $0.3&nbsp;million, related to the derivative instruments not designated as hedging instruments in other expense in the Consolidated Statements of Operations and the corresponding liability of $0.3&nbsp;million is recorded as other current liability in the Consolidated Balance Sheets.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash and available for sale securities consisted of the following as of December&nbsp;31, 2016 and December&nbsp;31, 2015 (in thousands):</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="11" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">As of December&nbsp;31, 2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Cost</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Unrealized<br />Gain</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Unrealized<br />Loss</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Fair<br />Value</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Cash balances</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>187,026
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>187,026
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Corporate debt securities, current portion</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>74,564
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(31
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>74,535
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Commercial paper</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>68,258
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>132
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>68,390
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Money market</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>350
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>350
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Certificate of deposit</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>50
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>50
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>330,248
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>134
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(31
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>330,351
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Included in cash and cash equivalents</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>187,026
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>187,026
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Included in marketable securities</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>143,222
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>134
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(31
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>143,325
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Total cash and marketable securities</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>330,248
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>134
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(31
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>330,351
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="11" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">As of December&nbsp;31, 2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Cost</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Unrealized<br />Gain</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Unrealized<br />Loss</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Fair<br />Value</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Cash balances</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>69,485
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>69,485
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Corporate debt securities, current portion</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>118,627
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(154
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>118,474
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Commercial paper</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,686
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>38
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,724
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Certificate of deposit</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>350
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>350
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>214,148
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>39
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(154
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>214,033
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Included in cash and cash equivalents</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>69,485
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>69,485
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Included in marketable securities</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>144,663
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>39
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(154
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>144,548
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Total cash and marketable securities</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>214,148
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>39
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(154
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>214,033
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For the years ended December&nbsp;31, 2016 and 2015, there were no realized gains or losses. The cost of securities sold is based on the specific identification method.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unrealized loss positions in the available for sale securities as of December&nbsp;31, 2016 and December&nbsp;31, 2015 reflect temporary impairments that have been in a loss position for less than twelve months and as such are recognized in other comprehensive gain/ (loss). The fair value of these available for sale securities in unrealized loss positions was $58.7&nbsp;million and $118.5&nbsp;million as of December&nbsp;31, 2016 and 2015, respectively.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company holds available-for-sale investment securities which are reported at fair value on the Company's balance sheet. Unrealized holding gains and losses are reported within accumulated other comprehensive income ("AOCI") in the statements of comprehensive loss.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6811832800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventories</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;">6. Inventories</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories consist of work in process and finished goods related to the manufacture of Galafold. The following table summarizes the components of inventories at December&nbsp;31, 2016 (in thousands):</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31,&nbsp;2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Work-in-process</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,308&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Finished goods</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>108&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">Total inventories</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,416&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There were no inventories on-hand as of December&nbsp;31, 2015. Inventory manufactured prior to commercialization was expensed to research and development. Inventories are reviewed periodically to identify slow-moving or obsolete inventory based on projected sales activity, as well as product shelf-life. In evaluating the recoverability of inventories produced, the Company considers the probability that revenue will be obtained from the future sale of the related inventory. Inventory becomes obsolete when it has aged past its shelf-life, cannot be recertified and is no longer usable or able to be sold, or the inventory has been damaged. In such instances, a full reserve is taken against such inventory. Expired inventory is disposed of and the related costs are recognized as cost of product sales in the consolidated statement of operations. There have been no write-downs of inventory from the time inventory was first capitalized.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 6<br> -Subparagraph a, b, c<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6811988160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;">7. Property and Equipment</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property and equipment consist of the following (in thousands):</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Property and equipment consist of the following:</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Computer equipment</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,511
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,075
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Computer software</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,347
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,354
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Research equipment</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,465
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,483
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Furniture and fixtures</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,018
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,444
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Leasehold improvements</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,970
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,175
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>22,311
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,531
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Less accumulated depreciation</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(12,495
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(13,353
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,816
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,178
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation expense was $3.2&nbsp;million and $1.8&nbsp;million for the years ended December&nbsp;31, 2016 and 2015, respectively. As of December&nbsp;31, 2016, $0.2&nbsp;million of the depreciation expense was related to capital lease obligation. There were no capital lease obligations outstanding as of December&nbsp;31, 2015.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13-14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51717284&amp;loc=d3e1361-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=51719941&amp;loc=d3e2921-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6811900064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accounts Payable and Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Expenses</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;">8. Accounts Payable and Accrued Expenses</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and accrued expenses consist of the following (in thousands):</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Accounts payable</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,905&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>16,477&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Accrued professional fees</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,079&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,578&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Accrued contract manufacturing&nbsp;&amp; contract research costs</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,042&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,940&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Accrued compensation and benefits</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,981&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,201&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Accrued facility costs</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,740&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,321&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Foreign currency forward contract</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>265&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Capital lease, short term portion</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>283&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Accrued other</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,713&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,699&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>41,008&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>32,216&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6821602000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;">9. Stockholders' Equity</font>
		</p>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Common Stock and Warrants</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of December&nbsp;31, 2016, the Company was authorized to issue 250&nbsp;million shares of common stock. Dividends on common stock will be paid when, and if, declared by the board of directors. Each holder of common stock is entitled to vote on all matters that are appropriate for stockholder voting and is entitled to one vote for each share held.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As discussed in "&#x2014;&nbsp;Note&nbsp;16. Debt Instruments and Related Party Transactions", on December&nbsp;21, 2016, the Company issued $250&nbsp;million aggregate principal amount of 3.0% unsecured Convertible Senior Notes due 2023 (the "Convertible Notes), in a private offering. The Notes will mature on December&nbsp;15, 2023, unless earlier repurchased, redeemed, or converted in accordance with their terms. The Notes are convertible at the option of the holders, under certain circumstances and during certain periods, into cash, shares of the Company's common stock, par value $0.01 per share ("Common Stock"), or a combination thereof. Prior to the close of business on the business day immediately preceding September&nbsp;15, 2023, the Notes are convertible at the option of the holders of the Notes only under certain conditions. On or after September&nbsp;15, 2023, until the close of business on the second business day immediately preceding the maturity date, holders of the Notes may convert their Notes at their option at the conversion rate then in effect, irrespective of these conditions. The Company will settle conversions of the Notes by paying or delivering, as the case may be, cash, shares of Common Stock, or a combination of cash and shares of Common Stock, at the Company's election. The conversion rate will initially be 163.3987 shares of Common Stock per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $6.12 per share of Common Stock). The conversion rate is subject to customary adjustments upon the occurrence of certain events.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beginning in April 2016 and through July 2016, the Company sold 15.0&nbsp;million shares of Common Stock under an ATM equity program with Cowen and Company,&nbsp;LLC ("Cowen") acting as sales agent. Cowen was compensated at a fixed commission rate up to 3.0%. The ATM sales agreement resulted in net proceeds of $97.1&nbsp;million, after Cowen's commission of $2.7&nbsp;million and other expenses of $0.2&nbsp;million. The Company has completed all sales under the ATM equity program.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As discussed in "&#x2014;&nbsp;Note&nbsp;16. Debt instruments and Related Party Transactions," the Company issued approximately 1.8&nbsp;million and 1.3&nbsp;million of warrants in February 2016 and June 2016, respectively. The closing balance of the warrants was $16.1&nbsp;million as of December&nbsp;31, 2016 and is recorded within equity on the Consolidated Balance Sheets.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As discussed in "&#x2014;&nbsp;Note&nbsp;3. Acquisitions, in July 2016, the Company entered into an Agreement and Plan of Merger (the "MiaMed Agreement") with MiaMed. Under the terms of the MiaMed Agreement, the former holders of MiaMed's capital stock received an aggregate of $6.5&nbsp;million, comprised of (i)&nbsp;approximately $1.8&nbsp;million in cash (plus MiaMed's cash and cash equivalents at closing and less any of MiaMed's unpaid third-party fees and expenses related to the transaction), and (ii)&nbsp;825,603 shares of the Company's Common Stock. In addition, the Company also agreed to pay up to an additional $83.0&nbsp;million in connection with the achievement of certain clinical, regulatory and commercial milestones, for a potential aggregate deal value of $89.5&nbsp;million.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As discussed in "&#x2014;&nbsp;Note&nbsp;3. Acquisitions, in September 2015, the Company acquired Scioderm with cash and stock. As part of the acquisition, the Company paid holders of Scioderm an amount equal to $223.9&nbsp;million, of which approximately $141.1&nbsp;million was paid in cash and approximately $82.8&nbsp;million was paid through the issuance of 5.9&nbsp;million newly issued shares. The Company agreed to pay up to an additional $361&nbsp;million upon achievement of certain clinical and regulatory milestones, and $257&nbsp;million to Scioderm shareholders, option holders, and warrant holders upon achievement of certain sales milestones.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In June 2015, the Company issued a total of 19.5&nbsp;million shares through a public offering at a price of $13.25 per share, with net proceeds of $243.0&nbsp;million. The Company expects to use the net proceeds of the offering for investment in the global commercialization infrastructure for Galafold for Fabry disease, the continued clinical development of its product candidates and for other general corporate purposes.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In November 2014, the Company sold a total of 15.9&nbsp;million shares of our common stock, par value $0.01 per share, at a public offering price of $6.50 per share. The aggregate offering proceeds were approximately $97.2&nbsp;million.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In July 2014, the Company completed a $40&nbsp;million ATM equity offering under which the Company sold shares of its common stock, par value $0.01 per shares with Cowen and Company&nbsp;LLC as sales agent. Under the ATM equity program the Company sold 14.3&nbsp;million shares of common stock resulting in net proceeds of $38.6&nbsp;million.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Nonqualified Cash Plan</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company's Deferral Plan, (the "Deferral Plan") provides certain key employees and members of the Board of Directors as selected by the Compensation Committee, with an opportunity to defer the receipt of such participant's base salary, bonus and director's fees, as applicable. The Deferral Plan is intended to be a nonqualified deferred compensation plan that complies with the provisions of Section&nbsp;409A of the Internal Revenue Code of 1986 as amended.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred compensation amounts under the Deferral Plan as of December&nbsp;31, 2016 were approximately $1.5&nbsp;million, as compared to $0.7&nbsp;million on December&nbsp;31, 2015 and are included in other long-term liabilities. Deferral Plan assets as of December&nbsp;31, 2016 were $1.5&nbsp;million as compared to $0.7&nbsp;million as of December&nbsp;31, 2015 and are classified as trading securities. The Deferred Plan assets are recorded at fair value with changes in the investments' fair value recognized in AOCI in the period they occur. The income from investment for the year ended December&nbsp;31, 2016 and 2015 was $34&nbsp;thousand and $17&nbsp;thousand respectively. Unrealized gain approximated $32&nbsp;thousand for the year ended December&nbsp;31, 2016, as compared to unrealized loss of $50&nbsp;thousand for the year ended December&nbsp;31, 2015.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Equity Incentive Plans</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company's Equity Incentive Plans consist of the Amended and Restated 2007 Equity Incentive Plan (the "Plan") and the 2007 Director Option Plan (the "2007 Director Plan"). The Plan provides for the granting of restricted stock and options to purchase common stock in the Company to employees, advisors and consultants at a price to be determined by the Company's board of directors. The Plan is intended to encourage ownership of stock by employees and consultants of the Company and to provide additional incentives for them to promote the success of the Company's business. The 2007 Director Plan is intended to promote the recruiting and retention of highly qualified eligible directors and strengthen the commonality of interest between directors and stockholders by encouraging ownership of common stock of the Company. Under the provisions of each plan, no option will have a term in excess of 10&nbsp;years.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board of Directors, or its committee, is responsible for determining the individuals to be granted options, the number of options each individual will receive, the option price per share, and the exercise period of each option. Options granted pursuant to the Plan generally vest 25% on the first year anniversary date of grant plus an additional 1/48th&nbsp;for each month thereafter and may be exercised in whole or in part for 100% of the shares vested at any time after the date of grant. Options under the 2007 Director Plan may be granted to new directors upon joining the Board and vest in the same manner as options under the Plan. In addition, options are automatically granted to all directors at each annual meeting of stockholders and vest on the date of the annual meeting of stockholders of the Company in the year following the year during which the options were granted.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of December&nbsp;31, 2016, the Company has reserved up to 12,630,511 shares for issuance under the Plan and the 2007 Director Plan.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Stock Option Grants</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company adopted the fair value method of measuring stock-based compensation, using the fair value of each equity award granted. The Company chose the "straight-line" attribution method for allocating compensation costs and recognized the fair value of each stock option on a straight-line basis over the vesting period of the related awards.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company uses the Black-Scholes option pricing model when estimating the grant date fair value for stock-based awards. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs. Expected volatility was based on our historical volatility since our initial public offering in May 2007.The average expected life was determined using the "simplified" method of estimating the expected exercise term which is the mid-point between the vesting date and the end of the contractual term. As the Company's stock price volatility has been over 75% and it has experienced significant business transactions, the Company does not have sufficient reliable exercise data in order to justify a change in the use of the "simplified" method of estimating the expected exercise term of employee stock option grants. The risk-free interest rate is based on U.S. Treasury, zero-coupon issues with a remaining term equal to the expected life assumed at the date of grant. Forfeitures are estimated based on voluntary termination behavior, as well as a historical analysis of actual option forfeitures.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The weighted average assumptions used in the Black-Scholes option pricing model are as follows:</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Years Ended<br />December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Expected stock price volatility</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>81.3&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>75.9&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>81.3&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Risk free interest rate</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.5&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.7&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.9&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Expected life of options (years)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.25&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.25&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.25&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Expected annual dividend per share</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.00&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.00&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.00&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The weighted average grant-date fair value per share of options granted during 2016, 2015 and 2014 were $5.28, $7.51 and $2.12, respectively.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes information about stock options outstanding:</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Number of<br />Shares</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Weighted<br />Average<br />Exercise<br />Price</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Weighted<br />Average<br />Remaining<br />Contractual Life</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Aggregate<br />Intrinsic<br />Value</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(in thousands)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(in millions)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Options outstanding, December&nbsp;31, 2013</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,041.1
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.65
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Granted</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,993.1
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.99
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Exercised</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(965.6
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.80
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Forfeited</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,047.9
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.76
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Options outstanding, December&nbsp;31, 2014</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,020.7
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.02
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Granted</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,917.2
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11.61
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Exercised</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,070.3
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.43
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Forfeited</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(138.4
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.76
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Options outstanding, December&nbsp;31, 2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,729.2
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.11
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Granted</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,114.1
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.67
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Exercised</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(723.1
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.20
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Forfeited</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(622.7
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.62
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Options outstanding, December&nbsp;31, 2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,497.5
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.37
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">7.3&nbsp;years</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.8
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Vested and unvested expected to vest, December&nbsp;31, 2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(14,593.7
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.31
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">7.2&nbsp;years</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.7
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Exercisable at December&nbsp;31, 2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,545.3
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.57
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">5.8&nbsp;years</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.8
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The aggregate intrinsic value of options exercised during the years ended December&nbsp;31, 2016, 2015 and 2014 was $2.6&nbsp;million, $14.7&nbsp;million and $2.8&nbsp;million respectively. Cash proceeds from stock options exercised during the years ended December&nbsp;31, 2016, 2015, and 2014 were $3.0&nbsp;million, $11.2&nbsp;million, and $3.7&nbsp;million, respectively. As of December&nbsp;31, 2016, the total unrecognized compensation cost related to non-vested stock options granted was $33.7&nbsp;million and is expected to be recognized over a weighted average period of 2.8&nbsp;years.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Restricted Stock Units</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;RSUs awarded under the Plan are generally subject to graded vesting and are contingent on an employee's continued service. RSUs are generally subject to forfeiture if employment terminates prior to the release of vesting restrictions. The Company expenses the cost of the RSUs, which is determined to be the fair market value of the shares of common stock underlying the RSUs at the date of grant, ratably over the period during which the vesting restrictions lapse.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A summary of non-vested RSU activity under the Plan for the year ended December&nbsp;31, 2016 is as follows:</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Number of<br />Share</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Weighted<br />Average Grant<br />Date Fair<br />Value</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Weighted<br />Average<br />Remaining<br />Years</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Aggregate<br />Intrinsic<br />Value</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(in thousands)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(in millions)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Non-vested units as of December&nbsp;31, 2014</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>955.0
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.28
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Granted</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>366.0
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12.63
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Vested</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(842.5
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Forfeited</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Non-vested units as of December&nbsp;31, 2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>478.5
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10.38
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Granted</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>582.7
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.21
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Vested</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(281.9
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.73
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Forfeited</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(34.9
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.71
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Non-vested units as of December&nbsp;31, 2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>744.4
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.86
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.62
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For the year ended December&nbsp;31, 2016, 0.3&nbsp;million of the RSUs vested and all non-vested units are expected to vest over their normal term. As of December&nbsp;31, 2016, there was $4.2&nbsp;million of total unrecognized compensation cost related to unvested RSUs with service-based vesting conditions. These costs are expected to be recognized over a weighted average period of 2.62&nbsp;years.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On December&nbsp;30, 2016, the Compensation Committee approved a form of Performance-Based Restricted Stock Unit Award Agreement (the "Performance-Based RSU Agreement"), to be used for performance-based RSUs granted to participants under the Amended and Restated Amicus Therapeutics,&nbsp;Inc. 2007 Equity Incentive Plan, including named executive officers. Awards under the form of Performance-Based RSU Agreement will vest based on the Company meeting specified performance criteria. Vesting of the RSUs is generally subject to the participant's continuous service with the Company through a specified date. As of December&nbsp;31, 2016 there were no RSUs issued under the Performance-Based RSU Agreement.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Compensation Expense Related to Equity Awards</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes the equity-based compensation expense recognized in the statements of operations (in thousands):</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Years Ended December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Equity compensation expense recognized in:</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Research and development expense</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,071&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,600&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,703&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Selling, general and administrative expense</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,433&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,372&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,305&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Total equity compensation expense</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17,504&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,972&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,008&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(d),(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Preferred Stock<br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section E<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section C<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6821541312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Assets and Liabilities Measured at Fair Value<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Assets and Liabilities Measured at Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Assets and Liabilities Measured at Fair Value</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;">10. Assets and Liabilities Measured at Fair Value</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company's financial assets and liabilities are measured at fair value and classified within the fair value hierarchy which is defined as follows:</font>
		</p>
		<p style="margin:5pt 0pt 5pt 72pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Level&nbsp;1 &#x2014;</font><font style="display:inline;font-family:Times;"> Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 72pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Level&nbsp;2 &#x2014;</font><font style="display:inline;font-family:Times;"> Inputs other than quoted prices in active markets that are observable for the asset or liability, either directly or indirectly.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 72pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Level&nbsp;3 &#x2014;</font><font style="display:inline;font-family:Times;"> Inputs that are unobservable for the asset or liability.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December&nbsp;31, 2016 are identified in the following table (in thousands):</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Level&nbsp;2</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Total</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Commercial paper</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>68,390&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>68,390&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Corporate debt securities</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>74,535&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>74,535&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Money market funds</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,829&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,829&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>144,754&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>144,754&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Level&nbsp;2</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Level&nbsp;3</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Total</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Liabilities:</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Contingent consideration payable</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>269,722&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>269,722&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Derivative liability</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>265&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>265&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Deferred compensation plan liability</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,479&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,479&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,744&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>269,722&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>271,466&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A summary of the fair value of the Company's assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December&nbsp;31, 2015 are identified in the following table (in thousands):</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Level&nbsp;2</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Total</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Commercial paper</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,724&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,724&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Corporate debt securities</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>118,474&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>118,474&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Certificate of deposit</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>350&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>350&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Market exchanged mutual funds</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>658&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>658&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>145,206&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>145,206&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Level&nbsp;2</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Level&nbsp;3</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Total</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Liabilities:</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Contingent consideration payable</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>274,077&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>274,077&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Deferred compensation plan liability</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>667&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>667&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>667&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>274,077&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>274,744&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;See "&#x2014; Note&nbsp;16. Debt Instruments and Related Party Transactions" for the carrying amount and estimated fair value of the Company's Convertible Notes due in 2023. The Company did not have any Level&nbsp;3 assets as of December&nbsp;31, 2016 or 2015.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Cash, Money Market Funds and Marketable Securities</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company classifies its cash and money market funds within the fair value hierarchy as Level&nbsp;1 as these assets are valued using quoted prices in active market for identical assets at the measurement date. The Company considers its investments in marketable securities as available for sale and classifies these assets within the fair value hierarchy as Level&nbsp;2 primarily utilizing broker quotes in a non-active market for valuation of these securities. No changes in valuation techniques or inputs occurred during the year ended December&nbsp;31, 2016. No transfers of assets between Level&nbsp;1 and Level&nbsp;2 of the fair value measurement hierarchy occurred during the year ended December&nbsp;31, 2016.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Contingent Consideration Payable</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The contingent consideration payable resulted from the acquisitions of Scioderm and Callidus, as discussed in "&#x2014; Note&nbsp;3. Acquisitions." The most recent valuation was determined using a probability weighted discounted cash flow valuation approach. Using this approach, expected future cash flows are calculated over the expected life of the agreement, are discounted, and then exercise scenario probabilities are applied. The valuation is performed quarterly. Gains and losses are included in the statement of operations.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As discussed in "&#x2014; Note&nbsp;3. Acquisitions," on July&nbsp;5, 2016, the Company entered into the MiaMed Agreement with MiaMed. MiaMed is a pre-clinical biotechnology company focused on developing protein replacement for CDKL5 and related diseases. Under the terms of the MiaMed Agreement, the Company agreed to pay up to an additional $83.0&nbsp;million in connection with the achievement of certain clinical, regulatory and commercial milestones, for a potential aggregate deal value of $89.5&nbsp;million. The MiaMed Agreement was accounted for as an asset acquisition and as such the Company determined that a liability for future milestone payments is not required to be recorded until the actual contingencies are met and will be recorded to research and development expenses when the contingency is resolved.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The contingent consideration payable for Scioderm and Callidus has been classified as a Level&nbsp;3 recurring liability as its valuation requires substantial judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for the various inputs to the valuation approach the estimated fair value could be significantly higher or lower than the fair value the Company determined. The Company may be required to record losses in future periods, including expenses related to CDKL5.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following significant unobservable inputs were used in the valuation of the contingent consideration payable to former Scioderm stockholders:</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Contingent Consideration Liability </font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Fair value as of<br />December&nbsp;31,<br />2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Valuation Technique</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Unobservable Input</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Range</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Discount rate</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">0.62%&nbsp;-&nbsp;3.8%</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:12pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Clinical and regulatory milestones</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$237.2&nbsp;million</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Probability weighted discounted cash flow</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Probability of achievement of milestones</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">66.5%&nbsp;-&nbsp;100.0%</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Projected year of payments</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">2017-2019</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Revenue volatility</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">58%</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Probability of achievement of milestones</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">66.5%</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:12pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Revenue-based milestones</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$22.8&nbsp;million</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Monte Carlo</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Discount rate</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">1.47%&nbsp;-&nbsp;2.55%</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:12pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Projected year of payments</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">2019-2029</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following significant unobservable inputs were used in the valuation of the contingent consideration payable of Callidus for the ATB-200 Pompe program:</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Contingent Consideration Liability </font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Fair value as of<br />December&nbsp;31,<br />2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Valuation Technique</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Unobservable Input</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Range</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Discount rate</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">12.5%</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:12pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Clinical and regulatory milestones</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$9.3&nbsp;million</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Probability weighted discounted cash flow</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Probability of achievement of milestones</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">30.4%-42.8%</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Projected year of payments</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">2018-2022</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Contingent consideration liabilities are remeasured to fair value each reporting period using projected revenues, discount rates, probabilities of payment and projected payment dates. Projected contingent payment amounts related to clinical and regulatory based milestones are discounted back to the current period using a discounted cash flow model. Revenue-based payments are valued using a monte-carlo valuation model, which simulates future revenues during the earn out-period using management's best estimates. Projected revenues are based on our most recent internal operational budgets and long-range strategic plans. Increases in projected revenues and probabilities of payment may result in higher fair value measurements. Increases in discount rates and the time to payment may result in lower fair value measurements. Increases or decreases in any of those inputs together, or in isolation, may result in a significantly lower or higher fair value measurement. There is no assurance that any of the conditions for the milestone payments will be met.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table shows the change in the balance of contingent consideration payable for the year ended December&nbsp;31, 2016 and 2015, respectively (in thousands):</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Year ended December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Balance, beginning of the period</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>274,077
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,700
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Additions, from business acquisitions</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>259,000
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Payment of contingent consideration in cash</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(5,000
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Payment of contingent consideration in stock</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(6,115
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Unrealized change in fair value change during the period, included in Statement of Operations</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,760
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,377
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Balance, end of the period</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>269,722
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>274,077
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Deferred Compensation Plan- Investment and Liability</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As disclosed in "&#x2014; Note&nbsp;9. Stockholders' Equity," the Deferral Plan provides certain key employees and members of the Board of Directors with an opportunity to defer the receipt of such participant's base salary, bonus and director's fees, as applicable. Deferral Plan assets are classified as trading securities and recorded at fair value with changes in the investments' fair value recognized in the period they occur. The asset investments consist of market exchanged mutual funds. The Company considers its investments in marketable securities, as available-for-sale and classifies these assets and related liability within the fair value hierarchy as Level&nbsp;2 primarily utilizing broker quotes in a non-active market for valuation of these securities.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Foreign Currency Exchange Rate Exposure</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company transacts business in various foreign countries and therefore, is subject to risk of foreign currency exchange rate fluctuations. As such, in June 2016, the Company entered into a forward contract to economically hedge transactional exposure associated with commitments arising from trade accounts payable denominated in a currency other than the functional currency of the respective operating entity. The Company did not designate this forward contract as a hedging instrument under applicable accounting guidance and, therefore, the change in fair value is recorded in the Consolidated Statements of Operations. The forward contract settles in monthly installments with the final installment settlement in June 2017.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There were no outstanding forward contracts at December&nbsp;31, 2015.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For the year ended December&nbsp;31, 2016, the Company recognized a loss of $265&nbsp;thousand, related to the derivative instruments not designated as hedging instruments in the Consolidated Statements of Operations and the corresponding liability of $265&nbsp;thousand is recorded as other current liability in the Consolidated Balance Sheets.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The impact of gains and losses on foreign exchange contracts not designated as hedging instruments related to changes in the fair value of assets and liabilities denominated in foreign currencies are generally offset by net foreign exchange gains and losses, which are also included on the Consolidated Statements of Operations in other income (expense), net for all periods presented. When the Company enters into foreign exchange contracts not designated as hedging instruments to mitigate the impact of exchange rate volatility in the translation of foreign earnings, gains and losses will generally be offset by fluctuations in the U.S. Dollar translated amounts of each account within the Consolidated Statements of Operations in current and/or future periods.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13504-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6821767584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>401(k) Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">401(k) Plan</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;">11. 401(k) Plan</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has a 401(k) plan (the "401(k) Plan") covering all eligible employees and provides for a company match of up to 5% of salary and bonus paid during the year. The Company's vesting policy is that the Company match vests immediately upon enrollment. There were no changes to the policy in 2016 or 2015. The Company's total contribution to the 401(k) Plan was $1.2&nbsp;million, $0.9&nbsp;million and $0.6&nbsp;million for the years ended December&nbsp;31, 2016, 2015 and 2014, respectively.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 80<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=49170332&amp;loc=SL14450702-114947<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=58740216&amp;loc=d3e2410-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39675-114964<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6414199&amp;loc=d3e39622-114963<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6821541312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOfLesseeDisclosureTextBlock', window );">Leases</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;">12. Leases</font>
		</p>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Operating Leases</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company currently leases office space and research laboratory space in various facilities under operating agreements expiring at various dates through 2025.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table contains information about our current significant leased properties as of December&nbsp;31, 2016:</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Location </font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Approximate<br />Square Feet</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Use</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Lease expiry date</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Cranbury, New Jersey</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>90,000&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Office and laboratory</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">September 2025</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Durham, North Carolina</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,603&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Office</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">June 2018</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Buckinghamshire, United Kingdom</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,821&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Office</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">September 2020</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Munich, Germany</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,316&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Office</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">April 2017</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition to the above, we also maintain small offices in the Italy, France, Netherlands and Spain. We believe that our current office and laboratory facilities are adequate and suitable for our current and anticipated needs. We believe that, to the extent required, we will be able to lease or buy additional facilities at commercially reasonable rates.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rent expenses for the Company's facilities are recognized over the term of the lease. The Company recognizes rent starting when possession of the facility is taken from the landlord. When a lease contains a predetermined fixed escalation of the minimum rent, the Company recognizes the related rent expense on a straight-line basis and records the difference between the recognized rental expense and the amounts payable under the lease as deferred rent liability. Tenant leasehold improvement allowances are reflected in accrued expenses on the consolidated balance sheets and are amortized as a reduction to rent expense in the statement of operations over the term of the lease.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At December&nbsp;31, 2016, aggregate annual future minimum lease payments under these leases are as follows:</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(in thousands) </font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2018</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2019</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2020</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2021 and<br />beyond</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Total</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Minimum lease payments</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,666&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,483&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,421&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,349&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,537&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,456&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rent expense, including fees for utilities and common area maintenances for the years ended December&nbsp;31, 2016, 2015 and 2014 were $3.5&nbsp;million, $2.6&nbsp;million and $2.4&nbsp;million, respectively.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Capital Leases</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In 2016, the Company purchased equipment of approximately $0.9&nbsp;million through financing arrangements. These financing arrangements include interest of approximately 0.2-5.7%, and lease terms of 36-48&nbsp;months.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At December&nbsp;31, 2016, aggregate annual future minimum lease payments under these leases, including interest, are as follows (in thousands):</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Years ending December&nbsp;31: </font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">2017</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>355&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">2018</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>355&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">2019</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>134&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">2020</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">2021 and beyond</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Total principal obligation</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>844&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6452660&amp;loc=d3e36991-112694<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 1,3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6851643&amp;loc=d3e12069-110248<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6821608656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;">13. Income Taxes</font>
		</p>
		<p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For financial reporting purposes, income (loss) before income taxes includes the following components (in thousands):</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Years Ended December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">United States</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(174,913
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(123,697
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(70,030
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Foreign</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(28,868
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(8,421
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(9
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Total</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(203,781
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(132,118
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(70,039
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A reconciliation of the statutory tax rates and the effective tax rates for the years ended December&nbsp;31, 2016, 2015 and 2014 are as follows:</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Years Ended<br />December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Statutory rate</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(34
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(34
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(34
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)%</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">State taxes, net of federal benefit</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(5
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(5
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Permanent adjustments</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">R&amp;D credit</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Foreign income tax rate differential</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Other</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Valuation allowance</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>36
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>37
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>38
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Net</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)%</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company recognized a tax benefit of $1.1&nbsp;million in connection with the sale of net operating losses and research and development credits in the New Jersey Transfer Program for the year ended December&nbsp;31, 2014. There were no sales of net operating losses and research and development credits for the years ended December&nbsp;31, 2016 and 2015.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company recorded an income tax benefit of $3.7&nbsp;million in the Consolidated Statement of Operations for the year ended December&nbsp;31, 2016. The benefit was primarily from $2.7&nbsp;million in income tax benefit in connection with the reduction in state tax rates in North Carolina, and $1.2&nbsp;million from reduction in its valuation allowance to reflect the income tax associated with the gain on foreign currency translation recorded in the Consolidated Statement of Comprehensive Loss for the year ended December&nbsp;31, 2016.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company did not recognize interest or penalties related to income tax during the period ended December&nbsp;31, 2016 and did not accrue for interest or penalties as of December&nbsp;31, 2016. The Company does not have an accrual for uncertain tax positions as of December&nbsp;31, 2016. Tax returns for all years 2009 and thereafter are subject to future examination by tax authorities.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred income taxes reflect the net effect of temporary difference between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The significant components of the deferred tax assets and liabilities are as follows (in thousands):</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">For Years Ended<br />December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Non-current deferred tax assets</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Intellectual property</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>95,956
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Amortization/depreciation</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,781
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,657
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Research tax credit</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>32,851
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,170
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Net operating loss carry forwards</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>253,661
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>159,889
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Deferred revenue</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,281
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,281
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Non-cash stock issue</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,649
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,767
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Others</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,358
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,964
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Gross deferred tax assets</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>413,537
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>213,728
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Deferred tax liability related to business acquisition</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(173,771
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(176,219
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Deferred tax liability related to royalty payable</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(96,829
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Deferred tax liability related to convertible notes</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(29,845
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Total net deferred tax asset</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>113,092
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>37,509
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Less valuation allowance</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(286,863
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(213,728
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Net deferred tax assets (liability)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(173,771
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(176,219
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company records a valuation allowance for temporary differences for which it is more likely than not that the Company will not receive future tax benefits. At December&nbsp;31, 2016 and 2015, the Company recorded valuation allowances of $286.9 million and $213.7&nbsp;million, respectively, representing an increase in the valuation allowance of $73.2&nbsp;million in 2016 and an increase of $65.3&nbsp;million in 2015, due to the uncertainty regarding the realization of such deferred tax assets, to offset the benefits of net operating losses generated during those years. The deferred tax liability related to business acquisitions pertains to the basis difference in IPR&amp;D acquired by the Company. The Company's policy is to record a deferred tax liability related to acquired IPR&amp;D that may eventually be realized either upon amortization of the asset when the research is completed and a product is successfully launched or the write-off of the asset if it is abandoned or unsuccessful.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of December&nbsp;31, 2016, the Company had federal, state, and foreign net operating loss carry forwards ("NOLs") of approximately $637&nbsp;million, $623&nbsp;million, and $40&nbsp;million respectively. The federal carry forward will expire in 2029 through 2036. Most of the state carry forwards generated prior to 2009 have expired through 2015. The remaining state carry forwards including those generated in 2009 through 2016 will expire in 2029 through 2036. The foreign NOLs have indefinite expiration. Utilization of NOLs may be subject to a substantial limitation pursuant to Section&nbsp;382 of the Code as well as similar state statutes in the event of an ownership change. Such ownership changes have occurred in the past, and could occur again in the future As a result of these ownership changes, Section&nbsp;382 places an annual limitation on the amount of NOLs that can be utilized to offset future taxable income each year, which is based on the value of the company at the change date. This limitation could result in expiration of those carry forwards before utilization. In general, an ownership change, as defined by Section&nbsp;382, results from transactions that increase the ownership of certain stockholders or public groups in the stock of a corporation by more than 50&nbsp;percentage points over a three year period. The Company completed a detailed study of its cumulative ownership changes for 2016 and determined that in 2016, there was no ownership change in excess of 50%; therefore there was no write-down to net realizable value of the federal NOLs and research and development credits subject to the 382 limitations. A tax benefit of $4.6&nbsp;million associated with the exercise of stock options will be recorded in additional paid-in capital when the associated net operating loss is recognized.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6644375472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Licenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Licenses</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;">14. Licenses</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company acquired rights to develop and commercialize its product candidates through licenses granted by various parties. The following summarizes the Company's material rights and obligations under those licenses:</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;GSK&nbsp;&#x2014;</font><font style="display:inline;font-family:Times;">&nbsp;For discussion of the royalties and milestone payments potentially due to GSK, see "&#x2014;&nbsp;Note&nbsp;15. Collaborative Agreements."</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mt. Sinai School of Medicine of New York University ("MSSM")&nbsp;&#x2014;</font><font style="display:inline;font-family:Times;">&nbsp;The company acquired exclusive worldwide patent rights to develop and commercialize migalastat and other pharmacological chaperones for the prevention or treatment of human diseases or clinical conditions by increasing the activity of wild-type and mutant enzymes pursuant to a license agreement with Mt. Sinai School of Medicine ("MSSM") of New York University. Under this agreement, to date, the Company has paid no upfront or annual license fees and there are no milestone or future payments other than royalties on net sales. This agreement expires upon expiration of the last of the licensed patent rights, which will be in 2019, subject to any patent term extension that may be granted, or 2024 if the Company develops a product for combination therapy (pharmacological chaperone plus/ERT) and a patent issues from the pending application covering the combination therapy, subject to any patent term extension that may be granted.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under its license agreements, if the Company owes royalties on net sales for one of its products to more than one of the above licensors, then the Company has the right to reduce the royalties owed to one licensor for royalties paid to another. The amount of royalties to be offset is generally limited in each license and can vary under each agreement. For migalastat, in 2016, the Company incurred $0.1&nbsp;million of royalty expense under the agreement with MSSM.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company's rights with respect to these agreements to develop and commercialize migalastat may terminate, in whole or in part, if the Company fails to meet certain development or commercialization requirements or if the Company does not meet its obligations to make royalty payments.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16265-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6821578256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_CollaborativeArrangementDisclosureAbstract', window );"><strong>Collaborative Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Agreements</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;">15. Collaborative Agreements</font>
		</p>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">GSK</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In November 2013, Amicus entered into the Revised Agreement with GSK, pursuant to which Amicus has obtained global rights to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease. The Revised Agreement amends and replaces in its entirety the earlier agreement entered into between Amicus and GSK in July 2012. Under the terms of the Revised Agreement, there was no upfront payment from Amicus to GSK. For migalastat monotherapy, GSK is eligible to receive post-approval and sales-based milestones up to $40&nbsp;million, as well as tiered royalties in the mid-teens in eight major markets outside the U.S. In the second half of 2016, the Company recognized approximately $0.5&nbsp;million under the revised agreement with GSK.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the terms of the Revised Agreement, GSK will no longer jointly fund development costs for all formulations of migalastat.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In evaluating the impact of both the Expanded Collaboration Agreement and the Revised Agreement, the Company applied the accounting guidance regarding the impact of potential future payments it may make in its role as a vendor (i.e.,&nbsp;Amicus) to its customer (i.e.,&nbsp;GSK) and evaluated if these potential future payments could be a reduction of revenue from GSK. If the potential future payments to GSK are as follows:</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:15;margin-left:0pt;">
			<tr style="CellSpacing:15;">
				<td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:AngsanaUPC;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:AngsanaUPC;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:AngsanaUPC;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:15;">
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2022;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">a payment for an identifiable benefit, and </font></p>
				</td>
			</tr>
			<tr style="CellSpacing:15;">
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2022;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">the identifiable benefit is separable from the existing relationship between the Company and GSK, and </font></p>
				</td>
			</tr>
			<tr style="CellSpacing:15;">
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2022;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">the identifiable benefit can be obtained from a party other than GSK, and </font></p>
				</td>
			</tr>
			<tr style="CellSpacing:15;">
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2022;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">the Company can reasonably estimate the fair value of the identifiable benefit,</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">then the potential future payments would be treated separately from the collaboration and research revenue. However, if all these criteria are not satisfied, then the potential future payments are treated as a reduction of revenue.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accordingly, the Company did not believe that, for accounting purposes, the new U.S. licensing rights to migalastat obtained from GSK under the Expanded Collaboration Agreement, nor the ex U.S. licensing rights to migalastat obtained from GSK under the Revised Agreement, represented a separate, identifiable benefit from the licenses in the Original Collaboration Agreement entered into between Amicus and GSK in 2010. The contingent amounts payable to GSK were not sufficiently separable from GSK's original license and the research and development reimbursements such that Amicus could not have entered into a similar exchange transaction with another party. Additionally, the Company cannot reasonably estimate the fair value of the worldwide licensing rights to migalastat.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company determined that the potential future payments to GSK would be treated as a reduction of revenue and that the total amount of revenue to be received under the arrangement is no longer fixed or determinable as the contingent milestone payments are subject to significant uncertainty.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As a result, the Company no longer recognized any of the upfront license fees and premiums on the equity purchase from GSK until such time as the arrangement consideration becomes fixed or determinable, because an indeterminable amount may ultimately be payable back to GSK. These amounts (the balance of the unrecognized upfront license fee and the premium on the equity purchases) are classified as deferred reimbursements on the balance sheet.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The recognition of Research Revenue was also affected by the determination that the overall total arrangement consideration was no longer fixed and determinable, despite the fact that the research activities continued and that the research expense reimbursements by GSK to Amicus were received as the research activities related to the reimbursement had been completed. Therefore the research reimbursements from GSK were recorded as deferred reimbursements on the balance sheet and would not recognized until the total arrangement consideration becomes fixed and determinable.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As a result, all revenue recognition was suspended until the total arrangement consideration would become fixed and determinable. In addition, future milestone payments made by the Company will be applied against the balance of this deferred reimbursements account. Revenue recognition for research expense reimbursements, the original upfront license fee, and the equity premiums will resume once the total arrangement consideration becomes fixed and determinable which will occur when the balance of the deferred reimbursements account is sufficient to cover all the remaining contingent milestone payments.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Biogen</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In September 2013, the Company entered into a license and collaboration agreement (the "Biogen Agreement") with Biogen to discover, develop and commercialize novel small molecules for the treatment of Parkinson's disease. Under terms of the multi-year agreement, the Company and Biogen will collaborate in the discovery of a new class of small molecules that target the GCase enzyme, for further development and commercialization by Biogen. Biogen was responsible for funding all discovery, development, and commercialization activities. In addition the Company was reimbursed for all full-time employees working on the project as part of a cost sharing arrangement. The Company was also eligible to receive development and regulatory milestones, as well as modest royalties in global net sales.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of December&nbsp;31, 2014, the Company recognized $1.2&nbsp;million in Research Revenue for work performed under the cost sharing arrangement of the Biogen Agreement.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In September 2014, the Company and Biogen concluded their research collaboration. The Company's most advanced Parkinson's candidate is AT3375, which was developed outside the collaboration and is wholly-owned by the Company.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_CollaborativeArrangementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_CollaborativeArrangementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6811904528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Instruments and Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentsAndRelatedPartyTransactionsAbstract', window );"><strong>Debt Instruments and Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentsAndRelatedPartyTransactionsDisclosureTextBlock', window );">Debt Instruments and Related Party Transactions</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;">16. Debt Instruments and Related Party Transactions</font>
		</p>
		<p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">October 2015 and February 2016 Notes and Warrants Purchase Agreement</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In October 2015, the Company entered into the October 2015 Purchase Agreement with Redmile, who beneficially owned approximately 6.7% of the Common Stock as of December&nbsp;31, 2015, whereby it sold, on a private placement basis, (a)&nbsp;$50.0&nbsp;million aggregate principal amount of its unsecured promissory notes ("Notes") and (b)&nbsp;five-year warrants ("Warrants") for 1.3&nbsp;million shares of Common Stock. The payment terms under the purchase agreement contained two installments, the first $15.0&nbsp;million in October 2017 and the balance $35.0&nbsp;million in October 2020. Interest was payable at 4.1% on a monthly basis over the term of the loan. Due to the embedded redemption (put and/or call) features in the note agreement, it was determined that the fair value of the warrants should be bifurcated from the value of the notes payable and recorded as a debt discount. The relative fair value of the warrants and the debt discount as related to the October 2015 purchase agreement was determined to be $8.8&nbsp;million.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Purchase Agreement was modified in February 2016 when the Company entered into a Note and Warrant Purchase Agreement (the "February 2016 Purchase Agreement") with Redmile for an aggregate amount of up to $75.0&nbsp;million. The Company agreed with Redmile that in full consideration of the purchase price for the notes issued under the October 2015 Purchase Agreement, Redmile surrendered for cancellation all notes and warrants acquired from the October 2015 Purchase Agreement and the Company paid Redmile any unpaid interest accrued thereunder. Pursuant to the February 2016 agreement, at closing, it sold, on a private placement basis (a)&nbsp;$50.0&nbsp;million aggregate principal amount of unsecured promissory notes ("Initial Notes") and (b)&nbsp;five year warrants to purchase up to 37 shares of the Company's Common Stock for every $1,000 of the principal amount of Initial Notes purchased ("Initial Warrants"), for an aggregate of up to 1,850,000 shares of Common Stock issuable under the Initial Warrants. The payment terms contained two installments, the first $15.0&nbsp;million in October 2017 and the balance $35.0&nbsp;million in October 2021. The interest rate was 3.875% and payable upon of maturity. This transaction was accounted for as a debt modification in accordance with ASC 470-50. The incremental fair value between the warrants that were cancelled and the February issued warrants of $3.5&nbsp;million was recorded as additional unamortized debt discount on the balance sheet and added to the prior warrant balance within equity.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Notes mentioned above were cancelled in December 2016. For more details, refer to section&nbsp;</font><font style="display:inline;font-family:Times;font-style:italic;">December 2016 Note Purchase Agreement</font><font style="display:inline;font-family:Times;">&nbsp;below in this footnote.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">June 2016 Amended Purchase Agreement</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In June 2016, following the marketing approval for migalastat in Europe, the Company entered into the Amended Purchase Agreement with Redmile. Such amendment joined GCM to the February 2016 Purchase Agreement. Pursuant to the Amended Purchase Agreement, the Company sold an additional $30&nbsp;million unsecured promissory notes and five year warrants to purchase up to purchase up to 42 shares of our Common Stock, par value $0.01 per share for every $1,000 of the principal amount of additional notes purchased, for an aggregate of up to 1,260,000 shares of Common Stock issuable from the additional warrants. The payment was due in October 2021. The interest rate was 3.875% and payable upon of maturity. The Notes mentioned above were cancelled in December 2016. For more details, refer to section </font><font style="display:inline;font-family:Times;font-style:italic;">December 2016 Note Purchase Agreement</font><font style="display:inline;font-family:Times;"> below in this footnote.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">December 2016 Note Purchase Agreement</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On December&nbsp;15, 2016, the Company entered into a Note Purchase Agreement ("Note Purchase Agreement") with GCM and RedMile, pursuant to which the Company agreed to prepay all outstanding principal and accrued and unpaid interest on the notes issued by the Company and held by GCM and Redmile. Such prepayment was made on December&nbsp;21, 2016. The Note Purchase Agreement did not cancel the warrants, under the Amended Purchase Agreement. The net loss on extinguishment of the debt was $13.3&nbsp;million and is included as loss on extinguishment in the Consolidated Statement of Operations for the year ended December&nbsp;31, 2016.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">2016 Convertible Debt</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On December&nbsp;21, 2016, the Company issued at par value $250&nbsp;million aggregate principal amount of unsecured Convertible Senior Notes due 2023 (the "Convertible Notes"), which included the exercise in full of the $25&nbsp;million over-allotment option granted to the initial purchasers of the Notes, in a private offering to qualified institutional buyers pursuant to Rule&nbsp;144A under the Securities Act. Interest is payable semiannually on June&nbsp;15 and December&nbsp;15 of each year, beginning on June&nbsp;15, 2017. The Notes will mature on December&nbsp;15, 2023, unless earlier repurchased, redeemed, or converted in accordance with their terms. The Notes are convertible at the option of the holders, under certain circumstances and during certain periods, into cash, shares of the Company's common stock or a combination thereof and may be settled as described below. The net proceeds from the Note Offering were $243.1&nbsp;million, after deducting fees and estimated expenses payable by the Company. In addition, the Company used approximately $13.5&nbsp;million of the net proceeds from the issuance of the Convertible Notes to pay the cost of the capped call transactions ("Capped Call Confirmations") that the Company entered into in connection with the issuance of the Convertible Notes.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Convertible Notes are governed by an indenture dated December&nbsp;21, 2016 (the "Indenture") by and between Amicus and Wilmington Trust, National Association, as trustee.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Convertible Notes are initially convertible into approximately 40,849,675 shares of the Company's common stock under certain circumstances prior to maturity at a conversion rate of 163.3987 shares per $1,000 principal amount of Convertible Notes, which represents a conversion price of approximately $6.12 per share of Common Stock, subject to adjustment under certain conditions. Holders may convert their Convertible Notes at their option at specified times prior to the maturity date of December&nbsp;15, 2023, only if:</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:15;margin-left:0pt;">
			<tr style="CellSpacing:15;">
				<td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Aparajita;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Aparajita;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Aparajita;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:15;">
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2022;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">during any fiscal quarter commencing after March&nbsp;31, 2017, if the last reported sale price of the Company's common stock for at least 20 trading days in the period of 30 consecutive trading days ending on the last trading day of the immediately preceding fiscal quarter is equal to or more than 130% of the conversion price of the Convertible Notes on the last day of such preceding fiscal quarter; </font></p>
				</td>
			</tr>
			<tr style="CellSpacing:15;">
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2022;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">a Holder submits its Convertible Notes for conversion during the five business day period following any five consecutive trading day period in which the trading price for the Convertible Notes, per $1,000 principal amount of the Convertible Notes, for each such trading day was less than 98% of the product of the last reported sale price of the Company's common stock and the conversion rate of the Convertible Notes on such date; or </font></p>
				</td>
			</tr>
			<tr style="CellSpacing:15;">
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2022;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">the Company issues to all or substantially all of the holders of common stock rights options or warrants entitling then them for a period of not more than 60 calendar days after the date of such issuance to subscribe for or purchase shares of the Common Stock, at a price per share less than the average of the Last Reported Sale Prices of the Common Stock for the 10 consecutive Trading Day period ending on, and including, the Trading Day immediately preceding the date of announcement of such issuance or distributes to all or substantially all holders of the Common Stock the Company's assets, debt securities or rights to purchase the Company's securities which distribution has a per share value of exceeding 10% of the Last Reported Sale Price of the Common Stock on the Trading Day immediately preceding the date of announcement of such distribution </font></p>
				</td>
			</tr>
			<tr style="CellSpacing:15;">
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2022;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">the Company enters into specified corporate transactions. </font></p>
				</td>
			</tr>
			<tr style="CellSpacing:15;">
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2022;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">the Company has had a call for redemption, the holder can convert up until the second trading day immediately preceding the redemption date</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Convertible Notes will be convertible, at the option of the note holders, regardless of whether any of the foregoing conditions have been satisfied, on or after September&nbsp;15, 2023 at any time prior to the close of business on the second scheduled trading day immediately preceding the stated maturity date of December&nbsp;15, 2023.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon the occurrence of a make-whole fundamental change or if the Company call all or any portion of the Convertible Notes for redemption prior to July&nbsp;1, 2020, the Company will, in certain circumstances, increase the conversion rate by a number of additional shares for a holder that elects to convert its Convertible Notes in connection with such make-whole fundamental change or during the related redemption period.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon conversion, the Company may pay cash, shares of the Company's common stock or a combination of cash and stock, as determined by the Company in its discretion.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company accounts for the Convertible Notes as a liability and equity component where the carrying value of the liability component will be valued based on a similar instrument. In accounting for the issuance of the Convertible Notes, the Company separated the Convertible Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the fair value of a similar liability that does not have an associated convertible feature. The carrying amount of the equity component representing the conversion option was determined by deducting the fair value of the liability component from the par value of the Convertible Notes as a whole. The excess of the principal amount of the liability component over its carrying amount, referred to as the debt discount, is amortized to interest expense over the seven-year term of the Convertible Notes. The equity component is not re-measured as long as it continues to meet the conditions for equity classification.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In accounting for the issuance of the Convertible Notes, the Company separated the Convertible Notes into liability and equity components based on their relative values. The carrying amount of the liability component was calculated by measuring the fair value of a similar liability that does not have an associated convertible feature. The carrying amount of the equity component, representing the conversion option, was determined by deducting the fair value of the liability component from the par value of the Convertible Notes. The difference between the principal amount of the Convertible Notes and the liability component represents the debt discount, which is recorded as a direct deduction from the related debt liability in the Consolidated Balance Sheets and amortized to interest expense using the effective interest method over the seven-year term of the Convertible Notes. The equity component of the Convertible Notes of approximately $88.3&nbsp;million is included in additional paid-in capital in the Consolidated Balance Sheets and is not remeasured as long as it continues to meet the conditions for equity classification. Additionally, the Company recorded a deferred tax liability of $29.8&nbsp;million in relation to the Convertible Notes.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company incurred transaction costs of approximately $7.5&nbsp;million, including approximately $6.9&nbsp;million that was paid from the gross proceeds of the Convertible Notes offering. In accounting for the transaction costs, the Company allocated the total amount incurred to the liability and equity components using the same proportions as the proceeds from the Convertible Notes. Transaction costs attributable to the liability component were recorded as a direct deduction from the related debt liability in the Consolidated Balance Sheets and amortized to interest expense over the seven-year term of the Convertible Notes. Transaction costs attributable to the equity component were netted with the equity component in additional-paid-in-capital.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Convertible Notes consist of the following as of December&nbsp;31, 2016:</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Liability component </font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(In thousands)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Principal</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>250,000
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Less: debt discount&nbsp;</font><font style="display:inline;font-family:Times;font-size:6pt;top:-4pt;position:relative;line-height:100%">(1)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(90,807
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Less: deferred financing&nbsp;</font><font style="display:inline;font-family:Times;font-size:6pt;top:-4pt;position:relative;line-height:100%">(1)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,729
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Net carrying value of the debt</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>154,464
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<div><hr style="border-width:0;width:26%;height:1.5pt;color:black;background-color:black;" align="left"></hr></div>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:15;margin-left:0pt;">
			<tr style="CellSpacing:15;">
				<td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:15;">
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Included in the Consolidated Balance Sheets within Convertible Senior Notes (due 2023) and amortized to interest expense over the remaining life of the Convertible Senior Notes using the effective interest rate method.</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The fair value of the debt at December&nbsp;31, 2016 was approximately $258.8&nbsp;million.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth total interest expense recognized related to the Convertible Notes for the year ended December&nbsp;31, 2016:</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Components </font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(In thousands)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Contractual interest expense</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>208&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Amortization of deferred financing</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>26&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Amortization of debt discount</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>248&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Total</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>482&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Effective interest rate of the liability component</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10.85&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Capped Call Confirmations of $13.5&nbsp;million are expected generally to reduce the potential dilution to the Common Stock upon any conversion of the Convertible Notes and/or offset the cash payments the Company is required to make in excess of the principal amount upon conversion of the Notes in the event that the market price of the Common Stock is greater than the strike price of the Capped Call Confirmations (which initially corresponds to the initial conversion price of the Convertible Notes and is subject to certain adjustments under the terms of the Capped Call Confirmations), with such reduction and/or offset subject to a cap based on the cap price of the Capped Call Confirmations. The Capped Call Confirmations have an initial cap price of $7.20 per share, which represents a premium of approximately 50% over the closing price of the Company's Common Stock on The NASDAQ Global Market on December&nbsp;15, 2016, and is subject to certain adjustments under the terms of the Capped Call Confirmations. The Capped Call Confirmations will cover, subject to anti-dilution adjustments substantially similar to those applicable to the Convertible Notes, the number of shares of Common Stock that will underlie the Convertible Notes. The Capped Call Confirmations do not meet the criteria for separate accounting as a derivative as they are indexed to the Company's Common Stock. The premiums paid for the Capped Call Confirmations have been included as a net reduction to additional paid-in capital.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DebtInstrumentsAndRelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DebtInstrumentsAndRelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DebtInstrumentsAndRelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents entire disclosure of Debt Instruments and related Party Transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DebtInstrumentsAndRelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6811845088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings per Share</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;">17. Earnings per Share</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss attributable to common stockholders per common share (in thousands except share amounts):</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Years Ended December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;text-decoration:underline;">Historical </font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Numerator:</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Net loss attributable to common stockholders</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(200,042
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(132,118
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(68,926
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Denominator:</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Weighted average common shares outstanding&#x2014;basic and diluted</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>134,401,588
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>109,923,815
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>74,444,157
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dilutive common stock equivalents would include the dilutive effect of common stock options, convertible debt units, RSUs and warrants for common stock equivalents. Potentially dilutive common stock equivalents were excluded from the diluted earnings per share denominator for all periods because of their anti-dilutive effect. For the year ended 2016 there was 40.9&nbsp;million potential common shares outstanding as a result of the convertible debt that was excluded from the diluted net loss per share calculation because their effect would have been anti-dilutive.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The table below presents potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method (in thousands):</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Year ended December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Options to purchase common stock</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,528&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,729&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,021&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Convertible debt</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>40,850&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Outstanding warrants, convertible to common stock</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,110&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,350&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,600&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Unvested restricted stock units</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>744&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>479&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>955&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Total number of potentially issuable shares</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>60,232&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13,558&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,576&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=32703322&amp;loc=d3e4984-109258<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6644375472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;">Note&nbsp;18. Commitments and Contingencies</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since October&nbsp;1, 2015, three purported securities class action lawsuits have been commenced in the United States District Court for New Jersey, naming as defendants the Company, its Chairman and Chief Executive Officer, and in one of the actions, its Chief Medical Officer. The lawsuits allege violations of the Securities Exchange Act of 1934 in connection with allegedly false and misleading statements made by the Company related to the regulatory approval path for migalastat. The plaintiffs seek, among other things, damages for purchasers of the Company's Common Stock during different periods, all of which fall between March&nbsp;19, 2015 and October&nbsp;1, 2015. It is possible that additional suits will be filed, or allegations received from stockholders, with respect to similar matters and also naming the Company and/or its officers and directors as defendants. On May&nbsp;26, 2016, the Court consolidated these lawsuits into a single action and appointed a lead plaintiff. The lead plaintiff filed a Consolidated Amended Class Action Complaint on July&nbsp;11, 2016. On August&nbsp;25, 2016, the defendants filed a motion to dismiss in response to the Consolidated Amended Class Action Complaint. This motion to dismiss was fully briefed on October&nbsp;28, 2016. Lead plaintiff and defendants have reached an agreement in principal to fully and finally settle all claims asserted in the Consolidated Amended Class Action Complaint. The settlement is immaterial to the Company's consolidated financial statements and is subject to, among other things, documentation and court approval. The settlement amount is expected to be fully covered under insurance.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On or about November&nbsp;2, 2015, a derivative lawsuit was filed by an Amicus shareholder purportedly on Amicus' behalf in the Superior Court of New Jersey, Middlesex County, Chancery Division, against the individuals who serve on the Amicus Board of Directors. Amicus itself was named as a nominal defendant. The derivative lawsuit alleged claims for breach of state law fiduciary duties, waste of corporate assets, and unjust enrichment based on allegedly false and misleading statements made by Amicus related to the regulatory approval path for migalastat HCl. On February&nbsp;19, 2016, the complaint was dismissed by the Court and plaintiffs have not refiled.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On or about March&nbsp;3, 2016, a derivative lawsuit was filed by an Amicus shareholder purportedly on Amicus' behalf in the Superior Court of New Jersey, Middlesex County, Chancery Division, against various officers and directors of the Company. Amicus itself is named as a nominal defendant. The derivative lawsuit alleges similar facts and circumstances as the three purported securities class action lawsuits described above and further alleges claims for breach of state law fiduciary duties, waste of corporate assets, unjust enrichment, abuse of control, and gross mismanagement based on allegedly false and misleading statements made by Amicus related to the regulatory approval path for migalastat HCl. The plaintiff seeks, among other things, to require the Amicus Board to take certain actions to reform its corporate governance procedures, including greater shareholder input and a provision to permit shareholders to nominate candidates for election to the Board, along with restitution, costs of suit and attorney's fees. On February&nbsp;7, 2017, the complaint was dismissed by the Court without prejudice.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These lawsuits and any other related lawsuits are subject to inherent uncertainties and the actual cost will depend upon many unknown factors. The outcome of the litigation is necessarily uncertain and we could be forced to expend significant resources in the defense of these suits, and we may not prevail.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=51674963&amp;loc=d3e12565-110249<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6821607616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;">19. Subsequent Events</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company evaluated events that occurred subsequent to December&nbsp;31, 2016 and found there were no material recognized or non-recognized subsequent events during this period.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6811874720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Data (Unaudited - in thousands except per share data)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Selected Quarterly Financial Data (Unaudited - in thousands except per share data)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Selected Quarterly Financial Data (Unaudited - in thousands except per share data)</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;">20. Selected Quarterly Financial Data (Unaudited&#x2014;in thousands except per share data)</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="11" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Quarters Ended</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">March&nbsp;31</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">June&nbsp;30</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">September&nbsp;30</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(43,691
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(51,050
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(46,654
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(58,647
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Basic and diluted net loss per common share&nbsp;</font><font style="display:inline;font-family:Times;font-size:6pt;top:-4pt;position:relative;line-height:100%">(1)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.35
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.40
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.33
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.41
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(24,288
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(27,133
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(37,800
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(42,897
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Basic and diluted net loss per common share&nbsp;</font><font style="display:inline;font-family:Times;font-size:6pt;top:-4pt;position:relative;line-height:100%">(1)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.25
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.27
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.32
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.34
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
		</table></div>
		<div><hr style="border-width:0;width:26%;height:1.5pt;color:black;background-color:black;" align="left"></hr></div>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:15;margin-left:0pt;">
			<tr style="CellSpacing:15;">
				<td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:15;">
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Per common share amounts for the quarters and full years have been calculated separately. Accordingly, quarterly amounts do not add to the annual amounts because of differences on the weighted-average common shares outstanding during each period principally due to the effect of the Company issuing shares of its common stock during the year.</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the quarterly financial data in the annual financial statements.  The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=51655806&amp;loc=d3e765-108305<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)-(j)<br> -URI http://asc.fasb.org/extlink&amp;oid=51825399&amp;loc=d3e1280-108306<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=51655806&amp;loc=d3e725-108305<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 6<br> -Section G<br> -Subsection 1<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 302<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6834289904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Basis of Presentation</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("U.S.&nbsp;GAAP") and include all adjustments necessary for the fair presentation of the Company's financial position for the periods presented.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Consolidation</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The consolidated financial statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions are eliminated in consolidation.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Transactions</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Foreign Currency Transactions</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The functional currency for most of the Company's foreign subsidiaries is their local currency. For non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of the Company's foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of equity.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company transacts business in various foreign countries and therefore, is subject to risk of foreign currency exchange rate fluctuations. As such, in June 2016, the Company entered into a forward contract to economically hedge transactional exposure associated with commitments arising from trade accounts payable denominated in a currency other than the functional currency of the respective operating entity. The Company does not designate this forward contract as a hedging instrument under applicable accounting guidance and, therefore, changes in fair value are recorded as other expense the Consolidated Statements of Operations.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Use of Estimates</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The preparation of financial statements in conformity with U.S.&nbsp;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock', window );">Cash, Money Market Funds, and Marketable Securities</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Cash, Money Market Funds, and Marketable Securities</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company considers all highly liquid investments purchased with a maturity of three months or less at the date of acquisition, to be cash equivalents.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times;">Marketable securities consist of fixed income investments with a maturity of greater than three months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Company's balance sheet. Unrealized holding gains and losses are reported within comprehensive income/ (loss) in the statements of comprehensive loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations or other observable inputs. See "&#x2014;&nbsp;Note&nbsp;5. Cash, Money Market Funds and Marketable Securities", for a summary of available-for-sale securities as of December&nbsp;31, 2016 and 2015.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Concentration of Credit Risk</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company's financial instruments that are exposed to concentration of credit risk consist primarily of cash and cash equivalents and marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on cash and cash equivalents or its marketable securities.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times;">The Company is subject to credit risk from its accounts receivable related to its product sales of Galafold. The majority of the Company's accounts receivable at December&nbsp;31, 2016 have arisen from product sales in Germany. The Company will periodically assess the financial strength of its customers to establish allowances for anticipated losses, if any. For accounts receivable that have arisen from named patient sales, the payment terms are predetermined and the Company evaluates the creditworthiness of each customer on a regular basis. To date, the Company has not incurred any credit losses.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Property and Equipment</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is calculated over the estimated useful lives of the respective assets, which range from three to five years, or the lesser of the related initial term of the lease or useful life for leasehold improvements.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The initial cost of property and equipment consists of its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use. Expenditures incurred after the fixed assets have been put into operation, such as repairs and maintenance, are charged to income in the period in which the costs are incurred. Major replacements, improvements and additions are capitalized in accordance with Company policy.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Revenue Recognition</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company recognizes revenue when amounts are realized or realizable and earned, which is typically upon shipment to the end-customer. Revenue is considered realizable and earned when persuasive evidence an arrangement exists, title to product and associated risk of loss has passed to the customer, the price is fixed or determinable, collection of the amounts due are reasonably assured and the Company has no further performance obligations.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Net Product Sales</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company's net product sales consist solely of sales of Galafold for the treatment of Fabry disease in the EU. The Company has recorded revenue on sales where Galafold is available either on a commercial basis or through a reimbursed early access program. Orders for Galafold are generally received from pharmacies and the ultimate payor is typically a government authority.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company records revenue net of estimated third party discounts and rebates. Allowances are recorded as a reduction of revenue at the time revenues from product sales are recognized. These allowances are adjusted to reflect known changes in factors and may impact such allowances in the quarter those changes are known.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-style:italic;">Collaboration Revenue</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In multiple element arrangements, revenue is allocated to each separate unit of accounting and each deliverable in an arrangement is evaluated to determine whether it represents separate units of accounting. A deliverable constitutes a separate unit of accounting when it has standalone value and there is no general right of return for the delivered elements. In instances when the aforementioned criteria are not met, the deliverable is combined with the undelivered elements and the allocation of the arrangement consideration and revenue recognition is determined for the combined unit as a single unit of accounting. Allocation of the consideration is determined at arrangement inception on the basis of each unit's relative selling price. In instances where there is determined to be a single unit of accounting, the total consideration is applied as revenue for the single unit of accounting and is recognized over the period of inception through the date where the last deliverable within the single unit of accounting is expected to be delivered.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company's current revenue recognition policies provide that, when a collaboration arrangement contains multiple deliverables, such as license and research and development services, the Company allocates revenue to each separate unit of accounting based on a selling price hierarchy. The selling price hierarchy for a deliverable is based on (i)&nbsp;its vendor specific objective evidence ("VSOE") if available, (ii)&nbsp;third party evidence ("TPE") if VSOE is not available, or (iii)&nbsp;best estimated selling price ("BESP") if neither VSOE nor TPE is available. The Company would establish the VSOE of selling price using the price charged for a deliverable when sold separately. The TPE of selling price would be established by evaluating largely similar and interchangeable competitor products or services in standalone sales to similarly situated customers. The BESP would be established considering internal factors such as an internal pricing analysis or an income approach using a discounted cash flow model.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company also considers the impact of potential future payments it makes in its role as a vendor to its customers and evaluates if these potential future payments could be a reduction of revenue from that customer. If the potential future payments to the customer are:</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:15;margin-left:0pt;">
			<tr style="CellSpacing:15;">
				<td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Arabic Typesetting;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Arabic Typesetting;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Arabic Typesetting;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:15;">
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2022;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">a payment for an identifiable benefit; </font></p>
				</td>
			</tr>
			<tr style="CellSpacing:15;">
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;height:27.75pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;height:27.75pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2022;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;height:27.75pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">the identifiable benefit is separable from the existing relationship between the Company and its customer;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:15;">
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2022;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">the identifiable benefit can be obtained from a party other than the customer; and </font></p>
				</td>
			</tr>
			<tr style="CellSpacing:15;">
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2022;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">the Company can reasonably estimate the fair value of the identifiable benefit</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;then the payments are accounted for separate from the revenue received from that customer. If, however, all these criteria are not satisfied, then the payments are treated as a reduction of revenue from that customer.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the Company determines that any potential future payments to its customers are to be considered as a reduction of revenue, it must evaluate if the total amount of revenue to be received under the arrangement is fixed and determinable. If the total amount of revenue is not fixed and determinable due to the uncertain nature of the potential future payments to the customer, then any customer payments cannot be recognized as revenue until the total arrangement consideration becomes fixed and determinable.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The reimbursements for research and development costs under collaboration agreements that meet the criteria for revenue recognition are included in Research Revenue and the costs associated with these reimbursable amounts are included in research and development expenses.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In order to determine the revenue recognition for contingent milestones, the Company evaluates the contingent milestones using the criteria as provided by the Financial Accounting Standards Boards ("FASB") guidance on the milestone method of revenue recognition at the inception of a collaboration agreement. The criteria requires that (i)&nbsp;the Company determines if the milestone is commensurate with either its performance to achieve the milestone or the enhancement of value resulting from the Company's activities to achieve the milestone, (ii)&nbsp;the milestone be related to past performance, and (iii)&nbsp;the milestone be reasonable relative to all deliverable and payment terms of the collaboration arrangement. If these criteria are met then the contingent milestones can be considered as substantive milestones and will be recognized as revenue in the period that the milestone is achieved.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories and Cost of Cost of Goods Sold</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Inventories and Cost of Cost of Goods Sold</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Until regulatory approval of Galafold, the Company expensed all manufacturing costs of Galafold as research and development expense. Upon regulatory approval, the Company began capitalizing costs related to the purchase and manufacture of Galafold.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories are stated at the lower of cost or market determined by the first-in, first-out method. Inventories are reviewed periodically to identify slow-moving or obsolete inventory based on projected sales activity as well as product shelf-life. In evaluating the recoverability of inventories produced, the probability that revenue will be obtained from the future sale of the related inventory is considered and inventory value is written down for inventory quantities in excess of expected requirements. Expired inventory is disposed of and the related costs are recognized as cost of product sales in the consolidated statements of operations.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cost of goods sold includes the cost of inventory sold, manufacturing and supply chain costs, product shipping and handling costs, provisions for excess and obsolete inventory, as well as royalties payable. A portion of the inventory available for sale was expensed as research and development costs prior to regulatory approval and as such the cost of goods sold and related gross margins are not necessarily indicative of future cost of goods sold and gross margin.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Fair Value Measurements</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company records certain asset and liability balances under the fair value measurements as defined by the FASB guidance. Current FASB fair value guidance emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, current FASB guidance establishes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels&nbsp;1 and 2 of the hierarchy) and the reporting entity's own assumptions that market participants assumptions would use in pricing assets or liabilities (unobservable inputs classified within Level&nbsp;3 of the hierarchy).</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Level&nbsp;1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at measurement date. Level&nbsp;2 inputs are inputs other than quoted prices included in Level&nbsp;1 that are observable for the asset or liability, either directly or indirectly. Level&nbsp;2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals. Level&nbsp;3 inputs are unobservable inputs for the asset or liability, which is typically based on an entity's own assumptions, as there is little, if any, related market activity. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentLiabilityReserveEstimatePolicy', window );">Contingent Liabilities</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Contingent Liabilities</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On an ongoing basis, the Company may be involved in various claims, and legal proceedings. On a quarterly basis, the Company reviews the status of each significant matter and assesses its potential financial exposure. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated, the Company will accrue a liability for the estimated loss. Because of uncertainties related to claims and litigation, accruals will be based on our best estimates based on available information. On a periodic basis, as additional information becomes available, or based on specific events such as the outcome of litigation or settlement of claims, the Company may reassess the potential liability related to these matters and may revise these estimates, which could result in a material adverse adjustments to the Company's operating results.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Research and Development Costs</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development costs are expensed as incurred. Research and development expense consists primarily of costs related to personnel, including salaries and other personnel related expenses, consulting fees and the cost of facilities and support services used in drug development. Assets acquired that are used for research and development and have no future alternative use are expensed as in-process research and development.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_InterestIncomeAndInterestExpensePolicyTextBlock', window );">Interest Income and Interest Expense</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Interest Income and Interest Expense</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest income consists of interest earned on the Company's cash and cash equivalents and marketable securities. Interest expense consists of interest incurred on capital leases and debt.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Income Taxes</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company accounts for income taxes under the liability method. Under this method deferred income tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax basis of assets and liabilities and for operating losses and tax credit carry forwards, using enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance is recorded if it is "more likely than not" that a portion or all of a deferred tax asset will not be realized.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_OtherComprehensiveIncomePolicyPolicyTextBlock', window );">Other Comprehensive Income/ (Loss)</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Other Comprehensive Income/ (Loss)</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Components of other comprehensive income/(loss) include unrealized gains and losses on available-for-sale securities and gain/(loss) on foreign currency transactions, and are included in the statements of comprehensive loss.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasePolicyTextBlock', window );">Leases</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Leases</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the ordinary course of business, the Company enters into lease agreements for office space as well as leases for certain property and equipment. The leases have varying terms and expirations and have provisions to extend or renew the lease agreement, among other terms and conditions, as negotiated. Once the agreement is executed, the lease is assessed to determine whether the lease qualifies as a capital or operating lease.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;When a non-cancelable operating lease includes any fixed escalation clauses and lease incentives for rent holidays or build-out contributions, rent expense is recognized on a straight-line basis over the initial term of the lease. The excess between the average rental amount charged to expense and amounts payable under the lease is recorded in accrued expenses.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_NonqualifiedCashDeferralPlansPolicy', window );">Nonqualified Cash Deferral Plan</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Nonqualified Cash Deferral Plan</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times;">The Company's Cash Deferral Plan (the "Deferral Plan"), provides certain key employees and members of the Board of Directors as selected by the Compensation Committee of the Board of Directors of the Company (the "Compensation Committee"), with an opportunity to defer the receipt of such participant's base salary, bonus and director's fees, as applicable. The Deferral Plan is intended to be a nonqualified deferred compensation plan that complies with the provisions of Section&nbsp;409A of the Internal Revenue Code (the "Code"). All of the investments held in the Deferral Plan are classified as investments held-to-maturity and recorded at fair value with changes in the investments' fair value recognized as earnings in the period they occur. The corresponding liability for the Deferral Plan is included in other non-current liability in the consolidated balance sheets.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Equity-based Compensation</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Equity-based Compensation</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At December&nbsp;31, 2016, the Company had three equity-based employee compensation plans, which are described more fully in "&#x2014;&nbsp;Note&nbsp;9. Stockholders' Equity." The Company applies the fair value method of measuring equity-based compensation, which requires a public entity to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss per Common Share</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Loss per Common Share</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company calculates net loss per share as a measurement of the Company's performance while giving effect to all dilutive potential common shares that were outstanding during the reporting period. The Company had a net loss for all periods presented; accordingly, the inclusion of common stock options, unvested RSUs and warrants would be anti-dilutive. Therefore, the weighted average shares used to calculate both basic and diluted earnings per share are the same. See "&#x2014;&nbsp;Note&nbsp;18. Earnings per Share" for further discussion on net loss per share.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">Dividends</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Dividends</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has not paid cash dividends on its capital stock to date. The Company currently intends to retain its future earnings, if any, to fund the development and growth of the business and does not foresee payment of a dividend in any upcoming fiscal period.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Segment Information</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company currently operates in one business segment focused on the discovery, development and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases. The Company is not organized by market and is managed and operated as one business. A single management team reports to the chief operating decision maker who comprehensively manages the entire business. The Company does not operate any separate lines of business or separate business entities with respect to its products. Accordingly, the Company does not accumulate discrete financial information with respect to separate service lines and does not have separately reportable segments.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Business Combinations</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company allocates the purchase price of acquired businesses to the tangible and intangible assets acquired and liabilities assumed based upon their estimated fair values on the acquisition date. The purchase price allocation process requires management to make significant estimates and assumptions, especially at the acquisition date with respect to intangible assets and in-process research and development ("IPR&amp;D"). In connection with the purchase price allocations for acquisitions, the Company estimates the fair value of contingent payments utilizing a probability-based income approach inclusive of an estimated discount rate</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock', window );">Contingent Consideration Payable</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Contingent Consideration Payable</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company determines the fair value of contingent acquisition consideration payable on the acquisition date using a probability-based income approach utilizing an appropriate discount rate. Contingent acquisition consideration payable is shown as a non-current liability on the Company's consolidated balance sheets. The fair value of the contingent consideration payable will be determined each period end and the resulting change will be recorded on the consolidated statements of operations.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Intangible Assets and Goodwill</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company records goodwill in a business combination when the total consideration exceeds the fair value of the net tangible and identifiable intangible assets acquired. Purchased IPR&amp;D is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset, or abandoned, at which point the intangible asset will be written off or partially impaired. Goodwill and indefinite lived intangible assets are assessed annually for impairment and whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. If it is determined that the full carrying amount of an asset is not recoverable, an impairment loss is recorded in the amount by which the carrying amount of the asset exceeds its fair value.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt 5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Recent Accounting Pronouncements</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In January 2017, the FASB issued ASU 2017-04, </font><font style="display:inline;font-family:Times;font-style:italic;">Intangibles&nbsp;&#x2014; Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment</font><font style="display:inline;font-family:Times;">. To simplify the subsequent measurement of goodwill, ASU 2017-04 eliminates Step 2 from the goodwill impairment test. The annual, or interim, goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit's fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. In addition, income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit should be considered when measuring the goodwill impairment loss, if applicable. ASU 2017-04 also eliminates the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. ASU 2017-04 should be applied on a prospective basis. The nature of and reason for the change in accounting principle should be disclosed upon transition. A public business entity that is a U.S. SEC filer should adopt ASU 2017-04 for its annual or any interim goodwill impairment tests in fiscal years beginning after December&nbsp;15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January&nbsp;1, 2017. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In January 2017, the FASB issued ASU 2017-01</font><font style="display:inline;font-family:Times;font-style:italic;">, Business Combinations (Topic 805): Clarifying the Definition of a Business</font><font style="display:inline;font-family:Times;">. This Accounting Standards Update clarifies the definition of a business. The amendments affect all companies and other reporting organizations that must determine whether they have acquired or sold a business. The amendments in this Update are effective for public companies for annual periods beginning after December&nbsp;15, 2017, including interim periods within those periods. Early adoption is permitted under certain circumstances. The amendments should be applied prospectively as of the beginning of the period of adoption. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In October 2016, the FASB issued ASU 2016-17, </font><font style="display:inline;font-family:Times;font-style:italic;">Consolidation (Topic 810): Interests Held through Related Parties That Are under Common Control.</font><font style="display:inline;font-family:Times;"> This Accounting Standards Update changes the evaluation of whether a reporting entity is the primary beneficiary of a variable interest entity by changing how a reporting entity that is a single decision maker of a variable interest entity treats indirect interests in the entity held through related parties that are under common control with the reporting entity. If a reporting entity satisfies the first characteristic of a primary beneficiary (such that it is the single decision maker of a variable interest entity), the amendments require that reporting entity, in determining whether it satisfies the second characteristic of a primary beneficiary, to include all of its direct variable interests in a variable interest entity and, on a proportionate basis, its indirect variable interests in a variable interest entity held through related parties, including related parties that are under common control with the reporting entity. The amendments in this Update are effective for public business entities for fiscal years beginning after December&nbsp;15, 2016, including interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The Company adopted this ASU in 2016 and the adoption did not have a material impact on its consolidated financial statements.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In October 2016, the FASB issued ASU 2016-16, </font><font style="display:inline;font-family:Times;font-style:italic;">Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory.</font><font style="display:inline;font-family:Times;"> This Accounting Standards Update requires an entity to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. The amendments eliminate the exception for an intra-entity transfer of an asset other than inventory. The amendments in this Update are effective for public business entities for annual periods beginning after December&nbsp;15, 2017, including interim reporting periods within those annual reporting periods. Early adoption is permitted for all entities in the first interim period if an entity issues interim financial statements. The Company is currently assessing the impact that this standard will have on its consolidated financial statements. We have not completed our review of the impact of this guidance and do not expect this new guidance to have a material impact on our Consolidated Financial Statements. </font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In August 2016, the FASB issued ASU 2016-15, </font><font style="display:inline;font-family:Times;font-style:italic;">Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments.</font><font style="display:inline;font-family:Times;"> This Accounting Standards Update addresses the following eight specific cash flow issues including Debt prepayment or debt extinguishment costs, contingent consideration payments made after a business combination and separately identifiable cash flows and application of the predominance principle. The amendments in this ASU apply to all entities. The amendments in this Update are effective for public business entities for fiscal years beginning after December&nbsp;15, 2017, and interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The Company adopted this ASU in 2016 and the adoption did not have a material impact on its consolidated financial statements.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In March 2016, the FASB issued ASU 2016-09, </font><font style="display:inline;font-family:Times;font-style:italic;">Compensation&nbsp;&#x2014; Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting</font><font style="display:inline;font-family:Times;">. The amendments are intended to improve the accounting for employee share-based payments and affect all organizations that issue share-based payment awards to their employees. Several aspects of the accounting for share-based payment award transactions are simplified, including: (a) income tax consequences; (b) classification of awards as either equity or liabilities; and (c) classification on the statement of cash flows. For public companies, the amendments are effective for annual periods beginning after December&nbsp;15, 2016, and interim periods within those annual periods. Early adoption is permitted for any organization in any interim or annual period. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In February 2016, the FASB issued ASU No.&nbsp;2016-02</font><font style="display:inline;font-family:Times;font-style:italic;">, Leases (Topic 842).</font><font style="display:inline;font-family:Times;"> This update requires the recognition of lease assets and lease liabilities on the balance sheet for all lease obligations and disclosing key information about leasing arrangements. This update requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous generally accepted accounting principles. This update will be effective for the Company for all annual and interim periods beginning after December&nbsp;15, 2018, including interim periods within those fiscal years. Early application is permitted for all public business entities and all nonpublic business entities upon issuance. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In July 2015, the FASB issued ASU 2015-11</font><font style="display:inline;font-family:Times;font-style:italic;">, Inventory (Topic 330): Simplifying the Measurement of Inventory</font><font style="display:inline;font-family:Times;">, which requires an entity to measure in scope inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The amendments apply to inventory that is measured using first-in, first-out (FIFO) or average cost. The ASU is effective for public business entities for fiscal years beginning after December&nbsp;15, 2016, including interim periods within those fiscal years. A reporting entity should apply the amendments prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In August 2014, the FASB issued ASU 2014-15, </font><font style="display:inline;font-family:Times;font-style:italic;">Presentation of Financial Statements-Going Concern (Subtopic 205-40):</font><font style="display:inline;font-family:Times;"> Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern, which defines management's responsibility to assess an entity's ability to continue as a going concern, and to provide related footnote disclosures if there is substantial doubt about its ability to continue as a going concern. The pronouncement is effective for annual reporting periods ending after December&nbsp;15, 2016 with early adoption permitted. The Company adopted this ASU in 2016 and the adoption did not have a material impact on its consolidated financial statements.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In May 2014, FASB issued ASU 2014-09, </font><font style="display:inline;font-family:Times;font-style:italic;">Revenue from Contracts with Customers</font><font style="display:inline;font-family:Times;"> which along with amendments issued in 2015 and 2016, will replace substantially all current US&nbsp;GAAP guidance on this topic and eliminate industry-specific guidance. Early adoption of this standard is permitted but not before the original effective date for all annual periods and interim reporting periods beginning after December&nbsp;15, 2017. The guidance permits two methods of adoption: full retrospective method (retrospective application to each prior reporting period presented) or modified retrospective method (retrospective application with the cumulative effect of initially applying the guidance recognized at the date of initial application and providing certain additional disclosures). To complete its assessment of the impact of the standard to its financial statements, the Company continues to assess all implications of this standard, method of adoption and related financial disclosures. Additionally, the Company continues to monitor modifications, clarifications and interpretations issued by the FASB that may impact its assessment.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determination of contingent consideration, which is payable to acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_InterestIncomeAndInterestExpensePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for interest income and interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_InterestIncomeAndInterestExpensePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_NonqualifiedCashDeferralPlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for nonqualified cash deferral plans sponsored by the entity. This disclosure may include (1) the groups that participate in (or are covered by) each plan and (2) significant plan provisions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_NonqualifiedCashDeferralPlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_OtherComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_OtherComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6875567&amp;loc=d3e14489-108613<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=51676700&amp;loc=d3e61082-112788<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28088331&amp;loc=SL29635902-196195<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13531-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51676700&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph k<br> -Article 1<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02, 03<br> -Article 3A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentLiabilityReserveEstimatePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the claims loss reserve for insurance contracts with a life contingency (permanent life, some term life, accident and health, some annuities), describing the loss exposures and bases and methodologies for making the relevant accounting estimates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 13<br> -Subparagraph b<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentLiabilityReserveEstimatePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16265-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6423966&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for major classes of inventories, bases of stating inventories (for example, lower of cost or market), methods by which amounts are added and removed from inventory classes (for example, FIFO, LIFO, or average cost), loss recognition on impairment of inventories, and situations in which inventories are stated above cost. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28360613&amp;loc=d3e4492-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=28360613&amp;loc=d3e4556-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Financial Reporting Release (FRR)<br> -Number 206<br> -Paragraph b<br> -Subparagraph i, ii<br> -Chapter 2<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 6<br> -Subparagraph a<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangements (both lessor and lessee). This disclosure may address (1) lease classification (that is, operating versus capital), (2) how the term of a lease is determined (for example, the circumstances in which a renewal option is considered part of the lease term), (3) how rental revenue or expense is recognized for a lease that contains rent escalations, (4) an entity's accounting treatment for deferred rent, including that which arises from lease incentives, rent abatements, rent holidays, or tenant allowances (5) an entity's accounting treatment for contingent rental payments and (6) an entity's policy for reviewing, at least annually, the residual values of sales-type and direct-finance leases. The disclosure also may indicate how the entity accounts for its capital leases, leveraged leases or sale-leaseback transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6453394&amp;loc=d3e39740-112701<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6482485&amp;loc=d3e14754-158437<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6456037&amp;loc=d3e48589-112741<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Research and Development<br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18726-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section B<br> -Paragraph Question 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18726-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21459-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6646969136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of changes in goodwill</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(in millions)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Balance at December&nbsp;31, 2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>197.8&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Change in goodwill</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Balance at December&nbsp;31, 2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>197.8&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of changes in IPR&amp;D</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(in millions)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Balance at December&nbsp;31, 2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>486.7&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Change in IPR&amp;D</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Balance at December&nbsp;31, 2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>486.7&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6821553024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Money Market Funds and Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Money Market Funds and Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of cash and available-for-sale securities</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times;">Cash and available for sale securities consisted of the following as of December&nbsp;31, 2016 and December&nbsp;31, 2015 (in thousands):</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="11" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">As of December&nbsp;31, 2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Cost</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Unrealized<br />Gain</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Unrealized<br />Loss</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Fair<br />Value</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Cash balances</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>187,026
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>187,026
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Corporate debt securities, current portion</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>74,564
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(31
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>74,535
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Commercial paper</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>68,258
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>132
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>68,390
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Money market</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>350
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>350
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Certificate of deposit</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>50
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>50
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>330,248
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>134
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(31
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>330,351
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Included in cash and cash equivalents</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>187,026
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>187,026
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Included in marketable securities</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>143,222
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>134
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(31
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>143,325
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Total cash and marketable securities</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>330,248
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>134
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(31
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>330,351
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="11" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">As of December&nbsp;31, 2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Cost</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Unrealized<br />Gain</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Unrealized<br />Loss</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Fair<br />Value</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Cash balances</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>69,485
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>69,485
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Corporate debt securities, current portion</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>118,627
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(154
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>118,474
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Commercial paper</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,686
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>38
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,724
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Certificate of deposit</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>350
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>350
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>214,148
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>39
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(154
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>214,033
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Included in cash and cash equivalents</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>69,485
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>69,485
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Included in marketable securities</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>144,663
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>39
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(154
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>144,548
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Total cash and marketable securities</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>214,148
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>39
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(154
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>214,033
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6811985136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventories</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of inventories for the period</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The following table summarizes the components of inventories at December&nbsp;31, 2016 (in thousands):</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31,&nbsp;2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Work-in-process</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,308&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Finished goods</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>108&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">Total inventories</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,416&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 2<br> -Paragraph 6<br> -Subparagraph a,b,c<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6821594896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property and equipment consist of the following (in thousands):</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Property and equipment consist of the following:</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Computer equipment</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,511
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,075
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Computer software</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,347
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,354
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Research equipment</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,465
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,483
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Furniture and fixtures</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,018
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,444
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Leasehold improvements</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,970
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,175
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>22,311
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,531
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Less accumulated depreciation</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(12,495
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(13,353
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,816
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,178
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 13<br> -Subparagraph b<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6811985136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accounts Payable and Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of accounts payable and accrued expenses</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times;">Accounts payable and accrued expenses consist of the following (in thousands):</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Accounts payable</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,905&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>16,477&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Accrued professional fees</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,079&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,578&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Accrued contract manufacturing&nbsp;&amp; contract research costs</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,042&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,940&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Accrued compensation and benefits</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,981&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,201&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Accrued facility costs</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,740&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,321&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Foreign currency forward contract</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>265&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Capital lease, short term portion</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>283&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Accrued other</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,713&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,699&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>41,008&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>32,216&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6644813744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of fair value weighted-average assumptions</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Years Ended<br />December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Expected stock price volatility</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>81.3&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>75.9&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>81.3&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Risk free interest rate</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.5&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.7&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.9&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Expected life of options (years)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.25&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.25&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.25&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Expected annual dividend per share</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.00&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.00&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.00&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of stock options outstanding</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Number of<br />Shares</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Weighted<br />Average<br />Exercise<br />Price</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Weighted<br />Average<br />Remaining<br />Contractual Life</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Aggregate<br />Intrinsic<br />Value</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(in thousands)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(in millions)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Options outstanding, December&nbsp;31, 2013</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,041.1
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.65
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Granted</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,993.1
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.99
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Exercised</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(965.6
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.80
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Forfeited</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,047.9
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.76
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Options outstanding, December&nbsp;31, 2014</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,020.7
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.02
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Granted</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,917.2
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11.61
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Exercised</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,070.3
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.43
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Forfeited</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(138.4
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.76
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Options outstanding, December&nbsp;31, 2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,729.2
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.11
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Granted</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,114.1
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.67
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Exercised</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(723.1
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.20
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Forfeited</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(622.7
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.62
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Options outstanding, December&nbsp;31, 2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,497.5
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.37
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">7.3&nbsp;years</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.8
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Vested and unvested expected to vest, December&nbsp;31, 2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(14,593.7
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.31
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">7.2&nbsp;years</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.7
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Exercisable at December&nbsp;31, 2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,545.3
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.57
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">5.8&nbsp;years</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.8
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Summary of non-vested Restricted Stock Units activity</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Number of<br />Share</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Weighted<br />Average Grant<br />Date Fair<br />Value</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Weighted<br />Average<br />Remaining<br />Years</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Aggregate<br />Intrinsic<br />Value</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(in thousands)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(in millions)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Non-vested units as of December&nbsp;31, 2014</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>955.0
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.28
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Granted</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>366.0
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12.63
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Vested</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(842.5
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Forfeited</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Non-vested units as of December&nbsp;31, 2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>478.5
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10.38
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Granted</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>582.7
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.21
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Vested</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(281.9
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.73
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Forfeited</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(34.9
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.71
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Non-vested units as of December&nbsp;31, 2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>744.4
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.86
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.62
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of the equity-based compensation expense recognized in the statements of operations</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes the equity-based compensation expense recognized in the statements of operations (in thousands):</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Years Ended December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Equity compensation expense recognized in:</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Research and development expense</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,071&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,600&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,703&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Selling, general and administrative expense</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,433&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,372&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,305&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Total equity compensation expense</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17,504&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,972&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,008&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 14<br> -Section F<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6811847488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Assets and Liabilities Measured at Fair Value (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of assets and liabilities subject to fair value measurements</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December&nbsp;31, 2016 are identified in the following table (in thousands):</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Level&nbsp;2</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Total</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Commercial paper</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>68,390&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>68,390&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Corporate debt securities</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>74,535&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>74,535&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Money market funds</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,829&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,829&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>144,754&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>144,754&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Level&nbsp;2</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Level&nbsp;3</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Total</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Liabilities:</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Contingent consideration payable</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>269,722&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>269,722&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Derivative liability</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>265&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>265&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Deferred compensation plan liability</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,479&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,479&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,744&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>269,722&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>271,466&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A summary of the fair value of the Company's assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December&nbsp;31, 2015 are identified in the following table (in thousands):</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Level&nbsp;2</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Total</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Commercial paper</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,724&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,724&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Corporate debt securities</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>118,474&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>118,474&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Certificate of deposit</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>350&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>350&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Market exchanged mutual funds</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>658&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>658&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>145,206&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>145,206&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Level&nbsp;2</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Level&nbsp;3</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Total</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;">Liabilities:</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Contingent consideration payable</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>274,077&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>274,077&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Deferred compensation plan liability</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>667&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>667&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>667&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>274,077&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>274,744&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock', window );">Schedule of changes in contingent consideration payable</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table shows the change in the balance of contingent consideration payable for the year ended December&nbsp;31, 2016 and 2015, respectively (in thousands):</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Year ended December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Balance, beginning of the period</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>274,077
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,700
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Additions, from business acquisitions</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>259,000
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Payment of contingent consideration in cash</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(5,000
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Payment of contingent consideration in stock</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(6,115
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Unrealized change in fair value change during the period, included in Statement of Operations</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,760
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,377
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Balance, end of the period</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>269,722
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>274,077
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=fold_SciodermIncMember', window );">Scioderm</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of significant unobservable inputs used in the valuation of the contingent consideration payable</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Contingent Consideration Liability </font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Fair value as of<br />December&nbsp;31,<br />2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Valuation Technique</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Unobservable Input</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Range</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Discount rate</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">0.62%&nbsp;-&nbsp;3.8%</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:12pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Clinical and regulatory milestones</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$237.2&nbsp;million</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Probability weighted discounted cash flow</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Probability of achievement of milestones</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">66.5%&nbsp;-&nbsp;100.0%</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Projected year of payments</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">2017-2019</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Revenue volatility</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">58%</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Probability of achievement of milestones</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">66.5%</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:12pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Revenue-based milestones</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$22.8&nbsp;million</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Monte Carlo</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Discount rate</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">1.47%&nbsp;-&nbsp;2.55%</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:12pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Projected year of payments</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">2019-2029</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember', window );">Callidus</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of significant unobservable inputs used in the valuation of the contingent consideration payable</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Contingent Consideration Liability </font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Fair value as of<br />December&nbsp;31,<br />2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Valuation Technique</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Unobservable Input</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Range</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Discount rate</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">12.5%</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:12pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Clinical and regulatory milestones</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$9.3&nbsp;million</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Probability weighted discounted cash flow</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Probability of achievement of milestones</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">30.4%-42.8%</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Projected year of payments</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">2018-2022</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19279-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a,b,bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=SL7498348-110258<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the inputs and valuation techniques used to measure fair value, and a discussion of changes in valuation techniques and related inputs, if any, applied during the period to each separate class of assets, liabilities, and financial instruments classified in shareholders' equity that are measured on a recurring and/or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=fold_SciodermIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=fold_SciodermIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6818167920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock', window );">Schedule of current significant leased properties</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table contains information about our current significant leased properties as of December&nbsp;31, 2016:</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Location </font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Approximate<br />Square Feet</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Use</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Lease expiry date</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Cranbury, New Jersey</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>90,000&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Office and laboratory</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">September 2025</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Durham, North Carolina</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,603&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Office</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">June 2018</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Buckinghamshire, United Kingdom</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,821&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Office</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">September 2020</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Munich, Germany</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,316&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Office</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">April 2017</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of aggregate annual future minimum lease payments under the operating leases</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At December&nbsp;31, 2016, aggregate annual future minimum lease payments under these leases are as follows:</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(in thousands) </font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2018</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2019</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2020</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2021 and<br />beyond</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Total</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Minimum lease payments</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,666&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,483&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,421&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,349&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,537&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,456&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock', window );">Schedule of aggregate annual future minimum lease payments under the capital leases, including interest</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At December&nbsp;31, 2016, aggregate annual future minimum lease payments under these leases, including interest, are as follows (in thousands):</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Years ending December&nbsp;31: </font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">2017</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>355&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">2018</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>355&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">2019</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>134&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">2020</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">2021 and beyond</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Total principal obligation</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>844&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum lease payments as of the date of the latest balance sheet presented, in aggregate and for each of the five years succeeding fiscal years, with separate deductions from the total for the amount representing executor costs, including any profit thereon, included in the minimum lease payments and for the amount of the imputed interest necessary to reduce the net minimum lease payments to present value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of real estate properties and units in those properties that are included in the discussion of the nature of an entity's operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6801674832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of income (loss) before income taxes</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For financial reporting purposes, income (loss) before income taxes includes the following components (in thousands):</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Years Ended December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">United States</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(174,913
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(123,697
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(70,030
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Foreign</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(28,868
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(8,421
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(9
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Total</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(203,781
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(132,118
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(70,039
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of reconciliation of the statutory tax rates and the effective tax rates</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Years Ended<br />December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Statutory rate</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(34
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(34
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(34
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)%</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">State taxes, net of federal benefit</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(5
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(5
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Permanent adjustments</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">R&amp;D credit</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Foreign income tax rate differential</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Other</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Valuation allowance</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>36
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>37
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>38
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Net</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)%</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of significant components of the deferred tax assets and liabilities</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">The significant components of the deferred tax assets and liabilities are as follows (in thousands):</font>
		</p>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">For Years Ended<br />December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Non-current deferred tax assets</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Intellectual property</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>95,956
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Amortization/depreciation</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,781
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,657
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Research tax credit</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>32,851
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,170
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Net operating loss carry forwards</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>253,661
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>159,889
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Deferred revenue</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,281
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,281
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Non-cash stock issue</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,649
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,767
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Others</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,358
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,964
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Gross deferred tax assets</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>413,537
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>213,728
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Deferred tax liability related to business acquisition</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(173,771
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(176,219
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Deferred tax liability related to royalty payable</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(96,829
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Deferred tax liability related to convertible notes</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(29,845
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Total net deferred tax asset</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>113,092
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>37,509
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Less valuation allowance</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(286,863
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(213,728
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Net deferred tax assets (liability)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(173,771
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(176,219
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6821553312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Instruments and Related Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentsAndRelatedPartyTransactionsAbstract', window );"><strong>Debt Instruments and Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Schedule of liability components of the Convertible Notes</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Convertible Notes consist of the following as of December&nbsp;31, 2016:</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Liability component </font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(In thousands)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Principal</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>250,000
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Less: debt discount&nbsp;</font><font style="display:inline;font-family:Times;font-size:6pt;top:-4pt;position:relative;line-height:100%">(1)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(90,807
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Less: deferred financing&nbsp;</font><font style="display:inline;font-family:Times;font-size:6pt;top:-4pt;position:relative;line-height:100%">(1)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,729
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Net carrying value of the debt</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>154,464
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<div><hr style="border-width:0;width:26%;height:1.5pt;color:black;background-color:black;" align="left"></hr></div>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:15;margin-left:0pt;">
			<tr style="CellSpacing:15;">
				<td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:15;">
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Included in the Consolidated Balance Sheets within Convertible Senior Notes (due 2023) and amortized to interest expense over the remaining life of the Convertible Senior Notes using the effective interest rate method.</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Components of total interest expense recognized related to the Convertible Notes</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth total interest expense recognized related to the Convertible Notes for the year ended December&nbsp;31, 2016:</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Components </font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(In thousands)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Contractual interest expense</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>208&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Amortization of deferred financing</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>26&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Amortization of debt discount</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>248&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Total</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>482&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Effective interest rate of the liability component</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10.85&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DebtInstrumentsAndRelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DebtInstrumentsAndRelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6811869280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of reconciliation of the numerator and denominator used in computing basic and diluted net loss per common share</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss attributable to common stockholders per common share (in thousands except share amounts):</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Years Ended December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;text-decoration:underline;">Historical </font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Numerator:</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Net loss attributable to common stockholders</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(200,042
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(132,118
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(68,926
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Denominator:</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Weighted average common shares outstanding&#x2014;basic and diluted</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>134,401,588
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>109,923,815
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>74,444,157
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The table below presents potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method (in thousands):</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Year ended December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Options to purchase common stock</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,528&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,729&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,021&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Convertible debt</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>40,850&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Outstanding warrants, convertible to common stock</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,110&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,350&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,600&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Unvested restricted stock units</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>744&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>479&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>955&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Total number of potentially issuable shares</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>60,232&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13,558&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,576&nbsp;
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6638279392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Data (Unaudited - in thousands except per share data) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Selected Quarterly Financial Data (Unaudited - in thousands except per share data)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Schedule of selected quarterly financial data</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;">Selected Quarterly Financial Data (Unaudited&#x2014;in thousands except per share data)</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="11" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Quarters Ended</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">March&nbsp;31</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">June&nbsp;30</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">September&nbsp;30</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(43,691
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(51,050
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(46,654
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(58,647
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Basic and diluted net loss per common share&nbsp;</font><font style="display:inline;font-family:Times;font-size:6pt;top:-4pt;position:relative;line-height:100%">(1)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.35
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.40
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.33
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.41
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(24,288
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(27,133
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(37,800
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(42,897
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Basic and diluted net loss per common share&nbsp;</font><font style="display:inline;font-family:Times;font-size:6pt;top:-4pt;position:relative;line-height:100%">(1)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.25
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.27
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.32
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.34
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
		</table></div>
		<div><hr style="border-width:0;width:26%;height:1.5pt;color:black;background-color:black;" align="left"></hr></div>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:15;margin-left:0pt;">
			<tr style="CellSpacing:15;">
				<td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:15;">
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">Per common share amounts for the quarters and full years have been calculated separately. Accordingly, quarterly amounts do not add to the annual amounts because of differences on the weighted-average common shares outstanding during each period principally due to the effect of the Company issuing shares of its common stock during the year.</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the quarterly financial data in the annual financial statements. The disclosure includes financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income (loss) before extraordinary items and cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)-(j)<br> -URI http://asc.fasb.org/extlink&amp;oid=51825399&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6836628464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 21, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 05, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Feb. 29, 2016</div></th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2014 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jul. 31, 2014 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 01, 2016 </div>
<div>item</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Corporate Information, Status of Operations and Management Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_NumberOfFabryCausingMutationsIncludedInCHMPLabelApproval', window );">Number of Fabry causing mutations included in the label approved by the CHMP | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Net product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_PremiumsPaidForCappedCallConfirmations', window );">Net proceeds from convertible notes to pay capped call transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_StockIssuedDuringPeriodValueAtMarketOffering', window );">Net proceeds from stock issued at ATM transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock (in dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,068<span></span>
</td>
<td class="nump">$ 243,042<span></span>
</td>
<td class="nump">$ 135,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (779,608)<span></span>
</td>
<td class="num">$ (579,566)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=us-gaap_ProductMember', window );">Galafold | EU</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Corporate Information, Status of Operations and Management Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Net product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=fold_CowenAndCompanyLLCMember', window );">Cowen and Company, LLC | Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Corporate Information, Status of Operations and Management Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_StockIssuedDuringPeriodSharesAtMarketOffering', window );">Number of shares issued from ATM transactions (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_StockIssuedDuringPeriodValueAtMarketOffering', window );">Net proceeds from stock issued at ATM transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_CommonStockIssuanceCommissionExpenses', window );">Commission expenses incurred on issue of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Other expenses paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Corporate Information, Status of Operations and Management Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_StockIssuedDuringPeriodSharesAtMarketOffering', window );">Number of shares issued from ATM transactions (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,989,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,328,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_StockIssuedDuringPeriodValueAtMarketOffering', window );">Net proceeds from stock issued at ATM transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock (in dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 243,000<span></span>
</td>
<td class="nump">$ 97,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Cowen and Company, LLC | At the market ("ATM") equity offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Corporate Information, Status of Operations and Management Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_StockIssuedDuringPeriodSharesAtMarketOffering', window );">Number of shares issued from ATM transactions (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock (in dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Notes | 2016 Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Corporate Information, Status of Operations and Management Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principle amount</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Fixed interest rate (as a percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from Debt, Net of Issuance Costs</a></td>
<td class="nump">$ 243,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_PremiumsPaidForCappedCallConfirmations', window );">Net proceeds from convertible notes to pay capped call transactions</a></td>
<td class="nump">$ 13,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Corporate Information, Status of Operations and Management Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_PortionOfPatientsWithFabryCausedByMutationsIncludedInLabelApprovedByChmp', window );">Percentage of patients with Fabry disease caused by mutations included in the label approved by the CHMP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum | Cowen and Company, LLC | Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Corporate Information, Status of Operations and Management Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_FixedCommissionRateAsPercentageOfGrossProceedsPerShareSold', window );">Fixed commission rate as a percentage of gross proceeds per Share sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=fold_MiamedIncMember', window );">MiaMed Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Corporate Information, Status of Operations and Management Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration, stock and cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_BusinessCombinationContingentConsiderationMilestones', window );">Contingent consideration payable upon achievement of milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_BusinessCombinationConsiderationTransferredIncludingMilestonePayment', window );">Potential aggregate deal value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 89,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_BusinessCombinationConsiderationTransferredIncludingMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Includes payments for achievement of certain clinical, regulatory and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_BusinessCombinationConsiderationTransferredIncludingMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_BusinessCombinationContingentConsiderationMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contingent consideration payable in a business combination upon achievement of certain clinical, regulatory and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_BusinessCombinationContingentConsiderationMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_CommonStockIssuanceCommissionExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the commission expenses incurred for the issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_CommonStockIssuanceCommissionExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_FixedCommissionRateAsPercentageOfGrossProceedsPerShareSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the fixed commission rate, expressed as a percentage of gross proceeds per Share sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_FixedCommissionRateAsPercentageOfGrossProceedsPerShareSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_NumberOfFabryCausingMutationsIncludedInCHMPLabelApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of mutations causing Fabry disease included in approved CHMP label.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_NumberOfFabryCausingMutationsIncludedInCHMPLabelApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_PortionOfPatientsWithFabryCausedByMutationsIncludedInLabelApprovedByChmp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of patients with Fabry disease caused by mutations included in the label approved by the CHMP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_PortionOfPatientsWithFabryCausedByMutationsIncludedInLabelApprovedByChmp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_PremiumsPaidForCappedCallConfirmations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for premiums paid for capped call confirmations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_PremiumsPaidForCappedCallConfirmations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_StockIssuedDuringPeriodSharesAtMarketOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period related to at the market (ATM) equity offerings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_StockIssuedDuringPeriodSharesAtMarketOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_StockIssuedDuringPeriodValueAtMarketOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period related to at the market (ATM) equity offerings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_StockIssuedDuringPeriodValueAtMarketOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6578-128477<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=34725769&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents a sum total of expenses not separately reflected on the income statement for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4,6)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=us-gaap_EuropeanUnionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=us-gaap_EuropeanUnionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=fold_CowenAndCompanyLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=fold_CowenAndCompanyLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fold_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fold_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fold_AtMarketEquityOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fold_AtMarketEquityOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=fold_ConvertibleSeniorNotes2016Due2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=fold_ConvertibleSeniorNotes2016Due2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=fold_MiamedIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=fold_MiamedIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6834037824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Property and Equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6821589488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Equity Incentive Plan and Stock-Based Compensation (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>item</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ShareBasedCompensationNumberOfPlans', window );">Number of stock-based employee compensation plans</a></td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ShareBasedCompensationNumberOfPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of plans under the share-based arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ShareBasedCompensationNumberOfPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6821548960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Segment Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2016 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of business segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6836036320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 05, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Apr. 30, 2016</div></th>
<th class="th"><div>Nov. 30, 2013</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 269,722<span></span>
</td>
<td class="nump">$ 274,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration payable, current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,101<span></span>
</td>
<td class="nump">41,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Changes in fair value of contingent consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,760<span></span>
</td>
<td class="nump">4,377<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ContingentConsiderationPaidInStock', window );">Payment of contingent consideration in stock, impact on stockholder's equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=fold_SciodermIncMember', window );">Scioderm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_BusinessCombinationAdjustedConsiderationTransferred', window );">Initial amount to Effective Time Holders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 223,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_BusinessCombinationAdjustedCashConsiderationTransferred', window );">Initial amount cash payment excluding Series B Preferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_BusinessCombinationAdjustedEquityConsiderationTransferred', window );">Initial amount paid in shares of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_PriorityReviewVoucherTransferYears', window );">Priority review voucher transfer years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_BusinessCombinationPriorityReviewVoucherUsedPayment', window );">Payment to be made if Priority Review Voucher is obtained and used</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">259,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration payable, current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=fold_SciodermIncMember', window );">Scioderm | Changes in fair value of contingent consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Changes in fair value of contingent consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=fold_SciodermIncMember', window );">Scioderm | IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets-IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 463,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=fold_SciodermIncMember', window );">Scioderm | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_BusinessCombinationPriorityReviewVoucherSalePayment', window );">Priority Review Voucher sale proceeds shared</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_BusinessCombinationPriorityReviewVoucherSalePaymentPercent', window );">Priority Review Voucher sale proceeds shared (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=fold_SciodermIncMember', window );">Scioderm | Scioderm | Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Consideration paid in common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember', window );">Callidus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsDiscountRate', window );">Discount rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_StockIssuedDuringPeriodValueIssuedForContingentConsiderations', window );">Milestone payment, value of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ContingentConsiderationPaidInStock', window );">Payment of contingent consideration in stock, impact on stockholder's equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember', window );">Callidus | Changes in fair value of contingent consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Changes in fair value of contingent consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=fold_MiamedIncMember', window );">MiaMed Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration, stock and cash</a></td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates', window );">Cash consideration paid</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_BusinessCombinationContingentConsiderationMilestones', window );">Contingent consideration payable upon achievement of milestones</a></td>
<td class="nump">83,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_BusinessCombinationConsiderationTransferredIncludingMilestonePayment', window );">Potential aggregate deal value</a></td>
<td class="nump">89,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=fold_MiamedIncMember', window );">MiaMed Inc | Amicus | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Consideration paid in common stock</a></td>
<td class="nump">825,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember', window );">Clinical, Regulatory and Commercial milestones | MiaMed Inc | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_BusinessCombinationContingentConsiderationMilestones', window );">Contingent consideration payable upon achievement of milestones</a></td>
<td class="nump">$ 83,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember', window );">Clinical and Regulatory Approval milestones | Scioderm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ContingentConsiderationMilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember', window );">Clinical and Regulatory Approval milestones | Scioderm | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsDiscountRate', window );">Discount rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember', window );">Clinical and Regulatory Approval milestones | Scioderm | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Upfront cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 361,000<span></span>
</td>
<td class="nump">$ 361,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsDiscountRate', window );">Discount rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember', window );">Clinical and Regulatory Approval milestones | Callidus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember', window );">Revenue-based milestones | Scioderm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Upfront equity payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 257,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember', window );">Revenue-based milestones | Scioderm | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsDiscountRate', window );">Discount rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember', window );">Revenue-based milestones | Scioderm | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Upfront equity payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 257,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsDiscountRate', window );">Discount rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityClinicalMilestoneMember', window );">Clinical milestone | Scioderm | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Upfront cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityRegulatoryApprovalMilestoneMember', window );">Regulatory Approval milestone | Scioderm | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Upfront cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 280,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_BusinessCombinationAdjustedCashConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period, excluding payments to holders of Series B Preferred Stock related to the Series B Additional Purchase Price Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_BusinessCombinationAdjustedCashConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_BusinessCombinationAdjustedConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer, adjusted to excluding the exercise price of outstanding acquiree options and warrants and acquiree cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_BusinessCombinationAdjustedConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_BusinessCombinationAdjustedEquityConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the value of Common Stock outflow or payments associated with the acquisition of business during the period, excluding payments to holders of Series B Preferred Stock related to the Series B Additional Purchase Price Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_BusinessCombinationAdjustedEquityConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_BusinessCombinationConsiderationTransferredIncludingMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Includes payments for achievement of certain clinical, regulatory and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_BusinessCombinationConsiderationTransferredIncludingMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_BusinessCombinationContingentConsiderationMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contingent consideration payable in a business combination upon achievement of certain clinical, regulatory and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_BusinessCombinationContingentConsiderationMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_BusinessCombinationPriorityReviewVoucherSalePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of Priority Review Voucher sale proceeds shared with qualifying equity holders of the acquired entity in the event a specified PRV is obtained and sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_BusinessCombinationPriorityReviewVoucherSalePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_BusinessCombinationPriorityReviewVoucherSalePaymentPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of Priority Review Voucher sale proceeds shared with qualifying equity holders of the acquired entity in the event a specified PRV is obtained and sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_BusinessCombinationPriorityReviewVoucherSalePaymentPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_BusinessCombinationPriorityReviewVoucherUsedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the payment that will be made to qualifying equity holders of the acquired entity in the event that the Priority Review Voucher is obtained and used.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_BusinessCombinationPriorityReviewVoucherUsedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ContingentConsiderationMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ContingentConsiderationMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ContingentConsiderationPaidInStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of contingent consideration liability in stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ContingentConsiderationPaidInStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_PriorityReviewVoucherTransferYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of years of Priority Review Voucher sale transfer to third party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_PriorityReviewVoucherTransferYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_StockIssuedDuringPeriodValueIssuedForContingentConsiderations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued for noncash contingent consideration upon achieving event based milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_StockIssuedDuringPeriodValueIssuedForContingentConsiderations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6578-128477<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6578-128477<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInputsDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest rate used to find the present value of an amount to be paid or received in the future as an input to measure fair value.  For example, but not limited to, weighted average cost of capital (WACC), cost of capital, cost of equity and cost of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInputsDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a controlling interest in another entity or an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, joint venture or equity method investment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=fold_SciodermIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=fold_SciodermIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=fold_ChangesInFairValueOfContingentConsiderationPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=fold_ChangesInFairValueOfContingentConsiderationPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=fold_SciodermIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=fold_SciodermIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=fold_MiamedIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=fold_MiamedIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=us-gaap_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=us-gaap_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityClinicalMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityClinicalMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityRegulatoryApprovalMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityRegulatoryApprovalMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6835631616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Goodwill (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Changes in goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at beginning of the period</a></td>
<td class="nump">$ 197,797<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at end of the period</a></td>
<td class="nump">197,797<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=fold_BusinessAcquisitionsMember', window );">Business Acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Changes in goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at beginning of the period</a></td>
<td class="nump">197,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at end of the period</a></td>
<td class="nump">197,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment loss</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13854-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13777-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=fold_BusinessAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=fold_BusinessAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6643970496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - IPR&amp;D (Details) - Business Acquisitions<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsRollForward', window );"><strong>Changes in IPR&amp;D</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Balance at beginning of the period</a></td>
<td class="nump">$ 486.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Balance at end of the period</a></td>
<td class="nump">486.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of IPR&amp;D</a></td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=fold_BusinessAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=fold_BusinessAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6834467616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Money Market Funds and Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Cash, Money Market Funds, and Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 187,026<span></span>
</td>
<td class="nump">$ 69,485<span></span>
</td>
<td class="nump">$ 24,074<span></span>
</td>
<td class="nump">$ 43,640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,026<span></span>
</td>
<td class="nump">69,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Marketable securities, Fair Value current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,325<span></span>
</td>
<td class="nump">144,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Marketable securities, Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,222<span></span>
</td>
<td class="nump">144,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31)<span></span>
</td>
<td class="num">(154)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,325<span></span>
</td>
<td class="nump">144,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash and marketable securities, Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">330,248<span></span>
</td>
<td class="nump">214,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure', window );">Cash and marketable securities, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">330,351<span></span>
</td>
<td class="nump">214,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet', window );">Realized gain (loss) on securities available-for-sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue', window );">Fair value of available for sale securities in unrealized loss positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,700<span></span>
</td>
<td class="nump">118,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Cash, Money Market Funds, and Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Cash, Money Market Funds, and Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Gain (loss) on derivative instruments</a></td>
<td class="num">$ (300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=fold_ShortTermCorporateDebtSecuritiesMember', window );">Short term corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Cash, Money Market Funds, and Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_AvailableForSaleSecuritiesAmortizedCostCurrent', window );">Marketable securities, Amortized cost current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,564<span></span>
</td>
<td class="nump">118,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Unrealized Gain current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Unrealized Loss current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31)<span></span>
</td>
<td class="num">(154)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Marketable securities, Fair Value current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,535<span></span>
</td>
<td class="nump">118,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Cash, Money Market Funds, and Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Marketable securities, Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,258<span></span>
</td>
<td class="nump">25,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,390<span></span>
</td>
<td class="nump">25,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_MoneyMarketFundsMember', window );">Money market</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Cash, Money Market Funds, and Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Marketable securities, Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CertificatesOfDepositMember', window );">Certificate of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Cash, Money Market Funds, and Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Marketable securities, Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of current portion of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of current portion of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_AvailableForSaleSecuritiesAmortizedCostCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the current cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_AvailableForSaleSecuritiesAmortizedCostCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents cash and cash equivalents and short-term investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51813488&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the aggregate fair value of investments in debt and equity securities categorized neither as held-to-maturity nor trading securities that have been in a continuous unrealized loss position for less than twelve months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51813488&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the difference between the gross realized gains and losses realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities. Additionally, this item would include any losses recognized for other than temporary impairments (OTTI) of the subject investments in debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5618551-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a),(c),(d),(e)<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13433-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13495-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=fold_ShortTermCorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=fold_ShortTermCorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6644020416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventories</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">$ 3,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">3,416<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-downs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 5<br> -Section BB<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=51655945&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 5<br> -Section BB<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Charge to cost of goods sold that represents the reduction of the carrying amount of inventory, generally attributable to obsolescence or market conditions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28360613&amp;loc=d3e4542-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6814880352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 22,311,000<span></span>
</td>
<td class="nump">$ 19,531,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(12,495,000)<span></span>
</td>
<td class="num">(13,353,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">9,816,000<span></span>
</td>
<td class="nump">6,178,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation', window );">Depreciation expense for capital lease obligation</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligations', window );">Capital lease obligations outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">3,511,000<span></span>
</td>
<td class="nump">5,075,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Computer software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,347,000<span></span>
</td>
<td class="nump">1,354,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=fold_ResearchEquipmentMember', window );">Research equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">7,465,000<span></span>
</td>
<td class="nump">6,483,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">3,018,000<span></span>
</td>
<td class="nump">2,444,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 6,970,000<span></span>
</td>
<td class="nump">$ 4,175,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal through the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 16<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total charge for the use of long-lived depreciable assets subject to a lease meeting the criteria for capitalization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6455314&amp;loc=d3e45014-112735<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 13<br> -Subparagraph a<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 8<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=fold_ResearchEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=fold_ResearchEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6832961424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 12,905<span></span>
</td>
<td class="nump">$ 16,477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">5,079<span></span>
</td>
<td class="nump">3,578<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_AccruedContractManufacturingAndContractResearchCostsCurrent', window );">Accrued contract manufacturing &amp; contract research costs</a></td>
<td class="nump">8,042<span></span>
</td>
<td class="nump">2,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">9,981<span></span>
</td>
<td class="nump">6,201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_AccruedFacilityCostsCurrent', window );">Accrued facility costs</a></td>
<td class="nump">1,740<span></span>
</td>
<td class="nump">1,321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency forward contract</a></td>
<td class="nump">265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsCurrent', window );">Capital lease, short term portion</a></td>
<td class="nump">283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">2,713<span></span>
</td>
<td class="nump">1,699<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">$ 41,008<span></span>
</td>
<td class="nump">$ 32,216<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_AccruedContractManufacturingAndContractResearchCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the carrying value as of the balance sheet date of obligations incurred through that date and payable for contract manufacturing and contract research costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_AccruedContractManufacturingAndContractResearchCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_AccruedFacilityCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the carrying value as of the balance sheet date of obligations incurred through that date and payable for facility expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_AccruedFacilityCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of capital lease obligation due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6455314&amp;loc=d3e45023-112735<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 19<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6841361152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Common Stock and Warrants (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 21, 2016 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jul. 05, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 29, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2014 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2014 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2015 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Authorized number of shares of common stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_CommonStockVotingRightsForEachShareHeld', window );">Voting right for each share held, number | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_StockIssuedDuringPeriodValueAtMarketOffering', window );">Net proceeds from stock issued at ATM transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,076<span></span>
</td>
<td class="nump">$ 8,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from the issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97,068<span></span>
</td>
<td class="nump">$ 243,042<span></span>
</td>
<td class="nump">$ 135,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_StockIssuedDuringPeriodSharesAtMarketOffering', window );">Number of shares issued from ATM transactions (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,989,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,328,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_StockIssuedDuringPeriodValueAtMarketOffering', window );">Net proceeds from stock issued at ATM transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued from public offering / financing (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,500,000<span></span>
</td>
<td class="nump">15,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,528,302<span></span>
</td>
<td class="nump">15,927,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Public offering share price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.25<span></span>
</td>
<td class="nump">$ 6.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from the issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 243,000<span></span>
</td>
<td class="nump">$ 97,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=fold_CowenAndCompanyLLCMember', window );">Cowen and Company, LLC | Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_StockIssuedDuringPeriodSharesAtMarketOffering', window );">Number of shares issued from ATM transactions (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_StockIssuedDuringPeriodValueAtMarketOffering', window );">Net proceeds from stock issued at ATM transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_CommonStockIssuanceCommissionExpenses', window );">Commission expenses incurred on issue of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Other Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=fold_CowenAndCompanyLLCMember', window );">Cowen and Company, LLC | Sales Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_FixedCommissionRateAsPercentageOfGrossProceedsPerShareSold', window );">Fixed commission rate as a percentage of gross proceeds per Share sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=fold_CowenAndCompanyLLCMember', window );">Cowen and Company, LLC | At the market ("ATM") equity offering | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_StockIssuedDuringPeriodSharesAtMarketOffering', window );">Number of shares issued from ATM transactions (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from the issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ProceedsFromIssuanceOfCommonStockGross', window );">Aggregate offering proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=fold_SciodermIncMember', window );">Scioderm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_BusinessCombinationAdjustedConsiderationTransferred', window );">Initial amount to Effective Time Holders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 223,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_BusinessCombinationAdjustedCashConsiderationTransferred', window );">Initial amount cash payment excluding Series B Preferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_BusinessCombinationAdjustedEquityConsiderationTransferred', window );">Initial amount paid in shares of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=fold_SciodermIncMember', window );">Scioderm | Revenue-based milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Upfront equity payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">257,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=fold_SciodermIncMember', window );">Scioderm | Maximum | Clinical and Regulatory Approval milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Upfront cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 361,000<span></span>
</td>
<td class="nump">$ 361,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=fold_SciodermIncMember', window );">Scioderm | Maximum | Revenue-based milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Upfront equity payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 257,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=fold_MiamedIncMember', window );">MiaMed Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration, stock and cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates', window );">Cash consideration paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_BusinessCombinationContingentConsiderationMilestones', window );">Contingent consideration payable upon achievement of milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_BusinessCombinationConsiderationTransferredIncludingMilestonePayment', window );">Potential aggregate deal value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 89,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=fold_MiamedIncMember', window );">MiaMed Inc | Amicus | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Consideration paid in common stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">825,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=fold_NoteAndWarrantAgreement2015Member', window );">October 2015 Purchase Agreement | Redmile Group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Fixed interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=fold_NoteAndWarrantAgreement2015Member', window );">October 2015 Purchase Agreement | Redmile Group | Private Placement Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principle amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=fold_NoteAndWarrantAgreement2015Member', window );">October 2015 Purchase Agreement | Redmile Group | Private Placement Purchase Agreement | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares issuable for warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=fold_NoteAndWarrantAgreement2016Member', window );">February 2016 Purchase Agreement | Redmile Group | Private Placement Purchase Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares issuable for warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=fold_NoteAndWarrantAgreement2016Member', window );">February 2016 Purchase Agreement | Beneficial Owner | Redmile Group | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principle amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=fold_NoteAndWarrantAgreement2016Member', window );">February 2016 Purchase Agreement | Beneficial Owner | Redmile Group | Private Placement Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principle amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Fixed interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=fold_NoteAndWarrantAgreement2016Member', window );">February 2016 Purchase Agreement | Beneficial Owner | Redmile Group | Private Placement Purchase Agreement | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares issuable for warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=fold_ConvertibleSeniorNotes2016Due2023Member', window );">2016 Convertible Notes | Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principle amount</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Fixed interest rate (as a percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt conversion ratio (in shares)</a></td>
<td class="nump">0.1633987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=fold_AdditionalNoteAndWarrantAgreementJune2016Member', window );">Additional Note and Warrant Agreement June 2016 | Beneficial Owner | Redmile Group | Private Placement Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principle amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Fixed interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=fold_AdditionalNoteAndWarrantAgreementJune2016Member', window );">Additional Note and Warrant Agreement June 2016 | Beneficial Owner | Redmile Group | Private Placement Purchase Agreement | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares issuable for warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=fold_AdditionalNoteAndWarrantAgreementJune2016Member', window );">Additional Note and Warrant Agreement June 2016 | Beneficial Owner | Redmile Group | Private Placement Purchase Agreement | Maximum | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares issuable for warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_BusinessCombinationAdjustedCashConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period, excluding payments to holders of Series B Preferred Stock related to the Series B Additional Purchase Price Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_BusinessCombinationAdjustedCashConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_BusinessCombinationAdjustedConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer, adjusted to excluding the exercise price of outstanding acquiree options and warrants and acquiree cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_BusinessCombinationAdjustedConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_BusinessCombinationAdjustedEquityConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the value of Common Stock outflow or payments associated with the acquisition of business during the period, excluding payments to holders of Series B Preferred Stock related to the Series B Additional Purchase Price Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_BusinessCombinationAdjustedEquityConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_BusinessCombinationConsiderationTransferredIncludingMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Includes payments for achievement of certain clinical, regulatory and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_BusinessCombinationConsiderationTransferredIncludingMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_BusinessCombinationContingentConsiderationMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contingent consideration payable in a business combination upon achievement of certain clinical, regulatory and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_BusinessCombinationContingentConsiderationMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_CommonStockIssuanceCommissionExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the commission expenses incurred for the issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_CommonStockIssuanceCommissionExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_CommonStockVotingRightsForEachShareHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of votes entitled for each share held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_CommonStockVotingRightsForEachShareHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_FixedCommissionRateAsPercentageOfGrossProceedsPerShareSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the fixed commission rate, expressed as a percentage of gross proceeds per Share sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_FixedCommissionRateAsPercentageOfGrossProceedsPerShareSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ProceedsFromIssuanceOfCommonStockGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ProceedsFromIssuanceOfCommonStockGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_StockIssuedDuringPeriodSharesAtMarketOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period related to at the market (ATM) equity offerings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_StockIssuedDuringPeriodSharesAtMarketOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_StockIssuedDuringPeriodValueAtMarketOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period related to at the market (ATM) equity offerings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_StockIssuedDuringPeriodValueAtMarketOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6578-128477<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6578-128477<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Conversion Rate<br> -URI http://asc.fasb.org/extlink&amp;oid=6509012<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21521-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=34725769&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents a sum total of expenses not separately reflected on the income statement for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4,6)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a controlling interest in another entity or an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, joint venture or equity method investment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=fold_CowenAndCompanyLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=fold_CowenAndCompanyLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fold_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fold_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fold_AtMarketEquityOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fold_AtMarketEquityOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=fold_SciodermIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=fold_SciodermIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=fold_MiamedIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=fold_MiamedIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=us-gaap_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=us-gaap_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=fold_NoteAndWarrantAgreement2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=fold_NoteAndWarrantAgreement2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=fold_RedmileGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=fold_RedmileGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fold_PrivatePlacementPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fold_PrivatePlacementPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=fold_NoteAndWarrantAgreement2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=fold_NoteAndWarrantAgreement2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_BeneficialOwnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_BeneficialOwnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=fold_ConvertibleSeniorNotes2016Due2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=fold_ConvertibleSeniorNotes2016Due2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=fold_AdditionalNoteAndWarrantAgreementJune2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=fold_AdditionalNoteAndWarrantAgreementJune2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6838980832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Equity Incentive Plans (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent', window );">Deferred compensation liability, noncurrent</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Trading securities</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterestAndDividend', window );">Income from deferred compensation investments</a></td>
<td class="nump">34,000<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecuritiesUnrealizedHoldingGainLoss', window );">Unrealized gain/(loss)</a></td>
<td class="nump">$ 32,000<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair value weighted-average assumptions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Minimum stock price volatility (as a percent)</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=fold_EmployeeAndDirectorsStockOptionsMember', window );">Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair value weighted-average assumptions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Maximum term of option</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility (as a percent)</a></td>
<td class="nump">81.30%<span></span>
</td>
<td class="nump">75.90%<span></span>
</td>
<td class="nump">81.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate (as a percent)</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare', window );">Expected annual dividend per share (in dollars per share)</a></td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">$ 5.28<span></span>
</td>
<td class="nump">$ 7.51<span></span>
</td>
<td class="nump">$ 2.12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at the beginning of the period (in shares)</a></td>
<td class="nump">11,729,200<span></span>
</td>
<td class="nump">10,020,700<span></span>
</td>
<td class="nump">9,041,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="nump">5,114,100<span></span>
</td>
<td class="nump">3,917,200<span></span>
</td>
<td class="nump">2,993,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="num">(723,100)<span></span>
</td>
<td class="num">(2,070,300)<span></span>
</td>
<td class="num">(965,600)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options forfeited (in shares)</a></td>
<td class="num">(622,700)<span></span>
</td>
<td class="num">(138,400)<span></span>
</td>
<td class="num">(1,047,900)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at the end of the period (in shares)</a></td>
<td class="nump">15,497,500<span></span>
</td>
<td class="nump">11,729,200<span></span>
</td>
<td class="nump">10,020,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and unvested expected to vest as of the end of the period (in shares)</a></td>
<td class="nump">14,593,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at the end of the period (in shares)</a></td>
<td class="nump">7,545,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at the beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 7.11<span></span>
</td>
<td class="nump">$ 5.02<span></span>
</td>
<td class="nump">$ 5.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted (in dollars per share)</a></td>
<td class="nump">7.67<span></span>
</td>
<td class="nump">11.61<span></span>
</td>
<td class="nump">2.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised (in dollars per share)</a></td>
<td class="nump">4.20<span></span>
</td>
<td class="nump">5.43<span></span>
</td>
<td class="nump">3.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options forfeited (in dollars per share)</a></td>
<td class="nump">8.62<span></span>
</td>
<td class="nump">7.76<span></span>
</td>
<td class="nump">5.76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at the end of the period (in dollars per share)</a></td>
<td class="nump">7.37<span></span>
</td>
<td class="nump">$ 7.11<span></span>
</td>
<td class="nump">$ 5.02<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and unvested expected to vest as of the end of the period (in dollars per share)</a></td>
<td class="nump">7.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at the end of the period (in dollars per share)</a></td>
<td class="nump">$ 6.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageContractualLifeAbstract', window );"><strong>Weighted Average Remaining Contractual Life</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Balance at the end of the period</a></td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and unvested expected to vest at the end of the period</a></td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable at the end of the period</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value of options outstanding (in dollars)</a></td>
<td class="nump">$ 7,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value of options vested and unvested expected to vest (in dollars)</a></td>
<td class="nump">7,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate intrinsic value of options exercisable (in dollars)</a></td>
<td class="nump">5,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of options exercised (in dollars)</a></td>
<td class="nump">2,600,000<span></span>
</td>
<td class="nump">$ 14,700,000<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions', window );">Cash proceeds from stock options exercised (in dollars)</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">$ 11,200,000<span></span>
</td>
<td class="nump">$ 3,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unrecognized compensation cost related to non-vested stock options granted (in dollars)</a></td>
<td class="nump">$ 33,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period of recognition unrecognized compensation costs (in years)</a></td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=fold_EmployeeAndDirectorsStockOptionsMember', window );">Common stock options | 2002 Plan and 2007 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair value weighted-average assumptions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_VestingRightsPercentageOnFirstYearAnniversary', window );">Percentage of options vest on the first year anniversary</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Additional percentage of options that will vest each month after first anniversary</a></td>
<td class="nump">2.08%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionPercentageOfSharesVestedThatMayBeExercisedInWholeOrPart', window );">Percentage of shares vested that may be exercised in whole or part</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at the beginning of the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">955,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at the end of the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">955,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at the beginning of the period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at the end of the period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Units, Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested units as of the beginning of the period (in shares)</a></td>
<td class="nump">478,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">582,700<span></span>
</td>
<td class="nump">366,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(281,900)<span></span>
</td>
<td class="num">(842,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(34,900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested units as of the end of the period (in shares)</a></td>
<td class="nump">744,400<span></span>
</td>
<td class="nump">478,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested units as of the beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 10.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">6.21<span></span>
</td>
<td class="nump">$ 12.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">8.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">7.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested units as of the end of the period (in dollars per share)</a></td>
<td class="nump">$ 7.86<span></span>
</td>
<td class="nump">$ 10.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Years</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Non-vested units as of the end of the period</a></td>
<td class="text">2 years 7 months 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units (RSUs) | Performance-Based RSU Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Years</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Units issued under the Plan</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unrecognized compensation cost related to non-vested stock options granted (in dollars)</a></td>
<td class="nump">$ 4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period of recognition unrecognized compensation costs (in years)</a></td>
<td class="text">2 years 7 months 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum | Common stock options | 2007 Plan and 2007 Director Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair value weighted-average assumptions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares reserved for issuance</a></td>
<td class="nump">12,630,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the estimated dividend per share to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionPercentageOfSharesVestedThatMayBeExercisedInWholeOrPart">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of shares vested that may be exercised in whole or part.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionPercentageOfSharesVestedThatMayBeExercisedInWholeOrPart</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageContractualLifeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageContractualLifeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_VestingRightsPercentageOnFirstYearAnniversary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of award terms as to how many shares or portion of an award are no longer contingent on satisfaction of either a service condition, market condition or a performance condition, thereby giving the employee the legal right to convert the award to shares on the first anniversary (as defined), shown as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_VestingRightsPercentageOnFirstYearAnniversary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate proceeds received by the entity during the annual period from exercises of stock or unit options and conversion of similar instruments granted under equity-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested options awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterestAndDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterestAndDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of fully vested and expected to vest options that are exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to vest options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the weighted-average exercise price for outstanding stock options that are fully vested or expected to vest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share instruments newly issued under a share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 14<br> -Section D<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28,29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradingSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in debt and equity securities and other forms of securities that provide ownership interests classified as trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26626-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26610-111562<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Trading Securities<br> -URI http://asc.fasb.org/extlink&amp;oid=6526789<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradingSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradingSecuritiesUnrealizedHoldingGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized holding gain (loss) recognized in the income statement for investments in debt and equity securities and other forms of securities that provide ownership interests classified as trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Trading Securities<br> -URI http://asc.fasb.org/extlink&amp;oid=6526789<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=27723805&amp;loc=d3e24584-111560<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradingSecuritiesUnrealizedHoldingGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=fold_EmployeeAndDirectorsStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=fold_EmployeeAndDirectorsStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=fold_StockOptionPlan2002AndStockOptionPlan2007Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=fold_StockOptionPlan2002AndStockOptionPlan2007Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=fold_PerformanceBasedRestrictedStockUnitAwardAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=fold_PerformanceBasedRestrictedStockUnitAwardAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=fold_StockOptionPlan2007AndDirectorOptionPlan2007Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=fold_StockOptionPlan2007AndDirectorOptionPlan2007Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6817816480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Equity compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity compensation expense</a></td>
<td class="nump">$ 17,504<span></span>
</td>
<td class="nump">$ 9,972<span></span>
</td>
<td class="nump">$ 6,008<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Equity compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity compensation expense</a></td>
<td class="nump">8,071<span></span>
</td>
<td class="nump">4,600<span></span>
</td>
<td class="nump">2,703<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Equity compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity compensation expense</a></td>
<td class="nump">$ 9,433<span></span>
</td>
<td class="nump">$ 5,372<span></span>
</td>
<td class="nump">$ 3,305<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 14<br> -Section F<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6841566528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Assets and Liabilities Measured at Fair Value (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 05, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities subject to fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount', window );">Transfer of assets from Level 1 to Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount', window );">Transfer of assets from Level 2 to Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,754<span></span>
</td>
<td class="nump">$ 145,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Trading securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">269,722<span></span>
</td>
<td class="nump">274,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent', window );">Deferred compensation plan liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,479<span></span>
</td>
<td class="nump">667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value of liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271,466<span></span>
</td>
<td class="nump">274,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">269,722<span></span>
</td>
<td class="nump">274,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_BusinessCombinationContingentConsiderationLiabilityRollForward', window );"><strong>Contingent consideration payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">274,077<span></span>
</td>
<td class="nump">10,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityBusinessAcquisition', window );">Additions, from business acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">259,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_PaymentOfContingentConsideration', window );">Payment of contingent consideration in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payment of contingent consideration in stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,115)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Unrealized change in fair value change during the period, included in Statement of Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,760<span></span>
</td>
<td class="nump">4,377<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">269,722<span></span>
</td>
<td class="nump">$ 274,077<span></span>
</td>
<td class="nump">$ 10,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsAbstract', window );"><strong>Foreign Currency Exchange Rate Exposure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_NumberOfForwardContracts', window );">Number Of Forward Contracts | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss', window );">Non-cash changes in the fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(265)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsAbstract', window );"><strong>Foreign Currency Exchange Rate Exposure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember', window );">Callidus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,600<span></span>
</td>
<td class="nump">9,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,600<span></span>
</td>
<td class="nump">9,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsDiscountRate', window );">Discount rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=fold_SciodermIncMember', window );">Scioderm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 259,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 259,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=fold_MiamedIncMember', window );">MiaMed Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_BusinessCombinationContingentConsiderationMilestones', window );">Contingent consideration payable upon achievement of milestones</a></td>
<td class="nump">$ 83,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_BusinessCombinationConsiderationTransferredIncludingMilestonePayment', window );">Potential aggregate deal value</a></td>
<td class="nump">89,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember', window );">Clinical and Regulatory Approval milestones | Callidus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember', window );">Clinical and Regulatory Approval milestones | Scioderm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember', window );">Revenue-based milestones | Scioderm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum | Clinical and Regulatory Approval milestones | Scioderm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsDiscountRate', window );">Discount rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum | Revenue-based milestones | Scioderm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsDiscountRate', window );">Discount rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum | Clinical and Regulatory Approval milestones | Scioderm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsDiscountRate', window );">Discount rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum | Revenue-based milestones | Scioderm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsDiscountRate', window );">Discount rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum | Clinical, Regulatory and Commercial milestones | MiaMed Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_BusinessCombinationContingentConsiderationMilestones', window );">Contingent consideration payable upon achievement of milestones</a></td>
<td class="nump">$ 83,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,390<span></span>
</td>
<td class="nump">$ 25,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,535<span></span>
</td>
<td class="nump">118,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CertificatesOfDepositMember', window );">Certificate of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=fold_MarketExchangedMutualFundsMember', window );">Market exchanged mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,829<span></span>
</td>
<td class="nump">658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,754<span></span>
</td>
<td class="nump">145,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent', window );">Deferred compensation plan liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,479<span></span>
</td>
<td class="nump">667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value of liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,744<span></span>
</td>
<td class="nump">667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,390<span></span>
</td>
<td class="nump">25,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,535<span></span>
</td>
<td class="nump">118,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Certificate of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Market exchanged mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,829<span></span>
</td>
<td class="nump">658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">269,722<span></span>
</td>
<td class="nump">274,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value of liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">269,722<span></span>
</td>
<td class="nump">274,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 269,722<span></span>
</td>
<td class="nump">$ 274,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Clinical and Regulatory Approval milestones | Probability weighted discounted cash flow | Callidus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsDiscountRate', window );">Discount rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Revenue-based milestones | Monte Carlo | Scioderm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_FairValueInputsProbabilityOfAchievementOfMilestones', window );">Probability of achievement of milestones (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_FairValueAssumptionsRevenueVolatilityRate', window );">Revenue volatility (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Minimum | Clinical and Regulatory Approval milestones | Probability weighted discounted cash flow | Callidus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_FairValueInputsProbabilityOfAchievementOfMilestones', window );">Probability of achievement of milestones (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Minimum | Clinical and Regulatory Approval milestones | Probability weighted discounted cash flow | Scioderm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsDiscountRate', window );">Discount rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.62%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_FairValueInputsProbabilityOfAchievementOfMilestones', window );">Probability of achievement of milestones (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Minimum | Revenue-based milestones | Monte Carlo | Scioderm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsDiscountRate', window );">Discount rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.47%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Maximum | Clinical and Regulatory Approval milestones | Probability weighted discounted cash flow | Callidus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_FairValueInputsProbabilityOfAchievementOfMilestones', window );">Probability of achievement of milestones (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Maximum | Clinical and Regulatory Approval milestones | Probability weighted discounted cash flow | Scioderm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsDiscountRate', window );">Discount rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_FairValueInputsProbabilityOfAchievementOfMilestones', window );">Probability of achievement of milestones (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Maximum | Revenue-based milestones | Monte Carlo | Scioderm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsDiscountRate', window );">Discount rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=fold_RedmileGroupMember', window );">Redmile Group | October 2015 Purchase Agreement | Private Placement Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities subject to fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Proceeds from note and warrant purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=fold_RedmileGroupMember', window );">Redmile Group | Additional Note and Warrant Agreement June 2016 | Beneficial Owner | Private Placement Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities subject to fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Proceeds from note and warrant purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_BusinessCombinationConsiderationTransferredIncludingMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Includes payments for achievement of certain clinical, regulatory and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_BusinessCombinationConsiderationTransferredIncludingMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_BusinessCombinationContingentConsiderationLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent consideration payable rollforward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_BusinessCombinationContingentConsiderationLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_BusinessCombinationContingentConsiderationMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contingent consideration payable in a business combination upon achievement of certain clinical, regulatory and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_BusinessCombinationContingentConsiderationMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_FairValueAssumptionsRevenueVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of assumed revenue volatility, used as an input to measure fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_FairValueAssumptionsRevenueVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_FairValueInputsProbabilityOfAchievementOfMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of likelihood that milestones will be achieved, used as an input to measure fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_FairValueInputsProbabilityOfAchievementOfMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityBusinessAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from business acquisitions of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityBusinessAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_NumberOfForwardContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the number of forward contracts negotiated to purchase and sell a specific quantity of a financial instrument, foreign currency, or commodity at a price specified at origination of the contract, with delivery and settlement at a specified future date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_NumberOfForwardContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_PaymentOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the payment of contingent consideration liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_PaymentOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=34725769&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=51814546&amp;loc=SL51823488-111719<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5624163-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=51825145&amp;loc=SL20226000-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13433-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13495-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInputsDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest rate used to find the present value of an amount to be paid or received in the future as an input to measure fair value.  For example, but not limited to, weighted average cost of capital (WACC), cost of capital, cost of equity and cost of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInputsDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) recognized in the income statement for a financial instrument classified as derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradingSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in debt and equity securities and other forms of securities that provide ownership interests classified as trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26626-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26610-111562<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Trading Securities<br> -URI http://asc.fasb.org/extlink&amp;oid=6526789<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradingSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=fold_SciodermIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=fold_SciodermIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=fold_MiamedIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=fold_MiamedIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityRevenueBasedMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=fold_MarketExchangedMutualFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=fold_MarketExchangedMutualFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=fold_ProbabilityWeightedDiscountedCashFlowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=fold_ProbabilityWeightedDiscountedCashFlowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=fold_MonteCarloMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=fold_MonteCarloMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=fold_RedmileGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=fold_RedmileGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=fold_NoteAndWarrantAgreement2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=fold_NoteAndWarrantAgreement2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fold_PrivatePlacementPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fold_PrivatePlacementPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=fold_AdditionalNoteAndWarrantAgreementJune2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=fold_AdditionalNoteAndWarrantAgreementJune2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_BeneficialOwnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_BeneficialOwnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6811829920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Plan (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract', window );"><strong>401 (k) Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum contribution by the company as a percentage of employee's salary and bonus paid during the year</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Total contribution to the plan (in dollars)</a></td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the cost recognized during the period for defined contribution plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6814729312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Minimum lease payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2017</a></td>
<td class="nump">$ 2,666,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2018</a></td>
<td class="nump">2,483,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2019</a></td>
<td class="nump">2,421,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2020</a></td>
<td class="nump">2,349,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_OperatingLeasesFutureMinimumPaymentsDueInFiveYearsAndThereafter', window );">2021 and beyond</a></td>
<td class="nump">10,537,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
<td class="nump">20,456,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent expense, including fees for utilities and common area maintenances</a></td>
<td class="nump">3,500,000<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesCapitalAbstract', window );"><strong>Capital Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligations', window );">Capital lease obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesCapitalAbstract', window );"><strong>Capital Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligations', window );">Capital lease obligation</a></td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum', window );">Capital leases, interest rate, minimum</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMaximum', window );">Capital leases, interest rate, maximum</a></td>
<td class="nump">5.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent', window );">2017</a></td>
<td class="nump">$ 355,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears', window );">2018</a></td>
<td class="nump">355,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears', window );">2019</a></td>
<td class="nump">134,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDue', window );">Total principle obligation</a></td>
<td class="nump">$ 844,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesCapitalAbstract', window );"><strong>Capital Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_LesseeLeasingArrangementsCapitalLeasesTermOfContract', window );">Term of capital lease (in months)</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesCapitalAbstract', window );"><strong>Capital Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_LesseeLeasingArrangementsCapitalLeasesTermOfContract', window );">Term of capital lease (in months)</a></td>
<td class="text">48 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeographicDistributionAxis=fold_CranburyNewJerseyMember', window );">Cranbury, New Jersey | Office and laboratory space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of space leased (in square feet) | ft&#178;</a></td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeographicDistributionAxis=fold_DurhamNorthCarolinaMember', window );">Durham, North Carolina | Office space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of space leased (in square feet) | ft&#178;</a></td>
<td class="nump">5,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeographicDistributionAxis=fold_BuckinghamshireUnitedKingdomMember', window );">Buckinghamshire, United Kingdom | Office space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of space leased (in square feet) | ft&#178;</a></td>
<td class="nump">9,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeographicDistributionAxis=fold_MunichGermanyMember', window );">Munich, Germany | Office space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of space leased (in square feet) | ft&#178;</a></td>
<td class="nump">4,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_LesseeLeasingArrangementsCapitalLeasesTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of the lessee's capital leasing arrangement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_LesseeLeasingArrangementsCapitalLeasesTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_OperatingLeasesFutureMinimumPaymentsDueInFiveYearsAndThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of required minimum rental payments maturing in the fifth fiscal year following the latest fiscal year and thereafter for operating leases having an initial or remaining non-cancelable letter-term in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_OperatingLeasesFutureMinimumPaymentsDueInFiveYearsAndThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal through the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 16<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOperatingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOperatingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeographicDistributionAxis=fold_CranburyNewJerseyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeographicDistributionAxis=fold_CranburyNewJerseyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=fold_OfficeAndLaboratorySpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=fold_OfficeAndLaboratorySpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeographicDistributionAxis=fold_DurhamNorthCarolinaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeographicDistributionAxis=fold_DurhamNorthCarolinaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=fold_OfficeSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=fold_OfficeSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeographicDistributionAxis=fold_BuckinghamshireUnitedKingdomMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeographicDistributionAxis=fold_BuckinghamshireUnitedKingdomMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeographicDistributionAxis=fold_MunichGermanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeographicDistributionAxis=fold_MunichGermanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6817800560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Statutory Rate (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract', window );"><strong>Income (loss) before income taxes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United States</a></td>
<td class="num">$ (174,913)<span></span>
</td>
<td class="num">$ (123,697)<span></span>
</td>
<td class="num">$ (70,030)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(28,868)<span></span>
</td>
<td class="num">(8,421)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax benefit</a></td>
<td class="num">$ (203,781)<span></span>
</td>
<td class="num">$ (132,118)<span></span>
</td>
<td class="num">$ (70,039)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation of the statutory tax rates and the effective tax rates</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory rate (as a percent)</a></td>
<td class="num">(34.00%)<span></span>
</td>
<td class="num">(34.00%)<span></span>
</td>
<td class="num">(34.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit (as a percent)</a></td>
<td class="num">(5.00%)<span></span>
</td>
<td class="num">(5.00%)<span></span>
</td>
<td class="num">(4.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Permanent adjustments (as a percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">R&amp;D credit (as a percent)</a></td>
<td class="num">(3.00%)<span></span>
</td>
<td class="num">(3.00%)<span></span>
</td>
<td class="num">(4.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign income tax rate differential (as a percent)</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other (as a percent)</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance (as a percent)</a></td>
<td class="nump">36.00%<span></span>
</td>
<td class="nump">37.00%<span></span>
</td>
<td class="nump">38.00%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Net (as a percent)</a></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="nump">(0.00%)<span></span>
</td>
<td class="num">(2.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_IncomeTaxExpensesBenefitFromSaleOfNetOperatingLossesAndResearchAndDevelopmentCredits', window );">Income tax benefit from the sale of net operating losses and research and development credits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="num">(3,739)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,113)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Reduction in valuation allowance related to income tax associated with gain on foreign currency translation</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">Income tax benefit in connection with the reduction in North Carolina state tax rates</a></td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_IncomeTaxExpensesBenefitFromSaleOfNetOperatingLossesAndResearchAndDevelopmentCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the income tax benefit from the sale of net operating losses and research and development credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_IncomeTaxExpensesBenefitFromSaleOfNetOperatingLossesAndResearchAndDevelopmentCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51673353&amp;loc=d3e41242-110953<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 10<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 08<br> -Paragraph h<br> -Subparagraph 1<br> -Article 4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6836121264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Deferred and Valuation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Recognized interest and penalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrual for interest and penalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent', window );">Accrual for uncertain tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DeferredTaxAssetsNoncurrentAbstract', window );"><strong>Non-current deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DeferredTaxAssetsIntellectualProperty', window );">Intellectual property</a></td>
<td class="nump">$ 95,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Amortization/depreciation</a></td>
<td class="nump">1,781<span></span>
</td>
<td class="nump">2,657<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research tax credit</a></td>
<td class="nump">32,851<span></span>
</td>
<td class="nump">27,170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="nump">253,661<span></span>
</td>
<td class="nump">159,889<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">14,281<span></span>
</td>
<td class="nump">14,281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DeferredTaxAssetsNonCashStockIssueNonCurrent', window );">Non-cash stock issue</a></td>
<td class="nump">11,649<span></span>
</td>
<td class="nump">6,767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Others</a></td>
<td class="nump">3,358<span></span>
</td>
<td class="nump">2,964<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">413,537<span></span>
</td>
<td class="nump">213,728<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Deferred tax liability related to business acquisition</a></td>
<td class="num">(173,771)<span></span>
</td>
<td class="num">(176,219)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DeferredTaxLiabilitiesRoyaltyPayable', window );">Deferred tax liability related to royalty payable</a></td>
<td class="num">(96,829)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DeferredTaxLiabilitiesConvertibleNotes', window );">Deferred tax liability related to convertible notes</a></td>
<td class="num">(29,845)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DeferredTaxAssetsLiabilitiesGross', window );">Total net deferred tax asset</a></td>
<td class="nump">113,092<span></span>
</td>
<td class="nump">37,509<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(286,863)<span></span>
</td>
<td class="num">(213,728)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax assets (liability)</a></td>
<td class="num">(173,771)<span></span>
</td>
<td class="num">(176,219)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in the valuation allowance</a></td>
<td class="nump">$ 73,200<span></span>
</td>
<td class="nump">$ 65,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DeferredTaxAssetsIntellectualProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DeferredTaxAssetsIntellectualProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DeferredTaxAssetsLiabilitiesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards, net of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DeferredTaxAssetsLiabilitiesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DeferredTaxAssetsNonCashStockIssueNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from non-cash stock issue and carryforwards expected to be realized or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DeferredTaxAssetsNonCashStockIssueNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DeferredTaxAssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DeferredTaxAssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DeferredTaxLiabilitiesConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from convertible notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DeferredTaxLiabilitiesConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DeferredTaxLiabilitiesRoyaltyPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from royalty payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DeferredTaxLiabilitiesRoyaltyPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Liability<br> -URI http://asc.fasb.org/extlink&amp;oid=6510232<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 15<br> -Subparagraph b(2)<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Asset<br> -URI http://asc.fasb.org/extlink&amp;oid=6510090<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, before jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current portion of the amount recognized for uncertain tax positions as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6811842448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Loss Carryforwards (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Net operating loss carry forwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_OperatingLossCarryforwardsLimitationsOnUseMinimumPercentageOwnershipChangePeriod', window );">Period for measuring the change in ownership</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_OperatingLossCarryforwardsLimitationsOnUseMinimumOwnershipPercentageChangeRelatingToSection382', window );">Maximum change in ownership percentage allowed before statutory limitations imposed on the availability of net operating losses</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation', window );">Tax benefit associated with exercise of stock options to be recorded in additional paid-in capital on recognition of associated NOL</a></td>
<td class="nump">$ 4.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Net operating loss carry forwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Amount of net operating loss carry forwards</a></td>
<td class="nump">637.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_WritedownOfOperatingLossCarryforwardAndResearchAndDevelopmentCreditsSubjectToSection382Limitations', window );">Writedown of NOL's and R&amp;D credits subject to Section 382 limitation</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Net operating loss carry forwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Amount of net operating loss carry forwards</a></td>
<td class="nump">40.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Net operating loss carry forwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Amount of net operating loss carry forwards</a></td>
<td class="nump">$ 623.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_OperatingLossCarryforwardsLimitationsOnUseMinimumOwnershipPercentageChangeRelatingToSection382">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The limitation imposed by Section 382 related to the use of all operating loss carryforwards available to reduce future taxable income in the event of a more than specified percentage change in ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_OperatingLossCarryforwardsLimitationsOnUseMinimumOwnershipPercentageChangeRelatingToSection382</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_OperatingLossCarryforwardsLimitationsOnUseMinimumPercentageOwnershipChangePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the period over which the basis percentage increase in the shareholders' equity is measured for the purpose of calculating the ownership change as defined in section 382 of the Internal Revenue Code of 1986, as amended, which will affect the ability of the entity to utilize its net operating loss carry forwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_OperatingLossCarryforwardsLimitationsOnUseMinimumPercentageOwnershipChangePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_WritedownOfOperatingLossCarryforwardAndResearchAndDevelopmentCreditsSubjectToSection382Limitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Writedown to net realizable value of the federal NOL's and research and development credits subject to Section 382 limitations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_WritedownOfOperatingLossCarryforwardAndResearchAndDevelopmentCreditsSubjectToSection382Limitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from a tax benefit associated with share-based compensation plan other than an employee stock ownership plan (ESOP). Includes, but is not limited to, excess tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6419406&amp;loc=d3e23524-113945<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6801289328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licenses (Details) - License agreement - MSSM<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Licenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_LicenseAgreementUpfrontPaymentAndAnnualLicenseFees', window );">Upfront and annual license fees paid</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_LicenseAgreementMilestonePaymentsPotential', window );">Potential milestone payments</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_LicenseAgreementMilestonePaymentsPotential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of potential payments that the entity could be required to make under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_LicenseAgreementMilestonePaymentsPotential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_LicenseAgreementUpfrontPaymentAndAnnualLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of upfront and annual license fees paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_LicenseAgreementUpfrontPaymentAndAnnualLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=fold_MtSinaiSchoolOfMedicineOfNewYorkUniversityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=fold_MtSinaiSchoolOfMedicineOfNewYorkUniversityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6811920304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2013 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ResearchRevenue', window );">Research revenue for work performed under cost sharing arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,224<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=fold_GlaxoSmithKlinePLCMember', window );">GSK | Revised Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Upfront payment received</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments', window );">Potential milestone payments upon achievement of post-approval and sales-based milestones</a></td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones', window );">Number of major markets outside the U.S. from whom parties to contractual arrangement is eligible to receive post-approval and sales-based milestones | item</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Milestone revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=fold_BiogenIdecMember', window );">Biogen Idec</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ResearchRevenue', window );">Research revenue for work performed under cost sharing arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of potential payments upon achievement of post-approval and sales-based milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents information pertaining to the number of major markets outside the U.S. from whom parties to contractual arrangement is eligible to receive post-approval and sales-based milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ResearchRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents reimbursements for research and development costs under collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ResearchRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLicenseFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from licensees for license fees during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLicenseFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration recognized during the period for the milestone or milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 28<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=51671726&amp;loc=SL6892177-166501<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=fold_GlaxoSmithKlinePLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=fold_GlaxoSmithKlinePLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fold_RevisedCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fold_RevisedCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=fold_BiogenIdecMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=fold_BiogenIdecMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6835051232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Instruments and Related Party Transactions - Note and Warrant Purchase Agreements (Details)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 29, 2016 </div>
<div>USD ($) </div>
<div>item </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2015 </div>
<div>USD ($) </div>
<div>installment </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems', window );"><strong>Debt Instruments and Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,076,000<span></span>
</td>
<td class="nump">$ 8,755,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtGainLossNetOfTax', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,302,000<span></span>
</td>
<td class="nump">$ 952,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=fold_RedmileGroupMember', window );">Redmile Group | October 2015 Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems', window );"><strong>Debt Instruments and Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentsNumberOfInstallments', window );">Number of installments for repayment of debt | installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Fixed interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=fold_RedmileGroupMember', window );">Redmile Group | October 2015 Purchase Agreement | Private Placement Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems', window );"><strong>Debt Instruments and Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Ownership position in the company (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Proceeds from note and warrant purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=fold_RedmileGroupMember', window );">Redmile Group | October 2015 Purchase Agreement | Private Placement Purchase Agreement | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems', window );"><strong>Debt Instruments and Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_WarrantTerm', window );">Warrant Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares issuable for warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=fold_RedmileGroupMember', window );">Redmile Group | February 2016 Purchase Agreement | Beneficial Owner | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems', window );"><strong>Debt Instruments and Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Proceeds from note and warrant purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=fold_RedmileGroupMember', window );">Redmile Group | February 2016 Purchase Agreement | Private Placement Purchase Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems', window );"><strong>Debt Instruments and Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares issuable for warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=fold_RedmileGroupMember', window );">Redmile Group | February 2016 Purchase Agreement | Private Placement Purchase Agreement | Warrants | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems', window );"><strong>Debt Instruments and Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt', window );">Shares of common stock issued per increment of note principal | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=fold_RedmileGroupMember', window );">Redmile Group | February 2016 Purchase Agreement | Private Placement Purchase Agreement | Beneficial Owner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems', window );"><strong>Debt Instruments and Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Proceeds from note and warrant purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentsNumberOfInstallments', window );">Number of installments for repayment of debt | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Fixed interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=fold_RedmileGroupMember', window );">Redmile Group | February 2016 Purchase Agreement | Private Placement Purchase Agreement | Beneficial Owner | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems', window );"><strong>Debt Instruments and Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_WarrantTerm', window );">Warrant Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares issuable for warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ConvertibleDebtPrincipalIncrementForConversion', window );">Increment used for debt conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_WarrantsNotSettleableInCashIncrementalFairValueDisclosure', window );">Incremental fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=fold_RedmileGroupMember', window );">Redmile Group | Additional Note and Warrant Agreement June 2016 | Private Placement Purchase Agreement | Beneficial Owner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems', window );"><strong>Debt Instruments and Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Proceeds from note and warrant purchase agreement</a></td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Fixed interest rate (as a percent)</a></td>
<td class="nump">3.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=fold_RedmileGroupMember', window );">Redmile Group | Additional Note and Warrant Agreement June 2016 | Private Placement Purchase Agreement | Beneficial Owner | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems', window );"><strong>Debt Instruments and Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_WarrantTerm', window );">Warrant Term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares issuable for warrants (in shares) | shares</a></td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ConvertibleDebtPrincipalIncrementForConversion', window );">Increment used for debt conversion</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=fold_RedmileGroupMember', window );">Redmile Group | Additional Note and Warrant Agreement June 2016 | Private Placement Purchase Agreement | Beneficial Owner | Warrants | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems', window );"><strong>Debt Instruments and Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares issuable for warrants (in shares) | shares</a></td>
<td class="nump">1,260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt', window );">Shares of common stock issued per increment of note principal | shares</a></td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=fold_RedmileGroupMember', window );">Redmile Group | December Note Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems', window );"><strong>Debt Instruments and Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtGainLossNetOfTax', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=fold_RedmileGroupMember', window );">Redmile Group | October 2017 payment | October 2015 Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems', window );"><strong>Debt Instruments and Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Installment payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=fold_RedmileGroupMember', window );">Redmile Group | October 2017 payment | February 2016 Purchase Agreement | Private Placement Purchase Agreement | Beneficial Owner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems', window );"><strong>Debt Instruments and Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Installment payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=fold_RedmileGroupMember', window );">Redmile Group | October 2020 payment | October 2015 Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems', window );"><strong>Debt Instruments and Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Installment payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=fold_RedmileGroupMember', window );">Redmile Group | October 2021 payment | February 2016 Purchase Agreement | Private Placement Purchase Agreement | Beneficial Owner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems', window );"><strong>Debt Instruments and Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Installment payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ConvertibleDebtPrincipalIncrementForConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the increments of convertible debt principle used to determine the number of shares into which the debt may be converted. For example, X number of shares may be issued for each $1,000 principal of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ConvertibleDebtPrincipalIncrementForConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DebtInstrumentsAndRelatedPartyTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DebtInstrumentsNumberOfInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of installments for repayment of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DebtInstrumentsNumberOfInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of shares per increment of convertible debt that will be issued upon conversion. For example, X number of shares may be issued for every $1,000 of convertible debt principal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_WarrantTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the term of warrants issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_WarrantTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_WarrantsNotSettleableInCashIncrementalFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Incremental fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_WarrantsNotSettleableInCashIncrementalFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=34725769&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to principal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtGainLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the reacquisition price and the net carrying amount of the extinguished debt recognized currently as a component of income in the period of extinguishment, net of tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6401765&amp;loc=d3e13305-112630<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtGainLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=fold_RedmileGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=fold_RedmileGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=fold_NoteAndWarrantAgreement2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=fold_NoteAndWarrantAgreement2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fold_PrivatePlacementPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fold_PrivatePlacementPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=fold_NoteAndWarrantAgreement2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=fold_NoteAndWarrantAgreement2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_BeneficialOwnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_BeneficialOwnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=fold_AdditionalNoteAndWarrantAgreementJune2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=fold_AdditionalNoteAndWarrantAgreementJune2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=fold_NotePurchaseAgreementDecember2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=fold_NotePurchaseAgreementDecember2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6831783680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Instruments and Related Party Transactions - Convertible Debt (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 21, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 15, 2016 </div>
<div>$ / item</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_PremiumsPaidForCappedCallConfirmations', window );">Net proceeds from convertible notes to pay capped call transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,450,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Equity component of the Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,346,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DeferredTaxLiabilitiesConvertibleNotes', window );">Deferred tax liability in relation to the Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,845,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Convertible notes issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,709,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtAbstract', window );"><strong>Interest Expense, Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_AmortizationDeferredFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">248,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 482,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate of the liability component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.85%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Notes | 2016 Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principle amount</a></td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Net proceeds after deducting fees and estimated expenses</a></td>
<td class="nump">243,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_PremiumsPaidForCappedCallConfirmations', window );">Net proceeds from convertible notes to pay capped call transactions</a></td>
<td class="nump">$ 13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt', window );">Shares of common stock issued per increment of note principal | shares</a></td>
<td class="nump">40,849,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt conversion ratio (in shares)</a></td>
<td class="nump">0.1633987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ConvertibleDebtPrincipalIncrementForConversion', window );">Increment used for debt conversion</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentConvertibleMaximumCalendarDaysAllowedToHoldersOfCommonStockRightsOptionsOrWarrantsToPurchaseOfCommonStock', window );">Maximum calendar days allowed to holders of common stock rights options or warrants to purchase of common stock</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentConvertibleTradingDaysForPricePerShareBasedOnLastReportedSalePrice', window );">Trading days for price per share based on last reported sale price</a></td>
<td class="text">10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentConvertibleMinimumPercentageOfPerShareValueOfLastReportedSalePriceOfCommonStock', window );">Minimum percentage of per share value of last reported sale price of common stock</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Equity component of the Convertible Notes</a></td>
<td class="nump">$ 88,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Convertible notes issuance costs</a></td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Convertible notes issuance cost paid</a></td>
<td class="nump">$ 6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_LiabilityComponentsAbstract', window );"><strong>Liability components of convertible notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principle</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(90,807,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Less: deferred financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,729,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying value of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,464,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Fair value of the debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 258,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtAbstract', window );"><strong>Interest Expense, Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeCapPrice', window );">Initial cap price | $ / item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DerivativeCapPricePercentageOfPremiumOnCommonStockClosingPrice', window );">Capped call premium on closing price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Notes | 2016 Convertible Notes | Convertible Notes, condition 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays', window );">Threshold consecutive trading days</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Threshold percentage</a></td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Notes | 2016 Convertible Notes | Convertible Notes, condition 1 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentsConvertibleThresholdTradingDays', window );">Threshold trading days</a></td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Notes | 2016 Convertible Notes | Convertible Notes, condition 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentsConvertibleThresholdTradingDays', window );">Threshold trading days</a></td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays', window );">Threshold consecutive trading days</a></td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentsConvertibleThresholdMaximumPercentageOfStockPriceTrigger', window );">Maximum threshold percentage</a></td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-allotment Option | Private Placement Purchase Agreement | Convertible Notes | 2016 Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principle amount</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_AmortizationDeferredFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization of specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_AmortizationDeferredFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ConvertibleDebtPrincipalIncrementForConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the increments of convertible debt principle used to determine the number of shares into which the debt may be converted. For example, X number of shares may be issued for each $1,000 principal of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ConvertibleDebtPrincipalIncrementForConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DebtInstrumentConvertibleMaximumCalendarDaysAllowedToHoldersOfCommonStockRightsOptionsOrWarrantsToPurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum calendar days allowed to holders of common stock rights options or warrants to purchase of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DebtInstrumentConvertibleMaximumCalendarDaysAllowedToHoldersOfCommonStockRightsOptionsOrWarrantsToPurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DebtInstrumentConvertibleMinimumPercentageOfPerShareValueOfLastReportedSalePriceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of per share value of last reported sale price of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DebtInstrumentConvertibleMinimumPercentageOfPerShareValueOfLastReportedSalePriceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DebtInstrumentConvertibleTradingDaysForPricePerShareBasedOnLastReportedSalePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading days for price per share based on last reported sale price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DebtInstrumentConvertibleTradingDaysForPricePerShareBasedOnLastReportedSalePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DebtInstrumentsConvertibleThresholdMaximumPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DebtInstrumentsConvertibleThresholdMaximumPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DebtInstrumentsConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DebtInstrumentsConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DeferredTaxLiabilitiesConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from convertible notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DeferredTaxLiabilitiesConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DerivativeCapPricePercentageOfPremiumOnCommonStockClosingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of premium on closing price of common stock under derivative arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DerivativeCapPricePercentageOfPremiumOnCommonStockClosingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_LiabilityComponentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Pertains to components of the convertible notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_LiabilityComponentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of shares per increment of convertible debt that will be issued upon conversion. For example, X number of shares may be issued for every $1,000 of convertible debt principal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_NumberOfSharesIssuedPerIncrementOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_PremiumsPaidForCappedCallConfirmations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for premiums paid for capped call confirmations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_PremiumsPaidForCappedCallConfirmations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=51819886&amp;loc=SL6014347-161799<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Convertible Security<br> -URI http://asc.fasb.org/extlink&amp;oid=6509036<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt before deduction of unamortized discount or premium. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt, with initial maturities beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 20<br> -Article 5<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 16<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Conversion Rate<br> -URI http://asc.fasb.org/extlink&amp;oid=6509012<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21521-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instruments must exceed threshold percentage for a specified number of trading days to trigger conversion feature, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=34725769&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of debt discount that was originally recognized at the issuance of the instrument that has yet to be amortized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=34725769&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, the carrying amount (net of accumulated amortization) as of the balance sheet date of capitalized costs associated with the issuance of debt instruments (for example, legal, accounting, underwriting, printing, and registration costs) that will be charged against earnings over the life of the debt instruments to which such costs pertain.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28555-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=27011391&amp;loc=d3e105025-122735<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 5<br> -Section A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCapPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cap rate on a price risk derivative such as a cap or collar. A payment or receipt is triggered if the market rate exceeds the cap rate on the contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCapPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:perUnitItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term debt, net of unamortized discount or premium, including current and noncurrent amounts. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 20, 22<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=fold_ConvertibleSeniorNotes2016Due2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=fold_ConvertibleSeniorNotes2016Due2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=fold_ConvertibleNotesConditionOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=fold_ConvertibleNotesConditionOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=fold_ConvertibleNotesConditionTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=fold_ConvertibleNotesConditionTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fold_PrivatePlacementPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fold_PrivatePlacementPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6812120368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (200,042)<span></span>
</td>
<td class="num">$ (132,118)<span></span>
</td>
<td class="num">$ (68,926)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares outstanding - basic and diluted</a></td>
<td class="nump">134,401,588<span></span>
</td>
<td class="nump">109,923,815<span></span>
</td>
<td class="nump">74,444,157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted earnings per share (in shares)</a></td>
<td class="nump">60,232,000<span></span>
</td>
<td class="nump">13,558,000<span></span>
</td>
<td class="nump">12,576,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=fold_EmployeeAndDirectorsStockOptionsMember', window );">Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted earnings per share (in shares)</a></td>
<td class="nump">15,528,000<span></span>
</td>
<td class="nump">11,729,000<span></span>
</td>
<td class="nump">10,021,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted earnings per share (in shares)</a></td>
<td class="nump">40,850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted earnings per share (in shares)</a></td>
<td class="nump">3,110,000<span></span>
</td>
<td class="nump">1,350,000<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted earnings per share (in shares)</a></td>
<td class="nump">744,000<span></span>
</td>
<td class="nump">479,000<span></span>
</td>
<td class="nump">955,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Antidilution<br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Diluted Earnings Per Share<br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Contingent Stock Agreement<br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=fold_EmployeeAndDirectorsStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=fold_EmployeeAndDirectorsStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6831240384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>lawsuit</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_NumberOfLawsuits', window );">Number of purported securities class action lawsuits</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_NumberOfLawsuitsNamingAdditionalOfficer', window );">Number of purported securities class action lawsuits naming additional company officers as defendants</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_NumberOfLawsuits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of lawsuits commenced</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_NumberOfLawsuits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_NumberOfLawsuitsNamingAdditionalOfficer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of lawsuit that list one or more of the entity's officers as named defendant(s)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_NumberOfLawsuitsNamingAdditionalOfficer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6820912624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Data (Unaudited - in thousands except per share data) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SelectedQuarterlyFinancialInformationAbstract', window );"><strong>Selected Quarterly Financial Data</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (58,647)<span></span>
</td>
<td class="num">$ (46,654)<span></span>
</td>
<td class="num">$ (51,050)<span></span>
</td>
<td class="num">$ (43,691)<span></span>
</td>
<td class="num">$ (42,897)<span></span>
</td>
<td class="num">$ (37,800)<span></span>
</td>
<td class="num">$ (27,133)<span></span>
</td>
<td class="num">$ (24,288)<span></span>
</td>
<td class="num">$ (200,042)<span></span>
</td>
<td class="num">$ (132,118)<span></span>
</td>
<td class="num">$ (68,926)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per common share (in dollars per share)</a></td>
<td class="num">$ (0.41)<span></span>
</td>
<td class="num">$ (0.33)<span></span>
</td>
<td class="num">$ (0.40)<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="num">$ (0.34)<span></span>
</td>
<td class="num">$ (0.32)<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (1.49)<span></span>
</td>
<td class="num">$ (1.20)<span></span>
</td>
<td class="num">$ (0.93)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SelectedQuarterlyFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SelectedQuarterlyFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>87
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M#[^;L.N-/=A_;'P5;!OX=1?M%U!+ P04    " "F@6%*F5R<(Q &  "<)P
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M]J)6[AGM+TJ+9HABIM*PM_Y=M>Y]Z[]0,M!@ AD(9"00^BDA'0CI2,"?$^A
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M4,-4CIEIQ68B:#_>,MYTU97_ %!+ P04    " "F@6%*23@G[@\$   4$@
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M$$V4Q0>Y^#@J/LCEXD'03 E&-RP;"60G2@S*PH-<>!P5'N1B\8!*6[JY64M
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MZ);S!*,3E\-4C*GN&7K"R3"U0S#WY/(_4$L#!!0    ( *:!84JPY(V$OP$
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MZW_3C&Z@N@9JVT#)@PUTUT!O&VA[L('I&IAM WG8)=LUL*>ZY+H&[E27?-?
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MS>,P_@SI=W<\$#Y>#.W+?-B].IVXW_T/4$L#!!0    ( *:!84K=<&;6M0$
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M_FRF,9L,A_W\@]CRC8L_4$L#!!0    ( *:!84KV<G(6LP$  -(#   9
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MEXW]KQ$=>"G)E1^AUG^PQ5!0NW#\Y,]F&K/)<-C//X@MW[CX#5!+ P04
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M86_<( S]*X@?4"Y<VE6G)%*OT]1*FW3JM/4SES@)*L0ID$OW[P<DS;(MVQ?
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M=^5'J/4?;#$4U"X</_BSF<9L,ASV\P]BRS<N?@)02P,$%     @ IH%A2J$
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MU_..DKGX3W %Y<.#$I^C1&7C2LK!.M0SBY>BQ<NTRR[NXW23'F;8-H#/ +X
M[F(>-B6*RA^%$T5F<"1FZGTOPA,G1^Y[4P9G;$6\\^*M]UX+GAPR=@U$<\QI
MBN&KF&2)8)Y]2<&W4ISX/W"^#=]O*MQ'^/X_"O\@2#<)TDB0OEGB5LSM7TG8
MJJ<:3!.GR9(2ARY.\LJ[#.P]CV_R.WR:]L_"-+*SY(+.OVSL?XWHP$O9W?@1
M:OT'6PP%M0O'6W\VTYA-AL-^_D%L^<;%+U!+ P04    " "F@6%*;--=EK0!
M  #2 P  &0   'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q]4]MNW" 0_17$
M!X0UNVVW*]M2-E752HVT2M7DF;7'-@H7%_ Z^?L")H[;.'T!9IASYLPPY*,V
MC[8#<.A)"F4+W#G7'PBQ50>2V2O=@_(WC3:2.6^:EMC> *LC2 I"-YN/1#*N
M<)E'W\F4N1Z<X I.!ME!2F:>CR#T6. ,OSCN>-NYX"!EWK,6?H+[U9^,M\C,
M4G,)RG*MD(&FP-?9X;@+\3'@GL-H%V<4*CEK_1B,[W6!-T$0"*A<8&!^N\ -
M"!&(O(S?B1//*0-P>7YA_QIK][6<F84;+1YX[;H"[S&JH6&#<'=Z_ :IG@\8
MI>)_P 6$#P]*?(Y*"QM75 W6:9E8O!3)GJ:=J[B/Z88FV#J )@"= ?N8ATR)
MHO(OS+$R-WI$9NI]S\(39P?J>U,%9VQ%O//BK?=>2IKM<W()1"GF.,7014PV
M1Q#//J>@:RF.] V<KL.WJPJW$;Y]1^%?!+M5@ETDV/VWQ+68S_\D(8N>2C!M
MG":+*CVH.,D+[SRPU_$1R6OX-.VWS+1<6736SK]L['^CM0,O97/E1ZCS'VPV
M!#0N'#_YLYG&;#*<[M,/(O,W+O\ 4$L#!!0    ( *:!84H?YJBLL@$  -$#
M   9    >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;'U388_4(!#]*X0?<'39
MU;MLVB:W9XPFFFS.Z'UFVVE+#I@*='O^>X'V:M7J%V"&-V_>#$,^HGUV'8 G
M+UH95]#.^_[(F*LZT,+=8 \FW#1HM?#!M"USO051IR"M&,^RMTP+:6B9)]_9
MECD.7DD#9TO<H+6P/TZ@<"SHCKXZ'F7;^>A@9=Z+%KZ _]J?;;#8PE)+#<9)
M-,1"4]#[W?%TB/@$^"9A=*LSB95<$)^C\;$N:!8%@8+*1P81MBL\@%*1*,CX
M/G/2)64,7)]?V=^GVD,M%^'@ =63K'U7T#M*:FC$H/PCCA]@KN<-)7/QG^ *
M*L"CDI"C0N722JK!>=0S2Y"BQ<NT2Y/V<;JYG:.V\7S&\P5_E]*P*4\2_DYX
M4>861V*GUO<BOO#NR$-KJNA,G4AW0;L+WFO)>9:S:R2:,:<)PU>8W8)@@7U)
MP;=2G/A?X7P[?+^I<)_"]_]0^!O!89/@D @._RUQ"_-GD6S54PVV3</D2(6#
M28.\\B[S>L_3F_R"3\/^6=A6&D<NZ,/+IOXWB!Z"E.PF3% 7_M=B*&A\/-Z&
MLYVF;#(\]O,'8LLO+G\"4$L#!!0    ( *:!84K_0QBDL@$  -(#   9
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M:&5E=#(U+GAM;'U386_;(!#]*X@?4!+B;5ED6VHZ39NT2E&GM9^)?;91P7B
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MV/_&& \H);O!$>KP@RV&@L:'XQL\VWG,9L.;(?T@MGSC\B=02P,$%     @
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M[:-Y'VP[KMGH>.RF%\3F9US\ E!+ P04    " "F@6%*'^\'@O0"  "$#0
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M[E\+\RZ'>\'0T.(TWGFBZ>*U_@M02P,$%     @ IH%A2J,?38K& 0  -P0
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M4]MNW" 0_17$!P0ONTW2E6TIFZI*I59:I6KRS-IC&P4\#N!U^O<%['6<U"_
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MP>[5>*W'P,ANFEAD'IO97U!+ P04    " "F@6%*H*]-G,T!  "<!   &0
M 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6QM5&UOVR 0_BN('U <G+A59%MJ
M.DVKM$E1IVV?B7U^4<&X@./VWP^PXWH>7P)W?E[N"$<Z2O6J&P"#W@7O=(8;
M8_HC(;IH0#!])WOH[)=**L&,#55-=*^ E9XD.*%1E!#!V@[GJ<^=59[*P?"V
M@[-">A""J8\3<#EF>(=OB9>V;HQ+D#SM60T_P?SJS\I&9%$I6P&=;F6'%%09
M?MP=3XG#>\#O%D:]VB/7R47*5Q<\EQF.7$' H3!.@=GE"D_ N1.R9;S-FGBQ
M=,3U_J;^U?=N>[DP#4^2_VE+TV3X :,2*C9P\R+';S#W<\!H;OX[7(%;N*O$
M>A22:_^+BD$;*6856XI@[]/:=GX=9_T;+4R@,X%N"&0R\I5_88;EJ9(C4M/9
M]\S]Q;LCM6=3N*0_"O_-%J]M]IK'=)>2JQ.:,:<)0U>83P2QZHL%#5F<Z']T
M&J;'P0IC3X_7=!J%!?9!@;T7V/_3(MVT&,+$89-#T.00$-AO3$*80]@D"9HD
M 8%D8Q+"W&],R.IV"%"UGPN-"CET?B97V67T'JF_79_P:6Y_,%6WG487:>P=
M]3>IDM* +26ZLPTW]JE8 @Z5<=M[NU?3P$R!D?W\%I#E0<K_ E!+ P04
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MJVE@IL#(?GX+R/(@Y7\ 4$L#!!0    ( *:!84I'\KKRP@$  #<$   9
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MX'YU1^,],JM47(*R7"MDH,[QPW9_2 ,^ GYS&.S"1J&3D]9OP7FI<KP)!8&
MT@4%YH\S/((00<B7\3YIXCEE("[MB_I3[-WW<F(6'K7XPRO7YO@>HPIJU@OW
MJH=GF/JYQ6AJ_CN<07AXJ,3G*+6P\8O*WCHM)Q5?BF0?X\E5/(=)_T);)]")
M0*\(9$P4*__&'"LRHP=DQMEW+%SQ=D_];,H0C*.(_WSQUD?/19+>9N0<A";,
M8<30!68[(XA7GU/0M10'^A^=KM.3U0J32$^6]&2W+I"N"J11(/VGQ=U5BVN8
MNZLD9#%3"::)VV11J7L5-WD1G1?V@<8[^8*/V_Z#F88KBT[:^9N-\Z^U=N!+
MV=SX%6K] YL= ;4+YIVWS;AFH^-T-[T@,C_CXB]02P,$%     @ IH%A2FD-
MNF?%!   0!D  !D   !X;"]W;W)K<VAE971S+W-H965T-#,N>&ULE5E=<Z,X
M$/PK%.^WH \DD;)=M4DVV3AQ56JW[O:9Q$KL6C ^(/'>OS\!LF.D&0>_Q$!Z
MID?2=$O8DUU9_:Y76C?!GR+?U--PU33;BRBJGU>ZR.HOY59OS']>RJK(&G-;
MO4;UMM+9L@LJ\HC&L8B*;+T)9Y/NV6,UFY1O3;[>Z,<JJ-^*(JO^N]1YN9N&
M)-P_^+%^737M@V@VV6:O^J=N_MX^5N8N.F19K@N]J=?E)JCTRS3\2BX6/&T#
M.L0_:[VKCZZ#=BA/9?F[O;E;3L.XK4CG^KEI4V3FXUU?Z3QO,YDZ_K5)PP-G
M&WA\O<]^TPW>#.8IJ_55F?]:+YO5-%1AL-0OV5O>_"AWW[4=4!(&=O0/^EWG
M!MY68CB>R[SN_@;/;W53%C:+*:7(_O2?ZTWWN;/Y]V%P +4!]!! R<D 9@/8
MV !N _@A@/"3 8D-2,8R"!L@#@'L=("T ?(C0)X,4#9 C2TIM0'I1\!I!A+O
M5RX>6Q0Y+#89.W"R7VY"1Q>V7W#RL>)$=>W>]V+7W-=9D\TF5;D+JEZ?VZRU
M 7)AHDSR]FDGE^Z?IL%K\_1]QKB:1.]M)HNY[#%T@$F'F"L D\1#S#6$(4/,
M-PA#AY@;",.&F%L(PX>8[Q F&6+N((P88N801@XQ]Q#&F><'"./,\P+ B(]Y
MCLQB'U:<PBM.NPQLD(' &1B<@749^""#LT:+'I-TF$V/(0QFX3 +!UB<59[W
M&''$PM.C:1W0)#!- M XC3+O,?*()OX2.YU[_PEH4(N :Q% +4Y#SH4W9,)X
M@K2 A'DDP.,VM1PSYD] @UH47(L":G'$,U?>F%,9"U<^/HHIP01<30I7DP+5
M.#SSU&MMH)K[U*N&<A9S1R<//HP88X@3N.IV'P)=//;J]K1B,<=4?TF9BMBM
M' (F,DT$,I4$VUH(,)DID@,Q*W*&6Q'$K@CD5\S="Y@WZ"2.$5D1Q+((X%D2
MRX'X$4G.&#'B(P0P$NEH]\Z"CON8M$/&1XVX"8'L1+IL$M P0:D0LR" 6TCJ
M4BEO8%2B3(@1$, ))'.9 )%C1!21+O6E2PBB$HHHC9+Q/4.Q8P']?".\L:!Q
MAD\1/5)(C\)E8N<P(7JDD!X='<PM:* #GJHTIDX//X!(1A6E'*D+T3B%#AWN
MIF=!8JA/MR0 Q)%S%D7<@D+'#F=3^$;]<T>[G\6QNVX^+I6X*!!+H8"E2&R2
M$:^@Z@Q1("Y H?. (XI;"QK7J@RQ >;;@">*6PL:R828!0.V95<4MQ;DM/J)
MS8$AML(@6U$N&X6.;B@5]EH"^(I$#E(,<0S&SW@[0M3- '5+9RDOF2]<FIR8
M7D2[#-KII<L%@9"W)(8HDD&*3%TB?Y,W)H'N\@Q1+H/>"1*7RS_NFY,S2H4(
MG $"5T@.CDB7Q^-[AB.BY( HE2/*A06I@?R1!N>('CF@1T61'(C0.#MCP-C;
M/; U*^=\=0V!I&,>=Y^ AM4@DN6 9!6RWW!$BER<,2N(RCB@,N5T_A7W52;0
MQN>(QCB@,25<)O\DK1CJ41S1&(<T)ETJ_RBM4G]4T=$7F^UO"XNL>EUOZN"I
M;)JRZ+[(?"G+1IN41AIAL-+9\G"3ZY>FO93FNNJ_T^]OFG)K?Z^(#C^:S/X'
M4$L#!!0    ( *:!84I"NFSIW@$  /H$   9    >&PO=V]R:W-H965T<R]S
M:&5E=#0T+GAM;(U4VVZ<,!#]%<L?$ -[(RM RJ:J6JF55JF:/GMA "LVIK99
MTK^O;0BEB2/E!7O&9\Z<&3S.1JF>= M@T+/@G<YQ:TQ_)$27+0BJ;V0/G3VI
MI1+46%,U1/<*:.6#!"=)%.V)H*S#1>9]9U5D<C"<=7!62 ]"4/7G!%R..8[Q
MB^.!-:UQ#E)D/6W@!YB?_5E9BRPL%1/0:28[I*#.\5U\/*4.[P&/#$:]VB-7
MR47*)V=\K7(<.4' H32.@=KE"O? N2.R,G[/G'A)Z0+7^Q?VS[YV6\N%:KB7
M_!>K3)OC%*,*:CIP\R#'+S#7L\-H+OX;7(%;N%-B<Y22:_]%Y:"-%#.+E2+H
M\[2RSJ_C=')(Y[!P0#(')$M O/>U3(F\\D_4T")3<D1JZGU/W2^.CXGM3>F<
MOA7^S(K7UGLM-FF:D:LCFC&G"9.L,/&"()9]29&$4IR2-^%).'P35+CQX=O_
M%-Z&";9!@JTGV*SSQU&88!<DV+U5<!N]ZE$(\TZ7]L$D^T"9[Z@\! D.'R\S
M#1*D'R@SA'G]-\GJ[@E0C9\ZC4HY='[B5]YEL.\2?W?_P:=7X3M5#>LTNDAC
M)\#?TUI* U9*=&-;WMJ':#$XU,9M#W:OIG&<#"/[^:4ARW-7_ 502P,$%
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M\H U +P#<S&BP>H. -LPX&(D "(#5QR2261>S^@JR@+ ,7 X(H<!:&' C4<
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M-\U.;]KJ.-ZB6YVO\MW^!U!+ P04    " "F@6%*X1'+'U "  !(!P  &0
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M!(UPD>^/<C/1O4!U+Q#=#.CNF,5X'!K'80QD(UC,X&Q)$2K!!8>HX- 2G"R
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M+'T00G(ETK]3>3BI^]C0*/A!ZM=(O3?=I:1K2%'W%RYON/6M_P%02P,$%
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M0@[N9@2Q,QZ[<GP_2PAE5+B"?!P0*B"=D(2['T'LSUVM2^+[WPT15 AO$:%
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MT.:2NJO4"*'!5!/?&:^=>2O6!8-&V^G!S*7O&+_08EP> [R^2.4?4$L#!!0
M   ( *:!84K)@0"J5@(  ,X'   9    >&PO=V]R:W-H965T<R]S:&5E=#8T
M+GAM;(U5VXZ;,!#]%<0'+-A<LR)(N:AJI5:*MFK[[! GH 5,;2=L_[ZV(83
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M&*DQ[SI,-Y&LZ;NG,[3P]#]02P,$%     @ IH%A2N1VE-#M!   D1L  !D
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M[%Z:X#A-<) FB+E>RFM8FM_SPEF"Y_Z.A0*<"$R^ .23NV,4/OD_6!X$QE^
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M/N+>3O_3%'@SS$^%+>^U^@M02P,$%     @ IH%A2B>2!AWE @  Z H  !D
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MVNZ#7G[8+"[>OV$>GLYZ-9?[W[AWO$.0F-F<^#/0>:^NY20!T@VN8ILU>9]
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M2Y"]WF,7>.,FQ<_?IA771U8I#XT,OERAQ@Q,[B:;7V?^VG)4B\)O2,0E%IC
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MZ&YE*5)F'% K9L$R(*UP+4U?'"R680H0_[+GD8HL@<.&G )7_Z%3D8JA"![
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M?#PYXCF?3$Z^\LV7% ??\??WI$#*]P19M%/;;: <JNDW,?2GZYO.@2B!0B*
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MS2&+,#CRHOYTEY2<WV3*!5#W(ACB32$(CO-L(=LI\)B4DH,!1&H@C/8@-?;
MV# >!)4I3<MBHT#=/!5X G42LHM#LCP3;;1R+C0*O>VP&AC[*(5=G2N22N3T
M7B^I+""5!IZY$HU$B 5?DJ2D:!AG1\\NK!P7=5*4)]JWXA*8/G/:IX]ISBN:
MT63THG=TJ<YUUDF\J$$@OYX[>>R52[&"4JGIAHL1I)-WX5D"$@EH:J444N>8
MN5F!BL_QGW0FRG6PV^;K9[AU@@-1'YMC7$"#]2!XR4(ZCR>/;!Y/T-=*Q"D^
MK%*%"@L-H(M;X&O_;)Q"A;DY^D8H8[]C_X&BFU(>#Q=2!9&V2W&UQ>XD&'AF
MP20)!CX)?XA-09>41& HCF#@O=.3\-XN\^@053N]"[D:B):'?/1\,N(X!X)Y
MH8;],:/CJEN<K_^A=LCM@B^;F.:4*H [=_2D_WUAH,(W-5>!GE=.F/S$^II[
M//Z=7^8SIH>,_>KJKU&W$Y@5[+L.<I@3&32@4PJ,$6JKBF 7AT2BW#.JJE)V
M/E8,8>N$@"(G%0M0M3=FAZY4U+%TR6;KB=+8DEJ<-2NPSQEV"RMO0>VI;_(U
M\7::Z[0M:_R48K.0=SRT88H  >6<;!M7\N2JE.[; G;?-375C<P+Z)Y6>SG^
MH_!8!82B5G.5D=7'[A@L000V&^1)MLRY>GP>Q";98E567#?:4YQ/,@U)2NC$
MP/)9P9EHOQQ"@+27LM=$/WZW(P*)]\"K,K$$X]X[I#L4I9HBH>58RN%9=.]\
MTKT]/I+.:W0ANYH"N9]5)1.-('?MNB0Y5&G/.J"!(@V'OL&&"$R==$TRNPVL
M1A8;8A:4ZL.7A)80WE:8='*XC'U(@RG?:\5RO[-/:#74QJEU7_B]B=SXVB8$
M=Q*MT$8]($1#H7<ELO+DY/PK]85Q_A#7>A8%NO5K]-LI)B1]-2$O3FR0'G]S
M]A3DC\4D*7>7PT32=YJ2QLGWKDL@X7-[4W(2& :ST/K'3QP?!0QUT4X_,@H*
ML@5D(ICYQ!^FS X_O; '02WIN4<R&=TGV!ZL#0_T3&;LSV4X=*8> M++:C/G
M:@2'7L%>915W#6T/C8.U?$;Z$ 6!-^C";R0QT<T&?;_N=C6\KX(=L<HR9<K1
MG;/9R7%&6)[;7VUQ-UD>48)+A-4_21@RF#NZ)E*59!F3'2$:* 6'DO;FXNTX
M/AD_/CT:GQ\?Z_F3,:T.E7AW!V0?;?R( Q$B![_GU(/(UV*MY+(8LHZ:@<'D
M&;R.-#3\E" W>C5X+-7JK4_HS11;C'L\Z\Y$CH49=8HD\8S]%K!-_"%B+>S!
ML8/ G6Y<8K_V3R-L6.K,Y_1Q25 DWF\:WL"TA/=*!!5CZ-'8 I!@4.A(5:$C
M6SM]E/M+QSGLFUH2I9\O4]BWJQG>]-HS./S>"BR.)2>6*OJD;"7SFC9(JR5*
MR$'(R,D'[?42T"'YT]9Z-31DI-ZKZ2^9V9@>CI'T:%%$!<N?#4G^G")7OB1G
M$/SY(R+-<XY1A)F)/H\;T.[*BOPR[K$Z)Z?@IK)P8=O;D6NSP:,G$_)O2'_3
M3 ?%1-LV3$P@PKW0.'S/47)K?^UC)E)(?AKH(46K\_DA-W[P6-Y*"W0V)I@*
MHPI-IF($JFI%KMU8S6'J8RGGML;R?(GNG@APJ60<4WNC'..9\P@GU"+OOH%Z
MS&*LX)TTA7JS@%=SCOFA5;AT<A46E9+UJ&VQ,+**B>*IHD8+:]S4QEJ_:,/Q
M06M7[R\E70#M )#7OQPNJBP+*I@&A(WBHA8'X^2?654>@OZE#9?5-9 *1CE-
M"R=@SO)HDD1B=#%8[/;(V5=EM<@HCU:0, +PK<X)SG93-*A",)TJ,#R<0UY6
M4>)\ZJ^+1[062I)=681!F=_<9LBT<))R2X9P8W?@0PR$94#SH_^FK-27J&R[
M5$=T%(Z, ?23\N@K^I]W"%W1/3?Y]66TV4Y//""M]5%X0(3W7'+:@F8H196]
M&T''U(&YCG(.RI:Z*'*=A;3O0'HF3I#SR<G3,:*WGQ]+X& "PKJGE&E+]4RW
M[[NG^RB%]MO1CZI$C_XNZPO_<J%^WU&<I-K"<_NI^]UQ1RDYA5W\GG<!_NVE
MZJA4SRB$+O_UKT[+W&GZ9_^SIW_^/WOZB-F'#0WHVO[^&;R_^3__)M98@=B:
M8IJ9Y,"\5_A3WRX]HGTZL7V2@TXEIZ]O6\\G3^WQ.-:3(W806.FSH-F:G6TF
MID/HW5IBT.%VU!PIQ#C&&"-N%WSZ$'#LNZ08B 5,R&\:\[C/G>&XS9!=N!+G
M>!PB6Q+9=7T)=BZ?H%P)"NJAE]1,B8ZQX?,KBK(X%%*(EZJRA?V_IZU-S.N(
M<J:1=YK4P+0KV8(5<J+D,<%"'W5/LM7WH<!2@'=7'QCK%'>U;3FBL6K.$)=:
M=XTH37/3=,UU'Y"O&8!5-3?* M-@+)JR.?;0YJ&'Q@B:#"*T\I>DHR>K2E0)
MZ/)K8;,SZ6FI$U.7;#>/TU)@6",/;F:<U#BH^1T(/K,7!4HM G =B!72MG*?
M QVB5V<<H_8#M_TN&)9RE!V'0M\*DV6ZKK/)Z$*T"?)).KJ#<:THLWW4.\4J
M\CI2_WX%W>/',#L,+@[%F&+QS>S5Q!U6F00AJ'\)O_VKN?^.:SH?6M/O*]!W
MG/WC")[C]Q:XO_4_=P,T.XI3/.VJ?PSJ +<Q;.]PE774 ^, P&D*- ><KV!0
M*%524GC6JNY[H*@RG85F3U:Q\&SQ*BGS:27)UYFK ?XRJ?7X1,763SZ>?=1V
MD'9S%JS)*V,6D@/A;5:1257 "I[3"GJ%87)!3LB0>BHAQ.[;P$A=VNE8UDC6
M-#+2M7MCJF_4WGWMTB2B[.6^&*>T]WQ/';2I\7;-[9&V1#_'$NK'4RK2%7M5
M9ANI<5C 46(0D-;KQ]^R87[)')@A,HU 5U2XJA-=0%BRN=^19(:5VU6>3I*_
M"1WYRP(RIE<=(&$8)9>(1H&(F4*>(;G#PJF6_Q;F,M_6ED:OD12RRI0HU<Y)
MS.W;,QE%I"F5II9/#HN1,^/]O\\?0'XG>J''NVZ5NG'2 BDC$8Q(**?OE*PZ
M-TXR4+[*/AV>]?W#?QNJRCO- ?AY\<M<9<"DT&+4'#OBD:ZU\D=KV?*;\7:&
M \F&UR9S_;UET /_V2FB?D@3H_;+#^Z"U,KP<%V1!SKM5=8'J9VY0WD&(2?(
M=>!Q#]WD0#Y ;W=><U]P&VRGL7*#K>-$]);D_]N4% 5&[V3-18M$<X*FS&$U
M@D*9A;DC&).;NF$K^X =111#Q^.4TQD4A#DT?&)F)/,ZL7F]YBYB#MOV'_?,
MU,IF7;,QU>D9?]]-^VZLL,P<0D6#HZ+ ._^73NBT/2$;95/L-$[+%NG&VN*P
M1Y5I>XTA,E&KPK)<EC31K03!!*.F$\82HXY;BY0=[/T5,FA]"H)8X*QM9MUF
MJ'*<S%JZ.(3[VY ,(_A2A@?_8I;P1V!?NB="6;(WCI,@9LGV!F 1"N#^Z$5
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MP-!-]989]C'%C-;#:):A0@8+43'XK;(PVDO[($XPJG?Q]E&NV *FPZ.Z#'J
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MX8=>A.]\)GHI8);?A%"%G$*GJ=#9T?'!+X]((>MDNQY/$O=SW'J26+O\N@[
M8>[YO4<)=:\CGP3LDD%)Q;IJA"666G!LE3:(5[20P-0Y(?VPQDFOL=)):+JM
M6'(DJKZN R8)[!['0CJIJCP8/EA'31D(%2$KJI+Y>Z>]DUQM3<N7 8HX4Z,U
M':Y"(9I6S!9YW^V=@)?[*LW](P>:2B6;1Z'N=+<&6:WJU5:=9_OXJ<]9IY_4
M\<DDX5]&/YF.('^(%%^+S2S%K4'E%DD-=S$3A55B6:#H8G89NM#X5Z_J<6>F
MW,#M@V)BX6DJ#<T5S5??9 A;+7PX.3KIQ#E8\\:3H%O=Q1L@0%JY3=XG32LB
MRL5F=%OZX'X[^J'DAKNCBP!+./I09]Q%CB?.P%FC2V '4\+D^#&[3?X+^&%V
M-_J)=XTXCFW3R,-HGYR/7FRJFW0%[X$I=X,N>2#$(I5W1ZJ&/!T]W\Q^@87#
ML_5-CBH55OO 0OX*?YR7*WTA^OK1Z U8AZ@(?Y]AJ8=.:63-()Z,'&R5TC+,
M%;'*;D7 ()((0SNOD!4P+1A3? TW I;]JF*K_T=R;2U336:Z@EM>@-# IH=+
M=%;S!?:G4_9MDR<>$G5SQ# 1,)H:[&MS'/E/,>0DV[JX.0769G=&'P<DE(81
M8C@F1TM6AY>&NJ0>MP)CYL['U_W\&A<87Z+REM;P#.6ND&=U]"X*\^I]=[4%
M\6+;A6::'*"Z/LTIUNKM%=1?D.2;E/WP%%->D\"K@YD7NJ99#TW+KL'#6X*R
M)J(^E2VPNT;Y$2[(SNTXLAH,I2B.@Q4PJ\V*YC.@W=9BNK @K=PN#>-5!6\"
MOZT1XED6(1BY/<3OLKE&7U;U5>6V6F&A-HH73#D_XBV*-578^JPP9M)N)TG8
M7;?2SXE.<R'X4MQ1*F[*5_;T$(U:-]=6F@X3AC/]I\;L85Z;F=[;:.^VY]EL
MHZG110]$P]@E= A*C>50\!'SAIG3V':RSE2"M&%W6A75Q(J(SU$PE'@7_#]*
M5)/\W#>]8TG6*_^/OV8^>DY-(_#6D8/$?%)2WPY32YG)X:'.W 5]&)R$8#4X
MC&./+J%P$F<#2 W6CE#D\>NBQRRTIF6N?VK9Z3ODE0V5H5*]A&*VHHB,A"[>
MTR'U_ZJF10 VZHQU-#DY/)\\^8JSROAH+(WI]/'AV5/I\?Z;498_9YWGN$5N
M ]6"&1NN;E;?,B'NMTE17>]*DL!I[L#L?7!*-]?IA793H:OHK^\:;RM_K]G0
M>Y]^ZE$,3RF(9;^3QR(4O+FHKG0-&)O=B+;4(]@/M+?TCPU^0ZFG;E4QS$)3
M]<\MXA35APPIY "/[/_$7TDM=[^\Z>[68XS&_;W#&@_]YP7)QP)U@$AFH\C8
MD/X%9]@*D7*S.?0OA=\^BU,^ (+MRN9#^16/OI+_I:-G.F.'!5K\V9SJ;Z5#
MK-# 6])\22R'#FJC=]1]]D4R R%JCZJS.U Q^QHL!PWN@EWYGU#/A9="MHB)
M_=_LU$"Y#EOP>Y/0@R_-D'L3]UG.C%R'ODW/0-ZJ]K>GDS>C4E..O7W:SK7D
M S?K)5AK7$^"$;2WTE)CAZCT6=NKP T[OFAF#VN7/>GL*WM9(RKVN^O!F;9Z
MIUK.J5UB]&R2Z&C4,<EB4V1>1(WS\MXY#IQX4'8I(BZW7[A07K3,9\'%<CX8
M'C_Z2IS4:K>7M6E2V24<:7-LQWGP9^I;4';\O'>1/W*W$ <EMF'/M0SLKAH9
M[0_H^=]IYR,RT!"/73.GP2&R!]BOI 0[3[=;92=Q8"L1ZEALV$A'I+[!!MPL
MK>!4A.*:BKV$:B%J[X5&S7&:5*W(\8C!+R.%9*!/"OVB^X*OU<G1T;,0>!3\
M\BJ+L+M8$<T^I0'4E,6BM*OF"*DE%$2ZCR<@9 4L.TG*9BNLQZ0^3[V&:ZN"
MS5?QM$,-BWNTM(ZI:RG3[KBM$10=A'>5.4U-U .SA^4V#,$@;%&]4;/L%_B(
MVJ2.G)Z!1MC*9HF[NB$=FOQW=Q&$TP4;R'18W\PS;,O+ZDW \L#OB=#_L<.B
M>>\UK%>'LY6L-)XBYO9I*_ :_DB:P)<GSGQ?X0SZ%O["_RV$R]SM[<M.(I7F
M_E>K\@XNZ)T5MH8\H_O?]?V:"\PT<&__*CHVW9WNEHQ^P+7V\.Y?1>O_L7=,
MH&3;@S^.WM\5_G4$D!ZD&DF1'M[#7$001QIT!Z[0DEOFOZ!]3YD'R(\[81?R
MDXJ0P=X6RB^=+,=,C!ZCWV7RM9V")"-[9B_A[Z>/VV&4D^-![$O\+PE;,KXC
M,CW*S.QFGH=MPG&>G#J]02-"[%H.W\ ''Y\[M#1^$!:%9</B8#:)1??F&IB*
M2E9.X3/;B]*T>HB.7-42E6R";C6L8G(XT^$\<^HI Y$1AY]_%C>A>C_V_\K:
MV!OKA!ALP.NW:EA90]"XDT\[H.;B>E8/D^XP1?M\&)$H%!-HJ?WU1D.ZEBLI
M:#'<N]()"JN8I*PQ*\$R/3V/VC4C%5B[14I5(EB<Q0:'6Z9PX#?HM6>-[191
MP@[A^.(Q\H7<M'0*WRL+?F%3A&_MW%9CKE;OF)5B5GQ5%^U22$O")0=[/_[T
M0[WWJ,>+^/C47:S]QR>GX;_HZKEFB=W^SFJ+1\,QSZ"PF1;6/W-!OE/0V-XX
M%%/6\EL3#O1MN*FDRY&^R)^>NV]J"#?@X?=^-;@0^;J$46B:1WZ:V"SNWG5(
M<A*= NXPSR\O"- )B(+?3KFASP=*VS-BI.>E7,SIHVE4;K?,5WDC6=2N_X^V
M #Q]:G7=U/#/@?#7\"9F,/!&L,,GA//H\A U%*Z?$P?+)\D5LJGVGV5Q5AZN
MR9DI.6+)SXZ5=?1[DI*]I/DT+#(N.)I!:>^6A=@991PMCNIKN3"4_<9N0R2D
M(@@0NJ/<0C$M".60=IQ9B7#7(+ZD6HD49$KH0.;IX'0CN, (3$+S'T14:B*V
MX!W JVZ2O"DAV3\01"@8:%&I.%DW@5RHZY!DL(S[CFPL42QMJN:V<"R#UY::
M:' :O%<FZG M<6\O[?4;=1>JM,G)-=R$M5&4=0!+K?NLV%*D:)"&P?U>L:B$
M0#2Q'4FM&)MPL3(Q?MD<;2?IA@:N\PRFM<P0G7HSYVYFF/R[H7(9RHSLD.Z"
M,SW$EFU5#N<N!B.XI)@!V/I($O4C.S_ZZKN0^1B_R?)@#A_@9E2-J@%(<1$E
M*?\DRMW);=2"F<0[$J@--;&.)^C,!Z=Z/!L&#U N6G#?G>KF/"H]Q\2>0RIW
MX(B6R50W2H]HDBQ!]@MV,UKR&05,.Z&+LTFBO\5MGU1%J#""7'.&/.U;JY2=
M_"/]3925J2]E (,_!>K57!5*KL\L(=7J(&/PRZ#RH'RMR%[G>>%D0APHA+B0
M >BXWXZ^O_JK =FA"2TX"4Y_84-.8YL]I3Q6GP_27714^"HH#ET$'I":EYCG
M1MD8>'&L/K^>[(W>-" )\B+-$^RT4E);Z#= A3,,TB.[S6Z3_RXK J3%]G*H
MNQWLO;FZ>@.*A@[TWO-+/2JX1LL->;YNRVHYO\6NBYC)@4D:.YSB"C9QF:)(
MXUTEA6]]DU:K=(;P#53X!Y<6Z(YJ_-2SMB;[GGDOIO9E::/^N)O-*BT,K0%_
MM@I"5T UO5-NJ?J]893#-^"ZS ^;NS6G'JPV*,.3K/@GG$L=2>]4#SSD1PE(
MQ;8=MZWMW_J ,($:IX.3*$DR=1NU45X><*O-&@1#05X\D[$\NT46?$OH[6'?
M=R YE[FHQ.<2V0.AEJRBDM-<)&18..M7TJ6O+1TQ2R5HBC*O>4PK*K*56S$W
M?S:.E"H,JO-+W"@),X)J#IR+.1$Z"(XY+?#D##5XOVM"D;4S#9"T@#BGZCIL
M"/D8[L$@.5+/Q6]>OGO_2*T,GI<T=K+TG+6$K24#7Y0)R=44+:0][.>O>3)B
MZD$&V2%.# /'.U'>HO.S]X Y68LYA&.WG/)KFH \8&EH,B@U\FS:F<>*4DKG
MS18D?#)KL4.8$RMZ1?@:328\0B1/6T-T*F5$IC^&!QD11%3&".:9A"V+0E(:
M;;.02Z64%*D-"SA+V)"6B9\'UC6.U [7K5'4Z_TC%Q^SR5DW")?&U&8BP"4F
M+5!;X:KMCGBL@KLDS5W9+A*/];:@E;2[?W9(9@$J&Q-!!GNJJJ57<?@JV8 1
M"(EPEZIS)3600%\ECXF3L=H=T#D_6;BUM8LA*=C10K9(3)3=F,[S(^:'<6;F
M\>E8(=$[,$7OLH_4-*:%4T2BV@L+9F[R%;P)Y11W#MZ\7I;3H%_L+#%KKCXO
ME551Y481L1.:"; HNCZOTBEY$NN0C=B=.[675Q56C#:)O:'$K;*&_4.@W"YS
MU/<#__<;HP$262Y^#C6B7 "@8$=/!I&4.I-JZ?,JY[3TFSBM#,0Z4ON*^FT:
M\T3JD"+/GBSRB:[+NCED,'^!'"!6V('GD$1YYU.)^N8!ZR%%UMB0XN2 GMW
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M_^8LYGD-X*UMML*?94Q/T2[MV\%_:B;)9W[EG@Y^11!"$$:.9]MI;VR&,\-
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MQMB'X5"+J*\)RG)6E9PS'TO,J 9=#'QO115[P,]7%XT35YB'YQ#0BP$/?P3
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M%',35.-C$F&N>1WG%Q!7* CP:K&"^3]WZ_V +^4$LP9LQYGMDM\M#Q@4U1W
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MBF9D^^A!V)OA^;)<# ]\D8'73+Y!]QS'24A:1Y1A"#D--Z/L&\-*/1!TE4"
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MEN5-*XBC;TI!_$L'_$L'_$L'?+8_NTAF^EA&EE-$P@%TI6R_]2ZP;'B^5S<
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M*E9!Z><Z(3%C,./L$X)KG+WG9#^11CV.)S8%@AS[H7K!^VXLP,<;XOKFWH_
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MD!?L2#(/DZ)YC\/K2*S0_G4-[B ]N/OK8502<916$@*DT6-6?TP&4-^X/NR
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MQ,0LPXDM@X8]G$-,=(N$V#(X)K0,QRS#J2V#8L)=$HYYAI,O<+TM^1X[9'>
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M6=[ZLJ_ZWHA0WK[C>'CX^B=02P,$%     @ IH%A2E'],)-$ @  A"D  !H
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M7^Z?*%W&+<E=7V_^=W&=^B?"32ORTV]02P,$%     @ IH%A2@4-5&,! @
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M4$L! A0#%     @ IH%A2A\CSP/     $P(   L              ( !
M %]R96QS+RYR96QS4$L! A0#%     @ IH%A2F;S"V""    L0   !
M         ( !Z0   &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " "F@6%*
M01(E#.X    K @  $0              @ &9 0  9&]C4')O<',O8V]R92YX
M;6Q02P$"% ,4    " "F@6%*F5R<(Q &  "<)P  $P              @ &V
M @  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( *:!84K(DI3HG (
M *,)   8              "  ?<(  !X;"]W;W)K<VAE971S+W-H965T,2YX
M;6Q02P$"% ,4    " "F@6%*#2P\ISH$   0%   &               @ ')
M"P  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ IH%A2M?_
M&HY& @  ]@8  !@              ( !.1   'AL+W=O<FMS:&5E=',O<VAE
M970S+GAM;%!+ 0(4 Q0    ( *:!84I)."?N#P0  !02   8
M  "  ;42  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " "F
M@6%*>^4>_V4"  "?!P  &               @ 'Z%@  >&PO=V]R:W-H965T
M<R]S:&5E=#4N>&UL4$L! A0#%     @ IH%A2K#DC82_ 0  U0,  !@
M         ( !E1D  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0
M   ( *:!84JIN>\T_08  %$F   8              "  8H;  !X;"]W;W)K
M<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " "F@6%*:(1PMYP!  !; P
M&               @ &](@  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L!
M A0#%     @ IH%A2DL# X4*!@  ?1\  !@              ( !CR0  'AL
M+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( *:!84K=<&;6M0$
M -(#   9              "  <\J  !X;"]W;W)K<VAE971S+W-H965T,3 N
M>&UL4$L! A0#%     @ IH%A2@IU=H:R 0  T@,  !D              ( !
MNRP  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " "F@6%*
M]G)R%K,!  #2 P  &0              @ &D+@  >&PO=V]R:W-H965T<R]S
M:&5E=#$R+GAM;%!+ 0(4 Q0    ( *:!84IYR5'3M $  -(#   9
M      "  8XP  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%
M  @ IH%A2C(WA3JT 0  T@,  !D              ( !>3(  'AL+W=O<FMS
M:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " "F@6%*,HYH([,!  #/ P
M&0              @ %D-   >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+
M 0(4 Q0    ( *:!84J6STF^LP$  -(#   9              "  4XV  !X
M;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ IH%A2LTYOFFT
M 0  T@,  !D              ( !.#@  'AL+W=O<FMS:&5E=',O<VAE970Q
M-RYX;6Q02P$"% ,4    " "F@6%*:8IPL[0!  #2 P  &0
M@ $C.@  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( *:!
M84JA $&VM $  -(#   9              "  0X\  !X;"]W;W)K<VAE971S
M+W-H965T,3DN>&UL4$L! A0#%     @ IH%A2FS379:T 0  T@,  !D
M         ( !^3T  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4
M    " "F@6%*'^:HK+(!  #1 P  &0              @ 'D/P  >&PO=V]R
M:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( *:!84K_0QBDL@$  -(#
M   9              "  <U!  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL
M4$L! A0#%     @ IH%A2O\F22NS 0  T0,  !D              ( !MD,
M 'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " "F@6%*ELTF
M1;0!  #2 P  &0              @ &@10  >&PO=V]R:W-H965T<R]S:&5E
M=#(T+GAM;%!+ 0(4 Q0    ( *:!84I #(3=M $  -(#   9
M  "  8M'  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @
MIH%A2BI&?;>R 0  T@,  !D              ( !=DD  'AL+W=O<FMS:&5E
M=',O<VAE970R-BYX;6Q02P$"% ,4    " "F@6%*2+I9)+,!  #2 P  &0
M            @ %?2P  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4
M Q0    ( *:!84HBX)8#M $  -(#   9              "  4E-  !X;"]W
M;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ IH%A2BYL3YNQ 0
MT@,  !D              ( !-$\  'AL+W=O<FMS:&5E=',O<VAE970R.2YX
M;6Q02P$"% ,4    " "F@6%*'^\'@O0"  "$#0  &0              @ $<
M40  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( *:!84JC
M'TV*Q@$  #<$   9              "  4=4  !X;"]W;W)K<VAE971S+W-H
M965T,S$N>&UL4$L! A0#%     @ IH%A2EH!!V:V 0  T@,  !D
M     ( !1%8  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *:!84JL)2A]XP$  $(%   9              "
M 0Q@  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ IH%A
M2J"O39S- 0  G 0  !D              ( !)F(  'AL+W=O<FMS:&5E=',O
M<VAE970S."YX;6Q02P$"% ,4    " "F@6%*3$D0P\\!  "<!   &0
M        @ $J9   >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0
M   ( *:!84I'\KKRP@$  #<$   9              "  3!F  !X;"]W;W)K
M<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ IH%A2KC<YK;! 0  -P0
M !D              ( !*6@  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q0
M2P$"% ,4    " "F@6%*O)-<K+,!  #2 P  &0              @ $A:@
M>&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( *:!84II#;IG
MQ00  $ 9   9              "  0ML  !X;"]W;W)K<VAE971S+W-H965T
M-#,N>&UL4$L! A0#%     @ IH%A2D*Z;.G> 0  ^@0  !D
M ( !!W$  'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    " "F
M@6%*M;U.@9H!  !8 P  &0              @ $<<P  >&PO=V]R:W-H965T
M<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( *:!84JIR=JSO $  -(#   9
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M970U,"YX;6Q02P$"% ,4    " "F@6%*+6,(U ,"  !V!0  &0
M    @ &:A0  >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    (
M *:!84K&?=--Q@(  $\+   9              "  =2'  !X;"]W;W)K<VAE
M971S+W-H965T-3(N>&UL4$L! A0#%     @ IH%A2C94Q0MF @  ZP<  !D
M             ( !T8H  'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"
M% ,4    " "F@6%*O!.J9@0'  !U*P  &0              @ %NC0  >&PO
M=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( *:!84K:2^+@[@8
M -8G   9              "  :F4  !X;"]W;W)K<VAE971S+W-H965T-34N
M>&UL4$L! A0#%     @ IH%A2N$1RQ]0 @  2 <  !D              ( !
MSIL  'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    " "F@6%*
MTD_CBDD(  #X-@  &0              @ %5G@  >&PO=V]R:W-H965T<R]S
M:&5E=#4W+GAM;%!+ 0(4 Q0    ( *:!84HF\2#K^@$  #\%   9
M      "  =6F  !X;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%
M  @ IH%A2A8,!/29 P  'A$  !D              ( !!JD  'AL+W=O<FMS
M:&5E=',O<VAE970U.2YX;6Q02P$"% ,4    " "F@6%*&*4=.#L#   !#@
M&0              @ '6K   >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+
M 0(4 Q0    ( *:!84KNWE?S1P,  %4-   9              "  4BP  !X
M;"]W;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @ IH%A2BD5AJM-
M @  QP<  !D              ( !QK,  'AL+W=O<FMS:&5E=',O<VAE970V
M,BYX;6Q02P$"% ,4    " "F@6%*[W:[IMX!  "=!   &0
M@ %*M@  >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( *:!
M84K)@0"J5@(  ,X'   9              "  5^X  !X;"]W;W)K<VAE971S
M+W-H965T-C0N>&UL4$L! A0#%     @ IH%A2N1VE-#M!   D1L  !D
M         ( ![+H  'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q02P$"% ,4
M    " "F@6%*;'33IE\$  !H%@  &0              @ $0P   >&PO=V]R
M:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    ( *:!84K%[8J-\@(  %H+
M   9              "  :;$  !X;"]W;W)K<VAE971S+W-H965T-C<N>&UL
M4$L! A0#%     @ IH%A2J-.P@RJ 0  NP,  !D              ( !S\<
M 'AL+W=O<FMS:&5E=',O<VAE970V."YX;6Q02P$"% ,4    " "F@6%*)Y(&
M'>4"  #H"@  &0              @ &PR0  >&PO=V]R:W-H965T<R]S:&5E
M=#8Y+GAM;%!+ 0(4 Q0    ( *:!84I3F&S'#,4  (I- P 4
M  "  <S,  !X;"]S:&%R9613=')I;F=S+GAM;%!+ 0(4 Q0    ( *:!84HC
M./9M;P(  $8-   -              "  0J2 0!X;"]S='EL97,N>&UL4$L!
M A0#%     @ IH%A2L?956K_!   JRP   \              ( !I)0! 'AL
M+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( *:!84I1_3"31 (  (0I   :
M          "  ="9 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4
M Q0    ( *:!84H%#51C 0(  +,H   3              "  4R< 0!;0V]N
E=&5N=%]4>7!E<UTN>&UL4$L%!@    !. $X 5!4  'Z> 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.6.0.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>231</ContextCount>
  <ElementCount>423</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>87</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/StatementConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00305 - Statement - Consolidated Statements of Comprehensive Loss (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/StatementConsolidatedStatementsOfComprehensiveLossParenthetical</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00400 - Statement - Consolidated Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00405 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00500 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosureDescriptionOfBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosureAcquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosureGoodwillAndIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Cash, Money Market Funds and Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosureCashMoneyMarketFundsAndMarketableSecurities</Role>
      <ShortName>Cash, Money Market Funds and Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosureInventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosurePropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Accounts Payable and Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpenses</Role>
      <ShortName>Accounts Payable and Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Assets and Liabilities Measured at Fair Value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValue</Role>
      <ShortName>Assets and Liabilities Measured at Fair Value</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11101 - Disclosure - 401(k) Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/Disclosure401KPlan</Role>
      <ShortName>401(k) Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>11201 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>11301 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>11401 - Disclosure - Licenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosureLicenses</Role>
      <ShortName>Licenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>11501 - Disclosure - Collaborative Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosureCollaborativeAgreements</Role>
      <ShortName>Collaborative Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>11601 - Disclosure - Debt Instruments and Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosureDebtInstrumentsAndRelatedPartyTransactions</Role>
      <ShortName>Debt Instruments and Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>11701 - Disclosure - Earnings per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosureEarningsPerShare</Role>
      <ShortName>Earnings per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>11801 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>11901 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>12001 - Disclosure - Selected Quarterly Financial Data (Unaudited - in thousands except per share data)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosureSelectedQuarterlyFinancialDataUnauditedInThousandsExceptPerShareData</Role>
      <ShortName>Selected Quarterly Financial Data (Unaudited - in thousands except per share data)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosureGoodwillAndIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/DisclosureGoodwillAndIntangibleAssets</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Cash, Money Market Funds and Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosureCashMoneyMarketFundsAndMarketableSecuritiesTables</Role>
      <ShortName>Cash, Money Market Funds and Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/DisclosureCashMoneyMarketFundsAndMarketableSecurities</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>30603 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosureInventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/DisclosureInventories</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>30703 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosurePropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/DisclosurePropertyAndEquipment</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>30803 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesTables</Role>
      <ShortName>Accounts Payable and Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpenses</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>30903 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/DisclosureStockholdersEquity</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>31003 - Disclosure - Assets and Liabilities Measured at Fair Value (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueTables</Role>
      <ShortName>Assets and Liabilities Measured at Fair Value (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValue</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>31203 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/DisclosureLeases</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>31303 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>31603 - Disclosure - Debt Instruments and Related Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosureDebtInstrumentsAndRelatedPartyTransactionsTables</Role>
      <ShortName>Debt Instruments and Related Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/DisclosureDebtInstrumentsAndRelatedPartyTransactions</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>31703 - Disclosure - Earnings per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosureEarningsPerShareTables</Role>
      <ShortName>Earnings per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/DisclosureEarningsPerShare</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>32003 - Disclosure - Selected Quarterly Financial Data (Unaudited - in thousands except per share data) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosureSelectedQuarterlyFinancialDataUnauditedInThousandsExceptPerShareDataTables</Role>
      <ShortName>Selected Quarterly Financial Data (Unaudited - in thousands except per share data) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/DisclosureSelectedQuarterlyFinancialDataUnauditedInThousandsExceptPerShareData</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40101 - Disclosure - Description of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosureDescriptionOfBusinessDetails</Role>
      <ShortName>Description of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/DisclosureDescriptionOfBusiness</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40202 - Disclosure - Summary of Significant Accounting Policies - Equity Incentive Plan and Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEquityIncentivePlanAndStockBasedCompensationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Equity Incentive Plan and Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40203 - Disclosure - Summary of Significant Accounting Policies - Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Acquisitions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosureAcquisitionsDetails</Role>
      <ShortName>Acquisitions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/DisclosureAcquisitions</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Goodwill and Intangible Assets - Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosureGoodwillAndIntangibleAssetsGoodwillDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>40402 - Disclosure - Goodwill and Intangible Assets - IPR&amp;D (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosureGoodwillAndIntangibleAssetsIprDDetails</Role>
      <ShortName>Goodwill and Intangible Assets - IPR&amp;D (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Cash, Money Market Funds and Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosureCashMoneyMarketFundsAndMarketableSecuritiesDetails</Role>
      <ShortName>Cash, Money Market Funds and Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/DisclosureCashMoneyMarketFundsAndMarketableSecuritiesTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosureInventoriesDetails</Role>
      <ShortName>Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/DisclosureInventoriesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosurePropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/DisclosurePropertyAndEquipmentTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Accounts Payable and Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails</Role>
      <ShortName>Accounts Payable and Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Stockholders' Equity - Common Stock and Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosureStockholdersEquityCommonStockAndWarrantsDetails</Role>
      <ShortName>Stockholders' Equity - Common Stock and Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>40902 - Disclosure - Stockholders' Equity - Equity Incentive Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosureStockholdersEquityEquityIncentivePlansDetails</Role>
      <ShortName>Stockholders' Equity - Equity Incentive Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>40903 - Disclosure - Stockholders' Equity - Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosureStockholdersEquityCompensationExpenseDetails</Role>
      <ShortName>Stockholders' Equity - Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Assets and Liabilities Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetails</Role>
      <ShortName>Assets and Liabilities Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>41101 - Disclosure - 401(k) Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/Disclosure401KPlanDetails</Role>
      <ShortName>401(k) Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/Disclosure401KPlan</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>41201 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosureLeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/DisclosureLeasesTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>41301 - Disclosure - Income Taxes - Statutory Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosureIncomeTaxesStatutoryRateDetails</Role>
      <ShortName>Income Taxes - Statutory Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>41302 - Disclosure - Income Taxes - Deferred and Valuation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosureIncomeTaxesDeferredAndValuationDetails</Role>
      <ShortName>Income Taxes - Deferred and Valuation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>41303 - Disclosure - Income Taxes - Loss Carryforwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosureIncomeTaxesLossCarryforwardsDetails</Role>
      <ShortName>Income Taxes - Loss Carryforwards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>41401 - Disclosure - Licenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosureLicensesDetails</Role>
      <ShortName>Licenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/DisclosureLicenses</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>41501 - Disclosure - Collaborative Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosureCollaborativeAgreementsDetails</Role>
      <ShortName>Collaborative Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/DisclosureCollaborativeAgreements</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>41601 - Disclosure - Debt Instruments and Related Party Transactions - Note and Warrant Purchase Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosureDebtInstrumentsAndRelatedPartyTransactionsNoteAndWarrantPurchaseAgreementsDetails</Role>
      <ShortName>Debt Instruments and Related Party Transactions - Note and Warrant Purchase Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>41602 - Disclosure - Debt Instruments and Related Party Transactions - Convertible Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosureDebtInstrumentsAndRelatedPartyTransactionsConvertibleDebtDetails</Role>
      <ShortName>Debt Instruments and Related Party Transactions - Convertible Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>41701 - Disclosure - Earnings per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosureEarningsPerShareDetails</Role>
      <ShortName>Earnings per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/DisclosureEarningsPerShareTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>41801 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="fold-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>42001 - Disclosure - Selected Quarterly Financial Data (Unaudited - in thousands except per share data) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DisclosureSelectedQuarterlyFinancialDataUnauditedInThousandsExceptPerShareDataDetails</Role>
      <ShortName>Selected Quarterly Financial Data (Unaudited - in thousands except per share data) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/DisclosureSelectedQuarterlyFinancialDataUnauditedInThousandsExceptPerShareDataTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>fold-20161231.xml</File>
    <File>fold-20161231.xsd</File>
    <File>fold-20161231_cal.xml</File>
    <File>fold-20161231_def.xml</File>
    <File>fold-20161231_lab.xml</File>
    <File>fold-20161231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>93
<FILENAME>0001047469-17-001128-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001047469-17-001128-xbrl.zip
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M;C8;B.W,8"!X"T0XO F$AX$,@#3&5, T+NQS#>5I7X.7 &;A#N"7(2W!/=:
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M3!/%!&;'(-\)?G\;<$S?I%B@>ASOG>W;E"H:IO( \V X$;/27.8)%]48M0)
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M*9U/Z)-G8_-KPGALIHS'2VQ2SEWW0O_+%RX97!%"GW5A@V,_O+7T%.JPX1+
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M 7SH?>'>PX@$M-6_@P&Y/,EV.8I7^'B-\M,>X1JN'&Z(J:<ZDA2MA !HS18
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MX=3=\[4K@R<8.S(Y,_ W[>+ELE&KT1./,&QT9 6*%+D>$UBRW*[, QI:4;B
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MH6H")]^)B3Z40US0KHVP!+M+_Q.%D!-LJ0&H0VS, !::(2AZ#U#@L42$-%H
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M/D/Q5T V02(8$-JI;1N$.0BOC6U2Y\Q_3=S*Q#FI@*G^0@*&D!4'#@D?_\:
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M<;B9P:T-QH&\0%[E$P#(J]CDY9 KU5/3N0_#7^QLA=$D2=<SB:@@*!!4*04
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M"\RH9SZ98D9@1G7<Z1*A-$7)B"<W@<.WC,. EXO;E'A6H]^D)SF"8C7'G)[
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M829DPS,AN85HZ7*]V95]48"ID0+S)% J="BK56LTMCOR@0( I8,WDT:MM>4
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M>><;H%14E#8R-5<]V( 24(()0KF 4BE0@@E61+GV,)XJWQ8F5_0U-84J(YS
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MP9V^6%\N@O]VFWO42G/SA1M11^[8EQDCGB+>$.;Z']_)Z-J+7L+354+\?W'
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M;J>-F3?8!^P#]H$(;9D]3""),$6YA8@P!<(4H#Y07P6%".H#]8'Z$*$M,?Y
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M1:->Z];K$/=!N3COS#]E<G$N^TG"2TT,PF D>IP3I;06TOD[=K7];7?FN![
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M'=-XG9UUWE=<D&]>8&PQ:V7 P/!!]8G-QWY:^/2604+NZ;GGU &8Y?=4*-6
M6&.6OOKDF?M!1(5J I3!(TK1BP@P99EF\XM<7T=A;'P"(D2JTK0+2)O#M]W$
M;M^<\$XRK>6%.GL6?(ZZJ.2L#TB([8IDR.,' T>VKX">W5C MFFATD2=D6<9
M;43?#4ER7'42H7V'$8]!TF40<[\ECYK+G-ITG\%Q9;)NTO([_I\?B""."#7?
M=.?S M#<D2\]EY+![ #,,7<J1@,G#QSDN82T<JZ.%.2$&IOXH7G:F3X8#8ED
MC?6ES@,Q&;^#C-:]E88?IL:L9YG >&J+)J^?9)DIGY-.A$Q*@=64J0^SLLXS
M9$ UL>1GB2[*O6!9;9*T=O%EJ,A[6D?/RJ1CS(TNZ8QC?-L;&E%8L;#.4*/(
MFTO[TZP;G5KPXU0BIUYSCGJ.W:GPG#N;2I [_;DN;ZY[-VX!L<V-\DFMN/\-
M!@/VWGL3X5O/=+;V\TVLB;NA2T,<?HGT=##=JR9XBBI3S:P2TN/!2(D7U.73
M:%F]K*75H+=[R8"#^G/2=W8L^B?BWT/E+SH<VOH;SP:?WD$.AGMC>^^\K&?=
MHMN A#1C-,:#\3*//JN)#/F ,\)M05GN7&KA5! ]E9-%WNU*2_CSY N-"OG,
M\S KC5LRLCX/UU&R9*S7D!_1/%HF*250+7\F$0QHJ!:FP[Y[;9^O.*'YY_F8
MCLA_^.?/L3Z^D7)\\8Y4^5^LR6_LJ)^*T=?J>_3:HX']K__]7T+\<^'6]_Z8
M.DA^@-MG!@HL7GKJLQK\<O0FM@WYVFA\;7PECF]]O0[X0ZMN/R4O_/HZ<9XO
MIT>Q7'YW]=<!#5B^7I$LW'ZL7[O!>"C#D7SO.Q],'W(D>.1OBOJ3+AJM(](G
MAT: GO[EJ'7T:_VDT>HL:>%BM9_9OO.D11UNW_3#HYKWQ2%)JG"4M2I[C'0D
MV?3S*K_GY^O)]62L<O@LORV+95T1&[-G?^GW/ZN;F%0T""<?7'(=HX!J-5?H
M9[8H\_+TFP_RNSN*1X^%O-YH /+G0DZ//P7R>KORD']6M\J/U6NI57^+RMUL
M NDUD7ZB3C?JNT ZZ9A.3<?4_-I*/CVS8]HOGV0@O)YDE_^3ADU-R'1&,'.8
MF1M:<Z_\5QH:O5;.T'?_CG.5_Q0&O:2>_S9Q1M5/<5?]*ZF'[[S@[A%B;YL.
MN]DIO-P+UGUL0=P/\.1.U<*R0>L,6E% K<AS^N[)HEX_W4EW7&BU>%1W7%".
M^,!H7\G0"QXM\F9G)R,ZB'Q+!+"&R!OM[G-$_D%)#F9P?.53X+G.Q/X_BVT\
M10&.?DW"*ED@I42),HR8,)")'&8:\Q@S4[XV:C]-7[&I%OF8[T3T;(1>)Q.(
M<Y'B40Y<CGKVU8#:TN<@(]_Y[O++ZVQV\229D(_LU[FW9/./:D2C#P:/LRIF
M<TM<GM>T&0['G//2SY==,P%8Z2<SI\<\I^H.7"=_CYEZ3"<VY8I&"#T,8J_/
MX=*^BHCX;&M,>4D(FD"*1V,;U#253-(N<FDY6MR9M\3:S)N.0]=)-V&W$ ?A
M%&$S[RVY##N=FR6J\".+[YXI?W92-B^,6A9MG9&!((*5/<_50P[5+T]&,8TB
MY63>CNV=/17=*>4_5)T,I^2^OHRD"'JL6_2]F4K701PZ9M*AK\;*[*XTG0KG
M!*CI_+=X$?3(IF[-;+5K*-+6;2Y-*0E%&YK74T5O&$5NIF_/VO<RF^F:+_ G
M+8([_W$"SM^T5-C)!$I.TCP[\B+V%QNUHBVY:<7%1E1]JFP.H4:*I<V54C9%
MJF^D86&7_;]B35^]-*D:^80I:W4NJR*/259(SFA"?F9H*+6UZ(0H.2'%<<PI
M[-$,I?#$R,EB?E=285;FY#*7-3);_?R)#0L-STPBIUB#9+)ZD6UJ0KFF&)L@
MR%-T/$V6?EI=SY&<I/68JQT7IET2N Q731LN0&Y2Z^Z4QV@OV/:C&D+LL *N
MES6;)VG>S.E".C+3:E3HP@Q>\CW7=^(JLF)BS5NUO"XR,AE"@4^@)06:]Q-_
MZ@7<6GGY+C/Z^T1D)T&I.X@FXR21*:/6K)-;9"L#JLG>X6?I59''B5D#>F8R
M32Q(V,S(PW0_[WV;4&-Z^3OSN,T\L/U?/HUP5:_IYK@_;1^S?=\=#)1- S#L
MO.0U&:79G ESWY(IZ6GWE%"DQ8CO8CC"E54;$'QZIH*FF.".U2(MC6IL1<Y9
M;*0@[#MPYY8D8:QJM6]226WY<_E:/YDN@MA@E.OAIJ]V["1[TJ?$;#I)+9Y2
M(LF4QFRDX.*ON']C'2&3G)JEN@ZD33+.'*+D_4O<D&W,OSXT7GEXF/-ODO:?
M.?.Q0Z7/G.3G4+V-<G[FS%9VEUZS#Y4-+7\CM^/W0.OW"7N^]]\FT^7W#I/:
M,\.D]OR@KID?U!VWCGX];ICE,O>W?BO-*")ZG1GT.@^CUVYUNX!OU1C]0?A.
MNZ=EU+XO65;G9O$Z;30ZVX0K5^_-X*-7%&1C&WEH+O77CX.G$%>CWMT0<]U;
MR3WC\# %-;OM^H8XJ,A /&P<S=/S;K.Y-R#^4-&;+-OUDAV4[+&D]/['.;N[
M,E[\>W]Z&%[*5YMEV>;I"M;8:)WG<+%CE701RU6::Y@5L"3+[;GRGVOE&C6X
MMPW7TW48:9M?FX#<M?R^68&U3N>[Q<?7Y+%-T)=^_WJ:EZD1BW_D<JP\AHC(
MFXC\LA5"'"$8!3H;/4Y'EFD80\<]&N>YTJS'<LW8GX:-I'RYUYP(7KG JP1-
MAN_,(S:FE4C#+F%:NE1I=C63>4_?9 K75@5\..J1SR*.LG"TB;C,I#PG<;5D
MHD%H7@J0!,W>V_QM?GN2PDWC7S5:]GXSJKU5H;Q1*\(\6<C%9AR?B$L3$DSS
MXG7L1=,57XLYU^GR(^KD"!P]D^>\7#Q!/ON9!MXYX&P+J'XVKI>5N1!T\<W:
MUPP%?BJ_\$HZ3CR*+0C)N@NJ1JB&A)5=,\*/\GR'5F,9VCGBT3CPDZB$,HN;
MJQY,QC+(PUD&&2B]^W60N:4RN<C<C#%F"Y]2HGK\FLA-1M[6]59FG9[4)_KH
MDV=':F*R0CX.C(.K&YMUU1JS0Z_[BUZLIO[=K'?YZ+_]GDY8,L8?!V]4+]IL
MJ.J\TURHZKW%;[*V3\>UU:H_K[Y!T#>KB)XUNFZ<=[OG<R).7KQ&<8_+6EKR
MHUZ>HC-;W8ZI[ME<5&3]ZCXLI8VB\\B<KEVB0Z3SWH^(/%VB6FO#T['B3H=*
MA1@AF7>U3T0F3?8>I@ )BQ#&1*_>LXOE^\IT7=/E_S*GLF9+GU@OV])G^I[9
MO7U:Y%SEWC#K4_%\?FZE]DTJ(E[W3'I_<C9]#[7>HQ>DFQEX7G!G\GN,/Q&J
M9#VISFV?8%R'[)6#IZPEOUC3.;]_4S4>^;B#B?TJ^7!AIK./W;X*;D(Y'FY?
MF[:B.[C"%:YPA2M<'=35P_U\[E0WNT5HHU[_\55VK)MU0!SE><G>H+\<U8_,
M9VWW\#>?DRU''1-$RK8<339[=3@\.=;J(KUX90L29[Q&Z<=7LP<"6'?#;C!;
M7^CX-WF,P&$<)+?<X5\AXLWM$?M4<')^H-6"=>#J;AZMZ=N[<SO#KH\>Z3$I
M/\%'@]E";Z=<:B&^X)W=[*A)OX05[,P*YG9'WL7I+E=7;]\^X^SM1F'/WKY_
MC[S=;?^]'L#[!'#K'6 I4-KA@<,)./=OSKZ- X?G FF0^T%1^WH'#Q29VJ^R
MS6W3X.SNC+ R1V0#I:*BM)%35C8)6SJ!4W3@]HU3B;N+DIY3 R1QV%FYA8C#
MSG#8&:BO;(<U5S.<=XI 5;$&.(>'$L)YU90[QF<'V;4"28S/RBU$C,\P/@/U
ME6U\!ORAR>C$*R-$=.+HQ$%]N^S$[4?.K)^/?J2_8C'F_\_>MS^WC2,)_WY5
M]S^@O)G:I$KVZ"T[V9DJQTGFLIM,\L6>N]J?4A )69Q0)(<@;6O_^J^[ ;[T
ML"5;DO7HV[J)+)% H]_=:#16<1CS:-Z=N1^_?J.W\/_?T7',]FGWI%>,E!_'
M+)VDM7UI2M>=5H?)^M:8GEG4+=4\UE?4FWS@!5ZBCGWO!K[&]A"^O1QW%/G*
M-&>)A>S+P V#<HO74C,-/ 6*+6OID*^+G6;#B!Y5@T$8)_I$O$OCK"^\Z4E3
M]&:= FT2*#J\.C;7?&(_#(!;CK"=.:*LGR;F%_@V4=CVVO2X!MQZL0&7.@G+
M($BE;WO/(YA9HW?[ [ZKL8-PF31]A3UEX/E;:I!,[84%7N.!C2T<V^H,T5,Z
M^NIXL9..LB;#U'?(=$W'UM,.=O&0@"\W-2PV\T9:_&8F#?N V%O;^ZC41\21
M<3RF3NSF"M-E3^M6Y^(CNWQDES_Q)_[$G_@3?[*?'K;S?&1WN_=LZ1L^LKL-
MAQ4S[/&1W6T@(A_9Y2.[>UWCQT=VN<:/:_P>K/&;2+8RW7=*M>_SD=U*AG;K
M-\MVCUT92]N*)3ZW>S#LM3,V8T^K 1B37%*VWT3DDC(N*6/5MV]UX8>9T^-S
MNUL6X.P>ECBG=YATY_AL)TTK8Y+CL_TF(L=G')^QZMNW^(SQSYS,1OQ@B,A&
MG(TXJ[[M/K>[3V=V*S?,>E/G8J6Y]UW1B5USV-,?SS@C^L5)PDJ>M4$#W@Y5
MH&[PLG-[[#.>..&9'^NDHYYTLK)Z'-.<&S7@B)$<9V=8\=PO#(QD.Q$?!\)+
MA*>%JQ(5CP!];C'@(,7;D.\9U3,7Q9=&K.&/I07ZH=;X6'Z)NSUX:@?KCV&A
MGC.<!W]^6%>H.T<I%\8"7!2G5BL'?#$YG1VK+8%@B( ?:[C66SE[L=?WDW,H
M78M E2V0WK87V)M/XA;_$X3Y(=<DI+'[)J].M])7YJF>@ 7<X!I6>5O]<K=$
M+WS#],35]INX75K@OZWN\R@0^F:Z'!W??NTE8%<<,_K41=-$Y=]F77Q1I>LA
M*,RKB>8#,8AS+@W ^U+T[;WIV 2@[P72=$, 34A2E(2 Z?S OODQ4PNS#[,'
MH#@*04:YQHTV;^#1D; 9.AN[)8!<GXBO:0PRK*=Z(^ A?L=!]60/_$M-&B]O
M'2!,/X/)L4L-#L"[4+%/BBZ*PS^50WK4MCW K@-X<I^48A3",/3.U'!9ZX%I
M8,0#D-1*;166G>TV]I($J!$.!CA*)./$([.6*<2)>]<?1,N"9I(-XL(&<3.V
M8T+_S[8;'_-5?PI)IA>V$=_M4-_?6H50:F-R?N?I[P/0P;-^U)]IT_H(A,PS
M,_T!'QK-(R"GXX$7KG\Y.NX<_5J?7F45VHD5Q?#5US@< &O<MXQV91GM^\%H
M'?W::#;;$/V5@"DF>AP$D\;V(0C:C69G,0@*_'P93++#QUS.2<S?WSE^BN%2
MK@RVE/9/6=,$=@+LV(*<\R$.1Q>P7"](X>DOD;54^BWYB>:Y*WFG]#ML\9)X
MSDHYZKA7K[?J%8H^ ;3-K+%366/GX34VFJWN66^W%KFL8!XW>NVS1FMK%OG^
M+HDE6"SPRN+QQT2-].]A@ N.0Q^<R.N/>%84IEH]-Y\]%0>+@KX=.%I>&EK-
M1N/TL)"TM#0UZZW>:6-GD/0!_O2N@]4*TY,%R4*UD=4M+0:G[>:3Z;O)!2[/
MPJ>GW2>+^3TKA-]GI(0VEMI97SGLT[,]-%:CA>T/$5."4/F(;,Z6KG<MV1[@
M- '^,\3FGO2Q"2!V3L2<1QI'(<3[-8A\"9DO,21^!8$XY5'MEPEB&/\ IUO9
M]$[>5Q!S)6% 68"7%#Z'J9:!JU]Q5T#^Q)_X$W_B3_QIGS\];.>Y*^!VGPB9
M[63/(?'J2GRX']I\[.5= 4^Y*^#S$?'?2L9:O)_? )TE8V\Z!6Y 56\YAID_
M5ZJYN9_K,Q)QC:?C]QIOS/Q[0,0UMGO=:[PQ\^\!$7$#EIE_;]SR@VCV@]O,
M$&)>)C*9V,Q<ZX&J@VE;<F!8.H2F/B\;O7;MK-%:WYJVG,BO6 (.70*:K5KW
MK,<2P!)PH!+0J]?JK3H+P+9ZZOMW'X,MVMR<<!U,ZW?&TJ:P] R*NGE:.^V>
MKF])6T[L#7HJ+ G;+0FGM7:SP8+ @G#H@G#&0K!?;ON>-MIB3'*WQOTF(G=K
MY&Z-K/I8]1T@$5GUL>ICU<>J[P")R*J/51^KOGV[:&/_:B.OL-7LYAAX]RH]
MN":2ZV&R;=9ZJ]8[7<?VTCX6Q+ $[)\$-%K-6J.QCDH#E@"6@%V0 *J)7,?F
MZCX*P#-XZ!PA<:S):;:#(2*GV3C-QJJ/5=\!$I%5'ZL^5GVL^@Z0B*SZ6/6Q
MZMNWS57&/W,R&_&#(2(;<3;BK/I8]1T@$5GUL>ICU<>J[P")R*J/51^KODVF
M;LR?> E4_O)BEY6NH,YH:4Q,EEROY-.YB)43!H[G>W2IJP@'=,^F3F0"#!6/
M\1).$6-W8"$#EWY3@X%R$N]&E7X;A#']-J9[:]3\>VL$WH] _^W0@-@T6\A8
M":GMY9Z:+_#D3_R)/_$G_L2?]OG3PW:>+_#<[M,-] U?X/E8;!6C\P6>^T7$
MT@6>.$,_%C_CUWR7YWY?&L1W>3)_KE2)\XUN?)?GSN&-F7\/B,AW>3+S'S+S
M\UV>^^.6'T2_JLM\SP[WY#:WP[Q[[3C6'MHPEG:N>TFKS42'MU_]Q"+!(L$B
MP2+!(L$BL2*1> ;W_G%EC]ONWE/)'4PB I5@J=Y 080N?=%7@1IXR>8D\)%5
MI0>FIQA+2V#I&;1Y9WVKV7(ZOV(A8"%@(6 A8"$@(5B'6[^/0L")^A6@_*N*
M81: 14@73Z*,X*/F',-VZ2+&TE9G8EI,<A:,[<?2Y@6CR21GP=A^+&U>,-9X
M.='^DYPS^"O _3="/O[_.^'$RN6$_;8I)\;2=J=IUN'U[V.:AH6 A8"%@(5@
M?X6 $_9;Z[CO7\+^0Q@KP(/P B<<%6VOA.L-!BH&&#V^*'K;5!-C::NS,9RF
M9,'8 2QQFO+@2,Y86@>65M*B=Y5HP_:QC?;V(^ZY\<1[!<^"^R_)4,6<[M@N
MW<=8VNZDT#I\IWU,"K$0[*\0K".P9I(SEG9>,-9H'/:?Y+R-L +<_Z_T4W/+
MAL2++F3@<)>>+=-.C*6M3HZVNDQSEHSMQ](S2$:/:<Z2L?U8>@;).&6:[Y3C
M_\B@:C]O+&1,\K6W^TU$OO;VL?3D:V]9];&H[# 16?6QZF/5QZKO (G(JH]5
M'ZN^M:J^G4G=;/.>[>^*FS1L62:9L;35=38ON0(-W][DK1&[AYW#DH@ZTYPE
M@B6";<33)&)G'/H]#:@8DYR5VV\B<E:.LW*L^ECU'2 16?6QZF/5QZKO (G(
MJH]5'ZL^WHO=8_PS)MF([S<1V8BS$6?5QZKO (G(JH]5'ZL^5GT'2$16?:SZ
M6/5M,G5C_I1]7^4OVZ*F[-=)U'1,=?L*"HV6QL1D9=E*/ET-E;@(1Y$,QB)6
M3G@= *RND'0O2E\%:N E(AR(%XV31O$60.5CZS,O$$X8!,JA1FBW7C(4"0RH
MI:_PI4#!NY&*90*<)_Q0:\"3#%R822L9.T/ZPU4WR@\CO#C=WJ2H<6 <"''Z
M3Q5K-197L0ST0,7B:QQ>QW(D!F%,SXQA)*$"%Z!^IQPUZJNX +35J EL#7XB
M8*&Q$K?XGR D"/730"S/KQ\"H$O#P(?.285?<R:,#IGI8L2=K%S)4V:]UDEO
M)NLE-$Q =D@F,,1E O\0D>"U+X:J\/M2K-(E5LGGOY5:1+$'A "<B$$<CL2+
MYAQX9H _1T" A5+S%3R@$>K\'B+B_=_#&)Z\D#$L+9 U8AZ0P.;TM 1193CD
MS9OIYH0B">&Y@0^@$ @E8*76H>,1!G,(KR4,A>/;VY*<-(Y5X(Q%@G+HF\%S
MVCU(#*1VK(8JT-Z-$I] S)8D"DM-16I<\+R","E4-I @ =VF =NQB%0@_<2#
ME<;*)V( \4L$=],8M1UB'X3$"]W%U%<VJ72<.%5$P-FS2E*M#XE8OI807L%Q
MAQ)X ]0 C2]]FB %UHT39$8$/ JU9T1Z@2E0H%22QE8!@"1870UNPQDM"-OR
M*SF )0@)=D&G_3])/$(Q2.%%)=0=4#4PS-X?&V%)DV$8>[A.9LKHS3L%-CDF
M%9"Q%[%=H6C0PJK! /\$BH%*B,)8QN/\OC4'E6URJY31(8Z,XS%RIQR!&YL0
MF4%!J<289=^3?<\G]!-5!T"> )27#W/"P&3%HS0&1K%V',?,ADHU &K8-I>%
M[&'#DQITG3?P'(F&'O@30A@+ X[C9HNU6G,64,A($F%#Q:O%2U*-8:KA.?WJ
M]2,XYN&0Y\]4)]Y@;+ZR?[PFR3SV7(7>4C1</\.MA;WX$W_B3_R)/_&GG?KT
ML)TO':XS";Q&O?[3F_QT'66EA*-\WV;N?CFJ']'?VA07T=\V(>@HM/9Y0M"F
M8AWP062DU>OLPQLSD3BMG^!<U4HEXVZ8]&]]RO"OLKYI-P[UT3>WQN?JA[Z[
MH9.=3[B+SW#!8]#56SVVBM%[$WG;QV,/^!B8']#7.=KNS8Z])N('"*#^38'T
M>\P:X"S]6/R,/\V,QUE0-B8HZZY,W8#FWG(,,W^N5)$W69$_'Q$Q3\K,S\Q_
MJ,S?8>;?&\_D(.Z<^ST,CLU&;#)K+V)S-44'<V,*8VE;L;22DK_#0QMCB;'$
M(LC,M>W.V^.JEG/GK;E]SMM'\.Q]K(K!TJ8HQJ+39+PY9MV]AHK/(=*[AZ47
M&T?._47ZZ^@P>M:IG776<5OP[I&;A6([A6+G?2<\3=-H,U?MA??TQ-37%GI/
MYR,L[OT/E6+_[*HH5GAB ?Y@=W^[C 5C:0DL;=Z5:M1ZIPTF.PO']F-I\\+1
MK'4[/2;[3KDZ^Y<H^I:=/,:=/7/:F+WR[=)0C*6MSA>UFK73SCJ\'*8[8VGG
MI:/9JS5Z?(O9;KDY^Y?1^7VJ\XHY^XT'M&]E['(YTY8I+,;2=@>OG5:MV^7<
M#HO'#F#I&1*?G;/:Z>D9$WZGW)[]R^[D#7-B=:."5'%8MET*BK&TU<%KHUUK
MKF4#B^G.6&+I.'BZ<VIG%:D=/*<F]1#>"IT?PM-ZDW[.P?CCC*4]#E<;M6Z;
MHU66CAW TN:EHUOK=;E09[?<G/U+Y7S!_M$;W*8Z&"><L;2_(6JKUNJ<,ME9
M.+8?2\^PAUL[Z[:9[ ?@U^SI_5J,2;ZD<;^)R)<T/I:>?$DCJSX6E1TF(JL^
M5GVL^M:J^IXA?MF_-JF_Q7B8@!ND;GV>A;&TU;ML[4:KUFGQ/AN+QPY@Z1F2
MM2 >O>8Z]C(.AO [DZ[=9G?G7=G1R:ZB'9>O?NZG&MX'GT@Z?Z6>N4)YZQW\
MW>-FQM+^[LR];/1 V_?66%N]Y=1^Q:+ HI")0K?6;*RC.'4?18%3.AOQ<>)P
M+'WX*I)CO#F7H[3MTE:,I:V.95^>=6NGS36>-]AR8F_0NV%)6".6N*WZP; 7
MYXXVXE<Y87"CXL0#GPI,3*+XO,.6:4K&TG9'R\VSVFF[P\$R2\)620)[5LQ>
MN^Y9[6D1&&.2*XGWFXA<2<R5Q*SZ6/4=(!%9];'J8]7'ARBV/3-\%2;2%X%*
M9ARDX-V,[4KI,):V>G.]T6C5ZF=-)CR+Q_9C:?/BT>K5.G5N=7D("=MM=G@^
MX0$)P$5*UXH+Z?OAK0P<OJ!AR_048VG+][M/N[73;HLWO%D4#EX4UG9"=!]%
M86>\F#U-FS$F>>]EOXG(>R^\]\*JCU7? 1*151^K/E9]O.V\[5G8WV=N.&OQ
M,C^<M,'\RL%L(!P8EEX<P*[:&AO6\)%NEH#=D(!U]:G91PG@].O.1,Z,28Y9
M=Y"(G(/@' 2K/E9]!TA$5GVL^ECU[5OZE?'/G,Q&_&"(R$:<C3BK/E9]!TA$
M5GVL^ECU;3)^,7]2*_N)?:WLUTG4=$Q5QPIVG!ZWW53BH)5\NAHJ<1&.(AE@
M0UH'9%@+.>N$GAB$L4C4* IC&8^%ZPT&*E;P@Z9?;H>>,Q1>(CPM1F&LA._]
M4/Y8)$,98$M;_(#_*6:[]7R??H%IE7<#$Z1)"B]B/4I?!6K@)?I$G"?B'?P^
MZJNX +K5J(EFO=$5,G#Q0Z=6&=FL0[FSEJ%%.! OFJ?=DS,!N/7I1QCE1;/1
M.ND54]C?:C"8CI23 (#^&/^*X L5)"!*\)[P B=64BOX0"#,0AQ.V&N=-*<&
MQY?R990'PS>ZG9/6O#=@O6ZJL'$PSIG")'$BO8!Z"E_+&.6<?H'1?.\_!AX8
M4Z= HAEU/S4<*1P,X#.]EF$?W\'>%&&D8DDK]D-X08MK>""FWL5N&IO)0@![
MK&0,)$.6<A]U7986D5F)SM;6EQH8JF V1,#'K]\(,?C_[\SK.%-_7&8" X;]
MX^\P,!@K9XS<B==8$(, GS\,9CY\=5;BYI$<"W4#S) "L<> -HMP>%IY $LL
MT@@Y >0A*9$!H23$@]"HP!)* ^Y0@+1P &9?X?3$%B**0S=U2+" @,#!>I#B
M=+X$P@_A,91+&.,V]A)U#&2LSN$-K%3*/HP')IE>2(-BK).*!LW58G2?&MPG
M%7A.C#Y?RU25RU"Z8J# TY%^#> &/JD1H4 )@K$,9@B,<&0,&A,>N)6H7E\>
M_?[EDSYZA;/*",A[YXU@&"#IBVYKE@IZT6U.JP(SZXMV?5I)E%66D0,+<!42
MHX'5703\;11+\PR6"M[#]1#^:'5/Q.=0)QD[T5HGUU)H@BCVD!%#>+-^!E@"
MA6Z&=DMC-CH&GEB-0,H103-'!47HIVZA6(I9",QZ&4Q0GP^O@W!@"83(-_!A
M/>8 P$@LJ"2A)^*/Q"MK37H>11WD6Z?]/P&SI!CP#X >3 $@UO=&7F)>B=)8
MI_ U/G2)9 B#$D^=-C-\7H0NRJBX50 ]_*MA"%_&%B/XWS11.C,LI&>(8P"H
M6T"''GJ1<,"Z7JL3<8F:??)KN\K0<5+2<7:D2.K$,(\3IKYK?A?R&@B2/6(M
M\3FZ L!,J9\Q =JFR5EJLU<)@HS65J)Y#=(JBD(S#2C&U"R*<$PZU8$7 -$I
MT<"H8&N9"O< _37DD7 $>)&P<C0\M<P%T6@T4,L5%EEE.'>L$%M7Q*Q N(!P
MY!%XM02DP8Y=/B"F8!$S&C+F!-_V%3*9!=YRT\? LJ]?FT6[&I*>V-"8L%FX
MK%DHP-.*PY%(8AEHZ1B#24C+'0=<5#$#@&D] V"GT/DQ#'U0 QKU?Y3VP1X*
M#!6BG,?H(>(Q6'R,CAZM%J BCXY<N4Y)WX"6<X K): P"L']@)%OP.A)%#YE
MW $TZ%[H5JQQV<+!T@$^'S[J)'7'.#DZ'DXZ2L$$HU<XS=7H;N9N$[ROXA%A
MSZ*BT-D \RU@-PBG!C'T1/N',W;J/[TQSP_,.DMO&JOJP@#(BJC<K5.%/%CA
MK4S'$B\C:+E1-W""-@ZC$4HQ$,O%59:T"0Z 4E/P'_J^95^8G,+V27=:W8.=
M#QV/U.,MN!U&7=P!;3SC2EJR1H9A2%F2JV*=9$ %AH;X*T ?2<\]AJ\<&7G8
MFRQW44JSS#!Q(#HXX'6 0GN?0Y%5%OX\&7")\A__^#G5Q]=21J\_DIA?R;MW
MGG9@*E !5Q#LO_5A3;_^]W\)\8^I)]_?12K0ZJW%FP-PP!O?U."7HW>IX>GO
M#?@?=C;_?A5^;S2_M\Q?1^ 7>>;)/^!#HWD$='/ .OOZEZ/CUM&OQXU&HU6O
MUV? 5YWUZ:!U*Z!U'P:MU6N=/0&TK^0@Y[A="K9?+55S.BX61 O\M]5]'E>2
MOKDU^8T^*$8[-K[]&CG?<\SH!D$",#1Q*\OA.<IE'2X=!XVWT<;6%B>((^!3
MT(.D,HJ :J3 7H(5^,/^ADD"^JJ(P(HQ\O<\912I/9TB8U56]Q4K7XH0^RJY
M559I@5F%$!P=-/*JC/9%FTWA^\BL *<@14NQ)IH_.Q]\/PD*KG8J',X&,'I]
MPBFH"0QTKX4*P&3;2!-]6;*Z"J!VDLS^4OR,?QA/IKHNLWYP0I237<8()B76
M"NW$K+2#5<E&QV=!X-&LW,R1,9T0:F*@BOY-C.,83V Z7U!D;DH1[UIT_H1.
MFJ.YOL$J@<A *@3^@@S\QR"[= D>."=Z_F^&H_,<12O3OQTT#4U*A,]8QJ,!
M7&C!E\C9YX'[*72DGS^C]&I7U^PMMKIYT$PMA1Q6"+KIWX_!N=4G7\W-HC "
M?!.GROU4DL!5FO)NHSME+A\!T]K7U:FLJ_/@NAJ==K>W"PM;UL'I-5J-#:[K
M&V6ER<U?Y2H:[<:B;%= \!#,'P/,#H3QJE'>ZG8>0GEIZH>@_(*!U9?,>!J=
MMUKOO-E] -I9(*P<[&4EMMO="K"7YN16YR$]\QBXO\8*8]#,.MK8!429!EL+
MUS3/IF*Z1P"U]H4MRU?'K?KI+JQK::UTUE[#LA+PRO#^3?/KC&S#)B+BK0B$
M::Q&^T1\\AS$VV/"WGW>)L^W!*G4A#84;7;/9M5'(TR^45Q$V<QL!\^!GSV7
M8K]L>\*W*!;7L0P2DP*^D;$7IO":C-%AR78O,"B@'9-T!$B&L75Y7^KON$<!
ML3'&NA8N!";L^]ZUR2?F@3DFKK-Y7^\6;>?D:%9-[=\N_S7Q];Q[$)_"F1\@
MS(9WG%3KTLYP'(ZEG^<;X&VE$RRDBN08TQ>XDYTHVG2""-Y6 0"\-:&5$D<5
M8/.9?H=7BK]P$^X"V$GV*<-_H\3Y=:PH.:)/CI@A9GSZG)R(2R^0GKATAF%(
MJ9'/RO4<@(KVKV"=_P[C'P(L%B9E,.?U\NCSY>7GHU<;X*2K\M96IIW4G>.G
M&LE[&\:^>^NYR$3(.PLIKA'H#5]BVLPH$JIGB(8R'DFL++OV'-Q/'DKP[H ]
M31Z0MA=CVJJT::0$+'(RLEN7PQ0X 5D>K31M0SFP/C-0&+BV! 0TH-W/RLI8
M<*_K!E$*8]QZOGN<C"-EQ"/%#5BA@O^,D=W*6Z\RTW%"9MQMMD?NI65&M#E$
MK60P\W&I?L:E2H!JI8"F[13<1DJC08P$QLQ:MAUJH!NH+(-(VTZ8Y(/G"[F'
M-^S.9ZX!#"TH>U=HB]"4'FCI&Y-1!M!NCFM3CS*YD0G60!;;_!8NM\HKV>YJ
MMGMDMMG.:I4=<5BS?0F3M# /?";5EE?+P)O6T-4$[>(UVYB;+&/-<J0N5;X@
M:P%S]H%HB1D.(HH()&PN.XH(6/_G]]^N7F5%- 8N3^M49=NHR*PJH#(#&46P
M[FS?%XB=L=Z,:1^_YL<4VNR;(V7D![VB*?$$)IO@A? 6UCF;Q4TFWFC?DH]%
M2JW8K;8/D!+I UWMI&&L252#*7DE"XP<;Q+L,*2:L,H DZE*"(K1")CB$1)Z
M8@Z25./ %<4.Q8-8!J>R^@8OJZ:AXB[<!S:;LU3AD",+]30L[ 9K,(U#1[_G
M2#P1Z%84RKM6V1'/UPH:UA2%O*B?-*:WE',HQ[3C@#,7VSJ3^A04YJ&7D%5K
M#:UY)>S86BR[QU]A]X7M+VH1L^U%-H8VB$*?3 -\QC!A2G(&TO.-+"A@K:P*
MI%R$8'1J/J%1<;$BY\&:F7A*-X=*T\8/C4H5HJ7X F>3/U3..9F]6NW6T(-Q
M^OV!_>\J>7]GJ\M^"T.7#%HYLC_7W[\,EDFSM$^[TWLC#T^Z6C ?SIJL"DQP
M4G1B,RHKS<,UVJ>3>9W*9(^'9/DME-YDXFQ%D"R;ZNJTSAX/R3O57VV)2?NT
M>1\P.-^# .4,=EZNBEXEE,VIK.=B0,P&W6QAG@?NY#"%XL$=FKW/$J[-;!:)
M+3J'(RA=#/X4%K+1[9B>17SNB12%9N5"?6.G O#=$]1H G,>151*M8C@[,.S
M\PN]'Y,,>_A VI^I3KS!V'QE_WA-BSJ&D#R$V" :KI^B:Z$??^)/_(D_\2?^
MM%.?'K;SI>ZWYGAUHU[_Z4W>_M;X*H[R?7NN^I>C^A']K4W_(_K;'M?&0Q(J
MSH]KVX/R#F[!1%J]SCZ\,1.)T_H)SE5MIF3<#7,XOSYE^%?:@NGY>@1LH+=S
M;S4'TJ<+QW'T7G%"'5,FL#;,HZSIJ/^RR"JYI(8AMQE]<V1U4>R!2($< OH@
M.MPKCM\I(K[\B GV,-4R</5R?;)9#)XB!A-=+C;1I6__+DFY@*]CZ>#A_JD<
MQ.:ZM^S>K0=/5-T'@J5#N!NB63\MF(&IOE/Z_'%=H[99GY]/M&')#[;90X+!
M]>9$DN\49RSM_,WKS>Y:M?O!4)^]];5H]WY"U=58=<6.Z':I+,;2=OOM;?;;
M=U6S/]%O;VZ?9K_"*A!V.K=+-^T>EC:8<'DVC[Q]VF27_* 4]YZVZ69,\ET/
M^TU$ONN![WI@U;=O=]7M7U[M/74H]*A;MMT#Q^Z%Q6GAK,6CDQ4\<1IINT(U
MQM)6)]L:]9/3#J?;*@SPT[;K>;:S[+%PL'8P1.1@C8,U5GW[%JPQ_IF3V8@?
M#!'9B+,19]6WW;?K;J2YR7TYIASLQW:G>E33F-FM9[YB&[F5=EAJG$YVFB]F
M>B0,2S>[KW=6#<+2#8+.SJ;Z8,V%P=QN,#[X?N!=O,DPO^KA'IG9PA5-"OQ*
M/DW<N:$]TT+U%AO&8E>^.*3K!>G2*"_P--[4>QV&KIYL6@0+3P=XSC"F797?
MI"\'@/;)MM^V.U*U^;=3G#+'/I@ED.2]]V:_],HG<[GO$7_B3_R)/_$G_K3/
MGQZV\X?;]V@W]L=G>^=S2+RZS =W69F//6XVM U$G!GM%']@V,.RP1V(=JGV
M\O_"^ = <VQS"9M+:N]>Q=C:#>!>8.D0F@ZU:BUN.W1@I^"V68E_J"1_MWYC
M<O>XE+&T*2P]1W'\>E7YP9!_9U3YGE9&,":YO&Z_B<CE=5Q>QZIOWVKD]RJI
M-GOOY,K>,C:[N(DS2,\>?>P>E@XCS]9NK+<![.[1G8.SG;2KC$D.SO:;B!R<
M<7#&JF_?@C/&/W,R&_&#(2(;<3;BK/KX /,"V8>5?+H:JEB)6_Q/$%8.%X;!
M\1 /-DHZ=CCWG&&G.#,Z+A]S=$44>V&,!R"=<#12L>,!Y]J[6VYA4'O+(AV1
MC)56,G:&=)+253?*#Z,1C%DYCRHD !FK&T_=XNB WM#U'.G[8QS"P]2S-Q@+
M[8>WQZ/P!L]3POQA'W242E2^MK'H2YPVI/.;?RH'CVEJZ>,$V 332\8U7/0M
M>'/X+SSDI@Z0::C\P;'O#11")10(8@JKP5.;0X3+"6]4G#7*G#BH:<90;HV>
MQ6N#93 V)TI!7YICGO!,/WL]&<H$EZJ"%(CC 2!]!2M))'"&*P9Q.*)7!BD=
M*$7@LUZ=V;G3?+5E\O05'EG7!4YNARH07B*&L$YYC5B5.H$O=&FU->'(( @3
M! %6J6+ L@>/(JD\C5SCA\&UBD6JZ=P(X)S^!9K &S 1K!KY8%@F 4[85S"Y
M*T<X,:%4I\ !7J 3&3@@0$+" F'IR!PQ]B8%/,D?\(Z\EOA4]GR^T/=WD1>7
MUXZOH%B%1.\!@5Q&DA/J)&,K)[P.0$R)W_%[?#XG/7$'':=51#6T>C0"P)HH
MY%1\/ 2>)/[6=*X7AAU*@)O6"6BZC;U$';OA;5 YR#LNZ)F G)>^1RD9>#'
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M@'/_! EX<J3,7-![(&]>3@C/! OVN6&9++$E2V3)0B#(G"SVOGI;*V5\]FJ
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MTWIPWKX,+-1=1.<5"J@4GN:Z9P>S>'NF1#[+L=4@,[7'VG)WWQ18<6!+.E1
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MW=EPW3_MHV!=24_M9K?[*(AG=G==\-V/P8<PC?]-.9^G =]JGST&^!( CUS
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MYDEZ*AP8I5DV;QZ'  ?DLYI#4=E0U-+(;G!TJQE&&9A\G)OM2"OQ/HW#2,F
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M21@N(U*FBM__D7VR9ZS_2F6<F)*;?)>RE/_'ZANK(X66OCE9^*)S4B]( 1K
MM\6X. (K+3"RV+G+XCGR(H5S@Y_R[KA1;QC3DN$4S(E+>[OX.&XT@-N#A3U5
M.TEO@*$U&^5&HI+P&+#W0R45L3*-ID ^/:=F[!]0.; [1(DIF0><T)6=XGV$
MQX9 U,<H)V]!)X1:HKIX>_1JJB:&NI'Y5#Y/G19PTP&L/^D%>^HJ4PW'Y^Z-
M)+;\5K)X5[FYN_B?\V]79;4!V@F>2TRSK\R=\%1%IQL7 /6DQ9UQ K[BJ8A,
M.FI583$>1HXX?VQ5*ZPWU,!4N(444AU5AA(-T'VZ?*?GK=\S=RY<2UN6JAP@
M+>G%K""7_!P$$53MB$K.;,^=S!<I.RB90U(JJ7+&..2QJR(\0P%H^P%V0BM0
MH#]4P6 =Q.*[?WWJ .8*O56%&322![C3A7&8C6.C:RW!,K[,N!:#P+]2K,&*
M[.5250N4V.-N8$OC,%/A=BS#EY:,I.6QD04U08/'%G+46)>\^1+,V+)N-FHS
M_ &[5?BBV9FAGN7U=8R= /.S>I4.BZV3>OTG(#98!2I"+-W*)<P=7X(N^1(N
M*!"\XBN/$HKGZ(&C5S73 2,R=U#!X.!ET19S:)KXT8:V%X 8):G=(>ZG8Y2]
M*(VQ@)D:^'T#YZ.T1=]NG]N2<9SV$J$TE8SG9J>X<=9J&44Y,F>/#'C5!U&J
MLR8Z5(0@QV34M1IYIJ8 5036\ ;EN4U-Q:RZ 9R9=O/1':F5*P^G!RG7&!A4
M4GW&R+8,G$5E\U(3%I8&5)>:E4""\V!O]')!RRL7+_5RJ<FH8^AA8B^LH(_-
MEGY6$. ! D'EZS(<UDKD=+1"7:[>4,)V.Z[=UQ7+Z#?3]3)[P)9A(%-@(9?4
MPYHY7I77:Q;>O6UJHO&X6PT[G]BZWA?U$[";D;('LU#WF2?I8!QR''6!+#O5
M5&$6#FQ;1N/$F'ZE>>/6K%J^@*/*R@7GWF*UVHMFNW72F)*KFBTKL:U$L7)7
M64P4=<@JVT;-.,[NYMNE3W0M+8NTB3/1S;RCL8!!7S1:)YUI^;:K>-Q:244#
M<,9_P-)K^Z #<Z-[B6YIY>P;T,#\=($_71B_V[BX8)-RDW.19P02ZHU*7$ !
MD/%*RK4J#P)I#K&5*DN\<AI(*Q#X\KG) D?X=DFLNB?FL'5Q_YXA6+F3EFT&
M8I=[<L26J'RZ8<+P ']+TKI5IS!W(FQTAMT;RCZ3]9+(CR-OIN3+U,A7F.$S
MX4DA[ 85* AULZ@T"^UPI#S8-R6F05@NY\X"MCSHK/I,V(,V[)L+(LR9*$Q*
MZDHA$!;H^! =)ZE9 N@E6S];69Q94+;$K.,3E>I@ T6=G[/Z[,G/J+T_!@Y(
ME?DK\S\+HYTW?J:$FH();J6>U RG9S,T0Q9QVNC4Q7@VC8R[EO<:@*"N.TNK
MD%]OD6/U,ATJK3C6 B^YA%\#H]1-0/OBM#4C2ER1"+=.P)[G6-1'["A&;][F
MW@?HUW-PO_QRW;%AOSGR2VT\&S.C^L)6EVVN]0(P,P*1Z%!EH>C+H_.KSZ#_
M[='EC/M-06QXJRH,5<H[?_IT058=GH"WI3&DP-\FY2"O25#- ,CV3G84WE0H
M8I+ISB9!;,Z+=@D,(P(;_F3/R%Q]SD>T%Z%B&7SJ6W^I8CM1),YZ]UA\ L=Z
M+796?*=YTILM1B8.S%T!?+9^TIPA(9,*J>B?@Z;6+*#PA7%1572S,%32QI3X
ME.0-FV)8S Z2G3'A:E6%]GIG)]T9!$QF^.<M&X69$!I4(495B0GGP>30:=?0
M]H0Q\F?:.N7GHK+S!W.'[M'0?34. W>:,?H*!0K=(V#S01H8^ULZ:FLG#TW]
M;@8$Z?'<NZV9+C.9\V5WSO(^#.1"8A-"N@_9+5K:4QB1NXFA[\M^:%O0Y-)5
M;CH\R&Y;K1Y'/O##"_,3-DA*=>>9ON:YS:4/*.[@#^0(UL,P3DPRW22H1C9[
M;$Y'ZW1@O*HDYQ-3&FYJV I^@?4'QD,O)8BSQ#0>@%YE:?&J:P F*@R0Y\X=
M)TZ56[K+_>DWL6/]:O=LHO3MWLE6!=@B5Q\W6D\$C$[[XQW>*T%4HWXZ YZ)
M.9X(QB)U<MW'@8&"&:LAV&OO1IEJFOPJ*/!:T1(7":9S]\_42-[O*ODRN))W
M7TWKV/,DB;U^FI@+I""VG%S0T^^!;LT@^_J WUI,+7D3X R@%[^!\T QOO39
M@Q[C:?F+81_/F8>*[V4/,C0948^Y//7QC+F5",\*>LD#<,:EC"\XH?27;US2
M9^/3QEF[LQ#>UK*4'<'BYK3K#E #2Z]G33\YX95I2[@Z3FV>+>83+0'@XBO>
M6I][0> VM](U>7!;M\[E/8)N<\TKO?\T;?D^\-Z4:J-#)RK&3-SX=PEV$C4:
M5O9]ISPTJ!6;1OKTZ<)HL_S5JW&DO@S.BZQ;\>XE)I//LW3=(EH0ST5-GOHH
MKVW&LDN9AU5E%KJGC6D09LZS"G@6,=.]&>I@48#@Q[!ZB-9B<[4JJS=#DN=.
MO3(PES[W?#J#N]8/YM(GH=N]6?9N04"_2L_]&/S+"]R\'FF5I&Y.D'IZNB>!
MLRQ)VV?-=8*SM*;OGIXM"8_9#/DRP+*1CW:GY(*Z <X&K/F]60&M.:'-:9R\
M^J2LR_.2%U-U1W4O^.J[5&$IV(1J_Q0&UYCWQ_%0S4_XN?E@^/N"VKU[-J'>
M[UG];#1=A>?FBL@\E@-W[[(2RZV4V\%P]SJ3'+8P*.M9P[(BTCP]ZYQUMFL-
MRWM09V>M==$A.^(([DHAIA^#\\$ +"QMNLY<2N][I^14=:I2F(U9*B4I1/&S
M!UX6S.0L*#>-TSERL_@2%D;!;_'<QAYGWUOUG &+/Q9:\J7CA7@@(%]T6978
MVT8NRI>-O!WG2B=37[,>R_R@\84MCH+U?U/7N!<?QN//>?'0Q*3?T%^M:+3/
M\@Y[&2QX0+G5;4P>4'X(IZN@0-F/;UL"+,AS3(!#(4".\Q6C_)0Q/H'Q@L_/
M[7G'=>&^>3K5ZF%ER*>$ UYK=9[=OKW2'$^[4>\N#/D4+ ^LXJNMD<4C^ EH
M'DS.1J-59^2:K=/[%S 7C+6 OW2,=-J8C-F>%?YEG3_P7ANK@1]S;90GIX#Z
M*\09L4H\TZ[^+=WZRSU WC0:)Z)=;[S\\8HZ6W 57:4P4F:XH8HV<Q2LA*VC
M5X+.:5(Q(MY$YWO7=,HDORBJU-0TNT8T;VXQDHDS+.K<.S_A9RU]O%& JC7#
M(,63/IY;+I?$<L]*!>??M:"SI%AW1TTTS?4%$^=FS&0WYF+I$00DGJE3I?L^
M5!"'OI^?8HB5.:F$)QZR"]A-*5\V@>U$'=)%O)U)<)(PP0/^0#)*9GNF6RV^
M7\(=U5^_:,PH7*YA/?/9[-IG^&5&46UV8-D<YC?G]N97V=8J_8W;->I@GET1
ML,K*Q,=JH D]AC<Y>JY-_V6#F:JSE90A-CL396T+S+A2$!\V"NVSB1SI(T T
MY?@?XG TD<]:;>ZBW>RTNA.PSIUZ/HSX*_E'>YXE;+9;C4E?]T$TS$=;]ACX
ME73*Q!PR66F2L-4YK7?F CP3@)7 VRO!VYNJ5'S"MM["Q0X9?(MO"YXGG^D\
MCQGYBSTIL"!KM$XG^R9N!M&-"F<T;!CZB*+0*KX>7.]9;W)#=$/K?62FN=VJ
MMYO/ &^W!&]W*C&Y+NK@<I^3/,L:HK->?<JLKP#<2]/7X4&[N2PW=:93'@_-
MOTIPE\5N:Y7@?O(<]&(^*&RRZBCO9FY6QD+;JFBFU@)&X#=?WH67(R\9_@OC
MJ:_+U'9\4S>>5F _2D>SEBKU@#!Y#J)FK'P^FG";!^S89VQT0=9D0]N"G<Y9
MHSV7UDM M?ZE+:W#S^J-YMENK&UI3[S9:/7633=4FU^HOXE^?X=]T_0#&=5E
MF:_5[4U&/@],OTIHE\[_-AJG\X.?M8.[O!:_)U1;$MK_H].H2?;D:N6T?9^U
MF9QY"L;9V=)=2GW6U](7&,<NANZ=B Q7E!O*$<6GX-]4$*/*>7_M%3U^P%OP
MPUM,1+XTEW>F&I[7$_<:+IY5QA4>#PW9 FSNX;]![CR6OG<=O,;R;F\P-E_9
M/U[3I4?'GJNP@4$T7#\!UH)N_L2?^!-_XD_\::<^/6SG<?_,6M);STV&X(#5
M?[)6%'ZV]Z,KWX^PMU=P_<M1_8C^UI%TLK_) ?CE"%MZ8^[!CM>GSKO'U$(F
MTNIU]N&-F4B<UK$WZ9L+&.S2#/:Z_L:X&\>^&B2OI[W,),X&K[Y5/&4><[&M
M&L'4#Y,D'!U5URC3)'QC%S0QRSKWU%=7)3"'Q%7R6G(G[@:04_(##1<\!EV]
MU6.K&+UWTLF&?R+V@(^!^0%]$"<^C$DK!4D8O6Y$>"-NH,3?WIWA_T3V(W'[
MW%_-V/0[-=,1?S/19_X ]3*<\?Y>$W%F/0%+P\:DP?P=[[)ZWG(,,W^N5%LW
M65L_'Q$Q0\G,S\Q_J,S?8>;?&\^D+YT?UW&8!B[&MF'\6OSMXN+]^P\?EJ6&
MR/Z_D9/&H[MA7HOCQO.%G/3VDCL,K]?$WRO#]7/B<NW^'V-ILU@J:5$R:(PV
M9B[&$HO@]J-M][#T#-[<!_J_??+FL.HZQ;LMU,PBFK5RZN.PN8.<>F!8>K%Q
MY,P+)$WA6'.653@207@;R^B7(_-OOK%9VO<<^*%,7F-B(_\U.SO8JG4:#:8V
MRP3+1"X3G5J]UV%J[Y1'LW_YJ=RCT>$@N96Q8M=[NY0W8VD)+&U>BS=JK7:/
MR<["L?U8>A;AZ+29[#OEXNQ?TN:;TDK&SI"3-MNJH!A+6QVI]FKM+D>J+!P[
M@*7-"T>WUCYM,=EWRL?9OS3.AS0.O"2-%=49#;P[_*PY$-LN)<58VNIPM56K
M-TZ9["P<VX^ES0M'L]9N<RYGM_R<_<OE?%)2JV'HN\(;8?MIZM6V03_G8+QR
MQM(^AZQGO3J3G85C^[&T>>%HUQI<EG,0?LZL/FR/0?>3L5WBZ(E#>W^[:];K
M;[=?.1T\)I_OQ.\!$E&LWR#M*3U7<MIG+PA\>%+#HK('1&35QZJ/5=]:5=\S
MQ"_[MQ_-&TB,I3W TC-LLS5KK;4<E62Z,Y9V7CH:9[5.BZ7C$+*SV^S=?%):
M"^DXZ2CU9:)<X:HH5HY']\ILO=N^>TS+6-K?_;:7C6:M?;;&';<M)_8KE@26
M!"L)K5JKL\:S!%M.[.4D86<<F3U-DS$F>:]EOXG(>RV\U\*JCU7? 1*151^K
M/E9]O,V\[8E8WB)B+.U@S]%GVS\[JYTVNDQME@F6B=)IN$:/3_T_028X$[LS
M031CDL/7'20BIR,X'<&JCU7? 1*151^K/E9]^Y:)9?PS)[,1/Q@BLA%G(\ZJ
MCU7? 1*151^K/E9]FXQ?S)^R[ZO)G:[LU_5L.SUYSVDEG]Z53N()=1>I0"MQ
M*[5XT3II%H\!&#X^@=WR7S1.3J=_&82Q2(9*C)6,M5"!JUSQ3CEJU%=Q\72K
M41/->J-+ \&'3DW$2D?*2;P;Y8]/Q+D6X>">%VOB17T68/ 2SN[.6TZLS,G#
M)!2.C+Q$^L+'WK@B[(,\T?,GXFJH8G@<_Q/,?PX@3!.=P I EH2\'^#.284W
M<X:+RINN/T]RGBC_\8^?4WU\+67T^FL<1BI.QE]]&23G@?L^NZ#IG:<=/]1I
MK*Y "[[U0^?'K__]7T+\X\$W?XM#K84#X,&+W]3@EZ-S_?W+X'NC^;W5^(X+
M.!)IX)F?_H /C>818-GQ0!GH7XZ.6T>_-LXZK0:H_P7@I-E6!MEW.\;WN6.\
M'5^-(W5^Y^GO@]!WOV=76^4/?":J/;C$;ONTM?4KS)[-KBA==I&=>J^S,XO,
M+_" YS[8ZSL67&>SW6[OS#KS!MX?2_V[%UQHN[%#!+VT]^G"8]G'=PIL0D@O
M7(1ZX64W6IWGH&_W8<9KMAK/H2B[FU.4O7;W.5ANN14^55&V.CM QA4HRE:]
M<;HSZWR*HNR>]>H[L]!5*LIV;_7+_ETE3_,GNXW>@FP'4ZT&J(=U]]EIH[MJ
MH+Z&ON>,<X^] N"[-*9@XWOCN^65J[ ,[Z\V=LBCA0=BUHX]E(#_MKK/$\#2
M-[<FG= '2;5CX]NO,=+R'#-ZAC *$G-LW1-'/;#HO0G6*XC);^<5H $ +@IO
M);*Y3FH0M-[3<H?>EZ,P3KS_V-"WD@?P0&U)W[%O@C(UH;W2"4@$?I5J-4@A
M,H:@76>A=Q''0TRL5:)KXG;H.4,1R^!:B4$<CN"Y6"F,P0?X&*4*:L(F#A!B
MF"@?S4SN@31Z$(2#F1YEO]F /"[ &"C*/_@S;[NY+P(_A!3/%: L0R,R!Z(Q
MFLU)H(&T!P8$'_'@GR@%'Q"1'<6>8^Y*E,%8N![P2N+#VTD2>_V4LF<T-KW9
MC[W@&G,C2"SB!20YCG<;QC_P!YC']7).!.5G^ YIB(]YH <I@00$/A'O,8WC
MD@^#/SEI'".G#Q++E@/O#O\FGA-#"8S55RH V!,<*!2X4AJ_)G0*_$C9H$AZ
ML:;91Y*FDX&C:B1*L.+XVJ2*8+9PA-BCB6 <+T26M(R-WYE%XVL99"?BL_P3
M%@)S^-(Q+%BK,*3!HVLP8%ZVN29@(AH?!#>,701)W'K)4*"GBHB/R&)L)*4T
M89P6-&D;-69[(Z%S]+J5QDSM06#FA[<H/B^)(<-4P_/ZU>M'ZK?[]U#^3$';
M#\;F*_O':Y24^-AS57@=RVBX?@*L!=W\B3_Q)_[$G_C33GUZV,Z7CG":BH!&
MO?[3F_P,IW74E>_;4H!?CNI']+<V);OTMZTP<!1:^[S"P-9V.."%R$BKU]F'
M-V8B<5H_P;FJ];_&W3#U)/4IP[_*JN'=.#<ZE0+9S.'J99%3\@,-%SP&7;W5
M8ZL8O3=1"/)X[ $? _,#^CI'VUT]M==$G%E P=*P,6E8]Z&.#:CG+<<P\^=*
MM763M?7S$1&S=LS\S/R'ROP=9OZ]\4P.HO'?DCL,K]?$WX?<]HFQM*U86LG)
MH<-#&V.)L<0BR,RU[=[<_MVGEQ6N%Y[<YCB5+\7:3RQML'7ML]T8UJIUUG)7
M\.Y1FV6"9<+(1*=6[ZWQ-LD=HO;N>#3[EY_*/1IMCS2QZ[U=RINQM 26-J_%
M&[56N\=D9^'8?BP]BW!TVDSVG7)Q]B]ID[54X*3-MBHHQM)61ZJ]6KO+D2H+
MQPY@:?/"T:VU3UM,]IWR<?8OC9,W&Z(ZHX%M-\2!V'8I*<;25H>KK5J]P1<L
MLG#L )8V+QS-6KO-N9S=\G/V+Y?S:6:C*0[&MDM),9:V/&0]Z]69["P<VX^E
MS0M'N];@LIR#\'/V])85QB1?U;7?1.2KNAY+3[ZJBU4?B\H.$Y%5'ZL^5GUK
M57W/$+_LWWXT;R QEO8 2\^PS=:LM=9R5)+ISEC:>>EHG-4Z+9:.0\C.;K-W
M\^F^.YZVWFW?/:9E+.WO?MO+1K/6/EOCCMN6$_L52P)+@I6$5JW56>-9@BTG
M]G*2L#..S)ZFR1B3O->RWT3DO1;>:V'5QZKO (G(JH]5'ZL^WF;>]D0L;Q$Q
MEG:PY^BS[9^=U4X;7:8VRP3+1.DT7*/'I_Z?(!.<B=V9()HQR>'K#A*1TQ&<
MCF#5QZKO (G(JH]5'ZN^?<O$,OZ9D]F('PP1V8BS$6?5QZKO (G(JH]5'ZN^
M3<8OYD_9]]7D3E?VZZJVG:IH?PH6ZA4D&&9:S:<R(G/L1.4=PI\GT23*?_SC
MYU0?7TL9O?X:AY&*D_%77P;)>>"^SVX3N@)!?>N'SH]?__N_A/C'@\__H=4@
M]3]Y R4<@ S>_J8&OQR]2V,Z/_B] ?]KUAO=[U?A]T;S>\O^9<?]_DT&U^K\
MSM/Y-Y_EG3=*1Y_5J*_BHU^_=OZ] -0%%,\&MA=4P&X]!>S_E\HX4;$__N %
M,G \Z7\,!BCB"%M.H64@/_K5<DC.$P^(4<?42:U@!_=QHG1K%%L_]%TS5K-^
M(BZ5KQP\HIHC2.08$N]D(L7+/P*9NAX\DVN@1ON-%XAD&*9:!JX6ZLY1L+@(
MKPD=RE@)%UY\=8]LW:=I[C=U?Z8Z\09C\Y7] ]8-D!][K@JO8QD-UX_A]>@B
M_L2?^!-_XD_\:9<^/6SG2Y5V)G!KU.L_O<E+[2@:$8[R?1NQ_7)4/Z*_M=E9
MH;]M(.@HM/9Y(&A#<(C\?!EI]3K[\,9,)$[K)SA7=9O&N!LF[)^.4E:YN;,;
MY7VS_<,Y)%Y=Y+XL<DI^H.&"QZ"KMWIL%:/W)N+UQV,/^!B8']#7:!QM=Y9K
MKZEHPR(MW@<N1$ L!YN2@W7ONF] ,6\YAID_5ZJGFZRFGX^(G_$"]X*2K09+
M DO"04K"/]- E02ASH+ @G"0@G"IHH2VCE@:6!H.7AK>*6=2&-A'VI]H=M^[
M><S;P&YT-U=4=# 'MAE+VXJEE=3\'1[:&$N,)19!9B[&TEY@B460F8NQQ"*X
M>VC;/2P]0^)B_^Z#^ETEP@^UWAQ_\E4N^XFE#39<?+Y[;MJM6O=L';?X[>,]
M-RP ^R< G4:MWJFS +  '*@ M+NU;J?- L "<* "T#FM==L]%H!MC5'W:G.=
MWGXKM><(&;C"]?P43X0'-FJE<]U..!J%@3G>?4^HMM2\Q2JZB(XP>GW<A@]1
MJ#T\=_\Z5KY,O!M5.1*.)\<(X)>-#:K)@\GW,)8VA:5GL"KUD]8Z+E*V"]IR
M4K.V8#G(Y:"]CNB:Y8#E8,?DH+6.Z\19#E@.=DP.VNO8;MA'.7B&6'NO]H/I
MFUF%[!W.^6V7.F(LK1%+AUX_Q,S%6&(1W$6T,9882RR"S%R,I;W $HO@@3#7
M,R0N]J](8/.%[)PZW4\L;;"*Z_GRRLUVK7EZRIEE%H!#%8!>K<%;C"P !RL
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M%1%\XWB1] $@-U49! JF<1*<$?^Z"$?  V/A:9WB -G0 ^$!>-E\2>C\R*;
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MDF98*E10Y J#BZK#(%!^#0<W B"T].$-9;SP$/S,N'@N?]E.I&LT5>HG^.9
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M+ EG15BF!C8@@*SG4,"H_7%FBO%!'Z>"($-[(&(R-GH*4Y/&5[0&=A0IL+
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MXBE\C& SCG"$(QSA"$=M.;K?@CABO<9TNURCMU>UQGYS&^LQ;T5^DN^95,X
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MO2$5%4>I(7E<H'DS46K#>E%0^I9^GXH3N,3T+7!_%;F_N,&0]:,WLK9J&7\
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MD\ZHAQ:J+0P%U\B4^I7*5 0T,:,B%8.YKO^->1;&D51;J0&T>FW93\>=Z7B
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M!19D@OA J<8BTCOMG/8'G:DY O$A(M5'J7P1F8A%9#CLF*,):-\"-Z*A>UY
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M7[]GCB\O_$NS?SE09R>O]>NE+_0#/'"W$OH[#B-G?J,^TB>"N)'0CX[-_:N
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M/#)<O\SFS*WI6=@RE$IL&G.T?IY/AH/.^-0L[I4J3N.G$("6"\#([/1&/0@
M!*"E C <=\:C(00  M!2 1A-.^/A! )051^U49OK\M=O6.A8!O-LPW;<F"K"
M/>VURKINRU\N?4^5=]_AJCWHOME;C D.?_7BV5 <K/S0H7K\%P%W6>1<\[62
M<*H<DP_\Q"Q13;8FW@.4RD+I"*M*KSL8%?="%2<UM 7D()6#81'>->0 <E S
M.1@,( >0 \C!L(CMAB;*P1%\[4;M!\M/=B6RCQ#SJY8Z DH%HM3V_"$P%U""
M"-81-J $E"""8"Z@U B4(((M8:XC!"Z:ER10?B([0J?-1*D-TT^?](>=_G2*
MR#($H*T",.F8V&*$ +16  :3SK2'7!,(0%L%8-CO3$^+2&1OH@ <P4=MU.8Z
M$MD1[P%*9:-TE(2M?A&)[$TLCH(<-%L.4"0(.8 <= =]R 'D '(P0->$@J:X
MZU,Z7*0^N1XIH.#KZ9F3_?%/+Q,G3W:.5SC.7('L-KSJXW2\Y3IA%\$=C[-.
MO/)&:HH[;<W4-$=[#=44/[L]D+%T;-OE&SS:&\I[IRJH.Z50Q.;__Q"OYKWQ
MGTKAW$.J)*#S8'36QU.T!IL?#RO>*8Z1ORH*SR.N&A1]*WM(\H\R\Z[1.<VD
MPN>-R*S!EF*)C$)C[@=&M.#&?Y(YK!38G<>N:]QP)DX7[)H;,\X]PV*N%;N,
M KXA7[% '+DW7>/,LL1R)J!Q;SK)5=R;]/JV+TRNR!#H&9$O[\0\+V9N^H49
MMU@<<L.?&[8SG_. >Y9 1CPH?5E5<G'[F7B,@%WQM9<0WXJC,!)/+&YOV'%
M_^',6E @VO%M8R4^L9P5<\4#V3%/GH"+VU@1W9'.WOI+P0,WAA.&,5T@N?3<
M<,3C)?>+?.MK<@OZ%:'3+=8@*H:%'J$'T\=>Y<WFYYO/;^1/?GX>A\^N&%N]
M.+<6W(Y=_FG^_R5<\L'QF" 0<S]Z@@^7C(+Y%P3)A3#<W[@"\M?__(=A_+Q]
MB2^<N>\%Z2/^.? %M2.'A^N_%)3SR/[_PN>O3M[%@;SXI2G^T52;RPO_TNQ?
M#M39R>N< 6KDCF\CQ4AMSQ1/CON]KH,<70B.G@LKU/\F^5O9MN+6S/%"P\F(
M8["9$#DA=D*;Q($05?'<0FLZ<\=BXMCE+.0D=@E)#"8%:==PK(Y!R+^X@\'N
MDH.\@>#1T[EY9^_O.(R<^8WZ2)\(1 7//7-L[E\)SV]1OBCA"$<XPA&.<-2^
MH_O7^2-&W*;; ;?>7O&V/?.&ZC.4=0^KJ:S1H;_ZEC)2"]J)P-S5AT52&L'O
MM2+BV4JX7M\=X:MQNL,L4,[Y.85EN/&!\PBB4;IH0!R.1;@_0@Y^![^WAM]_
MI?";P;^OG.#&L/4B4.7D^.85<+\-F#>+@YN.O.7_\2#D-^4EQM2O1J=X70.4
M:E;2=-KK"$V>O3(X '+R@RA]FL\=B\LM;)<)2X!%?@#U"[9Z)$KG?!7)_4NC
MW^L_K(_L$8RJYE4<OHN#!5L*D\H/HH7QE@7"Y/=8>1R+K&R@5/O<]5%GW!L4
M:E6! 9J)DK*J@!#XZ'$H_5_L<4KZFE;=@FI>6.I-;'T5KR*LJ'#A!+QC_.$Y
ME,C[_XH/;7\)X[]:L@V4JAVAZDS[)@)456& &J%4MBE5/X3 1P^.2/6J;D\U
M+R+U6^PYUJ)C_,(#<;<20\SUL_KA&U4<I?+MIV%G8(X1BJH* ]0()82BP$>'
M0.EL%3@NQ:(FC[&=U&GE2GCOYXRB*SJ2I>#AI<'WU_7>5A%\3F7;,ZH_I8)N
M[H6R%N +#Z/ L2)NGU,%]YEG;WQ"@;#PS(J<:R>Z*;&"^(A%K-NU+/<QDS(%
MTM]5H)H(1SC"$8YPA*/C'=UN 25G[:UIK8<W(#_9&A=_"XD/YT0UN@SED>BA
ME+0*1/P]EML+_IRNGQ:2RJ$.$ F(1!M%XM^Z%UU>(LYT6[I? N9%^3^\8Q$W
M/C GR'_X)W-CR _D!_*S(3_YC[[P)7,\@4+^P[^H&24D!Y+32LDYN[H*^-5&
M5X^/7A0X7NA86&&.)R<;.T)U]*(KCC#XLWP]WF@DGSC46MJ/0^;9X5/P8L-X
ML;FX@>O =>"Z>J&'=7=MW14_<AW?P[+;(!>E%064O_O>LVL>4LUD3!EC]PTV
M&!;$X(VH7BE\10)*M2NI'(VZ/9 =PO&#*/UO"V2BW^U/06R(1/-0VI(4P ;F
M DH0P<K#5C^4CN#^/[+>OU\]]U^F=ZG,%9145D>(@=(#4"K?@1F,QX4X]2![
M,U$JT:D_FDR8_>YX &I#)IJ'4MM="C 74(((UA&V^J%T!*_^D9OZ%?3J_Y0;
M^H@Y54N&@5*E=R6?3(?][JBX-ZHXK9]"$"KAP#=EV^-_OE.V&-1K-=4K4&J%
M$-8#-J $E"""8*ZJ!PJ:M_W_P0_FW$$"0.7$&"BU*9A<NJ\$]FHF2N4G&D#V
MFL]5D+V&H50Y(:P';$ )*$$$P5S-C%/LFMJR#]R/1CNWS[O1(X)LM=Z;ZG-I
MZY$\7KO,%A+1*%Y_-Y2>!UF$&T'@]DD-D&PSDC61_#I""R2!9-60A+B#28%D
M:Y"$N(-)*Q610]_047G,WIH4.*!4%DIWZZ0BJI&&DVF1Q4@@>\-0:D/?4+/7
M':!Q*&2B@2BU/1T S 64(()UA*U^*!W!_V]>Y1 :AU92B('2 U JWX,93?O=
M"<@.X:B>5W\TF1AW^R:(#9%H'DIM]RC 7$ )(EA'V.J'TA&<>O0-/0Z"->1.
MH%062N7[+T_Z4[-[6MP;59S63R$(E?#?C\;_T^ZDB+D?]2,VUH:&H=1VYP',
M!90@@G6$K7XH'<%_;]ZF/-IY5E2,@5*EMR"?#(:%>/#ZA2I.ZA(]^/K)01MV
MX"?="7;@L30T$*6VNP]@+J $$:PC;/5#J38>?$/;&@!)-+IL-A'1Z')?>M:D
M(0X:7=9(]0').B!9$\FO([1 $DA6#4F(.Y@42+8&28@[F+12$3DTNAR7Q^RM
M20X#2F6A=(3D@^&P.P39(1S52\@YGDQTIV,0&R)1?93*EXU^=]P'U2$;E5TN
M:I\@4_I$]/IQ%5)D:AD0 9)(D6DV$9$BT_!0.E)D:J3Z@&0=D*R)Y-<16B )
M)*N&),0=3 HD6X,DQ!U,BHA<5?$'DHC(-9N(B,@U?.5&1*Y&J@](U@')FDA^
M':$%DD"R:DA"W,&D0+(U2$+<P:0_')%3IVSF\O3'.A$X^6LQJ8$/1F$S+_ Q
M1WF\4A!6"0"4)_U\$PTC?_+S\SA\=L78ZL6YM>!V[/)/\_,%"_B,A=Q^ZR]7
MW M9Y/C>%QY&@6-%W#Z/?.OKF6=O?/('U;R=69%S[40W%T2'"R&^;USQI]?_
M_(=A_'S+G=YLWDE>[=.*#F^YGF&)5Q8G7_C\U<F[.) _NS3%/RJKN[SP+\W^
MY4"=G;S62*3O_@-<<;<N^CL.(V=^HS[2)X+<$0^>.3;WKP*V6NS%6+T',Y82
MIMZ:+#V>JW"$(QSA"$<XJN?1[791<I:K(5,VM]GK_?0R+2*3AJ1A<=?5QO:K
MD]Z)/ _5-J\\US:\Q6GQ3VUXO14BC':7K4+^(CEXJ6YD3'M=NM?ZGK&R/M3V
MR[8=<,B=YGI4S\A/OBD3;.:[=DFE;(^HR5)<L ]<D\.CE5U]LN%J[8^>X&/!
M_ *^_DFU-QL;3<3?8^HF8OASNOXL4 Z>]*1"R 1DHI4R\6_Y!37-*A&)LVL>
ML"N>_^C]=QY83KCVV>? L3@$!X(#P;E=<+[P)7,\@4+^P[?B@@&SHIBYQJ_.
M'$($(6JG$)U=707\BD5K(O-1"(?CA8Z5__!/YL:0D_+D9&.+J(ZN=,41!G^6
MK\<;C>03QS.BA1^'S+/#I^#%AO%B<W$#UX'KP'7U0@_K[MJZ*W[D4M8-EMWF
MN"BM:+VNL\4,/X["2!B.XK4ZMS=>'Q3$WFUN6 B4RD+I-@557"/=TTYO:':+
M&/P.PC<3I3:T7A]UQR,0&R+1/)0JUV>Z'K !): $$01S5=W]WZ^(L,KN_R\!
M\W022Z7K,.O'GD"I+)3*=V#ZG=/302%N/0C?3)1*=.N/)Q7=TU,0&R+1/)3:
M[E. N8 21+".L-4/I2.X]<W;U4_*M4IT[%L3=P)*9:%4O@OSY'0\ZA8X%KKB
MM'X*0:B$"W\T_A]TIST0&VM#\U!JN_\ Y@)*$,$ZPE8_E([@PC=O9_Z#'\RY
M@[WYRHDQ4*KT+N03L],;3KH%[D16G-HE.O'U$X4V[,./NI,B0ECU(S96AX:A
MU'8/ LP%E"""=82M?BC5QHEOZ(P>((FIS<TF(J8V[TO/FDQWP]3F&JD^(%D'
M)&LB^76$%D@"R:HA"7$'DP+)UB )<0>35BHBU[S*F(?UNQR6Q^JMR0X#2F6A
M5'[J@=GK]/J][@24AWQ4+R/GB TO>WT0&R+1/)3:G@X Y@)*$,$ZPE8_E([@
M_S>OK 8-+RLIQ$"ITB4%@\ZI.>D6X<. \,U$J0V%-J;9':,)+&2B@2BUW:D
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M%TVLR^D:K6=)VYI,I([2(=GZIX),V>QH*['J,T_N$1JH45*8:/M$),)L^K?
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M]]^8C_.O4+=F7>96N>S2EIHJH-<5V:Y4/\5#[IA%X?^.[2ME#,E>PFGQ9%K
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MC&KD&OTYH'LP^UI<AZ_-UM7*-ULBLA%K>BA2T[7PEWP [5TN@$9A1FCCU3I
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M5A&VZJ%T *O^B8?Z);3J90\Q]CF5BX<9I5*?2AZ/>AV[7]R,2K[6+YD12F'
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M,=X$8Z)FE[YXK(UM2F_']$TC3(&IH[GV6)9C><&4ZPL52GKJ_ADRI5NA+FA
MF!_#9R>Q(?8:>N$1H+3B ']DF3BO8C9_[3&J@Q':]%!PNAP2^94&ER'WU"GW
MHK_(V*=WU TEM)*60=B"@QWA-T6$L8[_<G0M3L38T?4XA'O.JB9G555O!\]M
M!^<@[_'FQA"Q>5&+<%YAI<YQ;QJU3..*/X#80I8/ 08*.Z!OBX!F>/1]MQE
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MY@M5;<"^J;\!Z[S*L>X[Y5:W\.IBW8!)U>:>%?NJS;W>&K9I#3/"IU1=\;M
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M)2XV<XF9V3.#+5&9Q#).OB."U(>^BM+V $8S%D2/ P.'Z8"A7V6/(!5$K(P
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MF/+EQ+1<<"X4WVR'GR,D%4'"S 4OOYOFQ.N*O+O Z54"38^NWN8&CB)C>O9
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MKF4Q2S7N>B,B]L#>4)]+KOOV+#NQ=FKR6;MZ&M/9)I1TNG8.Y+S19[7.*F]
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MJTH@5U[8'GVVT-;ZK&S [##9@-8Z*-:8*()=2N)'>:XRK1%:5M$>K3902-T
MUF;8"5MNC3W33(#Z!#8$%1TQ[D1P_AJ/<V>]?'02#,L7GX5U9R"&5#8=)PVX
M=R)2?XW117@42&N)65V@J"EL.D@,.7<B)]4:D_F'=.NE"XKE6IL.! UN>SZU
MTC4A?U BGK&XCVGPZY+S!(D/ZER")O4W1,G=\.U$.JKU"4WX=[3G?5%X0Y3>
M@$DGDD\M3TR5CB:=*O9HNQ=/@#;+?;]:6S^;%WIX1V=^!#N:-*U6S2RNK+=A
MJFW'=ZTIW_)92"/]GE+R#%M6$;;W@\9KX]:@YO;H6(OS6GO<BL<_FP=Z.!6\
M4>^J;\N6Q:_WG*''^)+PF"63[&6Y+.'MK<_BV0/S"?<#>5!8 +:H9':@]FG]
M0$T0\0I-RY.TK'%/MNX5FQ>O5"]ZD-9VY+0M/Z#-0I]%UY4GW24EASG#7^O(
M^6L0):%(7U]XMT2?C]+J]DP"&KI:/E=OP>! +SP4NI5/9!>8P*0%?9:9[,N6
M]_I:SNFP#5].N.6+O(E4A#!9P\0K,N#>,C3!R40Q:FOK.:?J=IPYX5:_HN1)
MO -;L:HL%QG&DBQ:&=)?G4Z42<7!H;J*?3@LT\*RY6C(C1.9:):Y^DG\=)BA
M,!]=6KHMJ>>Z@G59ZMN;T^T^\$9<CU$8"Y5E752G+AN&#IO*S=WO>ZE(L[W*
MW_X?4$L#!!0    ( *:!84K[J-XX8T@  %'G!  5    9F]L9"TR,#$V,3(S
M,5]D968N>&UL[7UM<]LZLN;WK=K_H,VMVIFIVB2.G>2<G#WG;LEO&<^U+97M
MS+GS:0HF(0LG%*D!2=N:7[\ 2$JD!( @"9 MQU\26<);]]-H-!I ]Z__[WD1
MC!XQC4D4_O;FP[N#-R,<>I%/PH??WJ3Q6Q1[A+SY?__Y/__'K__K[=O1"<4H
MP?[H?C6ZPI22(!B=1'09492P!D9OW^8%__OXYG+D1UZZP&$R\O):3R29K^L=
M4^(_X-'H\[N/[SX=O#O85#Y&,2O,FA.M'+[[L/ZEZ#X*?QD=O?_P_O#@PT^C
MPU\.?OKEX,MH>K4N=\4(F!%IP0\?U@4#$G[_A?]SSSH</<?DE]B;XP6ZC#Q!
MSF]OYDFR_.7]^Z>GIW?/]S1X%]$'UM3!T?MU+64)_M?;HMA;_M7;#X=OCSZ\
M>X[]-R/&]3 6?1MT4A1G(ZR4?CHJRGYX_]]7E[=B\&])&"<H]#:U=GK)ZWWX
M\N7+>_'KNBCKGF@&M-,T^]5/UA7*A3^]SWY\PQ@]&OU*HP#?X-E(=/=+LEKB
MW][$9+$,>%OBNSG%L]_>S*+ 9\SZ\/G#8<:J_[A-&.)<BDZB,(X"XG,!6'\9
M3V8G<Q0^X/@BO$TB[_N<-<"D^>Q?*4E6;T:\WV\W%Q6:T()X:9S,,45+G";$
MB]]YT>(]+_J^6V^"*T: ON_*EE,2>T$4IQ2/XQ@G\3CT+PFZ)P%)"(ZO,.(_
M^>/D'!'Z=Q2D^ [=!SANSI'6'0W"C%,<>Y0L^>R=S([3F(0XCD]Q@DC0B79]
MNX.0>ILN%HBN)K-;\A R;>>A,!E[7I2&"5/>4R:\'@-H2J,EILF*P<:E=,G%
MV (_+'0^S&3QV#ABPG&T(1;2Y@8A[&L4^4]L666LO@B9DGX@;!9F,[;XR0*]
M37J!QH:+)3UURX)*#X.0?X+B^544XM45HM]Q<IZ&/E?8V5]<+]]B+Z5"<UM@
M19O>!F&+(R4(3[WM&B4GT6(19<8*&^;OB%*FJ6V W[@K( S)_KU@5BQ;JA[Q
M-$!65H*&'0%A!H-LB<-8[';.GOE'[$HTE/U -IIMF @->QJ$'9=L0%:6A*V&
M!B&&3;EHP;8ASSB^C.+XA"FBU2RB3XCZ-D@T:GX8%(G'9Y85'+>;&L:<B8(
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M4Q<0E2T,.??:BVT=@$IR!YV%XR1[XCV9S3#==6.TJ-\K>C_U/P=W*1YV"G9
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M*;Y/F(!DKZHVH]/LAXUK ]H?-\6SFB+$D%X NM]@K-HM=8/Z0+;6#66Y(;"
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MQYB1.]=/(7U1"-=!&W)?3Q" R7.>4L;)5,C%.7GFG_2S15<!PLW.EM-#1Q8
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MKAS#-B70A<T_%:$0\31 GNAWNFU#JS<"QE4A*,B6,KG>(Q@3Z_SI,G\Y%1O
M(R\'8:?6%0LY94X"@259$IWL/&DRFV%*P@<US_7E(=P8Z<I[/84 %I_+*'Q@
M>_X%3\13\Q!+7G0 .Z+V/;Y+.T+.!8!(:K=7JL) C *=5.K  +33/8G"1YZK
MBHD1'UW-@QMI60B&@%ZJJD<64B( 0,&'<Q'&"4UKMDJR@@/HM]H %"[UFXP'
MX#"L/692%P>BX=0RJ0;#]1'2=93@S26CM<7($5';< :5(.BQ.OE96VP&]/3+
M^\]M>/\9T@;& N\_N^1]:>6ZQ2';C_)QQ+S<:8H/#PZ/=">IAE4A;&:,<3"F
MRLDFTO=)UJ!"'/Z6AE@_+QHW >'>NC$ZC:D#L'S?<!M$=_:Z^7T @ZLV@+O3
MH]4-Z5" TFY6*B6 6%,[XK7#8$!SX0H]DT6ZT*?:KI:!8$%))*.20[LZ8@!\
M7J=/7=^D7T:AF+1J/5139P#=5)M)P*5NJF$' )"W!J;=%"K* M%A1N):!D=!
M#@!0<H-$J^&VRD#0<%I9*G-^:^P .%YZ)E07VF>['(0=HC'G)>,'P/WC-"8A
MYH\ &1U9"$9=3FM5Z0%6E]J$)2Y7%R4C@$+*/[(MEC[%<GT](.M-C=#6 ;5%
ME).C>X]$OHB%[6G.[7<+05A+C.5G<TR_2X@+IEX1M,"^EJ4[12 L$<T9ND,&
M +621>Y]$)?MV61E!(OGQ[5!4 WJ#?%0LS8?DMLW4K4\@8MX[0F]03T@"XFQ
M3!N 9^T07^WJEW5;)#9>G; FB(<")IXW^(''<XCHZHH$.$Z892J_@6FS80A+
ME['$EL\+;! _!. W^!&'*3Y&,?9MX*QO#\)":A]>/<T@='#G5>BR)OB=W2Z&
M"Y/G@E7R@'KV3(-]#;U7W*W:NCF5I_3,V9#_H4^BTZHE&,K(K;BU8@RTF$W5
MD^%SY.'Q@C_5-;K[5"X.P;KH(/3JFU%E(F&C=\%?6+,5\@8E6'C\_2G;7K$?
MT(,JU%"3!B#,:2<(Z\F&C7F)$=E'OKFZX3;4!R/(M?4A7"QR@KB6ZCT$?$J)
MASL 7M2'<%>I/\ +JJ$!7CJ(NITCIIG&:3)G(_SW)OZ>^NAMMP:$6>S:%M,R
MP'T*TTWO?X_X=O:&/,R3^#RB9\B;BP']%0?;X#6K"F%JND*Q&2< 3]<IHA.:
MF1 B'QZS(\3 ZZ>MNB:$0+<]3E\U(YQ/XW/RC'E\IP6)<WL C^.-*3B9B3CM
M4QIY&/MQ,;#;2#ZSN[0&(02NT\G>A3GNGW5S.;R(XQ3[IRE_4\OZ)Y&?+RSY
MJ]OBO:WTW+A9 [VBK;B/[!3MAOP8"F"A;SK@JZC?*[R**YU#P*M@1Y_6&!\4
M#ZR^T31GSTL<QGC;U=ZD8J]X*BY1]66)Z?@ S0Z;\ CH"GP59?IU6BIN-+@V
MKK9HA@:;2'$PF>7W7B=4F/W7*6?=9%;*2XV" /O'JR)J?%Y0>6;6M=5^16.@
M$[/.7((F3,4(^6T ,<1)FL0)"OW=E=RL2K]B,-!)EIX%T# N;NNQ->F>A.*Z
M0/6V 2>;61L4^RJ7:+,F^I6!@3QHS5@"32:F:"68<1?E%S<+<C#G3W' <Q&.
M9S,2$+;;5&:?:]%0O_+1LV^N"V.@28GDGF_V.J08?ISM8B94V+WW 5ZOA6*K
MFOUJ?CN_5>/]2M- #C];S'*^F92K1=F5M<WM--G>LET[_<K"$([ =GP9"';I
M:G@1>D'*+:7U '-5:2X&3=OM5RR&\!C:X=,08C+V_TCCA#NWY<,UE(KZ9OH5
M@B'\BJW8,BCF*)[;PEW;5+_8#^&#;,V:(?$OGAI;D8"ZQOJ]CM>S[[(K<Z#M
M/#2[)VTN]-IJ_4K!0&[*>C9 P[N!_2+=]_ M=;[QZ>["JN^A7RD:R,MIE6/0
M!$Y[Q'Z-G\1/ZLA$9I7[%9.!'*&FS  G 27'B+C96G/Y3%.^7YP'<FAJZ(<&
M;7$/ZIPQJ#B1YX_<UL?T*O.AOEZ_4 _D;33@@_-M0^T89'9@HYK]0CF$L]"4
M$_5@_OI^PR36W_?LR^IW>>\5+O&,]&A!/+8)F3.S88G3A'CQ.R]:O!?,.B4Q
M?_N94BS&,V>CQC3.S(G"J.!W'!GUTX"1G&>^?U-!"3\G./0W&\:$)'P('P^^
M'!R.WHXV?; _RMW\:91UP;[./ZP[&XG>1G_.^_L+:WH1A'&%KK4$'!X<'+WG
M/=^C&+\98BE;/^05"ED\_N8!O#"3D4RL-W)UO-J4R?<)XR=$_3N-[6RQ_4&2
M>HG^]4%=MLH,$<!%KB"L8UO)XU6E&L#2W9[(#2VASV=O;5X"-UT!"00CE?D=
M<\XZ]:\2U+6K2K;1+SS;Z"<XJ54'D2HI1UR8G&>+91"M,!_!*:'88_5B82],
M1#^:2#2F-2$\^G<Y/]:6IRE# .B+&QPG;#N;8%\,\!N#);ZY_::/NZZO ^'E
MOVN8#5D!#^ FP$+*&#(0H)" !)VX0C4/7=KO)8JAX/.:K^(U7X6<Q_N4KZ)0
MDQIM4RTR@,)1K1,N%4Z5:$! :?=I0/?H,B&3,1O0YKH%N\O;M\\'?/OV&<Z&
MMAD$4E*</;C.MDI\!(<'!S^5=E+5'S3AV%NT F&UJ-E;MB&K'Y .V3@DHVN"
M4$T3$':6C>&IH<G)Z2&FLX@N^(&76-PDN]1L:U3DZ5-CU+HI")O&&JQ:TP;M
MQ+_6U%%9.CN'ITU=O 8-#Q=!V!Y;Y'&#.UN8^QHN^!1G%]_*9)="K*,X)C."
M2Z'W%.+5HAT(2X ;N6K!#&AZZ(XB_K1F$PI @;ND'(3EP@VN$F*AX781/K*E
M+PMNZT4+7%QE%8;E(_%QJ'K&:E030C!"-]@:D0\-[1V!_!92C (>_?*OS"QB
M/WUE?+U4OS-HT@"$>(0]S6L-%Z")0&N.G"-"LTA=<9PNLM-,)NQ7.)E'?A1$
M#ZN:_ "]] PA(*(CX[,/]H&4UOMZHN^WB3Y[7I+LM49V*U\GDW;:A^! ZG%R
M[XBF'2XZOU[]=[9&KV,&EP*)AN>$QLD_,*+C,"0\\#>B*YE;I&$#>[UK:2<6
M;=CT8A2/^$=!O&TEI.]KK_=5 RDD/4?=QYMMRZ[<P5R*BYR]6N*D8/]NCI(K
MM#K&9\^L!(EY+(S?YPS,"9TB*HT_,M1(]GK#V$%=#L5OD'JW#1^J89]J$V$X
MZ&>O][L6]*U=;KX8P91QE@?9Y8=-?X\"UHQ(7XD2?,6D9I$N^M@^UPQ@KW?1
M XER"S;_@#(^G'##2)_P<J7ZA8OS#8F_GU.\]O/W)<SR?B&DBG@)HBSG+DA!
M;K.=U<W>.TP7JK#7+CN$D!5CW]P2!FR%ZYO0#;XX*E6$H.FS8Q I/O;*]=",
MOR"5:GN/2_R5\DP(%_G)Q>^8>PNQ/W[$%#U@\>,I6TS6/+)M*[0=Q5X;P6X.
M2-NR\J5)="F9QTT4!.<1Y3\Z$EQ59WMMV3J53Q7'7K 89NY!]Q)8]+/79_A&
ML]B10!8,?&FR6%T3=!%XG?2TUY<'>I='*0O!2:0N:F@Y4LCZQ$XE<"T:VNLK
M <WEJ06'P(E+1VXQ]LPP25(>P=3@*ISMGO;Z.+]W!29EX4N3R.QBPCCTUPZL
MB'_5E]5GWOU>G^?W+KOF?'UI IVO'IO<8XXD5]+/7I_3]RZB$@:^-%DL,7/+
M@578."*".6?TK"_WCO% ]OIDJ"_7CS$W?U#1'E:>7YP+J:$6&4#H]U#2E<$!
M3$XBK$B[S1&\,">52XFWR?87)_4%?8,*?L-!O#"'VI"RWY#S+T[\)<Z?(29
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MV,J:K5U37<I#60EI^0%@R5*,[U3H[V88%W5<+2D%MF_]O",]Q :R:P!4010
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MTPJ$HU7;HM*:&>X??FT-ZHH$.$ZB$!>WJ:=1POXC0AIK\=75AG"(V@NN.B9
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MEGW+O][M)?P[[.\L"+HJ(JIQ+0A+5JVXR;Q=2HKZO)A='80JGJEQ+0AQ3"V
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M14#Z):-10(-<1*#9,K1@25B#&!G&COW*@"'@0IQ45;:.0U#)FS^^^58:][_
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MGLT&C9CU1 X>/<37,<6@&V*HZ<.][1070Y(3C[T;()I#7$6#4$DD%?Z*6.C
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MN,B1?#35&4>\F R*&&W'DVU*+WT3"JI*@AH[*"-&9M%C$XXY\.-?Q1%0YDL
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M6N>7$"A6Y!DUHBW4@YRT(T%#@5&WZU.I2Z6(3_<^3_?6<0<\<$CL\#&"PBJ
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M7S'LR%L\"H]IEGB^Q8UFV1'INMI?>$,GG>J%>,?=@_E)CMODYYR.HZP ;A3
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M)[VD/)3//U!<JO>4\JN=-T9]UIGO7OJ(^%7./^,LA7^.TNYQ3C*N2AT)*$E
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M+1P2[*BJWD?8%[K;>\*IOKU[_[=_NWG_T\6WQ_4$Q3^#$%!J0U6MT.R225"
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MBCT(F<!_D,#$!)H-A@(SB_W+(&3\V3^'@XKPT+CBKVF*%$*Z**BO_:O:(=X
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M09+%5+G_CM+YMS!Z26!,"_G<A,N,%O:)0@\%^0W](XE6CC$CST&"DG7JA:\
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MKA;+(%I!^ 3C5^3!YN4]#NA<R..#:9'&Y ^\X< 81;A=(I"[7-?W!HG5??!
M6R*Z/?D*Z(4M7J^5(TZ1+\,?I^L4&C(G@-.3!H]!'CM#_ 25#XW*+XU .B+?
M&M&/#>1HL&;.AE*6ZX#?U,S3#I#"M?^7^8ZCVL@:%2#"^.UG&ZUD<(QP%,58
MX5#CR61L?26N>/R&6.D_&:VM$9V$2.IRE"%N6 (E/\807D8+@$()T6[ULT[(
M,O(2DW8[O<9/TXR'%4\>-B=HX(%W!Q<O,-Z1<G.C08BT72@;X4J0::LD+T 0
M(#]+SE&TQ ;E G!%RF[MIFPEZ77%,5%N9]@@AS?X1];^7&]H'0PZ;<V"=''$
M;7A77MN4O /1)'PD098Q"F>XP7T4QN4_:<$+(8>2^@_9BR ^&.HHVA-O-.PL
M&_R^'RY^UQ<8S]";A^C?F>"E\5Z^?41Y?W9IV&TWP/]@VL/:8+\DYZOM][C%
M(]VME[GB/M7>7W 'Q+J9HL'_OX'JQ_WZ6&F*,:F@J].SN@LU'V4@OM%\L@QO
MZ.X?S:J-1PB"JX2L@R):4#Y6JGT(:Q9^LV":5W9'LHP?W%4CY#I+\1*\0R%:
M9(M'(JB@B %)KJ-XLJ0*+9Q5EKDX='J,/4A,J:;7%0=",X/RY)0;_ER )<(<
MZX\TB8&'#[.^Q&J+1=C7\Z\BD[&D#?*^Z?D7&6I$QQJ();*FOO7]%[>EZ4=>
M9&KG<!I5Q'F)_Y-@H>/S85$O4?KM5X=1K5$' H)EO?M21;9SEL[5= I)C-:&
M+X_8^B-1,:&' I2?V^1 )C_D\!&FB&;G;)O+8MJ8(4V^+TED28TV?%#U)W?@
M=LPE?$EO0LRJ;%$\YW^$ 5Y7_@.(TZT:P5)F3L,K=_*E4>53-&ZM^-B(?FU4
M_9QV2XAQ$RW.$(;%TWD40X6L7HD/ G.:3%E(67#[6*,2>@ISIYZ5),&.V#!M
MA7LVZUL(.%V'<Q%32GDQ\+Q/N]G@I7::ANP)Y7BC)8Q'=,2!'*MW&<%Z(<EL
M9OB@LS,O<JE*SGZ7*,A28F/)G7%D1K-&1;2)D'&VZ4VK(SM.Y=EXF"*?D(]/
M?)LL;%=O7I!A-7"-F4W>FV1I\<BDID/$W^0K^M# (:B5#0/?H)Y@ ,FCN__.
M\!8/XV!UC4(0>@@$ER %WT*0^2@E&1N?YU&6X',-X1M<IB5S2"N93>VLX;%/
M.8?1>A*C]2Q&Y .CG]<3P<U1.$K+R8P@G0W=#A.Z'?JX_9\&LBG6F7X33J-X
M067;ZG^6[FU6ZW&G*[F!2HQEC>[J*.QFE=:7 0-/.7()$R]&RUQ?EP%%ES %
M*!#30Q].3D].ZVZ<]:BC:#HJQQW]7(QLN3:9Q#,0HC] $4.51 'R<V"'_D.%
M_9/I&C3K<"Z6QT?1F(:SJ$8!)B<BD0*O<!SC8^P,E@?<^PB?4IO_7/,0MJHE
M51^R1F<IA10C\:I.GC'5G"T/^1QXF;D?2=8A='S=>7S=.=37G7<(+,BABO,0
M<*?)(,0I_?I/A$CC,E2ST!^)ON/H^_7?K9.T,0W/9XG VT!#R;;IO!M7=D,+
MZ\3-YSI#2NZOWSOP1F)#N6+=:F.G8#ESJXNVG1Y'A'L;A3,\AP6] \<?X^CI
MIJ;6B=J8RA;F#B>VR+!%ODL"UPQO;FP='H3%TBY1FZUM+8%#7(W?V-9Z\0L9
MZ/(D.B+_[2@8SE90;VB=Y(UM!(*\X61#-&S$;Q-PC\^IW(V U=PZ1 @*IDVB
M+10:5P7L>N6E,GN"(8;8?93"A+2[S.#9R=E[3F8FL:Z6"[Q%;CO^F3XT&X>
MXE1->2)9$BD2A51OLC<&;A_K &)LCY!G4X&IIB+4AK>+'1*X>T5C6_M@(2V=
MNH3%*75$6V!2%T76_99SPTX[Z\0O+KJF(X,(=<Z(/"/Q[4L2(D]V5\Z^T-34
M.L$;VPZ$N5, YY,5M_J/<)G%WAPD<#R+(67 +B'<S4"XOW5 $997PYU!+Z*-
M*P[FX>('))$Q1&F"<'5[>\$[332WM4[*_415.T](4&U<S&H4!'&X3:85_<C9
M(!K;6@<)8SN$.'L*['RV8HNH,P8T\X)K,DJ.8AUJQ(57%[P*VHVK$U:F=T!*
M3Y:ZE9/LO:&==4)6(:B=/4.8;EL%/$[O0/P=%N?HR13/!84SMJ!Y[0]!X-+T
M.Y+WY"&._,Q+)W%1?HIC)S0UM0X:QLP$8>X4P/G-OB"$@@3"H(*(A'N*9+:W
M#A7"PF'*59!(X]N!4B1P3<.M-K9*7%!L3+';O/,KOFKZ"J-9#)9SY(% Y)II
MM[UU$#!_Q23$H@)'7^S;#Y[@;)<*[G[ ;&\?-*0DU"!A*4H=T117&4FP#<)O
M(9X^=VMH:&D?!*1$V'#+*$BC(\)7H$)O6\I.J?R$?7 S=\&EF:LEP$]Z(OP5
MQB^16B?(?4:6Y61Z#5[BU04@C\=F=T7*E>0FS%.QW(07_WGW0#\[7B[CZ)5,
MO>X@Z3J6=4C4#H@=SXI2QFFMBB4=Q<. W4,4Y^_3'S"1A+._HW2^)A_ZYZL&
M^BNTDQ87\\6R"8:JQCYX6&IEI-8:5H:*MU&7^"-\A6$&OT:1G]S#W<0=O*:'
M##AIOBA*@KR]I3:4EC(9W7X-/#A>D%M]H>CV3?,CDB1YPWGOT%\;?;$!2V6R
M5Y+!GI[M_0<8>P0&,U8"'?$!CGCKS2U."/5@:SI6XDT?0#R)<T;0FIEEGL+V
M.%Q6SR/FNK.)&:FI FR?C%W(>!#Z"<D;2M8B-APFTYLDR4#HP8LH23F7MBT=
MCU#KS"5FP%</USWK3!G#!<H6R0- ?EX=; E]4L?^(@JGJ,C!N L"B9Z'C(*^
M;.+<Z*NPU@WM;V6N):R&7U"XSL:W*8U+.)V3=\I0/C)#'#( E?&+<Y?8?^O[
M39$J:Z:RJ?KR'<+GY30*8:-BZS+.(:-,+=-4N?V;L?99*]8:5U3NY2/.Z9+P
MHAJG./;DQCUB41<32VSJN2:0QN8PSYNG!P/&WGPJ\<9+"RA]<&1%[I/ID:,)
M]"\S$J.,IX8BG\XN*:.8R_CEQI!^F0$.7D?UYU8)#I45#=7#ZAJ]0?)";H&2
M!$^/>/;&R<:K-YE^C:,D*<_)Y7)XBC9RJF*L^V@'#SC%K"O1I\?Y+WT5*:?4
MJ.KMH=,:^Q\\PGHSJ\24'G>^*HU6V<TWGKQR6155 1O/E4(=#QY%W;E4PL<I
M!_V$5(]AH*JQS2$#2)PA)5::7.R#Q4KUMJ%<.R0N=+V@!.YR&OL=,=65227.
M^OKPEQ&I2O *GQOQ9N@=QR.I)!5"OZPQ./:\;)'1&KN7<(H\Q(K :>]X1%QG
M+I60T^.L7T-M3Q4=L\4"Q*O)] G-0H2)!F&*^4!"DHB!&068#9"<6I8P3E=8
M%N2=]9)P7JZ VEF]@%KQ:5(\K?+QT>;KH_+SN'$Y@Q$(_=%Z#D,IME;G**."
M&J^AV;)HI0 > H*0"@[$BIWQNUNCC=H%U5R7K -Y5E4;>W2@WDP'&33L"2)5
M9"R2V;%PC%O/]>Y0V%XXIMK&3L'*%8YII<<5X1ZK CF=D*=Y^UD?2]C>@9:.
MUL% \:;;D0.N ^=; J=9<(NF+/-:H*=UT.DH:PG0M! _\&+F8@?V/!O:34@N
M']$K)#PB"76(&^T<GX%I2E48)G1.L@?YLUX'^7QFH_741F1N]%1/9_<+G=ZH
M.K_C(5_W(9]<1-=@P9B\6"=KU([D@5Z>*..F*>MFOI&4\DT_672-=Z@"W:R1
M;0^I[=ZL=Z3Z(/:2(N'.33B-BM<4LCO&^UX[1O']464"SFT)[1T(_DX_??KR
MY?3+R<GIV>F73X8NI<I5,5G2:-]P5LB'=;QAMK=.CT@RO[Y]R)$Z<.51*>6>
MR"F$]_6[H.I@0UG<#5'PK.7-;VKV8J><6U4$YZO*O\0N>,2&L6;-BPBO^:JG
M!Z%671\P7@^=KUI*6K?VLT;&2F57AT0W1G"TON$\00QZ6JM:M_:S#A#=)">,
M -L+7[.KG391<XO "PI(=3<\!,FV^0AG)$@FBE=Y;9X%C#T$@LVS0VY55)6?
M& JPA*MH[XU)0\<@IGA#ODKD<0<^;+S)L\;X!4U'E!69WJA#2 6X>.,=)J:D
M.:(HL9XQA;4FLK^*VAGJ, $DPPP-:?3VI(;6&WR16E<!BEH'/4P\=6.+AO1X
M)C,&50["' < H[5UN-%T[)<AGVD V2)E\F,,^>?[UG[625Y&1&(";J?7UA/5
MDX<B/+/%3>AQJD7N-AJ$2-N%LGO-*T2FUE3UJM(*D@1WR,^2<Q0MYR!> *Y\
MV:W=%+0DO;:>4^\06- 42FS)[C1Q4YPB1!H_(%8WZ01ZO\ZBUW<^1&1__D!^
M(/+]4-F6\:_^>0MG(+C"EFFZ:C"X&EI8)U_%1I8HR1QI*WFS*RK ?)J-YM/N
MGZT1G2B/MZ722HIQ TA1-#;E&PD# ^&*7T>SWM(J&;=*K&[ZBI)D7-:ZC5U#
M.?0DQ29#CG$;Y_A058L[0NC!:MWU>7RP>GRP>GRP>GRP>GRP6A/NH3Q8O0E]
M.,5(3N$M>B7'ZQ3S"N&=9YPD,,4[TAWX5Q1?! #O5.P-5W(4ZP"B:5M6P1;.
M[9+AQ%0MU&UHNP<+_N5"AY&L@Y *64LC2)@SCFQ%-R%-$)<DCUB^6#;S<>A?
MPE<81/31+W>+$NH[-%@) Z )6EWYX0B8:()X0BKEWV1*GQYS-CEF>^M HVD[
MDV, IY";X8VK.GU^4'NMH7VBEI))7::")+JRY&&,8'+^4$Z:DLW=-3@]K,."
MH"P;%K8DD8Z@H9)6EHN!6CMW)"]&FC-G72]:P+7&O"5?XD>Y<7I8AP%M9U@Y
M%NBHJJE5_"TG4TX?ZR @*RMA:=ML&;!BH^;$Z9?<A-< Q;0Z!LDCWAC_^P!6
M9$%P(J<ZCC44@$C$5*GDA''H: NIO6W)]L?K8AUH]A="S>>!HD*]ML#E4"OS
M2LN=#9V^E7;U1/<:JOA<E-1,GJ,BMK+D$B35$VY"/%F8I#?A>#I% <([ #,5
MJ?1 +F),$1<T')V,(ZV!NV6JR9PK25Z?;!+3$BYX2RAS(N6%%_._BF^-'09W
M$9$:.:,A;GJ#TE-%%GVSUC_0RN,]\*2EDKB>"I72"NY82-Q6:*DK#*ZG<*6A
MO;3Y\K6HJL<*D.3U<0E.W0GF7#[*0.45QB^1QBJG#4ME[/\K2U*2@[9YR0BJ
MH;9A7(*)4AYP_-=22B9*05##C:J*RSQB03)7A1W.4 >%'UD^:/!4[<4F*@G.
MCQ6*4,0?[)!PU($3!9+T5)F4/IAI=U1]C:.D@UN*=G,)2;UH+IV;)UI \]%Z
MKWFC4X3X[ JO2'^G>ML77(2B;O:4J-7CD]?H@WHH/O((7Q'\\?<H\^8P?@*!
MI-^@;1B7,*64!R5P]+C85:5JZ4#M XP]=?@I1MMBX7O"PB\'!R,>*THTZ7&%
MJT)3(X6E!OX'!'&CX[N]EW/HZ$ARB8*^7FV6_TBC'Z"1XF\)]!5L1Y5AG$.*
M*AZ4T-'CI394%4#\MFB=2U/*RN:.Y!+45+.A1%M?1[=59[UU;.%-N,S2A-0(
M(B69'D'*.KMQ>KB('EER2Y3T=FIK/5NUW3]S-C#!KBYAH3?=)2CT>*FM<A/Q
MDXAG<5R'5?\!70*;)FZ4$-3CWK8>@N,X)M'TU,.;!];?A.,%T>3,H/HU6^5"
M@Y5__;#!K9YU99BH'I_]%VM6PB/THEF(_H#^C8]9A*8(K',9%%<<Q%-<<HM4
MWTR2;%%/?# AE2F?,>^_1I'_ P6!^'K0-X<#615[9F"Y-NR^&:!O:/.KCLLL
M)N5C(?Z&GYOI]-?74<Q0#LU%N/L,Z!(2-7&CA)6>>P-5'C[FXSJ$5Q-EBL1Y
MJ-++.8!T)+E$05]_/\O3NS9"]U./N52D^1.5+65;_DFN3/.'>IGF<J 1"/W1
MYBNC_#/5!@.IX<QA6J72-;]FN^081O,=<6LY;S6R3DMT$E5C#B,V??86YVW0
MD3U+--D@4P&1L,U2$>($!&HH)443%>JK,=D@9!EYB4F[G5[C^05:;FVKS^C9
MR2?8K0<AY'8Q,2YB!>DU+F3%F_/:Z&W;H)NM8QM@T$FA"]+%>4]M6)>7ILEC
M% 3X+/H#Q*PGS@TM[94A7QQU.8H2IS4%@Z'(]A9?I+5N0E&9L:6M4\1+ZNG!
M@(Q36SS;W05MJ*:,5DFK*RR3B_HJ]&T3],UB"5"<Y\QBOE!I;FS=:N^MV@7H
MTYKVQ!Z?VLTROI3UIYU)^]-N'A[_7[!8_G^71X?:T:%V=*@='6I'A]K1H79T
MJ!T=:D>'VM&AYJY#K:7T3;N?37P >R4N>T;K2;-6KYQAF^ 8AF@*S3U!R39?
MC <EZO1MVA._?G#+Q;"7UKGUL@\/L:'ELG&&3J8U]^!:C@&1X]5;D>VR!?U]
MAK1.]W>W9%1S0:M/^G2_/FF2DNXN"N'J#L3?87J=A3Y)2Y[_BRSD)^AE,5VV
M<O[IC_5X3_*M_SFB7QOE'QC1[U%_]>:+H\TGA^*GIHG]\/^3A$6O("#/>3 3
MG^91G#[#>'$3OL(DI:]\&,[J+@,8.0RO2WB,7[%<B+CP!D)2HFR$QG5BB_:W
M1OUT%^W6&;H7W4P;T4P5]W]%\3/^2C*97L*7%',CS].UH83C^A;L;8WXU0BP
M#H@^?!@:'+@.<^'^UD&BCP@[ 6* #O6UGKR(XF448PN.T+8AB>U<%^LY1%"(
M.]Q[\, X(!095M%B 6,/@> !6['Q?93FF?ZA_SM*Z;Z,&;RS/;>68.TVH+-0
MT\0:1VJ][AZ.N.AJ;NP\<B3(UE @R(A>@C'Q='FD7!?AX3)*4,I7/.P>SN-#
MEG8-I8 LJA.LH$RT#2!1?2*2I=WF^V:=]:%MD+VLK(2E;?,11PTXZ"W'?11&
M2YI8()SEG"AJ$'&W$)&N0X&*U/[1F7!',',. A!Z\&D.H<@NPFIN'394;R%2
MA',L4=-Q)@UD\(-.F1VL$[F4B,0D?"![1I'_L'*/WKY9L/H, A;R6X04N8Y@
M0T2'WK9%KLJ,81UV5.\B_;GAR/GU$L;H%4OR%7[%"Y$\T9N$F]_=0]:+J]9^
M@X20;-A)-RYHC9LU]/9U0W5%,_.S)?.Z'!AZ!!FPGX>R^P^KJ=\YC-,+$,<K
M? RD21M9_E:1O@<!I>Z<4.2L9Z4T_&P3JM:E$#8A:U+(:NA_P.@2Y88&2TE]
MD2PVL\:+*$Y)Z/-%E*3-.UJ'$9S&C2I^%,CI71VIL;RVJM+('#H]+UMD 4BA
M3PNP?@MC" )".+$6S^$TBN$S>.N&*:FQ#QIM_3E5X%!/W223."0G%ETX;!K[
MB,->G"IPV+DRTY<<AR&<D5GT1Z(:6XW-,O[YL;6?TVCKQX4"27W+.;4F,K<%
M25LFAS2>MGH?.*K:>5%@ZXL6J\W0>;*W>2&/.;%Q#QV-/;A4NF'UE%&R3P6*
MV1\*@;HU[A&HG;E4 K7SA4&+W6<=5*4Q>.#@XJ)&SVV!H;."^$M-CF-7;("#
MP%1/=I08ZQWJWVCK*2N+)4QD^P5!_P&=QI4F]I0XZWV'T(@S0PG@.<8"/]MM
M>T>G,=:3#266>M\JV%1,@,T+:FT^5@Y%Q-YDQ_7(#V0=UCKB0@9@4KQP) B1
MXVBDU12S*-LYU3Q$16E&F"0DY]/S#QB\PCO<>K[1_/+.W3Y?.T2PJF>8MF>_
M^\F'1 R0$*\2Z7Q'G^KYCBIC#26143GEE7!Z?4X/@H^3L].3TP]GGS^>GGTX
M^VAH!US/\?<H_GX3/L21!ZE.GDP?,7CB5Z9;0:"G=6I#5B)U?=&5:D=VLS7Y
MURA$"39.238X.;BP>[H,%TFJ'<D0L2:?;3E7F[@,@!8S5Z4KR.P^@JTG>!G]
M8+_FWFWHLM3Y1&I[#+,?@Q!O?DL8IZLB!\:2^*;D+,//=<NP')1FOEP/.Q0C
ML9S]0P#"M,H7AJDHT-[LRSGF!,526?*[6[/RA<76_!BN Y56)2IDSO]\15+=
M<-[3"_2T1LA*Y%:'05<6# ,!A 3N WN!GM8AH*O()(3?0KTCQ\&+:+',\"36
M9+<E&&QJ/1QXM BUX9Y8@F)'(/$43=,?F,7DZK+X\1*^PB"B])/H1WYR!N'^
M#L.F'P^,^PX8\03$X8&Y.><K"UY3!T4N3:XC62*OLSA$:48Q?HW>R$]\O<#N
MX" J.A+M2'*-6XA/[W.\,&X6RSAZI<G1^.#@]' 8';)4JWH7:A@>3 ;>MN3R
M:>]H'5CV=5;E<\"X1:$9.#0N118TM)-U@.DH80FHL.EVY 13>7-P"?'4/93G
M7(/+ %))AG[QFHO^GLDH5HB.HN'=A9Y6#O75978^!F;R@'WQRNOB+K:DJ=9P
M/VL<+1=@B<ATB/V8D#@V"*M9)O/Z?^<KFNO^(@!)4EN15/;,MR)*1G<7@SH9
MI#5KD+%<9QM^35X"-*/DLY\J-;8^##BU$:SA"&BL/B=>%5&&3[P/8$7+ZF*K
MP//BC)0JI<G/):-4?ZO'(I1?&!6?H#$)Q4=&Y5<&$YJ0TY"4? (!Z\$,MZ4A
MB[Q9TO4$D&UO@.1'LD9Q" APQXI60JH[I[HJ.UIRY#0VM@8)JD7<"AZ!G#@.
MX(-P#N_*4VR141*N86LN)6ZGP\*++".,.Q59">%R4LCS'\* .Q!F4_S?+$;A
MC&3S+'Y?WMG1VUA>#KCNPQT ?K2PR)$KTJO%,HA6$#Y">O(33A#>VN\ <-6/
M%\;O4?FJZ1IXA(B5H.II:GX $.C$ D>N2*^C&*)9F%/JK4H-FI3,7(FG].XR
MU &@2SE[[$J6J]5QQ]^^^)T."%H=&-$WTZV-(*+EJY@\98"(W^F 0-2!$8J2
MW)K> R5XVM]9>$"(ZLL5K7EN/^SW"N(IC;SO) (/8STO WX1+1912'^/.?,[
MB&. >25W$_&E?A-1_=!_C/)/X5_G7\O_2B\GR@\.Y5(BIX3AM-_]H]F7D!=1
M@.<5Q;3RU)BP>99'7&(YWT>AQ_CS,_XIP=,G6[?8FTE5'[)&)S4+N?DII5;B
MK7IR=PE?TIL0\R2C#TW9;RSK#:V1[)[E5P>.(&\X=Q2&,]!M$W /%OS7EJSF
MUB%"4#!M$FVAT/C=$\-1=Q^E<+/]CV<QI"@G&& _>FKM9+F06V2UXYGK1NWP
M!/ZIB\ _'93 >=3:>DMX$86O,$[1"TD9&.)-A)"7D':7&3P[.7O/%KM@5Z>$
MWX=FX]=YK-L8WT?Y5!C0_J\LA'P-(#F$4Y!00;OQBSHU1N!YEJ 0DCA??%+*
MLXMRS@.,UM:!P]BA0(9!G/W%\,F@B0KR(UX=W"-":S_K@"(C+S%IM]-KJR'Y
MY*'(I]G^/?:V46LT")&V"V5GAQ CTU9)WB&\'?I<.>XT<5.*(D0:M_+5J.PB
MRN@!Q.FJNGF=KZI_X6SMX@-8AQ5CNWU/GG%.%YV+I:M'$W?'KS>T#AT]A<27
MNLW;O");$(9PBCP$@LF/$,;<7"B-;:T&A%32$W'R')']!;EMA_&2<(J<L#G;
M1U-3ZR1O;*,0Y@[3JV!F%UAFL3<'"5P[1G8):=D<!/M;!Q1A>37M#GV(-JXX
MF#[G'S"D#R(62Q"N;F\O>$[FYK;62;F?J&IN9@FJ;17S(_07*(!?XRA;\E(D
M[K9R6[2"]#IRDKR-PAF>PX(XV%M2<#<UM0X*QC9]8>YP7GX8/@?NDL#=[IL;
M6X<'8;&T2]3FC5S5"6!]>4J(;LFQW=#6>O%+)M46)=$1^1,.3:859<C9#1K;
M6B=_8]N!.'N8[[&,O&6H,08T\X*K&R1'L0XUXL*K"UX%[<;5">/ \!"C5Y#"
MAP!XE)R'7:N;?8H0[&H=%%2(<^> T8<5&I#1(_Z =;4,2/*@=DPTM3L$  C3
M;?R,R0I(2^] _!VF^7N+R13/!84S3O09I_TA"%R:?N.1B%5K(H'>K[/H]9T/
M$3$D/I ?""@^5.P'_*M_WL(9"*["%#7>/#>TL$[T>[<619G">6ZMQ&<@*N)\
MFHU^@=T_6R-<41YO2Z65%.,VFJIDC3'UEE(W-M>H;VAIE8Q;)5:WU45)<D36
MCT1-\8*"RK];(U?CQW@^2Y@)#(Q)E[N"*RVLDS"?T0S!N+]D[\ ;6F0+KEBW
MVM@I6"%369P>1X3[A 5!M=,ZH\,R"JDN8^MH;A_KA&],;\NSB9DMQ$A&QNU9
M<R_B&MO:AP1I@=2%*DZI(PJB>*C&U?Y;;:P3N[C(ZN)NI\P1,5=2^;25-=YN
MYY2XQ:@S[A)5=M.>(KS'D=-GF"!,$Q73IBPX^]:=W\\Z2!B,PNW"JE*EG-@7
MGL,@J#52I[6?=9CI)CIA"-@>S,/.!-%$S3H![ 4> GD@P,OI$<Y(%:<H7MVA
M "8IUL;--_;J!AX*B(2C@#2S9J@H>X2O,,S@.4B@KP)<O/$.$U/2'''&)NIM
M']RV%&96^0GKP&G0TM+,U5)7#OV@5T:C[@26ENEQ<VX)E1?K,))U>-4.FSI2
M5;%-:QB6H?3GVRF6KH$'QPORB(:!0%9SZV"F2N9U-$FQP'W(W) '5]A:>00I
MI.Y>_P'&'I'VC)6+6'R @X65-%,T6(/&@5;Q#3Z >!+GC*#53C WGN: 655&
MH.<!0:LK-S3$(QK'U/8RJ_ Z_Y'4%GPD4C\5TEV<_@>$KWX\T5I2W%Z4/<3(
M@SU0EO<_HDR0)UHKDYO?'ZD23\99.L=3^F-3](.]+^[VL Y)!@Z*LNQ19'1A
M]+Y$&E_F5,CZ>T2<D(]H-D^3ZRB^ MZ<4OJ?,-C%C$S70P9/;SYI-;,,99?=
MM^E^>C!PZ\TGK?:6]"4Y0V5=HS=2L7FQ0$EA/L)QLCD"3Z9?XRA)'N+(@]!/
M2H*?HF8MUGVT@U=LBEFGU0Q3]I*5+*J;),F@?TFKA&.R4.07)D'QJJ]\S]>$
M-ZD!#AYB_;FEM;CM)[VHHAJ[!Z@:^Q\QU9=96DO=?E1OV!-:0>C!C:J^>EO"
M,(&[E^+B'0\>1-VYI*'&[08][PT62F: JK'-(>-'G"&<>K6F(T\#D"23:1&0
M/XGID?8^(P%)D^D3]+!>I<5X01! _WQ5UH8M&C*#<?J->@25'A;R(J -' N5
MOJ0AHLA)GV1IDH+0KYM8(EVV&/<!,XYPZ\"P)\T?55%<+"?I9[/ED[!!\()"
M*O3MX%#"XYP\UB6/S!!'Z"G@5PE%/4$2TD:]JE0>*\KWYZBHG5.R"1)1E'$D
M-^%X.D4! BG3=I,?Z A*95PKH:GG$L 0-!OJ.^5/!4NV)/D)?1+3X]5+ -=&
M#/7]Y']MT9[]!C]"6"LG2UCKN6Q0Y49IWEB:7FML'F8T>56ZC'/( %3+M!)K
M>NX6]&*MT8BY";T@(W;UFO!BLQ''GMRX1RSJ8F*)33TW%!JQ.?;_E24IN0%L
M9H,@%-N&.2)/$<]*H-E];\&C%B1S56#C#'4$G$*^E:#3<]VQ!]"5"4R4P(X_
MV!%X2CE70J_I^F2PYV:.3X%&V\@[<&BW0X9>+QZ58;YZ[D8,.V<$;-U&;P#Q
M;A7N@/[^[;8O'*&KGYTERO6\536$<FYLV3W\0?_$SKHITOF(S5Z<*F&GYU+&
M4/A[U3%*'R6U!+TSVQ_!)<N<$D].W:24\=776!9E*!I)^+*.3V.9A&W]COCJ
MRJ029WVO-EAQ#;\IJ][50EW3D4*BYR$CJ"^;2@QI?@[QEW=5,6#BON>_WOUM
M05E-$F"!/'Q GV-#<PFS%'G)KUZTR#]]B1(OB)(LAI36.>8(GDQN@)9F*'DK
M@IG]$& .7\(4H&"-MQP)\"V%H;_QM*0H)5/X</+EY&STRVCS#?R/ZF?^8Y1_
M O^Z^&']L1']VNCGXGM_PD,O@C#A<))\^04D\"=CF;\9V9]V_VC$H%EG&:,[
M+\U21Q+^0KQF\K6]66?GJTV;XKP]_@%B_YES5E0VOC7JJ%FD6W:-5IJ9F8>&
M4X/&AMU$KY#JH.!S@I-.RO#K@,?.=6ALD#*?ZPPI<6@QGN;5ACHTU@B6,[>Z
M:-OI<42XN6KB)Y[?:F.=</>MF]NYP4P(8LP)U8DI&T)#G]C1]V#!3S:OXU/6
MP:U=_ S?U3X88UPI,=P/5XME$*T@H>(2Q=##_1)ZA)O0&7)2B(OUM XE>Y/X
MCANB![N,8T>1"0KQ60MY*?0IW=]"E":/3]_X1BFOSQ%;?1CE2'[Z'<)ET'1$
M40N*VM%C1RWT'A<W!9<X-G:UB7U8V;.)W<H,#BX,/S86,I0M-W%;V<^6V !M
MTXIY1*C 7_I<L9ZV_\"V4^5'L5;LXM:F(J*'@XPS3%X#T3*PX [A)";D*39N
M-+)NT6$\C>(%N=NE^UN#.9Q;2+,8TMV0#8R.0SD $)64NY@TM=7$8EE8ZWB%
MKNZYUH&M0]^^#5--+%24C'4[B,A,QOM\NE7N5.HE@B1!4P0KV=\94)4>QSYD
MZD%*'9)J6*6U0I&A<,GG&)"GN9M46 RPU=H=+IC$6*&URI AL-R$K]@.R8LN
M>=$"EL\FZ'GF%?DP9*4@$>AYN(#JRAP7BP[5%M>W,(8@('4E_A,;QOA/7[$)
M?<M^VB<^P.$"KB>/M%AB&^1]&=B1XAJ@.,^6G"39(K]"Q$OW#J;SR(^":,:*
M5MWCEP\7ZZ:8:U?Z?H5+Y*6=ER^[O+QZ6Z+\Z67^VHVW$%2,[P[<>Z*0L1ZT
M\5CK$4E5T8J_8]MJ77>H4J CO$9QDOX#@G@<AH@42@/QJLDO*37 $8O-+L[^
M3-1ZQ#(4'-YY>=+_8?!4M;KE?>L(=_6J5YK?6D^&JK(,=19,<456J:R4OWLF
M'(+^\QRD=V!U#J_>< N4D 1TO\\Q.9/X <2-&0'-S.2X4AB7H_9(PZX"<(;/
MN=NI;%L+J"K_SG&]J#_D2O%:ZY%V:*NA28:D>@VYH_][%.!AR-T2*0)XAT+R
M3&H?SA_N!([K9S].(GDA:"W*Y^[",K>BCDO)Y%+BK2&5V7P'OVP>4?+].H;K
M"\5]+9JF[QZ7S'Z6C##O-11>')3#C*=OGF&\8-6BTO?!XQ)1[SKKQG1.I4FS
MP?8Z-M<RQH21>'%_'S[B7[%#K#?S=92Z')155;P(_QJ30HXWQ<WG[Y#XX*$_
M?H4QF$'ZQTN\S:[9K=K&ZC8+=Y;3WF(^%#+Z>*:O\[52 /4Q"H+K*"9_U+1:
MFC]V7!1[X.>AG\7K',O][/J1GG_''9#+8T\K\#GL513YM,RSP:<@3@>,_.T-
ME%>)1<.7CNC79PNU)V@>NL[GE6>H)HE:1Q&P@"T]T!&WPG4RQ/G7-Q+J2P[+
M$,ZPQ>\/6"5C[D\A2C-2'T(@"EOMEX[05JF211G<-WK)&>S;9(B?'H&OF[^*
MXI1R4_PJ'#+R\]#'<>BO[SPB\JM]+0C1SQ_W!Y7+I!?7-?@MA[AP"JN2I#W1
MND)JWSDN!95+08R]&OR5=KS55".VG0N0\L!%"\P1D4[WY<<7G(@[2\B@C[\/
MKUT*+=+/3;/KQIW%HA;#QA;7\7:!G89.Y'Y>R=I2-X/C^E*VOC0+Q94;C+YL
M+#EE=(%)3>*XQO:VQOK+Q9%R!;TYV>#%-['0)*=Q7&I[6VHJ)*/A ;N5B\W1
MDY@[ET6N',6.UTMR-PT&EEN_21TW.'NNJ;IN=\?+J_6MAX'U)_CUXT(S< G6
M=469"^77DSPLV6'$1132YW@9"&[1%#(2]N[QR^ZL#M$[+-/,-?[FU_![^%8M
M]@A)]2+\^PI7R1/J,]4/Y;O/Q)I58QK,C$W$ FD8KV-GQS*3-GY97%:>ID+Y
M!(^+4MNBU"PDEV[$>G"9;3_O>U%VF,EQ]6E;?:JD<2@W8BVR'?L^RBF_1(D7
M1 FY^=!5.D7DF]8LG<'%$<JS54>F&>/%K!1ZE&ZP'D%A@CR="6:8WW-G)70&
MJ-9+* %NVU59Q8[UT6[^CF>SF#Y?W,OZZ3R?X_HR<K\D(PVMQ6;<6G\5N]B*
M]=<^G^/ZV]_ZZR@-NTK:V+'^:L&8SU$*@KTL-9%/N[.J]GU^ZLS=TDK48R8:
M2CMXM5@&T0K")QB_(@\V,_<")/-'Z$'T"OUK+/62A9-I-5D,8S4H_,+A@EXW
M$TMLZS'!;,;V?40KA,.\$%Q"E<$64Z,DO8_2?\ 4LS::A:2"CRK4]_WV<3WL
MG[WE2M%C+!DZK&AC9[[#7D=Q\2O2CG6!L]])'->.03Z7BTA/\;^AG?BO_IWA
M>=^$^ 29T<<KDW0.X^<Y" M%M!:&QLS.G29QN(O( CZ7BTA/S<"A'=O%^:HG
MYY#L]]U9.NH0;629F<@[/=S;TU:^;B<*V/LJV_[\<9&9760"TM!Z]^/<ZLK]
M_L96U_;GCZO+[.H2D(:6%-V;]?7)M?55Y 4PN,1J,SBN,K.K3$P@6O*!.[S0
M[#^-#34_Q#!7F9 \-&6'<-A>7+.UM=">%:Y%F5FZLR]:Z'OL+8C2=:*G1N,!
MKU.+%Z<[*W*/"\7.Y7UTAVKQ@-FWN@^V[K&C2UQA>>6C2[:#%\Z^%2XYO^,*
MMWR%JY"GUH!_YU9X)5FL?<M;9G);6/A(L."^DVM0:[NW,#7D)'9X8;MWZCXN
M:OL6=4]1'IW>L@S?:[*3?K-Q9_':X\269WCIV-)3I-"Y]26? HWU2LJJ.;JS
M%C4LD7TN8%6RTYK696CQ\?2WR4V29/J"FYJ^X<ZJVML.)\S&$N JBX$V[%M_
M>5<5$V;#]_S7N[\M>%"3%%@@+TO((@=+F*7(2W[UHD7^Z8W^H2\OYU& 24IR
M%5%E&\ES$2;P$J8 !>OM) <*?$MAZ,.UO%.4DAE\./ER\G[TRVCS"?R/ZE?^
M8Y1_!_^Z^JE1\:W1S\77_H0'7@1APF$C^>X+EN-/)AYO4B(8]NWN'XWH+&\.
M_2R DZG0T\-Q0.>"?YI,=Q\7DF>'R3/);\+273J^98T.:Q;UEM+9&_W,W=4$
MQ&Y"K%&P"L&G::)&;PNBQF^(97IR>E@C[OT+M0XH63X- 1:7$3$CY8"1][$.
M&K+B$18PAUY'TLP_8F%A1L_'H7\)7V$0+0G]Q>9_!SEAR0(]AP(4CICK4.E*
MMR. >8(!'G/V%8;8D@TP$\;^ I]&R6:<HE=8\"'A0D=J#"=!U)\#CJ3.5[.7
MKT^E?;*JB'_%.DB:M(WVP5M%8'^%\4MD%.X%'Z#?S*9BW3-0+-;9.G#N R!U
M6/9@EJ*=N@EM^_$BC9,$I@G>56X1>$$!2A'92@#YDS].US>M4GZDTY.3TUT_
M4OZ=$0C]4>5+H_)3(Y".R,=&]&M#\21MV--Z;\IO:D*_K&?$@\ DQ"LLBV.2
MH#KT[Z,P+O^)EPGB>I:4C6^-EA(1=U6OZ.6 58Z#BR@+L7V(>9>N[L$"<AQ)
M34VM$?%^1%>'BC!3.!N.X71NCW"9X;,N5L7C60SI>6>7*JX?2;B_=6 1%EZ3
MAZ /T<;]!(R"N(\0'U$#^#6.LF7CZ9[1RCK)]A//1MPR]!H7JAIU< E?TDW,
M F<_J#>T#@;[W@T$6<(\ZIJ7=ZNV9S6W3O:"LF@3XD U^7V40HSFWP&)PDC7
M2I!@@*W86SM9+F0YM=Z-6EL%OHET8]#U7UD(23>V^"6'< H,*FAWQ%V_WC3/
M5^L?_Q/!F%R(K6[)=1C'*!#K;!UT]FTH]& 3\TFC4:P4/*)AKG6*N!:%U!CV
M(D=>DAQ8=&:%\>U),:YNPF66)I2/9]S[9DX/>S'36<P<Z C2[S!0WDL#Y?V!
M X5'OR-6S2,,R$WA W'_/&/++@$>?8-QOJK^A6/9B ]@+XSV9-WT9!7G;;?A
M0EO5Z;?XQ'<;6@>*GD+B2]U]"^4<AG"*/ 2"R8\0QMPMI[&MU8"0VE'$R7-$
M]G?@7U'\C+^23*;$Z4#*T]('"T]$95*MRME(!'M;AX]][R)]^,3,)6 I7+B;
MB7!_ZR#31X2= .'^OG,1+1:DVBD('L 2QO=1>A-Z0>9#_W>4SDEE5,P6\A_"
MFE<0D!,#=W/J/N 0X2:UL2EFC=9GVH:"1RZB>!G%V&X@_-ZPN05QG#X' "I9
MZATY@5_ .$783L2D4U8NHP2E?*"P>[@/$TG:-60Z5'(O>0?B[S"]>O/F)!N
M?Y>15!;76>@WZPBA/LX*OSOU6O/A&=I;"$,GTTH>"<ZAJK&M=3C9]Q%*G"L%
M?NI5#(R\H-E,.,E9 #:_J?JJN+N'Y"C6@45<>'7!JZ#=^(&)L:,\Q-C63N%#
M #Q*SL-NI"=[8Q'L:AT45(AS9Y?IPPKCR%#DS2<<Y-WXE'^W#@][O]#A<J*
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MWOG+NUR4Q1;]O_Y_4$L! A0#%     @ IH%A2KLGMAM@W@$ A0<H !$
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7;%!+!08     !@ & (H!  !5A@,    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
